In O O
spite O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
medical O B_PERSON/B_ORGANIZATION
help O I_PERSON/I_ORGANIZATION
: O O
the O O
puzzle O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
eighteenth O B_SEQUENCE[MEASURE]/B_LOCATION
- O O
century O B_PERSON
Prime O I_PERSON
Minister O I_PERSON
' O O
s O B_DISEASE
illness O I_DISEASE
. O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Medical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
History O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
1990 O B_MEASURE
, O O
34 O B_MEASURE
: O O
178 O B_MEASURE
- O O
184 O B_MEASURE
. O O

IN O O
SPITE O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OF O O
MEDICAL O B_PERSON/B_ORGANIZATION
HELP O I_PERSON/I_ORGANIZATION
: O O
THE O O
PUZZLE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
OF O O
AN O O

EIGHTEENTH O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CENTURY O B_TIME[MEASURE]/B_PERSON
PRIME O I_TIME[MEASURE]/I_PERSON
MINISTER O I_TIME[MEASURE]/I_PERSON
' O O
S O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

ILLNESS O B_DISEASE

by O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

MARJORIE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
BLOY O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
* O O

Charles O B_PERSON
Watson O I_PERSON
Wentworth O I_PERSON
, O O
second O B_PERSON
Marquis O I_PERSON
of O O
Rockingham O B_LOCATION
, O O
died O O
suddenly O O
and O O
unexpectedly O O
on O O
1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
July O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
1782 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
when O O
he O O
was O O
only O O
52 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
old O I_NUMBER[MEASURE]/I_ENT
. O O

He O O
had O O
suffered O O
- O O
or O O
enjoyed O O
- O O
ill O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
health O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
all O O
his O O
life O B_TIME[MEASURE]/B_PERSON
but O O
in O O
1782 O B_TIME[MEASURE]/B_PERSON
appeared O O
to O O
be O O
no O O
worse O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
he O O
had O O
ever O O
been O O
. O O

His O O
death O B_PERSON/B_DISEASE
in O O
London O B_LOCATION/B_MEASURE
terminated O O
his O O
second O B_TIME[MEASURE]/B_PERSON
period O B_TIME[MEASURE]/I_PERSON
of O O
office O B_ORGANIZATION/B_PERSON
as O O
Prime O B_PERSON
Minister O I_PERSON
, O O
to O O
which O O
he O O
had O O
been O O
appointed O O
only O O
14 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
earlier O O
. O O

In O O
May O B_TIME[MEASURE]/B_LOCATION
he O O
had O O
reported O O
to O O
the O O
Duke O B_PERSON/B_LOCATION
of O O
Portland O B_LOCATION/B_ORGANIZATION
that O O
he O O
had O O
" O O
for O O
some O O
weeks O B_TIME[MEASURE]/B_PERSON
past O O
undergone O O
much O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Pain O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
much O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inconvenience O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
something O B_PERSON/B_ENT
similar O I_PERSON/I_ENT
to O O
my O O
old O B_DISEASE
Complaint O I_DISEASE
in O O
my O O
Side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
Stomach O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
" O O
but O O
that O O
he O O
felt O O
much O O
better O O
than O O
he O O
had O O
. O O
' O O
By O O
17 O B_TIME[MEASURE]
June O I_TIME[MEASURE]
he O O
was O O
recovering O O
from O O
both O O
influenza O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
his O O
" O O
old O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
complaint O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
" O O
. O O
2 O B_MEASURE/B_LOCATION
On O O
1 O B_TIME[MEASURE]
July O I_TIME[MEASURE]
he O O
died O O
and O O
on O O
the O O
20th O B_SEQUENCE[MEASURE]
he O O
was O O
interred O O
in O O
York O B_LOCATION
Minster O I_LOCATION
. O O

The O O
first O O
recorded O O
bout O O
of O O
illness O O
suffered O O
by O O
the O O
marquis O O
, O O
then O O
Lord O O
Higham O O
, O O
was O O
in O O
July O O
1741 O O
when O O
the O O
11 O O
- O O
year O O
- O O
old O O
was O O
" O O
a O O
little O O
indisposed O O
, O O
something O O
Feaverish O O
I O O
guess O O
it O O
proceeds O O
from O O
Worms O O
and O O
will O O
Soon O O
be O O
removed O O
" O O
. O O
3 O O
He O O
also O O
had O O
a O O
rash O O
and O O
it O O
was O O
thought O O
that O O
the O O
cause O O
of O O
the O O
problem O O
was O O
that O O
the O O
boy B B_PERSON/B_BIO
had O O
overheated O O
himself O O
. O O
4 O O
He O O
was O O
still O O
ill O O
at O O
the O O
beginning O O
of O O
August O O
: O O
he O O
had O O
been O O
" O O
much O O
out O O
of O O
order O O
" O O
for O O
a O O
long O O
time O O
but O O
had O O
been O O
recommended O O
to O O
take O O
warm O O
baths O O
by O O
Dr O O
Wilmot O O
and O O
Mr O O
Ranby O O
when O O
they O O
were O O
consulted O O
in O O
London O O
. O O
5 O O
Charles O O
' O O
s O O
aunt O O
, O O
Lady O O
Isabella O O
Finch O O
, O O
was O O
sure O O
that O O
the O O
baths O O
" O O
and O O
other O O
Things O O
They O O
' O O
ll O O
prescribe O O
will O O
in O O
a O O
short O O
Time O O
entirely O O
Cure O O
his O O
Complaints O O
w O O
[ O O
hic O O
] O O
h O O
neither O O
of O O
Them O O
thought O O
proceed O O
from O O
any O O
dangerous O O
Causes O O
" O O
. O O
6 O O
In O O
spite O O
of O O
Lady O O
Isabella O O
' O O
s O O
hopes O O
, O O
Charles O O
did O O
not O O
greatly O O
improve O O
, O O
even O O
though O O
his O O
mother O O
believed O O
that O O
he O O
continued O O
mending O O
every O O
day O O
. O O

The O O
main O B_TIME[MEASURE]
reason O I_TIME[MEASURE]
that O O
Higham O B_PERSON
and O O
his O O
mother O B_PERSON
had O O
gone O O
to O O
London O B_LOCATION
to O O
consult O O
Dr O B_PERSON
Wilmot O I_PERSON
and O O
Mr O B_PERSON

* O B_PERSON/B_LOCATION
Marjorie O I_PERSON/I_LOCATION
Bloy O I_PERSON/I_LOCATION
, O O
Ph O B_PROTEIN[GENE]/B_LOCATION
. O O
D O B_OTHER/B_LOCATION
. O O
, O O
18 O B_LOCATION/B_PERSON
Farm O I_LOCATION/I_PERSON
View O I_LOCATION/I_PERSON
Road O I_LOCATION/I_PERSON
, O O
Kimberworth O B_PERSON/B_LOCATION
, O O
Rotherham O B_LOCATION
, O O
S O B_OTHER/B_LOCATION
. O O

Yorks O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O

S61 O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
2BA O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

The O O
Rockingham O B_ENT/B_LOCATION
Papers O I_ENT/I_LOCATION
are O O
in O O
the O O
holdings O B_ORGANIZATION/B_LOCATION
of O O
the O O
Wentworth O B_LOCATION/B_ORGANIZATION
Woodhouse O I_LOCATION/I_ORGANIZATION
Muniments O I_LOCATION/I_ORGANIZATION
at O O
Sheffield O B_LOCATION/B_TIME[MEASURE]
City O B_LOCATION/I_TIME[MEASURE]
Archives O B_LOCATION/I_TIME[MEASURE]
Department O B_LOCATION/I_TIME[MEASURE]
, O O
Sheffield O B_LOCATION
City O I_LOCATION
Library O I_LOCATION
. O O

I O O
am O O
grateful O B_PERSON/B_ORGANISM_FUNCTION
to O O
Dr O B_PERSON/B_LOCATION
R O I_PERSON/I_LOCATION
. O O

S O B_OTHER/B_DISEASE
. O O

Morton O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
his O O
advice O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
help O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
diagnostic O B_TIME[MEASURE]/B_PERSON
sections O B_TIME[MEASURE]/I_PERSON
of O O
this O O
essay O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

' O O
WWM O B_LOCATION
, O O
RI O B_MEASURE
- O O
2094 O B_MEASURE/B_LOCATION
. O O

Rockingham O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Portland O B_LOCATION/B_ORGANIZATION
, O O
25 O B_LOCATION/B_PERSON
May O I_LOCATION/I_PERSON
1782 O I_LOCATION/I_PERSON
. O O

2WWM O B_LOCATION/B_PERSON
, O O
RI O B_MEASURE
- O O
2094 O B_NUMBER[MEASURE]
. O O

Rockingham O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Charlemont O B_LOCATION
, O O
17 O B_LOCATION/B_PERSON
June O I_LOCATION/I_PERSON
1782 O I_LOCATION/I_PERSON
. O O

3 O B_MEASURE
WWM O I_MEASURE
, O O
M8 O B_MEASURE
- O O
25 O B_MEASURE
. O O

Malton O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
Nottingham O B_LOCATION
, O O
after O O
16 O B_LOCATION/B_PERSON
June O I_LOCATION/I_PERSON
1741 O I_LOCATION/I_PERSON
. O O

4 O B_MEASURE
WWM O I_MEASURE
, O O
M8 O B_MEASURE
- O O
26 O B_MEASURE
. O O

Lady O B_PERSON
Finch O I_PERSON
to O O
Lady O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
30 O B_PERSON/B_LOCATION
July O I_PERSON/I_LOCATION
1741 O I_PERSON/I_LOCATION
. O O

5 O B_MEASURE/B_LOCATION
WWM O I_MEASURE/I_LOCATION
, O O
M8 O B_MEASURE
- O O
28 O B_MEASURE
. O O

Winchelsea O B_LOCATION/B_BIO
to O O
Malton O B_LOCATION/B_PERSON
, O O
7 O B_LOCATION/B_PERSON
August O I_LOCATION/I_PERSON
1741 O I_LOCATION/I_PERSON
. O O

6 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M8 O B_MEASURE
- O O
29 O B_MEASURE
. O O

Lady O B_PERSON
Finch O I_PERSON
to O O
Malton O B_LOCATION/B_PERSON
, O O
7 O B_LOCATION/B_PERSON
August O I_LOCATION/I_PERSON
1741 O I_LOCATION/I_PERSON
. O O

178 O B_NUMBER[MEASURE]

An O O
eighteenth O B_SEQUENCE[MEASURE]
- O O
century O B_PERSON
Prime O I_PERSON
Minister O I_PERSON
' O O
s O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
illness O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION

Ranby O B_PERSON/B_LOCATION
was O O
his O O
mother O B_PERSON
' O O
s O B_PERSON/B_ORGANISM_FUNCTION
concern O I_PERSON/I_ORGANISM_FUNCTION
about O O
a O O
" O O
swelling O O
in O O
a O O
certain O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
was O O
larger O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
when O O
we O O
left O O
Wentworth O B_LOCATION/B_PERSON
" O I_LOCATION/I_PERSON
. O O

The O O
doctors O B_PERSON
hoped O O
that O O
it O O
would O O
burst O O
outwards O B_LOCATION
" O I_LOCATION
which O O
they O O
assure O O
me O O
will O O
be O O
the O O
safest O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
way O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O O
give O O
the O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Monkey O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
but O O
very O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
pain O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
' O O
7 O B_TIME[MEASURE]/B_LOCATION

On O O
20 O O
August O O
Lord O O
Winchelsea O O
, O O
Higham O O
' O O
s O O
uncle O O
, O O
surprised O O
to O O
see O O
the O O
boy B B_PERSON/B_LOCATION
so O O
well O O
and O O
brisk O O
, O O
hoped O O
that O O
Charles O O
was O O
" O O
now O O
safe O O
from O O
this O O
complaint O O
" O O
- O O
the O O
same O O
one O O
from O O
which O O
he O O
had O O
suffered O O
in O O
1738 O O
- O O
39 O O
- O O
but O O
thought O O
that O O
he O O
would O O
never O O
be O O
safe O O
" O O
if O O
he O O
continues O O
the O O
practice O O
of O O
overheating O O
himself O O
and O O
then O O
drinking O O
Cold O O
Water O O
" O O
. O O

He O O
said O O
that O O
Charles O B_PERSON
was O O
of O O
a O O
" O O
pretty O O
healthy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strong O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Constitution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
" O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O O
8 O B_PERSON
Lady O I_PERSON
Malton O I_PERSON
was O O
not O O
so O O
sure O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
same O B_TIME[MEASURE]/B_LOCATION
day O I_TIME[MEASURE]/I_LOCATION
she O O
wrote O O
a O O
progress O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
her O O
husband O B_PERSON
saying O O
that O O
Charles O B_PERSON
' O I_PERSON
s O O
swelling O O
continued O O
to O O
grow O O
, O O
as O O
did O O
the O O
pain O B_DISEASE/B_PERSON
" O O
in O O
that O O
part O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
but O O
not O O
the O O
lease O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sic O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trouble O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
making O O
Water O B_LOCATION/B_BIO
or O O
going O O
to O O
Stool O O
) O O
& O O
less O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Fever O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
c O B_OTHER/B_LOCATION
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oulJd O B_PERSON/B_LOCATION
be O O
imagined O O
where O O
Matter O B_PERSON/B_LOCATION
is O O
as O O
they O O
now O O
imagine O O
certainly O O
gathering O O
and O O
must O O
end O O
in O O
an O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
" O O
. O O

In O O
spite O O
of O O
it O O
all O O
, O O
Charles O O
was O O
in O O
fine O O
spirits O O
. O O
9 O O
Lady O O
Malton O O
dosed O O
the O O
boy B B_PERSON/B_BIO
with O O
cinchona B B_BIO/B_COLOR
bark O O
, O O
which O O
removed O O
the O O
pains O O
in O O
his O O
legs O O
and O O
reduced O O
his O O
fever O O
, O O
and O O
she O O
was O O
convinced O O
that O O
they O O
would O O
soon O O
have O O
" O O
a O O
clear O O
Stage O O
to O O
act O O
in O O
a O O
proper O O
manner O O
a O O
[ O O
bou O O
] O O
t O O
his O O
other O O
Complaints O O
w O O
[ O O
hic O O
] O O
h O O
the O O
Learned O O
assure O O
me O O
are O O
to O O
be O O
conquered O O
also O O
" O O
. O O

10 O B_PERSON
Charles O I_PERSON
was O O
soon O O
allowed O O
to O O
eat O O
meat O B_BIO/B_TIME[MEASURE]
and O O
Mr O B_PERSON
Ranby O I_PERSON
still O O
assured O O
her O O
that O O
the O O
swelling O O
would O O
break O O
outwards O B_LOCATION
. O O

1 O B_MEASURE
" O O
Three O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
later O O
he O O
decided O O
to O O
lance O O
it O O
, O O
even O O
though O O
Dr O B_PERSON
Bourne O I_PERSON
disagreed O O
. O O

The O O
boy B B_PERSON
' O O
s O O
mother O O
was O O
puzzled O O
because O O
the O O
swelling O O
" O O
sometimes O O
pushes O O
forward O O
very O O
fast O O
then O O
retires O O
a O O
little O O
" O O
but O O
the O O
doctor O O
and O O
Ranby O O
seemed O O
happy O O
with O O
his O O
condition O O
. O O
' O O
2 O O
At O O
this O O
point O O
the O O
letters O O
cease O O
, O O
presumably O O
because O O
Malton O O
arrived O O
in O O
London O O
with O O
his O O
daughters O O
, O O
to O O
have O O
them O O
inoculated O O
against O O
smallpox B B_DISEASE/B_PERSON
, O O
but O O
a O O
later O O
letter O O
states O O
that O O
surgery O O
to O O
open O O
the O O
swelling O O
was O O
not O O
undertaken O O
. O O

13 O B_NUMBER[MEASURE]

By O O
the O O
end O B_SEQUENCE[MEASURE]/B_LOCATION
of O O
October O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
correspondence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
recommenced O O
. O O

Charles O B_PERSON
was O O
ill O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
again O O
. O O

He O O
was O O
just O O
the O O
same O O
as O O
when O O
he O O
left O O
Kensington O O
, O O
so O O
John O O
Bourne O O
had O O
bled O O
him O O
and O O
the O O
child B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
started O O
on O O
Sir O O
Edward O O
Hulse O O
' O O
s O O
prescription O O
, O O
unfortunately O O
not O O
defined O O
in O O
the O O
letter O O
, O O
but O O
which O O
was O O
apparently O O
as O O
bad O O
as O O
the O O
last O O
one O O
, O O
if O O
not O O
worse O O
. O O

Lady O B_PERSON
Malton O I_PERSON
thought O O
that O O
" O O
with O O
such O O
a O O
State O B_LOCATION/B_PERSON
of O O
Blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
Continuation O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Health O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cannot O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
be O O
expected O O
" O O
but O O
was O O
hopeful O B_PERSON
that O O
the O O
" O O
Cinnabar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O O
prove O O
a O O
more O O
Efficacious O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remedie O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
any O O
than O O
has O O
been O O
tryed O O
yet O O
" O O
" O O
. O O
" O O
4 O B_MEASURE
That O O
night O B_TIME[MEASURE]
she O O
applied O O
" O O
a O O
Blister O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O
. O O
. O O
without O O
the O O
least O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Symptom O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
tendency O B_TIME[MEASURE]/B_DISEASE
to O O
anything O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O O
Strangury O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
" O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

He O O
bore O O
the O O
treatment O O
well O O
, O O
as O O
he O O
had O O
done O O
three O O
years O O
previously O O
, O O
and O O
it O O
seemed O O
so O O
successful O O
that O O
Lady O O
Malton O O
was O O
" O O
determined O O
to O O
keep O O
it O O
running O O
full O O
as O O
long O O
as O O
I O O
did O O
last O O
time O O
by O O
the O O
help O O
of O O
John O O
Borne O O
[ O O
sic O O
] O O
with O O
much O O
ease O O
to O O
the O O
Dear O O
Child B B_PERSON
" O O
. O O
' O O
5 O O
She O O

7 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
51 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
18 O B_PERSON/B_LOCATION
August O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

8 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M2 O B_MEASURE
- O O
84 O B_NUMBER[MEASURE]
. O O

Winchelsea O B_LOCATION/B_BIO
to O O
Malton O B_LOCATION/B_PERSON
, O O
20 O B_LOCATION/B_PERSON
August O I_LOCATION/I_PERSON
1741 O I_LOCATION/I_PERSON
. O O

9 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
52 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
20 O B_PERSON/B_LOCATION
August O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

' O O
0 O B_MEASURE
WWM O I_MEASURE
, O O
M7 O B_MEASURE
- O O
53 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
25 O B_PERSON/B_LOCATION
August O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

WWM O B_MEASURE/B_LOCATION
, O O
M7 O B_MEASURE
- O O
54 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
29 O B_PERSON/B_LOCATION
August O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

WWM O B_MEASURE/B_LOCATION
, O O
M7 O B_MEASURE
- O O
55 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O I_PERSON/I_LOCATION
, O O
1 O B_PERSON/B_LOCATION
September O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

3 O B_MEASURE
WWM O I_MEASURE
, O O
R170 O B_MEASURE/B_LOCATION
- O O
20 O B_MEASURE
. O O

Nicol6 O B_PERSON/B_LOCATION
Scanagati O I_PERSON/I_LOCATION
of O O
Padua O B_LOCATION
, O O
20 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
July O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1750 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

I O O
am O O
grateful O B_PERSON
to O O
Fr O B_PERSON
John O I_PERSON
McMahon O I_PERSON
and O O
Dr O B_PERSON
Stephen O I_PERSON
Bemrose O I_PERSON
for O O
their O O
translations O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
letter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

4 O B_MEASURE
WWM O I_MEASURE
, O O
M7 O B_MEASURE
- O O
14 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
31 O B_PERSON/B_LOCATION
October O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

5 O B_MEASURE/B_LOCATION
WWM O I_MEASURE/I_LOCATION
, O O
M7 O B_MEASURE
- O O
19 O B_MEASURE
. O O

Lady O B_PERSON
Malton O I_PERSON
to O O
Lady O B_LOCATION/B_PERSON
Finch O I_LOCATION/I_PERSON
, O O
2 O B_PERSON/B_LOCATION
November O I_PERSON/I_LOCATION
1741 O I_PERSON/I_LOCATION
. O O

179 O B_NUMBER[MEASURE]

Marjorie O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Bloy O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]

continued O O
with O O
the O O
blister O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
applied O O
" O O
ointment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
flyes O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O I_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
apparently O O
some O O
sort O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
irritant O B_DISEASE
potion O I_DISEASE
, O O
with O O
no O O
sign O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
strangury O B_DISEASE
. O O

Charles O B_PERSON
found O O
her O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
" O O
not O O
near O O
the O O
pain O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
he O O
expected O O
" O O
and O O
she O O
was O O
" O O
full O B_MEASURE/B_PERSON
of O O
hopes O B_PERSON/B_LANGUAGE
that O O
he O O
will O O
rec O O
[ O B_LOCATION/B_PERSON
eiv O I_LOCATION/I_PERSON
] O I_LOCATION/I_PERSON
e O O
great O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
benefit O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
from O O
it O O
" O O
. O O
1 O B_TIME[MEASURE]/B_PERSON

Apart O O
from O O
his O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
troubles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
Charles O B_PERSON
' O I_PERSON
s O I_PERSON
knees O I_PERSON
had O O
swollen O O
but O O
this O O
had O O
much O O
abated O O
since O O
the O O
application O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
the O O
blisters O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
which O O
Lady O B_PERSON
Malton O I_PERSON
believed O O
" O O
must O O
be O O
acting O O
upon O O
the O O
whole O B_LOCATION/B_PERSON
Mass O I_LOCATION/I_PERSON
of O O
Blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
" O O
since O O
it O O
had O O
" O O
reached O O
the O O
remote O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
part O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
" O O
. O O

She O O
thought O O
that O O
Sir O O
Edward O O
Hulse O O
' O O
s O O
powders O O
were O O
too O O
slow O O
in O O
taking O O
effect O O
although O O
the O O
boy B B_PERSON
took O O
them O O
very O O
quietly O O
. O O
' O O
7 O O
Sir O O
Edward O O
did O O
not O O
" O O
apprehend O O
any O O
great O O
danger O O
from O O
the O O
Siziness O O
[ O O
thickness O O
] O O
of O O
Charles O O
' O O
blood O O
" O O
; O O
Lady O O
Malton O O
thought O O
that O O
the O O
condition O O
was O O
the O O
cause O O
of O O
all O O
the O O
child B B_PERSON/B_LOCATION
' O O
s O O
problems O O
, O O
which O O
would O O
not O O
end O O
until O O
it O O
was O O
set O O
to O O
rights O O
. O O

At O O
any O O
rate O B_MEASURE/B_PERSON
, O O
he O O
was O O
fit O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enough O O
to O O
go O O
hunting O B_PERSON/B_LOCATION
. O O
' O O
8 O B_PERSON
Charles O I_PERSON
continued O O
in O O
the O O
same O B_LOCATION/B_PERSON
state O I_LOCATION/I_PERSON
of O O
health O B_PERSON/B_DISEASE
. O O

He O O
slept O O
well O O
at O O
night O B_TIME[MEASURE]/B_LOCATION
, O O
ate O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
his O O
mother O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
thought O O
was O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
for O O
him O O
, O O
and O O
was O O
able O B_TIME[MEASURE]/B_PERSON
to O O
exercise O O
strenuously O O
without O O
tiring O O
. O O

He O O
put O O
on O O
no O O
weight O B_MEASURE/B_PRODUCT[OBJECT]
though O O
, O O
and O O
" O O
as O O
for O O
them O O
swellings O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
at O O
his O O
throat O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
they O O
are O O
almost O O
gone O O
one O B_TIME[MEASURE]/B_LOCATION
day O B_TIME[MEASURE]/I_LOCATION
and O O
rise O O
the O O
next O B_TIME[MEASURE]/B_LOCATION
" O O
. O O

His O O
mother O B_PERSON
did O O
not O O
expect O O
a O O
speedy O B_PERSON/B_ORGANIZATION
recovery O I_PERSON/I_ORGANIZATION
and O O
" O O
if O O
the O O
D O B_PERSON
[ O I_PERSON
octo O I_PERSON
] O I_PERSON
rs O I_PERSON
think O O
him O O
in O O
a O O
good O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
state O B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
health O B_PERSON/B_DISEASE
now O O
, O O
I O O
s O O
[ O B_PERSON/B_LOCATION
houl O I_PERSON/I_LOCATION
] O I_PERSON/I_LOCATION
d O I_PERSON/I_LOCATION
be O O
glad O B_TIME[MEASURE]/B_PERSON
to O O
see O O
him O O
in O O
a O O
better O B_PERSON/B_LOCATION
" O O
. O O
' O O
9 O B_MEASURE
He O O
began O O
to O O
improve O O
and O O
by O O
the O O
end O B_LOCATION/B_TIME[MEASURE]
of O O
November O B_TIME[MEASURE]
even O O
she O O
thought O O
he O O
was O O
on O O
the O O
mend O B_LOCATION/B_PERSON
and O O
gaining O O
weight O B_MEASURE/B_LOCATION
. O O
20 O B_MEASURE
Unfortunately O O
, O O
Lady O B_PERSON
Malton O I_PERSON
again O O
had O O
cause O B_DISEASE/B_PERSON
for O O
concern O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O O
his O O
health O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
January O B_TIME[MEASURE]/B_PERSON
1742 O I_TIME[MEASURE]/I_PERSON
when O O
he O O
began O O
to O O
suffer O O
from O O
an O O
intermittent O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hoarseness O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
2 O B_MEASURE
' O O
Otherwise O O
he O O
was O O
as O O
well O O
as O O
one O O
could O O
expect O O
, O O
with O O
no O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complaints O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
22 O B_MEASURE
It O O
was O O
not O O
to O O
last O O
. O O

In O O
May O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1742 O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Charles O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
his O O
mother O B_PERSON/B_ORGANIZATION
were O O
again O O
in O O
Bristol O B_LOCATION/B_PERSON
, O O
taking O O
the O O
waters O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
he O O
had O O
been O O
indisposed O O
. O O

Lady O B_PERSON
Malton O I_PERSON
thought O O
the O O
waters O B_LOCATION/B_PERSON
were O O
doing O O
them O O
good O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
because O O
they O O
were O O
both O O
being O O
violently O O
sick O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O
23 O B_MEASURE
However O O
, O O
Charles O B_PERSON
had O O
had O O
no O O
dinner O B_TIME[MEASURE]/B_LOCATION
on O O
25 O B_SEQUENCE[MEASURE]
or O O
26 O B_TIME[MEASURE]/B_PERSON
May O I_TIME[MEASURE]/I_PERSON
and O O
was O O
hot O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
lazy O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
inclined O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
stir O O
, O O
" O O
from O O
which O O
I O O
conclude O O
he O O
is O O
not O O
well O O
, O O
. O O

. O O
. O O
and O O
therefore O O
Intend O O
to O O
give O O
him O O
a O O
gentle O O
Vomit O O
. O O
. O O
. O O
and O O
to O O
let O O
him O O
take O O
his O O
old O O
Remedie O O
the O O
Salt O O
Draughts O O
for O O
a O O
few O O
Daies O O
which O O
I O O
dare O O
say O O
will O O
set O O
him O O
quite O O
to O O
rights O O
" O O
. O O
24 O O
By O O
29 O O
May O O
Dr O O
Boume O O
had O O
bled O O
the O O
boy B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
which O O
succeeded O O
very O O
well O O
but O O
. O O
. O O
. O O
found O O
it O O
[ O O
his O O
blood O O
] O O
as O O
bad O O
as O O
ever O O
" O O
. O O

The O O
waters O B_LOCATION/B_PERSON
were O O
not O O
working O O
" O O
but O O
there O O
is O O
a O O
great O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
deal O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
for O O
them O O
to O O
do O O
which O O
grant O O
God O B_PERSON/B_LOCATION
they O O
may O O
effect O O
" O O
. O O

The O O
weather O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
had O O
turned O O
warm O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
so O O
Lady O B_PERSON/B_LOCATION
Malton O I_PERSON/I_LOCATION
had O O
" O O
shorn O O
him O O
. O O
. O O
. O O
which O O
has O O
display O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
d O B_OTHER/B_LOCATION
a O O
most O O
scabby O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
head O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
indeed O O
several O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
other O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
untoward O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blotches O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
he O O
has O O
out O O
upon O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
his O O
Body O B_BODY_PART_OR_ORGAN_COMPONENT
" O O
, O O
which O O
made O O
her O O
uneasy O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O
25 O B_TIME[MEASURE]/B_LOCATION
The O O
blotches O B_DISEASE/B_BIO
on O O
his O O
head O B_BODY_PART_OR_ORGAN_COMPONENT
were O O
not O O
numerous O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
" O O
yet O O
they O O
made O O
up O O
in O O
quality O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
so O O
virulent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
a O O
Corrosive O B_PERSON/B_BIO
Humour O I_PERSON/I_BIO
is O O
not O O
easily O O
conceived O O
without O O
seeing O O
it O O
" O O
. O O

The O O
pustules O B_DISEASE
on O O
his O O
body O B_BODY_PART_OR_ORGAN_COMPONENT
were O O
of O O
the O O
same O B_PERSON/B_BIO
sort O B_PERSON/I_BIO

16 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
17 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
4 O B_PERSON/B_LOCATION
November O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

7 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
18 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
4 O B_PERSON/B_LOCATION
November O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

18 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
16 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
7 O B_PERSON/B_LOCATION
November O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

' O O
9WWM O B_NUMBER[MEASURE]/B_PERSON
, O O
M7 O B_MEASURE
- O O
15 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
9 O B_PERSON/B_LOCATION
November O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

20 O B_MEASURE
WWM O I_MEASURE
, O O
M7 O B_MEASURE
- O O
22 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
25 O B_PERSON/B_LOCATION
November O B_PERSON/I_LOCATION
1741 O B_PERSON/I_LOCATION
. O O

21 O B_NUMBER[MEASURE]/B_PERSON
WWM O I_NUMBER[MEASURE]/I_PERSON
, O O
M7 O B_PROTEIN[GENE]/B_DISEASE
- O O
1 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
25 O B_PERSON/B_LOCATION
January O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

22 O B_NUMBER[MEASURE]/B_PERSON
WWM O I_NUMBER[MEASURE]/I_PERSON
, O O
M7 O B_MEASURE/B_PROTEIN[GENE]
- O O
4 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O I_PERSON/I_LOCATION
, O O
8 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
February O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
1742 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
WWM O B_LOCATION/B_TIME[MEASURE]
, O O
M7 O B_MEASURE
- O O
9 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
22 O B_PERSON/B_LOCATION
February O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

23 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
29 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
12 O B_PERSON/B_LOCATION
May O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

24 O B_MEASURE/B_ORGANIZATION
WWM O I_MEASURE/I_ORGANIZATION
, O O
M7 O B_MEASURE
- O O
35 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O I_PERSON/I_LOCATION
, O O
26 O B_PERSON/B_LOCATION
May O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

25 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
36 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
29 O B_PERSON/B_LOCATION
May O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

180 O B_NUMBER[MEASURE]

An O O
eighteenth O B_SEQUENCE[MEASURE]
- O O
century O B_PERSON
Prime O I_PERSON
Minister O I_PERSON
' O O
s O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
illness O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION

and O O
his O O
mother O B_PERSON/B_ORGANIZATION
intended O O
to O O
put O O
plasters O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
them O O
to O O
prevent O O
them O O
from O O
spreading O O
. O O

Charles O B_PERSON
was O O
also O O
feverish O B_DISEASE_ADJECTIVE[DISEASE]
; O O
his O O
glands O B_BODY_PART_OR_ORGAN_COMPONENT
were O O
swollen O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
his O O
pulse O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
erratic O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
" O O
but O O
out O O
of O O
compassion O B_PERSON
to O O
you O O
I O O
must O O
tell O O
you O O
that O O
he O O
is O O
with O O
me O O
as O O
Brisk O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
lively O B_TIME[MEASURE]/B_PERSON
as O O
you O O
ever O O
Saw O O
him O O
" O O
. O O

Lady O O
Malton O O
had O O
called O O
in O O
two O O
eminent O O
Bristol O O
men B B_PERSON
, O O
Dr O O
Logan O O
and O O
Mr O O
Pye O O
, O O
to O O
treat O O
the O O
boy B B_PERSON/B_DISEASE
; O O
Mr O O
Pye O O
prescribed O O
" O O
the O O
Precipitate O O
Per O O
se O O
" O O
as O O
the O O
cure O O
for O O
the O O
" O O
hectic O O
" O O
. O O

Pye O B_PERSON
made O O
it O O
himself O O
and O O
said O O
that O O
it O O
was O O
the O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
remedy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
would O O
work O O
. O O

Clearly O O
Charles O B_PERSON
was O O
impatient O B_TIME[MEASURE]
to O O
be O O
cured O O
because O O
he O O
told O O
his O O
mother O B_PERSON
to O O
give O O
him O O
the O O
medicine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
" O O
to O O
cure O O
me O O
which O O
I O O
am O O
sure O B_PERSON
it O O
will O O
do O O
or O O
shoot O O
me O O
through O O
the O O
head O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
once O O
" O O
. O O

She O O
thought O O
that O O
this O O
attitude O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
" O O
odd O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
from O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
his O O
Age O B_TIME[MEASURE]/B_PERSON
and O O
[ O O
it O O
] O O
does O O
not O O
a O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disturb O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
" O O
. O O
26 O B_MEASURE
The O O
blotches O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
began O O
to O O
burst O O
and O O
indent O O
but O O
the O O
doctor O B_PERSON
thought O O
that O O
all O O
would O O
be O O
well O O
in O O
the O O
end O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
27 O B_TIME[MEASURE]/B_PERSON
Meanwhile O I_TIME[MEASURE]
, O O
Charles O B_PERSON
was O O
still O O
losing O O
weight O B_MEASURE/B_PERSON
even O O
though O O
" O O
he O O
had O O
none O B_PERSON/B_TIME[MEASURE]
to O O
spare O O
before O O
" O O
and O O
he O O
was O O
inclined O O
to O O
be O O
lazy O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
which O O
was O O
not O O
his O O
natural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
turn O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

His O O
father O B_PERSON
recommended O O
some O O
unknown O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
cure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
which O O
he O O
called O O
Gascoin O B_PERSON
' O O
s O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Powder O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
a O O
dose O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
five O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
grains O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
made O O
up O O
with O O
syrup O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
a O O
pill O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- O O
every O O
night O B_TIME[MEASURE]
. O O

To O O
make O O
matters O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
worse O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
doctors O B_PERSON/B_ORGANIZATION
disagreed O O
about O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

" O O
Dr O B_PERSON
Pye O I_PERSON
is O O
Vehemently O O
for O O
the O O
P O B_OTHER/B_PERSON
. O O

Per O O
se O O
, O O
Dr O O
Logan O O
saies O O
that O O
it O O
is O O
a O O
Medicine O O
that O O
may O O
prove O O
too O O
rough O O
in O O
its O O
operation O O
for O O
his O O
Constitution O O
& O O
therefore O O
begs O O
a O O
tryal O O
of O O
Beazor O O
mineral O O
[ O O
gall O O
stones O O
from O O
a O O
goat B B_BIO/B_PERSON
] O O
and O O
Viper O O
Broth O O
" O O
. O O

The O O
Bristol O O
water O O
had O O
not O O
yet O O
acted O O
" O O
because O O
his O O
case O O
is O O
of O O
too O O
obstinate O O
a O O
Nature O O
" O O
and O O
Lady O O
Malton O O
herself O O
was O O
satisfied O O
that O O
since O O
nothing O O
else O O
had O O
worked O O
to O O
cure O O
the O O
boy B B_PERSON/B_DISEASE
, O O
the O O
time O O
had O O
come O O
to O O
try O O
mercurials O O
, O O
even O O
though O O
she O O
knew O O
that O O
they O O
were O O
" O O
powerful O O
and O O
perhaps O O
in O O
some O O
cases O O
hazardous O O
medicines O O
" O O
. O O
28 O O
She O O
wanted O O
to O O
see O O
some O O
remedy O O
succeed O O
but O O
was O O
" O O
afraid O O
of O O
violent O O
ones O O
and O O
at O O
the O O
same O O
time O O
vastly O O
distrustfull O O
[ O O
sic O O
] O O
of O O
mild O O
ones O O
" O O
. O O

It O O
would O O
appear O O
that O O
the O O
" O O
precipitate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Per O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
se O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
" O O
, O O
probably O O
mercury O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
based O O
, O O
could O O
be O O
a O O
kill O O
- O O
or O O
- O O
cure O O
remedy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Her O O
" O O
terrors O B_DISEASE_ADJECTIVE[DISEASE]
" O I_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
arise O O
from O O
any O O
immediate O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
danger O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
her O O
son O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
her O O
" O O
perfect O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Knowledge O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
of O O
his O O
disorder O B_DISEASE/B_PERSON
convinced O O
her O O
that O O
whatever O O
remedies O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
he O O
took O O
, O O
the O O
cure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
in O O
the O O
hands O B_LOCATION/B_MEASURE
of O O
God O B_PERSON/B_RELIGION[SOCIAL_CIRCUMSTANCES]
. O O
29 O B_TIME[MEASURE]/B_PERSON

To O O
add O O
to O O
Charles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disorders O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
on O O
12 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
June O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
he O O
developed O O
a O O
" O O
very O O
inflamed O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bad O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Eye O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
. O O
. O O
the O O
same O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Eye O B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
. O O
. O O
. O O

he O O
did O O
not O O
see O O
so O O
well O O
of O O
[ O O
as O O
] O B_OTHER/B_LOCATION
the O O
other O B_PERSON/B_LOCATION
. O O
. O O
. O O

He O O
sais O O
[ O B_LOCATION/B_PERSON
sic O I_LOCATION/I_PERSON
] O O
that O O
from O O
that O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Alone O O
he O O
can O O
Scarcely O O
distinguish O O
anything O B_PERSON/B_ORGANIZATION
" O O
. O O

The O O
doctors O B_PERSON
suggested O O
bathing O O
the O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
: O O
Lady O B_PERSON
Malton O I_PERSON
knew O O
that O O
the O O
" O B_DISEASE_ADJECTIVE[DISEASE]
frightful O I_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
" O I_DISEASE_ADJECTIVE[DISEASE]
which O O
were O O
" O O
shocking O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
behold O O
" O O
were O O
a O O
result O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
" O O
the O O
Same O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
as O O
produces O O
all O O
the O O
rest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
his O O
complaints O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
whichever O O
Shape O B_MEASURE/B_LOCATION
they O O
appear O O
" O O
. O O

30 O B_MEASURE
The O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
very O O
bloodshot O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
inflamed O O
; O O
the O O
eyelid O B_BODY_PART_OR_ORGAN_COMPONENT
was O O
swollen O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
so O O
he O O
could O O
hardly O O
open O O
it O O
. O O

The O O
other O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
eye O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
dull O B_DISEASE_ADJECTIVE[DISEASE]
and O O
" O O
he O O
had O O
very O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sight O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O O
it O O
" O O
. O O
31 O B_MEASURE
By O O
14 O B_TIME[MEASURE]
June O I_TIME[MEASURE]
the O O
eye O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
problem O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
had O O
eased O O
somewhat O O
but O O
Lady O B_PERSON
Malton O I_PERSON
could O O
find O O
no O O
cause O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
attribute O O
the O O
improvement O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
any O O
of O O
the O O
" O O
cures O B_PERSON/B_ORGANIZATION
" O I_PERSON/I_ORGANIZATION
. O O

Charles O O
was O O
still O O
being O O
subjected O O
to O O
Bristol O O
water O O
, O O
Beazor O O
mineral O O
, O O
Viper O O
broth O O
, O O
cinnabar O O
and O O
the O O
precipitate O O
per O O
se O O
. O O
32 O O
She O O
decided O O
to O O
take O O
the O O
boy B B_PERSON/B_BIO
home O O
to O O
Wentworth O O
because O O
he O O
was O O

26 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
38 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
1 O B_PERSON/B_LOCATION
June O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

27 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
39 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O I_PERSON/I_LOCATION
, O O
2 O B_PERSON/B_LOCATION
June O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

28 O B_MEASURE
WWM O I_MEASURE
, O O
M7 O B_MEASURE
- O O
41 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
5 O B_PERSON/B_LOCATION
June O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

29 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
43 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
7 O B_PERSON/B_LOCATION
June O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

30 O B_MEASURE
WWM O I_MEASURE
, O O
M7 O B_MEASURE
- O O
45 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
12 O B_PERSON/B_LOCATION
June O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

31 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
56 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON
Malton O I_PERSON
, O O
undated O B_TIME[MEASURE]/B_LOCATION
: O O
12 O B_TIME[MEASURE]/B_PERSON
June O B_TIME[MEASURE]/I_PERSON
? O O

1742 O B_NUMBER[MEASURE]
. O O

32 O B_MEASURE
WWM O I_MEASURE
, O O
M7 O B_MEASURE
- O O
46 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O I_PERSON/I_LOCATION
, O O
14 O B_TIME[MEASURE]/B_LOCATION
June O B_TIME[MEASURE]/I_LOCATION
? O O

1742 O B_NUMBER[MEASURE]
. O O

181 O B_NUMBER[MEASURE]

Marjorie O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Bloy O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]

more O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
recover O O
there O O
than O O
anywhere O O
else O O
. O O
33 O B_TIME[MEASURE]/B_LOCATION
He O O
still O O
ate O O
and O O
slept O O
well O O
and O O
was O O
" O O
pretty O O
cheerful O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O O
his O O
looks O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
are O O
bitter O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bad O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O O
. O O

The O O
flesh O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
he O O
lost O O
in O O
the O O
Accidental O B_TIME[MEASURE]/B_DISEASE
Feavour O I_TIME[MEASURE]/I_DISEASE
he O O
has O O
not O O
Recover O O
' O O
d O B_OTHER/B_DISEASE
and O O
his O O
complexion O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
of O O
the O O
most O O
sickly O O
sort O B_MEASURE/B_LOCATION
his O O
hands O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
of O O
the O O
same O B_PERSON/B_TIME[MEASURE]
Hue O B_PERSON/I_TIME[MEASURE]
his O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
are O O
tollerable O B_PERSON/B_LOCATION
[ O B_PERSON/I_LOCATION
sic O B_PERSON/I_LOCATION
] O O
well O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
. O O
34 O B_TIME[MEASURE]/B_PERSON

They O O
returned O O
to O O
Wentworth O B_TIME[MEASURE]/B_LOCATION
in O O
short O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
stages O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
6 O B_TIME[MEASURE]/B_PERSON
September O I_TIME[MEASURE]/I_PERSON
Higham O I_TIME[MEASURE]/I_PERSON
was O O
" O O
perfectly O O
recovered O O
. O O

. O O
. O O
after O O
the O O
long O O
and O O
successful O O
Care O O
that O O
Lady O O
Malton O O
has O O
taken O O
" O O
of O O
him O O
. O O
35 O O
In O O
May O O
1743 O O
he O O
was O O
inoculated O O
against O O
smallpox B B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
made O O
a O O
perfect O O
recovery O O
after O O
which O O
he O O
caught O O
cold O O
" O O
by O O
stripping O O
when O O
He O O
was O O
hot O O
" O O
. O O
36 O O
Lord O O
Higham O O
does O O
not O O
seem O O
to O O
have O O
been O O
seriously O O
ill O O
after O O
that O O
until O O
, O O
at O O
the O O
age O O
of O O
19 O O
, O O
he O O
undertook O O
his O O
Grand O O
Tour O O
in O O
1749 O O
. O O

In O O
July O B_TIME[MEASURE]/B_LOCATION
1750 O I_TIME[MEASURE]/I_LOCATION
, O O
by O O
then O O
Lord O B_TIME[MEASURE]/B_LOCATION
Malton O B_TIME[MEASURE]/I_LOCATION
, O O
he O O
had O O
cause O B_DISEASE/B_PERSON
to O O
consult O O
Nicolo O B_PERSON
Scanagati O I_PERSON
in O O
Padua O B_LOCATION
for O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
gonorrhoea O B_DISEASE/B_BIO
. O O

Scanagati O O
produced O O
a O O
lengthy O O
medical O O
report O O
of O O
Malton O O
' O O
s O O
treatment O O
, O O
presumably O O
for O O
his O O
English O O
doctor O O
' O O
s O O
enlightenment O O
. O O
37 O O
The O O
initial O O
treatment O O
was O O
an O O
" O O
electuary O O
, O O
consisting O O
of O O
three O O
ounces O O
of O O
emollient O O
, O O
three O O
drams O O
of O O
powdered O O
jalap B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
a O O
half O O
[ O O
dram O O
] O O
of O O
purified O O
nitre O O
, O O
bound O O
together O O
with O O
lemon B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
juice O O
taken O O
twice O O
a O O
day O O
" O O
. O O

The O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
satisfactory O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
" O O
The O O
dark O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
greenish O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poison O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
oozing O O
slowly O O
from O O
his O O
penis O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
which O O
was O O
all O O
contracted O O
and O O
the O O
sharp O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
constant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pain O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended O O
from O O
the O O
perineum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
up O O
to O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bladder O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
producing O O
small O B_DISEASE_ADJECTIVE[DISEASE]
swellings O I_DISEASE_ADJECTIVE[DISEASE]
now O O
in O O
this O O
place O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
now O O
in O O
that O O
. O O
" O O
There O O
was O O
a O O
fierce O B_DISEASE
burning O I_DISEASE
sensation O I_DISEASE
in O O
the O O
glands O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
which O O
prevented O O
him O O
from O O
sleeping O O
. O O

Because O O
of O O
this O O
, O O
it O O
seemed O O
reasonable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
bathe O O
that O O
part O B_TIME[MEASURE]/B_BIO
in O O
tepid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
milk O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
to O O
apply O O
poultices O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
areas O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affected O O
by O O
swelling O O
and O O
contractions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
together O O
with O O
cold O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
drinks O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
a O O
few O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
grains O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
laudanum O B_BIO
at O O
night O B_TIME[MEASURE]/B_LOCATION
. O O

Malton O B_PERSON
was O O
blooded O O
regularly O O
besides O O
being O O
given O O
purgatives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
then O O
moved O O
on O O
to O O
the O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
mercury O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
both O O
internal O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O O
on O O
the O O
gums O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
since O O
it O O
was O O
widely O O
believed O O
at O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
that O O
gonorrhoea O B_DISEASE/B_BIO
and O O
syphilis O B_DISEASE
were O O
steps O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
same O B_DISEASE/B_LOCATION
disease O I_DISEASE/I_LOCATION
, O O
" O O
the O O
Venereal O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
" O B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O O

Scanagati O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
at O O
this O O
point O B_LOCATION
ruled O O
out O O
the O O
suggestion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
syphilitic O B_DISEASE
chancre O I_DISEASE
because O O
Malton O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
urine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
fine O B_PERSON/B_COLOR
and O O
light O B_COLOR/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
pungent O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
odour O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Scanagati O B_PERSON
did O O
ask O O
if O O
Malton O B_PERSON
had O O
previously O O
ever O O
had O O
a O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peculiarity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
his O O
urine O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
. O O

Malton O B_PERSON
replied O O
that O O
when O O
he O O
was O O
very O O
young O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
still O O
inexperienced O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sexually O O
, O O
for O O
some O O
time O B_TIME[MEASURE]
following O O
a O O
fever O B_DISEASE/B_TIME[MEASURE]
he O O
had O O
had O O
the O O
same O B_DISEASE
unusual O I_DISEASE
urine O I_DISEASE
, O O
and O O
indeed O O
that O O
on O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occasion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O O
symptom O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coincided O O
with O O
certain O B_DISEASE
tumours O I_DISEASE
on O O
the O O
testicles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
was O O
only O O
by O O
chance O B_PERSON/B_TIME[MEASURE]
that O O
he O O
had O O
not O O
had O O
recourse O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
, O O
the O O
reason O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
being O O
that O O
he O O
was O O
also O O
afflicted O O
with O O
a O O
throat O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infection O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
to O O
which O O
he O O
was O O
prone O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
and O O
therefore O O
had O O
his O O
vein O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
opened O O
four O B_TIME[MEASURE]/B_ENT
times O I_TIME[MEASURE]/I_ENT
. O O

Thereupon O O
the O O
inflammation O B_DISEASE/B_BACTERIUM[BIO]
subsided O O
, O O
and O O
equally O O
the O O
tumours O B_DISEASE
and O O
sediment O B_DISEASE/B_BIO
disappeared O O
. O O

He O O
told O O
me O O
that O O
as O O
a O O
youth O B_PERSON
he O O
had O O
sometimes O O
experienced O O
some O O
difficulty O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
burning O O
sensation O B_DISEASE
when O O
urinating O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
which O O
subsided O O
when O O
his O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
let O O
and O O
with O O
the O O
application O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
poultices O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

I O O
observed O O
that O O
from O O
time O B_TIME[MEASURE]/B_LOCATION
to O O
time O B_TIME[MEASURE]/B_LOCATION
his O O
face O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
body O B_BODY_PART_OR_ORGAN_COMPONENT
were O O
covered O O
with O O
purplish O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spots O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
which O O
, O O
having O O
produced O O
a O O
little O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
fluid O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
would O O
disappearas O O
indeed O O
happened O O
in O O
the O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
the O O
cure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
, O O
at O O
the O O
end O B_LOCATION/B_MEASURE
of O O
which O O
his O O
face O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
entirely O O

33 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
47 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
15 O B_PERSON/B_LOCATION
June O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

34 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M7 O B_MEASURE
- O O
48 O B_MEASURE
. O O

Lady O B_PERSON
to O O
Lord O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
16 O B_PERSON/B_LOCATION
June O B_PERSON/I_LOCATION
1742 O B_PERSON/I_LOCATION
. O O

35 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M2 O B_MEASURE/B_PROTEIN[GENE]
- O O
104 O B_MEASURE
/ O O
5 O B_MEASURE
. O O

Lady O B_PERSON
Finch O I_PERSON
to O O
Lady O B_PERSON/B_LOCATION
Malton O B_PERSON/I_LOCATION
, O O
6 O B_PERSON/B_LOCATION
September O I_PERSON/I_LOCATION
1742 O I_PERSON/I_LOCATION
. O O

36 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
M2 O B_MEASURE
- O O
135 O B_MEASURE
. O O

Lady O B_PERSON
Finch O I_PERSON
to O O
Malton O B_LOCATION/B_PERSON
, O O
18 O B_LOCATION/B_PERSON
June O I_LOCATION/I_PERSON
1742 O I_LOCATION/I_PERSON
. O O

37 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
R170 O B_MEASURE/B_LOCATION
- O O
20 O B_MEASURE
. O O

Nicol6 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Scanagati O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

182 O B_NUMBER[MEASURE]

An O O
eighteenth O B_SEQUENCE[MEASURE]
- O O
century O B_PERSON
Prime O I_PERSON
Minister O I_PERSON
' O O
s O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
illness O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION

free O B_MEASURE/B_LOCATION
from O O
these O O
spots O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
this O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
it O O
seemed O O
to O O
me O O
simple O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
deduce O O
both O O
the O O
original O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cause O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
the O O
more O O
immediate O B_DISEASE_ADJECTIVE[DISEASE]
cause O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
said O O
sediment O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
: O O
namely O O
a O O
natural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
humours O B_DISEASE_ADJECTIVE[DISEASE]
which O O
are O O
exacerbated O O
by O O
muriatic O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
[ O O
i O O
. O O
e O O
. O O
, O O
acidic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sourness O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
together O O
with O O
the O O
marked O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inflammation O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
motion O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
contracted O O
poison O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Scanagati O O
then O O
recommended O O
the O O
continuation O O
of O O
the O O
electuary O O
made O O
of O O
emollient O O
, O O
guaiacum O O
resin O O
, O O
balsam O O
, O O
rhubarb B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
nitre O O
. O O

What O O
does O O
all O O
this O O
add O O
up O O
to O O
in O O
terms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
? O O

The O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
illness O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
mystery O B_DISEASE
. O O

Did O O
he O O
have O O
an O O
inguinal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hernia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
; O O
or O O
perhaps O O
mumps O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
epididymitis O B_DISEASE
? O O

His O O
was O O
a O O
childless O B_PERSON
marriage O I_PERSON
. O O

He O O
seems O O
to O O
have O O
been O O
too O O
fit O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
illness O B_DISEASE/B_PERSON
to O O
have O O
been O O
rheumatic O B_DISEASE_ADJECTIVE[DISEASE]
fever O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cystitis O B_DISEASE
was O O
not O O
uncommon O B_DISEASE_ADJECTIVE[DISEASE]
and O O
this O O
could O O
certainly O O
lead O O
to O O
" O O
strangury O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
" O O
. O O

Perhaps O O
Rockingham O B_PERSON/B_LOCATION
suffered O O
from O O
a O O
congenital O B_DISEASE_ADJECTIVE[DISEASE]
defect O I_DISEASE_ADJECTIVE[DISEASE]
of O O
his O O
urinogenitary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
which O O
would O O
result O O
in O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]
attacks O I_DISEASE_ADJECTIVE[DISEASE]
of O O
cystitis O B_DISEASE
and O O
might O O
cause O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
eventual O B_DISEASE
destruction O I_DISEASE
of O O
the O O
kidneys O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
precipitating O O
sudden O B_DISEASE
and O O
unexpected O B_DISEASE_ADJECTIVE[DISEASE]
death O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Another O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
be O O
diabetes O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Rockingham O B_PERSON/B_LOCATION
had O O
a O O
urinary O B_DISEASE/B_PERSON
infection O I_DISEASE/I_PERSON
and O O
certainly O O
suffered O O
from O O
recurrent O B_DISEASE
skin O I_DISEASE
infections O I_DISEASE
, O O
although O O
it O O
appears O O
from O O
Scanagati O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
these O O
cleared O O
up O O
when O O
mercury O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
. O O

Certainly O O
the O O
marquis O B_PERSON
complained O O
often O O
about O O
pains O B_DISEASE
in O O
his O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
stomach O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
made O O
no O O
secret O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
his O O
" O O
old O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
complaint O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
" O O
. O O

He O O
was O O
noticeably O O
less O O
physically O O
active O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
he O O
moved O O
into O O
his O O
thirties O B_LOCATION/B_ENT
and O O
only O O
occasionally O O
exerted O O
himself O O
by O O
riding O O
any O O
distance O B_TIME[MEASURE]/B_LOCATION
, O O
even O O
though O O
he O O
had O O
enjoyed O O
hunting O B_PERSON/B_SPORT[ENT]
when O O
he O O
was O O
younger O B_NUMBER[MEASURE]/B_PERSON
. O O

He O O
found O O
the O O
pains O B_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
his O O
" O B_DISEASE/B_PERSON
old O B_DISEASE/I_PERSON
complaint O B_DISEASE/I_PERSON
" O O
made O O
him O O
feel O O
so O O
ill O B_DISEASE_ADJECTIVE[DISEASE]
that O O
he O O
was O O
unable O B_PERSON/B_TIME[MEASURE]
to O O
concentrate O O
on O O
" O O
any O O
Manner O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Business O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
and O O
on O O
occasion O B_TIME[MEASURE]/B_PERSON
it O O
seemed O O
likely O B_DISEASE_ADJECTIVE[DISEASE]
to O O
prevent O O
him O O
from O O
attending O O
Parliament O B_ORGANIZATION/B_PERSON
. O O
38 O B_MEASURE
He O O
may O O
well O O
have O O
suffered O O
from O O
a O O
problem O B_TIME[MEASURE]/B_DISEASE
with O O
gallstones O B_DISEASE/B_LOCATION
from O O
an O O
early O B_DISEASE
age O I_DISEASE
. O O
39 O B_MEASURE
He O O
appears O O
to O O
have O O
suffered O O
from O O
a O O
nervous O B_DISEASE
disorder O I_DISEASE
which O O
manifested O O
itself O O
in O O
severe O B_DISEASE
palpitations O I_DISEASE
, O O
trembling O B_DISEASE
, O O
and O O
other O B_DISEASE
types O I_DISEASE
of O O
physical O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discomforts O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
boils O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
headaches O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
with O O
which O O
he O O
was O O
frequently O O
afflicted O O
. O O
40 O B_MEASURE
He O O
probably O O
had O O
constipation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
too O O
, O O
since O O
he O O
was O O
always O O
dosing O O
himself O O
with O O
purgatives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
fact O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
April O B_TIME[MEASURE]
1772 O I_TIME[MEASURE]
the O O
Duke O B_PERSON/B_LOCATION
of O O
Richmond O B_LOCATION
decided O O
that O O
Rockingham O B_PERSON/B_ENT
' O I_PERSON/I_ENT
s O I_PERSON/I_ENT
real O I_PERSON/I_ENT
problem O I_PERSON/I_ENT
was O O
a O O
" O O
surfeit O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
physick O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
41 O B_TIME[MEASURE]/B_LOCATION
although O O
Edmund O B_PERSON/B_LOCATION
Burke O I_PERSON/I_LOCATION
noted O O
in O O
June O B_MEASURE/B_ENT
1772 O I_MEASURE/I_ENT
that O O
the O O
marquis O B_PERSON
had O O
had O O
a O O
long O B_DISEASE_ADJECTIVE[DISEASE]
and O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
illness O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O O
42 O B_MEASURE
Whatever O O
his O O
many O B_NUMBER[MEASURE]/B_DISEASE
and O O
varied O B_NUMBER[MEASURE]/B_PERSON
ailments O I_NUMBER[MEASURE]/I_PERSON
, O O
Rockingham O B_LOCATION/B_PERSON
survived O O
until O O
he O O
was O O
52 O B_NUMBER[MEASURE]
in O O
spite O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
attentions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
doctors O B_PERSON/B_BIO
and O O
quacks O B_PERSON
and O O
that O O
, O O
for O O
the O O
mid O B_SEQUENCE[MEASURE]/B_LOCATION
- O O
eighteenth O B_TIME[MEASURE]/B_ENT
century O I_TIME[MEASURE]/I_ENT
, O O
was O O
a O O
good O B_PERSON
age O I_PERSON
. O O

The O O
mystery O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O O
remains O O
, O O
however O O
. O O

Contemporary O B_PERSON
opinion O I_PERSON
had O O
it O O
that O O
he O O
died O O
of O O
pneumonia O B_DISEASE/B_PERSON
but O O
it O O
must O O
have O O
struck O O

38 O B_MEASURE/B_PERSON
WWM O I_MEASURE/I_PERSON
, O O
R153 O B_MEASURE/B_DISEASE
- O O
1 O B_MEASURE
. O O

Rockingham O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Burke O B_PERSON/B_LOCATION
, O O
31 O B_LOCATION/B_PERSON
October O I_LOCATION/I_PERSON
1767 O I_LOCATION/I_PERSON
; O O
WWM O B_LOCATION/B_PERSON
, O O
RI O B_MEASURE
- O O
1238 O B_MEASURE/B_LOCATION
. O O

Rockingham O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Dowdeswell O B_LOCATION
, O O
20 O B_LOCATION/B_PERSON
October O I_LOCATION/I_PERSON
1769 O I_LOCATION/I_PERSON
; O O
WWM O O
, O O
RI O B_MEASURE
- O O
1928 O B_MEASURE/B_LOCATION
. O O

Rockingham O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Savile O B_LOCATION/B_PERSON
, O O
September O B_LOCATION/B_ENT
1780 O I_LOCATION/I_ENT
. O O

39 O B_PERSON/B_MEASURE
Ross O I_PERSON/I_MEASURE
J O I_PERSON/I_MEASURE
. O O

S O B_OTHER/B_DISEASE
. O O

Hoffman O B_PERSON/B_LOCATION
, O O
The O O
Marquis O B_PERSON/B_LOCATION
. O O

A O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
Lord O B_PERSON/B_LOCATION
Rockingham O B_PERSON/I_LOCATION
, O O
1730 O B_MEASURE
- O O
1782 O B_MEASURE
, O O
New O B_LOCATION/B_PERSON
York O I_LOCATION/I_PERSON
, O O
Fordham O B_LOCATION/B_PERSON
University O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
, O O
1973 O B_MEASURE
, O O
p O B_OTHER/B_LOCATION
. O O

35 O B_NUMBER[MEASURE]
. O O

This O O
is O O
the O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
recent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
biography O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
second O B_PERSON
Marquis O I_PERSON
of O O
Rockingham O B_LOCATION/B_PERSON
, O O
and O O
does O O
not O O
deal O O
with O O
his O O
illnesses O B_PERSON
. O O

Although O O
he O O
does O O
not O O
give O O
the O O
source O B_PERSON/B_LOCATION
of O O
his O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
Hoffman O B_PERSON/B_LOCATION
asserts O O
that O O
Rockingham O B_PERSON/B_LOCATION
was O O
in O O
Bath O B_LOCATION
between O O
March O B_TIME[MEASURE]/B_LOCATION
and O O
August O B_TIME[MEASURE]/B_PERSON
1761 O I_TIME[MEASURE]/I_PERSON
suffering O O
from O O
gallstones O B_DISEASE
. O O

The O O
marquis O B_PERSON
would O O
then O O
have O O
been O O
31 O B_ENT/B_TIME[MEASURE]
years O B_ENT/I_TIME[MEASURE]
old O B_ENT/I_TIME[MEASURE]
. O O

40 O B_MEASURE/B_LOCATION
Historical O I_MEASURE/I_LOCATION
Manuscripts O I_MEASURE/I_LOCATION
Commission O I_MEASURE/I_LOCATION
, O O
Lindley O B_MEASURE/B_LOCATION
Wood O I_MEASURE/I_LOCATION
, O O
p O B_OTHER/B_LOCATION
. O O

184 O B_NUMBER[MEASURE]
. O O

41 O B_LOCATION/B_PERSON
WWM O I_LOCATION/I_PERSON
, O O
RI O B_MEASURE/B_PROTEIN[GENE]
- O O
1403 O B_MEASURE/B_LOCATION
. O O

Richmond O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O O
Rockingham O B_LOCATION
, O O
26 O B_LOCATION/B_PERSON
April O I_LOCATION/I_PERSON
1772 O I_LOCATION/I_PERSON
. O O

42 O B_PERSON
Burke O I_PERSON
to O O
James O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
de O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lancey O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
30 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
June O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1772 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
correspondence O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Edmund O B_PERSON/B_LOCATION
Burke O B_PERSON/I_LOCATION
, O O
vol O B_LOCATION/B_MEASURE
. O O

2 O B_TIME[MEASURE]/B_PERSON
, O O
ed O O
. O O

T O B_OTHER/B_GENE
. O O

W O B_OTHER/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Copeland O B_PERSON
and O O
others O B_PERSON
, O O
Cambridge O B_PERSON/B_LOCATION
University O B_PERSON/I_LOCATION
Press O B_PERSON/I_LOCATION
, O O
1958 O B_MEASURE
- O O
1978 O B_MEASURE
, O O
p O B_OTHER/B_MEASURE
. O O

311 O B_NUMBER[MEASURE]
. O O

183 O B_NUMBER[MEASURE]

Marjorie O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Bloy O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]

suddenly O O
: O O
it O O
was O O
only O O
two O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
from O O
him O O
" O O
recovering O O
" O O
to O O
dying O O
. O O

Another O O
almost O O
contemporary O B_TIME[MEASURE]/B_PERSON
account O B_TIME[MEASURE]/I_PERSON
of O O
the O O
marquis O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
s O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
death O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
came O O
from O O
the O O
Earl O B_PERSON/B_LOCATION
of O O
Albemarle O B_LOCATION
. O O

He O O
noted O O
that O O
Rockingham O B_PERSON/B_LOCATION
had O O
" O O
for O O
some O O
time O B_TIME[MEASURE]
past O O
been O O
afflicted O O
with O O
water O B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
chest O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
: O O
and O O
to O O
this O O
well O O
- O O
known O O
malady O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
was O O
superadded O O
the O O
then O O
novel O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
of O O
influenza O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
" O O
. O O
43 O B_MEASURE
This O O
conceivably O O
could O O
be O O
an O O
uninformed O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
account O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
handed O O
down O O
orally O O
by O O
surviving O O
members O B_PERSON
of O O
the O O
marquis O B_ORGANIZATION/B_PERSON
' O I_ORGANIZATION/I_PERSON
s O I_ORGANIZATION/I_PERSON
family O I_ORGANIZATION/I_PERSON
, O O
of O O
emphysema O B_DISEASE
. O O

More O O
fascinating O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
cause O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
death O B_DISEASE
, O O
however O O
, O O
is O O
- O O
what O O
was O O
wrong O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
him O O
during O O
his O O
lifetime O B_TIME[MEASURE]/B_PERSON
? O O

Or O O
is O O
it O O
yet O O
another O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
" O B_DISEASE/B_PERSON
English O I_DISEASE/I_PERSON
disease O I_DISEASE/I_PERSON
" O O
: O O
hypochondria O B_DISEASE/B_LOCATION
? O O

43Albemarle O O
, O O
George O B_PERSON
Thomas O I_PERSON
, O O
Earl O B_PERSON
of O O
, O O
Memoirs O B_TIME[MEASURE]/B_PERSON
of O O
the O O
Marquis O B_PERSON
of O O
Rockingham O B_LOCATION
and O O
his O O
contemporaries O B_PERSON/B_LOCATION
, O O
London O B_LOCATION/B_PERSON
, O O
Richard O B_MEASURE/B_LOCATION
Bentley O I_MEASURE/I_LOCATION
, O O
2 O B_TIME[MEASURE]/B_LOCATION
vols O B_TIME[MEASURE]/I_LOCATION
. O O
, O O
1852 O B_MEASURE
, O O
vol O B_GENE/B_LOCATION
. O O

2 O B_NUMBER[MEASURE]
, O O
p O O
. O O

483 O B_NUMBER[MEASURE]
. O O

This O O
is O O
the O O
only O B_TIME[MEASURE]/B_ENT
contemporary O I_TIME[MEASURE]/I_ENT
work O I_TIME[MEASURE]/I_ENT
concerning O O
Rockingham O B_PERSON/B_LOCATION
, O O
but O O
does O O
not O O
mention O O
his O O
early O B_DISEASE_ADJECTIVE[DISEASE]
life O I_DISEASE_ADJECTIVE[DISEASE]
and O O
illnesses O B_DISEASE/B_PERSON
. O O

184 O B_NUMBER[MEASURE]

Tissue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
mammalian O B_GENE/B_BIO
Fox O I_GENE/I_BIO
- O O
1 O B_PROTEIN[GENE]/B_MEASURE
homologs O I_PROTEIN[GENE]/I_MEASURE
are O O
associated O O
with O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_DISEASE_ADJECTIVE[DISEASE]
activities O I_DISEASE_ADJECTIVE[DISEASE]

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

An O O
intronic O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hexanucleotide O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
UGCAUG O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
shown O O
to O O
play O O
a O O
critical O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
regulation O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
wide O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
of O O
tissues O B_DISEASE/B_BIO
. O O

Vertebrate O B_PROTEIN[GENE]/B_BIO
Fox O I_PROTEIN[GENE]/I_BIO
- O O
1 O B_MEASURE
has O O
been O O
shown O O
to O O
bind O O
to O O
this O O
element O B_GENE/B_LOCATION
, O O
in O O
a O O
highly O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
through O O
its O O
RNA O B_GENE/B_TIME[MEASURE]
recognition O I_GENE/I_TIME[MEASURE]
motif O I_GENE/I_TIME[MEASURE]
( O O
RRM O B_DISEASE/B_GENE
) O O
. O O

In O O
mammals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
there O O
are O O
at O O
least O O
two O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fox O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
- O O
related O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ataxin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_PROTEIN[GENE]/B_MEASURE
binding O I_PROTEIN[GENE]/I_MEASURE
protein O I_PROTEIN[GENE]/I_MEASURE
1 O I_PROTEIN[GENE]/I_MEASURE
( O O
A2BP1 O B_GENE/B_DISEASE
) O O
/ O O
Fox O B_GENE/B_BIO
- O O
1 O B_NUMBER[MEASURE]
and O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Rbm9 O B_GENE
, O O
which O O
encode O O
an O O
identical O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RRM O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
both O O
mouse B B_SPECIES[BIO]/B_DISEASE
Fxh O O
and O O
A2BP1 O O
transcripts O O
undergo O O
tissue O O
- O O
specific O O
alternative O O
splicing O O
, O O
generating O O
protein O O
isoforms O O
specific O O
to O O
brain O O
and O O
muscle O O
. O O

These O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
characterized O O
for O O
their O O
abilities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
regulate O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- O O
specific O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
cassette O B_GENE
exon O I_GENE
, O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
in O O
the O O
non O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
muscle O B_GENE/B_DISEASE
myosin O I_GENE/I_DISEASE
heavy O I_GENE/I_DISEASE
chain O I_GENE/I_DISEASE
II O I_GENE/I_DISEASE
- O O
B O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mRNA O B_GENE
, O O
previously O O
shown O O
to O O
be O O
regulated O O
through O O
an O O
intronic O B_PROTEIN[GENE]
distal O I_PROTEIN[GENE]
downstream O I_PROTEIN[GENE]
enhancer O I_PROTEIN[GENE]
( O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

All O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_NUMBER[MEASURE]/B_LOCATION
isoforms O B_NUMBER[MEASURE]/I_LOCATION
with O O
the O O
RRM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
capable O B_PERSON
of O O
binding O O
to O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
through O O
the O O
UGCAUG O B_GENE/B_BIO
elements O I_GENE/I_BIO
. O O

Each O O
isoform O B_GENE/B_LOCATION
, O O
however O O
, O O
shows O O
quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
splicing O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
nuclear O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distribution O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
transfected O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

All O O
Fxh O B_GENE/B_BIO
isoforms O I_GENE/I_BIO
and O O
a O O
brain O B_GENE/B_MEASURE
isoform O I_GENE/I_MEASURE
of O O
A2BP1 O B_GENE
show O O
a O O
predominant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localization O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Brain O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
isoforms O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
both O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
promote O O
N30 O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
splicing O B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
much O O
more O O
efficiently O O
than O O
do O O
the O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
isoforms O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Skeletal O B_PERSON
muscles O I_PERSON
express O O
additional O B_GENE
isoforms O I_GENE
that O O
lack O O
a O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
RRM O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
isoforms O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
incapable O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
activating O O
neural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
specific O B_GENE/B_DISEASE
splicing O I_GENE/I_DISEASE
and O O
, O O
moreover O O
, O O
can O O
inhibit O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
N30 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
play O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
determining O O
tissue O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
alternative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

INTRODUCTION O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Alternative O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
splicing O B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
pre O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mRNA O B_GENE
is O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
fundamental O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
for O O
the O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
higher O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
eukaryotes O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O B_NUMBER[MEASURE]
, O O
2 O B_MEASURE
) O O
. O O

Developmentally O O
regulated O O
, O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
type O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
- O O
or O O
tissue O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
signal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
alternative O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
takes O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
in O O
multicellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
organisms O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
throughout O O
their O O
lifetimes O B_TIME[MEASURE]/B_LOCATION
. O O

Misregulation O O
or O O
abnormalities O O
in O O
pre O O
- O O
mRNA O O
splicing O O
, O O
in O O
some O O
instances O O
, O O
leads O O
to O O
cellular O O
dysfunctions O O
found O O
in O O
human B B_PERSON/B_SPECIES[BIO]
and O O
animal O O
diseases O O
( O O
3 O O
- O O
5 O O
) O O
. O O

Using O O
various O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
regulated O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alternative O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
number O B_MEASURE/B_LOCATION
of O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mRNA O B_GENE/B_LOCATION
features O I_GENE/I_LOCATION
that O O
influence O O
alternative O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
splice O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
site O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
selection O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
have O O
been O O
defined O O
( O O
1 O B_NUMBER[MEASURE]
, O O
2 O B_MEASURE
) O O
. O O

These O O
include O O
enhancer O B_GENE/B_PERSON
and O O
repressor O B_GENE/B_MEASURE
RNA O I_GENE/I_MEASURE
sequences O I_GENE/I_MEASURE
located O O
in O O
exons O B_GENE/B_LOCATION
and O O
introns O B_GENE/B_LOCATION
. O O

Identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
RNA O B_GENE/B_BIO
- O O
binding O O
proteins O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
targeting O O
these O O
cis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
regulatory O B_GENE/B_LOCATION
elements O I_GENE/I_LOCATION
is O O
currently O O
in O O
progress O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
vertebrates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
participation O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
SR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
family O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
hnRNP O B_GENE/B_BIO
proteins O I_GENE/I_BIO
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
PTB O B_GENE/B_DISEASE
and O O
hnRNPA1 O B_PROTEIN[GENE]/B_DISEASE
, O O
in O O
alternative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
via O O
binding O O
to O O
the O O
cis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
regulatory O B_GENE
elements O I_GENE
have O O
been O O
shown O O
in O O
many O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O O
specific O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
splicing O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
models O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
6 O B_NUMBER[MEASURE]
, O O
7 O B_MEASURE
) O O
. O O

Although O O
these O O
RNA O B_GENE/B_BIO
- O O
binding O O
proteins O B_LOCATION/B_PROTEIN[GENE]
are O O
ubiquitously O O
expressed O O
, O O
their O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abundance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
different O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
their O O
post O B_DISEASE
- O O
translational O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifications O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
contexts O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
their O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abilities O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
assemble O O
multiprotein O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
complexes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
different O B_DISEASE/B_GENE
pre O B_DISEASE/I_GENE
- O O
mRNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contexts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
thought O O
to O O
contribute O O
to O O
the O O
determination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
cell O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
type O I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alternative O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
the O O
last O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
few O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
years O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
enriched O O
RNA O B_GENE/B_BIO
- O O
binding O O
proteins O B_LOCATION/B_PROTEIN[GENE]
have O O
begun O O
to O O
be O O
identified O O
as O O
splicing O B_GENE/B_PERSON
regulators O I_GENE/I_PERSON
. O O

These O O
include O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
or O O
enriched O O
) O O
Nova O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
, O O
nPTB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
brPTB O B_MEASURE
) O O
and O O
some O O
of O O
the O O
CELF O B_MEASURE/B_GENE
family O I_MEASURE/I_GENE
proteins O I_MEASURE/I_GENE
( O O
8 O B_MEASURE/B_LOCATION
- O O
12 O B_MEASURE
) O O
. O O

Discovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
proteins O B_LOCATION/B_GENE
has O O
had O O
a O O
great O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
impact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
aimed O O
at O O
understanding O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alternative O B_DISEASE/B_GENE
splicing O I_DISEASE/I_GENE
regulation O I_DISEASE/I_GENE
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
intronic O B_PROTEIN[GENE]/B_DISEASE
cis O I_PROTEIN[GENE]/I_DISEASE
- O O
elements O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
are O O
involved O O
in O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
differentiation O B_GENE/B_DISEASE
stage O I_GENE/I_DISEASE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
alternative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
the O O
hexanucleotide O B_GENE
UGCAUG O I_GENE
. O O

The O O
importance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
element O B_LOCATION
was O O
originally O O
recognized O O
in O O
fibronectin O B_PROTEIN[GENE]/B_DISEASE
pre O I_PROTEIN[GENE]/I_DISEASE
- O O
mRNA O B_GENE
by O O
Huh O B_PERSON
and O O
Hynes O B_PERSON
( O O
13 O B_MEASURE
) O O
. O O

Since O O
then O O
, O O
alternative O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
splicing O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
specific O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
a O O
variety O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tissues O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
or O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
including O O
neural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
muscles O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
epithelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
erythrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
has O O
been O O
shown O O
to O O
be O O
modulated O O
via O O
this O O
element O B_GENE/B_LOCATION
( O O
14 O B_MEASURE/B_LOCATION
- O O
21 O B_MEASURE
) O O
. O O

Recently O O
, O O
Jin O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O I_PERSON/I_LOCATION
. O O

( O O
21 O O
) O O
discovered O O
that O O
a O O
zebrafish B B_SPECIES[BIO]
homolog O O
of O O
Caenorhabditis B B_SPECIES[BIO]/B_PROTEIN[GENE]
elegans I B_SPECIES[BIO]/I_PROTEIN[GENE]
Fox O O
- O O
1 O O
( O O
22 O O
) O O
could O O
bind O O
specifically O O
to O O
the O O
pentanucleotide O O
GCAUG O O
by O O
in O O
vitro O O
selection O O
from O O
randomized O O
RNA O O
sequences O O
. O O

This O O
pentanucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
almost O O
identical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
the O O
hexanucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
UGCAUG O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
except O O
for O O
the O O
first O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Moreover O O
, O O
the O O
zebrafish B B_SPECIES[BIO]
Fox O O
- O O
1 O O
homolog O O
, O O
as O O
well O O
as O O
the O O
mouse B B_SPECIES[BIO]/B_DISEASE
Fox O O
- O O
1 O O
homolog O O
, O O
are O O
capable O O
of O O
repressing O O
the O O
inclusion O O
of O O
an O O
alternative O O
cassette O O
exon O O
of O O
the O O
ATP O O
synthase O O
F1 O O
gamma O O
pre O O
- O O
mRNA O O
via O O
binding O O
to O O
GCAUG O O
, O O
which O O
mimics O O
muscle O O
- O O
specific O O
exclusion O O
of O O
this O O
exon O O
. O O

This O O
mouse B B_SPECIES[BIO]/B_DISEASE
homolog O O
is O O
identical O O
to O O
the O O
ataxin O O
- O O
2 O O
binding O O
protein O O
1 O O
( O O
A2BP1 O O
) O O
, O O
which O O
has O O
been O O
previously O O
cloned O O
in O O
humans B B_SPECIES[BIO]
and O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
cDNA O O
encoding O O
a O O
protein O O
, O O
which O O
interacts O O
with O O
ataxin O O
- O O
2 O O
, O O
the O O
product O O
of O O
the O O
causative O O
gene O O
for O O
spinocerebellar O O
ataxia O O
type O O
2 O O
( O O
23 O O
, O O
24 O O
) O O
. O O

In O O
addition O O
to O O
A2BP1 O O
/ O O
Fox O O
- O O
1 O O
, O O
another O O
mouse B B_SPECIES[BIO]/B_DISEASE
homolog O O
of O O
C B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
elegans I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
Fox O O
- O O
1 O O
, O O
Fxh O O
, O O
has O O
been O O
independently O O
cloned O O
as O O
a O O
cDNA O O
, O O
which O O
is O O
induced O O
by O O
androgen O O
in O O
motor O O
neurons O O
( O O
25 O O
) O O
. O O

Of O O
note O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
that O O
A2BP1 O B_GENE/B_LOCATION
/ O O
Fox O B_GENE/B_BIO
- O O
1 O B_NUMBER[MEASURE]
and O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
share O O
an O O
identical O B_GENE/B_MEASURE
RNA O I_GENE/I_MEASURE
recognition O I_GENE/I_MEASURE
motif O I_GENE/I_MEASURE
( O O
RRM O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
at O O
the O O
amino O B_MEASURE/B_GENE
acid O B_MEASURE/I_GENE
level O B_MEASURE/I_GENE
. O O

Therefore O O
, O O
two O O
genes O O
in O O
the O O
mouse B B_SPECIES[BIO]/B_DISEASE
genome O O
encode O O
homologs O O
of O O
nematode O O
Fox O O
- O O
1 O O
. O O

According O O
to O O
the O O
names O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
given O O
by O O
the O O
first O B_PERSON/B_ORGANIZATION
cDNA O I_PERSON/I_ORGANIZATION
cloning O I_PERSON/I_ORGANIZATION
, O O
we O O
used O O
the O O
nomenclature O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
A2BP1 O B_GENE/B_LOCATION
and O O
Fxh O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

A2BP1 O O
and O O
Fxh O O
have O O
been O O
named O O
A2BP1 O O
and O O
Rbm9 O O
, O O
respectively O O
, O O
in O O
the O O
human B B_SPECIES[BIO]
and O O
mouse B B_SPECIES[BIO]/B_DISEASE
genomes O O
. O O

We O O
have O O
been O O
studying O O
regulatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanisms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- O O
specific O B_DISEASE/B_ORGANISM_FUNCTION
alternative O I_DISEASE/I_ORGANISM_FUNCTION
splicing O I_DISEASE/I_ORGANISM_FUNCTION
using O O
the O O
non O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
muscle O B_GENE
myosin O I_GENE
heavy O I_GENE
chain O I_GENE
II O I_GENE
- O O
B O B_PROTEIN[GENE]/B_DISEASE
( O O
NMHC O B_MEASURE/B_DISEASE
- O O
B O B_PROTEIN[GENE]/B_DISEASE
) O O
gene O B_GENE/B_LOCATION
as O O
a O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
14 O B_MEASURE
, O O
26 O B_MEASURE
) O O
. O O

NMHC O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
B O B_PROTEIN[GENE]/B_MEASURE
mRNA O I_PROTEIN[GENE]/I_MEASURE
is O O
expressed O O
ubiquitously O O
. O O

However O O
, O O
an O O
alternative O B_GENE
exon O I_GENE
, O O
N30 O B_MEASURE/B_LOCATION
, O O
which O O
encodes O O
a O O
30 O B_GENE
nt O I_GENE
coding O I_GENE
sequence O I_GENE
, O O
is O O
included O O
in O O
the O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O O
some O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
is O O
skipped O O
in O O
those O O
from O O
all O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
in O O
mammals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
birds O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
27 O B_MEASURE
, O O
28 O B_MEASURE
) O O
. O O

In O O
cultured O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O O
a O O
switch O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
exclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
to O O
inclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
be O O
seen O O
in O O
neural O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
retinoblastoma O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Y79 O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
post O B_DISEASE
- O O
mitotic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
differentiated O O
stages O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
triggered O O
by O O
butyrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
have O O
previously O O
defined O O
an O O
intronic O B_PROTEIN[GENE]
distal O I_PROTEIN[GENE]
downstream O I_PROTEIN[GENE]
enhancer O I_PROTEIN[GENE]
( O O
IDDE O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
which O O
confers O O
neural O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
using O O
this O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
line O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
14 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

The O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
includes O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
copies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
UGCAUG O B_PERSON/B_ENT
. O O

Mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
these O O
hexanucleotides O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
skipping O O
in O O
post O B_DISEASE/B_LOCATION
- O O
mitotic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
differentiated O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
investigated O O
the O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
involvement O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O O
A2BP1 O B_GENE
and O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
N30 O B_DISEASE/B_GENE
splicing O I_DISEASE/I_GENE
. O O

To O O
this O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
we O O
have O O
isolated O O
cDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
A2BP1 O B_GENE
and O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
muscles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

cDNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cloning O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
enriched O O
) O O
isoforms O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
A2BP1 O B_GENE
and O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Of O O
importance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
isoforms O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O O
A2BP1 O B_GENE
and O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
respect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
subcellular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
localizations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O O

MATERIALS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Database O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disposition O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE

The O O
sequences O B_DISEASE/B_GENE
reported O O
in O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
have O O
been O O
deposited O O
in O O
the O O
GenBank O B_LOCATION/B_ORGANIZATION
database O I_LOCATION/I_ORGANIZATION
with O O
accession O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
numbers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
AY659951 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
AY659952 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
F411 O B_PROTEIN[GENE]
) O O
, O O
AY659953 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
F402 O B_PROTEIN[GENE]
) O O
, O O
AY659954 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
AY659955 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A030 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
AY659956 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A713 O B_PROTEIN[GENE]
) O O
, O O
AY659957 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A715 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
AY659958 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
A704 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

RNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
preparation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE

Total O O
RNAs O O
were O O
isolated O O
from O O
mouse B B_BIO/B_DISEASE
tissues O O
and O O
cultured O O
cells O O
using O O
an O O
RNA O O
isolation O O
kit O O
( O O
Stratagene O O
) O O
or O O
an O O
RNeasy O O
mini O O
kit O O
( O O
Qiagen O O
) O O
. O O

To O O
obtain O O
the O O
full O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
length O B_GENE/B_MEASURE
coding O I_GENE/I_MEASURE
regions O I_GENE/I_MEASURE
of O O
cDNAs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
for O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
, O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCRs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
performed O O
using O O
Superscript O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
reverse O O
transcriptase O B_GENE
( O O
Invitrogen O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
Pfu O B_GENE/B_SPECIES[BIO]
Turbo O I_GENE/I_SPECIES[BIO]
DNA O I_GENE/I_SPECIES[BIO]
polymerase O I_GENE/I_SPECIES[BIO]
( O O
Stratagene O B_BIO/B_GENE
) O O
. O O

The O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
primers O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
used O O
to O O
obtain O O
all O O
Fxh O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNAs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
5 O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
' O I_NUMBER[MEASURE]/I_PROTEIN[GENE]
- O O
ctcaggcctccactagttATGGAGAAAAAGAAAATGGTAACTC O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
and O O
5 O B_MEASURE
' O I_MEASURE
- O O
ctcaggcctcctctagaaGTAGGGGGCAAATCGGCTGTA O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_MEASURE
' O O
. O O

The O O
upstream O B_GENE
primers O I_GENE
for O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
A713 O B_PROTEIN[GENE]
, O O
A715 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A704 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
A2BP1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
5 O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
' O I_NUMBER[MEASURE]/I_PROTEIN[GENE]
- O O
ctcaggcctccactagtgATGAATTGTGAAAGAGAGCAGCT O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
and O O
5 O B_MEASURE
' O I_MEASURE
- O O
ctcaggcctccactagtcATGTTGGCGTCGCAAGGAGTCC O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
, O O
respectively O O
, O O
and O O
the O O
downstream O B_GENE/B_PERSON
primer O I_GENE/I_PERSON
for O O
all O O
A2BP1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
5 O B_NUMBER[MEASURE]
' O I_NUMBER[MEASURE]
- O O
ctcaggcctcctctagagATATGGAGCAAAACGGTTGTATCC O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
. O O

Lower O B_MEASURE/B_PERSON
case O B_MEASURE/I_PERSON
letters O B_MEASURE/I_PERSON
represent O O
adapter O B_LOCATION/B_PERSON
sequences O I_LOCATION/I_PERSON
including O O
restriction O B_PERSON/B_MEASURE
enzyme O I_PERSON/I_MEASURE
sites O I_PERSON/I_MEASURE
. O O

5 O O
' O O
Rapid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amplification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cDNA O B_GENE
ends O I_GENE
( O O
RACE O B_ENT/B_DISEASE
) O O
was O O
performed O O
using O O
Marathon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
Ready O B_MEASURE/B_LOCATION
cDNA O B_MEASURE/I_LOCATION
( O O
BD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Biosciences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Clontech O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

For O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
minigene O B_GENE
and O O
NMHC O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
B O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCRs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
performed O O
as O O
described O O
previously O O
( O O
14 O B_MEASURE
, O O
26 O B_MEASURE
) O O
. O O

Sequences O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
primers O B_PROTEIN[GENE]
P1 O I_PROTEIN[GENE]
- O O
P9 O B_PROTEIN[GENE]
shown O O
in O O
Figures O B_PROTEIN[GENE]
1 O I_PROTEIN[GENE]
, O O
4 O B_NUMBER[MEASURE]
and O O
6 O B_NUMBER[MEASURE]
are O O
as O O
follows O O
: O O
P1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
AATTCACCCAGCAACCAGAAT O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
3 O B_NUMBER[MEASURE]
' O O
; O O
P2 O B_PROTEIN[GENE]
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
TAGAGGGATGTAAGTGTTGATGCC O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
; O O
P3 O B_PROTEIN[GENE]
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
CAGAGGGCGGACAGTGTATGGT O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
; O O
P4 O B_PROTEIN[GENE]
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
GGCGGCAGGGGCGAGGGCAT O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
; O O
P5 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
CCGTGGTCGCACCGTGTACAAC O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
; O O
P6 O B_PROTEIN[GENE]
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
CAGCGGCAGTGGCAGGGGTG O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
3 O B_NUMBER[MEASURE]
' O O
; O O
P7 O B_MEASURE/B_GENE
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
AGGAAGAAAGGACCATAATATTCC O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
3 O B_NUMBER[MEASURE]
' O O
; O O
P8 O B_MEASURE/B_PROTEIN[GENE]
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
CCTCCACCCAGCTCCAGTTGT O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
; O O
and O O
P9 O B_MEASURE/B_GENE
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
CCTGTAGTTATTAAATCCTTCAAG O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
. O O

Preparation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
expression O B_GENE/B_SPECIES[BIO]
constructs O I_GENE/I_SPECIES[BIO]
and O O
minigenes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO

The O O
cDNAs O O
of O O
Fxh O O
and O O
A2BP1 O O
were O O
introduced O O
into O O
a O O
plasmid O O
pCS3 O O
+ O O
MT O O
, O O
which O O
contains O O
a O O
myc O O
- O O
epitope O O
, O O
and O O
its O O
modified O O
version O O
pCS3 O O
+ O O
MT O O
+ O O
NLS O O
, O O
which O O
in O O
addition O O
contains O O
the O O
nuclear O O
localization O O
signal O O
( O O
NLS O O
) O O
of O O
the O O
SV40 B B_SPECIES[BIO]/B_DISEASE
large O O
T O O
antigen O O
( O O
26 O O
) O O
. O O

Minigenes O B_PROTEIN[GENE]
G O I_PROTEIN[GENE]
, O O
J O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
, O O
and O O
H O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
wild O B_BIO/B_PROTEIN[GENE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
IDDE O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
the O O
same O B_MEASURE/B_PERSON
as O O
minigenes O B_PROTEIN[GENE]
W O I_PROTEIN[GENE]
, O O
D4 O B_PROTEIN[GENE]
and O O
Cm0 O B_PROTEIN[GENE]
, O O
respectively O O
in O O
ref O B_SPECIES[BIO]/B_DISEASE
. O O

( O O
14 O B_MEASURE
) O O
. O O

The O O
201 O B_GENE
nt O I_GENE
IDDEs O I_GENE
with O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O O
generated O O
by O O
recombinant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
the O O
appropriate O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
primers O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
which O O
included O O
mutated O O
sequences O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
hexanucleotide O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
TGCATG O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequences O O
at O O
the O O
5 O B_MEASURE
' O O
and O O
3 O B_MEASURE
' O O
sides O B_LOCATION
were O O
changed O O
to O O
GTTACT O B_ORGANIZATION/B_LOCATION
and O O
ACCTAC O B_LOCATION/B_ORGANIZATION
, O O
respectively O O
. O O

Electrophoresis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mobility O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shift O O
assay O O

Template O O
DNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transcription O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
prepared O O
by O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
using O O
the O O
wild O B_BIO
- O O
type O B_MEASURE/B_LOCATION
and O O
mutant O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
IDDEs O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
the O O
minigenes O B_GENE/B_BIO
as O O
templates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
an O O
upstream O B_GENE
primer O I_GENE
that O O
included O O
the O O
T7 O B_GENE
promoter O I_GENE
sequence O I_GENE
at O O
the O O
5 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
competitor O B_GENE/B_BIO
RNAs O I_GENE/I_BIO
were O O
transcribed O O
by O O
T7 O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
32P O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
UTP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
a O O
trace O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amount O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
UTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
respectively O O
, O O
using O O
a O O
MAXIscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
( O O
Ambion O B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

Mole O B_MEASURE/B_LOCATION
concentrations O I_MEASURE/I_LOCATION
of O O
synthesized O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RNAs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
estimated O O
by O O
radioactivities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
with O O
a O O
myc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tag O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
synthesized O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
by O O
using O O
a O O
TNT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
quick O O
- O O
coupled O O
transcription O B_GENE
/ O O
translation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Promega O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
from O O
pCS3 O B_SPECIES[BIO]/B_GENE
+ O I_SPECIES[BIO]/I_GENE
MT O I_SPECIES[BIO]/I_GENE
constructs O I_SPECIES[BIO]/I_GENE
, O O
which O O
include O O
the O O
SP6 O B_GENE/B_MEASURE
promoter O I_GENE/I_MEASURE
. O O

Binding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
carried O O
out O O
in O O
a O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mu O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
contains O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HEPES O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
pH O B_MEASURE/B_LOCATION
7 O I_MEASURE/I_LOCATION
. O O
9 O B_MEASURE
) O O
, O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MgCl2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
50 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KCl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycerol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mM O I_MEASURE
DTT O I_MEASURE
, O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mu O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
g O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tRNA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mu O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
l O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reticulocyte O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lysate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
15 O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fmol O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
on O O
ice O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
20 O B_MEASURE
- O O
30 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
. O O

An O O
aliquot O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
5 O B_MEASURE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mu O B_MEASURE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g O B_MEASURE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
heparin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
added O O
to O O
the O O
reaction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
gel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
reaction O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixtures O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
analyzed O O
by O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polyacrylamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gel O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O O
a O O
0 O B_MEASURE
. O O
5 O B_MEASURE
x O O
TBE O B_MEASURE
buffer O I_MEASURE
( O O
Invitrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

Cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
transfection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO

The O O
human B B_SPECIES[BIO]/B_DISEASE
retinoblastoma O O
cell O O
line O O
Y79 O O
was O O
cultured O O
and O O
transfected O O
with O O
DNAs O O
as O O
described O O
previously O O
( O O
14 O O
, O O
26 O O
) O O
. O O

Total O B_MEASURE/B_ORGANIZATION
amounts O I_MEASURE/I_ORGANIZATION
of O O
transfected O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
adjusted O O
to O O
be O O
constant O B_MEASURE
by O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
empty O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
vector O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Either O O
Lipofectin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Invitrogen O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
or O O
Effectene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transfection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reagent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Qiagen O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
used O O
for O O
the O O
transfection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
stable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
pCS3 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
MT O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
constructs O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
transfected O O
with O O
a O O
plasmid O B_GENE
carrying O O
a O O
neomycin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
resistant O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
selected O O
by O O
0 O B_MEASURE
. O O
2 O B_MEASURE
mM O I_MEASURE
geneticin O I_MEASURE
( O O
Invitrogen O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

For O O
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
plated O O
on O O
the O O
poly O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
d O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
lysine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
coated O O
plates O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
then O O
treated O O
with O O
2 O B_NUMBER[MEASURE]
. O O
0 O B_MEASURE
- O O
2 O B_MEASURE
. O O
5 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
butyrate O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
4 O B_NUMBER[MEASURE]
- O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

HeLa O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
cultured O O
as O O
described O O
and O O
transfected O O
with O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O O
Effectene O B_LOCATION/B_GENE
reagent O B_LOCATION/I_GENE
( O O
14 O B_MEASURE
, O O
26 O B_MEASURE
) O O
. O O

Immunoblot O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
that O O
required O O
both O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
mRNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
split O O
upon O O
harvesting O O
. O O

Total O B_PERSON/B_ENT
cell O I_PERSON/I_ENT
proteins O I_PERSON/I_ENT
were O O
subjected O O
to O O
SDS O B_PROTEIN[GENE]/B_DISEASE
- O O
PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
blotted O O
as O O
described O O
previously O O
( O O
26 O B_MEASURE
) O O
. O O

The O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
are O O
monoclonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
myc O B_PERSON/B_BIO
- O O
epitope O B_PROTEIN[GENE]
( O O
Invitrogen O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
green O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GFP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
Clontech O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
. O O

Binding O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
detected O O
with O O
the O O
SuperSignal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
System O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Pierce O B_PERSON/B_ORGANIZATION
) O O
or O O
ECL O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
Amersham O B_LOCATION
) O O
. O O

Immunofluorescent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]

HeLa O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
or O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
grown O O
in O O
a O O
four O B_NUMBER[MEASURE]
- O O
chamber O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
glass O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
slide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
transfected O O
as O O
described O O
above O O
. O O

Cells O O
were O O
fixed O O
with O O
10 O O
% O O
formaldehyde O O
24 O O
- O O
48 O O
h O O
after O O
transfection O O
, O O
and O O
permealized O O
with O O
0 O O
. O O
5 O O
% O O
Triton O O
X O O
- O O
100 O O
then O O
blocked O O
with O O
5 O O
% O O
goat B B_SPECIES[BIO]
serum O O
. O O

Primary O O
antibodies O O
used O O
were O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
myc O O
( O O
Invitrogen O O
) O O
, O O
rabbit B B_SPECIES[BIO]
anti O O
- O O
NMHC O O
- O O
B O O
( O O
29 O O
) O O
. O O

Secondary O O
antibodies O O
were O O
Alexa O O
Fluor O O
594 O O
goat B B_SPECIES[BIO]
anti O O
- O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG O O
and O O
Alexa O O
Fluor O O
488 O O
goat B B_SPECIES[BIO]
anti O O
- O O
rabbit B B_SPECIES[BIO]
IgG O O
( O O
Molecular O O
Probes O O
) O O
. O O

DAPI O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
used O O
for O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Specimens O B_BIO/B_PERSON
were O O
mounted O O
in O O
ProLong O B_LOCATION/B_PERSON
antifed O I_LOCATION/I_PERSON
kit O I_LOCATION/I_PERSON
( O O
Molecular O B_MEASURE/B_LOCATION
Probe O I_MEASURE/I_LOCATION
) O O
. O O

The O O
images O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
collected O O
using O O
Leica O B_PRODUCT[OBJECT]/B_ENT
SP O I_PRODUCT[OBJECT]/I_ENT
confocal O I_PRODUCT[OBJECT]/I_ENT
microscopy O I_PRODUCT[OBJECT]/I_ENT
( O O
Leica O B_DISEASE/B_MEASURE
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Tissue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
and O O
their O O
subcellular O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
A2BP1 O O
mRNAs O O
are O O
detected O O
almost O O
exclusively O O
in O O
brain O O
and O O
striated O O
muscles O O
( O O
heart O O
and O O
skeletal O O
muscles O O
) O O
in O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
the O O
Fxh O O
mRNAs O O
are O O
expressed O O
in O O
a O O
wide O O
variety O O
of O O
tissues O O
with O O
the O O
highest O O
expression O O
in O O
brain O O
and O O
heart O O
[ O O
( O O
21 O O
, O O
25 O O
) O O
and O O
S O O
. O O
Kawamoto O O
, O O
unpublished O O
data O O
] O O
. O O

These O O
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
prompted O O
us O O
to O O
characterize O O
the O O
mRNAs O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
A2BP1 O B_GENE
and O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
muscles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
cloned O O
cDNAs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
two O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
skeletal O B_BODY_PART_OR_ORGAN_COMPONENT
muscles O I_BODY_PART_OR_ORGAN_COMPONENT
by O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
5 O B_NUMBER[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RACE O B_SPORT[ENT]/B_ORGANIZATION
. O O

The O O
isolated O B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNAs O I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
schematically O O
presented O O
with O O
genomic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
structures O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
Figure O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
( O O
for O O
amino O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
see O O
also O O
Figure O B_LOCATION/B_ENT
8 O I_LOCATION/I_ENT
) O O
. O O

Both O O
gene O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
found O O
to O O
undergo O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
alternative O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O O

In O O
both O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
striated O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
express O O
unique O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splice O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variants O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generated O O
by O O
mutually O O
exclusive O B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_DISEASE_ADJECTIVE[DISEASE]
of O O
exons O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
B40 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
M43 O B_PROTEIN[GENE]
, O O
respectively O O
, O O
which O O
provide O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coding O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
middle O B_LOCATION/B_DISEASE
of O O
the O O
carboxyl O B_MEASURE/B_LOCATION
half O B_MEASURE/I_LOCATION
of O O
the O O
molecules O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Southern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Fxh O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
different O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
probed O O
by O O
oligonucleotides O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corresponding O O
to O O
B40 O B_PROTEIN[GENE]
and O O
M43 O B_PROTEIN[GENE]
shows O O
that O O
M43 O B_PROTEIN[GENE]
is O O
exclusively O O
used O O
in O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
skeletal O B_BODY_PART_OR_ORGAN_COMPONENT
muscles O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
while O O
B40 O O
is O O
predominantly O O
used O O
in O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_BODY_PART_OR_ORGAN_COMPONENT
2A O I_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

Digestion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCR O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
products O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
A2BP1 O B_GENE
mRNAs O I_GENE
with O O
restriction O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzymes O O
unique O B_DISEASE_ADJECTIVE[DISEASE]
to O O
B40 O B_PROTEIN[GENE]
and O O
M43 O B_PROTEIN[GENE]
demonstrates O O
that O O
B40 O B_PROTEIN[GENE]
and O O
M43 O B_PROTEIN[GENE]
are O O
used O O
almost O O
exclusively O O
in O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
muscles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
( O O
Figure O B_MEASURE/B_LOCATION
2B O I_MEASURE/I_LOCATION
) O O
. O O

A2BP1 O B_GENE/B_PERSON
contains O O
an O O
additional O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cassette O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alternative O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exon O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A53 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
consisting O O
of O O
53 O B_GENE
nt O I_GENE
. O O

Inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
exclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
exon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A53 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
different O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
amino O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acid O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
owing O O
to O O
a O O
frame O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
shift O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
. O O

In O O
the O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
A2BP1 O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene O B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
moreover O O
, O O
it O O
appears O O
that O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
striated O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
utilize O O
alternative O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
promoters O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
, O O
resulting O O
in O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amino O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
acid O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
at O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminus O B_LOCATION
. O O

The O O
5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
RACE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
skeletal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
muscle O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
mRNAs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
yielded O O
essentially O O
a O O
single O B_BIO/B_MEASURE
species O B_BIO/I_MEASURE
of O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
29 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unique O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RACE O B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
brain O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
however O O
, O O
yielded O O
multiple O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
multiple O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deduced O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
amino O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
all O O
of O O
which O O
differ O O
from O O
the O O
muscle O B_GENE/B_LOCATION
amino O I_GENE/I_LOCATION
acid O I_GENE/I_LOCATION
sequence O I_GENE/I_LOCATION
at O O
the O O
very O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminus O B_LOCATION/B_MEASURE
. O O

Here O O
, O O
we O O
focus O O
our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O O
a O O
clone O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
containing O O
nine O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unique O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminus O B_LOCATION
, O O
which O O
was O O
obtained O O
most O O
frequently O O
. O O

Exon O B_GENE/B_PERSON
- O O
intron O B_MEASURE/B_ORGANIZATION
organization O I_MEASURE/I_ORGANIZATION
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
shows O O
remarkable O B_DISEASE_ADJECTIVE[DISEASE]
similarities O I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
RRM O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
encoded O O
in O O
four O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
exons O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_NUMBER[MEASURE]/B_PERSON
1B O I_NUMBER[MEASURE]/I_PERSON
) O O
. O O

Of O O
note O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
that O O
the O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amounts O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
mRNAs O I_GENE
from O O
skeletal O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
are O O
missing O O
a O O
part O B_MEASURE/B_LOCATION
of O O
the O O
RRM O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
exon O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
skipping O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Typically O O
, O O
as O O
shown O O
in O O
Figure O B_SPECIES[BIO]
2C O I_SPECIES[BIO]
, O O
they O O
lack O O
the O O
93 O B_GENE
nt O I_GENE
exon O I_GENE
that O O
encodes O O
RNP1 O B_GENE
, O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
two O B_NUMBER[MEASURE]
most O O
critical O B_MEASURE/B_LOCATION
motifs O I_MEASURE/I_LOCATION
of O O
the O O
RRM O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O B_NUMBER[MEASURE]/B_BIO
) O O
. O O

Some O O
of O O
them O O
lack O O
almost O O
the O O
entire O B_LOCATION/B_MEASURE
RRM O I_LOCATION/I_MEASURE
( O O
e O B_OTHER/B_PROTEIN[GENE]
. O O
g O B_LOCATION/B_MEASURE
. O O
F402 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Figure O B_LOCATION
1A O I_LOCATION
) O O
. O O

To O O
examine O O
the O O
subcellular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
distribution O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
each O O
isoform O B_GENE/B_MEASURE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
, O O
myc O B_GENE/B_SPECIES[BIO]
- O O
tagged O O
proteins O B_GENE/B_DISEASE
were O O
transiently O O
expressed O O
in O O
cultured O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
immunostained O O
with O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
myc O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Initially O O
, O O
HeLa O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O O
used O O
to O O
investigate O O
subcellular O B_DISEASE/B_GENE
localization O I_DISEASE/I_GENE
, O O
since O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
more O O
suited O O
for O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Representative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
confocal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
images O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
shown O O
in O O
Figure O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3A O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

DAPI O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
NMHC O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
B O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
serve O O
as O O
markers O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
nuclei O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
cytoplasm O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
respectively O O
. O O

As O O
noted O O
, O O
the O O
ratio O B_MEASURE/B_PERSON
of O O
protein O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
distributed O O
between O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
differs O O
among O O
the O O
proteins O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

All O O
isoforms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
a O O
predominant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
nuclear O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
localization O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
brain O B_GENE/B_DISEASE
isoform O I_GENE/I_DISEASE
of O O
A2BP1 O B_GENE
without O O
the O O
A53 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exon O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
localizes O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
both O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
whereas O O
the O O
other O B_GENE/B_MEASURE
brain O I_GENE/I_MEASURE
isoform O I_GENE/I_MEASURE
with O O
the O O
A53 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exon O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
A030 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
localizes O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
predominantly O O
to O O
cytoplasm O O
with O O
only O O
a O O
minimum O B_MEASURE/B_PERSON
being O I_MEASURE/I_PERSON
in O O
the O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O O

The O O
relative O B_MEASURE
amounts O I_MEASURE
of O O
both O O
muscle O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
A2BP1 O B_GENE
( O O
A713 O B_PROTEIN[GENE]
and O O
A715 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
are O O
somewhat O O
between O O
the O O
amounts O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
two O B_GENE/B_MEASURE
brain O I_GENE/I_MEASURE
isoforms O I_GENE/I_MEASURE
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
summarized O O
in O O
Figure O B_MEASURE/B_LOCATION
1A O I_MEASURE/I_LOCATION
. O O

The O O
subcellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
representative O B_GENE
isoforms O I_GENE
( O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
also O O
examined O O
in O O
retinoblastoma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Y79 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
were O O
used O O
as O O
host O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cells O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
the O O
transfection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
order O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
characterize O O
splicing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP O B_GENE
proteins O I_GENE
( O O
see O O
below O O
) O O
. O O

Although O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
have O O
a O O
spherical O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
shape O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O O
have O O
only O O
thin O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cytoplasm O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O O
exogenously O O
expressed O O
isoforms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
show O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
subcellular O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
distribution O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O O
in O O
HeLa O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE/B_LOCATION
3B O I_MEASURE/I_LOCATION
) O O
. O O

F011 O B_MEASURE/B_PROTEIN[GENE]
localizes O I_MEASURE/I_PROTEIN[GENE]
predominantly O O
to O O
nuclei O O
, O O
A016 O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
both O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
A030 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predominantly O O
to O O
cytoplasm O O
. O O

Specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
with O O
IDDE O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
a O O
hexanucleotide O B_GENE
UGCAUG O I_GENE

Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_TIME[MEASURE]/B_LOCATION
share O I_TIME[MEASURE]/I_LOCATION
an O O
identical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RRM O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
A2BP1 O B_GENE/B_MEASURE
has O O
been O O
reported O O
to O O
bind O O
specifically O O
to O O
the O O
pentanucleotide O B_GENE
GCAUG O I_GENE
through O O
this O O
RRM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
21 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

We O O
have O O
previously O O
reported O O
that O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
NMHC O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
B O B_GENE/B_LOCATION
transcript O I_GENE/I_LOCATION
, O O
which O O
is O O
indispensable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
regulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cassette O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
type O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
exon O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
N30 O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
has O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
copies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
GCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
14 O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
. O O

Therefore O O
, O O
we O O
investigated O O
whether O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
/ O O
or O O
A2BP1 O B_GENE
bound O O
to O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Electrophoretic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shift O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assays O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EMSAs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
were O O
carried O O
out O O
using O O
labeled O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
in O O
vitro O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcribed O O
and O O
translated O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
, O O
which O O
include O O
a O O
myc O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
epitope O B_GENE/B_LOCATION
. O O

Since O O
all O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
isoforms O I_GENE
, O O
except O O
F402 O B_PROTEIN[GENE]
and O O
A704 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
contain O O
the O O
identical O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RRM O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
representative O B_NUMBER[MEASURE]/B_PERSON
isoforms O B_NUMBER[MEASURE]/I_PERSON
were O O
analyzed O O
. O O

The O O
expression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
reticulocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
lysate O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
causes O O
the O O
formation O B_PERSON/B_DISEASE
of O O
a O O
RNA O B_GENE/B_BIO
- O O
protein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complex O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whose O O
migration O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shift O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distinguishes O O
it O O
from O O
those O O
of O O
the O O
control O B_BIO/B_GENE
reticulocyte O I_BIO/I_GENE
lysate O I_BIO/I_GENE
( O O
C O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
Figure O B_MEASURE
4B O I_MEASURE
, O O
lanes O O
3 O B_NUMBER[MEASURE]
and O O
10 O B_NUMBER[MEASURE]
) O O
. O O

The O O
unlabeled O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
wild O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
type O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IDDE O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
competes O O
with O O
the O O
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
efficiently O O
for O O
the O O
formation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
specific O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complex O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
C O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE
4B O I_MEASURE
, O O
lane O B_TIME[MEASURE]/B_LOCATION
4 O I_TIME[MEASURE]/I_LOCATION
) O O
. O O

On O O
the O O
other O B_PERSON/B_LOCATION
hand O B_PERSON/I_LOCATION
, O O
the O O
mutant O B_PERSON/B_GENE
mc O I_PERSON/I_GENE
( O O
Figure O B_NUMBER[MEASURE]/B_PERSON
4A O I_NUMBER[MEASURE]/I_PERSON
) O O
, O O
which O O
has O O
a O O
mutation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
both O O
copies O B_GENE/B_LOCATION
of O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
does O O
not O O
( O O
Figure O O
4B O B_MEASURE/B_LOCATION
, O O
lane O B_LOCATION/B_PROTEIN[GENE]
7 O B_LOCATION/I_PROTEIN[GENE]
) O O
. O O

The O O
mutant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ma O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
has O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
the O O
hexanucleotide O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
5 O B_NUMBER[MEASURE]
' O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
shows O O
less O O
efficient O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
competition O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
compared O O
with O O
mb O B_LOCATION/B_GENE
, O O
which O O
has O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
the O O
3 O B_LOCATION/B_MEASURE
' O I_LOCATION/I_MEASURE
side O I_LOCATION/I_MEASURE
of O O
the O O
hexanucleotide O B_GENE
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
4B O I_PROTEIN[GENE]/I_LOCATION
, O O
lanes O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
5 O I_NUMBER[MEASURE]/I_PROTEIN[GENE]
and O O
6 O B_MEASURE
) O O
, O O
indicating O O
that O O
the O O
nucleotides O B_DISEASE
at O O
the O O
5 O B_DISEASE/B_LOCATION
' O B_DISEASE/I_LOCATION
side O B_DISEASE/I_LOCATION
are O O
more O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
those O O
at O O
the O O
3 O B_LOCATION/B_SEQUENCE[MEASURE]
' O I_LOCATION/I_SEQUENCE[MEASURE]
side O I_LOCATION/I_SEQUENCE[MEASURE]
. O O

The O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
myc O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
a O O
non O B_DISEASE/B_GENE
- O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
inhibits O O
the O O
formation O B_PERSON/B_DISEASE
of O O
the O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_PROTEIN[GENE]/B_MEASURE
4B O I_PROTEIN[GENE]/I_MEASURE
, O O
lane O B_TIME[MEASURE]/B_LOCATION
8 O I_TIME[MEASURE]/I_LOCATION
) O O
. O O

Synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
full O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
length O B_GENE/B_MEASURE
F011 O I_GENE/I_MEASURE
protein O I_GENE/I_MEASURE
using O O
a O O
reticulocyte O B_GENE
lysate O I_GENE
and O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
myc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
expressed O O
protein O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
are O O
verified O O
by O O
immunoblot O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4B O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lanes O B_SEQUENCE[MEASURE]/B_LOCATION
11 O I_SEQUENCE[MEASURE]/I_LOCATION
and O O
12 O B_NUMBER[MEASURE]
) O O
. O O

A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_MEASURE/B_PROTEIN[GENE]
show O O
essentially O O
identical O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
those O O
with O O
F011 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
can O O
bind O O
to O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
that O O
the O O
hexanucleotide O B_GENE/B_LOCATION
UGCAUG O I_GENE/I_LOCATION
is O O
required O O
for O O
their O O
binding O B_TIME[MEASURE]/B_GENE
. O O

Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enhance O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
a O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

To O O
study O O
whether O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
regulate O O
neural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
specific O B_DISEASE/B_GENE
splicing O I_DISEASE/I_GENE
via O O
binding O O
to O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
expression O I_GENE
constructs O I_GENE
were O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
transfected O O
into O O
retinoblastoma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Y79 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
number O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
reporter O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minigene O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constructs O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
include O O
the O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE/B_MEASURE
or O O
a O O
mutant O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
version O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
of O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Figure O B_GENE
4A O I_GENE
) O O
. O O

Minigenes O B_PROTEIN[GENE]/B_LOCATION
H O I_PROTEIN[GENE]/I_LOCATION
and O O
J O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consist O O
of O O
the O O
exons O B_PROTEIN[GENE]
E5 O I_PROTEIN[GENE]
, O O
N30 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
E6 O B_PROTEIN[GENE]
and O O
their O O
flanking O B_GENE/B_LOCATION
introns O I_GENE/I_LOCATION
with O O
some O O
deletions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
the O O
introns O B_GENE/B_MEASURE
. O O

The O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
or O O
without O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
hexanucleotide O B_GENE
is O O
included O O
or O O
excluded O O
between O O
N30 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
E6 O B_PROTEIN[GENE]
. O O

As O O
described O O
above O O
, O O
each O O
isoform O B_GENE/B_MEASURE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
enters O O
the O O
nucleus O B_BODY_PART_OR_ORGAN_COMPONENT
to O O
a O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
extent O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

To O O
see O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O O
itself O O
, O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
their O O
differential O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
properties O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
in O O
nuclear O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
localization O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
added O O
to O O
the O O
expressed O O
proteins O B_GENE/B_DISEASE
. O O

Since O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
contain O O
the O O
identical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RRM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
F011 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_PROTEIN[GENE]/B_MEASURE
all O O
show O O
the O O
same O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
UGCAUG O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_GENE/B_LOCATION
were O O
used O O
for O O
these O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Host O B_PERSON/B_GENE
cells O I_PERSON/I_GENE
Y79 O I_PERSON
at O O
the O O
proliferating O O
stage O B_MEASURE/B_LOCATION
exclude O O
the O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]
exon O I_DISEASE_ADJECTIVE[DISEASE]
in O O
~ O B_MEASURE
90 O I_MEASURE
% O I_MEASURE
of O O
the O O
endogenous O B_GENE/B_DISEASE
NMHC O I_GENE/I_DISEASE
- O O
B O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
e O B_OTHER/B_GENE
. O O
g O B_PROTEIN[GENE]/B_LOCATION
. O O
see O O
Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
6A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
lane O B_TIME[MEASURE]/B_LOCATION
1 O I_TIME[MEASURE]/I_LOCATION
) O O
. O O

As O O
shown O O
in O O
Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4C O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
minigene O B_PROTEIN[GENE]/B_LOCATION
J O I_PROTEIN[GENE]/I_LOCATION
exclude O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]
without O O
exogenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
A2BP1 O B_GENE
in O O
Y79 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
endogenous O B_GENE/B_DISEASE
NMHC O I_GENE/I_DISEASE
- O O
B O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE
4C O I_MEASURE
, O O
upper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
panel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
lanes O O
1 O B_NUMBER[MEASURE]
- O O
5 O B_MEASURE
) O O
. O O

However O O
, O O
in O O
the O O
presence O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
expression O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
increased O O
( O O
Figure O B_MEASURE/B_LOCATION
4C O I_MEASURE/I_LOCATION
, O O
upper O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lanes O O
7 O B_NUMBER[MEASURE]
and O O
12 O B_NUMBER[MEASURE]
) O O
. O O

The O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
absolutely O O
dependent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
Figure O B_LOCATION/B_PERSON
4C O I_LOCATION/I_PERSON
, O O
upper O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lanes O O
6 O B_NUMBER[MEASURE]
and O O
11 O B_NUMBER[MEASURE]
) O O
. O O

Moreover O O
, O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
either O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
two O B_GENE/B_LOCATION
copies O I_GENE/I_LOCATION
of O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ma O B_LOCATION/B_MEASURE
, O O
mb O B_GENE/B_TIME[MEASURE]
) O O
abolishes O O
the O O
inclusion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE/B_LOCATION
4C O I_MEASURE/I_LOCATION
, O O
upper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
panel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
lanes O O
8 O B_MEASURE
- O O
10 O B_NUMBER[MEASURE]
, O O
13 O B_MEASURE
- O O
15 O B_MEASURE
) O O
. O O

In O O
the O O
context O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
minigene O B_SPECIES[BIO]/B_GENE
H O I_SPECIES[BIO]/I_GENE
, O O
which O O
contains O O
shorter O B_GENE
introns O I_GENE
, O O
the O O
larger O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extent O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
is O O
induced O O
by O O
either O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
A030 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
overexpression O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE/B_LOCATION
4C O I_MEASURE/I_LOCATION
, O O
middle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
panel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
lanes O O
7 O B_NUMBER[MEASURE]
and O O
12 O B_NUMBER[MEASURE]
) O O
. O O

The O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
minigene O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNAs O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
depends O O
on O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
IDDE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
Figure O B_MEASURE/B_LOCATION
4C O I_MEASURE/I_LOCATION
, O O
middle O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lanes O O
6 O B_NUMBER[MEASURE]
and O O
11 O B_NUMBER[MEASURE]
) O O
. O O

Mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
copies O B_ENT/B_GENE
of O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
mc O B_LOCATION/B_MEASURE
) O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
complete O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
loss O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Figure O B_MEASURE/B_LOCATION
4C O I_MEASURE/I_LOCATION
, O O
middle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
panel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
lanes O O
10 O B_MEASURE
and O O
15 O B_MEASURE
) O O
. O O

The O O
mutant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ma O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shows O O
stronger O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
compared O O
with O O
mb O B_LOCATION/B_GENE
( O O
Figure O B_LOCATION/B_MEASURE
4C O I_LOCATION/I_MEASURE
, O O
middle O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lanes O O
8 O B_NUMBER[MEASURE]
and O O
9 O B_NUMBER[MEASURE]
) O O
. O O

This O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
competition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
EMSA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O O
in O O
Figure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
4B O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
indicating O O
that O O
the O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hexanucleotide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
more O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
the O O
3 O B_MEASURE
' O O
hexanucleotide O B_LOCATION
for O O
binding O B_TIME[MEASURE]/B_GENE
of O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
A2BP1 O B_GENE/B_LOCATION
to O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
well O O
as O O
an O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Comparable O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
expressed O O
in O O
each O O
transfection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
as O O
verified O O
by O O
immunoblots O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
myc O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_MEASURE/B_PERSON
4C O I_MEASURE/I_PERSON
, O O
lower O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
panel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
lanes O B_MEASURE/B_LOCATION
6 O I_MEASURE/I_LOCATION
- O O
17 O B_NUMBER[MEASURE]
) O O
. O O

Since O O
minigenes O B_LOCATION
J O I_LOCATION
and O O
H O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lack O O
a O O
portion O B_MEASURE/B_LOCATION
of O O
the O O
intron O B_GENE/B_LOCATION
between O O
exons O B_PROTEIN[GENE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
N30 O I_PROTEIN[GENE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
and O O
E6 O B_PROTEIN[GENE]
and O O
, O O
therefore O O
, O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
located O O
~ O B_LOCATION
100 O I_LOCATION
nt O I_LOCATION
downstream O I_LOCATION
of O O
N30 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
instead O O
of O O
1 O B_MEASURE
. O O
5 O B_MEASURE/B_LOCATION
kb O I_MEASURE/I_LOCATION
as O O
in O O
the O O
native O B_GENE/B_PERSON
gene O I_GENE/I_PERSON
, O O
we O O
also O O
analyzed O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
on O O
the O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
wild O B_SPECIES[BIO]
- O O
type O B_GENE/B_MEASURE
minigene O B_GENE/I_MEASURE
G O B_GENE/I_MEASURE
, O O
which O O
includes O O
full O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
length O B_GENE/B_MEASURE
introns O I_GENE/I_MEASURE
among O O
E5 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N30 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
E6 O B_PROTEIN[GENE]
( O O
Figure O B_PROTEIN[GENE]
4A O I_PROTEIN[GENE]
) O O
. O O

As O O
shown O O
in O O
Figure O B_SPECIES[BIO]
4C O I_SPECIES[BIO]
( O O
right O B_MEASURE/B_LOCATION
panel O I_MEASURE/I_LOCATION
) O O
, O O
both O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
capable O B_PERSON/B_LOCATION
of O O
promoting O O
N30 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
with O O
F011 O B_PERSON
showing O O
a O O
higher O B_MEASURE/B_LOCATION
activity O I_MEASURE/I_LOCATION
( O O
Figure O B_MEASURE
4C O I_MEASURE
, O O
lanes O B_MEASURE/B_LOCATION
16 O I_MEASURE/I_LOCATION
and O O
17 O B_MEASURE
) O O
. O O

Although O O
A030 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
promote O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
as O O
efficiently O O
as O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
contexts O B_LOCATION
of O O
the O O
minigene O B_PROTEIN[GENE]/B_LOCATION
J O I_PROTEIN[GENE]/I_LOCATION
and O O
H O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
can O O
do O O
so O O
less O O
efficiently O O
than O O
F011 O B_PROTEIN[GENE]/B_PERSON
in O O
the O O
context O B_LOCATION
of O O
the O O
minigene O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcript O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
discussed O O
below O O
. O O

Taken O O
together O O
, O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
activate O O
N30 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inclusion O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
an O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O B_LOCATION
manner O I_LOCATION
. O O

The O O
hexanucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
motif O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
UGCAUG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
indispensable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
this O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
alternatively O O
spliced O O
isoforms O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
in O O
promoting O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

Both O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
mRNAs O I_GENE
are O O
expressed O O
in O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
A2BP1 O B_GENE/B_PERSON
is O O
also O O
expressed O O
in O O
striated O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Fxh O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
expressed O O
in O O
an O O
even O O
wider O B_MEASURE/B_LOCATION
variety O I_MEASURE/I_LOCATION
of O O
tissues O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

As O O
demonstrated O O
above O O
, O O
however O O
, O O
both O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
undergo O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
producing O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O O
enriched O O
isoforms O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
the O O
relative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
individual O B_GENE/B_MEASURE
isoform O I_GENE/I_MEASURE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
in O O
promoting O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
compared O O
using O O
minigene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
G O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

First O O
, O O
in O O
order O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
evaluate O O
the O O
relative O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specific O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
activity O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
each O O
isoform O B_GENE/B_MEASURE
in O O
the O O
splicing O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reaction O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
separately O O
from O O
its O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
localize O O
to O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
an O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
included O O
in O O
the O O
expressed O O
protein O B_GENE/B_BACTERIUM[BIO]
to O O
equalize O O
the O O
nuclear O B_MEASURE
concentration O I_MEASURE
of O O
the O O
expressed O O
protein O B_GENE/B_BACTERIUM[BIO]
in O O
these O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Essentially O O
, O O
all O O
of O O
the O O
expressed O O
proteins O B_GENE/B_DISEASE
with O O
the O O
exogenous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
NLS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
localized O O
to O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

Therefore O O
, O O
the O O
relative O B_MEASURE/B_LOCATION
nuclear O I_MEASURE/I_LOCATION
concentrations O I_MEASURE/I_LOCATION
of O O
the O O
expressed O O
proteins O B_GENE/B_DISEASE
can O O
be O O
estimated O O
easily O O
by O O
immunoblots O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
shown O O
in O O
immunoblots O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Figure O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
5A O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O O
similar O B_MEASURE/B_LOCATION
quantities O I_MEASURE/I_LOCATION
of O O
proteins O B_GENE/B_DISEASE
are O O
expressed O O
in O O
a O O
dose O B_MEASURE/B_LOCATION
- O O
dependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
manner O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Expression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
the O O
brain O B_GENE
isoform O I_GENE
F011 O I_BIO
causes O O
a O O
dose O B_MEASURE/B_LOCATION
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
the O O
extent O B_MEASURE/B_LOCATION
of O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
reaches O O
a O O
plateau O B_LOCATION/B_MEASURE
with O O
~ O O
85 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
mRNAs O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
including O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
inclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoted O O
by O O
F411 O B_GENE
, O O
the O O
predominant O B_GENE
isoform O I_GENE
from O O
skeletal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
muscles O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O O
reaches O O
a O O
plateau O B_LOCATION/B_MEASURE
with O O
only O O
40 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
mRNAs O B_MEASURE/B_BIO
. O O

With O O
respect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
A2BP1 O B_GENE
, O O
the O O
brain O B_GENE
isoform O I_GENE
A030 O I_GENE
shows O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
activity O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
than O O
the O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
isoform O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
A715 O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
, O O
which O O
shows O O
almost O O
no O O
activation O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
shown O O
in O O
Figure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
5A O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

Including O O
additional O B_MEASURE/B_PERSON
isoforms O I_MEASURE/I_PERSON
, O O
the O O
activities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
individual O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
with O O
an O O
exogenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
NLS O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
promoting O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
are O O
shown O O
in O O
Figure O B_PERSON/B_LOCATION
5B O I_PERSON/I_LOCATION
( O O
lanes O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
- O O
13 O B_MEASURE
) O O
and O O
are O O
also O O
summarized O O
in O O
Figure O B_LOCATION/B_PERSON
1A O B_LOCATION/I_PERSON
( O O
nls O B_MEASURE
) O O
. O O

Special O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
taken O O
to O O
ensure O O
that O O
a O O
similar O B_MEASURE/B_LOCATION
quantity O I_MEASURE/I_LOCATION
of O O
each O O
protein O B_GENE/B_BACTERIUM[BIO]
was O O
expressed O O
and O O
, O O
if O O
not O O
, O O
different O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
tested O O
to O O
obtain O O
comparable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NLS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
nls O B_PROTEIN[GENE]/B_MEASURE
) O O
, O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
the O O
highest O B_MEASURE/B_LOCATION
activities O I_MEASURE/I_LOCATION
among O O
all O O
isoforms O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tested O O
. O O

A30 O B_PROTEIN[GENE]
shows O O
a O O
considerably O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
activity O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Each O O
of O O
the O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
F411 O B_PROTEIN[GENE]
, O O
A713 O B_PROTEIN[GENE]
and O O
A715 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
has O O
a O O
lower O B_MEASURE
activity O I_MEASURE
than O O
that O O
of O O
their O O
brain O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
counterparts O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A030 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
) O O
. O O

As O O
expected O O
, O O
isoforms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacking O O
a O O
part O B_MEASURE/B_LOCATION
or O O
all O O
of O O
the O O
RRM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
F402 O B_PROTEIN[GENE]
and O O
A704 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
have O O
no O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Next O B_TIME[MEASURE]/B_LOCATION
, O O
the O O
splicing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
wild O B_BIO/B_GENE
- O O
type O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
without O O
an O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
examined O O
. O O

Representative O B_ORGANIZATION/B_PERSON
data O I_ORGANIZATION/I_PERSON
are O O
shown O O
in O O
Figure O B_MEASURE/B_LOCATION
5B O I_MEASURE/I_LOCATION
( O O
lanes O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
- O O
7 O B_MEASURE
) O O
and O O
the O O
relative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
summarized O O
in O O
Figure O B_MEASURE/B_LOCATION
1A O I_MEASURE/I_LOCATION
( O O
wt O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

The O O
protein O B_MEASURE/B_BACTERIUM[BIO]
amounts O O
detected O O
by O O
immunoblots O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
these O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represent O O
the O O
total O B_MEASURE
amounts O I_MEASURE
of O O
the O O
proteins O B_PROTEIN[GENE]/B_DISEASE
distributed O O
to O O
both O O
the O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
splicing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
wild O B_BIO
- O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
activities O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
combine O O
the O O
splicing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
the O O
proteins O B_GENE/B_DISEASE
with O O
the O O
exogenous O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
NLS O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
activities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
native O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
localize O O
to O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

In O O
the O O
absence O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
wt O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
, O O
the O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
A016 O B_GENE/B_LOCATION
to O O
a O O
lesser O B_MEASURE/B_DISEASE
extent O I_MEASURE/I_DISEASE
, O O
are O O
still O O
capable O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
activating O O
N30 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inclusion O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficiently O O
. O O

The O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
isoforms O O
for O O
both O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
( O O
F411 O B_GENE
, O O
A713 O B_PROTEIN[GENE]
and O O
A715 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
as O O
well O O
as O O
the O O
brain O B_GENE/B_BIO
isoform O I_GENE/I_BIO
A030 O I_GENE/I_BIO
, O O
show O O
only O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minimal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A016 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O O
to O O
have O O
the O O
most O O
physiological O B_DISEASE_ADJECTIVE[DISEASE]
relevance O I_DISEASE_ADJECTIVE[DISEASE]
to O O
N30 O B_DISEASE/B_BIO
splicing O I_DISEASE/I_BIO
activation O I_DISEASE/I_BIO
. O O

Overexpression O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
activates O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
endogenous O B_GENE/B_DISEASE
NMHC O I_GENE/I_DISEASE
- O O
B O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]

The O O
human B B_SPECIES[BIO]/B_MEASURE
NMHC O O
- O O
B O O
gene O O
consists O O
of O O
41 O O
constitutive O O
exons O O
and O O
3 O O
alternative O O
exons O O
. O O

Its O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mRNA O B_GENE
is O O
~ O O
156 O B_MEASURE/B_PERSON
kb O I_MEASURE/I_PERSON
in O O
length O B_MEASURE/B_LOCATION
and O O
it O O
is O O
much O O
more O O
complex O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mRNA O B_GENE
from O O
the O O
minigenes O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
the O O
minigene O B_GENE/B_LOCATION
pre O I_GENE/I_LOCATION
- O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O O
driven O O
by O O
a O O
heterologous O B_GENE
promoter O I_GENE
. O O

Therefore O O
, O O
we O O
next O O
examined O O
if O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
were O O
capable O B_PERSON
of O O
promoting O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
endogenous O B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transcript O B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Y79 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
stably O O
transfected O O
with O O
the O O
expression O B_GENE
construct O I_GENE
for O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
A016 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Both O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
enriched O O
in O O
the O O
brain O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
show O O
higher O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
N30 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inclusion O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
minigene O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding O O
endogenous O B_GENE
NMHC O I_GENE
- O O
B O B_PROTEIN[GENE]/B_DISEASE
were O O
analyzed O O
by O O
using O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

As O O
shown O O
in O O
Figure O B_MEASURE/B_PERSON
6 O I_MEASURE/I_PERSON
, O O
the O O
inclusion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
exon O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
N30 O I_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
with O O
and O O
without O O
another O O
alternative O B_GENE
exon O I_GENE
, O O
R18 O O
, O O
in O O
the O O
endogenous O B_GENE
mRNAs O I_GENE
is O O
markedly O O
increased O O
in O O
the O O
clones O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
which O O
were O O
stably O O
transfected O O
with O O
the O O
construct O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
A016 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
an O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Figure O B_MEASURE/B_GENE
6 O B_MEASURE/I_GENE
, O O
lanes O B_NUMBER[MEASURE]/B_LOCATION
4 O I_NUMBER[MEASURE]/I_LOCATION
and O O
5 O B_NUMBER[MEASURE]
) O O
. O O

Although O O
to O O
a O O
lesser O B_MEASURE/B_DISEASE
extent O I_MEASURE/I_DISEASE
, O O
transfection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
wild O B_BIO/B_GENE
- O O
type O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
constructs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
without O O
an O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O O
results O O
in O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
6 O B_MEASURE/I_PROTEIN[GENE]
, O O
lanes O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O B_NUMBER[MEASURE]
and O O
3 O B_NUMBER[MEASURE]
) O O
. O O

Thus O O
, O O
exogenously O O
expressed O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
are O O
capable O B_PERSON/B_LOCATION
of O O
activating O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
not O O
only O O
in O O
the O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
minigenes O B_GENE/B_BIO
, O O
but O O
also O O
in O O
those O O
from O O
the O O
native O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NMHC O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
B O B_GENE
gene O I_GENE
in O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

Fxh O B_PERSON
may O O
cooperate O O
with O O
other O B_PERSON/B_DISEASE
factor O I_PERSON/I_DISEASE
( O O
s O O
) O O
to O O
promote O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

To O O
address O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
endogenous O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fxh O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
its O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
with O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
promoting O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
we O O
made O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
isoform O B_GENE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
F402 O B_PROTEIN[GENE]
, O O
which O O
lacks O O
the O O
RRM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
mutant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lacking O O
an O O
RRM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
other O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
binding O O
proteins O B_LOCATION/B_PROTEIN[GENE]
have O O
previously O O
been O O
reported O O
to O O
function O O
in O O
a O O
dominant O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fashion O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
inhibit O O
the O O
activities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
the O O
wild O B_SPECIES[BIO]
- O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
26 O B_MEASURE
, O O
31 O B_MEASURE
) O O
. O O

Therefore O O
, O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
F402 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inclusion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
minigene O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
H O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
examined O O
in O O
the O O
context O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
of O O
the O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
treated O O
with O O
butyrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Upon O O
butyrate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
as O O
reported O O
previously O O
, O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
enter O O
in O O
a O O
post O B_DISEASE/B_MEASURE
- O O
mitotic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
differentiated O B_DISEASE
stage O I_DISEASE
, O O
and O O
importantly O O
, O O
the O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
well O O
as O O
the O O
minigene O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNAs O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
those O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
include O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
to O O
a O O
large O B_MEASURE/B_LOCATION
extent O I_MEASURE/I_LOCATION
, O O
unlike O O
those O O
in O O
the O O
untreated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
that O O
predominantly O O
exclude O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
14 O B_NUMBER[MEASURE]
) O O
. O O

As O O
shown O O
in O O
Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
7 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
in O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
exogenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
F402 O B_GENE
, O O
large O B_NUMBER[MEASURE]/B_PERSON
quantities O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
minigene O B_PROTEIN[GENE]/B_DISEASE
H O I_PROTEIN[GENE]/I_DISEASE
- O O
wt O B_MEASURE/B_LOCATION
, O O
which O O
contains O O
the O O
wild O B_BIO/B_PROTEIN[GENE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
IDDE O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
include O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
Figure O B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
7 O I_SEQUENCE[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
upper O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lane O B_LOCATION/B_MEASURE
4 O I_LOCATION/I_MEASURE
) O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
only O O
small O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
quantities O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
are O O
detected O O
in O O
the O O
mRNAs O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
from O O
minigene O B_PROTEIN[GENE]/B_DISEASE
H O I_PROTEIN[GENE]/I_DISEASE
- O O
mc O B_MEASURE/B_LOCATION
, O O
which O O
has O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
both O O
copies O B_GENE/B_LOCATION
of O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
IDDE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Figure O B_MEASURE/B_LOCATION
7 O I_MEASURE/I_LOCATION
, O O
upper O B_MEASURE/B_LOCATION
panel O I_MEASURE/I_LOCATION
, O O
lane O B_LOCATION/B_MEASURE
8 O I_LOCATION/I_MEASURE
) O O
. O O

Therefore O O
, O O
the O O
butyrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
factor O B_GENE
( O O
s O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
which O O
are O O
capable O B_PERSON/B_LOCATION
of O O
activating O O
the O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
transfection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
wild O B_BIO
- O O
type O B_GENE/B_MEASURE
minigene O B_GENE/I_MEASURE
H O B_GENE/I_MEASURE
- O O
wt O B_MEASURE/B_LOCATION
with O O
the O O
F402 O B_GENE
expression O I_GENE
construct O I_GENE
causes O O
a O O
dose O B_MEASURE/B_LOCATION
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
( O O
Figure O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
7 O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
lanes O O
1 O B_NUMBER[MEASURE]
- O O
3 O B_MEASURE
) O O
, O O
indicating O O
that O O
F402 O B_GENE
has O O
an O O
antagonistic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
endogenous O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
respect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Notably O O
, O O
the O O
UGCAUG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N30 O B_LOCATION
inclusion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
seen O O
in O O
the O O
mutant O B_GENE/B_DISEASE
minigene O B_GENE/I_DISEASE
H O B_GENE/I_DISEASE
- O O
mc O B_MEASURE/B_LOCATION
is O O
not O O
affected O O
by O O
the O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
expression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
F402 O B_GENE/B_DISEASE
( O O
Figure O B_TIME[MEASURE]/B_LOCATION
7 O B_TIME[MEASURE]/I_LOCATION
, O O
lanes O O
5 O B_NUMBER[MEASURE]
- O O
7 O B_MEASURE
) O O
, O O
indicating O O
that O O
the O O
inhibitory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
F402 O B_GENE
depends O O
on O O
the O O
UGCAUG O B_GENE/B_LOCATION
element O I_GENE/I_LOCATION
. O O

The O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
F011 O B_GENE
expression O I_GENE
construct O I_GENE
does O O
not O O
show O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
effect O I_DISEASE_ADJECTIVE[DISEASE]
on O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
in O O
either O O
the O O
wild O B_BIO
- O O
type O B_DISEASE/B_MEASURE
or O O
mutant O B_GENE
minigene O I_GENE
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
7 O B_MEASURE/I_PROTEIN[GENE]
, O O
lanes O B_MEASURE/B_LOCATION
9 O I_MEASURE/I_LOCATION
- O O
16 O B_MEASURE
) O O
. O O

This O O
may O O
be O O
due O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
wild O B_BIO/B_PROTEIN[GENE]
- O O
type O B_GENE
minigene O I_GENE
mRNAs O I_GENE
has O O
already O O
reached O O
a O O
maximal O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
and O O
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
butyrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
sufficient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amounts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
protein O B_GENE/B_BACTERIUM[BIO]
( O O
s O B_PROTEIN[GENE]/B_DISEASE
) O O
functionally O O
equivalent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
F011 O B_GENE/B_PERSON
, O O
which O O
can O O
promote O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
in O O
a O O
UGCAUG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
dependent O B_GENE/B_LOCATION
manner O I_GENE/I_LOCATION
. O O

Since O O
F402 O B_GENE
does O O
not O O
bind O O
to O O
the O O
UGCAUG O B_GENE
element O I_GENE
, O O
and O O
has O O
a O O
UGCAUG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
dependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonistic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
most O O
probably O O
disrupts O O
protein O B_GENE/B_BACTERIUM[BIO]
- O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
endogenous O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
required O O
for O O
the O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Endogenous O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fxh O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
and O O
/ O O
or O O
A2BP1 O B_GENE/B_BIO
) O O
would O O
be O O
a O O
good O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
candidate O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whose O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
could O O
be O O
antagonized O O
by O O
exogenously O O
expressed O O
F402 O B_GENE
. O O

Thus O O
, O O
this O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O O
that O O
the O O
endogenous O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fxh O I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
an O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
activation O B_GENE/B_MEASURE
of O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
other O B_GENE/B_BIO
proteins O I_GENE/I_BIO
cooperate O O
with O O
Fxh O B_GENE/B_BIO
for O O
N30 O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Since O O
muscle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
express O O
the O O
RRM O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
defective O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O O
a O O
significant O B_MEASURE/B_PERSON
extent O I_MEASURE/I_PERSON
( O O
Figure O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
2C O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
) O O
and O O
the O O
wild O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
type O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
F402 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
localize O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
nuclei O O
efficiently O O
, O O
this O O
also O O
raises O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
RRM O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
defective O B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_DISEASE_ADJECTIVE[DISEASE]
may O O
have O O
an O O
inhibitory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
muscle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DISCUSSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
major O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
described O O
in O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

First O O
, O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
facilitate O O
neural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
cassette O B_ENT/B_PROTEIN[GENE]
- O O
type O B_GENE/B_LOCATION
exon O I_GENE/I_LOCATION
via O O
binding O O
to O O
the O O
specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
intronic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UGCAUG O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
a O O
minigene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
, O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
are O O
capable O B_PERSON/B_LOCATION
of O O
facilitating O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pre O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
mRNA O B_GENE
. O O

This O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
physiological O B_PROTEIN[GENE]
relevance O I_PROTEIN[GENE]
and O O
supports O O
the O O
notion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
NMHC O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
B O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mRNA O B_GENE
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
the O O
true O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
A2BP1 O B_GENE
- O O
mediated O O
regulation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
whether O O
the O O
endogenous O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fxh O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
A2BP1 O B_GENE
regulates O O
endogenous O B_PROTEIN[GENE]/B_LOCATION
NMHC O I_PROTEIN[GENE]/I_LOCATION
- O O
B O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mRNA O B_GENE
splicing O I_GENE
needs O O
to O O
be O O
determined O O
in O O
a O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
vertebrates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
small O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interfering O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
gene O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
targeting O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strategies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
recently O O
been O O
used O O
successfully O O
to O O
address O O
the O O
roles O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
endogenous O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulators O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
alternative O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
target O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
pre O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
8 O B_MEASURE
, O O
32 O B_MEASURE
- O O
36 O B_MEASURE
) O O
. O O

A O O
second O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
novel O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
finding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
the O O
identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_LOCATION
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
splicing O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activities O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O O
well O O
as O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subcellular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
raises O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
products O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
genes O I_GENE
can O O
contribute O O
to O O
a O O
mechanism O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
as O O
to O O
how O O
tissue O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
specificity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
alternative O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
achieved O O
. O O

Many O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
splicing O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
are O O
detected O O
not O O
only O O
in O O
the O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O O
but O O
also O O
in O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( O O
37 O B_TIME[MEASURE]/B_BIO
) O O
. O O

They O O
are O O
shuttling O O
between O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
, O O
in O O
some O O
instances O B_LOCATION/B_BIO
, O O
extracellular O B_DISEASE_ADJECTIVE[DISEASE]
stimuli O I_DISEASE_ADJECTIVE[DISEASE]
trigger O I_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
subcellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
proteins O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
translocations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
have O O
been O O
reported O O
for O O
hnRNPA1 O B_LOCATION/B_ORGANIZATION
and O O
PTB O B_GENE/B_DISEASE
( O O
38 O B_MEASURE
, O O
39 O B_MEASURE
) O O
. O O

Moreover O O
, O O
a O O
number O B_MEASURE/B_PERSON
of O O
RNA O B_GENE/B_BIO
- O O
binding O O
proteins O B_LOCATION/B_PROTEIN[GENE]
have O O
been O O
demonstrated O O
to O O
play O O
a O O
role O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
steps O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
during O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
subcellular O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
compartments O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
pre O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mRNA O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
mRNA O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
export O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
to O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
mRNA O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
localization O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
stability O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
translation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
( O O
37 O B_MEASURE
, O O
40 O B_MEASURE
) O O
. O O

Therefore O O
, O O
not O O
surprisingly O O
, O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
isoforms O I_GENE
were O O
found O O
to O O
be O O
distributed O O
in O O
both O O
the O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
HeLa O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O O
Y79 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
the O O
relative O B_MEASURE/B_LOCATION
ratios O I_MEASURE/I_LOCATION
of O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
distributed O O
between O O
the O O
two O B_LOCATION/B_BIO
subcellular O I_LOCATION/I_BIO
compartments O I_LOCATION/I_BIO
at O O
steady O B_DISEASE/B_MEASURE
- O O
state O B_LOCATION/B_MEASURE
differ O O
among O O
the O O
isoforms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
agreement O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Jin O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O O
. O O

( O O
21 O O
) O O
, O O
substantial O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
brain O B_GENE
isoform O I_GENE
A016 O I_GENE
are O O
detected O O
in O O
nuclei O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Other O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
A2BP1 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
isoform O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
A030 O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
and O O
the O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
isoforms O O
A713 O B_PROTEIN[GENE]
and O O
A715 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
only O O
poorly O O
detected O O
in O O
nuclei O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

This O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
where O O
endogenous O B_GENE
A2BP1 O I_GENE
in O O
cerebellar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Purkinje O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
neurons O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
cardiac O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
myocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
shown O O
to O O
be O O
localized O O
essentially O O
to O O
the O O
cytoplasm O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O O
23 O B_MEASURE
, O O
24 O B_MEASURE
) O O
. O O

Thus O O
, O O
inclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
exclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
A53 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
differences O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
very O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
A2BP1 O B_PROTEIN[GENE]/B_LOCATION
isoforms O I_PROTEIN[GENE]/I_LOCATION
with O O
a O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subcellular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localization O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
likely O B_DISEASE_ADJECTIVE[DISEASE]
that O O
A2BP1 O B_GENE
proteins O I_GENE
have O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
roles O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
involving O O
both O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
cytoplasmic O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
all O O
three O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fxh O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
predominantly O O
localized O O
to O O
the O O
nuclei O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Therefore O O
, O O
in O O
terms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
their O O
localization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
Fxh O B_PERSON/B_GENE
proteins O I_PERSON/I_GENE
are O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
candidates O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
regulators O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
the O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
mRNA O B_GENE
splicing O I_GENE
that O O
takes O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
nuclei O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

Of O O
note O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
however O O
, O O
our O O
preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
5 O B_MEASURE
' O O
RACE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
as O O
well O O
as O O
the O O
EST O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
detect O O
multiple O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
end O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
both O O
Fxh O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
mRNAs O I_GENE
, O O
which O O
are O O
presumably O O
generated O O
by O O
alternative O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
promoters O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
and O O
alternative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
diversity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
5 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
' O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
end O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
the O O
generation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
a O O
number O B_MEASURE/B_LOCATION
of O O
unique O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_GENE/B_LOCATION
amino O I_GENE/I_LOCATION
acid O I_GENE/I_LOCATION
sequences O I_GENE/I_LOCATION
. O O

Therefore O O
, O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
exclude O O
the O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
existence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subcellular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
both O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
. O O

Our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
does O O
not O O
exclude O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
some O O
of O O
the O O
isoforms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
translocate O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
following O O
stimuli O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
main O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
aim O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
to O O
determine O O
the O O
relative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_DISEASE
in O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
UGCAUG O B_GENE/B_LOCATION
element O I_GENE/I_LOCATION
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
alternative O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
splicing O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

To O O
obtain O O
an O O
indication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
relative O B_MEASURE/B_LOCATION
specific O I_MEASURE/I_LOCATION
activity O I_MEASURE/I_LOCATION
of O O
each O O
isoform O B_GENE/B_MEASURE
in O O
transfected O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O O
the O O
same O B_MEASURE/B_LOCATION
amounts O B_MEASURE/I_LOCATION
of O O
the O O
expressed O O
proteins O B_GENE/B_DISEASE
should O O
be O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
splicing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
nuclei O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

For O O
this O O
reason O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
an O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
included O O
in O O
the O O
expressed O O
proteins O B_GENE/B_DISEASE
. O O

Essentially O O
, O O
all O O
of O O
the O O
expressed O O
proteins O B_GENE/B_DISEASE
with O O
the O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
NLS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
localized O O
to O O
nuclei O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Thus O O
, O O
the O O
amounts O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
expressed O O
proteins O B_PROTEIN[GENE]/B_DISEASE
determined O O
by O O
immunoblots O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represent O O
the O O
nuclear O B_MEASURE
concentrations O I_MEASURE
. O O

The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
the O O
proteins O B_GENE/B_DISEASE
expressed O O
with O O
the O O
exogenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
NLS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
allowed O O
us O O
to O O
compare O O
directly O O
the O O
splicing O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
these O O
proteins O B_GENE/B_DISEASE
. O O

Furthermore O O
, O O
this O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
also O O
allowed O O
us O O
to O O
define O O
the O O
critical O B_LOCATION
regions O I_LOCATION
of O O
the O O
proteins O B_GENE/B_DISEASE
for O O
splicing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
shown O O
in O O
Figure O B_MEASURE/B_PERSON
5 O I_MEASURE/I_PERSON
, O O
the O O
splicing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_LOCATION
are O O
intrinsically O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
regardless O O
of O O
the O O
subcellular O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
localization O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
wild O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Among O O
the O O
isoforms O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tested O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
include O O
B40 O B_GENE
, O O
are O O
found O O
to O O
have O O
higher O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
promoting O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

When O O
the O O
primary O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O O
, O O
outside O O
of O O
the O O
RRM O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
of O O
these O O
two O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
compared O O
, O O
the O O
C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION
regions O I_LOCATION
( O O
amino O B_MEASURE
acids O I_MEASURE
190 O I_MEASURE
- O O
377 O B_MEASURE
of O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
show O O
a O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
homology O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
with O O
71 O B_GENE/B_PERSON
% O I_GENE/I_PERSON
identity O I_GENE/I_PERSON
, O O
whereas O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
terminal O B_LOCATION
regions O I_LOCATION
( O O
amino O B_MEASURE
acids O I_MEASURE
1 O I_MEASURE
- O O
112 O B_MEASURE
of O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
show O O
only O O
53 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
identity O I_MEASURE/I_PERSON
. O O

The O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION/B_ORGANIZATION
region O I_LOCATION/I_ORGANIZATION
includes O O
four O B_LOCATION/B_ORGANIZATION
subregions O I_LOCATION/I_ORGANIZATION
of O O
nearly O O
identical O B_MEASURE
stretches O I_MEASURE
of O O
amino O B_LOCATION/B_GENE
acids O I_LOCATION/I_GENE
( O O
Figure O B_TIME[MEASURE]/B_LOCATION
8 O I_TIME[MEASURE]/I_LOCATION
, O O
I O B_OTHER/B_PROTEIN[GENE]
- O O
IV O B_SEQUENCE[MEASURE]
) O O
. O O

One O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
subregion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
II O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
includes O O
13 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoded O O
by O O
exon O B_GENE
B40 O I_GENE
. O O

Substitution O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
subregion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
exon O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M43 O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Fxh O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O O
substantial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
amino O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resulting O O
in O O
only O O
a O O
21 O B_PERSON/B_LOCATION
% O B_PERSON/I_LOCATION
identity O B_PERSON/I_LOCATION
in O O
this O O
region O B_LOCATION/B_BIO
between O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
F411 O B_GENE
. O O

Another O O
subregion O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IV O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
located O O
at O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_DISEASE/B_LOCATION
end O B_DISEASE/I_LOCATION
and O O
A030 O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacks O O
this O O
homologous O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
by O O
the O O
inclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
exon O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A53 O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
results O O
in O O
a O O
frame O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
shift O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Since O O
F411 O B_GENE
and O O
A030 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
with O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
, O O
these O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subregions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A016 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O O
to O O
serve O O
as O O
activation O B_GENE/B_PERSON
domains O I_GENE/I_PERSON
, O O
presumably O O
by O O
interacting O O
with O O
other O B_GENE/B_BIO
proteins O I_GENE/I_BIO
. O O

This O O
notion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
supported O O
by O O
the O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
RRM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
lacking O O
isoform O B_GENE/B_LOCATION
F402 O I_GENE/I_LOCATION
, O O
which O O
includes O O
the O O
same O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
subregions O I_SEQUENCE[MEASURE]/I_PROTEIN[GENE]
II O I_SEQUENCE[MEASURE]/I_PROTEIN[GENE]
and O O
IV O B_TIME[MEASURE]/B_PROTEIN[GENE]
as O O
F011 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
functions O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apparently O O
as O O
a O O
dominant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
Fxh O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
mutant O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
and O O
wild O B_BIO/B_DISEASE
- O O
type O B_DISEASE/B_PROTEIN[GENE]
are O O
competing O O
to O O
interact O O
with O O
other O B_PROTEIN[GENE]/B_BIO
protein O I_PROTEIN[GENE]/I_BIO
( O O
s O B_OTHER/B_DISEASE
) O O
. O O

To O O
date O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Fyn O B_GENE
tyrosine O I_GENE
kinase O I_GENE
and O O
estrogen O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
alpha O B_PROTEIN[GENE]/B_LOCATION
have O O
been O O
reported O O
to O O
interact O O
with O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
ataxin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]
with O O
A2BP1 O B_GENE/B_MEASURE
( O O
23 O B_MEASURE
, O O
41 O B_MEASURE
, O O
42 O B_MEASURE
) O O
. O O

Whether O O
these O O
proteins O B_LOCATION/B_GENE
participate O O
in O O
the O O
regulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
pre O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mRNA O B_GENE/B_ORGANISM_FUNCTION
splicing O B_GENE/I_ORGANISM_FUNCTION
is O O
currently O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Of O O
interest O B_PERSON/B_NUMBER[MEASURE]
, O O
A030 O O
with O O
the O O
exogenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
NLS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
activates O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
efficiently O O
as O O
F011 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
minigenes O B_PROTEIN[GENE]/B_LOCATION
J O I_PROTEIN[GENE]/I_LOCATION
and O O
H O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
contain O O
the O O
shorter O B_GENE/B_MEASURE
intron O I_GENE/I_MEASURE
, O O
whereas O O
this O O
isoform O B_PROTEIN[GENE]/B_LOCATION
poorly O O
activates O O
N30 O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mRNA O B_GENE
from O O
minigene O B_LOCATION/B_PROTEIN[GENE]
G O I_LOCATION/I_PROTEIN[GENE]
, O O
which O O
contains O O
the O O
full O B_MEASURE/B_COLOR
- O O
length O B_GENE
intron O I_GENE
. O O

This O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
implies O O
that O O
the O O
interactions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
A030 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
different O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
required O O
in O O
the O O
different O B_DISEASE/B_GENE
pre O B_DISEASE/I_GENE
- O O
mRNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contexts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Therefore O O
, O O
the O O
isoforms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_LOCATION
described O O
here O O
may O O
have O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
UGCAUG O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
regulated O O
alternative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
involvement O B_PERSON/B_DISEASE
of O O
the O O
hexanucleotide O B_GENE
UGCAUG O I_GENE
in O O
regulated O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alternative O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
experimentally O O
demonstrated O O
in O O
a O O
number O B_MEASURE/B_LOCATION
of O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
as O O
well O O
as O O
other O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
model O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
13 O B_MEASURE/B_LOCATION
- O O
21 O B_MEASURE
) O O
. O O

This O O
hexanucleotide O B_LOCATION/B_GENE
element O B_LOCATION/I_GENE
plays O O
a O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
most O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
an O O
enhancer O B_GENE/B_PERSON
in O O
regulating O O
alternative O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cassette O B_LOCATION/B_GENE
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
exons O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O O
well O O
as O O
mutually O O
exclusive O B_GENE
exons O I_GENE
. O O

Furthermore O O
, O O
computational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
revealed O O
that O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
over O O
- O O
represented O O
in O O
the O O
introns O B_GENE/B_LOCATION
in O O
which O O
splicing O B_GENE
is O O
regulated O O
, O O
compared O O
with O O
the O O
constitutively O O
spliced O O
introns O B_GENE/B_LOCATION
( O O
43 O B_NUMBER[MEASURE]/B_BIO
) O O
. O O

This O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
pointed O O
to O O
the O O
UGCAUG O B_GENE/B_LOCATION
element O I_GENE/I_LOCATION
as O O
playing O O
a O O
role O B_MEASURE/B_PERSON
in O O
the O O
regulation O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
wide O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
of O O
tissues O B_DISEASE/B_BIO
, O O
but O O
not O O
in O O
specific O B_DISEASE/B_BIO
tissues O I_DISEASE/I_BIO
. O O

To O O
date O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
KH O B_PERSON/B_GENE
- O O
type O B_MEASURE/B_GENE
splicing O I_MEASURE/I_GENE
regulatory O I_MEASURE/I_GENE
protein O I_MEASURE/I_GENE
( O O
KSRP O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
( O O
44 O B_MEASURE
) O O
, O O
A2BP1 O B_GENE
( O O
21 O B_MEASURE
) O O
and O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
this O O
study O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
are O O
known O O
to O O
be O O
capable O B_PERSON/B_LOCATION
of O O
binding O O
to O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

KSRP O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
expressed O O
ubiquitously O O
and O O
tissue O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variants O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
gene O B_GENE
have O O
not O O
been O O
described O O
so O O
far O O
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
have O O
described O O
the O O
existence O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tissue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
, O O
which O O
, O O
while O O
not O O
identical O B_DISEASE_ADJECTIVE[DISEASE]
in O O
some O O
areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
molecule O B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
, O O
may O O
contain O O
the O O
same O B_MEASURE/B_PROTEIN[GENE]
RRM O I_MEASURE/I_PROTEIN[GENE]
. O O

The O O
physiological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relevance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
isoforms O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
that O O
they O O
have O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
splicing O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activities O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subcellular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
promote O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
more O O
efficiently O O
than O O
the O O
muscle O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
. O O

The O O
isoforms O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacking O O
the O O
RRM O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
are O O
normally O O
expressed O O
to O O
a O O
significant O B_MEASURE/B_LOCATION
extent O I_MEASURE/I_LOCATION
in O O
skeletal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
muscles O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

This O O
isoform O B_GENE/B_LOCATION
is O O
incapable O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
activating O O
N30 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
, O O
moreover O O
, O O
can O O
inhibit O O
N30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
properties O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
isoforms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE
acting O O
as O O
regulators O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
N30 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
since O O
N30 O B_GENE/B_LOCATION
is O O
included O O
in O O
neuronal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
but O O
excluded O O
in O O
muscles O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
despite O O
the O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
independent O B_DISEASE_ADJECTIVE[DISEASE]
occurrence O I_DISEASE_ADJECTIVE[DISEASE]
of O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
regulatory O B_GENE
element O I_GENE
, O O
given O O
the O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
binding O O
proteins O B_BIO/B_LOCATION
( O O
Fxh O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A2BP1 O B_GENE/B_LOCATION
) O O
with O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
hexanucleotide O B_PROTEIN[GENE]/B_LOCATION
UGCAUG O I_PROTEIN[GENE]/I_LOCATION
could O O
confer O O
tissue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
regulated O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problems O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
understanding O O
the O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responsible O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
alternative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pre O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
mRNA O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
manner O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
which O O
tissue O B_MEASURE/B_GENE
specificity O I_MEASURE/I_GENE
is O O
determined O O
. O O

In O O
vertebrates O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
to O O
date O B_TIME[MEASURE]
, O O
only O O
a O O
few O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O O
specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
identified O O
as O O
splicing O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulators O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
8 O B_MEASURE/B_LOCATION
- O O
12 O B_MEASURE
) O O
. O O

Here O O
, O O
we O O
have O O
shown O O
that O O
the O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
sequence O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
RNA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O O
binding O O
proteins O B_GENE/B_DISEASE
, O O
which O O
themselves O O
are O O
generated O O
by O O
alternative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
have O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
target O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
mRNA O B_GENE
. O O

Therefore O O
, O O
these O O
isoforms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
play O O
a O O
role O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
determination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
tissue O B_MEASURE
specificity O I_MEASURE
of O O
target O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pre O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
mRNA O B_GENE
splicing O I_GENE
. O O

The O O
discovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
isoforms O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
binding O O
proteins O B_BIO/B_LOCATION
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activities O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
adds O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
new O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
dimension O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
the O O
molecular O B_LOCATION
mechanisms O I_LOCATION
responsible O I_LOCATION
for O O
regulating O O
tissue O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
via O O
UGCAUG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PIK3CA O B_GENE
in O O
gastric O B_DISEASE
adenocarcinoma O I_DISEASE

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Activation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O O
the O O
phosphatidylinositol O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
kinase O B_ENZYME[GENE]
( O O
PI3K O B_GENE/B_LOCATION
) O O
through O O
mutational O B_DISEASE_ADJECTIVE[DISEASE]
inactivation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
PTEN O B_GENE
tumour O I_GENE
suppressor O I_GENE
gene O I_GENE
is O O
common O B_DISEASE_ADJECTIVE[DISEASE]
in O O
diverse O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
types O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
rarely O O
reported O O
in O O
gastric O B_DISEASE/B_PERSON
cancer O I_DISEASE/I_PERSON
. O O

Recently O O
, O O
mutations O O
in O O
PIK3CA O O
, O O
which O O
encodes O O
the O O
p110 O O
alpha O O
catalytic O O
subunit O O
of O O
PI3K O O
, O O
have O O
been O O
identified O O
in O O
various O O
human B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
cancers O O
, O O
including O O
3 O O
of O O
12 O O
gastric O O
cancers O O
. O O

Eighty O B_NUMBER[MEASURE]
percent O I_NUMBER[MEASURE]
of O O
these O O
reported O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
clustered O O
within O O
2 O B_LOCATION/B_BIO
regions O I_LOCATION/I_BIO
involving O O
the O O
helical O B_ENZYME[GENE]/B_DISEASE
and O O
kinase O B_LOCATION/B_GENE
domains O I_LOCATION/I_GENE
. O O

In O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O O
the O O
" O B_PERSON/B_NUMBER[MEASURE]
hot O I_PERSON/I_NUMBER[MEASURE]
- O O
spot O B_LOCATION/B_BIO
" O O
mutants O B_DISEASE/B_BIO
has O O
demonstrated O O
it O O
as O O
an O O
activating O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_PROTEIN[GENE]
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Based O O
on O O
these O O
data O O
, O O
we O O
initiated O O
PIK3CA O O
mutation O O
screening O O
in O O
94 O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
gastric O O
cancers O O
by O O
direct O O
sequencing O O
of O O
the O O
gene O O
regions O O
in O O
which O O
80 O O
% O O
of O O
all O O
the O O
known O O
PIK3CA O O
mutations O O
were O O
found O O
. O O

We O O
also O O
examined O O
PIK3CA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
level O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
extracting O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
scale O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
profiling O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Using O O
Significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
Microarrays O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
SAM O B_PERSON/B_DISEASE
) O O
, O O
we O O
further O O
searched O O
for O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
show O O
correlating O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
PIK3CA O B_DISEASE/B_GENE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

We O O
have O O
identified O O
PIK3CA O B_DISEASE/B_LOCATION
mutations O I_DISEASE/I_LOCATION
in O O
4 O B_NUMBER[MEASURE]/B_BIO
cases O B_NUMBER[MEASURE]/I_BIO
( O O
4 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
) O O
, O O
all O O
involving O O
the O O
previously O O
reported O O
hotspots O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Among O O
these O O
4 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
3 O B_NUMBER[MEASURE]/B_ENT
tumours O I_NUMBER[MEASURE]/I_ENT
demonstrated O O
microsatellite O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
instability O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
2 O B_NUMBER[MEASURE]/B_ENT
tumours O I_NUMBER[MEASURE]/I_ENT
harboured O O
concurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
KRAS O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
extracted O O
from O O
microarray O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
an O O
increased O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PIK3CA O B_GENE
in O O
gastric O B_DISEASE
cancers O I_DISEASE
when O O
compared O O
with O O
the O O
non O B_DISEASE/B_LOCATION
- O O
neoplastic O B_DISEASE/B_PERSON
gastric O I_DISEASE/I_PERSON
mucosae O I_DISEASE/I_PERSON
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

SAM O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
further O O
identified O O
2910 O B_GENE
genes O I_GENE
whose O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
positively O O
associated O O
with O O
that O O
of O O
PIK3CA O B_GENE/B_DISEASE
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggested O O
that O O
activation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
PI3K O B_GENE/B_LOCATION
signalling O I_GENE/I_LOCATION
pathway O I_GENE/I_LOCATION
in O O
gastric O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
may O O
be O O
achieved O O
through O O
up O O
- O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
or O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
PIK3CA O B_GENE
, O O
in O O
which O O
the O O
latter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
a O O
consequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
mismatch O B_DISEASE/B_GENE
repair O I_DISEASE/I_GENE
deficiency O I_DISEASE/I_GENE
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
phosphatidylinositol O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
kinase O B_ENZYME[GENE]
( O O
PI3K O B_GENE
) O O
- O O
AKT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
involved O O
in O O
the O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
diverse O B_DISEASE
cellular O I_DISEASE
processes O I_DISEASE
, O O
including O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
survival O B_DISEASE/B_ORGANISM_FUNCTION
and O O
motility O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Abnormal O B_DISEASE_ADJECTIVE[DISEASE]
activation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
pathway O B_LOCATION
is O O
frequently O O
observed O O
in O O
various O B_DISEASE
cancer O I_DISEASE
types O I_DISEASE
, O O
leading O O
to O O
aberrant O B_DISEASE
cell O I_DISEASE
cycle O I_DISEASE
progression O I_DISEASE
, O O
altered O B_DISEASE
adhesion O I_DISEASE
and O O
motility O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
apoptosis O B_DISEASE
and O O
induction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
angiogenesis O B_DISEASE/B_GENE
[ O O
1 O B_DISEASE
] O I_DISEASE
. O O

It O O
has O O
been O O
previously O O
reported O O
that O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
alterations O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
involving O O
various O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
members O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
along O O
this O O
signalling O O
pathway O B_LOCATION/B_ORGANIZATION
could O O
lead O O
to O O
its O O
activation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
cancer O B_DISEASE/B_LOCATION
. O O

These O O
include O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O O
allelic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
loss O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
promoter O B_DISEASE_ADJECTIVE[DISEASE]
methylation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
negative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulator O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PTEN O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
2 O B_NUMBER[MEASURE]
] O O
; O O
or O O
alternatively O O
, O O
chromosomal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
amplification O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
or O O
over O O
- O O
expression O B_GENE
of O O
the O O
positive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulators O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PIK3CA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
3 O B_MEASURE
- O O
5 O B_MEASURE
] O I_MEASURE
and O O
the O O
various O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AKT O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
6 O B_NUMBER[MEASURE]
, O O
7 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Furthermore O O
, O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
other O B_DISEASE/B_GENE
related O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
that O O
are O O
commonly O O
altered O O
in O O
cancer O B_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
those O O
involved O O
in O O
growth O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
factor O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
via O O
the O O
G O B_GENE
- O O
protein O B_GENE/B_BACTERIUM[BIO]
- O O
coupled O O
receptors O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
through O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
with O O
the O O
activated O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
small O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GTPase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RAS O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
can O O
also O O
lead O O
to O O
PI3K O B_GENE
- O O
AKT O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
pathway O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
[ O O
8 O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Activation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
this O O
pathway O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
phosphorylation O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
AKT O B_GENE
at O O
Thr O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
308 O B_MEASURE
/ O O
309 O B_MEASURE
and O O
Ser O B_LOCATION/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
473 O B_MEASURE
/ O O
474 O B_MEASURE
. O O

These O O
phosphorylated O O
forms O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
AKT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
detected O O
by O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
immunohistochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
various O B_DISEASE
cancer O I_DISEASE
types O I_DISEASE
, O O
suggesting O O
the O O
frequent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
PI3K O B_GENE
- O O
AKT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
carcinogenic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
process O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
7 O B_NUMBER[MEASURE]
, O O
9 O B_MEASURE
] O O
. O O

Although O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
along O O
the O O
PI3K O B_GENE
- O O
AKT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
repeatedly O O
documented O O
in O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
ovarian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
endometrial O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
breast O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
prostate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
thyroid O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancers O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
1 O B_NUMBER[MEASURE]
, O O
2 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
, O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
its O O
mechanism O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
gastric O B_DISEASE/B_BIO
cancer O I_DISEASE/I_BIO
are O O
limited O O
. O O

Gastric O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
is O O
the O O
second O B_SEQUENCE[MEASURE]
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cancer O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
worldwide O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
but O O
its O O
molecular O B_LOCATION
basis O I_LOCATION
of O O
tumourigenesis O B_DISEASE_ADJECTIVE[DISEASE]
is O O
still O O
poorly O O
understood O O
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
immunohistochemical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
has O O
demonstrated O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
phosphorylated O B_ENZYME[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_ENZYME[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
AKT O B_GENE
in O O
78 O B_LOCATION/B_PERSON
% O I_LOCATION/I_PERSON
of O O
gastric O B_DISEASE/B_PERSON
cancer O I_DISEASE/I_PERSON
[ O I_DISEASE/I_PERSON
10 O I_DISEASE/I_PERSON
] O I_DISEASE/I_PERSON
, O O
suggesting O O
that O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O O
this O O
pathway O B_ENZYME[GENE]/B_DISEASE
may O O
also O O
be O O
common O B_DISEASE_ADJECTIVE[DISEASE]
in O O
gastric O B_DISEASE/B_BIO
cancer O I_DISEASE/I_BIO
. O O

Though O O
loss O B_DISEASE_ADJECTIVE[DISEASE]
of O O
heterozygosity O B_GENE/B_DISEASE
( O O
LOH O B_DISEASE/B_PROTEIN[GENE]
) O O
involving O O
the O O
PTEN O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
demonstrated O O
in O O
47 O B_PERSON
% O I_PERSON
of O O
gastric O B_DISEASE/B_PERSON
cancer O I_DISEASE/I_PERSON
in O O
a O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
mutation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
promoter O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
methylation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
even O O
in O O
cases O B_PERSON/B_DISEASE
with O O
LOH O B_DISEASE/B_GENE
[ O I_DISEASE/I_GENE
11 O I_DISEASE/I_GENE
] O I_DISEASE/I_GENE
. O O

Thus O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
could O O
not O O
support O O
the O O
two O B_NUMBER[MEASURE]/B_LOCATION
- O O
hit O B_DISEASE_ADJECTIVE[DISEASE]
inactivation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
PTEN O B_GENE
in O O
gastric O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
, O O
while O O
the O O
biological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
PTEN O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
haploinsufficiency O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
remains O O
controversial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Alternatively O O
, O O
amplification O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
AKT1 O B_GENE
has O O
been O O
reported O O
in O O
a O O
single O B_MEASURE
case O I_MEASURE
of O O
gastric O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
[ O I_DISEASE/I_LOCATION
12 O I_DISEASE/I_LOCATION
] O I_DISEASE/I_LOCATION
, O O
and O O
amplification O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PIK3CA O B_GENE
associated O O
with O O
elevated O B_DISEASE/B_GENE
mRNA O I_DISEASE/I_GENE
levels O I_DISEASE/I_GENE
has O O
been O O
found O O
in O O
36 O B_PERSON
% O I_PERSON
of O O
gastric O B_DISEASE/B_PERSON
cancer O I_DISEASE/I_PERSON
[ O I_DISEASE/I_PERSON
11 O I_DISEASE/I_PERSON
] O I_DISEASE/I_PERSON
. O O

More O O
recently O O
, O O
Samuels O O
et O O
al O O
. O O
screened O O
a O O
diverse O O
spectrum O O
of O O
human B B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
cancers O O
for O O
mutation O O
in O O
16 O O
PI3K O O
or O O
PI3K O O
- O O
like O O
genes O O
and O O
found O O
a O O
high O O
frequency O O
of O O
somatic O O
mutation O O
in O O
PIK3CA O O
, O O
which O O
encodes O O
the O O
p110 O O
alpha O O
catalytic O O
subunit O O
. O O

Major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
colorectal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CRC O B_DISEASE/B_LOCATION
) O O
identified O O
PIK3CA O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
in O O
74 O B_MEASURE
out O O
of O O
234 O B_MEASURE
( O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
cases O B_PERSON/B_DISEASE
, O O
while O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
were O O
also O O
noted O O
in O O
3 O B_NUMBER[MEASURE]
out O O
of O O
12 O B_MEASURE
( O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
gastric O B_DISEASE/B_PERSON
cancers O I_DISEASE/I_PERSON
. O O

Reported O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O O
mostly O O
of O O
missense O B_DISEASE/B_GENE
type O B_DISEASE/I_GENE
, O O
and O O
clustered O O
within O O
2 O B_LOCATION/B_BIO
regions O I_LOCATION/I_BIO
in O O
the O O
helical O B_ENZYME[GENE]/B_DISEASE
and O O
kinase O B_GENE/B_LOCATION
domains O I_GENE/I_LOCATION
. O O

Expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
a O O
" O B_PERSON/B_COLOR
hot O B_PERSON/I_COLOR
- O O
spot O B_LOCATION/B_BIO
" O O
mutant O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O O
H1047R O B_TIME[MEASURE]/B_GENE
, O O
conferred O O
a O O
significant O B_LOCATION
up O I_LOCATION
- O O
regulation O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
lipid O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
PIK3CA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
suggesting O O
it O O
as O O
an O O
activating O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_ENZYME[GENE]
[ O O
13 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

In O O
this O O
study O O
, O O
we O O
have O O
examined O O
a O O
series O O
of O O
94 O O
human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
gastric O O
adenocarcinomas O O
for O O
PIK3CA O O
mutation O O
. O O

We O O
have O O
also O O
examined O O
PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
expression O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
level O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
by O O
extracting O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
a O O
large O B_GENE/B_MEASURE
- O O
scale O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
gene O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profiling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
previously O O
performed O O
for O O
these O O
cases O B_PERSON/B_DISEASE
[ O O
14 O B_MEASURE
, O O
15 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Using O O
SAM O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlating O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
PIK3CA O B_DISEASE/B_GENE
have O O
also O O
been O O
identified O O
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Patient B B_PERSON/B_LOCATION
samples O O
preparation O O

DNA O O
samples O O
used O O
for O O
sequencing O O
were O O
prepared O O
from O O
frozen O O
tumour O O
and O O
non O O
- O O
tumour O O
gastric O O
mucosae O O
from O O
94 O O
gastric O O
cancer O O
patients B B_PERSON
who O O
underwent O O
gastrectomy O O
in O O
the O O
Department O O
of O O
Surgery O O
, O O
Queen O O
Mary O O
Hospital O O
, O O
The O O
University O O
of O O
Hong O O
Kong O O
, O O
as O O
previously O O
described O O
[ O O
16 O O
] O O
. O O

Majority O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O O
the O O
frozen O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
n O B_OTHER/B_MEASURE
= O O
81 O B_MEASURE
) O O
showed O O
tumour O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component O B_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
over O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
whereas O O
in O O
13 O B_MEASURE/B_LOCATION
cases O B_MEASURE/I_LOCATION
a O O
lower O B_MEASURE
proportion O I_MEASURE
between O O
50 O B_MEASURE
to O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
was O O
accepted O O
due O O
to O O
the O O
tumours O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inherent O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diffuse O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infiltrative O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
entrapment O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
non O B_DISEASE
- O O
neoplastic O B_DISEASE
components O I_DISEASE
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
microsatellite O B_DISEASE/B_LOCATION
instability O I_DISEASE/I_LOCATION
( O O
MSI O B_DISEASE/B_LOCATION
) O O
, O O
BRAF O B_GENE/B_DISEASE
and O O
KRAS O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
performed O O
and O O
reported O O
previously O O
[ O O
16 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

RNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
preparation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiling O O
using O O
a O O
cDNA O B_MEASURE/B_LOCATION
microarray O B_MEASURE/I_LOCATION
containing O O
44 O B_MEASURE
, O O
500 O B_MEASURE
cDNA O I_MEASURE
clones O I_MEASURE
, O O
representing O O
around O O
30 O B_MEASURE
, O O
300 O B_MEASURE
unique O I_MEASURE
genes O I_MEASURE
, O O
has O O
been O O
performed O O
and O O
reported O O
in O O
90 O B_NUMBER[MEASURE]
of O O
these O O
tumours O B_DISEASE/B_BIO
in O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
22 O B_PERSON/B_PROTEIN[GENE]
non O B_PERSON/I_PROTEIN[GENE]
- O O
tumour O B_DISEASE/B_BIO
gastric O I_DISEASE/I_BIO
mucosae O I_DISEASE/I_BIO
[ O O
14 O B_MEASURE
, O O
15 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
approved O O
by O O
the O O
Ethics O B_PERSON/B_ORGANIZATION
Committee O I_PERSON/I_ORGANIZATION
of O O
the O O
University O B_LOCATION/B_ORGANIZATION
of O O
Hong O B_LOCATION
Kong O I_LOCATION
. O O

Mutational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Mutation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
PIK3CA O B_GENE/B_DISEASE
was O O
performed O O
for O O
exons O B_MEASURE
9 O I_MEASURE
and O O
20 O B_NUMBER[MEASURE]
, O O
covering O O
the O O
mutational O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hotspots O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
and O O
for O O
exon O B_GENE
18 O I_GENE
, O O
from O O
which O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
was O O
found O O
in O O
a O O
gastric O B_DISEASE/B_PERSON
cancer O I_DISEASE/I_PERSON
. O O

Mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_PERSON
in O O
these O O
3 O B_GENE/B_BIO
exons O I_GENE/I_BIO
constituted O O
80 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
all O O
PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
detected O O
in O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O O
13 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
intron O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
external O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
amplification O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
primers O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
internal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
primers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
designed O O
according O O
to O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O O
13 O B_LOCATION/B_MEASURE
] O I_LOCATION/I_MEASURE
with O O
some O O
modifications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
[ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
see O O
Additional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
file O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
primers O B_GENE
for O O
exon O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
modified O O
to O O
avoid O O
amplification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
homologous O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
located O O
in O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chromosomes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
products O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O O
generated O O
using O O
the O O
external O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
directly O O
sequenced O O
using O O
the O O
internal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
the O O
DYEnamic O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(TM) O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ET O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Terminator O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cycle O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sequencing O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Kit O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Amersham O B_MEASURE/B_LOCATION
Biosciences O I_MEASURE/I_LOCATION
, O O
Freiburg O B_LOCATION
, O O
Germany O B_LOCATION/B_MEASURE
) O O
according O O
to O O
the O O
manufacturer O B_PERSON
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
instruction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Electrophoresis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
performed O O
in O O
the O O
ABI O B_LOCATION
Prism O I_LOCATION
(R) O I_LOCATION
3700 O I_LOCATION
DNA O I_LOCATION
Analyzer O I_LOCATION
( O O
Applied O B_MEASURE/B_ORGANIZATION
Biosystems O I_MEASURE/I_ORGANIZATION
, O O
Foster O B_LOCATION/B_PERSON
City O I_LOCATION/I_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

For O O
each O O
exon O B_GENE/B_PERSON
, O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
generated O O
from O O
2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
independent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reactions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
sequencing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
forward O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reverse O B_LOCATION/B_GENE
strands O I_LOCATION/I_GENE
. O O

For O O
exon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
9 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
independent O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
followed O O
by O O
sequencing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
forward O B_GENE
strand O I_GENE
were O O
performed O O
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
chromatograms O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
was O O
performed O O
using O O
the O O
mutation O B_PRODUCT[OBJECT]/B_ORGANIZATION
analysis O I_PRODUCT[OBJECT]/I_ORGANIZATION
software O I_PRODUCT[OBJECT]/I_ORGANIZATION
Mutation O I_PRODUCT[OBJECT]/I_ORGANIZATION
Explorer O I_PRODUCT[OBJECT]/I_ORGANIZATION
(TM) O I_PRODUCT[OBJECT]/I_ORGANIZATION
( O O
SoftGenetics O B_MEASURE/B_ORGANIZATION
, O O
State O B_LOCATION
College O I_LOCATION
, O O
PA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

Extraction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

Gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
extracted O O
from O O
the O O
microarray O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
containing O O
126 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
90 O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
gastric O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
14 O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lymph O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
node O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
metastasis O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
22 O B_DISEASE/B_LOCATION
non O I_DISEASE/I_LOCATION
- O O
tumour O B_DISEASE
gastric O I_DISEASE
mucosae O I_DISEASE
) O O
based O O
on O O
a O O
3 O B_NUMBER[MEASURE]
- O O
fold O B_TIME[MEASURE]/B_LOCATION
signal O I_TIME[MEASURE]/I_LOCATION
above O O
background O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
for O O
either O O
channel O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
with O O
80 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
good O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
14 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

Gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
20 O B_MEASURE
, O O
336 O B_MEASURE/B_PERSON
cDNA O I_MEASURE/I_PERSON
clones O I_MEASURE/I_PERSON
satisfied O O
this O O
selection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
were O O
extracted O O
, O O
which O O
included O O
a O O
cDNA O B_MEASURE/B_GENE
clone O I_MEASURE/I_GENE
corresponding O I_MEASURE/I_GENE
to O O
PIK3CA O B_GENE
( O O
IMAGE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
clone O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
number O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
345430 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
GenBank O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accession O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
no O O
. O O
W72473 O B_MEASURE
) O O
. O O

Expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
PIK3CA O B_GENE
was O O
extracted O O
and O O
the O O
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
tumour O B_DISEASE
and O O
non O B_DISEASE/B_LOCATION
- O O
tumour O B_DISEASE
tissues O I_DISEASE
were O O
examined O O
using O O
the O O
Student O B_LOCATION/B_PERSON
' O I_LOCATION/I_PERSON
s O I_LOCATION/I_PERSON
t O I_LOCATION/I_PERSON
- O O
Test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

SAM O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
performed O O
to O O
identify O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlating O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
PIK3CA O B_GENE/B_DISEASE
[ O O
17 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
missing O B_MEASURE
values O I_MEASURE
in O O
the O O
dataset O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
estimated O O
by O O
a O O
K O B_OTHER/B_NUMBER[MEASURE]
- O O
nearest O B_LOCATION/B_MEASURE
neighbours O B_LOCATION/I_MEASURE
impute O O
algorithm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
10 O B_PERSON/B_LOCATION
nearest O I_PERSON/I_LOCATION
neighbour O I_PERSON/I_LOCATION
[ O I_PERSON/I_LOCATION
18 O I_PERSON/I_LOCATION
] O I_PERSON/I_LOCATION
followed O O
by O O
5000 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
permutations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
SAM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Among O O
the O O
94 O B_DISEASE/B_GENE
gastric O B_DISEASE/I_GENE
adenocarcinoma O B_DISEASE/I_GENE
analysed O O
, O O
we O O
have O O
detected O O
PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
4 O B_MEASURE
cases O I_MEASURE
. O O

Two O B_PERSON
cases O I_PERSON
harboured O O
the O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
A3140G O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O O
H1047R O B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
in O O
exon O B_GENE
20 O I_GENE
, O O
and O O
the O O
other O B_SEQUENCE[MEASURE]/B_PERSON
2 O I_SEQUENCE[MEASURE]/I_PERSON
cases O I_SEQUENCE[MEASURE]/I_PERSON
with O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
G1624A O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
E542K O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
G1633A O B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
( O O
E545K O B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
in O O
exon O B_GENE/B_PERSON
9 O I_GENE/I_PERSON
. O O

Representative O B_PERSON
sequence O I_PERSON
chromatograms O I_PERSON
are O O
shown O O
in O O
figure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
four O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
corresponding O B_DISEASE/B_GENE
non O I_DISEASE/I_GENE
- O O
neoplastic O B_DISEASE/B_PERSON
mucosae O I_DISEASE/I_PERSON
and O O
thus O O
were O O
confirmed O O
as O O
somatic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Though O O
the O O
overall O B_MEASURE
mutation O I_MEASURE
frequency O I_MEASURE
( O O
4 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
) O O
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
of O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
nature O B_LOCATION/B_DISEASE
of O O
the O O
4 O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
found O O
were O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
those O O
identified O O
at O O
the O O
reported O O
hotspots O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
H1047R O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O O
been O O
reported O O
in O O
2 O B_NUMBER[MEASURE]/B_DISEASE
gastric O I_NUMBER[MEASURE]/I_DISEASE
cancers O I_NUMBER[MEASURE]/I_DISEASE
and O O
15 O B_DISEASE
colorectal O I_DISEASE
cancers O I_DISEASE
[ O O
13 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

While O O
the O O
E542K O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
E545K O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
not O O
found O O
in O O
gastric O B_DISEASE/B_PERSON
cancer O I_DISEASE/I_PERSON
in O O
the O O
previous O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
large O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
colorectal O B_DISEASE/B_PERSON
tumours O I_DISEASE/I_PERSON
did O O
harbour O O
these O O
2 O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
spectrum O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
their O O
corresponding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
clinico O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
pathological O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
listed O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

We O O
noted O O
a O O
higher O B_MEASURE
tendency O I_MEASURE
of O O
high O B_GENE
- O O
level O B_DISEASE/B_MEASURE
MSI O I_DISEASE/I_MEASURE
in O O
gastric O B_PERSON/B_ORGANIZATION
cancers O I_PERSON/I_ORGANIZATION
with O O
PIK3CA O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
( O O
3 O B_MEASURE
in O O
4 O B_MEASURE
, O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
than O O
in O O
those O O
without O O
( O O
18 O B_NUMBER[MEASURE]
in O O
90 O B_NUMBER[MEASURE]
, O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
. O O

Moreover O O
, O O
though O O
the O O
overall O B_MEASURE
incidence O I_MEASURE
of O O
KRAS O B_DISEASE/B_GENE
mutation O I_DISEASE/I_GENE
in O O
the O O
studied O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
population O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
8 O B_NUMBER[MEASURE]
in O O
94 O B_MEASURE/B_PERSON
) O O
, O O
2 O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
4 O B_PERSON/B_DISEASE
gastric O I_PERSON/I_DISEASE
cancers O I_PERSON/I_DISEASE
with O O
PIK3CA O B_DISEASE
mutation O I_DISEASE
also O O
harboured O O
a O O
KRAS O B_DISEASE/B_GENE
mutation O I_DISEASE/I_GENE
. O O

Since O O
over O O
- O O
expression O B_GENE
of O O
PIK3CA O B_GENE
has O O
been O O
reported O O
in O O
gastric O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
[ O I_DISEASE/I_LOCATION
11 O I_DISEASE/I_LOCATION
] O I_DISEASE/I_LOCATION
, O O
we O O
have O O
also O O
extracted O O
PIK3CA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cDNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
microarray O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
these O O
cases O B_PERSON/B_DISEASE
[ O O
14 O B_MEASURE
, O O
15 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

We O O
have O O
confirmed O O
that O O
expression O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
of O O
PIK3CA O B_GENE
was O O
significantly O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
gastric O B_DISEASE
cancers O I_DISEASE
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
87 O B_MEASURE
, O O
mean O B_MEASURE/B_LOCATION
= O O
0 O B_MEASURE
. O O
099 O B_MEASURE
, O O
SD O B_DISEASE/B_PROTEIN[GENE]
= O O
0 O B_NUMBER[MEASURE]
. O O
428 O B_MEASURE
) O O
when O O
compared O O
with O O
non O B_DISEASE/B_LOCATION
- O O
neoplastic O B_DISEASE/B_PERSON
gastric O I_DISEASE/I_PERSON
mucosae O I_DISEASE/I_PERSON
( O O
n O B_MEASURE/B_LOCATION
= O O
22 O B_MEASURE
, O O
mean O B_MEASURE/B_LOCATION
= O O
- O O
0 O B_MEASURE
. O O
418 O B_MEASURE
, O O
SD O B_DISEASE/B_MEASURE
= O O
0 O B_NUMBER[MEASURE]
. O O
426 O B_MEASURE
; O O
Student O B_PERSON
' O O
s O B_PERSON/B_LOCATION
t O B_PERSON/I_LOCATION
- O O
Test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Using O O
PIK3CA O B_GENE/B_MEASURE
expression O I_GENE/I_MEASURE
level O I_GENE/I_MEASURE
as O O
a O O
continuous O B_MEASURE/B_PERSON
variable O B_MEASURE/I_PERSON
for O O
SAM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
17 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
we O O
found O O
2910 O B_GENE/B_BIO
cDNA O I_GENE/I_BIO
clones O I_GENE/I_BIO
( O O
corresponding O O
to O O
about O O
2546 O B_MEASURE
unique O I_MEASURE
genes O I_MEASURE
) O O
whose O O
expression O B_GENE/B_MEASURE
associated O O
positively O O
with O O
PIK3CA O B_DISEASE/B_GENE
expression O I_DISEASE/I_GENE
( O O
median O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
false O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
= O O
0 O B_MEASURE
. O O
372 O B_MEASURE
, O O
Delta O B_PROTEIN[GENE]/B_MEASURE
= O O
1 O B_MEASURE
. O O
107 O B_MEASURE
) O O
[ O B_OTHER/B_LOCATION
see O O
Additional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
file O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Interestingly O O
, O O
no O O
gene O B_GENE/B_DISEASE
was O O
found O O
to O O
be O O
negatively O O
associated O O
with O O
PIK3CA O B_DISEASE
expression O I_DISEASE
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
have O O
reported O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
4 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
of O O
gastric O B_DISEASE/B_PERSON
cancer O I_DISEASE/I_PERSON
. O O

A O O
high O B_MEASURE
tendency O I_MEASURE
( O O
3 O B_SEQUENCE[MEASURE]
in O O
4 O B_MEASURE
) O O
of O O
mismatch O B_DISEASE/B_GENE
repair O I_DISEASE/I_GENE
deficiency O I_DISEASE/I_GENE
was O O
noted O O
in O O
cases O B_PERSON/B_DISEASE
harbouring O O
PIK3CA O B_DISEASE
mutation O I_DISEASE
. O O

Though O O
the O O
small O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O O
not O O
justify O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
claim O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
significance O B_TIME[MEASURE]/B_DISEASE
; O O
suggestion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O O
such O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
despite O O
of O O
its O O
not O O
being O O
mentioned O O
by O O
the O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
can O O
be O O
found O O
from O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
CRC O B_MEASURE
by O O
Samuels O B_PERSON
et O I_PERSON
al O I_PERSON
. O O
. O O

From O O
their O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
33 O B_MEASURE
MSI O I_MEASURE
and O O
201 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
microsatellite O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
stable O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
MSS O B_DISEASE/B_PROTEIN[GENE]
) O O
CRC O B_DISEASE/B_MEASURE
cases O I_DISEASE/I_MEASURE
, O O
PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
48 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
MSI O B_DISEASE/B_PERSON
tumours O I_DISEASE/I_PERSON
, O O
but O O
only O O
in O O
29 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
MSS O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tumours O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

A O O
significant O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
association O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
have O O
been O O
revealed O O
if O O
statistical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O O
been O O
applied O O
( O O
Fisher O B_MEASURE/B_LOCATION
' O I_MEASURE/I_LOCATION
s O I_MEASURE/I_LOCATION
exact O I_MEASURE/I_LOCATION
test O I_MEASURE/I_LOCATION
, O O
p O O
= O O
0 O B_MEASURE
. O O
014 O B_MEASURE
) O O
[ O O
13 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

Gastrointestinal O B_DISEASE/B_PERSON
tract O I_DISEASE/I_PERSON
cancers O I_DISEASE/I_PERSON
with O O
MSI O B_DISEASE
are O O
known O O
to O O
have O O
a O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
molecular O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
tumour O B_DISEASE_ADJECTIVE[DISEASE]
evolution O I_DISEASE_ADJECTIVE[DISEASE]
compared O O
with O O
their O O
MSS O B_PERSON/B_LOCATION
counterparts O I_PERSON/I_LOCATION
[ O O
19 O B_MEASURE
, O O
20 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

This O O
can O O
be O O
attributed O O
to O O
their O O
propensity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
frameshift O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
repeat O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
resulting O O
in O O
selective O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disruption O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
within O O
their O O
coding O B_GENE/B_LOCATION
regions O I_GENE/I_LOCATION
. O O

With O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
poly O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
adenine O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
its O O
coding O B_LOCATION/B_PERSON
region O I_LOCATION/I_PERSON
, O O
PTEN O B_GENE
can O O
be O O
inactivated O O
through O O
frameshift O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
MSI O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CRC O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
resulting O O
in O O
the O O
selective O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
targeting O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
PI3K O B_GENE
- O O
AKT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
21 O B_MEASURE
, O O
22 O B_MEASURE
] O O
. O O

It O O
is O O
also O O
known O O
that O O
mismatch O B_DISEASE
repair O I_DISEASE
deficiency O I_DISEASE
would O O
lead O O
to O O
an O O
elevated O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
missense O B_DISEASE
mutation O I_DISEASE
due O O
to O O
impaired O B_DISEASE/B_GENE
single O I_DISEASE/I_GENE
nucleotide O I_DISEASE/I_GENE
mismatch O I_DISEASE/I_GENE
repair O I_DISEASE/I_GENE
[ O O
23 O B_DISEASE/B_GENE
] O B_DISEASE/I_GENE
. O O

Thus O O
, O O
the O O
observed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
higher O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PIK3CA O B_DISEASE/B_GENE
missense O I_DISEASE/I_GENE
mutation O I_DISEASE/I_GENE
in O O
MSI O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
colorectal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
gastric O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancers O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
suggests O O
yet O O
another O O
mechanism O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O O
the O O
PI3K O B_GENE
- O O
AKT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O O
mismatch O B_DISEASE/B_GENE
repair O B_DISEASE/I_GENE
deficiency O B_DISEASE/I_GENE
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O O
showed O O
a O O
higher O B_MEASURE
tendency O I_MEASURE
of O O
KRAS O B_DISEASE/B_GENE
mutation O I_DISEASE/I_GENE
in O O
cases O B_PERSON/B_DISEASE
with O O
PIK3CA O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
( O O
2 O B_NUMBER[MEASURE]
in O O
4 O B_MEASURE
) O O
than O O
in O O
those O O
without O O
( O O
6 O B_NUMBER[MEASURE]
in O O
90 O B_NUMBER[MEASURE]
) O O
. O O

Yet O O
again O O
due O O
to O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
mutations O B_DISEASE
in O O
our O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O O
not O O
be O O
claimed O O
. O O

In O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
by O O
Samuels O B_LOCATION/B_PERSON
et O I_LOCATION/I_PERSON
al O O
. O O
, O O
some O O
of O O
the O O
colorectal O B_DISEASE/B_PERSON
tumours O I_DISEASE/I_PERSON
with O O
PIK3CA O B_DISEASE
mutation O I_DISEASE
also O O
harboured O O
KRAS O B_GENE/B_LOCATION
or O O
BRAF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
13 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
PI3K O B_GENE
- O O
AKT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
to O O
have O O
a O O
close O B_PERSON/B_MEASURE
association O I_PERSON/I_MEASURE
with O O
the O O
RAS O B_GENE/B_DISEASE
- O O
MEKK O B_GENE/B_LOCATION
signalling O I_GENE/I_LOCATION
pathway O I_GENE/I_LOCATION
[ O O
8 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Constitutively O O
active O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
RAS O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
interact O O
with O O
the O O
catalytic O B_ENZYME[GENE]
subunit O I_ENZYME[GENE]
of O O
PI3K O B_GENE
and O O
lead O O
to O O
its O O
activation O B_GENE
. O O

Ras O B_GENE/B_DISEASE
- O O
dependent O B_GENE
PI3K O I_GENE
activation O I_GENE
contributes O O
to O O
the O O
transforming O O
phenotype O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
mediating O O
anchorage O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
independent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cytoskeletal O B_DISEASE/B_ORGANISM_FUNCTION
reorganisation O I_DISEASE/I_ORGANISM_FUNCTION
and O O
apoptosis O B_DISEASE_ADJECTIVE[DISEASE]
evasion O I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
has O O
been O O
observed O O
that O O
genes O B_BIO/B_DISEASE
involved O O
in O O
the O O
same O B_DISEASE/B_LOCATION
signalling O I_DISEASE/I_LOCATION
pathway O I_DISEASE/I_LOCATION
may O O
manifest O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
cancer O B_GENE/B_BIO
cells O I_GENE/I_BIO
in O O
a O O
mutually O O
exclusive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
presumably O O
due O O
to O O
the O O
lack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
selective O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
growth O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
advantage O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
having O O
a O O
second O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
hit O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
the O O
already O O
altered O O
pathway O B_DISEASE/B_GENE
. O O

A O O
prominent O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
example O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
mutually O O
exclusive O B_DISEASE_ADJECTIVE[DISEASE]
occurrence O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
BRAF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hotspot O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
V600E O B_MEASURE/B_GENE
) O O
and O O
KRAS O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
colorectal O B_MEASURE
cancer O I_MEASURE
[ O I_MEASURE
24 O I_MEASURE
, O O
25 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

However O O
, O O
there O O
exist O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
examples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
alterations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
components O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
same O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
may O O
lead O O
to O O
a O O
multi O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
level O B_DISEASE_ADJECTIVE[DISEASE]
modulation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
its O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
non O B_GENE/B_DISEASE
- O O
V600E O B_DISEASE/B_GENE
BRAF O I_DISEASE/I_GENE
mutations O I_DISEASE/I_GENE
tend O O
to O O
occur O O
together O O
with O O
KRAS O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
[ O O
26 O B_MEASURE
] O I_MEASURE
, O O
and O O
inactivation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
secreted O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
frizzled O O
- O O
related O O
proteins O B_GENE/B_DISEASE
( O O
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
WNT O B_GENE
) O O
by O O
promoter O B_GENE/B_BIO
methylation O I_GENE/I_BIO
frequently O O
coincides O O
with O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
the O O
Adenomatous O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Polyposis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Coli O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
achieve O O
multi O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
level O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
WNT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
colorectal O B_DISEASE/B_BIO
cancers O I_DISEASE/I_BIO
[ O O
27 O B_MEASURE
] O I_MEASURE
. O O

Whether O O
PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independently O O
from O O
RAS O B_GENE/B_DISEASE
, O O
or O O
acts O O
synergistically O O
with O O
RAS O B_GENE/B_DISEASE
to O O
produce O O
additive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
the O O
activation O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
same O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
awaits O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clarification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
extracting O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
we O O
have O O
confirmed O O
the O O
up O B_LOCATION/B_LANGUAGE
- O O
regulation O B_MEASURE/B_LOCATION
of O O
PIK3CA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
gastric O B_DISEASE
cancer O I_DISEASE
tissues O I_DISEASE
compared O O
with O O
the O O
non O B_DISEASE/B_LOCATION
- O O
neoplastic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
gastric O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
mucosae O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
identified O O
a O O
large O B_MEASURE/B_PERSON
number O B_MEASURE/I_PERSON
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
showed O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
expression O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
PIK3CA O B_DISEASE/B_GENE
. O O

These O O
genes O B_BIO/B_GENE
participate O O
in O O
diverse O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
177 O B_MEASURE/B_PERSON
as O O
putative O B_TIME[MEASURE]/B_DISEASE
cell O B_TIME[MEASURE]/I_DISEASE
cycle O B_TIME[MEASURE]/I_DISEASE
- O O
regulated O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
28 O B_MEASURE
] O I_MEASURE
and O O
126 O B_TIME[MEASURE]/B_LOCATION
mapped O O
to O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
known O O
functions O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycle O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
regulation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]
replication O I_DISEASE_ADJECTIVE[DISEASE]
[ O I_DISEASE_ADJECTIVE[DISEASE]
see O O
Additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
file O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

While O O
some O O
of O O
these O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
maybe O O
induced O O
by O O
PIK3CA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
others O B_PERSON/B_LOCATION
maybe O O
co O O
- O O
ordinately O O
regulated O O
by O O
common O B_GENE
upstream O I_GENE
signals O I_GENE
. O O

Expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
set O O
at O O
one O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
point O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
limited O O
in O O
differentiating O O
the O O
above O B_DISEASE
cause O I_DISEASE
and O O
consequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
yet O O
it O O
certainly O O
revealed O O
the O O
complexity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
carcinogenic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
the O O
intricate O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
relationship O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
PIK3CA O B_GENE
signalling O O
with O O
other O B_DISEASE/B_ORGANISM_FUNCTION
cellular O I_DISEASE/I_ORGANISM_FUNCTION
processes O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Contrary O B_PERSON/B_MEASURE
to O O
our O O
expectation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O O
the O O
incidence O B_MEASURE
of O O
PIK3CA O B_DISEASE/B_LOCATION
mutation O I_DISEASE/I_LOCATION
found O O
in O O
the O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
is O O
much O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
compared O O
with O O
that O O
observed O O
by O O
Samuel O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O I_PERSON/I_LOCATION
. O O

( O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
[ O O
13 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

The O O
reason O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
discrepancy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O O
simply O O
be O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sample O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bias O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
involved O O
only O O
a O O
small O B_MEASURE
number O I_MEASURE
of O O
gastric O B_PERSON/B_ORGANIZATION
cancers O I_PERSON/I_ORGANIZATION
( O O
n O B_OTHER/B_MEASURE
= O O
12 O B_MEASURE
) O O
. O O

However O O
, O O
ethnic O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
differences O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
can O O
also O O
be O O
another O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
diverse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrum O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
aetiological O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gastric O B_DISEASE
cancers O I_DISEASE
in O O
different O B_LOCATION/B_PERSON
geographical O I_LOCATION/I_PERSON
locations O I_LOCATION/I_PERSON
may O O
be O O
paralleled O O
by O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
tumour O B_DISEASE/B_GENE
development O I_DISEASE/I_GENE
. O O

Since O O
our O O
current O O
study O O
is O O
only O O
based O O
on O O
a O O
Chinese O O
population O O
with O O
an O O
intermediate O O
gastric O O
cancer O O
incidence O O
, O O
further O O
studies O O
involving O O
patients B B_PERSON
from O O
different O O
ethnic O O
groups O O
will O O
be O O
able O O
to O O
address O O
this O O
possibility O O
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Large O B_MEASURE/B_LOCATION
- O O
scale O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gastric O B_DISEASE/B_PERSON
adenocarcinomas O I_DISEASE/I_PERSON
for O O
PIK3CA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
revealed O O
a O O
mutation O B_MEASURE
incidence O I_MEASURE
of O O
4 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
. O O

Increased O O
PIK3CA O B_DISEASE/B_GENE
expression O I_DISEASE/I_GENE
level O I_DISEASE/I_GENE
was O O
observed O O
in O O
gastric O B_DISEASE
tumours O I_DISEASE
compared O O
with O O
non O B_DISEASE/B_LOCATION
- O O
neoplastic O B_DISEASE/B_BIO
mucosae O I_DISEASE/I_BIO
. O O

This O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
PIK3CA O B_GENE/B_DISEASE
level O I_GENE/I_DISEASE
was O O
associated O O
with O O
the O O
elevated O B_GENE
expression O I_GENE
of O O
a O O
large O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
may O O
constitute O O
the O O
upstream O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
regulators O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or O O
downstream O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targets O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PIK3CA O B_GENE
along O O
the O O
PI3K O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
signalling O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
pathway O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Competing O O
interests O B_DISEASE

The O O
author O B_PERSON/B_LOCATION
( O O
s O O
) O O
declare O O
that O O
they O O
have O O
no O O
competing O O
interests O B_PERSON/B_ORGANIZATION
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

VSWL O B_PERSON
carried O O
out O O
the O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
performed O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
drafted O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

CWW O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
TLC O B_LOCATION/B_ORGANIZATION
, O O
WZ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assisted O O
in O O
the O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

KMC O B_PERSON/B_ORGANIZATION
provided O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

ASWC O B_PERSON
assisted O O
in O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
edited O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

SS O B_LOCATION/B_ORGANIZATION
and O O
XC O B_LOCATION/B_ORGANIZATION
participated O O
in O O
the O O
microarray O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

STY O B_PERSON/B_ORGANIZATION
and O O
SYL O B_PERSON/B_ORGANIZATION
conceived O O
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
participated O O
in O O
its O O
design O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
coordination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
and O O
edited O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

All O O
authors O B_PERSON/B_NUMBER[MEASURE]
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

Pre O B_LOCATION/B_PERSON
- O O
publication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

The O O
pre O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
publication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
accessed O O
here O O
: O O

Supplementary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
Material O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE

Identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
novel O B_PERSON/B_DISEASE
Beh O I_PERSON/I_DISEASE
c O I_PERSON/I_DISEASE
et O I_PERSON/I_DISEASE
' O O
s O B_DISEASE/B_GENE
disease O B_DISEASE/I_GENE
autoantigen O B_DISEASE/I_GENE

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

There O O
has O O
been O O
some O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
Beh O B_DISEASE/B_GENE
c O I_DISEASE/I_GENE
et O I_DISEASE/I_GENE
' O O
s O O
disease O B_DISEASE
( O O
BD O B_DISEASE/B_PROTEIN[GENE]
) O O
has O O
a O O
significant O B_DISEASE/B_LOCATION
autoimmune O I_DISEASE/I_LOCATION
component O I_DISEASE/I_LOCATION
but O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
putative O B_DISEASE/B_LOCATION
autoantigens O I_DISEASE/I_LOCATION
has O O
not O O
been O O
well O O
characterized O O
. O O

In O O
the O O
initial O O
analysis O O
of O O
the O O
autoantibody O O
profile O O
in O O
39 O O
Chinese O O
BD O O
patients B B_PERSON/B_LOCATION
, O O
autoantibodies O O
to O O
cellular O O
proteins O O
were O O
uncovered O O
in O O
23 O O
% O O
as O O
determined O O
by O O
immunoblotting O O
. O O

We O O
have O O
now O O
identified O O
one O B_NUMBER[MEASURE]
of O O
the O O
major O B_GENE/B_MEASURE
autoantibody O I_GENE/I_MEASURE
specificities O I_GENE/I_MEASURE
using O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cloning O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Serum O O
from O O
a O O
BD O O
patient B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
as O O
a O O
probe O O
to O O
immunoscreen O O
a O O
lambda O O
ZAP O O
expression O O
cDNA O O
library O O
. O O

Candidate O B_PERSON/B_GENE
autoantigen O I_PERSON/I_GENE
cDNAs O I_PERSON/I_GENE
were O O
characterized O O
by O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
their O O
expressed O O
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
examined O O
for O O
reactivity O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
entire O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
panel O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
BD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sera O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
immunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Reactivity O O
was O O
also O O
examined O O
with O O
normal O O
control O O
sera O O
and O O
disease O O
control O O
sera O O
from O O
patients B B_PERSON/B_BIO
with O O
lupus O O
and O O
Sj O O
o O O
gren O O
' O O
s O O
syndrome O O
. O O

Six O O
independent O O
candidate O O
clones O O
were O O
isolated O O
from O O
the O O
cDNA O O
library O O
screen O O
and O O
were O O
identified O O
as O O
overlapping O O
partial O O
human B B_SPECIES[BIO]/B_GENE
kinectin O O
cDNAs O O
. O O

The O O
finding O O
that O O
kinectin O O
was O O
an O O
autoantigen O O
was O O
verified O O
in O O
9 O O
out O O
of O O
39 O O
( O O
23 O O
% O O
) O O
BD O O
patient B B_PERSON/B_LOCATION
sera O O
by O O
immunoprecipitation O O
of O O
the O O
in O O
vitro O O
translation O O
products O O
. O O

Sera O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
from O O
controls O B_LOCATION
showed O O
no O O
reactivity O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
participant O B_PERSON/B_MEASURE
in O O
autoimmune O B_DISEASE
pathogenesis O I_DISEASE
in O O
BD O B_DISEASE/B_PERSON
and O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
autoantibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
kinectin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
serodiagnostics O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
discussed O O
. O O

Introduction O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Beh O B_PERSON/B_LOCATION
c O I_PERSON/I_LOCATION
et O I_PERSON/I_LOCATION
' O O
s O O
disease O B_DISEASE/B_LOCATION
( O O
BD O B_DISEASE/B_PROTEIN[GENE]
) O O
is O O
a O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]
vasculitic O I_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
typified O O
by O O
a O O
triad O B_DISEASE/B_MEASURE
of O O
symptoms O B_DISEASE
including O O
recurrent O B_DISEASE
oral O I_DISEASE
ulcers O I_DISEASE
, O O
genital O B_DISEASE
ulcers O I_DISEASE
and O O
uveitis O B_DISEASE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
skin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
joint O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
large O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vessels O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
nervous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
gastrointestinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
systems O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O O
be O O
involved O O
. O O

BD O B_DISEASE
is O O
a O O
global O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
but O O
has O O
the O O
highest O B_MEASURE/B_LOCATION
prevalence O I_MEASURE/I_LOCATION
in O O
the O O
region O B_LOCATION
along O O
the O O
ancient O B_TIME[MEASURE]/B_LOCATION
' O I_LOCATION
Silk O B_LOCATION/B_PERSON
Road O I_LOCATION
' O O
in O O
China O B_LOCATION
. O O

The O O
etiopathogenesis O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
disease O B_DISEASE
remains O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
microbial O B_DISEASE/B_BACTERIUM[BIO]
agent O I_DISEASE/I_BACTERIUM[BIO]
triggers O I_DISEASE/I_BACTERIUM[BIO]
, O O
environmental O B_DISEASE_ADJECTIVE[DISEASE]
factors O I_DISEASE_ADJECTIVE[DISEASE]
, O O
genetic O B_DISEASE/B_GENE
predisposition O I_DISEASE/I_GENE
, O O
neutrophil O B_DISEASE/B_GENE
hyperfunction O I_DISEASE/I_GENE
, O O
endothelial O B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
dysfunction O I_DISEASE_ADJECTIVE[DISEASE]
and O O
immunological O B_DISEASE
abnormalities O I_DISEASE
involving O O
both O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
implicated O O
. O O

Increasing O O
amounts O B_MEASURE
of O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
supports O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
it O O
is O O
an O O
immune O B_DISEASE
- O O
mediated O O
vasculitis O B_DISEASE
, O O
and O O
that O O
abnormal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
B O B_OTHER/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reactions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
autoantigen O B_GENE
- O O
driven O O
autoimmunity O B_DISEASE
play O O
pivotal O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
roles O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
[ O O
1 O B_DISEASE/B_LOCATION
] O I_DISEASE/I_LOCATION
. O O

Systemic O B_DISEASE
lupus O I_DISEASE
erythematosus O I_DISEASE
( O O
SLE O B_LOCATION/B_ORGANIZATION
) O O
is O O
the O O
prototypic O B_DISEASE/B_PERSON
systemic O I_DISEASE/I_PERSON
autoimmune O I_DISEASE/I_PERSON
rheumatic O I_DISEASE/I_PERSON
disease O I_DISEASE/I_PERSON
with O O
autoantibodies O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
cellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O O
particularly O O
nuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
) O O
antigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
some O O
of O O
which O O
are O O
critically O O
implicated O O
in O O
the O O
autoimmune O B_DISEASE
pathology O I_DISEASE
while O O
others O B_PERSON
provide O O
valuable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serodiagnostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
markers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
the O O
disease O B_DISEASE
. O O

Unlike O O
the O O
picture O B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
in O O
SLE O B_DISEASE/B_LOCATION
and O O
other O B_DISEASE/B_PROTEIN[GENE]
related O B_DISEASE/I_PROTEIN[GENE]
rheumatic O B_DISEASE/I_PROTEIN[GENE]
diseases O B_DISEASE/I_PROTEIN[GENE]
, O O
in O O
BD O B_DISEASE/B_PERSON
, O O
antinuclear O B_DISEASE
antibodies O I_DISEASE
and O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
neutrophil O O
cytoplasmic O B_GENE/B_DISEASE
antigens O I_GENE/I_DISEASE
etc O I_GENE/I_DISEASE
. O O
are O O
not O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
date O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
since O O
neither O O
a O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantibody O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
pathognomonic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
help O O
establish O O
the O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BD O B_DISEASE/B_LOCATION
, O O
it O O
is O O
largely O O
or O O
solely O O
based O O
on O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestations O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
2 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
dilemma O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
a O O
rare O B_DISEASE/B_MEASURE
occurrence O I_DISEASE/I_MEASURE
in O O
clinical O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
practice O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nevertheless O O
, O O
since O O
the O O
1960s O O
, O O
there O O
have O O
been O O
reports O O
of O O
autoantibodies O O
against O O
certain O O
unknown O O
components O O
of O O
human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oral O O
mucosa O O
in O O
sera O O
of O O
patients B B_PERSON/B_BIO
with O O
BD O O
. O O

Since O O
then O O
, O O
sporadic O O
reports O O
on O O
findings O O
of O O
autoantibodies O O
in O O
this O O
disease O O
have O O
been O O
described O O
, O O
such O O
as O O
antibodies O O
to O O
retinal O O
antigen O O
( O O
s O O
) O O
, O O
heat O O
shock O O
protein O O
( O O
HSP O O
) O O
of O O
some O O
strains O O
of O O
Streptococcus B B_SPECIES[BIO]
sanguis I I_SPECIES[BIO]
cross O O
- O O
reactive O O
with O O
human B B_PERSON/B_SPECIES[BIO]
HSP O O
polypeptide O O
[ O O
3 O O
] O O
, O O
antibodies O O
to O O
endothelial O O
cell O O
antigens O O
( O O
AECA O O
) O O
and O O
antibodies O O
to O O
alpha O O
- O O
tropomyosin O O
[ O O
4 O O
, O O
5 O O
] O O
, O O
attesting O O
to O O
the O O
complicated O O
humoral O O
immune O O
disorders O O
in O O
this O O
disease O O
. O O

This O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
aimed O O
at O O
defining O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
autoantigens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O O
time O B_TIME[MEASURE]/B_LOCATION
- O O
tested O O
and O O
well O O
- O O
established O O
molecular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Immunoscreening O O
of O O
expression O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
libraries O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O O
BD O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sera O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
used O O
since O O
this O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O O
been O O
successfully O O
employed O O
in O O
the O O
characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
many O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinically O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
antigens O I_DISEASE_ADJECTIVE[DISEASE]
in O O
systemic O B_DISEASE/B_BIO
rheumatic O I_DISEASE/I_BIO
diseases O I_DISEASE/I_BIO
such O I_DISEASE/I_BIO
as O O
SS O B_LOCATION
- O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Ro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
9 O B_MEASURE
] O I_MEASURE
and O O
SS O B_LOCATION
- O O
B O B_PROTEIN[GENE]/B_DISEASE
/ O O
La O B_LOCATION
[ O O
10 O B_MEASURE
] O O
antigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
Sj O B_DISEASE/B_LOCATION
o O O
gren O B_LOCATION/B_MEASURE
' O O
s O B_DISEASE
syndrome O I_DISEASE
( O O
SjS O B_MEASURE/B_DISEASE
) O O
and O O
centromere O B_LOCATION
antigen O I_LOCATION
CENP O I_LOCATION
- O O
B O B_OTHER/B_MEASURE
[ O O
11 O B_MEASURE
] O O
in O O
scleroderma O B_DISEASE/B_BIO
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
have O O
been O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
using O O
this O O
strategy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
identify O O
interesting O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
autoantigens O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O O
have O O
other O B_DISEASE_ADJECTIVE[DISEASE]
biological O I_DISEASE_ADJECTIVE[DISEASE]
significance O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Examples O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
include O O
NOR90 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
hUBF O B_MEASURE
[ O O
12 O B_MEASURE
] O O
, O O
p80 O O
- O O
coilin O B_MEASURE/B_GENE
[ O O
13 O B_MEASURE
] O I_MEASURE
, O O
Golgi O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
autoantigens O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
14 O B_MEASURE
- O O
16 O B_MEASURE
] O I_MEASURE
and O O
, O O
more O O
recently O O
, O O
GW182 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O O
17 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Patients B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
sera O O

The O O
currently O O
used O O
empirical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BD O B_DISEASE
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
the O O
criteria O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
proposed O O
by O O
the O O
International O B_ORGANIZATION/B_LOCATION
Study O I_ORGANIZATION/I_LOCATION
Group O I_ORGANIZATION/I_LOCATION
for O O
BD O B_DISEASE/B_MEASURE
( O O
abbreviated O O
as O O
' O B_LOCATION/B_ORGANIZATION
International O I_LOCATION/I_ORGANIZATION
Criteria O I_LOCATION/I_ORGANIZATION
' O I_LOCATION/I_ORGANIZATION
) O O
[ O O
2 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
study O O
subjects O O
of O O
39 O O
Chinese O O
BD O O
patients B B_PERSON
comprised O O
17 O O
males O O
and O O
22 O O
females O O
, O O
mean O O
age O O
37 O O
+/- O O
11 O O
. O O
3 O O
years O O
old O O
, O O
who O O
were O O
divided O O
into O O
two O O
subgroups O O
: O O
25 O O
typical O O
BD O O
patients B B_PERSON
( O O
Group O O
I O O
, O O
satisfying O O
the O O
International O O
Criteria O O
) O O
and O O
14 O O
clinically O O
diagnosed O O
BD O O
patients B B_PERSON
who O O
had O O
recurrent O O
oral O O
ulcers O O
and O O
one O O
of O O
the O O
symptoms O O
of O O
genital O O
ulcers O O
, O O
eye O O
symptoms O O
or O O
skin O O
lesions O O
as O O
defined O O
by O O
the O O
International O O
Criteria O O
, O O
as O O
well O O
as O O
additional O O
symptom O O
( O O
s O O
) O O
closely O O
related O O
to O O
BD O O
as O O
listed O O
in O O
the O O
International O O
Criteria O O
, O O
that O O
is O O
, O O
gastrointestinal O O
ulcerations O O
, O O
deep O O
vein O O
thrombosis O O
or O O
arthralgia O O
/ O O
arthritis O O
without O O
evidence O O
that O O
the O O
latter O O
symptoms O O
might O O
be O O
related O O
to O O
any O O
other O O
disease O O
( O O
Group O O
II O O
, O O
defined O O
as O O
' O O
probable O O
BD O O
' O O
in O O
this O O
study O O
) O O
. O O

Disease O O
controls O O
included O O
10 O O
patients B B_PERSON
with O O
SLE O O
and O O
10 O O
with O O
SjS O O
, O O
all O O
satisfying O O
corresponding O O
international O O
classification O O
criteria O O
. O O

All O O
BD O O
patients B B_PERSON
and O O
disease O O
controls O O
involved O O
in O O
the O O
study O O
were O O
patients B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
treated O O
at O O
the O O
Rheumatology O O
Department O O
of O O
Ren O O
Ji O O
Hospital O O
, O O
Shanghai O O
, O O
China O O
, O O
where O O
their O O
clinical O O
data O O
and O O
serum O O
samples O O
were O O
collected O O
. O O

Twenty O B_PERSON
normal O I_PERSON
control O I_PERSON
sera O I_PERSON
were O O
randomly O O
selected O O
from O O
healthy O B_PERSON
blood O I_PERSON
donors O I_PERSON
working O O
in O O
the O O
same O B_LOCATION
hospital O I_LOCATION
. O O

This O O
study O O
was O O
approved O O
by O O
the O O
institution O O
review O O
board O O
of O O
Ren O O
Ji O O
Hospital O O
which O O
is O O
affiliated O O
with O O
Shanghai O O
Second O O
Medical O O
University O O
, O O
and O O
each O O
patient B B_PERSON/B_LOCATION
involved O O
gave O O
informed O O
consent O O
. O O

All O O
serum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
preserved O O
at O O
- O O
20 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
or O O
- O O
70 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
until O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Cell O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
lines O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
and O O
cell O B_BIO/B_LOCATION
extracts O I_BIO/I_LOCATION

HeLa O O
( O O
ATCC O O
CCL O O
2 O O
. O O
2 O O
) O O
and O O
T24 O O
( O O
human B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
transitional O O
cell O O
bladder O O
carcinoma O O
) O O
were O O
obtained O O
from O O
the O O
American O O
Type O O
Culture O O
Collection O O
( O O
Rockville O O
, O O
MD O O
, O O
USA O O
) O O
. O O

A O O
bovine B B_PERSON/B_SPECIES[BIO]
aortic O O
endothelial O O
cell O O
line O O
was O O
kindly O O
provided O O
by O O
Dr O O
Eugene O O
G O O
Levin O O
from O O
the O O
Scripps O O
Research O O
Institute O O
( O O
La O O
Jolla O O
, O O
CA O O
, O O
USA O O
) O O
. O O

Cells O O
were O O
cultured O O
in O O
DMEM O O
containing O O
10 O O
% O O
calf B B_SPECIES[BIO]/B_PERSON
serum O O
, O O
harvested O O
and O O
extracted O O
in O O
Buffer O O
A O O
( O O
150 O O
mM O O
NaCl O O
, O O
10 O O
mM O O
Tris O O
- O O
HCl O O
, O O
pH7 O O
. O O
2 O O
, O O
0 O O
. O O
5 O O
% O O
Nonidet O O
P O O
- O O
40 O O
) O O
with O O
protease O O
inhibitor O O
( O O
Complete O O
(TM) O O
; O O
Boehringer O O
Mannheim O O
, O O
Indianapolis O O
, O O
IN O O
, O O
USA O O
) O O
. O O

For O O
the O O
preparation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
whole O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extract O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
10 O B_MEASURE/B_BIO
volumes O B_MEASURE/I_BIO
of O O
Laemmli O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gel O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
buffer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
18 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
added O O
to O O
the O O
cell O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pellet O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
boiled O O
for O O
3 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
stored O O
at O O
- O O
20 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
until O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Western O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
blot O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION

Whole O O
cell O O
lysates O O
from O O
bovine B B_SPECIES[BIO]/B_PROTEIN[GENE]
aortic O O
endothelial O O
cell O O
, O O
HeLa O O
and O O
T24 O O
cells O O
were O O
resolved O O
individually O O
by O O
discontinuous O O
7 O O
. O O
5 O O
% O O
gel O O
SDS O O
- O O
PAGE O O
according O O
to O O
Laemmli O O
' O O
s O O
method O O
[ O O
18 O O
] O O
. O O

Immunoblotting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
performed O O
as O O
described O O
by O O
Towbin O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

[ O O
19 O B_TIME[MEASURE]
] O O
with O O
modifications O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Nitrocellulose O O
strips O O
were O O
blocked O O
with O O
3 O O
% O O
nonfat O O
milk O O
in O O
PBS O O
containing O O
0 O O
. O O
05 O O
% O O
Tween O O
- O O
20 O O
( O O
PBS O O
- O O
T O O
) O O
and O O
then O O
incubated O O
with O O
BD O O
patient B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
sera O O
and O O
normal O O
control O O
sera O O
( O O
1 O O
: O O
100 O O
dilution O O
) O O
at O O
room O O
temperature O O
for O O
1 O O
h O O
. O O

Filters O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
washed O O
extensively O O
with O O
PBS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
T O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
remove O O
any O O
unbound O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Bound O O
antibodies O O
were O O
detected O O
with O O
polyvalent O O
, O O
peroxidase O O
- O O
conjugated O O
goat B B_SPECIES[BIO]
anti O O
- O O
human B B_SPECIES[BIO]
Ig O O
and O O
visualized O O
by O O
incubating O O
the O O
nitrocellulose O O
strips O O
in O O
chemiluminescent O O
reagents O O
( O O
NEN O O
Life O O
Science O O
Products O O
Inc O O
. O O
, O O
Boston O O
, O O
MA O O
, O O
USA O O
) O O
and O O
exposing O O
to O O
Kodak O O
XAR O O
- O O
5 O O
films O O
. O O

Screening O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phage O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
antibody O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
probes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]

Serum O O
from O O
a O O
BD O O
patient B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O O
the O O
highest O O
antibody O O
titer O O
in O O
immunoblotting O O
was O O
selected O O
as O O
a O O
probe O O
and O O
used O O
at O O
a O O
dilution O O
of O O
1 O O
: O O
300 O O
for O O
initial O O
immunoscreening O O
of O O
approximately O O
106 O O
recombinants O O
from O O
a O O
T24 O O
cDNA O O
expression O O
library O O
. O O

The O O
latter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
constructed O O
in O O
lambda O B_MEASURE
ZAPExpress O I_MEASURE
vector O I_MEASURE
( O O
Stratagene O B_MEASURE
, O O
La O B_LOCATION/B_PERSON
Jolla O I_LOCATION/I_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
and O O
screened O O
as O O
previously O O
described O O
[ O O
20 O B_MEASURE
- O O
22 O B_MEASURE
] O I_MEASURE
. O O

All O O
screenings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
on O O
duplicate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isopropyl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
thiogalactoside O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
IPTG O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
impregnated O O
nitrocellulose O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
filters O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
, O O
and O O
immunoreactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
detected O O
by O O
chemiluminescence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Positive O B_BIO/B_PERSON
phages O I_BIO/I_PERSON
were O O
subsequently O O
plaque O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
purified O O
to O O
100 O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
two O B_NUMBER[MEASURE]
repeated O O
rounds O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
screening O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
low O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
plaque O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
densities O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Before O O
screening O O
the O O
cDNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
the O O
BD O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serum O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
extensively O O
adsorbed O O
against O O
bacteria O B_SPECIES[BIO]/B_GENE
and O O
wild O B_BIO/B_PROTEIN[GENE]
- O O
type O B_BIO/B_GENE
lambda O I_BIO/I_GENE
ZAP O I_BIO/I_GENE
phage O I_BIO/I_GENE
mixture O I_BIO/I_GENE
to O O
reduce O O
background O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
candidate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cDNAs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Purified O B_PERSON/B_BIO
candidate O I_PERSON/I_BIO
plaques O I_PERSON/I_BIO
were O O
subcloned O O
in O O
vivo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
into O O
pBK O B_PROTEIN[GENE]/B_DISEASE
- O O
CMV O B_NUMBER[MEASURE]/B_BIO
plasmids O I_NUMBER[MEASURE]/I_BIO
using O O
ExAssist O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
(TM) O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
helper O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
phage O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
as O O
recommended O O
in O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
' O O
s O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instructions O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Stratagene O B_MEASURE/B_BIO
) O O
. O O

The O O
recombinant O B_DISEASE
pBK O I_DISEASE
- O O
CMV O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasmids O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
then O O
purified O O
using O O
QIAprep O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Spin O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Minprep O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Kit O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Qiagen O B_MEASURE/B_PERSON
, O O
Valencia O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

Restriction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
digestion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
plasmids O B_GENE/B_BACTERIUM[BIO]
with O O
EcoRI O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
XhoI O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
standard O B_MEASURE
1 O I_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
agarose O I_MEASURE
gel O I_MEASURE
was O O
used O O
to O O
analyze O O
the O O
length O B_MEASURE/B_LOCATION
of O O
cDNA O B_GENE
insert O I_GENE
of O O
each O O
candidate O B_GENE/B_BIO
plasmid O I_GENE/I_BIO
. O O

The O O
complete O B_GENE
nucleotide O I_GENE
sequence O I_GENE
was O O
determined O O
using O O
Bigdye O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
terminator O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
a O O
semi O B_DISEASE/B_PROTEIN[GENE]
- O O
automated O O
sequencer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
377 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
ABI O B_MEASURE
, O O
Foster O B_LOCATION/B_PERSON
City O I_LOCATION/I_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

Both O O
nucleotide O O
and O O
deduced O O
amino O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
analyzed O O
for O O
similarity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
known O O
sequences O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
using O O
BLAST O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
search O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
23 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
ExPASy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Proteomics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tools O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
coiled O O
- O O
coil O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motifs O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
conducted O O
with O O
the O O
software O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
COILS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
24 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

Immunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
in O O
vitro O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
translation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
products O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Candidate O B_GENE/B_PERSON
cDNA O I_GENE/I_PERSON
clones O I_GENE/I_PERSON
were O O
used O O
as O O
templates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
in O O
vitro O B_GENE
transcription O I_GENE
and O O
translation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
used O O
as O O
substrates O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
immunoprecipitation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
confirm O O
the O O
specificity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
reaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
BD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sera O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
brief O O
, O O
1 O O
mu O O
g O O
of O O
the O O
pBK O O
- O O
CMV O O
plasmid O O
identified O O
in O O
the O O
screening O O
outlined O O
above O O
was O O
added O O
as O O
template O O
in O O
a O O
50 O O
- O O
mu O O
l O O
reaction O O
for O O
the O O
coupled O O
in O O
vitro O O
transcription O O
and O O
translation O O
reaction O O
with O O
a O O
rabbit B B_SPECIES[BIO]/B_DISEASE
reticulocyte O O
lysate O O
system O O
( O O
Promega O O
, O O
Madison O O
, O O
WI O O
, O O
USA O O
) O O
in O O
the O O
presence O O
of O O
35S O O
- O O
methionine O O
( O O
Trans O O
- O O
35S O O
label O O
; O O
ICN O O
Biochemicals O O
, O O
Costa O O
Mesa O O
, O O
CA O O
, O O
USA O O
) O O
and O O
RNasin O O
(R) O O
Ribonuclease O O
Inhibitor O O
( O O
Stratagene O O
) O O
as O O
recommended O O
by O O
the O O
manufacturer O O
( O O
Promega O O
) O O
. O O

Translation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
at O O
30 O B_TIME[MEASURE]/B_LOCATION
degrees O B_TIME[MEASURE]/I_LOCATION
C O B_TIME[MEASURE]/I_LOCATION
for O O
1 O B_MEASURE
. O O
5 O B_MEASURE
h O O
. O O

Products O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
analyzed O O
in O O
a O O
12 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
gel O I_MEASURE
SDS O I_MEASURE
- O O
PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
stored O O
at O O
- O O
80 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
for O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immunoprecipitation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
translation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
proteins O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
were O O
examined O O
for O O
reactivity O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
sera O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
using O O
immunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
described O O
[ O O
8 O B_MEASURE
, O O
25 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

Autoantibody O O
detection O O
in O O
sera O O
from O O
BD O O
patients B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Initial O O
examination O O
of O O
a O O
group O O
of O O
39 O O
BD O O
patients B B_PERSON/B_BIO
using O O
indirect O O
immunofluorescence O O
( O O
IIF O O
) O O
on O O
a O O
HEp O O
- O O
2 O O
cell O O
substrate O O
did O O
not O O
yield O O
any O O
characteristic O O
nuclear O O
or O O
cytoplasmic O O
staining O O
patterns O O
. O O

BD O B_DISEASE
is O O
thought O O
by O O
some O O
to O O
be O O
a O O
vasculitic O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
involving O O
pathophysiology O B_DISEASE
of O O
endothelial O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cells O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
antibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
endothelial O B_DISEASE/B_GENE
cell O I_DISEASE/I_GENE
antigen O I_DISEASE/I_GENE
( O O
AECA O B_DISEASE/B_GENE
) O O
has O O
been O O
reported O O
. O O

Reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
prevalence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
AECA O B_DISEASE
have O O
varied O O
largely O O
and O O
alpha O B_PROTEIN[GENE]
- O O
enolase O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
reported O O
as O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
putative O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
26 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

In O O
this O O
study O O
, O O
the O O
use O O
of O O
bovine B B_PERSON/B_SPECIES[BIO]
aortic O O
endothelial O O
cells O O
as O O
substrate O O
for O O
IIF O O
did O O
not O O
provide O O
any O O
additional O O
data O O
. O O

However O O
, O O
Western O O
blot O O
analysis O O
of O O
the O O
BD O O
sera O O
began O O
to O O
show O O
some O O
interesting O O
autoreactivity O O
using O O
cell O O
lysates O O
from O O
both O O
HeLa O O
and O O
bovine B B_SPECIES[BIO]/B_PROTEIN[GENE]
aortic O O
endothelial O O
cells O O
. O O

HeLa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
initially O O
used O O
for O O
this O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
they O O
are O O
commonly O O
used O O
in O O
the O O
laboratory O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
Western O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
substrate O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Fig O B_BIO/B_GENE
. O O

1 O B_NUMBER[MEASURE]/B_PERSON
illustrates O O
the O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactivity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
49 O B_MEASURE
kDa O I_MEASURE
and O O
120 O B_GENE
kDa O I_GENE
proteins O I_GENE
in O O
the O O
endothelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lysates O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
antigens O B_GENE/B_DISEASE
were O O
also O O
detected O O
in O O
HeLa O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O O
T24 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
; O O
the O O
latter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
analyzed O O
because O O
our O O
laboratory O B_LOCATION/B_PERSON
at O O
The O O
Scripps O B_LOCATION/B_PERSON
Research O I_LOCATION/I_PERSON
Institute O I_LOCATION/I_PERSON
has O O
produced O O
an O O
excellent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cDNA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
library O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
the O O
T24 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
the O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
result O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
T24 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extracts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
allowed O O
us O O
to O O
screen O O
the O O
T24 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Ig O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
isotype O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
that O O
all O O
reactivity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
largely O O
IgG O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
antibodies O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Since O O
the O O
49 O O
kDa O O
and O O
120 O O
kDa O O
bands O O
were O O
observed O O
in O O
cell O O
extracts O O
from O O
bovine B B_SPECIES[BIO]/B_PROTEIN[GENE]
as O O
well O O
as O O
human B B_SPECIES[BIO]
cell O O
lines O O
, O O
these O O
autoantigens O O
might O O
be O O
evolutionarily O O
conserved O O
. O O

In O O
total O B_MEASURE
, O O
nine O B_NUMBER[MEASURE]
out O O
of O O
39 O B_NUMBER[MEASURE]/B_PERSON
BD O I_NUMBER[MEASURE]/I_PERSON
sera O I_NUMBER[MEASURE]/I_PERSON
( O O
23 O B_MEASURE
% O I_MEASURE
) O O
had O O
autoantibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
the O O
49 O B_MEASURE/B_GENE
kDa O I_MEASURE/I_GENE
antigen O I_MEASURE/I_GENE
and O O
eight O B_NUMBER[MEASURE]
( O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
to O O
the O O
120 O B_GENE/B_DISEASE
kDa O I_GENE/I_DISEASE
antigen O I_GENE/I_DISEASE
. O O

Four O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BD O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sera O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O B_MEASURE/B_BIO
% O B_MEASURE/I_BIO
) O O
reacted O O
with O O
both O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Additionally O O
, O O
sera O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
showed O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactivity O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
120 O B_PROTEIN[GENE]
kDa O I_PROTEIN[GENE]
protein O I_PROTEIN[GENE]
also O O
demonstrated O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
band O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O O
migrated O O
at O O
~ O B_PROTEIN[GENE]/B_TIME[MEASURE]
150 O B_PROTEIN[GENE]/I_TIME[MEASURE]
kDa O B_PROTEIN[GENE]/I_TIME[MEASURE]
, O O
although O O
it O O
appeared O O
weaker O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
the O O
120 O B_MEASURE/B_BIO
kDa O I_MEASURE/I_BIO
band O I_MEASURE/I_BIO
. O O

These O O
antigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
appeared O O
to O O
have O O
different O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
molecular O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
weights O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
those O O
of O O
the O O
known O O
autoantigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
rheumatic O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
diseases O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reactive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
bands O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
detected O O
but O O
they O O
were O O
not O O
as O O
commonly O O
shared O O
as O O
the O O
49 O B_MEASURE
kDa O I_MEASURE
and O O
120 O B_GENE/B_MEASURE
kDa O I_GENE/I_MEASURE
bands O I_GENE/I_MEASURE
. O O

The O O
49 O B_PROTEIN[GENE]/B_MEASURE
kDa O I_PROTEIN[GENE]/I_MEASURE
protein O I_PROTEIN[GENE]/I_MEASURE
was O O
shown O O
to O O
be O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]
from O O
48 O B_PROTEIN[GENE]/B_LOCATION
kDa O I_PROTEIN[GENE]/I_LOCATION
SS O I_PROTEIN[GENE]/I_LOCATION
- O O
B O B_OTHER/B_MEASURE
/ O O
La O B_PROTEIN[GENE]/B_MEASURE
or O O
50 O B_LOCATION/B_PERSON
kDa O I_LOCATION/I_PERSON
Jo O I_LOCATION/I_PERSON
- O O
1 O B_PROTEIN[GENE]/B_MEASURE
proteins O I_PROTEIN[GENE]/I_MEASURE
( O O
Fig O B_MEASURE/B_LOCATION
. O O
1 O B_NUMBER[MEASURE]
) O O
. O O

The O O
120 O B_PROTEIN[GENE]
kDa O I_PROTEIN[GENE]
antigen O I_PROTEIN[GENE]
was O O
also O O
shown O O
to O O
migrate O O
differently O O
from O O
alanyl O B_GENE/B_PERSON
tRNA O I_GENE/I_PERSON
synthetase O I_GENE/I_PERSON
in O O
another O O
Western O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O O
shown O O
) O O
and O O
did O O
not O O
share O O
any O O
apparent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
crossreactive O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
epitopes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
the O O
49 O B_PROTEIN[GENE]/B_BIO
kDa O I_PROTEIN[GENE]/I_BIO
antigen O I_PROTEIN[GENE]/I_BIO
. O O

Western O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
blot O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
of O O
20 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
normal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sera O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
did O O
not O O
show O O
the O O
reactivities O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
with O O
BD O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sera O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
order O O
to O O
further O O
characterize O O
these O O
autoreactivities O O
, O O
a O O
serum O O
sample O O
from O O
the O O
Group O O
I O O
definitive O O
BD O O
patients B B_PERSON/B_GENE
with O O
the O O
strongest O O
reactivity O O
to O O
49 O O
kDa O O
and O O
120 O O
kDa O O
antigens O O
( O O
Fig O O
. O O
1 O O
, O O
lane O O
2 O O
) O O
was O O
selected O O
as O O
antibody O O
probe O O
for O O
expression O O
library O O
screening O O
. O O

Kinectin O B_TIME[MEASURE]/B_LOCATION
identified O O
as O O
a O O
novel O B_PERSON/B_GENE
BD O I_PERSON/I_GENE
autoantigen O I_PERSON/I_GENE

After O O
screening O O
500 O B_MEASURE
, O O
000 O B_MEASURE/B_ENT
clones O I_MEASURE/I_ENT
from O O
the O O
T24 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cell O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
lambda O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
ZAPExpress O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
seven O B_GENE/B_NUMBER[MEASURE]
immunoreactive O I_GENE/I_NUMBER[MEASURE]
clones O I_GENE/I_NUMBER[MEASURE]
were O O
isolated O O
and O O
plaque O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
purified O O
in O O
two O B_NUMBER[MEASURE]/B_LOCATION
to O O
three O B_NUMBER[MEASURE]
rounds O I_NUMBER[MEASURE]
to O O
achieve O O
100 O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homogeneity O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
cDNA O B_GENE/B_BIO
inserts O I_GENE/I_BIO
were O O
subcloned O O
in O O
vivo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O O
pBK O B_PROTEIN[GENE]/B_DISEASE
- O O
CMV O B_NUMBER[MEASURE]/B_BIO
plasmids O I_NUMBER[MEASURE]/I_BIO
, O O
analyzed O O
by O O
restriction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
digestion O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
EcoRI O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
XhoI O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzymes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
submitted O O
to O O
direct O B_GENE
nucleotide O I_GENE
sequencing O O
across O O
the O O
polylinker O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
arms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
cDNA O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inserts O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represented O O
six O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
independent O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
clones O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
designated O O
BD41 O B_PROTEIN[GENE]/B_DISEASE
( O O
identical O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
BD44 O B_GENE/B_MEASURE
) O O
, O O
BD481 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
BD42 O B_GENE
, O O
BD47 O B_PROTEIN[GENE]
, O O
BD482 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
BD49 O B_GENE
. O O

Their O O
identities O O
were O O
established O O
as O O
overlapping O O
partial O O
cDNAs O O
of O O
human B B_SPECIES[BIO]/B_GENE
kinectin O O
, O O
ranging O O
from O O
1 O O
. O O
9 O O
kb O O
to O O
3 O O
kb O O
( O O
Fig O O
. O O
2a O O
) O O
. O O

The O O
full O O
- O O
length O O
human B B_SPECIES[BIO]/B_GENE
kinectin O O
( O O
GenBank O O
accession O O
number O O
NM O O
_ O O
182926 O O
[ O O
27 O O
] O O
) O O
has O O
4 O O
, O O
816 O O
bases O O
containing O O
an O O
open O O
reading O O
frame O O
coding O O
1 O O
, O O
357 O O
amino O O
acid O O
residues O O
with O O
molecular O O
mass O O
156 O O
kDa O O
. O O

All O O
six O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cDNAs O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
lacked O O
the O O
5 O B_MEASURE/B_LOCATION
' O I_MEASURE/I_LOCATION
portion O I_MEASURE/I_LOCATION
of O O
the O O
kinectin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
different O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
but O O
spanned O O
a O O
sequence O B_LOCATION/B_GENE
of O O
kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
extended O O
to O O
the O O
3 O B_TIME[MEASURE]/B_LOCATION
' O I_TIME[MEASURE]/I_LOCATION
- O O
untranslated O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
. O O

Secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
kinectin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
the O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
COILS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identified O O
a O O
long O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
of O O
alpha O B_NUMBER[MEASURE]/B_GENE
- O O
helical O B_GENE/B_DISEASE
coiled O O
- O O
coil O B_LOCATION/B_PERSON
domain O I_LOCATION/I_PERSON
that O O
extended O O
from O O
amino O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
acid O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
residue O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
327 O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
the O O
C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminus O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fig O B_MEASURE/B_PROTEIN[GENE]
. O O
2a O B_MEASURE
, O O
hatched O O
boxes O B_LOCATION/B_MEASURE
) O O
. O O

In O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
coupled O O
transcription O B_GENE
and O O
translation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BD44 O B_GENE
and O O
BD42 O B_GENE
clones O I_GENE
directed O O
the O O
synthesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
[ O O
35S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
methionine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
labeled O O
polypeptides O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
migrated O O
at O O
95 O B_MEASURE
and O O
60 O B_MEASURE
kDa O I_MEASURE
, O O
respectively O O
, O O
in O O
addition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
smaller O B_GENE
polypeptides O I_GENE
( O O
Fig O B_PROTEIN[GENE]/B_MEASURE
. O O
2b O B_MEASURE
) O O
. O O

These O O
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
had O O
predicted O O
molecular O B_MEASURE
weights O I_MEASURE
of O O
103 O B_MEASURE
kDa O I_MEASURE
and O O
75 O B_MEASURE
kDa O I_MEASURE
. O O

Kinectin O O
was O O
initially O O
identified O O
in O O
chick B B_SPECIES[BIO]/B_DISEASE
embryo O O
brain O O
microsome O O
as O O
an O O
integral O O
membrane O O
protein O O
anchored O O
in O O
endoplasmic O O
reticulum O O
and O O
involved O O
in O O
kinesin O O
- O O
driven O O
vesicle O O
motility O O
along O O
microtubules O O
[ O O
28 O O
, O O
29 O O
] O O
. O O

Kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consists O O
of O O
a O O
120 O B_MEASURE
- O O
kDa O B_PROTEIN[GENE]
and O O
a O O
160 O B_MEASURE
- O O
kDa O B_PROTEIN[GENE]/B_MEASURE
polypeptide O I_PROTEIN[GENE]/I_MEASURE
interacting O O
through O O
the O O
alpha O B_NUMBER[MEASURE]/B_GENE
- O O
helical O B_GENE/B_DISEASE
coiled O O
- O O
coil O B_LOCATION/B_PERSON
domain O I_LOCATION/I_PERSON
to O O
form O O
a O O
heterodimer O B_GENE/B_LOCATION
[ O O
30 O B_GENE
] O I_GENE
. O O

The O O
full O B_MEASURE/B_COLOR
- O O
length O B_GENE/B_MEASURE
kinectin O I_GENE/I_MEASURE
is O O
the O O
160 O B_MEASURE/B_LOCATION
kDa O B_MEASURE/I_LOCATION
polypeptide O B_MEASURE/I_LOCATION
containing O O
an O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION/B_PROTEIN[GENE]
transmembrane O I_LOCATION/I_PROTEIN[GENE]
helix O I_LOCATION/I_PROTEIN[GENE]
followed O O
by O O
a O O
bipartite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
nuclear O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
localization O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
sequence O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION
leucine O I_LOCATION
zipper O I_LOCATION
motifs O I_LOCATION
. O O

We O O
presume O O
that O O
the O O
120 O B_PROTEIN[GENE]/B_MEASURE
kDa O I_PROTEIN[GENE]/I_MEASURE
polypeptide O I_PROTEIN[GENE]/I_MEASURE
detected O O
in O O
Western O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fig O B_MEASURE/B_LOCATION
. O O
1 O B_NUMBER[MEASURE]
) O O
is O O
the O O
truncated O B_MEASURE/B_PERSON
version O B_MEASURE/I_PERSON
of O O
the O O
160 O B_MEASURE
- O O
kDa O B_PROTEIN[GENE]/B_MEASURE
polypeptide O I_PROTEIN[GENE]/I_MEASURE
, O O
lacking O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
terminal O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
first O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
232 O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminus O B_LOCATION/B_MEASURE
of O O
the O O
160 O B_MEASURE
- O O
kDa O B_PROTEIN[GENE]/B_LOCATION
polypeptide O I_PROTEIN[GENE]/I_LOCATION
consists O O
of O O
a O O
transmembrane O B_LOCATION
domain O I_LOCATION
that O O
anchors O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinectin O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
endoplasmic O B_MEASURE/B_BIO
reticulum O I_MEASURE/I_BIO
[ O I_MEASURE/I_BIO
30 O I_MEASURE/I_BIO
, O O
31 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

This O O
120 O B_PROTEIN[GENE]/B_LOCATION
kDa O I_PROTEIN[GENE]/I_LOCATION
polypeptide O I_PROTEIN[GENE]/I_LOCATION
is O O
probably O O
the O O
predominant O B_MEASURE
form O I_MEASURE
detected O O
in O O
the O O
Western O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fig O B_MEASURE/B_LOCATION
. O O
1 O B_NUMBER[MEASURE]
) O O
because O O
of O O
its O O
preferential O B_MEASURE/B_LOCATION
solubility O B_MEASURE/I_LOCATION
due O O
to O O
the O O
omission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]
transmembrane O I_PROTEIN[GENE]
domain O I_PROTEIN[GENE]
. O O

Other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
kinectin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
have O O
been O O
reported O O
. O O

Yeast B B_SPECIES[BIO]/B_NUMBER[MEASURE]
two O O
- O O
hybrid O O
screen O O
studies O O
from O O
several O O
laboratories O O
have O O
revealed O O
the O O
interaction O O
of O O
the O O
Rho O O
family O O
of O O
GTPase O O
with O O
kinectin O O
, O O
and O O
have O O
shown O O
the O O
functional O O
links O O
among O O
RhoG O O
, O O
kinectin O O
and O O
kinesin O O
, O O
with O O
kinectin O O
as O O
a O O
key O O
effector O O
of O O
RhoG O O
microtubule O O
- O O
dependent O O
cellular O O
activity O O
[ O O
32 O O
] O O
. O O

Kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
identified O O
as O O
an O O
important O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
constituent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
integrin O B_GENE
- O O
based O O
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
which O O
link O O
integrins O B_GENE/B_BIO
to O O
the O O
cytoskeleton O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
recruit O O
signaling O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
molecules O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
33 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
] O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

A O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O O
that O O
a O O
kinectin O B_GENE
isoform O I_GENE
lacking O O
a O O
major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
portion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
kinesin O B_GENE/B_BIO
- O O
binding O O
domain O B_LOCATION/B_GENE
is O O
very O O
probably O O
the O O
most O O
conservative O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
form O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
it O O
does O O
not O O
bind O O
kinesin O B_GENE/B_BIO
but O O
act O O
as O O
a O O
membrane O B_PERSON/B_GENE
anchor O I_PERSON/I_GENE
for O O
the O O
translation O B_PROTEIN[GENE]/B_DISEASE
elongation O I_PROTEIN[GENE]/I_DISEASE
factor O I_PROTEIN[GENE]/I_DISEASE
- O O
1 O B_TIME[MEASURE]/B_LOCATION
delta O I_TIME[MEASURE]/I_LOCATION
in O O
the O O
endoplasmic O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
34 O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
] O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

Prevalence O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
kinectin O B_DISEASE/B_GENE
autoantibodies O I_DISEASE/I_GENE

The O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O O
35S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
methionine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
labeled O O
translation O B_PROTEIN[GENE]
product O I_PROTEIN[GENE]
of O O
BD44 O B_GENE
, O O
representing O O
the O O
largest O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recombinant O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinectin O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
used O O
as O O
the O O
antigen O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrate O B_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
an O O
immunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Out O O
of O O
39 O O
BD O O
patient B B_PERSON/B_MEASURE
sera O O
, O O
nine O O
( O O
23 O O
% O O
) O O
recognized O O
the O O
BD44 O O
translation O O
product O O
( O O
Fig O O
. O O
3 O O
) O O
, O O
whereas O O
sera O O
from O O
20 O O
normal O O
controls O O
, O O
10 O O
SLE O O
and O O
10 O O
SjS O O
patients B B_PERSON/B_BIO
did O O
not O O
show O O
reactivity O O
. O O

Among O O
the O O
nine O O
anti O O
- O O
kinectin O O
positive O O
patients B B_PERSON
, O O
six O O
( O O
6 O O
/ O O
25 O O
, O O
24 O O
% O O
) O O
were O O
from O O
Group O O
I O O
( O O
definitive O O
BD O O
) O O
including O O
the O O
BD O O
patient B B_PERSON/B_BIO
whose O O
serum O O
was O O
used O O
in O O
the O O
immunoscreening O O
of O O
expression O O
cDNA O O
library O O
, O O
and O O
three O O
( O O
3 O O
/ O O
14 O O
, O O
21 O O
. O O
4 O O
% O O
) O O
patients B B_PERSON/B_LOCATION
were O O
from O O
the O O
Group O O
II O O
( O O
probable O O
BD O O
) O O
in O O
this O O
study O O
. O O

According O O
to O O
the O O
Fisher O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Exact O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Probability O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
calculation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
1 O B_MEASURE
. O O
00 O B_MEASURE
) O O
, O O
there O O
is O O
no O O
statistically O O
significant O B_MEASURE
difference O I_MEASURE
for O O
antibody O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
kinectin O O
between O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
combined O O
data O O
substantiated O O
the O O
finding O O
that O O
kinectin O O
is O O
an O O
autoantigen O O
that O O
can O O
be O O
recognized O O
by O O
sera O O
from O O
23 O O
% O O
of O O
Chinese O O
BD O O
patients B B_PERSON/B_BIO
in O O
this O O
study O O
with O O
at O O
least O O
one O O
immunoreactive O O
region O O
or O O
autoepitope O O
residing O O
within O O
the O O
BD44 O O
encoded O O
polypeptide O O
. O O

Currently O O
, O O
there O O
are O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
six O B_NUMBER[MEASURE]
diagnostic O I_NUMBER[MEASURE]
/ O O
classification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
BD O B_DISEASE/B_LOCATION
, O O
among O O
which O O
the O O
International O B_NUMBER[MEASURE]
Criteria O I_NUMBER[MEASURE]
have O O
been O O
applied O O
most O O
extensively O O
due O O
to O O
its O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sensitivity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
91 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
96 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
[ O O
2 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
discussed O O
above O O
, O O
differential O O
diagnosis O O
of O O
BD O O
might O O
be O O
confusing O O
in O O
clinical O O
practice O O
since O O
no O O
specific O O
laboratory O O
test O O
is O O
available O O
, O O
and O O
some O O
patients B B_PERSON/B_DISEASE
may O O
have O O
symptoms O O
and O O
signs O O
strongly O O
suggestive O O
of O O
BD O O
but O O
do O O
not O O
fully O O
satisfy O O
the O O
International O O
Criteria O O
, O O
as O O
in O O
the O O
Group O O
II O O
( O O
probable O O
BD O O
) O O
patients B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
our O O
study O O
group O O
. O O

A O O
number O O
of O O
investigators O O
have O O
pointed O O
out O O
that O O
a O O
comprehensive O O
analysis O O
of O O
the O O
clinical O O
data O O
for O O
a O O
given O O
patient B B_PERSON
is O O
very O O
important O O
for O O
correct O O
clinical O O
diagnosis O O
of O O
BD O O
, O O
and O O
that O O
classification O O
/ O O
diagnosis O O
criteria O O
, O O
including O O
the O O
International O O
Criteria O O
, O O
should O O
be O O
followed O O
but O O
should O O
not O O
be O O
exclusive O O
. O O

The O O
observation O O
that O O
three O O
out O O
of O O
14 O O
patients B B_PERSON/B_BIO
in O O
the O O
probable O O
BD O O
group O O
also O O
had O O
antibody O O
to O O
kinectin O O
and O O
the O O
similar O O
percentage O O
of O O
positive O O
reactors O O
between O O
this O O
group O O
and O O
Group O O
I O O
( O O
21 O O
. O O
4 O O
% O O
versus O O
24 O O
% O O
) O O
supports O O
this O O
notion O O
. O O

The O O
further O O
use O O
of O O
non O O
- O O
clinical O O
parameters O O
such O O
as O O
immunological O O
biomarkers O O
as O O
adjuncts O O
to O O
identify O O
BD O O
patients B B_PERSON/B_LOCATION
could O O
be O O
of O O
help O O
in O O
the O O
classification O O
of O O
this O O
disease O O
entity O O

While O O
our O O
work O O
was O O
ongoing O O
, O O
anti O O
- O O
kinectin O O
antibodies O O
were O O
reported O O
in O O
sera O O
from O O
patients B B_PERSON/B_BIO
with O O
hepatocellular O O
carcinoma O O
( O O
HCC O O
) O O
[ O O
35 O O
, O O
36 O O
] O O
and O O
aplastic O O
anemia O O
[ O O
37 O O
, O O
38 O O
] O O
. O O

The O O
first O O
HCC O O
report O O
[ O O
35 O O
] O O
identified O O
kinectin O O
as O O
a O O
tumor O O
- O O
associated O O
antigen O O
from O O
the O O
screening O O
of O O
an O O
autologous O O
cDNA O O
library O O
constructed O O
from O O
the O O
cancer O O
of O O
a O O
30 O O
- O O
year O O
- O O
old O O
patient B B_PERSON
from O O
Guangxi O O
, O O
China O O
. O O

This O O
report O O
stated O O
that O O
four O O
out O O
of O O
five O O
HCC O O
patients B B_PERSON/B_BIO
tested O O
were O O
positive O O
for O O
anti O O
- O O
kinectin O O
antibody O O
[ O O
35 O O
] O O
. O O

In O O
2004 O O
, O O
another O O
laboratory O O
also O O
reported O O
the O O
cloning O O
of O O
kinectin O O
as O O
a O O
tumor O O
- O O
associated O O
antigen O O
from O O
a O O
( O O
presumably O O
) O O
different O O
30 O O
- O O
year O O
- O O
old O O
Chinese O O
HCC O O
patient B B_PERSON/B_BIO
[ O O
36 O O
] O O
. O O

In O O
contrast O O
, O O
anti O O
- O O
kinectin O O
antibodies O O
were O O
not O O
detected O O
in O O
other O O
studies O O
of O O
HCC O O
patients B B_PERSON/B_BIO
associated O O
with O O
our O O
laboratory O O
[ O O
39 O O
, O O
40 O O
] O O
. O O

The O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
kinectin O B_DISEASE/B_GENE
antibodies O B_DISEASE/I_GENE
in O O
aplastic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
anemia O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
also O O
very O O
interesting O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
37 O B_MEASURE
, O O
38 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
initial O O
report O O
by O O
Hirano O O
et O O
al O O
. O O
identified O O
kinectin O O
by O O
screening O O
an O O
aplastic O O
anemia O O
patient B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
candidate O O
antigens O O
using O O
a O O
Clontech O O
human B B_SPECIES[BIO]/B_PERSON
fetal O O
liver O O
cDNA O O
expression O O
library O O
and O O
it O O
was O O
concluded O O
that O O
seven O O
out O O
of O O
18 O O
aplastic O O
anemia O O
patients B B_PERSON
were O O
positive O O
for O O
anti O O
- O O
kinectin O O
while O O
none O O
of O O
the O O
normal O O
or O O
disease O O
controls O O
had O O
this O O
antibody O O
[ O O
37 O O
] O O
. O O

In O O
their O O
recent O O
report O O
, O O
Hirano O O
et O O
al O O
. O O
reported O O
that O O
anti O O
- O O
kinectin O O
antibodies O O
were O O
found O O
in O O
39 O O
% O O
of O O
aplastic O O
anemia O O
patients B B_PERSON/B_DISEASE
from O O
the O O
United O O
States O O
but O O
only O O
in O O
three O O
out O O
of O O
30 O O
( O O
10 O O
% O O
) O O
cases O O
in O O
Japan O O
[ O O
38 O O
] O O
. O O

In O O
our O O
study O O
reported O O
here O O
, O O
kinectin O O
antibodies O O
were O O
only O O
detected O O
in O O
BD O O
patients B B_PERSON/B_LOCATION
and O O
not O O
in O O
normal O O
controls O O
and O O
SLE O O
and O O
SjS O O
disease O O
controls O O
. O O

None O O
of O O
the O O
BD O O
patients B B_PERSON/B_BIO
with O O
anti O O
- O O
kinectin O O
had O O
signs O O
of O O
HCC O O
or O O
aplastic O O
anemia O O
at O O
the O O
time O O
of O O
diagnosis O O
and O O
at O O
up O O
to O O
4 O O
years O O
of O O
follow O O
- O O
up O O
. O O

Mapping O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
epitope O B_PROTEIN[GENE]
( O O
s O O
) O O
recognized O O
by O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
kinectin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
shed O O
light O B_COLOR/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
question O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
whether O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
autoepitopes O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
reside O O
within O O
the O O
kinectin O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecule O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognized O O
by O O
sera O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
different O B_DISEASE/B_BIO
diseases O I_DISEASE/I_BIO
. O O

Kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
a O O
new O B_PERSON/B_LOCATION
member O I_PERSON/I_LOCATION
of O O
coiled O B_DISEASE/B_NUMBER[MEASURE]
- O O
coil O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytoplasmic O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantigens O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

We O O
have O O
recently O O
reviewed O O
the O O
literature O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
growing O O
number O B_MEASURE/B_LOCATION
of O O
cytoplasmic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
autoantigens O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
rich O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
alpha O B_NUMBER[MEASURE]/B_GENE
- O O
helical O B_GENE/B_DISEASE
coiled O O
- O O
coil O B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
domains O B_MEDICAL_DEVICE[OBJECT]/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
typified O O
from O O
our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Golgi O B_DISEASE/B_BIO
autoantigens O I_DISEASE/I_BIO
[ O O
41 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Golgi O B_PERSON/B_GENE
autoantigens O I_PERSON/I_GENE
are O O
generally O O
high O B_DISEASE_ADJECTIVE[DISEASE]
molecular O I_DISEASE_ADJECTIVE[DISEASE]
weight O I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_DISEASE_ADJECTIVE[DISEASE]
between O O
100 O B_MEASURE
and O O
350 O B_MEASURE
kDa O I_MEASURE
and O O
rich O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
coiled O B_NUMBER[MEASURE]/B_DISEASE
- O O
coil O B_LOCATION/B_MEDICAL_DEVICE[OBJECT]
domains O I_LOCATION/I_MEDICAL_DEVICE[OBJECT]
in O O
the O O
central O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
non O B_DISEASE
- O O
coiled O O
- O O
coil O B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
globular O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
domains O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
at O O
both O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
C O B_PROTEIN[GENE]/B_LOCATION
termini O I_PROTEIN[GENE]/I_LOCATION
. O O

Golgi O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
autoantigens O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
are O O
displayed O O
on O O
the O O
cytoplasmic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
face O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
of O O
the O O
Golgi O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
complex O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
are O O
not O O
localized O O
to O O
apoptotic O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blebs O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
apoptosis O B_DISEASE
[ O I_DISEASE
42 O I_DISEASE
] O I_DISEASE
. O O

Giantin O O
, O O
the O O
highest O O
molecular O O
weight O O
Golgi O O
autoantigen O O
reported O O
, O O
is O O
the O O
predominant O O
target O O
of O O
human B B_PERSON/B_SPECIES[BIO]
anti O O
- O O
Golgi O O
complex O O
antibodies O O
and O O
multiple O O
non O O
- O O
cross O O
- O O
reactive O O
epitopes O O
have O O
been O O
mapped O O
spanning O O
the O O
350 O O
kDa O O
protein O O
[ O O
43 O O
] O O
. O O

Other O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
high O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
molecular O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
weight O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
autoantigens O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
reported O O
in O O
cytoplasmic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
mitotic O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
organelles O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
suggesting O O
that O O
these O O
selected O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
become O O
autoimmunogenic O B_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
their O O
subcellular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
association O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
41 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
in O O
the O O
endosomal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
compartment O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
known O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
autoantigens O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
early O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endosomal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EEA1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
180 O B_NUMBER[MEASURE]/B_LOCATION
kDa O I_NUMBER[MEASURE]/I_LOCATION
) O O
[ O O
44 O B_MEASURE
] O I_MEASURE
and O O
CLIP O B_LOCATION/B_PROTEIN[GENE]
- O O
170 O B_MEASURE/B_BIO
( O O
170 O B_PROTEIN[GENE]/B_MEASURE
kDa O B_PROTEIN[GENE]/I_MEASURE
) O O
[ O O
45 O B_MEASURE
] O I_MEASURE
. O O

There O O
is O O
also O O
a O O
series O B_SPORT[ENT]/B_LOCATION
of O O
centrosomal O B_GENE/B_BIO
autoantigens O I_GENE/I_BIO
identified O O
as O O
coiled O B_DISEASE/B_MEASURE
- O O
coil O B_MEDICAL_DEVICE[OBJECT]/B_PROTEIN[GENE]
- O O
rich O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
including O O
pericentrin O B_GENE
, O O
a O O
220 O B_ENZYME[GENE]/B_MEASURE
kDa O I_ENZYME[GENE]/I_MEASURE
protein O I_ENZYME[GENE]/I_MEASURE
[ O O
46 O B_MEASURE
] O I_MEASURE
, O O
ninein O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
protein O B_BIO/B_PROTEIN[GENE]
with O O
alternatively O O
spliced O O
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O O
245 O B_MEASURE
and O O
249 O B_MEASURE
kDa O I_MEASURE
[ O I_MEASURE
47 O I_MEASURE
] O I_MEASURE
, O O
Cep250 O B_GENE
( O O
250 O B_MEASURE
kDa O I_MEASURE
) O O
and O O
Cep110 O B_GENE
( O O
110 O B_MEASURE/B_GENE
kDa O I_MEASURE/I_GENE
) O O
[ O O
48 O B_MEASURE
] O I_MEASURE
. O O

Centromere O B_NUMBER[MEASURE]/B_PERSON
autoantigens O I_NUMBER[MEASURE]/I_PERSON
have O O
been O O
described O O
but O O
the O O
two O B_NUMBER[MEASURE]/B_PERSON
interesting O I_NUMBER[MEASURE]/I_PERSON
ones O I_NUMBER[MEASURE]/I_PERSON
related O O
to O O
this O O
discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
are O O
CENP O B_LOCATION
- O O
E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
49 O B_MEASURE
] O I_MEASURE
and O O
CENP O B_LOCATION
- O O
F O B_OTHER/B_PROTEIN[GENE]
[ O O
50 O B_MEASURE
] O I_MEASURE
; O O
both O O
are O O
high O B_DISEASE_ADJECTIVE[DISEASE]
molecular O I_DISEASE_ADJECTIVE[DISEASE]
weight O I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_DISEASE_ADJECTIVE[DISEASE]
( O O
312 O B_MEASURE/B_LOCATION
to O O
400 O B_MEASURE
kDa O I_MEASURE
) O O
and O O
have O O
the O O
same O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
type O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
overall O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
discussed O O
above O O
. O O

NuMA O B_GENE/B_BACTERIUM[BIO]
is O O
another O O
large O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
coiled O O
- O O
coil O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
protein O B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
located O O
at O O
the O O
mitotic O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
spindle O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
pole O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
is O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
target O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
autoantigen O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
sera O B_PERSON/B_DISEASE
with O O
mitotic O B_DISEASE_ADJECTIVE[DISEASE]
spindle O I_DISEASE_ADJECTIVE[DISEASE]
apparatus O I_DISEASE_ADJECTIVE[DISEASE]
staining O O
[ O O
51 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Non O B_DISEASE/B_PERSON
- O O
muscle O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
myosin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
~ O B_MEASURE/B_PROTEIN[GENE]
200 O I_MEASURE/I_PROTEIN[GENE]
kDa O I_MEASURE/I_PROTEIN[GENE]
) O O
is O O
a O O
cytoskeletal O B_GENE
autoantigen O I_GENE
[ O I_GENE
52 O I_GENE
] O O
that O O
falls O O
in O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
molecular O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
weight O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
coiled O B_DISEASE
- O O
coil O B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
rich O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
autoantigens O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

These O O
endosomal O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
centrosomal O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
mitotic O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
apparatus O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
intracellular O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
autoantigens O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
, O O
like O O
the O O
golgins O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
proteins O B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weights O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
an O O
overall O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
coiled O O
- O O
coil O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
domains O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
these O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
physical O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
features O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
autoantigens O B_DISEASE
may O O
contribute O O
to O O
the O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
production O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
autoimmune O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
certain O B_DISEASE/B_PERSON
disease O I_DISEASE/I_PERSON
states O I_DISEASE/I_PERSON
. O O

Kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
integral O B_GENE
membrane O I_GENE
protein O I_GENE
largely O O
confined O O
to O O
the O O
endoplasmic O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
28 O B_MEASURE
, O O
31 O B_MEASURE
] O I_MEASURE
and O O
it O O
fits O O
into O O
this O O
new O B_MEASURE/B_LOCATION
category O B_MEASURE/I_LOCATION
of O O
autoantigens O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
large O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
coiled O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
coil O B_LOCATION/B_GENE
rich O I_LOCATION/I_GENE
proteins O I_LOCATION/I_GENE
( O O
>= O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
100 O I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kDa O I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
in O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Here O O
we O O
report O O
the O O
detection O O
of O O
kinectin O O
autoantibody O O
in O O
23 O O
% O O
of O O
Chinese O O
patients B B_PERSON
with O O
BD O O
. O O

The O O
identity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
BD O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
related O O
autoantigen O B_GENE
has O O
not O O
been O O
reported O O
to O O
date O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Autoantibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O O
kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
BD O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
observed O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
further O O
confirms O O
the O O
autoimmune O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement O B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
BD O B_DISEASE
and O O
may O O
provide O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inroads O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
into O O
elucidating O O
the O O
immunopathogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
of O O
the O O
disease O B_DISEASE
. O O

In O O
an O O
effort O O
to O O
clarify O O
the O O
association O O
of O O
BD O O
with O O
antibody O O
to O O
kinectin O O
, O O
it O O
is O O
essential O O
to O O
measure O O
antibody O O
to O O
kinectin O O
in O O
larger O O
patient B B_PERSON/B_DISEASE
populations O O
including O O
both O O
BD O O
, O O
probable O O
BD O O
and O O
important O O
autoimmune O O
rheumatic O O
diseases O O
such O O
as O O
SLE O O
, O O
SjS O O
, O O
rheumatoid O O
arthritis O O
etc O O
. O O
, O O
as O O
well O O
as O O
those O O
diseases O O
not O O
easily O O
differentiated O O
from O O
BD O O
, O O
such O O
as O O
recurrent O O
aphthous O O
oral O O
ulcer O O
, O O
Reiter O O
' O O
s O O
syndrome O O
, O O
inflammatory O O
bowel O O
diseases O O
etc O O
. O O

On O O
the O O
other O B_PERSON/B_LOCATION
hand O B_PERSON/I_LOCATION
, O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]
manifestations O I_DISEASE_ADJECTIVE[DISEASE]
or O O
disease O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' O O
subtypes O B_DISEASE_ADJECTIVE[DISEASE]
' O I_DISEASE_ADJECTIVE[DISEASE]
of O O
BD O B_DISEASE/B_LOCATION
is O O
another O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
kinectin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
clearly O O
only O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
antigen O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O O
antibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
identified O O
because O O
there O O
were O O
many O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
other O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
antibodies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
observed O O
in O O
the O O
Western O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
BD O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sera O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Using O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sera O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
immunoscreening O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
probably O O
lead O O
to O O
the O O
identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
other O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
potentially O O
important O B_DISEASE/B_SPECIES[BIO]
antigen O I_DISEASE/I_SPECIES[BIO]
- O O
antibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Abbreviations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

AECA O B_LOCATION/B_DISEASE
= O O
antibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
endothelial O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
BD O B_LOCATION
= O O
Beh O B_DISEASE/B_GENE
c O I_DISEASE/I_GENE
et O I_DISEASE/I_GENE
' O O
s O B_DISEASE/B_BIO
disease O I_DISEASE/I_BIO
; O O
DMEM O B_LOCATION
= O O
Dulbecco O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
s O B_DISEASE/B_LOCATION
modified O O
Eagle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O O
s O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
medium O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
; O O
HCC O B_LOCATION
= O O
hepatocellular O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carcinoma O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
HSP O B_DISEASE/B_LOCATION
= O O
heat O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
shock O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
IIF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
= O O
indirect O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immunofluorescence O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O O
PBS O B_ORGANIZATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
= O O
phosphate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
buffered O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
SjS O B_LOCATION
= O O
Sj O B_PERSON/B_DISEASE
o O I_PERSON/I_DISEASE
gren O I_PERSON/I_DISEASE
' O O
s O B_DISEASE
syndrome O I_DISEASE
; O O
SLE O B_LOCATION
= O O
systemic O B_DISEASE/B_PERSON
lupus O I_DISEASE/I_PERSON
erythematosus O I_DISEASE/I_PERSON
. O O

Competing O O
interests O B_DISEASE

The O O
authors O B_PERSON
declare O O
that O O
they O O
have O O
no O O
competing O O
interests O B_PERSON/B_ORGANIZATION
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

YL O B_PERSON
performed O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
drafted O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

PY O B_PERSON
provided O O
technical O B_PERSON/B_TIME[MEASURE]
help O I_PERSON/I_TIME[MEASURE]
throughout O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

SLC O B_PERSON
and O O
EMT O B_ORGANIZATION/B_PERSON
conceived O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
participated O O
in O O
the O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
helped O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

EKLC O B_PERSON/B_ORGANIZATION
participated O O
in O O
the O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
interpreted O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
helped O O
to O O
draft O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
authors O B_PERSON/B_NUMBER[MEASURE]
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
: O O
an O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resource O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
endocrine O B_DISEASE/B_ORGANISM_FUNCTION
networks O I_DISEASE/I_ORGANISM_FUNCTION

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

EndoNet O B_PERSON/B_LOCATION
is O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
provides O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O O
the O O
components O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
endocrine O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
networks O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
their O O
relations O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
focuses O O
on O O
the O O
endocrine O O
cell O O
- O O
to O O
- O O
cell O O
communication O O
and O O
enables O O
the O O
analysis O O
of O O
intercellular O O
regulatory O O
pathways O O
in O O
humans B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
the O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
, O O
two O B_LOCATION/B_MEASURE
classes O I_LOCATION/I_MEASURE
of O O
components O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
span O O
a O O
bipartite O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
directed O O
graph O B_LOCATION
. O O

One O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
class O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
represents O O
the O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
in O O
the O O
broadest O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sense O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
secreted O O
by O O
defined O O
donor O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O O

The O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
class O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
consists O O
of O O
the O O
acceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
or O O
target O B_PERSON/B_LOCATION
cells O I_PERSON/I_LOCATION
expressing O O
the O O
corresponding O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
identity O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
anatomical O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
environment O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
types O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
tissues O B_LOCATION/B_DISEASE
and O O
organs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
is O O
defined O O
through O O
references O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
CYTOMER O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
(R) O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ontology O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

With O O
the O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
user O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
interface O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
query O O
the O O
database O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
tissues O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
to O O
combine O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
items O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
from O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
search O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rounds O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
result O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
set O O
, O O
from O O
which O O
a O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O O
be O O
reconstructed O O
and O O
visualized O O
. O O

For O O
each O O
entity O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
page O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Some O O
well O O
- O O
established O O
endocrine O B_LOCATION/B_ENT
pathways O B_LOCATION/I_ENT
are O O
offered O O
as O O
showcases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
predefined O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
result O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sets O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

These O O
sets O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
used O O
as O O
a O O
starting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
point O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
a O O
more O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
query O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
for O O
obtaining O O
a O O
quick O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
overview O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
EndoNet O B_LOCATION/B_ORGANIZATION
database O I_LOCATION/I_ORGANIZATION
is O O
accessible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
. O O

INTRODUCTION O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Theoretical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
post O B_DISEASE/B_GENE
- O O
sequencing O O
era O B_TIME[MEASURE]/B_LOCATION
, O O
in O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
context O B_LOCATION/B_PERSON
of O O
systems O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
biology O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
approaches O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
increasingly O O
investigate O O
the O O
properties O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
all O O
kinds O B_MEASURE/B_LOCATION
of O O
pathways O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
networks O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
metabolic O B_GENE/B_DISEASE
and O O
signaling O O
pathways O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

It O O
is O O
commonly O O
accepted O O
that O O
we O O
need O O
formal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
descriptions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
networks O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
make O O
systematic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
overwhelming O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
body O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
facts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
gathered O O
over O O
decades O B_TIME[MEASURE]/B_LOCATION
of O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
both O O
in O O
narrow O B_MEASURE/B_LOCATION
or O O
global O B_MEASURE/B_ORGANIZATION
scale O I_MEASURE/I_ORGANIZATION
. O O

Corresponding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
databases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
have O O
been O O
created O O
and O O
are O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
now O O
for O O
metabolic O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
networks O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
KEGG O B_PROTEIN[GENE]/B_LOCATION
) O O
( O O
1 O B_NUMBER[MEASURE]
, O O
2 O B_MEASURE
) O O
, O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
networks O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BIND O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
DIP O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
) O O
and O O
signaling O O
pathways O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
CSNDB O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Patika O B_LOCATION/B_PERSON
and O O
TRANSPATH O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
(R) O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
( O O
5 O B_NUMBER[MEASURE]
- O O
8 O B_MEASURE
) O O
, O O
just O O
to O O
name O O
a O O
few O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

So O O
far O O
, O O
however O O
, O O
their O O
main O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
focus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
on O O
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_SPORT[ENT]
processes O I_DISEASE_ADJECTIVE[DISEASE]/I_SPORT[ENT]
. O O

Intercellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
signaling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
addressed O O
only O O
insofar O O
as O O
usually O O
the O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
modeled O O
start O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
extracellular O B_BIO/B_GENE
ligands O I_BIO/I_GENE
, O O
and O O
as O O
there O O
exist O O
catalogs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
databases O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
secreted O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
, O O
or O O
the O O
' O O
secretome O B_BACTERIUM[BIO]/B_LOCATION
' O O
, O O
of O O
certain O B_GENE/B_BIO
systems O I_GENE/I_BIO
( O O
9 O B_NUMBER[MEASURE]
- O O
12 O B_MEASURE
) O O
. O O

This O O
shortcoming O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
more O O
comprehensive O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
problem O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
the O O
genotype O B_GENE
- O O
phenotype O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gap O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
from O O
a O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genotype O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
are O O
able O B_TIME[MEASURE]/B_PERSON
to O O
infer O O
a O O
' O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
, O O
but O O
for O O
correlating O O
it O O
with O O
a O O
more O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
phenotype O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
such O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O O
a O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
or O O
even O O
a O O
certain O B_DISEASE/B_GENE
disease O I_DISEASE/I_GENE
and O O
its O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
appearance O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
still O O
depend O O
largely O O
on O O
the O O
mere O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
an O O
observed O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

There O O
is O O
no O O
way O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
infer O O
such O O
a O O
phenotype O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
through O O
all O O
the O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
layers O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
increasing O O
complexity O B_ORGANIZATION/B_MEASURE
between O O
genomic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
DNA O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
sequences O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
the O O
physiological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
whole O B_GENE/B_BIO
organs O I_GENE/I_BIO
and O O
their O O
interplay O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
within O O
an O O
organism O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

There O O
may O O
be O O
principal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
barriers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preventing O O
such O O
an O O
inference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
complexity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
levels O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
but O O
even O O
to O O
explore O O
these O O
limits O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
have O O
to O O
make O O
attempts O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
bridge O O
the O O
genotype O B_GENE/B_MEASURE
- O O
phenotype O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
gap O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

We O O
have O O
to O O
do O O
the O O
next O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
towards O O
modeling O O
intercellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
networks O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
are O O
inextricably O O
linked O O
to O O
the O O
physiology O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
multicellular O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
organisms O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
13 O B_MEASURE/B_BIO
) O O
. O O

Being O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
most O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
constructs O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
the O O
endocrine O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
comprises O O
numerous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
tissues O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
that O O
secrete O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
pass O O
through O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
activate O O
specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
target O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
initiate O O
there O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
, O O
we O O
present O O
a O O
new O O
database O O
, O O
EndoNet O O
, O O
which O O
provides O O
information O O
about O O
the O O
components O O
of O O
endocrine O O
networks O O
and O O
their O O
relations O O
, O O
and O O
enables O O
the O O
analysis O O
of O O
intercellular O O
regulatory O O
pathways O O
in O O
humans B B_BIO/B_DISEASE
. O O

The O O
EndoNet O B_LOCATION/B_ORGANIZATION
database O I_LOCATION/I_ORGANIZATION
is O O
accessible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
schema O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
endocrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
actions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Development O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
organs O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
well O O
as O O
the O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
whole O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
multicellular O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
organism O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
its O O
environment O B_LOCATION
is O O
coordinated O O
through O O
a O O
complex O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
communication O I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
specialized O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
its O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

This O O
communication O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
mostly O O
mediated O O
by O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
a O O
broader O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sense O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
this O O
functional O B_MEASURE/B_LOCATION
class O B_MEASURE/I_LOCATION
of O O
biomolecules O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
also O O
comprises O O
growth O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
cytokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
chemokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
signal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transmitters O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

This O O
generic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
view O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
is O O
supported O O
, O O
for O O
instance O B_TIME[MEASURE]/B_DISEASE
, O O
by O O
the O O
definition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
for O O
' O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
' O O
by O O
Gene O B_ORGANIZATION/B_LOCATION
Ontology O I_ORGANIZATION/I_LOCATION
( O O
GO O O
) O O
( O O
14 O B_MEASURE
) O O
: O O
' O O
Any O O
substance O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
formed O O
in O O
very O O
small O B_DISEASE_ADJECTIVE[DISEASE]
amounts O I_DISEASE_ADJECTIVE[DISEASE]
in O O
one O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
specialized O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
organ O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
or O O
group O B_ORGANIZATION/B_MEASURE
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
carried O O
( O O
sometimes O O
in O O
the O O
bloodstream O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
to O O
another O O
organ O B_ENT/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
group O B_ORGANIZATION/B_MEASURE
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
in O O
the O O
same O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
organism O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O O
upon O O
which O O
it O O
has O O
a O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regulatory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
action O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
' O O
. O O

This O O
definition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O O
also O O
broad O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
enough O O
to O O
include O O
modes O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
actions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
diverse O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
endocrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
paracrine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
autocrine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Accordingly O O
, O O
with O O
the O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hormone O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
' O O
one O B_NUMBER[MEASURE]/B_PERSON
might O O
refer O O
to O O
any O O
extracellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
substance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
induces O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
target O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O O
helps O O
to O O
coordinate O O
growth O B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
activities O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
various O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
tissues O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
in O O
multicellular O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
organisms O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O O
15 O B_MEASURE/B_BIO
) O O
. O O

Hormones O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
can O O
be O O
classified O O
based O O
on O O
their O O
chemical O B_MEASURE/B_ORGANIZATION
nature O I_MEASURE/I_ORGANIZATION
, O O
solubility O B_TIME[MEASURE]/B_LOCATION
, O O
the O O
distance O B_MEASURE/B_LOCATION
over O O
which O O
the O O
signal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
acts O O
and O O
so O O
on O O
( O O
15 O B_MEASURE
, O O
16 O B_MEASURE
) O O
. O O

From O O
the O O
viewpoint O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
phenotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
relations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
it O O
is O O
reasonable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
distinguish O O
between O O
polypeptide O B_GENE/B_PERSON
, O O
thus O O
, O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
encoded O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
one O B_PERSON/B_NUMBER[MEASURE]
hand O B_PERSON/I_NUMBER[MEASURE]
, O O
and O O
those O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormones O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
with O O
only O O
the O O
machinery O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
their O O
synthesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
being O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
encoded O O
, O O
on O O
the O O
other O B_PERSON/B_SEQUENCE[MEASURE]
hand O B_PERSON/I_SEQUENCE[MEASURE]
. O O

Another O O
classification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
seems O O
to O O
be O O
overlapping O O
with O O
the O O
previous O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
one O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
refers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
the O O
intracellular O B_LOCATION
location O I_LOCATION
of O O
their O O
receptors O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
, O O
thus O O
, O O
how O O
the O O
subsequent O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signal O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
further O O
transduced O O
: O O
membrane O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
bound O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usually O O
trigger O O
more O B_TIME[MEASURE]
or O O
less O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
signaling O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cascades O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
towards O O
the O O
nucleus O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
whereas O O
nuclear O B_GENE/B_BIO
receptors O I_GENE/I_BIO
, O O
mainly O O
bound O O
by O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
molecular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
weight O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
have O O
a O O
very O O
short O B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_DISEASE_ADJECTIVE[DISEASE]
downstream O I_DISEASE_ADJECTIVE[DISEASE]
since O O
they O O
act O O
as O O
transcription O B_GENE/B_BIO
factors O I_GENE/I_BIO
themselves O O
( O O
15 O B_MEASURE/B_PERSON
, O O
16 O B_MEASURE
) O O
. O O

In O O
intercellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
communication O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
we O O
can O O
basically O O
differentiate O O
between O O
two O B_MEASURE/B_LOCATION
kinds O I_MEASURE/I_LOCATION
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O O
donor O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
which O O
synthesize O O
and O O
secrete O O
a O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
acceptor O B_PERSON/B_BIO
cells O I_PERSON/I_BIO
which O O
express O O
a O O
hormone O B_GENE
receptor O I_GENE
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
1a O I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

Donor O B_PERSON/B_BIO
cells O I_PERSON/I_BIO
become O O
active O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O O
the O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
an O O
external O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
mostly O O
environmental O B_DISEASE_ADJECTIVE[DISEASE]
, O O
stimulus O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O O

In O O
the O O
acceptor O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
receptor O B_GENE
triggers O O
an O O
intracellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
signal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
transduction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cascade O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinds O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
end O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nodes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
effects O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
transcription O B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affecting O O
the O O
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O O
the O O
acceptor O B_PERSON/B_BIO
cell O I_PERSON/I_BIO
, O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
enzymes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
controlling O O
the O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
' O O
s O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
metabolism O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
structural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
components O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
which O O
define O O
the O O
acceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
' O O
s O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
morphological O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
or O O
components O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
secretory O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
apparatus O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
regulating O O
the O O
release O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extracellular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

If O O
synthesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
secretion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
another O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
among O O
the O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exerted O O
by O O
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
acceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
turned O O
into O O
a O O
donor O B_LOCATION
cell O I_LOCATION
, O O
thus O O
becoming O O
an O O
internal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
node O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
organism O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
endocrine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Acceptor O B_PERSON/B_BIO
cells O I_PERSON/I_BIO
which O O
do O O
not O O
become O O
producers O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
another O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
called O O
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
terminal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
target O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cells O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
endocrine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
finally O O
constitute O O
the O O
overall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
physiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
respective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormonal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
simply O O
the O O
phenotype O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
Figure O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1a O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

The O O
EndoNet O B_PERSON/B_EDU[ORGANIZATION]
data O I_PERSON/I_EDU[ORGANIZATION]
model O I_PERSON/I_EDU[ORGANIZATION]

In O O
the O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
two O B_LOCATION/B_MEASURE
classes O I_LOCATION/I_MEASURE
of O O
entities O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
-- O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
in O O
the O O
broadest O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sense O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
their O O
acceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
or O O
target O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
expressing O O
the O O
corresponding O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-- O O
span O O
a O O
bipartite O B_MEASURE/B_BACTERIUM[BIO]
directed O O
graph O B_ORGANIZATION/B_LOCATION
. O O

Since O O
one O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
the O O
same O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
hormone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
may O O
be O O
secreted O O
by O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
types O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
donor O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
) O O
, O O
each O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
secretion O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
event O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O O
represented O O
by O O
a O O
hormone O B_DISEASE/B_PROTEIN[GENE]
node O B_DISEASE/I_PROTEIN[GENE]
on O O
its O O
own O B_PERSON/B_LOCATION
. O O

Similarly O O
, O O
each O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
type O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
known O O
to O O
express O O
a O O
hormone O B_GENE
receptor O I_GENE
( O O
acceptor O B_PERSON/B_PROTEIN[GENE]
cell O B_PERSON/I_PROTEIN[GENE]
) O O
leads O O
to O O
an O O
individual O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
node O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
graph O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
s O B_LOCATION/B_PERSON
edges O I_LOCATION/I_PERSON
represent O O
hormone O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transport O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
binding O O
to O O
a O O
receptor O B_GENE
( O O
intercellular O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
edges O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
on O O
one O B_PERSON/B_MEASURE
hand O B_PERSON/I_MEASURE
, O O
and O O
triggering O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
or O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hormone O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
secretion O B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
by O O
a O O
receptor O B_GENE
activated O O
by O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
intracellular O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
edges O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
on O O
the O O
other O B_PERSON/B_SEQUENCE[MEASURE]
hand O B_PERSON/I_SEQUENCE[MEASURE]
. O O

Optionally O O
, O O
an O O
edge O B_PERSON/B_LOCATION
representing O O
the O O
transport O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
subdivided O O
by O O
introducing O O
the O O
transport O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
usually O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
as O O
an O O
additional O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O O
intermediary O B_LOCATION/B_MEASURE
node O I_LOCATION/I_MEASURE
. O O

Thus O O
, O O
in O O
the O O
conceptual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
schema O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Figure O B_MEASURE/B_LOCATION
1b O I_MEASURE/I_LOCATION
) O O
, O O
the O O
links O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
define O O
donor O B_PERSON/B_LOCATION
cells O B_PERSON/I_LOCATION
( O O
' O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
) O O
, O O
those O O
between O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acceptor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
' O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O O
) O O
. O O

If O O
an O O
acceptor O B_PERSON/B_BIO
cell O I_PERSON/I_BIO
synthesizes O O
another O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
an O O
incoming O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signal O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
it O O
becomes O O
an O O
internal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
node O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
emerging O O
hormonal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
network O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
the O O
pathway O B_LOCATION/B_MEASURE
between O O
a O O
hormone O B_GENE
receptor O I_GENE
expressed O O
in O O
an O O
acceptor O B_PERSON/B_BIO
cell O I_PERSON/I_BIO
and O O
a O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
synthesized O O
in O O
the O O
same O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
( O O
intracellular O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
edge O I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
is O O
handled O O
as O O
a O O
black O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
box O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
encoded O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
cross O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
references O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
entries O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
TRANSPATH O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
(R) O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
which O O
describe O O
the O O
signaling O O
cascade O B_LOCATION
starting O O
from O O
the O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
s O B_GENE
receptor O I_GENE
and O O
ending O O
at O O
the O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O O
s O B_GENE/B_PERSON
gene O I_GENE/I_PERSON
, O O
are O O
provided O O
, O O
if O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Datasets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
non O B_DISEASE
- O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
in O O
future O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
be O O
enriched O O
by O O
a O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
metabolic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
add O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
on O O
which O O
will O O
include O O
references O B_PERSON/B_LOCATION
to O O
the O O
databases O B_DISEASE/B_GENE
KEGG O I_DISEASE/I_GENE
( O O
1 O B_MEASURE
) O O
and O O
BRENDA O B_PERSON/B_LOCATION
( O O
17 O B_NUMBER[MEASURE]
) O O
, O O
allowing O O
for O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characterization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
steps O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
performed O O
during O O
the O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
s O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
enzymes O B_GENE
involved O O
. O O

By O O
now O O
, O O
the O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
already O O
allows O O
for O O
including O O
descriptions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
physiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
see O O
below O O
, O O
Future O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Developments O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
contents O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
EndoNet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION

In O O
the O O
present O O
version O O
of O O
EndoNet O O
, O O
and O O
as O O
a O O
first O O
approach O O
, O O
we O O
consider O O
the O O
endocrine O O
( O O
hormonal O O
) O O
network O O
of O O
the O O
human B B_PERSON/B_SPECIES[BIO]
body O O
. O O

For O O
each O O
molecule O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
or O O
receptor O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
a O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
name O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
synonyms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
given O O
. O O

In O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
the O O
sequence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
processed O O
polypeptide O B_PROTEIN[GENE]
, O O
rather O O
than O O
that O O
of O O
the O O
protein O B_GENE/B_BIO
precursor O I_GENE/I_BIO
, O O
is O O
specified O O
. O O

For O O
a O O
multimeric O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
hormone O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
subunit O B_MEASURE/B_LOCATION
composition O B_MEASURE/I_LOCATION
as O O
well O O
as O O
the O O
sequences O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
all O O
subunits O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
stored O O
; O O
the O O
same O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
holds O O
true O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Additionally O O
, O O
all O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
receptor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
datasets O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
links O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
HumanPSD O B_DISEASE/B_LOCATION
(TM) O B_DISEASE/I_LOCATION
( O O
18 O B_MEASURE/B_LOCATION
) O O
and O O
to O O
the O O
Swiss O B_LOCATION/B_PROTEIN[GENE]
- O O
Prot O B_LOCATION/B_ORGANIZATION
database O I_LOCATION/I_ORGANIZATION
, O O
The O O
structures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
non O B_DISEASE/B_PROTEIN[GENE]
- O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
can O O
be O O
accessed O O
through O O
the O O
corresponding O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyperlinks O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
KEGG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
COMPOUND O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
section O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Finally O O
, O O
all O O
molecules O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
have O O
links O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
the O O
TRANSPATH O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
database O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
described O O
, O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
utilizes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
about O O
the O O
tissues O B_LOCATION/B_DISEASE
from O O
which O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
secreted O O
and O O
in O O
which O O
receptors O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
expressed O O
to O O
define O O
donor O B_PERSON
and O O
acceptor O B_PERSON/B_LOCATION
cells O I_PERSON/I_LOCATION
, O O
respectively O O
. O O

The O O
identity O O
and O O
anatomical O O
environment O O
of O O
cell O O
types O O
, O O
tissues O O
and O O
organs O O
is O O
defined O O
through O O
references O O
to O O
the O O
CYTOMER O O
(R) O O
ontology O O
( O O
19 O O
, O O
20 O O
) O O
; O O
in O O
the O O
numerous O O
cases O O
where O O
the O O
receptors O O
are O O
ubiquitously O O
expressed O O
, O O
just O O
the O O
root O O
term O O
' O O
human B B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
body O O
' O O
is O O
linked O O
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
whether O O
a O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' O O
s O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
triggered O O
or O O
inhibited O O
by O O
another O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
its O O
respective O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
particular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
obtained O O
by O O
manual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
selection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
textbooks O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
e O B_OTHER/B_PROTEIN[GENE]
. O O
g O B_OTHER/B_GENE
. O O
( O O
16 O B_MEASURE
) O O
, O O
] O B_OTHER/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
monographies O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
21 O B_MEASURE
) O O
, O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
literature O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
the O O
EST O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
linked O O
databases O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TRANSPATH O B_ORGANIZATION/B_LOCATION
(R) O I_ORGANIZATION/I_LOCATION
, O O
HumanPSD O B_DISEASE/B_ORGANIZATION
(TM) O I_DISEASE/I_ORGANIZATION
and O O
Swiss O B_LOCATION
- O O
Prot O B_LOCATION/B_PERSON
) O O
. O O

The O O
contents O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
EndoNet O B_ORGANIZATION/B_PERSON
are O O
summarized O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Web O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interface O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
queries O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
visualization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION

EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
can O O
be O O
accessed O O
through O O
the O O
WWW O B_ORGANIZATION/B_LOCATION
via O O
a O O
JSP O B_MEASURE/B_ORGANIZATION
- O O
based O O
web O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interface O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
tissues O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
be O O
queried O O
for O O
their O O
names O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
and O O
detailed O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
all O O
identified O O
components O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
individual O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pages O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Each O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
individual O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
entry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
page O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
displays O O
its O O
source O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
target O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tissues O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
donor O B_PERSON/B_BIO
and O O
acceptor O B_PERSON/B_LOCATION
cells O I_PERSON/I_LOCATION
) O O
as O O
well O O
as O O
its O O
receptors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
along O O
with O O
some O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Similarly O O
, O O
each O O
receptor O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
entry O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
exhibits O O
the O O
tissues O B_LOCATION/B_DISEASE
in O O
which O O
the O O
receptor O B_GENE
is O O
expressed O O
, O O
and O O
the O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
it O O
interacts O O
with O O
. O O

Finally O O
, O O
each O O
tissue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
entry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lists O O
the O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
found O O
in O O
, O O
as O O
well O O
as O O
the O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
synthesized O O
and O O
secreted O O
by O O
the O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
also O O
indicated O O
whether O O
the O O
corresponding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tissue O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
exerts O O
gender O B_PERSON/B_LOCATION
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
properties O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
; O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O O
on O O
the O O
CYTOMER O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
(R) O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
ontology O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
through O O
the O O
corresponding O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
link O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
tissue O B_LOCATION/B_PERSON
detail O I_LOCATION/I_PERSON
page O I_LOCATION/I_PERSON
. O O

Instead O O
of O O
searching O O
for O O
a O O
name O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
a O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
one O O
can O O
also O O
browse O O
the O O
hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hormone O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
featured O O
by O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
( O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
' O O
Search O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O O
page O B_LOCATION/B_MEASURE
) O O
. O O

Each O O
query O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
result O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
can O O
be O O
used O O
as O O
starting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
point O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
an O O
extended O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
query O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
items O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
interest O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
selected O O
and O O
added O O
to O O
a O O
common O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
result O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
set O O
. O O

Since O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
search O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O O
be O O
combined O O
, O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
create O O
sets O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
multiple O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
search O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
parameters O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

At O O
any O O
step O B_MEASURE/B_LOCATION
of O O
this O O
incremental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
retrieval O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
sets O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
tissues O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
obtained O O
so O O
far O O
can O O
be O O
used O O
as O O
starting O O
points O B_LOCATION/B_BIO
for O O
reconstructing O O
a O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
a O O
depth O B_MEASURE/B_LOCATION
- O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
graph O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
traversal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
maximum O B_MEASURE/B_LOCATION
number O B_MEASURE/I_LOCATION
of O O
steps O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
can O O
be O O
selected O O
separately O O
for O O
the O O
upstream O B_LOCATION/B_MEASURE
and O O
downstream O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
reconstruction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Subsequently O O
, O O
the O O
graph O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
displayed O O
using O O
a O O
Graphviz O B_PERSON/B_LOCATION
- O O
based O O
visualization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
22 O B_TIME[MEASURE]/B_ENT
) O O
, O O
] O O
. O O

In O O
the O O
resulting O O
image O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
represented O O
as O O
nodes O B_LOCATION/B_PERSON
grouped O O
together O O
into O O
subgraphs O B_LOCATION/B_ORGANIZATION
representing O O
the O O
tissues O B_LOCATION/B_DISEASE
( O O
cells O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
/ O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
) O O
they O O
are O O
secreted O O
from O O
or O O
expressed O O
in O O
, O O
respectively O O
( O O
Figure O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
2 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
) O O
. O O

Autocrine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
loops O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
donor O B_PERSON
and O O
acceptor O B_PERSON/B_BIO
cell O I_PERSON/I_BIO
being O O
identical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
are O O
treated O O
specially O O
for O O
visualization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
. O O

On O O
demand O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
the O O
hormones O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
transport O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
media O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
can O O
be O O
included O O
in O O
the O O
visualization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
intercellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
edges O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
, O O
enabling O O
the O O
user O B_PERSON/B_BIO
to O O
choose O O
between O O
different O B_LOCATION
complexities O I_LOCATION
of O O
output O B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Intracellular O B_LOCATION/B_ENT
edges O I_LOCATION/I_ENT
, O O
which O O
connect O O
a O O
receptor O B_GENE
to O O
a O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
represent O O
the O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
receptor O B_GENE
' O O
s O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
secretion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
a O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
the O O
same O B_BODY_PART_OR_ORGAN_COMPONENT
cell O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
are O O
displayed O O
differently O O
, O O
depending O O
on O O
whether O O
this O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
triggering O O
or O O
inhibitory O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
nature O B_LOCATION/B_DISEASE
. O O

The O O
graph O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
displayed O O
as O O
a O O
clickable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
image O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
map O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
linking O O
each O O
entity O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
its O O
detailed O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
page O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
thus O O
making O O
the O O
database O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
entries O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
accessible O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O O
the O O
graphical O B_LOCATION/B_PERSON
overview O I_LOCATION/I_PERSON
of O O
a O O
network O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
too O O
. O O

The O O
graph O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
two O B_MEASURE/B_LOCATION
different O B_MEASURE/I_LOCATION
formats O B_MEASURE/I_LOCATION
: O O
PNG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
SVG O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

While O O
virtually O O
every O O
browser O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supports O O
PNG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
a O O
' O O
pixel O B_MEASURE/B_ENT
' O O
or O O
' O O
bitmap O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
' O O
format O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
, O O
only O O
a O O
few O B_MEASURE/B_PERSON
of O O
them O O
provide O O
a O O
zoom O B_LOCATION/B_PERSON
functionality O I_LOCATION/I_PERSON
for O O
bitmap O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
pictures O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Scalable O B_TIME[MEASURE]/B_LOCATION
vector O I_TIME[MEASURE]/I_LOCATION
graphics O I_TIME[MEASURE]/I_LOCATION
, O O
( O O
SVG O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
provides O O
more O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
functionality O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
including O O
perfect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
image O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
quality O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
throughout O O
all O O
zoom O B_LOCATION/B_ENT
factors O B_LOCATION/I_ENT
) O O
, O O
but O O
until O O
now O O
most O B_PERSON
browsers O I_PERSON
do O O
not O O
support O O
SVG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
natively O O
and O O
require O O
an O O
SVG O B_PERSON/B_LOCATION
plugin O I_PERSON/I_LOCATION
( O O
) O O
for O O
displaying O O
this O O
vector O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
based O O
format O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Some O O
well O O
- O O
established O O
endocrine O B_LOCATION/B_ENT
pathways O B_LOCATION/I_ENT
are O O
offered O O
as O O
showcases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
predefined O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
result O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sets O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

For O O
instance O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sets O O
representing O O
the O O
hypothalamic O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
hypophyseal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
focus O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
either O O
thyroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
adrenal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
growth O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
prolactin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
provided O O
. O O

These O O
predefined O O
sets O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
used O O
for O O
obtaining O O
a O O
quick O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
overview O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
or O O
as O O
starting O O
points O B_LOCATION/B_ENT
for O O
more O O
complex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
queries O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

FUTURE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DEVELOPMENTS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Among O O
the O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
improvements O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
which O O
we O O
are O O
currently O O
working O O
on O O
is O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
represent O O
intercellular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
communication O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O O
different O B_MEASURE/B_LOCATION
levels O B_MEASURE/I_LOCATION
of O O
the O O
hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
organization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
tissues O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O O
the O O
organism O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
as O O
well O O
as O O
to O O
distinguish O O
between O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
communications O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
male O B_PERSON
and O O
female O B_PERSON
organisms O I_PERSON
. O O

These O O
options O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O O
be O O
introduced O O
by O O
a O O
tighter O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
integration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
the O O
CYTOMER O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
based O O
ontology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
19 O B_MEASURE
, O O
20 O B_MEASURE
) O O
. O O

The O O
next O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
step O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
will O O
be O O
to O O
expand O O
the O O
contents O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
towards O O
the O O
details O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
processes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
occurring O O
in O O
the O O
transport O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
usually O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Since O O
not O O
all O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
transported O O
as O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
molecules O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
some O O
hydrophobic O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hormones O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
thyroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
need O O
to O O
be O O
bound O O
to O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
carrier O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
proteins O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
proper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transporters O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
their O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O O
the O O
corresponding O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
will O O
be O O
required O O
. O O

It O O
is O O
planned O O
to O O
involve O O
quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
about O O
the O O
regular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
pathological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
overall O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kinetics O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
each O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O O
monotonous O B_LOCATION/B_MEASURE
decay O B_LOCATION/I_MEASURE
, O O
oscillating O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
concentrations O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O O
increase O O
in O O
response O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
etc O B_GENE/B_DISEASE
. O O
) O O
, O O
its O O
turnover O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
products O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O O
etc O B_LOCATION/B_DISEASE
. O O

That O O
will O O
allow O O
utilization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
EndoNet O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contents O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
diagnostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
purposes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

In O O
future O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
extended O O
in O O
order O B_LOCATION/B_DISEASE
to O O
incorporate O O
external O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
light O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
and O O
physiological O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
states O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
stress O B_DISEASE/B_ORGANISM_FUNCTION
, O O
age O B_DISEASE/B_ORGANISM_FUNCTION
, O O
etc O B_LOCATION/B_DISEASE
. O O
) O O
in O O
a O O
formalized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manner O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
allowing O O
to O O
determine O O
whether O O
or O O
not O O
and O O
in O O
which O O
quantity O B_MEASURE/B_LOCATION
a O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
will O O
be O O
secreted O O
under O O
the O O
given O O
circumstances O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O O
then O O
link O O
the O O
physiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
the O O
intracellular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
molecular O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leading O O
to O O
its O O
synthesis O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_GENE
and O O
secretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
donor O B_BODY_PART_OR_ORGAN_COMPONENT
cells O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
to O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
its O O
acceptor O B_PERSON/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
cells O B_PERSON/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

At O O
many O B_MEASURE/B_LOCATION
places O B_MEASURE/I_LOCATION
of O O
these O O
intracellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
intercellular O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
networks O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
genetically O O
determined O O
aberrations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
may O O
cause O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
sometimes O O
pathological O B_DISEASE_ADJECTIVE[DISEASE]
phenotypes O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O O
enable O O
to O O
bridge O O
the O O
gap O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
between O O
known O O
genotypes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
their O O
molecular O B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
phenotypes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
this O O
area O B_LOCATION/B_MEASURE
of O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
its O O
applications O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

DISCUSSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

At O O
its O O
present O B_LOCATION
state O I_LOCATION
, O O
EndoNet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
provides O O
a O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
coverage O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
molecules O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
are O O
conventionally O O
considered O O
as O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
well O O
as O O
other O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
molecules O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
are O O
involved O O
in O O
intercellular O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
communication O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
growth O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
lymphokines O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
chemokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
their O O
known O O
receptors O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
database O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
to O O
provide O O
a O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resource O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
studying O O
the O O
principal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
features O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
hormonal O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
networks O I_ORGANIZATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
comprehensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
way O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
as O O
it O O
was O O
done O O
more O O
exemplarily O O
in O O
the O O
past O B_TIME[MEASURE]/B_LOCATION
for O O
these O O
kinds O B_MEASURE/B_LOCATION
of O O
networks O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
23 O B_MEASURE
) O O
, O O
but O O
was O O
done O O
globally O O
for O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
other O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
intracellular O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
network O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
types O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
metabolic O B_ENZYME[GENE]/B_DISEASE
, O O
protein O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
transcription O B_ORGANIZATION/B_GENE
networks O I_ORGANIZATION/I_GENE
[ O O
reviewed O O
in O O
( O O
24 O B_MEASURE
, O O
25 O B_MEASURE
) O O
] O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

EndoNet O B_PERSON/B_ORGANIZATION
database O I_PERSON/I_ORGANIZATION
certainly O O
is O O
not O O
yet O O
complete O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O O
will O O
grow O O
rapidly O O
. O O

Gender O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
influencing O O
insulin O B_DISEASE/B_GENE
resistance O I_DISEASE/I_GENE
in O O
elderly O B_DISEASE/B_MEASURE
hyperlipemic O I_DISEASE/I_MEASURE
non O I_DISEASE/I_MEASURE
- O O
diabetic O B_PERSON
subjects O I_PERSON

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
prevalence O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
insulin O B_DISEASE
resistance O I_DISEASE
- O O
related O O
metabolic O B_DISEASE
syndrome O I_DISEASE
, O O
a O O
disorder O B_DISEASE
that O O
greatly O O
increases O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
diabetes O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
heart O B_DISEASE
attack O I_DISEASE
and O O
stroke O B_DISEASE
, O O
is O O
alarming O B_DISEASE_ADJECTIVE[DISEASE]
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
most O O
frequent O B_DISEASE_ADJECTIVE[DISEASE]
and O O
early O B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
of O O
metabolic O B_DISEASE
syndrome O I_DISEASE
is O O
hypertriglyceridemia O B_DISEASE
. O O

We O O
examined O O
the O O
gender O O
differences O O
between O O
various O O
metabolic O O
factors O O
related O O
to O O
insulin O O
resistance O O
in O O
elderly O O
non O O
- O O
diabetic O O
men B B_PERSON
and O O
postmenopausal O O
women B B_PERSON
of O O
comparable O O
age O O
suffering O O
from O O
hypertriglyceridemia O O
, O O
and O O
compared O O
them O O
with O O
healthy O O
subjects O O
of O O
equal O O
age O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
indexes O O
of O O
insulin O O
resistance O O
HOMA O O
IR O O
and O O
QUICKI O O
were O O
significantly O O
higher O O
in O O
both O O
hyperlipemic O O
men B B_PERSON
and O O
women B B_PERSON/B_BIO
than O O
in O O
controls O O
; O O
95 O O
% O O
confidence O O
limits O O
of O O
hyperlipemic O O
subjects O O
did O O
not O O
overlap O O
with O O
controls O O
. O O

In O O
both O O
normolipemic O O
and O O
hyperlipemic O O
men B B_PERSON
and O O
women B B_PERSON/B_BIO
serum O O
leptin O O
correlated O O
significantly O O
with O O
insulin O O
resistance O O
, O O
while O O
HDL O O
- O O
cholesterol O O
correlated O O
inversely O O
with O O
HOMA O O
- O O
IR O O
only O O
in O O
women B B_PERSON/B_BIO
( O O
both O O
normo O O
- O O
and O O
hyperlipemic O O
) O O
, O O
and O O
serum O O
tumor O O
necrosis O O
factor O O
alpha O O
( O O
TNF O O
alpha O O
) O O
only O O
in O O
hyperlipemic O O
women B B_PERSON/B_BIO
. O O

According O O
to O O
results O O
of O O
multiple O O
regression O O
analysis O O
with O O
HOMA O O
- O O
IR O O
as O O
a O O
dependent O O
variable O O
, O O
leptin O O
played O O
a O O
significant O O
role O O
in O O
determining O O
insulin O O
resistance O O
in O O
both O O
genders O O
, O O
but O O
- O O
aside O O
from O O
leptin O O
- O O
triglycerides O O
, O O
TNF O O
alpha O O
and O O
decreased O O
HDL O O
- O O
cholesterol O O
were O O
significant O O
determinants O O
in O O
women B B_PERSON/B_BIO
, O O
while O O
body O O
mass O O
index O O
and O O
decreased O O
HDL O O
- O O
cholesterol O O
were O O
significant O O
determinants O O
in O O
men B B_PERSON
. O O

The O O
coefficient O O
of O O
determination O O
( O O
R2 O O
) O O
of O O
HOMA O O
IR O O
by O O
above O O
mentioned O O
metabolic O O
variables O O
was O O
in O O
women B B_PERSON/B_BIO
above O O
60 O O
% O O
, O O
in O O
men B B_PERSON
only O O
about O O
40 O O
% O O
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

The O O
significant O O
role O O
of O O
serum O O
leptin O O
in O O
determination O O
of O O
insulin O O
resistance O O
in O O
both O O
elderly O O
men B B_PERSON
and O O
postmenopausal O O
women B B_PERSON
of O O
equal O O
age O O
was O O
confirmed O O
. O O

However O O
, O O
the O O
study O O
also O O
revealed O O
significant O O
gender O O
differences O O
: O O
in O O
women B B_PERSON/B_BIO
a O O
strong O O
influence O O
of O O
triglycerides O O
, O O
TNF O O
alpha O O
and O O
decreased O O
HDL O O
- O O
cholesterol O O
, O O
in O O
men B B_PERSON
only O O
a O O
mild O O
role O O
of O O
BMI O O
and O O
decreased O O
HDL O O
- O O
cholesterol O O
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
association O B_ORGANIZATION/B_PERSON
with O O
pandemic O B_DISEASE/B_ORGANISM_FUNCTION
obesity O I_DISEASE/I_ORGANISM_FUNCTION
the O O
prevalence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
insulin O B_DISEASE
resistance O I_DISEASE
- O O
related O O
metabolic O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
is O O
constantly O O
growing O O
[ O O
1 O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
] O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
a O O
consequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
type O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
2 O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
diabetes O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
mellitus O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
cardiovascular O B_DISEASE
mortality O I_DISEASE
occurs O O
in O O
much O O
younger O B_PERSON/B_MEASURE
age O I_PERSON/I_MEASURE
groups O I_PERSON/I_MEASURE
[ O O
2 O B_MEASURE/B_DISEASE
] O I_MEASURE/I_DISEASE
. O O

A O O
typical O B_DISEASE
hyperlipemia O I_DISEASE
, O O
consisting O O
of O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triglycerides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
serum O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HDL O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
cholesterol O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
a O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
an O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptom O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
syndrome O B_DISEASE/B_PERSON
[ O O
3 O B_LOCATION/B_TIME[MEASURE]
] O B_LOCATION/I_TIME[MEASURE]
. O O

With O O
increasing O O
age O B_MEASURE/B_DISEASE
, O O
body O B_MEASURE/B_DISEASE
mass O B_MEASURE/I_DISEASE
index O B_MEASURE/I_DISEASE
( O O
BMI O B_MEASURE/B_DISEASE
) O O
and O O
adiposity O B_DISEASE/B_MEASURE
, O O
insulin O B_DISEASE/B_MEASURE
sensitivity O I_DISEASE/I_MEASURE
declines O I_DISEASE/I_MEASURE
and O O
the O O
number O B_MEASURE
of O O
cardiovascular O B_DISEASE/B_PERSON
risk O I_DISEASE/I_PERSON
factors O I_DISEASE/I_PERSON
increases O I_DISEASE/I_PERSON
in O O
both O O
genders O B_PERSON/B_MEASURE
[ O O
4 O B_TIME[MEASURE]
- O O
6 O B_MEASURE
] O I_MEASURE
. O O

It O O
was O O
repeatedly O O
demonstrated O O
that O O
plasma O O
concentration O O
of O O
leptin O O
- O O
a O O
hormone O O
produced O O
mainly O O
by O O
adipose O O
tissue O O
- O O
is O O
substantially O O
higher O O
in O O
all O O
age O O
groups O O
of O O
women B B_PERSON/B_BIO
than O O
in O O
men B B_PERSON/B_BIO
[ O O
7 O O
- O O
10 O O
] O O
. O O

This O O
may O O
be O O
caused O O
by O O
different O B_MEASURE/B_LOCATION
size O B_MEASURE/I_LOCATION
and O O
/ O O
or O O
distribution O B_ORGANIZATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
compartments O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
influenced O O
by O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
estrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulate O O
, O O
whereas O O
testosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibits O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leptin O O
secretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
women B B_PERSON/B_BIO
subcutaneous O O
fat O O
mass O O
prevails O O
- O O
and O O
during O O
augmentation O O
of O O
overweight O O
it O O
increases O O
- O O
while O O
in O O
men B B_PERSON
intra O O
- O O
abdominal O O
fat O O
mass O O
prevails O O
[ O O
11 O O
- O O
13 O O
] O O
. O O

Subcutaneous O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
fat O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
in O O
particular O B_DISEASE/B_SPECIES[BIO]
serves O O
as O O
a O O
substantial O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
source O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tumor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
which O O
represents O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
interfere O O
with O O
insulin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
signal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
transduction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
into O O
the O O
cells O B_BODY_PART_OR_ORGAN_COMPONENT
[ O O
14 O B_MEASURE/B_LOCATION
- O O
16 O B_MEASURE
] O I_MEASURE
. O O

Leptin O B_MEASURE/B_GENE
, O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
some O O
other O B_MEASURE/B_GENE
factors O I_MEASURE/I_GENE
are O O
abundantly O O
expressed O O
in O O
adipose O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
contribute O O
to O O
the O O
insulin O B_DISEASE
resistance O I_DISEASE
that O O
accompanies O O
overweight O B_DISEASE/B_ORGANISM_FUNCTION
and O O
obesity O B_DISEASE
. O O

Leptin O B_GENE/B_BIO
correlates O O
positively O O
with O O
hyperinsulinemia O B_DISEASE
, O O
BMI O B_DISEASE/B_GENE
, O O
fat O B_DISEASE
mass O I_DISEASE
and O O
hypertriglyceridemia O B_DISEASE/B_PROTEIN[GENE]
, O O
respectively O O
, O O
and O O
correlates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inversely O O
with O O
HDL O B_GENE
- O O
cholesterol O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
lean O B_MEASURE/B_PROTEIN[GENE]
body O B_MEASURE/I_PROTEIN[GENE]
mass O B_MEASURE/I_PROTEIN[GENE]
[ O B_MEASURE/I_PROTEIN[GENE]
17 O B_MEASURE/I_PROTEIN[GENE]
- O O
25 O B_MEASURE
] O I_MEASURE
. O O

The O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
mortality O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ischemic O B_DISEASE
heart O I_DISEASE
disease O I_DISEASE
and O O
of O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
consequences O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
atherosclerosis O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increases O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
age O B_TIME[MEASURE]/B_PERSON
in O O
both O O
genders O B_PERSON/B_LOCATION
, O O
especially O O
after O O
the O O
age O B_TIME[MEASURE]/B_LOCATION
of O O
sixty O B_NUMBER[MEASURE]
. O O

In O O
premenopausal O O
women B B_PERSON
, O O
however O O
, O O
the O O
incidence O O
of O O
these O O
disorders O O
is O O
considerably O O
less O O
frequent O O
than O O
in O O
men B B_PERSON
of O O
appropriate O O
age O O
. O O

After O O
the O O
menopause O O
the O O
prevalence O O
of O O
metabolic O O
syndrome O O
and O O
cardiovascular O O
mortality O O
in O O
women B B_PERSON/B_BIO
gradually O O
increases O O
, O O
attaining O O
values O O
comparable O O
to O O
men B B_PERSON/B_MEASURE
at O O
about O O
the O O
age O O
of O O
70 O O
[ O O
2 O O
, O O
26 O O
] O O
. O O

Paradoxically O O
, O O
it O O
takes O O
place O O
at O O
the O O
time O O
when O O
serum O O
leptin O O
concentration O O
in O O
women B B_PERSON/B_BIO
has O O
relatively O O
decreased O O
[ O O
27 O O
, O O
28 O O
] O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
analyze O O
the O O
interrelations O O
between O O
several O O
metabolic O O
variables O O
and O O
factors O O
related O O
to O O
insulin O O
resistance O O
in O O
groups O O
of O O
both O O
normal O O
and O O
hyperlipemic O O
postmenopausal O O
women B B_PERSON
and O O
men B B_PERSON
of O O
appropriate O O
age O O
, O O
and O O
to O O
attempt O O
to O O
elucidate O O
the O O
gender O O
differences O O
and O O
some O O
pathophysiologic O O
mechanisms O O
of O O
these O O
differences O O
. O O

We O O
compared O O
homeostatic O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indexes O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
insulin O B_GENE/B_DISEASE
resistance O B_GENE/I_DISEASE
HOMA O B_GENE/I_DISEASE
IR O B_GENE/I_DISEASE
and O O
QUICKI O B_LOCATION/B_ORGANIZATION
, O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lipid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
insulin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
uric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
leptin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
groups O B_ORGANIZATION/B_PERSON
of O O
subjects O B_PERSON/B_BIO
without O O
apparent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
metabolic O B_DISEASE/B_LOCATION
syndrome O I_DISEASE/I_LOCATION
, O O
and O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
hypertriglyceridemia O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
decreased O O
HDL O B_GENE
- O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
serum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
heart O B_MEASURE/B_LOCATION
fraction O B_MEASURE/I_LOCATION
of O O
fatty O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
hFATP O B_GENE/B_DISEASE
) O O
was O O
explored O O
as O O
a O O
factor O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
might O O
reflect O O
the O O
regulative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PPAR O B_GENE
gamma O I_GENE
in O O
lipid O B_DISEASE
homeostasis O I_DISEASE
[ O O
29 O B_MEASURE
, O O
30 O B_MEASURE
] O I_MEASURE
, O O
and O O
serum O O
IgG O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anticardiolipin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ACL O B_DISEASE/B_LOCATION
- O O
IgG O B_PROTEIN[GENE]/B_LOCATION
) O O
was O O
investigated O O
as O O
an O O
indirect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicator O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
oxidized O B_DISEASE_ADJECTIVE[DISEASE]
lipid O I_DISEASE_ADJECTIVE[DISEASE]
fractions O I_DISEASE_ADJECTIVE[DISEASE]
related O O
to O O
atherosclerotic O B_DISEASE
complications O I_DISEASE
[ O O
31 O B_MEASURE
, O O
32 O B_MEASURE
] O I_MEASURE
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Subjects O B_PERSON

The O O
study O O
was O O
carried O O
out O O
on O O
70 O O
out O O
- O O
patients B B_PERSON/B_LOCATION
of O O
the O O
Metabolic O O
Center O O
at O O
the O O
hospital O O
in O O
Sternberk O O
, O O
Czech O O
Republic O O
. O O

From O O
these O O
, O O
40 O O
patients B B_PERSON
( O O
20 O O
men B B_PERSON
and O O
20 O O
women B B_PERSON/B_BIO
) O O
were O O
selected O O
with O O
mild O O
hyperlipidemia O O
, O O
i O O
. O O
e O O
. O O
with O O
plasma O O
triglyceride O O
concentration O O
exceeding O O
2 O O
. O O
0 O O
mmol O O
/ O O
l O O
, O O
total O O
cholesterol O O
exceeding O O
6 O O
. O O
0 O O
mmol O O
/ O O
l O O
, O O
LDL O O
cholesterol O O
exceeding O O
4 O O
. O O
0 O O
mmol O O
/ O O
l O O
, O O
and O O
with O O
HDL O O
cholesterol O O
concentration O O
in O O
men B B_PERSON/B_BIO
under O O
1 O O
. O O
0 O O
mmol O O
/ O O
l O O
, O O
and O O
in O O
women B B_PERSON/B_BIO
under O O
1 O O
. O O
2 O O
mmol O O
/ O O
l O O
. O O

These O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O O
denominated O O
as O O
" O O
hyperlipemic O B_PERSON/B_ORGANIZATION
" O O
. O O

Two O O
other O O
groups O O
( O O
10 O O
men B B_PERSON
and O O
20 O O
women B B_PERSON/B_BIO
) O O
with O O
approximately O O
normal O O
serum O O
values O O
of O O
these O O
variables O O
were O O
taken O O
as O O
" O O
controls O O
" O O
. O O

The O O
average O O
age O O
in O O
men B B_PERSON/B_LOCATION
was O O
59 O O
. O O
1 O O
+/- O O
10 O O
. O O
6 O O
y O O
, O O
and O O
in O O
women B B_PERSON/B_BIO
59 O O
. O O
4 O O
+/- O O
10 O O
. O O
1 O O
y O O
, O O
respectively O O
. O O

The O O
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
lipid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
hyperlipemic O B_DISEASE/B_PERSON
and O O
control O B_DISEASE/B_MEASURE
groups O I_DISEASE/I_MEASURE
were O O
highly O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
while O O
the O O
age O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
insignificant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

None O O
of O O
the O O
patients B B_PERSON/B_DISEASE
had O O
clinically O O
apparent O O
diabetes O O
mellitus O O
, O O
but O O
some O O
of O O
the O O
hyperlipemic O O
patients B B_PERSON/B_BIO
exerted O O
impaired O O
glucose O O
tolerance O O
or O O
impaired O O
fasting O O
glucose O O
( O O
values O O
between O O
6 O O
. O O
1 O O
and O O
7 O O
. O O
0 O O
mmol O O
/ O O
l O O
, O O
or O O
between O O
6 O O
. O O
1 O O
and O O
7 O O
. O O
8 O O
mmol O O
/ O O
l O O
, O O
respectively O O
) O O
. O O

None O O
of O O
the O O
patients B B_PERSON/B_DISEASE
was O O
treated O O
with O O
insulin O O
, O O
peroral O O
antidiabetics O O
or O O
antihyperlipemic O O
drugs O O
; O O
some O O
of O O
them O O
were O O
treated O O
with O O
antihypertensive O O
therapy O O
. O O

No O O
signs O O
of O O
major O O
clinical O O
or O O
laboratory O O
symptoms O O
of O O
other O O
diseases O O
were O O
present O O
in O O
any O O
group O O
of O O
the O O
explored O O
patients B B_PERSON/B_LOCATION
. O O

Blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
obtained O O
in O O
the O O
morning O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
via O O
a O O
venipuncture O B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
after O O
overnight O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasting O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

After O O
clotting O O
the O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
separated O O
and O O
stored O O
at O O
- O O
20 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
until O O
used O O
. O O

An O O
informed O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
consent O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
obtained O O
from O O
all O O
probands O B_PERSON
. O O

Body O B_MEASURE/B_LOCATION
mass O I_MEASURE/I_LOCATION
indexes O I_MEASURE/I_LOCATION
( O O
BMI O B_MEASURE/B_ORGANIZATION
) O O
, O O
defined O O
as O O
weight O B_MEASURE/B_PERSON
in O O
kilograms O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
divided O O
by O O
the O O
square O B_MEASURE/B_LOCATION
of O O
height O B_MEASURE/B_LOCATION
in O O
meters O B_MEASURE/B_PERSON
, O O
were O O
calculated O O
. O O

Biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Serum O O
leptin O O
concentrations O O
were O O
measured O O
by O O
a O O
sandwich O O
ELISA O O
test O O
kit O O
( O O
Human B B_PERSON/B_SPECIES[BIO]
Leptin O O
ELISA O O
, O O
BioVendor O O
Laboratory O O
Medicine O O
, O O
Inc O O
, O O
Czech O O
Republic O O
) O O
. O O

Its O O
sensitivity O B_MEASURE/B_ENT
limit O I_MEASURE/I_ENT
was O O
0 O B_MEASURE
. O O
2 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
, O O
intraassay O B_MEASURE
CV O I_MEASURE
6 O I_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
at O O
the O O
level O B_MEASURE/B_LOCATION
of O O
7 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
m O B_OTHER/B_MEASURE
, O O
inter O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
assay O B_MEASURE
CV O I_MEASURE
8 O I_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
at O O
the O O
level O B_MEASURE/B_LOCATION
of O O
4 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
. O O

Tetramethylbenzidine O O
was O O
used O O
as O O
a O O
substrate O O
; O O
quality O O
controls O O
were O O
human B B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
. O O

Several O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
were O O
estimated O O
by O O
routine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immunochemical O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tests O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O O
insulin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
C O B_GENE/B_LOCATION
- O O
peptide O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
TNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IMMULITE O B_LOCATION/B_ORGANIZATION
, O O
Diagnostic O B_LOCATION/B_ORGANIZATION
Products O I_LOCATION/I_ORGANIZATION
Corporation O I_LOCATION/I_ORGANIZATION
, O O
Los O B_LOCATION/B_PERSON
Angeles O I_LOCATION/I_PERSON
, O O
CA O B_LOCATION
, O O
U O B_OTHER/B_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
) O O
, O O
proinsulin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
intact O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DAKO O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Denmark O B_LOCATION
) O O
, O O
IgG O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anticardiolipin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ACL O B_LOCATION
- O O
IgG O B_GENE/B_MEASURE
, O O
IMMCO O B_LOCATION/B_ORGANIZATION
Diagnostics O B_LOCATION/I_ORGANIZATION
, O O
Buffalo O B_LOCATION
, O O
NY O B_LOCATION
, O O
U O B_OTHER/B_LOCATION
. O O
S O B_OTHER/B_LOCATION
. O O
A O B_OTHER/B_LOCATION
. O O
) O O
and O O
heart O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fatty O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
hFABP O B_LOCATION/B_GENE
, O O
Hbt O B_LOCATION
HUMAN O I_LOCATION
H O I_LOCATION
- O O
FABP O B_GENE/B_MEASURE
, O O
HyCult O B_LOCATION
Biotechnology O I_LOCATION
, O O
Uden O B_LOCATION
, O O
the O O
Netherlands O B_LOCATION/B_PERSON
) O O
. O O

Serum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
glucose O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cholesterol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
triglycerides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
HDL O B_GENE
- O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
LDL O B_PROTEIN[GENE]
- O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Apoprotein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
uric O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
measured O O
on O O
a O O
ILAB O B_MEASURE/B_PROTEIN[GENE]
- O O
600 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
biochemical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
analyzer O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O O
Instrumentation O B_LOCATION
Laboratory O I_LOCATION
, O O
Lexington O B_LOCATION/B_PERSON
, O O
Ma O B_LOCATION
, O O
U O B_OTHER/B_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
A O B_OTHER/B_LOCATION
. O O
) O O
using O O
BioVendor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sets O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
processed O O
and O O
examined O O
according O O
to O O
principles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
good O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
laboratory O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
practice O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
under O O
constant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
intralaboratory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
external O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quality O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
homeostatic O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indexes O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
insulin O B_DISEASE
resistance O I_DISEASE
( O O
HOMA O B_LOCATION/B_ORGANIZATION
IR O I_LOCATION/I_ORGANIZATION
and O O
QUICKI O B_LOCATION/B_ORGANIZATION
) O O
were O O
calculated O O
according O O
to O O
the O O
homeostasis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O O
33 O B_MEASURE
- O O
35 O B_MEASURE
] O O
as O O
follows O O
: O O

HOMA O B_PROTEIN[GENE]/B_DISEASE
IR O I_PROTEIN[GENE]/I_DISEASE
= O O
fasting O O
insulin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
mu O B_MEASURE/B_GENE
U O I_MEASURE/I_GENE
/ O O
ml O B_MEASURE/B_PERSON
) O O
* O O
fasting O B_MEASURE/B_LOCATION
glucose O I_MEASURE/I_LOCATION
( O O
mmol O B_MEASURE/B_LOCATION
/ O O
l O B_MEASURE/B_DISEASE
) O O
/ O O
22 O B_MEASURE
. O O
5 O B_MEASURE
; O O

QUICKI O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
1 O B_MEASURE
/ O O
[ O B_MEASURE/B_LOCATION
log O I_MEASURE/I_LOCATION
fasting O I_MEASURE/I_LOCATION
insulin O I_MEASURE/I_LOCATION
( O O
mu O B_MEASURE/B_PERSON
U O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
) O O
+ O B_MEASURE
log O I_MEASURE
fasting O I_MEASURE
glucose O I_MEASURE
( O O
mg O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
100 O B_MEASURE
ml O I_MEASURE
) O O
] O O
. O O

Statistics O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
using O O
the O O
Version O B_LOCATION/B_ORGANIZATION
6 O I_LOCATION/I_ORGANIZATION
SAS O I_LOCATION/I_ORGANIZATION
/ O O
STAT O B_NUMBER[MEASURE]/B_PERSON
software O I_NUMBER[MEASURE]/I_PERSON
( O O
SAS O B_ORGANIZATION/B_LOCATION
Institute O I_ORGANIZATION/I_LOCATION
, O O
Inc O B_ORGANIZATION/B_LOCATION
. O O
, O O
Cary O B_PERSON/B_LOCATION
, O O
NC O B_LOCATION
, O O
U O B_OTHER/B_LOCATION
. O O
S O B_PROTEIN[GENE]/B_DISEASE
. O O
A O B_OTHER/B_LOCATION
. O O
) O O
. O O

The O O
Shapiro O B_PERSON
- O O
Wilks O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
used O O
in O O
testing O O
the O O
normality O B_MEASURE
of O O
distribution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Some O O
of O O
the O O
data O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
were O O
not O O
normally O O
distributed O O
. O O

The O O
statistical O B_MEASURE
significance O I_MEASURE
of O O
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
the O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
hyperlipemic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
control O B_DISEASE/B_MEASURE
groups O I_DISEASE/I_MEASURE
were O O
evaluated O O
using O O
the O O
unpaired O B_LOCATION/B_MEASURE
Student O I_LOCATION/I_MEASURE
' O I_LOCATION/I_MEASURE
s O I_LOCATION/I_MEASURE
T O I_LOCATION/I_MEASURE
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
normal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sets O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
using O O
the O O
Kolmogorov O B_PERSON/B_COLOR
- O O
Smirnov O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
when O O
at O O
least O O
in O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sets O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
the O O
normal O B_MEASURE/B_PERSON
distribution O I_MEASURE/I_PERSON
was O O
excluded O O
. O O

Spearman O B_PERSON
' O O
s O O
rank O B_PERSON/B_SEQUENCE[MEASURE]
- O O
order O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
for O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
performed O O
using O O
HOMA O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IR O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indexes O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
insulin O B_DISEASE/B_GENE
resistance O I_DISEASE/I_GENE
as O O
dependent O B_MEASURE
variables O I_MEASURE
, O O
and O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hormonal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
lipid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
BMI O B_MEASURE/B_GENE
, O O
leptin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
TNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
hFABP O B_GENE
, O O
ACL O B_DISEASE/B_GENE
- O O
IgG O B_PROTEIN[GENE]/B_MEASURE
) O O
as O O
independent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
so O O
- O O
called O O
step O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
down O O
regression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
used O O
to O O
select O O
dominant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
independent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Various O B_NUMBER[MEASURE]/B_ENT
four O I_NUMBER[MEASURE]/I_ENT
- O O
member O B_PERSON/B_MEASURE
groups O I_PERSON/I_MEASURE
of O O
independent O B_NUMBER[MEASURE]
( O O
explanatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
variables O B_MEASURE/B_PERSON
were O O
used O O
for O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
the O O
non O B_MEASURE/B_LOCATION
- O O
zero O B_MEASURE
intercept O I_MEASURE
was O O
taken O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
then O O
dropped O O
, O O
one O B_NUMBER[MEASURE]/B_LOCATION
at O O
a O O
time O B_MEASURE/B_LOCATION
; O O
at O O
each O O
stage O B_MEASURE/B_LOCATION
one O I_MEASURE/I_LOCATION
variable O I_MEASURE/I_LOCATION
making O O
the O O
least O B_MEASURE/B_PERSON
contribution O I_MEASURE/I_PERSON
to O O
the O O
dependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
i O O
. O O
e O B_DISEASE/B_PROTEIN[GENE]
. O O
that O O
showed O O
the O O
least O B_MEASURE/B_LOCATION
p O I_MEASURE/I_LOCATION
- O O
value O B_MEASURE
in O O
the O O
test O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
regression O B_MEASURE
coefficient O I_MEASURE
being O O
zero O B_MEASURE
) O O
was O O
excluded O O
. O O

The O O
coefficient O B_MEASURE
of O O
determination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
R2 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
which O O
can O O
be O O
viewed O O
as O O
a O O
percentage O B_MEASURE
explaining O O
the O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variance O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
simultaneously O O
monitored O O
. O O

A O O
great O B_MEASURE
drop O I_MEASURE
in O O
R2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O O
excluding O O
some O O
independent O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variable O I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enabled O O
selection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
those O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
could O O
be O O
thought O O
to O O
be O O
the O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
determinants O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
dependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrates O O
mean O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
subjects O B_PERSON/B_BIO
matched O O
according O O
to O O
sex O B_PERSON/B_DISEASE
, O O
lipid O B_MEASURE/B_PERSON
parameters O I_MEASURE/I_PERSON
and O O
age O B_MEASURE/B_DISEASE
. O O

While O O
the O O
age O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
all O O
four O B_PERSON/B_BIO
groups O I_PERSON/I_BIO
did O O
not O O
differ O O
substantially O O
, O O
the O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
triglycerides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
HDL O B_PROTEIN[GENE]
- O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
LDL O B_PROTEIN[GENE]
- O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differ O O
very O O
significantly O O
in O O
both O O
male O B_PERSON
and O O
female O B_PERSON/B_BIO
hyperlipemic O I_PERSON/I_BIO
groups O I_PERSON/I_BIO
as O O
compared O O
with O O
controls O B_PERSON
. O O

In O O
addition O O
, O O
the O O
concentration O O
of O O
triglycerides O O
in O O
control O O
women B B_PERSON
was O O
significantly O O
higher O O
than O O
in O O
control O O
men B B_PERSON
, O O
the O O
concentration O O
of O O
triglycerides O O
in O O
hyperlipemic O O
women B B_PERSON
was O O
lower O O
than O O
in O O
hyperlipemic O O
men B B_PERSON
, O O
and O O
the O O
concentration O O
of O O
HDL O O
- O O
cholesterol O O
in O O
hyperlipemic O O
women B B_PERSON
was O O
very O O
significantly O O
higher O O
when O O
compared O O
with O O
hyperlipemic O O
men B B_PERSON
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O O
the O O
values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
other O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolic O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
insulin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
parameters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
factors O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O O
to O O
insulin O B_DISEASE/B_ORGANISM_FUNCTION
resistance O I_DISEASE/I_ORGANISM_FUNCTION
and O O
indexes O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
insulin O B_DISEASE/B_GENE
resistance O I_DISEASE/I_GENE
, O O
respectively O O
. O O

Body O O
mass O O
indexes O O
and O O
uric O O
acid O O
concentration O O
were O O
significantly O O
higher O O
in O O
hyperlipemic O O
men B B_PERSON
as O O
compared O O
to O O
controls O O
, O O
but O O
not O O
in O O
hyperlipemic O O
women B B_PERSON
. O O

Uric O O
acid O O
concentration O O
was O O
substantially O O
lower O O
in O O
hyperlipemic O O
women B B_PERSON/B_BIO
than O O
in O O
hyperlipemic O O
men B B_PERSON
. O O

Plasma O O
concentrations O O
of O O
glycemia O O
, O O
insulin O O
and O O
intact O O
proinsulin O O
were O O
significantly O O
higher O O
in O O
both O O
hyperlipemic O O
men B B_PERSON
and O O
women B B_PERSON/B_BIO
as O O
compared O O
with O O
controls O O
of O O
identical O O
gender O O
, O O
while O O
the O O
concentration O O
of O O
leptin O O
increased O O
only O O
in O O
hyperlipemic O O
men B B_PERSON/B_BIO
. O O

However O O
, O O
serum O O
leptin O O
concentrations O O
of O O
both O O
control O O
and O O
hyperlipemic O O
women B B_PERSON/B_BIO
were O O
significantly O O
higher O O
than O O
in O O
corresponding O O
groups O O
of O O
men B B_PERSON
. O O

Serum O O
concentrations O O
of O O
TNF O O
alpha O O
, O O
hFABP O O
and O O
ACL O O
- O O
IgG O O
in O O
hyperlipemic O O
groups O O
of O O
both O O
men B B_PERSON
and O O
women B B_PERSON/B_BIO
were O O
not O O
significantly O O
different O O
from O O
control O O
groups O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
indexes O O
of O O
insulin O O
resistance O O
HOMA O O
IR O O
and O O
QUICKI O O
differed O O
very O O
significantly O O
in O O
hyperlipemic O O
groups O O
of O O
both O O
men B B_PERSON/B_BIO
and O O
women B B_PERSON/B_BIO
as O O
compared O O
with O O
corresponding O O
control O O
groups O O
, O O
more O O
distinctly O O
in O O
women B B_PERSON/B_BIO
. O O

From O O
Fig O B_LOCATION
. O O

1 O O
, O O
presenting O O
95 O O
% O O
confidence O O
limits O O
of O O
insulin O O
resistance O O
indexes O O
HOMA O O
IR O O
and O O
QUICKI O O
, O O
we O O
concluded O O
that O O
in O O
groups O O
of O O
hyperlipemic O O
patients B B_PERSON/B_BIO
of O O
both O O
genders O O
the O O
insulin O O
resistance O O
was O O
substantially O O
higher O O
than O O
in O O
control O O
groups O O
; O O
the O O
groups O O
did O O
not O O
overlap O O
each O O
other O O
. O O

In O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Spearman O B_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
insulin O B_MEASURE/B_DISEASE
resistance O I_MEASURE/I_DISEASE
index O I_MEASURE/I_DISEASE
HOMA O I_MEASURE/I_DISEASE
IR O I_MEASURE/I_DISEASE
and O O
various O B_DISEASE/B_GENE
metabolic O B_DISEASE/I_GENE
parameters O B_DISEASE/I_GENE
are O O
presented O O
. O O

In O O
the O O
control O O
group O O
of O O
men B B_PERSON/B_BIO
, O O
positive O O
significant O O
correlation O O
between O O
HOMA O O
IR O O
and O O
serum O O
leptin O O
concentration O O
, O O
and O O
inverse O O
significant O O
correlation O O
between O O
HOMA O O
IR O O
and O O
ACL O O
IgG O O
, O O
respectively O O
, O O
were O O
found O O
. O O

In O O
the O O
control O O
group O O
of O O
women B B_PERSON/B_BIO
, O O
the O O
significance O O
of O O
Spearman O O
' O O
s O O
correlation O O
between O O
HOMA O O
IR O O
and O O
leptin O O
was O O
more O O
expressive O O
; O O
inverse O O
correlation O O
between O O
HOMA O O
IR O O
and O O
HDL O O
- O O
cholesterol O O
was O O
also O O
present O O
. O O

In O O
the O O
hyperlipemic O O
group O O
of O O
men B B_PERSON/B_BIO
, O O
the O O
significance O O
of O O
the O O
correlation O O
between O O
HOMA O O
IR O O
was O O
more O O
expressive O O
in O O
relation O O
to O O
the O O
control O O
group O O
, O O
and O O
no O O
significant O O
correlation O O
between O O
HOMA O O
IR O O
and O O
ACL O O
IgG O O
was O O
found O O
. O O

In O O
the O O
hyperlipemic O O
group O O
of O O
women B B_PERSON/B_BIO
, O O
however O O
, O O
the O O
significance O O
of O O
Spearman O O
' O O
s O O
correlation O O
between O O
HOMA O O
IR O O
and O O
serum O O
leptin O O
concentration O O
weakened O O
, O O
the O O
inverse O O
correlation O O
between O O
HOMA O O
IR O O
and O O
HDL O O
- O O
cholesterol O O
remained O O
approximately O O
unchanged O O
, O O
and O O
a O O
positive O O
correlation O O
between O O
HOMA O O
IR O O
and O O
serum O O
concentration O O
of O O
TNF O O
alpha O O
appeared O O
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
when O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
both O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
hyperlipemic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
groups O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O O
each O O
gender O B_PERSON/B_MEASURE
were O O
judged O O
together O O
. O O

HOMA O B_DISEASE/B_MEASURE
IR O I_DISEASE/I_MEASURE
was O O
considered O O
as O O
a O O
dependent O B_MEASURE
variable O I_MEASURE
and O O
differently O O
changed O O
constellations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
metabolic O B_DISEASE
and O O
other O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
taken O O
as O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
men B B_PERSON/B_MEASURE
, O O
BMI O O
and O O
leptin O O
seemed O O
to O O
play O O
a O O
main O O
role O O
in O O
influencing O O
the O O
insulin O O
resistance O O
index O O
HOMA O O
IR O O
, O O
while O O
TGL O O
, O O
ACL O O
IgG O O
and O O
LDL O O
- O O
cholesterol O O
didn O O
' O O
t O O
play O O
any O O
significant O O
role O O
( O O
see O O
left O O
columns O O
of O O
Table O O
4 O O
) O O
. O O

The O O
decreasing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
HDL O B_GENE
- O O
cholesterol O B_MEASURE
concentration O I_MEASURE
may O O
also O O
have O O
some O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
see O O
a O O
significant O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drop O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
R2 O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
exclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
this O O
factor O B_MEASURE
in O O
Table O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4A O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4B O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

But O O
in O O
the O O
presence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
leptin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
group O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
independent O B_PERSON/B_MEASURE
factors O I_PERSON/I_MEASURE
, O O
the O O
drop O B_MEASURE/B_DISEASE
of O O
R2 O B_GENE
after O O
exclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
HDL O B_GENE
- O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
from O O
these O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O O
minimal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
4C O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

On O O
the O O
other O B_PERSON/B_LOCATION
hand O B_PERSON/I_LOCATION
, O O
after O O
the O O
exclusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
TNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
alpha O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
from O O
the O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
independent O B_PERSON/B_BIO
variables O I_PERSON/I_BIO
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4B O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
4D O B_TIME[MEASURE]/B_LOCATION
) O O
the O O
value O B_MEASURE
of O O
R2 O B_PROTEIN[GENE]/B_DISEASE
has O O
unexpectedly O O
risen O O
, O O
which O O
could O O
reflect O O
the O O
interference O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increasing O O
the O O
insulin O B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
women B B_PERSON/B_MEASURE
( O O
see O O
right O O
columns O O
of O O
Table O O
4 O O
) O O
, O O
the O O
maximal O O
values O O
of O O
R2 O O
were O O
achieved O O
with O O
combination O O
of O O
independent O O
variables O O
containing O O
TGL O O
, O O
leptin O O
and O O
HDL O O
- O O
cholesterol O O
( O O
about O O
60 O O
% O O
influence O O
on O O
HOMA O O
IR O O
! O O
- O O
see O O
Table O O
4A O O
, O O
4B O O
, O O
4C O O
) O O
. O O

TNF O O
alpha O O
seemed O O
to O O
play O O
quite O O
a O O
different O O
role O O
than O O
in O O
men B B_PERSON/B_BIO
: O O
after O O
exclusion O O
of O O
this O O
factor O O
from O O
the O O
group O O
of O O
independent O O
factors O O
R2significantly O O
decreased O O
( O O
see O O
Table O O
4B O O
, O O
4D O O
) O O
. O O

In O O
contrast O O
to O O
men B B_PERSON/B_ORGANIZATION
, O O
the O O
role O O
of O O
BMI O O
seemed O O
to O O
be O O
minimal O O
. O O

As O O
in O O
men B B_PERSON/B_BIO
, O O
the O O
role O O
of O O
ACL O O
IgG O O
and O O
LDL O O
- O O
cholesterol O O
in O O
influencing O O
HOMA O O
IR O O
was O O
negligible O O
, O O
but O O
in O O
contrast O O
to O O
men B B_PERSON/B_BIO
, O O
hFABP O O
might O O
play O O
a O O
certain O O
role O O
in O O
this O O
process O O
( O O
see O O
Table O O
4D O O
) O O
. O O

Generally O O
, O O
the O O
insulin O O
resistance O O
( O O
represented O O
by O O
HOMA O O
IR O O
) O O
was O O
in O O
men B B_PERSON/B_BIO
much O O
less O O
influenced O O
by O O
metabolic O O
variables O O
than O O
in O O
women B B_PERSON/B_BIO
; O O
while O O
in O O
women B B_PERSON/B_BIO
in O O
some O O
combinations O O
of O O
dependent O O
variables O O
R2 O O
reached O O
64 O O
% O O
, O O
in O O
men B B_PERSON/B_BIO
the O O
maximal O O
value O O
of O O
R2 O O
was O O
only O O
39 O O
% O O
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
paper O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O O
36 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
mean O B_MEASURE
value O I_MEASURE
of O O
HOMA O B_DISEASE
IR O I_DISEASE
in O O
healthy O B_PERSON/B_LOCATION
subjects O I_PERSON/I_LOCATION
of O O
both O O
genders O B_PERSON/B_MEASURE
and O O
of O O
age O B_PERSON/B_MEASURE
comparable O I_PERSON/I_MEASURE
with O O
our O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
1 O B_MEASURE
. O O
57 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
. O O
87 O B_MEASURE
, O O
and O O
the O O
mean O B_MEASURE/B_LOCATION
value O I_MEASURE/I_LOCATION
of O O
index O B_MEASURE
QUICKI O I_MEASURE
0 O I_MEASURE
. O O
366 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
. O O
029 O B_MEASURE
, O O
respectively O O
. O O

These O O
values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
as O O
well O O
as O O
the O O
95 O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confidence O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
limits O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
correspond O O
to O O
values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
found O O
in O O
controls O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
accordance O O
with O O
many O O
previous O O
papers O O
, O O
serum O O
concentrations O O
of O O
leptin O O
in O O
women B B_PERSON/B_BIO
( O O
both O O
control O O
and O O
hyperlipemic O O
) O O
were O O
substantially O O
higher O O
than O O
in O O
men B B_PERSON/B_BIO
. O O

In O O
the O O
control O O
group O O
of O O
women B B_PERSON/B_BIO
the O O
correlation O O
between O O
leptin O O
and O O
HOMA O O
IR O O
was O O
highly O O
significant O O
. O O

However O O
, O O
in O O
hyperlipemic O O
women B B_PERSON/B_DISEASE
the O O
significance O O
of O O
this O O
correlation O O
lessened O O
, O O
because O O
HOMA O O
IR O O
increased O O
considerably O O
( O O
and O O
significantly O O
) O O
but O O
serum O O
concentration O O
of O O
leptin O O
only O O
slightly O O
( O O
insignificantly O O
) O O
. O O

In O O
men B B_PERSON/B_MEASURE
the O O
significance O O
of O O
correlations O O
between O O
serum O O
leptin O O
and O O
HOMA O O
IR O O
was O O
high O O
and O O
approximately O O
the O O
same O O
in O O
both O O
the O O
control O O
and O O
hyperlipemic O O
groups O O
, O O
because O O
the O O
values O O
of O O
HOMA O O
IR O O
as O O
well O O
as O O
serum O O
leptin O O
have O O
nearly O O
doubled O O
in O O
hyperlipemic O O
in O O
relation O O
to O O
control O O
groups O O
. O O

In O O
non O O
- O O
hyperlipemic O O
postmenopausal O O
women B B_PERSON
the O O
high O O
concentration O O
of O O
serum O O
leptin O O
was O O
not O O
associated O O
with O O
higher O O
insulin O O
resistance O O
: O O
HOMA O O
IR O O
did O O
not O O
differ O O
substantially O O
from O O
men B B_PERSON/B_DISEASE
. O O

A O O
significant O O
increase O O
of O O
insulin O O
resistance O O
in O O
hyperlipemic O O
women B B_PERSON/B_BIO
was O O
associated O O
by O O
only O O
slight O O
and O O
insignificant O O
increase O O
of O O
leptin O O
concentration O O
. O O

According O O
to O O
Spearman O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
serum O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
TNF O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
HDL O B_GENE
- O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
might O O
also O O
play O O
a O O
distinct O B_PERSON/B_MEASURE
role O I_PERSON/I_MEASURE
in O O
this O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
see O O
Table O B_LOCATION/B_ENT
3 O I_LOCATION/I_ENT
) O O
. O O

In O O
contrast O O
to O O
women B B_PERSON/B_DISEASE
, O O
in O O
hyperlipemic O O
men B B_PERSON/B_DISEASE
the O O
increase O O
of O O
insulin O O
resistance O O
index O O
was O O
approximately O O
proportional O O
with O O
the O O
increase O O
of O O
leptin O O
concentration O O
. O O

Multiple O B_PERSON/B_EDU[ORGANIZATION]
regression O I_PERSON/I_EDU[ORGANIZATION]
analysis O I_PERSON/I_EDU[ORGANIZATION]
affirmed O O
the O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
leptin O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
increasing O O
of O O
insulin O B_DISEASE/B_GENE
resistance O I_DISEASE/I_GENE
in O O
both O O
genders O B_PERSON/B_MEASURE
. O O

In O O
men B B_PERSON/B_MEASURE
, O O
only O O
BMI O O
and O O
HDL O O
- O O
cholesterol O O
from O O
other O O
factors O O
studied O O
seemed O O
to O O
play O O
a O O
certain O O
role O O
, O O
but O O
the O O
maximal O O
values O O
of O O
influencing O O
HOMA O O
IR O O
reached O O
only O O
39 O O
% O O
, O O
with O O
leptin O O
and O O
BMI O O
being O O
the O O
more O O
important O O
factors O O
. O O

On O O
the O O
other O O
hand O O
, O O
in O O
women B B_PERSON/B_MEASURE
the O O
maximal O O
determination O O
of O O
HOMA O O
IR O O
as O O
high O O
as O O
60 O O
% O O
was O O
registered O O
in O O
combination O O
of O O
serum O O
leptin O O
, O O
TGL O O
and O O
decreased O O
HDL O O
- O O
cholesterol O O
as O O
independent O O
factors O O
; O O
the O O
role O O
of O O
BMI O O
was O O
insignificant O O
. O O

It O O
is O O
not O O
known O O
how O O
leptin O B_GENE/B_BIO
is O O
regulated O O
. O O

A O O
strong O O
correlation O O
between O O
plasma O O
leptin O O
and O O
fasting O O
insulin O O
undoubtedly O O
exists O O
, O O
but O O
hyperleptinemia O O
in O O
both O O
obese O O
and O O
lean O O
humans B B_PERSON/B_BIO
is O O
not O O
likely O O
the O O
result O O
of O O
hyperinsulinemia O O
[ O O
37 O O
] O O
. O O

A O O
relationship O B_PERSON/B_MEASURE
between O O
leptin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
insulin O B_DISEASE_ADJECTIVE[DISEASE]
dependent O I_DISEASE_ADJECTIVE[DISEASE]
on O O
sex O B_PERSON
or O O
BMI O B_MEASURE/B_DISEASE
was O O
reported O O
, O O
but O O
relationship O B_PERSON/B_MEASURE
between O O
triglyceride O B_GENE
concentrations O I_GENE
and O O
leptin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
sex O B_PERSON
, O O
BMI O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
insulin O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
18 O B_MEASURE
, O O
24 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Hyperleptinemia O B_DISEASE
, O O
as O O
an O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sign O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
obesity O B_DISEASE
, O O
was O O
closely O O
linked O O
to O O
subcutaneous O B_DISEASE
fat O I_DISEASE
mass O I_DISEASE
[ O O
39 O B_MEASURE
, O O
40 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Percentage O O
of O O
body O O
fat O O
has O O
been O O
shown O O
to O O
be O O
the O O
strongest O O
predictor O O
of O O
leptin O O
levels O O
even O O
in O O
lean O O
women B B_PERSON/B_BIO
[ O O
41 O O
] O O
. O O

Leptin O O
was O O
highly O O
correlated O O
with O O
percentage O O
of O O
body O O
fat O O
and O O
with O O
fat O O
mass O O
in O O
adults O O
irrespective O O
of O O
gender O O
and O O
age O O
; O O
however O O
, O O
the O O
mean O O
determinant O O
of O O
leptin O O
plasma O O
concentration O O
in O O
men B B_PERSON
and O O
postmenopausal O O
women B B_PERSON
was O O
BMI O O
, O O
while O O
in O O
premenopausal O O
women B B_PERSON
it O O
was O O
only O O
the O O
fat O O
mass O O
[ O O
42 O O
] O O
. O O

These O O
findings O O
contrast O O
with O O
our O O
results O O
showing O O
minimal O O
influence O O
of O O
BMI O O
on O O
HOMA O O
IR O O
in O O
postmenopausal O O
women B B_PERSON
. O O

All O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
mentioned O O
are O O
connected O O
with O O
fat O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
: O O
leptin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
directly O O
produced O O
chiefly O O
by O O
adipocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
BMI O B_DISEASE/B_GENE
growth O I_DISEASE/I_GENE
is O O
obviously O O
accompanied O O
by O O
fat O B_DISEASE/B_GENE
mass O I_DISEASE/I_GENE
increase O I_DISEASE/I_GENE
, O O
and O O
the O O
typical O B_DISEASE/B_MEASURE
hypertriglyceridemia O I_DISEASE/I_MEASURE
associated O O
with O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
HDL O B_GENE
- O O
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
goes O O
along O O
with O O
obesity O B_DISEASE/B_GENE
and O O
fat O B_DISEASE
mass O I_DISEASE
growth O I_DISEASE
. O O

The O O
gender O B_DISEASE_ADJECTIVE[DISEASE]
differences O I_DISEASE_ADJECTIVE[DISEASE]
in O O
circulating O O
leptin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
best O O
explained O O
by O O
percentage O B_MEASURE
of O O
body O B_DISEASE/B_MEASURE
fat O I_DISEASE/I_MEASURE
and O O
- O O
inversely O O
- O O
by O O
lean O B_MEASURE/B_PERSON
body O I_MEASURE/I_PERSON
mass O I_MEASURE/I_PERSON
[ O O
25 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
both O O
genders O B_PERSON/B_MEASURE
the O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
abdominal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fat O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
correlated O O
with O O
insulin O B_DISEASE/B_GENE
resistance O B_DISEASE/I_GENE
, O O
while O O
the O O
subcutaneous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
fat O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
correlated O O
with O O
circulating O O
leptin O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
12 O B_MEASURE
] O I_MEASURE
. O O

In O O
men B B_PERSON/B_BIO
obesity O O
led O O
to O O
a O O
prevalent O O
increase O O
of O O
intra O O
- O O
abdominal O O
fat O O
, O O
while O O
in O O
women B B_PERSON
of O O
subcutaneous O O
fat O O
[ O O
13 O O
] O O
. O O

Influences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compartments O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
adipose O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissues O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
could O O
elucidate O O
the O O
variability O B_MEASURE/B_LOCATION
of O O
correlations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
insulin O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resistance O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
high O B_DISEASE
leptin O I_DISEASE
concentrations O I_DISEASE
in O O
lean O B_DISEASE/B_PERSON
and O O
obese O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
subjects O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
both O O
genders O B_PERSON/B_MEASURE
[ O O
43 O B_MEASURE/B_PERSON
] O B_MEASURE/I_PERSON
. O O

In O O
our O O
non O O
- O O
hyperlipemic O O
postmenopausal O O
women B B_PERSON
the O O
content O O
of O O
subcutaneous O O
fat O O
mass O O
might O O
be O O
higher O O
than O O
in O O
non O O
- O O
hyperlipemic O O
men B B_PERSON
of O O
appropriate O O
age O O
, O O
which O O
indicated O O
a O O
higher O O
serum O O
concentration O O
of O O
leptin O O
. O O

However O O
, O O
the O O
insulin O O
resistance O O
- O O
related O O
to O O
intra O O
- O O
abdominal O O
fat O O
mass O O
- O O
did O O
not O O
differ O O
from O O
men B B_PERSON/B_DISEASE
. O O

The O O
significant O O
increase O O
of O O
insulin O O
resistance O O
and O O
leptin O O
concentration O O
in O O
hyperlipemic O O
men B B_PERSON/B_BIO
might O O
reflect O O
the O O
growing O O
content O O
of O O
both O O
subcutaneous O O
and O O
intra O O
- O O
abdominal O O
fat O O
mass O O
( O O
see O O
the O O
significant O O
increase O O
of O O
BMI O O
) O O
. O O

In O O
hyperlipemic O O
women B B_PERSON/B_DISEASE
the O O
significant O O
increase O O
of O O
insulin O O
resistance O O
accompanying O O
only O O
minimal O O
insignificant O O
increase O O
of O O
leptin O O
could O O
be O O
caused O O
by O O
prevalent O O
growing O O
of O O
intra O O
- O O
abdominal O O
fat O O
mass O O
. O O

In O O
elderly O O
postmenopausal O O
women B B_PERSON/B_BIO
, O O
an O O
association O O
between O O
leptin O O
and O O
plasma O O
lipoprotein O O
concentration O O
was O O
found O O
which O O
depended O O
on O O
adiposity O O
[ O O
17 O O
] O O
, O O
and O O
inverse O O
correlations O O
between O O
serum O O
leptin O O
and O O
HDL O O
- O O
cholesterol O O
were O O
described O O
[ O O
44 O O
] O O
. O O

In O O
our O O
study O O
, O O
insulin O O
resistance O O
in O O
women B B_PERSON/B_BIO
seemed O O
to O O
be O O
more O O
notably O O
than O O
in O O
men B B_PERSON/B_LOCATION
influenced O O
by O O
lipid O O
disorders O O
, O O
i O O
. O O
e O O
. O O
positively O O
by O O
serum O O
triglycerides O O
and O O
inversely O O
by O O
HDL O O
- O O
cholesterol O O
. O O

These O O
findings O O
might O O
be O O
important O O
in O O
considering O O
the O O
concept O O
of O O
treatment O O
of O O
insulin O O
resistance O O
- O O
related O O
disorders O O
in O O
postmenopausal O O
women B B_PERSON
. O O

The O O
significant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
insulin O B_DISEASE/B_GENE
resistance O I_DISEASE/I_GENE
, O O
caused O O
by O O
inhibiting O O
the O O
transduction O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
insulin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
down O B_LOCATION/B_DISEASE
- O O
regulation O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
glucose O B_GENE
transporter O I_GENE
GLUT O I_GENE
- O O
4 O B_NUMBER[MEASURE]
and O O
insulin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
substrate O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
1 O B_TIME[MEASURE]
, O O
has O O
been O O
repeatedly O O
confirmed O O
[ O B_MEASURE/B_LOCATION
45 O I_MEASURE/I_LOCATION
- O O
48 O B_MEASURE
] O I_MEASURE
. O O

Our O O
results O O
supported O O
these O O
findings O O
unambiguously O O
only O O
in O O
women B B_PERSON/B_BIO
, O O
while O O
in O O
men B B_PERSON/B_BIO
TNF O O
alpha O O
seemed O O
paradoxically O O
to O O
interfere O O
with O O
other O O
factors O O
- O O
mainly O O
BMI O O
and O O
leptin O O
- O O
in O O
influencing O O
insulin O O
resistance O O
, O O
thus O O
playing O O
a O O
quite O O
different O O
role O O
. O O

Previously O O
it O O
was O O
found O O
[ O O
46 O O
] O O
that O O
correlation O O
between O O
serum O O
TNF O O
alpha O O
on O O
the O O
one O O
side O O
, O O
and O O
insulin O O
, O O
HOMA O O
IR O O
, O O
serum O O
triglycerids O O
, O O
respectively O O
, O O
on O O
the O O
other O O
side O O
, O O
was O O
substantially O O
more O O
significant O O
in O O
women B B_PERSON/B_BIO
than O O
in O O
men B B_PERSON
. O O

Serum O O
concentration O O
of O O
TNF O O
alpha O O
in O O
patients B B_PERSON/B_BIO
with O O
type O O
2 O O
diabetes O O
of O O
both O O
genders O O
correlated O O
only O O
with O O
the O O
quantity O O
of O O
intra O O
- O O
abdominal O O
fat O O
compartment O O
[ O O
50 O O
] O O
. O O

Visceral O O
obesity O O
correlated O O
with O O
plasmatic O O
aldosterone O O
and O O
with O O
insulin O O
resistance O O
only O O
in O O
premenopausal O O
women B B_PERSON
, O O
but O O
not O O
in O O
men B B_PERSON
[ O O
51 O O
] O O
. O O

From O O
all O O
these O O
data O O
we O O
might O O
support O O
our O O
above O O
mentioned O O
conclusion O O
- O O
that O O
rising O O
of O O
insulin O O
resistance O O
in O O
hyperlipemic O O
women B B_PERSON/B_BIO
was O O
associated O O
with O O
an O O
increase O O
of O O
intra O O
- O O
abdominal O O
fat O O
, O O
because O O
this O O
fat O O
mass O O
in O O
particular O O
is O O
a O O
source O O
of O O
TNF O O
alpha O O
, O O
which O O
interfered O O
with O O
insulin O O
sensitivity O O
only O O
in O O
women B B_PERSON/B_BIO
. O O

We O O
came O O
to O O
this O O
conclusion O O
irrespective O O
of O O
the O O
finding O O
that O O
the O O
increase O O
of O O
serum O O
TNF O O
alpha O O
in O O
hyperlipemic O O
women B B_PERSON/B_BIO
was O O
statistically O O
insignificant O O
; O O
results O O
of O O
Spearman O O
' O O
s O O
correlation O O
( O O
Table O O
3 O O
) O O
and O O
multiple O O
regression O O
analysis O O
confirm O O
a O O
distinct O O
role O O
of O O
this O O
factor O O
. O O

In O O
hyperlipemic O O
men B B_PERSON/B_BIO
not O O
only O O
the O O
serum O O
concentration O O
of O O
TNF O O
alpha O O
has O O
decreased O O
instead O O
of O O
increasing O O
, O O
but O O
according O O
to O O
multiple O O
regression O O
analysis O O
it O O
played O O
a O O
quite O O
different O O
role O O
in O O
influencing O O
insulin O O
sensitivity O O
, O O
interfering O O
with O O
factors O O
that O O
determined O O
insulin O O
resistance O O
( O O
leptin O O
and O O
BMI O O
) O O
. O O

In O O
the O O
control O O
group O O
of O O
men B B_PERSON/B_BIO
IgG O O
anticardiolipin O O
was O O
inversely O O
correlated O O
to O O
HOMA O O
IR O O
. O O

The O O
significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
clear O B_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
antibodies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
vascular O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
thrombotic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oxidative O B_DISEASE_ADJECTIVE[DISEASE]
modification O I_DISEASE_ADJECTIVE[DISEASE]
of O O
lipoproteins O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
[ O O
52 O B_MEASURE
, O O
53 O B_MEASURE
] O I_MEASURE
and O O
may O O
represent O O
an O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
atherogenic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
inflammatory O B_DISEASE
complications O I_DISEASE
. O O

In O O
this O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
their O O
growing O O
might O O
be O O
connected O O
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
insulin O B_DISEASE/B_MEASURE
sensitivity O I_DISEASE/I_MEASURE
. O O

Anyway O O
, O O
ACL O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
IgG O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
evidently O O
did O O
not O O
participate O O
significantly O O
in O O
influencing O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
insulin O B_DISEASE/B_GENE
resistance O B_DISEASE/I_GENE
associated O O
with O O
hyperlipidemia O B_DISEASE
, O O
although O O
other O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
cardiolipin O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
masked O O
by O O
the O O
relatively O O
large O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inter O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
individual O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
parameter O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Neither O O
serum O B_MEASURE/B_LOCATION
concentration O I_MEASURE/I_LOCATION
of O O
hFABP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
factor O B_MEASURE/B_PROTEIN[GENE]
ensuring O O
transmembrane O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
transport O I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
oxidative O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
metabolisation O I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
long O B_MEASURE
- O O
chain O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fatty O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
54 O B_MEASURE
, O O
55 O B_MEASURE
] O I_MEASURE
, O O
was O O
significantly O O
changed O O
in O O
hyperlipemic O B_DISEASE/B_PERSON
and O O
insulin O B_DISEASE/B_PERSON
resistant O I_DISEASE/I_PERSON
subjects O I_DISEASE/I_PERSON
of O O
both O O
genders O B_PERSON/B_MEASURE
. O O

This O O
factor O O
was O O
very O O
weakly O O
associated O O
only O O
with O O
HOMA O O
IR O O
in O O
women B B_PERSON/B_BIO
( O O
see O O
Table O O
4D O O
) O O
, O O
indicating O O
that O O
enhanced O O
metabolisation O O
of O O
fatty O O
acids O O
in O O
cells O O
might O O
to O O
some O O
degree O O
contribute O O
to O O
insulin O O
resistance O O
. O O

Conclusions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
postmenopausal O O
women B B_PERSON/B_BIO
as O O
well O O
as O O
in O O
men B B_PERSON
of O O
approximately O O
equal O O
age O O
serum O O
leptin O O
plays O O
a O O
significant O O
role O O
as O O
an O O
important O O
determinant O O
of O O
insulin O O
resistance O O
. O O

In O O
addition O O
to O O
this O O
factor O O
, O O
in O O
women B B_PERSON/B_BIO
the O O
grade O O
of O O
insulin O O
resistance O O
is O O
very O O
considerably O O
influenced O O
by O O
serum O O
triglycerides O O
, O O
tumor O O
necrosis O O
factor O O
alpha O O
, O O
and O O
by O O
decreased O O
concentration O O
of O O
HDL O O
- O O
cholesterol O O
, O O
while O O
in O O
men B B_PERSON/B_BIO
only O O
a O O
mild O O
influence O O
of O O
BMI O O
and O O
decreased O O
HDL O O
- O O
cholesterol O O
is O O
observed O O
. O O

These O O
findings O O
are O O
explained O O
as O O
a O O
consequence O O
of O O
gender O O
- O O
related O O
differences O O
in O O
adipose O O
tissue O O
composition O O
and O O
/ O O
or O O
distribution O O
in O O
both O O
normal O O
- O O
weight O O
and O O
over O O
- O O
weight O O
subjects O O
and O O
should O O
be O O
taken O O
into O O
account O O
in O O
treatment O O
of O O
patients B B_PERSON/B_BIO
with O O
metabolic O O
risk O O
factors O O
of O O
cardiovascular O O
diseases O O
. O O

List O B_LOCATION/B_MEASURE
of O O
abbreviations O B_PERSON/B_ENT

HDL O B_GENE
- O O
Cholesterol O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
density O B_MEASURE
cholesterol O I_MEASURE

LDL O B_PROTEIN[GENE]/B_DISEASE
- O O
cholesterol O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
density O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]

HOMA O B_MEASURE/B_DISEASE
IR O I_MEASURE/I_DISEASE
= O O
Homeostasis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Insulin O B_DISEASE
Resistance O I_DISEASE

= O O
fasting O O
insulin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
mu O B_MEASURE/B_PERSON
U O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
) O O
* O O
fasting O B_MEASURE
glucose O I_MEASURE
( O O
mmol O B_MEASURE/B_LOCATION
/ O O
l O B_MEASURE/B_OTHER
) O O
/ O O
22 O B_MEASURE
, O O
5 O B_MEASURE/B_LOCATION

QUICKI O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
1 O B_MEASURE
/ O O
[ O B_MEASURE/B_LOCATION
log O I_MEASURE/I_LOCATION
fasting O I_MEASURE/I_LOCATION
insulin O I_MEASURE/I_LOCATION
( O O
mu O B_MEASURE/B_PERSON
U O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
) O O
+ O B_MEASURE
log O I_MEASURE
fasting O I_MEASURE
glucose O I_MEASURE
( O O
mg O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
100 O B_MEASURE
ml O I_MEASURE
) O O
] O O

TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
tumor O B_MEASURE/B_LOCATION
necrosis O I_MEASURE/I_LOCATION
factor O I_MEASURE/I_LOCATION
alpha O I_MEASURE/I_LOCATION

BMI O B_LOCATION/B_ORGANIZATION
= O O
body O B_MEASURE/B_LOCATION
mass O B_MEASURE/I_LOCATION
index O B_MEASURE/I_LOCATION

R2 O O
= O O
coefficient O B_MEASURE/B_LOCATION
of O O
determination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

hFABP O B_GENE/B_DISEASE
= O O
heart O B_MEASURE/B_LOCATION
fatty O I_MEASURE/I_LOCATION
acid O I_MEASURE/I_LOCATION
binding O I_MEASURE/I_LOCATION
protein O I_MEASURE/I_LOCATION

ACL O B_DISEASE/B_GENE
- O O
IgG O B_MEASURE/B_GENE
= O O
IgG O B_TIME[MEASURE]/B_PERSON
fraction O I_TIME[MEASURE]/I_PERSON
of O O
anticardiolipin O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

TGL O B_DISEASE/B_GENE
= O O
triglycerides O B_PERSON/B_LOCATION

GLUT O B_GENE
- O O
4 O B_NUMBER[MEASURE]/B_LOCATION
= O O
glucose O B_GENE
transporter O I_GENE
- O O
4 O B_NUMBER[MEASURE]/B_BIO

PPAR O B_GENE/B_LOCATION
gamma O I_GENE/I_LOCATION
= O O
Peroxisome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Proliferator O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
Associated O O
Receptor O B_PROTEIN[GENE]/B_MEASURE
gamma O I_PROTEIN[GENE]/I_MEASURE

CV O B_LOCATION/B_DISEASE
= O O
coefficient O B_MEASURE/B_LOCATION
of O O
variation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Dr O B_PERSON
. O O
Radka O B_PERSON/B_LOCATION
Lichnovsk O I_PERSON/I_LOCATION
a O O
collected O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
material O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
performed O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
values O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
edited O O
the O O
manuscript O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Dr O B_PERSON
. O O
Simona O B_PERSON
Gwozdziewiczov O I_PERSON
a O O
performed O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
edited O O
the O O
manuscript O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Prof O B_PERSON
. O O

Jir O B_PERSON/B_LOCATION
i O O
Hreb O O
i O O
cek O O
initiated O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
participated O O
in O O
its O O
design O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
coordination O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
wrote O O
and O O
edited O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

Alexithymia O O
and O O
anxiety O O
in O O
female O O
chronic O O
pain O O
patients B B_PERSON/B_DISEASE

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Objectives O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Alexithymia O O
is O O
highly O O
prevalent O O
among O O
chronic O O
pain O O
patients B B_PERSON/B_DISEASE
. O O

Pain O B_DISEASE
is O O
a O O
remarkable O B_DISEASE/B_MEASURE
cause O B_DISEASE/I_MEASURE
for O O
high O B_DISEASE_ADJECTIVE[DISEASE]
levels O I_DISEASE_ADJECTIVE[DISEASE]
of O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]
anxiety O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
investigate O O
the O O
prevalence O O
of O O
alexithymia O O
and O O
to O O
determine O O
anxiety O O
levels O O
among O O
DSM O O
- O O
IV O O
somatoform O O
pain O O
disorder O O
( O O
chronic O O
pain O O
) O O
female O O
patients B B_PERSON
and O O
to O O
examine O O
the O O
relationship O O
between O O
alexithymia O O
and O O
the O O
self O O
- O O
reporting O O
of O O
pain O O
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Thirty O B_PERSON
adult O I_PERSON
females O I_PERSON
( O O
mean O B_TIME[MEASURE]/B_PERSON
age O B_TIME[MEASURE]/I_PERSON
: O O
34 O B_MEASURE
, O O
63 O B_MEASURE
+/- O O
10 O B_MEASURE
, O O
62 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
) O O
, O O
who O O
applied O O
to O O
the O O
outpatient O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psychiatry O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinic O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
public O B_LOCATION/B_PERSON
hospital O I_LOCATION/I_PERSON
with O O
the O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chronic O B_DISEASE/B_LOCATION
pain O I_DISEASE/I_LOCATION
disorder O I_DISEASE/I_LOCATION
( O O
DSM O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
IV O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
, O O
were O O
included O O
in O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thirty O O
seven O O
healthy O O
females O O
( O O
mean O O
age O O
: O O
34 O O
, O O
46 O O
+/- O O
7 O O
, O O
43 O O
years O O
) O O
, O O
who O O
matched O O
for O O
sociodemographic O O
features O O
with O O
the O O
patient B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
, O O
consisted O O
the O O
control O O
group O O
. O O

A O O
sociodemographic O O
data O O
form O O
, O O
26 O O
- O O
item O O
Toronto O O
Alexithymia O O
Scale O O
( O O
TAS O O
- O O
26 O O
) O O
, O O
Spielberger O O
Trait O O
Anxiety O O
Inventory O O
( O O
STAI O O
) O O
were O O
administered O O
to O O
each O O
subject O O
and O O
information O O
was O O
obtained O O
on O O
several O O
aspects O O
of O O
the O O
patients B B_PERSON/B_DISEASE
' O O
pain O O
, O O
including O O
intensity O O
( O O
measured O O
by O O
VAS O O
) O O
, O O
and O O
duration O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Chronic O O
pain O O
patients B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
significantly O O
more O O
alexithymic O O
than O O
controls O O
. O O

There O O
was O O
a O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
TAS O B_MEASURE/B_DISEASE
- O O
26 O B_MEASURE
scores O I_MEASURE
and O O
the O O
duration O B_MEASURE
of O O
pain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
alexithymic O B_DISEASE/B_PERSON
and O O
nonalexithymic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
did O O
not O O
differ O O
in O O
their O O
perception O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
pain O B_DISEASE/B_PERSON
. O O

Neither O O
positive O O
correlation O O
nor O O
significant O O
difference O O
was O O
found O O
between O O
alexithymia O O
and O O
trait O O
anxiety O O
in O O
pain O O
patients B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Alexithymia O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
may O O
be O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
addressing O O
the O O
diversity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
subjective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
involved O O
in O O
pain O B_DISEASE
. O O

The O O
conceptualization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
alexithymia O B_DISEASE/B_LOCATION
as O O
a O O
personality O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trait O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O O
well O O
as O O
a O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]
state O I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DISEASE_ADJECTIVE[DISEASE]
is O O
underlined O O
by O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
original O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
definition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alexithymia O B_DISEASE
is O O
the O O
inability O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
identify O O
and O O
use O O
verbal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
language O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
describe O O
feelings O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O O
1 O B_NUMBER[MEASURE]
, O O
2 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

Alexithymia O B_DISEASE
has O O
been O O
associated O O
with O O
a O O
variety O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
psychiatric O B_DISEASE_ADJECTIVE[DISEASE]
disorders O I_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
physical O B_DISEASE
illness O I_DISEASE
[ O O
3 O B_MEASURE
- O O
10 O B_SEQUENCE[MEASURE]/B_LOCATION
] O I_SEQUENCE[MEASURE]/I_LOCATION
. O O

As O O
a O O
measure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
Toronto O B_DISEASE/B_TIME[MEASURE]
Alexithymia O I_DISEASE/I_TIME[MEASURE]
Scale O I_DISEASE/I_TIME[MEASURE]
was O O
significantly O O
correlated O O
with O O
the O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
tendency O B_TIME[MEASURE]/B_DISEASE
to O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O O
report O O
physical O B_DISEASE_ADJECTIVE[DISEASE]
signs O I_DISEASE_ADJECTIVE[DISEASE]
and O O
symptoms O B_DISEASE
[ O O
11 O B_DISEASE/B_MEASURE
] O I_DISEASE/I_MEASURE
. O O

Several O O
studies O O
have O O
found O O
a O O
high O O
prevalence O O
of O O
alexithymia O O
in O O
pain O O
patients B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Chronic O O
pain O O
patients B B_PERSON/B_DISEASE
frequently O O
exhibit O O
many O O
of O O
the O O
core O O
features O O
of O O
alexithymia O O
, O O
such O O
as O O
problems O O
in O O
identifying O O
and O O
describing O O
subjective O O
feelings O O
, O O
impoverished O O
imaginative O O
abilities O O
, O O
and O O
excessive O O
preoccupation O O
with O O
physical O O
symptoms O O
and O O
external O O
events O O
. O O

Although O O
several O O
studies O O
have O O
found O O
a O O
high O O
prevalence O O
of O O
alexithymia O O
in O O
pain O O
patients B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
way O O
alexithymia O O
may O O
possibly O O
influence O O
pain O O
experience O O
is O O
still O O
unclear O O
[ O O
12 O O
, O O
13 O O
] O O
. O O

DSM O B_LOCATION
- O O
IV O B_NUMBER[MEASURE]
- O O
TR O B_MEASURE/B_PROTEIN[GENE]
defines O O
pain O B_DISEASE
disorder O I_DISEASE
as O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pain O B_DISEASE
that O O
is O O
" O O
the O O
predominant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
focus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
attention O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
" O O
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
chronic O O
pain O O
disorder O O
, O O
patients B B_PERSON
complain O O
of O O
chronic O O
pain O O
, O O
for O O
which O O
no O O
physical O O
etiology O O
could O O
be O O
found O O
or O O
the O O
underlying O O
disorder O O
is O O
insufficient O O
in O O
explaining O O
the O O
symptoms O O
. O O

The O O
pain O B_DISEASE
causes O O
clinically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
distress O I_DISEASE_ADJECTIVE[DISEASE]
or O O
impairment O B_DISEASE_ADJECTIVE[DISEASE]
in O O
social O B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
occupational O B_EDU[ORGANIZATION]/B_DISEASE
, O O
or O O
other O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
important O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
areas O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
functioning O O
. O O

Psychological O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
judged O O
to O O
have O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]
, O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
exacerbation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
or O O
maintenance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
pain O B_DISEASE
[ O O
15 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

The O O
alexithymic O O
person B B_PERSON
' O O
s O O
difficulty O O
in O O
identifying O O
and O O
describing O O
feelings O O
may O O
increase O O
symptom O O
reporting O O
by O O
several O O
mechanisms O O
. O O

Consequently O O
, O O
due O O
to O O
the O O
difficulty O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
experience O O
and O O
express O O
emotions O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
alexithymia O B_DISEASE
has O O
been O O
linked O O
with O O
somatosensory O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplification O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
the O O
tendency O B_MEASURE/B_DISEASE
to O O
focus O O
on O O
benign O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
somatic O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensations O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Alexithymic O B_PERSON
subjects O I_PERSON
are O O
considered O O
to O O
focus O O
on O O
somatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
emotional O B_DISEASE
arousal O I_DISEASE
, O O
resulting O O
in O O
misinterpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
somatic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensations O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
physical O B_DISEASE
illness O I_DISEASE
[ O O
12 O B_MEASURE
, O O
13 O B_SEQUENCE[MEASURE]
, O O
16 O B_MEASURE
] O I_MEASURE
. O O

Accordingly O O
, O O
previous O O
studies O O
have O O
found O O
evidence O O
of O O
an O O
association O O
between O O
alexithymia O O
and O O
the O O
development O O
of O O
functional O O
somatic O O
symptoms O O
, O O
as O O
seen O O
in O O
patients B B_PERSON/B_BIO
with O O
somatoform O O
disorders O O
. O O

On O O
the O O
other O B_PERSON/B_MEASURE
hand O I_PERSON/I_MEASURE
, O O
alexithymia O B_DISEASE/B_PERSON
may O O
also O O
occur O O
as O O
a O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
state O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
severe O B_DISEASE
and O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
medical O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
illness O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
[ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
17 O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O O
21 O B_MEASURE
] O I_MEASURE
. O O

Based O O
on O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
these O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
are O O
worth O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attention O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
terms O B_LOCATION/B_DISEASE
of O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
research O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
prevalence O O
of O O
alexithymia O O
among O O
DSM O O
- O O
IV O O
somatoform O O
pain O O
disorder O O
( O O
chronic O O
pain O O
) O O
female O O
patients B B_PERSON
and O O
to O O
examine O O
the O O
relationship O O
between O O
alexithymia O O
and O O
the O O
self O O
- O O
reporting O O
of O O
pain O O
in O O
this O O
group O O
of O O
patients B B_PERSON
. O O

Besides O O
, O O
the O O
study O O
searched O O
for O O
the O O
anxiety O O
levels O O
of O O
chronic O O
pain O O
patients B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
with O O
or O O
without O O
alexithymia O O
. O O

Materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
consisted O O
of O O
30 O B_PERSON
females O I_PERSON
who O O
applied O O
to O O
the O O
outpatient O B_LOCATION
psychiatry O I_LOCATION
clinic O I_LOCATION
at O O
a O O
public O B_LOCATION/B_MEASURE
hospital O I_LOCATION/I_MEASURE
and O O
who O O
met O O
DSM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
IV O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
chronic O B_DISEASE/B_LOCATION
pain O I_DISEASE/I_LOCATION
disorder O I_DISEASE/I_LOCATION
. O O

Patients B B_PERSON
with O O
concomitant O O
psychiatric O O
disorders O O
, O O
such O O
as O O
major O O
depression O O
, O O
anxiety O O
disorders O O
and O O
somatoform O O
disorders O O
other O O
than O O
pain O O
disorder O O
were O O
excluded O O
. O O

Patients B B_PERSON
either O O
directly O O
applied O O
to O O
the O O
psychiatry O O
clinic O O
themselves O O
or O O
were O O
referred O O
for O O
psychiatric O O
assessment O O
from O O
another O O
outpatient O O
clinic O O
, O O
mainly O O
physical O O
medicine O O
and O O
rehabilitation O O
. O O

After O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
description O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
written O O
informed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
consent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
obtained O O
from O O
each O O
subject O B_PERSON
. O O

The O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
was O O
37 O B_PERSON
healthy O I_PERSON
females O I_PERSON
, O O
who O O
matched O O
for O O
age O B_TIME[MEASURE]
, O O
and O O
education O B_PERSON/B_TIME[MEASURE]
with O O
the O O
subjects O B_PERSON/B_LOCATION
. O O

All O O
subjects O B_PERSON
participated O O
voluntarily O O
in O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
gave O O
consent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
after O O
the O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
had O O
been O O
fully O O
explained O O
to O O
them O O
. O O

The O O
mean O O
age O O
of O O
the O O
patients B B_PERSON/B_BIO
and O O
the O O
healthy O O
controls O O
was O O
34 O O
, O O
63 O O
+/- O O
10 O O
, O O
62 O O
( O O
range O O
: O O
16 O O
- O O
62 O O
) O O
and O O
34 O O
, O O
46 O O
+/- O O
7 O O
, O O
43 O O
( O O
range O O
: O O
22 O O
- O O
57 O O
) O O
years O O
and O O
the O O
educational O O
level O O
was O O
6 O O
, O O
13 O O
+/- O O
3 O O
, O O
03 O O
( O O
range O O
: O O
5 O O
- O O
11 O O
) O O
and O O
6 O O
, O O
59 O O
+/- O O
2 O O
, O O
9 O O
( O O
range O O
: O O
5 O O
- O O
14 O O
) O O
years O O
, O O
respectively O O
. O O

There O O
were O O
no O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
age O B_MEASURE/B_PERSON
( O O
t O B_PROTEIN[GENE]/B_DISEASE
= O O
0 O B_MEASURE
, O O
79 O B_MEASURE
, O O
df O B_PROTEIN[GENE]/B_DISEASE
= O O
65 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
> O O
0 O B_MEASURE
, O O
05 O B_MEASURE
) O O
, O O
educational O B_MEASURE/B_PERSON
level O I_MEASURE/I_PERSON
( O O
t O B_PROTEIN[GENE]/B_DISEASE
= O O
1 O B_MEASURE
, O O
02 O B_MEASURE
, O O
df O B_PROTEIN[GENE]/B_DISEASE
= O O
65 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
> O O
0 O B_MEASURE
, O O
05 O B_MEASURE
) O O
, O O
and O O
marital O B_PERSON/B_ORGANIZATION
status O I_PERSON/I_ORGANIZATION
( O O
x2 O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
, O O
51 O B_MEASURE
, O O
df O B_MEASURE/B_PROTEIN[GENE]
= O O
1 O B_MEASURE
, O O
P O B_MEASURE
> O I_MEASURE
0 O I_MEASURE
, O O
05 O B_MEASURE
) O O
. O O

Measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sociodemographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
used O O
for O O
all O O
subjects O B_PERSON/B_ORGANIZATION
. O O

All O O
participants B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
applied O O
Structured O O
Clinical O O
Interview O O
for O O
DSM O O
- O O
IV O O
( O O
SCID O O
- O O
I O O
) O O
[ O O
22 O O
] O O
, O O
Turkish O O
version O O
[ O O
23 O O
] O O
. O O

Regarding O O
the O O
pain O O
assessment O O
, O O
information O O
was O O
first O O
obtained O O
on O O
several O O
aspects O O
of O O
the O O
patients B B_PERSON/B_DISEASE
' O O
pain O O
, O O
such O O
as O O
intensity O O
, O O
and O O
duration O O
. O O

Pain O B_DISEASE
intensity O I_DISEASE
was O O
measured O O
by O O
Visual O B_MEASURE
Analogue O I_MEASURE
Scale O I_MEASURE
( O O
VAS O B_MEASURE/B_DISEASE
) O O
, O O
using O O
a O O
horizontal O B_MEASURE/B_LOCATION
10 O I_MEASURE/I_LOCATION
- O O
cm O B_MEASURE/B_LOCATION
line O I_MEASURE/I_LOCATION
with O O
the O O
statement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O O
no O O
pain O B_DISEASE
at O O
all O O
' O O
at O O
the O O
extreme O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
left O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
- O O
hand O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
' O O
the O O
worst O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
possible O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pain O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
' O O
or O O
' O O
unbearable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' O O
at O O
the O O
right O B_SEQUENCE[MEASURE]/B_LOCATION
- O O
hand O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
extreme O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

VAS O O
is O O
scored O O
by O O
measuring O O
the O O
distance O O
from O O
the O O
end O O
of O O
the O O
scale O O
indicating O O
absence O O
of O O
pain O O
( O O
or O O
no O O
distress O O
or O O
no O O
pain O O
relief O O
) O O
to O O
the O O
place O O
marked O O
by O O
the O O
patient B B_PERSON/B_MEASURE
[ O O
24 O O
] O O
. O O

The O O
psychometric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scales O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
used O O
in O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
the O O
26 O B_NUMBER[MEASURE]
- O O
item O B_MEASURE
Toronto O I_MEASURE
Alexithymia O I_MEASURE
Scale O I_MEASURE
( O O
TAS O B_MEASURE/B_DISEASE
- O O
26 O B_MEASURE
] O I_MEASURE
and O O
the O O
Trait O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Anxiety O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Inventory O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
STAI O B_LOCATION/B_ORGANIZATION
) O O
, O O
which O O
were O O
both O O
validated O O
in O O
Turkish O B_MEASURE/B_PERSON
population O I_MEASURE/I_PERSON
studies O I_MEASURE/I_PERSON
[ O O
25 O B_MEASURE
- O O
28 O B_MEASURE
] O I_MEASURE
. O O

TAS O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
psychometrically O O
well O O
validated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
alexithymia O B_DISEASE
. O O
TAS O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
validated O O
in O O
Turkish O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
a O O
true O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
or O O
false O B_DISEASE_ADJECTIVE[DISEASE]
scale O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Twenty O B_NUMBER[MEASURE]
- O O
six O B_NUMBER[MEASURE]/B_PERSON
items O I_NUMBER[MEASURE]/I_PERSON
are O O
scored O O
either O O
as O O
1 O B_MEASURE
or O O
0 O B_MEASURE
and O O
the O O
higher O B_MEASURE
scores O I_MEASURE
indicate O O
higher O B_MEASURE/B_DISEASE
degrees O I_MEASURE/I_DISEASE
of O O
alexithymia O B_DISEASE_ADJECTIVE[DISEASE]
. O O

TAS O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
an O O
interval O B_MEASURE
consistency O I_MEASURE
of O O
0 O B_MEASURE
. O O
65 O B_MEASURE/B_PERSON
[ O I_MEASURE/I_PERSON
Kuder O I_MEASURE/I_PERSON
- O O
Richardson O B_MEASURE
) O O
and O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
retest O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reliability O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
r O B_PROTEIN[GENE]/B_DISEASE
= O O
0 O B_MEASURE
. O O
71 O B_MEASURE
, O O
p O O
< O O
0 O B_NUMBER[MEASURE]
. O O
01 O B_MEASURE
in O O
Turkish O B_MEASURE
reliability O I_MEASURE
and O O
validity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
divided O O
into O O
nonalexithymic O B_DISEASE_ADJECTIVE[DISEASE]
and O O
alexityhmic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
the O O
recommended O O
cut O O
- O O
off O O
score O B_MEASURE
of O O
11 O B_MEASURE
[ O I_MEASURE
27 O I_MEASURE
] O I_MEASURE
. O O

Spielberger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Trait O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Anxiety O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Inventory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
STAI O B_LOCATION/B_ORGANIZATION
) O O
is O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
two O B_MEASURE/B_LOCATION
sections O B_MEASURE/I_LOCATION
of O O
the O O
Spielberger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Anxiety O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Inventory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
the O O
other O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
measuring O O
state O B_DISEASE
anxiety O I_DISEASE
) O O
. O O

' O O
Trait O B_DISEASE
anxiety O I_DISEASE
' O O
has O O
been O O
defined O O
as O O
anxiety O B_DISEASE_ADJECTIVE[DISEASE]
proneness O I_DISEASE_ADJECTIVE[DISEASE]
, O O
that O O
is O O
, O O
the O O
tendency O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
respond O O
to O O
situations O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
perceived O O
as O O
threatening O O
with O O
elevations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
intensity O B_MEASURE/B_LOCATION
of O O
state O B_DISEASE_ADJECTIVE[DISEASE]
anxiety O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
26 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]

In O O
order O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
determine O O
the O O
relative O B_MEASURE/B_PERSON
importance O B_MEASURE/I_PERSON
of O O
a O O
number O B_MEASURE/B_LOCATION
of O O
factors O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
pain O B_DISEASE_ADJECTIVE[DISEASE]
disorders O I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
used O O
both O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
alexithymic O B_DISEASE/B_PERSON
and O O
nonalexithymic O B_DISEASE/B_ORGANIZATION
groups O I_DISEASE/I_ORGANIZATION
were O O
compared O O
using O O
the O O
independent O B_LOCATION/B_DISEASE
sample O I_LOCATION/I_DISEASE
t O I_LOCATION/I_DISEASE
- O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
scores O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
psychological O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
was O O
carried O O
out O O
by O O
a O O
SPSS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
package O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
Windows O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
using O O
Chi O B_PERSON/B_NUMBER[MEASURE]
- O O
square O B_LOCATION/B_MEASURE
, O O
Fisher O B_MEASURE/B_LOCATION
' O I_MEASURE/I_LOCATION
s O I_MEASURE/I_LOCATION
exact O I_MEASURE/I_LOCATION
test O I_MEASURE/I_LOCATION
, O O
two O B_MEASURE/B_PERSON
tailed O O
t O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
Pearson O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
also O O
used O O
to O O
determine O O
group O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
alexithymics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
versus O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
nonalexithymics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
in O O
sociodemographic O B_DISEASE_ADJECTIVE[DISEASE]
variables O I_DISEASE_ADJECTIVE[DISEASE]
and O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pain O B_DISEASE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
the O O
chronic O O
pain O O
group O O
, O O
56 O O
. O O
7 O O
% O O
of O O
patients B B_PERSON/B_BIO
( O O
n O O
= O O
17 O O
) O O
had O O
a O O
score O O
greater O O
than O O
11 O O
on O O
the O O
TAS O O
- O O
26 O O
, O O
and O O
were O O
considered O O
alexithymic O O
. O O

The O O
mean O B_MEASURE
TAS O I_MEASURE
- O O
26 O B_MEASURE
score O I_MEASURE
of O O
the O O
alexithymic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
17 O B_MEASURE
) O O
was O O
17 O B_MEASURE
. O O
88 O B_MEASURE
+/- O I_MEASURE
3 O I_MEASURE
. O O
43 O B_MEASURE
and O O
the O O
nonalexithymic O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_LOCATION
= O O
13 O B_MEASURE
) O O
was O O
8 O B_MEASURE
. O O
39 O B_MEASURE
+/- O I_MEASURE
2 O I_MEASURE
. O O
02 O B_MEASURE
. O O

Age O B_TIME[MEASURE]/B_PERSON
( O O
t O O
= O O
1 O B_MEASURE
, O O
38 O B_MEASURE
, O O
df O B_PROTEIN[GENE]/B_DISEASE
= O O
28 O B_MEASURE
, O O
p O B_OTHER/B_LOCATION
> O O
0 O B_MEASURE
, O O
18 O B_MEASURE
) O O
, O O
education O B_PERSON/B_LOCATION
( O O
t O B_PROTEIN[GENE]/B_DISEASE
= O O
- O O
0 O B_MEASURE
, O O
21 O B_MEASURE
, O O
df O B_PROTEIN[GENE]/B_DISEASE
= O I_MEASURE
28 O I_MEASURE
, O O
p O B_MEASURE/B_PROTEIN[GENE]
> O O
0 O B_MEASURE
, O O
16 O B_MEASURE
) O O
and O O
marital O B_PERSON/B_ORGANIZATION
status O I_PERSON/I_ORGANIZATION
( O O
x2 O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
, O O
27 O B_MEASURE
, O O
df O B_PROTEIN[GENE]/B_DISEASE
= O O
1 O B_MEASURE
, O O
p O B_MEASURE/B_LOCATION
> O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
, O O
87 O B_MEASURE
) O O
were O O
not O O
associated O O
with O O
alexithymia O B_DISEASE_ADJECTIVE[DISEASE]
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

In O O
the O O
control O O
group O O
, O O
24 O O
, O O
3 O O
% O O
of O O
patients B B_PERSON/B_BIO
( O O
n O O
= O O
9 O O
) O O
were O O
alexithymic O O
according O O
to O O
TAS O O
- O O
26 O O
. O O

The O O
mean O B_MEASURE
TAS O I_MEASURE
- O O
26 O B_MEASURE
score O I_MEASURE
of O O
the O O
alexithymic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
n O B_MEASURE
= O O
9 O B_MEASURE
) O O
was O O
13 O B_MEASURE
, O O
82 O B_MEASURE
+/- O I_MEASURE
1 O I_MEASURE
, O O
93 O B_MEASURE
and O O
the O O
nonalexithymic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
n O B_MEASURE/B_LOCATION
= O O
28 O B_MEASURE
) O O
was O O
10 O B_MEASURE
, O O
33 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
, O O
86 O B_MEASURE
. O O

Alexithymia O B_DISEASE
was O O
not O O
associated O O
with O O
age O B_MEASURE/B_PERSON
( O O
t O O
= O O
- O O
1 O B_MEASURE
, O O
08 O B_MEASURE
, O O
df O B_PROTEIN[GENE]/B_DISEASE
= O O
35 O B_MEASURE
, O O
p O B_PROTEIN[GENE]/B_LOCATION
> O O
0 O B_MEASURE
, O O
29 O B_MEASURE
) O O
, O O
educational O B_MEASURE/B_PERSON
level O I_MEASURE/I_PERSON
( O O
t O B_MEASURE/B_DISEASE
= O O
1 O B_MEASURE
, O O
1 O B_MEASURE
, O O
df O B_MEASURE/B_PROTEIN[GENE]
= O O
35 O B_MEASURE
, O O
p O B_MEASURE/B_LOCATION
> O O
0 O B_MEASURE
, O O
28 O B_MEASURE
) O O
, O O
or O O
marital O B_DISEASE
status O I_DISEASE
( O O
x2 O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
, O O
74 O B_MEASURE
, O O
df O B_DISEASE/B_PROTEIN[GENE]
= O O
1 O B_MEASURE
, O O
p O B_MEASURE/B_LOCATION
> O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
, O O
79 O B_MEASURE
) O O
or O O
anxiety O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
control O B_PERSON/B_LOCATION
subjects O I_PERSON/I_LOCATION
( O O
Table O B_MEASURE
1 O I_MEASURE
) O O
. O O

The O O
duration O O
and O O
severity O O
of O O
pain O O
, O O
TAS O O
- O O
26 O O
scores O O
, O O
and O O
STAI O O
scores O O
of O O
the O O
female O O
pain O O
patients B B_PERSON/B_ORGANIZATION
are O O
shown O O
in O O
Table O O
2 O O
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
alexithymics O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
nonalexithymics O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
either O O
the O O
severity O B_MEASURE/B_PERSON
of O O
pain O B_DISEASE
or O O
pain O B_DISEASE
duration O I_DISEASE
showed O O
no O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
t O B_PROTEIN[GENE]/B_DISEASE
= O O
0 O B_MEASURE
, O O
64 O B_MEASURE
, O O
df O B_PROTEIN[GENE]/B_DISEASE
= O O
28 O B_MEASURE
, O O
p O B_MEASURE/B_LOCATION
> O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
, O O
52 O B_MEASURE
, O O
t O O
= O O
2 O B_MEASURE
, O O
05 O B_MEASURE
, O O
df O B_PROTEIN[GENE]/B_DISEASE
= O O
28 O B_MEASURE
, O O
p O B_MEASURE
> O I_MEASURE
0 O B_MEASURE
, O O
05 O B_MEASURE
, O O
respectively O O
) O O
. O O

TAS O B_MEASURE/B_DISEASE
- O O
26 O B_MEASURE
score O I_MEASURE
and O O
duration O B_MEASURE
of O O
pain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
found O O
positively O O
correlated O O
( O O
r O B_OTHER/B_GENE
= O O
0 O B_MEASURE
, O O
50 O B_MEASURE
, O O
n O B_OTHER/B_MEASURE
= O O
30 O B_MEASURE
, O O
p O B_MEASURE/B_LOCATION
> O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
, O O
005 O B_MEASURE
) O O
. O O

STAI O B_DISEASE/B_MEASURE
( O O
trait O B_MEASURE/B_DISEASE
) O O
scores O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
alexithymics O B_PERSON/B_BIO
in O O
the O O
pain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
did O O
not O O
significantly O O
differ O O
from O O
the O O
nonlalexithymics O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
t O B_PROTEIN[GENE]/B_DISEASE
= O O
0 O B_MEASURE
, O O
06 O B_MEASURE
, O O
df O B_DISEASE/B_PROTEIN[GENE]
= O O
28 O B_MEASURE
, O O
p O B_MEASURE/B_PROTEIN[GENE]
> O O
0 O B_MEASURE
, O O
95 O B_MEASURE
) O O
and O O
besides O O
, O O
TAS O B_LOCATION/B_ORGANIZATION
- O O
26 O B_MEASURE/B_LOCATION
and O O
STAI O B_DISEASE/B_GENE
scores O I_DISEASE/I_GENE
were O O
not O O
correlated O O
( O O
r O B_PROTEIN[GENE]/B_DISEASE
= O O
0 O B_MEASURE
, O O
06 O B_MEASURE
, O O
p O B_MEASURE/B_LOCATION
> O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
, O O
72 O B_MEASURE
) O O
. O O

In O O
summary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
are O O
three O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
points O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
be O O
emphasized O O
. O O

First O O
, O O
chronic O O
pain O O
patients B B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
significantly O O
more O O
alexithymic O O
than O O
controls O O
( O O
56 O O
, O O
7 O O
% O O
to O O
24 O O
, O O
3 O O
% O O
) O O
. O O

Second O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
positive O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
between O O
TAS O B_MEASURE/B_DISEASE
- O O
26 O B_MEASURE
scores O I_MEASURE
and O O
duration O B_MEASURE
of O O
pain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Third O O
, O O
neither O O
positive O O
correlation O O
nor O O
significant O O
difference O O
was O O
found O O
between O O
alexithymia O O
and O O
trait O O
anxiety O O
in O O
pain O O
patients B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
results O O
of O O
the O O
present O O
study O O
suggest O O
that O O
patients B B_PERSON
with O O
chronic O O
pain O O
disorder O O
are O O
more O O
alexithymic O O
than O O
individuals O O
with O O
no O O
pain O O
. O O

This O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
obtained O O
with O O
earlier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
alexithymia O B_DISEASE/B_MEASURE
[ O O
11 O B_MEASURE
- O O
13 O B_MEASURE
] O I_MEASURE
. O O

Although O O
they O O
may O O
share O O
common O B_DISEASE_ADJECTIVE[DISEASE]
clinical O I_DISEASE_ADJECTIVE[DISEASE]
features O I_DISEASE_ADJECTIVE[DISEASE]
, O O
alexithymia O B_DISEASE
and O O
somatoform O B_DISEASE
pain O I_DISEASE
are O O
independent O B_DISEASE_ADJECTIVE[DISEASE]
constructs O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Alexithymia O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
may O O
be O O
a O O
consequence O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
effects O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
physical O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
reduced O B_DISEASE_ADJECTIVE[DISEASE]
quality O I_DISEASE_ADJECTIVE[DISEASE]
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
limitations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
daily O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Besides O O
, O O
alexithymia O B_DISEASE/B_LOCATION
may O O
be O O
conceptualized O O
as O O
a O O
personality O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trait O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O O
well O O
as O O
a O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
state O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
2 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
, O O
15 O B_MEASURE
- O O
17 O B_MEASURE
] O I_MEASURE
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
question O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigated O O
was O O
whether O O
alexithymia O B_DISEASE/B_PERSON
has O O
any O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
duration O B_MEASURE/B_LOCATION
or O O
severity O B_MEASURE/B_LOCATION
of O O
the O O
pain O B_DISEASE
itself O O
. O O

There O O
were O O
no O O
significant O O
differences O O
between O O
alexithymic O O
and O O
nonalexitymic O O
patients B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
self O O
reports O O
of O O
current O O
pain O O
severity O O
. O O

This O O
is O O
in O O
accordance O O
with O O
Cox O O
' O O
s O O
study O O
[ O O
1994 O O
] O O
in O O
which O O
it O O
was O O
further O O
pointed O O
out O O
that O O
alexithymic O O
patients B B_PERSON
were O O
found O O
to O O
use O O
significantly O O
more O O
verbal O O
descriptors O O
of O O
pain O O
compared O O
to O O
nonalexithymic O O
patients B B_PERSON/B_DISEASE
[ O O
13 O O
] O O
. O O

In O O
our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
pain O B_DISEASE
intensity O I_DISEASE
was O O
only O O
evaluated O O
by O O
using O O
VAS O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
trying O O
to O O
measure O O
the O O
intensity O B_MEASURE/B_DISEASE
of O O
pain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
the O O
lack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
an O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
way O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Pain O O
is O O
a O O
subjective O O
experience O O
and O O
each O O
patient B B_PERSON
may O O
communicate O O
in O O
a O O
different O O
way O O
, O O
verbally O O
or O O
nonverbally O O
[ O O
29 O O
] O O
. O O

Patients B B_PERSON
in O O
this O O
sample O O
were O O
sufferers O O
of O O
chronic O O
pain O O
, O O
who O O
had O O
already O O
chosen O O
an O O
approved O O
way O O
of O O
expressing O O
their O O
distress O O
. O O

Since O O
this O O
is O O
true O B_DISEASE_ADJECTIVE[DISEASE]
regardless O O
of O O
alexithymia O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O O
alexithymic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
nonalexithymic O B_PERSON/B_LOCATION
groups O I_PERSON/I_LOCATION
in O O
this O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O O
no O O
difference O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
pain O B_DISEASE/B_GENE
severity O I_DISEASE/I_GENE
. O O

The O O
positive O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O O
alexithymia O B_DISEASE
and O O
the O O
duration O B_MEASURE
of O O
pain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
this O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
supports O O
the O O
assumption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
a O O
two O B_NUMBER[MEASURE]
- O O
way O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

It O O
is O O
often O O
assumed O O
that O O
pain O B_DISEASE
can O O
be O O
caused O O
by O O
alexithymic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
personality O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
traits O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
also O O
that O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
and O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]
pain O I_DISEASE_ADJECTIVE[DISEASE]
may O O
cause O O
emotional O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
limitations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
that O O
because O O
of O O
the O O
cross O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sectional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
we O O
are O O
unable O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
draw O O
conclusions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O O
the O O
direction O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
causality O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O O
alexithymia O B_DISEASE
and O O
pain O B_DISEASE
. O O

The O O
duration O O
of O O
the O O
patients B B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
pain O O
could O O
approximately O O
be O O
determined O O
, O O
yet O O
the O O
preexisting O O
level O O
of O O
alexithymia O O
was O O
not O O
known O O
. O O

In O O
the O O
usual O O
absence O O
of O O
internal O O
stimuli O O
, O O
alexithymic O O
person B B_PERSON/B_BIO
may O O
be O O
expected O O
to O O
maintain O O
an O O
external O O
focus O O
of O O
attention O O
, O O
such O O
as O O
pain O O
. O O

Symptom O O
chronicity O O
may O O
force O O
the O O
alexithymic O O
person B B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
attent O O
to O O
and O O
amplify O O
this O O
somatic O O
sensation O O
. O O

Difficulties O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
identify O O
and O O
differentiate O O
emotions O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
somatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
experiences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
core O B_DISEASE_ADJECTIVE[DISEASE]
features O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
alexithymic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
construct O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Therefore O O
, O O
alexithymic O O
patients B B_PERSON/B_BIO
might O O
be O O
expected O O
to O O
differ O O
from O O
nonalexithymic O O
ones O O
in O O
their O O
anxiety O O
levels O O
. O O

Yet O O
, O O
in O O
our O O
pain O O
group O O
alexithymic O O
patients B B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
no O O
significant O O
difference O O
from O O
the O O
nonalexithymics O O
on O O
trait O O
anxiety O O
. O O

Besides O O
, O O
alexithymia O B_DISEASE/B_MEASURE
and O O
anxiety O B_DISEASE/B_PERSON
were O O
not O O
correlated O O
at O O
all O O
. O O

The O O
reasons O O
may O O
be O O
lying O O
in O O
the O O
specific O O
characteristics O O
of O O
this O O
patient B B_PERSON/B_EDU[ORGANIZATION]
group O O
itself O O
. O O

The O O
study O O
included O O
patients B B_PERSON
suffering O O
from O O
chronic O O
symptoms O O
; O O
with O O
an O O
average O O
of O O
7 O O
, O O
44 O O
+/- O O
6 O O
, O O
82 O O
years O O
of O O
pain O O
in O O
the O O
alexithymic O O
and O O
3 O O
, O O
31 O O
+/- O O
2 O O
, O O
79 O O
years O O
in O O
the O O
nonalexithymic O O
groups O O
. O O

Persistency O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
any O O
physical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
symptom O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O O
bring O O
along O O
alexithymia O B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
coping O O
strategy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
their O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Crook O B_PERSON/B_COLOR
and O O
Tunks O B_PERSON/B_COLOR
( O O
1988 O B_MEASURE
) O O
examined O O
the O O
types O B_MEASURE/B_DISEASE
of O O
coping O O
strategies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
used O O
by O O
persistent O B_PERSON/B_ORGANIZATION
pain O I_PERSON/I_ORGANIZATION
sufferers O I_PERSON/I_ORGANIZATION
and O O
addressed O O
to O O
the O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
alter O O
their O O
attitudes O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
behavior O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
tend O O
toward O O
catastrophizing O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
avoidance O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
rather O O
than O O
simply O O
concentrate O O
on O O
trying O O
to O O
teach O O
them O O
techniques O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
for O O
' O O
coping O O
with O O
stress O B_DISEASE/B_PERSON
' O O
to O O
help O O
persistent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pain O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
sufferers O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
[ O O
30 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
] O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Sufferers O B_PERSON/B_ORGANIZATION
of O O
chronic O B_DISEASE/B_LOCATION
symptoms O I_DISEASE/I_LOCATION
in O O
this O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
members O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
subgroup O B_MEASURE/B_PERSON
who O O
have O O
been O O
seeking O O
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O O
a O O
long O B_TIME[MEASURE]/B_DISEASE
time O I_TIME[MEASURE]/I_DISEASE
and O O
besides O O
given O O
the O O
chance O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
being O O
referred O O
to O O
a O O
psychiatrist O B_PERSON/B_LOCATION
. O O

Therefore O O
, O O
alexithymic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
not O O
, O O
their O O
anxiety O B_DISEASE/B_PERSON
might O O
have O O
induced O O
unique O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
coping O O
strategies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
illness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Alexithymia O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
addressing O O
the O O
diversity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
subjective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
involved O O
in O O
pain O B_DISEASE
[ O O
31 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
] O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

It O O
is O O
not O O
known O O
whether O O
it O O
should O O
be O O
addressed O O
in O O
the O O
treatment O O
of O O
pain O O
patients B B_PERSON/B_DISEASE
, O O
but O O
a O O
high O O
level O O
of O O
alexithymia O O
may O O
effect O O
the O O
nature O O
of O O
assessment O O
. O O

In O O
summary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
conceptualization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
alexithymia O B_DISEASE/B_LOCATION
as O O
a O O
personality O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trait O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O O
well O O
as O O
a O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]
state O I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DISEASE_ADJECTIVE[DISEASE]
is O O
underlined O O
by O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

However O O
, O O
regarding O O
the O O
cross O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sectional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
design O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
only O O
limited O O
conclusions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
can O O
be O O
drawn O O
about O O
the O O
nature O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
causal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
relationship O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
between O O
alexithymia O B_DISEASE
and O O
chronic O B_DISEASE
pain O I_DISEASE
. O O

Therefore O O
, O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
longitudinal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
assessing O O
the O O
cause O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alexithymic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
required O O
to O O
fully O O
elucidate O O
the O O
concepts O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
primary O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
alexithymia O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Molecular O O
polymorphism O O
, O O
differentiation O O
and O O
introgression O O
in O O
the O O
period O O
gene O O
between O O
Lutzomyia B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
intermedia I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Lutzomyia B B_SPECIES[BIO]/B_LOCATION
whitmani I I_SPECIES[BIO]/I_LOCATION

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Lutzomyia B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
intermedia I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Lutzomyia B B_SPECIES[BIO]/B_LOCATION
whitmani I I_SPECIES[BIO]/I_LOCATION
( O O
Diptera O O
: O O
Psychodidae O O
) O O
are O O
important O O
and O O
very O O
closely O O
related O O
vector O O
species O O
of O O
cutaneous O O
leishmaniasis O O
in O O
Brazil O O
, O O
which O O
are O O
distinguishable O O
by O O
a O O
few O O
morphological O O
differences O O
. O O

There O O
is O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mitochondrial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introgression O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_BIO/B_PERSON
species O I_BIO/I_PERSON
but O O
it O O
is O O
not O O
clear O B_DISEASE_ADJECTIVE[DISEASE]
whether O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flow O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
also O O
occurs O O
in O O
nuclear O B_SPECIES[BIO]/B_GENE
genes O I_SPECIES[BIO]/I_GENE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

We O O
analyzed O O
the O O
molecular O B_GENE/B_MEASURE
variation O B_GENE/I_MEASURE
within O O
the O O
clock O B_MEASURE/B_BIO
gene O I_MEASURE/I_BIO
period O I_MEASURE/I_BIO
( O O
per O O
) O O
of O O
these O O
two O B_BIO/B_GENE
species O I_BIO/I_GENE
in O O
five O B_MEASURE
different O I_MEASURE
localities O I_MEASURE
in O O
Eastern O B_LOCATION
Brazil O I_LOCATION
. O O

AMOVA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
Fst O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
estimates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
no O O
evidence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
geographical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O O
species O B_BIO/B_LOCATION
. O O

On O O
the O O
other O B_PERSON/B_MEASURE
hand O I_PERSON/I_MEASURE
, O O
the O O
values O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
highly O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
both O O
analyses O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
species O B_BIO/B_PERSON
. O O

The O O
two O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
no O O
fixed O B_MEASURE
differences O I_MEASURE
and O O
a O O
higher O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
shared O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphisms O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
compared O O
to O O
exclusive O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
some O O
haplotypes O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
that O O
are O O
" O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
typical O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
" O O
of O O
one O B_PERSON/B_BIO
species O I_PERSON/I_BIO
were O O
found O O
in O O
some O O
individuals O B_PERSON/B_LOCATION
of O O
the O O
other O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
species O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
suggesting O O
either O O
the O O
persistence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
old O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
of O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
linkage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disequilibrium O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
MCMC O B_SEQUENCE[MEASURE]/B_ORGANIZATION
analysis O I_SEQUENCE[MEASURE]/I_ORGANIZATION
based O O
on O O
coalescence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
suggest O O
that O O
the O O
two O B_BIO/B_PERSON
species O I_BIO/I_PERSON
might O O
be O O
exchanging O O
alleles O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
per O O
locus O B_GENE/B_MEASURE
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Introgression O O
might O O
be O O
occurring O O
between O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
intermedia I I_SPECIES[BIO]/I_PERSON
and O O
L B B_SPECIES[BIO]/B_PROTEIN[GENE]
. I B_SPECIES[BIO]/I_PROTEIN[GENE]
whitmani I B_SPECIES[BIO]/I_PROTEIN[GENE]
in O O
period O O
, O O
a O O
gene O O
controlling O O
behavioral O O
rhythms O O
in O O
Drosophila O O
. O O

This O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
raises O O
the O O
question O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
whether O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenomena O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
are O O
occurring O O
at O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
loci O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
controlling O O
important O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
behavior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
vectorial O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
capacity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
Phlebotominae O O
sand O O
flies O O
Lutzomyia B B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
intermedia I I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Lutz O O
& O O
Neiva O O
1912 O O
and O O
Lutzomyia B B_PERSON/B_LOCATION
whitmani I I_PERSON/I_LOCATION
Antunes O O
& O O
Coutinho O O
1912 O O
are O O
vectors O O
of O O
cutaneous O O
leishmaniasis O O
in O O
Brazil O O
. O O

These O O
are O O
closely O O
related O O
species O B_BIO
that O O
can O O
be O O
only O O
distinguished O O
by O O
a O O
few O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphological O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
1 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
and O O
both O O
show O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
anthropophily O O
and O O
reported O O
natural O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Leishmania O B_SPECIES[BIO]/B_DISEASE
in O O
different O B_LOCATION/B_MEASURE
regions O I_LOCATION/I_MEASURE
of O O
Brazil O B_LOCATION
[ O I_LOCATION
2 O I_LOCATION
] O I_LOCATION
. O O

Despite O O
their O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
vectors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
only O O
a O O
handful O B_SEQUENCE[MEASURE]/B_PERSON
of O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
have O O
been O O
carried O O
out O O
in O O
these O O
two O B_BIO/B_LOCATION
species O I_BIO/I_LOCATION
using O O
molecular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
techniques O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
6 O B_MEASURE
] O I_MEASURE
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
findings O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
from O O
an O O
epidemiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
the O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
for O O
introgression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
two O B_BIO/B_PERSON
species O I_BIO/I_PERSON
using O O
mitochondrial O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
4 O B_LOCATION/B_GENE
] O I_LOCATION/I_GENE
. O O

This O O
was O O
particularly O O
interesting O O
because O O
apparently O O
, O O
only O O
lineages O O
of O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
whitmani I I_SPECIES[BIO]
sympatric O O
with O O
L B B_SPECIES[BIO]/B_LOCATION
. I I_SPECIES[BIO]/I_LOCATION
intermedia I I_SPECIES[BIO]/I_LOCATION
have O O
been O O
involved O O
in O O
cutaneous O O
leishmaniasis O O
transmission O O
in O O
the O O
peridomestic O O
environment O O
[ O O
4 O O
] O O
, O O
which O O
suggests O O
that O O
genes O O
controlling O O
aspects O O
of O O
vectorial O O
capacity O O
could O O
be O O
passing O O
from O O
one O O
species O O
to O O
the O O
other O O
. O O

In O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
mitochondrial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introgression O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
reported O O
in O O
other O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
sand O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
fly O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
species O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
7 O B_MEASURE
, O O
8 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
suggesting O O
that O O
might O O
be O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenomenon O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
insect O B_BIO/B_PERSON
vectors O I_BIO/I_PERSON
. O O

However O O
, O O
because O O
mitochondrial O B_GENE/B_BIO
genes O I_GENE/I_BIO
can O O
introgress O O
relatively O O
easily O O
between O O
closely O O
related O B_BIO/B_PERSON
species O I_BIO/I_PERSON
[ O O
9 O B_MEASURE/B_SPECIES[BIO]
] O I_MEASURE/I_SPECIES[BIO]
, O O
it O O
becomes O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
examine O O
whether O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
occur O O
with O O
nuclear O B_MEASURE/B_GENE
genes O I_MEASURE/I_GENE
. O O

The O O
Drosophila O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
period O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
per O O
) O O
gene O B_GENE/B_BIO
homologue O I_GENE/I_BIO
was O O
isolated O O
in O O
sand O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
flies O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Peixoto O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
et O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
al O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
circadian O O
clock O O
gene O O
was O O
originally O O
identified O O
using O O
mutagenesis O O
by O O
Konopka O O
and O O
Benzer O O
[ O O
11 O O
] O O
, O O
but O O
is O O
also O O
known O O
to O O
control O O
the O O
differences O O
in O O
the O O
" O O
lovesong O O
" O O
rhythms O O
between O O
D B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
melanogaster I I_SPECIES[BIO]/I_PERSON
and O O
D B B_SPECIES[BIO]
. I I_SPECIES[BIO]
simulans I I_SPECIES[BIO]
[ O O
12 O O
] O O
, O O
that O O
are O O
important O O
to O O
the O O
sexual O O
isolation O O
between O O
these O O
two O O
species O O
[ O O
13 O O
- O O
15 O O
] O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
per O O
was O O
implicated O O
in O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
species O B_BIO/B_PERSON
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
circadian O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mating O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rhythms O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
Drosophila O B_SPECIES[BIO]
and O O
Bractocera O B_SPECIES[BIO]
, O O
which O O
might O O
also O O
constitute O O
a O O
reproductive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
isolation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mechanism O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
[ O O
16 O B_NUMBER[MEASURE]
- O O
18 O B_MEASURE
] O I_MEASURE
. O O

Thus O O
per O O
may O O
possibly O O
represent O O
an O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
a O O
Drosophila O B_GENE/B_BIO
speciation O I_GENE/I_BIO
gene O I_GENE/I_BIO
[ O O
19 O B_MEASURE
] O I_MEASURE
, O O
and O O
in O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
it O O
has O O
been O O
used O O
as O O
a O O
molecular O B_GENE/B_PERSON
marker O I_GENE/I_PERSON
in O O
a O O
number O B_MEASURE/B_LOCATION
of O O
speciation O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
evolutionary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O O
not O O
only O O
in O O
Drosophila O B_SPECIES[BIO]
( O O
reviewed O O
in O O
[ O B_TIME[MEASURE]
20 O I_TIME[MEASURE]
] O O
) O O
but O O
also O O
in O O
other O B_SPECIES[BIO]
insects O I_SPECIES[BIO]
( O O
e O B_OTHER/B_DISEASE
. O O
g O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O
[ O O
21 O B_MEASURE
] O I_MEASURE
) O O
including O O
sand O B_BIO/B_LOCATION
flies O O
[ O B_TIME[MEASURE]
22 O I_TIME[MEASURE]
- O O
24 O B_MEASURE
] O I_MEASURE
. O O

Because O O
per O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
the O O
circadian O B_MEASURE/B_ORGANISM_FUNCTION
clock O B_MEASURE/I_ORGANISM_FUNCTION
in O O
different O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
insects O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
25 O B_MEASURE
] O I_MEASURE
, O O
it O O
is O O
almost O O
certainly O O
involved O O
in O O
the O O
rhythms O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
biting O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sand O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
flies O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
[ O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
26 O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
] O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
very O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
leishmaniasis O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
transmission O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

In O O
addition O O
, O O
per O O
might O O
be O O
involved O O
in O O
reproductive O O
isolation O O
in O O
sand O O
flies O O
, O O
via O O
mating O O
rhythms O O
, O O
or O O
via O O
their O O
" O O
lovesongs O O
" O O
[ O O
2 O O
, O O
27 O O
] O O
. O O
per O O
is O O
thus O O
a O O
particularly O O
interesting O O
marker O O
, O O
among O O
the O O
few O O
available O O
, O O
for O O
an O O
introgression O O
analysis O O
in O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
whitmani I I_SPECIES[BIO]
. O O

Evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
per O O
might O O
suggest O O
that O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
flow O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
between O O
these O O
two O B_BIO/B_LOCATION
vector O B_BIO/I_LOCATION
species O B_BIO/I_LOCATION
is O O
occurring O O
at O O
other O B_TIME[MEASURE]/B_LOCATION
genes O I_TIME[MEASURE]/I_LOCATION
controlling O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
behavior O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
vectorial O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
capacity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
might O O
also O O
suggest O O
that O O
per O O
does O O
not O O
have O O
a O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
their O O
reproductive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
isolation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
the O O
current O O
study O O
, O O
we O O
analyzed O O
the O O
molecular O O
variation O O
within O O
the O O
per O O
gene O O
of O O
L B B_SPECIES[BIO]/B_DISEASE
. I I_SPECIES[BIO]/I_DISEASE
intermedia I I_SPECIES[BIO]/I_DISEASE
and O O
L B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whitmani I B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
five O O
different O O
localities O O
in O O
Eastern O O
Brazil O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Polymorphism O O
and O O
divergence O O
between O O
L B B_SPECIES[BIO]/B_LOCATION
. I I_SPECIES[BIO]/I_LOCATION
intermedia I I_SPECIES[BIO]/I_LOCATION
and O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON

A O O
total O O
of O O
68 O O
sequences O O
from O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
intermedia I I_SPECIES[BIO]/I_PERSON
and O O
53 O O
from O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
homologue O O
to O O
a O O
fragment O O
of O O
the O O
period O O
gene O O
were O O
analyzed O O
from O O
populations O O
of O O
five O O
localities O O
in O O
Eastern O O
Brazil O O
( O O
Fig O O
1 O O
) O O
. O O

The O O
alignment O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
72 O B_MEASURE/B_LOCATION
variable O I_MEASURE/I_LOCATION
sites O I_MEASURE/I_LOCATION
is O O
shown O O
in O O
Fig O B_MEASURE/B_COLOR
2 O I_MEASURE/I_COLOR
. O O

Although O O
most O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
are O O
either O O
synonymous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
occur O O
within O O
the O O
58 O B_GENE/B_LOCATION
bp O I_GENE/I_LOCATION
intron O I_GENE/I_LOCATION
, O O
non O B_DISEASE
- O O
synonymous O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
substitutions O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
observed O O
causing O O
9 O B_MEASURE
amino O I_MEASURE
acid O I_MEASURE
differences O I_MEASURE
among O O
the O O
sequences O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Fig O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
) O O
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O O
the O O
number O B_MEASURE
of O O
sequences O B_LOCATION/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O O
each O O
population O B_PERSON/B_BIO
of O O
the O O
two O B_BIO
species O I_BIO
, O O
the O O
number O B_MEASURE/B_LOCATION
of O O
polymorphic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
S O B_PROTEIN[GENE]/B_DISEASE
) O O
and O O
the O O
estimates O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
molecular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymorphism O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
theta O O
( O O
based O O
on O O
the O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
mutations O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
) O O
and O O
pi O B_PROTEIN[GENE]/B_DISEASE
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O O
shows O O
the O O
Tajima O B_PERSON/B_ORGANIZATION
' O I_PERSON/I_ORGANIZATION
s O I_PERSON/I_ORGANIZATION
[ O I_PERSON/I_ORGANIZATION
28 O I_PERSON/I_ORGANIZATION
] O I_PERSON/I_ORGANIZATION
and O O
Fu O B_PERSON/B_LOCATION
& O O
Li O B_PERSON/B_LOCATION
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
29 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
statistics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Within O O
each O O
species O O
, O O
all O O
populations O O
present O O
similar O O
levels O O
of O O
polymorphism O O
with O O
the O O
exception O O
of O O
L B B_BIO/B_PERSON
. I I_BIO/I_PERSON
whitmani I I_BIO/I_PERSON
from O O
Ilh O O
e O O
us O O
, O O
which O O
seems O O
to O O
be O O
less O O
polymorphic O O
than O O
the O O
others O O
. O O

This O O
population O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
the O O
only O B_PERSON/B_MEASURE
one O I_PERSON/I_MEASURE
presenting O O
a O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
value O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
Fu O B_PERSON/B_LOCATION
& O O
Li O B_PERSON/B_LOCATION
test O I_PERSON/I_LOCATION
but O O
only O O
at O O
the O O
5 O B_MEASURE/B_LOCATION
% O B_MEASURE/I_LOCATION
level O B_MEASURE/I_LOCATION
. O O

Finally O O
, O O
the O O
last O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
column O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
presents O O
the O O
recombination O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
estimator O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
indicating O O
that O O
both O O
species O B_BIO/B_GENE
show O O
evidence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
intragenic O B_DISEASE_ADJECTIVE[DISEASE]
recombination O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
per O O
gene O B_GENE/B_BIO
. O O

To O O
investigate O O
the O O
level O B_MEASURE/B_LOCATION
of O O
intra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
interspecific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
initially O O
an O O
AMOVA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
as O O
shown O O
in O O
Table O B_LOCATION/B_PERSON
2 O I_LOCATION/I_PERSON
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
show O O
a O O
non O B_DISEASE/B_MEASURE
- O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
within O O
species O B_BIO/B_PERSON
and O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
between O O
species O B_MEASURE/B_BIO
molecular O I_MEASURE/I_BIO
variation O I_MEASURE/I_BIO
at O O
the O O
per O O
locus O B_PERSON/B_LOCATION
. O O

Table O O
3 O O
shows O O
a O O
more O O
detailed O O
analysis O O
of O O
the O O
intraspecific O O
differentiation O O
among O O
populations O O
of O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
. O O

None O O
of O O
the O O
pairwise O O
and O O
overall O O
fixation O O
indexes O O
( O O
Fst O O
) O O
are O O
significant O O
in O O
the O O
case O O
of O O
L B B_BIO/B_PERSON
. I I_BIO/I_PERSON
intermedia I I_BIO/I_PERSON
and O O
only O O
one O O
( O O
Posse O O
x O O
Ilh O O
e O O
us O O
) O O
has O O
a O O
borderline O O
significant O O
value O O
in O O
L B B_BIO/B_PERSON
. I I_BIO/I_PERSON
whitmani I I_BIO/I_PERSON
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therefore O O
show O O
that O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
geographical O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heterogeneity O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
detected O O
among O O
the O O
populations O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
two O B_LOCATION/B_BIO
species O I_LOCATION/I_BIO
. O O

The O O
estimated O O
number O O
of O O
migrants O O
per O O
generation O O
, O O
based O O
on O O
the O O
overall O O
Fst O O
values O O
, O O
is O O
20 O O
. O O
683 O O
for O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
intermedia I I_SPECIES[BIO]/I_PERSON
and O O
23 O O
. O O
125 O O
for O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
divergence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O O
species O B_BIO/B_GENE
( O O
Dxy O B_LOCATION
and O O
Da O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
as O O
well O O
as O O
the O O
Fst O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Nm O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considering O O
each O O
species O B_BIO/B_GENE
as O O
a O O
unique O B_PERSON/B_BIO
population O B_PERSON/I_BIO
. O O

Dxy O B_MEASURE/B_LOCATION
is O O
the O O
average O B_MEASURE
number O I_MEASURE
of O O
nucleotide O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitutions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O O
site O B_LOCATION/B_BIO
between O O
alleles O B_BIO/B_GENE
from O O
two O B_LOCATION/B_PERSON
different O I_LOCATION/I_PERSON
populations O I_LOCATION/I_PERSON
and O O
Da O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
number O B_MEASURE
of O O
net O B_LOCATION/B_GENE
nucleotide O B_LOCATION/I_GENE
substitutions O B_LOCATION/I_GENE
between O O
two O B_NUMBER[MEASURE]/B_GENE
populations O I_NUMBER[MEASURE]/I_GENE
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O O
shows O O
the O O
number O B_MEASURE
of O O
polymorphisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exclusive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
each O O
species O B_BIO/B_GENE
( O O
Sint O B_LOCATION/B_PERSON
and O O
Swhit O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
the O O
number O B_MEASURE
of O O
shared O O
polymorphisms O B_GENE
( O O
Ss O B_LOCATION
) O O
and O O
the O O
number O B_MEASURE/B_LOCATION
of O O
fixed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Sf O B_PROTEIN[GENE]/B_LOCATION
) O O
between O O
species O B_BIO/B_GENE
. O O

As O O
one O B_NUMBER[MEASURE]/B_PERSON
can O O
note O O
, O O
there O O
is O O
a O O
high O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
shared O O
polymorphisms O B_GENE
between O O
species O B_BIO/B_PERSON
, O O
and O O
no O O
fixed O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
them O O
suggesting O O
either O O
the O O
persistence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ancestral O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphisms O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
of O O
introgression O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
. O O

In O O
fact O O
, O O
there O O
is O O
one O O
shared O O
haplotype O O
between O O
the O O
two O O
species O O
( O O
IPO13 O O
, O O
WPO10 O O
and O O
WPO19 O O
) O O
and O O
three O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
sequences O O
( O O
WAC02 O O
, O O
WPO13 O O
and O O
WPO14 O O
) O O
which O O
show O O
only O O
one O O
nucleotide O O
difference O O
to O O
" O O
typical O O
" O O
L B B_SPECIES[BIO]/B_LOCATION
. I I_SPECIES[BIO]/I_LOCATION
intermedia I I_SPECIES[BIO]/I_LOCATION
haplotypes O O
( O O
see O O
also O O
below O O
) O O
. O O

Genealogy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
period O B_LOCATION
sequences O I_LOCATION

A O O
phylogenetic O O
analysis O O
of O O
the O O
period O O
gene O O
sequences O O
from O O
L B B_PERSON/B_LOCATION
. I I_PERSON/I_LOCATION
intermedia I I_PERSON/I_LOCATION
and O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
was O O
carried O O
out O O
with O O
the O O
Minimum O O
Evolution O O
method O O
using O O
the O O
Kimura O O
2 O O
- O O
parameter O O
distance O O
( O O
Fig O O
3 O O
) O O
. O O

A O O
sequence O O
from O O
L B B_SPECIES[BIO]/B_MEASURE
. I I_SPECIES[BIO]/I_MEASURE
umbratilis I I_SPECIES[BIO]/I_MEASURE
, O O
a O O
related O O
species O O
from O O
the O O
same O O
subgenus O O
Nyssomyia O O
, O O
was O O
used O O
as O O
outgroup O O
[ O O
24 O O
] O O
. O O

The O O
tree O O
shows O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
whitmani I I_SPECIES[BIO]
as O O
non O O
- O O
monophyletic O O
. O O

However O O
, O O
despite O O
the O O
low O O
bootstrap O O
values O O
, O O
which O O
are O O
below O O
50 O O
% O O
in O O
most O O
cases O O
, O O
there O O
is O O
a O O
large O O
group O O
that O O
contains O O
most O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
sequences O O
and O O
a O O
second O O
large O O
group O O
with O O
most O O
L B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. I B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
whitmani I B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
sequences O O
. O O

A O O
few O B_MEASURE/B_PERSON
other O I_MEASURE/I_PERSON
sequences O I_MEASURE/I_PERSON
are O O
clustered O O
outside O O
these O O
two O B_LOCATION
main O I_LOCATION
groups O I_LOCATION
. O O

It O O
is O O
interesting O O
to O O
note O O
that O O
there O O
are O O
three O O
L B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
. I I_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
whitmani I I_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
alleles O O
( O O
WAC2 O O
, O O
WPO13 O O
and O O
WPO14 O O
) O O
inside O O
L B B_PERSON/B_LOCATION
. I I_PERSON/I_LOCATION
intermedia I I_PERSON/I_LOCATION
main O O
group O O
, O O
as O O
well O O
as O O
one O O
L B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. I I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
intermedia I I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
allele O O
( O O
ICP16 O O
) O O
inside O O
the O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
main O O
group O O
. O O

In O O
addition O O
, O O
a O O
second O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
intermedia I I_SPECIES[BIO]/I_PERSON
allele O O
( O O
IPO13 O O
) O O
is O O
a O O
shared O O
haplotype O O
between O O
the O O
two O O
species O O
as O O
mentioned O O
above O O
. O O

Again O O
, O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggest O O
either O O
the O O
persistence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ancestral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polymorphisms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
the O O
occurrence O B_DISEASE/B_MEASURE
of O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_BIO/B_PERSON
species O I_BIO/I_PERSON
. O O

Very O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
obtained O O
using O O
the O O
maximum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
likelihood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
implemented O O
in O O
PAUP O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
0b10 O B_MEASURE/B_ORGANIZATION
software O I_MEASURE/I_ORGANIZATION
[ O O
31 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

As O O
mentioned O O
before O O
, O O
there O O
is O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intragenic O B_DISEASE_ADJECTIVE[DISEASE]
recombination O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
per O O
gene O B_GENE
fragment O I_GENE
of O O
both O O
species O B_BIO/B_GENE
( O O
see O O
Table O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
) O O
and O O
for O O
that O O
reason O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
bifurcating O O
tree O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
shown O O
in O O
Fig O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
to O O
be O O
viewed O O
with O O
caution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
as O O
different O B_DISEASE/B_LOCATION
regions O I_DISEASE/I_LOCATION
of O O
the O O
gene O B_GENE/B_BIO
might O O
have O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
phylogenetic O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
histories O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
[ O O
32 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Therefore O O
, O O
we O O
constructed O O
Minimum O B_GENE/B_BIO
Evolution O I_GENE/I_BIO
trees O I_GENE/I_BIO
with O O
the O O
two O B_NUMBER[MEASURE]/B_LOCATION
most O O
polymorphic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
non O O
- O O
recombining O O
blocks O B_LOCATION/B_PERSON
of O O
the O O
per O O
gene O B_GENE/B_LOCATION
fragment O I_GENE/I_LOCATION
identified O O
using O O
the O O
Hudson O B_PERSON
and O O
Kaplan O B_PERSON
[ O O
33 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
DNAsp O B_GENE/B_MEASURE
4 O I_GENE/I_MEASURE
. O O
1 O B_MEASURE/B_ORGANIZATION
program O I_MEASURE/I_ORGANIZATION
[ O O
34 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

We O O
did O O
not O O
observed O O
major O O
changes O O
in O O
the O O
genealogy O O
of O O
the O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
per O O
sequences O O
, O O
especially O O
regarding O O
the O O
five O O
haplotypes O O
( O O
ICP16 O O
, O O
IPO13 O O
, O O
WAC2 O O
, O O
WPO13 O O
and O O
WPO14 O O
) O O
that O O
clearly O O
cluster O O
with O O
sequences O O
of O O
the O O
other O O
species O O
( O O
data O O
not O O
shown O O
) O O
. O O

Finally O O
, O O
a O O
haplotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
estimated O O
from O O
per O O
sequences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
using O O
statistical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
parsimony O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
as O O
described O O
by O O
Templeton O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O O
. O O

[ O O
35 O B_MEASURE
] O I_MEASURE
and O O
implemented O O
in O O
the O O
TCS1 O B_GENE/B_MEASURE
. O O
21 O B_MEASURE/B_ORGANIZATION
software O I_MEASURE/I_ORGANIZATION
[ O I_MEASURE/I_ORGANIZATION
36 O I_MEASURE/I_ORGANIZATION
] O I_MEASURE/I_ORGANIZATION
( O O
Fig O B_MEASURE
4 O I_MEASURE
) O O
. O O

A O O
small O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
ambiguities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
resolved O O
as O O
suggested O O
by O O
Crandall O B_PERSON/B_LOCATION
and O O
Templeton O B_PERSON
[ O O
37 O B_TIME[MEASURE]/B_PERSON
] O B_TIME[MEASURE]/I_PERSON
. O O

The O O
haplotype O O
network O O
shows O O
connections O O
between O O
sequences O O
from O O
each O O
species O O
, O O
separating O O
most O O
of O O
the O O
sequences O O
of O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
in O O
two O O
groups O O
. O O

No O O
intraspecific O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
geographical O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structuring O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
. O O

Once O O
again O O
, O O
some O O
of O O
the O O
L B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whitmani I B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O O
( O O
WAC2 O O
, O O
WAC10 O O
, O O
WPO13 O O
and O O
WPO14 O O
) O O
appear O O
more O O
closely O O
related O O
to O O
L B B_SPECIES[BIO]/B_TIME[MEASURE]
. I I_SPECIES[BIO]/I_TIME[MEASURE]
intermedia I I_SPECIES[BIO]/I_TIME[MEASURE]
haplotypes O O
. O O

In O O
addition O O
, O O
one O O
L B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. I I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
intermedia I I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
allele O O
( O O
ICP16 O O
) O O
is O O
connected O O
by O O
a O O
small O O
number O O
of O O
mutations O O
to O O
some O O
of O O
the O O
main O O
L B B_SPECIES[BIO]/B_GENE
. I I_SPECIES[BIO]/I_GENE
whitmani I I_SPECIES[BIO]/I_GENE
haplotypes O O
and O O
IPO13 O O
is O O
a O O
shared O O
haplotype O O
between O O
the O O
two O O
species O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
confirm O O
the O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
putative O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introgressed O O
sequences O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
indicated O O
by O O
the O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reconstructions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

LD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

We O O
tested O O
the O O
hypothesis O O
of O O
gene O O
flow O O
between O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
whitmani I I_SPECIES[BIO]
using O O
a O O
method O O
based O O
on O O
linkage O O
disequilibrium O O
( O O
LD O O
) O O
developed O O
by O O
Machado O O
et O O
al O O
. O O

[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
38 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
x O O
is O O
the O O
difference O B_MEASURE/B_LOCATION
between O O
the O O
average O B_MEASURE/B_LOCATION
LD O B_MEASURE/I_LOCATION
found O O
among O O
all O O
pairs O B_PERSON/B_LOCATION
of O O
shared O B_GENE/B_LOCATION
polymorphisms O I_GENE/I_LOCATION
( O O
DSS O B_LOCATION/B_ORGANIZATION
) O O
between O O
the O O
two O B_PERSON/B_LOCATION
species O I_PERSON/I_LOCATION
and O O
the O O
average O B_MEASURE/B_PERSON
LD O I_MEASURE/I_PERSON
among O O
all O O
pairs O B_PERSON/B_LOCATION
of O O
sites O B_GENE
for O O
which O O
one O B_PERSON/B_NUMBER[MEASURE]
member O B_PERSON/I_NUMBER[MEASURE]
is O O
a O O
shared O O
polymorphism O B_GENE/B_MEASURE
and O O
the O O
other O B_SEQUENCE[MEASURE]/B_LOCATION
is O O
an O O
exclusive O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
polymorphism O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DSX O B_LOCATION
) O O
. O O

In O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
tend O O
to O O
be O O
positive O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
see O O
[ O O
38 O B_MEASURE/B_LOCATION
] O O
for O O
more O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
details O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Because O O
of O O
limitations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
the O O
total O B_MEASURE
number O I_MEASURE
of O O
sequences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
could O O
be O O
handled O O
by O O
the O O
WH O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
could O O
not O O
perform O O
the O O
simulations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
all O O
sequences O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
we O O
carried O O
out O O
the O O
LD O O
test O O
of O O
introgression O O
between O O
each O O
pair O O
of O O
sympatric O O
populations O O
of O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_BIO/B_PERSON
. I I_BIO/I_PERSON
whitmani I I_BIO/I_PERSON
from O O
the O O
localities O O
of O O
Posse O O
, O O
Afonso O O
Claudio O O
and O O
Corte O O
de O O
Pedra O O
. O O

The O O
input O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
files O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
prepared O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
using O O
the O O
values O B_MEASURE
of O O
recombination O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
and O O
linkage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disequilibrium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
calculated O O
by O O
the O O
SITES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
30 O B_TIME[MEASURE]
] O O
for O O
each O O
population O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
not O O
shown O O
) O O
. O O

Although O O
no O O
significant O O
values O O
were O O
found O O
for O O
the O O
smaller O O
samples O O
of O O
Afonso O O
Claudio O O
and O O
Corte O O
de O O
Pedra O O
, O O
the O O
results O O
( O O
Table O O
5 O O
) O O
present O O
evidence O O
for O O
introgression O O
in O O
the O O
period O O
gene O O
in O O
both O O
directions O O
( O O
from O O
L B B_SPECIES[BIO]/B_LOCATION
. I B_SPECIES[BIO]/I_LOCATION
intermedia I B_SPECIES[BIO]/I_LOCATION
to O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
and O O
vice O O
- O O
versa O O
) O O
in O O
the O O
locality O O
of O O
Posse O O
. O O

Isolation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
Migration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

To O O
further O O
examine O O
the O O
gene O O
flow O O
between O O
L B B_BIO
. I I_BIO
intermedia I I_BIO
and O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
whitmani I I_SPECIES[BIO]
we O O
used O O
the O O
IM O O
software O O
[ O O
39 O O
] O O
. O O

The O O
Isolation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
Migration O B_LOCATION/B_PERSON
model O I_LOCATION/I_PERSON
has O O
six O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
demographic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
parameters O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
include O O
two O B_MEASURE/B_PERSON
migration O B_MEASURE/I_PERSON
rates O B_MEASURE/I_PERSON
, O O
one O B_NUMBER[MEASURE]/B_PERSON
for O O
each O O
population O B_PERSON/B_LOCATION
. O O

The O O
IM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
estimates O O
the O O
posterior O B_MEASURE
probability O I_MEASURE
for O O
each O O
of O O
the O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
fitting O O
the O O
Isolation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Migration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
assumptions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
that O O
the O O
loci O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
studied O O
do O O
not O O
have O O
internal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
recombination O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Therefore O O
, O O
we O O
identified O O
four O B_NUMBER[MEASURE]/B_ENT
different O I_NUMBER[MEASURE]/I_ENT
non O O
- O O
recombining O O
blocks O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
our O O
fragment O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
per O B_GENE/B_DISEASE
, O O
which O O
were O O
then O O
treated O O
as O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
loci O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
four O B_NUMBER[MEASURE]
- O O
gametes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
33 O B_NUMBER[MEASURE]
] O O
implemented O O
in O O
DnaSP4 O B_GENE
. O O
1 O B_MEASURE
was O O
used O O
for O O
the O O
identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
possible O B_DISEASE/B_BIO
recombination O I_DISEASE/I_BIO
events O I_DISEASE/I_BIO
. O O

Since O O
the O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
estimates O O
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
a O O
pair O B_PERSON/B_LOCATION
of O O
closely O O
related O O
populations O B_LOCATION/B_BIO
or O O
species O B_BIO/B_GENE
, O O
all O O
sequences O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
each O O
species O B_BIO/B_GENE
were O O
used O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

We O O
performed O O
MCMC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
runs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
the O O
IM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
with O O
different O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seed O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
order O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
guarantee O O
convergence O B_TIME[MEASURE]/B_PERSON
of O O
the O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Maximum O O
likelihood O O
estimates O O
of O O
migration O O
parameters O O
revealed O O
a O O
non O O
- O O
zero O O
value O O
for O O
both O O
species O O
, O O
m1 O O
= O O
1 O O
. O O
398 O O
and O O
m2 O O
= O O
1 O O
. O O
014 O O
( O O
m1 O O
- O O
from O O
L B B_BIO/B_LOCATION
. I I_BIO/I_LOCATION
whitmani I I_BIO/I_LOCATION
towards O O
L B B_LOCATION/B_PERSON
. I I_LOCATION/I_PERSON
intermedia I I_LOCATION/I_PERSON
; O O
m2 O O
- O O
from O O
L B B_BIO
. I I_BIO
whitmani I I_BIO
towards O O
L B B_LOCATION/B_PERSON
. I I_LOCATION/I_PERSON
intermedia I I_LOCATION/I_PERSON
) O O
. O O

Fig O O
5 O O
shows O O
the O O
posterior O O
distributions O O
for O O
migration O O
rates O O
and O O
reveals O O
a O O
null O O
probability O O
for O O
the O O
absence O O
of O O
migration O O
from O O
L B B_BIO/B_LOCATION
. I I_BIO/I_LOCATION
whitmani I I_BIO/I_LOCATION
towards O O
L B B_LOCATION
. I I_LOCATION
intermedia I I_LOCATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
migration O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
opposite O B_LOCATION
direction O I_LOCATION
is O O
not O O
included O O
in O O
the O O
95 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
values O B_MEASURE/B_DISEASE
range O O
from O O
0 O B_MEASURE
. O O
222 O B_MEASURE
to O O
8 O B_MEASURE
. O O
898 O B_MEASURE
) O O
, O O
thus O O
supporting O O
the O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
migration O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
directions O B_LOCATION/B_PERSON
. O O

The O O
conversion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
migration O B_MEASURE
rate O I_MEASURE
estimate O I_MEASURE
to O O
population O B_MEASURE/B_PERSON
migration O I_MEASURE/I_PERSON
rate O I_MEASURE/I_PERSON
per O O
generation O B_MEASURE/B_LOCATION
( O O
m1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
m2 O B_PROTEIN[GENE]
) O O
is O O
not O O
accurate O B_DISEASE_ADJECTIVE[DISEASE]
when O O
the O O
population O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
size O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
based O O
on O O
a O O
single O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locus O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
the O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
of O O
the O O
migrant O B_MEASURE
number O I_MEASURE
per O O
generation O B_TIME[MEASURE]/B_BIO
for O O
both O O
species O B_BIO
was O O
very O O
close O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
Nm O B_MEASURE/B_LOCATION
estimate O I_MEASURE/I_LOCATION
based O O
on O O
Fst O B_MEASURE
values O I_MEASURE
( O O
Nm O B_PROTEIN[GENE]/B_DISEASE
~ O O
0 O B_MEASURE
. O O
49 O B_MEASURE
in O O
Table O B_MEASURE
4 O I_MEASURE
, O O
m1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
~ O O
0 O B_MEASURE
. O O
52 O B_MEASURE
and O O
m2 O B_PROTEIN[GENE]/B_LOCATION
~ O O
0 O B_MEASURE
. O O
34 O B_MEASURE
) O O
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

There O O
is O O
some O O
evidence O O
that O O
L B B_SPECIES[BIO]/B_DISEASE
. I I_SPECIES[BIO]/I_DISEASE
intermedia I I_SPECIES[BIO]/I_DISEASE
and O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
whitmani I I_SPECIES[BIO]
might O O
represent O O
sibling O O
- O O
species O O
complexes O O
in O O
Brazil O O
. O O

Lutzomyia B B_BIO/B_MEASURE
neivai I B_BIO/I_MEASURE
Pinto O O
1926 O O
, O O
a O O
sibling O O
of O O
L B B_SPECIES[BIO]/B_LOCATION
. I B_SPECIES[BIO]/I_LOCATION
intermedia I B_SPECIES[BIO]/I_LOCATION
is O O
found O O
in O O
parts O O
of O O
Southern O O
and O O
Western O O
Brazil O O
and O O
some O O
other O O
countries O O
of O O
South O O
America O O
[ O O
40 O O
] O O
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
include O O
populations O B_LOCATION/B_BIO
of O O
this O O
species O B_BIO/B_MEASURE
. O O

In O O
the O O
case O O
of O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
whitmani I I_SPECIES[BIO]
, O O
mitochondrial O O
data O O
[ O O
3 O O
, O O
6 O O
] O O
indicates O O
three O O
main O O
lineages O O
in O O
Brazil O O
: O O
an O O
Amazonian O O
group O O
, O O
a O O
North O O
- O O
South O O
group O O
and O O
a O O
Northeast O O
group O O
. O O

We O O
did O O
not O O
find O O
strong O O
evidence O O
of O O
a O O
geographical O O
differentiation O O
in O O
the O O
period O O
gene O O
among O O
populations O O
of O O
L B B_SPECIES[BIO]/B_LOCATION
. I B_SPECIES[BIO]/I_LOCATION
whitmani I B_SPECIES[BIO]/I_LOCATION
although O O
one O O
of O O
the O O
pairwise O O
Fst O O
comparisons O O
( O O
Posse O O
x O O
Ilh O O
e O O
us O O
) O O
was O O
significant O O
at O O
the O O
5 O O
% O O
level O O
. O O

When O O
we O O
compare O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
intermedia I I_SPECIES[BIO]/I_PERSON
and O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
, O O
we O O
find O O
a O O
highly O O
significant O O
Fst O O
value O O
( O O
0 O O
. O O
3373 O O
) O O
, O O
which O O
is O O
however O O
smaller O O
than O O
that O O
observed O O
for O O
the O O
period O O
gene O O
between O O
sympatric O O
siblings O O
of O O
Lutzomyia B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
longipalpis I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fst O O
= O O
0 O O
. O O
3952 O O
) O O
[ O O
23 O O
] O O
, O O
a O O
complex O O
of O O
cryptic O O
species O O
that O O
are O O
vectors O O
of O O
American O O
visceral O O
leishmaniasis O O
. O O

Therefore O O
, O O
despite O O
the O O
presence O O
of O O
diagnostic O O
morphological O O
characters O O
to O O
identify O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
intermedia I I_SPECIES[BIO]/I_PERSON
and O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
[ O O
1 O O
] O O
the O O
level O O
of O O
molecular O O
divergence O O
in O O
period O O
is O O
not O O
as O O
high O O
as O O
the O O
cryptic O O
L B B_SPECIES[BIO]/B_NUMBER[MEASURE]
. I I_SPECIES[BIO]/I_NUMBER[MEASURE]
longipalpis I I_SPECIES[BIO]/I_NUMBER[MEASURE]
siblings O O
. O O

Even O O
though O O
it O O
is O O
hard O O
to O O
distinguish O O
introgression O O
from O O
the O O
persistence O O
of O O
ancestral O O
polymorphisms O O
, O O
a O O
test O O
of O O
gene O O
flow O O
based O O
on O O
the O O
signature O O
introgression O O
leaves O O
on O O
the O O
patterns O O
of O O
linkage O O
disequilibrium O O
[ O O
38 O O
] O O
as O O
well O O
as O O
simulations O O
that O O
fit O O
the O O
" O O
Isolation O O
with O O
Migration O O
" O O
model O O
to O O
the O O
data O O
suggest O O
that O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
intermedia I I_SPECIES[BIO]/I_PERSON
and O O
L B B_BIO
. I I_BIO
whitmani I I_BIO
might O O
be O O
exchanging O O
alleles O O
at O O
the O O
per O O
locus O O
. O O

This O O
is O O
further O O
supported O O
by O O
the O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
shared O O
haplotypes O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
two O B_BIO/B_PERSON
species O I_BIO/I_PERSON
in O O
Posse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
very O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sequences O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
all O O
sympatric O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
populations O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
is O O
mounting O O
evidence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plays O O
a O O
major O B_ENT/B_LOCATION
role O I_ENT/I_LOCATION
in O O
the O O
evolution O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
closely O O
related O O
insect O B_BIO/B_GENE
vector O I_BIO/I_GENE
species O I_BIO/I_GENE
. O O

Introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
vectors O B_PROTEIN[GENE]/B_PERSON
may O O
have O O
important O B_DISEASE_ADJECTIVE[DISEASE]
epidemiological O I_DISEASE_ADJECTIVE[DISEASE]
consequences O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
flow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
loci O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
affect O O
vectorial O B_DISEASE/B_ORGANISM_FUNCTION
capacity O I_DISEASE/I_ORGANISM_FUNCTION
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
those O O
controlling O O
host O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
susceptibility O B_DISEASE/B_MEASURE
to O O
parasite O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
can O O
change O O
the O O
transmission O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
consequently O O
make O O
the O O
disease O B_DISEASE/B_BIO
control O O
a O O
harder O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Introgression O O
of O O
genes O O
that O O
control O O
adaptation O O
to O O
particular O O
types O O
of O O
environment O O
can O O
also O O
have O O
a O O
major O O
impact O O
on O O
the O O
spread O O
of O O
vector O O
- O O
borne O O
diseases O O
as O O
was O O
proposed O O
for O O
the O O
major O O
African O O
malaria O O
vector O O
Anopheles B B_SPECIES[BIO]/B_LOCATION
gambiae I I_SPECIES[BIO]/I_LOCATION
[ O O
41 O O
] O O
. O O

The O O
same O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
said O O
about O O
genes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
controlling O O
insecticide O B_DISEASE/B_ORGANISM_FUNCTION
resistance O I_DISEASE/I_ORGANISM_FUNCTION
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
Weill O B_LOCATION/B_PERSON
et O I_LOCATION/I_PERSON
al O O
. O O

[ O O
42 O O
] O O
found O O
a O O
kdr O O
mutation O O
responsible O O
for O O
pyrethroid O O
resistance O O
in O O
the O O
Mopti O O
form O O
of O O
Anopheles B B_SPECIES[BIO]/B_LOCATION
gambiae I I_SPECIES[BIO]/I_LOCATION
, O O
a O O
normally O O
susceptible O O
taxon O O
of O O
this O O
species O O
complex O O
. O O

Sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
that O O
this O O
resistant O B_GENE/B_BIO
allele O I_GENE/I_BIO
probably O O
originates O O
through O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
Savanna O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
L B B_PERSON/B_COLOR
. I I_PERSON/I_COLOR
intermedia I I_PERSON/I_COLOR
and O O
L B B_BIO/B_PERSON
. I I_BIO/I_PERSON
whitmani I I_BIO/I_PERSON
are O O
closely O O
related O O
and O O
only O O
distinguished O O
by O O
a O O
few O O
morphological O O
differences O O
, O O
they O O
do O O
show O O
differentiation O O
in O O
some O O
other O O
important O O
traits O O
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
in O O
Posse O B_LOCATION/B_PERSON
, O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
localities O B_LOCATION/B_ENT
we O O
studied O O
, O O
the O O
two O B_BIO
species O I_BIO
show O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
abundance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
year O B_TIME[MEASURE]/B_LOCATION
. O O

L B B_BACTERIUM[BIO]/B_DISEASE
. I I_BACTERIUM[BIO]/I_DISEASE
intermedia I I_BACTERIUM[BIO]/I_DISEASE
is O O
more O O
abundant O O
in O O
the O O
summer O O
while O O
L B B_BACTERIUM[BIO]/B_PERSON
. I I_BACTERIUM[BIO]/I_PERSON
whitmani I I_BACTERIUM[BIO]/I_PERSON
is O O
more O O
frequent O O
in O O
the O O
winter O O
months O O
[ O O
2 O O
] O O
. O O

They O O
also O O
show O O
differences O O
in O O
microhabitat O O
preferences O O
, O O
L B B_PERSON
. I I_PERSON
intermedia I I_PERSON
being O O
more O O
common O O
in O O
the O O
peridomestic O O
area O O
while O O
L B B_BACTERIUM[BIO]/B_PERSON
. I I_BACTERIUM[BIO]/I_PERSON
whitmani I I_BACTERIUM[BIO]/I_PERSON
is O O
found O O
mainly O O
in O O
the O O
surrounding O O
forest O O
[ O O
2 O O
] O O
. O O

In O O
addition O O
, O O
the O O
two O O
species O O
show O O
marked O O
differences O O
in O O
their O O
tendencies O O
to O O
bite O O
humans B B_BIO
in O O
the O O
early O O
morning O O
, O O
with O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
showing O O
higher O O
feeding O O
rates O O
than O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
intermedia I I_SPECIES[BIO]/I_PERSON
[ O O
26 O O
] O O
. O O

Therefore O O
, O O
despite O O
the O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
gene O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
this O O
locality O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O O
there O O
are O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ecological O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
behavioral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
two O B_BIO/B_PERSON
species O I_BIO/I_PERSON
in O O
Posse O B_LOCATION/B_PERSON
suggesting O O
that O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flow O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
probably O O
rather O O
limited O O
in O O
loci O B_LOCATION
controlling O O
these O O
traits O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Hence O O
, O O
it O O
is O O
yet O O
not O O
clear O O
whether O O
introgression O O
has O O
played O O
an O O
important O O
role O O
in O O
the O O
evolution O O
of O O
L B B_SPECIES[BIO]/B_LOCATION
. I I_SPECIES[BIO]/I_LOCATION
intermedia I I_SPECIES[BIO]/I_LOCATION
and O O
L B B_BIO
. I I_BIO
whitmani I I_BIO
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
other O B_NUMBER[MEASURE]/B_PERSON
genes O B_NUMBER[MEASURE]/I_PERSON
might O O
help O O
clarify O O
the O O
issue O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Evidence O O
for O O
introgression O O
between O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_BIO
. I I_BIO
whitmani I I_BIO
obtained O O
using O O
mitochondrial O O
DNA O O
[ O O
4 O O
] O O
seems O O
to O O
be O O
corroborated O O
by O O
our O O
data O O
on O O
the O O
period O O
gene O O
, O O
a O O
nuclear O O
marker O O
. O O

Nevertheless O O
, O O
considering O O
that O O
period O B_TIME[MEASURE]/B_GENE
is O O
potentially O O
involved O O
in O O
reproductive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
isolation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
might O O
be O O
, O O
therefore O O
, O O
less O O
prone O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
introgression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
the O O
" O O
average O B_TIME[MEASURE]/B_PERSON
" O O
gene O B_PERSON/B_GENE
[ O O
43 O B_TIME[MEASURE]/B_LOCATION
] O B_TIME[MEASURE]/I_LOCATION
, O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
much O O
higher O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
of O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flow O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
the O O
two O B_BIO/B_PERSON
species O I_BIO/I_PERSON
occur O O
at O O
other O B_TIME[MEASURE]/B_PERSON
genes O I_TIME[MEASURE]/I_PERSON
. O O

It O O
might O O
, O O
on O O
the O O
other O O
hand O O
, O O
suggest O O
that O O
this O O
behavioral O O
gene O O
, O O
or O O
at O O
least O O
the O O
fragment O O
we O O
analyzed O O
, O O
did O O
not O O
play O O
a O O
role O O
in O O
speciation O O
between O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_BIO
. I I_BIO
whitmani I I_BIO
. O O

In O O
fact O O
the O O
same O O
has O O
been O O
suggested O O
for O O
some O O
Drosophila O O
species O O
[ O O
44 O O
] O O
despite O O
per O O
' O O
s O O
role O O
controlling O O
lovesong O O
and O O
mating O O
rhythm O O
differences O O
between O O
D B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
melanogaster I I_SPECIES[BIO]/I_PERSON
and O O
D B B_SPECIES[BIO]
. I I_SPECIES[BIO]
simulans I I_SPECIES[BIO]
[ O O
13 O O
- O O
16 O O
] O O
. O O

Although O O
the O O
evidence O O
for O O
introgression O O
in O O
the O O
per O O
gene O O
between O O
L B B_SPECIES[BIO]
. I I_SPECIES[BIO]
intermedia I I_SPECIES[BIO]
and O O
L B B_BIO
. I I_BIO
whitmani I I_BIO
is O O
not O O
overwhelming O O
, O O
it O O
does O O
indicate O O
the O O
need O O
to O O
extend O O
this O O
analysis O O
to O O
other O O
loci O O
in O O
the O O
future O O
. O O

We O O
are O O
currently O O
isolating O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
molecular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
markers O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
two O B_BIO/B_LOCATION
species O B_BIO/I_LOCATION
to O O
carry O O
out O O
a O O
multi O B_NUMBER[MEASURE]/B_ENT
- O O
locus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O O
39 O B_TIME[MEASURE]/B_LOCATION
] O O
that O O
might O O
help O O
determining O O
how O O
much O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
differentiation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
there O O
is O O
across O O
the O O
genome O B_BIO/B_LOCATION
of O O
these O O
two O B_NUMBER[MEASURE]/B_LOCATION
very O O
important O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
leishmaniasis O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
vectors O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Sand O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
fly O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
samples O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION

Sand O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
fly O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
samples O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
used O O
in O O
this O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
all O O
the O O
F1 O B_PERSON/B_ORGANIZATION
generation O I_PERSON/I_ORGANIZATION
from O O
wild O B_PERSON/B_BIO
collected O O
females O B_PERSON/B_BIO
from O O
the O O
Brazilian O B_LOCATION
localities O I_LOCATION
of O O
Posse O B_PERSON/B_LOCATION
( O O
Petr O B_PERSON/B_LOCATION
o O I_PERSON/I_LOCATION
polis O I_PERSON/I_LOCATION
, O O
Rio O B_LOCATION/B_PERSON
de O I_LOCATION/I_PERSON
Janeiro O I_LOCATION/I_PERSON
State O I_LOCATION/I_PERSON
, O O
22 O B_TIME[MEASURE]
degrees O I_TIME[MEASURE]
30 O I_TIME[MEASURE]
' O O
S O B_MEASURE
43 O I_MEASURE
degrees O I_MEASURE
10 O I_MEASURE
' O O
W O B_OTHER/B_LOCATION
) O O
, O O
Jacarepagu O B_PERSON/B_LOCATION
a O O
( O O
Rio O B_LOCATION/B_PERSON
de O B_LOCATION/I_PERSON
Janeiro O B_LOCATION/I_PERSON
, O O
Rio O B_LOCATION/B_PERSON
de O I_LOCATION/I_PERSON
Janeiro O I_LOCATION/I_PERSON
State O I_LOCATION/I_PERSON
, O O
22 O B_TIME[MEASURE]
degrees O I_TIME[MEASURE]
55 O I_TIME[MEASURE]
' O O
S O B_TIME[MEASURE]
43 O I_TIME[MEASURE]
degrees O I_TIME[MEASURE]
21 O I_TIME[MEASURE]
' O O
W O B_OTHER/B_LOCATION
) O O
, O O
Afonso O B_PERSON/B_LOCATION
Claudio O I_PERSON/I_LOCATION
( O O
Esp O B_PERSON/B_LOCATION
i O O
rito O B_LOCATION
Santo O I_LOCATION
State O I_LOCATION
, O O
20 O B_TIME[MEASURE]
degrees O I_TIME[MEASURE]
04 O I_TIME[MEASURE]
' O O
S O B_MEASURE/B_LOCATION
41 O I_MEASURE/I_LOCATION
degrees O I_MEASURE/I_LOCATION
07 O I_MEASURE/I_LOCATION
' O O
W O B_OTHER/B_LOCATION
) O O
, O O
Corte O B_LOCATION/B_PERSON
de O B_LOCATION/I_PERSON
Pedra O B_LOCATION/I_PERSON
( O O
Presidente O B_PERSON/B_LOCATION
Tancredo O B_PERSON/I_LOCATION
Neves O B_PERSON/I_LOCATION
, O O
Bahia O B_LOCATION/B_PERSON
State O I_LOCATION/I_PERSON
, O O
13 O B_TIME[MEASURE]
degrees O I_TIME[MEASURE]
27 O I_TIME[MEASURE]
' O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
39 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
degrees O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
25 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
' O O
W O B_OTHER/B_LOCATION
) O O
and O O
Ilh O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
e O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
us O O
( O O
Bahia O B_LOCATION/B_PERSON
State O I_LOCATION/I_PERSON
, O O
14 O B_TIME[MEASURE]
degrees O I_TIME[MEASURE]
50 O I_TIME[MEASURE]
' O O
S O B_MEASURE/B_LOCATION
39 O I_MEASURE/I_LOCATION
degrees O I_MEASURE/I_LOCATION
06 O I_MEASURE/I_LOCATION
' O O
W O B_OTHER/B_LOCATION
) O O
. O O

L B B_BACTERIUM[BIO]/B_PERSON
. I I_BACTERIUM[BIO]/I_PERSON
intermedia I I_BACTERIUM[BIO]/I_PERSON
and O O
L B B_BACTERIUM[BIO]/B_PERSON
. I I_BACTERIUM[BIO]/I_PERSON
whitmani I I_BACTERIUM[BIO]/I_PERSON
were O O
identified O O
according O O
to O O
Young O O
and O O
Duncan O O
[ O O
1 O O
] O O
. O O

The O O
progeny O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
each O O
wild O B_PERSON/B_TIME[MEASURE]
caught O O
female O B_PERSON/B_BIO
was O O
raised O O
separately O O
according O O
to O O
Souza O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

[ O O
45 O O
] O O
and O O
only O O
one O O
F1 O O
male O O
of O O
each O O
female O O
was O O
used O O
for O O
the O O
molecular O O
analysis O O
, O O
which O O
included O O
68 O O
individuals O O
of O O
L B B_SPECIES[BIO]/B_LOCATION
. I I_SPECIES[BIO]/I_LOCATION
intermedia I I_SPECIES[BIO]/I_LOCATION
( O O
12 O O
from O O
Afonso O O
Claudio O O
, O O
18 O O
from O O
Posse O O
, O O
20 O O
from O O
Corte O O
de O O
Pedra O O
and O O
18 O O
from O O
Jacarepagu O O
a O O
) O O
and O O
51 O O
individuals O O
of O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
( O O
12 O O
from O O
Afonso O O
Claudio O O
, O O
17 O O
from O O
Posse O O
, O O
3 O O
from O O
Corte O O
de O O
Pedra O O
and O O
19 O O
from O O
Ilh O O
e O O
us O O
) O O
. O O

Note O O
that O O
, O O
although O O
the O O
distribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
two O B_BIO
species O I_BIO
shows O O
considerable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
overlap O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
Eastern O B_LOCATION/B_MEASURE
Brazil O I_LOCATION/I_MEASURE
, O O
in O O
many O B_LOCATION
localities O I_LOCATION
only O O
one O B_SPECIES[BIO]/B_PERSON
species O I_SPECIES[BIO]/I_PERSON
is O O
found O O
or O O
is O O
far O O
more O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
than O O
the O O
other O B_SEQUENCE[MEASURE]/B_LOCATION
. O O

There O O
are O O
also O O
seasonal O B_LOCATION/B_DISEASE
and O O
microhabitat O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
abundance O B_MEASURE/B_LOCATION
between O O
them O O
in O O
areas O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sympatry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Genomic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
prepared O O
according O O
to O O
Jowett O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
46 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
slight O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
modifications O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
the O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
for O O
30 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cycles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
95 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
for O O
30 O B_LOCATION/B_ORGANIZATION
sec O I_LOCATION/I_ORGANIZATION
, O O
60 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
for O O
30 O B_MEASURE/B_LOCATION
sec O I_MEASURE/I_LOCATION
and O O
72 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
for O O
30 O B_LOCATION/B_ORGANIZATION
sec O I_LOCATION/I_ORGANIZATION
, O O
using O O
Abgene O B_GENE/B_PERSON
, O O
Amersham O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Biosciences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
Biotools O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reagents O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
according O O
to O O
manufacturers O B_PERSON
directions O I_PERSON
. O O

The O O
per O O
primer O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
: O O
5llper2 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
5 O B_NUMBER[MEASURE]
' O O
- O O
AGCATCCTTTTGTAGCAAAC O B_DISEASE/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
( O O
forward O O
) O O
and O O
3llper2 O B_NUMBER[MEASURE]
: O O
5 O B_NUMBER[MEASURE]
' O O
- O O
TCAGATGAACTCTTGCTGTC O B_PROTEIN[GENE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
' O O
( O O
reverse O O
) O O
. O O

These O O
primers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amplify O O
a O O
486 O B_GENE/B_LOCATION
bp O B_GENE/I_LOCATION
fragment O B_GENE/I_LOCATION
of O O
the O O
sand O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fly O I_BIO
per O O
gene O B_GENE/B_LOCATION
homologue O I_GENE/I_LOCATION
that O O
includes O O
part O B_MEASURE/B_LOCATION
of O O
the O O
PAS O B_LOCATION
/ O O
CLD O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domain O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
intron O B_GENE
( O O
58 O B_TIME[MEASURE]
bp O I_TIME[MEASURE]
) O O
and O O
the O O
beginning O B_MEASURE/B_LOCATION
of O O
the O O
perS O B_GENE
domain O I_GENE
[ O O
24 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

The O O
amplified O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
cloned O O
using O O
the O O
pMOSBlue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blunt O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ended O O
cloning O B_GENE/B_LOCATION
kit O B_GENE/I_LOCATION
( O O
Amersham O B_LOCATION/B_ORGANIZATION
Biosciences O B_LOCATION/I_ORGANIZATION
) O O
and O O
plasmid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
using O O
the O O
" O O
Flexiprep O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
" O O
Kit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Amersham O B_LOCATION/B_ORGANIZATION
Biosciences O I_LOCATION/I_ORGANIZATION
) O O
. O O

Cloned O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
sequenced O O
at O O
Funda O B_PERSON/B_LOCATION
c O I_PERSON/I_LOCATION
a O O
o O O
Oswaldo O B_LOCATION/B_PERSON
Cruz O I_LOCATION/I_PERSON
and O O
at O O
University O B_LOCATION/B_PERSON
of O O
Leicester O B_LOCATION
using O O
ABI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
377 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

With O O
the O O
exception O O
of O O
two O O
L B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
whitmani I I_SPECIES[BIO]/I_PERSON
individuals O O
from O O
Corte O O
de O O
Pedra O O
( O O
see O O
below O O
) O O
, O O
only O O
one O O
sequence O O
of O O
each O O
sand O O
fly O O
( O O
representing O O
one O O
of O O
the O O
two O O
possible O O
alleles O O
) O O
was O O
used O O
in O O
the O O
analysis O O
but O O
an O O
average O O
of O O
three O O
sequences O O
per O O
individual O O
were O O
obtained O O
in O O
order O O
to O O
check O O
possible O O
PCR O O
induced O O
mutations O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
PCR O B_GENE/B_MEASURE
fragments O I_GENE/I_MEASURE
were O O
also O O
sequenced O O
directly O O
in O O
some O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
same O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reason O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
the O O
case O O
of O O
the O O
two O O
L B B_BIO/B_PERSON
. I I_BIO/I_PERSON
whitmani I I_BIO/I_PERSON
mentioned O O
above O O
6 O O
and O O
9 O O
clones O O
were O O
sequenced O O
respectively O O
from O O
specimens O O
WCP01 O O
and O O
WCP03 O O
to O O
determine O O
both O O
alleles O O
simply O O
to O O
increase O O
the O O
size O O
of O O
this O O
small O O
sample O O
. O O

Negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
performed O O
for O O
all O O
amplification O B_PERSON
reactions O I_PERSON
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cloning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
sequencing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
repeated O O
for O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
individuals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
to O O
confirm O O
putative O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
introgressed O O
sequences O B_DISEASE/B_GENE
and O O
to O O
exclude O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
they O O
were O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
PCR O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contamination O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Finally O O
, O O
for O O
at O O
least O O
two O B_PERSON/B_NUMBER[MEASURE]
individuals O I_PERSON/I_NUMBER[MEASURE]
with O O
putative O B_GENE
introgressed O I_GENE
sequences O I_GENE
, O O
we O O
could O O
define O O
the O O
other O B_GENE/B_BIO
allele O B_GENE/I_BIO
from O O
additional O B_PERSON/B_ENT
clones O I_PERSON/I_ENT
( O O
not O O
included O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
which O O
showed O O
to O O
be O O
typical O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
species O B_BIO/B_PERSON
, O O
indicating O O
no O O
identification O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
problems O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

The O O
sequences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
submitted O O
to O O
GenBank O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
accession O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
numbers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
AY927062 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
AY927182 O B_MEASURE/B_LOCATION
) O O
. O O

Sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

The O O
preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
editing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
carried O O
out O O
using O O
the O O
Wisconsin O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Package O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Version O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
1 O B_MEASURE
, O O
Genetics O O
Computer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
GCG O B_ORGANIZATION/B_LOCATION
) O O
, O O
Madison O B_PERSON/B_ORGANIZATION
, O O
and O O
ClustalX O B_LOCATION/B_PERSON
[ O O
47 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
was O O
used O O
to O O
perform O O
the O O
multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
population O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
differentiation O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
between O O
populations O B_LOCATION/B_PERSON
were O O
carried O O
out O O
using O O
DNAsp4 O B_PROTEIN[GENE]/B_MEASURE
. O O
1 O B_MEASURE/B_ORGANIZATION
[ O I_MEASURE/I_ORGANIZATION
34 O I_MEASURE/I_ORGANIZATION
] O I_MEASURE/I_ORGANIZATION
and O O
ProSeq O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
48 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
softwares O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
while O O
Arlequin O B_PERSON
v O O
. O O

2 O O
. O O
0 O B_MEASURE
[ O O
49 O B_MEASURE
] O I_MEASURE
was O O
used O O
for O O
an O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
molecular O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variance O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AMOVA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
between O O
populations O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Minimum O B_LOCATION/B_PERSON
Evolution O I_LOCATION/I_PERSON
phylogenetic O I_LOCATION/I_PERSON
tree O I_LOCATION/I_PERSON
was O O
constructed O O
using O O
MEGA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O
1 O B_MEASURE/B_ORGANIZATION
software O I_MEASURE/I_ORGANIZATION
[ O O
50 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

The O O
haplotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
estimated O O
using O O
TCS1 O B_GENE/B_MEASURE
. O O
21 O B_MEASURE
[ O I_MEASURE
36 O I_MEASURE
] O I_MEASURE
. O O

Recombination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
linkage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disequilibrium O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
using O O
the O O
DNAsp4 O B_PROTEIN[GENE]/B_MEASURE
. O O
1 O B_MEASURE/B_ORGANIZATION
and O O
SITES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O O
30 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Linkage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disequilibrium O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
carried O O
out O O
by O O
the O O
WH O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O O
51 O B_MEASURE
, O O
52 O B_MEASURE
] O O
and O O
Markov O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Chain O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Monte O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Carlo O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
MCMC O B_LOCATION/B_ORGANIZATION
) O O
simulations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
isolation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
migration O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
using O O
the O O
algorithm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implemented O O
in O O
the O O
IM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
39 O B_MEASURE
] O I_MEASURE
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

CJM O B_PERSON/B_LOCATION
generate O O
and O O
analyzed O O
all O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
drafted O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

NAS O B_ORGANIZATION/B_PERSON
and O O
CAC O B_ORGANIZATION/B_LOCATION
collected O O
and O O
maintained O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sand O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fly O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O O

CPK O B_PERSON/B_LOCATION
helped O O
to O O
write O O
the O O
manuscript O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
supervised O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
CJM O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
during O O
her O O
stay O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
Leicester O B_LOCATION
. O O

AAP O B_PERSON/B_LOCATION
is O O
the O O
principal O B_PERSON
investigator O I_PERSON
, O O
participated O O
in O O
its O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
coordination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
and O O
helped O O
to O O
write O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

All O O
authors O B_PERSON/B_NUMBER[MEASURE]
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

Presence O O
of O O
antibodies O O
against O O
cyclic O O
citrullinated O O
peptides O O
in O O
patients B B_PERSON/B_BIO
with O O
' O O
rhupus O O
' O O
: O O
a O O
cross O O
- O O
sectional O O
study O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

' O O
Rhupus O B_DISEASE/B_GENE
' O O
is O O
a O O
rare O B_DISEASE/B_MEASURE
condition O I_DISEASE/I_MEASURE
sharing O O
features O B_ENT/B_DISEASE
of O O
rheumatoid O B_DISEASE
arthritis O I_DISEASE
( O O
RA O B_LOCATION/B_ORGANIZATION
) O O
and O O
systemic O B_DISEASE
lupus O I_DISEASE
erythematosus O I_DISEASE
( O O
SLE O B_LOCATION
) O O
. O O

If O O
rhupus O B_DISEASE
is O O
a O O
distinctive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
entity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
an O O
overlap O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
RA O B_DISEASE
and O O
SLE O B_DISEASE
or O O
a O O
subset O B_DISEASE
of O O
SLE O B_DISEASE/B_MEASURE
is O O
currently O O
debated O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
to O O
explore O O
the O O
prevalence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
against O O
cyclic O B_DISEASE/B_GENE
citrullinated O I_DISEASE/I_GENE
peptides O I_DISEASE/I_GENE
( O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
CCP O B_DISEASE/B_GENE
antibodies O I_DISEASE/I_GENE
) O O
in O O
rhupus O B_DISEASE/B_BIO
. O O

Patients B B_PERSON/B_LOCATION
meeting O O
American O O
College O O
of O O
Rheumatology O O
criteria O O
for O O
RA O O
, O O
SLE O O
, O O
or O O
both O O
were O O
included O O
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
and O O
radiographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
recorded O O
and O O
sera O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
searched O O
for O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
CCP O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
rheumatoid O B_GENE/B_DISEASE
factor O I_GENE/I_DISEASE
, O O
antinuclear O B_DISEASE/B_GENE
antibodies O B_DISEASE/I_GENE
, O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
extractable O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O O
double O B_MEASURE
- O O
stranded O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dsDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Seven O O
patients B B_PERSON
for O O
each O O
group O O
were O O
included O O
. O O

Clinical O O
and O O
serological O O
features O O
for O O
RA O O
or O O
SLE O O
were O O
similar O O
between O O
rhupus O O
and O O
RA O O
patients B B_PERSON/B_DISEASE
, O O
and O O
between O O
rhupus O O
and O O
SLE O O
patients B B_PERSON
, O O
respectively O O
. O O

Values O O
for O O
anti O O
- O O
CCP O O
antibodies O O
obtained O O
were O O
significantly O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
higher O O
in O O
RA O O
( O O
6 O O
/ O O
7 O O
) O O
and O O
rhupus O O
( O O
4 O O
/ O O
7 O O
) O O
than O O
in O O
SLE O O
patients B B_PERSON/B_BIO
( O O
0 O O
/ O O
7 O O
) O O
and O O
healthy O O
subjects O O
( O O
0 O O
/ O O
7 O O
) O O
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
rhupus O B_LOCATION/B_PERSON
is O O
an O O
overlap O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
RA O B_LOCATION
and O O
SLE O B_LOCATION/B_ORGANIZATION
, O O
because O O
highly O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantibodies O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
RA O B_DISEASE/B_LOCATION
( O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
CCP O B_LOCATION/B_ORGANIZATION
) O O
and O O
for O O
SLE O B_LOCATION/B_ORGANIZATION
( O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dsDNA O B_LOCATION/B_ORGANIZATION
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Sm O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
are O O
detected O O
in O O
coexistence O B_DISEASE/B_BIO
. O O

Introduction O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
clinical O B_DISEASE/B_MEASURE
coexistence O I_DISEASE/I_MEASURE
of O O
rheumatoid O B_DISEASE
arthritis O I_DISEASE
( O O
RA O B_LOCATION/B_ORGANIZATION
) O O
and O O
systemic O B_DISEASE
lupus O I_DISEASE
erythematosus O I_DISEASE
( O O
SLE O B_DISEASE/B_LOCATION
) O O
was O O
first O O
described O O
in O O
1969 O B_MEASURE
by O O
Kantor O B_PERSON
and O O
was O O
termed O O
' O O
rhupus O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
syndrome O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
' O O
by O O
Schur O B_PERSON
( O O
both O O
cited O O
in O O
[ O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
] O I_MEASURE/I_LOCATION
) O O
. O O

Since O O
then O O
, O O
fewer O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
100 O B_MEASURE
cases O I_MEASURE
of O O
rhupus O B_DISEASE/B_GENE
have O O
been O O
published O O
[ O O
1 O B_NUMBER[MEASURE]
- O O
3 O B_MEASURE
] O I_MEASURE
. O O

In O O
an O O
epidemiological O O
study O O
including O O
about O O
7 O O
, O O
000 O O
new O O
patients B B_PERSON/B_BIO
, O O
the O O
prevalence O O
of O O
RA O O
was O O
15 O O
% O O
and O O
for O O
SLE O O
it O O
was O O
8 O O
. O O
9 O O
% O O
. O O

The O O
expected O O
coincidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
RA O B_LOCATION
and O O
SLE O B_LOCATION
by O O
chance O B_PERSON/B_MEASURE
would O O
therefore O O
be O O
1 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
. O O

However O O
, O O
the O O
observed O B_MEASURE/B_DISEASE
prevalence O I_MEASURE/I_DISEASE
of O O
rhupus O B_DISEASE
was O O
0 O B_MEASURE
. O O
09 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
less O B_MEASURE
than O O
one O B_NUMBER[MEASURE]/B_PERSON
- O O
tenth O B_SEQUENCE[MEASURE]
of O O
that O O
expected O O
[ O O
1 O B_LOCATION/B_PERSON
] O I_LOCATION/I_PERSON
. O O

Previous O O
reports O O
have O O
shown O O
that O O
the O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
display O O
an O O
array O O
of O O
autoantibodies O O
including O O
anti O O
- O O
double O O
- O O
stranded O O
DNA O O
( O O
anti O O
- O O
dsDNA O O
) O O
, O O
anti O O
- O O
Sm O O
( O O
both O O
highly O O
specific O O
for O O
SLE O O
) O O
, O O
anti O O
- O O
SSA O O
, O O
anti O O
- O O
SSB O O
, O O
anti O O
- O O
ribonucleoprotein O O
, O O
antinuclear O O
antibodies O O
( O O
ANA O O
) O O
, O O
anti O O
- O O
cardiolipins O O
, O O
and O O
rheumatoid O O
factor O O
( O O
RF O O
) O O
[ O O
1 O O
, O O
2 O O
] O O
. O O

However O O
, O O
no O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
yet O O
been O O
performed O O
to O O
investigate O O
the O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O O
cyclic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
citrullinated O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
peptides O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
CCP O B_DISEASE/B_GENE
antibodies O I_DISEASE/I_GENE
) O O
, O O
which O O
have O O
a O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
RA O B_DISEASE/B_LOCATION
of O O
96 O B_MEASURE/B_LOCATION
to O O
98 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
for O O
second O B_SEQUENCE[MEASURE]
- O O
generation O B_MEASURE/B_ENT
assays O I_MEASURE/I_ENT
( O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
CCP2 O B_GENE/B_DISEASE
) O O
) O O
[ O O
4 O B_MEASURE
, O O
5 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
confirmed O O
that O O
these O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
rarely O O
if O O
ever O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
other O B_DISEASE/B_PERSON
autoimmune O I_DISEASE/I_PERSON
diseases O I_DISEASE/I_PERSON
such O I_DISEASE/I_PERSON
as O O
SLE O B_DISEASE/B_LOCATION
, O O
Sj O B_PERSON/B_LOCATION
o O I_PERSON/I_LOCATION
gren O I_PERSON/I_LOCATION
' O O
s O O
syndrome O B_DISEASE/B_MEASURE
( O O
SS O B_DISEASE/B_LOCATION
) O O
, O O
scleroderma O B_DISEASE/B_LOCATION
and O O
myositis O B_DISEASE
[ O O
6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Nowadays O O
, O O
it O O
is O O
a O O
matter O O
of O O
debate O O
whether O O
rhupus O O
is O O
a O O
clinically O O
and O O
immunologically O O
distinctive O O
entity O O
[ O O
2 O O
] O O
, O O
a O O
true O O
overlap O O
between O O
SLE O O
and O O
RA O O
[ O O
7 O O
] O O
, O O
or O O
a O O
subgroup O O
of O O
patients B B_PERSON/B_BIO
with O O
lupus O O
[ O O
8 O O
] O O
. O O

This O O
descriptive O O
, O O
cross O O
- O O
sectional O O
study O O
was O O
performed O O
to O O
investigate O O
the O O
frequency O O
of O O
anti O O
- O O
CCP O O
antibodies O O
in O O
a O O
cohort O O
of O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
. O O

Materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

We O O
included O O
all O O
patients B B_PERSON
fulfilling O O
American O O
College O O
of O O
Rheumatology O O
( O O
ACR O O
) O O
classification O O
criteria O O
for O O
both O O
RA O O
[ O O
9 O O
] O O
and O O
SLE O O
[ O O
10 O O
] O O
who O O
belonged O O
to O O
our O O
cohorts O O
of O O
patients B B_PERSON
with O O
RA O O
and O O
with O O
SLE O O
. O O

Comparisons O O
were O O
made O O
with O O
age O O
- O O
and O O
gender O O
- O O
matched O O
patients B B_PERSON
with O O
RA O O
and O O
with O O
SLE O O
, O O
and O O
healthy O O
subjects O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
approved O O
by O O
the O O
local O B_ORGANIZATION/B_LOCATION
ethics O I_ORGANIZATION/I_LOCATION
committee O I_ORGANIZATION/I_LOCATION
, O O
and O O
informed O O
consent O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
obtained O O
. O O

Serum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
obtained O O
and O O
stored O O
at O O
- O O
75 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
until O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

Sera O B_PERSON/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
were O O
analyzed O O
for O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CCP2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
Inova O B_MEASURE/B_DISEASE
Diagnostics O I_MEASURE/I_DISEASE
, O O
San O B_LOCATION/B_PERSON
Diego O I_LOCATION/I_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
with O O
a O O
cutoff O B_MEASURE
value O I_MEASURE
of O O
60 O B_MEASURE
U O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
. O O

Fine O B_DISEASE/B_GENE
antinuclear O B_DISEASE/I_GENE
reactivities O B_DISEASE/I_GENE
( O O
ELISA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O O
Inova O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Diagnostics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
RF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
nephelometry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
ANA O B_PROTEIN[GENE]/B_DISEASE
( O O
indirect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
immunofluorescence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
HEp O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE/B_LOCATION
slides O I_MEASURE/I_LOCATION
) O O
, O O
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
dsDNA O B_GENE/B_DISEASE
( O O
indirect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
immunofluorescence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
Crithidia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
luciliae O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
substrate O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
) O O
antibodies O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
also O O
determined O O
. O O

Except O O
for O O
healthy O B_PERSON
individuals O I_PERSON
, O O
standard O B_MEASURE/B_PERSON
radiographs O I_MEASURE/I_PERSON
of O O
hands O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
were O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ANOVA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
the O O
Mann O B_PERSON/B_LOCATION
- O O
Whitney O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
U O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
performed O O
as O O
appropriate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
GraphPad O B_MEASURE
Prism O I_MEASURE
4 O I_MEASURE
. O O
0 O B_MEASURE/B_ORGANIZATION
software O I_MEASURE/I_ORGANIZATION
( O O
GraphPad O B_MEASURE/B_ORGANIZATION
Inc O I_MEASURE/I_ORGANIZATION
, O O
San O B_LOCATION/B_PERSON
Diego O I_LOCATION/I_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Seven O O
female O O
patients B B_PERSON
with O O
a O O
median O O
age O O
of O O
44 O O
years O O
( O O
range O O
25 O O
to O O
64 O O
) O O
met O O
our O O
inclusion O O
criteria O O
. O O

The O O
major O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinical O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
presented O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Healthy O O
individuals O O
and O O
all O O
patients B B_PERSON/B_LOCATION
belonged O O
to O O
cohorts O O
from O O
the O O
same O O
ethnic O O
group O O
( O O
Hispanic O O
mestizo O O
) O O
. O O

No O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
demographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
found O O
between O O
groups O B_ORGANIZATION/B_LOCATION
. O O

Mean O B_MEASURE/B_PERSON
ACR O B_MEASURE/I_PERSON
criteria O B_MEASURE/I_PERSON
for O O
SLE O B_DISEASE/B_LOCATION
were O O
5 O B_MEASURE
. O O
57 O B_MEASURE
( O O
range O B_NUMBER[MEASURE]/B_LOCATION
4 O I_NUMBER[MEASURE]/I_LOCATION
to O O
8 O B_NUMBER[MEASURE]
) O O
in O O
the O O
SLE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
5 O B_MEASURE
. O O
57 O B_MEASURE
( O O
4 O B_NUMBER[MEASURE]
to O O
8 O B_NUMBER[MEASURE]
) O O
in O O
the O O
rhupus O B_LOCATION/B_PERSON
group O I_LOCATION/I_PERSON
. O O

In O O
the O O
same O O
way O O
, O O
mean O O
ACR O O
criteria O O
for O O
RA O O
were O O
6 O O
( O O
4 O O
to O O
7 O O
) O O
in O O
the O O
RA O O
group O O
, O O
and O O
5 O O
. O O
14 O O
( O O
4 O O
to O O
6 O O
) O O
for O O
the O O
patients B B_PERSON/B_ORGANIZATION
with O O
rhupus O O
. O O

In O O
all O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
, O O
RA O O
was O O
presented O O
as O O
the O O
initial O O
disease O O
, O O
as O O
has O O
been O O
described O O
previously O O
[ O O
2 O O
] O O
. O O

In O O
accordance O O
with O O
another O O
report O O
, O O
in O O
two O O
patients B B_PERSON/B_LOCATION
the O O
disease O O
started O O
during O O
their O O
childhood O O
as O O
juvenile O O
chronic O O
arthritis O O
[ O O
1 O O
] O O
. O O

Anti O O
- O O
CCP O O
antibodies O O
were O O
found O O
in O O
four O O
of O O
seven O O
( O O
57 O O
% O O
) O O
patients B B_PERSON
with O O
rhupus O O
, O O
and O O
in O O
six O O
of O O
seven O O
( O O
86 O O
% O O
) O O
patients B B_PERSON/B_DISEASE
with O O
RA O O
, O O
whereas O O
neither O O
patients B B_PERSON
with O O
SLE O O
nor O O
healthy O O
individuals O O
showed O O
reactivity O O
. O O

When O O
the O O
concentrations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
each O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
compared O O
, O O
a O O
statistical O B_MEASURE/B_PERSON
significant O I_MEASURE/I_PERSON
difference O I_MEASURE/I_PERSON
between O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
( O O
ANOVA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

The O O
mean O O
concentration O O
of O O
anti O O
- O O
CCP O O
antibodies O O
was O O
584 O O
U O O
/ O O
ml O O
( O O
range O O
0 O O
to O O
1 O O
, O O
237 O O
) O O
in O O
patients B B_PERSON
with O O
rhupus O O
( O O
Figure O O
1 O O
) O O
, O O
875 O O
U O O
/ O O
ml O O
( O O
0 O O
to O O
1 O O
, O O
178 O O
) O O
in O O
the O O
RA O O
group O O
( O O
not O O
significant O O
compared O O
with O O
rhupus O O
) O O
, O O
1 O O
U O O
/ O O
ml O O
( O O
0 O O
to O O
10 O O
) O O
for O O
SLE O O
individuals O O
( O O
p O O
< O O
0 O O
. O O
05 O O
compared O O
with O O
rhupus O O
) O O
, O O
and O O
0 O O
U O O
/ O O
ml O O
( O O
0 O O
to O O
2 O O
) O O
for O O
healthy O O
controls O O
( O O
p O O
< O O
0 O O
. O O
05 O O
compared O O
with O O
rhupus O O
) O O
. O O

Two O O
of O O
three O O
patients B B_PERSON
with O O
rhupus O O
who O O
were O O
negative O O
for O O
anti O O
- O O
CCP O O
antibodies O O
were O O
also O O
negative O O
for O O
anti O O
- O O
dsDNA O O
antibodies O O
, O O
RF O O
and O O
anti O O
- O O
extractable O O
nuclear O O
antigen O O
antibodies O O
, O O
although O O
both O O
patients B B_PERSON/B_LOCATION
met O O
RA O O
and O O
SLE O O
classification O O
criteria O O
, O O
including O O
ANA O O
and O O
erosive O O
arthritis O O
. O O

Differences O O
in O O
ANA O O
, O O
anti O O
- O O
dsDNA O O
and O O
anti O O
- O O
extractable O O
nuclear O O
antigen O O
autoantibodies O O
between O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
and O O
those O O
with O O
SLE O O
were O O
not O O
found O O
. O O

We O O
also O O
found O O
no O O
difference O O
in O O
the O O
prevalence O O
of O O
RF O O
between O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
and O O
those O O
with O O
RA O O
. O O

Surprisingly O O
, O O
one O B_PERSON
healthy O I_PERSON
subject O I_PERSON
was O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
RF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
ANA O B_DISEASE/B_PROTEIN[GENE]
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
SSA O B_DISEASE/B_GENE
antibodies O B_DISEASE/I_GENE
, O O
although O O
she O O
was O O
asymptomatic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
no O O
features O B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
any O O
disease O B_DISEASE
were O O
found O O
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
close O O
association O O
between O O
different O O
type O O
II O O
human B B_SPECIES[BIO]
leukocyte O O
antigen O O
( O O
HLA O O
) O O
molecules O O
and O O
the O O
risk O O
of O O
RA O O
is O O
well O O
established O O
. O O

These O O
major O B_GENE/B_BIO
histocompatibility O I_GENE/I_BIO
complex O I_GENE/I_BIO
( O O
MHC O B_LOCATION/B_ORGANIZATION
) O O
class O B_GENE/B_LOCATION
II O I_GENE/I_LOCATION
molecules O I_GENE/I_LOCATION
share O O
the O O
same O B_GENE/B_LOCATION
amino O I_GENE/I_LOCATION
acid O I_GENE/I_LOCATION
sequence O I_GENE/I_LOCATION
( O O
QKRAA O B_LOCATION/B_ORGANIZATION
or O O
QRRAA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
in O O
positions O B_MEASURE
69 O I_MEASURE
to O O
74 O B_MEASURE
of O O
the O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
chain O B_LOCATION/B_GENE
, O O
namely O O
the O O
' O O
shared O O
epitope O B_PROTEIN[GENE]/B_LOCATION
' O O
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
works O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
demonstrated O O
that O O
this O O
' O O
shared O O
epitope O B_PROTEIN[GENE]/B_LOCATION
' O I_PROTEIN[GENE]/I_LOCATION
preferentially O O
binds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
peptides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
containing O O
the O O
non O B_DISEASE/B_LOCATION
- O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amino O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
citrulline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
deiminated O B_MEASURE/B_LOCATION
arginine O I_MEASURE/I_LOCATION
) O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
11 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
addition O O
, O O
an O O
abnormally O O
increased O O
function O O
of O O
the O O
enzyme O O
peptidylarginine O O
deiminase O O
4 O O
( O O
PAD4 O O
; O O
responsible O O
for O O
the O O
deimination O O
of O O
arginine O O
) O O
and O O
an O O
elevated O O
anti O O
- O O
CCP O O
autoantibody O O
production O O
in O O
patients B B_PERSON/B_BIO
with O O
RA O O
have O O
been O O
demonstrated O O
[ O O
12 O O
] O O
. O O

These O O
facts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
built O O
the O O
first O B_LOCATION/B_PERSON
bridge O I_LOCATION/I_PERSON
between O O
cellular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
humoral O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
autoimmunity O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
a O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rheumatic O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
supporting O O
a O O
pathogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
an O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_DISEASE_ADJECTIVE[DISEASE]
of O O
citrulline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
RA O B_DISEASE/B_LOCATION
[ O I_DISEASE/I_LOCATION
13 O I_DISEASE/I_LOCATION
, O O
14 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Patients B B_PERSON/B_BIO
with O O
SLE O O
are O O
often O O
part O O
of O O
the O O
control O O
group O O
when O O
determining O O
the O O
specificity O O
of O O
anti O O
- O O
CCP O O
antibodies O O
for O O
RA O O
[ O O
15 O O
] O O
, O O
although O O
some O O
studies O O
have O O
been O O
performed O O
specifically O O
on O O
patients B B_PERSON/B_DISEASE
with O O
SLE O O
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
contribute O O
some O O
clues O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CCP O B_DISEASE/B_GENE
antibodies O B_DISEASE/I_GENE
in O O
rhupus O B_DISEASE/B_LOCATION
. O O

Mediwake O O
and O O
colleagues O O
[ O O
16 O O
] O O
, O O
in O O
a O O
study O O
exploring O O
the O O
predictive O O
value O O
of O O
anti O O
- O O
CCP O O
antibodies O O
to O O
distinguish O O
erosive O O
arthritis O O
in O O
SLE O O
, O O
found O O
ten O O
patients B B_PERSON
( O O
out O O
of O O
231 O O
) O O
with O O
erosive O O
arthritis O O
, O O
two O O
of O O
whom O O
had O O
anti O O
- O O
CCP O O
antibodies O O
. O O

In O O
concord O O
with O O
this O O
, O O
Hoffman O O
and O O
colleagues O O
[ O O
15 O O
] O O
demonstrate O O
that O O
three O O
patients B B_PERSON/B_BIO
with O O
erosive O O
arthritis O O
, O O
included O O
in O O
a O O
cohort O O
of O O
235 O O
patients B B_PERSON
with O O
SLE O O
, O O
were O O
positive O O
for O O
anti O O
- O O
CCP O O
antibodies O O
. O O

These O O
authors O O
suggest O O
that O O
the O O
presence O O
of O O
anti O O
- O O
CCP O O
antibodies O O
can O O
predispose O O
for O O
a O O
chronic O O
RA O O
- O O
like O O
arthritis O O
in O O
patients B B_PERSON/B_BIO
with O O
SLE O O
. O O

Additionally O O
Weissman O O
and O O
colleagues O O
[ O O
17 O O
] O O
demonstrated O O
that O O
patients B B_PERSON/B_BIO
with O O
SLE O O
can O O
display O O
radiographic O O
abnormalities O O
similar O O
to O O
those O O
of O O
RA O O
, O O
although O O
the O O
presence O O
of O O
marginal O O
erosions O O
is O O
a O O
rare O O
finding O O
. O O

In O O
the O O
present O O
study O O
we O O
demonstrate O O
that O O
the O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
show O O
a O O
very O O
similar O O
arthritis O O
pattern O O
( O O
including O O
erosive O O
disease O O
) O O
and O O
similar O O
autoantibody O O
production O O
( O O
RF O O
and O O
anti O O
- O O
CCP O O
antibodies O O
) O O
to O O
those O O
in O O
patients B B_PERSON/B_ORGANIZATION
with O O
RA O O
. O O

In O O
addition O O
, O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
display O O
a O O
clinical O O
and O O
serological O O
profile O O
indistinguishable O O
from O O
patients B B_PERSON
with O O
SLE O O
. O O

Moreover O O
, O O
the O O
presence O O
of O O
other O O
coexistent O O
autoimmune O O
diseases O O
was O O
similar O O
in O O
all O O
groups O O
of O O
patients B B_PERSON
( O O
two O O
patients B B_PERSON/B_DISEASE
with O O
rhupus O O
, O O
three O O
patients B B_PERSON/B_DISEASE
with O O
RA O O
, O O
and O O
three O O
patients B B_PERSON
with O O
SLE O O
also O O
had O O
SS O O
) O O
. O O

We O O
found O O
high O O
titers O O
of O O
anti O O
- O O
CCP O O
antibodies O O
in O O
four O O
of O O
seven O O
( O O
57 O O
% O O
) O O
patients B B_PERSON/B_LOCATION
with O O
rhupus O O
, O O
a O O
frequency O O
similar O O
to O O
that O O
reported O O
for O O
RA O O
[ O O
4 O O
] O O
. O O

This O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
together O O
with O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
similarity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
supports O O
the O O
contention O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
rhupus O B_DISEASE/B_LOCATION
belongs O O
to O O
the O O
RA O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
spectrum O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

The O O
high O O
prevalence O O
of O O
anti O O
- O O
CCP O O
antibodies O O
in O O
RA O O
found O O
in O O
our O O
study O O
could O O
be O O
explained O O
by O O
a O O
selection O O
bias O O
because O O
only O O
patients B B_PERSON/B_BIO
with O O
RA O O
with O O
an O O
aggressive O O
disease O O
( O O
namely O O
erosive O O
arthritis O O
and O O
RF O O
+ O O
) O O
were O O
included O O
. O O

In O O
contrast O O
, O O
the O O
mean O O
ACR O O
criterion O O
for O O
SLE O O
was O O
similar O O
between O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
and O O
those O O
with O O
SLE O O
, O O
including O O
the O O
' O O
robust O O
' O O
features O O
of O O
SLE O O
such O O
as O O
renal O O
and O O
neurological O O
involvement O O
, O O
and O O
anti O O
- O O
dsDNA O O
and O O
anti O O
- O O
Sm O O
antibodies O O
. O O

These O O
clinical O O
and O O
serological O O
features O O
shared O O
between O O
patients B B_PERSON
with O O
rhupus O O
and O O
those O O
with O O
SLE O O
also O O
place O O
rhupus O O
in O O
the O O
SLE O O
spectrum O O
. O O

Titration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CCP O B_DISEASE/B_GENE
antibodies O B_DISEASE/I_GENE
in O O
the O O
rhupus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
clearly O O
shows O O
a O O
bimodal O B_MEASURE/B_LOCATION
distribution O I_MEASURE/I_LOCATION
, O O
suggesting O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
of O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subpopulations O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Because O O
of O O
the O O
small O O
number O O
of O O
patients B B_PERSON/B_LOCATION
, O O
we O O
are O O
unable O O
to O O
define O O
the O O
differential O O
features O O
underlying O O
each O O
subset O O
. O O

However O O
, O O
two O O
of O O
three O O
patients B B_PERSON
negative O O
for O O
anti O O
- O O
CCP O O
antibodies O O
were O O
also O O
negative O O
for O O
both O O
RF O O
and O O
anti O O
- O O
dsDNA O O
antibodies O O
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

On O O
the O O
basis O O
of O O
the O O
presence O O
of O O
shared O O
clinical O O
features O O
of O O
RA O O
( O O
mainly O O
erosive O O
arthritis O O
) O O
and O O
SLE O O
( O O
including O O
renal O O
and O O
neurological O O
involvement O O
) O O
along O O
with O O
the O O
presence O O
of O O
anti O O
- O O
dsDNA O O
and O O
anti O O
- O O
CCP O O
autoantibodies O O
in O O
our O O
patients B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
rhupus O O
, O O
our O O
findings O O
strongly O O
support O O
the O O
contention O O
that O O
rhupus O O
is O O
a O O
true O O
overlap O O
between O O
RA O O
and O O
SLE O O
, O O
not O O
merely O O
a O O
part O O
of O O
the O O
clinical O O
spectrum O O
of O O
the O O
articular O O
involvement O O
seen O O
in O O
SLE O O
. O O

Moreover O O
, O O
on O O
the O O
basis O O
of O O
the O O
mean O O
ACR O O
criteria O O
for O O
both O O
diseases O O
, O O
we O O
have O O
confirmed O O
that O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
have O O
more O O
RA O O
- O O
associated O O
and O O
less O O
SLE O O
- O O
associated O O
damage O O
, O O
an O O
issue O O
that O O
has O O
been O O
suggested O O
previously O O
[ O O
2 O O
] O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
report O O
exploring O O
the O O
prevalence O O
of O O
anti O O
- O O
CCP O O
antibodies O O
specifically O O
in O O
patients B B_PERSON/B_BIO
with O O
rhupus O O
. O O

More O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
are O O
needed O O
to O O
expand O O
the O O
pathogenetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
knowledge O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
this O O
overlap O B_DISEASE_ADJECTIVE[DISEASE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Abbreviations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

ANA O B_PERSON/B_LOCATION
= O O
antinuclear O B_DISEASE/B_GENE
antibodies O I_DISEASE/I_GENE
; O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
CCP O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
= O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
cyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
citrullinated O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dsDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
= O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
double O B_MEASURE
- O O
stranded O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
ELISA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
= O O
enzyme O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
linked O O
immunosorbent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
RA O B_LOCATION
= O O
rheumatoid O B_DISEASE/B_PERSON
arthritis O I_DISEASE/I_PERSON
; O O
RF O B_LOCATION
= O O
rheumatoid O B_DISEASE
factor O I_DISEASE
; O O
SLE O B_LOCATION
= O O
systemic O B_DISEASE
lupus O I_DISEASE
erythematosus O I_DISEASE
; O O
SS O B_LOCATION
= O O
Sj O B_GENE/B_LOCATION
o O O
gren O B_LOCATION/B_PROTEIN[GENE]
' O O
s O B_DISEASE
syndrome O I_DISEASE
. O O

Competing O O
interests O B_DISEASE

The O O
authors O B_PERSON
declare O O
that O O
they O O
have O O
no O O
competing O O
interests O B_PERSON/B_ORGANIZATION
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

LA O B_LOCATION/B_PERSON
- O O
G O B_OTHER/B_PROTEIN[GENE]
participated O O
in O O
the O O
conception O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
in O O
the O O
acquisition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
and O O
was O O
involved O O
in O O
drafting O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RS O B_PERSON/B_LOCATION
performed O O
the O O
immunoassays O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

RM O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
V O B_OTHER/B_NUMBER[MEASURE]
participated O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
performed O O
the O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

LG O B_LOCATION/B_PROTEIN[GENE]
- O O
G O B_OTHER/B_NUMBER[MEASURE]
participated O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

AV O O
participated O O
in O O
the O O
recruitment O O
of O O
patients B B_PERSON
and O O
the O O
acquisition O O
of O O
data O O
. O O

RB O B_PROTEIN[GENE]/B_PERSON
participated O O
in O O
the O O
interpretation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
revising O O
the O O
manuscript O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
intellectual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
content O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
giving O O
the O O
final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
approval O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
version O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
to O O
be O O
published O O
. O O

All O O
authors O B_PERSON/B_NUMBER[MEASURE]
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

Identification O O
of O O
a O O
human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O O
blood O O
monocyte O O
subset O O
that O O
differentiates O O
into O O
osteoclasts O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Increased O O
bone O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
resorption O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
mediated O O
by O O
osteoclasts O B_DISEASE/B_GENE
causes O O
various O B_DISEASE_ADJECTIVE[DISEASE]
diseases O I_DISEASE_ADJECTIVE[DISEASE]
such O I_DISEASE_ADJECTIVE[DISEASE]
as O O
osteoporosis O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
bone O B_DISEASE
erosion O I_DISEASE
in O O
rheumatoid O B_DISEASE/B_PERSON
arthritis O I_DISEASE/I_PERSON
( O O
RA O B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

Osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
are O O
derived O O
from O O
the O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
macrophage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lineage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
the O O
precise O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
origin O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
present O O
study O O
, O O
we O O
show O O
that O O
the O O
purified O O
CD16 O O
- O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
peripheral O O
blood O O
monocyte O O
subset O O
, O O
but O O
not O O
the O O
CD16 O O
+ O O
monocyte O O
subset O O
, O O
differentiates O O
into O O
osteoclast O O
by O O
stimulation O O
with O O
receptor O O
activator O O
of O O
NF O O
- O O
kappa O O
B O O
ligand O O
( O O
RANKL O O
) O O
in O O
combination O O
with O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
( O O
M O O
- O O
CSF O O
) O O
. O O

Integrin O B_GENE
- O O
beta O B_PROTEIN[GENE]/B_MEASURE
3 O I_PROTEIN[GENE]/I_MEASURE
mRNA O I_PROTEIN[GENE]/I_MEASURE
and O O
the O O
integrin O B_GENE
- O O
alpha O B_GENE
v O I_GENE
beta O I_GENE
3 O I_GENE
heterodimer O I_GENE
were O O
only O O
expressed O O
on O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
when O O
they O O
were O O
stimulated O O
with O O
RANKL O B_PROTEIN[GENE]/B_LOCATION
+ O I_PROTEIN[GENE]/I_LOCATION
M O I_PROTEIN[GENE]/I_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Downregulation O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
beta O B_GENE
3 O I_GENE
- O O
subunit O B_GENE
expression O I_GENE
by O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
interfering O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
RNA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
targeting O O
beta O B_GENE
3 O I_GENE
abrogated O O
osteoclastogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocyte O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
subset O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
expressed O O
larger O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
amounts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
tumor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
than O O
the O O
CD16 O B_GENE
- O O
subset O B_MEASURE/B_PERSON
, O O
which O O
was O O
further O O
enhanced O O
by O O
RANKL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
RA O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovial O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
accumulation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE/B_DISEASE
- O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
consist O O
of O O
two O B_NUMBER[MEASURE]
functionally O O
heterogeneous O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subsets O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O O
distinct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
RANKL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
seem O O
to O O
originate O O
from O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
is O O
necessary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
osteoclastogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

Blockade O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
accumulation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
activation O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CD16 O B_PROTEIN[GENE]/B_DISEASE
- O O
monocytes O B_GENE
could O O
therefore O O
be O O
a O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
bone O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resorptive O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
especially O O
for O O
RA O B_DISEASE/B_LOCATION
. O O

Introduction O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Rheumatoid O B_DISEASE
arthritis O I_DISEASE
( O O
RA O B_LOCATION/B_ORGANIZATION
) O O
is O O
an O O
autoimmune O B_DISEASE/B_LOCATION
disease O I_DISEASE/I_LOCATION
characterized O O
by O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]
inflammation O I_DISEASE_ADJECTIVE[DISEASE]
and O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
synovium O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
in O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
joints O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

A O O
large O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
inflammatory O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
dendritic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
accumulate O O
in O O
the O O
affected O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
these O O
inflammatory O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O O
together O O
with O O
fibroblast O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
- O O
like O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synoviocytes O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
express O O
various O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
tumor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF O B_GENE/B_LOCATION
alpha O I_GENE/I_LOCATION
) O O
, O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
and O O
receptor O B_GENE
activator O I_GENE
of O O
NF O B_DISEASE/B_GENE
- O O
kappa O B_PROTEIN[GENE]/B_MEASURE
B O I_PROTEIN[GENE]/I_MEASURE
ligand O I_PROTEIN[GENE]/I_MEASURE
( O O
RANKL O B_GENE
) O O
, O O
which O O
are O O
known O O
to O O
induce O O
differentiation O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
activation O B_GENE/B_ORGANISM_FUNCTION
of O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

The O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
synovial O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
tissue O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
known O O
as O O
pannus O B_LOCATION/B_DISEASE
, O O
invades O O
the O O
articular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
bone O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
causes O O
focal O B_DISEASE
bone O I_DISEASE
erosion O I_DISEASE
, O O
which O O
is O O
the O O
hallmark O B_DISEASE_ADJECTIVE[DISEASE]
of O O
RA O B_DISEASE/B_LOCATION
. O O

Histopathologically O O
, O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
interface O B_LOCATION
of O O
the O O
pannus O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
and O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Interestingly O O
, O O
the O O
deletion O O
of O O
RANKL O O
or O O
c O O
- O O
Fos O O
gene O O
, O O
which O O
is O O
important O O
for O O
osteoclastogenesis O O
, O O
results O O
in O O
minimal O O
bone O O
destruction O O
in O O
mouse B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
models O O
of O O
arthritis O O
[ O O
1 O O
, O O
2 O O
] O O
. O O

Furthermore O O
, O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O O
that O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
osteoclastogenesis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
by O O
osteoprotegerin O B_GENE
, O O
a O O
decoy O B_GENE
receptor O I_GENE
for O O
RANKL O B_GENE
, O O
limits O O
bone O B_DISEASE
destruction O I_DISEASE
in O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
arthritis O B_DISEASE
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
are O O
involved O O
in O O
focal O B_DISEASE
bone O I_DISEASE
erosion O I_DISEASE
in O O
RA O B_DISEASE
[ O I_DISEASE
3 O I_DISEASE
] O I_DISEASE
. O O

Osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
are O O
derived O O
from O O
the O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
macrophage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lineage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
is O O
reported O O
that O O
osteoclast O O
precursors O O
reside O O
in O O
human B B_PERSON/B_SPECIES[BIO]
peripheral O O
blood O O
monocytes O O
[ O O
4 O O
, O O
5 O O
] O O
. O O

A O O
marked O O
increase O O
of O O
the O O
circulating O O
osteoclast O O
precursors O O
was O O
demonstrated O O
in O O
patients B B_PERSON/B_BIO
with O O
erosive O O
psoriatic O O
arthritis O O
as O O
well O O
as O O
in O O
arthritic O O
TNF O O
alpha O O
transgenic O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
6 O O
, O O
7 O O
] O O
. O O

It O O
was O O
also O O
shown O O
that O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
differentiate O O
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
when O O
seeded O O
on O O
RANKL O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
osteoclast O B_LOCATION/B_ORGANIZATION
differentiation O I_LOCATION/I_ORGANIZATION
factor O I_LOCATION/I_ORGANIZATION
- O O
producing O O
RA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
fibroblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
8 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
RA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
thought O O
to O O
originate O O
from O O
peripheral O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
shown O O
to O O
differentiate O O
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
[ O O
9 O B_MEASURE
, O O
10 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
are O O
therefore O O
involved O O
not O O
only O O
in O O
synovial O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
inflammation O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
also O O
in O O
bone O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
remodeling O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O O
potential O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precursors O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
synovial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

Human B B_PERSON/B_MEASURE
peripheral O O
blood O O
monocytes O O
consist O O
of O O
two O O
major O O
subsets O O
, O O
CD16 O O
+ O O
and O O
CD16 O O
- O O
, O O
comprising O O
5 O O
- O O
10 O O
% O O
and O O
90 O O
- O O
95 O O
% O O
of O O
the O O
monocytes O O
, O O
respectively O O
. O O

These O O
two O B_MEASURE/B_PROTEIN[GENE]
subsets O B_MEASURE/I_PROTEIN[GENE]
exhibit O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemotaxis O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activities O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
potential O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
production O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
[ O O
11 O B_MEASURE
, O O
12 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Moreover O O
, O O
activation O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
Toll O B_GENE
- O O
like O B_PROTEIN[GENE]/B_LOCATION
receptor O I_PROTEIN[GENE]/I_LOCATION
induces O O
distinct O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
subsets O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CD1b O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
dendritic O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
DC O B_GENE/B_LOCATION
- O O
SIGN O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
+ O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
dendritic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
C O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
type O B_PROTEIN[GENE]/B_LOCATION
lectin O I_PROTEIN[GENE]/I_LOCATION
ICAM O I_PROTEIN[GENE]/I_LOCATION
- O O
3 O B_MEASURE/B_BIO
- O O
grabbing O O
nonintegrin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE
- O O
monocytes O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
respectively O O
[ O O
13 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
has O O
not O O
been O O
revealed O O
, O O
however O O
, O O
which O O
monocyte O B_DISEASE
subset O I_DISEASE
develops O O
into O O
osteoclasts O B_DISEASE/B_LOCATION
. O O

In O O
the O O
present O O
study O O
, O O
we O O
determined O O
the O O
human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O O
blood O O
monocyte O O
subset O O
that O O
differentiates O O
into O O
osteoclasts O O
, O O
and O O
revealed O O
that O O
each O O
subset O O
exhibits O O
a O O
different O O
response O O
for O O
osteoclastogenic O O
stimuli O O
. O O

Materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Purification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
peripheral O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]

Peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
healthy O B_PERSON/B_BIO
donors O I_PERSON/I_BIO
were O O
collected O O
using O O
Ficoll O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
Conray O B_PERSON/B_LOCATION
( O O
Imuuno O B_BIO/B_LOCATION
- O O
Biological O B_LOCATION/B_PERSON
Laboratories O I_LOCATION/I_PERSON
, O O
Gunma O B_LOCATION
, O O
Japan O B_LOCATION/B_MEASURE
) O O
gradient O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
centrifugation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
selection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
monocytes O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
using O O
MACS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
microbeads O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O O
Miltenyi O B_MEASURE/B_PERSON
Biotec O I_MEASURE/I_PERSON
, O O
Auburn O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
according O O
to O O
the O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supplied O O
by O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
. O O

The O O
purified O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
separated O O
into O O
two O B_MEASURE
subsets O I_MEASURE
, O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE
- O O
monocytes O B_GENE/B_MEASURE
, O O
using O O
CD16 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MicroBeads O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Miltenyi O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Biotec O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Flow O O
cytometry O O
analysis O O
using O O
FITC O O
- O O
conjugated O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
CD14 O O
mAb O O
( O O
MY4 O O
; O O
Bechman O O
Coulter O O
, O O
Fullerton O O
, O O
CA O O
, O O
USA O O
) O O
and O O
phycoerythin O O
- O O
conjugated O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
CD16 O O
mAb O O
( O O
3G8 O O
; O O
BD O O
Biosciences O O
, O O
San O O
Jose O O
, O O
CA O O
, O O
USA O O
) O O
showed O O
that O O
the O O
purities O O
of O O
the O O
CD16 O O
+ O O
and O O
CD16 O O
- O O
monocytes O O
were O O
more O O
than O O
90 O O
% O O
and O O
92 O O
% O O
, O O
respectively O O
. O O

For O O
the O O
other O O
experiment O O
, O O
monocytes O O
were O O
purified O O
using O O
CD14 O O
MicroBeads O O
( O O
Miltenyi O O
Biotec O O
) O O
, O O
and O O
then O O
stained O O
either O O
with O O
FITC O O
- O O
conjugated O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
CD33 O O
mAb O O
( O O
MY9 O O
; O O
Bechman O O
Coulter O O
) O O
or O O
phycoerythin O O
- O O
conjugated O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
CD16 O O
mAb O O
( O O
3G8 O O
) O O
. O O

Cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sorting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
stained O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
performed O O
using O O
a O O
FACS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Vantage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytometer O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BD O B_LOCATION/B_ORGANIZATION
Biosciences O I_LOCATION/I_ORGANIZATION
) O O
or O O
a O O
MoFlo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cell O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sorter O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Dako O B_PERSON/B_MEASURE
, O O
Glostrup O B_LOCATION/B_PERSON
, O O
Denmark O B_LOCATION/B_MEASURE
) O O
. O O

Osteoclast O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiation O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Purified O O
CD16 O O
+ O O
and O O
CD16 O O
- O O
monocytes O O
( O O
5 O O
x O O
104 O O
cells O O
/ O O
well O O
) O O
were O O
incubated O O
in O O
96 O O
- O O
well O O
plates O O
in O O
alpha O O
MEM O O
( O O
Sigma O O
, O O
St O O
Louis O O
, O O
MO O O
, O O
USA O O
) O O
with O O
heat O O
- O O
inactivated O O
10 O O
% O O
fetal O O
bovine B B_SPECIES[BIO]/B_PROTEIN[GENE]
serum O O
( O O
FBS O O
) O O
( O O
Sigma O O
) O O
or O O
with O O
Ultra O O
- O O
Low O O
IgG O O
FBS O O
( O O
IgG O O
< O O
5 O O
mu O O
g O O
/ O O
ml O O
; O O
Invitrogen O O
, O O
Carlsbad O O
, O O
CA O O
, O O
USA O O
) O O
, O O
and O O
where O O
indicated O O
with O O
M O O
- O O
CSF O O
+ O O
RANKL O O
( O O
Peprotech O O
, O O
Rocky O O
Hill O O
, O O
NJ O O
, O O
USA O O
) O O
. O O

For O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
varied O O
numbers O B_MEASURE/B_LOCATION
of O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O O
1 O B_MEASURE
x O O
103 O B_MEASURE
, O O
2 O B_MEASURE
. O O
5 O B_MEASURE
x O O
103 O B_MEASURE
, O O
5 O B_MEASURE
x O O
103 O B_MEASURE
) O O
were O O
mixed O O
with O O
CD16 O B_GENE/B_LOCATION
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
5 O B_MEASURE
x O O
104 O B_MEASURE
cells O I_MEASURE
/ O O
well O O
) O O
, O O
and O O
were O O
cultured O O
in O O
96 O B_MEASURE/B_LOCATION
- O O
well O O
plates O B_PRODUCT[OBJECT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
MEM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
heat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
inactivated O O
10 O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
% O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
FBS O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
replaced O O
with O O
fresh O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
later O O
, O O
and O O
after O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
for O O
7 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
stained O O
for O O
tartrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
resistant O B_ENZYME[GENE]/B_DISEASE
acid O I_ENZYME[GENE]/I_DISEASE
phosphatase O I_ENZYME[GENE]/I_DISEASE
( O O
TRAP O B_GENE/B_LOCATION
) O O
expression O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
a O O
commercial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kit O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Hokudo O B_MEASURE/B_PERSON
, O O
Sapporo O B_LOCATION/B_ORGANIZATION
, O O
Japan O B_LOCATION/B_MEASURE
) O O
. O O

The O O
number O B_MEASURE/B_PERSON
of O O
TRAP O B_GENE/B_DISEASE
- O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
multinucleated O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
MNC O B_DISEASE/B_LOCATION
) O O
in O O
three O B_NUMBER[MEASURE]/B_LOCATION
randomly O O
selected O O
fields O B_LOCATION
examined O O
at O O
100 O B_NUMBER[MEASURE]
x O O
magnification O B_MEASURE
or O O
the O O
total O B_MEASURE
number O I_MEASURE
of O O
TRAP O B_GENE/B_DISEASE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O O
well O O
was O O
counted O O
under O O
light O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Resorption O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
seeded O O
onto O O
plates O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coated O O
with O O
calcium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
phosphate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
thin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
films O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Biocoat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Osteologic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O O
BD O B_LOCATION/B_ORGANIZATION
Biosciences O I_LOCATION/I_ORGANIZATION
) O O
and O O
were O O
incubated O O
with O O
RANKL O B_GENE
( O O
40 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
) O O
+ O B_DISEASE/B_PROTEIN[GENE]
M O B_DISEASE/I_PROTEIN[GENE]
- O O
CSF O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
25 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
) O O
for O O
7 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
cells O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O O
then O O
lysed O O
in O O
bleach O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaOCl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
NaCl O I_MEASURE
) O O
. O O

The O O
resorption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
lacunae O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
examined O O
under O O
light O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Enzyme O O
- O O
linked O O
immunosorbent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Purified O B_PERSON/B_GENE
monocytes O I_PERSON/I_GENE
were O O
cultured O O
in O O
96 O B_MEASURE/B_LOCATION
- O O
well O O
plates O B_PRODUCT[OBJECT]/B_LOCATION
where O O
indicated O O
either O O
with O O
RANKL O B_LOCATION/B_ORGANIZATION
or O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
for O O
24 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
in O O
the O O
culture O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
supernatant O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_BACTERIUM[BIO]
were O O
measured O O
with O O
an O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kit O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BioSourse O B_MEASURE/B_LOCATION
International O I_MEASURE/I_LOCATION
, O O
Camarillo O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

For O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
matrix O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
metalloproteinase O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MMP O B_GENE/B_BIO
) O O
- O O
9 O B_NUMBER[MEASURE]
and O O
TRAP O B_GENE/B_DISEASE
- O O
5b O B_NUMBER[MEASURE]
, O O
culture O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
supernatants O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
collected O O
on O O
day O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
7 O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
the O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
enzymes O B_ENZYME[GENE]
were O O
measured O O
using O O
an O O
MMP O B_GENE/B_BIO
- O O
9 O B_MEASURE
ELISA O I_MEASURE
kit O I_MEASURE
( O O
Amersham O B_LOCATION/B_PERSON
Biosciences O I_LOCATION/I_PERSON
, O O
Piscataway O B_LOCATION/B_PERSON
, O O
NJ O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
or O O
a O O
TRAP O B_GENE/B_DISEASE
- O O
5b O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ELISA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kit O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Suomen O B_LOCATION/B_ORGANIZATION
, O O
Turku O B_LOCATION
, O O
Finland O B_LOCATION
) O O
. O O

Reverse O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcriptase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
polymerase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
( O O
1 O B_MEASURE
x O O
106 O B_MEASURE
cells O I_MEASURE
/ O O
well O O
) O O
were O O
cultured O O
in O O
six O B_MEASURE/B_LOCATION
- O O
well O B_TIME[MEASURE]/B_LOCATION
plates O I_TIME[MEASURE]/I_LOCATION
with O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
alone O O
or O O
with O O
M O B_OTHER/B_LOCATION
- O O
CSF O B_GENE
+ O I_GENE
RANKL O I_GENE
for O O
3 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Total O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
extracted O O
using O O
RNeasy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Micro O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Qiagen O B_MEASURE/B_PERSON
, O O
Valencia O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

The O O
RNA O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
then O O
treated O O
with O O
DNase O B_GENE
I O I_GENE
( O O
Qiagen O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
. O O

The O O
oligo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
dT O B_PROTEIN[GENE]/B_LOCATION
) O O
- O O
primed O O
cDNA O B_GENE
was O O
synthesized O O
using O O
Superscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reverse O O
transcriptase O B_GENE
( O O
Invitrogen O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
amount O B_MEASURE
of O O
cDNA O B_GENE
for O O
amplification O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
adjusted O O
by O O
the O O
amount O B_MEASURE
of O O
RNA O B_GENE/B_BIO
measured O O
by O O
an O O
optical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
density O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
meter O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
also O O
by O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
actin O B_GENE/B_BACTERIUM[BIO]
or O O
GAPDH O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PCR O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

One O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microliter O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cDNA O B_GENE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
was O O
amplified O O
in O O
a O O
50 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mu O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
l O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
final O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
volume O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
containing O O
25 O B_GENE
pmol O I_GENE
appropriate O I_GENE
primer O I_GENE
pair O I_GENE
, O O
10 O B_NUMBER[MEASURE]
pmol O O
each O O
of O O
the O O
four O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
deoxynucleotide O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
triphosphates O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
and O O
5 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
units O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FastStart O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Taq O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Roche O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
Manheim O B_LOCATION
, O O
Germany O B_LOCATION
) O O
in O O
a O O
thermal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cycler O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
PTC O B_LOCATION/B_ORGANIZATION
- O O
200 O B_NUMBER[MEASURE]
; O O
MJ O B_LOCATION/B_PERSON
GeneWorks O B_LOCATION/I_PERSON
, O O
Waltham O B_LOCATION/B_PERSON
, O O
MA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

The O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
25 O B_MEASURE
- O O
40 O B_TIME[MEASURE]
cycles O I_TIME[MEASURE]
of O O
denaturation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
95 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
for O O
30 O B_MEASURE
s O I_MEASURE
) O O
, O O
annealing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
60 O B_MEASURE
- O O
62 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
for O O
1 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
) O O
and O O
extension O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
72 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
for O O
1 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
) O O
. O O

The O O
sequences O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
primers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
are O O
presented O O
in O O
Table O B_MEASURE/B_LOCATION
1 O B_MEASURE/I_LOCATION
. O O

The O O
PCR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
separated O O
by O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
agarose O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gel O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Western O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
immunoblot O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
analysis O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE

Purified O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
cultured O O
for O O
3 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
in O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
40 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_GENE
M O I_MEASURE/I_GENE
- O O
CSF O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
with O O
or O O
without O O
25 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
RANKL O I_MEASURE/I_PERSON
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
lysed O O
in O O
RIPA O B_LOCATION
Lysis O I_LOCATION
buffer O I_LOCATION
( O O
upstate O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Lake O B_LOCATION
Placid O I_LOCATION
, O O
NY O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
containing O O
protease O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Roche O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
for O O
15 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
4 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
. O O

A O O
total O B_MEASURE
of O O
20 O B_MEASURE
mu O I_MEASURE
g O I_MEASURE
protein O I_MEASURE
was O O
boiled O O
in O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
6 O B_MEASURE
x O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dodecyl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
buffer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
was O O
separated O O
on O O
7 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
or O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
dodecyl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sulfate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
polyacrylamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
gel O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
ATTO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
Tokyo O B_LOCATION/B_ORGANIZATION
, O O
Japan O B_LOCATION/B_MEASURE
) O O
. O O

Proteins O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
then O O
electrotransferred O O
to O O
a O O
polyvinylidene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microporous O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Millipore O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Billerica O B_LOCATION/B_PERSON
, O O
MA O B_LOCATION
, O O
USA O B_LOCATION
) O O
in O O
a O O
semidry O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
system O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Membranes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
incubated O O
in O O
10 O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
skim O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
milk O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prepared O O
in O O
phosphate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
buffered O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PBS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O O
containing O O
0 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
Tween O I_MEASURE
20 O I_MEASURE
, O O
and O O
were O O
subjected O O
to O O
immunoblotting O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Antibodies O O
used O O
were O O
goat B B_SPECIES[BIO]
anti O O
- O O
RANK O O
antibody O O
( O O
Techne O O
Corporation O O
, O O
Minneapolis O O
, O O
MN O O
, O O
USA O O
) O O
, O O
goat B B_SPECIES[BIO]
anti O O
- O O
c O O
- O O
fms O O
antibody O O
( O O
R O O
& O O
D O O
systems O O
, O O
Minneapolis O O
, O O
MN O O
, O O
USA O O
) O O
, O O
and O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
beta O O
- O O
actin O O
mAb O O
( O O
AC O O
- O O
15 O O
; O O
Sigma O O
) O O
. O O

Peroxidase O O
- O O
conjugated O O
rabbit B B_SPECIES[BIO]
anti O O
- O O
goat B B_SPECIES[BIO]
IgG O O
antibody O O
( O O
Dako O O
) O O
or O O
peroxidase O O
- O O
conjugated O O
rabbit B B_SPECIES[BIO]
anti O O
- O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG O O
antibody O O
( O O
Dako O O
) O O
was O O
used O O
as O O
the O O
second O O
antibody O O
. O O

The O O
signals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
visualized O O
by O O
chemiluminescence O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reagent O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
( O O
ECL O B_MEASURE/B_DISEASE
; O O
Amersham O B_MEASURE/B_LOCATION
Biocsiences O I_MEASURE/I_LOCATION
, O O
Little O B_LOCATION
Chalfont O I_LOCATION
, O O
UK O B_LOCATION/B_MEASURE
) O O
. O O

Cell O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
surface O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
expression O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
c O B_GENE/B_DISEASE
- O O
fms O B_GENE/B_DISEASE

The O O
following O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mAbs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
for O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
c O B_GENE/B_DISEASE
- O O
fms O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
Alexa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
647 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
conjugated O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CD14 O B_GENE
mAb O I_GENE
( O O
UCHM1 O B_GENE
; O O
Serotec O B_LOCATION/B_PERSON
, O O
Oxford O B_LOCATION
, O O
UK O B_LOCATION/B_MEASURE
) O O
, O O
FITC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
conjugated O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CD16 O B_GENE
mAb O I_GENE
( O O
3G8 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Bechman O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Coulter O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
phycoerythin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
conjugated O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
c O B_DISEASE/B_GENE
- O O
fms O B_GENE
mAb O I_GENE
( O O
61708 O B_TIME[MEASURE]/B_LOCATION
; O O
R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O O
D O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
systems O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

Alexa O O
647 O O
- O O
conjugated O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG2a O O
( O O
Serotec O O
) O O
, O O
FITC O O
- O O
conjugated O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG1 O O
( O O
BD O O
Biosciences O O
) O O
and O O
phycoerythin O O
- O O
conjugated O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG1 O O
( O O
Bechman O O
Coulter O O
) O O
were O O
used O O
as O O
isotype O O
controls O O
. O O

Peripheral O O
blood O O
monocytes O O
( O O
1 O O
x O O
105 O O
cells O O
) O O
were O O
incubated O O
with O O
1 O O
mu O O
g O O
human B B_SPECIES[BIO]
IgG O O
for O O
15 O O
minutes O O
, O O
and O O
were O O
then O O
stained O O
with O O
three O O
fluorochrome O O
- O O
labeled O O
mAbs O O
for O O
45 O O
minutes O O
on O O
ice O O
. O O

The O O
stained O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
analyzed O O
with O O
a O O
FACS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Calibur O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
BD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Biosciences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O O
. O O

Immunofluorescent O B_DISEASE_ADJECTIVE[DISEASE]
staining O I_DISEASE_ADJECTIVE[DISEASE]

Monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
( O O
8 O B_MEASURE
x O O
104 O B_MEASURE
cells O I_MEASURE
/ O O
well O O
) O O
were O O
allowed O O
to O O
adhere O O
on O O
96 O B_MEASURE/B_LOCATION
- O O
well O O
plates O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
overnight O O
or O O
were O O
cultured O O
with O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
RANKL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
2 O B_NUMBER[MEASURE]/B_LOCATION
- O O
4 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

The O O
cells O O
were O O
fixed O O
in O O
acetone O O
and O O
then O O
stained O O
with O O
anti O O
- O O
alpha O O
v O O
beta O O
3 O O
mAb O O
( O O
LM609 O O
; O O
Chemicon O O
, O O
Temecula O O
, O O
CA O O
, O O
USA O O
) O O
or O O
mouse B B_DISEASE/B_SPECIES[BIO]
IgG1 O O
( O O
11711 O O
; O O
R O O
& O O
D O O
Systems O O
) O O
as O O
an O O
isotype O O
- O O
matched O O
control O O
. O O

Alexa O O
fluor546 O O
- O O
conjugated O O
goat B B_SPECIES[BIO]/B_GENE
anti O O
- O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG1 O O
antibody O O
( O O
Molecular O O
Probes O O
, O O
Eugene O O
, O O
OR O O
, O O
USA O O
) O O
was O O
used O O
as O O
the O O
second O O
antibody O O
. O O

TOTO O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_NUMBER[MEASURE]/B_LOCATION
( O O
Molecular O B_NUMBER[MEASURE]/B_ORGANIZATION
Probes O I_NUMBER[MEASURE]/I_ORGANIZATION
) O O
was O O
used O O
for O O
nuclear O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Flow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometric O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
p38 O B_GENE/B_DISEASE
MAPK O I_GENE/I_DISEASE
and O O
ERK1 O B_GENE
/ O O
2 O B_GENE/B_MEASURE
phosphorylation O I_GENE/I_MEASURE

Purified O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
cultured O O
in O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
25 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_LOCATION
M O I_MEASURE/I_LOCATION
- O O
CSF O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
for O O
3 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
, O O
and O O
were O O
either O O
left O O
unstimulated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
were O O
stimulated O O
with O O
40 O B_MEASURE/B_LOCATION
ng O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE/B_PERSON
RANKL O I_MEASURE/I_PERSON
at O O
37 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
. O O

Stimulations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
stopped O O
by O O
adding O O
an O O
equal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
volume O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
PhosFlow O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Fix O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Buffer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
I O O
solution O O
( O O
BD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Biosciences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
to O O
the O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

After O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
for O O
10 O B_TIME[MEASURE]
minutes O I_TIME[MEASURE]
at O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
permeabilized O O
by O O
washing O O
twice O O
at O O
room O B_TIME[MEASURE]/B_LOCATION
temperature O I_TIME[MEASURE]/I_LOCATION
in O O
PhosFlow O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perm O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Wash O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Buffer O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BD O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Biosciences O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

A O O
total O O
of O O
1 O O
x O O
105 O O
cells O O
was O O
then O O
Fc O O
blocked O O
with O O
1 O O
mu O O
g O O
human B B_SPECIES[BIO]
IgG O O
for O O
15 O O
minutes O O
, O O
and O O
was O O
stained O O
with O O
Alexa O O
Fluor O O
647 O O
- O O
conjugated O O
mAb O O
either O O
to O O
phospho O O
- O O
p38 O O
MAPK O O
( O O
T180 O O
/ O O
Y182 O O
) O O
or O O
to O O
phospho O O
- O O
ERK1 O O
/ O O
2 O O
( O O
T202 O O
/ O O
Y204 O O
) O O
( O O
BD O O
Biosciences O O
) O O
for O O
30 O O
minutes O O
at O O
room O O
temperature O O
. O O

Alexa O O
Fluor O O
647 O O
- O O
conjugated O O
mouse B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
IgG1 O O
( O O
BD O O
Biosciences O O
) O O
was O O
used O O
as O O
an O O
isotype O O
control O O
. O O

The O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
washed O O
in O O
PhosFlow O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perm O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Wash O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Buffer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
I O O
, O O
and O O
were O O
analyzed O O
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
already O O
described O O
. O O

RNA O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interference O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

RNA O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
oligonucleotides O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
iGENE O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Tsukuba O B_PERSON/B_LOCATION
, O O
Japan O B_LOCATION/B_MEASURE
) O O
were O O
designed O O
based O O
on O O
the O O
algorithm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
that O O
incorporates O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nucleotide O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
homology O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
ensure O O
a O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interference O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
sense O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
and O O
antisense O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oligonucleotides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
used O O
: O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
GCU O B_LOCATION/B_PERSON
UCA O I_LOCATION/I_PERSON
AUG O I_LOCATION/I_PERSON
AGG O I_LOCATION/I_PERSON
AAG O I_LOCATION/I_PERSON
UGA O I_LOCATION/I_PERSON
AGA O I_LOCATION/I_PERSON
AGC O I_LOCATION/I_PERSON
A O I_LOCATION/I_PERSON
- O O
AG O B_LOCATION/B_PROTEIN[GENE]
and O O
3 O B_NUMBER[MEASURE]
' O O
- O O
UA O B_LOCATION/B_MEASURE
- O O
CGA O B_LOCATION/B_ORGANIZATION
AGU O I_LOCATION/I_ORGANIZATION
UAC O I_LOCATION/I_ORGANIZATION
UCC O I_LOCATION/I_ORGANIZATION
UUC O I_LOCATION/I_ORGANIZATION
ACU O I_LOCATION/I_ORGANIZATION
UCU O I_LOCATION/I_ORGANIZATION
UCG O I_LOCATION/I_ORGANIZATION
U O I_LOCATION/I_ORGANIZATION
; O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
CGA O B_LOCATION
UUC O I_LOCATION
GCU O I_LOCATION
AGA O I_LOCATION
CCG O I_LOCATION
GCU O I_LOCATION
UCA O I_LOCATION
UUG O I_LOCATION
C O I_LOCATION
- O O
AG O B_LOCATION/B_PROTEIN[GENE]
and O O
3 O B_NUMBER[MEASURE]/B_LOCATION
' O I_NUMBER[MEASURE]/I_LOCATION
- O O
UA O B_LOCATION
- O O
GCU O B_LOCATION/B_ORGANIZATION
AAG O I_LOCATION/I_ORGANIZATION
CGA O I_LOCATION/I_ORGANIZATION
UCU O I_LOCATION/I_ORGANIZATION
GGC O I_LOCATION/I_ORGANIZATION
CGA O I_LOCATION/I_ORGANIZATION
AGU O I_LOCATION/I_ORGANIZATION
AAC O I_LOCATION/I_ORGANIZATION
G O I_LOCATION/I_ORGANIZATION
; O O
and O O
lamin O B_PERSON/B_PROTEIN[GENE]
, O O
5 O B_NUMBER[MEASURE]
' O O
- O O
GAG O B_LOCATION/B_ORGANIZATION
GAA O I_LOCATION/I_ORGANIZATION
CUG O I_LOCATION/I_ORGANIZATION
GAC O I_LOCATION/I_ORGANIZATION
UUC O I_LOCATION/I_ORGANIZATION
CAG O I_LOCATION/I_ORGANIZATION
AAG O I_LOCATION/I_ORGANIZATION
AAC O I_LOCATION/I_ORGANIZATION
A O I_LOCATION/I_ORGANIZATION
- O O
AG O B_LOCATION/B_ORGANIZATION
and O O
3 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
UA O B_PROTEIN[GENE]/B_LOCATION
- O O
CUC O B_LOCATION/B_ORGANIZATION
CUU O I_LOCATION/I_ORGANIZATION
GAC O I_LOCATION/I_ORGANIZATION
CUG O I_LOCATION/I_ORGANIZATION
AAG O I_LOCATION/I_ORGANIZATION
GUC O I_LOCATION/I_ORGANIZATION
UUC O I_LOCATION/I_ORGANIZATION
UUG O I_LOCATION/I_ORGANIZATION
U O I_LOCATION/I_ORGANIZATION
. O O

CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
8 O B_MEASURE
x O O
104 O B_MEASURE
cells O I_MEASURE
/ O O
well O O
) O O
were O O
incubated O O
in O O
96 O B_MEASURE/B_LOCATION
- O O
well O O
plates O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O O
optimem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Invitrogen O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

After O O
1 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hour O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
siRNAs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O O
transfected O O
into O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
using O O
oligofectamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Qiagen O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
based O O
on O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
recommended O O
by O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
. O O

After O O
2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
washed O O
once O O
with O O
PBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
followed O O
by O O
the O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MEM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
supplemented O O
with O O
10 O B_GENE
% O I_GENE
FBS O I_GENE
, O O
M O B_PROTEIN[GENE]
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
RANKL O B_GENE
. O O

After O O
a O O
2 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]/B_LOCATION
incubation O I_TIME[MEASURE]/I_LOCATION
, O O
the O O
beta O B_GENE
3 O I_GENE
mRNA O I_GENE
expression O I_GENE
was O O
analyzed O O
by O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cycles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
described O O
earlier O O
. O O

Immunofluorescent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
alpha O B_PROTEIN[GENE]/B_DISEASE
v O O
beta O B_GENE
3 O I_GENE
heterodimer O I_GENE
was O O
also O O
performed O O
as O O
described O O
above O O
, O O
and O O
numbers O B_MEASURE/B_LOCATION
of O O
alpha O B_PROTEIN[GENE]/B_DISEASE
v O O
beta O B_GENE
3 O I_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
counted O O
in O O
randomly O O
selected O O
three O B_LOCATION/B_MEASURE
fields O I_LOCATION/I_MEASURE
at O O
100 O B_MEASURE
x O I_MEASURE
magnification O I_MEASURE
. O O

Seven O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
the O O
transfection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
siRNAs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
the O O
number O B_MEASURE
of O O
TRAP O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
five O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fields O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
examined O O
at O O
100 O B_MEASURE
x O O
magnification O B_MEASURE
was O O
counted O O
under O O
light O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Inhibition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
osteoclastogenesis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
cyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RGDfV O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE

CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O O
incubated O O
in O O
96 O B_MEASURE/B_LOCATION
- O O
well O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
plates O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
RANKL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
2 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
containing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
either O O
cyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
RGDfV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
( O O
Arg O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Gly O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Asp O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
D O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Phe O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
Val O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
Calbiochem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
San O B_LOCATION/B_PERSON
Diego O I_LOCATION/I_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
or O O
dimethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sulfoxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
then O O
added O O
. O O

After O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
for O O
a O O
further O B_TIME[MEASURE]
5 O I_TIME[MEASURE]
days O I_TIME[MEASURE]
, O O
the O O
number O B_MEASURE
of O O
TRAP O B_GENE
- O O
positive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MNC O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
five O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fields O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
examined O O
at O O
100 O B_MEASURE
x O O
magnification O B_MEASURE
was O O
counted O O
under O O
light O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Immunohistochemistry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Synovial O O
tissue O O
samples O O
were O O
obtained O O
during O O
total O O
knee O O
joint O O
replacement O O
surgery O O
from O O
four O O
RA O O
patients B B_PERSON/B_LOCATION
. O O

Signed O O
consent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
obtained O O
before O O
the O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
approved O O
by O O
the O O
ethics O B_PERSON/B_ORGANIZATION
committee O I_PERSON/I_ORGANIZATION
of O O
the O O
Tokyo O B_PERSON/B_LOCATION
Medical O I_PERSON/I_LOCATION
and O O
Dental O B_LOCATION
University O I_LOCATION
. O O

RA O B_LOCATION/B_PERSON
was O O
diagnosed O O
according O O
to O O
the O O
American O B_LOCATION/B_ORGANIZATION
College O B_LOCATION/I_ORGANIZATION
of O O
Rheumatology O B_PERSON/B_DISEASE
criteria O I_PERSON/I_DISEASE
[ O O
14 O B_TIME[MEASURE]/B_LOCATION
] O B_TIME[MEASURE]/I_LOCATION
. O O

Double O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
immunofluorescent O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
staining O O
for O O
CD68 O B_GENE
and O O
CD16 O B_GENE
antigens O I_GENE
was O O
conducted O O
on O O
optimal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cutting O O
temperature O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
embedded O O
sections O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
frozen O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synovial O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Eight O B_NUMBER[MEASURE]
- O O
micrometer O B_MEASURE
- O O
thick O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cryostat O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sections O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
RA O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
fixed O O
in O O
acetone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minutes O B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
were O O
then O O
rehydrated O O
in O O
PBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O O
5 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minutes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
incubated O O
in O O
5 O B_MEASURE/B_LOCATION
mu O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE/B_PERSON
proteinase O I_MEASURE/I_PERSON
K O I_MEASURE/I_PERSON
( O O
Roche O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
50 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethylenediamine O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetraacetic O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
100 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tris O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
HCl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pH O O
8 O B_MEASURE
. O O
0 O B_MEASURE
, O O
for O O
15 O B_TIME[MEASURE]
minutes O I_TIME[MEASURE]
at O O
room O B_TIME[MEASURE]/B_LOCATION
temperature O I_TIME[MEASURE]/I_LOCATION
followed O O
by O O
a O O
wash O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
PBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
samples O O
were O O
then O O
blocked O O
with O O
10 O O
% O O
goat B B_SPECIES[BIO]
serum O O
in O O
PBS O O
for O O
60 O O
minutes O O
at O O
room O O
temperature O O
, O O
and O O
were O O
incubated O O
with O O
anti O O
- O O
CD16 O O
mAb O O
( O O
3G8 O O
; O O
Immunotech O O
, O O
Marseille O O
, O O
France O O
) O O
or O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG1 O O
( O O
11711 O O
) O O
as O O
an O O
isotype O O
- O O
matched O O
control O O
in O O
1 O O
% O O
bovine B B_SPECIES[BIO]/B_PROTEIN[GENE]
serum O O
albumin O O
/ O O
PBS O O
for O O
60 O O
minutes O O
at O O
room O O
temperature O O
. O O

The O O
samples O O
were O O
then O O
washed O O
three O O
times O O
in O O
PBS O O
, O O
for O O
5 O O
minutes O O
each O O
, O O
and O O
incubated O O
with O O
Alexa O O
fluor546 O O
- O O
conjugated O O
goat B B_SPECIES[BIO]/B_GENE
anti O O
- O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG1 O O
antibody O O
( O O
Molecular O O
Probes O O
) O O
in O O
1 O O
% O O
bovine B B_PERSON/B_SPECIES[BIO]
serum O O
albumin O O
/ O O
PBS O O
for O O
60 O O
minutes O O
at O O
room O O
temperature O O
. O O

The O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
then O O
sequentially O O
stained O O
for O O
CD68 O B_GENE
antigen O I_GENE
in O O
a O O
manner O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
similar O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
that O O
used O O
for O O
CD16 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
samples O O
were O O
stained O O
with O O
anti O O
- O O
CD68 O O
mAb O O
( O O
PGM1 O O
; O O
Immunotech O O
) O O
or O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG3 O O
( O O
6A3 O O
; O O
MBL O O
, O O
Nagoya O O
, O O
Japan O O
) O O
followed O O
by O O
labeling O O
with O O
Alexa O O
fluor488 O O
- O O
conjugated O O
goat B B_SPECIES[BIO]
anti O O
- O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG3 O O
antibody O O
( O O
Molecular O O
Probes O O
) O O
. O O

The O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
examined O O
by O O
confocal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laser O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scanning O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscope O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Olympus O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Tokyo O B_LOCATION
, O O
Japan O B_LOCATION/B_MEASURE
) O O
. O O

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
expressed O O
as O O
the O O
mean O B_MEASURE
+/- O O
standard O B_MEASURE
error O I_MEASURE
of O O
the O O
mean O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
nonpaired O B_PERSON
Student O I_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
t O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
used O O
for O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
using O O
the O O
StatView O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
Abacus O B_MEASURE/B_EDU[ORGANIZATION]
Concepts O I_MEASURE/I_EDU[ORGANIZATION]
, O O
Berkeley O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

P O B_OTHER/B_MEASURE
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
was O O
considered O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Induction O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
osteoclasts O B_DISEASE/B_GENE
from O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
peripheral O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]

To O O
identify O O
the O O
monocyte O O
subset O O
that O O
differentiates O O
into O O
osteoclasts O O
, O O
we O O
examined O O
osteoclast O O
formation O O
from O O
CD16 O O
+ O O
and O O
CD16 O O
- O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
peripheral O O
blood O O
monocytes O O
. O O

The O O
monocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subsets O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
purified O O
using O O
magnetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beads O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O O
M O B_GENE/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
alone O O
did O O
not O O
induce O O
osteoclast O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
either O O
subset O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
Figure O B_PROTEIN[GENE]
1a O I_PROTEIN[GENE]
) O O
. O O

Culture O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
M O B_PROTEIN[GENE]/B_DISEASE
- O O
CSF O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
RANKL O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
induced O O
a O O
significant O B_MEASURE/B_ORGANIZATION
number O I_MEASURE/I_ORGANIZATION
of O O
TRAP O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
CD16 O B_GENE
- O O
subset O B_MEASURE/B_LOCATION
, O O
whereas O O
only O O
few O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
CD16 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
differentiated O O
into O O
TRAP O B_GENE/B_DISEASE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
MNC O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
Figure O B_PROTEIN[GENE]/B_DISEASE
1a O I_PROTEIN[GENE]/I_DISEASE
, O O
b O O
) O O
. O O

We O O
then O O
assessed O O
the O O
bone O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resorptive O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ability O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
culturing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
on O O
calcium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
phosphate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
coated O O
plates O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
M O B_PROTEIN[GENE]
- O O
CSF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RANKL O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Resorption O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacunae O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
detected O O
only O O
in O O
the O O
CD16 O B_GENE
- O O
subset O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O O
Figure O B_MEASURE
1c O I_MEASURE
) O O
, O O
indicating O O
the O O
TRAP O B_GENE
- O O
positive O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
CD16 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
derived O O
MNC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
possessed O O
the O O
osteoclast O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
obtained O O
using O O
purified O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
by O O
FACS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sorting O O
( O O
purities O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
: O O
CD16 O B_GENE
+ O I_GENE
, O O
96 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
CD16 O B_GENE
- O O
, O O
97 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

The O O
number O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TRAP O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
induced O O
were O O
36 O B_MEASURE
+/- O I_MEASURE
3 O I_MEASURE
cells O I_MEASURE
/ O O
well O O
and O O
348 O B_MEASURE
+/- O O
13 O B_MEASURE/B_BIO
cells O I_MEASURE/I_BIO
/ O O
well O O
from O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE
- O O
monocytes O B_MEASURE
, O O
respectively O O
. O O

To O O
exclude O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
CD16 O B_GENE
antibody O I_GENE
used O O
for O O
isolation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
inhibits O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
osteoclast O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
formation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
separated O O
the O O
two O B_MEASURE/B_BIO
subsets O B_MEASURE/I_BIO
, O O
CD33low O B_GENE
monocytes O I_GENE
and O O
CD33high O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
using O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CD33 O B_GENE
mAb O I_GENE
and O O
a O O
fluorescent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sorter O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
since O O
it O O
was O O
reported O O
that O O
CD33low O B_GENE/B_PERSON
monocytes O I_GENE/I_PERSON
correspond O O
to O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
that O O
CD33high O B_LOCATION/B_GENE
correspond O O
to O O
CD16 O B_GENE/B_LOCATION
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
[ O O
15 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

On O O
average O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
CD33low O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
population O I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
contained O O
CD16 O B_GENE
- O O
( O O
10 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
) O O
/ O O
CD16 O B_GENE
+ O I_GENE
( O O
89 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
and O O
the O O
CD33high O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
population O I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
contained O O
CD16 O B_GENE
- O O
( O O
86 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
) O O
/ O O
CD16 O B_GENE
+ O O
( O O
13 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Culture O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RANKL O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
TRAP O B_GENE/B_DISEASE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
CD33high O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
whereas O O
no O O
or O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
CD33low O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
monocytes O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
differentiated O O
into O O
TRAP O B_GENE/B_DISEASE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]
MNC O I_DISEASE_ADJECTIVE[DISEASE]
( O O
CD33low O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
CD33high O I_MEASURE/I_SPORT[ENT]
, O O
2 O B_MEASURE
+/- O O
1 O B_MEASURE
vs O I_MEASURE
192 O I_MEASURE
+/- O O
71 O B_MEASURE
cells O I_MEASURE
/ O O
well O O
; O O
n O B_OTHER/B_MEASURE
= O O
3 O B_MEASURE
) O O
. O O

TRAP O B_GENE/B_LOCATION
- O O
5b O B_MEASURE
and O O
MMP O B_GENE/B_BIO
- O O
9 O B_MEASURE
in O O
the O O
culture O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
supernatants O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
both O O
of O O
which O O
are O O
known O O
to O O
be O O
produced O O
by O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
were O O
measured O O
by O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
both O O
enzymes O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
culture O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
supernatant O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_BACTERIUM[BIO]
of O O
CD16 O B_GENE/B_LOCATION
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
than O O
in O O
that O O
of O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
Figure O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1d O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
the O O
CD16 O B_GENE/B_DISEASE
- O O
peripheral O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocyte O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
not O O
the O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
differentiate O O
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
by O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O O
RANKL O B_PROTEIN[GENE]/B_LOCATION
+ O I_PROTEIN[GENE]/I_LOCATION
M O I_PROTEIN[GENE]/I_LOCATION
- O O
CSF O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
do O O
not O O
affect O O
the O O
osteoclastogenesis O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE

To O O
examine O O
whether O O
CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
affect O O
osteoclastogenesis O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
CD16 O B_GENE/B_DISEASE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
varied O O
numbers O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
mixed O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
CD16 O B_GENE/B_DISEASE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
5 O B_MEASURE
x O O
104 O B_MEASURE
cells O I_MEASURE
/ O O
well O O
) O O
, O O
and O O
were O O
cultured O O
for O O
7 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
in O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE
+ O I_GENE
RANKL O I_GENE
. O O

The O O
number O B_MEASURE
of O O
TRAP O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
not O O
altered O O
by O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
CD16 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_GENE
monocytes O B_BIO/B_MEASURE
( O O
Figure O B_MEASURE/B_LOCATION
2 O B_MEASURE/I_LOCATION
) O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O O
that O O
CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
did O O
not O O
hamper O O
or O O
enhance O O
the O O
osteoclastogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
production O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
RANKL O B_GENE
- O O
stimulated O O
or O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
stimulated O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE

To O O
compare O O
the O O
biological O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE
- O O
subsets O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
either O O
RANKL O B_GENE
or O O
M O B_OTHER/B_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
stimulation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
we O O
measured O O
the O O
amount O B_MEASURE
of O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE/B_ORGANIZATION
production O I_MEASURE/I_ORGANIZATION
after O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
various O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
RANKL O B_GENE/B_DISEASE
or O O
M O B_OTHER/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
with O O
an O O
ELISA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Without O O
RANKL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
subset O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
produced O O
a O O
significant O B_MEASURE/B_LOCATION
amount O I_MEASURE/I_LOCATION
of O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
, O O
whereas O O
the O O
CD16 O B_GENE
- O O
subset O B_MEASURE/B_PERSON
produced O O
undetectable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Figure O B_MEASURE/B_PERSON
3a O I_MEASURE/I_PERSON
) O O
. O O

RANKL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O O
TNF O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
alpha O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
production O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
from O O
both O O
subsets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
a O O
dose O B_MEASURE/B_LOCATION
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
although O O
the O O
CD16 O B_GENE
+ O I_GENE
subset O I_GENE
produced O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
TNF O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
alpha O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
did O O
the O O
CD16 O B_GENE
- O O
subset O B_MEASURE/B_LOCATION
. O O

RANKL O B_PERSON/B_LOCATION
stimulation O I_PERSON/I_LOCATION
also O O
enhanced O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE/B_ORGANIZATION
production O I_MEASURE/I_ORGANIZATION
from O O
the O O
CD16 O B_GENE
+ O I_GENE
subset O I_GENE
, O O
but O O
not O O
from O O
the O O
CD16 O B_GENE
- O O
subset O B_MEASURE/B_LOCATION
. O O

M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE/B_ORGANIZATION
production O I_MEASURE/I_ORGANIZATION
from O O
both O O
subsets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
although O O
the O O
CD16 O B_GENE/B_MEASURE
+ O I_GENE/I_MEASURE
subset O I_GENE/I_MEASURE
produced O O
more O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
CD16 O B_GENE
- O O
subset O B_MEASURE/B_PERSON
( O O
Figure O B_MEASURE/B_LOCATION
3b O I_MEASURE/I_LOCATION
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
also O O
respond O O
both O O
to O O
RANKL O B_GENE
and O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
although O O
such O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
does O O
not O O
result O O
in O O
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O O
also O O
noted O O
to O O
express O O
higher O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
amounts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
inflammatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
compared O O
with O O
CD16 O B_GENE/B_LOCATION
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
with O O
or O O
without O O
RANKL O B_GENE
or O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
molecules O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
involved O O
in O O
osteoclastogenesis O B_DISEASE
between O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
CD16 O B_GENE/B_LOCATION
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE

Diverse O B_PERSON/B_GENE
molecules O I_PERSON/I_GENE
are O O
involved O O
in O O
RANKL O B_GENE
/ O O
RANK O B_GENE
and O O
its O O
costimulatory O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signal O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transduction O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O O
16 O B_GENE/B_DISEASE
] O I_GENE/I_DISEASE
. O O

The O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
RANKL O B_GENE
+ O O
M O B_PROTEIN[GENE]/B_DISEASE
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
the O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocyte O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
the O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subset O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
might O O
be O O
explained O O
by O O
the O O
expression O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
molecules O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

We O O
therefore O O
examined O O
the O O
mRNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
molecules O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O O
receptor O B_GENE/B_BIO
activator O I_GENE/I_BIO
of O O
NF O B_DISEASE/B_GENE
- O O
kappa O B_PROTEIN[GENE]/B_MEASURE
B O I_PROTEIN[GENE]/I_MEASURE
( O O
RANK O B_GENE
) O O
, O O
the O O
receptor O B_GENE
for O O
RANKL O B_GENE
; O O
c O O
- O O
fms O B_GENE/B_DISEASE
, O O
the O O
receptor O B_GENE
for O O
M O B_GENE
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
; O O
tumor O B_DISEASE/B_GENE
necrosis O B_DISEASE/I_GENE
factor O B_DISEASE/I_GENE
receptor O B_DISEASE/I_GENE
- O O
associated O O
factor O B_PROTEIN[GENE]/B_MEASURE
6 O I_PROTEIN[GENE]/I_MEASURE
( O O
TRAF O B_LOCATION/B_ORGANIZATION
- O O
6 O B_SEQUENCE[MEASURE]/B_LOCATION
) O O
, O O
the O O
adaptor O B_GENE
protein O I_GENE
for O O
RANK O B_GENE
; O O
c O O
- O O
Fos O B_GENE
and O O
nuclear O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
activated O O
T O B_GENE
cells O I_GENE
c1 O I_GENE
( O O
NFATc1 O B_GENE/B_DISEASE
) O O
, O O
transcription O B_GENE/B_BIO
factors O I_GENE/I_BIO
that O O
are O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
osteoclastogenesis O B_DISEASE/B_GENE
; O O
DNAX O B_GENE/B_DISEASE
- O O
activation O B_MEASURE/B_PERSON
protein O I_MEASURE/I_PERSON
12 O I_MEASURE/I_PERSON
( O O
DAP12 O B_GENE/B_PERSON
) O O
and O O
Fc O B_GENE
receptor O I_GENE
gamma O I_GENE
chain O I_GENE
( O O
FcR O B_GENE/B_PERSON
gamma O I_GENE/I_PERSON
) O O
, O O
adaptor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O O
to O O
deliver O O
costimulatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
RANKL O B_GENE
- O O
induced O O
osteoclastogenesis O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
signal O B_GENE
regulatory O I_GENE
protein O I_GENE
beta O I_GENE
1 O I_GENE
( O O
SIRP O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- O O
beta O B_GENE
1 O I_GENE
) O O
, O O
triggering O O
receptor O B_PROTEIN[GENE]/B_LOCATION
expressed O O
on O O
myeloid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O O
TREM O B_LOCATION
- O O
2 O B_MEASURE
) O O
and O O
osteoclast O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
associated O O
receptor O B_GENE/B_LOCATION
( O O
OSCAR O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
transmembrane O B_GENE/B_BIO
receptors O I_GENE/I_BIO
that O O
associate O B_PROTEIN[GENE]/B_LOCATION
with O O
either O O
DAP12 O B_LOCATION/B_GENE
or O O
FcR O B_GENE
gamma O I_GENE
; O O
and O O
alpha O B_GENE
v O O
and O O
beta O B_GENE
3 O I_GENE
, O O
integrins O B_PROTEIN[GENE]/B_DISEASE
known O O
to O O
be O O
expressed O O
as O O
the O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
heterodimer O I_GENE
on O O
osteoclasts O B_DISEASE/B_PROTEIN[GENE]
. O O

The O O
mRNA O B_MEASURE
levels O I_MEASURE
of O O
RANK O B_GENE
, O O
c O B_OTHER/B_GENE
- O O
fms O B_GENE/B_DISEASE
, O O
TRAF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
6 O B_MEASURE
, O O
DAP12 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SIRP O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
beta O B_MEASURE/B_PROTEIN[GENE]
1 O I_MEASURE/I_PROTEIN[GENE]
under O O
the O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
no O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
) O O
varied O O
between O O
the O O
donors O B_PERSON/B_BIO
; O O
however O O
, O O
we O O
did O O
not O O
find O O
consistent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
mRNA O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
of O O
these O O
molecules O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
between O O
the O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocyte O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
subset O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
the O O
CD16 O B_GENE
- O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subset O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
among O O
three O B_NUMBER[MEASURE]/B_LOCATION
to O O
six O B_NUMBER[MEASURE]/B_PERSON
donors O I_NUMBER[MEASURE]/I_PERSON
( O O
Figure O B_MEASURE/B_PERSON
4a O I_MEASURE/I_PERSON
) O O
. O O

The O O
mRNA O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
apart O O
from O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
, O O
were O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
under O O
the O O
no O O
- O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
condition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O

Although O O
the O O
mRNA O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
RANK O B_GENE
, O O
c O O
- O O
fms O B_GENE/B_DISEASE
, O O
DAP12 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
FcR O B_GENE
gamma O I_GENE
, O O
TREM O B_GENE/B_DISEASE
- O O
2 O B_MEASURE
and O O
OSCAR O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
in O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
alone O O
or O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
+ O O
RANKL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
subsets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
not O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_MEASURE/B_LOCATION
subsets O B_MEASURE/I_LOCATION
. O O

Expressions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
TRAF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
6 O B_MEASURE/B_PROTEIN[GENE]
, O O
c O O
- O O
Fos O B_GENE
and O O
SIRP O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
beta O B_MEASURE/B_GENE
1 O I_MEASURE/I_GENE
mRNA O I_MEASURE/I_GENE
did O O
not O O
change O O
following O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE
+ O I_GENE
RANKL O I_GENE
. O O

Of O O
note O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
expression O B_GENE
of O O
NFATc1 O B_GENE
mRNA O I_GENE
was O O
enhanced O O
by O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
RANKL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
only O O
in O O
the O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
subset O B_MEASURE/B_LOCATION
. O O

Furthermore O O
, O O
expression O B_GENE
of O O
integrin O B_GENE/B_LOCATION
alpha O I_GENE/I_LOCATION
v O O
in O O
both O O
subsets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
enhanced O O
by O O
M O B_PROTEIN[GENE]/B_DISEASE
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
with O O
or O O
without O O
RANKL O B_GENE
; O O
however O O
, O O
the O O
expression O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
was O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
CD16 O B_GENE
- O O
subset O B_MEASURE/B_LOCATION
. O O

It O O
was O O
noted O O
that O O
integrin O B_GENE
- O O
beta O B_GENE
3 O I_GENE
mRNA O I_GENE
was O O
detected O O
only O O
in O O
the O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
subset O B_MEASURE/B_LOCATION
and O O
was O O
increased O O
by O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
RANKL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
but O O
not O O
by O O
M O B_OTHER/B_LOCATION
- O O
CSF O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
alone O O
. O O

The O O
protein O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
RANK O B_GENE
under O O
the O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
weakly O O
detected O O
in O O
both O O
subsets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
the O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
varied O O
between O O
donors O B_PERSON/B_LOCATION
by O O
western O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
immunoblotting O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
protein O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
c O B_GENE/B_DISEASE
- O O
fms O B_GENE/B_DISEASE
was O O
weakly O O
detected O O
in O O
unstimulated O B_GENE
CD16 O I_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
but O O
not O O
in O O
CD16 O B_GENE/B_DISEASE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
Figure O B_MEASURE/B_GENE
4b O B_MEASURE/I_GENE
) O O
. O O

Flow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
c O B_GENE/B_DISEASE
- O O
fms O B_GENE/B_DISEASE
in O O
fresh O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O O
however O O
, O O
showed O O
that O O
both O O
subsets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
express O O
the O O
molecule O B_PROTEIN[GENE]
on O O
the O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
surface O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O O
Figure O B_GENE/B_LOCATION
4c O I_GENE/I_LOCATION
) O O
. O O

Expressions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
both O O
RANK O B_GENE
and O O
c O B_GENE/B_DISEASE
- O O
fms O B_GENE/B_DISEASE
were O O
upregulated O O
by O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
alone O O
and O O
by O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE
+ O I_GENE
RANKL O I_GENE
, O O
and O O
we O O
did O O
not O O
find O O
consistent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
protein O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
molecules O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
monocyte O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subsets O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
profiles O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
expression O B_GENE
levels O I_GENE
of O O
molecules O B_BIO/B_GENE
involved O O
in O O
RANKL O B_GENE
/ O O
RANK O B_GENE
and O O
its O O
costimulatory O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
are O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_MEASURE/B_PERSON
subsets O B_MEASURE/I_PERSON
, O O
except O O
for O O
NFATc1 O B_GENE
, O O
integrin O B_GENE
alpha O I_GENE
v O O
and O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
. O O

We O O
therefore O O
assumed O O
that O O
the O O
distinct O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
NFATc1 O B_GENE
, O O
integrin O B_GENE
alpha O I_GENE
v O O
and O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
RANKL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
among O O
the O O
two O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocyte O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
subsets O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
might O O
explain O O
the O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
their O O
abilities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
differentiate O O
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

RANKL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induces O O
alpha O B_GENE/B_LOCATION
v O O
beta O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]

The O O
integrin O B_GENE/B_DISEASE
- O O
beta O B_PROTEIN[GENE]/B_LOCATION
3 O I_PROTEIN[GENE]/I_LOCATION
subunit O I_PROTEIN[GENE]/I_LOCATION
binds O O
to O O
integrin O O
alpha O B_PROTEIN[GENE]
v O O
only O O
and O O
is O O
expressed O O
as O O
the O O
heterodimeric O B_PROTEIN[GENE]
protein O I_PROTEIN[GENE]
alpha O I_PROTEIN[GENE]
v O O
beta O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
3 O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
[ O O
17 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
examined O O
the O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
alpha O B_GENE/B_LOCATION
v O O
beta O B_GENE
3 O I_GENE
on O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
by O O
immunofluorescent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Neither O O
unstimulated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nor O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
stimulated O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subsets O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
expressed O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
( O O
Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4d O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
not O O
shown O O
) O O
. O O

After O O
48 O B_MEASURE
and O O
72 O B_TIME[MEASURE]
hours O I_TIME[MEASURE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
with O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE
+ O I_GENE
RANKL O I_GENE
, O O
alpha O B_GENE/B_LOCATION
v O O
beta O B_GENE
3 O I_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mononuclear O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
observed O O
in O O
CD16 O B_GENE
- O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
in O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocyte O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cultures O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

At O O
96 O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
, O O
both O O
alpha O B_GENE/B_LOCATION
v O O
beta O B_GENE/B_DISEASE
3 O I_GENE/I_DISEASE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mononuclear O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
multinucleated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocyte O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
culture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
was O O
selectively O O
expressed O O
on O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
the O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE
+ O I_GENE
RANKL O I_GENE
, O O
and O O
the O O
expression O B_GENE
was O O
revealed O O
before O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
differentiate O O
into O O
typical O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
multinucleated O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
osteoclasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RANKL O B_GENE
activates O O
ERK O B_GENE
and O O
p38 O O
kinases O O
only O O
in O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE

Since O O
ERK O B_GENE
and O O
p38 O B_GENE
MAPK O I_GENE
are O O
essential O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
RANKL O B_GENE
- O O
induced O O
osteoclastogenesis O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
[ O O
18 O B_MEASURE/B_LOCATION
- O O
20 O B_MEASURE
] O O
, O O
we O O
next O O
examined O O
whether O O
these O O
kinases O B_GENE/B_LOCATION
were O O
activated O O
differently O O
in O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
in O O
CD16 O B_GENE/B_DISEASE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Purified O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O O
precultured O O
with O O
25 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_GENE/B_MEASURE
M O B_GENE/I_MEASURE
- O O
CSF O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
for O O
3 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
enhance O O
RANK O B_DISEASE/B_GENE
expression O I_DISEASE/I_GENE
, O O
and O O
were O O
then O O
treated O O
with O O
RANKL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
RANKL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induced O O
phosphorylation O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
both O O
ERK O B_GENE
and O O
p38 O O
MAPK O B_GENE
in O O
CD16 O B_GENE/B_DISEASE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
at O O
5 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
postexposure O I_TIME[MEASURE]/I_ENT
, O O
although O O
the O O
p38 O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MAPK O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
weak O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Both O O
phosphorylations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
declined O O
to O O
a O O
basal O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
within O O
20 O B_TIME[MEASURE]
minutes O I_TIME[MEASURE]
( O O
Figure O B_MEASURE/B_PERSON
5 O I_MEASURE/I_PERSON
) O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ERK O B_GENE
and O O
p38 O B_GENE
MAPK O I_GENE
were O O
not O O
detectably O O
phosphorylated O O
in O O
CD16 O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ O B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
monocytes O B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
RANKL O B_GENE/B_DISEASE
. O O

siRNA O O
targeting O O
integrin O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
osteoclastogenesis O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]

The O O
integrin O B_GENE/B_DISEASE
- O O
beta O B_LOCATION/B_PROTEIN[GENE]
3 O B_LOCATION/I_PROTEIN[GENE]
cytoplasmic O B_LOCATION/I_PROTEIN[GENE]
domain O B_LOCATION/I_PROTEIN[GENE]
is O O
essential O B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
activation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
intracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signals O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
alpha O B_GENE/B_DISEASE
v O O
beta O B_GENE
3 O I_GENE
heterodimers O I_GENE
[ O O
17 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
therefore O O
examined O O
the O O
involvement O O
of O O
alpha O O
v O O
beta O O
3 O O
in O O
RANKL O O
+ O O
M O O
- O O
CSF O O
- O O
induced O O
osteoclastogenesis O O
in O O
human B B_PERSON/B_SPECIES[BIO]
CD16 O O
- O O
monocytes O O
using O O
siRNA O O
targeting O O
the O O
integrin O O
- O O
beta O O
3 O O
subunit O O
. O O

The O O
integrin O B_GENE/B_LOCATION
- O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
siRNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
control O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
randomized O O
siRNA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
transfected O O
into O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

At O O
48 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
transfection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
we O O
determined O O
the O O
integrin O B_GENE/B_LOCATION
- O O
beta O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
3 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
level O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
alpha O B_GENE
v O O
beta O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimer O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
integrin O B_GENE
- O O
beta O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
in O O
the O O
integrin O B_GENE
- O O
beta O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
siRNA O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
transfected O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
siRNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
transfected O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
( O O
Figure O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
6a O B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

The O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
heterodimer O I_GENE
expression O I_GENE
was O O
evaluated O O
by O O
immunofluorescent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
number O B_MEASURE
of O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
decreased O O
in O O
integrin O B_GENE/B_DISEASE
- O O
beta O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
siRNA O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
transfected O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
compared O O
with O O
that O O
in O O
control O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
siRNA O I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_MEASURE/B_BIO
6b O B_MEASURE/I_BIO
) O O
. O O

After O O
7 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
, O O
the O O
number O B_MEASURE
of O O
TRAP O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
counted O O
. O O

Transfection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
integrin O B_GENE/B_LOCATION
- O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
siRNA O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
reduced O O
the O O
number O B_MEASURE
of O O
TRAP O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
dose O B_MEASURE/B_LOCATION
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
compared O O
with O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
siRNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transfection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Figure O B_LOCATION/B_MEASURE
6c O I_LOCATION/I_MEASURE
) O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
siRNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
directed O O
toward O O
a O O
different O B_MEASURE/B_GENE
site O B_MEASURE/I_GENE
of O O
integrin O B_GENE/B_LOCATION
- O O
beta O B_GENE/B_MEASURE
3 O I_GENE/I_MEASURE
mRNA O I_GENE/I_MEASURE
also O O
inhibited O O
osteoclast O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
from O O
CD16 O B_PROTEIN[GENE]/B_DISEASE
- O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

On O O
the O O
other O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hand O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
siRNA O O
that O O
targeted O O
lamin O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
which O O
was O O
used O O
as O O
a O O
negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
did O O
not O O
inhibit O O
the O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
osteoclasts O B_GENE/B_DISEASE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
the O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
in O O
RANKL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
osteoclast O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
from O O
CD16 O B_GENE/B_DISEASE
- O O
peripheral O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Cyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
RGDfV O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
inhibits O O
the O O
osteoclastogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
from O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]

Integrin O B_GENE/B_LOCATION
alpha O I_GENE/I_LOCATION
v O O
beta O B_GENE/B_LOCATION
3 O I_GENE/I_LOCATION
recognizes O O
a O O
common O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tripeptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
sequence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
RGD O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Arg O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Gly O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Asp O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
which O O
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
matrix O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
such O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
as O O
vitronectin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
fibronectin O B_GENE
[ O O
21 O B_GENE/B_LOCATION
] O I_GENE/I_LOCATION
. O O

Cyclic O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RGDfV O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Arg O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Gly O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Asp O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
D O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Phe O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
Val O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
inhibits O O
binding O B_TIME[MEASURE]/B_PERSON
of O O
the O O
RGD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
containing O O
molecules O B_LOCATION/B_PROTEIN[GENE]
to O O
alpha O B_GENE
v O O
beta O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
22 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
investigate O O
the O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ligand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
heterodimer O I_GENE
in O O
the O O
osteoclastogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
examined O O
whether O O
cyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RGDfV O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibits O O
the O O
formation O B_DISEASE/B_ORGANISM_FUNCTION
of O O
osteoclasts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Cyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
RGDfV O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
significantly O O
reduced O O
the O O
number O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TRAP O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MNC O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
a O O
dose O B_MEASURE/B_LOCATION
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
Figure O B_MEASURE/B_LOCATION
6d O I_MEASURE/I_LOCATION
) O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
imply O O
possible O B_DISEASE_ADJECTIVE[DISEASE]
involvement O I_DISEASE_ADJECTIVE[DISEASE]
of O O
ligand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
bindings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
in O O
the O O
osteoclastogenesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Knockdown O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
did O O
not O O
affect O O
the O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
NFATc1 O B_GENE
mRNA O I_GENE

In O O
the O O
next O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
determined O O
whether O O
integrin O B_GENE/B_LOCATION
- O O
beta O B_PROTEIN[GENE]/B_MEASURE
3 O I_PROTEIN[GENE]/I_MEASURE
- O O
siRNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
induced O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
osteoclastogenesis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reflects O O
downregulation O B_GENE
of O O
NFATc1 O B_GENE
, O O
which O O
is O O
a O O
key O B_GENE/B_MEASURE
transcription O I_GENE/I_MEASURE
factor O I_GENE/I_MEASURE
in O O
osteoclastogenesis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
[ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
23 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
this O O
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
compared O O
NFATc1 O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
integrin O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
beta O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
3 O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
control O O
siRNA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
transfected O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Interestingly O O
, O O
integrin O B_GENE
- O O
beta O B_PROTEIN[GENE]/B_MEASURE
3 O I_PROTEIN[GENE]/I_MEASURE
knockdown O I_PROTEIN[GENE]/I_MEASURE
did O O
not O O
alter O O
the O O
NFATc1 O B_GENE/B_MEASURE
mRNA O I_GENE/I_MEASURE
level O I_GENE/I_MEASURE
( O O
Figure O B_TIME[MEASURE]/B_LOCATION
7 O I_TIME[MEASURE]/I_LOCATION
) O O
, O O
suggesting O O
that O O
signal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transduction O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mediated O O
by O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
does O O
not O O
affect O O
the O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
NFATc1 O B_GENE
. O O

Detection O O
of O O
CD16 O O
+ O O
and O O
CD16 O O
- O O
macrophages O O
in O O
synovium O O
of O O
RA O O
patients B B_PERSON/B_BIO

RA O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synovial O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
macrophages O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
derived O O
from O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
their O O
recruitment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
into O O
the O O
synovium O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
is O O
facilitated O O
by O O
various O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adhesion O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
chemokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O O
24 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
] O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

To O O
analyze O O
CD16 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
synovial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
RA O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
synovial O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tissues O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
double O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
stained O O
for O O
CD16 O B_GENE
and O O
a O O
macrophage O B_GENE/B_MEASURE
marker O B_GENE/I_MEASURE
, O O
CD68 O B_GENE
. O O

CD16 O B_GENE
- O O
/ O O
CD68 O B_GENE
+ O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O O
widespread O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
synovium O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
. O O

Although O O
less O O
frequent O B_DISEASE_ADJECTIVE[DISEASE]
, O O
CD16 O B_GENE
+ O I_GENE
/ O O
CD68 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
also O O
observed O O
both O O
in O O
the O O
synovial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
intima O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
subintima O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE/B_LOCATION
8 O B_MEASURE/I_LOCATION
) O O
. O O

The O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
two O B_MEASURE/B_LOCATION
subsets O B_MEASURE/I_LOCATION
of O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE
- O O
, O O
in O O
RA O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
synovium O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
indicates O O
that O O
both O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE
- O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
are O O
recruited O O
into O O
the O O
synovium O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Human B B_PERSON
peripheral O O
blood O O
monocytes O O
are O O
a O O
heterogeneous O O
population O O
, O O
and O O
they O O
are O O
divided O O
into O O
two O O
subsets O O
based O O
on O O
the O O
expression O O
of O O
CD16 O O
. O O

The O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE
- O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subsets O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
show O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
migration O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
cytokine O B_DISEASE_ADJECTIVE[DISEASE]
production O I_DISEASE_ADJECTIVE[DISEASE]
and O O
differentiation O B_PROTEIN[GENE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
into O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
dendritic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
11 O B_SEQUENCE[MEASURE]
- O O
13 O B_MEASURE
, O O
15 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

We O O
focused O O
on O O
the O O
heterogeneity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
monocytes O B_BIO/B_GENE
, O O
and O O
the O O
primary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
question O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
addressed O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O O
which O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
subset O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
could O O
be O O
the O O
source O B_PERSON/B_LOCATION
of O O
osteoclasts O B_DISEASE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrated O O
that O O
CD16 O B_GENE/B_DISEASE
- O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
differentiated O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
by O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
RANKL O B_PROTEIN[GENE]/B_LOCATION
+ O I_PROTEIN[GENE]/I_LOCATION
M O I_PROTEIN[GENE]/I_LOCATION
- O O
CSF O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

To O O
investigate O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
RANKL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
between O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
, O O
we O O
examined O O
the O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
molecules O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
known O O
to O O
be O O
involved O O
in O O
osteoclastogenesis O B_DISEASE
. O O

The O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
integrin O B_GENE
alpha O I_GENE
v O O
, O O
integrin O B_PROTEIN[GENE]/B_MEASURE
beta O I_PROTEIN[GENE]/I_MEASURE
3 O I_PROTEIN[GENE]/I_MEASURE
and O O
NFATc1 O B_GENE
were O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_MEASURE/B_PERSON
subsets O B_MEASURE/I_PERSON
. O O

Integrin O B_GENE/B_LOCATION
alpha O I_GENE/I_LOCATION
v O O
beta O B_GENE
3 O I_GENE
heterodimer O I_GENE
was O O
expressed O O
only O O
on O O
RANKL O B_GENE/B_BIO
and O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
stimulated O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

It O O
is O O
known O O
that O O
alpha O B_GENE/B_LOCATION
v O O
beta O B_GENE
3 O I_GENE
expressed O O
on O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
bone O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
resorption O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
as O O
well O O
as O O
in O O
attachment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
to O O
the O O
bone O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
25 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
was O O
recently O O
reported O O
that O O
bone O O
marrow O O
macrophages O O
of O O
integrin O O
- O O
beta O O
3 O O
- O O
deficient O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
not O O
differentiate O O
into O O
mature O O
osteoclasts O O
in O O
vitro O O
, O O
suggesting O O
that O O
alpha O O
v O O
beta O O
3 O O
is O O
involved O O
not O O
only O O
in O O
activation O O
, O O
but O O
also O O
in O O
differentiation O O
, O O
of O O
osteoclasts O O
in O O
mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
26 O O
, O O
27 O O
] O O
. O O

The O O
authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
showed O O
that O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
and O O
c O B_GENE/B_DISEASE
- O O
fms O B_GENE/B_BIO
share O I_GENE/I_BIO
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
intracellular O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
signaling O O
pathway O B_LOCATION
, O O
including O O
the O O
activation O B_GENE
of O O
ERK O B_GENE
and O O
the O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
c O B_GENE/B_DISEASE
- O O
Fos O B_GENE
[ O O
27 O B_MEASURE
] O I_MEASURE
, O O
both O O
of O O
which O O
are O O
essential O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
osteoclastogenesis O B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
28 O I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
29 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

In O O
addition O O
, O O
it O O
was O O
reported O O
that O O
echistatin O O
, O O
an O O
alpha O O
v O O
beta O O
3 O O
antagonist O O
, O O
inhibited O O
osteoclast O O
formation O O
of O O
mouse B B_SPECIES[BIO]/B_DISEASE
bone O O
marrow O O
cells O O
[ O O
30 O O
] O O
. O O

In O O
accordance O O
with O O
these O O
reports O O
, O O
our O O
data O O
showed O O
that O O
knockdown O O
of O O
integrin O O
- O O
beta O O
3 O O
expression O O
resulted O O
in O O
downregulation O O
of O O
the O O
alpha O O
v O O
beta O O
3 O O
heterodimer O O
, O O
and O O
abrogated O O
osteoclastogenesis O O
from O O
human B B_PERSON/B_SPECIES[BIO]
peripheral O O
blood O O
CD16 O O
- O O
monocytes O O
. O O

We O O
also O O
showed O O
that O O
blocking O O
of O O
adhesive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ligands O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
bind O O
to O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
by O O
RGDfV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibited O O
osteoclast O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
from O O
CD16 O B_GENE
- O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Taken O O
together O O
, O O
the O O
process O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
ligand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
alpha O B_GENE/B_LOCATION
v O O
beta O B_GENE
3 O I_GENE
may O O
be O O
involved O O
in O O
the O O
osteoclastogenesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Blockade O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
alpha O B_GENE/B_LOCATION
v O O
beta O B_GENE
3 O I_GENE
could O O
therefore O O
be O O
a O O
therapeutically O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
modulate O O
osteoclastogenesis O B_DISEASE/B_ORGANISM_FUNCTION
. O O

Indeed O O
, O O
integrin O O
alpha O O
v O O
beta O O
3 O O
antagonists O O
effectively O O
treated O O
osteoporosis O O
in O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rats B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
humans B B_PERSON/B_SPECIES[BIO]
, O O
and O O
protected O O
bone O O
destruction O O
in O O
rat O O
adjuvant O O
- O O
induced O O
arthritis O O
in O O
vivo O O
[ O O
31 O O
- O O
34 O O
] O O
. O O

Of O O
note O O
, O O
it O O
is O O
reported O O
that O O
patients B B_PERSON/B_BIO
with O O
Iraqi O O
- O O
Jewish O O
- O O
type O O
Glanzmann O O
thrombasthenia O O
who O O
are O O
deficient O O
in O O
integrin O O
beta O O
3 O O
do O O
not O O
develop O O
osteopetrosis O O
because O O
of O O
the O O
upregulation O O
of O O
alpha O O
2 O O
beta O O
1 O O
expression O O
on O O
osteoclasts O O
, O O
although O O
the O O
bone O O
- O O
resorptive O O
ability O O
of O O
the O O
osteoclasts O O
was O O
decreased O O
in O O
vitro O O
[ O O
35 O O
] O O
. O O

The O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alpha O B_GENE/B_LOCATION
v O O
beta O B_GENE
3 O I_GENE
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
osteoclast O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
resorptive O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
function O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
could O O
therefore O O
be O O
partially O O
compensated O O
by O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
integrins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
all O O
the O O
multinucleated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
osteoclasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
expressed O O
alpha O B_PROTEIN[GENE]
v O O
beta O B_PROTEIN[GENE]/B_MEASURE
3 O I_PROTEIN[GENE]/I_MEASURE
( O O
Figure O B_MEASURE/B_LOCATION
4d O I_MEASURE/I_LOCATION
) O O
[ O O
36 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
, O O
a O O
small O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE
+ O I_GENE
RANKL O I_GENE
- O O
stimulated O O
mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CD16 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
expressed O O
alpha O B_PROTEIN[GENE]
v O O
beta O B_PROTEIN[GENE]/B_MEASURE
3 O I_PROTEIN[GENE]/I_MEASURE
( O O
Figure O B_MEASURE/B_LOCATION
4d O I_MEASURE/I_LOCATION
) O O
. O O

Multinucleated O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
osteoclasts O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
formed O O
by O O
fusion O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
osteoclast O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
precursor O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
[ O O
37 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

It O O
was O O
reported O O
that O O
alpha O B_GENE
v O O
beta O B_GENE
3 O I_GENE
is O O
involved O O
in O O
the O O
migration O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
osteoclast O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
precursors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
30 O B_GENE/B_LOCATION
] O I_GENE/I_LOCATION
. O O

The O O
alpha O B_PROTEIN[GENE]/B_DISEASE
v O O
beta O B_PROTEIN[GENE]
3 O I_PROTEIN[GENE]
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
could O O
therefore O O
be O O
forced O O
to O O
migrate O O
by O O
the O O
ligands O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
may O O
fuse O O
with O O
closed O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
v O O
beta O B_PROTEIN[GENE]
3 O I_PROTEIN[GENE]
- O O
negative O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Alternatively O O
, O O
only O O
alpha O B_GENE/B_NUMBER[MEASURE]
v O O
beta O B_GENE
3 O I_GENE
- O O
positive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
fused O O
with O O
each O O
other O B_NUMBER[MEASURE]/B_DISEASE
. O O

It O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
consider O O
that O O
signaling O O
from O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CD16 O B_GENE
mAb O I_GENE
- O O
coated O O
magnetic O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
beads O B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
were O O
used O O
for O O
the O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
separation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
by O O
IgG O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contained O O
in O O
FBS O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
might O O
inhibit O O
osteoclastogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
from O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

We O O
therefore O O
separated O O
the O O
two O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CD33 O B_GENE
mAb O I_GENE
and O O
a O O
fluorescent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sorter O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
stimulated O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
M O B_GENE/B_LOCATION
- O O
CSF O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
+ O O
RANKL O B_GENE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
CD33low O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
which O O
correspond O O
to O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
still O O
could O O
not O O
differentiate O O
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

CD16 O B_GENE
is O O
a O O
heterodimer O B_GENE
consisting O O
of O O
Fc O B_GENE
gamma O I_GENE
IIIa O I_GENE
and O O
Fc O B_GENE
gamma O I_GENE
, O O
and O O
has O O
low O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affinity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
the O O
Fc O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region O B_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
IgG O B_GENE
. O O

Aggregation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CD16 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
immune O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
transmission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
activating O O
signals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
via O O
the O O
immunoreceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tyrosine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
based O O
activation O B_LOCATION/B_BIO
motif O I_LOCATION/I_BIO
in O O
the O O
gamma O B_GENE
chain O I_GENE
[ O O
38 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
also O O
assessed O O
osteoclastogenesis O O
from O O
the O O
two O O
monocyte O O
subsets O O
using O O
IgG O O
- O O
depleted O O
bovine B B_PERSON/B_SPECIES[BIO]
serum O O
. O O

Even O O
in O O
the O O
IgG O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
free O B_LOCATION/B_MEASURE
medium O I_LOCATION/I_MEASURE
, O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
but O O
not O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
differentiated O O
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

We O O
could O O
therefore O O
exclude O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
signal O B_GENE
transduction O I_GENE
through O O
CD16 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibits O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
osteoclastogenesis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

NFATc1 O B_GENE
is O O
a O O
key O B_GENE/B_MEASURE
transcription O I_GENE/I_MEASURE
factor O I_GENE/I_MEASURE
in O O
osteoclastogenesis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
M O B_PROTEIN[GENE]/B_DISEASE
- O O
CSF O B_GENE
+ O I_GENE
RANKL O I_GENE
increased O O
the O O
NFATc1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
subset O B_MEASURE/B_LOCATION
only O O
, O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
integrin O B_GENE/B_LOCATION
alpha O I_GENE/I_LOCATION
v O O
and O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
. O O

The O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
NFATc1 O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
induction O B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
might O O
therefore O O
also O O
explain O O
the O O
difference O B_MEASURE
in O O
osteoclastogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
monocyte O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subsets O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

It O O
is O O
of O O
interest O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
knockdown O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
did O O
not O O
lower O O
the O O
mRNA O B_MEASURE
level O I_MEASURE
of O O
NFATc1 O B_GENE
. O O

This O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
supports O O
the O O
notion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
NFATc1 O B_GENE
is O O
located O O
upstream O O
of O O
integrin O B_GENE
- O O
beta O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
3 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
39 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

It O O
is O O
also O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
two O B_NUMBER[MEASURE]
signaling O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
mediated O O
by O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
and O O
NFATc1 O B_GENE
contributes O O
to O O
osteoclastogenesis O O
independently O O
or O O
cooperatively O O
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
needed O O
to O O
determine O O
the O O
mechanisms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
integrin O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
beta O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
3 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
involvement O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
RANKL O B_GENE/B_PERSON
/ O O
RANK O B_GENE
- O O
mediated O O
osteoclast O B_DISEASE
differentiation O I_DISEASE
. O O

It O O
has O O
been O O
demonstrated O O
that O O
MAPK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
families O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ERK O B_GENE
and O O
p38 O O
MAPK O B_GENE/B_BIO
, O O
were O O
activated O O
by O O
RANKL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
signalings O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
osteoclast O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
precursors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
18 O B_NUMBER[MEASURE]
, O O
19 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
these O O
kinases O B_GENE
are O O
involved O O
in O O
the O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
[ O O
20 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
showed O O
that O O
RANKL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induced O O
phosphorylation O B_GENE
of O O
ERK O B_GENE
and O O
p38 O O
MAPK O B_GENE
only O O
in O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

It O O
is O O
suggested O O
that O O
differential O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
these O O
kinases O B_GENE
may O O
partially O O
explain O O
the O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]
properties O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
two O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocyte O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
upon O O
RANKL O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
produce O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
inflammatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
compared O O
with O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O O
that O O
CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
produced O O
larger O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
amounts O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
TNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
upon O O
lipopolysaccharide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
lipopeptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
than O O
did O O
CD16 O B_GENE
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
[ O O
40 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Interestingly O O
, O O
we O O
showed O O
that O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
either O O
with O O
RANKL O B_GENE
or O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
upregulated O O
the O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE/B_ORGANIZATION
production O I_MEASURE/I_ORGANIZATION
by O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

A O O
marked O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
is O O
reported O O
in O O
inflammatory O B_DISEASE/B_LOCATION
diseases O I_DISEASE/I_LOCATION
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
infection O B_DISEASE
, O O
malignancy O B_DISEASE
, O O
Kawasaki O B_DISEASE
disease O I_DISEASE
and O O
RA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
41 O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
44 O B_MEASURE
] O I_MEASURE
. O O

Taken O O
together O O
, O O
CD16 O B_GENE
+ O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O O
be O O
an O O
important O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
source O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
inflammatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
mice B B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
peripheral O O
blood O O
Ly O O
- O O
6Chigh O O
monocytes O O
, O O
which O O
are O O
thought O O
to O O
correspond O O
to O O
human B B_PERSON/B_SPECIES[BIO]
CD16 O O
- O O
monocytes O O
, O O
increase O O
in O O
inflammatory O O
conditions O O
, O O
and O O
these O O
cells O O
are O O
recruited O O
into O O
sites O O
of O O
inflammation O O
[ O O
45 O O
] O O
. O O

In O O
contrast O O
, O O
Ly O O
- O O
6Clow O O
monocytes O O
, O O
which O O
are O O
thought O O
to O O
correspond O O
to O O
human B B_PERSON/B_SPECIES[BIO]
CD16 O O
+ O O
, O O
migrate O O
into O O
noninflamed O O
tissues O O
[ O O
12 O O
] O O
. O O

These O O
data O O
on O O
mouse B B_SPECIES[BIO]/B_DISEASE
monocytes O O
seem O O
to O O
be O O
in O O
contrast O O
to O O
the O O
data O O
on O O
human B B_SPECIES[BIO]
monocytes O O
, O O
which O O
show O O
expansion O O
of O O
CD16 O O
+ O O
monocytes O O
in O O
inflammatory O O
conditions O O
where O O
they O O
produce O O
larger O O
amounts O O
of O O
inflammatory O O
cytokines O O
. O O

At O O
present O O
, O O
it O O
is O O
not O O
clear O O
whether O O
mouse B B_SPECIES[BIO]/B_DISEASE
monocyte O O
subsets O O
, O O
Ly O O
- O O
6Clow O O
/ O O
Ly O O
- O O
6Chigh O O
, O O
represent O O
human B B_PERSON/B_SPECIES[BIO]
monocyte O O
subsets O O
, O O
CD16 O O
+ O O
/ O O
CD16 O O
- O O
monocytes O O
, O O
and O O
whether O O
the O O
biologic O O
functions O O
of O O
mouse B B_SPECIES[BIO]/B_DISEASE
monocytes O O
are O O
analogous O O
to O O
those O O
of O O
human B B_PERSON/B_SPECIES[BIO]
monocytes O O
. O O

In O O
mice B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
blood O O
monocytes O O
newly O O
released O O
from O O
the O O
bone O O
marrow O O
are O O
exclusively O O
Ly O O
- O O
6Chigh O O
and O O
the O O
level O O
of O O
Ly O O
- O O
6C O O
is O O
downregulated O O
while O O
in O O
circulation O O
[ O O
45 O O
] O O
. O O

It O O
is O O
thus O O
suggested O O
that O O
in O O
mice B B_BIO/B_DISEASE
the O O
two O O
monocyte O O
subsets O O
differing O O
in O O
Ly O O
- O O
6C O O
expression O O
represent O O
different O O
stages O O
in O O
the O O
maturation O O
pathway O O
. O O

In O O
the O O
human B B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
, O O
transition O O
from O O
CD16 O O
- O O
monocytes O O
to O O
CD16 O O
+ O O
monocytes O O
is O O
observed O O
upon O O
culture O O
with O O
IL O O
- O O
10 O O
, O O
M O O
- O O
CSF O O
and O O
transforming O O
growth O O
factor O O
beta O O
in O O
vitro O O
[ O O
42 O O
, O O
46 O O
] O O
. O O

Similar O O
to O O
mouse B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O O
, O O
therefore O O
, O O
human B B_PERSON/B_SPECIES[BIO]
peripheral O O
blood O O
CD16 O O
- O O
monocytes O O
may O O
also O O
maturate O O
into O O
CD16 O O
+ O O
monocytes O O
. O O

It O O
is O O
reported O O
that O O
a O O
significant O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
RA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
intima O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
express O O
CD16 O B_GENE
, O O
suggesting O O
that O O
CD16 O B_GENE
+ O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
synovial O B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
47 O B_MEASURE/B_DISEASE
] O I_MEASURE/I_DISEASE
. O O

We O O
confirmed O O
that O O
both O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
CD16 O B_GENE
- O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
accumulate O O
in O O
the O O
RA O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O O
double O B_NUMBER[MEASURE]/B_COLOR
- O O
color O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunohistochemical O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
CD68 O B_GENE
and O O
CD16 O B_GENE
. O O

A O O
number O B_MEASURE/B_PERSON
of O O
chemokines O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O O
abundantly O O
expressed O O
in O O
the O O
RA O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
24 O B_MEASURE
, O O
48 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Among O O
these O O
cytokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
MCP O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
, O O
MIP O B_GENE
- O O
1 O B_MEASURE/B_PROTEIN[GENE]
alpha O I_MEASURE/I_PROTEIN[GENE]
, O O
SDF O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
1 O B_MEASURE
, O O
RANTES O B_GENE
and O O
fractalkine O B_GENE/B_BACTERIUM[BIO]
can O O
induce O O
migration O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
[ O O
11 O B_MEASURE
, O O
12 O B_TIME[MEASURE]
] O I_TIME[MEASURE]
and O O
unpublished O B_MEASURE
data O I_MEASURE
) O O
. O O

On O O
the O O
other O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
hand O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
migration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
is O O
induced O O
only O O
by O O
fractalkine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

These O O
chemokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
therefore O O
seem O O
to O O
play O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
recruitment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
CD16 O B_GENE
+ O I_GENE
and O O
CD16 O B_GENE/B_LOCATION
- O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
the O O
circulating O O
pool O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
into O O
the O O
RA O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
osteoclast O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inducers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
also O O
produced O O
in O O
the O O
RA O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RANKL O B_GENE/B_LOCATION
is O O
expressed O O
by O O
synovial O B_DISEASE_ADJECTIVE[DISEASE]
fibroblasts O I_DISEASE_ADJECTIVE[DISEASE]
and O O
activated O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
[ O O
49 O B_MEASURE
- O O
51 O B_MEASURE
] O I_MEASURE
, O O
while O O
M O B_PROTEIN[GENE]/B_LOCATION
- O O
CSF O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
expressed O O
on O O
RA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
fibroblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
52 O B_MEASURE
, O O
53 O B_MEASURE
] O I_MEASURE
. O O

TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
, O O
which O O
are O O
mainly O O
expressed O O
on O O
RA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
fibroblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
respectively O O
, O O
could O O
also O O
enhance O O
osteoclast O B_DISEASE/B_GENE
differentiation O I_DISEASE/I_GENE
[ O O
54 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Collectively O O
, O O
it O O
is O O
probable O B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
recruited O O
CD16 O B_PROTEIN[GENE]/B_DISEASE
- O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
differentiate O O
into O O
osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O O
the O O
RA O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
contribute O O
to O O
bone O B_DISEASE
destruction O I_DISEASE
. O O

On O O
the O O
other O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
hand O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CD16 O B_GENE
+ O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
might O O
also O O
be O O
involved O O
in O O
RA O B_DISEASE
pathogenesis O I_DISEASE
by O O
producing O O
inflammatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
. O O

Since O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
enhance O O
osteoclast O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
[ O O
54 O B_MEASURE
, O O
55 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
, O O
CD16 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
/ O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
may O O
also O O
contribute O O
to O O
osteoclastogenesis O B_DISEASE
in O O
RA O B_DISEASE/B_LOCATION
synovium O I_DISEASE/I_LOCATION
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

We O O
have O O
shown O O
that O O
human B B_PERSON/B_SPECIES[BIO]
peripheral O O
blood O O
monocytes O O
consist O O
of O O
two O O
functionally O O
heterogeneous O O
subsets O O
with O O
distinct O O
response O O
to O O
osteoclastogenic O O
stimuli O O
. O O

Osteoclasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
seem O O
to O O
originate O O
from O O
CD16 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
monocytes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
integrin O B_GENE
beta O I_GENE
3 O I_GENE
is O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
osteoclastogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
blockade O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
accumulation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
activation O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CD16 O B_PROTEIN[GENE]/B_DISEASE
- O O
monocytes O B_GENE
could O O
therefore O O
be O O
a O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
bone O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resorptive O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
especially O O
for O O
RA O B_DISEASE/B_LOCATION
. O O

Abbreviations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

DAP O O
= O O
DNAX O O
- O O
activation O O
protein O O
; O O
ELISA O O
= O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
; O O
FBS O O
= O O
fetal O O
bovine B B_SPECIES[BIO]/B_PROTEIN[GENE]
serum O O
; O O
FcR O O
gamma O O
= O O
Fc O O
receptor O O
gamma O O
chain O O
; O O
IL O O
= O O
interleukin O O
; O O
FITC O O
= O O
fluorescein O O
isothiocianate O O
; O O
mAb O O
, O O
monoclonal O O
antibody O O
; O O
M O O
- O O
CSF O O
= O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
; O O
MEM O O
= O O
modified O O
Eagle O O
' O O
s O O
medium O O
; O O
MMP O O
= O O
matrix O O
metalloproteinase O O
; O O
MNC O O
= O O
multinucleated O O
cells O O
; O O
NF O O
= O O
nuclear O O
factor O O
; O O
OSCAR O O
= O O
osteoclast O O
- O O
associated O O
receptor O O
; O O
PBS O O
= O O
phosphate O O
- O O
buffered O O
saline O O
; O O
PCR O O
= O O
polymerase O O
chain O O
reaction O O
; O O
RA O O
= O O
rheumatoid O O
arthritis O O
; O O
RANK O O
= O O
receptor O O
activator O O
of O O
NF O O
- O O
kappa O O
B O O
; O O
RANKL O O
= O O
receptor O O
activator O O
of O O
NF O O
- O O
kappa O O
B O O
ligand O O
; O O
RT O O
= O O
reverse O O
transcriptase O O
; O O
siRNA O O
= O O
small O O
interfering O O
RNA O O
; O O
SIRP O O
- O O
beta O O
1 O O
= O O
signal O O
regulatory O O
protein O O
- O O
beta O O
1 O O
; O O
TNF O O
alpha O O
= O O
tumor O O
necrosis O O
factor O O
alpha O O
; O O
TRAF O O
= O O
tumor O O
necrosis O O
factor O O
receptor O O
- O O
associated O O
factor O O
; O O
TRAP O O
= O O
tartrate O O
- O O
resistant O O
acid O O
phosphatase O O
; O O
TREM O O
= O O
triggering O O
receptor O O
expressed O O
on O O
myeloid O O
cells O O
. O O

Competing O O
interests O B_DISEASE

The O O
authors O B_PERSON
declare O O
that O O
they O O
have O O
no O O
competing O O
interests O B_PERSON/B_ORGANIZATION
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

YK O B_PERSON
participated O O
in O O
the O O
design O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
carried O O
out O O
the O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
drafted O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

KH O B_PERSON/B_LOCATION
and O O
KT O B_PERSON/B_LOCATION
participated O O
in O O
the O O
design O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
its O O
coordination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

TN O B_PERSON/B_ORGANIZATION
and O O
NM O B_MEASURE/B_ORGANIZATION
conceived O O
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
participated O O
in O O
its O O
design O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
coordination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
and O O
helped O O
to O O
draft O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
authors O B_PERSON/B_NUMBER[MEASURE]
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

Embryonic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathoblasts O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transiently O O
express O O
TrkB O B_GENE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
proliferate O O
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
brain O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
derived O O
neurotrophic O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Nerve O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
neurotrophin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
3 O B_MEASURE
are O O
involved O O
in O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
sympathetic O B_DISEASE
neurons O I_DISEASE
; O O
however O O
, O O
whether O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
derived O O
neurotrophic O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
plays O O
a O O
role O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
known O O
. O O

The O O
purpose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
whether O O
BDNF O B_GENE
and O O
its O O
receptor O B_GENE
, O O
TrkB O B_GENE/B_LOCATION
, O O
are O O
expressed O O
during O O
the O O
development O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
paravertebral O B_DISEASE
sympathetic O I_DISEASE
ganglia O I_DISEASE
in O O
vivo O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
to O O
determine O O
the O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
vitro O B_LOCATION/B_SPECIES[BIO]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

As O O
neural O O
crest O O
cells O O
coalesce O O
to O O
form O O
sympathetic O O
ganglia O O
, O O
TrkB O O
- O O
positive O O
cells O O
are O O
seen O O
in O O
both O O
chicken B B_SPECIES[BIO]
and O O
mouse B B_SPECIES[BIO]/B_DISEASE
embryos O O
. O O

In O O
chicken B B_SPECIES[BIO]
embryos O O
, O O
TrkB O O
- O O
expressing O O
cells O O
first O O
appear O O
at O O
Hamburger O O
- O O
Hamilton O O
Stage O O
( O O
St O O
) O O
27 O O
and O O
they O O
co O O
- O O
express O O
HNK O O
- O O
1 O O
, O O
confirming O O
that O O
they O O
are O O
migrating O O
neural O O
crest O O
cells O O
. O O

The O O
TrkB O B_GENE/B_MEASURE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lack O O
neural O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
markers O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
this O O
stage O B_ENT/B_MEASURE
; O O
however O O
, O O
they O O
migrate O O
with O O
other O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
neurally O O
differentiating O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O O
are O O
TrkA O B_GENE
and O O
TrkC O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

By O O
St O B_LOCATION/B_PERSON
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
, O O
TrkB O B_GENE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
begin O O
to O O
express O O
the O O
neural O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
specific O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
markers O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Hu O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_OTHER/B_PROTEIN[GENE]
and O O
Islet O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
1 O B_TIME[MEASURE]/B_LOCATION
; O O
eventually O O
, O O
all O O
TrkB O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
positive O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
commence O O
neural O B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
St O B_LOCATION/B_PERSON
. O O

34 O B_MEASURE/B_LOCATION
, O O
TrkB O B_GENE
and O O
TrkC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
lost O O
. O O

BDNF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
transcript O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
parallels O O
that O O
of O O
TrkB O B_GENE
. O O

In O O
the O O
mouse B B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
TrkB O O
- O O
positive O O
cells O O
surround O O
newly O O
formed O O
sympathetic O O
ganglia O O
and O O
a O O
small O O
number O O
of O O
TrkB O O
positive O O
cells O O
that O O
co O O
- O O
express O O
tyrosine O O
hydroxylase O O
are O O
seen O O
within O O
ganglia O O
between O O
E13 O O
. O O
5 O O
- O O
15 O O
. O O

In O O
cell O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
many O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
St O B_LOCATION/B_BIO
. O O

29 O O
- O O
30 O O
chicken B B_SPECIES[BIO]/B_MEASURE
lumbar O O
sympathetic O O
ganglia O O
express O O
neural O O
markers O O
and O O
are O O
dividing O O
, O O
indicating O O
that O O
they O O
are O O
sympathoblasts O O
. O O

Sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
require O O
both O O
nerve O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
neurotrophin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
3 O B_MEASURE
for O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O O

BDNF O B_GENE
increases O O
the O O
number O B_MEASURE/B_PERSON
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expressing O O
neural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
markers O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
culture O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
increasing O O
number O B_MEASURE/B_PERSON
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O O
incorporate O O
bromodeoxyuridine O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
most O B_GENE
TrkB O I_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
actively O O
proliferating O O
between O O
E6 O B_PROTEIN[GENE]
- O O
E8 O B_MEASURE/B_PROTEIN[GENE]
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Developing O O
paravertebral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
avian O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
murine O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
embryos O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
a O O
subpopulation O B_MEASURE/B_LOCATION
of O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
transiently O O
express O O
TrkB O B_GENE
and O O
ultimately O O
commence O O
neuronal O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

These O O
TrkB O B_GENE/B_DISEASE
expressing O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
not O O
actively O O
dividing O O
in O O
vivo O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O O
yet O O
, O O
when O O
placed O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
will O O
divide O O
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
BDNF O B_GENE
. O O

This O O
suggests O O
that O O
the O O
availability O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
BDNF O B_GENE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fails O O
to O O
reach O O
a O O
threshold O B_MEASURE/B_LOCATION
necessary O B_MEASURE/I_LOCATION
to O O
induce O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
suggest O O
that O O
excess O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
TrkB O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
lead O O
to O O
the O O
genesis O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
neuroblastoma O B_DISEASE
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
crest O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
destined O O
to O O
become O O
paravertebral O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neurons O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
proliferate O O
and O O
differentiate O O
during O O
migration O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
gangliogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O O

In O O
chicken B B_SPECIES[BIO]
embryos O O
, O O
migrating O O
neural O O
crest O O
cells O O
express O O
catecholamines O O
at O O
Hamburger O O
/ O O
Hamilton O O
Stage O O
( O O
St O O
. O O
) O O
19 O O
, O O
and O O
these O O
cells O O
form O O
the O O
primary O O
sympathetic O O
chain O O
dorsolateral O O
to O O
the O O
aorta O O
at O O
St O O
. O O

22 O B_NUMBER[MEASURE]
( O O
E3 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
) O O
[ O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Between O O
St O B_LOCATION/B_PERSON
. O O

23 O B_TIME[MEASURE]/B_PERSON
( O O
E4 O B_MEASURE
) O O
and O O
St O B_PROTEIN[GENE]/B_MEASURE
. O O

28 O O
( O O
E6 O B_MEASURE
) O O
, O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
disperse O O
and O O
undergo O O
a O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
migration O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
form O O
the O O
paravertebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
chain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
resides O O
ventral O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
dorsal O B_BODY_PART_OR_ORGAN_COMPONENT
root O I_BODY_PART_OR_ORGAN_COMPONENT
ganglion O I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
1 O B_PROTEIN[GENE]/B_LOCATION
] O I_PROTEIN[GENE]/I_LOCATION
. O O

After O O
ganglia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
coalesce O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
, O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
express O O
markers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
neuronal O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
Q211 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
tyrosine O B_GENE
hydroxylase O I_GENE
( O O
TH O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
at O O
a O O
time O B_TIME[MEASURE]/B_LOCATION
when O O
they O O
also O O
incorporate O O
[ O O
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
thymidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O O
2 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Time O O
lapse O O
photography O O
has O O
shown O O
that O O
cultured O O
E15 O O
. O O
5 O O
- O O
E16 O O
. O O
5 O O
sympathetic O O
neurons O O
from O O
rat B B_SPECIES[BIO]/B_GENE
embryos O O
extend O O
axons O O
while O O
they O O
divide O O
[ O O
3 O O
- O O
5 O O
] O O
. O O

Although O O
proliferation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
appears O O
to O O
be O O
an O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
expand O O
the O O
sympathetic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neuron O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
population O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O O
differentiation O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
, O O
the O O
mechanisms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
guide O O
sympathoblast O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
have O O
not O O
been O O
identified O O
. O O

The O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
guided O O
by O O
neurotrophins O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Neurotrophin O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O O
3 O B_NUMBER[MEASURE]/B_LOCATION
( O O
NT O B_LOCATION/B_ORGANIZATION
- O O
3 O B_NUMBER[MEASURE]/B_LOCATION
) O O
binds O B_TIME[MEASURE]/B_PERSON
to O O
its O O
receptor O B_GENE
, O O
TrkC O B_GENE
, O O
to O O
promote O O
the O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathoblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lumbar O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
paravertebral O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
ganglia O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
6 O B_GENE/B_LOCATION
] O I_GENE/I_LOCATION
. O O

Nerve O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
signals O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
through O O
its O O
receptor O B_GENE
, O O
TrkA O B_GENE/B_LOCATION
, O O
to O O
promote O O
the O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
upon O O
target O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
innervation O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
7 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

There O O
are O O
severe O O
sympathetic O O
defects O O
in O O
the O O
superior O O
cervical O O
ganglion O O
of O O
individual O O
NT O O
- O O
3 O O
and O O
NGF O O
knockout O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
8 O O
- O O
10 O O
] O O
. O O

Furthermore O O
, O O
there O O
is O O
no O O
additional O O
cell O O
death O O
in O O
the O O
superior O O
cervical O O
ganglion O O
of O O
NT O O
- O O
3 O O
and O O
NGF O O
double O O
knockout O O
mouse B B_SPECIES[BIO]/B_DISEASE
embryos O O
, O O
suggesting O O
that O O
all O O
of O O
the O O
neurons O O
are O O
dependent O O
on O O
both O O
neurotrophins O O
for O O
survival O O
[ O O
11 O O
] O O
. O O

There O O
is O O
also O O
an O O
increase O O
in O O
sympathetic O O
neuron O O
cell O O
death O O
in O O
TrkA O O
knockout O O
mice B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
12 O O
] O O
. O O

However O O
, O O
in O O
TrkB O O
and O O
BDNF O O
knockout O O
mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
is O O
no O O
apparent O O
phenotype O O
in O O
the O O
superior O O
cervical O O
ganglion O O
, O O
and O O
there O O
is O O
little O O
evidence O O
that O O
TrkB O O
or O O
BDNF O O
is O O
expressed O O
in O O
sympathetic O O
ganglia O O
. O O

Thus O O
, O O
it O O
is O O
generally O O
thought O O
that O O
TrkB O B_GENE
and O O
BDNF O B_GENE/B_LOCATION
have O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
no O O
roles O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O O
guiding O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
sympathetic O B_DISEASE
neurons O I_DISEASE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
their O O
developmental O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
neurotrophin O B_GENE/B_PERSON
receptors O I_GENE/I_PERSON
regulate O O
cell O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
behavior O B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
neuroblastoma O B_DISEASE
, O O
a O O
tumor O B_DISEASE
found O O
in O O
sympathetic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
adrenal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
medulla O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

Tumors O B_DISEASE/B_PERSON
that O O
express O O
TrkA O B_GENE
often O O
spontaneously O O
regress O O
, O O
while O O
those O O
that O O
express O O
TrkB O B_GENE
and O O
its O O
ligand O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O O
derived O O
neurotrophic O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BDNF O B_GENE
) O O
, O O
grow O O
aggressively O O
, O O
are O O
invasive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
fail O O
to O O
respond O O
to O O
chemotherapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
13 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
] O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
TrkA O B_GENE
in O O
neuroblastoma O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tumors O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
its O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
developing O O
sympathetic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
suggests O O
that O O
regressive O B_DISEASE/B_PERSON
neuroblastoma O I_DISEASE/I_PERSON
tumors O I_DISEASE/I_PERSON
arise O O
from O O
early O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
express O O
TrkA O B_GENE
. O O

The O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TrkB O B_GENE
in O O
early O B_DISEASE
sympathetic O I_DISEASE
development O I_DISEASE
is O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
which O O
makes O O
understanding O O
the O O
etiology O B_DISEASE
of O O
aggressive O B_DISEASE
neuroblastoma O I_DISEASE
tumors O I_DISEASE
difficult O I_DISEASE
. O O

Based O O
on O O
its O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
neuroblastoma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
tumors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O O
we O O
hypothesize O O
that O O
BDNF O B_GENE
and O O
TrkB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
differentiating O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
responsible O B_DISEASE_ADJECTIVE[DISEASE]
for O O
expanding O O
the O O
neuronal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
population O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
through O O
proliferation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
. O O

We O O
sought O O
to O O
determine O O
whether O O
BDNF O B_GENE
and O O
TrkB O B_GENE
are O O
involved O O
in O O
sympathetic O B_DISEASE
development O I_DISEASE
. O O

We O O
report O O
that O O
during O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
embryonic O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
TrkB O B_GENE
is O O
expressed O O
in O O
a O O
subset O B_MEASURE/B_LOCATION
of O O
differentiating O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
avian O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
murine O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
embryos O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
also O O
find O O
that O O
BDNF O B_GENE
promotes O O
the O O
proliferation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
TrkB O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathoblasts O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
culture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

However O O
, O O
the O O
majority O B_PERSON/B_MEASURE
of O O
TrkB O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
positive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
fail O O
to O O
take O O
up O O
bromodeoxyuridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
BrdU O B_PROTEIN[GENE]/B_LOCATION
) O O
over O O
a O O
24 O B_TIME[MEASURE]/B_LOCATION
hr O I_TIME[MEASURE]/I_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
, O O
suggesting O O
that O O
endogenous O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
BDNF O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
concentrations O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
do O O
not O O
reach O O
a O O
threshold O B_MEASURE/B_LOCATION
necessary O I_MEASURE/I_LOCATION
to O O
stimulate O O
proliferation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Shortly O O
after O O
all O O
of O O
the O O
TrkB O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
positive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
commence O O
neuronal O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
TrkB O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoreactivity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
lost O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
prolonged O O
expression O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
activation O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
TrkB O B_GENE
signaling O I_GENE
at O O
these O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
may O O
be O O
an O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triggering O O
the O O
formation O B_DISEASE/B_ORGANISM_FUNCTION
of O O
neuroblastoma O B_DISEASE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

TrkB O B_GENE
is O O
expressed O O
during O O
migration O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
crest O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]

We O O
first O O
determined O O
whether O O
TrkB O B_GENE
is O O
expressed O O
in O O
neural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
crest O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
region O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventral O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
dorsal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
root O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
where O O
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ganglia O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coalesce O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
Hamburger O B_PERSON
/ O O
Hamilton O B_PERSON
Stages O I_PERSON
( O O
St O B_LOCATION/B_PERSON
. O O
) O O
25 O B_MEASURE
- O O
28 O B_MEASURE
/ O O
29 O B_MEASURE
. O O

To O O
identify O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
that O O
have O O
commenced O O
neuronal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
transverse O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
sections O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
of O O
the O O
lumbar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
spinal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
column O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
were O O
stained O O
with O O
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O O
Hu O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_MEASURE/B_GENE
[ O I_MEASURE/I_GENE
14 O I_MEASURE/I_GENE
] O I_MEASURE/I_GENE
, O O
a O O
neuronal O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O O
specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
binding O O
protein O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
or O O
Islet O B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
, O O
a O O
transcription O B_GENE
factor O I_GENE
found O O
in O O
sympathetic O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neurons O I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
15 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

We O O
found O O
that O O
Hu O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Islet O B_LOCATION/B_GENE
- O O
1 O B_MEASURE/B_LOCATION
are O O
expressed O O
in O O
the O O
same O B_BODY_PART_OR_ORGAN_COMPONENT
cells O I_BODY_PART_OR_ORGAN_COMPONENT
both O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
in O O
vitro O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
throughout O O
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

In O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
done O O
between O O
St O B_LOCATION/B_PERSON
. O O

25 O O
and O O
28 O B_MEASURE/B_LOCATION
, O O
Islet O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
1 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
staining O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
appeared O O
weaker O B_MEASURE/B_DISEASE
than O O
Hu O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
thus O O
we O O
used O O
Hu O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
identify O O
differentiating O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
these O O
stages O B_DISEASE/B_TIME[MEASURE]
. O O

At O O
later O B_TIME[MEASURE]/B_LOCATION
stages O I_TIME[MEASURE]/I_LOCATION
, O O
Islet O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
1 O B_NUMBER[MEASURE]
was O O
used O O
to O O
facilitate O O
the O O
identification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
because O O
of O O
the O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
location O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
its O O
immunoreactivity O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expressing O O
Hu O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
/ O O
D O B_OTHER/B_PROTEIN[GENE]
are O O
first O O
detected O O
at O O
St O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

25 O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
ventral O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
to O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
dorsal O B_MEASURE/B_LOCATION
root O B_MEASURE/I_LOCATION
ganglion O B_MEASURE/I_LOCATION
and O O
lateral O B_MEASURE/B_LOCATION
to O O
the O O
dorsal O B_BODY_PART_OR_ORGAN_COMPONENT
aorta O I_BODY_PART_OR_ORGAN_COMPONENT
( O O
Figure O B_PROTEIN[GENE]
1A O I_PROTEIN[GENE]
, O O
1B O B_MEASURE/B_PROTEIN[GENE]
) O O
. O O

By O O
St O B_LOCATION/B_PERSON
. O O

26 O O
, O O
the O O
number O B_MEASURE/B_PERSON
of O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
express O O
Hu O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_OTHER/B_PROTEIN[GENE]
in O O
this O O
region O B_LOCATION
increases O O
dramatically O O
( O O
Figure O B_MEASURE/B_LOCATION
1C O I_MEASURE/I_LOCATION
) O O
. O O

TrkB O O
- O O
expressing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
first O O
appear O O
at O O
St O B_LOCATION/B_ORGANISM_FUNCTION
. O O

27 O B_TIME[MEASURE]/B_LOCATION
in O O
the O O
same O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
are O O
adjacent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
Hu O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_LOCATION/B_MEASURE
cells O I_LOCATION/I_MEASURE
( O O
Figure O B_PROTEIN[GENE]
1D O I_PROTEIN[GENE]
, O O
2A O B_PROTEIN[GENE]/B_DISEASE
, O O
2H O B_PROTEIN[GENE]/B_MEASURE
) O O
. O O

TrkB O B_GENE
- O O
positive O B_DISEASE/B_LOCATION
cells O I_DISEASE/I_LOCATION
co O I_DISEASE/I_LOCATION
- O O
localize O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
neural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
crest O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
marker O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
HNK O B_LOCATION/B_GENE
- O O
1 O B_NUMBER[MEASURE]
( O O
Figures O B_PROTEIN[GENE]/B_MEASURE
2B O I_PROTEIN[GENE]/I_MEASURE
, O O
2C O B_PROTEIN[GENE]/B_DISEASE
, O O
2D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
Hu O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_OTHER/B_PROTEIN[GENE]
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
this O O
region O B_LOCATION
are O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neurons O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
since O O
they O O
appear O O
in O O
the O O
region O B_LOCATION/B_BIO
where O O
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ganglia O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
form O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
express O O
tyrosine O B_ENZYME[GENE]
hydroxylase O I_ENZYME[GENE]
, O O
a O O
rate O B_MEASURE
- O O
limiting O O
enzyme O B_ENZYME[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
synthesis O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_GENE
of O O
catecholamines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Figures O B_PROTEIN[GENE]/B_LOCATION
2E O I_PROTEIN[GENE]/I_LOCATION
, O O
2F O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
2G O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

At O O
St O B_LOCATION/B_MEASURE
. O O

28 O B_MEASURE
/ O O
29 O B_MEASURE
, O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
begin O O
to O O
coalesce O O
ventral O B_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
to O O
the O O
dorsal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
root O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
ganglion O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O O
the O O
Hu O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TrkB O B_GENE
- O O
positive O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
remain O O
as O O
two O B_MEASURE/B_PERSON
separate O B_MEASURE/I_PERSON
cell O B_MEASURE/I_PERSON
populations O B_MEASURE/I_PERSON
( O O
Figure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1E O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
; O O
however O O
, O O
shortly O O
afterwards O O
, O O
all O O
of O O
the O O
TrkB O B_GENE/B_MEASURE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
begin O O
to O O
express O O
Islet O B_LOCATION/B_PERSON
- O O
1 O B_NUMBER[MEASURE]/B_PERSON
( O O
Figure O B_GENE/B_LOCATION
3B O I_GENE/I_LOCATION
) O O
and O O
Hu O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

Developmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
TrkA O B_GENE
, O O
TrkB O B_GENE/B_LOCATION
, O O
TrkC O B_GENE
, O O
and O O
BDNF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
TrkB O B_GENE
, O O
the O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neurotrophin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
TrkA O B_GENE
and O O
TrkC O B_GENE
, O O
are O O
co O B_LOCATION/B_MEASURE
- O O
expressed O O
in O O
both O O
Hu O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Hu O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]
cells O I_DISEASE_ADJECTIVE[DISEASE]
at O O
St O B_MEASURE
. O O

27 O O
( O O
Figures O B_MEASURE/B_PROTEIN[GENE]
2I O I_MEASURE/I_PROTEIN[GENE]
, O O
2J O B_TIME[MEASURE]
) O O
. O O

We O O
find O O
that O O
approximately O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
the O O
Islet O B_LOCATION/B_PROTEIN[GENE]
- O O
1 O B_MEASURE/B_DISEASE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
express O O
TrkA O B_GENE
( O O
Figure O B_MEASURE/B_DISEASE
3A O I_MEASURE/I_DISEASE
) O O
, O O
while O O
50 O B_PERSON/B_NUMBER[MEASURE]
% O B_PERSON/I_NUMBER[MEASURE]
express O O
TrkB O B_GENE
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
3B O B_MEASURE/I_PROTEIN[GENE]
) O O
and O O
100 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
express O O
TrkC O B_GENE
( O O
Figure O B_MEASURE/B_LOCATION
3C O I_MEASURE/I_LOCATION
) O O
at O O
St O B_MEASURE
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_TIME[MEASURE]/B_LOCATION
. O O
5 O B_MEASURE
) O O
. O O

Thus O O
, O O
all O O
developing O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
express O O
TrkC O B_GENE
in O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O O
either O O
TrkA O B_GENE
or O O
TrkB O B_GENE
. O O

By O O
St O B_LOCATION/B_PERSON
. O O

31 O B_MEASURE/B_LOCATION
( O O
E7 O B_MEASURE
) O O
, O O
the O O
number O B_MEASURE/B_PERSON
of O O
TrkA O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Islet O B_LOCATION
- O O
1 O B_NUMBER[MEASURE]/B_LOCATION
- O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
increases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
100 O B_MEASURE
% O I_MEASURE
( O O
Figure O B_PROTEIN[GENE]
3D O I_PROTEIN[GENE]
) O O
and O O
immunoreactivities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
both O O
TrkB O B_GENE/B_LOCATION
and O O
TrkC O B_GENE
appear O O
dispersed O O
( O O
Figure O B_PROTEIN[GENE]
3E O I_PROTEIN[GENE]
, O O
3F O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

By O O
St O B_LOCATION/B_PERSON
. O O

34 O B_MEASURE/B_LOCATION
( O O
E8 O B_MEASURE/B_GENE
) O O
, O O
TrkA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
well O O
- O O
sustained O O
( O O
Figure O B_PROTEIN[GENE]
3G O I_PROTEIN[GENE]
) O O
and O O
TrkB O B_LOCATION
and O O
TrkC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoreactivities O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
lost O O
( O O
Figure O B_PROTEIN[GENE]
3H O I_PROTEIN[GENE]
, O O
3I O B_MEASURE/B_PROTEIN[GENE]
) O O
. O O

We O O
also O O
examined O O
the O O
early O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
development O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
murine O B_PERSON/B_EDU[ORGANIZATION]
sympathetic O B_PERSON/I_EDU[ORGANIZATION]
ganglia O B_PERSON/I_EDU[ORGANIZATION]
( O O
Figure O B_TIME[MEASURE]/B_LOCATION
4 O I_TIME[MEASURE]/I_LOCATION
) O O
. O O

At O O
E13 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
, O O
the O O
newly O O
formed O O
lumbar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
observed O O
ventral O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
notochord O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
their O O
staining O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
Hu O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_OTHER/B_PROTEIN[GENE]
and O O
TH O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Figure O B_MEASURE/B_PERSON
4A O I_MEASURE/I_PERSON
) O O
. O O

TrkB O B_GENE/B_DISEASE
- O O
positive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
seen O O
surrounding O O
developing O O
ganglia O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
well O O
as O O
in O O
occasional O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
within O O
the O O
ganglia O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
4C O I_PROTEIN[GENE]/I_LOCATION
, O O
D O B_OTHER/B_MEASURE
) O O
. O O

These O O
TrkB O B_GENE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
ganglia O B_DISEASE/B_PROTEIN[GENE]
co O B_DISEASE/I_PROTEIN[GENE]
- O O
express O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
TH O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
are O O
seen O O
at O O
a O O
frequency O B_MEASURE
of O O
1 O B_MEASURE/B_LOCATION
- O O
2 O B_MEASURE
cells O I_MEASURE
per O O
section O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
starting O O
at O O
E13 O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
4A O B_MEASURE/I_PROTEIN[GENE]
- O O
D O B_OTHER/B_MEASURE
) O O
and O O
are O O
still O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
E15 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
5 O B_MEASURE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
not O O
shown O O
) O O
. O O

In O O
neuroblastoma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
BDNF O B_GENE
is O O
co O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
expressed O O
with O O
TrkB O B_GENE
, O O
suggesting O O
that O O
autocrine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
a O O
means O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
which O O
proliferation O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
sustained O O
in O O
the O O
transformed O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O O

To O O
test O O
whether O O
BDNF O O
, O O
the O O
ligand O O
for O O
TrkB O O
, O O
was O O
present O O
in O O
embryonic O O
chick B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
sympathetic O O
ganglia O O
, O O
we O O
used O O
quantitative O O
real O O
- O O
time O O
PCR O O
with O O
TaqMan O O
probes O O
to O O
determine O O
the O O
relative O O
abundance O O
of O O
BDNF O O
transcripts O O
in O O
total O O
RNA O O
extracted O O
from O O
lumbar O O
sympathetic O O
ganglia O O
at O O
St O O
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_TIME[MEASURE]/B_LOCATION
. O O
5 O B_MEASURE
) O O
, O O
St O B_LOCATION/B_PERSON
. O O

31 O B_TIME[MEASURE]/B_PERSON
( O O
E7 O B_MEASURE
) O O
, O O
St O B_GENE/B_MEASURE
. O O

34 O B_NUMBER[MEASURE]
( O O
E8 O B_MEASURE/B_PROTEIN[GENE]
) O O
, O O
and O O
E9 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BDNF O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
ganglia O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parallels O O
that O O
of O O
TrkB O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
: O O
BDNF O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
highest O B_MEASURE
at O O
St O B_MEASURE/B_LOCATION
29 O I_MEASURE/I_LOCATION
/ O O
30 O B_MEASURE
( O O
E6 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
) O O
, O O
and O O
these O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decrease O O
2 O B_NUMBER[MEASURE]
- O O
fold O B_SEQUENCE[MEASURE]
at O O
St O B_PROTEIN[GENE]
. O O

31 O B_TIME[MEASURE]/B_PERSON
( O O
E7 O B_MEASURE
) O O
and O O
St O B_LOCATION/B_GENE
. O O

34 O B_TIME[MEASURE]/B_LOCATION
( O O
E8 O O
; O O
Figure O B_MEASURE/B_PERSON
5 O I_MEASURE/I_PERSON
) O O
. O O

By O O
E9 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
BDNF O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
7 O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
times O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lower O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
at O O
St O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_TIME[MEASURE]/B_LOCATION
. O O
5 O B_MEASURE
; O O
Figure O B_MEASURE/B_PERSON
5 O I_MEASURE/I_PERSON
) O O
. O O

NT3 O B_GENE
and O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promote O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
differentiating O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
culture O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

To O O
determine O O
the O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
neurotrophins O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
cultured O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
dispersed O O
from O O
lumbar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
St O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
) O O
because O O
, O O
at O O
this O O
stage O B_MEASURE/B_ENT
, O O
ganglion O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
the O O
number O B_MEASURE/B_LOCATION
of O O
TrkA O B_GENE
- O O
, O O
TrkB O B_GENE
- O O
, O O
and O O
TrkC O B_GENE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
peaked O O
, O O
and O O
all O O
Trk O B_GENE/B_LOCATION
- O O
expressing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
have O O
initiated O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

First O O
, O O
we O O
identified O O
markers O B_GENE/B_DISEASE
expressed O O
by O O
acutely O O
isolated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
. O O

As O O
shown O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
80 O B_MEASURE
- O O
91 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
p75 O O
neurotrophin O B_PROTEIN[GENE]
receptor O I_PROTEIN[GENE]
( O O
NTR O B_LOCATION/B_ORGANIZATION
) O O
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
indicating O O
that O O
most O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
crest O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
derived O O
and O O
little O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mesenchymal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contamination O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
introduced O O
by O O
the O O
isolation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
28 O B_MEASURE
- O O
33 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
express O O
the O O
neural O B_GENE
marker O I_GENE
Hu O I_GENE
C O I_GENE
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Approximately O O
half O B_MEASURE
of O O
these O O
Hu O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_OTHER/B_PROTEIN[GENE]
- O O
positive O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
express O O
TrkB O B_GENE/B_DISEASE
. O O

Conversely O O
, O O
all O O
of O O
the O O
TrkB O B_DISEASE/B_LOCATION
positive O I_DISEASE/I_LOCATION
cells O I_DISEASE/I_LOCATION
express O O
Hu O B_LOCATION/B_GENE
C O I_LOCATION/I_GENE
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
TrkB O B_GENE/B_MEASURE
- O O
positive O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
comprise O O
approximately O O
14 O B_NUMBER[MEASURE]
- O O
17 O B_SEQUENCE[MEASURE]/B_PERSON
% O I_SEQUENCE[MEASURE]/I_PERSON
of O O
the O O
total O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
population O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

We O O
then O O
determined O O
how O O
many O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
acutely O O
isolated O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
proliferating O O
by O O
incubating O O
them O O
for O O
12 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
BrdU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
containing O O
medium O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

For O O
these O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
identified O O
differentiating O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
with O O
the O O
transcription O B_GENE/B_DISEASE
factor O I_GENE/I_DISEASE
Islet O I_GENE/I_DISEASE
- O O
1 O B_NUMBER[MEASURE]
because O O
this O O
marker O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
labels O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nuclei O O
, O O
thus O O
it O O
co O O
localizes O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
any O O
BrdU O B_GENE
that O O
has O O
been O O
incorporated O O
into O O
the O O
DNA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
allowing O O
us O O
to O O
determine O O
whether O O
the O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
had O O
undergone O O
S O B_DISEASE/B_PROTEIN[GENE]
- O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
the O O
cell O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
12 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
BrdU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
59 O B_PERSON/B_MEASURE
% O I_PERSON/I_MEASURE
of O O
Islet O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
1 O B_MEASURE/B_DISEASE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclei O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stain O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
BrdU O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoreactivity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
cultures O B_LOCATION/B_PERSON
of O O
St O B_LOCATION/B_PERSON
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE/B_PERSON
sympathetic O I_MEASURE/I_PERSON
ganglia O I_MEASURE/I_PERSON
contain O O
many O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
proliferate O O
while O O
exhibiting O O
markers O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
neuronal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
confirming O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
call O O
these O O
dividing O O
neuronal O B_LOCATION
precursors O I_LOCATION
sympathoblasts O I_LOCATION
. O O

The O O
remaining O O
non O B_DISEASE_ADJECTIVE[DISEASE]
- O O
BrdU O B_DISEASE_ADJECTIVE[DISEASE]
incorporating O I_DISEASE_ADJECTIVE[DISEASE]
, O O
Islet O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
1 O B_NUMBER[MEASURE]/B_LOCATION
positive O I_NUMBER[MEASURE]/I_LOCATION
cells O I_NUMBER[MEASURE]/I_LOCATION
are O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
post O O
mitotic O B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Finally O O
, O O
we O O
determined O O
the O O
trophic O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
St O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
) O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
monitored O O
cultures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
over O O
a O O
three O B_TIME[MEASURE]
day O I_TIME[MEASURE]
period O I_TIME[MEASURE]
after O O
plating O O
and O O
counted O O
the O O
number O B_MEASURE
of O O
phase O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
bright O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
neurites O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O O
a O O
morphological O B_MEASURE
feature O I_MEASURE
of O O
both O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
trophic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
more O B_MEASURE
than O O
2 O B_NUMBER[MEASURE]
/ O O
3 O B_SEQUENCE[MEASURE]
of O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
die O O
by O O
24 O B_TIME[MEASURE]/B_DISEASE
hours O B_TIME[MEASURE]/I_DISEASE
in O O
culture O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
BDNF O B_GENE
, O O
NT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
, O O
or O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
is O O
not O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
promote O O
survival O B_DISEASE/B_ORGANISM_FUNCTION
( O O
Figure O B_MEASURE/B_DISEASE
6 O B_MEASURE/I_DISEASE
) O O
. O O

However O O
, O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
together O O
with O O
NT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE/B_BIO
supports O O
the O O
survival O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
significantly O O
larger O B_MEASURE
number O I_MEASURE
of O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
Figure O B_MEASURE/B_PERSON
6 O I_MEASURE/I_PERSON
) O O
. O O

For O O
the O O
subsequent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
all O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
cultured O O
with O O
25 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE
NT O I_MEASURE
- O O
3 O B_NUMBER[MEASURE]/B_LOCATION
and O O
1 O B_MEASURE/B_LOCATION
mu O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE
7S O I_MEASURE
NGF O I_MEASURE
to O O
optimize O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BDNF O B_GENE
promotes O O
proliferation O B_DISEASE/B_ORGANISM_FUNCTION
of O O
TrkB O B_GENE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
culture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO

To O O
determine O O
the O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
cultures O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
St O B_LOCATION/B_SPECIES[BIO]
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_MEASURE
. O O
5 O B_MEASURE
) O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
supplemented O O
with O O
200 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_GENE
BDNF O I_MEASURE/I_GENE
and O O
the O O
number O B_MEASURE/B_LOCATION
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
counted O O
at O O
24 O B_MEASURE
, O O
48 O B_MEASURE
, O O
and O O
72 O B_TIME[MEASURE]
hours O I_TIME[MEASURE]
using O O
phase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_LOCATION/B_PROTEIN[GENE]
7A O I_LOCATION/I_PROTEIN[GENE]
) O O
. O O

A O O
1 O B_MEASURE
. O O
6 O B_MEASURE
- O O
fold O B_MEASURE/B_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
the O O
number O B_MEASURE
of O O
neurons O B_BIO/B_DISEASE
due O O
to O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
observed O O
by O O
24 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hours O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
and O O
this O O
number O B_MEASURE/B_PERSON
does O O
not O O
increase O O
further O O
at O O
48 O B_MEASURE
or O O
72 O B_MEASURE/B_LOCATION
hours O I_MEASURE/I_LOCATION
. O O

This O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
concentration O B_MEASURE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
with O O
an O O
EC50 O B_MEASURE
of O O
75 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
( O O
Figure O B_MEASURE/B_PERSON
7B O I_MEASURE/I_PERSON
) O O
. O O

To O O
test O O
whether O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
number O B_MEASURE/B_PERSON
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
BDNF O B_GENE
is O O
due O O
to O O
the O O
differentiation O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
pluripotent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
neural O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
crest O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O O
we O O
quantified O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BDNF O B_GENE
on O O
the O O
number O B_MEASURE/B_LOCATION
of O O
neurally O O
differentiating O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
Hu O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
versus O O
the O O
number O B_MEASURE
of O O
non O B_DISEASE
- O O
neuronal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
( O O
Hu O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
/ O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O O
) O O
after O O
identifying O O
all O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
crest O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
staining O O
for O O
p75NTR O B_GENE
in O O
St O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_TIME[MEASURE]/B_LOCATION
. O O
5 O B_MEASURE
) O O
cultures O B_LOCATION/B_RELIGION[SOCIAL_CIRCUMSTANCES]
. O O

If O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increases O O
the O O
number O B_MEASURE/B_LOCATION
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
by O O
inducing O O
a O O
non O B_DISEASE
- O O
neuronal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O O
express O O
Hu O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
then O O
we O O
expected O O
that O O
the O O
total O B_MEASURE
cell O I_MEASURE
number O I_MEASURE
would O O
remain O O
the O O
same O B_MEASURE/B_LOCATION
and O O
that O O
there O O
would O O
be O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
number O B_MEASURE/B_PERSON
of O O
non O B_DISEASE
- O O
neuronal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
as O O
well O O
as O O
a O O
corresponding O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
number O B_MEASURE/B_PERSON
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

After O O
24 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hours O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O O
increases O O
the O O
number O B_MEASURE/B_PERSON
of O O
p75NTR O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
the O O
number O B_MEASURE
of O O
Hu O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
D O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8A O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

However O O
, O O
there O O
was O O
no O O
statistically O O
significant O B_MEASURE
change O I_MEASURE
in O O
the O O
number O B_MEASURE
of O O
non O B_DISEASE
- O O
neuronal O B_PERSON
cells O I_PERSON
. O O

Thus O O
, O O
it O O
is O O
unlikely O B_DISEASE_ADJECTIVE[DISEASE]
that O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increases O O
the O O
number O B_MEASURE
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
by O O
inducing O O
differentiation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O O
non O B_DISEASE
- O O
neuronal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

To O O
determine O O
whether O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
total O B_MEASURE/B_ENT
number O I_MEASURE/I_ENT
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
caused O O
by O O
BDNF O B_GENE
- O O
induced O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
BDNF O B_GENE
- O O
treated O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
exposed O O
to O O
BrdU O B_GENE
for O O
12 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
plating O O
, O O
and O O
the O O
number O B_MEASURE/B_LOCATION
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
incorporated O O
BrdU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O O
their O O
DNA O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O O
determined O O
after O O
24 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
culture O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Even O O
in O O
the O O
control O B_LOCATION
condition O I_LOCATION
, O O
a O O
number O B_MEASURE/B_PERSON
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
culture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
are O O
dividing O O
, O O
giving O O
a O O
high O B_MEASURE
baseline O I_MEASURE
of O O
BrdU O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
incorporation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
8B O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

When O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
added O O
, O O
the O O
total O B_MEASURE
number O I_MEASURE
of O O
BrdU O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
positive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
increases O O
approximately O O
1 O B_MEASURE
. O O
6 O B_MEASURE
- O O
fold O B_MEASURE/B_LOCATION
( O O
Figure O B_TIME[MEASURE]/B_PERSON
8B O I_TIME[MEASURE]/I_PERSON
) O O
. O O

This O O
BDNF O B_GENE
- O O
induced O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
total O B_MEASURE/B_ENT
number O I_MEASURE/I_ENT
of O O
BrdU O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
positive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
occurs O O
in O O
sympathoblasts O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
because O O
the O O
number O B_MEASURE/B_ENT
of O O
Islet O B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cultures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
label O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
BrdU O B_GENE
is O O
268 O B_MEASURE
+/- O I_MEASURE
59 O I_MEASURE
and O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
raises O O
this O O
number O B_MEASURE/B_PERSON
to O O
424 O B_MEASURE
+/- O O
80 O B_MEASURE
, O O
which O O
corresponds O O
to O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
of O O
1 O B_MEASURE
. O O
6 O B_MEASURE
- O O
fold O B_MEASURE
. O O

This O O
accounts O O
for O O
the O O
1 O B_MEASURE
. O O
6 O B_MEASURE
- O O
fold O B_MEASURE/B_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
total O B_MEASURE/B_PERSON
neuron O I_MEASURE/I_PERSON
number O I_MEASURE/I_PERSON
and O O
total O B_GENE
BrdU O I_GENE
- O O
positive O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
described O O
above O O
. O O

We O O
then O O
confirmed O O
that O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
TrkB O B_GENE
- O O
positive O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
BDNF O B_GENE
increases O O
the O O
number O B_MEASURE
of O O
TrkB O B_GENE
- O O
expressing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
incorporate O O
BrdU O B_MEASURE
2 O I_MEASURE
. O O
6 O B_MEASURE
- O O
4 O B_NUMBER[MEASURE]
- O O
fold O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
over O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
and O O
it O O
also O O
increases O O
the O O
overall O B_MEASURE
number O I_MEASURE
of O O
TrkB O B_GENE
- O O
positive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
2 O B_MEASURE
. O O
5 O B_MEASURE
- O O
fold O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
over O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
not O O
increase O O
the O O
number O B_MEASURE/B_PERSON
of O O
BrdU O B_GENE
- O O
positive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
TrkB O B_GENE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
overall O B_MEASURE
number O I_MEASURE
of O O
TrkB O B_GENE
- O O
negative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

In O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
BDNF O B_GENE
acts O O
directly O O
on O O
TrkB O B_GENE
- O O
expressing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O O
an O O
antibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
directed O O
against O O
the O O
extracellular O B_PROTEIN[GENE]/B_LOCATION
domain O I_PROTEIN[GENE]/I_LOCATION
of O O
TrkB O B_GENE
completely O O
prevents O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BDNF O B_GENE
in O O
promoting O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
TrkB O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
TrkB O B_GENE/B_LOCATION
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]
cells O I_DISEASE_ADJECTIVE[DISEASE]
( O O
compare O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Figure O B_MEASURE
9A O I_MEASURE
to O O
9B O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Thus O O
, O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BDNF O B_GENE
is O O
restricted O O
to O O
the O O
population O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
expresses O O
TrkB O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
which O O
are O O
developing O O
sympathoblasts O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

To O O
determine O O
whether O O
TrkB O B_GENE/B_MEASURE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
actively O O
proliferating O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
embryos O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
injected O O
with O O
BrdU O B_GENE
at O O
St O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
. O O

27 O B_TIME[MEASURE]/B_PERSON
and O O
harvested O O
at O O
St O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

29 O B_TIME[MEASURE]/B_LOCATION
, O O
approximately O O
24 O B_TIME[MEASURE]
hrs O I_TIME[MEASURE]
later O O
. O O

The O O
majority O B_PERSON/B_MEASURE
( O O
85 O B_MEASURE
- O O
90 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
of O O
TrkB O B_GENE
- O O
positive O B_DISEASE/B_BIO
cells O I_DISEASE/I_BIO
do O O
not O O
incorporate O O
BrdU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O O
their O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
under O O
basal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
Figure O B_MEASURE
10 O I_MEASURE
) O O
, O O
although O O
a O O
few O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TrkB O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
labeled O O
nuclei O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
observed O O
( O O
arrows O B_MEASURE/B_BIO
) O O
. O O

This O O
contrasts O O
with O O
our O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
71 O B_MEASURE
- O O
76 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
TrkB O B_GENE
- O O
positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
incorporate O O
BrdU O B_GENE
in O O
culture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
BDNF O B_GENE
( O O
Table O B_NUMBER[MEASURE]/B_LOCATION
2 O I_NUMBER[MEASURE]/I_LOCATION
) O O
, O O
suggesting O O
that O O
endogenous O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BDNF O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
achieve O O
a O O
threshold O B_MEASURE
sufficient O I_MEASURE
to O O
support O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sympathoblast O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

We O O
report O O
that O O
the O O
neurotrophin O O
receptor O O
TrkB O O
is O O
expressed O O
in O O
a O O
subset O O
of O O
embryonic O O
sympathoblasts O O
during O O
the O O
early O O
development O O
of O O
lumbar O O
paravertebral O O
sympathetic O O
ganglia O O
in O O
chicken B B_SPECIES[BIO]
and O O
mouse B B_SPECIES[BIO]/B_DISEASE
embryos O O
. O O

In O O
the O O
chicken B B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
TrkB O O
expression O O
is O O
transient O O
, O O
and O O
completely O O
lost O O
by O O
St O O
34 O O
( O O
E8 O O
) O O
. O O

Since O O
BDNF O B_GENE
induces O O
the O O
proliferation O B_TIME[MEASURE]/B_DISEASE
of O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
yet O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
there O O
is O O
little O B_DISEASE_ADJECTIVE[DISEASE]
proliferation O I_DISEASE_ADJECTIVE[DISEASE]
observed O O
in O O
TrkB O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
nascent O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ganglia O I_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
propose O O
that O O
if O O
TrkB O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
becomes O O
unregulated O B_DISEASE_ADJECTIVE[DISEASE]
by O O
excess O B_DISEASE_ADJECTIVE[DISEASE]
BDNF O I_DISEASE_ADJECTIVE[DISEASE]
or O O
constitutive O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
phosphorylation O B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
TrkB O B_GENE
[ O O
16 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
] O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
this O O
transient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TrkB O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sympathoblasts O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
may O O
trigger O O
the O O
genesis O B_DISEASE/B_ORGANISM_FUNCTION
of O O
neuroblastoma O B_DISEASE/B_GENE
, O O
a O O
childhood O B_DISEASE_ADJECTIVE[DISEASE]
tumor O I_DISEASE_ADJECTIVE[DISEASE]
found O O
in O O
the O O
paravertebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
chain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
adrenal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
medulla O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

The O O
two O B_MEASURE/B_LOCATION
populations O B_MEASURE/I_LOCATION
of O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
we O O
observe O O
support O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
heterogeneity O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
among O O
developing O O
sympathetic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
crest O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Early O B_PERSON/B_DISEASE
sympathetic O I_PERSON/I_DISEASE
ganglia O I_PERSON/I_DISEASE
contain O O
at O O
least O O
two O B_NUMBER[MEASURE]/B_LOCATION
subpopulations O I_NUMBER[MEASURE]/I_LOCATION
: O O
early O B_DISEASE_ADJECTIVE[DISEASE]
differentiating O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
lack O O
TrkB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
express O O
TrkA O B_LOCATION/B_ORGANIZATION
and O O
TrkC O B_GENE
, O O
and O O
late O B_DISEASE_ADJECTIVE[DISEASE]
differentiating O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
that O O
express O O
TrkB O B_GENE/B_LOCATION
. O O

Explant O O
cultures O O
of O O
sympathetic O O
ganglia O O
from O O
E16 O O
chick B B_SPECIES[BIO]
embryos O O
give O O
rise O O
to O O
two O O
neuronal O O
populations O O
: O O
one O O
that O O
remains O O
close O O
to O O
the O O
explant O O
, O O
and O O
one O O
that O O
migrates O O
away O O
from O O
the O O
explant O O
[ O O
1 O O
] O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuronal O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subpopulations O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
observed O O
in O O
cultures O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
neural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
crest O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
St O B_LOCATION/B_SPECIES[BIO]
. O O

13 O B_MEASURE
/ O O
14 O B_MEASURE
quail O I_MEASURE
embryos O I_MEASURE
as O O
evidenced O O
by O O
the O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
neuronal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
type O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O O
specific O B_MEASURE/B_PROTEIN[GENE]
gangliosides O I_MEASURE/I_PROTEIN[GENE]
[ O O
17 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Perhaps O O
these O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subpopulations O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
will O O
ultimately O O
give O O
rise O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
the O O
two O B_NUMBER[MEASURE]
neurochemically O O
distinct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
populations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
found O O
in O O
lumbar O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
the O O
noradrenergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
NPY O B_GENE
- O O
containing O O
neurons O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
innervate O B_TIME[MEASURE]/B_PERSON
internal O I_TIME[MEASURE]/I_PERSON
organs O I_TIME[MEASURE]/I_PERSON
and O O
enteric O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
cholinergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
VIP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
neurons O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
innervate O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
vasculature O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
hind O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
limbs O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

The O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
BDNF O B_GENE
and O O
TrkB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deletion O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
over O O
expression O B_GENE
have O O
been O O
studied O O
on O O
superior O B_BODY_PART_OR_ORGAN_COMPONENT
cervical O I_BODY_PART_OR_ORGAN_COMPONENT
ganglion O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
preganglionic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
thoracic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
segments O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
spinal O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
column O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
on O O
paravertebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
sympathetic O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
neurons O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
. O O

In O O
the O O
superior O O
cervical O O
ganglion O O
, O O
an O O
increase O O
in O O
the O O
number O O
of O O
neurons O O
of O O
BDNF O O
null O O
mice B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
likely O O
due O O
to O O
apoptosis O O
induced O O
by O O
BDNF O O
via O O
p75NTR O O
[ O O
18 O O
] O O
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
the O O
responses O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
paravertebral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
complex O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
subtype O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Over O O
expression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
BDNF O B_GENE
leads O O
to O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
number O B_MEASURE
of O O
noradrenergic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
fibers O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
innervating O O
the O O
erector O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pilli O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
muscles O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
hair O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
follicles O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
noradrenergic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
fibers O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
innervating O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
vessels O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
were O O
unaffected O B_DISEASE_ADJECTIVE[DISEASE]
[ O I_DISEASE_ADJECTIVE[DISEASE]
19 O I_DISEASE_ADJECTIVE[DISEASE]
] O I_DISEASE_ADJECTIVE[DISEASE]
. O O

If O O
our O O
results O O
indicating O O
that O O
BDNF O O
promotes O O
proliferation O O
of O O
TrkB O O
- O O
positive O O
sympathoblasts O O
in O O
the O O
chicken B B_SPECIES[BIO]/B_DISEASE
embryo O O
can O O
be O O
extrapolated O O
to O O
the O O
subset O O
of O O
TrkB O O
- O O
positive O O
sympathoblasts O O
in O O
murine O O
ganglia O O
, O O
then O O
these O O
TrkB O O
- O O
positive O O
cells O O
may O O
be O O
neurons O O
destined O O
to O O
innervate O O
the O O
erector O O
pilli O O
. O O

In O O
other O O
studies O O
, O O
TrkB O O
null O O
mice B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O O
no O O
changes O O
in O O
morphology O O
or O O
cell O O
number O O
in O O
superior O O
cervical O O
ganglia O O
[ O O
12 O O
] O O
or O O
in O O
the O O
intermediolateral O O
column O O
[ O O
20 O O
] O O
; O O
but O O
this O O
may O O
not O O
be O O
predictive O O
of O O
a O O
phenotype O O
in O O
the O O
lumbar O O
paravertebral O O
chain O O
. O O

It O O
is O O
thus O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
BDNF O B_GENE/B_LOCATION
/ O O
TrkB O B_GENE/B_LOCATION
signaling O I_GENE/I_LOCATION
could O O
play O O
a O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
regions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
paravertebral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
chain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
the O O
lumbar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

However O O
, O O
if O O
TrkB O O
- O O
positive O O
cells O O
are O O
not O O
normally O O
actively O O
proliferating O O
in O O
vivo O O
, O O
then O O
it O O
would O O
not O O
be O O
surprising O O
that O O
the O O
development O O
of O O
the O O
paravertebral O O
sympathetic O O
chain O O
is O O
not O O
disrupted O O
in O O
TrkB O O
or O O
BDNF O O
null O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
may O O
be O O
more O O
informative O O
to O O
examine O O
mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
over O O
express O O
BDNF O O
on O O
a O O
promoter O O
that O O
targets O O
expression O O
to O O
embryonic O O
lumbar O O
ganglia O O
. O O

Unfortunately O O
, O O
such O O
mice B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
do O O
not O O
exist O O
. O O

Our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
St O B_LOCATION/B_PERSON
. O O

29 O O
/ O O
30 O O
( O O
E6 O O
. O O
5 O O
) O O
sympathoblasts O O
are O O
dependent O O
on O O
both O O
NT O O
- O O
3 O O
and O O
NGF O O
for O O
survival O O
in O O
culture O O
are O O
consistent O O
with O O
previous O O
work O O
on O O
mouse B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
sympathoblasts O O
from O O
the O O
superior O O
cervical O O
ganglion O O
[ O O
11 O O
] O O
. O O

In O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
NT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
and O O
NGF O B_GENE/B_DISEASE
deletion O I_GENE/I_DISEASE
separately O O
led O O
to O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
number O B_MEASURE/B_ENT
of O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
E17 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
5 O B_MEASURE
compared O O
to O O
control O O
. O O

Deletion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O O
both O O
NT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE/B_LOCATION
and O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
together O O
did O O
not O O
enhance O O
cell O B_DISEASE
death O I_DISEASE
. O O

In O O
contrast O O
, O O
cultured O O
rat B B_SPECIES[BIO]/B_GENE
superior O O
cervical O O
ganglion O O
sympathetic O O
neurons O O
respond O O
to O O
NT O O
- O O
3 O O
at O O
E14 O O
. O O
5 O O
and O O
then O O
to O O
NGF O O
at O O
E19 O O
. O O
5 O O
, O O
although O O
time O O
points O O
in O O
between O O
were O O
not O O
analyzed O O
[ O O
6 O O
] O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
promoting O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
, O O
NT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
, O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
BDNF O B_GENE/B_LOCATION
also O O
induce O O
proliferation O B_TIME[MEASURE]/B_ORGANISM_FUNCTION
of O O
various O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neuronal O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
precursors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stages O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
development O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

NT O O
- O O
3 O O
can O O
promote O O
the O O
incorporation O O
of O O
[ O O
3H O O
] O O
- O O
thymidine O O
into O O
cultured O O
quail O O
neural O O
crest O O
cells O O
from O O
the O O
trunk O O
region O O
[ O O
21 O O
, O O
22 O O
] O O
, O O
Later O O
in O O
rat B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
sympathetic O O
development O O
, O O
NT O O
- O O
3 O O
supports O O
survival O O
of O O
neurons O O
, O O
but O O
does O O
not O O
promote O O
proliferation O O
[ O O
6 O O
] O O
, O O
which O O
is O O
consistent O O
with O O
our O O
results O O
. O O

NGF O O
promotes O O
an O O
increase O O
in O O
BrdU O O
incorporation O O
from O O
25 O O
% O O
to O O
35 O O
% O O
in O O
the O O
DRG O O
cervical O O
segment O O
2 O O
in O O
the O O
chick B B_SPECIES[BIO]/B_DISEASE
embryo O O
[ O O
23 O O
] O O
. O O

In O O
chicken B B_SPECIES[BIO]
embryos O O
that O O
are O O
treated O O
with O O
NGF O O
in O O
ovo O O
at O O
St O O
. O O

18 O O
and O O
21 O B_TIME[MEASURE]/B_LOCATION
, O O
there O O
is O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
BrdU O B_DISEASE/B_MEASURE
uptake O B_DISEASE/I_MEASURE
after O O
formation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
primary O B_LOCATION/B_PERSON
sympathetic O I_LOCATION/I_PERSON
chain O I_LOCATION/I_PERSON
at O O
St O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
. O O

23 O B_MEASURE
[ O O
24 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

Since O O
NGF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
does O O
not O O
appear O O
to O O
affect O O
proliferation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
St O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

29 O O
/ O O
30 O O
( O O
E6 O O
. O O
5 O O
) O O
chick B B_PERSON/B_MEASURE
sympathoblasts O O
, O O
NGF O O
may O O
only O O
promote O O
proliferation O O
in O O
primary O O
, O O
but O O
not O O
secondary O O
chain O O
sympathoblasts O O
. O O

Motor O O
neuron O O
progenitors O O
in O O
the O O
ventral O O
neural O O
tube O O
from O O
the O O
chick B B_SPECIES[BIO]/B_DISEASE
embryo O O
express O O
TrkB O O
and O O
when O O
ventral O O
neural O O
tube O O
explants O O
are O O
treated O O
with O O
BDNF O O
, O O
there O O
is O O
an O O
increase O O
in O O
the O O
number O O
of O O
motor O O
neurons O O
produced O O
and O O
BrdU O O
incorporation O O
[ O O
25 O O
] O O
. O O

BDNF O B_GENE/B_LOCATION
also O O
promotes O O
the O O
proliferation O B_DISEASE/B_ORGANISM_FUNCTION
of O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
neuroblastoma O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
[ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
13 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

Taken O O
together O O
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
NT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
and O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
not O O
promote O O
proliferation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
St O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
) O O
sympathoblasts O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
support O O
the O O
assertion O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
BDNF O B_GENE
promotes O O
proliferation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
TrkB O B_GENE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathoblasts O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
culture O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
a O O
transient O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
TrkB O B_GENE
during O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
supporting O O
proliferation O B_MEASURE/B_ORGANISM_FUNCTION
of O O
this O O
early O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
subpopulation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
the O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
labeling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
suggests O O
that O O
only O O
a O O
minority O B_PERSON/B_SEQUENCE[MEASURE]
( O O
10 O B_NUMBER[MEASURE]
- O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
of O O
this O O
population O B_PERSON/B_MEASURE
is O O
dividing O O
during O O
the O O
window O B_LOCATION/B_TIME[MEASURE]
that O O
TrkB O B_GENE
is O O
expressed O O
. O O

In O O
light O B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
very O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proliferative O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
in O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
culture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
these O O
TrkB O B_GENE
expressing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
could O O
respond O O
more O O
strongly O O
if O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
rises O O
to O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
or O O
if O O
the O O
mechanism O B_GENE/B_DISEASE
that O O
down O O
regulates O O
TrkB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
becomes O O
nonfunctional O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Such O B_DISEASE/B_GENE
events O B_DISEASE/I_GENE
could O O
trigger O O
an O O
early O B_DISEASE_ADJECTIVE[DISEASE]
proliferative O I_DISEASE_ADJECTIVE[DISEASE]
event O I_DISEASE_ADJECTIVE[DISEASE]
that O O
leads O O
to O O
a O O
cascade O B_DISEASE/B_MEASURE
of O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
initiates O O
transformation O B_DISEASE/B_ORGANISM_FUNCTION
of O O
cells O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
neuroblastoma O B_DISEASE
. O O

Thus O O
, O O
these O O
early O B_GENE
TrkB O I_GENE
expressing O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
help O O
solve O O
the O O
puzzle O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
to O O
why O O
TrkB O B_GENE/B_LOCATION
is O O
expressed O O
in O O
aggressive O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
invasive O B_DISEASE_ADJECTIVE[DISEASE]
forms O I_DISEASE_ADJECTIVE[DISEASE]
of O O
neuroblastoma O B_DISEASE
, O O
particularly O O
because O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
cultured O O
neuroblastoma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
become O O
more O O
proliferative O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
invasive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
angiogenic O B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
chemotherapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reagents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
than O O
untreated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cultures O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
13 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Future O O
studies O O
will O O
determine O O
whether O O
constitutive O O
expression O O
of O O
BDNF O O
and O O
TrkB O O
in O O
the O O
chick B B_SPECIES[BIO]/B_DISEASE
embryo O O
sustains O O
proliferation O O
of O O
differentiating O O
sympathoblasts O O
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

We O O
have O O
identified O O
a O O
time O B_MEASURE/B_LOCATION
point O B_MEASURE/I_LOCATION
during O O
development O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
when O O
differentiating O O
lumbar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
transiently O O
express O O
TrkB O B_GENE
and O O
proliferate O O
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
culture O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
elevated O O
BDNF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
above O O
basal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
levels O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O O
signaling O O
through O O
TrkB O B_GENE
may O O
be O O
a O O
mechanism O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
contributes O O
to O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
neuroblastoma O B_DISEASE
. O O

A O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
populations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
fate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
TrkB O B_GENE/B_MEASURE
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
will O O
provide O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
insight O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
into O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
paravertebral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
sympathetic O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
ganglia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
genesis O B_DISEASE/B_PERSON
of O O
neuroblastoma O B_DISEASE
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Preparation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
tissue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
immunohistochemistry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
lumbar O O
spinal O O
column O O
and O O
surrounding O O
tissues O O
were O O
dissected O O
from O O
chicken B B_SPECIES[BIO]
embryos O O
at O O
the O O
indicated O O
stages O O
and O O
placed O O
in O O
Zamboni O O
' O O
s O O
fixative O O
( O O
4 O O
% O O
( O O
w O O
/ O O
v O O
) O O
paraformaldehyde O O
, O O
15 O O
% O O
( O O
v O O
/ O O
v O O
) O O
picric O O
acid O O
in O O
0 O O
. O O
1 O O
M O O
sodium O O
phosphate O O
buffer O O
, O O
pH O O
7 O O
. O O
4 O O
) O O
for O O
two O O
hours O O
at O O
room O O
temperature O O
. O O

Mouse B B_BIO/B_PERSON
embryos O O
at O O
13 O O
- O O
15 O O
days O O
post O O
- O O
coitus O O
were O O
collected O O
according O O
to O O
an O O
IACUC O O
- O O
approved O O
protocol O O
to O O
Dr O O
. O O
L O O
. O O

Sherman O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
Oregon O B_EDU[ORGANIZATION]/B_PERSON
Health O I_EDU[ORGANIZATION]/I_PERSON
and O O
Science O B_LOCATION/B_EDU[ORGANIZATION]
University O B_LOCATION/I_EDU[ORGANIZATION]
. O O

The O O
mouse B B_DISEASE/B_SPECIES[BIO]
embryos O O
were O O
immersion O O
- O O
fixed O O
in O O
Zamboni O O
' O O
s O O
fixative O O
overnight O O
at O O
4 O O
degrees O O
C O O
then O O
washed O O
with O O
phosphate O O
buffered O O
saline O O
( O O
PBS O O
; O O
130 O O
mM O O
NaCl O O
, O O
20 O O
mM O O
sodium O O
phosphate O O
buffer O O
, O O
pH O O
7 O O
. O O
4 O O
) O O
. O O

Fixed O O
tissues O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
were O O
equilibrated O O
in O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sucrose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
buffered O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PBS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
) O O
. O O

Fixed O O
mouse B B_SPECIES[BIO]/B_DISEASE
embryos O O
were O O
shipped O O
to O O
Vermont O O
in O O
sucrose O O
. O O

Transverse O B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
30 O B_LOCATION/B_BIO
mu O I_NUMBER[MEASURE]/I_LOCATION
M O I_NUMBER[MEASURE]/I_LOCATION
sections O I_NUMBER[MEASURE]/I_LOCATION
of O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
columns O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
cut O O
at O O
on O O
a O O
Microm O B_LOCATION/B_MEASURE
HM O I_LOCATION/I_MEASURE
cryostat O I_LOCATION/I_MEASURE
( O O
knife O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperature O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
16 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
; O O
object O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
temperature O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
: O O
23 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
) O O
and O O
collected O O
on O O
Superfrost O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Plus O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
slides O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Fisher O B_PERSON/B_MEASURE
) O O
. O O

Sections O O
were O O
dried O O
at O O
room O O
temperature O O
, O O
washed O O
in O O
1 O O
x O O
PBS O O
and O O
incubated O O
overnight O O
in O O
blocking O O
buffer O O
( O O
1 O O
x O O
PBS O O
consisting O O
of O O
10 O O
% O O
( O O
v O O
/ O O
v O O
) O O
heat O O
- O O
inactivated O O
horse B B_SPECIES[BIO]
serum O O
( O O
Invitrogen O O
/ O O
Gibco O O
) O O
, O O
0 O O
. O O
5 O O
% O O
Triton O O
X O O
- O O
100 O O
( O O
Sigma O O
) O O
, O O
and O O
0 O O
. O O
1 O O
% O O
sodium O O
azide O O
( O O
Fisher O O
) O O
) O O
. O O

Immunohistochemistry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Sections O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
incubated O O
with O O
primary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
overnight O O
at O O
4 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
, O O
followed O O
by O O
incubation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
secondary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
2 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
room O B_MEASURE/B_LOCATION
temperature O I_MEASURE/I_LOCATION
. O O

Primary O O
antibodies O O
used O O
were O O
: O O
rabbit B B_SPECIES[BIO]/B_GENE
anti O O
- O O
p75 O O
( O O
1 O O
: O O
1500 O O
, O O
generous O O
gift O O
from O O
Louis O O
Reichardt O O
, O O
UCSF O O
[ O O
26 O O
] O O
) O O
, O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG2b O O
anti O O
- O O
Hu O O
C O O
/ O O
D O O
, O O
( O O
1 O O
: O O
250 O O
, O O
Molecular O O
Probes O O
) O O
; O O
mouse B B_SPECIES[BIO]/B_DISEASE
IgG1 O O
anti O O
- O O
Islet O O
- O O
1 O O
, O O
( O O
1 O O
: O O
10 O O
, O O
Developmental O O
Studies O O
Hybridoma O O
Bank O O
) O O
; O O
rabbit B B_SPECIES[BIO]
anti O O
- O O
chicken B B_SPECIES[BIO]
TrkA O O
( O O
1 O O
: O O
500 O O
) O O
; O O
rabbit B B_SPECIES[BIO]
anti O O
- O O
chicken B B_SPECIES[BIO]
TrkB O O
( O O
1 O O
: O O
500 O O
) O O
; O O
rabbit B B_SPECIES[BIO]
anti O O
- O O
chicken B B_SPECIES[BIO]
TrkC O O
( O O
1 O O
: O O
500 O O
) O O
( O O
all O O
Trk O O
antibodies O O
were O O
generous O O
gifts O O
of O O
Dr O O
. O O
Louis O O
Reichardt O O
, O O
UCSF O O
[ O O
26 O O
- O O
28 O O
] O O
) O O
; O O
mouse B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O O
- O O
HNK O O
- O O
1 O O
( O O
1 O O
: O O
50 O O
, O O
Developmental O O
Studies O O
Hybridoma O O
Bank O O
) O O
; O O
mouse B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgG2a O O
anti O O
- O O
tyrosine O O
hydroxylase O O
( O O
1 O O
: O O
10 O O
, O O
Developmental O O
Studies O O
Hybridoma O O
Bank O O
) O O
, O O
sheep B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
anti O O
- O O
BrdU O O
( O O
1 O O
: O O
100 O O
, O O
Biodesign O O
International O O
) O O
, O O
rabbit B B_MEASURE
anti O O
- O O
tyrosine O O
hydroxylase O O
( O O
1 O O
: O O
100 O O
, O O
Chemicon O O
) O O
, O O
and O O
goat B B_SPECIES[BIO]/B_LOCATION
anti O O
- O O
TrkB O O
( O O
1 O O
: O O
1000 O O
, O O
R O O
& O O
D O O
Systems O O
) O O
. O O

Immunofluorescence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
imaged O O
using O O
a O O
Nikon O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
C1 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
confocal O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mounted O O
on O O
a O O
Nikon O B_LOCATION/B_PERSON
Eclipse O I_LOCATION/I_PERSON
E800 O I_LOCATION/I_PERSON
microscope O I_LOCATION/I_PERSON
with O O
a O O
10 O B_MEASURE
x O O
Plan O B_MEASURE/B_LOCATION
Apo O I_MEASURE/I_LOCATION
( O O
NA O B_MEASURE/B_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
785 O B_MEASURE
) O O
air O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
objective O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
a O O
60 O B_MEASURE
x O O
Plan O B_MEASURE/B_LOCATION
Apo O I_MEASURE/I_LOCATION
( O O
NA O B_MEASURE/B_LOCATION
1 O B_MEASURE/I_LOCATION
. O O
4 O B_MEASURE
) O O
oil O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
objective O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
lens O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
, O O
E7 O B_PROTEIN[GENE]/B_LOCATION
- O O
C1 O B_MEASURE/B_ORGANIZATION
software O I_MEASURE/I_ORGANIZATION
, O O
and O O
UV O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Argon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
and O O
He O O
/ O O
Ne O B_PERSON/B_ORGANIZATION
lasers O I_PERSON/I_ORGANIZATION
exciting O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
408 O B_MEASURE
, O O
488 O B_MEASURE
, O O
and O O
543 O B_MEASURE
nm O I_MEASURE
and O O
emitting O O
at O O
404 O B_MEASURE
500 O I_MEASURE
- O O
530 O B_MEASURE
, O O
and O O
555 O B_MEASURE
- O O
615 O B_MEASURE
nm O I_MEASURE
, O O
respectively O O
. O O

A O O
Nikon O B_ORGANIZATION/B_TIME[MEASURE]
Eclipse O B_ORGANIZATION/I_TIME[MEASURE]
E800 O O
microscope O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
nearby O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
COBRE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Molecular O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Cellular O B_LOCATION/B_ORGANIZATION
Core O I_LOCATION/I_ORGANIZATION
Facility O I_LOCATION/I_ORGANIZATION
was O O
used O O
for O O
counting O O
immunofluorescent O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
200 O B_MEASURE/B_LOCATION
x O I_MEASURE/I_LOCATION
using O O
epifluorescence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
optics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

RNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Extraction O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
cDNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Sympathetic O O
ganglia O O
were O O
removed O O
from O O
chick B B_PERSON/B_SPECIES[BIO]
embryos O O
and O O
RNA O O
was O O
isolated O O
using O O
TriReagent O O
( O O
Molecular O O
Research O O
Center O O
) O O
, O O
an O O
acidified O O
guanidinium O O
with O O
phenol O O
extraction O O
method O O
[ O O
29 O O
] O O
. O O

RNA O B_GENE/B_BIO
was O O
transcribed O O
to O O
cDNA O B_GENE
using O O
oligo O B_GENE
- O O
dT O B_GENE
with O O
Superscript O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Reverse O I_GENE
Transcriptase O B_TIME[MEASURE]/B_PERSON
( O O
Invitrogen O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
at O O
42 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
for O O
1 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hour O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Real O B_PERSON/B_MEASURE
- O O
time O B_TIME[MEASURE]/B_LOCATION
PCR O B_TIME[MEASURE]/I_LOCATION

Relative O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RNA O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
determined O O
using O O
quantitative O B_MEASURE
real O I_MEASURE
- O O
time O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
an O O
ABI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7500 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Fast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Real O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Time O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
System O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

TaqMan O O
probes O O
were O O
used O O
to O O
quantify O O
the O O
progression O O
of O O
the O O
PCR O O
reaction O O
and O O
reactions O O
were O O
normalized O O
using O O
the O O
constitutively O O
expressed O O
gene O O
chick B B_BIO/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
ribosomal O O
binding O O
protein O O
s17 O O
( O O
CHRPS O O
) O O
. O O

The O O
sequences O O
were O O
used O O
for O O
primer O O
/ O O
probes O O
sets O O
: O O
for O O
BDNF O O
: O O
forward O O
: O O
5 O O
' O O
- O O
AGCCCAGTGAGGAAAACAAG O O
- O O
3 O O
' O O
, O O
reverse O O
: O O
5 O O
' O O
- O O
ACTCCTCGAGCAGAAAGAGC O O
- O O
3 O O
' O O
, O O
probe O O
: O O
5 O O
' O O
- O O
[ O O
6 O O
- O O
FAM O O
] O O
- O O
TACACATCCCGAGTCATGCTGAGCA O O
- O O
[ O O
BHQ O O
] O O
- O O
3 O O
' O O
; O O
for O O
CHRPS O O
( O O
chick B B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
ribosomal O O
binding O O
protein O O
S O O
- O O
17 O O
) O O
: O O
5 O O
' O O
AACGACTTCCACACCAACAA3 O O
' O O
, O O
reverse O O
: O O
5 O O
' O O
CTTCATCAGGTGGGTGACAT3 O O
' O O
, O O
probe O O
: O O
5 O O
' O O
- O O
[ O O
6 O O
- O O
FAM O O
] O O
- O O
CGCCATCATCCCCAGCAAGA O O
[ O O
BHQ O O
] O O
- O O
3 O O
' O O
. O O

Primers O B_GENE
and O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
were O O
synthesized O O
by O O
Operon O B_ORGANIZATION/B_DISEASE
Technologies O I_ORGANIZATION/I_DISEASE
, O O
Inc O B_ORGANIZATION/B_LOCATION
( O O
Alameda O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION
) O O
. O O

The O O
primers O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
BDNF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
validated O O
against O O
primers O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
CHRPS O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
according O O
to O O
an O O
Applied O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
BioSystems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
by O O
serially O O
diluting O O
the O O
target O B_MEASURE/B_PERSON
cDNA O I_MEASURE/I_PERSON
1 O I_MEASURE/I_PERSON
: O O
10 O B_MEASURE
, O O
determining O O
the O O
cycle O B_MEASURE/B_LOCATION
threshold O I_MEASURE/I_LOCATION
( O O
Ct O B_LOCATION/B_PROTEIN[GENE]
) O O
for O O
each O O
reaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
plotting O O
the O O
Ct O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
log O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Slopes O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
resulting O O
lines O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
calculated O O
and O O
primers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
accepted O O
if O O
their O O
Ct O B_MEASURE/B_LOCATION
slopes O I_MEASURE/I_LOCATION
were O O
between O O
- O O
3 O B_NUMBER[MEASURE]
. O O
2 O B_MEASURE
and O O
- O O
3 O B_NUMBER[MEASURE]
. O O
4 O B_MEASURE
( O O
a O O
perfect O B_MEASURE/B_LOCATION
efficiency O I_MEASURE/I_LOCATION
of O O
1 O B_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
yields O I_MEASURE/I_LOCATION
a O O
slope O B_MEASURE
of O O
- O O
3 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
) O O
. O O

To O O
analyze O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
the O O
delta O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Ct O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
relative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
quantification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
used O O
, O O
where O O
the O O
Ct O B_MEASURE
of O O
Chrps O B_GENE/B_BACTERIUM[BIO]
was O O
subtracted O O
from O O
the O O
Ct O B_MEASURE
of O O
the O O
gene O B_GENE
of O O
interest O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Delta O B_GENE
Ct O I_GENE
) O O
and O O
the O O
arbitrary O B_MEASURE
units O I_MEASURE
of O O
mRNA O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
expressed O O
as O O
10000 O B_MEASURE/B_LOCATION
/ O O
2 O B_MEASURE
^ O O
( O O
Delta O B_MEASURE/B_LOCATION
Ct O B_MEASURE/I_LOCATION
) O O
. O O

Cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Sympathetic O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O O
cultured O O
as O O
previously O O
described O O
[ O O
30 O B_TIME[MEASURE]/B_LOCATION
] O O
with O O
a O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sympathetic O B_PERSON
ganglia O I_PERSON
were O O
removed O O
from O O
the O O
lumbar O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
paravertebral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
chain O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
St O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

29 O O
/ O O
30 O O
( O O
E6 O O
. O O
5 O O
) O O
chick B B_PERSON/B_NUMBER[MEASURE]
embryos O O
and O O
placed O O
in O O
Modified O O
Puck O O
' O O
s O O
solution O O
with O O
glucose O O
( O O
MPG O O
) O O
. O O

The O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
dissociated O O
by O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
0 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
trypsin O I_MEASURE
in O O
MPG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
for O O
10 O B_TIME[MEASURE]
minutes O I_TIME[MEASURE]
followed O O
by O O
triturating O O
with O O
a O O
fire O B_LOCATION/B_TIME[MEASURE]
polished O O
9 O B_NUMBER[MEASURE]/B_PERSON
" O O
Pasteur O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pipette O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Cells O O
were O O
then O O
resuspended O O
in O O
Dulbecco O O
' O O
s O O
Modified O O
Eagle O O
Medium O O
( O O
DMEM O O
) O O
consisting O O
of O O
10 O O
% O O
horse B B_SPECIES[BIO]/B_PERSON
serum O O
, O O
2 O O
% O O
fetal O O
calf O O
serum O O
, O O
and O O
10 O O
mg O O
/ O O
ml O O
penicillin O O
/ O O
streptomycin O O
. O O

For O O
neurotrophin O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
culture O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
medium O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
was O O
supplemented O O
with O O
25 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_LOCATION
NT O I_MEASURE/I_LOCATION
- O O
3 O B_NUMBER[MEASURE]/B_LOCATION
( O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Systems O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
1 O B_MEASURE/B_LOCATION
mu O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE/B_LOCATION
7S O I_MEASURE/I_LOCATION
NGF O I_MEASURE/I_LOCATION
( O O
Alomone O B_LOCATION
Labs O I_LOCATION
) O O
upon O O
plating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
50 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
, O O
100 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
, O O
or O O
200 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE
BDNF O I_MEASURE
( O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Systems O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
once O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
adhered O O
to O O
the O O
wells O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
plated O O
on O O
poly O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
lysine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
laminin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
coated O O
wells O B_PERSON/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
cover O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
slips O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fisher O B_PERSON/B_MEASURE
) O O
as O O
previously O O
described O O
[ O O
30 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

Quantification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
sympathoblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
using O O
phase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Embryonic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathoblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
neurons O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
phase O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
bright O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O O
neurites O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

The O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
with O O
neurites O B_MEASURE/B_LOCATION
the O O
length O B_MEASURE/B_COLOR
of O O
two O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
bodies O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
counted O O
in O O
10 O B_NUMBER[MEASURE]
non O O
- O O
overlapping O O
fields O B_LOCATION
of O O
view O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evenly O O
spaced O O
in O O
a O O
grid O B_LOCATION/B_BIO
- O O
like O B_LOCATION/B_PERSON
pattern O I_LOCATION/I_PERSON
across O O
the O O
bottom O B_LOCATION/B_MEASURE
of O O
a O O
well O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
a O O
24 O B_MEASURE/B_LOCATION
well O I_MEASURE/I_LOCATION
plate O I_MEASURE/I_LOCATION
at O O
200 O B_MEASURE/B_LOCATION
x O I_MEASURE/I_LOCATION
using O O
a O O
Nikon O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Eclipse O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
TE200 O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
microscope O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

BrdU O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labeling O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

For O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
approximately O O
2 O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
after O O
plating O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
St O B_LOCATION/B_BIO
. O O

29 O B_MEASURE
/ O O
30 O B_MEASURE
( O O
E6 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
) O O
sympathetic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_TIME[MEASURE]
ganglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_TIME[MEASURE]
, O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
labeled O O
with O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mu O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
M O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bromodeoxyuridine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BrdU O B_LOCATION/B_PROTEIN[GENE]
, O O
Sigma O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
12 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
37 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
. O O

Following O O
this O O
labeling O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
incubated O O
in O O
complete O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
BrdU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
an O O
additional O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
then O O
fixed O O
in O O
Zamboni O B_BIO/B_LOCATION
' O I_LOCATION
s O I_LOCATION
fixative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
30 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
room O B_TIME[MEASURE]/B_LOCATION
temperature O I_TIME[MEASURE]/I_LOCATION
and O O
rinsed O O
with O O
1 O B_MEASURE
x O O
PBS O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
in O O
vivo O O
studies O O
, O O
25 O O
mu O O
g O O
BrdU O O
was O O
injected O O
into O O
the O O
amnion O O
of O O
chick B B_SPECIES[BIO]
embryos O O
at O O
St O O
. O O

27 O B_NUMBER[MEASURE]
. O O

The O O
cells O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
sections O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
denatured O O
with O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HCl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
for O O
1 O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hr O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
were O O
then O O
neutralized O O
with O O
0 O B_MEASURE
. O O
1 O B_MEASURE
M O I_MEASURE
borate O I_MEASURE
buffer O I_MEASURE
, O O
pH O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
. O O
5 O B_MEASURE
, O O
for O O
10 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
room O B_MEASURE/B_LOCATION
temperature O I_MEASURE/I_LOCATION
. O O

Immunochemistry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
as O O
described O O
above O O
. O O

Abbreviations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

BDNF O O
, O O
brain O O
- O O
derived O O
neurotrophic O O
factor O O
; O O
BrdU O O
, O O
Bromodeoxyuridine O O
; O O
DA O O
, O O
dorsal O O
aorta O O
; O O
DMEM O O
, O O
Dulbecco O O
' O O
s O O
Modified O O
Eagle O O
' O O
s O O
Medium O O
; O O
DRG O O
, O O
dorsal O O
root O O
ganglion O O
; O O
E O O
, O O
embryonic O O
day O O
; O O
HS O O
, O O
horse B B_BIO/B_PERSON
serum O O
; O O
MPG O O
, O O
Modified O O
Puck O O
' O O
s O O
solution O O
with O O
glucose O O
; O O
NGF O O
, O O
nerve O O
growth O O
factor O O
; O O
NC O O
, O O
notochord O O
; O O
NT O O
, O O
neural O O
tube O O
; O O
NT O O
- O O
3 O O
, O O
neurotrophin O O
- O O
3 O O
; O O
NTR O O
, O O
neurotrophin O O
receptor O O
; O O
PBS O O
, O O
phosphate O O
- O O
buffered O O
saline O O
; O O
SC O O
, O O
spinal O O
cord O O
; O O
SCG O O
, O O
superior O O
cervical O O
ganglion O O
; O O
SEM O O
, O O
standard O O
error O O
of O O
the O O
mean O O
; O O
SG O O
, O O
sympathetic O O
ganglion O O
; O O
St O O
. O O
, O O
stage O O
; O O
w O O
/ O O
v O O
, O O
weight O O
/ O O
volume O O
; O O
v O O
/ O O
v O O
, O O
volume O O
/ O O
volume O O
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

JAS O B_PERSON/B_LOCATION
designed O O
the O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
performed O O
the O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
analyzed O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
and O O
wrote O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

GLSS O B_PERSON
contributed O O
intellectually O O
to O O
the O O
conception O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
design O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
assisted O O
in O O
the O O
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RN O B_PERSON
supervised O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
participated O O
in O O
the O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
edited O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O O
and O O
obtained O O
funding O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
project O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

All O O
authors O B_PERSON/B_NUMBER[MEASURE]
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

Video O O
analysis O O
of O O
the O O
escape O O
flight O O
of O O
Pileated B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Woodpecker I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Dryocopus B I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
pileatus I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
does O O
the O O
Ivory B B_BIO
- I I_BIO
billed I I_BIO
Woodpecker I I_BIO
Campephilus B I_BIO
principalis I I_BIO
persist O O
in O O
continental O O
North O O
America O O
? O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
apparent O O
rediscovery O O
of O O
the O O
Ivory B B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
billed I I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
Woodpecker I I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
Campephilus B I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
principalis I I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
Arkansas O O
, O O
USA O O
, O O
previously O O
feared O O
extinct O O
, O O
was O O
supported O O
by O O
video O O
evidence O O
of O O
a O O
single O O
bird O O
in O O
flight O O
( O O
Fitzpatrick O O
et O O
al O O
, O O
Science O O
2005 O O
, O O
308 O O
: O O
1460 O O
- O O
1462 O O
) O O
. O O

Plumage O O
patterns O O
and O O
wingbeat O O
frequency O O
of O O
the O O
putative O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
said O O
to O O
be O O
incompatible O O
with O O
the O O
only O O
possible O O
confusion O O
species O O
native O O
to O O
the O O
area O O
, O O
the O O
Pileated B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Woodpecker I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Dryocopus B I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
pileatus I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

New O O
video O O
analysis O O
of O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Woodpeckers I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O O
escape O O
flights O O
comparable O O
to O O
that O O
of O O
the O O
putative O O
Ivory B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
filmed O O
in O O
Arkansas O O
shows O O
that O O
Pileated B B_PERSON/B_BIO
Woodpeckers I I_PERSON/I_BIO
can O O
display O O
a O O
wingbeat O O
frequency O O
equivalent O O
to O O
that O O
of O O
the O O
Arkansas O O
bird O O
during O O
escape O O
flight O O
. O O

The O O
critical O O
frames O O
from O O
the O O
Arkansas O O
video O O
that O O
were O O
used O O
to O O
identify O O
the O O
bird O O
as O O
an O O
Ivory B B_BIO/B_PERSON
- I I_BIO/I_PERSON
billed I I_BIO/I_PERSON
Woodpecker I I_BIO/I_PERSON
are O O
shown O O
to O O
be O O
equally O O
, O O
or O O
more O O
, O O
compatible O O
with O O
the O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

The O O
identification O O
of O O
the O O
bird O O
filmed O O
in O O
Arkansas O O
in O O
April O O
2004 O O
as O O
an O O
Ivory B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
billed I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
Woodpecker I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O O
best O O
regarded O O
as O O
unsafe O O
. O O

The O O
similarities O O
between O O
the O O
Arkansas O O
bird O O
and O O
known O O
Pileated B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
suggest O O
that O O
it O O
was O O
most O O
likely O O
a O O
Pileated B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
reported O O
rediscovery O O
of O O
the O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
2004 O O
- O O
5 O O
in O O
the O O
Big O O
Woods O O
of O O
Arkansas O O
gave O O
new O O
impetus O O
to O O
efforts O O
to O O
conserve O O
the O O
mature O O
bottomland O O
woodlands O O
of O O
the O O
south O O
- O O
eastern O O
USA O O
. O O

Several O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sightings O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
have O O
been O O
reported O O
without O O
photographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
being O O
obtained O O
[ O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Unless O O
sightings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
are O O
, O O
however O O
, O O
independently O O
verifiable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
photographic O B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
other O B_TIME[MEASURE]/B_LOCATION
recorded O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
mistakes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
been O O
made O O
cannot O O
be O O
eliminated O O
. O O

Crucial O O
to O O
the O O
scientific O O
case O O
for O O
the O O
persistence O O
of O O
the O O
Ivory B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
billed I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
a O O
4 O O
s O O
video O O
of O O
a O O
large O O
woodpecker O O
in O O
flight O O
recorded O O
by O O
M O O
. O O
D O O
. O O

Luneau O O
on O O
25 O O
April O O
2004 O O
( O O
henceforth O O
referred O O
to O O
as O O
the O O
' O O
Luneau O O
video O O
' O O
) O O
and O O
published O O
in O O
2005 O O
[ O O
1 O O
] O O
, O O
which O O
was O O
claimed O O
to O O
be O O
inconsistent O O
with O O
the O O
plumage O O
patterns O O
of O O
the O O
superficially O O
similar O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
a O O
common O O
resident O O
bird O O
of O O
the O O
area O O
) O O
. O O

Both O O
species O B_BIO/B_PERSON
are O O
large O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
black O B_COLOR/B_LOCATION
- O O
and O O
- O O
white O B_COLOR/B_BIO
woodpeckers O I_COLOR/I_BIO
[ O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
upperwing O O
of O O
the O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
black O O
, O O
with O O
white O O
secondary O O
feathers O O
and O O
white O O
on O O
some O O
inner O O
primary O O
feathers O O
. O O

Pileated B B_PERSON/B_BIO
Woodpeckers I I_PERSON/I_BIO
have O O
a O O
largely O O
black O O
upperwing O O
, O O
with O O
white O O
restricted O O
to O O
the O O
' O O
wrist O O
' O O
due O O
to O O
white O O
bases O O
to O O
the O O
primary O O
feathers O O
. O O

The O O
underwing O O
of O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
all O O
- O O
white O O
underwing O O
coverts O O
, O O
giving O O
an O O
appearance O O
of O O
a O O
white O O
underwing O O
with O O
a O O
broad O O
black O O
outline O O
( O O
the O O
black O O
flight O O
feathers O O
) O O
. O O

These O O
plumage O O
differences O O
result O O
in O O
the O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
a O O
white O O
trailing O O
edge O O
to O O
the O O
wings O O
( O O
upper O O
and O O
lower O O
sides O O
) O O
, O O
whereas O O
the O O
Pileated B B_PERSON/B_LOCATION
Woodpecker I I_PERSON/I_LOCATION
has O O
a O O
black O O
trailing O O
edge O O
to O O
the O O
wings O O
. O O

Both O O
species O B_BIO/B_PERSON
have O O
black O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
wing O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
tips O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
and O O
other O B_MEASURE/B_PERSON
plumage O B_MEASURE/I_PERSON
characteristics O B_MEASURE/I_PERSON
are O O
shown O O
in O O
[ O B_LOCATION/B_MEASURE
1 O B_LOCATION/I_MEASURE
, O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
wingbeat O O
frequency O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
was O O
measured O O
at O O
8 O O
. O O
6 O O
beats O O
s O O
- O O
1 O O
, O O
similar O O
to O O
that O O
inferred O O
from O O
archival O O
sound O O
recording O O
of O O
a O O
single O O
Ivory B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
claimed O O
to O O
be O O
outside O O
the O O
range O O
of O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
which O O
generally O O
have O O
slower O O
wingbeats O O
) O O
[ O O
1 O O
, O O
3 O O
] O O
. O O

Sibley O B_PERSON
et O I_PERSON
al O I_PERSON
[ O O
4 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
questioned O O
the O O
video O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
in O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
providing O O
alternative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
explanations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
plumage O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Luneau O B_BIO
bird O I_BIO
in O O
flight O B_LOCATION
and O O
at O O
rest O B_LOCATION/B_TIME[MEASURE]
. O O

They O O
pointed O O
out O O
individual O O
frames O O
of O O
the O O
Luneau O O
video O O
that O O
appear O O
to O O
show O O
three O O
features O O
that O O
are O O
each O O
inconsistent O O
with O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
( O O
1 O O
) O O
apparently O O
black O O
secondary O O
feathers O O
on O O
the O O
upper O O
surface O O
of O O
the O O
left O O
wing O O
, O O
( O O
2 O O
) O O
particularly O O
bright O O
white O O
primary O O
bases O O
, O O
and O O
( O O
3 O O
) O O
a O O
black O O
band O O
curving O O
smoothly O O
round O O
the O O
wing O O
tip O O
( O O
see O O
Figure O O
3 O O
in O O
[ O O
4 O O
] O O
) O O
. O O

They O O
hypothesized O O
that O O
flexing O O
of O O
a O O
Pileated B B_BIO/B_PERSON
Woodpecker I I_BIO/I_PERSON
' O O
s O O
wings O O
during O O
flight O O
could O O
produce O O
the O O
appearance O O
of O O
white O O
trailing O O
edges O O
on O O
both O O
wings O O
in O O
low O O
- O O
quality O O
videos O O
[ O O
4 O O
] O O
. O O

They O O
offered O O
, O O
however O O
, O O
no O O
direct O O
evidence O O
to O O
show O O
that O O
this O O
could O O
cause O O
a O O
video O O
of O O
a O O
Pileated B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
look O O
like O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
. O O

Fitzpatrick O O
et O O
al O O
[ O O
5 O O
] O O
in O O
turn O O
rebutted O O
some O O
aspects O O
of O O
the O O
hypothesis O O
of O O
Sibley O O
et O O
al O O
[ O O
4 O O
] O O
, O O
publishing O O
video O O
stills O O
of O O
Pileated B B_PERSON/B_BIO
Woodpeckers I I_PERSON/I_BIO
, O O
and O O
a O O
model O O
of O O
a O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpecker I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
that O O
appeared O O
to O O
show O O
a O O
black O O
trailing O O
edge O O
to O O
the O O
wings O O
inconsistent O O
with O O
Ivory B B_PERSON
- I I_PERSON
billed I I_PERSON
Woodpecker I I_PERSON
and O O
the O O
Luneau O O
video O O
. O O

Fitzpatrick O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O I_PERSON/I_LOCATION
[ O O
5 O B_MEASURE
] O O
neither O O
rebutted O O
nor O O
discussed O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
key O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inconsistencies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
described O O
above O O
. O O

Without O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
this O O
became O O
largely O O
a O O
theoretical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
debate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
over O O
interpretation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
field O B_LOCATION/B_ENT
characters O I_LOCATION/I_ENT
that O O
were O O
barely O O
visible O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
very O O
small O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
images O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
originally O O
obtained O O
. O O

On O O
one O O
hand O O
, O O
as O O
pointed O O
out O O
in O O
Sibley O O
et O O
al O O
[ O O
4 O O
] O O
, O O
some O O
of O O
the O O
frames O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
do O O
appear O O
to O O
be O O
inconsistent O O
with O O
Ivory B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
flight O O
pattern O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
is O O
asserted O O
to O O
be O O
atypical O O
for O O
Pileated B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
but O O
matching O O
anecdotal O O
descriptions O O
of O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Furthermore O O
, O O
the O O
general O O
impression O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
was O O
that O O
there O O
is O O
far O O
too O O
much O O
white O O
in O O
the O O
wings O O
for O O
it O O
to O O
be O O
a O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
that O O
if O O
it O O
was O O
a O O
Pileated O O
, O O
then O O
it O O
must O O
be O O
an O O
aberrant O O
one O O
with O O
abnormally O O
extensive O O
white O O
plumage O O
. O O

Such O B_DISEASE/B_PERSON
birds O I_DISEASE/I_PERSON
occasionally O O
occur O O
, O O
and O O
have O O
been O O
observed O O
in O O
the O O
Arkansas O B_LOCATION
study O I_LOCATION
area O I_LOCATION
[ O O
6 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

This O O
study O O
was O O
undertaken O O
to O O
determine O O
whether O O
the O O
flight O O
and O O
plumage O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
really O O
was O O
inconsistent O O
with O O
either O O
a O O
normal O O
or O O
partial O O
albino O O
Pileated B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Woodpecker I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Independent O O
analyses O O
of O O
the O O
plumage O O
patterns O O
and O O
wingbeat O O
frequencies O O
observable O O
in O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Woodpeckers I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
presented O O
, O O
and O O
it O O
is O O
concluded O O
that O O
the O O
identification O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
as O O
definite O O
Ivory B B_BIO/B_PERSON
- I I_BIO/I_PERSON
billed I I_BIO/I_PERSON
Woodpecker I I_BIO/I_PERSON
is O O
probably O O
unsafe O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

On O O
January O O
28 O O
and O O
February O O
5 O O
, O O
2006 O O
, O O
David O O
Nolin O O
( O O
DN O O
) O O
video O O
- O O
recorded O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpeckers I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Dryocopus B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
pileatus I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
at O O
a O O
bird O O
- O O
feeder O O
in O O
Dayton O O
, O O
Ohio O O
, O O
USA O O
. O O

A O O
Hi O B_PROTEIN[GENE]/B_MEASURE
- O O
8 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
Sony O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
Handycam O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
was O O
used O O
, O O
hand O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
- O O
held O O
, O O
at O O
approximately O O
5 O B_MEASURE/B_LOCATION
m O I_MEASURE/I_LOCATION
from O O
the O O
feeder O B_LOCATION/B_ENT
. O O

Birds O B_BIO/B_PERSON
on O O
the O O
tree O B_LOCATION
trunk O I_LOCATION
were O O
alarmed O O
by O O
movement O B_ORGANIZATION/B_BIO
, O O
and O O
their O O
escape O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
flights O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
recorded O O
. O O

Four O O
escape O O
flights O O
were O O
captured O O
that O O
approximate O O
to O O
that O O
recorded O O
for O O
the O O
putative O O
Ivory B B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Campephilus B B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
principalis I B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
Luneau O O
in O O
April O O
2004 O O
and O O
published O O
in O O
Fitzpatrick O O
et O O
al O O
[ O O
1 O O
] O O
. O O

The O O
videos O O
are O O
not O O
directly O O
equivalent O O
because O O
the O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
made O O
only O O
short O O
escape O O
flights O O
to O O
nearby O O
trees O O
, O O
whereas O O
the O O
putative O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
Luneau O O
video O O
showed O O
little O O
sign O O
of O O
coming O O
to O O
rest O O
before O O
being O O
lost O O
from O O
view O O
. O O

Nevertheless O O
, O O
interesting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparisons O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
made O O
. O O

Wingbeat O O
frequency O O
of O O
Pileated B B_BIO/B_DISEASE
Woodpecker I I_BIO/I_DISEASE

The O O
woodpecker O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
Luneau O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
video O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
maintains O O
a O O
steady O B_MEASURE
rapid O I_MEASURE
wingbeat O I_MEASURE
rate O I_MEASURE
of O O
8 O B_MEASURE
. O O
6 O B_MEASURE
beats O I_MEASURE
s O O
- O O
1 O B_MEASURE/B_LOCATION
for O O
at O O
least O O
8 O B_TIME[MEASURE]/B_ENT
wingbeats O I_TIME[MEASURE]/I_ENT
[ O O
1 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
, O O
a O O
figure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
was O O
confirmed O O
by O O
independent O B_PERSON
analysis O I_PERSON
during O O
preparation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
this O O
paper O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Pileated B B_PERSON/B_BIO
woodpeckers I I_PERSON/I_BIO
in O O
DN O O
' O O
s O O
video O O
do O O
not O O
do O O
this O O
- O O
after O O
initial O O
rapid O O
flapping O O
immediately O O
after O O
take O O
- O O
off O O
, O O
they O O
settle O O
into O O
a O O
more O O
relaxed O O
level O O
flight O O
. O O

As O O
shown O O
in O O
Tables O O
1 O O
and O O
2 O O
, O O
although O O
the O O
mean O O
wingbeat O O
frequencies O O
of O O
the O O
Pileated B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
DN O O
' O O
s O O
video O O
are O O
slower O O
than O O
the O O
8 O O
. O O
6 O O
s O O
- O O
1 O O
recorded O O
for O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
[ O O
1 O O
, O O
3 O O
, O O
5 O O
] O O
the O O
first O O
four O O
wingbeats O O
, O O
the O O
initial O O
escape O O
response O O
, O O
are O O
faster O O
than O O
those O O
claimed O O
for O O
Pileated B B_BIO/B_PERSON
Woodpeckers I I_BIO/I_PERSON
in O O
the O O
literature O O
[ O O
1 O O
, O O
3 O O
, O O
5 O O
] O O
. O O

For O O
the O O
four O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
escape O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
flights O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
mean O B_MEASURE
frequency O I_MEASURE
values O I_MEASURE
for O O
the O O
first O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
four O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
wingbeats O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
7 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE
, O O
6 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
, O O
8 O B_NUMBER[MEASURE]
. O O
6 O B_MEASURE
, O O
and O O
8 O B_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
s O I_MEASURE/I_LOCATION
- O O
1 O B_MEASURE/B_LOCATION
, O O
respectively O O
. O O

The O O
8 O O
. O O
6 O O
beats O O
s O O
- O O
1 O O
of O O
the O O
bird O O
identified O O
in O O
the O O
Luneau O O
video O O
, O O
while O O
consistent O O
with O O
the O O
limited O O
data O O
( O O
n O O
= O O
1 O O
; O O
see O O
Discussion O O
) O O
for O O
Ivory B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
equally O O
consistent O O
with O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
its O O
initial O O
escape O O
flight O O
. O O

The O O
bird O O
in O O
the O O
Luneau O O
video O O
maintains O O
a O O
frequency O O
of O O
8 O O
. O O
6 O O
s O O
- O O
1 O O
for O O
the O O
next O O
four O O
wingbeats O O
too O O
, O O
whereas O O
the O O
Pileated B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
recorded O O
here O O
all O O
slowed O O
their O O
flight O O
as O O
they O O
prepared O O
to O O
land O O
in O O
nearby O O
trees O O
. O O

There O O
are O O
no O O
data O O
to O O
suggest O O
whether O O
Pileated B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
can O O
maintain O O
a O O
wingbeat O O
frequency O O
approaching O O
8 O O
. O O
6 O O
s O O
- O O
1 O O
for O O
eight O O
or O O
more O O
wingbeats O O
, O O
like O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
. O O

It O O
remains O O
possible O O
that O O
the O O
flight O O
pattern O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
is O O
unusual O O
for O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
a O O
frequency O O
of O O
8 O O
. O O
6 O O
s O O
- O O
1 O O
is O O
consistent O O
with O O
a O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Woodpecker I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
gaining O O
initial O O
speed O O
and O O
height O O
in O O
escape O O
flight O O
, O O
and O O
by O O
itself O O
cannot O O
be O O
taken O O
as O O
strong O O
evidence O O
that O O
the O O
Luneau O O
video O O
bird O O
was O O
an O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
discussed O O
further O O
below O O
. O O

Plumage O O
pattern O O
of O O
Pileated B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
in O O
flight O O

The O O
video O O
of O O
Pileated B B_PERSON
Woodpeckers I I_PERSON
in O O
flight O O
was O O
obtained O O
in O O
avi O O
format O O
, O O
decompiled O O
and O O
examined O O
frame O O
by O O
frame O O
. O O

Comparisons O O
of O O
Pileated B B_PERSON/B_LOCATION
Woodpecker I I_PERSON/I_LOCATION
images O O
with O O
key O O
images O O
of O O
Luneau O O
video O O
are O O
shown O O
in O O
Figures O O
1 O O
and O O
2 O O
, O O
and O O
suggest O O
a O O
genuine O O
resemblance O O
between O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
and O O
a O O
Pileated B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
complicated O O
by O O
the O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
digital O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
two O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
videos O I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
in O O
the O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Nolin O B_ENT
videos O I_ENT
it O O
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
concentrate O O
only O O
on O O
those O O
frames O B_TIME[MEASURE]/B_ENT
or O O
part O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
frames O B_TIME[MEASURE]/B_LOCATION
where O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plumage O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
an O O
artifact O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
blurred O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
images O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thirty O B_NUMBER[MEASURE]
- O O
six O B_NUMBER[MEASURE]/B_ENT
frames O I_NUMBER[MEASURE]/I_ENT
from O O
the O O
fourth O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
example O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Pileated O B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
escape O I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
flight O I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
most O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
resembled O O
the O O
flight O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
path O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
Luneau O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
video O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
bird O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
analysed O O
systematically O O
frame O B_TIME[MEASURE]/B_ENT
by O O
frame O B_LOCATION/B_ENT
. O O

They O O
represent O O
seven O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
complete O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
wingbeats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
( O O
1 O B_MEASURE/B_LOCATION
. O O
20 O B_MEASURE
s O I_MEASURE
from O O
the O O
middle O B_SEQUENCE[MEASURE]/B_LOCATION
of O O
the O O
second O B_ENT/B_LOCATION
wingbeat O I_ENT/I_LOCATION
to O O
middle O B_SEQUENCE[MEASURE]/B_LOCATION
of O O
wingbeat O B_SEQUENCE[MEASURE]/B_PERSON
9 O I_SEQUENCE[MEASURE]/I_PERSON
) O O
and O O
were O O
directly O O
compared O O
frame O B_LOCATION/B_TIME[MEASURE]
- O O
by O O
- O O
frame O B_LOCATION/B_TIME[MEASURE]
with O O
the O O
equivalent O B_SEQUENCE[MEASURE]/B_LOCATION
fields O I_SEQUENCE[MEASURE]/I_LOCATION
( O O
middle O B_LOCATION/B_MEASURE
wingbeat O I_LOCATION/I_MEASURE
2 O I_LOCATION/I_MEASURE
- O O
middle O B_MEASURE
wingbeat O I_MEASURE
9 O I_MEASURE
) O O
of O O
the O O
Luneau O B_LOCATION/B_TIME[MEASURE]
video O B_LOCATION/I_TIME[MEASURE]
. O O

This O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
shown O O
in O O
Figure O B_MEASURE/B_LOCATION
3 O I_MEASURE/I_LOCATION
. O O

The O O
images O O
of O O
the O O
birds O O
are O O
not O O
identical O O
, O O
but O O
in O O
every O O
frame O O
of O O
the O O
36 O O
frames O O
available O O
, O O
there O O
are O O
sufficient O O
similarities O O
to O O
suggest O O
that O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
is O O
consistent O O
with O O
the O O
known O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Further O O
comparisons O O
of O O
the O O
Luneau O O
bird O O
with O O
the O O
other O O
three O O
Pileated B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
escape O O
flights O O
recorded O O
are O O
presented O O
in O O
the O O
supplementary O O
material O O
( O O
see O O
Additional O O
file O O
1 O O
) O O
. O O

Key O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
video O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
: O O

1 O B_NUMBER[MEASURE]
. O O

Pileated B B_PERSON/B_BIO
Woodpeckers I I_PERSON/I_BIO
flying O O
near O O
- O O
horizontally O O
away O O
from O O
the O O
observer O O
show O O
much O O
more O O
white O O
in O O
poor O O
- O O
quality O O
video O O
than O O
would O O
be O O
expected O O
from O O
their O O
general O O
plumage O O
pattern O O
. O O

They O O
present O O
an O O
appearance O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
black O B_COLOR/B_DISEASE_ADJECTIVE[DISEASE]
- O O
bodied O B_BIO/B_LOCATION
bird O I_BIO/I_LOCATION
with O O
largely O O
white O B_COLOR/B_DISEASE_ADJECTIVE[DISEASE]
wings O I_COLOR/I_DISEASE_ADJECTIVE[DISEASE]
and O O
black O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wingtips O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
very O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
bird O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
Luneau O B_ENT/B_LOCATION
video O I_ENT/I_LOCATION
; O O
compare O O
in O O
particular O B_MEASURE/B_ENT
Figure O I_MEASURE/I_ENT
1B O I_MEASURE/I_ENT
, O O
frame O B_TIME[MEASURE]/B_LOCATION
758 O I_TIME[MEASURE]/I_LOCATION
, O O
with O O
Figure O B_PROTEIN[GENE]
1A O I_PROTEIN[GENE]
, O O
frame O B_GENE/B_DISEASE
283 O I_GENE/I_DISEASE
. O O
3 O B_MEASURE
. O O

The O O
expected O O
appearance O O
of O O
the O O
upperwing O O
of O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mostly O O
black O O
with O O
a O O
small O O
white O O
patch O O
at O O
the O O
base O O
of O O
the O O
primaries O O
- O O
is O O
often O O
not O O
seen O O
, O O
and O O
is O O
only O O
clearly O O
resolvable O O
when O O
birds O O
are O O
flying O O
near O O
- O O
vertically O O
before O O
landing O O
on O O
a O O
tree O O
trunk O O
; O O
something O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
did O O
not O O
do O O
. O O

2 O B_NUMBER[MEASURE]
. O O

The O O
black O O
trailing O O
edge O O
to O O
the O O
underwing O O
of O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Woodpecker I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
often O O
very O O
inconspicuous O O
and O O
may O O
disappear O O
completely O O
. O O

Due O O
to O O
motion O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
flexion O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
the O O
wing O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
black O B_DISEASE/B_MEASURE
trailing O I_DISEASE/I_MEASURE
edge O I_DISEASE/I_MEASURE
is O O
much O O
more O O
obvious O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
towards O O
the O O
wingtips O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

This O O
produces O O
an O O
apparent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plumage O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pattern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
matches O O
the O O
patterns O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shown O O
by O O
the O O
Luneau O B_ENT/B_PERSON
video O I_ENT/I_PERSON
bird O I_ENT/I_PERSON
( O O
compare O O
Figure O B_PROTEIN[GENE]/B_MEASURE
1B O I_PROTEIN[GENE]/I_MEASURE
, O O
frames O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
175 O B_MEASURE
and O O
457 O B_MEASURE
with O O
Figure O B_ENT/B_LOCATION
1A O I_ENT/I_LOCATION
, O O
frames O B_MEASURE
300 O I_MEASURE
and O O
416 O B_MEASURE
. O O
7 O B_MEASURE
) O O
. O O

In O O
many O O
frames O O
of O O
Pileated B B_ENT/B_LOCATION
Woodpecker I I_ENT/I_LOCATION
, O O
a O O
black O O
trailing O O
edge O O
to O O
the O O
wing O O
is O O
discernable O O
( O O
though O O
due O O
to O O
bleeding O O
of O O
white O O
as O O
a O O
video O O
artifact O O
, O O
it O O
appears O O
narrower O O
than O O
it O O
really O O
is O O
) O O
. O O

However O O
, O O
analysis O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
in O O
light O O
of O O
images O O
of O O
known O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confirms O O
that O O
a O O
similar O O
black O O
trailing O O
edge O O
to O O
the O O
wing O O
is O O
discernable O O
in O O
some O O
frames O O
of O O
the O O
Luneau O O
video O O
( O O
compare O O
Figure O O
1B O O
, O O
frame O O
775 O O
with O O
Figure O O
1A O O
, O O
frame O O
366 O O
. O O
7 O O
: O O
the O O
apparent O O
plumage O O
patterns O O
are O O
similar O O
, O O
and O O
inconsistent O O
with O O
Ivory B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
billed I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
) O O
. O O

It O O
is O O
argued O O
here O O
that O O
the O O
hypothesis O O
put O O
forward O O
in O O
Sibley O O
et O O
al O O
[ O O
4 O O
] O O
is O O
correct O O
, O O
and O O
that O O
the O O
black O O
trailing O O
edge O O
of O O
the O O
underwing O O
of O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
indeed O O
, O O
due O O
to O O
flexion O O
of O O
the O O
wings O O
during O O
the O O
downstroke O O
, O O
be O O
misinterpreted O O
as O O
the O O
black O O
leading O O
edge O O
and O O
wingtips O O
of O O
the O O
upperwing O O
of O O
an O O
Ivory B B_BIO/B_LOCATION
- I I_BIO/I_LOCATION
billed I I_BIO/I_LOCATION
Woodpecker I I_BIO/I_LOCATION
. O O

3 O B_NUMBER[MEASURE]
. O O

Figure O O
3 O O
shows O O
that O O
the O O
plumage O O
patterns O O
shown O O
by O O
the O O
Luneau O O
bird O O
, O O
throughout O O
several O O
wingbeat O O
cycles O O
, O O
are O O
compatible O O
with O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpecker I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

The O O
three O O
plumage O O
features O O
described O O
in O O
Sibley O O
et O O
al O O
[ O O
4 O O
] O O
that O O
are O O
incompatible O O
with O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
black O O
secondary O O
feathers O O
on O O
upper O O
surface O O
of O O
left O O
wing O O
, O O
brighter O O
white O O
primary O O
bases O O
, O O
and O O
a O O
black O O
band O O
curling O O
round O O
the O O
wing O O
tip O O
) O O
are O O
seen O O
consistently O O
in O O
the O O
Luneau O O
video O O
and O O
are O O
recapitulated O O
throughout O O
the O O
video O O
of O O
Pileated B B_PERSON/B_LOCATION
Woodpecker I I_PERSON/I_LOCATION
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Evidence O O
is O O
presented O O
here O O
to O O
show O O
that O O
the O O
distinctive O O
plumage O O
features O O
of O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
surprisingly O O
difficult O O
to O O
resolve O O
in O O
poor O O
- O O
quality O O
video O O
of O O
birds O O
in O O
escape O O
flight O O
away O O
from O O
the O O
camera O O
, O O
and O O
that O O
they O O
can O O
show O O
apparent O O
plumage O O
patterns O O
that O O
might O O
more O O
readily O O
be O O
associated O O
with O O
Ivory B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Irrespective O O
of O O
the O O
identity O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
, O O
this O O
knowledge O O
will O O
be O O
critical O O
to O O
assessment O O
of O O
further O O
claims O O
of O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
current O O
intensive O O
search O O
effort O O
. O O

It O O
is O O
, O O
however O O
, O O
suggested O O
here O O
that O O
critical O O
frames O O
used O O
for O O
identification O O
of O O
the O O
Luneau O O
video O O
woodpecker O O
as O O
an O O
Ivory B B_BIO/B_PERSON
- I I_BIO/I_PERSON
billed I I_BIO/I_PERSON
Woodpecker I I_BIO/I_PERSON
are O O
also O O
consistent O O
with O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

The O O
wingbeat O O
frequency O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
is O O
also O O
perhaps O O
consistent O O
with O O
Pileated B B_MEASURE/B_LOCATION
Woodpecker I I_MEASURE/I_LOCATION
, O O
at O O
least O O
for O O
short O O
periods O O
of O O
flight O O
. O O

Analysis O O
of O O
the O O
videos O O
of O O
Pileated B B_PERSON/B_LOCATION
Woodpecker I I_PERSON/I_LOCATION
has O O
supported O O
the O O
hypothesised O O
interpretations O O
of O O
key O O
frames O O
of O O
the O O
Luneau O O
video O O
by O O
Sibley O O
et O O
al O O
[ O O
4 O O
] O O
. O O

Although O O
the O O
rebuttal O O
of O O
that O O
comment O O
in O O
Fitzpatrick O O
et O O
al O O
[ O O
5 O O
] O O
asserted O O
that O O
flexion O O
and O O
motion O O
of O O
wings O O
of O O
Pileated B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
could O O
not O O
produce O O
the O O
images O O
seen O O
in O O
the O O
Luneau O O
video O O
, O O
it O O
has O O
been O O
shown O O
here O O
that O O
they O O
can O O
. O O

The O O
Luneau O O
video O O
as O O
presented O O
in O O
Fitzpatrick O O
et O O
al O O
[ O O
1 O O
] O O
, O O
shows O O
features O O
that O O
are O O
consistent O O
with O O
Pileated B B_PERSON/B_LOCATION
Woodpecker I I_PERSON/I_LOCATION
, O O
and O O
inconsistent O O
with O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
argued O O
in O O
this O O
paper O O
that O O
, O O
in O O
fact O O
, O O
the O O
black O O
trailing O O
edge O O
of O O
the O O
wing O O
of O O
a O O
Pileated B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
seen O O
clearly O O
in O O
the O O
Luneau O O
video O O
, O O
during O O
the O O
downstroke O O
of O O
the O O
wingbeat O O
cycle O O
, O O
but O O
that O O
it O O
has O O
been O O
misinterpreted O O
as O O
black O O
wingtips O O
( O O
Figure O O
1 O O
, O O
2 O O
, O O
3 O O
) O O
. O O

A O O
fuller O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
Luneau O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
video O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
by O O
the O O
Cornell O B_PERSON/B_ORGANIZATION
University O I_PERSON/I_ORGANIZATION
team O I_PERSON/I_ORGANIZATION
is O O
presented O O
online O B_TIME[MEASURE]/B_ORGANIZATION
[ O I_TIME[MEASURE]/I_ORGANIZATION
7 O I_TIME[MEASURE]/I_ORGANIZATION
] O I_TIME[MEASURE]/I_ORGANIZATION
. O O

Although O O
it O O
is O O
not O O
peer O B_PERSON/B_LOCATION
- O O
reviewed O O
, O O
the O O
points O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O O
article O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
makes O O
should O O
be O O
taken O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
authors O O
summarise O O
nine O O
diagnostic O O
traits O O
from O O
their O O
analysis O O
of O O
the O O
Luneau O O
video O O
that O O
identify O O
the O O
bird O O
as O O
Ivory B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
are O O
listed O O
and O O
discussed O O
point O B_LOCATION/B_MEASURE
- O O
by O O
point O B_LOCATION/B_PERSON
below O O
. O O

1 O B_NUMBER[MEASURE]
. O O

' O O
The O O
underwing O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
pattern O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
flight O B_BIO
consistently O O
appears O O
largely O O
white O B_COLOR/B_LOCATION
, O O
giving O O
the O O
appearance O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
having O O
black O B_COLOR/B_BIO
wingtips O I_COLOR/I_BIO
but O O
lacking O O
any O O
black O B_COLOR/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O O
the O O
rear O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
or O O
trailing O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
edge O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O
' O O

Data O O
presented O O
in O O
this O O
paper O O
show O O
that O O
this O O
statement O O
is O O
not O O
wholly O O
supported O O
, O O
and O O
in O O
any O O
case O O
the O O
underwing O O
of O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Woodpeckers I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O O
present O O
the O O
same O O
appearance O O
. O O

2 O B_NUMBER[MEASURE]
. O O

' O O
The O O
upperwing O O
pattern O O
in O O
flight O O
consistently O O
shows O O
a O O
broad O O
, O O
white O O
trailing O O
edge O O
, O O
with O O
no O O
frames O O
demonstrating O O
the O O
conspicuous O O
dark O O
rear O O
border O O
to O O
be O O
expected O O
of O O
normal O O
Pileated B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
' O O

Notwithstanding O O
that O O
certain O O
frames O O
of O O
the O O
Luneau O O
video O O
( O O
e O O
. O O
g O O
. O O
frame O O
350 O O
) O O
do O O
appear O O
to O O
show O O
a O O
black O O
trailing O O
edge O O
to O O
the O O
upperwing O O
, O O
data O O
presented O O
in O O
this O O
paper O O
shows O O
that O O
, O O
at O O
this O O
angle O O
of O O
view O O
and O O
resolution O O
of O O
video O O
, O O
Pileated B B_PERSON/B_ENT
Woodpeckers I I_PERSON/I_ENT
also O O
may O O
fail O O
to O O
show O O
this O O
feature O O
. O O

This O O
analysis O O
has O O
shown O O
that O O
the O O
hypothesis O O
presented O O
in O O
Sibley O O
et O O
al O O
[ O O
4 O O
] O O
is O O
plausible O O
, O O
i O O
. O O
e O O
. O O
that O O
some O O
of O O
the O O
frames O O
interpreted O O
by O O
[ O O
1 O O
] O O
to O O
show O O
the O O
upperwing O O
of O O
an O O
Ivory B B_BIO/B_LOCATION
- I I_BIO/I_LOCATION
billed I I_BIO/I_LOCATION
Woodpecker I I_BIO/I_LOCATION
may O O
in O O
fact O O
show O O
large O O
amounts O O
of O O
white O O
and O O
the O O
black O O
trailing O O
edge O O
from O O
the O O
underwing O O
of O O
a O O
Pileated B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

3 O B_NUMBER[MEASURE]
. O O

' O O
The O O
wings O O
are O O
longer O O
relative O O
to O O
the O O
body O O
diameter O O
than O O
in O O
Pileated B B_PERSON/B_BIO
Woodpecker I I_PERSON/I_BIO
and O O
consistent O O
with O O
the O O
wing O O
shape O O
of O O
Ivory B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
billed I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Woodpecker I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O
' O O

Fitzpatrick O B_PERSON/B_ORGANIZATION
et O I_PERSON/I_ORGANIZATION
al O I_PERSON/I_ORGANIZATION
[ O O
5 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
agreed O O
that O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
not O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
video O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
images O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
in O O
their O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
paper O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
[ O O
1 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
, O O
and O O
it O O
seems O O
unlikely O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
that O O
much O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
confidence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
placed O O
in O O
the O O
wing O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
length O B_MEASURE/B_LOCATION
measurements O I_MEASURE/I_LOCATION
of O O
the O O
bird O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
Luneau O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
video O I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
, O O
for O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
Figure O B_PROTEIN[GENE]
1A O I_PROTEIN[GENE]
, O O
frame O B_MEASURE/B_LOCATION
283 O I_MEASURE/I_LOCATION
. O O
3 O B_MEASURE
with O O
Figure O B_MEASURE/B_LOCATION
1B O I_MEASURE/I_LOCATION
, O O
frame O B_LOCATION
578 O I_LOCATION
suggests O O
that O O
any O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O O
be O O
very O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prove O O
. O O

4 O B_NUMBER[MEASURE]
. O O

' O O
Reenactment O O
of O O
the O O
scene O O
using O O
life O O
- O O
sized O O
, O O
realistically O O
painted O O
, O O
dynamically O O
flapping O O
models O O
produced O O
images O O
remarkably O O
similar O O
to O O
those O O
of O O
the O O
Luneau O O
video O O
using O O
the O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O O
, O O
and O O
images O O
clearly O O
identifiable O O
as O O
Pileated B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
Woodpecker I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
using O O
a O O
model O O
of O O
that O O
species O O
. O O
' O O

Interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
re O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
enactments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
is O O
hampered O O
by O O
the O O
fact O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
the O O
stiff O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
flat O B_NUMBER[MEASURE]/B_DISEASE
- O O
winged O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
cannot O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
reflect O O
the O O
wing O B_MEASURE/B_LOCATION
flexion O I_MEASURE/I_LOCATION
and O O
curvature O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
real O B_BIO/B_ENT
birds O I_BIO/I_ENT
. O O

Reenactment O O
of O O
the O O
scene O O
using O O
real O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
Woodpeckers I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
has O O
produced O O
images O O
remarkably O O
similar O O
to O O
the O O
Luneau O O
video O O
. O O

5 O B_NUMBER[MEASURE]
. O O

' O O
The O O
wingbeat O O
frequency O O
is O O
8 O O
. O O
6 O O
beats O O
per O O
second O O
, O O
which O O
is O O
almost O O
identical O O
to O O
that O O
recorded O O
for O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
as O O
documented O O
by O O
one O O
acoustic O O
record O O
from O O
1935 O O
) O O
. O O

The O O
wing O O
- O O
beat O O
frequencies O O
of O O
Pileated B B_PERSON/B_ENT
Woodpecker I B_PERSON/I_ENT
are O O
not O O
known O O
to O O
exceed O O
7 O O
. O O
5 O O
beats O O
per O O
second O O
, O O
and O O
more O O
typically O O
range O O
between O O
3 O O
and O O
6 O O
beats O O
per O O
second O O
. O O
' O O

The O O
fact O O
that O O
in O O
only O O
four O O
recorded O O
escape O O
flights O O
of O O
Pileated B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
two O O
were O O
recorded O O
for O O
which O O
the O O
initial O O
escape O O
flight O O
wingbeat O O
frequency O O
( O O
8 O O
. O O
0 O O
s O O
- O O
1 O O
and O O
8 O O
. O O
6 O O
s O O
- O O
1 O O
) O O
exceeded O O
that O O
previously O O
recorded O O
for O O
this O O
species O O
shows O O
that O O
previous O O
datasets O O
were O O
too O O
limited O O
to O O
make O O
this O O
conclusion O O
. O O

Birds O O
flap O O
more O O
rapidly O O
at O O
take O O
off O O
to O O
gain O O
altitude O O
and O O
speed O O
than O O
they O O
do O O
in O O
sustained O O
level O O
flight O O
: O O
Pileated B B_TIME[MEASURE]/B_LOCATION
Woodpecker I I_TIME[MEASURE]/I_LOCATION
flight O O
data O O
in O O
the O O
literature O O
[ O O
1 O O
, O O
4 O O
, O O
5 O O
] O O
was O O
derived O O
from O O
the O O
work O O
of O O
Tobalske O O
[ O O
8 O O
] O O
, O O
which O O
explicitly O O
excluded O O
the O O
initial O O
take O O
- O O
off O O
period O O
, O O
and O O
therefore O O
cannot O O
be O O
used O O
to O O
support O O
the O O
elimination O O
of O O
Pileated B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
Luneau O O
video O O
. O O

Furthermore O O
, O O
the O O
bird O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
Luneau O B_LOCATION/B_ENT
video O I_LOCATION/I_ENT
is O O
consistently O O
gaining O O
height O B_MEASURE/B_LOCATION
from O O
a O O
low O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
position O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
above O O
water O B_LOCATION/B_BIO
and O O
, O O
whatever O O
its O O
species O B_MEASURE/B_BIO
, O O
might O O
be O O
expected O O
to O O
flap O O
more O O
rapidly O O
than O O
if O O
it O O
were O O
in O O
level O B_LOCATION
flight O I_LOCATION
. O O

Tanner O O
[ O O
9 O O
] O O
noted O O
that O O
Pileated B B_PERSON
Woodpeckers I I_PERSON
can O O
maintain O O
extended O O
fast O O
direct O O
flight O O
. O O

He O O
was O O
of O O
the O O
opinion O O
that O O
flight O O
pattern O O
was O O
not O O
a O O
useful O O
character O O
for O O
separating O O
the O O
two O O
species O O
in O O
the O O
field O O
, O O
and O O
that O O
Pileated B B_BIO/B_PERSON
Woodpeckers I I_BIO/I_PERSON
frequently O O
fly O O
in O O
a O O
manner O O
that O O
was O O
in O O
no O O
way O O
different O O
to O O
Ivory B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
billed I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
figure O O
of O O
8 O O
. O O
6 O O
wingbeats O O
per O O
second O O
for O O
the O O
Luneau O O
bird O O
( O O
data O O
reanalysed O O
here O O
) O O
is O O
taken O O
as O O
consistent O O
with O O
Ivory B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
billed I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
on O O
the O O
basis O O
of O O
analysis O O
of O O
a O O
single O O
archival O O
audio O O
recording O O
[ O O
3 O O
] O O
. O O

The O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
that O O
audio O O
tape O O
is O O
clearly O O
flapping O O
its O O
wings O O
, O O
but O O
without O O
accompanying O O
visual O O
confirmation O O
it O O
is O O
not O O
clear O O
that O O
it O O
is O O
in O O
flight O O
. O O

In O O
general O B_PERSON/B_LOCATION
, O O
larger O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
birds O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
are O O
expected O O
to O O
flap O O
their O O
wings O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
more O O
slowly O O
than O O
smaller O B_PERSON/B_BIO
birds O I_PERSON/I_BIO
of O O
comparable O B_BIO/B_LOCATION
wing O I_BIO/I_LOCATION
morphology O I_BIO/I_LOCATION
. O O

Tobalske O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
8 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
showed O O
that O O
, O O
across O O
species O B_BIO/B_LOCATION
, O O
smaller O B_BIO/B_PERSON
woodpeckers O I_BIO/I_PERSON
tend O O
to O O
flap O O
more O O
quickly O O
than O O
larger O B_MEASURE/B_PERSON
ones O B_MEASURE/I_PERSON
, O O
and O O
that O O
there O O
was O O
considerable O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intraspecific O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
assertion O O
that O O
Ivory B B_BIO/B_PERSON
- I I_BIO/I_PERSON
billed I I_BIO/I_PERSON
Woodpeckers I I_BIO/I_PERSON
flap O O
their O O
wings O O
more O O
quickly O O
than O O
Pileated B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
is O O
therefore O O
counterintuitive O O
. O O

Further O O
comment O O
is O O
conjecture O O
: O O
while O O
the O O
flight O O
pattern O O
and O O
wing O O
posture O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
may O O
be O O
unusual O O
, O O
it O O
has O O
not O O
been O O
shown O O
that O O
it O O
is O O
outside O O
the O O
range O O
of O O
variability O O
of O O
Pileated B B_SPECIES[BIO]/B_LOCATION
Woodpecker I I_SPECIES[BIO]/I_LOCATION
, O O
and O O
cannot O O
therefore O O
be O O
used O O
to O O
eliminate O O
the O O
possibility O O
that O O
it O O
was O O
the O O
commoner O O
species O O
. O O

6 O B_NUMBER[MEASURE]
. O O

' O O
White O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
plumage O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
on O O
the O O
back O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
visible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O O
the O O
retreating O O
bird O B_LOCATION/B_SPECIES[BIO]
as O O
it O O
begins O O
to O O
gain O O
altitude O B_LOCATION/B_MEASURE
. O O

Ivory B B_BIO/B_PERSON
- I I_BIO/I_PERSON
billed I I_BIO/I_PERSON
Woodpecker I I_BIO/I_PERSON
has O O
white O O
on O O
the O O
back O O
; O O
Pileated B B_PERSON/B_LOCATION
Woodpecker I I_PERSON/I_LOCATION
has O O
entirely O O
black O O
back O O
. O O
' O O

This O O
was O O
discussed O O
by O O
Sibley O B_PERSON
et O I_PERSON
al O I_PERSON
[ O O
4 O B_MEASURE
] O I_MEASURE
, O O
who O O
argued O O
that O O
the O O
images O B_ENT/B_BODY_PART_OR_ORGAN_COMPONENT
thought O O
to O O
show O O
white O B_DISEASE
on O O
the O O
dorsum O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
too O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
be O O
accepted O O
uncritically O O
. O O

In O O
all O O
the O O
frames O B_TIME[MEASURE]/B_ENT
of O O
the O O
Luneau O B_ENT/B_LOCATION
video O I_ENT/I_LOCATION
that O O
appear O O
to O O
show O O
white O B_COLOR/B_PERSON
on O O
the O O
dorsum O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
bird O B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
is O O
distant O B_LOCATION/B_DISEASE
( O O
dorsal O B_COLOR/B_LOCATION
white O B_COLOR/I_LOCATION
is O O
not O O
visible O B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
resolution O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
images O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
earlier O O
in O O
the O O
video O B_ENT
) O O
and O O
partially O O
obscured O O
, O O
making O O
it O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
distinguish O O
dorsum O B_BIO/B_LOCATION
from O O
wing O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Spurious O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
areas O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
white O B_DISEASE
pixels O I_DISEASE
appear O O
as O O
artifacts O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
videos O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nevertheless O O
, O O
this O O
remains O O
the O O
best O O
evidence O O
that O O
the O O
Luneau O O
bird O O
was O O
not O O
a O O
standard O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

7 O B_NUMBER[MEASURE]
. O O

' O O
The O O
dorsal O O
view O O
of O O
the O O
right O O
wing O O
as O O
it O O
begins O O
to O O
unfold O O
shows O O
a O O
triangle O O
of O O
white O O
that O O
matches O O
in O O
size O O
and O O
position O O
the O O
white O O
on O O
the O O
folded O O
wing O O
of O O
an O O
Ivory B B_BIO/B_PERSON
- I I_BIO/I_PERSON
billed I I_BIO/I_PERSON
Woodpecker I I_BIO/I_PERSON
beginning O O
to O O
launch O O
into O O
flight O O
. O O
' O O

No O O
further O B_LOCATION
comment O I_LOCATION
is O O
provided O O
here O O
. O O

An O O
alternative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
explanation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
offered O O
by O O
Sibley O B_PERSON
et O I_PERSON
al O I_PERSON
[ O O
4 O B_MEASURE
] O I_MEASURE
and O O
rebutted O O
by O O
Fitzpatrick O B_PERSON
et O I_PERSON
al O I_PERSON
[ O O
5 O B_MEASURE
] O I_MEASURE
. O O

The O O
statement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
requires O O
a O O
degree O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
certainty O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
the O O
position O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
wing O B_PERSON/B_ORGANIZATION
. O O

( O O
8 O O
) O O
' O O
The O O
distance O O
between O O
the O O
wrist O O
area O O
and O O
the O O
tip O O
of O O
the O O
tail O O
( O O
32 O O
- O O
36 O O
cm O O
, O O
as O O
measured O O
when O O
the O O
bird O O
begins O O
to O O
take O O
flight O O
) O O
is O O
comparable O O
to O O
known O O
measurements O O
of O O
Ivory B B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
considerably O O
larger O O
than O O
even O O
the O O
largest O O
Pileated B B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
measured O O
. O O
' O O

As O O
stated O O
under O O
( O O
3 O B_MEASURE
) O O
, O O
above O O
, O O
there O O
is O O
general O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agreement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
not O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
Luneau O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
video O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
too O O
many O B_NUMBER[MEASURE]/B_PERSON
uncontrolled O I_NUMBER[MEASURE]/I_PERSON
variables O I_NUMBER[MEASURE]/I_PERSON
are O O
involved O O
[ O O
4 O B_NUMBER[MEASURE]
, O O
5 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

9 O B_NUMBER[MEASURE]
. O O

' O O
Only O O
20 O O
seconds O O
before O O
the O O
woodpecker O O
flees O O
, O O
a O O
bird O O
with O O
the O O
size O O
and O O
color O O
pattern O O
of O O
an O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
perched O O
within O O
3 O O
m O O
of O O
the O O
site O O
from O O
which O O
the O O
woodpecker O O
took O O
flight O O
. O O
' O O

This O O
would O O
be O O
a O O
strong O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
argument O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
if O O
it O O
could O O
be O O
shown O O
that O O
the O O
object O B_PERSON/B_LOCATION
in O O
question O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
a O O
bird O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
not O O
, O O
as O O
is O O
now O O
apparently O O
thought O O
likely O O
, O O
a O O
section O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
branch O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
tree O B_BIO/B_DISEASE
stump O I_BIO/I_DISEASE
[ O I_BIO/I_DISEASE
10 O I_BIO/I_DISEASE
] O I_BIO/I_DISEASE
. O O

The O O
Luneau O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
video O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
reveals O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
white O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triangular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patches O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apparently O O
visible O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
on O O
or O O
around O O
tree O B_PERSON/B_LOCATION
trunks O B_PERSON/I_LOCATION
, O O
most O B_NUMBER[MEASURE]/B_LOCATION
or O O
all O O
of O O
which O O
must O O
therefore O O
be O O
images O B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
tree O B_ENT/B_LOCATION
topography O I_ENT/I_LOCATION
or O O
video O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
artifacts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

This O O
was O O
discussed O O
in O O
the O O
literature O B_PERSON/B_TIME[MEASURE]
( O O
see O O
[ O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE
] O I_MEASURE
) O O
. O O

Central O O
to O O
the O O
identification O O
of O O
the O O
flying O O
bird O O
seen O O
in O O
the O O
Luneau O O
video O O
was O O
the O O
evidence O O
that O O
plumage O O
and O O
flight O O
patterns O O
were O O
inconsistent O O
with O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

A O O
very O O
basic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
video O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
presented O O
here O O
has O O
suggested O O
that O O
this O O
may O O
not O O
be O O
the O O
case O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
that O O
further O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
research O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
is O O
needed O O
. O O

Any O O
identification O O
of O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
as O O
an O O
Ivory B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
bill I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
must O O
take O O
into O O
account O O
the O O
data O O
presented O O
here O O
and O O
in O O
Sibley O O
et O O
al O O
[ O O
4 O O
] O O
, O O
which O O
shows O O
it O O
is O O
largely O O
consistent O O
with O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
points O O
out O O
apparent O O
inconsistencies O O
with O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
does O O
not O O
of O O
course O O
necessarily O O
imply O O
that O O
the O O
Ivory B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
extinct O O
, O O
nor O O
indeed O O
entirely O O
rule O O
out O O
the O O
possibility O O
that O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
was O O
one O O
. O O

There O O
appears O O
to O O
be O O
no O O
reason O O
to O O
question O O
the O O
anecdotal O O
sight O O
records O O
of O O
Ivory B B_PERSON
- I I_PERSON
billed I I_PERSON
Woodpecker I I_PERSON
presented O O
in O O
Fitzpatrick O O
et O O
al O O
[ O O
1 O O
] O O
( O O
or O O
in O O
many O O
online O O
sources O O
) O O
, O O
because O O
some O O
of O O
them O O
appear O O
credible O O
, O O
albeit O O
brief O O
. O O

Audio O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
has O O
since O O
been O O
published O O
[ O O
11 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
although O O
this O O
too O O
is O O
far O O
from O O
conclusive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
to O O
regard O O
the O O
Luneau O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
video O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
by O O
itself O O
as O O
presenting O O
anything O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
other O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
than O O
an O O
unidentified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
woodpecker O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
falls O O
below O O
the O O
standards O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
proof O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
normally O O
required O O
for O O
scientific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
publication O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
the O O
images O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
enough O O
. O O

The O O
Ivory B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
billed I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
Woodpecker I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
may O O
persist O O
in O O
continental O O
North O O
America O O
, O O
and O O
there O O
is O O
enough O O
anecdotal O O
evidence O O
to O O
make O O
this O O
a O O
possibility O O
, O O
but O O
the O O
Luneau O O
video O O
does O O
not O O
support O O
the O O
case O O
. O O

The O O
balance O O
of O O
evidence O O
would O O
suggest O O
that O O
the O O
bird O O
in O O
the O O
Luneau O O
video O O
is O O
more O O
likely O O
to O O
have O O
been O O
a O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
the O O
search O O
for O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
continue O O
. O O

While O O
this O O
paper O O
was O O
under O O
review O O
, O O
a O O
report O O
of O O
sight O O
records O O
and O O
sound O O
recordings O O
of O O
Ivory B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
billed I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
published O O
from O O
a O O
location O O
in O O
Florida O O
[ O O
12 O O
] O O
. O O

This O O
very O O
exciting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
claim O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
strengthened O O
by O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sighting O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
white O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
dorsal O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
stripes O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
on O O
one O B_BIO/B_PERSON
bird O I_BIO/I_PERSON
in O O
flight O B_LOCATION
. O O

Unfortunately O O
, O O
several O B_PERSON/B_ENT
sightings O I_PERSON/I_ENT
were O O
made O O
without O O
optical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
aids O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cannot O B_PERSON/B_LOCATION
be O O
considered O O
proven O O
. O O

The O O
' O O
kent O O
' O O
calls O O
recorded O O
from O O
the O O
Florida O O
location O O
are O O
spectrographically O O
similar O O
to O O
the O O
' O O
bleat O O
' O O
calls O O
of O O
young O O
White B B_BIO/B_PERSON
- I B_BIO/I_PERSON
tailed I B_BIO/I_PERSON
Deer I B_BIO/I_PERSON
, O O
as O O
described O O
in O O
Richardson O O
et O O
al O O
[ O O
13 O O
] O O
. O O

A O O
clear O O
photograph O O
will O O
be O O
required O O
from O O
this O O
location O O
too O O
before O O
the O O
presence O O
of O O
Ivory B B_DISEASE
- I I_DISEASE
billed I I_DISEASE
Woodpeckers I I_DISEASE
can O O
be O O
considered O O
confirmed O O
. O O

It O O
is O O
hoped O O
that O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
help O O
with O O
assessment O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
any O O
further O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
low O I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quality O I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
photographs O I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
videos O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Flight O O
and O O
plumage O O
patterns O O
of O O
the O O
putative O O
Ivory B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recorded O O
in O O
Arkansas O O
in O O
2005 O O
are O O
recapitulated O O
by O O
confirmed O O
Pileated B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
bird O O
in O O
the O O
Arkansas O O
video O O
is O O
best O O
regarded O O
as O O
not O O
fully O O
identified O O
, O O
and O O
is O O
probably O O
a O O
Pileated B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Video O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
recording O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT

Pileated B B_PERSON/B_BIO
Woodpeckers I I_PERSON/I_BIO
were O O
attracted O O
to O O
a O O
bird O O
feeder O O
containing O O
suet O O
at O O
Grants O O
Trail O O
, O O
Dayton O O
, O O
OH O O
45459 O O
. O O

The O O
suet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
feeder O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O O
placed O O
approximately O O
2 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
m O I_MEASURE/I_LOCATION
high O I_MEASURE/I_LOCATION
on O O
a O O
tree O B_LOCATION
trunk O I_LOCATION
, O O
and O O
the O O
distance O B_MEASURE/B_LOCATION
to O O
the O O
suet O B_LOCATION
feeder O I_LOCATION
from O O
the O O
observation O B_LOCATION/B_BIO
point O I_LOCATION/I_BIO
was O O
approximately O O
5 O B_MEASURE
m O I_MEASURE
. O O

Birds O B_BIO/B_PERSON
on O O
the O O
feeder O B_LOCATION/B_BIO
were O O
startled O O
by O O
movement O B_ORGANIZATION/B_LOCATION
of O O
window O B_PERSON/B_BIO
blinds O B_PERSON/I_BIO
on O O
January O B_TIME[MEASURE]
28 O I_TIME[MEASURE]
and O O
February O B_TIME[MEASURE]
5 O I_TIME[MEASURE]
, O O
2006 O B_MEASURE
, O O
and O O
their O O
escape O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
flights O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
filmed O O
using O O
a O O
Sony O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
Hi O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
8 O B_PERSON/B_LOCATION
SteadyShot O I_PERSON/I_LOCATION
video O I_PERSON/I_LOCATION
camera O I_PERSON/I_LOCATION
at O O
29 O B_MEASURE
. O O
97 O B_MEASURE
frames O I_MEASURE
s O I_MEASURE
- O O
1 O B_MEASURE/B_LOCATION
. O O

At O O
least O O
two O B_NUMBER[MEASURE]/B_ENT
birds O I_NUMBER[MEASURE]/I_ENT
feature O O
in O O
the O O
videos O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
male O B_PERSON/B_COLOR
and O O
female O B_PERSON
. O O

Analogue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
tape O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
was O O
converted O O
to O O
digital O B_PRODUCT[OBJECT]/B_ENT
by O O
connecting O O
the O O
Hi O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
- O O
8 O B_PRODUCT[OBJECT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
camera O I_PRODUCT[OBJECT]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directly O O
to O O
a O O
Sony O B_DISEASE/B_LOCATION
DCR O B_DISEASE/I_LOCATION
- O O
HC30 O B_MEASURE/B_LOCATION
digital O I_MEASURE/I_LOCATION
video O I_MEASURE/I_LOCATION
camera O I_MEASURE/I_LOCATION
and O O
recording O O
onto O O
that O O
camera O B_ENT/B_PRODUCT[OBJECT]
' O O
s O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
mini O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
dv O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
cassette O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O O

The O O
resulting O O
images O B_ENT/B_RELIGION[SOCIAL_CIRCUMSTANCES]
were O O
converted O O
to O O
an O O
avi O B_ENT/B_ORGANIZATION
file O I_ENT/I_ORGANIZATION
using O O
Windows O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Movie O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Maker O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
a O O
Windows O B_PRODUCT[OBJECT]/B_PERSON
XP O I_PRODUCT[OBJECT]/I_PERSON
PC O I_PRODUCT[OBJECT]/I_PERSON
. O O

The O O
video O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
freely O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
wmv O B_MEASURE/B_ENT
format O I_MEASURE/I_ENT
[ O O
14 O B_TIME[MEASURE]/B_ENT
] O B_TIME[MEASURE]/I_ENT
and O O
in O O
avi O B_ENT/B_PERSON
format O B_ENT/I_PERSON
from O O
the O O
author O B_PERSON/B_ORGANIZATION
or O O
David O B_PERSON
Nolin O I_PERSON
( O O
via O O
the O O
author O B_PERSON/B_ORGANIZATION
) O O
. O O

The O O
video O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
decompiled O O
using O O
Blaze O B_ORGANIZATION/B_LOCATION
Media O B_ORGANIZATION/I_LOCATION
Pro O B_ORGANIZATION/I_LOCATION
( O O
Mystik O B_MEASURE/B_PERSON
Media O I_MEASURE/I_PERSON
, O O
Hampstead O B_LOCATION/B_PERSON
, O O
NC O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
for O O
a O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Import O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
Avid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
(R) O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Xpress O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Pro O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
HD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
deinterlacing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
did O O
not O O
reduce O O
the O O
wing O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
flicker O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
seen O O
in O O
the O O
images O B_ENT/B_RELIGION[SOCIAL_CIRCUMSTANCES]
, O O
and O O
further O B_TIME[MEASURE]/B_LOCATION
professional O I_TIME[MEASURE]/I_LOCATION
processing O I_TIME[MEASURE]/I_LOCATION
could O O
not O O
improve O O
the O O
resolution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
so O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
decompiled O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
file O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
was O O
used O O
for O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hence O O
some O O
frames O B_TIME[MEASURE]/B_ENT
contain O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
overlaid O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
images O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
which O O
may O O
lower O O
the O O
resolution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
some O O
cases O B_PERSON/B_LOCATION
. O O

The O O
decompiled O O
file O O
was O O
examined O O
frame O O
by O O
frame O O
and O O
compared O O
to O O
the O O
decompiled O O
images O O
of O O
the O O
putative O O
Ivory B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
billed I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Woodpecker I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
presented O O
in O O
Fitzpatrick O O
et O O
al O O
[ O O
1 O O
] O O
. O O

Wingbeat O B_TIME[MEASURE]/B_PERSON
frequencies O I_TIME[MEASURE]/I_PERSON
were O O
calculated O O
by O O
noting O O
the O O
frame O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
the O O
midpoint O B_LOCATION/B_MEASURE
of O O
the O O
downstroke O B_DISEASE_ADJECTIVE[DISEASE]/B_SPORT[ENT]
of O O
each O O
wingbeat O B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
e O B_DISEASE/B_PROTEIN[GENE]
. O O
g O B_PROTEIN[GENE]/B_MEASURE
. O O
Figure O B_MEASURE/B_PERSON
1B O I_MEASURE/I_PERSON
, O O
frame O B_TIME[MEASURE]
758 O I_TIME[MEASURE]
) O O
and O O
calculating O O
the O O
length O B_MEASURE/B_ORGANIZATION
of O O
time O B_TIME[MEASURE]/B_LOCATION
taken O O
per O O
wingbeat O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
( O O
number O B_MEASURE
of O O
frames O B_TIME[MEASURE]/B_LOCATION
between O O
downstroke O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
midpoints O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
/ O O
29 O B_MEASURE
. O O
97 O B_MEASURE
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

JMC O B_PERSON/B_ORGANIZATION
performed O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
drafted O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

Supplementary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
Material O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE

A O O
global O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
evolution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
Vibrionaceae O B_BIO
family O I_BIO
using O O
phylogenetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
profile O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Vibrionaceae O B_BACTERIUM[BIO]/B_PERSON
represent O O
a O O
significant O B_MEASURE/B_PERSON
portion O I_MEASURE/I_PERSON
of O O
the O O
cultivable O B_BACTERIUM[BIO]/B_LOCATION
heterotrophic O B_BACTERIUM[BIO]/I_LOCATION
sea O B_BACTERIUM[BIO]/I_LOCATION
bacteria O B_BACTERIUM[BIO]/I_LOCATION
; O O
they O O
strongly O O
affect O O
nutrient O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cycling O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O O
some O O
species O B_BIO/B_PERSON
are O O
devastating O B_DISEASE_ADJECTIVE[DISEASE]
pathogens O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
work O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
propose O O
an O O
improved O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
phylogenetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
on O O
14 O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Vibrionaceae O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
genomes O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
to O O
study O O
the O O
evolution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O O
this O O
family O B_PERSON/B_BIO
on O O
the O O
basis O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
based O O
on O O
the O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
genes O O
involved O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
e O B_GENE/B_DISEASE
. O O
g O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O
metabolic O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
structural O B_GENE/B_BIO
complex O I_GENE/I_BIO
) O O
tend O O
to O O
be O O
concurrently O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
within O O
different O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
genomes O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
allows O O
the O O
prediction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
hypothetical O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
basis O B_PERSON/B_LOCATION
of O O
a O O
shared O O
phylogenetic O B_MEASURE/B_LOCATION
profiles O I_MEASURE/I_LOCATION
. O O

Moreover O O
this O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
identify O O
putative O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
laterally O O
transferred O O
elements O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
basis O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
their O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
distantly O O
phylogenetically O O
related O O
bacteria O B_BIO/B_GENE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Vibrionaceae O B_PERSON/B_BIO
ORFs O I_PERSON/I_BIO
were O O
aligned O O
against O O
all O O
the O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bacterial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
proteomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
profile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
defined O O
as O O
an O O
array O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
distances O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
based O O
on O O
aminoacid O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitution O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrixes O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
from O O
single O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
all O O
their O O
orthologues O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Final O B_MEASURE
phylogenetic O I_MEASURE
profiles O I_MEASURE
, O O
derived O O
from O O
non O B_DISEASE/B_MEASURE
- O O
redundant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
list O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
all O O
ORFs O B_BIO
, O O
was O O
defined O O
as O O
the O O
median O B_MEASURE
of O O
all O O
the O O
profiles O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O O
to O O
the O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
resulting O O
phylogenetic O B_BIO/B_GENE
profiles O O
matrix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contains O O
gene O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
clusters O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
rows O B_LOCATION
and O O
organisms O B_BIO/B_LOCATION
on O O
the O O
columns O B_LOCATION
. O O

Cluster O B_PERSON
analysis O I_PERSON
identified O O
groups O B_ORGANIZATION/B_MEASURE
of O O
" O B_GENE/B_BIO
core O I_GENE/I_BIO
genes O I_GENE/I_BIO
" O I_GENE/I_BIO
with O O
a O O
widespread O B_MEASURE/B_LOCATION
high O I_MEASURE/I_LOCATION
similarity O I_MEASURE/I_LOCATION
across O O
all O O
the O O
organisms O B_BIO/B_LOCATION
and O O
several O B_LOCATION/B_MEASURE
clusters O I_LOCATION/I_MEASURE
that O O
contain O O
genes O B_GENE/B_PERSON
homologous O I_GENE/I_PERSON
only O O
to O O
a O O
limited O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
organisms O B_GENE/B_BIO
. O O

On O O
each O O
of O O
these O O
clusters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
COG O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
class O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
enrichment O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
been O O
calculated O O
. O O

The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
reveals O O
that O O
clusters O B_LOCATION/B_NUMBER[MEASURE]
of O O
core O B_GENE/B_LOCATION
genes O I_GENE/I_LOCATION
have O O
the O O
highest O B_MEASURE/B_LOCATION
number O B_MEASURE/I_LOCATION
of O O
enriched O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classes O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
while O O
the O O
others O B_PERSON/B_LOCATION
are O O
enriched O O
just O O
for O O
few O B_NUMBER[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
them O O
like O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
replication O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
recombination O B_GENE/B_TIME[MEASURE]
and O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

We O O
found O O
that O O
mobile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
elements O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
have O O
heterogeneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O O
only O O
across O O
the O O
entire O B_MEASURE/B_PERSON
set O B_MEASURE/I_PERSON
of O O
organisms O B_BIO/B_GENE
, O O
but O O
also O O
within O O
Vibrionaceae O B_BIO/B_PERSON
; O O
this O O
confirms O O
their O O
great O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
bacteria O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
evolution O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
even O O
inside O O
the O O
same O B_PERSON/B_BIO
family O B_PERSON/I_BIO
. O O

Furthermore O O
, O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
hypothetical O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
proteins O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
highly O O
correlate O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
mobile O B_GENE/B_PERSON
elements O I_GENE/I_PERSON
profiles O I_GENE/I_PERSON
suggesting O O
a O O
possible O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
horizontal O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
evolution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
genes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Finally O O
, O O
we O O
suggested O O
the O O
putative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
role O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
some O O
ORFs O B_GENE/B_BIO
having O O
an O O
unknown O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
the O O
basis O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
their O O
phylogenetic O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similarity O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
well O O
characterized O O
genes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Over O O
the O O
past O B_TIME[MEASURE]/B_ORGANIZATION
ten O I_TIME[MEASURE]/I_ORGANIZATION
years O I_TIME[MEASURE]/I_ORGANIZATION
, O O
a O O
great O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
microbial O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
sequenced O O
covering O O
a O O
wide O B_MEASURE/B_LOCATION
representation O I_MEASURE/I_LOCATION
of O O
prokaryots O B_BIO/B_GENE
as O O
well O O
as O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
strains O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O O
some O O
species O B_BIO/B_PERSON
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
these O O
genomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
both O O
by O O
computational O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
experimental O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
highly O O
improved O O
our O O
understanding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
physiology O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
phylogenetic O B_DISEASE_ADJECTIVE[DISEASE]/B_EDU[ORGANIZATION]
relationship O I_DISEASE_ADJECTIVE[DISEASE]/I_EDU[ORGANIZATION]
and O O
pathogenicity O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
many O B_BIO
organisms O I_BIO
. O O

Furthermore O O
, O O
it O O
has O O
provided O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
knowledge O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
microbial O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
genome O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
evolution O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
revealing O O
a O O
gene O B_GENE/B_LOCATION
core O I_GENE/I_LOCATION
shared O O
by O O
the O O
great O B_PERSON/B_GENE
majority O I_PERSON/I_GENE
of O O
bacteria O B_BIO/B_GENE
, O O
genes O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
characteristic O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
particular O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
" O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
novel O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
possibly O O
originated O O
by O O
lateral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
transfer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
from O O
some O O
unknown O B_PERSON/B_BIO
source O I_PERSON/I_BIO
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O O
on O O
closely O O
related O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
genomes O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
revealed O O
that O O
a O O
substantial O B_MEASURE/B_PERSON
fraction O I_MEASURE/I_PERSON
of O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
any O O
genome O B_BIO/B_GENE
seem O O
to O O
be O O
strain O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
sometime O O
arise O O
by O O
gene O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duplication O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
followed O O
by O O
a O O
rapid O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
divergence O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
or O O
by O O
lineage O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
loss O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
one O B_SPECIES[BIO]/B_PERSON
strain O I_SPECIES[BIO]/I_PERSON
, O O
resulting O O
in O O
a O O
unique O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
gene O B_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
other O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
strains O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
there O O
are O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
lines O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicating O O
that O O
lateral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transfer O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
may O O
be O O
the O O
main O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
acquire O O
novel O B_DISEASE/B_GENE
genes O I_DISEASE/I_GENE
. O O

Indeed O O
, O O
this O O
could O O
be O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
main O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
forces O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
driving O O
bacterial O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
adaptation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
evolution O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O O

Phage O B_GENE
DNA O I_GENE
is O O
thought O O
to O O
be O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
main O B_LOCATION/B_PERSON
vectors O I_LOCATION/I_PERSON
for O O
lateral O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
bacteria O B_BACTERIUM[BIO]
[ O O
1 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
and O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
virulence O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
from O O
bacterial O B_BACTERIUM[BIO]/B_PERSON
pathogen O I_BACTERIUM[BIO]/I_PERSON
are O O
phage O B_BACTERIUM[BIO]/B_TIME[MEASURE]
encoded O O
[ O O
2 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

For O O
example O O
, O O
the O O
genes O O
for O O
CT O O
, O O
the O O
most O O
important O O
virulence O O
factor O O
of O O
V B B_BACTERIUM[BIO]/B_GENE
. I I_BACTERIUM[BIO]/I_GENE
cholerae I I_BACTERIUM[BIO]/I_GENE
, O O
are O O
encoded O O
in O O
the O O
genome O O
of O O
phage O O
CTX O O
phi O O
, O O
integrated O O
in O O
the O O
bacterial O O
chromosome O O
1 O O
. O O

Since O O
lateral O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plays O O
a O O
relevant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
bacterial O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
evolution O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
reconstruction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
phylogeny O B_BIO/B_GENE
is O O
very O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
trees O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
built O O
by O O
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
may O O
not O O
lead O O
to O O
a O O
reliable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
picture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
evolutionary O B_PERSON/B_BIO
history O B_PERSON/I_BIO
. O O

In O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
alternative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
trees O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
obtained O O
when O O
different O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
considered O O
. O O

For O O
many O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
the O O
classification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bacteria O B_BIO/B_GENE
on O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
their O O
global O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
give O O
a O O
better O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
their O O
evolutionary O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
may O O
be O O
particularly O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
bacteria O B_BIO/B_PERSON
of O O
the O O
same O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
compared O O
, O O
since O O
newly O O
acquired O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
could O O
be O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
confer O O
peculiar O B_DISEASE_ADJECTIVE[DISEASE]
features O I_DISEASE_ADJECTIVE[DISEASE]
that O O
allows O O
the O O
exploitation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
different O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ecological O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
niches O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
we O O
propose O O
a O O
bioinformatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
investigate O O
bacterial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genome O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
evolution O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
taking O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O O
global O B_MEASURE/B_LOCATION
gene O B_MEASURE/I_LOCATION
content O B_MEASURE/I_LOCATION
, O O
as O O
well O O
as O O
sequence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similarity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
based O O
our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
modified O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
3 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
however O O
, O O
we O O
do O O
not O O
consider O O
only O O
the O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
absence O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
orthologue O B_GENE/B_MEASURE
genes O I_GENE/I_MEASURE
, O O
but O O
also O O
their O O
distance O B_MEASURE/B_LOCATION
, O O
based O O
on O O
a O O
substitution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
matrix O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

A O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
a O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
sequence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
homology O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
based O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
developed O O
to O O
infer O O
a O O
possible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
functional O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
relationship O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O O
genes O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
based O O
on O O
the O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
proteins O B_BIO/B_LOCATION
that O O
are O O
involved O O
in O O
the O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
or O O
structural O B_LOCATION
complex O I_LOCATION
are O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
evolve O O
in O O
a O O
correlate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fashion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
during O O
evolution O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
appear O O
phylogenetically O O
linked O O
, O O
showing O O
a O O
tendency O B_MEASURE/B_DISEASE
to O O
be O O
either O O
preserved O O
or O O
eliminated O O
as O O
a O O
whole O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
genes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phylogenetic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
functionally O O
related O O
. O O

We O O
extended O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
produce O O
an O O
evolutionary O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tree O B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
a O O
hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
clusterization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
organisms O B_BIO/B_GENE
with O O
similar O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
phylogenetic O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
profiles O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O O
took O O
the O O
whole O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dataset O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
320 O B_SPECIES[BIO]/B_GENE
prokaryotic O I_SPECIES[BIO]/I_GENE
genomes O I_SPECIES[BIO]/I_GENE
, O O
however O O
, O O
we O O
limited O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
orthologous O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
groups O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O O
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
at O O
least O O
one O B_NUMBER[MEASURE]
of O O
the O O
14 O B_NUMBER[MEASURE]
considered O O
species O B_BIO/B_GENE
of O O
the O O
Vibrionaceae O B_BIO/B_LOCATION
family O I_BIO/I_LOCATION
. O O

These O O
bacteria O B_BIO/B_PERSON
belong O O
to O O
the O O
Gammaproteobacteria O B_BACTERIUM[BIO]/B_MEASURE
group O I_BACTERIUM[BIO]/I_MEASURE
and O O
are O O
highly O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
aquatic O B_LOCATION/B_BIO
environment O I_LOCATION/I_BIO
, O O
they O O
strongly O O
influence O O
nutrient O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cycling O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O O
various O B_TIME[MEASURE]/B_ENT
species O I_TIME[MEASURE]/I_ENT
are O O
also O O
devastating O B_DISEASE_ADJECTIVE[DISEASE]
pathogens O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Since O O
we O O
focused O O
our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
this O O
particular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O O
not O O
the O O
construction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
global O B_BIO
evolutionary O I_BIO
tree O I_BIO
, O O
but O O
rather O O
a O O
Vibrionaceae O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O O
bacterial O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
diversity O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
based O O
on O O
phylogenetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

Phylogenetic O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
on O O
14 O B_BIO/B_PERSON
bacteria O I_BIO/I_PERSON
belonging O O
to O O
the O O
Vibrionaceae O B_BIO/B_LOCATION
family O I_BIO/I_LOCATION
( O O
Table O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

The O O
redundant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
list O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
Vibrionaceae O B_BIO/B_GENE
ORFs O B_BIO/I_GENE
was O O
clustered O O
to O O
reduce O O
the O O
number O B_MEASURE/B_PERSON
of O O
proteins O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
analyze O O
and O O
the O O
phylogenetic O B_MEASURE
profile O I_MEASURE
for O O
each O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
calculated O O
as O O
described O O
in O O
the O O
Method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
section O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Many O B_PERSON
authors O I_PERSON
proposed O O
and O O
successfully O O
applied O O
different O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
measure O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methods O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
calculate O O
the O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
values O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Pellegrini O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
et O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
al O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

[ O O
3 O O
] O O
firstly O O
proposed O O
a O O
phylogenetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
described O O
as O O
a O O
string O B_ENT/B_MEASURE
of O O
bits O B_BIO/B_LOCATION
, O O
each O O
bit O B_MEASURE
representing O O
the O O
absence O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
homologous O B_GENE/B_BIO
gene O I_GENE/I_BIO
in O O
a O O
given O O
genome O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lacks O O
a O O
weighting O B_MEASURE/B_LOCATION
procedure O I_MEASURE/I_LOCATION
, O O
giving O O
the O O
same O B_MEASURE
weight O I_MEASURE
( O O
value O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
) O O
to O O
all O O
the O O
sequences O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
considered O O
homologous O B_TIME[MEASURE]/B_LOCATION
given O O
a O O
similarity O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
threshold O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Enault O B_PERSON/B_LOCATION
and O O
colleagues O B_PERSON
proposed O O
an O O
improved O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phylogenetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O O
on O O
a O O
normalized O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blastp O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bit O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
score O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
4 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

This O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
compared O O
to O O
the O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
implemented O O
by O O
Pellegrini O B_PERSON/B_ORGANIZATION
, O O
allows O O
weighting O O
each O O
point O B_LOCATION/B_MEASURE
of O O
the O O
profile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
proportionally O O
to O O
the O O
length O B_MEASURE/B_LOCATION
and O O
the O O
quality O B_MEASURE/B_LOCATION
of O O
the O O
alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Jingchun O B_PERSON/B_LOCATION
and O O
colleagues O B_PERSON
optimized O O
the O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
by O O
integrating O O
phylogenetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relationships O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
among O O
reference O B_BIO/B_LOCATION
organisms O I_BIO/I_LOCATION
and O O
sequence O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homology O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
based O O
on O O
E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
value O B_MEASURE/B_LOCATION
score O B_MEASURE/I_LOCATION
, O O
to O O
improve O O
prediction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
accuracy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
5 O B_MEASURE/B_PERSON
] O B_MEASURE/I_PERSON
. O O

The O O
measure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
index O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
I O O
proposed O O
in O O
this O O
work O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
others O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
described O O
above O O
, O O
taking O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
both O O
the O O
quality O B_MEASURE/B_LOCATION
and O O
the O O
length O B_MEASURE
of O O
the O O
alignment O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
a O O
substitution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
matrix O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Moreover O O
our O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considers O O
also O O
the O O
total O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
of O O
the O O
sequences O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
penalizing O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurring O O
between O O
ORFs O B_GENE/B_LOCATION
having O O
different O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
lengths O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O O
taking O O
into O O
consideration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
ORFs O B_PERSON/B_BIO
could O O
differentiate O O
mainly O O
for O O
the O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
domains O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

The O O
final O B_MEASURE/B_LOCATION
phylogenetic O B_MEASURE/I_LOCATION
profile O B_MEASURE/I_LOCATION
for O O
each O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O O
defined O O
as O O
the O O
median O B_MEASURE
of O O
all O O
the O O
profiles O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O O
to O O
the O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
named O O
" O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meta O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
profile O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
, O O
which O O
describes O O
the O O
profile O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
conserved O B_GENE/B_LOCATION
ORFs O I_GENE/I_LOCATION
belonging O O
to O O
an O O
entire O B_PERSON/B_LOCATION
family O B_PERSON/I_LOCATION
. O O

Hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cluster O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cluster O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O O
performed O O
on O O
the O O
entire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phylogenetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
matrix O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
it O O
was O O
calculated O O
a O O
statistical O B_MEASURE/B_LOCATION
support O I_MEASURE/I_LOCATION
based O O
on O O
bootstrap O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
for O O
the O O
nodes O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
columns O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
tree O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fig O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
branch O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tree O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
colors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
represent O O
the O O
bootstrap O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
percentage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
support O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

This O O
constitutes O O
a O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tree O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
based O O
on O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O O
Vibrionaceae O B_BIO/B_GENE
ORFs O B_BIO/I_GENE
as O O
a O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Genomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O O
to O O
the O O
same O B_BIO/B_ORGANIZATION
taxonomic O I_BIO/I_ORGANIZATION
group O I_BIO/I_ORGANIZATION
tend O O
to O O
cluster O O
together O O
and O O
the O O
Vibrionaceae O B_BIO/B_NUMBER[MEASURE]
species O B_BIO/I_NUMBER[MEASURE]
are O O
closely O O
related O O
. O O

As O O
expected O O
, O O
according O O
to O O
the O O
Vibrionaceae O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
branch O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lengths O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
it O O
is O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
variability O B_MEASURE/B_BIO
within O O
this O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
compared O O
to O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
dataset O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
used O O
for O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calculation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
indeed O O
composed O O
by O O
Vibrionaceae O B_BIO/B_GENE
ORFs O I_BIO/I_GENE
. O O

This O O
implies O O
that O O
the O O
similarity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures O O
between O O
these O O
ORFs O B_GENE/B_BIO
and O O
the O O
corresponding O B_GENE/B_BIO
orthologues O I_GENE/I_BIO
will O O
be O O
nearly O O
zero O B_MEASURE
in O O
most O B_NUMBER[MEASURE]/B_DISEASE
of O O
the O O
other O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
species O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O O
significantly O O
higher O B_MEASURE
in O O
the O O
Vibrionaceae O B_SPECIES[BIO]/B_MEASURE
family O I_SPECIES[BIO]/I_MEASURE
, O O
increasing O O
the O O
variability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
into O O
this O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Moreover O O
the O O
average O B_MEASURE/B_PERSON
percentage O I_MEASURE/I_PERSON
of O O
clusters O B_LOCATION/B_BIO
shared O O
by O O
the O O
Vibrionaceae O B_PERSON/B_BIO
members O I_PERSON/I_BIO
is O O
only O O
47 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
( O O
average O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
shared O O
clusters O B_LOCATION/B_BIO
divided O O
by O O
the O O
total O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
clusters O B_LOCATION/B_PERSON
) O O
that O O
again O O
indicates O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inside O O
this O O
family O B_PERSON/B_LOCATION
. O O

It O O
is O O
also O O
interesting O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
note O O
that O O
organisms O B_BIO/B_PERSON
belonging O O
to O O
the O O
same O B_MEASURE/B_LOCATION
or O O
closely O O
related O O
taxa O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
split O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
into O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
subgroups O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

This O O
highlights O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
variability O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
among O O
lineages O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
due O O
to O O
genetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
evolutionary O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
processes O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
such O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
as O O
lateral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
concerted O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evolution O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
duplication O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
6 O B_BIO/B_LOCATION
] O I_BIO/I_LOCATION
. O O

In O O
terms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
content O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
the O O
organisms O B_BIO/B_PERSON
more O O
related O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
Vibrionaceae O B_BIO
belong O O
to O O
the O O
gamma O B_PROTEIN[GENE]
and O O
beta O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
proteobacteria O I_PROTEIN[GENE]/I_BACTERIUM[BIO]
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
Altermonadales O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
Enterobacteriales O B_BACTERIUM[BIO]
and O O
Burkholderiales O B_BACTERIUM[BIO]
are O O
closely O O
related O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
Vibrionaceae O B_BACTERIUM[BIO]/B_PERSON
, O O
and O O
share O O
the O O
higher O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
genes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
average O B_MEASURE/B_LOCATION
percentage O I_MEASURE/I_LOCATION
of O O
20 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
% O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

As O O
expected O O
, O O
Archea O B_PERSON/B_BIO
are O O
the O O
most O O
distant O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
group O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sharing O O
just O O
3 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
clusters O B_GENE/B_DISEASE
. O O

Clusters O B_LOCATION/B_ORGANIZATION
and O O
genes O B_GENE/B_LOCATION
distribution O I_GENE/I_LOCATION
, O O
as O O
shown O O
in O O
Fig O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reveals O O
that O O
the O O
number O B_MEASURE/B_PERSON
of O O
clusters O B_LOCATION/B_BIO
and O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O O
by O O
the O O
organisms O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
decreases O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O O
the O O
number O B_MEASURE/B_LOCATION
of O O
organisms O B_BIO/B_GENE
considered O O
increases O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

The O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
performed O O
considering O O
for O O
each O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
the O O
number O B_MEASURE/B_LOCATION
of O O
organisms O B_BIO/B_GENE
sharing O O
the O O
same O B_MEASURE/B_LOCATION
numbers O I_MEASURE/I_LOCATION
of O O
clusters O B_LOCATION/B_BIO
( O O
and O O
genes O B_PROTEIN[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
majority O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gene O B_BIO/B_PERSON
cluster O I_BIO/I_PERSON
groups O I_BIO/I_PERSON
no O O
more O B_MEASURE/B_PERSON
than O O
21 O B_NUMBER[MEASURE]/B_LOCATION
species O I_NUMBER[MEASURE]/I_LOCATION
on O O
a O O
total O B_MEASURE/B_LOCATION
of O O
320 O B_NUMBER[MEASURE]/B_LOCATION
. O O

The O O
highest O B_MEASURE
blue O I_MEASURE
spike O I_MEASURE
corresponds O O
to O O
the O O
higher O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O O
by O O
105 O B_NUMBER[MEASURE]
groups O I_NUMBER[MEASURE]
of O O
14 O B_BIO/B_GENE
organisms O I_BIO/I_GENE
. O O

Among O O
these O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
expected O O
, O O
Vibrionaceae O B_PERSON
are O O
highly O O
represented O O
. O O

Other O O
species O O
represented O O
are O O
Colwellia B B_BACTERIUM[BIO]
psychrerythraea I I_BACTERIUM[BIO]
34H I I_BACTERIUM[BIO]
and O O
Shewanella B B_MEASURE/B_BACTERIUM[BIO]
oneidensis I I_MEASURE/I_BACTERIUM[BIO]
, O O
that O O
belong O O
to O O
the O O
Alteromonadales O O
family O O
. O O

The O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O O
on O O
genes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
shown O O
in O O
Fig O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

3 O B_NUMBER[MEASURE]
. O O

From O O
now O O
on O O
, O O
to O O
avoid O O
confusing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O O
clusters O B_LOCATION/B_BIO
derived O O
from O O
the O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O O
from O O
the O O
ORFs O B_GENE/B_MEASURE
clustering O O
we O O
will O O
use O O
the O O
term O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
in O O
place O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ORFs O B_GENE/B_BIO
. O O

The O O
different O B_DISEASE_ADJECTIVE[DISEASE]
gradient O I_DISEASE_ADJECTIVE[DISEASE]
of O O
color O B_ENT/B_MEASURE
, O O
from O O
bright O B_COLOR/B_PERSON
to O O
dark O B_COLOR
red O I_COLOR
, O O
represents O O
decreasing O O
similarity O B_MEASURE/B_COLOR
values O I_MEASURE/I_COLOR
. O O

The O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
allows O O
the O O
detection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
three O B_MEASURE/B_LOCATION
main O B_MEASURE/I_LOCATION
groups O B_MEASURE/I_LOCATION
of O O
genes O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
( O O
Fig O B_MEASURE/B_PROTEIN[GENE]
3 O I_MEASURE/I_PROTEIN[GENE]
, O O
panel O B_MEASURE/B_LOCATION
B O I_MEASURE/I_LOCATION
) O O
contains O O
the O O
most O O
conserved O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
established O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
genes O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
shared O O
almost O O
by O O
all O O
the O O
organisms O B_BIO/B_PERSON
. O O

These O O
core O B_GENE/B_LOCATION
genes O I_GENE/I_LOCATION
can O O
be O O
defined O O
as O O
the O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
all O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O O
as O O
orthologous O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
by O O
all O O
members O B_PERSON/B_LOCATION
of O O
an O O
evolutionary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
coherent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

In O O
our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
we O O
identify O O
four O B_NUMBER[MEASURE]/B_LOCATION
clusters O I_NUMBER[MEASURE]/I_LOCATION
, O O
for O O
a O O
total O B_MEASURE/B_LOCATION
of O O
145 O B_NUMBER[MEASURE]
genes O I_NUMBER[MEASURE]
, O O
shared O O
by O O
all O O
the O O
320 O B_BIO/B_MEASURE
organisms O I_BIO/I_MEASURE
. O O

The O O
ORFs O B_GENE/B_LOCATION
belonging O O
to O O
these O O
clusters O B_LOCATION/B_BIO
are O O
predicted O O
to O O
codify O O
for O O
the O O
ATP O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ABC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transporters O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
annotated O O
as O O
ABC O B_ORGANIZATION/B_LOCATION
- O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
polar O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
amino O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transport O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
system O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ABC O B_ORGANIZATION/B_LOCATION
- O O
type O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
antimicrobial O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
peptide O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
transport O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
system O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ABC O B_ORGANIZATION/B_LOCATION
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
histidine O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
transport O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
system O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
ABC O B_ORGANIZATION/B_LOCATION
- O O
type O B_MEASURE/B_LOCATION
transport O B_MEASURE/I_LOCATION
system O B_MEASURE/I_LOCATION
involved O O
in O O
lysophospholipase O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_GENE
L1 O I_CELL_FUNCTION[ORGANISM_FUNCTION]/I_GENE
biosynthesis O I_CELL_FUNCTION[ORGANISM_FUNCTION]/I_GENE
) O O
. O O

This O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
surprising O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O O
this O O
is O O
the O O
first O B_LOCATION/B_MEASURE
report O I_LOCATION/I_MEASURE
where O O
these O O
ORFs O B_GENE/B_BIO
are O O
assigned O O
to O O
the O O
core O B_GENE/B_MEASURE
genes O I_GENE/I_MEASURE
. O O

Anyway O O
two O B_PERSON/B_LOCATION
different O I_PERSON/I_LOCATION
explanations O I_PERSON/I_LOCATION
can O O
be O O
traced O O
. O O

First O O
, O O
it O O
is O O
known O O
that O O
the O O
ABC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transporters O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
represent O O
an O O
essential O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transport O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
prokaryotes O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
that O O
their O O
ATP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
subunits O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
apparently O O
overrepresented O O
compared O O
to O O
the O O
other O B_GENE/B_NUMBER[MEASURE]
two O I_GENE/I_NUMBER[MEASURE]
subunits O I_GENE/I_NUMBER[MEASURE]
( O O
ligand O B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
permease O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
subunit O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
) O O
in O O
all O O
genomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequenced O O
thus O O
far O O
[ O O
7 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Second O O
, O O
one O O
organism O O
, O O
Buchnera B B_BIO/B_LOCATION
aphidicola I B_BIO/I_LOCATION
, O O
presents O O
these O O
genes O O
with O O
a O O
similarity O O
just O O
below O O
the O O
cut O O
- O O
off O O
used O O
for O O
the O O
analysis O O
, O O
but O O
they O O
have O O
been O O
considered O O
since O O
it O O
is O O
well O O
known O O
that O O
in O O
this O O
mutualistic O O
endosymbiont O O
the O O
accelerated O O
evolution O O
and O O
AT O O
bias O O
affect O O
all O O
its O O
genes O O
, O O
including O O
the O O
16S O O
rRNA O O
[ O O
8 O O
, O O
9 O O
] O O
. O O

The O O
dataset O O
used O O
for O O
the O O
analysis O O
includes O O
genomes O O
in O O
draft O O
quality O O
( O O
Vibrio B B_BACTERIUM[BIO]/B_GENE
cholerae I I_BACTERIUM[BIO]/I_GENE
0395 I I_BACTERIUM[BIO]/I_GENE
, O O
Vibrio B B_BACTERIUM[BIO]/B_PROTEIN[GENE]
cholerae I B_BACTERIUM[BIO]/I_PROTEIN[GENE]
MO10 I B_BACTERIUM[BIO]/I_PROTEIN[GENE]
, O O
Vibrio B B_MEASURE/B_BACTERIUM[BIO]
cholerae I I_MEASURE/I_BACTERIUM[BIO]
RC385 I I_MEASURE/I_BACTERIUM[BIO]
, O O
Vibrio B B_BACTERIUM[BIO]
cholerae I I_BACTERIUM[BIO]
V51 I I_BACTERIUM[BIO]
, O O
Vibrio B B_BACTERIUM[BIO]/B_GENE
cholerae I B_BACTERIUM[BIO]/I_GENE
V52 I B_BACTERIUM[BIO]/I_GENE
, O O
Photobacterium B B_BACTERIUM[BIO]
profundum I I_BACTERIUM[BIO]
3TCK I I_BACTERIUM[BIO]
, O O
Vibrio B B_BACTERIUM[BIO]/B_GENE
MED222 I I_BACTERIUM[BIO]/I_GENE
, O O
Vibrio B B_MEASURE/B_BACTERIUM[BIO]
splendidus12B01 I I_MEASURE/I_BACTERIUM[BIO]
) O O
. O O

Wrong O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
ORFs O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
prediction O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
or O O
missing O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
incomplete O B_DISEASE_ADJECTIVE[DISEASE]
genome O I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_DISEASE_ADJECTIVE[DISEASE]
can O O
explain O O
the O O
low O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
core O B_GENE
genes O I_GENE
identified O O
. O O

To O O
avoid O O
such O B_DISEASE_ADJECTIVE[DISEASE]
problems O I_DISEASE_ADJECTIVE[DISEASE]
we O O
repeated O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
excluding O O
the O O
draft O B_GENE/B_BIO
genomes O I_GENE/I_BIO
and O O
thus O O
considering O O
312 O B_GENE/B_PERSON
genomes O I_GENE/I_PERSON
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
reported O O
in O O
Table O B_MEASURE
2 O I_MEASURE
, O O
show O O
an O O
increased O O
number O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
core O B_GENE
genes O I_GENE
and O O
in O O
particular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ribosomal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
tRNA O B_GENE
synthetase O I_GENE
, O O
as O O
reported O O
by O O
Charlesbois O B_PERSON
and O O
Doolittle O B_PERSON
[ O O
10 O B_GENE/B_TIME[MEASURE]
] O I_GENE/I_TIME[MEASURE]
. O O

This O O
could O O
be O O
considered O O
as O O
a O O
sort O B_MEASURE/B_LOCATION
of O O
" O O
minimal O B_MEASURE/B_BIO
genome O B_MEASURE/I_BIO
" O O
containing O O
the O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
maintain O O
a O O
free O B_TIME[MEASURE]/B_LOCATION
- O O
living O B_BACTERIUM[BIO]/B_LOCATION
organism O I_BACTERIUM[BIO]/I_LOCATION
. O O

The O O
low O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O O
by O O
all O O
the O O
organisms O B_BIO/B_PERSON
can O O
be O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
many O B_DISEASE_ADJECTIVE[DISEASE]
factors O I_DISEASE_ADJECTIVE[DISEASE]
. O O

First O O
of O O
all O O
we O O
used O O
the O O
Vibrionaceae O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ORFs O B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
limiting O O
the O O
number O B_MEASURE/B_LOCATION
of O O
genes O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
were O O
able O B_TIME[MEASURE]/B_PERSON
to O O
identify O O
. O O

It O O
was O O
further O O
demonstrated O O
that O O
the O O
core O B_MEASURE
gene O I_MEASURE
size O I_MEASURE
decreases O O
as O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genome O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
analyzed O O
[ O O
10 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
considered O O
to O O
belong O O
to O O
the O O
core O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
set O O
when O O
close O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
organisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
compared O O
, O O
are O O
classified O O
as O O
flexible O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
genes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
when O O
distantly O O
related O O
genomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
analyzed O O
[ O O
6 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Finally O O
, O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
within O O
core O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
genomes O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
might O O
be O O
transferred O O
or O O
replaced O O
, O O
introducing O O
new O B_MEASURE/B_LOCATION
versions O I_MEASURE/I_LOCATION
of O O
existing O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
genomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Such O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
transfers O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
can O O
replace O O
even O O
highly O O
conserved O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
genes O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
by O O
non O B_DISEASE/B_GENE
- O O
homologous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
counterparts O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
but O O
the O O
advantages O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provided O O
are O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
explain O O
. O O

It O O
is O O
also O O
to O O
take O O
into O O
consideration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
many O B_SPECIES[BIO]
symbiotic O I_SPECIES[BIO]
and O O
parasitic O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
bacteria O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
undergo O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
their O O
genomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
loosing O O
many O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
by O O
free O B_MEASURE/B_PERSON
- O O
living O B_PERSON/B_MEASURE
cell O I_PERSON/I_MEASURE
. O O

The O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
( O O
Fig O B_MEASURE/B_PROTEIN[GENE]
3 O I_MEASURE/I_PROTEIN[GENE]
, O O
panel O B_MEASURE/B_LOCATION
C O I_MEASURE/I_LOCATION
) O O
represents O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O O
mainly O O
among O O
Vibrionaceae O B_BACTERIUM[BIO]
and O O
other O B_BACTERIUM[BIO]/B_PERSON
gamma O I_BACTERIUM[BIO]/I_PERSON
proteobacteria O I_BACTERIUM[BIO]/I_PERSON
( O O
as O O
Altermonadales O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Burkholderiales O B_BACTERIUM[BIO]
and O O
Enterobactidiales O B_BACTERIUM[BIO]
) O O
. O O

Finally O O
, O O
the O O
third O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Fig O B_MEASURE/B_PROTEIN[GENE]
. O O
3 O B_NUMBER[MEASURE]
, O O
panel O B_MEASURE/B_LOCATION
D O I_MEASURE/I_LOCATION
) O O
is O O
composed O O
by O O
genes O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
mainly O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
Vibrionaceae O B_BIO/B_DISEASE
. O O

k O O
- O O
mean O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enrichment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

We O O
performed O O
a O O
k O B_OTHER/B_NUMBER[MEASURE]
- O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cluster O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
setting O O
the O O
k O B_MEASURE
value O I_MEASURE
to O O
14 O B_MEASURE
. O O

As O O
shown O O
in O O
Fig O B_MEASURE/B_LOCATION
. O O

4 O O
, O O
the O O
clusters O B_SEQUENCE[MEASURE]/B_PERSON
3 O I_SEQUENCE[MEASURE]/I_PERSON
, O O
4 O B_NUMBER[MEASURE]
, O O
11 O B_NUMBER[MEASURE]
, O O
13 O B_NUMBER[MEASURE]
and O O
14 O B_MEASURE
contain O O
the O O
higher O B_MEASURE
percentage O I_MEASURE
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
accounting O O
for O O
more O B_MEASURE/B_LOCATION
that O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
total O B_GENE/B_MEASURE
genes O I_GENE/I_MEASURE
, O O
while O O
clusters O B_NUMBER[MEASURE]/B_PERSON
9 O I_NUMBER[MEASURE]/I_PERSON
and O O
10 O B_NUMBER[MEASURE]
contain O O
the O O
lower O B_MEASURE
number O I_MEASURE
of O O
ORFs O B_GENE/B_BIO
( O O
3 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
variance O B_MEASURE/B_LOCATION
in O O
each O O
k O B_OTHER/B_MEASURE
- O O
means O B_LOCATION/B_MEASURE
cluster O I_LOCATION/I_MEASURE
is O O
very O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
Fig O B_MEASURE
. O O
4 O B_NUMBER[MEASURE]
) O O
, O O
meaning O O
that O O
the O O
clusters O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contain O O
genes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
compact O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
similar O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
profiles O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
described O O
in O O
Fig O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

4 O B_TIME[MEASURE]/B_LOCATION
, O O
the O O
majority O B_PERSON/B_MEASURE
of O O
the O O
clusters O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_NUMBER[MEASURE]
, O O
2 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
, O O
5 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
, O O
7 O B_NUMBER[MEASURE]
, O O
9 O B_NUMBER[MEASURE]
, O O
12 O B_NUMBER[MEASURE]
, O O
13 O B_MEASURE
) O O
contains O O
genes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
a O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
with O O
the O O
average O B_MEASURE/B_LOCATION
values O I_MEASURE/I_LOCATION
( O O
red O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
near O O
zero O B_MEASURE
, O O
except O O
for O O
the O O
presence O B_LOCATION/B_DISEASE
of O O
some O O
spikes O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correspondent O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
an O O
increasing O O
similarity O B_MEASURE
with O O
some O O
isolated O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
organisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

As O O
shown O O
in O O
Table O B_MEASURE
3 O I_MEASURE
, O O
clusters O B_PROTEIN[GENE]/B_MEASURE
1 O I_PROTEIN[GENE]/I_MEASURE
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
, O O
5 O B_NUMBER[MEASURE]
, O O
and O O
9 O B_NUMBER[MEASURE]
contains O O
genes O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
have O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
similarity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
a O O
small O B_LOCATION/B_MEASURE
subset O B_LOCATION/I_MEASURE
of O O
organisms O B_BIO/B_GENE
. O O

The O O
majority O B_PERSON/B_LOCATION
of O O
these O O
ORFs O B_GENE/B_BIO
are O O
annotated O O
as O O
hypothetical O B_SPECIES[BIO]/B_GENE
proteins O I_SPECIES[BIO]/I_GENE
or O O
phage O O
related O O
proteins O B_BIO/B_GENE
. O O

Clusters O B_NUMBER[MEASURE]/B_PERSON
8 O I_NUMBER[MEASURE]/I_PERSON
, O O
10 O B_NUMBER[MEASURE]
and O O
14 O B_MEASURE
present O I_MEASURE
genes O I_MEASURE
shared O O
among O O
almost O O
all O O
the O O
organisms O B_BIO/B_PERSON
. O O

In O O
particular O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cluster O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
10 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
composed O O
by O O
the O O
core O B_GENE/B_BIO
genes O I_GENE/I_BIO
described O O
before O O
having O O
an O O
high O B_MEASURE
value O I_MEASURE
of O O
similarity O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
widespread O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
all O O
the O O
organisms O B_BIO/B_PERSON
; O O
cluster O B_NUMBER[MEASURE]
8 O I_NUMBER[MEASURE]
contains O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O O
mainly O O
by O O
gamma O B_BACTERIUM[BIO]
proteobacteria O I_BACTERIUM[BIO]
and O O
cluster O B_TIME[MEASURE]/B_LOCATION
14 O I_TIME[MEASURE]/I_LOCATION
is O O
composed O O
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
common O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
between O O
Vibrionaceae O B_BACTERIUM[BIO]
and O O
Enterobacteriaceae O B_BACTERIUM[BIO]
. O O

A O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
annotation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
performed O O
on O O
each O O
gene O B_GENE/B_MEASURE
cluster O I_GENE/I_MEASURE
using O O
COG O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Cluster O B_LOCATION/B_ORGANIZATION
of O O
Orthologous O B_GENE/B_MEASURE
Genes O I_GENE/I_MEASURE
) O O
, O O
KEGG O B_LOCATION/B_ORGANIZATION
pathway O I_LOCATION/I_ORGANIZATION
map O I_LOCATION/I_ORGANIZATION
and O O
GO O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
databases O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
each O O
k O B_OTHER/B_MEASURE
- O O
mean O B_LOCATION/B_MEASURE
cluster O I_LOCATION/I_MEASURE
the O O
enrichment O B_MEASURE
probability O I_MEASURE
with O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
clusters O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
obtained O O
with O O
the O O
hypergeometric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distribution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Fig O B_BIO/B_GENE
. O O

5 O B_MEASURE/B_PERSON
shows O O
COG O O
enrichment O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
each O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

As O O
expected O O
clusters O B_LOCATION/B_DISEASE
represented O O
by O O
conserved O B_BIO/B_NUMBER[MEASURE]
genes O I_BIO/I_NUMBER[MEASURE]
( O O
cluster O B_MEASURE
8 O I_MEASURE
, O O
10 O B_NUMBER[MEASURE]
and O O
14 O B_MEASURE
) O O
have O O
the O O
higher O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
enriched O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
COG O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
codes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
while O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
specific O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
few O B_BIO/B_GENE
organisms O B_BIO/I_GENE
are O O
characterized O O
by O O
a O O
small O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
enriched O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
COGs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
majority O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
clusters O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presents O O
COG O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
codes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enrichment O O
for O O
S O B_OTHER/B_LOCATION
( O O
function O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
unknown O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
, O O
R O B_OTHER/B_PROTEIN[GENE]
( O O
poorly O O
characterized O O
) O O
and O O
- O O
( O O
absence O B_DISEASE/B_LOCATION
of O O
COG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
categories O B_LOCATION
. O O

This O O
is O O
due O O
to O O
the O O
large O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
abundance O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
hypothetical O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
presents O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
Vibrionaceae O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
proteomes O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

It O O
is O O
worth O O
noting O O
that O O
cluster O O
3 O O
, O O
mainly O O
represented O O
by O O
Photobacterium B B_NUMBER[MEASURE]/B_PERSON
profundum I I_NUMBER[MEASURE]/I_PERSON
SS9 I I_NUMBER[MEASURE]/I_PERSON
ORFs O O
, O O
is O O
enriched O O
only O O
by O O
C O O
( O O
Energy O O
production O O
and O O
conversion O O
) O O
, O O
L O O
( O O
DNA O O
replication O O
, O O
recombination O O
and O O
repair O O
) O O
and O O
M O O
( O O
Cell O O
envelope O O
biogenesis O O
, O O
outer O O
membrane O O
) O O
. O O

Probably O O
the O O
L O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overrepresentation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
determined O O
by O O
the O O
high O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
transposons O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
SS9 O B_GENE
genome O I_GENE
[ O I_GENE
11 O I_GENE
] O I_GENE
. O O

The O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
played O O
by O O
these O O
transposable O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
elements O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O O
the O O
survival O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
deep O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O O
sea O B_LOCATION/B_BIO
bacterium O I_LOCATION/I_BIO
it O O
is O O
still O O
a O O
matter O B_PERSON/B_LOCATION
of O O
debate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
12 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
V B B_BACTERIUM[BIO]
. I I_BACTERIUM[BIO]
vulnificus I I_BACTERIUM[BIO]
YJ016 I I_BACTERIUM[BIO]
and O O
V B B_TIME[MEASURE]/B_BACTERIUM[BIO]
. I I_TIME[MEASURE]/I_BACTERIUM[BIO]
vulnificus I I_TIME[MEASURE]/I_BACTERIUM[BIO]
CMCP6 I I_TIME[MEASURE]/I_BACTERIUM[BIO]
( O O
cluster O O
13 O O
) O O
seem O O
to O O
share O O
genes O O
belonging O O
to O O
the O O
enriched O O
COG O O
classes O O
K O O
( O O
Transcription O O
) O O
, O O
L O O
and O O
T O O
( O O
Signal O O
transduction O O
mechanisms O O
) O O
. O O

It O O
was O O
previously O O
reported O O
an O O
enrichment O O
in O O
genes O O
belonging O O
to O O
the O O
transcription O O
class O O
in O O
the O O
genome O O
of O O
V B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
vulnificus I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
respect O O
to O O
the O O
V B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
cholerae I I_SPECIES[BIO]/I_PERSON
genome O O
[ O O
13 O O
] O O
. O O

This O O
class O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
clearly O O
related O O
to O O
the O O
T O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
class O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
seems O O
to O O
indicate O O
that O O
this O O
organism O B_BIO/B_GENE
is O O
able O B_TIME[MEASURE]/B_PERSON
to O O
receive O O
and O O
translate O O
in O O
a O O
transcriptional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
response O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
environmental O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
signals O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Despite O O
this O O
, O O
the O O
large O B_SEQUENCE[MEASURE]/B_PERSON
majority O I_SEQUENCE[MEASURE]/I_PERSON
of O O
the O O
genes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
clusters O B_NUMBER[MEASURE]/B_PERSON
3 O I_NUMBER[MEASURE]/I_PERSON
and O O
13 O B_NUMBER[MEASURE]
lacks O O
COG O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
annotation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Cluster O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
7 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
shown O O
in O O
Table O B_MEASURE/B_LOCATION
3 O I_MEASURE/I_LOCATION
, O O
accounts O O
organisms O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
with O O
large O B_MEASURE/B_BIO
genome O I_MEASURE/I_BIO
size O I_MEASURE/I_BIO
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

This O O
can O O
explain O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O O
this O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
contains O O
almost O O
all O O
the O O
COG O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enriched O O
and O O
suggests O O
a O O
more O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
flexible O B_PERSON/B_LOCATION
life O I_PERSON/I_LOCATION
- O O
style O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
these O O
organisms O B_BIO/B_GENE
compared O O
to O O
the O O
other O B_TIME[MEASURE]/B_LOCATION
Vibrionaceae O I_TIME[MEASURE]/I_LOCATION
members O I_TIME[MEASURE]/I_LOCATION
. O O

KEGG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
annotation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
limited O O
to O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
or O O
structural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complex O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
network O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
so O O
a O O
reduced O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
genes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
have O O
a O O
KEGG O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
entry O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
causes O O
the O O
presence O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
clusters O B_LOCATION
without O O
enriched O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
map O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
cluster O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
5 O B_NUMBER[MEASURE]
, O O
7 O B_NUMBER[MEASURE]
, O O
13 O B_SEQUENCE[MEASURE]
, O O
see O O
Fig O B_MEASURE/B_LOCATION
5 O B_MEASURE/I_LOCATION
) O O
. O O

Also O O
in O O
this O O
case O B_PERSON/B_LOCATION
, O O
the O O
clusters O B_LOCATION/B_BIO
presenting O O
the O O
higher O B_MEASURE/B_LOCATION
number O B_MEASURE/I_LOCATION
of O O
significant O B_LOCATION/B_GENE
KEGG O I_LOCATION/I_GENE
map O I_LOCATION/I_GENE
are O O
those O O
containing O O
the O O
conserved O B_GENE/B_MEASURE
genes O I_GENE/I_MEASURE
. O O

The O O
most O O
enriched O B_DISEASE_ADJECTIVE[DISEASE]
KEGG O I_DISEASE_ADJECTIVE[DISEASE]
clusters O I_DISEASE_ADJECTIVE[DISEASE]
are O O
cluster O B_NUMBER[MEASURE]
14 O I_NUMBER[MEASURE]
, O O
10 O B_MEASURE
and O O
8 O B_MEASURE
accounting O I_MEASURE
for O O
the O O
majority O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cluster O B_GENE/B_LOCATION
1 O I_GENE/I_LOCATION
is O O
enriched O O
for O O
map3080 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
IV O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
system O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) O O
. O O

In O O
fact O O
V B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
fischeri I I_PERSON/I_SPECIES[BIO]
genome O O
contains O O
10 O O
separate O O
pilus O O
gene O O
clusters O O
, O O
including O O
eight O O
type O O
- O O
IV O O
pilus O O
loci O O
. O O

The O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pilus O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
gene O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
clusters O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
suggests O O
that O O
different O B_DISEASE/B_BIO
pili O I_DISEASE/I_BIO
may O O
be O O
expressed O O
in O O
different O B_NUMBER[MEASURE]/B_LOCATION
environments O I_NUMBER[MEASURE]/I_LOCATION
or O O
during O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
stages O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O O
its O O
development O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
symbiont O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
14 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
] O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

Cluster O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
11 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
enriched O O
for O O
map3090 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
type O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
II O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
secretion O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
system O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
type O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
II O B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
pathway O B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
conserved O O
among O O
gram O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
bacteria O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
many O B_BACTERIUM[BIO]
pathogens O I_BACTERIUM[BIO]
, O O
and O O
secretes O O
a O O
variety O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
virulence O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
degradative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
enzymes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
[ O O
15 O B_SPECIES[BIO]/B_LOCATION
] O I_SPECIES[BIO]/I_LOCATION
. O O

Cluster O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
9 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
enriched O O
for O O
map O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
00860 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Porphyrin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
chlorophyll O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

These O O
genes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
involved O O
in O O
the O O
cobalamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
coenzyme O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B12 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
biosynthetic O B_LOCATION/B_ORGANIZATION
pathway O I_LOCATION/I_ORGANIZATION
[ O O
16 O B_TIME[MEASURE]
] O O
. O O

Some O O
organisms O O
, O O
such O O
as O O
Salmonella B B_BACTERIUM[BIO]
typhimurium I I_BACTERIUM[BIO]
and O O
Klebsiella B B_BACTERIUM[BIO]
pneumoniae I I_BACTERIUM[BIO]
, O O
can O O
synthesize O O
cobalamin O O
de O O
novo O O
[ O O
17 O O
] O O
, O O
while O O
E B B_PERSON/B_BIO
. I I_PERSON/I_BIO
coli I I_PERSON/I_BIO
and O O
large O O
part O O
of O O
the O O
Vibrionaceae O O
perform O O
cobalamin O O
biosynthesis O O
only O O
when O O
provided O O
with O O
cobinamide O O
. O O

It O O
is O O
interesting O O
to O O
observe O O
that O O
the O O
genes O O
belonging O O
to O O
the O O
de O O
novo O O
pathway O O
are O O
only O O
shared O O
by O O
Archea O O
, O O
some O O
other O O
organisms O O
like O O
Salmonella O O
, O O
Pseudomonas O O
and O O
Vibrio B B_BACTERIUM[BIO]
MED222 I I_BACTERIUM[BIO]
. O O

Finally O O
cluster O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
6 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
enriched O O
by O O
map2010 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ABC O B_GENE
transporter O I_GENE
) O O
, O O
map2020 O B_GENE
( O O
two O B_NUMBER[MEASURE]/B_LOCATION
- O O
component O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ENZYME[GENE]
system O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ENZYME[GENE]
) O O
, O O
map2030 O B_GENE
and O O
map2031 O B_MEASURE/B_GENE
( O O
bacterial O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
chemotaxis O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
map2040 O B_GENE/B_ORGANIZATION
( O O
Flagellar O B_BIO/B_ENZYME[GENE]
assembly O B_BIO/I_ENZYME[GENE]
) O O
and O O
map3090 O B_GENE/B_MEASURE
( O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
II O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
system O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) O O
. O O

This O O
cluster O O
contains O O
genes O O
shared O O
with O O
a O O
high O O
similarity O O
by O O
all O O
Vibrio O O
and O O
with O O
a O O
lower O O
similarity O O
with O O
Photobacterium B B_BACTERIUM[BIO]
profundum I I_BACTERIUM[BIO]
species O O
. O O

Among O O
the O O
Vibrio O O
species O O
the O O
organisms O O
showing O O
the O O
highest O O
similarity O O
( O O
Tab O O
. O O
3 O O
) O O
are O O
V B B_BACTERIUM[BIO]
. I I_BACTERIUM[BIO]
cholerae I I_BACTERIUM[BIO]
strains O O
. O O

Vibrionaceae O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
specific O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
genes O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]

We O O
identify O O
1940 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clusters O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
Vibrionaceae O B_LOCATION/B_PERSON
. O O

All O O
the O O
Vibrionaceae O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
share O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
108 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
clusters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Among O O
these O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
identify O O
ToxR O B_LOCATION/B_GENE
and O O
ToxS O B_LOCATION/B_ORGANIZATION
genes O I_LOCATION/I_ORGANIZATION
. O O

ToxR O O
gene O O
encodes O O
a O O
transmembrane O O
regulatory O O
protein O O
firstly O O
identified O O
in O O
V B B_BACTERIUM[BIO]
. I I_BACTERIUM[BIO]
cholerae I I_BACTERIUM[BIO]
, O O
in O O
which O O
it O O
co O O
- O O
ordinates O O
many O O
virulence O O
factors O O
in O O
response O O
to O O
several O O
environmental O O
parameters O O
[ O O
18 O O
] O O
. O O

V B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cholerae I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
ToxR O O
activity O O
is O O
enhanced O O
by O O
a O O
second O O
transmembrane O O
protein O O
, O O
ToxS O O
, O O
encoded O O
downstream O O
toxR O O
[ O O
19 O O
] O O
. O O

This O O
family O O
of O O
proteins O O
is O O
involved O O
in O O
response O O
to O O
temperature O O
, O O
pH O O
, O O
osmolarity O O
and O O
in O O
Photobacterium B B_BACTERIUM[BIO]/B_PERSON
profundum I I_BACTERIUM[BIO]/I_PERSON
SS9 I I_BACTERIUM[BIO]/I_PERSON
, O O
a O O
piezophilic O O
bacterium O O
, O O
to O O
hydrostatic O O
pressure O O
[ O O
20 O O
] O O
. O O

The O O
widespread O B_PERSON/B_MEASURE
presence O I_PERSON/I_MEASURE
of O O
these O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
the O O
Vibrionaceae O B_BIO/B_PERSON
suggests O O
their O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
regulatory O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
identify O O
two O B_MEASURE/B_LOCATION
other O I_MEASURE/I_LOCATION
noteworthy O I_MEASURE/I_LOCATION
groups O I_MEASURE/I_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composed O O
by O O
257 O B_MEASURE
and O O
160 O B_MEASURE
genes O I_MEASURE
respectively O O
shared O O
just O O
by O O
two O B_NUMBER[MEASURE]/B_PERSON
strains O I_NUMBER[MEASURE]/I_PERSON
, O O
mainly O O
annotated O O
as O O
" O B_PROTEIN[GENE]
hypothetical O I_PROTEIN[GENE]
protein O I_PROTEIN[GENE]
" O O
. O O

The O O
first O O
group O O
of O O
genes O O
is O O
shared O O
between O O
Photobacterium B B_BACTERIUM[BIO]
profundum I I_BACTERIUM[BIO]
SS9 I I_BACTERIUM[BIO]
and O O
Photobacterium B B_BACTERIUM[BIO]/B_PROTEIN[GENE]
profundum I B_BACTERIUM[BIO]/I_PROTEIN[GENE]
3TCK I B_BACTERIUM[BIO]/I_PROTEIN[GENE]
, O O
while O O
the O O
second O O
is O O
shared O O
between O O
V B B_BACTERIUM[BIO]/B_PROTEIN[GENE]
. I B_BACTERIUM[BIO]/I_PROTEIN[GENE]
vulnificus I B_BACTERIUM[BIO]/I_PROTEIN[GENE]
CMCP6 I B_BACTERIUM[BIO]/I_PROTEIN[GENE]
and O O
YJ016 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
strains O B_BIO/B_GENE
are O O
closely O O
related O O
and O O
this O O
explains O O
the O O
high O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
shared O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
while O O
, O O
inside O O
the O O
Vibrionaceae O B_BIO/B_LOCATION
family O I_BIO/I_LOCATION
, O O
the O O
number O B_MEASURE/B_LOCATION
of O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
shared O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highly O O
decreases O O
, O O
showing O O
a O O
high O B_DISEASE/B_MEASURE
inter O I_DISEASE/I_MEASURE
- O O
species O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
variability O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fig O B_MEASURE/B_LOCATION
. O O
6 O B_NUMBER[MEASURE]
) O O

Prophages O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
transposases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]

Prophages O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recover O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
biological O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
roles O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
both O O
as O O
quantitatively O O
important O B_PERSON/B_GENE
genetic O I_PERSON/I_GENE
elements O I_PERSON/I_GENE
of O O
the O O
bacterial O B_BIO/B_LOCATION
chromosome O I_BIO/I_LOCATION
, O O
and O O
as O O
vectors O B_PROTEIN[GENE]/B_LOCATION
of O O
lateral O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
bacteria O B_BIO/B_GENE
, O O
due O O
to O O
their O O
characters O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mobile O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements O I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Indeed O O
, O O
numerous O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virulence O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
bacterial O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pathogens O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
phage O B_BACTERIUM[BIO]/B_LOCATION
encoded O O
. O O

It O O
was O O
postulated O O
that O O
this O O
role O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
prophages O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
is O O
not O O
limited O O
to O O
pathogenic O O
bacteria O B_BIO/B_DISEASE
but O O
some O O
adaptations O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nonpathogenic O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
strains O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O O
their O O
ecological O B_LOCATION/B_PERSON
niche O I_LOCATION/I_PERSON
might O O
also O O
be O O
mediated O O
by O O
prophages O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
acquisition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
[ O O
21 O B_DISEASE/B_ORGANISM_FUNCTION
] O I_DISEASE/I_ORGANISM_FUNCTION
. O O

To O O
better O O
understand O O
the O O
importance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
mobile O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
elements O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
within O O
Vibrionaceae O B_BIO/B_GENE
family O I_BIO/I_GENE
, O O
we O O
performed O O
a O O
hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cluster O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
gene O B_GENE/B_MEASURE
profiles O I_GENE/I_MEASURE
annotated O O
as O O
" O O
phage O B_ENZYME[GENE]
protein O I_ENZYME[GENE]
" O O
and O O
" O O
transposase O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
" O O
, O O
for O O
a O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
172 O B_MEASURE
clusters O I_MEASURE
of O O
genes O B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fig O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
7 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

We O O
found O O
that O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
inter O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
strain O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exists O O
and O O
phages O B_BIO/B_GENE
and O O
transposases O B_BIO/B_GENE
are O O
both O O
shared O O
by O O
almost O O
all O O
Vibrionaceae O B_BIO/B_GENE
, O O
and O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
just O O
some O O
organisms O B_BIO/B_GENE
. O O

We O O
identified O O
five O B_MEASURE/B_LOCATION
major O I_MEASURE/I_LOCATION
clusters O I_MEASURE/I_LOCATION
of O O
mobile O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
elements O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
are O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
a O O
single O B_BIO/B_GENE
organism O I_BIO/I_GENE
. O O

A O O
group O O
composed O O
by O O
26 O O
clusters O O
containing O O
both O O
transposase O O
and O O
phage O O
proteins O O
seem O O
to O O
be O O
unique O O
to O O
V B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splendiduds I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12B01 I I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fig O O
7 O O
) O O
. O O

Another O O
one O O
composed O O
by O O
16 O O
clusters O O
is O O
specific O O
of O O
V B B_BIO
. I I_BIO
vulnificus I I_BIO
CMCP6 I I_BIO
( O O
Fig O O
7 O O
) O O
while O O
V B B_PERSON
. I I_PERSON
parahaemoliticus I I_PERSON
has O O
a O O
cluster O O
of O O
11 O O
genes O O
( O O
Fig O O
7 O O
) O O
. O O

Moreover O O
there O O
is O O
another O O
group O O
of O O
transposases O O
and O O
phage O O
genes O O
shared O O
mainly O O
by O O
V B B_BACTERIUM[BIO]/B_GENE
. I I_BACTERIUM[BIO]/I_GENE
cholerae I I_BACTERIUM[BIO]/I_GENE
0395 O O
, O O
Shewanella B B_MEASURE/B_BACTERIUM[BIO]
oneidensis I I_MEASURE/I_BACTERIUM[BIO]
and O O
V B B_BACTERIUM[BIO]/B_DISEASE
. I I_BACTERIUM[BIO]/I_DISEASE
cholerae I I_BACTERIUM[BIO]/I_DISEASE
V51 O O
( O O
Fig O O
7 O O
) O O
. O O

Finally O O
a O O
big O O
cluster O O
of O O
almost O O
30 O O
genes O O
, O O
all O O
predicted O O
to O O
codify O O
for O O
transposases O O
, O O
was O O
found O O
in O O
P B B_BIO/B_PERSON
. I I_BIO/I_PERSON
profundum I I_BIO/I_PERSON
SS9 I I_BIO/I_PERSON
genome O O
( O O
Fig O O
. O O
7 O O
) O O
. O O

The O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
transposases O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
bacterium O B_BIO/B_LOCATION
seems O O
to O O
correlate O O
with O O
its O O
deep O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O O
sea O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
habitat O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
feature O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
presumably O O
shared O O
with O O
other O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
deep O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O O
sea O B_BIO/B_LOCATION
microorganisms O B_BIO/I_LOCATION
[ O O
12 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

As O O
shown O O
in O O
Fig O B_MEASURE
7 O I_MEASURE
, O O
many O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
clusters O B_LOCATION/B_BIO
well O O
conserved O O
in O O
an O O
organism O B_BIO/B_GENE
, O O
are O O
partially O O
shared O O
with O O
a O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
similarity O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
by O O
other O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
organisms O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
agrees O O
with O O
the O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
prophages O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
maintained O O
in O O
the O O
genome O B_BIO/B_GENE
over O O
a O O
long O B_MEASURE/B_LOCATION
period O I_MEASURE/I_LOCATION
of O O
time O B_TIME[MEASURE]/B_LOCATION
and O O
part O B_NUMBER[MEASURE]/B_LOCATION
of O O
their O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
deleted O O
from O O
the O O
chromosome O B_BIO/B_GENE
. O O

Moreover O O
, O O
microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scanning O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
demonstrated O O
that O O
prophages O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
are O O
frequently O O
strain O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
within O O
a O O
given O O
bacterial O B_BIO/B_GENE
species O I_BIO/I_GENE
[ O O
22 O B_MEASURE
- O O
24 O B_MEASURE
] O I_MEASURE
. O O

According O O
to O O
the O O
modular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
of O O
phage O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
evolution O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
phage O B_GENE/B_BIO
genomes O I_GENE/I_BIO
are O O
mosaics O B_MEASURE/B_LOCATION
of O O
modules O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
, O O
groups O B_ORGANIZATION/B_LOCATION
of O O
genes O B_BIO/B_GENE
functionally O O
related O O
, O O
that O O
are O O
free O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
recombine O O
in O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
exchanges O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
between O O
distinct O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
phages O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
infecting O O
the O O
same O B_BIO
cell O I_BIO
[ O O
21 O B_GENE/B_BIO
] O I_GENE/I_BIO
. O O

This O O
can O O
result O O
in O O
the O O
occurrences O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
part O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
phage O B_BIO/B_GENE
distributed O O
in O O
far O O
related O O
genomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
some O O
transposases O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
is O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
phage O B_MEASURE/B_BIO
ones O I_MEASURE/I_BIO
, O O
suggesting O O
a O O
possible O B_BIO/B_GENE
transfer O B_BIO/I_GENE
mechanism O B_BIO/I_GENE
phage O B_BIO/I_GENE
- O O
mediated O O
for O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mobile O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
elements O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

In O O
this O O
work O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
propose O O
an O O
improved O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
phylogenetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
on O O
14 O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Vibrionaceae O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
genomes O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
to O O
study O O
this O O
family O B_PERSON/B_LOCATION
on O O
the O O
basis O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
content O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Using O O
a O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
each O O
cluster O B_LOCATION/B_MEASURE
of O O
genes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
defined O O
as O O
the O O
median O B_LOCATION/B_MEASURE
of O O
all O O
the O O
profiles O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O O
to O O
the O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
meta O B_DISEASE/B_PROTEIN[GENE]
- O O
profile O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
we O O
investigate O O
the O O
evolution O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
groups O B_ORGANIZATION/B_LOCATION
of O O
ORFs O B_BIO/B_GENE
belonging O O
to O O
the O O
entire O B_PERSON/B_LOCATION
family O I_PERSON/I_LOCATION
. O O

A O O
two O B_NUMBER[MEASURE]
- O O
way O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cluster O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
allows O O
us O O
to O O
identify O O
similarity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
structures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
on O O
the O O
entire O B_LOCATION/B_BIO
phylogenetic O B_LOCATION/I_BIO
matrix O B_LOCATION/I_BIO
composed O O
by O O
8 O B_MEASURE
, O O
239 O B_MEASURE
clusters O I_MEASURE
of O O
genes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
320 O B_BIO/B_GENE
organisms O B_BIO/I_GENE
. O O

The O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tree O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
obtained O O
with O O
the O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
does O O
not O O
reflect O O
the O O
global O B_BIO/B_LOCATION
evolutionary O I_BIO/I_LOCATION
tree O I_BIO/I_LOCATION
because O O
of O O
the O O
Vibrionaceae O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
ORFs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
dataset O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
used O O
for O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
but O O
rather O O
can O O
be O O
considered O O
as O O
the O O
Vibrionaceae O B_BIO/B_LOCATION
perspective O B_BIO/I_LOCATION
of O O
bacterial O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
diversity O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

The O O
phylogenetic O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tree O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reflects O O
the O O
evolutionary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
shape O O
genomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transfer O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
genes O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
genesis O B_PERSON/B_TIME[MEASURE]
and O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
this O O
context O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
tree O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allows O O
to O O
group O O
together O O
genomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
base O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
their O O
global O B_LOCATION/B_ORGANIZATION
gene O I_LOCATION/I_ORGANIZATION
content O I_LOCATION/I_ORGANIZATION
. O O

We O O
found O O
that O O
genomes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O O
to O O
the O O
same O B_BIO/B_MEASURE
taxonomic O I_BIO/I_MEASURE
group O I_BIO/I_MEASURE
tend O O
to O O
cluster O O
together O O
and O O
that O O
Vibrionaceae O B_PERSON/B_BIO
species O I_PERSON/I_BIO
are O O
closely O O
related O O
. O O

Moreover O O
organisms O B_BIO/B_PERSON
belonging O O
to O O
the O O
same O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
closely O O
related O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
taxa O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
split O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
into O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subgroups O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
confirming O O
the O O
existence O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variability O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
among O O
lineages O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
due O O
to O O
genetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
evolutionary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
lateral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
gene O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
transfer O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
concerted O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evolution O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
genes O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duplication O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

On O O
the O O
other O B_MEASURE/B_LOCATION
hand O B_MEASURE/I_LOCATION
several O B_MEASURE/I_LOCATION
groups O B_MEASURE/I_LOCATION
of O O
genes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
characterised O O
by O O
different O B_DISEASE/B_GENE
homogeneous O I_DISEASE/I_GENE
profiles O I_DISEASE/I_GENE
have O O
been O O
identified O O
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
we O O
found O O
, O O
1 O B_TIME[MEASURE]
) O O
a O O
set O B_GENE/B_LOCATION
of O O
conserved O B_GENE/B_BIO
genes O I_GENE/I_BIO
( O O
with O O
a O O
high O B_MEASURE/B_LOCATION
similarity O I_MEASURE/I_LOCATION
values O I_MEASURE/I_LOCATION
across O O
all O O
organisms O B_BIO/B_GENE
) O O
that O O
reflects O O
the O O
" O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minimal O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genome O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
composition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
defined O O
in O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
previous O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
works O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O O
2 O B_NUMBER[MEASURE]
) O O
a O O
set O B_PROTEIN[GENE]/B_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mainly O O
shared O O
by O O
Vibrionaceae O B_BACTERIUM[BIO]
and O O
other O B_SPECIES[BIO]
Gamma O I_SPECIES[BIO]
proteobacteria O I_SPECIES[BIO]
and O O
3 O B_NUMBER[MEASURE]
) O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specific O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
different O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
sets O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Vibrionaceae O B_BIO/B_GENE
. O O

Finally O O
a O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
prophage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
and O O
transposase O B_GENE/B_BACTERIUM[BIO]
has O O
confirmed O O
the O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
inter O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
strain O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O O
among O O
closely O O
related O O
species O B_BIO/B_GENE
. O O

The O O
increasing O O
number O B_MEASURE
of O O
genomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
included O O
in O O
this O O
type O B_DISEASE/B_LOCATION
of O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surely O O
add O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sorces O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
variability O B_MEASURE/B_DISEASE
and O O
noise O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
anyway O O
we O O
think O O
that O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
meta O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
profiles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
complexity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
study O O
global O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
gene O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
evolution O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Datasets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

The O O
Vibrionaceae O B_BIO/B_GENE
species O B_BIO/I_GENE
used O O
in O O
this O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
selected O O
among O O
the O O
freely O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complete O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
draft O B_TIME[MEASURE]/B_GENE
genome O I_TIME[MEASURE]/I_GENE
sequences O I_TIME[MEASURE]/I_GENE
. O O

The O O
proteomes O O
of O O
V B B_BACTERIUM[BIO]
. I I_BACTERIUM[BIO]
cholerae I I_BACTERIUM[BIO]
N16961 I I_BACTERIUM[BIO]
, O O
V B B_MEASURE/B_BACTERIUM[BIO]
. I I_MEASURE/I_BACTERIUM[BIO]
parahaemolyticus I I_MEASURE/I_BACTERIUM[BIO]
, O O
V B B_BACTERIUM[BIO]
. I I_BACTERIUM[BIO]
vulnificus I I_BACTERIUM[BIO]
YJ016 I I_BACTERIUM[BIO]
, O O
V B B_BACTERIUM[BIO]
. I I_BACTERIUM[BIO]
vulnificus I I_BACTERIUM[BIO]
CMCP6 I I_BACTERIUM[BIO]
, O O
V B B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fischeri I I_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ES114 I I_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Photobacterium B B_MEASURE/B_BACTERIUM[BIO]
profundum I I_MEASURE/I_BACTERIUM[BIO]
SS9 I I_MEASURE/I_BACTERIUM[BIO]
were O O
downloaded O O
from O O
the O O
NCBI O O
ftp O O
site O O
[ O O
25 O O
] O O
. O O

Protein O O
sequences O O
of O O
Vibrio B B_BACTERIUM[BIO]
cholerae I I_BACTERIUM[BIO]
MO10 I I_BACTERIUM[BIO]
, O O
Vibrio B B_MEASURE/B_BACTERIUM[BIO]
cholerae I I_MEASURE/I_BACTERIUM[BIO]
0395 I I_MEASURE/I_BACTERIUM[BIO]
, O O
Vibrio B B_TIME[MEASURE]/B_BACTERIUM[BIO]
cholerae I I_TIME[MEASURE]/I_BACTERIUM[BIO]
RC385 I I_TIME[MEASURE]/I_BACTERIUM[BIO]
, O O
Vibrio B B_BACTERIUM[BIO]/B_GENE
cholerae I I_BACTERIUM[BIO]/I_GENE
V51 I I_BACTERIUM[BIO]/I_GENE
, O O
Vibrio B B_MEASURE/B_BACTERIUM[BIO]
cholerae I I_MEASURE/I_BACTERIUM[BIO]
V52 I I_MEASURE/I_BACTERIUM[BIO]
were O O
downloaded O O
from O O
the O O
NCBI O O
genome O O
database O O
, O O
while O O
sequences O O
of O O
Vibrio B B_BACTERIUM[BIO]/B_GENE
MED222 I I_BACTERIUM[BIO]/I_GENE
, O O
Vibrio B B_BACTERIUM[BIO]/B_GENE
splendidus I B_BACTERIUM[BIO]/I_GENE
12B01 I B_BACTERIUM[BIO]/I_GENE
, O O
Photobacterium B B_BIO/B_TIME[MEASURE]
profundum I I_BIO/I_TIME[MEASURE]
3TCK I I_BIO/I_TIME[MEASURE]
from O O
the O O
J O O
. O O

Craig O B_LOCATION/B_ORGANIZATION
Venter O B_LOCATION/I_ORGANIZATION
Institute O B_LOCATION/I_ORGANIZATION
web O O
site O B_LOCATION/B_PERSON
. O O

The O O
320 O B_MEASURE
complete O I_MEASURE
genomes O I_MEASURE
update O O
at O O
03 O B_MEASURE
/ O O
06 O B_MEASURE
were O O
downloaded O O
from O O
the O O
NCBI O B_LOCATION/B_ORGANIZATION
ftp O I_LOCATION/I_ORGANIZATION
site O I_LOCATION/I_ORGANIZATION
. O O

Similarity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
search O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

All O O
the O O
Vibrionaceae O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ORFs O B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
merged O O
generating O O
a O O
redundant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
list O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
59 O B_MEASURE
, O O
669 O B_MEASURE
proteins O I_MEASURE
and O O
were O O
compared O O
to O O
all O O
open O B_GENE/B_PERSON
reading O I_GENE/I_PERSON
frame O I_GENE/I_PERSON
from O O
320 O B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
bacterial O I_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
archeal O B_SPECIES[BIO]/B_GENE
genomes O I_SPECIES[BIO]/I_GENE
using O O
Blastp O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
determine O O
the O O
presence O B_MEASURE/B_DISEASE
of O O
an O O
orthologous O B_DISEASE/B_BIO
we O O
used O O
a O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
three O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thresholds O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
a O O
similarity O B_MEASURE/B_LOCATION
value O I_MEASURE/I_LOCATION
equal O I_MEASURE/I_LOCATION
to O O
or O O
higher O B_MEASURE
than O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
an O O
alignment O B_MEASURE
length O I_MEASURE
equal O I_MEASURE
or O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
and O O
an O O
Evalue O B_MEASURE
score O I_MEASURE
lower O I_MEASURE
than O O
or O O
equal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
e O B_OTHER/B_MEASURE
- O O
6 O B_MEASURE
. O O

After O O
determining O O
the O O
presence O B_LOCATION/B_DISEASE
of O O
an O O
orthologous O B_GENE/B_MEASURE
gene O I_GENE/I_MEASURE
, O O
we O O
computed O O
a O O
similarity O B_MEASURE/B_LOCATION
index O I_MEASURE/I_LOCATION
I O O
for O O
each O O
pair O B_PERSON/B_LOCATION
of O O
orthologous O B_BIO/B_GENE
( O O
a O O
point O B_MEASURE
of O O
the O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
profile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
as O O
follow O O
: O O

I O O
= O O
SqsSqq O B_MEASURE
. O O
min O B_PERSON/B_LOCATION
( O O
lq O B_MEASURE/B_PROTEIN[GENE]
, O O
ls O B_PROTEIN[GENE]/B_DISEASE
) O O
max O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
lq O B_MEASURE/B_PROTEIN[GENE]
, O O
ls O B_PROTEIN[GENE]/B_DISEASE
) O O

MathType O B_MEASURE
@ O O
MTEF O B_MEASURE/B_ORGANIZATION
@ O O
5 O B_MEASURE
@ O O
5 O B_MEASURE
@ O O
+ O B_MEASURE/B_OTHER
= O O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O B_LOCATION/B_MEASURE
= O O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O B_MEASURE/B_LOCATION
= O O
OqFfea0dXdd9vqai O B_LOCATION/B_MEASURE
= O O
hGuQ8kuc9pgc9s8qqaq O B_GENE/B_LOCATION
= O O
dirpe0xb9q8qiLsFr0 O B_GENE/B_MEASURE
= O O
vr0 O B_MEASURE/B_LOCATION
= O O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGjbqscqGH9aqpdaWcaaqaaiabdofatnaaBaaaleaacqWGXbqCcqWGZbWCaeqaaaGcbaGaem4uam1aaSbaaSqaaiabdghaXjabdghaXbqabaaaaOGaeyyXIC9aaSaaaeaacyGGTbqBcqGGPbqAcqGGUbGBcqGGOaakcqWGSbaBdaWgaaWcbaGaemyCaehabeaakiabcYcaSiabdYgaSnaaBaaaleaacqWGZbWCaeqaaOGaeiykaKcabaGagiyBa0MaeiyyaeMaeiiEaGNaeiikaGIaemiBaW2aaSbaaSqaaiabdghaXbqabaGccqGGSaalcqWGSbaBdaWgaaWcbaGaem4CamhabeaakiabcMcaPaaaaaa O B_MEASURE
@ O O
532D O B_MEASURE/B_GENE
@ O O

where O O
lq O B_PROTEIN[GENE]/B_LOCATION
and O O
ls O B_PROTEIN[GENE]/B_DISEASE
are O O
the O O
query O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
subject O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
length O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
respectively O O
and O O
Sqs O B_PROTEIN[GENE]/B_LOCATION
is O O
the O O
similarity O B_MEASURE/B_LOCATION
score O I_MEASURE/I_LOCATION
between O O
the O O
query O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
the O O
subject O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Sqs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
defined O O
as O O
follow O O
: O O

Sqs O B_PROTEIN[GENE]/B_MEASURE
= O O
sum O B_MEASURE/B_PROTEIN[GENE]
i O O
= O O
1M O B_MEASURE/B_LOCATION
alpha O I_MEASURE/I_LOCATION
Aqi O I_MEASURE/I_LOCATION
, O O
Asi O B_LOCATION/B_PROTEIN[GENE]
+ O I_LOCATION/I_PROTEIN[GENE]
GP O I_LOCATION/I_PROTEIN[GENE]

MathType O B_MEASURE
@ O O
MTEF O B_MEASURE/B_ORGANIZATION
@ O O
5 O B_MEASURE
@ O O
5 O B_MEASURE
@ O O
+ O B_MEASURE/B_OTHER
= O O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O B_LOCATION/B_MEASURE
= O O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O B_MEASURE/B_LOCATION
= O O
OqFfea0dXdd9vqai O B_LOCATION/B_MEASURE
= O O
hGuQ8kuc9pgc9s8qqaq O B_GENE/B_LOCATION
= O O
dirpe0xb9q8qiLsFr0 O B_MEASURE/B_GENE
= O O
vr0 O B_MEASURE/B_LOCATION
= O O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGtbWudaWgaaWcbaGaemyCaeNaem4Camhabeaakiabg2da9maaqahabaacciGae8xSde2aaSbaaSqaaiabdgeabjabdghaXjabdMgaPjabcYcaSiabdgeabjabdohaZjabdMgaPbqabaaabaGaemyAaKMaeyypa0JaeGymaedabaGaemyta0eaniabggHiLdGccqGHRaWkcqWGhbWrcqWGqbauaaa O B_MEASURE
@ O O
4620 O B_MEASURE
@ O O

where O O
M O B_PROTEIN[GENE]
is O O
the O O
match O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
between O O
the O O
query O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
subject O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
; O O
Aqi O B_PERSON/B_LOCATION
and O O
Asi O B_SPECIES[BIO]/B_LOCATION
respectively O O
the O O
query O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
subject O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
amino O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acid O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
position O B_LOCATION/B_MEASURE
i O O
; O O
alpha O O
the O O
BLOSUM O B_MEASURE
substitution O I_MEASURE
matrix O I_MEASURE
value O I_MEASURE
for O O
amino O B_LOCATION/B_PERSON
acid O I_LOCATION/I_PERSON
pair O I_LOCATION/I_PERSON
Aqi O I_LOCATION/I_PERSON
, O O
Asi O B_PERSON/B_LOCATION
and O O
GP O B_PROTEIN[GENE]/B_LOCATION
the O O
gap O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
penalty O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

GP O B_DISEASE
is O O
defined O O
as O O
follow O O
: O O

GP O B_LOCATION
= O O
GOP O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
+ O O
GEP O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
k O B_MEASURE/B_OTHER
- O O
1 O B_MEASURE/B_LOCATION
) O O

where O O
GOP O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
Gap O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Open O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Penalty O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
set O O
to O O
- O O
11 O B_NUMBER[MEASURE]
, O O
GEP O B_MEASURE/B_ORGANIZATION
the O O
Gap O B_MEASURE/B_PERSON
Extension O I_MEASURE/I_PERSON
Penalty O I_MEASURE/I_PERSON
set O O
to O O
- O O
1 O B_MEASURE
and O O
k O B_OTHER/B_MEASURE
the O O
gap O B_MEASURE/B_PERSON
length O I_MEASURE/I_PERSON
. O O

Sqq O B_MEASURE/B_GENE
represents O O
the O O
score O B_MEASURE/B_LOCATION
of O O
the O O
self O B_PERSON/B_LOCATION
- O O
aligned O O
query O B_PERSON/B_LOCATION
sequence O I_PERSON/I_LOCATION
. O O

Sqs O B_GENE/B_LOCATION
is O O
always O O
smaller O B_MEASURE
than O O
Sqq O B_MEASURE/B_LOCATION
and O O
the O O
score O B_MEASURE
S O I_MEASURE
range O I_MEASURE
between O O
0 O B_NUMBER[MEASURE]
and O O
1 O B_NUMBER[MEASURE]
. O O

In O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
take O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
also O O
the O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lengths O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
we O O
multiplied O O
the O O
score O B_MEASURE
S O I_MEASURE
by O O
the O O
ratio O B_MEASURE/B_PERSON
between O O
the O O
minimum O B_MEASURE
length O I_MEASURE
between O O
query O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
subject O B_PERSON
and O O
the O O
maximum O B_MEASURE
length O I_MEASURE
between O O
query O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
subjects O B_PERSON
. O O

In O O
this O O
way O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
total O B_MEASURE
score O I_MEASURE
is O O
weighted O O
on O O
the O O
base O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
length O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
resulting O O
in O O
a O O
lower O B_MEASURE/B_PERSON
similarity O I_MEASURE/I_PERSON
value O I_MEASURE/I_PERSON
if O O
the O O
lengths O B_MEASURE/B_LOCATION
of O O
the O O
sequences O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
different O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
phylogenetic O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
each O O
ORF O B_BIO/B_GENE
is O O
an O O
array O B_LOCATION/B_MEASURE
of O O
index O B_MEASURE/B_GENE
I O O
with O O
length O B_MEASURE/B_PERSON
equal O I_MEASURE/I_PERSON
to O O
the O O
number O B_MEASURE/B_LOCATION
of O O
genomes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O O
( O O
320 O B_MEASURE/B_LOCATION
) O O
. O O

ORFs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clustering O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

The O O
redundant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
list O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
59 O B_MEASURE
, O O
669 O B_MEASURE
Vibrionaceae O I_MEASURE
ORFs O I_MEASURE
contained O O
multiple O B_NUMBER[MEASURE]
copies O I_NUMBER[MEASURE]
of O O
the O O
same O B_PERSON/B_BIO
genes O I_PERSON/I_BIO
due O O
to O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
conserved O O
genes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
considered O O
genomes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
order O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
reduce O O
the O O
redundancy O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
clustered O O
proteins O B_LOCATION/B_GENE
using O O
a O O
two O B_NUMBER[MEASURE]
- O O
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
based O O
on O O
COG O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Othologous O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
Genes O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) O O
annotation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

COG O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classifies O O
conserved O B_BIO/B_GENE
genes O I_BIO/I_GENE
according O O
to O O
their O O
homologous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relationships O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

All O O
the O O
Vibrionaceae O B_BIO/B_GENE
ORFs O B_BIO/I_GENE
were O O
annotated O O
using O O
COG O B_ORGANIZATION/B_BIO
clusters O I_ORGANIZATION/I_BIO
and O O
proteins O B_BIO/B_DISEASE
sharing O O
the O O
same O B_LOCATION/B_GENE
COG O I_LOCATION/I_GENE
code O I_LOCATION/I_GENE
were O O
considered O O
belonging O O
to O O
the O O
same O B_PERSON/B_LOCATION
cluster O I_PERSON/I_LOCATION
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
annotation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
consists O O
of O O
a O O
similarity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
search O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
all O O
the O O
ORFs O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
the O O
COG O B_GENE/B_BIO
proteins O I_GENE/I_BIO
using O O
blast O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
considering O O
the O O
best O B_PERSON/B_MEASURE
hit O O
for O O
each O O
protein O B_GENE/B_BACTERIUM[BIO]
. O O

43 O O
, O O
024 O B_MEASURE
ORFs O I_MEASURE
presented O O
a O O
similarity O B_MEASURE/B_LOCATION
with O O
a O O
COG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
entry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
producing O O
2 O B_MEASURE
, O O
463 O B_MEASURE
different O I_MEASURE
clusters O I_MEASURE
. O O

In O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
remaining O O
16 O B_MEASURE
, O O
645 O B_MEASURE/B_LOCATION
ORFs O I_MEASURE/I_LOCATION
without O O
similarity O B_MEASURE/B_LOCATION
with O O
any O O
COG O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
entry O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
clustered O O
using O O
CD O B_LOCATION/B_DISEASE
- O O
HIT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
26 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

CD O B_DISEASE/B_PROTEIN[GENE]
- O O
HIT O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O B_LOCATION/B_PERSON
clusters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
protein O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
identity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
threshold O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
efficiently O O
removes O O
high O B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_DISEASE_ADJECTIVE[DISEASE]
redundancy O I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
clustering O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
produced O O
9 O B_MEASURE
, O O
613 O B_MEASURE
different O I_MEASURE
groups O I_MEASURE
of O O
similar O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Finally O O
from O O
the O O
12 O B_MEASURE
, O O
076 O B_MEASURE
total O I_MEASURE
clusters O I_MEASURE
obtained O O
by O O
this O O
methodology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
those O O
composed O O
by O O
ORFs O B_GENE/B_LOCATION
that O O
do O O
not O O
have O O
any O O
ortologous O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
with O O
a O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
composed O O
by O O
an O O
array O B_LOCATION/B_GENE
with O O
all O O
zero O B_GENE/B_LOCATION
values O I_GENE/I_LOCATION
except O O
for O O
one O B_MEASURE/B_PERSON
position O I_MEASURE/I_PERSON
match O I_MEASURE/I_PERSON
with O O
itself O O
) O O
were O O
eliminated O O
, O O
resulting O O
in O O
a O O
dataset O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
composed O O
by O O
8 O B_MEASURE
, O O
239 O B_MEASURE
distinct O I_MEASURE
clusters O I_MEASURE
. O O

The O O
final O B_MEASURE/B_LOCATION
phylogenetic O I_MEASURE/I_LOCATION
profile O I_MEASURE/I_LOCATION
for O O
each O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
meta O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
profile O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
defined O O
as O O
the O O
median O B_MEASURE
of O O
all O O
the O O
profiles O B_LOCATION/B_BIO
belonging O O
to O O
the O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

At O O
the O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
these O O
procedures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phylogenetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
matrix O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
composed O O
by O O
8 O B_NUMBER[MEASURE]
, O O
239 O B_MEASURE/B_LOCATION
rows O I_MEASURE/I_LOCATION
( O O
cluster O B_LOCATION/B_MEASURE
of O O
genes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
320 O B_LOCATION/B_ORGANIZATION
columns O I_LOCATION/I_ORGANIZATION
( O O
organisms O B_BIO/B_GENE
) O O
. O O

In O O
each O O
cell O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
the O O
median O B_MEASURE
of O O
the O O
index O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reported O O
. O O

Cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
clustering O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
techniques O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
been O O
used O O
to O O
identify O O
the O O
similarity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
underneath O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

A O O
k O B_OTHER/B_MEASURE
- O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
a O O
two O B_NUMBER[MEASURE]
- O O
way O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
Euclidean O B_MEASURE
distance O I_MEASURE
and O O
complete O B_MEASURE/B_LOCATION
linkage O I_MEASURE/I_LOCATION
were O O
performed O O
on O O
the O O
phylogenetic O B_LOCATION
matrix O I_LOCATION
. O O

The O O
goal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O O
a O O
cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
to O O
partition O O
the O O
elements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
into O O
subsets O B_LOCATION/B_PERSON
without O O
any O O
constrains O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
a O O
priori O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
so O O
that O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
satisfied O O
: O O
homogeneity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
elements O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inside O O
a O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
highly O O
similar O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
each O O
other O B_NUMBER[MEASURE]/B_PERSON
; O O
and O O
separation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
elements O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
different O B_LOCATION/B_PERSON
clusters O I_LOCATION/I_PERSON
have O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
similarity O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
to O O
each O O
other O B_NUMBER[MEASURE]/B_PERSON
. O O

The O O
Figure O B_PERSON/B_MEASURE
of O O
Merit O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
FOM O B_LOCATION/B_ORGANIZATION
) O O
is O O
a O O
measure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fit O B_MEASURE
of O O
the O O
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patterns O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
clusters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produced O O
by O O
a O O
particular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
estimates O O
the O O
predictive O B_MEASURE
power O I_MEASURE
of O O
a O O
clustering O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

It O O
is O O
computed O O
by O O
removing O O
each O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
turn O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
set O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
clustering O O
genes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
based O O
on O O
the O O
remaining O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
and O O
calculating O O
the O O
fit O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
withheld O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
clustering O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
obtained O O
from O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

On O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
FOM O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
identified O O
the O O
best O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
k O B_MEASURE/B_OTHER
- O O
means O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clusters O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O O
10 O B_NUMBER[MEASURE]
and O O
15 O B_MEASURE
. O O

We O O
decided O O
to O O
set O O
k O B_MEASURE
( O O
in O O
the O O
k O B_MEASURE/B_OTHER
- O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
equal O B_MEASURE/B_PERSON
to O O
14 O B_NUMBER[MEASURE]/B_LOCATION
. O O

In O O
each O O
of O O
these O O
14 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
clusters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
subsequent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
hierarchical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cluster O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
performed O O
with O O
bootstrap O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cluster O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

All O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
with O O
TMEV O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
[ O O
27 O B_MEASURE
] O I_MEASURE
, O O
freely O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
[ O B_MEASURE/B_LOCATION
28 O B_MEASURE/I_LOCATION
] O B_MEASURE/I_LOCATION
. O O

Enrichment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
categories O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Each O O
cluster O B_LOCATION/B_MEASURE
of O O
genes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O O
been O O
annotated O O
according O O
to O O
COG O B_LOCATION/B_ORGANIZATION
code O I_LOCATION/I_ORGANIZATION
, O O
GO O O
terms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
KEGG O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maps O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Class O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
enrichment O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
with O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
entire O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
has O O
been O O
calculated O O
according O O
to O O
the O O
hypergeometric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distribution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
was O O
used O O
to O O
obtain O O
the O O
chance O B_PERSON/B_MEASURE
probability O B_PERSON/I_MEASURE
of O O
observing O O
the O O
number O B_MEASURE/B_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
annotated O O
with O O
a O O
particular O B_LOCATION
COG O I_LOCATION
, O O
GO O O
and O O
KEGG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
category O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
among O O
the O O
selected O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cluster O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
probability O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
observing O O
at O O
least O O
k O B_MEASURE/B_LOCATION
genes O B_MEASURE/I_LOCATION
of O O
a O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
category O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
within O O
a O O
group O B_ORGANIZATION/B_LOCATION
of O O
n O B_GENE/B_PERSON
genes O I_GENE/I_PERSON
is O O
given O O
by O O
: O O

P O B_MEASURE/B_PROTEIN[GENE]
= O O
sum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
i O O
= O O
kn O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
fi O B_LOCATION/B_MEASURE
) O O
( O O
g O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
fn O B_DISEASE/B_LOCATION
- O O
i O B_DISEASE/B_MEASURE
) O O
( O O
gn O B_MEASURE
) O O

MathType O B_MEASURE
@ O O
MTEF O B_MEASURE/B_ORGANIZATION
@ O O
5 O B_MEASURE
@ O O
5 O B_MEASURE
@ O O
+ O B_MEASURE/B_OTHER
= O O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY O B_MEASURE/B_LOCATION
= O O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 O B_MEASURE/B_LOCATION
= O O
OqFfea0dXdd9vqai O B_MEASURE/B_LOCATION
= O O
hGuQ8kuc9pgc9s8qqaq O B_GENE/B_LOCATION
= O O
dirpe0xb9q8qiLsFr0 O B_MEASURE/B_GENE
= O O
vr0 O B_MEASURE/B_LOCATION
= O O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGqbaucqGH9aqpdaaeWbqaamaalaaabaWaaeWaaeaafaqabeGabaaabaGaemOzaygabaGaemyAaKgaaaGaayjkaiaawMcaamaabmaabaqbaeqabiqaaaqaaiabdEgaNjabgkHiTiabdAgaMbqaaiabd6gaUjabgkHiTiabdMgaPbaaaiaawIcacaGLPaaaaeaadaqadaqaauaabeqaceaaaeaacqWGNbWzaeaacqWGUbGBaaaacaGLOaGaayzkaaaaaaWcbaGaemyAaKMaeyypa0Jaem4AaSgabaGaemOBa4ganiabggHiLdaaaa O B_MEASURE
@ O O
47C6 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
@ O O

where O O
f O O
is O O
the O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
category O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
in O O
the O O
matrix O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
g O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
the O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
our O O
matrix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

A O O
secondary O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
common O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
ribosomal O B_GENE/B_LOCATION
ITS2 O I_GENE/I_LOCATION
( O O
internal O B_GENE/B_BIO
transcribed O I_GENE/I_BIO
spacer O I_GENE/I_BIO
) O O
of O O

Culexspecies O B_PERSON/B_ENT
from O O
diverse O B_LOCATION
geographical O I_LOCATION
locations O I_LOCATION

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
structural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
ITS2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
the O O
spacer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
segment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
between O O
5 O B_MEASURE
. O O
8S O B_MEASURE
and O O
28S O B_MEASURE/B_GENE
rRNA O I_MEASURE/I_GENE
of O O

mature O O
rRNA O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
) O O
of O O
7 O B_BIO/B_PERSON
Culex O I_BIO/I_PERSON
species O I_BIO/I_PERSON
belonging O O
to O O
5 O B_LOCATION
different O I_LOCATION
geographical O I_LOCATION
locations O I_LOCATION
was O O
carried O O
out O O
. O O

Alignment O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O

ITS2 O B_GENE/B_BACTERIUM[BIO]
sequence O I_GENE/I_BACTERIUM[BIO]
from O O
the O O
7 O B_BIO/B_GENE
species O I_BIO/I_GENE
revealed O O
8 O B_MEASURE/B_GENE
homologous O I_MEASURE/I_GENE
domains O I_MEASURE/I_GENE
. O O

Four O O
species O O
namely O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
vishnui I I_SPECIES[BIO]
, O O
C B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
annulus I I_SPECIES[BIO]/I_PERSON
, O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
pipiens I I_SPECIES[BIO]
, O O

C B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
quiquefasciatusshowed I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
high O O
sequence O O
( O O
98 O O
- O O
100 O O
% O O
) O O
and O O
RNA O O
secondary O O
structure O O
similarity O O
. O O

The O O
ITS2 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
similarity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
among O O
different O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

species O B_BIO/B_PERSON
is O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
despite O O
their O O
varying O O
geographical O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
locations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Several O B_MEASURE/B_LOCATION
common O B_MEASURE/I_LOCATION
features O B_MEASURE/I_LOCATION
of O O
secondary O B_DISEASE/B_PERSON
structure O I_DISEASE/I_PERSON
are O O
shared O O
among O O

these O O
species O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O O
with O O
some O O
of O O
them O O
supported O O
by O O
compensatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
suggesting O O
the O O
significant O B_PERSON/B_MEASURE
role O I_PERSON/I_MEASURE
by O O
ITS2 O B_GENE/B_BACTERIUM[BIO]
as O O
an O O
RNA O B_GENE/B_PERSON
domain O I_GENE/I_PERSON

during O O
ribosome O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
biogenesis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Culex O B_BACTERIUM[BIO]/B_PERSON
mosquito O I_BACTERIUM[BIO]/I_PERSON
species O I_BACTERIUM[BIO]/I_PERSON
have O O
been O O
described O O
from O O
a O O
wide O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
of O O
environments O B_LOCATION/B_BIO
and O O
are O O
involved O O
in O O
pathogen O B_DISEASE/B_SPECIES[BIO]
transmission O B_DISEASE/I_SPECIES[BIO]
from O O

human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
reservoirs O O
and O O
vice O O
- O O
versa O O
. O O

[ O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
] O O
Sequence O B_PERSON/B_LOCATION
similarity O I_PERSON/I_LOCATION
have O O
been O O

reported O O
for O O
ITS2 O B_GENE/B_BACTERIUM[BIO]
( O O
the O O
spacer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
segments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
5 O B_MEASURE
. O O
8S O B_MEASURE
and O O
28S O B_MEASURE/B_GENE
rRNA O I_MEASURE/I_GENE
of O O
mature O B_GENE/B_SPECIES[BIO]
rRNA O B_GENE/I_SPECIES[BIO]
sequences O B_GENE/I_SPECIES[BIO]
) O O
from O O
5 O B_BIO/B_PERSON
Culex O I_BIO/I_PERSON
species O I_BIO/I_PERSON
of O O
diverse O B_LOCATION/B_SPECIES[BIO]

geographic O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locations O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

[ O O
3 O B_MEASURE
- O O
4 O B_MEASURE
- O O

5 O O
- O O
9 O B_MEASURE
- O O

20 O O
] O O
The O O
ITS O O
spacers O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
versatile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
have O O
been O O
used O O
for O O
the O O
determination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
taxonomic O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

classification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

[ O O
17 O O
] O O
Recent O O
functional O O
analyses O O
performed O O
on O O
yeast B B_SPECIES[BIO]
ribosomal O O

RNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
clearly O O
show O O
that O O
the O O
structural O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
transcribed O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
spacer O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
essential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prerequisite O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
correct O B_TIME[MEASURE]/B_DISEASE

processing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
mature O B_GENE
rRNA O I_GENE
and O O
for O O
the O O
biogenesis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
active O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ribosomal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

[ O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O

3 O O
] O O
The O O
derivation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
reliable O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
secondary O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
structure O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
each O O
transcribed O B_GENE
spacer O I_GENE

region O B_LOCATION/B_PERSON
would O O
represent O O
a O O
major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
towards O O
a O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
their O O
biological O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
roles O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Comparative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequence O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
provides O O
a O O
powerful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tool O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
identifying O O
biologically O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
folding O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patterns O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
RNA O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
molecules O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

[ O O
4 O O
] O O
This O O
involves O O
collection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
sequences O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exhibiting O O
substantial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
while O O
retaining O O
unequivocal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similarity O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
a O O
high O B_MEASURE
degree O I_MEASURE
of O O
sequence O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
variation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
transcribed O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ENT

spacers O B_PERSON/B_ORGANIZATION
is O O
known O O
even O O
among O O
closely O O
related O O
species O B_BIO/B_GENE
. O O

[ O O
5 O B_MEASURE
- O O
6 O B_MEASURE
- O O
7 O B_MEASURE
] O I_MEASURE
Here O O
, O O
we O O
analyze O O
ITS2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
7 O B_TIME[MEASURE]/B_LOCATION

Culex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
species O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characteristic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
geographical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
locations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
to O O
assemble O O
common O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
structural O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
features O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Methodology O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Dataset O B_PERSON/B_MEASURE

ITS2 O B_GENE/B_BIO
nucleotide O I_GENE/I_BIO
sequences O O
from O O
7 O B_NUMBER[MEASURE]/B_LOCATION
Culex O I_NUMBER[MEASURE]/I_LOCATION
mosquitoes O I_NUMBER[MEASURE]/I_LOCATION
characteristic O I_NUMBER[MEASURE]/I_LOCATION
of O O
5 O B_LOCATION/B_BIO
geographical O I_LOCATION/I_BIO
locations O I_LOCATION/I_BIO
( O O
Italy O B_LOCATION
, O O
China O B_LOCATION
, O O
Africa O B_LOCATION
, O O

America O B_LOCATION
, O O
and O O
Japan O B_LOCATION
) O O
were O O
downloaded O O
from O O
GenBank O B_ORGANIZATION/B_LOCATION
( O O
www O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
ncbi O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
nlm O B_LOCATION/B_GENE
. O O
nih O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O
gov O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
genbank O B_LOCATION/B_ORGANIZATION

) O O
. O O
The O O
GenBank O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
accession O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
numbers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
ITS2 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

from O O
C B B_LOCATION/B_PERSON
. I I_LOCATION/I_PERSON
pipens I I_LOCATION/I_PERSON
( O O
North O O
America O O
) O O
, O O
C B B_LOCATION/B_PERSON
. I I_LOCATION/I_PERSON
tritaeniorhynchus I I_LOCATION/I_PERSON
( O O
China O O
) O O
, O O
C B B_LOCATION/B_SPECIES[BIO]
. I I_LOCATION/I_SPECIES[BIO]
quinquefasciatus I I_LOCATION/I_SPECIES[BIO]

( O O
Africa O O
) O O
, O O
C B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tarsalis I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Italy O O
) O O
, O O
C B B_PERSON/B_LOCATION
. I I_PERSON/I_LOCATION
annulus I I_PERSON/I_LOCATION
( O O
China O O
) O O
, O O
C B B_BIO/B_LOCATION
. I B_BIO/I_LOCATION
pseudovishnui I B_BIO/I_LOCATION

( O O
China O O
) O O
, O O
and O O
C B B_PERSON/B_NUMBER[MEASURE]
. I B_PERSON/I_NUMBER[MEASURE]
vishnui I B_PERSON/I_NUMBER[MEASURE]
( O O
Japan O O
) O O
were O O
X75817 O O
, O O
AF305558 O O
, O O
Z48468 O O
, O O
U33031 O O
, O O
AF453488 O O
, O O
AF453498 O O
and O O
AF165900 O O
, O O

respectively O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sequence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
alignments O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE

Multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
performed O O
using O O
CLUSTALW O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
a O O
gap O B_MEASURE/B_PERSON
opening O I_MEASURE/I_PERSON
penalty O I_MEASURE/I_PERSON
of O O
15 O B_MEASURE
and O O
gap O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extension O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
penalty O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
6 O B_MEASURE
. O O
66 O B_MEASURE
. O O

[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prediction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
RNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
secondary O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
structures O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
ITS2 O B_GENE/B_MEASURE
were O O
predicted O O
using O O
RNADRAW O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

[ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

RNADRAW O B_PERSON/B_GENE
predicts O O
RNA O B_DISEASE_ADJECTIVE[DISEASE]
structures O I_DISEASE_ADJECTIVE[DISEASE]
by O O
identifying O O
suboptimal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
structures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
using O O
the O O
free O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
energy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
optimization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
methodology O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O O
a O O
default O B_MEASURE/B_LOCATION

temperature O B_MEASURE/B_LOCATION
of O O
370 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degrees O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
C O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
the O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
ITS2 O B_GENE/B_BACTERIUM[BIO]
and O O
5 O B_MEASURE
. O O
8S O B_MEASURE
regions O I_MEASURE
( O O
the O O
first O B_GENE/B_MEASURE
170 O I_GENE/I_MEASURE
nucleotides O I_GENE/I_MEASURE
) O O
were O O
used O O
for O O
RNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

prediction O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
minimum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
energy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
prediction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
RNADRAW O B_GENE/B_BACTERIUM[BIO]
was O O
ported O O
from O O
the O O
RNAFOLD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
included O O
in O O
the O O

Vienna O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
package O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

[ O O
24 O O
] O O
The O O
dynamic O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programming O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
algorithm O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
employed O O
in O O

RNADRAW O B_PERSON/B_LOCATION
was O O
based O O
on O O
the O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
Zuker O B_PERSON
and O O
Stiegler O B_PERSON
[ O O
25 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O O
uses O O
energy O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
taken O O
from O O
Turner O B_PERSON
[ O O
26 O B_MEASURE
] O I_MEASURE
, O O
Freier O B_PERSON
[ O O
27 O B_MEASURE
] O I_MEASURE
and O O
Jaeger O B_PERSON
. O O

[ O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
28 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
phylogenetic O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Genebee O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
service O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
for O O
phylogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tree O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
construction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

[ O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
22 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

] O B_OTHER/B_PERSON

RNA O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fold O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
Sribo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Sfold O B_MEASURE
( O O
Statistical O B_DISEASE_ADJECTIVE[DISEASE]
Folding O I_DISEASE_ADJECTIVE[DISEASE]
and O O
Rational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O O
was O O

used O O
to O O
predict O O
the O O
probable O B_LOCATION/B_BIO
target O I_LOCATION/I_BIO
accessibility O I_LOCATION/I_BIO
sites O I_LOCATION/I_BIO
( O O
loops O B_LOCATION
) O O
for O O
trans O B_LOCATION/B_GENE
- O O
cleaving O O
ribozymes O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
ITS2 O B_BIO
. O O

[ O O
24 O O
] O O
The O O
prediction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
accessibility O B_MEASURE/B_DISEASE
is O O
based O O
on O O
a O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sample O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
Boltzmann O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

ensemble O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
secondary O B_ENT/B_PERSON
structures O I_ENT/I_PERSON
. O O

Here O O
, O O
we O O
assessed O O
the O O
likelihood O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
unpaired O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ribozyme O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
target O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Each O O
mRNA O B_TIME[MEASURE]/B_GENE

exists O O
as O O
a O O
population O B_PERSON/B_LOCATION
of O O
different O B_NUMBER[MEASURE]/B_LOCATION
structures O I_NUMBER[MEASURE]/I_LOCATION
. O O

Hence O O
, O O
stochastic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
accessible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O

appropriate O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

[ O O
29 O O
] O O
The O O
probability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
profiling O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
Ding O B_PERSON
and O O
Lawrence O B_PERSON

[ O O
30 O O
] O O
reveals O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sites O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
are O O
commonly O O
accessible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O

a O O
large O B_MEASURE/B_LOCATION
number O B_MEASURE/I_LOCATION
of O O
statistically O O
representative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structures O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
bypasses O O
the O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
standing O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE

difficulty O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
accessibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
limited O O
representation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
probable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
due O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
high O B_MEASURE/B_DISEASE
statistical O B_MEASURE/I_DISEASE
confidence O B_MEASURE/I_DISEASE

in O O
predictions O B_PERSON
. O O

The O O
probability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
individual O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bases O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
W O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
= O O
1 O B_MEASURE
) O O
is O O
produced O O
for O O
the O O
region O B_LOCATION/B_TIME[MEASURE]
that O O

includes O O
a O O
triplet O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
two O B_LOCATION/B_MEASURE
flanking O I_LOCATION/I_MEASURE
sequences O I_LOCATION/I_MEASURE
of O O
15 O B_GENE
bases O I_GENE
each O O
in O O
every O O
site O B_LOCATION/B_MEASURE
of O O
the O O
selected O O
cleavage O B_GENE/B_LOCATION
triplet O I_GENE/I_LOCATION
( O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
, O O
GUC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

ITS2 O B_MEASURE/B_BIO
sequences O I_MEASURE/I_BIO
showed O O
a O O
taxonomic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trend O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
similar O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
that O O
in O O
phylogeny O B_LOCATION/B_SPECIES[BIO]
construction O B_LOCATION/I_SPECIES[BIO]
( O O
Figure O B_LOCATION/B_MEASURE
1A O I_LOCATION/I_MEASURE

) O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

of O O
5 O B_MEASURE
. O O
8S O B_MEASURE/B_GENE
rDNA O I_MEASURE/I_GENE
and O O
ITS2 O B_GENE/B_BACTERIUM[BIO]
showed O O
in O O
Figure O B_MEASURE/B_PERSON
1B O I_MEASURE/I_PERSON
indicated O O
that O O
more O O
distantly O O
related O O
species O B_BIO/B_PERSON
have O O

lower O B_MEASURE/B_LOCATION
sequence O B_MEASURE/I_LOCATION
similarity O B_MEASURE/I_LOCATION
in O O
the O O

ITS2 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
region O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
predicted O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
ITS2 O B_GENE/B_BACTERIUM[BIO]
using O O
RNADRAW O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
are O O
given O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
stems O B_BIO/B_PERSON

( O O
double O B_NUMBER[MEASURE]
stranded O O
paired O O
regions O B_GENE/B_DISEASE
) O O

stabilize O O
RNA O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
secondary O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
number O B_MEASURE/B_LOCATION
of O O
stems O B_PERSON/B_GENE
present O B_PERSON/I_GENE
in O O
each O O
ITS2 O B_GENE/B_BACTERIUM[BIO]
is O O
given O O
( O O
Table O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
) O O
. O O

ITS2 O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O

C B B_SPECIES[BIO]/B_DISEASE
. I I_SPECIES[BIO]/I_DISEASE
pipiens I I_SPECIES[BIO]/I_DISEASE
and O O
C B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
quinquefasciatus I I_SPECIES[BIO]/I_PERSON
have O O
the O O
highest O O
negative O O
free O O
energy O O
( O O
- O O
149 O O
. O O
38 O O
Kcal O O
and O O

- O O
148 O O
. O O
23 O O
Kcal O O
) O O
followed O O
by O O
C B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
tarsalis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
- O O
129 O O
. O O
2 O O
) O O
, O O
C B B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
annulus I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
then O O
by O O
C B B_LOCATION/B_BIO
. I I_LOCATION/I_BIO
vishnui I I_LOCATION/I_BIO

( O O
- O O
115 O O
. O O
3 O O
) O O
, O O
C B B_BACTERIUM[BIO]/B_LOCATION
. I I_BACTERIUM[BIO]/I_LOCATION
pseudovishnui I I_BACTERIUM[BIO]/I_LOCATION
( O O
- O O
105 O O
. O O
66 O O
) O O
and O O
C B B_BACTERIUM[BIO]
. I I_BACTERIUM[BIO]
tritaeniorhyncus I I_BACTERIUM[BIO]
( O O
- O O
82 O O
. O O
57 O O
) O O
. O O

Visual O B_NUMBER[MEASURE]/B_ENT
comparison O I_NUMBER[MEASURE]/I_ENT
shows O O

that O O
this O O
is O O
related O O
to O O
the O O
trend O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cladogram O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
given O O
in O O
Figure O B_LOCATION/B_MEASURE
1A O B_LOCATION/I_MEASURE
. O O

A O O
high O B_MEASURE
degree O I_MEASURE
of O O
sequence O B_MEASURE/B_DISEASE
similarity O I_MEASURE/I_DISEASE
is O O
observed O O
at O O
the O O

5 O B_MEASURE
' O O
end O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
the O O
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
( O O
Figure O B_LOCATION/B_MEASURE
1A O I_LOCATION/I_MEASURE
) O O
. O O

This O O
is O O
due O O
to O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
genetic O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
drift O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
relative O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
and O O
size O B_MEASURE/B_LOCATION
of O O
repeats O B_TIME[MEASURE]/B_GENE
, O O

rates O B_MEASURE/B_LOCATION
of O O
unequal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crossover O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conversion O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
immigration O B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
number O B_MEASURE/B_LOCATION
of O O
the O O
loci O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influencing O O
the O O
length O B_MEASURE/B_DISEASE
. O O

[ O B_MEASURE
10 O I_MEASURE
] O O
Furthermore O O
, O O
a O O
high O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sequence O B_MEASURE
similarity O I_MEASURE
is O O
found O O
between O O
C O B_OTHER/B_GENE
. O O

annulus O O
and O O
C B B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. I I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
vishnui I I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
as O O
well O O
as O O
C B B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. I B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
quinquefasciatus I B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
C B B_DISEASE/B_LOCATION
. I B_DISEASE/I_LOCATION

pipiens B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

The O O
simple O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tandem O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
repeats O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shown O O
in O O
Figure O B_LOCATION/B_COLOR
1B O B_LOCATION/I_COLOR
as O O
bolded O B_TIME[MEASURE]/B_LOCATION
regions O I_TIME[MEASURE]/I_LOCATION
are O O
found O O
to O O
be O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
similarity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
seen O O
in O O
corresponding O O

RNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
computed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
energies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Culex O B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O B_BIO/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
then O O
grouped O O
into O O
three O B_LOCATION/B_MEASURE
classes O I_LOCATION/I_MEASURE
based O O
on O O
the O O
similarity O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O

RNA O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
stems O O
and O O
loops O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Despite O O
their O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
geographic O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locations O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
varying O O
eco O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
climatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
class O B_LOCATION/B_MEASURE
I O I_LOCATION/I_MEASURE

( O O
C B B_LOCATION
. I I_LOCATION
annulus I I_LOCATION
, O O
C B B_BACTERIUM[BIO]/B_LOCATION
. I B_BACTERIUM[BIO]/I_LOCATION
pseudovishnui I B_BACTERIUM[BIO]/I_LOCATION
and O O
C B B_BACTERIUM[BIO]/B_LOCATION
. I I_BACTERIUM[BIO]/I_LOCATION
vishnui I I_BACTERIUM[BIO]/I_LOCATION
) O O
isolates O O
( O O
China O O
and O O
Japan O O
) O O
showed O O
high O O
similarity O O

in O O
secondary O B_PERSON
structural O I_PERSON
features O I_PERSON
. O O

Similar O O
observations O O
were O O
seen O O
in O O
class O O
II O O
( O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
pipiens I I_SPECIES[BIO]
, O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
quinquefasciatus I I_SPECIES[BIO]
and O O

C B B_MEASURE/B_PERSON
. I I_MEASURE/I_PERSON
tarsalis I I_MEASURE/I_PERSON
) O O
isolates O O
from O O
North O O
America O O
and O O
Africa O O
. O O

[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
19 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

A O O
high O B_MEASURE/B_LOCATION
degree O B_MEASURE/I_LOCATION
of O O
similarity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
5 O B_MEASURE
. O O
8S O B_MEASURE
region O I_MEASURE
unlike O O
the O O
ITS2 O B_NUMBER[MEASURE]/B_LOCATION
is O O
shown O O
for O O
different O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolates O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
relative O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
evolutionary O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]

selection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

[ O O
9 O B_TIME[MEASURE]
] O O
The O O
loops O B_SEQUENCE[MEASURE]/B_LOCATION
11 O I_SEQUENCE[MEASURE]/I_LOCATION
and O O
12 O B_NUMBER[MEASURE]
having O O
sequences O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
UGUCG O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
CUUCGGUG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O

respectively O O
are O O
highly O O
conserved O O
in O O
all O O
classes O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Figure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1C O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
shows O O
the O O
distribution O B_ORGANIZATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
types O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
loops O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
hairpin O B_LOCATION/B_MEASURE
, O O
bulge O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
multi O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
branched O O
, O O
interior O B_LOCATION/B_MEASURE
and O O
exterior O B_LOCATION
) O O
among O O

different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolates O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
segments O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
ITS2 O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
having O O
score O B_MEASURE/B_PERSON
>= O B_MEASURE/I_PERSON
50 O B_MEASURE/I_PERSON
are O O
further O O
probed O O
carefully O O
for O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
site O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
assess O O
the O O

likelihood O B_MEASURE/B_PERSON
of O O
unpaired O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
segments O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Interestingly O O
, O O
the O O
observed O B_PERSON
phylogenetic O I_PERSON
trend O I_PERSON
was O O
identified O O
with O O
respect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
target O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

accessibility O B_MEASURE/B_LOCATION
sites O I_MEASURE/I_LOCATION
for O O
the O O
seven O B_LOCATION/B_ORGANIZATION
Culex O I_LOCATION/I_ORGANIZATION
isolates O I_LOCATION/I_ORGANIZATION
. O O

The O O
order O B_LOCATION/B_DISEASE
of O O
preference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
interior O B_MEASURE
loop O I_MEASURE
, O O
bulge O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
loop O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
multiple O B_MEASURE/B_DISEASE

branched O O
loop O B_LOCATION/B_BIO
, O O
hairpin O B_LOCATION
loop O I_LOCATION
and O O
exterior O B_LOCATION/B_BIO
loops O I_LOCATION/I_BIO
in O O
all O O
the O O
isolates O B_BIO/B_LOCATION
. O O

Several O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
homologous O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
domains O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O O
observed O O
in O O
the O O
ITS O O
regions O B_GENE/B_DISEASE
of O O
Aedes O B_BIO/B_GENE
mosquito O B_BIO/I_GENE
species O B_BIO/I_GENE
by O O
Wesson O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

et O B_MEASURE/B_LOCATION
al O I_MEASURE/I_LOCATION
[ O O
11 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
was O O
shown O O
that O O
these O O
domains O B_MEASURE/B_GENE
base O I_MEASURE/I_GENE
pair O I_MEASURE/I_GENE
to O O

form O O
a O O
core O B_LOCATION
region O I_LOCATION
central O I_LOCATION
to O O

several O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stem O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
features O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

This O O
suggested O O
that O O
conserved O O
core O B_LOCATION/B_PERSON
region O I_LOCATION/I_PERSON
of O O
rDNA O B_GENE/B_BIO
is O O
more O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
rRNA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
folding O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE

pattern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Barker O O
found O O
that O O
ITS2 O O
is O O
unique O O
in O O
the O O
16 O O
populations O O
of O O
Boophilus B B_SPECIES[BIO]
microplus I I_SPECIES[BIO]
, O O
Boophilus B B_SPECIES[BIO]/B_LOCATION
decoloratus I B_SPECIES[BIO]/I_LOCATION
, O O

Rhipicephalus B B_BIO/B_PERSON
appendiculatus I I_BIO/I_PERSON
, O O
Rhipicephalus B B_SPECIES[BIO]/B_PERSON
zambesiensis I I_SPECIES[BIO]/I_PERSON
, O O
Rhipicephalus B B_SPECIES[BIO]
evertsi I I_SPECIES[BIO]
, O O
Rhipicephalus B B_SPECIES[BIO]/B_PERSON
sanguineus I I_SPECIES[BIO]/I_PERSON
, O O
Rhipicephalus O O

turanicus O O
, O O
Rhipicephalus B B_SPECIES[BIO]/B_LOCATION
pumilio I I_SPECIES[BIO]/I_LOCATION
and O O
Rhipicephalus B B_SPECIES[BIO]/B_PERSON
camicasi I I_SPECIES[BIO]/I_PERSON
from O O
different O O
geographical O O
locations O O
. O O

[ O O
12 O O
] O O
These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggest O O
that O O
the O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
similarity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O

in O O
the O O
ITS2 O B_GENE/B_MEASURE
of O O
different O B_SPECIES[BIO]
species O I_SPECIES[BIO]
are O O
not O O
simply O O
accumulated O O
due O O
to O O
random O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
have O O
evolved O O
for O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
selection O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]

in O O
ribosome O B_PERSON
biogenesis O I_PERSON
. O O

However O O
, O O
it O O
was O O
shown O O
in O O
three O O
related O O
mosquito O O
genera O O
( O O
Aedes O O
, O O
Psorophora O O
and O O
Haemogogus B B_PERSON/B_SPECIES[BIO]
) O O

that O O
the O O
intra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
spacer O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
variable O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
regions O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
appear O O
to O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
evolve O O
and O O
that O O
ITS2 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
variation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
constrained O O
by O O
its O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
11 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Further O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
demonstrated O O
that O O
the O O
ITS2 O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]

for O O
the O O
correct O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
efficient O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
processing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
maturation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
26S O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribosomal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
units O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

[ O B_OTHER/B_PERSON

13 O O
] O O
Furthermore O O
, O O
the O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
required O O
for O O
the O O
efficient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
removal O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
ITS2 O B_GENE/B_BACTERIUM[BIO]
from O O
its O O
RNA O B_LOCATION/B_PERSON
precursor O I_LOCATION/I_PERSON
is O O
not O O

localized O O
but O O
dispersed O O
throughout O O
the O O
ITS2 O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Thus O O
, O O
insertions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
and O O
deletions O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
indels O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
affect O O
secondary O B_DISEASE/B_GENE
structures O I_DISEASE/I_GENE

alter O O
rRNA O B_DISEASE_ADJECTIVE[DISEASE]
processing O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Critical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
rRNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
folding O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
due O O
to O O
evolutionary O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
sequence O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
variation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
the O O
ITS O O
spacer O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

regions O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
thus O O
have O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
kinetics O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
precursor O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
rRNA O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
for O O
the O O
efficient O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
functioning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O O
rDNA O B_GENE/B_BIO
clusters O I_GENE/I_BIO
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ITS2 O B_GENE/B_BIO
sequences O I_BIO
from O O
different O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
isolates O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Culex O B_BACTERIUM[BIO]
show O O
similarity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
variations O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Surprisingly O O
, O O
species O B_BIO/B_DISEASE
displaying O O

sequence O B_PERSON/B_LOCATION
similarity O I_PERSON/I_LOCATION
belong O O
to O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
geographical O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
locations O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O O
diverse O B_LOCATION/B_EDU[ORGANIZATION]
climatic O B_LOCATION/I_EDU[ORGANIZATION]
and O O
ecological O B_LOCATION/B_MEASURE
conditions O I_LOCATION/I_MEASURE
. O O

This O B_LOCATION/B_PERSON
implies O O
that O O

the O O
ITS2 O B_GENE/B_BIO
regions O I_GENE/I_BIO
have O O
less O O
selective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
than O O
the O O
ribosomal O B_MEASURE/B_LOCATION
regions O I_MEASURE/I_LOCATION
. O O

Several O B_PERSON/B_ENT
common O I_PERSON/I_ENT
structural O I_PERSON/I_ENT
folds O I_PERSON/I_ENT
were O O
shared O O
among O O
the O O

selected O O
mosquitoes O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
maintaining O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
equivalents O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Construction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
an O O
evolutionary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tree O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
using O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isolates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O

Culex O B_BIO/B_PERSON
will O O
provide O O
an O O
understanding O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
their O O
functional O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
selection O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Integration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
in O O
primary O B_LOCATION/B_ORGANIZATION
community O I_LOCATION/I_ORGANIZATION
care O I_LOCATION/I_ORGANIZATION
networks O I_LOCATION/I_ORGANIZATION
( O O
PCCNs O B_DISEASE/B_GENE
) O O
: O O
examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
governance O B_EDU[ORGANIZATION]/B_PERSON
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
marketing O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
financial O B_ORGANIZATION/B_PERSON
, O O
and O O
information O B_ORGANIZATION/B_PERSON
infrastructures O I_ORGANIZATION/I_PERSON
in O O
a O O
national O B_LOCATION/B_ORGANIZATION
demonstration O I_LOCATION/I_ORGANIZATION
project O I_LOCATION/I_ORGANIZATION
in O O
Taiwan O B_LOCATION

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Taiwan O O
' O O
s O O
primary O O
community O O
care O O
network O O
( O O
PCCN O O
) O O
demonstration O O
project O O
, O O
funded O O
by O O
the O O
Bureau O O
of O O
National O O
Health O O
Insurance O O
on O O
March O O
2003 O O
, O O
was O O
established O O
to O O
discourage O O
hospital O O
shopping O O
behavior O O
of O O
people B B_PERSON/B_LOCATION
and O O
drive O O
the O O
traditional O O
fragmented O O
health O O
care O O
providers O O
into O O
cooperate O O
care O O
models O O
. O O

Between O O
2003 O B_MEASURE
and O O
2005 O B_MEASURE
, O O
268 O B_NUMBER[MEASURE]/B_LOCATION
PCCNs O I_NUMBER[MEASURE]/I_LOCATION
were O O
established O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
profiled O O
the O O
individual O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
PCCNs O B_ORGANIZATION/B_LOCATION
to O O
study O O
the O O
nature O B_MEASURE/B_LOCATION
and O O
extent O B_MEASURE
to O O
which O O
their O O
network O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructures O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
integrated O O
among O O
the O O
members O B_PERSON/B_LOCATION
( O O
clinics O B_LOCATION/B_ORGANIZATION
and O O
hospitals O B_LOCATION/B_ORGANIZATION
) O O
within O O
individual O B_LOCATION/B_ORGANIZATION
PCCNs O I_LOCATION/I_ORGANIZATION
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
thorough O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
questionnaire O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
items O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
covering O O
the O O
network O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
working O O
infrastructures O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O O
governance O B_ORGANIZATION/B_PERSON
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
marketing O B_ORGANIZATION/B_SOCIAL_CIRCUMSTANCES
, O O
financial O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
information O B_ORGANIZATION
integration O I_ORGANIZATION
in O O
PCCNs O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
were O O
developed O O
with O O
validity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
reliability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
confirmed O O
. O O

One O B_NUMBER[MEASURE]/B_ENT
thousand O I_NUMBER[MEASURE]/I_ENT
five O I_NUMBER[MEASURE]/I_ENT
hundred O I_NUMBER[MEASURE]/I_ENT
and O O
fifty O B_NUMBER[MEASURE]
- O O
seven O B_NUMBER[MEASURE]/B_PERSON
clinics O I_NUMBER[MEASURE]/I_PERSON
that O O
had O O
belonged O O
to O O
PCCNs O B_LOCATION/B_PERSON
for O O
more O B_MEASURE/B_PERSON
than O O
one O B_TIME[MEASURE]
year O I_TIME[MEASURE]
, O O
based O O
on O O
the O O
2003 O B_MEASURE/B_LOCATION
- O O
2005 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Taiwan O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Primary O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Community O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Network O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
List O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
were O O
surveyed O O
by O O
mail O B_TIME[MEASURE]/B_PERSON
. O O

Nine O B_NUMBER[MEASURE]/B_LOCATION
hundred O I_NUMBER[MEASURE]/I_LOCATION
and O O
twenty O B_NUMBER[MEASURE]
- O O
eight O B_NUMBER[MEASURE]/B_ORGANIZATION
clinic O I_NUMBER[MEASURE]/I_ORGANIZATION
members O I_NUMBER[MEASURE]/I_ORGANIZATION
responded O O
to O O
the O O
surveys O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
giving O O
a O O
59 O B_MEASURE
. O O
6 O B_MEASURE
% O I_MEASURE
response O I_MEASURE
rate O I_MEASURE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Overall O O
, O O
the O O
PCCNs O B_ORGANIZATION/B_PERSON
' O I_ORGANIZATION/I_PERSON
members O I_ORGANIZATION/I_PERSON
had O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
involvement O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
the O O
governance O B_ORGANIZATION/B_LOCATION
infrastructure O B_ORGANIZATION/I_LOCATION
, O O
which O O
was O O
usually O O
viewed O O
as O O
the O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
establishment O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
core O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
PCCNs O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organization O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
management O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
integration O I_TIME[MEASURE]/I_LOCATION
stage O I_TIME[MEASURE]/I_LOCATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
it O O
found O O
that O O
there O O
existed O O
a O O
higher O B_MEASURE
extent O I_MEASURE
of O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
marketing O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
information O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructures O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
the O O
hospital O B_LOCATION/B_PERSON
- O O
clinic O B_PERSON/B_LOCATION
member O I_PERSON/I_LOCATION
relationship O I_PERSON/I_LOCATION
than O O
those O O
among O O
clinic O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
within O O
individual O B_LOCATION/B_ORGANIZATION
PCCNs O I_LOCATION/I_ORGANIZATION
. O O

The O O
financial O B_LOCATION/B_ORGANIZATION
infrastructure O I_LOCATION/I_ORGANIZATION
was O O
shown O O
the O O
least O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrated O O
relative O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
other O B_ORGANIZATION/B_PERSON
functional O I_ORGANIZATION/I_PERSON
infrastructures O I_ORGANIZATION/I_PERSON
at O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
stage O I_TIME[MEASURE]/I_LOCATION
of O O
PCCN O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

There O O
was O O
still O O
room O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
better O B_DISEASE_ADJECTIVE[DISEASE]
integrated O O
partnerships O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
evidenced O O
by O O
the O O
great O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
variety O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
of O O
relationships O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
extent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
provide O O
how O O
the O O
network O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
have O O
done O O
for O O
their O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
at O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
stage O I_TIME[MEASURE]/I_LOCATION
of O O
network O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forming O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
detailed O B_NUMBER[MEASURE]/B_LOCATION
surveyed O O
items O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
, O O
the O O
concepts O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
proposed O O
by O O
the O O
managerial O B_PERSON
and O O
theoretical O B_PERSON/B_ORGANIZATION
professionals O I_PERSON/I_ORGANIZATION
, O O
could O O
be O O
a O O
guide O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
those O O
health O B_PERSON/B_ORGANIZATION
care O I_PERSON/I_ORGANIZATION
providers O I_PERSON/I_ORGANIZATION
who O O
have O O
willingness O B_PERSON
to O O
turn O O
their O O
business O B_ORGANIZATION/B_PERSON
into O O
multi O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
organizations O B_ORGANIZATION/B_PERSON
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Taiwan O B_LOCATION/B_PERSON
' O I_LOCATION/I_PERSON
s O I_LOCATION/I_PERSON
National O I_LOCATION/I_PERSON
Health O I_LOCATION/I_PERSON
Insurance O I_LOCATION/I_PERSON
( O O
NHI O B_LOCATION/B_ORGANIZATION
) O O
under O O
the O O
control O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
Bureau O B_ORGANIZATION/B_PERSON
of O O
National O B_ORGANIZATION/B_LOCATION
Health O I_ORGANIZATION/I_LOCATION
Insurance O I_ORGANIZATION/I_LOCATION
( O O
BNHI O B_ORGANIZATION/B_LOCATION
) O O
, O O
was O O
launched O O
in O O
March O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1995 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
replace O O
its O O
social O B_PERSON/B_ORGANIZATION
insurance O I_PERSON/I_ORGANIZATION
system O I_PERSON/I_ORGANIZATION
that O O
was O O
covering O O
59 O B_PERSON/B_MEASURE
% O I_PERSON/I_MEASURE
of O O
its O O
population O B_PERSON/B_LOCATION
: O O
government O B_PERSON
employees O I_PERSON
, O O
labourers O B_PERSON/B_ORGANIZATION
, O O
farmers O B_PERSON
and O O
servicemen O B_PERSON
[ O O
1 O B_LOCATION/B_MEASURE
] O B_LOCATION/I_MEASURE
. O O

By O O
June O O
2003 O O
the O O
number O O
of O O
people B B_PERSON
insured O O
had O O
reached O O
21 O O
, O O
956 O O
, O O
729 O O
( O O
99 O O
% O O
) O O
. O O

There O O
were O O
17 O B_MEASURE
, O O
259 O B_MEASURE
medical O I_MEASURE
providers O I_MEASURE
( O O
92 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
including O O
575 O B_LOCATION/B_PERSON
hospitals O B_LOCATION/I_PERSON
and O O
16 O B_MEASURE
, O O
684 O B_TIME[MEASURE]
clinics O I_TIME[MEASURE]
contracted O O
with O O
the O O
BNHI O B_LOCATION/B_ORGANIZATION
for O O
serving O O
the O O
enrolled O B_LOCATION/B_PERSON
population O I_LOCATION/I_PERSON
. O O

The O O
unique O O
phenomenon O O
characterized O O
in O O
Taiwan O O
health O O
care O O
industry O O
different O O
from O O
those O O
in O O
the O O
western O O
countries O O
is O O
the O O
freedom O O
of O O
patients B B_PERSON
to O O
choose O O
the O O
health O O
care O O
providers O O
they O O
want O O
, O O
no O O
matter O O
what O O
their O O
disease O O
severity O O
is O O
. O O

Furthermore O O
, O O
Taiwan O O
people B B_PERSON/B_LOCATION
favor O O
the O O
larger O O
scales O O
of O O
facilities O O
and O O
this O O
fallacy O O
leads O O
to O O
the O O
phenomenon O O
of O O
big O O
- O O
hospital O O
shopping O O
. O O

For O O
example O O
, O O
people B B_PERSON/B_LOCATION
choose O O
the O O
medical O O
centers O O
which O O
are O O
accredited O O
as O O
the O O
highest O O
level O O
of O O
medical O O
science O O
in O O
Taiwan O O
when O O
they O O
only O O
suffer O O
from O O
a O O
common O O
cold O O
. O O

In O O
the O O
spring O O
of O O
2003 O O
, O O
the O O
SARS O O
epidemic O O
viciously O O
attacked O O
the O O
health O O
of O O
Taiwan O O
' O O
s O O
people B B_PERSON/B_ORGANIZATION
. O O

The O O
people B B_PERSON/B_LOCATION
' O O
s O O
freedom O O
to O O
choose O O
medical O O
providers O O
caused O O
the O O
national O O
health O O
authority O O
to O O
barely O O
control O O
and O O
traced O O
the O O
flow O O
of O O
epidemic O O
. O O

This O O
event O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
made O O
Taiwan O B_PERSON
national O I_PERSON
health O I_PERSON
authorities O I_PERSON
rethink O O
what O O
happened O O
and O O
how O O
it O O
damaged O O
under O O
the O O
traditional O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fragmented O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
health O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
care O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
providers O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
Taiwan O B_LOCATION
. O O

One O B_TIME[MEASURE]/B_ORGANIZATION
health O I_TIME[MEASURE]/I_ORGANIZATION
reform O I_TIME[MEASURE]/I_ORGANIZATION
launched O O
was O O
named O O
the O O
" O O
Primary O B_LOCATION/B_PERSON
Community O I_LOCATION/I_PERSON
Care O I_LOCATION/I_PERSON
Network O I_LOCATION/I_PERSON
( O O
PCCN O B_DISEASE/B_ORGANIZATION
) O O
demonstration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
" O O
, O O
a O O
nationwide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
financing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
funded O O
by O O
the O O
Bureau O B_ORGANIZATION/B_PERSON
of O O
National O B_LOCATION/B_ORGANIZATION
Health O I_LOCATION/I_ORGANIZATION
Insurance O I_LOCATION/I_ORGANIZATION
( O O
BNHI O B_ORGANIZATION/B_LOCATION
) O O
in O O
March O B_TIME[MEASURE]/B_LOCATION
2003 O I_TIME[MEASURE]/I_LOCATION
and O O
it O O
was O O
a O O
new O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
the O O
Taiwan O B_ORGANIZATION/B_LOCATION
government O I_ORGANIZATION/I_LOCATION
to O O
redefine O O
the O O
role O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
family O B_PERSON/B_ORGANIZATION
physicians O I_PERSON/I_ORGANIZATION
in O O
the O O
health O B_LOCATION/B_ORGANIZATION
care O I_LOCATION/I_ORGANIZATION
delivery O I_LOCATION/I_ORGANIZATION
system O I_LOCATION/I_ORGANIZATION
. O O

A O O
PCCN O B_LOCATION/B_PERSON
in O O
Taiwan O B_LOCATION
consists O O
of O O
a O O
group O B_ORGANIZATION/B_LOCATION
of O O
clinic O B_PERSON
physicians O I_PERSON
whose O O
medical O B_PERSON/B_LOCATION
jobs O I_PERSON/I_LOCATION
are O O
viewed O O
as O O
family O B_PERSON/B_ORGANIZATION
care O I_PERSON/I_ORGANIZATION
and O O
at O O
least O O
one O B_LOCATION/B_NUMBER[MEASURE]
hospital O B_LOCATION/I_NUMBER[MEASURE]
for O O
secondary O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
tertiary O B_LOCATION/B_TIME[MEASURE]
care O I_LOCATION/I_TIME[MEASURE]
. O O

The O O
idea O O
of O O
member O O
component O O
design O O
in O O
PCCNs O O
was O O
aimed O O
to O O
lead O O
the O O
Taiwan O O
citizens O O
to O O
choose O O
one O O
clinic O O
physician O O
as O O
their O O
personal O O
family O O
physician O O
for O O
health O O
maintenance O O
and O O
this O O
family O O
physician O O
also O O
would O O
have O O
the O O
responsibility O O
of O O
referring O O
the O O
patients B B_PERSON/B_LOCATION
to O O
specialty O O
care O O
if O O
necessary O O
. O O

From O O
a O O
national O O
health O O
authority O O
perspective O O
, O O
they O O
expected O O
the O O
Taiwan O O
people B B_PERSON/B_ORGANIZATION
to O O
put O O
an O O
end O O
to O O
their O O
fallacy O O
that O O
" O O
bigger O O
is O O
better O O
" O O
for O O
health O O
care O O
organizations O O
and O O
establish O O
the O O
idea O O
of O O
" O O
human B B_PERSON/B_LOCATION
health O O
" O O
, O O
starting O O
with O O
prevention O O
and O O
primary O O
care O O
, O O
followed O O
by O O
secondary O O
or O O
tertiary O O
care O O
, O O
emphasizing O O
health O O
promotion O O
and O O
maintenance O O
instead O O
of O O
disease O O
curing O O
. O O

Furthermore O O
, O O
it O O
could O O
decrease O O
the O O
inappropriateness O B_MEASURE/B_DISEASE
of O O
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
usage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
i O O
. O O
e O O
. O O
, O O
over O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
uses O B_PERSON/B_ORGANIZATION
of O O
secondary O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O O
tertiary O B_LOCATION/B_PERSON
medical O I_LOCATION/I_PERSON
services O I_LOCATION/I_PERSON
in O O
the O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
tech O B_LOCATION/B_MEASURE
hospitals O I_LOCATION/I_MEASURE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
national O B_ORGANIZATION/B_LOCATION
health O I_ORGANIZATION/I_LOCATION
authority O I_ORGANIZATION/I_LOCATION
was O O
expected O O
to O O
drive O O
the O O
traditional O B_PERSON/B_LOCATION
fragmented O I_PERSON/I_LOCATION
heath O I_PERSON/I_LOCATION
care O I_PERSON/I_LOCATION
providers O I_PERSON/I_LOCATION
into O O
coordinated O B_LOCATION/B_ORGANIZATION
medical O I_LOCATION/I_ORGANIZATION
multidisciplinary O I_LOCATION/I_ORGANIZATION
teams O I_LOCATION/I_ORGANIZATION
and O O
share O O
the O O
limited O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resources O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
through O O
the O O
PCCN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
demonstration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

In O O
summary O O
, O O
the O O
PCCN O O
demonstration O O
project O O
was O O
aimed O O
to O O
: O O
1 O O
) O O
change O O
the O O
traditional O O
patients B B_PERSON/B_LOCATION
' O O
customs O O
of O O
freely O O
choosing O O
health O O
care O O
organizations O O
and O O
establish O O
referral O O
channels O O
along O O
the O O
continuum O O
of O O
care O O
, O O
and O O
2 O O
) O O
establish O O
partnerships O O
among O O
the O O
primary O O
care O O
clinics O O
and O O
hospitals O O
to O O
provide O O
a O O
continuum O O
of O O
health O O
care O O
services O O
. O O

It O O
was O O
also O O
expected O O
to O O
establish O O
the O O
primary O O
care O O
system O O
of O O
family O O
physicians O O
to O O
provide O O
whole O O
- O O
people B B_PERSON/B_LOCATION
health O O
care O O
and O O
improve O O
care O O
quality O O
[ O O
1 O O
] O O
. O O

Partnership O B_ORGANIZATION/B_PERSON
structures O I_ORGANIZATION/I_PERSON
in O O
the O O
PCCNs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
represent O O
the O O
virtual O B_LOCATION/B_ORGANIZATION
vertical O I_LOCATION/I_ORGANIZATION
( O O
i O O
. O O
e O O
. O O
, O O
between O O
the O O
member O B_LOCATION/B_ORGANIZATION
clinics O I_LOCATION/I_ORGANIZATION
and O O
hospitals O B_LOCATION/B_ORGANIZATION
) O O
and O O
virtual O B_LOCATION/B_ORGANIZATION
horizontal O I_LOCATION/I_ORGANIZATION
( O O
i O O
. O O
e O O
. O O
, O O
among O O
the O O
member O B_PERSON/B_ORGANIZATION
clinics O I_PERSON/I_ORGANIZATION
) O O
aspects O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
organizing O B_TIME[MEASURE]/B_ORGANIZATION
, O O
which O O
designate O O
the O O
formal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relationships O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O O
individuals O B_PERSON/B_ORGANIZATION
and O O
the O O
total O B_ORGANIZATION/B_LOCATION
network O I_ORGANIZATION/I_LOCATION
and O O
include O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
ensure O O
effective O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
communication O I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
coordination O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O O
the O O
total O B_ORGANIZATION/B_LOCATION
network O I_ORGANIZATION/I_LOCATION
. O O

Each O O
PCCN O B_LOCATION/B_ORGANIZATION
consists O O
of O O
five O B_NUMBER[MEASURE]/B_LOCATION
to O O
ten O B_NUMBER[MEASURE]
clinics O I_NUMBER[MEASURE]
: O O
half O B_NUMBER[MEASURE]/B_PERSON
of O O
them O O
should O O
offer O O
the O O
services O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
general O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
medicine O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
internal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medicine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
, O O
obstetrics O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
gynecology O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
pediatric O B_DISEASE/B_PERSON
, O O
or O O
family O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
medicine O I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

And O O
each O O
PCCN O B_ORGANIZATION/B_LOCATION
has O O
a O O
central O B_LOCATION/B_PERSON
headquarters O I_LOCATION/I_PERSON
, O O
usually O O
in O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
clinic O B_LOCATION
facilities O I_LOCATION
, O O
to O O
coordinate O O
and O O
integrate O O
the O O
network O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
the O O
clinic O O
physicians O O
in O O
a O O
PCCN O O
are O O
assigned O O
the O O
roles O O
of O O
" O O
family O O
physicians O O
" O O
or O O
" O O
gatekeepers O O
" O O
who O O
recruit O O
people B B_PERSON
from O O
the O O
local O O
community O O
, O O
keep O O
background O O
and O O
medical O O
files O O
on O O
them O O
, O O
certify O O
family O O
physician O O
education O O
training O O
programs O O
, O O
and O O
hold O O
office O O
hours O O
in O O
the O O
member O O
hospital O O
, O O
where O O
they O O
serve O O
as O O
joint O O
faculty O O
members O O
for O O
further O O
medical O O
consultations O O
or O O
medical O O
utilizations O O
of O O
labs O O
and O O
tests O O
, O O
if O O
necessary O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
hospital O B_PERSON/B_ORGANIZATION
member O B_PERSON/I_ORGANIZATION
is O O
asked O O
to O O
help O O
clinic O B_PERSON/B_LOCATION
physicians O I_PERSON/I_LOCATION
in O O
their O O
network O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
set O O
up O O
a O O
medical O B_LOCATION/B_ORGANIZATION
information O I_LOCATION/I_ORGANIZATION
system O I_LOCATION/I_ORGANIZATION
, O O
share O B_ORGANIZATION/B_LOCATION
hospital O I_ORGANIZATION/I_LOCATION
resources O I_ORGANIZATION/I_LOCATION
( O O
medical O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
equipment O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
library O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
literature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O O
with O O
the O O
clinic O B_PERSON/B_LOCATION
physicians O I_PERSON/I_LOCATION
in O O
their O O
network O B_ORGANIZATION/B_LOCATION
and O O
establish O O
referral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
channels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
among O O
the O O
network O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
. O O

Furthermore O O
, O O
this O O
new O O
demonstration O O
model O O
tries O O
to O O
minimize O O
the O O
barriers O O
to O O
patient B B_PERSON/B_PRODUCT[OBJECT]
access O O
by O O
setting O O
up O O
24 O O
- O O
hour O O
a O O
day O O
, O O
7 O O
- O O
day O O
a O O
week O O
medical O O
consultation O O
telephone O O
lines O O
for O O
providing O O
urgent O O
services O O
onsite O O
and O O
for O O
taking O O
care O O
of O O
the O O
patients B B_PERSON
whose O O
family O O
physicians O O
' O O
practices O O
are O O
closed O O
to O O
assure O O
seamless O O
care O O
channels O O
. O O

The O O
BNHI O B_ORGANIZATION/B_LOCATION
funded O O
these O O
extra O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
demonstration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
actions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
at O O
around O O
one O B_MEASURE/B_PERSON
hundred O I_MEASURE/I_PERSON
thousand O I_MEASURE/I_PERSON
US O I_MEASURE/I_PERSON
dollars O I_MEASURE/I_PERSON
( O O
i O O
. O O
e O O
. O O
, O O
NT O O
$ O O
3 O B_MEASURE
, O O
500 O B_MEASURE
, O O
000 O B_MEASURE/B_LOCATION
) O O
for O O
each O O
PCCN O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O O
the O O
current O B_MEASURE/B_PERSON
fee O I_MEASURE/I_PERSON
- O O
for O O
- O O
service O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
payment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O O
1 O B_LOCATION/B_PERSON
] O I_LOCATION/I_PERSON
. O O

Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
describes O O
the O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
individual O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCCNs O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introduced O O
in O O
the O O
demonstration O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
project O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Taiwan O B_LOCATION
. O O

To O O
date O B_TIME[MEASURE]/B_PERSON
, O O
the O O
PCCN O B_LOCATION/B_ORGANIZATION
demonstration O I_LOCATION/I_ORGANIZATION
project O I_LOCATION/I_ORGANIZATION
has O O
been O O
in O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
for O O
more O B_MEASURE
than O O
three O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
. O O

There O O
have O O
been O O
268 O B_LOCATION/B_ORGANIZATION
PCCNs O I_LOCATION/I_ORGANIZATION
formed O O
in O O
the O O
period O B_TIME[MEASURE]/B_LOCATION
of O O
2003 O B_MEASURE
to O O
2005 O B_MEASURE
around O O
Taiwan O B_LOCATION
. O O

The O O
geographical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
distributions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
PCCNs O B_PERSON/B_BIO
and O O
their O O
members O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
described O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Analyzing O O
all O O
1 O B_MEASURE
, O O
557 O B_MEASURE
participating O O
clinic O B_LOCATION/B_ORGANIZATION
members O I_LOCATION/I_ORGANIZATION
in O O
the O O
demonstration O B_LOCATION/B_ORGANIZATION
project O I_LOCATION/I_ORGANIZATION
in O O
terms O B_NUMBER[MEASURE]/B_DISEASE
of O O
medical O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
specialties O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
they O O
cover O O
general O B_DISEASE/B_PERSON
medicine O I_DISEASE/I_PERSON
, O O
internal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medicine O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
surgeries O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
obstetrics O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
gynecology O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pediatrics O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
family O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
medicines O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
otolaryngology O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
ophthalmology O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
rehabilitation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medicine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
dermatology O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
and O O
psychiatry O B_DISEASE/B_PERSON
, O O
with O O
237 O B_NUMBER[MEASURE]/B_PERSON
clinics O I_NUMBER[MEASURE]/I_PERSON
providing O O
more O B_MEASURE/B_PERSON
than O O
two O B_NUMBER[MEASURE]/B_LOCATION
specialties O I_NUMBER[MEASURE]/I_LOCATION
. O O

On O O
the O O
other O B_PERSON/B_LOCATION
hand O I_PERSON/I_LOCATION
, O O
each O O
PCCN O B_LOCATION/B_ORGANIZATION
recruits O O
at O O
least O O
one O B_LOCATION
district O I_LOCATION
or O O
regional O B_LOCATION/B_ORGANIZATION
accredited O I_LOCATION/I_ORGANIZATION
hospital O I_LOCATION/I_ORGANIZATION
for O O
acute O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
care O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
demands O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
required O O
for O O
network O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
) O O
and O O
a O O
medical O B_LOCATION/B_PERSON
center O B_LOCATION/I_PERSON
for O O
tertiary O B_PERSON
care O I_PERSON
support O I_PERSON
( O O
not O O
required O O
for O O
network O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
) O O
. O O

There O O
are O O
6 O B_LOCATION
medical O I_LOCATION
centers O I_LOCATION
, O O
52 O B_LOCATION/B_ORGANIZATION
regional O I_LOCATION/I_ORGANIZATION
hospitals O I_LOCATION/I_ORGANIZATION
, O O
and O O
71 O B_LOCATION/B_PERSON
district O B_LOCATION/I_PERSON
hospitals O B_LOCATION/I_PERSON
joining O O
in O O
the O O
demonstration O B_LOCATION/B_ORGANIZATION
project O I_LOCATION/I_ORGANIZATION
. O O

See O O
Table O B_LOCATION/B_ORGANIZATION
1 O I_LOCATION/I_ORGANIZATION
for O O
more O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
about O O
the O O
PCCN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
members O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

To O O
date O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
have O O
been O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
empirical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
working O O
relationships O B_PERSON/B_LOCATION
that O O
have O O
developed O O
between O O
members O B_PERSON/B_LOCATION
of O O
the O O
PCCN O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Partnership O B_ORGANIZATION/B_LOCATION
needs O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
determine O O
at O O
an O O
early O B_MEASURE/B_LOCATION
stage O I_MEASURE/I_LOCATION
, O O
to O O
make O O
sure O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whether O O
they O O
are O O
making O O
the O O
most O B_MEASURE/B_DISEASE
of O O
collaboration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
2 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
acceptance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
contracting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
networks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O O
Taiwan O B_LOCATION
as O O
an O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
innovation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
worthy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
greater O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diffusion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deserves O O
to O O
be O O
explored O O
. O O

Therefore O O
, O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
used O O
a O O
structured O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
questionnaire O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
characterize O O
the O O
relationship O B_PERSON
among O O
the O O
members O B_PERSON/B_ORGANIZATION
in O O
the O O
individual O B_ORGANIZATION/B_LOCATION
PCCNs O I_ORGANIZATION/I_LOCATION
, O O
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
governance O B_ORGANIZATION/B_PERSON
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
marketing O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
financing O B_PERSON/B_ORGANIZATION
, O O
as O O
well O O
as O O
information O B_ORGANIZATION/B_PERSON
integration O I_ORGANIZATION/I_PERSON
infrastructures O I_ORGANIZATION/I_PERSON
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
descriptive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
detail O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
map O O
the O O
partnership O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
developments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
to O O
enrich O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
knowledge O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
partner O B_ORGANIZATION/B_LOCATION
relationships O I_ORGANIZATION/I_LOCATION
and O O
to O O
help O O
policy O B_PERSON
makers O I_PERSON
understand O O
the O O
coordinated O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
these O O
health O B_ORGANIZATION/B_PERSON
care O I_ORGANIZATION/I_PERSON
providers O I_ORGANIZATION/I_PERSON
which O O
have O O
developed O O
under O O
this O O
system O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
also O O
provides O O
the O O
recommendations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
heath O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
policy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
decision O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
- O O
making O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
management O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
networks O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
providers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
the O O
future O B_LOCATION/B_ORGANIZATION
involvement O I_LOCATION/I_ORGANIZATION
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O O
aimed O O
at O O
providing O O
descriptive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
map O O
the O O
partnership O B_LOCATION/B_ORGANIZATION
development O I_LOCATION/I_ORGANIZATION
. O O

To O O
understand O O
the O O
actual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
integration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
actions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
done O O
by O O
network O B_ORGANIZATION/B_PERSON
members O I_ORGANIZATION/I_PERSON
, O O
the O O
theoretical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
concept O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
employed O O
by O O
network O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partnerships O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
described O O
and O O
then O O
the O O
derived O O
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
instrument O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
developed O O
. O O

Theoretical O B_TIME[MEASURE]/B_PERSON
framework O B_TIME[MEASURE]/I_PERSON
for O O
organization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
network O B_ORGANIZATION/B_LOCATION
integration O I_ORGANIZATION/I_LOCATION

The O O
rapid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
organizational O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
health O B_LOCATION/B_ORGANIZATION
care O I_LOCATION/I_ORGANIZATION
industry O I_LOCATION/I_ORGANIZATION
have O O
driven O O
theorists O B_PERSON/B_ORGANIZATION
from O O
every O O
discipline O B_PERSON/B_LOCATION
and O O
across O O
the O O
world O B_LOCATION/B_ORGANIZATION
to O O
seek O O
an O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
allows O O
organizations O B_ORGANIZATION/B_PERSON
to O O
flourish O O
. O O

Organization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
allows O O
investigators O B_PERSON
to O O
profile O O
an O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
aspect O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patterns O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
regularities O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
organizational O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
design O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
behavior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
. O O

In O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
20th O I_TIME[MEASURE]/I_LOCATION
century O I_TIME[MEASURE]/I_LOCATION
, O O
classical O B_PERSON/B_ORGANIZATION
management O I_PERSON/I_ORGANIZATION
theorists O I_PERSON/I_ORGANIZATION
claimed O O
that O O
an O O
organization O B_ORGANIZATION/B_PERSON
has O O
" O O
a O O
best O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
way O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
" O O
to O O
be O O
organized O O
and O O
managed O O
[ O O
3 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

That O O
implied O O
that O O
all O O
organizations O B_ORGANIZATION/B_PERSON
would O O
own O O
the O O
" O B_LOCATION
same O I_LOCATION
" O I_LOCATION
organizational O I_LOCATION
styles O I_LOCATION
or O O
structures O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
1960s O B_TIME[MEASURE]/B_LOCATION
, O O
several O B_PERSON
theorists O I_PERSON
[ O O
4 O B_MEASURE
- O O
8 O B_MEASURE
] O I_MEASURE
challenged O O
this O O
assumption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
by O O
applying O O
a O O
" O O
contingency O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
" O O
to O O
propose O O
that O O
there O O
is O O
no O O
best O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
way O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
organize O O
an O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
that O O
the O O
effectiveness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
an O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
varies O O
with O O
the O O
situation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
an O O
organization O B_ORGANIZATION/B_PERSON
. O O

Furthermore O O
, O O
it O O
is O O
proposed O O
that O O
the O O
best O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
way O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
organize O O
an O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depends O O
on O O
the O O
nature O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
environment O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
which O O
the O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relates O O
. O O

Contingency O B_PERSON/B_EDU[ORGANIZATION]
theory O I_PERSON/I_EDU[ORGANIZATION]
delineates O O
the O O
concepts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
" O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
organization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
internal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
features O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
" O O
" O O
the O O
demands O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
environments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
" O O
" O O
best O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
adaptation O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
" O O
and O O
, O O
the O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
all O O
, O O
" O O
best O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
match O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
9 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Lawrence O B_PERSON
& O O
Lorsch O B_PERSON
[ O O
7 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
argued O O
that O O
environments O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characterized O O
by O O
uncertainty O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
rapid O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
change O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
in O O
market O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
technology O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impose O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
demands O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
constraints O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
opportunities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
on O O
organizations O B_ORGANIZATION/B_PERSON
than O O
do O O
placid O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
environments O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Similarly O O
to O O
Lawrence O B_PERSON
and O O
Lorsch O B_PERSON
' O I_PERSON
s O I_PERSON
views O I_PERSON
mentioned O O
above O O
, O O
Galbraith O B_PERSON
[ O O
10 O B_MEASURE
, O O
11 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
stressed O O
the O O
contingency O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
information O B_DISEASE_ADJECTIVE[DISEASE]
processing O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
processing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
emphasizes O O
that O O
environment O B_LOCATION/B_MEASURE
, O O
size O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
technology O B_ORGANIZATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impose O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
processing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
requirements O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
organizations O B_ORGANIZATION/B_PERSON
, O O
and O O
thus O O
an O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O O
be O O
designed O O
to O O
encourage O O
information O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
flow O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O O
both O O
vertical O B_LOCATION/B_MEASURE
and O O
horizontal O B_MEASURE/B_LOCATION
directions O B_MEASURE/I_LOCATION
to O O
achieve O O
the O O
overall O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tasks O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
organization O B_ORGANIZATION/B_PERSON
and O O
, O O
finally O O
, O O
organizational O B_MEASURE/B_LOCATION
effectiveness O I_MEASURE/I_LOCATION
[ O I_MEASURE/I_LOCATION
11 O I_MEASURE/I_LOCATION
- O O
14 O B_MEASURE
] O I_MEASURE
. O O

Some O O
theorists O B_PERSON/B_ORGANIZATION
have O O
criticized O O
conventional O B_PERSON/B_ORGANIZATION
contingency O I_PERSON/I_ORGANIZATION
theorists O I_PERSON/I_ORGANIZATION
who O O
presume O O
that O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
driven O O
by O O
the O O
environment O B_LOCATION/B_PERSON
. O O

Child O B_PERSON
[ O O
15 O B_MEASURE
] O I_MEASURE
, O O
Miller O B_PERSON
[ O I_PERSON
16 O I_PERSON
] O I_PERSON
, O O
Van O B_PERSON
de O I_PERSON
Ven O I_PERSON
and O O
Drazin O B_PERSON
[ O O
17 O B_MEASURE
] O I_MEASURE
, O O
and O O
Tushman O B_PERSON
and O O
Romanelli O B_PERSON
[ O O
18 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
raised O O
such O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
criticisms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
they O O
argued O O
that O O
organizations O B_ORGANIZATION/B_PERSON
become O O
what O O
they O O
are O O
not O O
only O O
because O O
of O O
the O O
environment O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
also O O
because O O
of O O
choices O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
made O O
by O O
members O B_PERSON/B_ORGANIZATION
, O O
especially O O
choices O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
strategy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
and O O
organizational O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
design O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

As O O
Thompson O B_PERSON
' O I_PERSON
s O I_PERSON
words O I_PERSON
in O O
the O O
book O B_ORGANIZATION/B_PERSON
Organizations O I_ORGANIZATION/I_PERSON
in O O
Action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
[ O O
8 O B_PERSON/B_LOCATION
] O I_PERSON/I_LOCATION
put O O
it O O
, O O
" O O
organizations O B_ORGANIZATION/B_PERSON
are O O
not O O
determined O O
simply O O
by O O
their O O
environments O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_MEASURE/B_GENE
. O O
27 O B_MEASURE
) O O
. O O
" O O
He O O
also O O
pointed O O
out O O
that O O
" O O
administration O B_ORGANIZATION/B_PERSON
may O O
innovate O O
on O O
any O O
or O O
all O O
of O O
the O O
necessary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dimensions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
but O O
only O O
to O O
the O O
extent O B_DISEASE/B_MEASURE
that O O
innovations O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
acceptable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
those O O
on O O
whom O O
the O O
organization O B_ORGANIZATION/B_PERSON
can O O
and O O
must O O
depend O O
. O O
" O O
Instead O O
of O O
assuming O O
that O O
administrators O B_PERSON/B_ORGANIZATION
are O O
highly O O
constrained O O
in O O
their O O
decisions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
strategic O B_PERSON/B_ORGANIZATION
contingency O I_PERSON/I_ORGANIZATION
theorists O I_PERSON/I_ORGANIZATION
emphasized O O
" O B_DISEASE/B_LOCATION
the O O
importance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
choice O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
" O O
that O O
is O O
, O O
" O O
the O O
freedom O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
agency O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
15 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Furthermore O O
, O O
Pfeffer O B_PERSON
[ O O
19 O B_LOCATION/B_PERSON
] O I_LOCATION/I_PERSON
explicitly O O
pointed O O
out O O
that O O
" O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
the O O
outcomes O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
political O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
contests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
within O O
organizations O B_ORGANIZATION/B_LOCATION
( O O
p O B_MEASURE/B_GENE
. O O
38 O B_MEASURE
) O O
. O O
" O O

Daft O B_PERSON
[ O O
14 O B_PERSON
] O I_PERSON
proposed O O
a O O
top O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
delineate O O
how O O
" O O
a O O
strategy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
is O O
a O O
plan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
interacting O O
with O O
the O O
competitive O B_PERSON/B_LOCATION
environment O I_PERSON/I_LOCATION
to O O
achieve O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
" O O
He O O
stated O O
that O O
the O O
major O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responsibility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
top O B_ORGANIZATION/B_PERSON
management O B_ORGANIZATION/I_PERSON
is O O
to O O
determine O O
the O O
goals O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
strategy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
and O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
an O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
adapt O O
to O O
a O O
changing O O
environment O B_LOCATION
. O O

To O O
assess O O
the O O
external O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
internal O B_LOCATION/B_ORGANIZATION
environments O I_LOCATION/I_ORGANIZATION
of O O
an O O
organization O B_ORGANIZATION/B_LOCATION
seems O O
to O O
be O O
the O O
first O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
task O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
top O B_PERSON
managers O I_PERSON
in O O
defining O O
an O O
organization O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
goals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
missions O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Then O O
, O O
guided O O
by O O
the O O
goals O O
and O O
missions O O
of O O
the O O
organization O O
, O O
top O O
managers O O
shape O O
the O O
design O O
of O O
the O O
organization O O
, O O
including O O
structural O O
forms O O
, O O
information O O
system O O
, O O
technology O O
, O O
human B B_PERSON/B_SPECIES[BIO]
resources O O
, O O
organizational O O
culture O O
, O O
and O O
inter O O
- O O
organizational O O
linkages O O
, O O
to O O
achieve O O
the O O
final O O
organizational O O
performance O O
. O O

Integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
refers O O
to O O
the O O
mechanisms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
coordination O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
ways O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
guided O O
to O O
partnership O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
fit O O
internal O B_TIME[MEASURE]/B_LOCATION
and O O
external O B_LOCATION/B_ORGANIZATION
conditions O I_LOCATION/I_ORGANIZATION
[ O O
7 O B_MEASURE
, O O
20 O B_MEASURE
, O O
21 O B_MEASURE
] O I_MEASURE
. O O

In O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
1990s O I_TIME[MEASURE]/I_LOCATION
, O O
proposals O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
US O B_ORGANIZATION
national O I_ORGANIZATION
health O I_ORGANIZATION
care O I_ORGANIZATION
reform O I_ORGANIZATION
recognized O O
the O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
integrating O O
mechanisms O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
achieve O O
both O O
financial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
success O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
care O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
well O O
- O O
organized O O
system O B_ORGANIZATION/B_LOCATION
of O O
care O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
[ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
22 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
23 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Several O B_PERSON
researchers O I_PERSON
also O O
viewed O O
inter O B_LOCATION/B_PERSON
- O O
organizational O B_ORGANIZATION/B_LOCATION
cooperation O I_ORGANIZATION/I_LOCATION
as O O
resource O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchanges O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
client O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
referrals O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
money O B_ORGANIZATION/B_PERSON
, O O
and O O
staff O B_PERSON/B_ORGANIZATION
[ O O
24 O B_MEASURE
- O O
27 O B_TIME[MEASURE]
] O I_TIME[MEASURE]
. O O

From O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ways O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
viewing O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
success O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lies O O
in O O
the O O
coordinative O B_ORGANIZATION/B_PERSON
mechanisms O I_ORGANIZATION/I_PERSON
and O O
partnership O B_ORGANIZATION/B_PERSON
working O O
that O O
support O B_PERSON/B_TIME[MEASURE]
it O O
[ O O
28 O B_TIME[MEASURE]
] O I_TIME[MEASURE]
, O O
including O O
an O O
administrative O B_ORGANIZATION/B_LOCATION
organization O I_ORGANIZATION/I_LOCATION
that O O
coordinates O O
the O O
operations O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
various O B_ORGANIZATION/B_LOCATION
health O I_ORGANIZATION/I_LOCATION
care O I_ORGANIZATION/I_LOCATION
services O I_ORGANIZATION/I_LOCATION
; O O
a O O
management O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
integrates O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
utilization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
and O O
financial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
follows O O
clients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
settings O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
a O O
care O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
coordination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
or O O
disease O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
works O O
with O O
clients O B_PERSON/B_ORGANIZATION
to O O
arrange O O
health O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
care O I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
services O I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
and O O
a O O
financial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanism O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
enables O O
pooling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
funds O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O O
services O B_MEASURE
[ O I_MEASURE
29 O I_MEASURE
- O O
35 O B_MEASURE
] O I_MEASURE
. O O

Fox O B_PERSON/B_ORGANIZATION
[ O O
36 O B_ORGANIZATION/B_PERSON
] O I_ORGANIZATION/I_PERSON
suggested O O
the O O
success O B_MEASURE/B_ORGANIZATION
of O O
integrated O B_ORGANIZATION/B_PERSON
health O I_ORGANIZATION/I_PERSON
networks O I_ORGANIZATION/I_PERSON
should O O
ensure O O
that O O
the O O
new O B_ORGANIZATION/B_PERSON
business O I_ORGANIZATION/I_PERSON
link O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
aspects O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
as O O
technology O B_ORGANIZATION/B_PERSON
, O O
functional O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
skills O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
customer O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
access O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
management O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
products O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
can O O
be O O
shared O O
across O O
both O O
the O O
core O B_PERSON/B_ORGANIZATION
and O O
the O O
new O B_ORGANIZATION/B_LOCATION
business O I_ORGANIZATION/I_LOCATION
; O O
to O O
conduct O O
market O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
financial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
; O O
to O O
share O O
the O O
risk O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vertical O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
integration O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
with O O
outside O B_PERSON/B_ORGANIZATION
entities O B_PERSON/I_ORGANIZATION
, O O
to O O
develop O O
the O O
management O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
can O O
reflect O O
the O O
degree O B_MEASURE/B_ORGANIZATION
of O O
coordination O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necessary O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
support O O
the O O
core O B_ORGANIZATION/B_PERSON
business O I_ORGANIZATION/I_PERSON
activities O I_ORGANIZATION/I_PERSON
; O O
to O O
ensure O O
that O O
the O O
integration O B_ORGANIZATION/B_LOCATION
strategy O I_ORGANIZATION/I_LOCATION
meets O O
the O O
needs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
customers O B_PERSON/B_ORGANIZATION
, O O
including O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
the O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
medical O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
technology O I_ORGANIZATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
preferred O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
purchase O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
and O O
to O O
measure O O
the O O
new O B_ORGANIZATION/B_LOCATION
business O I_ORGANIZATION/I_LOCATION
by O O
its O O
value O B_MEASURE/B_ORGANIZATION
to O O
the O O
enterprise O B_ORGANIZATION/B_LOCATION
as O O
a O O
whole O B_MEASURE/B_ORGANIZATION
, O O
rather O O
than O O
by O O
its O O
profitability O B_MEASURE/B_ORGANIZATION
as O O
a O O
stand O O
- O O
alone O O
entity O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
summary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
inter O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
organizational O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
designs O I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
on O O
network O B_ORGANIZATION/B_PERSON
management O I_ORGANIZATION/I_PERSON
were O O
substantial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
a O O
managerial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Borrowing O O
the O O
ideas O O
of O O
strategic O O
contingency O O
perspective O O
[ O O
8 O O
, O O
15 O O
, O O
19 O O
] O O
and O O
top O O
management O O
model O O
[ O O
14 O O
] O O
, O O
it O O
could O O
be O O
imply O O
that O O
success O O
( O O
organization O O
performance O O
) O O
in O O
reengineering O O
a O O
network O O
lies O O
in O O
the O O
integration O O
of O O
process O O
and O O
services O O
( O O
see O O
Figure O O
1 O O
) O O
, O O
including O O
leadership O O
/ O O
governing O O
structure O O
, O O
teamwork O O
between O O
disciplines O O
and O O
patient B B_PERSON/B_LOCATION
care O O
, O O
financial O O
planning O O
, O O
and O O
information O O
systems O O
, O O
characterized O O
as O O
the O O
constructs O O
of O O
governance O O
, O O
clinical O O
, O O
financial O O
, O O
and O O
information O O
infrastructures O O
, O O
respectively O O
, O O
in O O
this O O
study O O
. O O

In O O
addition O O
, O O
another O O
construct O O
, O O
marketing O O
infrastructure O O
, O O
was O O
especially O O
important O O
and O O
designed O O
to O O
explore O O
for O O
PCCNs O O
in O O
this O O
study O O
because O O
of O O
patients B B_PERSON/B_ORGANIZATION
' O O
freedom O O
of O O
making O O
healthcare O O
choice O O
and O O
the O O
traditional O O
fragmented O O
health O O
care O O
systems O O
by O O
individual O O
health O O
care O O
organizations O O
in O O
Taiwan O O
. O O

One O O
major O O
reason O O
for O O
Taiwan O O
people B B_PERSON/B_LOCATION
' O O
s O O
hospital O O
shopping O O
preferences O O
was O O
that O O
Taiwan O O
people B B_PERSON
usually O O
believe O O
the O O
bigger O O
the O O
facility O O
, O O
the O O
better O O
capacities O O
a O O
facility O O
has O O
no O O
matter O O
on O O
any O O
aspect O O
from O O
medical O O
professionals O O
to O O
tangible O O
medical O O
equipment O O
and O O
plants O O
. O O

And O O
this O O
fallacy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
made O O
the O O
public O B_ORGANIZATION/B_PERSON
want O O
to O O
overuse O O
the O O
facility O B_LOCATION/B_ORGANIZATION
with O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
tech O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medical O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
services O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
no O O
matter O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
if O O
it O O
fits O O
their O O
needs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

From O O
the O O
health O B_ORGANIZATION/B_PERSON
policy O I_ORGANIZATION/I_PERSON
and O O
management O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
perspectives O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
therefore O O
, O O
the O O
health O B_PERSON/B_ORGANIZATION
care O I_PERSON/I_ORGANIZATION
providers O I_PERSON/I_ORGANIZATION
were O O
encouraged O O
to O O
market O O
their O O
services O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
new O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corporate O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identity O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
brand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
strategy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O O
37 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
, O O
including O O
offering O O
tangible O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resources O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
books O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
libraries O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
medical O B_ORGANIZATION/B_LOCATION
equipment O I_ORGANIZATION/I_LOCATION
, O O
and O O
intangible O B_LOCATION/B_ORGANIZATION
resources O B_LOCATION/I_ORGANIZATION
such O B_LOCATION/I_ORGANIZATION
as O O
knowledge O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
exchanges O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
education O B_PERSON/B_MEASURE
) O O
and O O
reputation O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
sharing O O
one O B_NUMBER[MEASURE]/B_LOCATION
another O O
among O O
PCCN O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
. O O

Furthermore O O
, O O
through O O
the O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
marketing O O
resource O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
exchanges O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
therefore O O
, O O
each O O
PCCN O B_ORGANIZATION/B_PERSON
could O O
establish O O
the O O
images O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O O
" O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
one O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
brand O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
quality O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
for O O
the O O
public O B_ORGANIZATION/B_PERSON
and O O
for O O
the O O
health O B_ORGANIZATION/B_PERSON
care O I_ORGANIZATION/I_PERSON
providers O I_ORGANIZATION/I_PERSON
. O O

It O O
also O O
makes O O
it O O
be O O
more O O
visible O B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
public O B_ORGANIZATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
five O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
integration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
infrastructures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
network O B_LOCATION/B_ORGANIZATION
management O I_LOCATION/I_ORGANIZATION
were O O
constructed O O
as O O
a O O
conceptual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
framework O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
help O O
to O O
portray O O
how O O
the O O
PCCN O B_ORGANIZATION/B_PERSON
members O I_ORGANIZATION/I_PERSON
have O O
done O O
. O O

The O O
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
described O O
in O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
. O O

Survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
integration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
infrastructures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
partnerships O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Based O O
on O O
the O O
five O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
integration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
infrastructures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
network O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
management O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
structured O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
questionnaire O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
derived O O
from O O
extensive O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
literature O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Governance O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION

Governance O B_ORGANIZATION/B_PERSON
assumes O O
the O O
broad O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responsibility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
survival O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
involves O O
the O O
series O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
setting O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
monitoring O O
organizational O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
goals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
strategy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
through O O
a O O
board O B_ORGANIZATION/B_LOCATION
of O O
representatives O B_PERSON
[ O O
38 O B_MEASURE/B_PERSON
] O B_MEASURE/I_PERSON
. O O

Governance O O
or O O
administrative O O
integration O O
infrastructure O O
in O O
establishing O O
network O O
partnerships O O
refers O O
to O O
administrative O O
structures O O
( O O
or O O
responsibilities O O
) O O
created O O
to O O
facilitate O O
communication O O
, O O
clear O O
lines O O
of O O
authority O O
, O O
accountability O O
, O O
and O O
responsibility O O
for O O
patient B B_PERSON
care O O
services O O
; O O
to O O
negotiate O O
budgets O O
and O O
financial O O
trade O O
- O O
offs O O
; O O
and O O
to O O
present O O
a O O
cohesive O O
, O O
consistent O O
message O O
in O O
interactions O O
with O O
external O O
agencies O O
and O O
the O O
community O O
[ O O
29 O O
, O O
39 O O
- O O
41 O O
] O O
and O O
most O O
important O O
for O O
members O O
in O O
contract O O
agreements O O
, O O
to O O
manage O O
participation O O
[ O O
33 O O
] O O
. O O

From O O
a O O
multidisciplinary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
Mitchell O B_PERSON/B_COLOR
and O O
Shortell O B_PERSON/B_COLOR
[ O O
42 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
applied O O
the O O
concepts O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
governance O B_ORGANIZATION/B_PERSON
and O O
management O B_ORGANIZATION/B_PERSON
characteristics O I_ORGANIZATION/I_PERSON
in O O
effective O B_LOCATION/B_ORGANIZATION
community O I_LOCATION/I_ORGANIZATION
health O I_LOCATION/I_ORGANIZATION
partnerships O I_LOCATION/I_ORGANIZATION
. O O

The O O
construct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
governance O B_ORGANIZATION/B_PERSON
involved O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tasks O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
setting O O
priorities O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
strategic O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
choosing O O
the O O
membership O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
composition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
obtaining O O
the O O
necessary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
financial O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
resources O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
and O O
setting O O
up O O
the O O
accountability O B_ORGANIZATION/B_LOCATION
systems O I_ORGANIZATION/I_LOCATION
, O O
and O O
so O O
on O O
. O O

The O O
construct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
management O B_PERSON/B_ORGANIZATION
refers O O
to O O
the O O
tasks O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
engaging O O
and O O
maintaining O O
organizational O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
' O I_PERSON/I_ORGANIZATION
interest O I_PERSON/I_ORGANIZATION
in O O
a O O
shared O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vision O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
mission O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
providing O O
appropriate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
coordination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanisms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
the O O
specified O O
strategies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
promoting O O
constructive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conflicts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
managing O O
destructive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conflicts O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
implementing O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
monitor O O
the O O
dynamics O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
adjusting O O
the O O
leadership O B_PERSON
in O O
the O O
overall O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
membership O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
so O O
on O O
. O O

The O O
issues O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
governance O B_ORGANIZATION
and O O
administrative O B_ORGANIZATION/B_PERSON
integration O I_ORGANIZATION/I_PERSON
in O O
the O O
PCCNs O B_LOCATION/B_ORGANIZATION
could O O
include O O
[ O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
, O O
38 O B_MEASURE
, O O
40 O B_MEASURE
, O O
41 O B_MEASURE
, O O
43 O B_MEASURE
- O O
47 O B_MEASURE
] O I_MEASURE
: O O

* O B_OTHER/B_LOCATION
planning O O
the O O
shared O O
visions O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
missions O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

* O B_OTHER/B_LOCATION
determining O O
the O O
shared O O
service O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
cooperation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
priorities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
policies O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
principles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

* O B_OTHER/B_TIME[MEASURE]
identifying O O
the O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
needed O O
and O O
how O O
to O O
get O O
it O O

* O B_OTHER/B_TIME[MEASURE]
organizing O O
the O O
network O B_ORGANIZATION/B_PERSON
dynamics O I_ORGANIZATION/I_PERSON
and O O
member O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
roles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

* O B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
leading O O
and O O
managing O O
the O O
conflicts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
communication O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

* O B_OTHER/B_LOCATION
designing O O
and O O
controlling O O
the O O
shared O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
performance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
including O O
indicator O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
settings O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
feedbacks O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
and O O
accountability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION

The O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
care O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
begins O O
through O O
such O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
public O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programs O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
include O O
social O B_PERSON/B_ORGANIZATION
workers O I_PERSON/I_ORGANIZATION
in O O
public O B_LOCATION/B_PERSON
welfare O I_LOCATION/I_PERSON
departments O I_LOCATION/I_PERSON
, O O
caseworkers O B_PERSON/B_ORGANIZATION
in O O
mental O B_LOCATION/B_ORGANIZATION
health O I_LOCATION/I_ORGANIZATION
, O O
or O O
nurses O B_PERSON
in O O
public O B_LOCATION/B_PERSON
health O I_LOCATION/I_PERSON
departments O I_LOCATION/I_PERSON
. O O

In O O
the O O
late O B_TIME[MEASURE]/B_LOCATION
1980s O I_TIME[MEASURE]/I_LOCATION
, O O
care O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
integration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
deemed O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
streamlining O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
care O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
negotiating O O
the O O
maze O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
services O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

At O O
that O O
time O B_TIME[MEASURE]/B_LOCATION
, O O
it O O
was O O
referred O O
to O O
as O O
service O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
coordination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
or O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
or O O
in O O
other O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O O
terms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O O
29 O B_TIME[MEASURE]/B_PERSON
] O B_TIME[MEASURE]/I_PERSON
. O O

The O O
purpose O O
of O O
care O O
integration O O
is O O
to O O
work O O
directly O O
with O O
patients B B_PERSON
and O O
their O O
families O O
over O O
time O O
to O O
help O O
them O O
arrange O O
and O O
manage O O
the O O
complex O O
resources O O
that O O
patients B B_PERSON/B_LOCATION
may O O
need O O
to O O
maintain O O
health O O
and O O
independent O O
functioning O O
. O O

At O O
the O O
same O O
time O O
, O O
care O O
integration O O
is O O
used O O
to O O
achieve O O
the O O
most O O
cost O O
- O O
effective O O
use O O
possible O O
of O O
scarce O O
resources O O
, O O
by O O
steering O O
patients B B_PERSON/B_LOCATION
to O O
the O O
health O O
, O O
social O O
, O O
and O O
support O O
services O O
most O O
appropriate O O
for O O
them O O
at O O
a O O
given O O
time O O
[ O O
29 O O
] O O
. O O

Conrad O O
and O O
Dowling O O
[ O O
33 O O
] O O
pointed O O
out O O
that O O
to O O
coordinate O O
and O O
integrate O O
patient B B_PERSON/B_DISEASE
care O O
relies O O
on O O
connecting O O
patient B B_PERSON
services O O
at O O
the O O
different O O
stages O O
of O O
the O O
patient B B_PERSON
care O O
processes O O
. O O

Care O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
coordination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
integrated O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
networks O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
can O O
be O O
achieved O O
through O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
training O B_PERSON/B_ORGANIZATION
programs O I_PERSON/I_ORGANIZATION
and O O
some O O
clinical O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
services O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
provision O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
complementary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
capabilities O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
geographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
proximity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
clear O B_ORGANIZATION/B_PERSON
role O I_ORGANIZATION/I_PERSON
definition O I_ORGANIZATION/I_PERSON
of O O
each O O
institution O B_ORGANIZATION/B_PERSON
, O O
commitment O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
flexibility O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
leaderships O B_PERSON/B_ORGANIZATION
and O O
medical O B_ORGANIZATION/B_PERSON
staffs O B_ORGANIZATION/I_PERSON
, O O
and O O
the O O
support O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
large O B_MEASURE/B_LOCATION
referring O O
physician O B_ORGANIZATION/B_PERSON
groups O I_ORGANIZATION/I_PERSON
embracing O O
the O O
affiliation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
concepts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O O
48 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

The O O
issues O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
clinical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
integration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
PCCNs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O O
include O O
[ O B_MEASURE/B_LOCATION
48 O I_MEASURE/I_LOCATION
- O O
50 O B_MEASURE
] O I_MEASURE
: O O

* O B_OTHER/B_ORGANIZATION
planning O O
and O O
differentiating O O
target O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
markets O I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
based O O
on O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
services O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
network O B_ORGANIZATION/B_PERSON
members O B_ORGANIZATION/I_PERSON

* O B_DISEASE/B_LOCATION
uniting O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
professionals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
planning O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

* O O
designing O O
patient B B_PERSON/B_LOCATION
- O O
centered O O
care O O
or O O
case O O
management O O
teams O O

* O O
establishing O O
committees O O
responsible O O
for O O
patient B B_PERSON
- O O
centered O O
case O O
report O O
meetings O O
, O O
case O O
referral O O
, O O
transfer O O
, O O
and O O
tracing O O
, O O
file O O
management O O
( O O
record O O
and O O
information O O
exchanges O O
) O O
, O O
clinical O O
quality O O
management O O
( O O
quality O O
assurance O O
, O O
improvement O O
, O O
risk O O
and O O
malpractice O O
management O O
, O O
and O O
utilization O O
review O O
) O O
, O O
and O O
medical O O
continuing O O
education O O
and O O
on O O
- O O
job O O
education O O
. O O

Marketing O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION

Marketing O O
integration O O
refers O O
to O O
how O O
to O O
work O O
together O O
as O O
a O O
whole O O
both O O
from O O
the O O
provider O O
and O O
patient B B_PERSON/B_ORGANIZATION
perspectives O O
. O O

One O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
case O B_PERSON/B_ORGANIZATION
reports O I_PERSON/I_ORGANIZATION
interviewing O O
developing O O
integrated O O
delivery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
or O O
networks O B_LOCATION/B_ORGANIZATION
realized O O
that O O
the O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]
thing O I_DISEASE_ADJECTIVE[DISEASE]
is O O
how O O
an O O
integrated O O
system O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
network O B_ORGANIZATION/B_LOCATION
is O O
promoted O O
and O O
what O O
is O O
promoted O O
for O O
the O O
consumers O B_PERSON/B_ORGANIZATION
[ O O
51 O B_TIME[MEASURE]/B_LOCATION
] O B_TIME[MEASURE]/I_LOCATION
, O O
including O O
focusing O O
on O O
product O B_ORGANIZATION/B_PERSON
development O B_ORGANIZATION/I_PERSON
, O O
making O O
sure O B_PERSON/B_LOCATION
the O O
branding O B_PERSON/B_ORGANIZATION
holds O O
together O O
, O O
marketing O O
directly O O
to O O
consumers O B_PERSON/B_ORGANIZATION
, O O
demonstrating O O
values O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
consumers O B_PERSON/B_ORGANIZATION
, O O
and O O
even O O
conducting O O
marketing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
make O O
efforts O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
long O B_PERSON/B_ORGANIZATION
term O I_PERSON/I_ORGANIZATION
. O O

In O O
a O O
health O O
care O O
network O O
with O O
several O O
organizational O O
members O O
and O O
target O O
patients B B_PERSON/B_LOCATION
, O O
the O O
marketing O O
infrastructure O O
in O O
PCCNs O O
here O O
refers O O
to O O
provider O O
members O O
' O O
marketing O O
, O O
meaning O O
the O O
resource O O
sharing O O
and O O
market O O
development O O
in O O
a O O
PCCN O O
as O O
a O O
whole O O
. O O

The O O
issues O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
marketing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
integration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
PCCNs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O O
include O O
[ O B_NUMBER[MEASURE]/B_LOCATION
37 O I_NUMBER[MEASURE]/I_LOCATION
, O O
52 O B_MEASURE
- O O
54 O B_MEASURE
] O I_MEASURE
: O O

* O B_OTHER/B_TIME[MEASURE]
sharing O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
facility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
publications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
among O O
the O O
network O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION

* O B_OTHER/B_LOCATION
uniting O O
public O B_ORGANIZATION/B_PERSON
promotions O I_ORGANIZATION/I_PERSON
such O I_ORGANIZATION/I_PERSON
as O O
united O B_ORGANIZATION/B_ENT
activities O B_ORGANIZATION/I_ENT
, O O
electronic O B_PRODUCT[OBJECT]/B_ENT
and O O
paper O B_PERSON/B_PRODUCT[OBJECT]
media O B_PERSON/I_PRODUCT[OBJECT]
for O O
enhancing O O
the O O
network O B_ORGANIZATION/B_LOCATION
reputation O I_ORGANIZATION/I_LOCATION
as O O
" O O
one O B_NUMBER[MEASURE]/B_ORGANIZATION
system O I_NUMBER[MEASURE]/I_ORGANIZATION
, O O
one O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
brand O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
quality O B_NUMBER[MEASURE]/B_ORGANIZATION
" O O

* O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiating O O
target O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markets O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
network O B_ORGANIZATION/B_LOCATION
for O O
competing O O
in O O
the O O
medical O B_ORGANIZATION/B_LOCATION
industry O B_ORGANIZATION/I_LOCATION
. O O

Financial O B_ORGANIZATION/B_LOCATION
infrastructure O I_ORGANIZATION/I_LOCATION

Comprehensive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
flexible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
adequate O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
financing O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
goal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
ideal O B_ORGANIZATION/B_LOCATION
continuum O I_ORGANIZATION/I_LOCATION
of O O
care O B_PERSON/B_ORGANIZATION
. O O

That O O
component O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
most O O
critical O B_DISEASE_ADJECTIVE[DISEASE]
and O O
challenging O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
manage O O
under O O
the O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
health O B_LOCATION/B_ORGANIZATION
care O I_LOCATION/I_ORGANIZATION
delivery O I_LOCATION/I_ORGANIZATION
environment O I_LOCATION/I_ORGANIZATION
. O O

Gillies O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

[ O O
30 O B_NUMBER[MEASURE]/B_PERSON
] O O
suggested O O
that O O
integrating O O
financial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
across O O
operating O B_ORGANIZATION/B_LOCATION
units O I_ORGANIZATION/I_LOCATION
adds O O
the O O
greatest O B_MEASURE
value O I_MEASURE
to O O
systems O B_LOCATION/B_ORGANIZATION
or O O
organizations O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
one O B_MEASURE/B_ENT
case O I_MEASURE/I_ENT
study O I_MEASURE/I_ENT
, O O
Bramson O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O I_PERSON/I_LOCATION
. O O

[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
55 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
showed O O
that O O
reducing O O
costs O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
joint O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purchasing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
radiology O B_PERSON/B_LOCATION
departments O I_PERSON/I_LOCATION
of O O
a O O
vertically O O
integrated O O
health O B_ORGANIZATION/B_LOCATION
system O I_ORGANIZATION/I_LOCATION
could O O
yield O O
substantial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
savings O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
issues O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
financial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
integration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
PCCNs O B_LOCATION/B_ORGANIZATION
could O O
include O O
: O O

* O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
budgeting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

* O B_OTHER/B_TIME[MEASURE]
uniting O O
equipment O B_PRODUCT[OBJECT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
medical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
materials O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
and O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
purchasing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
routine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
administrative O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
stuff O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
management O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION

* O B_DISEASE/B_LOCATION
pooling O O
recruitment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
funds O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

* O B_OTHER/B_TIME[MEASURE]
designing O O
a O O
financial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
sharing O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mechanism O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Information O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION

Information O B_ORGANIZATION/B_PERSON
is O O
an O O
essential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
component O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
an O O
organization O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
can O O
help O O
an O O
organization O B_ORGANIZATION/B_PERSON
to O O
integrate O O
its O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
units O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
efficiently O O
manage O O
the O O
continuum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
ideal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
a O O
continuum O B_LOCATION/B_ORGANIZATION
of O O
care O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
conceived O O
of O O
and O O
formed O O
in O O
the O O
mid O B_TIME[MEASURE]/B_DISEASE
- O O
1980s O B_TIME[MEASURE]
[ O I_TIME[MEASURE]
56 O I_TIME[MEASURE]
] O I_TIME[MEASURE]
. O O

During O O
the O O
late O B_TIME[MEASURE]
1980s O I_TIME[MEASURE]
, O O
computer O B_ORGANIZATION/B_PERSON
technology O I_ORGANIZATION/I_PERSON
began O O
to O O
make O O
an O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
feasible O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
affordable O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
through O O
new O B_ORGANIZATION
computer O I_ORGANIZATION
chips O I_ORGANIZATION
with O O
expanded O O
capability O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
networking O B_ORGANIZATION/B_LOCATION
technology O B_ORGANIZATION/I_LOCATION
. O O

In O O
the O O
1990s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
individual O B_PERSON/B_ORGANIZATION
services O I_PERSON/I_ORGANIZATION
of O O
the O O
continuum O B_LOCATION/B_ORGANIZATION
upgraded O O
their O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
combine O O
clinical O B_ORGANIZATION/B_PERSON
, O O
financial O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
utilization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O O
29 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Some O O
studies O O
have O O
argued O O
that O O
the O O
quality O O
of O O
information O O
systems O O
can O O
drive O O
costs O O
down O O
, O O
because O O
a O O
good O O
information O O
system O O
can O O
give O O
physicians O O
easy O O
electronic O O
access O O
to O O
complete O O
the O O
documentation O O
of O O
the O O
patients B B_PERSON
' O O
clinical O O
records O O
, O O
better O O
inform O O
them O O
about O O
reimbursement O O
and O O
capitation O O
issues O O
, O O
help O O
them O O
easily O O
associate O O
and O O
manage O O
cases O O
together O O
, O O
and O O
achieve O O
a O O
higher O O
level O O
of O O
professional O O
satisfaction O O
[ O O
57 O O
, O O
58 O O
] O O
. O O

Using O O
Inova O B_ORGANIZATION/B_LOCATION
Health O I_ORGANIZATION/I_LOCATION
System O I_ORGANIZATION/I_LOCATION
, O O
an O O
integrated O B_ORGANIZATION/B_LOCATION
delivery O I_ORGANIZATION/I_LOCATION
system O I_ORGANIZATION/I_LOCATION
in O O
northern O B_LOCATION
Virginia O I_LOCATION
, O O
as O O
an O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
Wager O B_PERSON
, O O
Heda O B_PERSON
, O O
and O O
Austin O B_LOCATION/B_PERSON
[ O O
59 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
showed O O
that O O
by O O
developing O O
a O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
network O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
within O O
an O O
integrated O B_ORGANIZATION/B_LOCATION
delivery O I_ORGANIZATION/I_LOCATION
system O I_ORGANIZATION/I_LOCATION
, O O
Inova O B_PERSON/B_ORGANIZATION
can O O
have O O
a O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
transaction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
system O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
hospitals O B_LOCATION/B_PERSON
and O O
other O B_LOCATION/B_PERSON
entities O I_LOCATION/I_PERSON
, O O
a O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
repository O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O O
decision O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
support O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
and O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
a O O
managed O O
care O B_ORGANIZATION/B_LOCATION
information O B_ORGANIZATION/I_LOCATION
system O B_ORGANIZATION/I_LOCATION
to O O
support O O
managed O O
care O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
capitation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
contracts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
and O O
greater O B_LOCATION/B_ORGANIZATION
capability O I_LOCATION/I_ORGANIZATION
to O O
acquire O O
physicians O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
issues O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
coordination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
include O O
[ O B_MEASURE
60 O I_MEASURE
- O O
68 O B_MEASURE
] O I_MEASURE
: O O

* O O
establishing O O
an O O
electronic O O
medical O O
record O O
system O O
, O O
regional O O
information O O
network O O
for O O
patient B B_PERSON/B_TIME[MEASURE]
clinical O O
and O O
administrative O O
data O O
, O O
clinical O O
service O O
arrangements O O
and O O
administrative O O
work O O

* O B_OTHER/B_LOCATION
uniting O O
the O O
system O B_ORGANIZATION/B_ENT
information O I_ORGANIZATION/I_ENT
management O I_ORGANIZATION/I_ENT
and O O
web O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
pages O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

The O O
structured O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
questionnaire O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
developed O O
with O O
the O O
wording O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
practical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
managerial O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
actions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
based O O
on O O
the O O
five O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
just O O
mentioned O O
. O O

There O O
were O O
19 O B_MEASURE
survey O I_MEASURE
items O I_MEASURE
on O O
governance O B_ORGANIZATION/B_LOCATION
infrastructure O I_ORGANIZATION/I_LOCATION
, O O
25 O B_MEASURE
on O O
clinical O B_ORGANIZATION
infrastructure O I_ORGANIZATION
, O O
13 O B_MEASURE
on O O
marketing O B_ORGANIZATION/B_LOCATION
infrastructure O I_ORGANIZATION/I_LOCATION
, O O
20 O B_MEASURE
on O O
financial O B_ORGANIZATION
infrastructure O I_ORGANIZATION
, O O
and O O
7 O B_NUMBER[MEASURE]
on O O
information O B_ORGANIZATION
infrastructure O I_ORGANIZATION
. O O

All O O
84 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
items O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
, O O
simultaneously O O
, O O
applied O O
to O O
examine O O
the O O
relationships O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
clinic O B_LOCATION/B_ORGANIZATION
' O O
s O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peer O B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members O B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
relationship O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
clinic O B_LOCATION/B_PERSON
and O O
hospital O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
in O O
a O O
PCCN O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
it O O
resulted O O
in O O
a O O
total O B_MEASURE
of O O
168 O B_NUMBER[MEASURE]
survey O I_NUMBER[MEASURE]
questions O I_NUMBER[MEASURE]
. O O

The O O
detailed O B_MEASURE
information O I_MEASURE
of O O
the O O
item O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
questions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
listed O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
, O O
5 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
. O O

The O O
structured O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
questionnaires O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
drafted O O
from O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
literatures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
then O O
examined O O
by O O
two O B_PERSON
academic O I_PERSON
professors O I_PERSON
for O O
theoretical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
accuracy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Then O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pilot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
pre O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tested O O
for O O
the O O
PCCN O B_ORGANIZATION/B_LOCATION
pioneers O I_ORGANIZATION/I_LOCATION
( O O
i O O
. O O
e O O
. O O
, O O
92 O B_ORGANIZATION/B_LOCATION
network O B_ORGANIZATION/I_LOCATION
clinic O B_ORGANIZATION/I_LOCATION
members O B_ORGANIZATION/I_LOCATION
) O O
and O O
116 O B_PERSON/B_ORGANIZATION
hospital O I_PERSON/I_ORGANIZATION
providers O I_PERSON/I_ORGANIZATION
which O O
have O O
partner O B_PERSON/B_ORGANIZATION
relationships O I_PERSON/I_ORGANIZATION
with O O
other O B_PERSON/B_LOCATION
health O I_PERSON/I_LOCATION
care O I_PERSON/I_LOCATION
organizations O I_PERSON/I_LOCATION
( O O
i O O
. O O
e O O
. O O
, O O
hospitals O B_LOCATION/B_ORGANIZATION
, O O
clinics O B_LOCATION/B_ORGANIZATION
, O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_MEASURE/B_LOCATION
care O I_MEASURE/I_LOCATION
facilities O I_MEASURE/I_LOCATION
) O O
. O O

The O O
wordings O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
meanings O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
each O O
question O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
item O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
revised O O
to O O
assure O O
content O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
validity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
Cronbach O B_MEASURE/B_PERSON
alpha O I_MEASURE/I_PERSON
values O O
for O O
the O O
five O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
integration O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
constructs O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
- O O
governance O B_ORGANIZATION/B_PERSON
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
marketing O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
finance O B_ORGANIZATION
, O O
and O O
information O B_ORGANIZATION/B_PERSON
infrastructure O I_ORGANIZATION/I_PERSON
were O O
0 O B_MEASURE
. O O
946 O B_MEASURE
, O O
0 O B_NUMBER[MEASURE]
. O O
958 O B_MEASURE
, O O
0 O B_MEASURE/B_LOCATION
. O O
932 O B_MEASURE
, O O
0 O B_MEASURE/B_LOCATION
. O O
944 O B_MEASURE
, O O
and O O
0 O B_NUMBER[MEASURE]/B_LOCATION
. O O
898 O B_MEASURE
for O O
the O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
member O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
relationships O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
; O O
and O O
0 O B_MEASURE
. O O
945 O B_MEASURE
, O O
0 O B_MEASURE
. O O
949 O B_MEASURE
, O O
0 O B_MEASURE
. O O
916 O B_MEASURE
, O O
0 O B_MEASURE
. O O
948 O B_MEASURE
, O O
and O O
0 O B_NUMBER[MEASURE]
. O O
896 O B_MEASURE
for O O
the O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_PERSON/B_ORGANIZATION
member O I_PERSON/I_ORGANIZATION
relationships O I_PERSON/I_ORGANIZATION
. O O

Study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
subjects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

To O O
find O O
the O O
member O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partnership O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
sent O O
questionnaires O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
1 O B_MEASURE
, O O
557 O B_MEASURE
individual O I_MEASURE
clinics O I_MEASURE
which O O
had O O
belonged O O
to O O
PCCNs O B_LOCATION/B_PERSON
for O O
at O O
least O O
one O B_TIME[MEASURE]
year O I_TIME[MEASURE]
, O O
based O O
on O O
information O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
contained O O
in O O
the O O
Taiwan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Primary O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Community O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Network O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
List O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
Bureau O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
National O B_LOCATION/B_TIME[MEASURE]
Health O I_LOCATION/I_TIME[MEASURE]
Insurance O I_LOCATION/I_TIME[MEASURE]
2003 O I_LOCATION/I_TIME[MEASURE]
, O O
2004 O B_MEASURE
and O O
2005 O B_MEASURE
) O O
. O O

We O O
let O O
clinic O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
in O O
all O O
PCCNs O B_LOCATION/B_ORGANIZATION
point O O
out O O
how O O
they O O
coordinate O O
with O O
their O O
peer O B_PERSON/B_LOCATION
clinic O I_PERSON/I_LOCATION
members O I_PERSON/I_LOCATION
and O O
hospital O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
within O O
a O O
PCCN O B_ORGANIZATION/B_LOCATION
because O O
individual O B_PERSON/B_ORGANIZATION
clinic O I_PERSON/I_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
could O O
be O O
better O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
informants O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
hospital O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
, O O
which O O
need O O
to O O
deal O O
with O O
multiple O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relationships O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
therefore O O
might O O
find O O
it O O
hard O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
describe O O
the O O
coordination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
involvement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
one O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O O
one O B_NUMBER[MEASURE]/B_PERSON
with O O
clinic O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
. O O

Moreover O O
, O O
networks O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O O
for O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reasons O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
it O O
might O O
lead O O
to O O
the O O
various O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
involvements O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
individual O B_PERSON/B_ORGANIZATION
network O I_PERSON/I_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
( O O
i O O
. O O
e O O
. O O
, O O
hospital O B_LOCATION/B_PERSON
and O O
clinic O B_ORGANIZATION/B_LOCATION
members O I_ORGANIZATION/I_LOCATION
) O O
. O O

Therefore O O
, O O
using O O
the O O
participating O O
clinics O B_LOCATION/B_ORGANIZATION
as O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
survey O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
units O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
could O O
portray O O
the O O
overall O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
processes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
more O O
authentically O O
and O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
throughout O O
all O O
PCCNs O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
demonstration O B_LOCATION
project O I_LOCATION
. O O

Nine O B_NUMBER[MEASURE]/B_LOCATION
hundred O I_NUMBER[MEASURE]/I_LOCATION
and O O
twenty O B_NUMBER[MEASURE]
- O O
eight O B_NUMBER[MEASURE]
clinics O I_NUMBER[MEASURE]
responded O O
( O O
59 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
with O O
239 O B_MEASURE
clinics O I_MEASURE
in O O
the O O
Taipei O B_LOCATION
region O I_LOCATION
, O O
165 O B_MEASURE
in O O
the O O
northern O B_LOCATION
region O I_LOCATION
, O O
241 O B_MEASURE
in O O
the O O
central O B_LOCATION
region O I_LOCATION
, O O
108 O B_MEASURE
in O O
the O O
southern O B_LOCATION
region O I_LOCATION
, O O
150 O B_MEASURE
in O O
the O O
Kao O B_PERSON/B_LOCATION
- O O
Ping O B_LOCATION/B_PERSON
region O I_LOCATION/I_PERSON
, O O
and O O
15 O B_MEASURE
in O O
the O O
eastern O B_LOCATION
region O I_LOCATION
of O O
Taiwan O B_LOCATION
. O O

Ten O B_PERSON
clinics O I_PERSON
had O O
not O O
mentioned O O
their O O
practicing O O
locations O B_LOCATION/B_PERSON
. O O

There O O
is O O
no O O
statistically O O
significant O B_MEASURE
difference O I_MEASURE
in O O
geographical O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
respondents O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
the O O
study O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
chi O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
4 O B_MEASURE
. O O
208 O B_MEASURE
, O O
p O O
> O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Analytical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
first O O
analyzed O O
descriptively O O
with O O
frequency O B_MEASURE
counts O I_MEASURE
( O O
percentage O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
each O O
survey O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
item O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
instead O O
of O O
using O O
mean O O
as O O
a O O
statistical O B_MEASURE/B_EDU[ORGANIZATION]
method O I_MEASURE/I_EDU[ORGANIZATION]
, O O
because O O
the O O
variation O B_MEASURE
among O O
the O O
respondents O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O O
not O O
represent O O
the O O
normal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
it O O
might O O
ignore O O
the O O
extreme O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
respondents O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
answers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

To O O
compare O O
how O O
the O O
respondents O B_PERSON
perceived O O
the O O
strength O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
existing O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_LOCATION/B_PERSON
and O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
paired O O
t O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
performed O O
for O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
survey O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
items O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
using O O
the O O
original O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numerical O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Profiling O O
the O O
partnerships O B_ORGANIZATION/B_LOCATION
in O O
Taiwan O B_ORGANIZATION/B_LOCATION
PCCNs O I_ORGANIZATION/I_LOCATION
: O O
governance O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
infrastructure O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]

With O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
governance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
infrastructures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
frequency O B_MEASURE
was O O
counted O O
for O O
each O O
survey O B_MEASURE/B_PERSON
item O B_MEASURE/I_PERSON
with O O
recalculated O O
scales O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
disagree O O
( O O
Likert O B_NUMBER[MEASURE]/B_LOCATION
scale O I_NUMBER[MEASURE]/I_LOCATION
1 O I_NUMBER[MEASURE]/I_LOCATION
and O O
2 O B_NUMBER[MEASURE]
) O O
, O O
fair O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Likert O B_NUMBER[MEASURE]/B_LOCATION
scale O I_NUMBER[MEASURE]/I_LOCATION
3 O I_NUMBER[MEASURE]/I_LOCATION
) O O
, O O
and O O
agree O O
( O O
Likert O B_MEASURE
scale O I_MEASURE
4 O I_MEASURE
and O O
5 O B_NUMBER[MEASURE]
) O O
with O O
individual O B_MEASURE
items O I_MEASURE
. O O

In O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_PERSON/B_LOCATION
relationship O I_PERSON/I_LOCATION
( O O
Table O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
the O O
majority O B_PERSON/B_ORGANIZATION
of O O
clinic O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
agree O O
that O O
the O O
determined O O
deals O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
obeyed O O
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
item O B_MEASURE
1 O I_MEASURE
: O O
88 O B_MEASURE
. O O
69 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
the O O
goals O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
strategies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
members O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
well O O
- O O
understood O O
( O O
Table O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
, O O
item O B_MEASURE
16 O I_MEASURE
: O O
79 O B_MEASURE
. O O
74 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
and O O
the O O
united O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
principals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
members O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
developed O O
( O O
Table O B_MEASURE/B_PERSON
2 O I_MEASURE/I_PERSON
, O O
item O B_MEASURE
15 O I_MEASURE
: O O
79 O B_MEASURE
. O O
42 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

The O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
percentages O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
also O O
found O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_PERSON/B_LOCATION
relationship O I_PERSON/I_LOCATION
in O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
items O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
Table O B_MEASURE
2 O I_MEASURE
) O O
. O O

On O O
the O O
other O B_PERSON/B_LOCATION
hand O B_PERSON/I_LOCATION
, O O
establishing O O
fair O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coordination O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
item O B_MEASURE
11 O I_MEASURE
: O O
27 O B_MEASURE
. O O
91 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
designing O O
and O O
employing O O
the O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
performance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
indicators O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Table O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
item O B_MEASURE
3 O I_MEASURE
: O O
21 O B_MEASURE
. O O
23 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
and O O
establishing O O
communication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
channels O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
item O B_MEASURE
12 O I_MEASURE
: O O
19 O B_MEASURE
. O O
94 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
still O O
occupied O O
higher O B_MEASURE/B_LOCATION
percentages O B_MEASURE/I_LOCATION
not O O
developed O O
and O O
deserved O O
to O O
been O O
made O O
the O O
focus O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
future O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Paired O O
t O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
all O O
individual O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
survey O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
items O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
governance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infrastructure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
that O O
the O O
deals O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
obeyed O O
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
item1 O B_MEASURE/B_LOCATION
) O O
and O O
plans O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
goals O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
controlled O O
( O O
Table O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
item O B_MEASURE
2 O I_MEASURE
) O O
were O O
achieved O O
more O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_PERSON/B_LOCATION
relationships O B_PERSON/I_LOCATION
than O O
those O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_LOCATION/B_PERSON
relationships O I_LOCATION/I_PERSON
; O O
however O O
, O O
the O O
design O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
performance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
indicators O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
item O B_MEASURE
3 O I_MEASURE
) O O
, O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
disintegration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
policy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
principals O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
item O B_MEASURE
8 O I_MEASURE
) O O
, O O
and O O
the O O
establishment O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fair O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
coordination O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Table O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
item O B_MEASURE/B_LOCATION
11 O I_MEASURE/I_LOCATION
) O O
were O O
reached O O
more O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_PERSON/B_LOCATION
relationships O B_PERSON/I_LOCATION
than O O
those O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_LOCATION/B_PERSON
relationships O I_LOCATION/I_PERSON
. O O

Profiling O O
the O O
partnerships O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Taiwan O B_LOCATION/B_PERSON
PCCNs O I_LOCATION/I_PERSON
: O O
clinical O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructure O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Examining O O
the O O
extent O O
of O O
clinical O O
infrastructure O O
for O O
network O O
members O O
, O O
establishing O O
two O O
- O O
directed O O
patient B B_PERSON/B_LOCATION
referral O O
systems O O
and O O
patient B B_PERSON/B_LOCATION
referral O O
information O O
files O O
( O O
Table O O
3 O O
, O O
items O O
35 O O
& O O
37 O O
) O O
and O O
uniting O O
medical O O
continuing O O
education O O
and O O
on O O
- O O
job O O
education O O
( O O
Table O O
3 O O
, O O
item O O
34 O O
) O O
were O O
shown O O
at O O
a O O
highly O O
implemented O O
rate O O
in O O
clinic O O
- O O
clinic O O
( O O
more O O
than O O
70 O O
% O O
) O O
and O O
clinic O O
- O O
hospital O O
( O O
more O O
than O O
80 O O
% O O
) O O
relationships O O
. O O

On O O
the O O
other O O
hand O O
, O O
network O O
members O O
had O O
higher O O
percentages O O
( O O
more O O
than O O
40 O O
% O O
) O O
not O O
to O O
think O O
about O O
the O O
possible O O
integration O O
mechanisms O O
including O O
establishing O O
committees O O
to O O
deal O O
with O O
medical O O
malpractice O O
( O O
Table O O
3 O O
, O O
item O O
44 O O
) O O
, O O
planning O O
and O O
differentiating O O
clinical O O
market O O
areas O O
( O O
Table O O
3 O O
, O O
item O O
20 O O
) O O
, O O
and O O
designing O O
patient B B_PERSON/B_ORGANIZATION
- O O
centered O O
case O O
management O O
teams O O
( O O
Table O O
3 O O
, O O
item O O
22 O O
) O O
. O O

Overall O O
, O O
there O O
was O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
all O O
the O O
described O O
items O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
in O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relationships O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
than O O
those O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relationships O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
within O O
a O O
network O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
paired O O
t O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
p O B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Profiling O O
the O O
partnerships O B_ORGANIZATION/B_LOCATION
in O O
Taiwan O B_ORGANIZATION/B_LOCATION
PCCNs O B_ORGANIZATION/I_LOCATION
: O O
marketing O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructure O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

For O O
marketing O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
planning O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
clinics O B_LOCATION/B_PERSON
had O O
better O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
integrated O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
marketing O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
activities O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
with O O
their O O
respective O B_PERSON
hospitals O I_PERSON
than O O
with O O
peer O B_PERSON/B_LOCATION
clinic O I_PERSON/I_LOCATION
members O I_PERSON/I_LOCATION
within O O
PCCNs O B_LOCATION/B_PERSON
for O O
all O O
studied O O
items O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
paired O O
t O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
p O B_PROTEIN[GENE]/B_MEASURE
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Examining O O
the O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_PERSON/B_LOCATION
relationships O I_PERSON/I_LOCATION
, O O
uniting O O
social O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
activities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
Table O B_MEASURE
4 O I_MEASURE
, O O
item O B_MEASURE
53 O I_MEASURE
) O O
, O O
sharing O O
the O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
facility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O O
updated O O
services O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_MEASURE
4 O I_MEASURE
, O O
item O B_MEASURE
46 O I_MEASURE
) O O
, O O
public O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
promotion O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Table O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
item O B_MEASURE
54 O I_MEASURE
) O O
, O O
and O O
uniting O O
and O O
joining O O
the O O
facility O B_ORGANIZATION/B_LOCATION
activities O I_ORGANIZATION/I_LOCATION
( O O
Table O B_MEASURE
4 O I_MEASURE
, O O
item O B_MEASURE
51 O I_MEASURE
) O O
were O O
the O O
top O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
four O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
marketing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
works O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
done O O
among O O
clinic O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
( O O
more O B_MEASURE
than O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
implemented O O
rate O B_MEASURE/B_LOCATION
) O O
; O O
and O O
those O O
items O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
also O O
showed O O
a O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
implemented O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
rate O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
between O O
clinic O B_LOCATION/B_PERSON
and O O
hospital O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
. O O

On O O
the O O
other O B_PERSON/B_MEASURE
hand O I_PERSON/I_MEASURE
, O O
facility O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assets O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
reports O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
Table O B_MEASURE
4 O I_MEASURE
, O O
item O B_MEASURE
49 O I_MEASURE
) O O
, O O
and O O
professional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
literatures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
books O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_MEASURE
4 O I_MEASURE
, O O
item O B_MEASURE
45 O I_MEASURE
) O O
were O O
not O O
well O O
- O O
shared O O
among O O
clinic O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
( O O
" O O
never O O
- O O
thinking O O
" O O
rate O B_MEASURE/B_PERSON
: O O
42 O B_MEASURE
. O O
13 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
uniting O O
the O O
network O B_ORGANIZATION/B_PERSON
publication O B_ORGANIZATION/I_PERSON
could O O
make O O
more O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
efforts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
future O B_TIME[MEASURE]/B_LOCATION
( O O
" O O
never O O
- O O
thinking O O
" O O
rate O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
item O B_MEASURE/B_LOCATION
50 O I_MEASURE/I_LOCATION
: O O
39 O B_MEASURE
. O O
98 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

The O O
room O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_PERSON/B_ORGANIZATION
partnership O I_PERSON/I_ORGANIZATION
to O O
think O O
about O O
acting O O
was O O
kind O O
of O O
different O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
those O O
in O O
the O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_LOCATION/B_ORGANIZATION
relationship O I_LOCATION/I_ORGANIZATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
the O O
uniting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
publication O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
can O O
be O O
encouraged O O
to O O
improve O O
the O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
relationship O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
Table O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
item O B_MEASURE
50 O I_MEASURE
: O O
27 O B_MEASURE
. O O
48 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
cooperating O O
in O O
research O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projects O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_MEASURE
4 O I_MEASURE
, O O
item O B_MEASURE
52 O I_MEASURE
: O O
25 O B_MEASURE
. O O
00 O B_MEASURE
% O I_MEASURE
) O O
and O O
identifying O O
and O O
differentiating O O
target O B_PERSON/B_ORGANIZATION
markets O I_PERSON/I_ORGANIZATION
( O O
Table O B_MEASURE/B_LOCATION
4 O I_MEASURE/I_LOCATION
, O O
item O B_MEASURE
57 O I_MEASURE
: O O
24 O B_MEASURE
. O O
57 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
had O O
still O O
more O B_TIME[MEASURE]/B_PERSON
opportunities O I_TIME[MEASURE]/I_PERSON
to O O
be O O
focused O O
on O O
in O O
the O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Profiling O O
the O O
partnerships O B_ORGANIZATION/B_LOCATION
in O O
Taiwan O B_LOCATION/B_ORGANIZATION
PCCNs O I_LOCATION/I_ORGANIZATION
: O O
financial O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructure O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
PCCN O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
were O O
found O O
to O O
have O O
a O O
lower O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extent O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
financial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
evidenced O O
by O O
higher O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
percentage O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
' O O
' O O
never O O
thinking O B_PERSON/B_LOCATION
' O O
' O O
scale O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
the O O
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
items O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
almost O O
all O O
items O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

Slightly O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
that O O
is O O
, O O
' O O
' O O
acting O O
' O O
' O O
rate O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
found O O
in O O
only O O
four O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
items O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
both O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_LOCATION/B_PERSON
relationships O I_LOCATION/I_PERSON
and O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_ORGANIZATION/B_PERSON
relationships O I_ORGANIZATION/I_PERSON
, O O
including O O
uniting O O
budget O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
planning O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
Table O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
item O B_MEASURE
58 O I_MEASURE
) O O
, O O
sharing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
places O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
and O O
equipment O B_PRODUCT[OBJECT]/B_LOCATION
( O O
Table O B_MEASURE/B_LOCATION
5 O I_MEASURE/I_LOCATION
: O O
item O B_MEASURE
68 O I_MEASURE
) O O
, O O
uniting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
budgeting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
certain O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
services O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_NUMBER[MEASURE]/B_LOCATION
5 O I_NUMBER[MEASURE]/I_LOCATION
: O O
items O B_MEASURE
72 O I_MEASURE
) O O
, O O
and O O
designing O O
the O O
resource O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
principals O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
the O O
whole O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
network O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
item O B_MEASURE
77 O I_MEASURE
) O O
. O O

Further O O
examining O O
the O O
financial O B_ORGANIZATION/B_MEASURE
infrastructure O I_ORGANIZATION/I_MEASURE
in O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_PERSON/B_LOCATION
relationship O I_PERSON/I_LOCATION
and O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_PERSON/B_LOCATION
relationship O I_PERSON/I_LOCATION
, O O
paired O O
- O O
t O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
revealed O O
that O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_PERSON/B_LOCATION
partnerships O I_PERSON/I_LOCATION
were O O
involved O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
places O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
materials O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O O
and O O
equipment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
sharing O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
maintenance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
items O O
62 O B_MEASURE
and O O
68 O B_MEASURE
) O O
( O O
p O B_MEASURE
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
and O O
higher O B_MEASURE/B_LOCATION
financial O I_MEASURE/I_LOCATION
infrastructure O I_MEASURE/I_LOCATION
coordination O I_MEASURE/I_LOCATION
exists O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_LOCATION/B_PERSON
relationships O I_LOCATION/I_PERSON
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
items O B_MEASURE
58 O I_MEASURE
, O O
59 O B_MEASURE
, O O
63 O B_MEASURE
- O O
65 O B_MEASURE
, O O
72 O B_MEASURE
, O O
74 O B_MEASURE
, O O
75 O B_MEASURE
, O O
and O O
77 O B_MEASURE
) O O
( O O
p O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
05 O B_MEASURE
) O O
. O O

Profiling O O
the O O
partnerships O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Taiwan O B_ORGANIZATION/B_LOCATION
PCCNs O I_ORGANIZATION/I_LOCATION
: O O
information O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructure O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

There O O
was O O
significantly O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_LOCATION/B_PERSON
than O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_LOCATION/B_PERSON
relationships O I_LOCATION/I_PERSON
in O O
all O O
items O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
in O O
this O O
category O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
6 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
paired O O
t O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
p O B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

The O O
greatest O O
integration O O
was O O
found O O
in O O
electronic O O
patient B B_PERSON
records O O
( O O
Table O O
6 O O
: O O
item O O
78 O O
) O O
, O O
followed O O
by O O
information O O
integration O O
for O O
patient B B_PERSON
data O O
( O O
Table O O
6 O O
: O O
item O O
79 O O
) O O
and O O
clinical O O
service O O
arrangements O O
( O O
Table O O
6 O O
: O O
item O O
81 O O
) O O
. O O

The O O
lowest O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
information O B_ORGANIZATION/B_LOCATION
infrastructure O I_ORGANIZATION/I_LOCATION
was O O
found O O
in O O
administrative O B_LOCATION
works O I_LOCATION
such O I_LOCATION
as O O
registration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
billing O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
so O O
on O O
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
item O B_MEASURE/B_LOCATION
82 O I_MEASURE/I_LOCATION
, O O
' O O
' O O
never O O
- O O
thinking O O
' O O
' O O
rate O B_MEASURE
more O I_MEASURE
than O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
within O O
network O B_LOCATION/B_ORGANIZATION
members O I_LOCATION/I_ORGANIZATION
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
surveyed O O
943 O B_LOCATION/B_ORGANIZATION
clinics O B_LOCATION/I_ORGANIZATION
that O O
had O O
belonged O O
to O O
Taiwan O B_ORGANIZATION/B_LOCATION
PCCNs O I_ORGANIZATION/I_LOCATION
for O O
more O B_MEASURE/B_PERSON
than O O
a O O
year O B_TIME[MEASURE]
to O O
understand O O
the O O
nature O B_MEASURE/B_LOCATION
and O O
extent O B_MEASURE
of O O
integration O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
which O O
they O O
and O O
their O O
associated O O
PCCN O B_ORGANIZATION/B_LOCATION
members O I_ORGANIZATION/I_LOCATION
( O O
clinics O B_LOCATION/B_ORGANIZATION
and O O
hospitals O B_LOCATION/B_ORGANIZATION
) O O
had O O
in O O
governance O B_ORGANIZATION/B_PERSON
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
marketing O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
financial O B_ORGANIZATION/B_PERSON
, O O
and O O
information O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructures O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
was O O
found O O
a O O
wide O B_MEASURE
variance O I_MEASURE
in O O
the O O
kind O B_MEASURE
and O O
degree O B_MEASURE
of O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
them O O
and O O
a O O
lot O B_MEASURE
of O O
room O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
better O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
integration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
, O O
5 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
) O O
. O O

From O O
the O O
governance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
found O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
in O O
the O O
establishment O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fair O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
coordination O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
mechanism O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
item O B_MEASURE
11 O I_MEASURE
) O O
among O O
member O B_PERSON/B_ORGANIZATION
clinics O I_PERSON/I_ORGANIZATION
and O O
member O B_ORGANIZATION/B_LOCATION
hospitals O I_ORGANIZATION/I_LOCATION
. O O

Coordination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
could O O
be O O
viewed O O
from O O
different O B_LOCATION/B_PERSON
perspectives O I_LOCATION/I_PERSON
, O O
including O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
standardized O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
languages O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
forms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
organizational O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
rules O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
procedures O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
the O O
establishment O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
common O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
rules O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
policies O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
procedures O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
and O O
the O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
through O O
memos O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
computerized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O O
69 O B_MEASURE
, O O
70 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Facing O O
the O O
cumbersome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
integration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
suggests O O
that O O
each O O
PCCN O B_LOCATION/B_ORGANIZATION
' O B_LOCATION/I_ORGANIZATION
s O B_LOCATION/I_ORGANIZATION
headquarters O B_LOCATION/I_ORGANIZATION
should O O
become O O
actively O O
involved O O
and O O
clarify O O
the O O
authority O B_ORGANIZATION/B_PERSON
, O O
responsibility O B_PERSON/B_ORGANIZATION
and O O
accountability O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
individual O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
, O O
identify O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conflict O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sources O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
and O O
publicize O O
the O O
rules O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
regulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
network O B_ORGANIZATION/B_LOCATION
integration O I_ORGANIZATION/I_LOCATION
dynamics O I_ORGANIZATION/I_LOCATION
covering O O
decision O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
making O O
processes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
market O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
planning O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
teamwork O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
designs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
and O O
financial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
network O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
members O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

These O O
actions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O O
enhance O O
the O O
trust O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
respect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
network O B_NUMBER[MEASURE]/B_ORGANIZATION
members O I_NUMBER[MEASURE]/I_ORGANIZATION
one O I_NUMBER[MEASURE]/I_ORGANIZATION
another O O
and O O
could O O
improve O O
the O O
small O B_MEASURE
extent O I_MEASURE
of O O
integration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
found O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
about O O
the O O
mechanisms O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
communication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
channels O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
PCCNs O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
item O B_MEASURE
12 O I_MEASURE
) O O
. O O

From O O
the O O
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
communication O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
occur O O
between O O
the O O
various O B_PERSON/B_ORGANIZATION
entities O B_PERSON/I_ORGANIZATION
such O B_PERSON/I_ORGANIZATION
as O O
between O O
hospital O B_LOCATION/B_PERSON
and O O
clinics O B_LOCATION/B_PERSON
, O O
primary O B_PERSON/B_LOCATION
care O I_PERSON/I_LOCATION
physicians O I_PERSON/I_LOCATION
and O O
specialists O B_PERSON/B_LOCATION
, O O
managers O B_PERSON/B_ORGANIZATION
and O O
clinical O B_PERSON
professionals O I_PERSON
, O O
and O O
even O O
among O O
the O O
clinical O B_PERSON/B_ORGANIZATION
professionals O I_PERSON/I_ORGANIZATION
in O O
the O O
network O B_ORGANIZATION/B_LOCATION
. O O

To O O
develop O O
effective O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
timely O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
communication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channels O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
the O O
key O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
management O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
integrated O B_DISEASE
organizations O I_DISEASE
[ O O
30 O B_MEASURE
- O O
32 O B_MEASURE
] O I_MEASURE
and O O
could O O
alleviate O O
the O O
tensions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
sometimes O O
occur O O
in O O
the O O
dynamics O B_ORGANIZATION/B_LOCATION
of O O
the O O
multi O B_MEASURE/B_DISEASE
- O O
organizations O B_ORGANIZATION/B_LOCATION
. O O

In O O
this O O
study O O
, O O
it O O
was O O
found O O
a O O
low O O
level O O
of O O
involvement O O
of O O
medical O O
teams O O
in O O
medical O O
projects O O
, O O
patient B B_PERSON
- O O
centered O O
case O O
management O O
, O O
and O O
case O O
report O O
meetings O O
among O O
the O O
network O O
members O O
( O O
Table O O
3 O O
: O O
item O O
21 O O
, O O
22 O O
, O O
and O O
23 O O
) O O
from O O
a O O
clinical O O
integration O O
perspective O O
. O O

Several O O
researchers O O
have O O
addressed O O
that O O
clinical O O
integration O O
providing O O
a O O
process O O
of O O
medical O O
management O O
, O O
care O O
management O O
, O O
case O O
management O O
, O O
and O O
patient B B_PERSON/B_ORGANIZATION
management O O
designed O O
to O O
transform O O
the O O
traditionally O O
fragmented O O
delivery O O
system O O
into O O
a O O
more O O
cohesive O O
system O O
[ O O
71 O O
] O O
, O O
and O O
lead O O
to O O
higher O O
service O O
quality O O
and O O
assure O O
financial O O
objectives O O
[ O O
72 O O
, O O
73 O O
] O O
. O O

More O B_PERSON/B_MEASURE
attention O I_PERSON/I_MEASURE
could O O
be O O
paid O O
to O O
these O O
activities O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
future O B_TIME[MEASURE]/B_LOCATION
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
it O O
was O O
also O O
found O O
less O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
planning O O
and O O
differentiating O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
market O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
areas O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
Table O B_MEASURE
3 O I_MEASURE
, O O
item O B_MEASURE
20 O I_MEASURE
) O O
among O O
the O O
network O B_ORGANIZATION/B_LOCATION
members O B_ORGANIZATION/I_LOCATION
in O O
the O O
category O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
clinical O B_PERSON/B_ORGANIZATION
infrastructure O I_PERSON/I_ORGANIZATION
. O O

This O O
may O O
result O O
from O O
the O O
existing O O
specialty O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diversities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
PCCNs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
which O O
might O O
not O O
need O O
to O O
involve O O
planning O O
and O O
differentiating O O
market O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
the O O
members O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
services O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
at O O
the O O
early O B_MEASURE/B_LOCATION
stage O B_MEASURE/I_LOCATION
of O O
network O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
development O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

There O O
was O O
more O B_MEASURE
involvement O I_MEASURE
in O O
marketing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
clinic O B_LOCATION/B_PERSON
- O O
hospital O B_ORGANIZATION/B_PERSON
relationships O I_ORGANIZATION/I_PERSON
than O O
in O O
clinic O B_LOCATION/B_PERSON
- O O
clinic O B_LOCATION/B_PERSON
relationships O I_LOCATION/I_PERSON
. O O

Generally O O
speaking O O
, O O
hospitals O O
have O O
more O O
resources O O
( O O
i O O
. O O
e O O
. O O
, O O
money O O
, O O
human B B_PERSON/B_SPECIES[BIO]
resources O O
, O O
materials O O
, O O
and O O
physical O O
assets O O
) O O
than O O
clinics O O
, O O
which O O
might O O
explain O O
the O O
stronger O O
marketing O O
involvements O O
between O O
the O O
clinic O O
and O O
hospital O O
members O O
, O O
including O O
the O O
library O O
sharing O O
( O O
books O O
and O O
literatures O O
) O O
, O O
facility O O
brochure O O
dissemination O O
, O O
public O O
promoting O O
, O O
and O O
medical O O
research O O
cooperation O O
. O O

These O O
integration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
efforts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
also O O
meet O O
the O O
expectation O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
national O B_LOCATION/B_ORGANIZATION
health O B_LOCATION/I_ORGANIZATION
authority O B_LOCATION/I_ORGANIZATION
for O O
resource O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sharing O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
quality O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
image O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
enhancement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
among O O
the O O
health O B_PERSON/B_LOCATION
care O I_PERSON/I_LOCATION
providers O I_PERSON/I_LOCATION
. O O

Financial O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
was O O
found O O
to O O
be O O
the O O
least O O
integrated O O
, O O
with O O
most O B_MEASURE/B_PERSON
items O B_MEASURE/I_PERSON
never O O
considered O O
. O O

Perhaps O O
the O O
only O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reason O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
score O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
budget O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
planning O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
activities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
items O B_MEASURE
58 O I_MEASURE
and O O
77 O B_MEASURE
) O O
was O O
that O O
BHNI O B_PERSON/B_LOCATION
required O O
each O O
PCCN O B_ORGANIZATION/B_LOCATION
to O O
design O O
and O O
determine O O
its O O
budgeting O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
arrangement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
advance O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
before O O
joining O O
the O O
demonstration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

While O O
slightly O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
financial O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
involvement O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
made O O
among O O
network O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
items O B_MEASURE
68 O I_MEASURE
, O O
72 O B_MEASURE
& O O
73 O B_MEASURE
) O O
, O O
possibly O O
due O O
to O O
similar O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
needs O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
remains O O
a O O
lot O B_MEASURE
of O O
room O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
financial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
future O B_TIME[MEASURE]/B_LOCATION
. O O

There O O
was O O
a O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
networks O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
develop O O
electronic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
though O O
creating O O
and O O
managing O O
an O O
integrated O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involves O O
very O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Most O O
of O O
the O O
clinics O O
surveyed O O
have O O
focused O O
more O O
on O O
the O O
individual O O
public O O
members O O
' O O
administrative O O
works O O
such O O
as O O
filing O O
patient B B_PERSON/B_LOCATION
medical O O
records O O
, O O
collecting O O
and O O
managing O O
network O O
patient B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
clinical O O
data O O
, O O
and O O
scheduling O O
clinical O O
services O O
, O O
which O O
were O O
required O O
by O O
the O O
BNHI O O
. O O

The O O
factors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O O
the O O
health O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
managers O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
adopt O O
the O O
integrated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
include O O
the O O
decision O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
make O O
or O O
buy O O
, O O
adoption O B_PERSON/B_ORGANIZATION
leadership O I_PERSON/I_ORGANIZATION
, O O
adoption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
objectives O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
implementation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leadership O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
phased O O
versus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
simultaneous O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
implementation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
technology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
implementation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
policies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
practices O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
use O B_MEASURE
levels O I_MEASURE
and O O
resistance O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
realized O O
benefits O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
return O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
investment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calculation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
66 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
, O O
which O O
might O O
be O O
very O O
cumbersome O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
time O B_TIME[MEASURE]/B_LOCATION
- O O
consuming O O
. O O

It O O
suggests O O
that O O
the O O
network O O
partners O O
might O O
be O O
engaged O O
, O O
firstly O O
, O O
more O O
in O O
simpler O O
network O O
cooperation O O
such O O
as O O
the O O
administrative O O
systems O O
for O O
patient B B_PERSON
admission O O
to O O
the O O
network O O
members O O
and O O
establishing O O
united O O
web O O
pages O O
for O O
patients B B_PERSON
to O O
access O O
their O O
family O O
physicians O O
and O O
network O O
members O O
for O O
medical O O
and O O
public O O
promotion O O
purposes O O
. O O

And O O
for O O
further O B_PERSON
integrated O I_PERSON
information O I_PERSON
investments O I_PERSON
, O O
efforts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
must O O
be O O
redirected O O
for O O
network O B_ORGANIZATION/B_PERSON
members O B_ORGANIZATION/I_PERSON
to O O
work O O
together O O
to O O
define O O
the O O
approach O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
long O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
74 O B_MEASURE/B_PERSON
] O B_MEASURE/I_PERSON
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

This O O
study O O
tried O O
to O O
portray O O
and O O
trace O O
how O O
the O O
facility O O
participants B B_PERSON
were O O
involved O O
in O O
the O O
Taiwan O O
PCCNs O O
. O O

It O O
was O O
found O O
that O O
Taiwan O B_PERSON/B_ORGANIZATION
PCCNs O I_PERSON/I_ORGANIZATION
' O I_PERSON/I_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
had O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
involvement O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
the O O
governance O B_ORGANIZATION/B_LOCATION
infrastructure O I_ORGANIZATION/I_LOCATION
, O O
which O O
was O O
usually O O
viewed O O
as O O
the O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
establishment O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
core O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
PCCNs O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organization O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
management O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

There O O
existed O O
a O O
higher O B_MEASURE
extent O I_MEASURE
of O O
integration O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
marketing O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
information O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructures O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
the O O
hospital O B_LOCATION/B_PERSON
- O O
clinic O B_PERSON/B_LOCATION
member O I_PERSON/I_LOCATION
relationship O I_PERSON/I_LOCATION
than O O
those O O
among O O
clinic O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
within O O
individual O B_LOCATION/B_ORGANIZATION
PCCNs O I_LOCATION/I_ORGANIZATION
. O O

The O O
financial O B_LOCATION/B_ORGANIZATION
infrastructure O I_LOCATION/I_ORGANIZATION
was O O
shown O O
the O O
least O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrated O O
relative O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
other O B_ORGANIZATION/B_PERSON
functional O I_ORGANIZATION/I_PERSON
infrastructures O I_ORGANIZATION/I_PERSON
at O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
stage O I_TIME[MEASURE]/I_LOCATION
of O O
PCCN O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Page O B_PERSON/B_LOCATION
[ O O
43 O B_PERSON/B_LOCATION
] O I_PERSON/I_LOCATION
argued O O
that O O
networks O B_LOCATION/B_ORGANIZATION
form O O
and O O
grow O O
for O O
various O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reasons O I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
only O O
some O O
of O O
them O O
could O O
be O O
compatible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
iterative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
processes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
collaboration O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Some O O
participants B B_PERSON/B_ORGANIZATION
in O O
the O O
PCCNs O O
may O O
simply O O
seek O O
short O O
- O O
term O O
economic O O
gains O O
and O O
have O O
little O O
interest O O
in O O
joint O O
learning O O
and O O
continuous O O
improvement O O
. O O

From O O
an O O
organizational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
old O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phrase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
proposed O O
by O O
the O O
wisdom O B_TIME[MEASURE]/B_PERSON
of O O
the O O
saying O B_PERSON/B_ORGANIZATION
about O O
developing O O
the O O
integrated O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
organizations O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
networks O B_LOCATION/B_ORGANIZATION
) O O
should O O
be O O
- O O
" O O
coming O O
together O O
is O O
the O O
beginning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
working O O
together O O
is O O
the O O
success O B_SEQUENCE[MEASURE]/B_LOCATION
. O O
" O O
Page O B_PERSON/B_LOCATION
[ O O
43 O B_TIME[MEASURE]/B_PERSON
] O B_TIME[MEASURE]/I_PERSON
examined O O
the O O
virtual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
provider O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
organizations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
such O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O O
physician O B_PERSON/B_LOCATION
- O O
hospital O B_PERSON/B_ORGANIZATION
organizations O I_PERSON/I_ORGANIZATION
and O O
pointed O O
out O O
the O O
issue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
provider O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attitudes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
behaviors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
as O O
the O O
critically O O
successful O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
continuous O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
improvements O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
health O B_ORGANIZATION/B_LOCATION
care O I_ORGANIZATION/I_LOCATION
environments O I_ORGANIZATION/I_LOCATION
. O O

A O O
wide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
degree O B_MEASURE
of O O
network O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Taiwan O B_DISEASE/B_LOCATION
PCCNs O I_DISEASE/I_LOCATION
still O O
leaves O O
room O B_LOCATION
to O O
improve O O
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
thoroughly O O
surveyed O O
items O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
, O O
that O O
is O O
, O O
the O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
content O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
were O O
employed O O
. O O

In O O
addition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
provide O O
how O O
the O O
network O B_PERSON/B_ORGANIZATION
members O I_PERSON/I_ORGANIZATION
have O O
done O O
their O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O O
the O O
early O B_MEASURE/B_LOCATION
stage O B_MEASURE/I_LOCATION
of O O
network O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forming O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
detailed O B_NUMBER[MEASURE]/B_PERSON
surveyed O O
items O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
, O O
the O O
concepts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
proposed O O
by O O
the O O
managerial O B_PERSON
and O O
theoretical O B_PERSON/B_ORGANIZATION
professionals O I_PERSON/I_ORGANIZATION
, O O
could O O
be O O
also O O
a O O
guide O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
those O O
health O B_PERSON/B_ORGANIZATION
care O I_PERSON/I_ORGANIZATION
providers O I_PERSON/I_ORGANIZATION
who O O
have O O
a O O
willingness O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
join O O
multi O B_MEASURE/B_DISEASE
- O O
organizations O B_ORGANIZATION/B_LOCATION
. O O

It O O
suggests O O
that O O
health O B_PERSON/B_ORGANIZATION
care O I_PERSON/I_ORGANIZATION
providers O I_PERSON/I_ORGANIZATION
could O O
take O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detailed O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
looks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
those O O
surveyed O O
items O B_PRODUCT[OBJECT]/B_PERSON
and O O
give O O
some O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
opportunities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
create O O
the O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
actions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
empirically O O
done O O
to O O
explore O O
the O O
relative O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
integration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanisms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
the O O
effectiveness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
organizational O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
partnerships O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
partnerships O B_ORGANIZATION/B_PERSON
within O O
each O O
PCCN O B_ORGANIZATION/B_LOCATION
represent O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
depend O O
on O O
how O O
much O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
the O O
members O B_PERSON/B_ORGANIZATION
are O O
engaged O O
in O O
the O O
projects O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O O
to O O
the O O
macro O O
concepts O O
including O O
governance O O
, O O
clinical O O
, O O
marketing O O
, O O
financial O O
, O O
and O O
information O O
infrastructures O O
explored O O
in O O
this O O
study O O
, O O
other O O
managerial O O
issues O O
for O O
integrated O O
organizations O O
were O O
also O O
suggested O O
such O O
as O O
formation O O
of O O
an O O
integrated O O
cultural O O
atmosphere O O
, O O
human B B_PERSON/B_SPECIES[BIO]
resources O O
management O O
, O O
physician O O
involvement O O
, O O
mission O O
and O O
commitment O O
establishment O O
, O O
from O O
micro O O
organizational O O
behavior O O
perspective O O
[ O O
30 O O
- O O
32 O O
, O O
34 O O
, O O
36 O O
, O O
75 O O
, O O
76 O O
] O O
. O O

Micro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
managerial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
longitudinal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
designs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
could O O
be O O
employed O O
to O O
more O O
precisely O O
catch O O
the O O
never O O
completing O O
integration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
future O B_TIME[MEASURE]/B_LOCATION
. O O

Abbreviations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

primary O B_LOCATION/B_ORGANIZATION
community O I_LOCATION/I_ORGANIZATION
care O I_LOCATION/I_ORGANIZATION
network O I_LOCATION/I_ORGANIZATION
( O O
PCCN O B_DISEASE/B_ORGANIZATION
) O O
; O O
Bureau O B_ORGANIZATION/B_PERSON
of O O
National O B_LOCATION/B_PERSON
Health O I_LOCATION/I_PERSON
Insurance O I_LOCATION/I_PERSON
( O O
BNHI O B_ORGANIZATION/B_LOCATION
) O O

Competing O O
interests O B_DISEASE

The O O
author O B_PERSON/B_LOCATION
( O O
s O O
) O O
declare O O
that O O
they O O
have O O
no O O
competing O O
interests O B_PERSON/B_ORGANIZATION
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

BYJL O B_PERSON
independently O O
designed O O
and O O
conducted O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pre O B_LOCATION/B_PERSON
- O O
publication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

The O O
pre O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
publication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
accessed O O
here O O
: O O

Recombinant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activated O O
protein O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
sepsis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
endothelium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
or O O
endothelium O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
? O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Endothelium O B_DISEASE/B_GENE
dysfunction O I_DISEASE/I_GENE
is O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
hallmarks O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
sepsis O B_DISEASE/B_LOCATION
. O O

Looney O B_PERSON
and O O
Mattay O B_PERSON
, O O
in O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
issue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
Critical O B_DISEASE/B_EDU[ORGANIZATION]
Care O I_DISEASE/I_EDU[ORGANIZATION]
, O O
highlight O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
activated O O
protein O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
APC O B_GENE/B_BACTERIUM[BIO]
) O O
as O O
a O O
protective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
endothelial O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
septic O B_DISEASE
situations O I_DISEASE
. O O

Nevertheless O O
, O O
the O O
results O O
of O O
in O O
vivo O O
studies O O
are O O
less O O
explicit O O
and O O
it O O
remains O O
uncertain O O
whether O O
these O O
properties O O
are O O
relevant O O
in O O
human B B_PERSON/B_SPECIES[BIO]
septic O O
shock O O
. O O

Before O O
considering O O
recombinant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
APC O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
rAPC O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
as O O
a O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
endothelium O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O O
we O O
have O O
to O O
demonstrate O O
its O O
efficiency O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
protect O O
or O O
to O O
reduce O O
endothelium O B_DISEASE
injury O I_DISEASE
when O O
infused O O
a O O
long O B_TIME[MEASURE]/B_ENT
time O I_TIME[MEASURE]/I_ENT
after O O
the O O
septic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
challenge O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Nevertheless O O
, O O
if O O
rAPC O O
is O O
efficient O O
when O O
infused O O
in O O
the O O
early O O
phase O O
of O O
septic O O
challenge O O
, O O
we O O
thus O O
need O O
to O O
treat O O
our O O
patients B B_PERSON/B_DISEASE
earlier O O
. O O

At O O
the O O
least O B_TIME[MEASURE]/B_LOCATION
, O O
genetically O O
engineered O O
variants O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
designed O O
with O O
greater O B_DISEASE
anti O I_DISEASE
- O O
apoptotic O B_DISEASE/B_GENE
activity O I_DISEASE/I_GENE
and O O
reduced O O
anticoagulant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
relative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
wild O B_PERSON/B_BIO
- O O
type O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
APC O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
needed O O
to O O
demonstrate O O
the O O
usefulness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
variants O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
septic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
shock O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O O

The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
recombinant O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activated O O
protein O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
rAPC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
is O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
hottest O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
topics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O O
septic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
shock O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
pivotal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
placebo O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- O O
controlled O O
Protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
C O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Worldwide O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
Severe O B_DISEASE/B_LOCATION
Sepsis O I_DISEASE/I_LOCATION
( O O
PROWESS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
a O O
19 O B_MEASURE
. O O
4 O B_MEASURE
% O I_MEASURE
relative O I_MEASURE
risk O I_MEASURE
reduction O I_MEASURE
in O O
28 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]/B_PERSON
mortality O I_TIME[MEASURE]/I_PERSON
( O O
6 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
absolute O I_MEASURE
risk O I_MEASURE
reduction O I_MEASURE
) O O
with O O
an O O
increased O O
risk O B_MEASURE
( O O
3 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
versus O I_MEASURE
2 O I_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
) O O
of O O
serious O B_DISEASE
bleeding O I_DISEASE
events O I_DISEASE
compared O O
with O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O B_NUMBER[MEASURE]
recent O I_NUMBER[MEASURE]
and O O
important O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
articles O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
highlighted O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
APC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
as O O
a O O
protective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
endothelial O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O O
1 O B_NUMBER[MEASURE]/B_LOCATION
] O I_NUMBER[MEASURE]/I_LOCATION
and O O
as O O
a O O
cyto O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
protective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
2 O B_MEASURE/B_PROTEIN[GENE]
] O I_MEASURE/I_PROTEIN[GENE]
. O O

Beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
rAPC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
PROWESS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
thought O O
to O O
be O O
related O O
to O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
coagulation O B_DISEASE
and O O
, O O
to O O
a O O
lesser O B_DISEASE/B_MEASURE
extent O B_DISEASE/I_MEASURE
, O O
to O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
to O O
sepsis O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
3 O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Post O B_LOCATION/B_DISEASE
- O O
PROWESS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
investigations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O O
been O O
associated O O
with O O
a O O
myriad O B_MEASURE/B_LOCATION
of O O
cellular O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
demonstrating O O
that O O
rAPC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
through O O
reactions O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
by O O
endothelial O B_GENE
protein O I_GENE
C O I_GENE
receptor O I_GENE
and O O
the O O
effector O B_GENE
receptor O I_GENE
, O O
protease O B_GENE
activated O O
receptor O B_GENE
- O O
1 O B_NUMBER[MEASURE]
, O O
acts O O
directly O O
on O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
exert O O
multiple O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytoprotective O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O O
: O O
down O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE/B_GENE
gene O I_DISEASE/I_GENE
expression O I_DISEASE/I_GENE
[ O I_DISEASE/I_GENE
4 O I_DISEASE/I_GENE
] O I_DISEASE/I_GENE
; O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
activities O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
5 O B_MEASURE
] O I_MEASURE
; O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
apoptotic O B_DISEASE
activity O I_DISEASE
[ O O
6 O B_MEASURE
] O O
; O O
and O O
protection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
endothelial O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
barrier O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
function O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
1 O B_NUMBER[MEASURE]
, O O
2 O B_MEASURE/B_PROTEIN[GENE]
] O I_MEASURE/I_PROTEIN[GENE]
. O O

Endothelium O B_DISEASE/B_GENE
dysfunction O I_DISEASE/I_GENE
is O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
hallmarks O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
sepsis O B_DISEASE/B_LOCATION
[ O I_DISEASE/I_LOCATION
7 O I_DISEASE/I_LOCATION
] O I_DISEASE/I_LOCATION
. O O

Sepsis O B_DISEASE/B_BACTERIUM[BIO]
, O O
per O O
se O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
may O O
induce O O
phenotypic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulations O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
endothelium O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
through O O
direct O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
indirect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
endothelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
layer O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
with O O
components O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
bacterial O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
, O O
inducing O O
a O O
myriad O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
host O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
- O O
derived O O
factors O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
endothelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Phenotypic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
modifications O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
include O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
pro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
coagulant O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
proadhesive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
increased O O
endothelial O B_DISEASE
permeability O I_DISEASE
, O O
endothelial O B_DISEASE
cell O I_DISEASE
apoptosis O I_DISEASE
and O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vasomotor O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
; O O
the O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
is O O
crucial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O O
vasoplegia O B_DISEASE/B_PERSON
is O O
directly O O
related O O
to O O
septic O B_DISEASE
shock O I_DISEASE
mortality O I_DISEASE
. O O

Recent O O
animal O O
and O O
human B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O O
have O O
suggested O O
that O O
rAPC O O
may O O
improve O O
both O O
vascular O O
and O O
myocardial O O
dysfunction O O
and O O
vascular O O
reactivity O O
to O O
catecholamine O O
during O O
endotoxin O O
and O O
/ O O
or O O
septic O O
challenge O O
[ O O
8 O O
, O O
9 O O
] O O
. O O

From O O
bench O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
bedside O O

Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
supports O O
a O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
APC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O O
maintaining O O
the O O
integrity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
endothelium O B_BODY_PART_OR_ORGAN_COMPONENT
through O O
both O O
direct O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
indirect O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nevertheless O O
, O O
the O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
in O O
vivo O B_EDU[ORGANIZATION]/B_LOCATION
studies O I_EDU[ORGANIZATION]/I_LOCATION
are O O
less O O
explicit O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
a O O
retrospective O O
study O O
of O O
septic O O
shock O O
in O O
humans B B_PERSON/B_SPECIES[BIO]
, O O
Monnet O O
and O O
colleagues O O
[ O O
9 O O
] O O
demonstrated O O
that O O
APC O O
infusion O O
was O O
associated O O
with O O
a O O
decrease O O
in O O
the O O
amount O O
of O O
delivered O O
norepinephrine O O
. O O

Wiel O O
and O O
colleagues O O
[ O O
10 O O
] O O
demonstrated O O
in O O
a O O
rabbit B B_SPECIES[BIO]
model O O
of O O
endotoxin O O
induced O O
shock O O
that O O
APC O O
decreased O O
aorta O O
endothelial O O
injury O O
. O O

By O O
contrast O O
, O O
in O O
a O O
lung O O
model O O
of O O
endotoxin O O
induced O O
inflammation O O
, O O
Robriquet O O
and O O
colleagues O O
[ O O
11 O O
] O O
demonstrated O O
a O O
trend O O
to O O
an O O
increased O O
vascular O O
permeability O O
using O O
high O O
doses O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
APC O O
. O O

This O O
last O O
result O O
was O O
in O O
sharp O O
contrast O O
with O O
the O O
results O O
obtained O O
by O O
Nick O O
and O O
colleagues O O
[ O O
12 O O
] O O
in O O
a O O
human B B_SPECIES[BIO]
model O O
of O O
pulmonary O O
endotoxin O O
administration O O
. O O

APC O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
improve O O
mortality O B_DISEASE
in O O
septic O B_DISEASE/B_PERSON
shock O I_DISEASE/I_PERSON
with O O
a O O
high O B_DISEASE/B_GENE
APACHE O I_DISEASE/I_GENE
2 O I_DISEASE/I_GENE
score O I_DISEASE/I_GENE
and O O
is O O
potentially O O
detrimental O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sepsis O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

In O O
rats O O
, O O
APC O O
markedly O O
decreased O O
tumour O O
necrosis O O
factor O O
concentrations O O
whereas O O
they O O
remained O O
unchanged O O
in O O
either O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
septic O O
shock O O
or O O
endotoxemia O O
. O O

The O O
question O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arises O O
, O O
therefore O O
, O O
as O O
to O O
whether O O
it O O
is O O
truly O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
reconcile O O
all O O
these O O
discrepancies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
? O O

Moreover O O
, O O
can O O
these O O
stirring O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
be O O
translated O O
into O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
practice O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
? O O

Limitations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
experimental O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
studies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O O
endothelium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
versus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
endothelium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
therapy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Clearly O O
, O O
in O O
cellular O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
rAPC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
given O O
either O O
as O O
a O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
or O O
concurrent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
septic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
challenge O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
mode O O
of O O
administration O O
favours O O
the O O
anti O O
- O O
inflammatory O O
effects O O
of O O
rAPC O O
, O O
which O O
are O O
particularly O O
efficient O O
in O O
murine B B_DISEASE
models O O
in O O
protecting O O
the O O
endothelium O O
from O O
cytokine O O
- O O
mediated O O
apoptosis O O
or O O
upregulation O O
of O O
endothelial O O
adhesion O O
molecules O O
. O O

Thus O O
, O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
post O B_DISEASE
- O O
injury O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O O
needed O O
in O O
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
mimic O O
septic O B_DISEASE
shock O I_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
experimental O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pneumonia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
peritonitis O B_DISEASE
treated O O
by O O
antibiotics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
volume O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resuscitation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
where O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
rAPC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
would O O
be O O
investigated O O
16 O B_NUMBER[MEASURE]
to O O
24 O B_MEASURE/B_SPORT[ENT]
hours O I_MEASURE/I_SPORT[ENT]
after O O
septic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
challenge O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

If O O
we O O
can O O
demonstrate O O
the O O
efficiency O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
rAPC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
protect O O
or O O
to O O
reduce O O
endothelium O B_DISEASE/B_GENE
injury O I_DISEASE/I_GENE
in O O
these O O
conditions O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
can O O
ultimately O O
postulate O O
that O O
rAPC O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
also O O
a O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
endothelium O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

The O O
earlier O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
better O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

If O O
rAPC O O
is O O
efficient O O
when O O
infused O O
in O O
the O O
early O O
phase O O
of O O
septic O O
challenge O O
, O O
we O O
thus O O
need O O
to O O
treat O O
our O O
patients B B_PERSON/B_DISEASE
earlier O O
. O O

At O O
least O O
two O O
studies O O
suggest O O
that O O
treatment O O
with O O
rAPC O O
within O O
24 O O
hours O O
may O O
carry O O
a O O
larger O O
survival O O
advantage O O
for O O
patients B B_PERSON/B_BIO
with O O
severe O O
sepsis O O
, O O
compared O O
with O O
those O O
treated O O
more O O
than O O
24 O O
hours O O
after O O
organ O O
dysfunction O O
[ O O
13 O O
] O O
. O O

Interventions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
directed O O
at O O
specific O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
endpoints O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
when O O
initiated O O
early O O
in O O
the O O
' O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
golden O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
patient O B_PERSON
' O O
s O B_PERSON/B_TIME[MEASURE]
condition O I_PERSON/I_TIME[MEASURE]
, O O
seem O O
to O O
be O O
promising O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O O
14 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
] O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
beneficial O O
effects O O
of O O
earlier O O
administration O O
of O O
rAPC O O
to O O
appropriate O O
patients B B_PERSON/B_LOCATION
may O O
fit O O
into O O
this O O
paradigm O O
. O O

The O O
future O B_TIME[MEASURE]/B_PERSON

Extensive O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
have O O
focused O O
on O O
the O O
cytoprotective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
APC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
most O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
authors O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agree O O
that O O
its O O
anticoagulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cytoprotective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
mediated O O
by O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
APC O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
structural O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
features O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Positively O O
charged O O
residues O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
surface O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
loops O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
APC O B_PROTEIN[GENE]
protease O I_PROTEIN[GENE]
domain O I_PROTEIN[GENE]
have O O
been O O
identified O O
as O O
participating O O
in O O
the O O
anticoagulant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
activity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
but O O
not O O
in O O
cellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Hence O O
, O O
variants O B_LOCATION/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
have O O
been O O
designed O O
with O O
greater O B_DISEASE
anti O I_DISEASE
- O O
apoptotic O B_DISEASE/B_GENE
activity O I_DISEASE/I_GENE
and O O
reduced O O
anticoagulant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
relative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
wild O B_PERSON/B_BIO
- O O
type O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
APC O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Whether O O
these O O
genetically O O
engineered O O
variants O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
actually O O
provide O O
superior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O O
to O O
be O O
elucidated O O
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
investigations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
allow O O
the O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
APC O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
variants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
decreased O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticoagulant O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
reduce O O
the O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
bleeding O O
on O O
the O O
one O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hand O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
but O O
also O O
with O O
normal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytoprotective O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
properties O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
retain O O
full O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beneficial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
sepsis O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Abbreviations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

PROWESS O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
Protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
C O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Worldwide O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
Severe O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
Sepsis O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
; O O
rAPC O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
recombinant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activated O O
protein O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Competing O O
interests O B_DISEASE

BL O B_PERSON
has O O
received O O
reimbursements O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
funding O B_PERSON/B_ORGANIZATION
from O O
Eli O B_PERSON/B_LOCATION
Lilly O B_PERSON/I_LOCATION
, O O
France O B_LOCATION/B_ORGANIZATION
. O O

Carbonic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Anhydrase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
Inhibitors O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
541 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Metal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Complexes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
New O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Class O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
Antiglaucoma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
possessing O O
carbonic O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CA O B_LOCATION/B_ORGANIZATION
) O O
inhibitory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
recently O O
shown O O
to O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
intraocular O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IOP O B_DISEASE/B_LOCATION
) O O
lowering O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
and O O
might O O
be O O
developed O O
as O O
a O O
novel O B_PERSON/B_ENT
class O I_PERSON/I_ENT
of O O
antiglaucoma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
we O O
report O O
the O O
synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
a O O
heterocyclic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CA O O
inhibitor O B_NUMBER[MEASURE]
and O O
of O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
main O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metal O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
as O O
Be O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Mg O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Al O B_LOCATION/B_PERSON
( O O
III O B_TIME[MEASURE]/B_LOCATION
) O O
, O O
Zn O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Cd O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
Hg O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
5 O B_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
ligands O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
new O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
characterized O O
by O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
physico O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
chemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
assayed O O
as O O
inhibitors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
three O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isozymes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CA O O
I O O
, O O
II O B_TIME[MEASURE]/B_PROTEIN[GENE]
and O O
IV O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
. O O

Some O O
of O O
them O O
( O O
but O O
not O O
the O O
parent O O
sulfonamides O O
) O O
strongly O O
lowered O O
IOP O O
in O O
rabbits B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
administered O O
as O O
a O O
2 O O
% O O
solution O O
into O O
the O O
eye O O
. O O

CARBONIC O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
ANHYDRASE O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
INHIBITORS O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O O

Part O B_MEASURE
54 O I_MEASURE
METAL O I_MEASURE
COMPLEXES O I_MEASURE
OF O O
HETEROCYCLIC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
SULFONAMIDES O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
A O O
NEW O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
CLASS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
OF O O
ANTIGLAUCOMA O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AGENTS O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Claudiu O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Supuran O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
* O O
, O O
Andrea O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scozzafava O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

and O O
Andrei O B_PERSON/B_NUMBER[MEASURE]
Jitianu O B_PERSON/I_NUMBER[MEASURE]
2 O B_PERSON/I_NUMBER[MEASURE]

Universit O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O O
degli O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Studi O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
Dipartimento O B_LOCATION
di O I_LOCATION
Chimica O I_LOCATION
, O O
Laboratorio O B_LOCATION/B_PERSON
di O I_LOCATION/I_PERSON
Chimica O I_LOCATION/I_PERSON
Inorganica O I_LOCATION/I_PERSON
e O O
Bioinorganica O B_LOCATION/B_PERSON
, O O
Via O O
Gino O B_PERSON/B_LOCATION
Capponi O B_PERSON/I_LOCATION
7 O B_PERSON/I_LOCATION
, O O
1 O B_MEASURE
- O O
50121 O B_MEASURE
, O O
Florence O B_LOCATION
, O O
Italy O B_MEASURE/B_ORGANIZATION
2 O I_MEASURE/I_ORGANIZATION
" O O
I O O
. O O
G O B_PROTEIN[GENE]/B_LOCATION
. O O

Murgulescu O B_LOCATION/B_PERSON
" O I_LOCATION
Institute O I_LOCATION
of O O
Physical O B_EDU[ORGANIZATION]/B_PERSON
Chemistry O I_EDU[ORGANIZATION]/I_PERSON
, O O
Academia O B_LOCATION
Romana O I_LOCATION
, O O
Spl O B_LOCATION
. O O

Independentei O B_MEASURE/B_ORGANIZATION
202 O I_MEASURE/I_ORGANIZATION
, O O
R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
77208 O B_MEASURE/B_LOCATION
Bucharest O I_MEASURE/I_LOCATION
, O O
Roumania O B_LOCATION/B_MEASURE
Abstract O I_LOCATION/I_MEASURE
: O O
Metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
possessing O O
carbonic O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CA O B_LOCATION/B_ORGANIZATION
) O O
inhibitory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
recently O O
shown O O
to O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
intraocular O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IOP O B_DISEASE/B_LOCATION
) O O
lowering O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
animals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
and O O
might O O
be O O
developed O O
as O O
a O O
novel O B_PERSON/B_ENT
class O I_PERSON/I_ENT
of O O
antiglaucoma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
we O O
report O O
the O O
synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
a O O
heterocyclic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CA O O
inhibitor O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
of O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
main O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metal O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
as O O
Be O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Mg O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
AI O B_LOCATION/B_PERSON
( O O
III O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
, O O
Zn O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Cd O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
Hg O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_MEASURE
, O O
4thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
ligands O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
new O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
characterized O O
by O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
physico O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
chemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
assayed O O
as O O
inhibitors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
three O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isozymes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CA O O
I O O
, O O
II O B_TIME[MEASURE]/B_PROTEIN[GENE]
and O O
IV O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
. O O

Some O O
of O O
them O O
( O O
but O O
not O O
the O O
parent O O
sulfonamides O O
) O O
strongly O O
lowered O O
IOP O O
in O O
rabbits B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
administered O O
as O O
a O O
2 O O
% O O
solution O O
into O O
the O O
eye O O
. O O

Introduction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
possessing O O
carbonic O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CA O B_LOCATION/B_MEASURE
, O O
EC O B_MEASURE
4 O I_MEASURE
. O O
2 O B_MEASURE
. O O
1 O B_MEASURE
. O O
1 O B_MEASURE
) O O
inhibitory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
2 O B_DISEASE_ADJECTIVE[DISEASE]
] O I_DISEASE_ADJECTIVE[DISEASE]
such O I_DISEASE_ADJECTIVE[DISEASE]
as O O
acetazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
methazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
ethoxzolamide O B_NUMBER[MEASURE]
3 O I_NUMBER[MEASURE]
and O O
dichlorophenamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
used O O
for O O
more O B_MEASURE/B_PERSON
than O O
40 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
as O O
pressure O B_DISEASE
lowering O O
systemic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
open O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
angle O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
glaucoma O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
3 O B_NUMBER[MEASURE]/B_LOCATION
, O O
4 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Their O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
due O O
to O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
at O O
least O O
two O B_NUMBER[MEASURE]/B_BIO
CA O I_NUMBER[MEASURE]/I_BIO
isozymes O I_NUMBER[MEASURE]/I_BIO
present O I_NUMBER[MEASURE]/I_BIO
within O O
cilliary O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
processes O I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
of O O
the O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O O
ie O O
, O O
CA O B_PROTEIN[GENE]/B_LOCATION
II O I_PROTEIN[GENE]/I_LOCATION
and O O
CA O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
IV O I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
is O O
followed O O
by O O
lowered O O
bicarbonate O B_MEASURE/B_LOCATION
formation O I_MEASURE/I_LOCATION
and O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
aqueous O B_MEASURE/B_LOCATION
humor O B_MEASURE/I_LOCATION
secretion O B_MEASURE/I_LOCATION
[ O B_MEASURE/I_LOCATION
5 O B_MEASURE/I_LOCATION
- O O
7 O B_MEASURE
] O I_MEASURE
. O O

Their O O
main O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
drawback O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
constituted O O
by O O
side O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
such O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
fatigue O B_DISEASE
, O O
augmented O B_DISEASE
diuresis O I_DISEASE
, O O
or O O
paresthesias O B_DISEASE
, O O
due O O
to O O
CA O B_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_DISEASE_ADJECTIVE[DISEASE]
in O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
than O O
the O O
target O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ie O O
, O O
the O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT
[ O O
8 O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

N O B_OTHER/B_PROTEIN[GENE]
- O O
- O O
N O B_OTHER/B_MEASURE

XN O B_MEASURE/B_PROTEIN[GENE]
- O O
- O O
N O B_SEQUENCE[MEASURE]/B_LOCATION
EtO O I_SEQUENCE[MEASURE]/I_LOCATION
S O I_SEQUENCE[MEASURE]/I_LOCATION

NH O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

O O B_OTHER/B_PERSON

NH O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
S O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
- O O
- O O
O O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

NHEt O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
above O O
- O O
mentioned O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
case O B_PERSON/B_LOCATION
in O O
which O O
the O O
inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
topical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
activity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
is O O
applied O O
directly O O
into O O
the O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

This O O
route O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
been O O
demonstrated O O
only O O
in O O
1983 O B_MEASURE/B_LOCATION
by O O
Maren O B_MEASURE/B_ORGANIZATION
' O I_MEASURE/I_ORGANIZATION
s O I_MEASURE/I_ORGANIZATION
group O I_MEASURE/I_ORGANIZATION
[ O O
9 O B_TIME[MEASURE]
] O I_TIME[MEASURE]
and O O
was O O
followed O O
by O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
first O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
type O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
10 O B_NUMBER[MEASURE]
, O O
11 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Trusopt O B_PROTEIN[GENE]/B_LOCATION
) O O
has O O
been O O
introduced O O
in O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
1995 O B_MEASURE
in O O
USA O B_LOCATION
and O O
Europe O B_LOCATION
and O O
it O O
constituted O O
the O O
beginning O B_TIME[MEASURE]/B_PERSON
of O O
a O O
radically O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glaucoma O B_DISEASE
, O O
devoid O B_DISEASE/B_LOCATION
of O O
the O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
with O O
the O O
systemic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
inhibitors O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
[ O O
4 O B_TIME[MEASURE]/B_LOCATION
- O O
6 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
success O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
topical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antiglaucoma O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
CA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inhibitors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
fostered O O
much O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
other O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
types O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
such O B_LOCATION/B_MEASURE
compounds O I_LOCATION/I_MEASURE
[ O I_LOCATION/I_MEASURE
12 O I_LOCATION/I_MEASURE
- O O
15 O B_MEASURE
] O I_MEASURE
. O O

307 O B_NUMBER[MEASURE]

Vol O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

4 O O
, O O
No O O
. O O
6 O B_MEASURE
, O O
1997 O B_MEASURE/B_LOCATION

Metal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Complexes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
Heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
A O O
New O B_PERSON/B_ENT
Class O B_PERSON/I_ENT
ofAntiglaucoma O B_PERSON/I_ENT
Agents O B_PERSON/I_ENT

On O O
the O O
other O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hand O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
5 O B_MEASURE
have O O
been O O
recently O O
prepared O O
by O O
two O B_MEASURE
groups O I_MEASURE
16 O I_MEASURE
- O O
20 O B_MEASURE
] O I_MEASURE
, O O
and O O
it O O
was O O
proved O O
that O O
they O O
possess O O
much O O
stronger O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
CA O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
inhibitory O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
properties O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
the O O
sulfonamides O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
from O O
which O O
they O O
were O O
prepared O O
18 O B_MEASURE
- O O
22 O B_MEASURE
] O I_MEASURE
. O O

Although O O
the O O
mechanism O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
CA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
complexes O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
is O O
presently O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
was O O
hypothesized O O
that O O
their O O
increased O O
inhibitory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
power O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
be O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
two O B_LOCATION/B_MEASURE
processes O I_LOCATION/I_MEASURE
, O O
occurring O O
separately O O
or O O
in O O
concert O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
ie O O
, O O
( O O
i O O
) O O
dissociation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
complex O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
anions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
in O O
diluted O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
, O O
which O O
in O O
turn O B_GENE/B_PERSON
both O O
interact O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
thereafter O O
with O O
the O O
enzyme O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
at O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
binding O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
sites O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
and O O
( O O
ii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
the O O
undissociated O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
complex O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
with O O
the O O
enzyme O B_ENZYME[GENE]
, O O
and O O
more O O
specifically O O
with O O
the O O
hydrophilic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patch O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
entrance O B_LOCATION
of O O
CA O B_LOCATION/B_BIO
II O I_LOCATION/I_BIO
active O I_LOCATION/I_BIO
site O I_LOCATION/I_BIO
[ O O
23 O B_MEASURE
] O I_MEASURE
, O O
this O O
being O O
the O O
isozyme O B_ENZYME[GENE]/B_LOCATION
most O O
susceptible O B_DISEASE_ADJECTIVE[DISEASE]
to O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
this O O
class O B_PERSON/B_LOCATION
of O O
compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
22 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

Whether O O
initially O O
the O O
first O B_LOCATION
mechanism O I_LOCATION
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mentioned O O
above O O
was O O
favored O O
by O O
us O O
[ O O
22 O B_MEASURE
] O I_MEASURE
, O O
recent O B_PERSON
evidences O I_PERSON
suggested O O
that O O
the O O
undissociated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
complex O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
might O O
be O O
the O O
inhibitory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
species O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
at O O
least O O
for O O
some O O
isozymes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
[ O O
24 O B_MEASURE
] O I_MEASURE
. O O

Since O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
much O O
more O O
inhibitory O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O O
the O O
parent O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sulfonamide O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
which O O
they O O
were O O
prepared O O
, O O
it O O
appeared O O
of O O
interest O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
test O O
whether O O
this O O
property O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
their O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
lowering O O
IOP O B_DISEASE/B_GENE
in O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
whence O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
as O O
a O O
possible O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glaucoma O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recently O O
we O O
proved O O
[ O O
25 O B_MEASURE
, O O
26 O B_MEASURE
] O O
that O O
some O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
which O O
themselves O O
do O O
not O O
possess O O
IOP O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lowering O O
properties O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
act O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
very O O
powerful O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
administered O O
as O O
diluted O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
solutions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
directly O O
into O O
the O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT
of O O
experimental O B_SPECIES[BIO]/B_PERSON
animals O I_SPECIES[BIO]/I_PERSON
, O O
and O O
would O O
thus O O
offer O O
the O O
possibility O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
developing O O
such O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
totally O O
novel O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Here O O
we O O
report O O
the O O
synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
a O O
heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possessing O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CA O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitory O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ie O O
, O O
5 O B_NUMBER[MEASURE]
- O O
( O O
chloroacetamido O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_NUMBER[MEASURE]/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
of O O
the O O
metal O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
this O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
of O O
5 O B_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_TIME[MEASURE]/B_PROTEIN[GENE]
, O O
3 O B_NUMBER[MEASURE]/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
containing O O
some O O
main O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metal O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
new O O
compounds O O
have O O
been O O
characterized O O
by O O
standard O O
physico O O
- O O
chemical O O
procedures O O
, O O
and O O
were O O
assayed O O
as O O
inhibitors O O
of O O
three O O
CA O O
isozymes O O
, O O
hCA O O
I O O
, O O
hCA O O
II O O
and O O
bCA O O
IV O O
( O O
h O O
human B B_PROTEIN[GENE]/B_SPECIES[BIO]
; O O
b O O
bovine B B_SPECIES[BIO]/B_PROTEIN[GENE]
; O O
these O O
are O O
the O O
isozymes O O
considered O O
to O O
play O O
a O O
critical O O
role O O
in O O
aqueous O O
humour O O
secretion O O
within O O
the O O
eye O O
of O O
higher O O
vertebrates O O
[ O O
2 O O
- O O
5 O O
] O O
) O O
. O O

Materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Melting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
points O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
recorded O O
with O O
a O O
heating O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscope O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
are O O
not O O
corrected O O
. O O

IR O B_NUMBER[MEASURE]/B_ENT
spectra O B_NUMBER[MEASURE]/I_ENT
were O O
recorded O O
in O O
KBr O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pellets O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
Carl O B_LOCATION/B_PROTEIN[GENE]
Zeiss O I_LOCATION/I_PROTEIN[GENE]
IR O I_LOCATION/I_PROTEIN[GENE]
- O O
80 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
instrument O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

1H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
NMR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectra O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
recorded O O
in O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
d6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
solvent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
with O O
a O O
Bruker O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
CPX200 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
instrument O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Chemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shifts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
reported O O
as O O
values O B_MEASURE
, O O
relative O B_PERSON/B_MEASURE
to O O
Me4Si O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
internal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
standard O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Conductimetric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
done O O
at O O
room O B_MEASURE/B_LOCATION
temperature O I_MEASURE/I_LOCATION
( O O
1 O B_MEASURE/B_LOCATION
mM O B_MEASURE/I_LOCATION
concentration O B_MEASURE/I_LOCATION
of O O
complex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
a O O
Fisher O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conductimeter O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Elemental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
done O O
by O O
combustion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
C O B_LOCATION/B_GENE
, O O
H O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N O B_OTHER/B_LOCATION
with O O
an O O
automated O O
Carlo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Erba O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyzer O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
gravimetrically O O
for O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
were O O
0 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
theoretical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Thermogravimetric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
done O O
in O O
air O B_LOCATION/B_DISEASE
, O O
at O O
a O O
heating O B_MEASURE
rate O I_MEASURE
of O O
10C O B_MEASURE/B_PERSON
/ O O
min O B_PERSON/B_MEASURE
. O O
, O O
with O O
a O O
Perkin O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
Elmer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
3600 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
thermobalance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O O

Sulfonamides O B_TIME[MEASURE]/B_LOCATION
used O O
as O O
standards O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
the O O
enzymatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
except O O
for O O
5 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
acetazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pyridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
chloroacetyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
for O O
the O O
preparation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
compound O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
solvents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
inorganic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reagents O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
from O O
Sigma O B_GENE/B_LOCATION
, O O
Merck O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
Carlo O B_PERSON/B_ORGANIZATION
Erba O I_PERSON/I_ORGANIZATION
. O O

5 O B_MEASURE
- O O
Amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_MEASURE/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
prepared O O
from O O
acetazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O O
literature O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedures O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
27 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
, O O
by O O
desacetylation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
with O O
concentrated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrochloric O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
followed O O
by O O
neutralization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bicarbonate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
corresponding O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Scheme O B_MEASURE
1 O I_MEASURE
) O O
. O O

Dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hydrochloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
from O O
Merck O B_PERSON
, O O
Sharp O B_PERSON/B_COLOR
and O O
Dohme O B_PERSON
or O O
was O O
prepared O O
as O O
described O O
by O O
Ponticello O B_LOCATION/B_MEASURE
et O I_LOCATION/I_MEASURE
al O O
10 O B_MEASURE
, O O
11 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Human B B_PERSON/B_NUMBER[MEASURE]
CA O O
and O O
CA O O
II O O
cDNAs O O
were O O
expressed O O
in O O
Escherichia O O
coli O O
strain O O
BL21 O O
( O O
DE3 O O
) O O
from O O
the O O
plasmids O O
pACA O O
/ O O
hCA O O
I O O
and O O
pACAdaCA O O
II O O
described O O
by O O
Forsman O O
et O O
al O O
. O O

[ O O
28 O B_TIME[MEASURE]
] O O
( O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasmids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
a O O
gift O B_TIME[MEASURE]/B_PERSON
from O O
Prof O B_PERSON/B_LOCATION
. O O
Sven O B_PERSON
Lindskog O I_PERSON
, O O
Umea O B_LOCATION
University O I_LOCATION
, O O
Sweden O B_LOCATION/B_MEASURE
) O O
. O O

Cell O B_MEASURE/B_PERSON
growth O B_MEASURE/I_PERSON
conditions O B_MEASURE/I_PERSON
were O O
those O O
described O O
by O O
Lindskog O B_PERSON
' O I_PERSON
s O I_PERSON
group O I_PERSON
[ O O
29 O B_MEASURE
] O I_MEASURE
, O O
and O O
enzymes O B_BIO/B_PROTEIN[GENE]
were O O
purified O O
by O O
affinity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
according O O
to O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Khalifah O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
30 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Enzyme O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
determined O O
spectrophotometrically O O
at O O
280 O B_TIME[MEASURE]/B_LOCATION
nm O I_TIME[MEASURE]/I_LOCATION
, O O
utilizing O O
a O O
molar O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorptivity O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
49 O B_MEASURE
mM O I_MEASURE
- O O
l O B_MEASURE/B_DISEASE
. O O
cm O B_MEASURE
- O O
1 O B_NUMBER[MEASURE]
for O O
hCA O B_DISEASE/B_PROTEIN[GENE]
and O O
54 O B_MEASURE
mM O I_MEASURE
- O O
l O B_MEASURE/B_DISEASE
. O O
cm O B_MEASURE/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
for O O
hCA O B_DISEASE/B_PROTEIN[GENE]
II O B_DISEASE/I_PROTEIN[GENE]
, O O
respectively O O
, O O
based O O
on O O
M O B_MEASURE/B_LOCATION
28 O I_MEASURE/I_LOCATION
. O O
85 O B_MEASURE
kDa O I_MEASURE
for O O
hCA O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
29 O B_MEASURE
. O O
3 O B_MEASURE
kDa O I_MEASURE
for O O
hCA O B_DISEASE/B_LOCATION
II O I_DISEASE/I_LOCATION
, O O
respectively O O
[ O B_MEASURE
31 O I_MEASURE
, O O
32 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

bCA O O
IV O O
was O O
isolated O O
from O O
bovine B B_SPECIES[BIO]/B_PROTEIN[GENE]
lung O O
microsomes O O
as O O
described O O
by O O
Maren O O
et O O
al O O
, O O
and O O
its O O
concentration O O
has O O
been O O
determined O O
by O O
titration O O
with O O
ethoxzolamide O O
[ O O
33 O O
] O O
. O O

Synthesis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
5 O B_MEASURE
- O O
( O O
chloroacetamido O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_NUMBER[MEASURE]/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]/B_PERSON
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
An O O
amount O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
1 O B_MEASURE
. O O
80 O B_MEASURE
g O I_MEASURE
( O O
10 O B_MEASURE/B_LOCATION
mmol O I_MEASURE/I_LOCATION
) O O
of O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_TIME[MEASURE]/B_PROTEIN[GENE]
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]/B_PERSON
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
suspended O O
in O O
20 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
anhydrous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonitrile O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
0 O B_MEASURE
. O O
9 O B_MEASURE
mL O I_MEASURE
( O O
0 O B_MEASURE
. O O
87g O B_MEASURE
, O O
11 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mmol O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
pyridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
added O O
. O O

The O O
mixture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
magnetically O O
stirred O O
at O O
4 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
10 O B_TIME[MEASURE]
minutes O I_TIME[MEASURE]
, O O
then O O
10 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
mmol O I_MEASURE/I_PERSON
of O O
monochloroacetyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dissolved O O
in O O
3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonitrile O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
added O O
dropwise O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
5 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
min O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
stirring O O
was O O
continued O O
for O O
other O B_TIME[MEASURE]
2 O I_TIME[MEASURE]
hours O I_TIME[MEASURE]
at O O
room O B_TIME[MEASURE]/B_LOCATION
temperature O I_TIME[MEASURE]/I_LOCATION
. O O

After O O
an O O
additional O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
refluxation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
followed O O
by O O
cooling O O
, O O
the O O
precipitated O O
crystals O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
filtered O O
and O O
recrystallized O O
from O O
ethanol O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Yield O B_MEASURE/B_ENT
of O O
62 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
white O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
crystals O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
mp O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
246 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
248 O B_TIME[MEASURE]
o O I_TIME[MEASURE]
lit O I_TIME[MEASURE]
[ O I_TIME[MEASURE]
34 O I_TIME[MEASURE]
] O O
mp O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
IR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
KBr O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
cm O B_LOCATION/B_PROTEIN[GENE]
- O O
l O B_OTHER/B_MEASURE
: O O
590 O B_MEASURE
, O O
610 O B_MEASURE
, O O
660 O B_MEASURE
, O O
790 O B_MEASURE
, O O
935 O B_MEASURE
, O O
1090 O B_MEASURE
, O O
1115 O B_MEASURE
, O O
1170 O B_MEASURE
, O O
1350 O B_MEASURE
, O O
1400 O B_MEASURE
, O O
1550 O B_MEASURE
, O O
1650 O B_MEASURE
, O O
1720 O B_MEASURE
, O O
2870 O B_MEASURE
, O O
3280 O B_MEASURE/B_LOCATION
3370 O I_MEASURE/I_LOCATION
( O O
broad O B_MEASURE
) O O
; O O
UV O B_DISEASE/B_PROTEIN[GENE]
spectrum O B_DISEASE/I_PROTEIN[GENE]
, O O
, O O
max O B_PERSON/B_PROTEIN[GENE]
, O O
nm O B_MEASURE/B_DISEASE
( O O
lg O B_MEASURE/B_PROTEIN[GENE]
) O O
: O O
255 O B_MEASURE
( O O
3 O B_MEASURE
. O O
50 O B_MEASURE
) O O
; O O
288 O B_MEASURE
( O O
4 O B_MEASURE
. O O
37 O B_MEASURE
) O O
H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
NMR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
d6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
i O O
, O O
ppm O B_MEASURE/B_PROTEIN[GENE]
: O O
2 O B_MEASURE
. O O
96 O B_MEASURE
( O O
s O O
, O O
2H O B_LOCATION/B_MEASURE
, O O
CH2 O B_LOCATION/B_PROTEIN[GENE]
) O O
; O O
8 O B_MEASURE
. O O
20 O B_MEASURE
( O O
s O O
, O O
2H O B_LOCATION
, O O
SOzNH2 O B_LOCATION
) O O
; O O
12 O B_MEASURE
. O O
22 O B_MEASURE
( O O
s O O
, O O
1H O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CONH O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Analysis O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
found O O
: O O
C O B_OTHER/B_LOCATION
, O O
18 O B_MEASURE
. O O
56 O B_MEASURE
; O O
H O B_OTHER/B_LOCATION
, O O
1 O B_MEASURE
. O O
88 O B_MEASURE
; O O
N O B_OTHER/B_LOCATION
, O O
21 O B_MEASURE
. O O
76 O B_MEASURE
; O O
S O B_OTHER/B_LOCATION
, O O
24 O B_MEASURE
. O O
62 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
C4HsC1N403S2 O B_LOCATION
requires O O
" O O
C O B_OTHER/B_LOCATION
, O O
18 O B_MEASURE
. O O
72 O B_MEASURE
; O O
H O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
1 O B_MEASURE
. O O
96 O B_MEASURE
; O O
N O B_OTHER/B_LOCATION
, O O
21 O B_MEASURE
. O O
83 O B_MEASURE
; O O
S O B_OTHER/B_LOCATION
, O O
24 O B_MEASURE
. O O
98 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

General O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
for O O
the O O
preparation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
compounds O B_MEASURE/B_LOCATION
8 O B_MEASURE/I_LOCATION
- O O
20 O B_MEASURE
An O O
amount O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
6 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mmol O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sodium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
salt O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
sulfonamides O B_MEASURE
6 O I_MEASURE
or O O
7 O B_MEASURE/B_LOCATION
was O O
prepared O O
by O O
reacting O O
the O O
corresponding O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sulfonamide O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
the O O
required O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
amount O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
an O O
alcoholic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaOH O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
ethanol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
solvent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
this O O
308 O B_TIME[MEASURE]/B_LOCATION

Claudiu O B_MEASURE
T O I_MEASURE
. O O
Supuran O B_PERSON/B_LOCATION
et O B_PERSON/I_LOCATION
al O B_PERSON/I_LOCATION
. O O

Metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Based O O
Drugs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE

solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
added O O
the O O
aqueous O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
metal O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
salt O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Zn O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Mg O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
AI O B_LOCATION
( O O
III O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
, O O
Cd O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
chlorides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
and O O
Be O O
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Pb O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
Hg O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
nitrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
working O O
in O O
molar O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ratios O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
RSOzNH O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
Mn O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
of O O
2 O B_MEASURE
: O O
1 O B_NUMBER[MEASURE]
for O O
the O O
divalent O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cations O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
3 O B_MEASURE
: O O
1 O B_NUMBER[MEASURE]
for O O
the O O
trivalent O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cation O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

The O O
aqueous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
alcoholic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reaction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
mixture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
heated O O
on O O
a O O
steam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bath O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
one O B_TIME[MEASURE]/B_ENT
hour O I_TIME[MEASURE]/I_ENT
, O O
adjusting O O
the O O
pH O B_MEASURE
at O O
7 O B_MEASURE/B_LOCATION
if O O
necessary O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
after O O
being O O
cooled O O
at O O
0 O B_NUMBER[MEASURE]/B_LOCATION
C O I_NUMBER[MEASURE]/I_LOCATION
the O O
precipitated O O
complexes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
filtered O O
and O O
thoroughly O O
washed O O
with O O
alcohol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
water O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
: O O
1 O B_MEASURE
( O O
v O B_OTHER/B_MEASURE
/ O O
v O O
) O O
and O O
air O B_DISEASE_ADJECTIVE[DISEASE]
dried O O
. O O

Yields O B_MEASURE/B_PERSON
were O O
in O O
the O O
range O B_LOCATION/B_MEASURE
of O O
85 O B_MEASURE
- O O
90 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
. O O

The O O
obtained O O
white O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
powders O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
compounds O B_MEASURE/B_PROTEIN[GENE]
8 O I_MEASURE/I_PROTEIN[GENE]
- O O
20 O B_MEASURE
melted O O
with O O
decomposition O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
temperatures O B_MEASURE
higher O I_MEASURE
than O O
350 O B_MEASURE/B_LOCATION
C O I_MEASURE/I_LOCATION
, O O
and O O
were O O
poorly O O
soluble O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
alcohol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
but O O
had O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solubilities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
DMF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
mixtures O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
DMF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pharmacology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Carbonic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
anhydrase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
inhibition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Initial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
4 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
nitrophenyl O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
hydrolysis O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
catalysed O O
by O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
CA O B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
isozymes O B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
were O O
monitored O O
spectrophotometrically O O
, O O
at O O
400 O B_MEASURE/B_LOCATION
rim O I_MEASURE/I_LOCATION
, O O
with O O
a O O
Cary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interfaced O O
with O O
an O O
IBM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compatible O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PC O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
35 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Solutions O B_LOCATION
of O O
substrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
prepared O O
in O O
anhydrous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonitrile O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
the O O
substrate O B_MEASURE
concentrations O I_MEASURE
varied O O
between O O
2 O B_MEASURE
. O O
10 O B_MEASURE
- O O
2 O B_MEASURE
and O O
1 O B_MEASURE
. O O
10 O B_MEASURE
- O O
6 O B_MEASURE/B_LOCATION
M O I_MEASURE/I_LOCATION
, O O
working O O
at O O
25C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

A O O
molar O B_MEASURE
absorption O I_MEASURE
coefficient O I_MEASURE
of O O
18 O B_MEASURE
, O O
400 O B_MEASURE
M O I_MEASURE
- O O
l O B_OTHER/B_MEASURE
. O O
cm O B_MEASURE/B_LOCATION
- O O
1 O B_MEASURE
was O O
used O O
for O O
the O O
4 O B_MEASURE/B_PROTEIN[GENE]
- O O
nitrophenolate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formed O O
by O O
hydrolysis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
the O O
conditions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
pH O B_MEASURE/B_LOCATION
7 O I_MEASURE/I_LOCATION
. O O
40 O B_MEASURE
) O O
, O O
as O O
reported O O
in O O
the O O
literature O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
[ O O
35 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Non O B_DISEASE
- O O
enzymatic O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrolysis O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
always O O
subtracted O O
from O O
the O O
observed O B_MEASURE
rates O I_MEASURE
. O O

Duplicate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
done O O
for O O
each O O
inhibitor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
the O O
values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reported O O
throughout O O
the O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
are O O
the O O
mean O B_MEASURE/B_PERSON
of O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Stock O B_PERSON/B_LOCATION
solutions O B_PERSON/I_LOCATION
of O O
inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
were O O
prepared O O
in O O
distilled O O
- O O
deionized O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
1020 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
v O B_OTHER/B_MEASURE
/ O O
v O O
) O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
which O O
is O O
not O O
inhibitory O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
these O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O I_MEASURE
2 O I_MEASURE
] O I_MEASURE
) O O
and O O
dilutions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
up O O
to O O
0 O B_MEASURE
. O O
01 O B_MEASURE
nM O I_MEASURE
were O O
done O O
thereafter O O
with O O
distilled O O
- O O
deionized O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
enzyme O B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
solutions O B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
were O O
preincubated O O
together O O
for O O
10 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
at O O
room O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperature O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prior O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
assay O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
order O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
allow O O
for O O
the O O
formation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
E O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
I O O
complex O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
inhibition O B_MEASURE/B_LOCATION
constant O B_MEASURE/I_LOCATION
KI O B_MEASURE/I_LOCATION
was O O
determined O O
as O O
described O O
by O O
Pocket O B_TIME[MEASURE]/B_PERSON
and O O
Stone O B_PERSON
[ O O
35 O B_LOCATION/B_GENE
] O I_LOCATION/I_GENE
. O O

Enzyme O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
3 O B_MEASURE
. O O
3 O B_MEASURE/B_COLOR
nM O I_MEASURE/I_COLOR
for O O
hCA O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
l0 O O
nM O B_MEASURE
for O O
hCA O B_DISEASE/B_PROTEIN[GENE]
and O O
34 O B_MEASURE
nM O I_MEASURE
for O O
bCA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
this O O
isozyme O B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
decreased O O
esterase O B_MEASURE
activity O I_MEASURE
[ O O
36 O B_MEASURE
] O I_MEASURE
and O O
higher O B_TIME[MEASURE]/B_LOCATION
concentrations O I_TIME[MEASURE]/I_LOCATION
had O O
to O O
be O O
used O O
for O O
the O O
- O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Measurement O O
of O O
tonometric O O
lOP O O
Adult O O
male O O
New O O
Zealand O O
albino O O
rabbits B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weighing O O
2 O O
- O O
3 O O
kg O O
were O O
used O O
in O O
the O O
experiments O O
( O O
three O O
animals O O
were O O
used O O
for O O
each O O
inhibitor O O
studied O O
) O O
. O O

The O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
procedures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
conform O O
to O O
the O O
Association O B_ORGANIZATION/B_LOCATION
for O O
Research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
Vision O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
and O O
Ophthalmology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Resolution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
animals O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
rabbits B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
kept O O
in O O
individual O O
cages O O
with O O
food O O
and O O
water O O
provided O O
ad O O
libitum O O
. O O

The O O
animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
maintained O O
on O O
a O O
12 O B_MEASURE
h O O
: O O
12 O B_MEASURE
h O O
light O B_COLOR/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
dark O B_TIME[MEASURE]/B_ENT
cycle O I_TIME[MEASURE]/I_ENT
in O O
a O O
temperature O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
controlled O O
room O B_LOCATION
, O O
at O O
22 O B_MEASURE
- O O
26 O B_TIME[MEASURE]/B_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
. O O

Solutions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
inhibitors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
by O O
weight O B_MEASURE
) O O
were O O
obtained O O
in O O
DMSOwater O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
2 O B_MEASURE
: O O
3 O B_MEASURE
, O O
v O O
/ O O
v O O
) O O
due O O
to O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
water O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
solubility O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
some O O
of O O
these O O
derivatives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
at O O
the O O
same O B_MEASURE/B_LOCATION
concentration O I_MEASURE/I_LOCATION
as O O
that O O
used O O
for O O
obtaining O O
the O O
inhibitors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
solutions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
showed O O
that O O
it O O
does O O
not O O
possess O O
IOP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lowering O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
increasing O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

IOP O B_DISEASE/B_PROTEIN[GENE]
was O O
measured O O
using O O
a O O
Digilab O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
30R O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
pneumatonometer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
( O O
BioRad O B_MEASURE/B_ORGANIZATION
, O O
Cambridge O B_LOCATION/B_PERSON
, O O
MA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
as O O
described O O
by O O
Maren O B_PERSON/B_ORGANIZATION
' O I_PERSON/I_ORGANIZATION
s O I_PERSON/I_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
[ O O
37 O B_MEASURE
- O O
39 O B_MEASURE
] O I_MEASURE
. O O

The O O
pressure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
readings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
matched O O
with O O
two O B_NUMBER[MEASURE]/B_LOCATION
- O O
point O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
pressure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
least O O
twice O O
each O O
day O B_TIME[MEASURE]/B_LOCATION
using O O
a O O
Digilab O B_PRODUCT[OBJECT]/B_MEASURE
Calibration O I_PRODUCT[OBJECT]/I_MEASURE
verifier O I_PRODUCT[OBJECT]/I_MEASURE
. O O

All O O
IOP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
done O O
by O O
the O O
same O B_PERSON
investigator O I_PERSON
with O O
the O O
same O B_PERSON/B_MEASURE
tonometer O I_PERSON/I_MEASURE
. O O

One O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drop O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
0 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
oxybuprocaine O I_MEASURE
hydrochloride O I_MEASURE
( O O
novesine O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Sandoz O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
diluted O O
1 O B_MEASURE
" O O
1 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
instilled O O
in O O
each O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
immediately O O
before O O
each O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
pressure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

IOP O B_DISEASE
was O O
measured O O
three O B_TIME[MEASURE]/B_LOCATION
times O I_TIME[MEASURE]/I_LOCATION
at O O
each O O
time O B_LOCATION/B_MEASURE
interval O I_LOCATION/I_MEASURE
, O O
and O O
the O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O O
. O O

IOP O B_DISEASE/B_GENE
was O O
measured O O
first O O
immediately O O
before O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
then O O
at O O
30 O B_TIME[MEASURE]/B_LOCATION
min O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
instillation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
pharmacological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
then O O
each O O
30 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
for O O
a O O
period O B_MEASURE/B_LOCATION
of O O
several O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
. O O

For O O
all O O
IOP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
experiments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
drug O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
was O O
administered O O
to O O
only O O
one O B_PERSON
eye O I_PERSON
, O O
leaving O O
the O O
contralateral O B_PERSON/B_DISEASE
eye O B_PERSON/I_DISEASE
as O O
an O O
untreated O B_PERSON/B_ORGANIZATION
control O I_PERSON/I_ORGANIZATION
. O O

The O O
ocular O O
hypotensive O O
activity O O
is O O
expressed O O
as O O
the O O
average O O
difference O O
in O O
IOP O O
between O O
the O O
treated O O
and O O
control O O
eye O O
, O O
in O O
this O O
way O O
minimizing O O
the O O
diurnal O O
, O O
seasonal O O
and O O
interindividual O O
variations O O
commonly O O
observed O O
in O O
the O O
rabbit B B_BIO/B_PERSON
[ O O
37 O O
- O O
39 O O
] O O
. O O

All O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
expressed O O
as O O
mean O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SE O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
using O O
a O O
one O B_NUMBER[MEASURE]
- O O
tailed O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Reaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_NUMBER[MEASURE]/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]/B_PERSON
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_LOCATION
19b O I_LOCATION
] O O
with O O
chloroacteyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
pyridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
afforded O O
5 O B_NUMBER[MEASURE]/B_LOCATION
- O O
( O O
chloroacetamido O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]/B_PERSON
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
by O O
the O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
already O O
reported O O
by O O
Young O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O I_PERSON/I_LOCATION
. O O

[ O O
34 O B_TIME[MEASURE]/B_ORGANIZATION
] O I_TIME[MEASURE]/I_ORGANIZATION
( O O
Scheme O B_MEASURE
1 O I_MEASURE
) O O
. O O

The O O
sulfonamide O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
7 O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
been O O
characterized O O
by O O
elemental O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
spectroscopic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
methods O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O O
confirmed O O
its O O
structure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
only O O
its O O
m O B_DISEASE/B_PROTEIN[GENE]
. O O
p O B_MEASURE/B_GENE
. O O
has O O
been O O
reported O O
in O O
ref O B_TIME[MEASURE]/B_PERSON
. O O
[ O O
34 O B_MEASURE
] O I_MEASURE
) O O
. O O

The O O
sodium O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
salt O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
sulfonamides O B_NUMBER[MEASURE]
6 O I_NUMBER[MEASURE]
and O O
7 O B_NUMBER[MEASURE]
, O O
obtained O O
in O O
situ O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
corresponding O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
hydroxide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O O
were O O
then O O
used O O
for O O
the O O
preparation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
coordination O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
containing O O
the O O
following O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O O
Be O O
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Mg O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Al O B_LOCATION/B_PERSON
( O O
III O B_TIME[MEASURE]/B_LOCATION
) O O
, O O
Zn O B_LOCATION
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Cd O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
Hg O B_LOCATION/B_MEASURE
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Mention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
should O O
be O O
made O O
that O O
although O O
5 O B_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_MEASURE/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
parent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compound O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
important O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
sulfonamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
CA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
acetazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
benzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
methazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
etc O B_LOCATION/B_GENE
. O O
, O O
its O O
coordination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemistry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
scarcely O O
investigated O O
up O O
to O O
now O O
[ O O
22 O B_MEASURE
, O O
40 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
new O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
prepared O O
in O O
this O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
shown O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
I O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O
Both O O
compounds O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
containing O O
the O O
sulfonamide O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
deprotonated O O
species O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
LH O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
as O O
well O O
as O O
complexes O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
the O O
anion O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
5amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
tda O B_LOCATION/B_PROTEIN[GENE]
) O O
act O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
ligands O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
have O O
been O O
prepared O O
. O O

In O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
another O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O O
40 O B_TIME[MEASURE]
] O O
it O O
was O O
documented O O
that O O
in O O
some O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sulfonamides O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
derived O O
from O O
this O O
ring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
may O O
undergo O O
hydrolysis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O

309 O B_NUMBER[MEASURE]

Vol O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

4 O O
, O O
No O O
. O O
6 O B_MEASURE
, O O
1997 O B_MEASURE/B_LOCATION

Metal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Complexes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O
" O O
A O B_MEASURE/B_LOCATION
New O B_MEASURE/I_LOCATION
Class O B_MEASURE/I_LOCATION
ofAntiglaucoma O B_MEASURE/I_LOCATION
Agents O B_MEASURE/I_LOCATION

the O O
moiety O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
substituting O O
the O O
5 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
the O O
formation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_MEASURE
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
thereafter O O
coordinates O O
metal O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O I_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

N O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CIH O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

I O B_OTHER/B_PERSON

N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
NaHCO O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION

N O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

- O O
NaCl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

I O O
S O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

N O B_OTHER/B_PERSON

II O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

SO2NH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]

1 O B_MEASURE
_ O O
12 O B_TIME[MEASURE]
O O I_TIME[MEASURE]
Py O I_TIME[MEASURE]
/ O O
MeCN O B_LOCATION/B_MEASURE

6Htda O O
+ O O
CIOCCH2CI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

0 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Cl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
CH O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Scheme O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

HN O B_DISEASE/B_MEASURE

. O B_OTHER/B_MEASURE
I O O

N O B_OTHER/B_PERSON

N O B_OTHER/B_PERSON

S O B_LOCATION
7 O I_LOCATION
: O O
LH O B_MEASURE/B_PERSON

II O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

SqNH O B_GENE/B_MEASURE

Thus O O
, O O
the O O
X O B_NUMBER[MEASURE]/B_DISEASE
- O O
ray O B_LOCATION/B_MEASURE
crystal O I_LOCATION/I_MEASURE
structure O I_LOCATION/I_MEASURE
of O O
the O O
complex O B_LOCATION/B_BIO
[ O I_LOCATION/I_BIO
Zn O I_LOCATION/I_BIO
( O O
tda O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
2 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NH3 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
] O O
. O O
H20 O O
prepared O O
in O O
this O O
way O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O O
recently O O
been O O
reported O O
by O O
this O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
40 O B_LOCATION/B_PERSON
] O I_LOCATION/I_PERSON
. O O

On O O
the O O
other O B_PERSON/B_LOCATION
hand O B_PERSON/I_LOCATION
, O O
when O O
the O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O O
not O O
been O O
hydrolyzed O O
( O O
during O O
the O O
preparation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
coordination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
metal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_MEASURE/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
chloroacetate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
the O O
metal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
complexes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
contining O O
6 O B_NUMBER[MEASURE]/B_PERSON
as O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
have O O
been O O
prepared O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
last O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
pure O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
as O O
sodium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
salt O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
the O O
corresponding O B_MEASURE/B_LOCATION
metal O I_MEASURE/I_LOCATION
salt O I_MEASURE/I_LOCATION
, O O
by O O
the O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
described O O
in O O
the O O
Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
part O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Table O B_LOCATION/B_MEASURE
I O O
: O O
Prepared O O
complexes O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
- O O
20 O B_MEASURE
, O O
containing O O
the O O
conjugate O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bases O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
sulfonamides O B_NUMBER[MEASURE]
6 O I_NUMBER[MEASURE]
and O O
7 O B_NUMBER[MEASURE]
as O O
ligands O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
their O O
elemental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

L O B_PROTEIN[GENE]/B_MEASURE
stands O O
for O O
the O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deprotonated O O
species O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O O
7 O B_MEASURE/B_BIO
, O O
whereas O O
tda O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deprotonated O O
species O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

No O O
. O O
8 O B_TIME[MEASURE]/B_LOCATION
9 O B_TIME[MEASURE]/I_LOCATION
10 O B_TIME[MEASURE]/I_LOCATION
11 O B_TIME[MEASURE]/I_LOCATION
12 O B_TIME[MEASURE]/I_LOCATION
13 O B_TIME[MEASURE]/I_LOCATION
14 O B_TIME[MEASURE]/I_LOCATION
15 O B_TIME[MEASURE]/I_LOCATION
16 O B_TIME[MEASURE]/I_LOCATION
17 O B_TIME[MEASURE]/I_LOCATION
18 O B_TIME[MEASURE]/I_LOCATION
19 O B_TIME[MEASURE]/I_LOCATION
20 O B_TIME[MEASURE]/I_LOCATION

Complex O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Yield O B_TIME[MEASURE]

( O O
% O B_OTHER/B_MEASURE
) O O

% O B_PERSON/B_MEASURE
Ma O I_PERSON/I_MEASURE

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
calculated O O
/ O O
found O O
) O O
% O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
b O O
% O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
b O O
13 O B_MEASURE
. O O
0 O B_MEASURE
/ O O
13 O B_MEASURE
. O O
1 O B_MEASURE
11 O I_MEASURE
. O O
0 O B_MEASURE
/ O O
10 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
11 O I_TIME[MEASURE]
. O O
3 O B_MEASURE
/ O O
11 O B_MEASURE
. O O
4 O B_MEASURE
10 O I_MEASURE
. O O
2 O B_MEASURE
/ O O
10 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
. O O
5 O B_MEASURE
/ O O
8 O B_MEASURE
. O O
1 O B_MEASURE
7 O I_MEASURE
. O O
9 O B_MEASURE
/ O O
7 O B_MEASURE
. O O
9 O B_TIME[MEASURE]
12 O I_TIME[MEASURE]
. O O
7 O B_MEASURE
/ O O
12 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
18 O I_TIME[MEASURE]
. O O
4 O B_MEASURE
/ O O
18 O B_MEASURE
. O O
1 O B_MEASURE
18 O I_MEASURE
. O O
1 O B_MEASURE
/ O O
17 O B_MEASURE
. O O
9 O B_TIME[MEASURE]
16 O I_TIME[MEASURE]
. O O
6 O B_MEASURE
/ O O
16 O B_MEASURE
. O O
2 O B_TIME[MEASURE]
15 O I_TIME[MEASURE]
. O O
3 O B_MEASURE
/ O O
14 O B_MEASURE
. O O
9 O B_TIME[MEASURE]
13 O I_TIME[MEASURE]
. O O
4 O B_MEASURE
/ O O
13 O B_MEASURE
. O O
3 O B_TIME[MEASURE]
12 O I_TIME[MEASURE]
. O O
7 O B_MEASURE
/ O O
12 O B_MEASURE
. O O
5 O B_MEASURE
1 O I_MEASURE
. O O
6 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
2 O I_MEASURE
. O O
7 O B_MEASURE
/ O O
2 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
1 O I_MEASURE
. O O
4 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE
1 O I_MEASURE
. O O
2 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
2 O B_MEASURE
1 O I_MEASURE
. O O
0 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
2 O B_MEASURE
1 O I_MEASURE
. O O
6 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
1 O I_MEASURE
. O O
6 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
6 O B_MEASURE
1 O I_MEASURE
. O O
5 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
1 O I_MEASURE
. O O
5 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
1 O I_MEASURE
. O O
3 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
4 O B_MEASURE
1 O I_MEASURE
. O O
2 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE
1 O I_MEASURE
. O O
1 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
2 O B_MEASURE
1 O I_MEASURE
. O O
0 O B_MEASURE
/ O O
1 O B_NUMBER[MEASURE]
. O O
0 O B_MEASURE

% O B_MEASURE
N O I_MEASURE
b O O
30 O B_MEASURE
. O O
4 O B_MEASURE
/ O O
30 O B_MEASURE
. O O
2 O B_MEASURE
25 O I_MEASURE
. O O
6 O B_MEASURE
/ O O
25 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
26 O I_TIME[MEASURE]
. O O
4 O B_MEASURE
/ O O
26 O B_MEASURE
. O O
4 O B_TIME[MEASURE]
13 O I_TIME[MEASURE]
. O O
7 O B_MEASURE
/ O O
23 O B_MEASURE
. O O
3 O B_TIME[MEASURE]
20 O I_TIME[MEASURE]
. O O
0 O B_MEASURE
/ O O
19 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
18 O I_TIME[MEASURE]
. O O
6 O B_MEASURE
/ O O
18 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
29 O I_TIME[MEASURE]
. O O
7 O B_MEASURE
/ O O
29 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
21 O I_TIME[MEASURE]
. O O
5 O B_MEASURE
/ O O
21 O B_MEASURE
. O O
3 O B_TIME[MEASURE]
21 O I_TIME[MEASURE]
. O O
1 O B_MEASURE
/ O O
20 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
19 O I_TIME[MEASURE]
. O O
4 O B_MEASURE
/ O O
19 O B_MEASURE
. O O
3 O B_TIME[MEASURE]
17 O I_TIME[MEASURE]
. O O
9 O B_MEASURE
/ O O
17 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
15 O I_TIME[MEASURE]
. O O
7 O B_MEASURE
/ O O
15 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
14 O I_TIME[MEASURE]
. O O
8 O B_MEASURE
/ O O
14 O B_MEASURE
. O O
6 O B_MEASURE

[ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Be O O
( O O
tda O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Mg O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
tda O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O
3 O B_LOCATION/B_ORGANIZATION
H20 O I_LOCATION/I_ORGANIZATION
[ O I_LOCATION/I_ORGANIZATION
Zn O I_LOCATION/I_ORGANIZATION
( O O
tda O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
2 O B_LOCATION/B_ENT
] O I_LOCATION/I_ENT
[ O I_LOCATION/I_ENT
Cd O I_LOCATION/I_ENT
( O O
tda O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2 O B_PROTEIN[GENE]/B_LOCATION
] O B_PROTEIN[GENE]/I_LOCATION
[ O B_PROTEIN[GENE]/I_LOCATION
Hg O B_PROTEIN[GENE]/I_LOCATION
( O O
tda O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Pb O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
tda O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
z O B_MEASURE/B_LOCATION
( O O
OH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Al O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
tda O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
3 O B_NUMBER[MEASURE]
] O O
[ O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BeL2 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
[ O B_NUMBER[MEASURE]/B_PERSON
ALL3 O I_NUMBER[MEASURE]/I_PERSON
] O O
[ O B_MEASURE/B_LOCATION
ZnL2 O I_MEASURE/I_LOCATION
] O O
[ O B_MEASURE/B_LOCATION
CdL2 O I_MEASURE/I_LOCATION
] O O
[ O B_MEASURE/B_LOCATION
HgL2 O I_MEASURE/I_LOCATION
] O O
[ O B_LOCATION/B_ORGANIZATION
PbLz O I_LOCATION/I_ORGANIZATION
( O O
OH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

78 O B_MEASURE
76 O I_MEASURE
83 O I_MEASURE
90 O I_MEASURE
95 O I_MEASURE
84 O I_MEASURE
72 O I_MEASURE
75 O I_MEASURE
59 O I_MEASURE
87 O I_MEASURE
88 O I_MEASURE
92 O I_MEASURE
95 O I_MEASURE

2 O O
. O O
4 O B_MEASURE
/ O O
2 O B_MEASURE
. O O
5 O B_MEASURE
5 O I_MEASURE
. O O
5 O B_MEASURE
/ O O
5 O B_MEASURE
. O O
1 O B_MEASURE
15 O I_MEASURE
. O O
4 O B_MEASURE
/ O O
15 O B_MEASURE
. O O
0 O B_MEASURE
23 O I_MEASURE
. O O
8 O B_MEASURE
/ O O
24 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
35 O I_MEASURE/I_LOCATION
. O O
8 O B_MEASURE
/ O O
35 O B_MEASURE
. O O
7 O B_TIME[MEASURE]
34 O I_TIME[MEASURE]
. O O
4 O B_MEASURE
/ O O
34 O B_MEASURE
. O O
7 O B_MEASURE
4 O I_MEASURE
. O O
7 O B_MEASURE
/ O O
4 O B_MEASURE
. O O
4 O B_MEASURE
1 O I_MEASURE
. O O
7 O B_MEASURE
/ O O
1 O B_MEASURE
. O O
6 O B_MEASURE
3 O I_MEASURE
. O O
4 O B_MEASURE
/ O O
3 O B_MEASURE
. O O
5 O B_MEASURE
11 O I_MEASURE
. O O
3 O B_MEASURE
/ O O
11 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
18 O I_TIME[MEASURE]
. O O
0 O B_MEASURE
/ O O
18 O B_MEASURE
. O O
1 O B_MEASURE
28 O I_MEASURE
. O O
1 O B_MEASURE
/ O O
28 O B_MEASURE
. O O
3 O B_TIME[MEASURE]
27 O I_TIME[MEASURE]
. O O
4 O B_MEASURE
/ O O
27 O B_MEASURE
. O O
2 O B_MEASURE

aBy O O
gravimetry O B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
bBy O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
combustion O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

The O O
new O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
also O O
been O O
characterized O O
by O O
spectroscopic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
conductimetric O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
thermogravimetric O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
measurements O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Table O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

By O O
comparing O O
the O O
IR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spectra O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
complexes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
the O O
corresponding O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ligands O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
made O O
: O O
( O O
i O O
) O O
the O O
shift O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
two O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamido O B_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vibrations O B_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
both O O
the O O
symmetric O B_PERSON/B_MEASURE
as O O
well O O
as O O
the O O
the O O
assymetric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
towards O O
lower O B_DISEASE_ADJECTIVE[DISEASE]
wavenumbers O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
spectra O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
complexes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
compared O O
to O O
the O O
spectra O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
corresponding O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ligand O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Table O B_MEASURE
II O I_MEASURE
) O O
, O O
as O O
already O O
documented O O
previously O O
for O O
similar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
13 O B_NUMBER[MEASURE]
- O O
22 O B_MEASURE
] O I_MEASURE
. O O

This O O
is O O
a O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indication O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
the O O
deprotonated O B_LOCATION/B_PERSON
sulfonamido O I_LOCATION/I_PERSON
310 O I_LOCATION/I_PERSON

Claudiu O B_MEASURE
T O I_MEASURE
. O O
Supuran O B_PERSON/B_LOCATION
et O B_PERSON/I_LOCATION
al O B_PERSON/I_LOCATION
. O O

Metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Based O O
Drugs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE

moieties O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
ligands O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
newly O O
prepared O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
coordination O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
compounds O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O O
( O O
ii O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O O
the O O
amide O B_MEASURE/B_ENT
vibrations O I_MEASURE/I_ENT
( O O
the O O
most O O
intense O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bands O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
1670 O B_MEASURE
- O O
1680 O B_MEASURE
cm O I_MEASURE
- O O
1 O B_NUMBER[MEASURE]/B_LOCATION
) O O
of O O
ligand O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
7 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
appear O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O O
the O O
IR O B_LOCATION
spectra O I_LOCATION
of O O
complexes O B_SEQUENCE[MEASURE]/B_LOCATION
15 O I_SEQUENCE[MEASURE]/I_LOCATION
- O O
20 O B_MEASURE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
not O O
shown O O
) O O
, O O
suggesting O O
that O O
these O O
moieties O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
do O O
not O O
participate O O
in O O
coordination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O O
( O O
iii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
the O O
C O B_PROTEIN[GENE]/B_LOCATION
- O O
N O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stretching O O
vibration O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
spectra O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
prepared O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
shifted O O
with O O
5 O B_MEASURE
- O O
20 O B_MEASURE
cm O I_MEASURE
- O O
1 O B_MEASURE/B_LOCATION
towards O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wavenumbers O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
compared O O
to O O
the O O
same O B_MEASURE
vibration O I_MEASURE
in O O
the O O
spectra O B_LOCATION/B_ORGANIZATION
of O O
sulfonamides O B_MEASURE
6 O I_MEASURE
and O O
7 O B_NUMBER[MEASURE]
, O O
indicating O O
that O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
endocyclic O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrogens O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
thiadiazolic O B_LOCATION
ring O I_LOCATION
( O O
presumably O O
N3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
acts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
as O O
donor O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
atom O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
as O O
already O O
documented O O
by O O
X O B_OTHER/B_DISEASE
- O O
ray O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
crystallographic O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
spectroscopic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
determinations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
on O O
complexes O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sulfonamides O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O O
1 O B_MEASURE/B_LOCATION
- O O
3 O B_MEASURE
) O O
with O O
divalent O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
metal O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
13 O B_MEASURE
- O O
22 O B_MEASURE
] O I_MEASURE
( O O
Table O B_MEASURE
II O I_MEASURE
) O O
; O O
( O O
iv O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
region O B_MEASURE/B_LOCATION
3100 O I_MEASURE/I_LOCATION
- O O
3160 O B_MEASURE
cm O I_MEASURE
- O O
, O O
as O O
the O O
bands O B_TIME[MEASURE]/B_PERSON
present O I_TIME[MEASURE]/I_PERSON
in O O
the O O
spectra O B_LOCATION/B_MEASURE
of O O
sulfonamides O B_NUMBER[MEASURE]
6 O I_NUMBER[MEASURE]
, O O
7 O B_NUMBER[MEASURE]/B_PERSON
are O O
present O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
spectra O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
complexes O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
20 O B_MEASURE
too O O
, O O
but O O
they O O
are O O
not O O
well O O
resolved O O
, O O
and O O
have O O
a O O
smaller O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensity O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
is O O
probably O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
deprotonation O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
SO2NH2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moiety O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
participation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
cations O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O O
( O O
v O B_OTHER/B_PROTEIN[GENE]
) O O
the O O
amino O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vibrations O B_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
3320 O B_MEASURE
cm O I_MEASURE
- O O
in O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
spectra O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
6 O B_MEASURE
appear O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
spectra O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
its O O
complexes O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
14 O B_MEASURE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
not O O
s O O
. O O
hown O B_MEASURE/B_PERSON
) O O
. O O

In O O
the O O
1H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
NMR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectra O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
its O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
signal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
amino O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
been O O
evidenced O O
as O O
a O O
broad O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
singlet O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
centered O O
at O O
4 O B_MEASURE
. O O
54 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
, O O
which O O
is O O
not O O
exchangeable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
D20 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
NMR O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tube O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
in O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
sulfonamido O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
NH2 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
protons O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
which O O
readily O O
exchange O O
) O O
. O O

This O O
proves O O
that O O
the O O
5 O B_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
moiety O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
not O O
involved O O
in O O
binding O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
already O O
shown O O
in O O
the O O
X O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O O
ray O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
crystallographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
complex O B_LOCATION/B_BIO
[ O I_LOCATION/I_BIO
Zn O I_LOCATION/I_BIO
( O O
tda O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
z O B_MEASURE/B_LOCATION
( O O
NH3 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
] O B_OTHER/B_DISEASE
. O O
H20 O B_LOCATION/B_PERSON
previously O O
reported O O
[ O O
40 O B_LOCATION/B_PERSON
] O I_LOCATION/I_PERSON
. O O

For O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
the O O
CONH O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
proton O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
resonates O O
as O O
a O O
singlet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
12 O B_MEASURE
. O O
22 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
. O O

In O O
complexes O B_MEASURE/B_LOCATION
15 O I_MEASURE/I_LOCATION
- O O
20 O B_MEASURE
only O O
very O O
minor O B_DISEASE_ADJECTIVE[DISEASE]
shifts O I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
signal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
evidenced O O
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
proving O O
basically O O
that O O
the O O
CONH O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moiety O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
interact O O
with O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
complexes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Spectroscopic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
thermogravimetric O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
conductimetric O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
compounds O B_MEASURE/B_PROTEIN[GENE]
6 O I_MEASURE/I_PROTEIN[GENE]
- O O
20 O B_MEASURE
. O O

1H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
NMR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Spectrab O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Comp O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

IR O B_MEASURE
Spectraa O I_MEASURE
, O O
cm O B_MEASURE/B_LOCATION
- O O
1 O B_MEASURE
as O O
v O B_MEASURE/B_GENE
( O O
C O B_OTHER/B_PROTEIN[GENE]
= O O
N O B_OTHER/B_MEASURE
) O O
CONH O B_NUMBER[MEASURE]/B_ORGANIZATION
, O O
i O O
( O O
ppm O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
v O B_PROTEIN[GENE]/B_LOCATION
( O O
SO2 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
S O B_MEASURE/B_OTHER
; O O
v O B_PROTEIN[GENE]/B_LOCATION
( O O
SO2 O B_LOCATION/B_MEASURE
) O O
6 O B_LOCATION/B_PROTEIN[GENE]
8 O I_LOCATION/I_PROTEIN[GENE]
9 O I_LOCATION/I_PROTEIN[GENE]
10 O I_LOCATION/I_PROTEIN[GENE]
11 O I_LOCATION/I_PROTEIN[GENE]

TG O B_LOCATION/B_ORGANIZATION
analysisc O I_LOCATION/I_ORGANIZATION
calc O I_LOCATION/I_ORGANIZATION
. O O
/ O O
found O O

Conductimetryd O B_MEASURE
AM O I_MEASURE
( O O
- O O
1 O B_MEASURE/B_LOCATION
x O I_MEASURE/I_LOCATION
cm2x O I_MEASURE/I_LOCATION
mol O I_MEASURE/I_LOCATION
- O O
) O O
2 O B_MEASURE/B_LOCATION
7 O B_MEASURE/I_LOCATION
4 O B_MEASURE/I_LOCATION
5 O B_MEASURE/I_LOCATION
3 O B_MEASURE/I_LOCATION
2 O B_MEASURE/I_LOCATION
2 O B_MEASURE/I_LOCATION
6 O B_MEASURE/I_LOCATION
3 O B_MEASURE/I_LOCATION
4 O B_MEASURE/I_LOCATION
2 O B_MEASURE/I_LOCATION
9 O B_MEASURE/I_LOCATION
3 O B_MEASURE/I_LOCATION
2 O B_MEASURE/I_LOCATION
8 O B_MEASURE/I_LOCATION

12 O B_TIME[MEASURE]
13 O I_TIME[MEASURE]
14 O I_TIME[MEASURE]
7 O I_TIME[MEASURE]
15 O I_TIME[MEASURE]
16 O I_TIME[MEASURE]
17 O I_TIME[MEASURE]
18 O I_TIME[MEASURE]
19 O I_TIME[MEASURE]
20 O I_TIME[MEASURE]

1170 O B_NUMBER[MEASURE]
; O O
1150 O B_NUMBER[MEASURE]
; O O
1150 O B_NUMBER[MEASURE]
; O O
1145 O B_NUMBER[MEASURE]
; O O
1145 O B_TIME[MEASURE]
; O O
1140 O B_MEASURE/B_LOCATION
; O O
1145 O B_NUMBER[MEASURE]
; O O
1150 O B_SEQUENCE[MEASURE]
; O O
1170 O B_NUMBER[MEASURE]
; O O
1130 O B_TIME[MEASURE]
; O O
1140 O B_SEQUENCE[MEASURE]
; O O
1140 O B_SEQUENCE[MEASURE]/B_LOCATION
; O O
1150 O B_MEASURE/B_LOCATION
; O O
1140 O B_SEQUENCE[MEASURE]/B_LOCATION
; O O
1145 O B_SEQUENCE[MEASURE]
; O O

1350 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1305 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1305 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1350 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1335 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1330 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1330 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1330 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1335 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1330 O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

1610 O B_TIME[MEASURE]
1600 O I_TIME[MEASURE]
1600 O I_TIME[MEASURE]
1600 O I_TIME[MEASURE]
1600 O I_TIME[MEASURE]
1590 O I_TIME[MEASURE]
1605 O I_TIME[MEASURE]
1605 O I_TIME[MEASURE]
1610 O I_TIME[MEASURE]
1605 O I_TIME[MEASURE]
1610 O I_TIME[MEASURE]
1610 O I_TIME[MEASURE]
1605 O I_TIME[MEASURE]
1600 O I_TIME[MEASURE]
1600 O I_TIME[MEASURE]

A O O
A O B_OTHER/B_LOCATION
A O O
A O O
A O O
A O O
A O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

e O B_DISEASE
e O O

12 O O
. O O
3 O B_MEASURE
/ O O
12 O B_MEASURE
. O O
1f O B_MEASURE/B_LOCATION
e O O
e O O
e O B_MEASURE/B_LOCATION
5 O I_MEASURE/I_LOCATION
. O O
9 O B_MEASURE
/ O O
5 O B_MEASURE
. O O
7g O B_MEASURE

A O O
12 O B_MEASURE
. O O
22 O B_MEASURE
( O O
1H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
12 O B_NUMBER[MEASURE]
. O O
19 O B_MEASURE
( O I_MEASURE
2H O I_MEASURE
) O O
12 O B_NUMBER[MEASURE]
. O O
18 O B_MEASURE
( O I_MEASURE
3H O I_MEASURE
) O O
12 O B_NUMBER[MEASURE]
. O O
20 O B_MEASURE
( O I_MEASURE
2H O I_MEASURE
) O O
12 O B_NUMBER[MEASURE]
. O O
18 O B_MEASURE
( O I_MEASURE
2H O I_MEASURE
) O O
12 O B_NUMBER[MEASURE]
. O O
19 O B_MEASURE
( O I_MEASURE
2H O I_MEASURE
) O O
12 O B_NUMBER[MEASURE]
. O O
21 O B_MEASURE
( O I_MEASURE
2H O I_MEASURE
) O O

e O O
e O O
e O O
e O O
e O O
e O O
e O O
4 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
/ O O
4 O B_MEASURE
. O O
8g O B_MEASURE

a O O
In O O
KBr O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O O
bin O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DMSO O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
d6 O B_MEASURE/B_PERSON
; O O
A O O
the O O
signal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
of O O
the O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
6 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
appearing O O
in O O
the O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O O
4 O B_NUMBER[MEASURE]
. O O
54 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
as O O
a O O
broad O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
singlet O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
appears O O
at O O
the O O
same O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemical O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shift O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O B_MEASURE/B_LOCATION
. O O
50 O B_MEASURE
4 O I_MEASURE
. O O
55 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
) O O
in O O
complexes O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
- O O
14 O B_MEASURE
; O O
cWeight O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
70 O B_MEASURE
- O O
250 O B_MEASURE/B_PERSON
C O I_MEASURE/I_PERSON
; O O
d O O
mM O B_LOCATION
solution O I_LOCATION
, O O
in O O
DMF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
at O O
25C O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
e O B_PROTEIN[GENE]/B_DISEASE
No O O
weight O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
loss O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
seen O O
under O O
250 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O O
fCorresponding O O
to O O
three O B_LOCATION/B_BIO
lattice O B_LOCATION/I_BIO
water O B_LOCATION/I_BIO
molecules O B_LOCATION/I_BIO
lost O O
at O O
70 O B_MEASURE
- O O
110C O B_MEASURE/B_PERSON
, O O
and O O
gCorresponding O O
to O O
two O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coordinated O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecules O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lost O O
at O O
160 O B_MEASURE
- O O
180 O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thermogravimetric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
the O O
presence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
uncoordinated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
molecule O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O O
complex O B_MEASURE/B_LOCATION
9 O I_MEASURE/I_LOCATION
( O O
the O O
three O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
waters O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
lost O O
in O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
between O O
70 O B_MEASURE
- O O
110 O B_MEASURE/B_LOCATION
C O I_MEASURE/I_LOCATION
) O O
and O O
of O O
coordinated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
molecules O B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
lead O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
derivatives O B_MEASURE/B_PERSON
13 O I_MEASURE/I_PERSON
and O O
20 O B_MEASURE
. O O

All O O
these O O
compounds O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behaved O O
as O O
non O B_DISEASE
- O O
electrolytes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
DMF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
solvent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Mention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
made O O
that O O
the O O
Mg O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
II O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
complex O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O O
not O O
be O O
isolated O O
. O O

Instead O O
, O O
only O O
the O O
correponding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
l O B_PROTEIN[GENE]/B_DISEASE
, O O
3 O B_MEASURE/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
obtained O O
from O O
reaction O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mixtures O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
magnesium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
salts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
the O O
sodium O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
salt O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
7 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
probably O O
due O O
to O O
a O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion O O
assisted O O
hydrolysis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
7 O B_NUMBER[MEASURE]
to O O
6 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
chloroacetate O B_MEASURE
. O O

Generally O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrolytic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
involve O O
highly O O
acidic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prolonged O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heating O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
5 O B_MEASURE/B_PROTEIN[GENE]
- O O
alkylamido O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
- O O
thiadiazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE
- O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
41 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
, O O
but O O
they O O
might O O
become O O
milder O B_DISEASE_ADJECTIVE[DISEASE]
by O O
taking O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O O
putative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalytic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Mg2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
ions O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reported O O
here O O
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
shown O O
above O O
lead O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
ligand O O
7 O B_MEASURE/B_LOCATION
shares O B_MEASURE/I_LOCATION
a O O
common O B_LOCATION/B_ORGANIZATION
coordination O I_LOCATION/I_ORGANIZATION
chemistry O I_LOCATION/I_ORGANIZATION
with O O
acetazolamide O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
which O O
it O O
is O O
structurally O O
related O O
, O O
whereas O O
6 O B_NUMBER[MEASURE]/B_LOCATION
probably O O
also O O
behaves O O
similarly O O
to O O
acetazolamide O O
in O O
the O O
sense O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
5 O B_NUMBER[MEASURE]
- O O
amino O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
seems O O
not O O
to O O
be O O
involved O O
in O O
coordinating O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
at O O
311 O B_MEASURE/B_LOCATION

Vol O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

4 O O
, O O
No O O
. O O
6 O B_MEASURE
, O O
1997 O B_MEASURE/B_LOCATION

Metal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Complexes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
Heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
A O O
New O B_PERSON/B_ENT
Class O B_PERSON/I_ENT
ofAntiglaucoma O B_PERSON/I_ENT
Agents O B_PERSON/I_ENT

least O B_LOCATION/B_DISEASE
in O O
the O O
complexes O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O O
by O O
us O O
here O O
( O O
and O O
also O O
in O O
the O O
compound O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characterized O O
by O O
X O B_PROTEIN[GENE]/B_DISEASE
- O O
ray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
crystallography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mentioned O O
above O O
[ O B_MEASURE/B_LOCATION
40 O I_MEASURE/I_LOCATION
] O I_MEASURE/I_LOCATION
) O O
. O O

Thus O O
, O O
in O O
all O O
complexes O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O O
here O O
these O O
sulfonamides O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
as O O
monodeprotonated O O
species O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
at O O
the O O
SO2NH O B_LOCATION/B_MEASURE
2 O I_LOCATION/I_MEASURE
moieties O I_LOCATION/I_MEASURE
) O O
act O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
bidentate O B_LOCATION/B_PERSON
ligands O I_LOCATION/I_PERSON
, O O
through O O
the O O
endocyclic O B_LOCATION
N O I_LOCATION
- O O
3 O B_MEASURE/B_LOCATION
and O O
the O O
NH O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
proposed O O
formulae O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
complxes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
are O O
shown O O
below O O
. O O

Except O O
for O O
the O O
two O B_LOCATION/B_ORGANIZATION
Pb O I_LOCATION/I_ORGANIZATION
( O O
II O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
complexes O B_MEASURE/B_LOCATION
13 O I_MEASURE/I_LOCATION
and O O
20 O B_MEASURE
, O O
as O O
well O O
as O O
the O O
AI O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
III O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
derivatives O B_MEASURE/B_PERSON
14 O I_MEASURE/I_PERSON
and O O
16 O B_MEASURE
, O O
which O O
presumably O O
are O O
pseudo O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
octahedral O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
other O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derivatives O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
supposed O O
to O O
contain O O
tetrahedral O B_LOCATION
M O I_LOCATION
( O O
II O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
ions O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

R O B_OTHER/B_PERSON

R O O
13 O B_NUMBER[MEASURE]
" O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
= O O
20 O B_MEASURE
" O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O

H2N O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]

CICH2CONH O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]

14 O B_MEASURE
: O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
16 O B_MEASURE
: O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O

H2N O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
CICH2CONH O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

The O O
compounds O B_LOCATION
6 O I_LOCATION
- O O
20 O B_MEASURE
together O O
with O O
the O O
standard O B_NUMBER[MEASURE]/B_PERSON
CA O I_NUMBER[MEASURE]/I_PERSON
inhibitors O O
1 O B_MEASURE
- O O
5 O B_MEASURE
were O O
assayed O O
for O O
inhibition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
against O O
three O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isozymes O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
hCA O B_DISEASE/B_GENE
I O B_DISEASE/I_GENE
, O O
hCA O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
bCA O B_PROTEIN[GENE]/B_NUMBER[MEASURE]
IV O I_PROTEIN[GENE]/I_NUMBER[MEASURE]
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
III O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

As O O
seen O O
from O O
the O O
above O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
chloracetamido O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
derivative O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
is O O
more O O
inhibitory O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
acetazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
methazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dichlorophenamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
the O O
unacylated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
less O O
inhibitory O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
than O O
the O O
above O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O O

The O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
820 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
much O O
more O O
inhibitory O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
than O O
the O O
sulfonamides O B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
which O O
they O O
derive O O
6 O B_MEASURE/B_LOCATION
, O O
7 O B_MEASURE/B_LOCATION
and O O
than O O
all O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
simple O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
assayed O O
. O O

They O O
behave O O
similarly O O
to O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acetazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
methazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
previously O O
reported O O
by O O
this O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
were O O
all O O
more O O
inhibitory O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
parent O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sulfonamide O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
which O O
were O O
prepared O O
[ O B_TIME[MEASURE]/B_LOCATION
16 O B_TIME[MEASURE]/I_LOCATION
- O O
22 O B_MEASURE
, O O
40 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Particularly O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
for O O
the O O
Zn O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Hg O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Pb O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
Cd O B_LOCATION/B_PERSON
( O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
complexes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
especially O O
against O O
CA O B_LOCATION/B_ORGANIZATION
II O I_LOCATION/I_ORGANIZATION
and O O
CA O O
IV O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
, O O
the O O
isozymes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
critical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O O
aqueous O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
humor O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

In O O
vivo O O
IOP O O
lowering O O
experiments O O
were O O
done O O
in O O
rabbits B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
some O O
of O O
the O O
new O O
compounds O O
prepared O O
in O O
the O O
present O O
work O O
, O O
such O O
as O O
the O O
sulfonamides O O
6 O O
and O O
7 O O
, O O
and O O
their O O
Zn O O
( O O
II O O
) O O
complexes O O
, O O
which O O
were O O
among O O
the O O
strong O O
CA O O
II O O
and O O
CA O O
IV O O
inhibitors O O
in O O
the O O
obtained O O
series O O
. O O

Some O O
of O O
the O O
IOP O O
lowering O O
data O O
at O O
half O O
an O O
hour O O
and O O
one O O
hour O O
after O O
the O O
instillation O O
of O O
one O O
drop O O
of O O
2 O O
% O O
solution O O
of O O
inhibitor O O
within O O
the O O
rabbit B B_BIO/B_PERSON
eye O O
are O O
shown O O
in O O
312 O O

Claudiu O B_MEASURE
T O I_MEASURE
. O O
Supuran O B_PERSON/B_LOCATION
et O B_PERSON/I_LOCATION
al O B_PERSON/I_LOCATION
. O O

Metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Based O O
Drugs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IV O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
with O O
dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
at O O
the O O
same O B_LOCATION/B_MEASURE
concentration O I_LOCATION/I_MEASURE
) O O
as O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
Fig O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O
the O O
time O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dependence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
IOP O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
lowering O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
the O O
two O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Zn O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
II O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
complexes O B_MEASURE/B_LOCATION
10 O I_MEASURE/I_LOCATION
and O O
17 O B_MEASURE
is O O
presented O O
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CA O O
inhibition O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
the O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
5 O B_MEASURE
, O O
the O O
sulfonamides O B_SEQUENCE[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_SEQUENCE[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
7 O B_NUMBER[MEASURE]
, O O
and O O
their O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
8 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
20 O B_MEASURE
. O O

No O O
1 O B_NUMBER[MEASURE]/B_LOCATION
2 O I_NUMBER[MEASURE]/I_LOCATION
3 O I_NUMBER[MEASURE]/I_LOCATION
4 O I_NUMBER[MEASURE]/I_LOCATION
5 O I_NUMBER[MEASURE]/I_LOCATION
6 O I_NUMBER[MEASURE]/I_LOCATION
7 O I_NUMBER[MEASURE]/I_LOCATION
8 O I_NUMBER[MEASURE]/I_LOCATION
9 O I_NUMBER[MEASURE]/I_LOCATION
10 O I_NUMBER[MEASURE]/I_LOCATION
11 O I_NUMBER[MEASURE]/I_LOCATION
12 O I_NUMBER[MEASURE]/I_LOCATION
13 O I_NUMBER[MEASURE]/I_LOCATION
14 O I_NUMBER[MEASURE]/I_LOCATION
15 O I_NUMBER[MEASURE]/I_LOCATION
16 O I_NUMBER[MEASURE]/I_LOCATION
17 O I_NUMBER[MEASURE]/I_LOCATION
18 O I_NUMBER[MEASURE]/I_LOCATION
19 O I_NUMBER[MEASURE]/I_LOCATION
20 O I_NUMBER[MEASURE]/I_LOCATION
a O O

Inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

KI O B_MEASURE
hCA O I_MEASURE
Ia O I_MEASURE
900 O I_MEASURE
780 O I_MEASURE
25 O I_MEASURE
1200 O I_MEASURE
> O I_MEASURE
50 O I_MEASURE
, O O
000 O B_MEASURE/B_LOCATION
1550 O I_MEASURE/I_LOCATION
640 O I_MEASURE/I_LOCATION
1050 O I_MEASURE/I_LOCATION
350 O I_MEASURE/I_LOCATION
50 O I_MEASURE/I_LOCATION
40 O I_MEASURE/I_LOCATION
12 O I_MEASURE/I_LOCATION
80 O I_MEASURE/I_LOCATION
240 O I_MEASURE/I_LOCATION
120 O I_MEASURE/I_LOCATION
80 O I_MEASURE/I_LOCATION
40 O I_MEASURE/I_LOCATION
40 O I_MEASURE/I_LOCATION
9 O I_MEASURE/I_LOCATION
15 O I_MEASURE/I_LOCATION

( O O
nM O B_MEASURE
) O O
bCA O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVb O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
220 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
240 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
380 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
43 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
780 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
540 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
220 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
26 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
110 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

hCA O B_MEASURE/B_ORGANIZATION
IIa O O
12 O B_NUMBER[MEASURE]/B_GENE
14 O I_NUMBER[MEASURE]/I_GENE
8 O I_NUMBER[MEASURE]/I_GENE
38 O I_NUMBER[MEASURE]/I_GENE
9 O I_NUMBER[MEASURE]/I_GENE
230 O I_NUMBER[MEASURE]/I_GENE
5 O I_NUMBER[MEASURE]/I_GENE
190 O I_NUMBER[MEASURE]/I_GENE
110 O I_NUMBER[MEASURE]/I_GENE
15 O I_NUMBER[MEASURE]/I_GENE
14 O I_NUMBER[MEASURE]/I_GENE
7 O I_NUMBER[MEASURE]/I_GENE
10 O I_NUMBER[MEASURE]/I_GENE
76 O I_NUMBER[MEASURE]/I_GENE
5 O I_NUMBER[MEASURE]/I_GENE
4 O I_NUMBER[MEASURE]/I_GENE
3 O I_NUMBER[MEASURE]/I_GENE
3 O I_NUMBER[MEASURE]/I_GENE
2 O I_NUMBER[MEASURE]/I_GENE
5 O I_NUMBER[MEASURE]/I_GENE

Acetazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Methazolamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ethoxzolamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Dichlorophenamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Dorzolamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Human B B_SPECIES[BIO]/B_NUMBER[MEASURE]
( O O
cloned O O
) O O
isozymes O O
; O O
b O O
From O O
bovine B B_PERSON/B_SPECIES[BIO]
lung O O
microsomes O O
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IV O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
IOP O B_MEASURE/B_ORGANIZATION
lowering O O
following O O
topical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
application O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
half O O
an O O
hour O B_TIME[MEASURE]/B_ENT
and O O
one O B_TIME[MEASURE]/B_ENT
hour O I_TIME[MEASURE]/I_ENT
after O O
instillation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
into O O
the O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
a O O
drop O B_MEASURE/B_PERSON
( O O
50 O B_MEASURE/B_LOCATION
L O I_MEASURE/I_LOCATION
) O O
of O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

lOP O B_MEASURE
SE O I_MEASURE
1 O I_MEASURE
/ O O
2 O B_MEASURE
h O O

a O B_OTHER/B_PERSON

( O O
mm O B_TIME[MEASURE]/B_COLOR
Hg O I_TIME[MEASURE]/I_COLOR
) O O
lh O B_MEASURE
4 O I_MEASURE
. O O
1 O B_MEASURE
0 O I_MEASURE
. O O
15 O B_MEASURE
0 O I_MEASURE
0 O I_MEASURE
. O O
09 O B_MEASURE/B_SPORT[ENT]
0 O I_MEASURE/I_SPORT[ENT]
0 O I_MEASURE/I_SPORT[ENT]
. O O
09 O B_MEASURE
5 O I_MEASURE
. O O
0 O B_MEASURE
0 O I_MEASURE
. O O
12 O B_MEASURE
8 O I_MEASURE
. O O
1 O B_MEASURE
0 O I_MEASURE
. O O
21 O B_TIME[MEASURE]
Dorzolamide O I_TIME[MEASURE]
5 O I_TIME[MEASURE]
6 O I_TIME[MEASURE]
7 O I_TIME[MEASURE]
10 O I_TIME[MEASURE]
17 O I_TIME[MEASURE]
a O O

2 O O
. O O
2 O B_MEASURE
0 O I_MEASURE
. O O
10 O B_MEASURE/B_SPORT[ENT]
0 O I_MEASURE/I_SPORT[ENT]
0 O I_MEASURE/I_SPORT[ENT]
. O O
10 O B_MEASURE/B_SPORT[ENT]
0 O I_MEASURE/I_SPORT[ENT]
0 O I_MEASURE/I_SPORT[ENT]
. O O
10 O B_MEASURE
2 O I_MEASURE
. O O
00 O B_MEASURE
. O O
09 O B_TIME[MEASURE]
8 O I_TIME[MEASURE]
. O O
0 O B_MEASURE
0 O I_MEASURE
. O O
14 O B_MEASURE

IOP O B_DISEASE/B_ORGANIZATION

IOP O B_MEASURE
control O I_MEASURE
eye O I_MEASURE
" O O
IOP O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
treated O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
( O O
N O B_MEASURE/B_LOCATION
3 O I_MEASURE/I_LOCATION
) O O
. O O

As O O
seen O O
from O O
the O O
above O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
the O O
sulfonamides O B_NUMBER[MEASURE]
6 O I_NUMBER[MEASURE]
and O O
7 O B_NUMBER[MEASURE]
are O O
totally O O
ineffective O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
lOP O B_DISEASE/B_PROTEIN[GENE]
lowering O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
similarly O O
to O O
the O O
classical O B_NUMBER[MEASURE]
clinically O O
used O O
inhibitors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
type O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
5 O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
[ O O
2 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]/B_LOCATION
] O I_NUMBER[MEASURE]/I_LOCATION
. O O

On O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
first O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
topical O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
clinically O O
in O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
glaucoma O B_DISEASE
is O O
an O O
effective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
such O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
with O O
a O O
decrease O B_MEASURE/B_DISEASE
of O O
lOP O B_DISEASE/B_MEASURE
of O O
around O O
4 O B_NUMBER[MEASURE]
mm O I_NUMBER[MEASURE]
Hg O I_NUMBER[MEASURE]
, O O
one O B_TIME[MEASURE]
hour O I_TIME[MEASURE]
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
directly O O
into O O
the O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IV O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

From O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
is O O
obvious O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
investigated O O
by O O
us O O
behave O O
as O O
much O O
more O O
effective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
IOP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lowering O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
and O O
their O O
effect O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
is O O
generally O O
longerlasting O O
( O O
Fig O B_MEASURE/B_LOCATION
. O O
1 O B_NUMBER[MEASURE]
) O O
. O O

A O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remark O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
made O O
about O O
the O O
possible O B_LOCATION
mechanism O I_LOCATION
of O O
action O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
new O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
class O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
IOP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
lowering O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Obviously O O
, O O
their O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
due O O
to O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
isozymes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
present O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
cilliary O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
processes O I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
within O O
the O O
eye O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
similarly O O
to O O
other O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
topically O O
active O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamides O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
2 O B_MEASURE/B_LOCATION
- O O
6 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O O
se O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
inactive O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
via O O
the O O
topical O B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
route O B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
, O O
whereas O O
the O O
metal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O O
much O O
better O O
than O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

313 O B_NUMBER[MEASURE]

Vol O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

4 O O
, O O
No O O
. O O
6 O B_MEASURE
, O O
1997 O B_MEASURE/B_LOCATION

Metal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Complexes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Heterocyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O
" O O
A O B_MEASURE/B_LOCATION
New O B_MEASURE/I_LOCATION
Class O B_MEASURE/I_LOCATION
ofAntiglaucoma O B_MEASURE/I_LOCATION
Agents O B_MEASURE/I_LOCATION

dorzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
indicates O O
that O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
molecules O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
these O O
CA O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
essential O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
confers O O
them O O
completely O O
new O B_DISEASE_ADJECTIVE[DISEASE]
properties O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Lowering O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
IOP O B_DISEASE/B_MEASURE
( O O
ram O B_MEASURE/B_PERSON
Hg O I_MEASURE/I_PERSON
) O O

" O O
| O O
| O B_OTHER/B_DISEASE
, O O

/ O B_OTHER/B_PERSON

" O B_OTHER/B_TIME[MEASURE]
, O O
, O O

' O B_OTHER/B_MEASURE
" O O
, O O
. O O
, O O

, O O
< O B_MEASURE

. O O
7 O B_MEASURE/B_LOCATION
, O O
/ O O

/ O B_OTHER/B_PERSON

. O O
6 O B_MEASURE/B_LOCATION

- O O
0 O B_MEASURE/B_LOCATION

- O O
10 O B_MEASURE/B_LOCATION
0 O B_MEASURE/I_LOCATION

2 O B_NUMBER[MEASURE]/B_PERSON

Time O B_TIME[MEASURE]
( O O
hours O B_TIME[MEASURE]
) O O

Fig O O
l O O
" O O
Time O O
dependence O O
of O O
IOP O O
lowering O O
with O O
dorzolamide O O
( O O
curve O O
1 O O
) O O
; O O
the O O
zinc O O
complex O O
10 O O
( O O
curve O O
3 O O
) O O
and O O
the O O
zinc O O
complex O O
17 O O
( O O
curve O O
3 O O
) O O
, O O
after O O
topical O O
administration O O
of O O
one O O
drop O O
of O O
2 O O
% O O
solution O O
of O O
inhibitor O O
in O O
rabbit B B_SPECIES[BIO]/B_DISEASE
. O O

Preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
this O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
topically O O
active O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
show O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
increased O O
lOP O B_DISEASE/B_MEASURE
lowering O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
complexes O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prepared O O
in O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
42 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
that O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
molecules O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
these O O
complex O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
a O O
dramatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
change O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
their O O
physico O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
chemical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
compared O O
to O O
those O O
of O O
the O O
parent O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sulfonamide O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

This O O
phenomenon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
certainly O O
governed O O
by O O
the O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polarization O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
the O O
metal O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
this O O
way O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
is O O
quite O O
probable O B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
right O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
balance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
lipo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
and O O
hydrosolubility O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
achieved O O
, O O
which O O
has O O
been O O
considered O O
to O O
be O O
the O O
critical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
not O O
observing O O
topical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
classical O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CA O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
as O O
acetazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
methazolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ethoxzolamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
were O O
either O O
too O O
lipophilic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
too O O
hy O O
. O O
drosoluble O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ O O
2 O B_NUMBER[MEASURE]
, O O
3 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

So O O
, O O
by O O
choosing O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
metal O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
ions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
diverse O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
much O O
larger O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
possibilities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
arise O O
to O O
finely O O
tune O O
the O O
pharmacological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
properties O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
which O O
strongly O O
influence O O
the O O
value O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
a O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
we O O
describe O O
here O O
a O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
class O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
lOP O B_DISEASE
lowering O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ie O O
, O O
the O O
metal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
sulfonamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
derivatives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O O
to O O
be O O
very O O
active O B_DISEASE_ADJECTIVE[DISEASE]
and O O
longer O O
lasting O B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dorzolamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
might O O
constitute O O
the O O
premises O B_LOCATION/B_PERSON
for O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
generation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O O
antiglaucoma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Acknowledgments O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

We O O
are O O
grateful O B_PERSON
to O O
Prof O B_PERSON/B_LOCATION
. O O

S O B_OTHER/B_DISEASE
. O O

Lindskog O B_LOCATION/B_NUMBER[MEASURE]
( O O
Umea O B_LOCATION/B_PERSON
Univ O I_LOCATION/I_PERSON
. O O
, O O
Sweden O B_LOCATION/B_MEASURE
) O O
for O O
the O O
gift O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
hCA O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
and O O
II O B_PERSON/B_LOCATION
plasmids O B_PERSON/I_LOCATION
. O O

References O B_PERSON/B_NUMBER[MEASURE]
Preceding O O
part O B_TIME[MEASURE]/B_ENT
of O O
this O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
" O O
Supuran O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
CT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
Scozzafava O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Ilies O B_LOCATION/B_PERSON
MA O I_LOCATION/I_PERSON
, O O
Iorga O B_LOCATION/B_PERSON
B O I_LOCATION/I_PERSON
, O O
Cristea O B_PERSON/B_LOCATION
T O I_PERSON/I_LOCATION
, O O
Chiraleu O B_PERSON/B_ORGANIZATION
F O I_PERSON/I_ORGANIZATION
, O O
Banciu O B_PERSON/B_LOCATION
MD O I_PERSON/I_LOCATION
( O O
1997 O B_MEASURE
) O O
Eur O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chem O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
submitted O O
. O O

2 O B_MEASURE
Supuran O I_MEASURE
CT O I_MEASURE
( O O
1994 O B_MEASURE
) O O
" O O
Carbonic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anhydrase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
In O O
Carbonic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Anhydrase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Modulation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Physiologic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Pathologic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Processes O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
Organism O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O O
( O O
Puscas O B_PERSON
I O I_PERSON
, O O
Ed O B_PERSON/B_PROTEIN[GENE]
) O O
Helicon O B_PERSON/B_TIME[MEASURE]
, O O
Timisoara O B_MEASURE/B_LOCATION
, O O
pp O B_LOCATION/B_PERSON
. O O

29 O O
- O O
111 O B_MEASURE
. O O

3 O B_PERSON
Maren O I_PERSON
TH O I_PERSON
( O O
1991 O B_MEASURE
) O O
" O O
The O O
links O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
biochemistry O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
physiology O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pharmacology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
in O O
carbonic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anhydrase O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
systems O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
Carbonic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Anhydrase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
From O O
Biochemistry O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Genetics O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Physiology O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
Medicine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
, O O
( O O
Botr6 O B_PERSON
F O I_PERSON
, O O
Gros O B_MEASURE/B_LOCATION
G O I_MEASURE/I_LOCATION
, O O
Storey O B_MEASURE/B_LOCATION
BT O I_MEASURE/I_LOCATION
Eds O I_MEASURE/I_LOCATION
) O O
VCH O B_LOCATION/B_PERSON
, O O
Weinheim O B_MEASURE/B_LOCATION
, O O
pp O B_LOCATION/B_MEASURE
. O O

186 O O
- O O
207 O B_MEASURE
. O O

4 O B_PERSON/B_ORGANIZATION
Bayer O I_PERSON/I_ORGANIZATION
A O I_PERSON/I_ORGANIZATION
, O O
Ferrari O B_LOCATION/B_PERSON
F O I_LOCATION/I_PERSON
, O O
Maren O B_PERSON/B_LOCATION
TH O I_LOCATION
, O O
Erb O B_LOCATION/B_GENE
C O I_LOCATION/I_GENE
( O O
1996 O B_MEASURE
) O O
dFr O B_MEASURE
Ophtalrnol O I_MEASURE
19 O I_MEASURE
, O O
3 O B_MEASURE
: O O
57 O B_MEASURE
- O O
362 O B_MEASURE
. O O

: O O
5 O B_PERSON/B_LOCATION
Maren O I_PERSON/I_LOCATION
TH O I_LOCATION
, O O
Conroy O B_LOCATION/B_PERSON
CW O I_LOCATION/I_PERSON
, O O
Wynns O B_LOCATION/B_PERSON
GC O I_LOCATION/I_PERSON
, O O
Levy O B_PERSON/B_LOCATION
NS O I_PERSON/I_LOCATION
( O O
1997 O B_MEASURE
) O O
d O B_MEASURE
Ocul O I_MEASURE
Pharrnacol O I_MEASURE
Therapeut O I_MEASURE
13 O I_MEASURE
, O O
23 O B_MEASURE
- O O
30 O B_MEASURE
. O O

6 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sugrue O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MF O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1996 O B_MEASURE
) O O
d O B_MEASURE/B_PERSON
Ocul O I_MEASURE/I_PERSON
Pharmacol O I_MEASURE/I_PERSON
Ther O I_MEASURE/I_PERSON
12 O I_MEASURE/I_PERSON
, O O
363 O B_MEASURE
- O O
376 O B_MEASURE
. O O

7 O B_PERSON
Bartlett O I_PERSON
JD O I_PERSON
, O O
Jaanus O B_PERSON/B_MEASURE
SD O I_PERSON/I_MEASURE
( O O
1989 O B_MEASURE
) O O
" O O
Carbonic O B_TIME[MEASURE]/B_PERSON
anhydrase O I_TIME[MEASURE]/I_PERSON
inhibitors O I_TIME[MEASURE]/I_PERSON
" O I_TIME[MEASURE]/I_PERSON
. O O

In O O
Clinical O B_TIME[MEASURE]/B_PERSON
Ocular O I_TIME[MEASURE]/I_PERSON
Pharmacology O I_TIME[MEASURE]/I_PERSON
, O O
Second O B_NUMBER[MEASURE]/B_ENT
Edition O I_NUMBER[MEASURE]/I_ENT
, O O
Butterworths O B_MEASURE/B_LOCATION
Publishers O I_MEASURE/I_LOCATION
, O O
Boston O B_LOCATION/B_MEASURE
, O O
pp O B_LOCATION/B_MEASURE
. O O

2 O O
: O O
54 O O
- O O
263 O B_MEASURE
. O O

8 O B_PERSON
Alward O I_PERSON
PD O I_PERSON
, O O
Wilensky O B_PERSON/B_MEASURE
JT O I_PERSON/I_MEASURE
( O O
1981 O B_MEASURE/B_LOCATION
) O O
Arch O B_MEASURE/B_LOCATION
Ophthalmo199 O I_MEASURE/I_LOCATION
, O O
1973 O B_MEASURE
- O O
1976 O B_MEASURE
. O O

314 O B_NUMBER[MEASURE]

Claudiu O B_MEASURE
T O I_MEASURE
. O O
Supuran O B_PERSON/B_LOCATION
et O B_PERSON/I_LOCATION
al O B_PERSON/I_LOCATION
. O O

Metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Based O O
Drugs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE

9 O B_PERSON/B_LOCATION
Maren O I_PERSON/I_LOCATION
TH O I_LOCATION
, O O
Jankowska O B_LOCATION/B_NUMBER[MEASURE]
L O I_LOCATION/I_NUMBER[MEASURE]
, O O
Sanyal O B_PERSON/B_LOCATION
G O I_PERSON/I_LOCATION
, O O
Edelhauser O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
HF O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1983 O B_MEASURE
) O O
Exp O B_MEASURE
Eye O I_MEASURE
Res O I_MEASURE
36 O I_MEASURE
, O O
457 O B_MEASURE
- O O
480 O B_MEASURE
. O O

10 O B_NUMBER[MEASURE]/B_LOCATION
a O O
) O O
Ponticello O B_PERSON
GS O I_PERSON
, O O
Freedman O B_LOCATION/B_PERSON
MB O I_LOCATION/I_PERSON
, O O
Habecker O B_LOCATION/B_PERSON
CN O I_LOCATION/I_PERSON
, O O
Lyle O B_DISEASE/B_LOCATION
PA O B_DISEASE/I_LOCATION
, O O
Schwam O B_LOCATION/B_PERSON
H O I_LOCATION/I_PERSON
, O O
Varga O B_LOCATION
SL O I_LOCATION
, O O
Christy O O
ME O B_LOCATION
, O O
Randall O B_PERSON/B_LOCATION
WC O B_PERSON/I_LOCATION
, O O
Baldwin O B_PERSON/B_LOCATION
JJ O B_PERSON/I_LOCATION
( O O
1987 O B_MEASURE
) O O
J O B_MEASURE
Med O I_MEASURE
Chem O I_MEASURE
30 O I_MEASURE
, O O
591 O B_MEASURE
- O O
597 O B_MEASURE
; O O
b O O
) O O
Greer O B_PERSON
J O I_PERSON
, O O
Erickson O B_LOCATION/B_PERSON
JW O I_LOCATION/I_PERSON
, O O
Baldwin O B_LOCATION/B_PERSON
JJ O I_LOCATION/I_PERSON
, O O
Varney O B_PERSON/B_LOCATION
MD O I_PERSON/I_LOCATION
( O O
1994 O B_MEASURE
) O O
J O B_MEASURE
Med O I_MEASURE
Chem O I_MEASURE
37 O I_MEASURE
, O O
1035 O B_MEASURE
- O O
1054 O B_MEASURE
. O O

11 O B_PERSON/B_LOCATION
Baldwin O I_PERSON/I_LOCATION
JJ O I_PERSON/I_LOCATION
, O O
Ponticello O B_LOCATION/B_PERSON
GS O I_LOCATION/I_PERSON
, O O
Anderson O B_LOCATION/B_PERSON
GS O I_LOCATION/I_PERSON
, O O
Christy O B_PERSON/B_LOCATION
ME O B_PERSON/I_LOCATION
, O O
Murcko O B_PERSON/B_LOCATION
MA O I_PERSON/I_LOCATION
, O O
Randall O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
WC O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Schwam O B_LOCATION/B_PERSON
H O I_LOCATION/I_PERSON
, O O
Sugrue O B_LOCATION
MF O I_LOCATION
, O O
Springer O B_PERSON/B_LOCATION
JP O B_PERSON/I_LOCATION
, O O
Gautheron O B_LOCATION/B_PERSON
P O I_LOCATION/I_PERSON
, O O
Grove O B_LOCATION/B_PERSON
J O I_LOCATION/I_PERSON
, O O
Mallorga O B_LOCATION/B_PERSON
P O I_LOCATION/I_PERSON
, O O
Viader O B_PERSON/B_LOCATION
MP O B_PERSON/I_LOCATION
, O O
McKeever O B_LOCATION/B_PERSON
BM O I_LOCATION/I_PERSON
, O O
Navia O B_PERSON/B_LOCATION
MA O I_PERSON/I_LOCATION
( O O
1989 O B_MEASURE
) O O
J O B_MEASURE
Med O I_MEASURE
Chem O I_MEASURE
32 O I_MEASURE
, O O
2510 O B_MEASURE
- O O
2513 O B_MEASURE
. O O

12 O B_PERSON
Chow O I_PERSON
K O I_PERSON
, O O
Lai O B_LOCATION/B_PERSON
R O I_LOCATION/I_PERSON
, O O
Holmes O B_PERSON/B_LOCATION
JM O B_PERSON/I_LOCATION
, O O
Wijono O B_LOCATION/B_PERSON
M O I_LOCATION/I_PERSON
, O O
Wheeler O B_LOCATION/B_PERSON
LA O I_LOCATION/I_PERSON
, O O
Garst O B_PERSON/B_LOCATION
ME O I_PERSON/I_LOCATION
( O O
1996 O B_MEASURE
) O O
EurJMed O B_MEASURE/B_PERSON
Chem O I_MEASURE/I_PERSON
31 O I_MEASURE/I_PERSON
, O O
175 O B_MEASURE
- O O
186 O B_MEASURE
. O O

13 O B_PERSON/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Supuran O I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT O I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Nicolae O B_PERSON/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_PERSON/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Popescu O B_LOCATION/B_MEASURE
A O I_LOCATION/I_MEASURE
( O O
1996 O B_MEASURE
) O O
Eur O B_MEASURE
JMed O I_MEASURE
Chem O I_MEASURE
31 O I_MEASURE
, O O
431 O B_MEASURE
- O O
438 O B_MEASURE
. O O

14 O B_PERSON/B_LOCATION
Supuran O I_PERSON/I_LOCATION
CT O I_PERSON/I_LOCATION
, O O
Popescu O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Ilisiu O B_PERSON/B_LOCATION
M O B_PERSON/I_LOCATION
, O O
Costandache O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Banciu O B_PERSON/B_LOCATION
MD O I_PERSON/I_LOCATION
( O O
1996 O B_MEASURE
) O O
Eur O B_MEASURE
JMed O I_MEASURE
Chem O I_MEASURE
31 O I_MEASURE
, O O
439 O B_MEASURE
- O O
448 O B_MEASURE
. O O

15 O B_PERSON/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Supuran O I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT O I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Scozzafava O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Popescu O B_PERSON/B_LOCATION
A O B_PERSON/I_LOCATION
, O O
Bobes O B_PERSON
- O O
Tureac O B_LOCATION/B_PERSON
R O I_LOCATION/I_PERSON
, O O
Banciu O B_LOCATION/B_PERSON
A O B_LOCATION/I_PERSON
, O O
Creanga O B_LOCATION
A O I_LOCATION
, O O
Bobes O B_PERSON
- O O
Tureac O B_LOCATION
G O I_LOCATION
, O O
Banciu O B_PERSON/B_LOCATION
MD O I_PERSON/I_LOCATION
( O O
1997 O B_MEASURE
) O O
Eur O B_MEASURE
JMed O I_MEASURE
Chem O I_MEASURE
32 O I_MEASURE
, O O
445 O B_MEASURE
- O O
452 O B_MEASURE
. O O

16 O B_PERSON
Alzuet O I_PERSON
G O I_PERSON
, O O
Casanova O B_LOCATION
J O I_LOCATION
, O O
Ramirez O B_PERSON
JA O I_PERSON
, O O
Borras O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Carugo O B_LOCATION/B_MEASURE
O O I_LOCATION/I_MEASURE
( O O
1995 O B_MEASURE
) O O
J O B_MEASURE
Inorg O I_MEASURE
Bioehem O I_MEASURE
57 O I_MEASURE
, O O
219 O B_MEASURE
- O O
234 O B_MEASURE
. O O

17 O B_PERSON/B_LOCATION
Sumalan O I_PERSON/I_LOCATION
SL O I_PERSON/I_LOCATION
, O O
Casanova O B_LOCATION/B_PERSON
J O I_LOCATION/I_PERSON
, O O
Alzuet O B_PERSON
G O I_PERSON
, O O
Borras O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Castifieiras O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Supuran O B_PERSON/B_LOCATION
CT O I_PERSON/I_LOCATION
( O O
1996 O B_MEASURE
) O O
J O B_MEASURE
Inorg O I_MEASURE
Biochem O I_MEASURE
62 O I_MEASURE
, O O
3139 O B_MEASURE/B_LOCATION
. O O

18 O B_MEASURE/B_LOCATION
a O O
) O O
Supuran O B_LOCATION/B_DISEASE
CT O I_LOCATION/I_DISEASE
( O O
1995 O B_MEASURE
) O O
Metal O B_MEASURE/B_PERSON
Based O I_MEASURE/I_PERSON
Drugs O I_MEASURE/I_PERSON
2 O I_MEASURE/I_PERSON
, O O
327 O B_MEASURE
- O O
330 O B_MEASURE
; O O
b O O
) O O
Scozzafava O B_PERSON/B_MEASURE
A O I_PERSON/I_MEASURE
, O O
Supuran O B_LOCATION/B_MEASURE
CT O I_LOCATION/I_MEASURE
( O O
1997 O B_MEASURE
) O O
Metal O B_MEASURE
Based O I_MEASURE
Drugs O I_MEASURE
4 O I_MEASURE
, O O
19 O B_MEASURE
- O O
26 O B_MEASURE
. O O

19 O B_NUMBER[MEASURE]/B_LOCATION
a O O
) O O
Borras O B_PERSON
J O I_PERSON
, O O
Cristea O B_LOCATION
T O I_LOCATION
, O O
Supuran O B_LOCATION
CT O I_LOCATION
( O O
1996 O B_MEASURE
) O O
, O O
Main O B_MEASURE/B_ORGANIZATION
Group O I_MEASURE/I_ORGANIZATION
Met O I_MEASURE/I_ORGANIZATION
Chem O I_MEASURE/I_ORGANIZATION
19 O I_MEASURE/I_ORGANIZATION
, O O
339 O B_MEASURE
- O O
346 O B_MEASURE
; O O
b O O
) O O
Jitianu O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
, O O
Ilies O B_LOCATION/B_PERSON
MA O B_LOCATION/I_PERSON
, O O
Briganti O B_LOCATION/B_PERSON
F O I_LOCATION/I_PERSON
, O O
Scozzafava O B_PERSON
A O I_PERSON
, O O
Supuran O B_LOCATION/B_MEASURE
CT O I_LOCATION/I_MEASURE
( O O
1997 O B_MEASURE
) O O
Metal O B_MEASURE
Based O I_MEASURE
Drugs O I_MEASURE
4 O I_MEASURE
, O O
1 O B_MEASURE
- O O
7 O B_MEASURE
. O O

20 O B_NUMBER[MEASURE]/B_LOCATION
a O O
) O O
Supuran O B_LOCATION/B_PERSON
CT O I_LOCATION/I_PERSON
, O O
Scozzafava O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1997 O B_MEASURE
) O O
J O B_MEASURE/B_PERSON
Enzyme O I_MEASURE/I_PERSON
Inhibition O I_MEASURE/I_PERSON
12 O I_MEASURE/I_PERSON
, O O
37 O B_MEASURE
- O O
51 O B_MEASURE
; O O
b O O
) O O
Supuran O B_PERSON/B_LOCATION
CT O I_PERSON/I_LOCATION
, O O
Briganti O B_MEASURE/B_LOCATION
F O I_MEASURE/I_LOCATION
, O O
Scozzafava O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
( O O
1997 O B_MEASURE
) O O
J O B_MEASURE/B_PERSON
Enzyme O I_MEASURE/I_PERSON
Inhibition O I_MEASURE/I_PERSON
12 O I_MEASURE/I_PERSON
, O O
175 O B_MEASURE
- O O
190 O B_MEASURE
. O O

21 O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Mincione O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Scozzafava O B_MEASURE/B_PERSON
A O I_MEASURE/I_PERSON
, O O
Supuran O B_LOCATION
CT O I_LOCATION
( O O
1997 O B_MEASURE
) O O
Metal O B_MEASURE
Based O I_MEASURE
Drugs O I_MEASURE
4 O I_MEASURE
, O O
27 O B_MEASURE
- O O
34 O B_MEASURE
. O O

22 O B_PERSON
Alzuet O I_PERSON
G O I_PERSON
, O O
Ferrer O B_PERSON/B_LOCATION
S O I_PERSON/I_LOCATION
, O O
Borras O B_PERSON
J O I_PERSON
, O O
Supuran O B_LOCATION/B_NUMBER[MEASURE]
CT O B_LOCATION/I_NUMBER[MEASURE]
( O O
1994 O B_MEASURE
) O O
Roum O B_MEASURE/B_LOCATION
Chem O I_MEASURE/I_LOCATION
Quart O I_MEASURE/I_LOCATION
Rev O I_MEASURE/I_LOCATION
2 O I_MEASURE/I_LOCATION
, O O
283 O B_MEASURE
- O O
300 O B_MEASURE
. O O

23 O B_PERSON/B_LOCATION
Briganti O I_PERSON/I_LOCATION
F O I_PERSON/I_LOCATION
, O O
Mangani O B_LOCATION/B_PERSON
S O I_LOCATION/I_PERSON
, O O
Orioli O B_PERSON/B_LOCATION
P O I_PERSON/I_LOCATION
, O O
Scozzafava O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Vernaglione O B_LOCATION
G O I_LOCATION
, O O
Supuran O B_LOCATION/B_MEASURE
CT O I_LOCATION/I_MEASURE
( O O
1997 O B_MEASURE
) O O
Biochemistry O B_MEASURE
36 O I_MEASURE
, O O
10384 O B_MEASURE
- O O
10392 O B_MEASURE
. O O

24 O B_PERSON/B_LOCATION
Borras O I_PERSON/I_LOCATION
J O I_PERSON/I_LOCATION
, O O
Casanova O B_LOCATION
J O I_LOCATION
, O O
Cristea O B_LOCATION/B_PERSON
T O I_LOCATION/I_PERSON
, O O
Gheorghe O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
, O O
Scozzafava O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Supuran O B_LOCATION
CT O I_LOCATION
, O O
Tudor O B_NUMBER[MEASURE]/B_PERSON
V O I_NUMBER[MEASURE]/I_PERSON
( O O
1996 O B_MEASURE
) O O
Metal O B_MEASURE
Based O I_MEASURE
Drugs O I_MEASURE
3 O I_MEASURE
, O O
143 O B_MEASURE
- O O
148 O B_MEASURE
. O O

25 O B_MEASURE/B_LOCATION
Supuran O I_MEASURE/I_LOCATION
CT O I_MEASURE/I_LOCATION
, O O
Mincione O B_LOCATION/B_ORGANIZATION
F O I_LOCATION/I_ORGANIZATION
, O O
Scozzafava O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
, O O
Briganti O B_LOCATION/B_PERSON
F O I_LOCATION/I_PERSON
, O O
Mincione O B_PERSON/B_LOCATION
G O B_PERSON/I_LOCATION
, O O
Ilies O B_LOCATION/B_MEASURE
MA O I_LOCATION/I_MEASURE
( O O
1997 O B_MEASURE
) O O
Eur O B_MEASURE/B_LOCATION
J O I_MEASURE/I_LOCATION
Med O I_MEASURE/I_LOCATION
Chem O I_MEASURE/I_LOCATION
, O O
in O O

press O B_ENT/B_LOCATION
. O O

26 O B_MEASURE/B_LOCATION
Supuran O I_MEASURE/I_LOCATION
CT O I_MEASURE/I_LOCATION
, O O
Scozzafava O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Saramet O B_PERSON
I O O
, O O
Banciu O B_PERSON/B_LOCATION
MD O I_PERSON/I_LOCATION
( O O
1997 O B_MEASURE
) O O
J O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Enzyme O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Inhibition O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
press O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

27 O B_PERSON/B_LOCATION
Jitianu O I_PERSON/I_LOCATION
A O I_PERSON/I_LOCATION
, O O
Ilies O B_LOCATION/B_PERSON
MA O I_LOCATION/I_PERSON
, O O
Scozzafava O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Supuran O B_LOCATION/B_PERSON
CT O I_LOCATION/I_PERSON
( O O
1997 O B_MEASURE
) O O
Main O B_MEASURE/B_ORGANIZATION
Group O I_MEASURE/I_ORGANIZATION
Met O I_MEASURE/I_ORGANIZATION
Chem O I_MEASURE/I_ORGANIZATION
20 O I_MEASURE/I_ORGANIZATION
, O O
151 O B_MEASURE
- O O
156 O B_MEASURE
. O O

28 O B_PERSON
Forsman O I_PERSON
C O I_PERSON
, O O
Behravan O B_PERSON/B_LOCATION
G O I_PERSON/I_LOCATION
, O O
Osterman O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Jonsson O B_PERSON/B_MEASURE
BH O I_PERSON/I_MEASURE
( O O
1988 O B_MEASURE
) O O
Acta O B_MEASURE
Chem O I_MEASURE
Scand O I_MEASURE
B42 O I_MEASURE
, O O
314 O B_MEASURE
- O O
318 O B_MEASURE
. O O

29 O B_PERSON
Behravan O I_PERSON
G O I_PERSON
, O O
Jonasson O B_LOCATION/B_PERSON
P O I_LOCATION/I_PERSON
, O O
Jonsson O B_PERSON/B_LOCATION
BH O I_PERSON/I_LOCATION
, O O
Lindskog O B_NUMBER[MEASURE]/B_LOCATION
S O I_NUMBER[MEASURE]/I_LOCATION
( O O
1991 O B_MEASURE
) O O
Eur O B_MEASURE
JBiochem O I_MEASURE
198 O I_MEASURE
, O O
589 O B_MEASURE
- O O
592 O B_MEASURE
. O O

30 O B_PERSON/B_LOCATION
Khalifah O I_PERSON/I_LOCATION
RG O I_PERSON/I_LOCATION
, O O
Strader O B_LOCATION
DJ O I_LOCATION
, O O
Bryant O B_LOCATION/B_ORGANIZATION
SH O I_LOCATION/I_ORGANIZATION
, O O
Gibson O B_LOCATION/B_PERSON
SM O I_LOCATION/I_PERSON
( O O
1977 O B_MEASURE
) O O
Biochemistry O B_MEASURE
16 O I_MEASURE
, O O
2241 O B_MEASURE
- O O
2247 O B_MEASURE
. O O

31 O B_PERSON/B_LOCATION
Nyman O I_PERSON/I_LOCATION
PO O I_PERSON/I_LOCATION
, O O
Lindskog O B_PERSON/B_LOCATION
S O I_PERSON/I_LOCATION
( O O
1964 O B_MEASURE
) O O
Biochim O B_MEASURE/B_LOCATION
Biophys O I_MEASURE/I_LOCATION
Acta O I_MEASURE/I_LOCATION
85 O I_MEASURE/I_LOCATION
, O O
141 O B_MEASURE
- O O
151 O B_MEASURE
. O O

32 O B_PERSON
Henderson O I_PERSON
LE O I_PERSON
, O O
Henriksson O B_PERSON/B_LOCATION
D O I_PERSON/I_LOCATION
, O O
Nyman O B_PERSON/B_LOCATION
PO O B_PERSON/I_LOCATION
( O O
1976 O B_MEASURE
) O O
JBiol O B_MEASURE
Chem O I_MEASURE
251 O I_MEASURE
, O O
5457 O B_MEASURE
- O O
5463 O B_MEASURE
. O O

33 O B_MEASURE/B_LOCATION
Maren O I_MEASURE/I_LOCATION
TH O I_LOCATION
, O O
Wynns O B_PERSON/B_LOCATION
GC O I_PERSON/I_LOCATION
, O O
Wistrand O B_PERSON/B_LOCATION
PJ O I_PERSON/I_LOCATION
( O O
1993 O B_MEASURE
) O O
Mol O B_MEASURE/B_PERSON
Pharmaco144 O I_MEASURE/I_PERSON
, O O
901 O B_MEASURE
- O O
906 O B_MEASURE
. O O

34 O B_PERSON/B_LOCATION
Young O I_PERSON/I_LOCATION
RW O I_PERSON/I_LOCATION
, O O
Wood O B_LOCATION/B_PERSON
KH O I_LOCATION/I_PERSON
, O O
Vaughan O B_LOCATION/B_PERSON
JR O I_LOCATION/I_PERSON
, O O
Anderson O B_PERSON/B_LOCATION
GW O I_PERSON/I_LOCATION
( O O
1956 O B_MEASURE
) O O
J O B_MEASURE/B_LOCATION
Am O I_MEASURE/I_LOCATION
Chem O I_MEASURE/I_LOCATION
Soc O I_MEASURE
78 O I_MEASURE
, O O
4649 O B_MEASURE
- O O
4654 O B_MEASURE
. O O

35 O B_PERSON/B_LOCATION
Pocker O I_PERSON/I_LOCATION
Y O I_PERSON/I_LOCATION
, O O
Stone O B_MEASURE/B_PERSON
JT O I_MEASURE/I_PERSON
( O O
1967 O B_MEASURE
) O O
Biochemistry O B_MEASURE
6 O I_MEASURE
, O O
668 O B_MEASURE
- O O
678 O B_MEASURE
. O O

36 O B_PERSON
Baird O I_PERSON
TT O I_PERSON
, O O
Waheed O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Okuyama O B_LOCATION/B_PERSON
T O I_LOCATION/I_PERSON
, O O
Sly O B_LOCATION
WS O I_LOCATION
, O O
Fierke O B_LOCATION/B_PERSON
CA O B_LOCATION/I_PERSON
( O O
1997 O B_MEASURE
) O O
Biochemistry O B_MEASURE
36 O I_MEASURE
, O O
2669 O B_MEASURE
- O O
2678 O B_MEASURE
. O O

37 O B_MEASURE/B_LOCATION
Maren O I_MEASURE/I_LOCATION
TH O I_LOCATION
, O O
Bar O B_LOCATION/B_PERSON
- O O
Ilan O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
, O O
Conroy O B_PERSON/B_LOCATION
CW O I_PERSON/I_LOCATION
, O O
Brechue O B_MEASURE/B_LOCATION
WF O I_MEASURE/I_LOCATION
( O O
1990 O B_MEASURE
) O O
Exp O B_MEASURE/B_LOCATION
Eye O I_MEASURE/I_LOCATION
Res O I_MEASURE/I_LOCATION
50 O I_MEASURE/I_LOCATION
, O O
27 O B_MEASURE
- O O
36 O B_MEASURE
. O O

38 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Maren O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TH O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Brechue O B_MEASURE/B_LOCATION
WF O I_MEASURE/I_LOCATION
, O O
Bar O B_LOCATION/B_PERSON
- O O
Ilan O B_MEASURE/B_PERSON
A O I_MEASURE/I_PERSON
( O O
1992 O B_MEASURE
) O O
Exp O B_MEASURE
Eye O I_MEASURE
Res O I_MEASURE
55 O I_MEASURE
, O O
73 O B_MEASURE
- O O
79 O B_MEASURE
. O O

39 O B_PERSON
Brechue O I_PERSON
WF O I_PERSON
, O O
Maren O B_NUMBER[MEASURE]/B_LOCATION
TH O I_NUMBER[MEASURE]/I_LOCATION
( O O
1993 O B_TIME[MEASURE]/B_LOCATION
) O O
Invest O O
Ophthalmol O B_MEASURE/B_PERSON
Vis O I_MEASURE/I_PERSON
Sci O I_MEASURE/I_PERSON
34 O I_MEASURE/I_PERSON
, O O
2581 O B_MEASURE
- O O
2587 O B_MEASURE
. O O

40 O B_PERSON/B_LOCATION
Borja O I_PERSON/I_LOCATION
P O I_PERSON/I_LOCATION
, O O
Alzuet O B_LOCATION
G O I_LOCATION
, O O
Server O B_PERSON
- O O
Carri6 O B_LOCATION/B_MEASURE
J O I_LOCATION/I_MEASURE
, O O
Borras O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Supuran O B_PERSON/B_MEASURE
CT O I_PERSON/I_MEASURE
( O O
1997 O B_MEASURE
) O O
J O B_LOCATION/B_TIME[MEASURE]
Biol O B_LOCATION/I_TIME[MEASURE]
Inorg O B_LOCATION/I_TIME[MEASURE]
Chem O B_LOCATION/I_TIME[MEASURE]
( O O
JBIC O B_MEASURE
) O O
, O O
in O O
press O B_LOCATION/B_MEASURE
. O O

41 O B_PERSON/B_LOCATION
Supuran O I_PERSON/I_LOCATION
CT O I_PERSON/I_LOCATION
, O O
Balaban O B_NUMBER[MEASURE]/B_LOCATION
AT O I_NUMBER[MEASURE]/I_LOCATION
, O O
Gheorghiu O B_PERSON/B_LOCATION
MD O I_PERSON/I_LOCATION
, O O
Schiketanz O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Dinculescu O B_LOCATION
A O I_LOCATION
, O O
Puscas O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
I O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1990 O B_MEASURE
) O O
Rev O B_MEASURE/B_LOCATION
Roum O I_MEASURE/I_LOCATION
Chim O I_MEASURE/I_LOCATION
35 O I_MEASURE/I_LOCATION
, O O
399 O B_MEASURE
- O O
405 O B_MEASURE
. O O

42 O B_PERSON/B_LOCATION
Supuran O I_PERSON/I_LOCATION
CT O I_PERSON/I_LOCATION
, O O
Scozzafava O B_NUMBER[MEASURE]/B_PERSON
A O I_NUMBER[MEASURE]/I_PERSON
( O O
1997 O B_MEASURE
) O O
unpublished O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

Received O O
: O O
September O B_TIME[MEASURE]
24 O I_TIME[MEASURE]
, O O
1997 O B_MEASURE
Accepted O O
: O O
October O B_TIME[MEASURE]
17 O I_TIME[MEASURE]
, O O
1997 O B_MEASURE
Received O O
in O O
revised O O
camera O B_SPORT[ENT]/B_ORGANIZATION
- O O
ready O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
format O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
" O O
October O B_TIME[MEASURE]
23 O I_TIME[MEASURE]
, O O
1997 O B_MEASURE

315 O B_NUMBER[MEASURE]

Synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
Characterization O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
Antitumour O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Some O O
Butyltin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IV O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O O
Cysteaminates O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
N O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N O B_OTHER/B_PROTEIN[GENE]
- O O
Dimethylcysteaminates O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
synthesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
four O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
di O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
and O O
tri O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
butyltin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dimethylcysteaminates O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
three O B_NUMBER[MEASURE]/B_PERSON
protonated O O
/ O O
quaternized O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
reported O O
. O O

They O O
all O O
exhibit O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
vitro O B_MEASURE/B_DISEASE
cytotoxic O I_MEASURE/I_DISEASE
activity O I_MEASURE/I_DISEASE
. O O

Six O B_NUMBER[MEASURE]
of O O
seven O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds O B_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
in O O
this O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
more O O
active O B_DISEASE_ADJECTIVE[DISEASE]
than O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
etoposide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
less O O
active O B_DISEASE_ADJECTIVE[DISEASE]
than O O
methotrexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
doxorubicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Metal O B_ORGANIZATION
Based O I_ORGANIZATION
Drugs O I_ORGANIZATION

Vol O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

7 O B_MEASURE
, O O
Nr O B_MEASURE/B_BIO
. O O

5 O B_TIME[MEASURE]/B_LOCATION
, O O
2000 O B_MEASURE/B_LOCATION

SYNTHESIS O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CHARACTERIZATION O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
AND O O
ANTITUMOUR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ACTITY O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OF O O
SOME O O
BUTYLTIN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IV O B_NUMBER[MEASURE]/B_DISEASE
) O O
CYSTEAMINATES O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O O
N O B_OTHER/B_PROTEIN[GENE]
, O O
N O B_OTHER/B_PROTEIN[GENE]
- O O
DIMETHYLCYSTEAMINATES O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Marcel O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Gielen O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Karel O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Handlir O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
2 O B_NUMBER[MEASURE]/B_PERSON
, O O
Martin O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hollein O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Dick O B_PERSON/B_ENT
de O I_PERSON/I_ENT
Vos O I_PERSON/I_ENT
2 O I_PERSON/I_ENT
3 O I_PERSON/I_ENT

Departement O B_LOCATION/B_ORGANIZATION
of O O
General O B_PERSON/B_EDU[ORGANIZATION]
and O O
Organic O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chemistry O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AOSC O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Faculty O B_PERSON/B_LOCATION
of O O
Applied O B_EDU[ORGANIZATION]/B_PERSON
Sciences O I_EDU[ORGANIZATION]/I_PERSON
, O O
Free O B_LOCATION
University O I_LOCATION
of O O
Brussels O B_LOCATION/B_PERSON
VUV O I_LOCATION/I_PERSON
, O O
Pleinlaan O B_LOCATION/B_PERSON
2 O I_LOCATION/I_PERSON
, O O
B O B_OTHER/B_MEASURE
- O O
1050 O B_LOCATION/B_MEASURE
Brussels O I_LOCATION/I_MEASURE
, O O
Belgium O B_LOCATION/B_ORGANIZATION
Departement O I_LOCATION/I_ORGANIZATION
of O O
General O B_PERSON/B_EDU[ORGANIZATION]
and O O
Inorganic O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chemistry O I_EDU[ORGANIZATION]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Faculty O B_PERSON/B_LOCATION
of O O
Chemical O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Technology O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
University O B_LOCATION/B_ORGANIZATION
of O O
Pafdubice O B_PERSON/B_LOCATION
, O O
Nam O B_PERSON/B_LOCATION
. O O

Cs O B_LOCATION/B_PERSON
. O O
legii O B_NUMBER[MEASURE]/B_PERSON
565 O I_NUMBER[MEASURE]/I_PERSON
, O O
53210 O B_LOCATION/B_MEASURE
Pardubice O I_LOCATION/I_MEASURE
, O O
Czech O B_LOCATION
Republic O I_LOCATION
Pharmachemie O I_LOCATION
B O I_LOCATION
. O O

V O B_OTHER/B_DISEASE
. O O
, O O
Haarlem O B_LOCATION
, O O
the O O
Netherlands O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Abstract O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
synthesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
four O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
di O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
and O O
tri O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
butyltin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
_ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
N O B_OTHER/B_LOCATION
, O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
dimethylcysteaminates O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
three O B_NUMBER[MEASURE]/B_PERSON
protonated O O
/ O O
quaternized O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
reported O O
. O O

They O O
all O O
exhibit O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
vitro O B_MEASURE/B_DISEASE
cytotoxic O I_MEASURE/I_DISEASE
activity O I_MEASURE/I_DISEASE
. O O

Six O B_NUMBER[MEASURE]
of O O
seven O B_MEASURE/B_PERSON
compounds O B_MEASURE/I_PERSON
presented O O
in O O
this O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
more O O
active O B_DISEASE_ADJECTIVE[DISEASE]
than O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
etoposide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
less O O
active O B_DISEASE_ADJECTIVE[DISEASE]
than O O
methotrexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
doxorubiein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Introduction O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Several O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organotin O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminates O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
aminoethylthiolates O B_DISEASE/B_PROTEIN[GENE]
) O O
have O O
been O O
studied O O
1 O B_MEASURE/B_LOCATION
- O O
4 O B_MEASURE
as O O
compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
potentially O O
high O B_DISEASE_ADJECTIVE[DISEASE]
biological O I_DISEASE_ADJECTIVE[DISEASE]
activity O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
their O O
cytotoxic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
paper O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
reports O O
the O O
synthesis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
di O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
tri O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
butyltin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
their O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dimethyl O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analogues O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
their O O
in O O
vitro O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cytotoxicity O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

It O O
is O O
shown O O
that O O
a O O
correct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
biological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
organotin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compounds O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
remains O O
5 O B_TIME[MEASURE]/B_LOCATION
often O O
hampered O O
by O O
their O O
low O B_DISEASE_ADJECTIVE[DISEASE]
water O I_DISEASE_ADJECTIVE[DISEASE]
solubility O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Therefore O O
, O O
we O O
focused O O
on O O
the O O
synthesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
derivatives O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
potentially O O
higher O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
solubility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
introducing O O
ionic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
molecule O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
by O O
protonation O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
quatemization O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
nitrogen O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atom O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

3 O B_NUMBER[MEASURE]/B_PERSON

2 O B_NUMBER[MEASURE]/B_PERSON

4 O B_NUMBER[MEASURE]/B_PERSON

( O O
n O O
- O O
Bu O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
n O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sn O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SCH2 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CH2 O B_MEASURE/B_LOCATION
- O O
NHm O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
CH3 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2 O B_MEASURE/B_LOCATION
- O O
m O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
4 O I_MEASURE/I_LOCATION
- O O
n O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

n O O
= O O
3 O B_NUMBER[MEASURE]
, O O
n O O
= O O
3 O B_NUMBER[MEASURE]
, O O
n O B_OTHER/B_MEASURE
= O O
2 O B_NUMBER[MEASURE]
, O O
n O B_OTHER/B_MEASURE
= O O
2 O B_NUMBER[MEASURE]
, O O

m O O
= O O
2 O B_MEASURE/B_LOCATION
m O I_MEASURE/I_LOCATION
= O O
O O B_MEASURE/B_LOCATION
m O I_MEASURE/I_LOCATION
= O O
2 O B_MEASURE/B_LOCATION
m O I_MEASURE/I_LOCATION
= O O
O O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

( O O
1 O B_MEASURE
) O O
( O O
2 O B_NUMBER[MEASURE]
) O O
( O O
3 O B_NUMBER[MEASURE]
) O O
( O O
4 O B_NUMBER[MEASURE]
) O O

3 O B_NUMBER[MEASURE]/B_PERSON

2 O B_NUMBER[MEASURE]/B_PERSON

4 O B_NUMBER[MEASURE]/B_PERSON

( O O
n O O
- O O
Bu O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
3 O B_MEASURE/B_PERSON
Sn O I_MEASURE/I_PERSON
S O I_MEASURE/I_PERSON
- O O
CH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
CH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
NHm O B_LOCATION/B_MEASURE
( O O
CH3 O B_LOCATION/B_PERSON
) O O
3 O B_MEASURE
. O O
m O B_NUMBER[MEASURE]/B_LOCATION
X O I_NUMBER[MEASURE]/I_LOCATION

m O O
= O O
3 O B_NUMBER[MEASURE]
, O O
x O O
= O O
cn3so3 O B_LOCATION/B_MEASURE
( O O
5 O B_MEASURE
) O O
m O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
, O O
X O B_PROTEIN[GENE]/B_DISEASE
= O O
CH3SO3 O B_LOCATION/B_MEASURE
( O O
6 O B_MEASURE
) O O
m O B_MEASURE/B_LOCATION
0 O I_MEASURE/I_LOCATION
, O O
X O B_MEASURE/B_LOCATION
I O I_MEASURE/I_LOCATION
( O O
7 O B_MEASURE
) O O

n O O
- O O
Bu O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CH3 O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CH2 O B_PROTEIN[GENE]/B_LOCATION
- O O
CH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
CH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

( O O
2 O B_NUMBER[MEASURE]
) O O
, O O
di O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
nTri O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
butyltin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_NUMBER[MEASURE]
) O O
, O O
tri O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
butyltin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
dimethylcysteaminate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
butyltin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
cysteaminate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
3 O B_NUMBER[MEASURE]
) O O
and O O
di O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
butyltin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
dimethylcysteaminate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
4 O B_NUMBER[MEASURE]
) O O
were O O
prepared O O
by O O
the O O
reaction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
prepared O O
in O O
situ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
the O O
reaction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methylate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
hydrochloride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
eysteamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
with O O
the O O
suitable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
di O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
or O O
tri O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
butyltin O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
chloroform O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
following O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
the O O
reactions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
The O O
methanesulphonates O B_SEQUENCE[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_SEQUENCE[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
6 O B_NUMBER[MEASURE]
were O O
respectively O O
synthesized O O
equimolar O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amount O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
methane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphonic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
unprotonated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
2 O B_NUMBER[MEASURE]
with O O
an O O
chloroform O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

After O O
purification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
a O O
short O B_LOCATION
column O I_LOCATION
of O O
alumina O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
evaporation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
solvent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
colourless O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
viscous O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oils O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
obtained O O
. O O

The O O
quaternized O B_TIME[MEASURE]/B_LOCATION
methyl O I_TIME[MEASURE]/I_LOCATION
derivative O I_TIME[MEASURE]/I_LOCATION
of O O
2 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
methiodide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
7 O B_TIME[MEASURE]/B_LOCATION
) O O
, O O
was O O
prepared O O
by O O
its O O
reaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
methyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iodide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
benzene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
purified O O
by O O
recrystalization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
chloroform O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

233 O B_NUMBER[MEASURE]

M O B_OTHER/B_MEASURE
. O O

Gielen O B_PERSON
, O O
K O B_OTHER/B_PERSON
. O O

Handlir O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

Hollein O B_PERSON/B_COLOR
and O O
D O B_OTHER/B_PERSON
. O O

de O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Vos O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Synthesis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
Characterization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
Antitumor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ofSome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Butyltin O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IV O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
Cysteaminates O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
N O B_OTHER/B_PROTEIN[GENE]
- O O
Dimethylcysteaminates O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE

86 O B_MEASURE
77 O I_MEASURE
85 O I_MEASURE
3 O I_MEASURE
( O O
C4H9 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2Sn O B_MEASURE/B_LOCATION
( O O
SCH2CH2NH2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
2 O B_MEASURE
90 O I_MEASURE
4 O I_MEASURE
( O O
C4Hg O B_MEASURE/B_LOCATION
) O O
zSn O B_MEASURE/B_LOCATION
( O O
SCH2CHzN O B_LOCATION
( O O
CH3 O B_LOCATION/B_PERSON
) O O
2 O B_MEASURE
) O O
2 O B_MEASURE
92 O I_MEASURE
oil O I_MEASURE
5 O I_MEASURE
( O O
C4H9 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
3 O B_MEASURE/B_PERSON
SnSCH2CH2NH3 O I_MEASURE/I_PERSON
CH3SO3 O I_MEASURE/I_PERSON
94 O I_MEASURE/I_PERSON
6 O I_MEASURE/I_PERSON
oil O I_MEASURE/I_PERSON
( O O
C4H9 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
3 O B_MEASURE/B_LOCATION
SnSCH2CH2NH O I_MEASURE/I_LOCATION
( O O
CH3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
2 O B_MEASURE/B_PERSON
CH3SO3 O I_MEASURE/I_PERSON
118 O I_MEASURE/I_PERSON
- O O
120 O B_MEASURE
74 O I_MEASURE
7 O I_MEASURE
( O O
C4H9 O B_MEASURE/B_GENE
) O O
. O O
SnSCH O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O
CH O B_LOCATION/B_DISEASE
. O O
N O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CH3 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
31 O B_MEASURE
The O O
elemental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
C O B_LOCATION/B_GENE
, O O
H O B_OTHER/B_LOCATION
, O O
N O B_OTHER/B_LOCATION
, O O
Sn O B_LOCATION/B_PERSON
) O O
agree O O
satisfactorily O O
with O O
the O O
proposed O O
formul O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Melting O O
points O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
yields O B_MEASURE
for O O
. O O
. O O
c0mP0unds O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
) O O
rmula O B_PROTEIN[GENE]/B_MEASURE
, O O
2 O B_LOCATION/B_MEASURE
comp O I_LOCATION/I_MEASURE
. O O

1 O B_NUMBER[MEASURE]
( O O
C4H9 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
3SnSCHzCH2NH2 O B_PROTEIN[GENE]/B_LOCATION
2 O B_PROTEIN[GENE]/I_LOCATION
( O O
C4H9 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
3SnSCHzCH2N O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CH3 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2 O B_MEASURE/B_LOCATION

7 O B_NUMBER[MEASURE]
. O O

m O B_PROTEIN[GENE]/B_DISEASE
. O O
p O B_MEASURE/B_PROTEIN[GENE]
. O O
, O O
. O O
. O O
b O O
. O O
p O B_MEASURE/B_PROTEIN[GENE]
. O O
. O O
, O O
. O O
C O B_MEASURE
120 O I_MEASURE
- O O
123 O B_MEASURE
/ O O
40 O B_TIME[MEASURE]
Pa O I_TIME[MEASURE]
129 O I_TIME[MEASURE]
- O O
131 O B_MEASURE
/ O O
35 O B_TIME[MEASURE]
Pa O I_TIME[MEASURE]
167 O I_TIME[MEASURE]
- O O
169 O B_MEASURE
/ O O
35 O B_TIME[MEASURE]
Pa O I_TIME[MEASURE]
172 O I_TIME[MEASURE]
- O O
174 O B_MEASURE
/ O O
40 O B_MEASURE/B_LOCATION
Pa O I_MEASURE/I_LOCATION

' O B_OTHER/B_DISEASE
o O O
' O O

yield O B_MEASURE
, O O
. O O
% O B_OTHER/B_MEASURE

Compounds O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
4 O B_NUMBER[MEASURE]
, O O
and O O
7 O B_MEASURE/B_LOCATION
, O O
are O O
poorly O O
soluble O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O O
aqueous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solutions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
< O B_MEASURE/B_LOCATION
mg O I_MEASURE/I_LOCATION
/ O O
mL O B_MEASURE/B_LOCATION
) O O
. O O

Compounds O B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O B_NUMBER[MEASURE]
and O O
6 O B_MEASURE
exhibit O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
water O I_DISEASE_ADJECTIVE[DISEASE]
solubilities O I_DISEASE_ADJECTIVE[DISEASE]
( O O
ca O O
. O O
2 O B_MEASURE
mg O I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
) O O
. O O

Compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O B_PERSON/B_LOCATION
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
soluble O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O O
a O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
0 O B_MEASURE
, O O
103 O B_MEASURE
M O I_MEASURE
solution O I_MEASURE
of O O
NaCl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
DMSO O B_MEASURE
1 O I_MEASURE
/ O O
9 O B_NUMBER[MEASURE]
) O O
. O O

A O O
white O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
turbidity O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
in O O
these O O
solutions O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
after O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
slow O O
hydrolysis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Compounds O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
characterized O O
by O O
multinuclear O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NMR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectroscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
NMR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
given O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Resonances O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
13C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
( O O
ca O O
20 O B_MEASURE
% O I_MEASURE
sol O I_MEASURE
. O O
v O B_OTHER/B_PROTEIN[GENE]
/ O O
v O O
) O O
1 O B_NUMBER[MEASURE]
' O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

SN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ll9Sn O B_MEASURE/B_LOCATION
NMR O I_MEASURE/I_LOCATION
spectra O I_MEASURE/I_LOCATION
of O O
2 O B_MEASURE/B_LOCATION

the O O
compounds O B_DISEASE/B_PROTEIN[GENE]
1 O B_DISEASE/I_PROTEIN[GENE]
- O O
7 O B_MEASURE
in O O
CDCI3 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
86 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
3 O B_TIME[MEASURE]
13 O I_TIME[MEASURE]
. O O
45 O B_MEASURE

6 O B_MEASURE/B_LOCATION
' O O
' O O
S O B_OTHER/B_MEASURE
' O O
n O B_MEASURE
) O O
, O O
" O O
ppm O B_TIME[MEASURE]/B_PROTEIN[GENE]
6 O I_TIME[MEASURE]/I_PROTEIN[GENE]
( O O
3c O B_MEASURE/B_LOCATION
) O O
a O O
, O O
ppm O B_MEASURE/B_LOCATION

x O B_OTHER/B_PERSON

77 O O
. O O
6 O B_MEASURE/B_LOCATION
12 O I_MEASURE/I_LOCATION
. O O
3 O B_MEASURE

77 O O
. O O
5 O B_TIME[MEASURE]
12 O I_TIME[MEASURE]
. O O
75 O B_MEASURE

3 O B_MEASURE
- O O
28 O B_MEASURE
. O O
9 O B_MEASURE/B_LOCATION
22 O I_MEASURE/I_LOCATION
. O O
38 O B_MEASURE

38 O O
. O O
' O O
18 O B_MEASURE/B_LOCATION
. O O
78 O B_TIME[MEASURE]/B_LOCATION

4 O B_NUMBER[MEASURE]/B_PERSON

6 O B_MEASURE
' O O
' O O
89 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
13 O I_TIME[MEASURE]
. O O
45 O B_MEASURE

7 O B_MEASURE
93 O I_MEASURE
. O O
2 O B_MEASURE
13 O I_MEASURE
. O O
60 O B_MEASURE

( O O
332 O O
) O O
27 O B_MEASURE/B_LOCATION
. O O
93 O B_TIME[MEASURE]/B_LOCATION

( O O
331 O O
) O O
27 O B_MEASURE/B_LOCATION
. O O
97 O B_MEASURE/B_LOCATION

( O O
495 O O
) O O
28 O B_MEASURE/B_LOCATION
. O O
27 O B_MEASURE/B_LOCATION

( O O
438 O O
) O O
27 O B_MEASURE/B_LOCATION
. O O
51 O B_TIME[MEASURE]/B_LOCATION

( O O
322 O O
) O O
28 O B_MEASURE/B_LOCATION
. O O
30 O B_TIME[MEASURE]/B_PERSON

( O O
350 O O
) O O
28 O B_MEASURE/B_LOCATION
. O O
34 O B_MEASURE/B_LOCATION

( O O
339 O O
) O O
28 O B_MEASURE/B_LOCATION
. O O
47 O B_TIME[MEASURE]/B_LOCATION

( O O
21 O O
. O O
3 O B_MEASURE
) O O
26 O B_MEASURE/B_LOCATION
. O O
32 O B_MEASURE

( O O
21 O O
. O O
1 O B_MEASURE
) O O
26 O B_MEASURE/B_LOCATION
. O O
38 O B_MEASURE

( O O
28 O O
. O O
4 O B_MEASURE
) O O
26 O B_MEASURE/B_LOCATION
. O O
42 O B_MEASURE

( O O
26 O O
. O O
4 O B_MEASURE
) O O
25 O B_MEASURE/B_LOCATION
. O O
90 O B_MEASURE

( O O
21 O O
. O O
4 O B_MEASURE
) O O
26 O B_MEASURE/B_LOCATION
. O O
85 O B_MEASURE

( O O
21 O O
. O O
3 O B_MEASURE
) O O
26 O B_MEASURE/B_LOCATION
. O O
81 O B_MEASURE

( O O
22 O O
. O O
0 O B_MEASURE
) O O
26 O B_MEASURE
. O O
91 O B_MEASURE

( O O
59 O O
. O O
6 O B_MEASURE
) O O
12 O B_MEASURE/B_LOCATION
. O O
89 O B_MEASURE

( O O
59 O O
. O O
8 O B_MEASURE
) O O
12 O B_MEASURE/B_LOCATION
. O O
95 O B_MEASURE

( O O
87 O O
. O O
1 O B_MEASURE
) O O
13 O B_MEASURE/B_LOCATION
. O O
35 O B_MEASURE

( O O
83 O O
. O O
8 O B_MEASURE
) O O
12 O B_MEASURE/B_LOCATION
. O O
82 O B_MEASURE

( O O
62 O O
. O O
7 O B_MEASURE
) O O
13 O B_MEASURE/B_LOCATION
. O O
45 O B_MEASURE

( O O
61 O O
. O O
4 O B_MEASURE
) O O
13 O B_MEASURE/B_LOCATION
. O O
58 O B_MEASURE

62 O O
. O O
2 O B_MEASURE
) O O
14 O B_MEASURE
. O O
00 O B_MEASURE

( O O
- O O
) O O
30 O B_MEASURE
. O O
31 O B_TIME[MEASURE]
45 O I_TIME[MEASURE]
. O O
02 O B_MEASURE

( O O
- O O
) O O
23 O B_MEASURE
. O O
59 O B_TIME[MEASURE]
63 O I_TIME[MEASURE]
. O O
12 O B_TIME[MEASURE]
44 O I_TIME[MEASURE]
. O O
71 O B_MEASURE

( O O
- O O
) O O
30 O B_MEASURE
. O O
04 O B_TIME[MEASURE]
44 O I_TIME[MEASURE]
. O O
44 O B_MEASURE

( O O
- O O
) O O
23 O B_MEASURE
. O O
84 O B_MEASURE/B_LOCATION
61 O I_MEASURE/I_LOCATION
. O O
84 O B_TIME[MEASURE]
44 O I_TIME[MEASURE]
. O O
46 O B_MEASURE

( O O
- O O
) O O
23 O B_MEASURE
. O O
92 O B_MEASURE
43 O I_MEASURE
. O O
08 O B_MEASURE

( O B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
- O O
; O O

( O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
) O O

20 O B_MEASURE
. O O
94 O B_MEASURE/B_LOCATION
19 O I_MEASURE/I_LOCATION
. O O
70 O B_MEASURE
60 O I_MEASURE
. O O
94 O B_MEASURE
69 O I_MEASURE
. O O
49 O B_MEASURE
43 O I_MEASURE
. O O
42 O B_TIME[MEASURE]
54 O I_TIME[MEASURE]
. O O
18 O B_TIME[MEASURE]
39 O I_TIME[MEASURE]
. O O
15 O B_TIME[MEASURE]
39 O I_TIME[MEASURE]
. O O
16 O B_MEASURE
- O O
360 O B_MEASURE
. O O
4 O B_MEASURE
- O O
354 O B_MEASURE
. O O
0 O B_SEQUENCE[MEASURE]
- O O
355 O B_MEASURE
. O O
3 O B_MEASURE
- O O
354 O B_MEASURE
. O O
4 O B_MEASURE
- O O
349 O B_MEASURE
. O O
4 O B_MEASURE
- O O
344 O B_MEASURE
. O O
2 O B_MEASURE
- O O
325 O B_MEASURE
. O O
8 O B_MEASURE
1 O I_MEASURE
. O O
1 O B_MEASURE
6 O I_MEASURE
. O O
2 O B_MEASURE
1 O I_MEASURE
. O O
5 O B_MEASURE
1 O I_MEASURE
. O O
5 O B_TIME[MEASURE]
12 O I_TIME[MEASURE]
. O O
7 O B_TIME[MEASURE]
11 O I_TIME[MEASURE]
. O O
7 O B_TIME[MEASURE]
30 O I_TIME[MEASURE]
. O O
1 O B_MEASURE/B_LOCATION
13 O I_MEASURE/I_LOCATION
a O O
' O O
values O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nJ O B_LOCATION/B_NUMBER[MEASURE]
( O O
n O B_LOCATION
J O I_LOCATION
9 O I_LOCATION
Sn O I_LOCATION
, O O
, O O
C O B_OTHER/B_MEASURE
) O O
c0uplihg O B_MEASURE/B_PERSON
constants O I_MEASURE/I_PERSON
in O O
Hz O B_MEASURE
' O O
for O O
Carbon O B_LOCATION/B_MEASURE
ato O I_LOCATION/I_MEASURE
] O O
ns O B_MEASURE
in O O
parentlee O B_PERSON
' O O
s O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
btween O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N O B_OTHER/B_MEASURE
) O O
for O O
the O O
organo O B_LOCATION/B_ENT
. O O
i O O
compound O O
and O O
free O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteamine O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
6 O B_NUMBER[MEASURE]
( O O
N O B_MEASURE/B_OTHER
) O O
361 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
; O O
N O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dimethylcysteamine O B_LOCATION/B_MEASURE
, O O
5 O B_NUMBER[MEASURE]
( O O
N O B_OTHER/B_MEASURE
) O O
- O O
355 O B_MEASURE
. O O
9 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
) O O
not O O
observed O O

C O B_LOCATION/B_PERSON
resonances O I_LOCATION/I_PERSON
were O O
assigned O O
on O O
the O O
basis O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
values O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
n O B_NUMBER[MEASURE]/B_LOCATION
J O I_NUMBER[MEASURE]/I_LOCATION
( O O
119 O B_MEASURE/B_LOCATION
Sn O I_MEASURE/I_LOCATION
, O O
13 O B_LOCATION/B_MEASURE
C O I_LOCATION/I_MEASURE
) O O
coupling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
constants O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
13 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
APT O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
utilization O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
agreement O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
ref O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O
. O O

The O O
values O B_MEASURE
of O O
119 O B_NUMBER[MEASURE]/B_PERSON
Sn O I_NUMBER[MEASURE]/I_PERSON
chemical O I_NUMBER[MEASURE]/I_PERSON
shifts O I_NUMBER[MEASURE]/I_PERSON
are O O
found O O
in O O
the O O
interval O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
characteristic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
fourcoordinated O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tin O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
7 O B_MEASURE/B_LOCATION
. O O

The O O
values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
coupling O B_MEASURE/B_LOCATION
constants O I_MEASURE/I_LOCATION
j O O
( O O
1 O B_MEASURE/B_PROTEIN[GENE]
lqSn O I_MEASURE/I_PROTEIN[GENE]
, O O
13C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
agree O O
with O O
the O O
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
proposed O O
. O O

Compound O B_PERSON
3 O I_PERSON
is O O
characterized O O
by O O
a O O
somewhat O O
larger O B_MEASURE
upfield O I_MEASURE
shift O I_MEASURE
, O O
close O B_LOCATION/B_MEASURE
to O O
the O O
upper O B_MEASURE/B_LOCATION
limit O I_MEASURE/I_LOCATION
of O O
the O O
above O B_TIME[MEASURE]/B_LOCATION
mentioned O O
interval O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
together O O
with O O
a O O
high O B_MEASURE/B_LOCATION
value O I_MEASURE/I_LOCATION
of O O
1j O B_MEASURE/B_PROTEIN[GENE]
( O O
l O B_MEASURE/B_PROTEIN[GENE]
lqSn O I_MEASURE/I_PROTEIN[GENE]
, O O
13C O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
495 O B_MEASURE/B_LOCATION
Hz O I_MEASURE/I_LOCATION
) O O
. O O

67 O B_MEASURE
The O O
C O B_PROTEIN[GENE]/B_LOCATION
- O O
Sn O B_LOCATION/B_PERSON
- O O
C O B_MEASURE/B_LOCATION
angle O B_MEASURE/I_LOCATION
, O O
est O B_LOCATION/B_PROTEIN[GENE]
' O O
mated O O
, O O
from O O
this O O
value O B_MEASURE
of O O
coupling O O
constant O B_MEASURE
is O O
124 O B_TIME[MEASURE]
According O O
to O O
ref O O
. O O
this O O
behaviour O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O O
be O O
due O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
intermolecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
association O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
increasing O O
the O O
coordinatitn O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
tin O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
concentrated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
solutions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
as O O
suggested O O
by O O
the O O
concentration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dependence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
tS O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Sn O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
and O O
cryoscopic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
benzene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
values O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
6 O B_MEASURE
( O O
SN O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
chemical O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shifts O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
compounds O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
2 O B_SEQUENCE[MEASURE]
and O O
4 O B_NUMBER[MEASURE]
only O O
slightly O O
differ O O
from O O
the O O
( O O
15N O B_LOCATION
) O O
values O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
free O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cysteamine O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
significantly O O
larger O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i O O
( O O
15N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
chemical O B_MEASURE
shift O I_MEASURE
of O O
compound O B_MEASURE
3 O I_MEASURE
is O O
however O O
much O O
lower O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
those O O
of O O
compounds O B_NUMBER[MEASURE]
5 O I_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
and O O
7 O B_NUMBER[MEASURE]
containing O O
a O O
N O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interaction O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tetracoordinated O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nitrogen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
atom O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
can O O
be O O
stated O O
that O O
the O O
Sn O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
4 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
negligible O B_DISEASE_ADJECTIVE[DISEASE]
or O O
only O O
very O O
weak O B_DISEASE_ADJECTIVE[DISEASE]
in O O
chlorofom O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
solutions O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

This O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
not O O
in O O
contradiction O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
proved O O
Sn O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
N O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interaction O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
found O O
in O O
the O O
solid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
state O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

13 O B_NUMBER[MEASURE]

, O B_OTHER/B_PERSON

234 O B_NUMBER[MEASURE]

Metal O B_ORGANIZATION
Based O I_ORGANIZATION
Drugs O I_ORGANIZATION

Vol O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

7 O B_MEASURE
, O O
Nr O B_MEASURE/B_BIO
. O O

5 O B_TIME[MEASURE]/B_LOCATION
, O O
2000 O B_MEASURE/B_LOCATION

Antitumour O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antitumour O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
given O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
the O O
inhibition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
doses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
IDs0 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
observed O O
against O O
a O O
panel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
seven O B_DISEASE
human O I_DISEASE
tumour O I_DISEASE
cell O I_DISEASE
lines O I_DISEASE
, O O
MCF O B_PROTEIN[GENE]/B_BIO
- O O
7 O B_TIME[MEASURE]/B_LOCATION
and O O
EVSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
T O B_MEASURE/B_OTHER
, O O
two O B_DISEASE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
breast O B_DISEASE/I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
cancers O B_DISEASE/I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
, O O
WiDr O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
, O O
a O O
colon O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
IGROV O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
ovarian O B_DISEASE
cancer O I_DISEASE
, O O
M19 O B_DISEASE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
MEL O B_DISEASE/I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
, O O
a O O
melanoma O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
A248 O B_GENE/B_DISEASE
, O O
a O O
renal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
H226 O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
small O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
lung O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancer O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
antitumour O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
compared O O
with O O
those O O
obtained O O
for O O
clinically O O
used O O
reference O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds9 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
doxorubicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
etoposide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
methotrexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Inhibition O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

comp O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O O

1 O B_MEASURE
2 O I_MEASURE
3 O I_MEASURE
4 O I_MEASURE
5 O I_MEASURE
6 O I_MEASURE
7 O I_MEASURE

MF O B_MEASURE
- O O
7 O B_MEASURE
41 O I_MEASURE
41 O I_MEASURE
51 O I_MEASURE
78 O I_MEASURE
30 O I_MEASURE
90 O I_MEASURE
385 O I_MEASURE
699 O I_MEASURE
10 O I_MEASURE
2 O I_MEASURE
594 O I_MEASURE
750 O I_MEASURE
18 O I_MEASURE

EVSA O B_MEASURE/B_GENE
- O O
T O B_MEASURE/B_LOCATION
33 O I_MEASURE/I_LOCATION
35 O I_MEASURE/I_LOCATION
45 O I_MEASURE/I_LOCATION
65 O I_MEASURE/I_LOCATION
< O O
3 O B_MEASURE/B_LOCATION
57 O I_MEASURE/I_LOCATION
367 O I_MEASURE/I_LOCATION

IDs0 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
compounds O B_PERSON/B_DISEASE
WiDr O I_PERSON/I_DISEASE
39 O I_PERSON/I_DISEASE
39 O I_PERSON/I_DISEASE
211 O I_PERSON/I_DISEASE
331 O I_PERSON/I_DISEASE
19 O I_PERSON/I_DISEASE
40 O I_PERSON/I_DISEASE
339 O I_PERSON/I_DISEASE

1 O B_NUMBER[MEASURE]/B_LOCATION
- O O
7 O B_MEASURE
and O O
of O O
five O B_MEASURE/B_LOCATION
reference O B_MEASURE/I_LOCATION
compounds O B_MEASURE/I_LOCATION
. O O

IGROV O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
M19MEL O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
A498 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
H226 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
67 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
44 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
85 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
39 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
46 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
78 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
88 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
39 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
68 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
70 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
118 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
72 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
110 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
129 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
108 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
112 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
31 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
29 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
36 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
42 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
83 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
133 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
77 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
111 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
327 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
758 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
576 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
411 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
169 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
60 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
580 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
297 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
7 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
558 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
16 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
505 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
442 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
23 O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]

cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
doxorubicin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO

etoposide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

422 O B_TIME[MEASURE]
8 O I_TIME[MEASURE]
317 O I_TIME[MEASURE]
475 O I_TIME[MEASURE]
5 O I_TIME[MEASURE]

methotrexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

967 O B_TIME[MEASURE]
11 O I_TIME[MEASURE]
150 O I_TIME[MEASURE]
225 O I_TIME[MEASURE]
< O O
3 O B_MEASURE/B_LOCATION

2 O B_TIME[MEASURE]
253 O I_TIME[MEASURE]
90 O I_TIME[MEASURE]
314 O I_TIME[MEASURE]
143 O I_TIME[MEASURE]
37 O I_TIME[MEASURE]

3 O B_MEASURE
369 O I_MEASURE
199 O I_MEASURE
3 O I_MEASURE
934 O I_MEASURE
340 O I_MEASURE
2 O I_MEASURE
287 O I_MEASURE

It O O
is O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
all O O
studied O O
compounds O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
exhibit O O
excellent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cytostatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activities O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
except O O
compound O B_NUMBER[MEASURE]/B_BIO
7 O I_NUMBER[MEASURE]/I_BIO
showing O O
only O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moderate O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O B_LOCATION
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
more O O
active O B_DISEASE_ADJECTIVE[DISEASE]
than O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
, O O
in O O
most O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
than O O
etoposide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Their O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
of O O
doxorubicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
methotrexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
most O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
studied O O
cancer O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
very O O
limited O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
acquired O O
activity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
the O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
tri O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
butyltin O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
those O O
of O O
di O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
n O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
butyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analogues O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O B_NUMBER[MEASURE]/B_LOCATION
> O O
3 O B_NUMBER[MEASURE]
, O O
2 O B_NUMBER[MEASURE]
> O O
4 O B_NUMBER[MEASURE]
) O O
for O O
all O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lines O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
especially O O
compounds O O
against O O
WiDr O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dimethyl O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derivatives O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exhibit O O
an O O
activity O B_MEASURE/B_LOCATION
comparable O I_MEASURE/I_LOCATION
to O O
or O O
somewhat O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
of O O
unmethylated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Compound O B_MEASURE
8 O I_MEASURE
, O O
with O O
a O O
quaternized O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrogen O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
exhibits O O
the O O
lowest O B_MEASURE/B_LOCATION
cytotoxic O I_MEASURE/I_LOCATION
activities O I_MEASURE/I_LOCATION
, O O
approximatively O O
9 O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
times O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lower O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
compound O B_NUMBER[MEASURE]/B_LOCATION
2 O I_NUMBER[MEASURE]/I_LOCATION
. O O

It O O
might O O
be O O
underlined O O
that O O
the O O
ionic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
more O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
soluble O B_NUMBER[MEASURE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds O I_NUMBER[MEASURE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_NUMBER[MEASURE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
6 O B_NUMBER[MEASURE]
are O O
not O O
more O O
active O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
the O O
uncharged O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analogs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
4 O B_MEASURE
, O O
whereas O O
the O O
hydrophilic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
organotin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
polyoxacarboxylates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
exhibit O O
much O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
than O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
organotin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
carxylates O O
51 O B_NUMBER[MEASURE]
Compounds O I_NUMBER[MEASURE]
5 O I_NUMBER[MEASURE]
and O O
6 O B_NUMBER[MEASURE]
( O O
with O O
a O O
protonated O O
nitrogen O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
exhibit O B_LOCATION/B_PERSON
activities O I_LOCATION/I_PERSON
comparable O I_LOCATION/I_PERSON
or O O
even O O
considerably O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
compound O B_MEASURE
5 O I_MEASURE
) O O
against O O
EVSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
T O B_PROTEIN[GENE]/B_MEASURE
than O O
the O O
corresponding O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unprotonated O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Compound O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
with O O
a O O
quaternized O B_MEASURE
nitrogen O I_MEASURE
) O O
exhibits O O
the O O
lowest O B_MEASURE/B_LOCATION
cytostatic O I_MEASURE/I_LOCATION
activities O I_MEASURE/I_LOCATION
, O O
approximately O O
9 O B_TIME[MEASURE]/B_LOCATION
times O B_TIME[MEASURE]/I_LOCATION
should O O
however O O
be O O
mentioned O O
that O O
another O O
ionic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organotin O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lower O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
compound O B_NUMBER[MEASURE]/B_LOCATION
2 O I_NUMBER[MEASURE]/I_LOCATION
. O O

It O O
compound O O
, O O
bis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
dicyclohexyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
ammonium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
- O O
pyridinecarboxyla O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
to O O
) O O
di O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
n O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
butylstannate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
where O O
the O O
organotin O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moiety O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
this O O
time O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
anionic O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
is O O
also O O
as O O
active O B_DISEASE_ADJECTIVE[DISEASE]
as O O
the O O
uncharged O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analog O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
l O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

All O O
NMR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spectra O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
recorded O O
on O O
a O O
Bruker O B_MEASURE/B_PRODUCT[OBJECT]
AMX O I_MEASURE/I_PRODUCT[OBJECT]
360 O I_MEASURE/I_PRODUCT[OBJECT]
instrument O I_MEASURE/I_PRODUCT[OBJECT]
using O O
a O O
5 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mm O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
multinuclear O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
tuneable O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
probe O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
residual O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CHCI3 O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resonance O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
7 O B_MEASURE
. O O
24 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
was O O
used O O
as O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
the O O
H O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
soectra O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
central O B_SEQUENCE[MEASURE]/B_LOCATION
13CDCI3 O I_SEQUENCE[MEASURE]/I_LOCATION
resonance O I_SEQUENCE[MEASURE]/I_LOCATION
at O O
77 O B_MEASURE
. O O
0 O B_TIME[MEASURE]
ppm O I_TIME[MEASURE]
, O O
for O O
the O O
13C O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spectra O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
119 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Sn O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chemical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
shifts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
refered O O
to O O
the O O
external O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tetramethyltin O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
6 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
119 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sn O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
0 O B_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
15N O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NMR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectra O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
measur O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O O
l O B_DISEASE/B_LOCATION
using O O
the O O
INEPT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
or O O
in O O
inverse O B_MEASURE
- O O
gated O O
mode O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

( O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Instrumentation O B_PERSON/B_LOCATION
. O O

external O B_MEASURE
nitromethane O I_MEASURE
, O O
[ O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
' O O
N O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
0 O B_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
) O O
. O O

The O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
followed O O
for O O
the O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antitumour O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
screenings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O O
been O O
already O O
reported O O
10 O B_TIME[MEASURE]/B_LOCATION
. O O

Acknowledgements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

K O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

H O B_PROTEIN[GENE]/B_LOCATION
. O O
and O O
M O B_LOCATION/B_PERSON
H O I_LOCATION/I_PERSON
. O O
thank O O
the O O
Grant O B_ORGANIZATION/B_LOCATION
Agency O I_ORGANIZATION/I_LOCATION
of O O
the O O
Czech O B_LOCATION/B_ORGANIZATION
Republic O I_LOCATION/I_ORGANIZATION
( O O
Grant O B_MEASURE/B_ORGANIZATION
No O I_MEASURE
. O O
203 O B_MEASURE
/ O O
00 O B_MEASURE
/ O O
0920 O B_MEASURE
) O O
and O O
the O O
Ministry O B_ORGANIZATION/B_PERSON
o O O
" O O
Education O B_PERSON/B_LOCATION
, O O
Youth O B_PERSON/B_EDU[ORGANIZATION]
and O O
Sport O B_SPORT[ENT]/B_PERSON
of O O
the O O
Czech O B_LOCATION/B_ORGANIZATION
republic O I_LOCATION/I_ORGANIZATION
, O O
associated O O
with O O
EU O B_LOCATION/B_PERSON
in O O
the O O
COST O B_TIME[MEASURE]/B_LOCATION
8 O I_TIME[MEASURE]/I_LOCATION
. O O
20 O B_MEASURE
program O I_MEASURE
for O O
financial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
this O O
work O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
are O O
grateful O B_PERSON
to O O
Mr O B_PERSON/B_PROTEIN[GENE]
. O O
R O B_OTHER/B_PERSON
. O O

G O B_OTHER/B_GENE
. O O

Experimental O B_PERSON/B_LOCATION
Oostrum O I_PERSON/I_LOCATION
, O O
Dr O B_PERSON/B_LOCATION
. O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
verweij O B_PERSON
, O O
Prof O B_PERSON/B_LOCATION
. O O

Dr O B_TIME[MEASURE]
. O O
G O B_OTHER/B_PERSON
. O O

Stoter O B_PERSON
, O O
r O O
. O O
K O B_GENE/B_LOCATION
. O O

Nooter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
Laboratory O B_LOCATION/B_PERSON
of O O
Chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
Pharmacology O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
Department O B_ORGANIZATION/B_LOCATION
of O O
Medical O B_EDU[ORGANIZATION]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Oncology O I_EDU[ORGANIZATION]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
Rotterdam O B_LOCATION
Cancer O I_LOCATION
235 O I_LOCATION

M O B_OTHER/B_MEASURE
. O O

Gielen O B_PERSON
, O O
K O B_OTHER/B_PERSON
. O O

Handlir O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

HoHein O B_PERSON/B_COLOR
and O O
D O B_OTHER/B_PERSON
. O O

de O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Vos O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Synthesis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
Characterization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
Antitumor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ofSome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Butyltin O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IV O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
Cysteaminates O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
N O B_OTHER/B_PROTEIN[GENE]
- O O
Dimethylcysteaminates O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE

Institute O B_LOCATION/B_ORGANIZATION
, O O
NL O B_LOCATION/B_ORGANIZATION
3008 O I_LOCATION/I_ORGANIZATION
AE O I_LOCATION/I_ORGANIZATION
, O O
Rotterdam O B_LOCATION
, O O
The O O
Netherlands O B_LOCATION
, O O
for O O
performing O O
the O O
in O O
vitro O B_ENT/B_ORGANIZATION
tests O I_ENT/I_ORGANIZATION
. O O

This O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O O
supported O O
by O O
the O O
Fund O B_ORGANIZATION/B_LOCATION
for O O
Scientific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Flanders O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Belgium O B_LOCATION/B_MEASURE
) O O
, O O
grant O B_MEASURE/B_LOCATION
nr O I_MEASURE/I_LOCATION
G O I_MEASURE/I_LOCATION
. O O
0074 O B_MEASURE
. O O
00 O B_TIME[MEASURE]/B_PERSON
, O O
M O B_OTHER/B_LOCATION
. O O

G O B_OTHER/B_MEASURE
. O O
) O O
. O O

References O B_PERSON/B_DISEASE
. O O

1 O B_NUMBER[MEASURE]
. O O

B O B_PROTEIN[GENE]/B_DISEASE
. O O
S O B_OTHER/B_DISEASE
. O O

Saraswat O B_PERSON/B_LOCATION
, O O
J O B_OTHER/B_LOCATION
. O O

Mason O B_PERSON/B_MEASURE
, O O
Polyhedron O B_MEASURE/B_LOCATION
( O O
9 O B_NUMBER[MEASURE]
) O O
, O O
5 O B_MEASURE
( O O
1986 O B_MEASURE
) O O
, O O
1449 O B_MEASURE/B_LOCATION
. O O

2 O B_NUMBER[MEASURE]
. O O

G O B_OTHER/B_GENE
. O O

Domazetis O B_PERSON/B_COLOR
, O O
R O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Magee O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

D O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

James O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

Organomet O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

Chem O B_MEASURE/B_PERSON
, O O
162 O B_MEASURE/B_PERSON
( O O
1978 O B_MEASURE
) O O
, O O
239 O B_MEASURE/B_LOCATION
. O O

3 O B_NUMBER[MEASURE]
. O O

J O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
D O B_OTHER/B_PERSON
. O O

Cashion O B_PERSON/B_LOCATION
, O O
G O B_OTHER/B_PERSON
. O O

Domazetis O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

D O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

James O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

Organomet O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

Chem O B_MEASURE/B_PERSON
, O O
185 O B_MEASURE
( O O
1980 O B_MEASURE
) O O
, O O
433 O B_MEASURE/B_LOCATION
. O O

4 O B_NUMBER[MEASURE]
. O O

G O B_OTHER/B_GENE
. O O

Domazetis O B_PERSON/B_COLOR
, O O
R O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Magee O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

D O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

James O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

Organomet O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

Chem O B_MEASURE/B_PERSON
, O O
148 O B_MEASURE
( O O
1978 O B_MEASURE
) O O
, O O
339 O B_MEASURE/B_LOCATION
. O O

5 O B_NUMBER[MEASURE]
. O O

G O B_OTHER/B_GENE
. O O

Atassi O B_PERSON/B_TIME[MEASURE]
, O O
Rev O B_PERSON/B_LOCATION
. O O

Si O B_MEASURE
Ge O I_MEASURE
Sn O I_MEASURE
Pb O I_MEASURE
Cpds O I_MEASURE
, O O
8 O B_MEASURE
( O O
1985 O B_MEASURE
) O O
, O O
219 O B_MEASURE
; O O
M O B_MEASURE
. O O

Kemmer O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

Gielen O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

Biesemans O B_PERSON
, O O
D O B_OTHER/B_PERSON
. O O

de O B_PERSON/B_COLOR
Vos O I_PERSON/I_COLOR
, O O
R O B_OTHER/B_LOCATION
. O O

Willem O B_PERSON/B_LOCATION
, O O
Metal O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Based O O
Drugs O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1998 O B_MEASURE
) O O
, O O
189 O B_MEASURE
; O O
M O B_MEASURE/B_GENE
. O O

Gielen O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

Biesemans O B_PERSON
, O O
D O B_OTHER/B_PERSON
. O O

de O B_PERSON/B_COLOR
Vos O I_PERSON/I_COLOR
, O O
R O B_OTHER/B_LOCATION
. O O

Willem O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_LOCATION
. O O

Inorg O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Biochem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O
, O O
79 O B_MEASURE
( O O
2000 O B_MEASURE
) O O
, O O
139 O B_MEASURE/B_LOCATION
. O O

6 O B_NUMBER[MEASURE]
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Holecek O B_PERSON/B_COLOR
, O O
A O O
. O O

Lycka O B_PERSON/B_LOCATION
, O O
Inorg O B_LOCATION/B_PERSON
. O O

Chim O B_PERSON/B_DISEASE
. O O

Acta O B_MEASURE/B_PERSON
, O O
118 O B_NUMBER[MEASURE]
( O O
1986 O B_NUMBER[MEASURE]
) O O
, O O
L O B_GENE/B_MEASURE
15 O I_GENE/I_MEASURE
. O O

7 O B_NUMBER[MEASURE]
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Holecek O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

Nadvomik O B_PERSON/B_LOCATION
, O O
K O B_OTHER/B_PERSON
. O O

Handlir O B_PERSON/B_COLOR
, O O
A O O
. O O

Lycka O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

Organomet O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

Chem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O
, O O
315 O B_MEASURE
( O O
1986 O B_MEASURE
) O O
, O O
299 O B_MEASURE/B_LOCATION
. O O

8 O B_NUMBER[MEASURE]
. O O

B O B_MEASURE/B_DISEASE
. O O
D O B_OTHER/B_BACTERIUM[BIO]
. O O

James O B_PERSON/B_COLOR
, O O
R O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Magee O B_PERSON/B_LOCATION
, O O
W O B_OTHER/B_PERSON
. O O

C O B_OTHER/B_GENE
. O O

Patalinghug O B_PERSON/B_LOCATION
, O O
B O B_OTHER/B_PERSON
. O O

W O B_OTHER/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Skelton O B_PERSON/B_COLOR
, O O
A O O
. O O

H O B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

White O B_COLOR/B_PERSON
, O O
J O B_OTHER/B_PERSON
. O O

Organomet O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

Chem O B_MEASURE/B_PERSON
, O O
467 O B_MEASURE/B_PERSON
( O O
1994 O B_MEASURE
) O O
, O O
51 O B_MEASURE/B_GENE
9 O I_MEASURE/I_GENE
. O O

P O B_OTHER/B_MEASURE
. O O

Skehan O B_PERSON/B_COLOR
, O O
R O B_OTHER/B_PERSON
. O O

Storeng O B_PERSON/B_LOCATION
, O O
D O B_OTHER/B_PERSON
. O O

Scudiero O B_PERSON/B_COLOR
, O O
A O O
. O O

Monks O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_LOCATION
. O O

McMahon O B_PERSON/B_LOCATION
, O O
D O B_OTHER/B_PERSON
. O O

Vistica O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

T O B_OTHER/B_GENE
. O O

Warren O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_PERSON
. O O

Bokesh O B_PERSON/B_LOCATION
, O O
S O B_OTHER/B_PERSON
. O O

Kenney O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

R O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Boyd O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O
. O O

Natl O B_PERSON/B_BACTERIUM[BIO]
. O O

Cancer O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lnst O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O
, O O
82 O B_MEASURE
( O O
1990 O B_MEASURE
) O O
, O O
1107 O B_MEASURE/B_LOCATION
. O O

10 O B_NUMBER[MEASURE]
. O O

Y O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

P O B_OTHER/B_MEASURE
. O O

Kepers O B_PERSON/B_LOCATION
, O O
G O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Peters O B_PERSON/B_ORGANIZATION
, O O
J O B_OTHER/B_PERSON
. O O

Van O B_PERSON/B_LOCATION
Ark O I_PERSON/I_LOCATION
- O O
Otte O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

Winograd O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_PERSON
. O O

M O B_OTHER/B_MEASURE
. O O

Pinedo O B_PERSON/B_LOCATION
, O O
Eur O B_LOCATION/B_PERSON
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cancer O B_DISEASE/B_MEASURE
, O O
27 O B_MEASURE
( O O
1991 O B_MEASURE
) O O
, O O
897 O B_MEASURE/B_LOCATION
. O O

11 O B_NUMBER[MEASURE]
. O O

M O B_OTHER/B_MEASURE
. O O

Kemmer O B_PERSON/B_COLOR
, O O
L O B_OTHER/B_PERSON
. O O

Ghys O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

Gielen O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

Biesemans O B_PERSON/B_COLOR
, O O
E O B_OTHER/B_PERSON
. O O

R O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

T O B_OTHER/B_GENE
. O O

Tiekink O B_PERSON/B_LOCATION
, O O
R O B_OTHER/B_PERSON
. O O

Willem O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_LOCATION
. O O

Organomet O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

Chem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

582 O B_MEASURE
( O O
1999 O B_MEASURE
) O O
, O O
195 O B_MEASURE/B_LOCATION
. O O

12 O B_NUMBER[MEASURE]
. O O

S O B_OTHER/B_DISEASE
. O O

W O B_OTHER/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Ng O B_PERSON
, O O
V O B_OTHER/B_PERSON
. O O

G O B_OTHER/B_GENE
. O O

Kumar O B_PERSON/B_COLOR
Das O I_PERSON/I_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

Holecek O B_PERSON/B_COLOR
, O O
A O O
. O O

Lycka O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

Gielen O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

G O B_OTHER/B_GENE
. O O

B O B_OTHER/B_DISEASE
. O O

Drew O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
Appl O B_PERSON/B_LOCATION
. O O

Organomet O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

Chem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

11 O B_MEASURE
( O O
1997 O B_MEASURE
) O O
, O O
3 O B_MEASURE/B_PERSON
9 O I_MEASURE/I_PERSON
. O O

Received O O
" O O
September O B_TIME[MEASURE]
22 O I_TIME[MEASURE]
, O O
2000 O B_MEASURE
Accepted O O
- O O
October O B_TIME[MEASURE]
19 O I_TIME[MEASURE]
, O O
2000 O B_MEASURE
Received O O
in O O
revised O O
camera O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ready O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
format O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
October O B_TIME[MEASURE]
20 O I_TIME[MEASURE]
, O O
2000 O B_MEASURE

236 O B_NUMBER[MEASURE]

Genomic O O
- O O
Bioinformatic O O
Analysis O O
of O O
Transcripts O O
Enriched O O
in O O
the O O
Third O O
- O O
Stage O O
Larva O O
of O O
the O O
Parasitic O O
Nematode O O
Ascaris B B_SPECIES[BIO]/B_DISEASE
suum I I_SPECIES[BIO]/I_DISEASE

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Differential O O
transcription O O
in O O
Ascaris B B_DISEASE/B_SPECIES[BIO]
suum I I_DISEASE/I_SPECIES[BIO]
was O O
investigated O O
using O O
a O O
genomic O O
- O O
bioinformatic O O
approach O O
. O O

A O O
cDNA O O
archive O O
enriched O O
for O O
molecules O O
in O O
the O O
infective O O
third O O
- O O
stage O O
larva O O
( O O
L3 O O
) O O
of O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
was O O
constructed O O
by O O
suppressive O O
- O O
subtractive O O
hybridization O O
( O O
SSH O O
) O O
, O O
and O O
a O O
subset O O
of O O
cDNAs O O
from O O
3075 O O
clones O O
subjected O O
to O O
microarray O O
analysis O O
using O O
cDNA O O
probes O O
derived O O
from O O
RNA O O
from O O
different O O
developmental O O
stages O O
of O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
. O O

The O O
cDNAs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
n O B_OTHER/B_MEASURE
= O O
498 O B_MEASURE
) O O
shown O O
by O O
microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
be O O
enriched O O
in O O
the O O
L3 O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O O
sequenced O O
and O O
subjected O O
to O O
bioinformatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
a O O
semi O B_DISEASE
- O O
automated O O
pipeline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
ESTExplorer O B_LOCATION/B_ORGANIZATION
) O O
. O O

Using O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
ontology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
GO O O
) O O
, O O
235 O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
molecules O B_BIO/B_LOCATION
were O O
assigned O O
to O O
' O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
' O O
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
68 O B_MEASURE
) O O
, O O
' O O
cellular O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
( O O
n O B_OTHER/B_MEASURE
= O O
50 O B_MEASURE
) O O
, O O
or O O
' O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
function O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
' O O
( O O
n O B_OTHER/B_MEASURE
= O O
117 O B_MEASURE
) O O
. O O

Of O O
the O O
91 O O
clusters O O
assembled O O
, O O
56 O O
molecules O O
( O O
61 O O
. O O
5 O O
% O O
) O O
had O O
homologues O O
/ O O
orthologues O O
in O O
the O O
free O O
- O O
living O O
nematodes O O
Caenorhabditis B B_SPECIES[BIO]
elegans I I_SPECIES[BIO]
and O O
C B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
briggsae I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
other O O
organisms O O
, O O
whereas O O
35 O O
( O O
38 O O
. O O
5 O O
% O O
) O O
had O O
no O O
significant O O
similarity O O
to O O
any O O
sequences O O
available O O
in O O
current O O
gene O O
databases O O
. O O

Transcripts O O
encoding O O
protein O O
kinases O O
, O O
protein O O
phosphatases O O
( O O
and O O
their O O
precursors O O
) O O
, O O
and O O
enolases O O
were O O
abundantly O O
represented O O
in O O
the O O
L3 O O
of O O
A B B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. I I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
suum I I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
as O O
were O O
molecules O O
involved O O
in O O
cellular O O
processes O O
, O O
such O O
as O O
ubiquitination O O
and O O
proteasome O O
function O O
, O O
gene O O
transcription O O
, O O
protein O O
- O O
protein O O
interactions O O
, O O
and O O
function O O
. O O

In O O
silico O O
analyses O O
inferred O O
the O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
orthologues O O
/ O O
homologues O O
( O O
n O O
= O O
50 O O
) O O
to O O
be O O
involved O O
in O O
apoptosis O O
and O O
insulin O O
signaling O O
( O O
2 O O
% O O
) O O
, O O
ATP O O
synthesis O O
( O O
2 O O
% O O
) O O
, O O
carbon O O
metabolism O O
( O O
6 O O
% O O
) O O
, O O
fatty O O
acid O O
biosynthesis O O
( O O
2 O O
% O O
) O O
, O O
gap O O
junction O O
( O O
2 O O
% O O
) O O
, O O
glucose O O
metabolism O O
( O O
6 O O
% O O
) O O
, O O
or O O
porphyrin O O
metabolism O O
( O O
2 O O
% O O
) O O
, O O
although O O
34 O O
( O O
68 O O
% O O
) O O
of O O
them O O
could O O
not O O
be O O
mapped O O
to O O
a O O
specific O O
metabolic O O
pathway O O
. O O

Small O B_NUMBER[MEASURE]
numbers O I_NUMBER[MEASURE]
of O O
these O O
50 O B_GENE/B_BIO
molecules O I_GENE/I_BIO
were O O
predicted O O
to O O
be O O
secreted O O
( O O
10 O B_MEASURE
% O I_MEASURE
) O O
, O O
anchored O O
( O O
2 O B_MEASURE
% O I_MEASURE
) O O
, O O
and O O
/ O O
or O O
transmembrane O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( O O
12 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
) O O
proteins O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

Functionally O O
, O O
17 O O
( O O
34 O O
% O O
) O O
of O O
them O O
were O O
predicted O O
to O O
be O O
associated O O
with O O
( O O
non O O
- O O
wild O O
- O O
type O O
) O O
RNAi O O
phenotypes O O
in O O
C B B_BIO
. I I_BIO
elegans I I_BIO
, O O
the O O
majority O O
being O O
embryonic O O
lethality O O
( O O
Emb O O
) O O
( O O
13 O O
types O O
; O O
58 O O
. O O
8 O O
% O O
) O O
, O O
larval O O
arrest O O
( O O
Lva O O
) O O
( O O
23 O O
. O O
5 O O
% O O
) O O
and O O
larval O O
lethality O O
( O O
Lvl O O
) O O
( O O
47 O O
% O O
) O O
. O O

A O O
genetic O O
interaction O O
network O O
was O O
predicted O O
for O O
these O O
17 O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
orthologues O O
, O O
revealing O O
highly O O
significant O O
interactions O O
for O O
nine O O
molecules O O
associated O O
with O O
embryonic O O
and O O
larval O O
development O O
( O O
66 O O
. O O
9 O O
% O O
) O O
, O O
information O O
storage O O
and O O
processing O O
( O O
5 O O
. O O
1 O O
% O O
) O O
, O O
cellular O O
processing O O
and O O
signaling O O
( O O
15 O O
. O O
2 O O
% O O
) O O
, O O
metabolism O O
( O O
6 O O
. O O
1 O O
% O O
) O O
, O O
and O O
unknown O O
function O O
( O O
6 O O
. O O
7 O O
% O O
) O O
. O O

The O O
potential O O
roles O O
of O O
these O O
molecules O O
in O O
development O O
are O O
discussed O O
in O O
relation O O
to O O
the O O
known O O
roles O O
of O O
their O O
homologues O O
/ O O
orthologues O O
in O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
and O O
some O O
other O O
nematodes O O
. O O

The O O
results O O
of O O
the O O
present O O
study O O
provide O O
a O O
basis O O
for O O
future O O
functional O O
genomic O O
studies O O
to O O
elucidate O O
molecular O O
aspects O O
governing O O
larval O O
developmental O O
processes O O
in O O
A B B_BIO/B_ORGANISM_FUNCTION
. I I_BIO/I_ORGANISM_FUNCTION
suum I I_BIO/I_ORGANISM_FUNCTION
and O O
/ O O
or O O
the O O
transition O O
to O O
parasitism O O
. O O

Introduction O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Parasitic O B_DISEASE/B_BIO
nematodes O I_DISEASE/I_BIO
are O O
of O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
socio O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O O
economic O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
animals O B_BIO/B_LOCATION
. O O

For O O
example O O
, O O
hundreds O O
of O O
millions O O
of O O
people B B_PERSON/B_BIO
are O O
infected O O
with O O
geohelminths O O
( O O
soil O O
- O O
transmitted O O
worms O O
) O O
, O O
such O O
as O O
blood O O
- O O
feeding O O
hookworms O O
Ancylostoma B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
duodenale I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
Necator B B_SPECIES[BIO]/B_PERSON
americanus I I_SPECIES[BIO]/I_PERSON
, O O
Trichuris B B_SPECIES[BIO]/B_DISEASE
trichiura I I_SPECIES[BIO]/I_DISEASE
and O O
Ascaris O O
spp O O
. O O

[ O O
1 O O
] O O
, O O
causing O O
serious O O
adverse O O
effects O O
on O O
human B B_PERSON/B_BIO
health O O
, O O
particularly O O
in O O
children B B_PERSON/B_LOCATION
. O O

Similarly O O
, O O
parasitic O O
nematodes O O
of O O
livestock O O
, O O
such O O
as O O
pigs B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
also O O
cause O O
substantial O O
economic O O
losses O O
due O O
to O O
subclinical O O
and O O
clinical O O
diseases O O
, O O
with O O
billions O O
of O O
dollars O O
spent O O
annually O O
on O O
the O O
treatment O O
and O O
control O O
of O O
gastro O O
- O O
intestinal O O
nematodes O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
the O O
socioeconomic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impact O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
these O O
parasites O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
, O O
there O O
is O O
potential O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
emergence O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
resistance O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
them O O
against O O
all O O
of O O
the O O
main O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
( O O
nematocidal O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
compounds O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
to O O
treat O O
the O O
diseases O B_DISEASE
they O O
cause O O
[ O B_LOCATION
2 O I_LOCATION
] O I_LOCATION
- O O
[ O O
5 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Therefore O O
, O O
there O O
is O O
a O O
significant O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
need O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
work O O
toward O O
discovering O O
new O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
compounds O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
control O O
these O O
parasites O B_DISEASE
. O O

Gaining O O
an O O
improved O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
molecular O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
parasite O B_DISEASE
development O I_DISEASE
provides O O
such O O
an O O
avenue O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Compared O O
with O O
the O O
free O O
- O O
living O O
nematode O O
Caenorhabditis B B_BIO/B_LOCATION
elegans I I_BIO/I_LOCATION
, O O
there O O
is O O
very O O
little O O
information O O
on O O
fundamental O O
molecular O O
aspects O O
of O O
development O O
in O O
parasitic O O
nematodes O O
[ O O
6 O O
] O O
- O O
[ O O
8 O O
] O O
. O O

Since O O
the O O
genome O O
sequence O O
of O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
was O O
published O O
in O O
1998 O O
[ O O
9 O O
] O O
, O O
many O O
aspects O O
of O O
the O O
molecular O O
biology O O
of O O
this O O
nematode O O
have O O
been O O
elucidated O O
. O O

For O O
instance O O
, O O
microarray O O
analyses O O
have O O
been O O
used O O
to O O
examine O O
developmental O O
and O O
gender O O
- O O
enriched O O
gene O O
expression O O
[ O O
10 O O
] O O
, O O
[ O O
11 O O
] O O
, O O
and O O
the O O
functions O O
of O O
more O O
than O O
96 O O
% O O
of O O
the O O
C B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elegans I B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O O
have O O
been O O
assessed O O
by O O
double O O
- O O
stranded O O
RNA O O
interference O O
( O O
RNAi O O
, O O
or O O
gene O O
silencing O O
; O O
[ O O
12 O O
] O O
) O O
[ O O
13 O O
] O O
- O O
[ O O
18 O O
] O O
. O O

Comparative O O
analyses O O
of O O
genetic O O
data O O
sets O O
have O O
shown O O
that O O
parasitic O O
nematodes O O
usually O O
share O O
~ O O
50 O O
- O O
70 O O
% O O
of O O
genes O O
with O O
C B B_SPECIES[BIO]/B_GENE
. I I_SPECIES[BIO]/I_GENE
elegans I I_SPECIES[BIO]/I_GENE
( O O
e O O
. O O
g O O
. O O
, O O
[ O O
19 O O
] O O
, O O
[ O O
20 O O
] O O
) O O
. O O

There O O
is O O
similarity O O
in O O
other O O
features O O
( O O
such O O
as O O
basic O O
body O O
plan O O
and O O
moulting O O
) O O
between O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
and O O
parasitic O O
nematodes O O
, O O
suggesting O O
that O O
some O O
molecular O O
pathways O O
are O O
relatively O O
conserved O O
[ O O
8 O O
] O O
, O O
[ O O
21 O O
] O O
. O O

Understanding O O
the O O
pathways O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
linked O O
to O O
basic O B_DISEASE/B_BIO
nematode O I_DISEASE/I_BIO
biology O I_DISEASE/I_BIO
and O O
development O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
have O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
finding O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
ways O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O O
disrupting O O
these O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
thus O O
facilitate O O
the O O
identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
targets O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Despite O O
the O O
advances O O
in O O
genomic O O
technologies O O
[ O O
7 O O
] O O
, O O
[ O O
22 O O
] O O
- O O
[ O O
29 O O
] O O
and O O
the O O
study O O
of O O
C B B_BIO/B_GENE
. I I_BIO/I_GENE
elegans I I_BIO/I_GENE
, O O
there O O
is O O
a O O
paucity O O
of O O
information O O
on O O
the O O
genomics O O
of O O
parasitic O O
nematodes O O
of O O
animals O O
, O O
particularly O O
in O O
relation O O
to O O
development O O
. O O

Also O O
considering O O
the O O
major O O
socioeconomic O O
impact O O
of O O
Ascaris O O
and O O
ascariasis O O
in O O
humans B B_SPECIES[BIO]
and O O
pigs B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
30 O O
] O O
- O O
[ O O
32 O O
] O O
, O O
several O O
characteristics O O
, O O
including O O
the O O
large O O
size O O
of O O
the O O
adult O O
worm O O
( O O
providing O O
the O O
opportunity O O
of O O
investigating O O
individual O O
organ O O
systems O O
and O O
tissues O O
) O O
, O O
the O O
ability O O
to O O
maintain O O
Ascaris O O
in O O
the O O
pig B B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
store O O
eggs O O
and O O
culture O O
larvae O O
in O O
vitro O O
for O O
relatively O O
long O O
periods O O
of O O
time O O
( O O
months O O
to O O
years O O
) O O
[ O O
32 O O
] O O
as O O
well O O
as O O
the O O
discovery O O
that O O
RNAi O O
achieves O O
" O O
cross O O
- O O
species O O
" O O
gene O O
silencing O O
for O O
a O O
selected O O
number O O
of O O
genes O O
[ O O
33 O O
] O O
, O O
[ O O
34 O O
] O O
and O O
the O O
imminent O O
genome O O
sequence O O
( O O
http O O
: O O
/ O O
/ O O
www O O
. O O
sanger O O
. O O
ac O O
. O O
uk O O
/ O O
Projects O O
/ O O
Helminths O O
/ O O
) O O
all O O
indicate O O
that O O
Ascaris O O
could O O
serve O O
as O O
a O O
powerful O O
model O O
system O O
for O O
investigating O O
reproductive O O
and O O
developmental O O
processes O O
in O O
nematodes O O
. O O

In O O
the O O
present O O
study O O
, O O
Ascaris O O
from O O
pigs B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
to O O
study O O
molecules O O
abundantly O O
transcribed O O
in O O
the O O
infective O O
third O O
- O O
stage O O
larva O O
( O O
L3 O O
) O O
. O O

Following O O
the O O
oral O O
ingestion O O
of O O
Ascaris O O
eggs O O
by O O
the O O
host O O
( O O
human B B_SPECIES[BIO]
or O O
pig B B_SPECIES[BIO]
) O O
, O O
L3s O O
are O O
released O O
and O O
then O O
invade O O
/ O O
penetrate O O
predominantly O O
the O O
caecal O O
wall O O
[ O O
35 O O
] O O
to O O
then O O
undergo O O
hepato O O
- O O
pulmonary O O
migration O O
, O O
after O O
which O O
ultimately O O
the O O
adult O O
females O O
and O O
males O O
establish O O
and O O
develop O O
in O O
the O O
small O O
intestine O O
[ O O
36 O O
] O O
, O O
[ O O
37 O O
] O O
. O O

The O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
linked O O
to O O
host O B_DISEASE
invasion O I_DISEASE
and O O
parasite O B_DISEASE_ADJECTIVE[DISEASE]
development O I_DISEASE_ADJECTIVE[DISEASE]
are O O
largely O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
, O O
we O O
constructed O O
an O O
L3 O O
- O O
enriched O O
cDNA O O
library O O
using O O
the O O
method O O
of O O
suppressive O O
- O O
subtractive O O
hybridization O O
( O O
SSH O O
) O O
, O O
explored O O
transcription O O
of O O
a O O
representative O O
subset O O
of O O
molecules O O
by O O
microarray O O
analysis O O
and O O
conducted O O
bioinformatic O O
analyses O O
to O O
characterize O O
these O O
molecules O O
, O O
map O O
them O O
to O O
biochemical O O
pathways O O
and O O
predict O O
genetic O O
interactions O O
based O O
on O O
comparisons O O
with O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
and O O
/ O O
or O O
other O O
organisms O O
. O O

Materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Production O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Different O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Developmental O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Stages O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Ascaris O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]

Experimental O O
pigs B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
8 O O
- O O
12 O O
weeks O O
of O O
age O O
) O O
were O O
purchased O O
from O O
and O O
maintained O O
in O O
the O O
Experimental O O
Animal O O
Center O O
of O O
South O O
China O O
Agricultural O O
University O O
. O O

These O O
pigs B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
treated O O
humanely O O
, O O
according O O
to O O
the O O
Animal O O
Ethics O O
procedures O O
and O O
guidelines O O
of O O
the O O
People O O
' O O
s O O
Republic O O
of O O
China O O
. O O

Adult O O
worms O O
( O O
males O O
and O O
females O O
) O O
of O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
were O O
collected O O
from O O
the O O
small O O
intestines O O
of O O
pigs B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
an O O
abattoir O O
in O O
Shenzhen O O
, O O
China O O
. O O

Infective O O
eggs O O
and O O
infective O O
L3s O O
of O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
were O O
produced O O
according O O
to O O
the O O
methods O O
described O O
previously O O
[ O O
38 O O
] O O
. O O

In O O
brief O O
, O O
eggs O O
from O O
the O O
uteri O O
of O O
adult O O
females O O
of O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
were O O
collected O O
and O O
incubated O O
at O O
28 O O
degrees O O
C O O
for O O
28 O O
days O O
to O O
allow O O
them O O
to O O
develop O O
to O O
infective O O
eggs O O
( O O
containing O O
infective O O
L3s O O
) O O
. O O

To O O
obtain O O
pure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
L3s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
7 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
v O I_MEASURE
/ O O
v O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypochlorite O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
to O O
treat O O
the O O
larvated O O
eggs O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
37 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
overnight O O
and O O
then O O
the O O
eggs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O O
shaken O O
with O O
glass O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
beads O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
then O O
, O O
the O O
exsheathed O O
L3s O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
shells O B_BIO/B_PERSON
were O O
separated O O
by O O
density O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gradient O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
centrifugation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
lymphocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
separating O O
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LSM O B_MEASURE/B_DISEASE
) O O
[ O O
38 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Following O O
the O O
experimental O O
infection O O
of O O
helminth O O
- O O
free O O
pigs B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
infective O O
Ascaris O O
eggs O O
as O O
described O O
previously O O
[ O O
39 O O
] O O
, O O
the O O
L3s O O
from O O
livers O O
and O O
in O O
lungs O O
as O O
well O O
as O O
L4s O O
in O O
intestines O O
were O O
isolated O O
according O O
to O O
an O O
established O O
method O O
[ O O
40 O O
] O O
. O O

All O O
parasite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
snap O O
- O O
frozen O O
in O O
liquid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
nitrogen O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
prior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
storage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
at O O
- O O
70 O B_LOCATION/B_MEASURE
degrees O I_LOCATION/I_MEASURE
C O I_LOCATION/I_MEASURE
. O O

Construction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
cDNA O B_GENE
Library O I_GENE
by O O
Subtractive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
Suppressive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Hybridization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
SSH O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O

Total O O
RNA O O
was O O
isolated O O
from O O
adult O O
females O O
and O O
males O O
, O O
different O O
larval O O
stages O O
or O O
eggs O O
of O O
A B B_PERSON/B_BIO
. I I_PERSON/I_BIO
suum I I_PERSON/I_BIO
using O O
TriPure O O
reagent O O
( O O
Roche O O
) O O
as O O
recommended O O
by O O
the O O
manufacturer O O
. O O

Equal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amounts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
total O B_DISEASE/B_MEASURE
RNA O I_DISEASE/I_MEASURE
from O O
each O O
stage O B_ENT/B_MEASURE
or O O
sex O B_PERSON/B_LOCATION
were O O
pooled O O
. O O

The O O
mRNA O B_GENE
was O O
isolated O O
using O O
the O O
Oligotex O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mRNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Kit O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Qiagen O B_LOCATION/B_BACTERIUM[BIO]
) O O
, O O
following O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
protocol O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

SSH O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
carried O O
out O O
using O O
the O O
PCR O B_LOCATION/B_PERSON
- O O
Select O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Subtraction O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kit O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Clontech O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
according O O
to O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
protocol O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

In O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
cDNA O B_GENE
synthesized O O
from O O
mRNAs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O O
infective O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L3s O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
subtracted O O
against O O
cDNA O B_GENE/B_BIO
synthesized O O
from O O
the O O
pooled O O
mRNA O B_GENE/B_BIO
from O O
all O O
other O B_TIME[MEASURE]/B_BIO
stages O I_TIME[MEASURE]/I_BIO
included O O
herein O B_LOCATION/B_SPECIES[BIO]
. O O

The O O
SSH O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
constructed O O
using O O
infective O B_SPECIES[BIO]/B_DISEASE
L3s O I_SPECIES[BIO]/I_DISEASE
as O O
the O O
tester O B_PERSON
and O O
pooled O O
cDNAs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
all O O
other O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
driver O B_PERSON
. O O

The O O
effectiveness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
subtraction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O O
already O O
been O O
demonstrated O O
in O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O O
41 O B_MEASURE
] O I_MEASURE
, O O
[ O O
42 O B_MEASURE
] O I_MEASURE
. O O

The O O
cDNA O O
obtained O O
following O O
SSH O O
was O O
cloned O O
into O O
the O O
pGEM O O
- O O
T O O
Easy O O
plasmid O O
vector O O
( O O
Promega O O
) O O
and O O
competent O O
Escherichia B B_BACTERIUM[BIO]
coli I I_BACTERIUM[BIO]
( O O
JM109 O O
) O O
transformed O O
. O O

Positive O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O O
picked O O
randomly O O
( O O
based O O
on O O
blue O B_COLOR
/ O O
white O B_COLOR
selection O I_COLOR
) O O
, O O
were O O
grown O O
overnight O O
in O O
Luria O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Bertani O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LB O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
shaking O O
, O O
37 O B_PROTEIN[GENE]/B_LOCATION
degrees O I_PROTEIN[GENE]/I_LOCATION
C O I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

Individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
inserts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
amplified O O
using O O
" O B_OTHER/B_NUMBER[MEASURE]
nested O O
primers O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
" O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
2R O B_SEQUENCE[MEASURE]/B_LOCATION
from O O
the O O
Subtraction O B_LOCATION/B_PERSON
kit O I_LOCATION/I_PERSON
( O O
Clontech O B_LOCATION/B_DISEASE
) O O
and O O
examined O O
by O O
agarose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
electrophoresis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Preparation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Microarray O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Slides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Clones O B_LOCATION/B_BIO
( O O
n O B_OTHER/B_MEASURE
= O O
3075 O B_MEASURE
) O O
from O O
the O O
subtracted O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
picked O O
and O O
cultured O O
overnight O O
in O O
LB O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
ampicillin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1000 O B_MEASURE/B_LOCATION
IU O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE/B_PERSON
) O O
in O O
sealed O O
96 O B_MEASURE/B_LOCATION
- O O
well O O
blocks O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Five O B_MEASURE/B_LOCATION
micro O B_MEASURE/I_LOCATION
l O B_MEASURE/I_LOCATION
of O O
culture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
suspension O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
each O O
well O O
were O O
transferred O O
into O O
individual O B_NUMBER[MEASURE]/B_PERSON
wells O I_NUMBER[MEASURE]/I_PERSON
thermocycling O O
( O O
96 O B_NUMBER[MEASURE]/B_LOCATION
- O O
well O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
plates O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
inserts O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
amplified O O
using O O
primers O B_LOCATION/B_ORGANIZATION
1 O I_LOCATION/I_ORGANIZATION
and O O
2R O B_NUMBER[MEASURE]/B_LOCATION
. O O

Following O O
a O O
10 O B_TIME[MEASURE]/B_LOCATION
min O I_TIME[MEASURE]/I_LOCATION
denaturation O I_TIME[MEASURE]/I_LOCATION
step O I_TIME[MEASURE]/I_LOCATION
at O O
94 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
, O O
the O O
amplification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proceeded O O
for O O
25 O B_TIME[MEASURE]/B_LOCATION
cycles O I_TIME[MEASURE]/I_LOCATION
of O O
10 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
s O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
94 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
30 O B_TIME[MEASURE]
s O I_TIME[MEASURE]
at O O
68 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
and O O
1 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
at O O
72 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
with O O
a O O
final O B_SEQUENCE[MEASURE]/B_LOCATION
extension O I_SEQUENCE[MEASURE]/I_LOCATION
for O O
5 O B_TIME[MEASURE]/B_LOCATION
min O I_TIME[MEASURE]/I_LOCATION
at O O
72 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
. O O

Products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O O
resolved O O
in O O
agarose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ethanol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
precipitated O O
, O O
re O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
suspended O O
in O O
16 O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
micro O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
l O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
" O O
spotting O O
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
( O O
Shanghai O B_ORGANIZATION/B_LOCATION
BioStar O I_ORGANIZATION/I_LOCATION
Genechip O I_ORGANIZATION/I_LOCATION
, O O
Inc O B_ORGANIZATION/B_MEASURE
) O O
to O O
a O O
final O B_MEASURE
concentration O I_MEASURE
of O O
~ O B_MEASURE
500 O I_MEASURE
ng O I_MEASURE
per O O
micro O B_MEASURE
l O I_MEASURE
, O O
before O O
being O O
printed O O
on O O
to O O
glass O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
slides O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
in O O
duplicate O O
) O O
using O O
a O O
robotic O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arrayer O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sixteen O O
blanks O O
( O O
using O O
spotting O O
solution O O
only O O
) O O
and O O
the O O
same O O
number O O
of O O
negative O O
( O O
irrelevant O O
cDNAs O O
with O O
no O O
relationship O O
to O O
Ascaris O O
) O O
were O O
also O O
printed O O
on O O
to O O
slides O O
and O O
served O O
as O O
negative O O
controls O O
; O O
beta O O
- O O
actin O O
of O O
A B B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. I I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
suum I I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
served O O
as O O
a O O
positive O O
control O O
to O O
assess O O
the O O
efficiency O O
of O O
labeling O O
and O O
hybridization O O
. O O

The O O
slides O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
air O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dried O O
for O O
2 O B_MEASURE
h O O
, O O
and O O
cDNA O B_GENE/B_LOCATION
in O O
the O O
spots O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
cross O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
linked O O
at O O
254 O B_TIME[MEASURE]/B_LOCATION
mJ O I_TIME[MEASURE]/I_LOCATION
. O O

The O O
printed O O
slides O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
stored O O
at O O
4 O B_LOCATION/B_PERSON
degrees O I_LOCATION/I_PERSON
C O I_LOCATION/I_PERSON
. O O

Labeling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cDNA O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Probes O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
Fluorescent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Dyes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
Microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
cDNAs O O
produced O O
from O O
total O O
RNA O O
from O O
A B B_PERSON/B_BIO
. I B_PERSON/I_BIO
suum I B_PERSON/I_BIO
eggs O O
, O O
infective O O
L3s O O
, O O
L3s O O
isolated O O
from O O
pig B B_SPECIES[BIO]/B_PERSON
liver O O
or O O
lung O O
, O O
fourth O O
- O O
stage O O
larvae O O
( O O
L4s O O
) O O
, O O
adult O O
males O O
or O O
females O O
[ O O
as O O
described O O
in O O
the O O
section O O
' O O
Construction O O
of O O
the O O
cDNA O O
Library O O
by O O
Subtractive O O
- O O
Suppressive O O
Hybridization O O
( O O
SSH O O
) O O
' O O
] O O
were O O
labeled O O
with O O
cyanine O O
dyes O O
. O O

Cy3 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Cy5 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dCTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
incorporated O O
into O O
cDNA O B_GENE
produced O O
from O O
30 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
micro O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
g O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
of O O
total O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
labeling O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
reverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcription O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
an O O
oligo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
dT O B_PROTEIN[GENE]/B_LOCATION
) O O
primer O B_GENE
. O O

Labeled O O
cDNA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
purified O O
using O O
DyeEx O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
columns O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Qiagen O B_MEASURE/B_BACTERIUM[BIO]
) O O
. O O

Microarray O O
slides O O
were O O
incubated O O
with O O
a O O
pre O O
- O O
hybridization O O
solution O O
[ O O
5 O O
x O O
SSC O O
, O O
1 O O
% O O
bovine B B_PERSON/B_SPECIES[BIO]
serum O O
albumin O O
( O O
BSA O O
) O O
, O O
0 O O
. O O
1 O O
% O O
sodium O O
dodecyl O O
- O O
sulphate O O
( O O
SDS O O
) O O
] O O
for O O
6 O O
h O O
at O O
42 O O
degrees O O
C O O
. O O

After O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
slides O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
incubated O O
with O O
' O O
pooled O O
' O O
Cy3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
Cy5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
labeled O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
hybridization O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O B_NUMBER[MEASURE]
x O O
SSC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BSA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE
% O I_MEASURE
SDS O I_MEASURE
) O O
, O O
in O O
the O O
dark O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O O
42 O B_MEASURE/B_PROTEIN[GENE]
degrees O I_MEASURE/I_PROTEIN[GENE]
C O I_MEASURE/I_PROTEIN[GENE]
for O O
18 O B_MEASURE
h O O
, O O
and O O
then O O
washed O O
in O O
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
I O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
1 O B_MEASURE
x O O
SSC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
0 O B_MEASURE
. O O
2 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
SDS O I_MEASURE/I_PERSON
) O O
for O O
10 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
, O O
followed O O
by O O
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
0 O B_MEASURE
. O O
1 O B_MEASURE
x O O
SSC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
0 O B_NUMBER[MEASURE]
. O O
2 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
SDS O I_MEASURE/I_PERSON
) O O
for O O
10 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
60 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
, O O
according O O
to O O
the O O
protocols O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
provided O O
by O O
Shanghai O B_ORGANIZATION/B_LOCATION
BioStar O I_ORGANIZATION/I_LOCATION
Genechip O I_ORGANIZATION/I_LOCATION
, O O
Inc O B_ORGANIZATION/B_LOCATION
. O O

A O O
" O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dye O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
flip O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
" O O
was O O
carried O O
out O O
to O O
control O O
for O O
any O O
bias O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
Cy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
labeled O O
cDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
probes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
produced O O
for O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distinct O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
populations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
slides O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
dried O O
and O O
scanned O O
( O O
ScanArray O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4000 O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scanner O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
using O O
image O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquisition O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Shanghai O B_LOCATION/B_PERSON
BioStar O B_LOCATION/I_PERSON
Genechip O B_LOCATION/I_PERSON
Inc O B_LOCATION/I_PERSON
. O O
) O O
and O O
a O O
range O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
laser O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
power O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
photo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
multiplier O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tube O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensities O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
mean O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybridization O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signal O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
derived O O
from O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
replicates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
array O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
corrected O O
for O O
background O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
normalized O O
[ O O
43 O B_MEASURE
] O I_MEASURE
, O O
log2 O B_MEASURE/B_LOCATION
- O O
transformed O O
and O O
then O O
subjected O O
to O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
employing O O
the O O
students O B_MEASURE/B_PERSON
t O I_MEASURE/I_PERSON
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
a O O
spreadsheet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
Excel O B_ORGANIZATION/B_LOCATION
, O O
Microsoft O B_ORGANIZATION/B_LOCATION
, O O
USA O B_LOCATION/B_ORGANIZATION
) O O
. O O

The O O
microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
analysed O O
for O O
differential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cDNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hybridization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
> O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
. O O
0 O B_MEASURE
- O O
fold O B_LOCATION/B_MEASURE
to O O
114 O B_MEASURE
. O O
3 O B_MEASURE
- O O
fold O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
between O O
L3 O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
each O O
of O O
the O O
other O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
eggs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L3s O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
L4 O B_PERSON/B_BIO
, O O
adult O B_PERSON/B_BIO
female O I_PERSON/I_BIO
and O O
adult O B_PERSON
male O I_PERSON
) O O
. O O

Verification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Differential O B_DISEASE/B_GENE
Hybridization O I_DISEASE/I_GENE
by O O
Reverse O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Transcription O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
Coupled O O
Polymerase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
RT O B_LOCATION
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

For O O
a O O
subset O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_MEASURE
= O O
17 O B_MEASURE
) O O
of O O
representative O B_MEASURE/B_PERSON
ESTs O I_MEASURE/I_PERSON
( O O
rESTs O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
used O O
to O O
verify O O
the O O
differential O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription O B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recorded O O
by O O
microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Double O O
- O O
stranded O O
cDNA O O
was O O
synthesized O O
from O O
total O O
RNA O O
( O O
separately O O
) O O
from O O
each O O
stage O O
or O O
sex O O
of O O
A B B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
. I I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANISM_FUNCTION
suum I I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANISM_FUNCTION
using O O
reverse O O
transcriptase O O
( O O
Superscript O O
III O O
, O O
Invitrogen O O
) O O
. O O

Briefly O B_TIME[MEASURE]/B_LOCATION
, O O
5 O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
micro O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
g O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
added O O
to O O
14 O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
micro O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
l O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
H2O O B_GENE/B_DISEASE
and O O
1 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micro O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
oligo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
d O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
T O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
12 O B_MEASURE
- O O
18 O B_MEASURE/B_ENT
primer O I_MEASURE/I_ENT
( O O
0 O B_MEASURE
. O O
5 O B_MEASURE
micro O I_MEASURE
g O I_MEASURE
/ O O
micro O B_MEASURE/B_LOCATION
l O I_MEASURE/I_LOCATION
) O O
, O O
heated O O
to O O
70 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
degrees O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
10 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
and O O
chilled O O
on O O
ice O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

First O O
- O O
and O O
second O B_SEQUENCE[MEASURE]/B_LOCATION
- O O
strand O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNAs O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
synthesized O O
via O O
the O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
4 O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
micro O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
l O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
first O B_NUMBER[MEASURE]/B_LOCATION
- O O
strand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
buffer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
250 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tris O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
HCl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pH O B_MEASURE/B_GENE
8 O B_MEASURE
. O O
3 O B_MEASURE
, O O
375 O B_MEASURE
mM O I_MEASURE
KCl O I_MEASURE
and O O
15 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MgCl2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
2 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
micro O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
l O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
0 O B_MEASURE
. O O
1 O B_MEASURE
M O I_MEASURE
dithiothreitol O I_MEASURE
, O O
and O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
micro O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
l O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
of O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
each O O
dNTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
followed O O
by O O
an O O
incubation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
25 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
( O O
10 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
) O O
, O O
42 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
( O O
50 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
) O O
and O O
70 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
( O O
15 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
) O O
. O O

One O B_NUMBER[MEASURE]
- O O
tenth O B_SEQUENCE[MEASURE]/B_LOCATION
of O O
each O O
double O B_NUMBER[MEASURE]/B_DISEASE
- O O
stranded O B_GENE/B_LOCATION
cDNA O I_GENE/I_LOCATION
produced O O
was O O
then O O
used O O
as O O
a O O
template O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

The O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
amplified O O
from O O
individual O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
using O O
oligonucleotide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
primers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
sequences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upon O O
request O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
designed O O
to O O
each O O
EST O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
PCR O O
amplification O O
of O O
a O O
portion O O
( O O
209 O O
bp O O
) O O
of O O
the O O
beta O O
- O O
actin O O
gene O O
( O O
accession O O
no O O
. O O
BI594141 O O
) O O
using O O
forward O O
primer O O
( O O
5 O O
' O O
- O O
CTCGAAACAAGAATACGATG O O
- O O
3 O O
' O O
) O O
and O O
reverse O O
primer O O
( O O
5 O O
' O O
- O O
ACATGTGCCGTTGTATGATG O O
- O O
3 O O
' O O
) O O
, O O
previously O O
determined O O
to O O
be O O
present O O
in O O
all O O
developmental O O
stages O O
and O O
both O O
sexes O O
of O O
A B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
suum I I_PERSON/I_SPECIES[BIO]
[ O O
44 O O
] O O
, O O
served O O
as O O
a O O
positive O O
control O O
. O O

Samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
without O O
template O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
no O O
- O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
controls O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
were O O
included O O
in O O
each O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
run O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
following O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cycling O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
conditions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
employed O O
: O O
one O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
cycle O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
at O O
94 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
( O O
5 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
) O O
, O O
94 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
( O O
30 O B_MEASURE
s O I_MEASURE
) O O
, O O
60 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
( O O
30 O B_MEASURE
s O O
) O O
and O O
72 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
( O O
30 O B_MEASURE/B_LOCATION
s O I_MEASURE/I_LOCATION
) O O
for O O
30 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycles O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
followed O O
by O O
a O O
final O B_MEASURE/B_GENE
extension O I_MEASURE/I_GENE
of O O
70 O B_NUMBER[MEASURE]/B_LOCATION
degrees O I_NUMBER[MEASURE]/I_LOCATION
C O I_NUMBER[MEASURE]/I_LOCATION
( O O
7 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
) O O
. O O

Following O O
the O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_LOCATION/B_GENE
micro O I_LOCATION/I_GENE
l O I_LOCATION/I_GENE
of O O
individual O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplicons O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
resolved O O
in O O
ethidium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
bromide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
stained O O
agarose O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gels O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
and O O
then O O
photographed O O
upon O O
transillumination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
relative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
band O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
intensities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
analyzed O O
using O O
UVIsoft O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Image O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Acquisition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
UVITEC O B_ORGANIZATION/B_LOCATION
) O O
. O O

The O O
specificity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
identity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amplicons O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
confirmed O O
by O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O O
the O O
same O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
separately O O
) O O
as O O
employed O O
for O O
their O O
amplification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

Sequencing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
and O O
Bioinformatics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Clones O B_LOCATION/B_GENE
from O O
the O O
SSH O B_LOCATION/B_BIO
cDNA O I_LOCATION/I_BIO
library O I_LOCATION/I_BIO
with O O
increased O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
the O O
infective O B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
L3 O I_BODY_PART_OR_ORGAN_COMPONENT/I_SPECIES[BIO]
compared O O
with O O
other O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
sequenced O O
using O O
standard O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
technology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O O
45 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
nucleotide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O O
been O O
deposited O O
in O O
the O O
GenBank O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
under O O
accession O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
numbers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
ES290984 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
ES291074 O B_MEASURE
. O O

Following O O
the O O
processing O O
of O O
the O O
sequences O O
( O O
i O O
. O O
e O O
. O O
, O O
removal O O
of O O
vector O O
sequences O O
, O O
quality O O
assurance O O
and O O
clustering O O
) O O
, O O
contigs O O
or O O
singletons O O
from O O
individual O O
clusters O O
were O O
subjected O O
to O O
BLASTx O O
( O O
NCBI O O
: O O
www O O
. O O
ncbi O O
. O O
nlm O O
. O O
nih O O
. O O
gov O O
) O O
and O O
BLASTn O O
( O O
EMBL O O
- O O
EBI O O
Parasite O O
Genome O O
Blast O O
Server O O
: O O
www O O
. O O
ebi O O
. O O
ac O O
. O O
uk O O
) O O
analysis O O
to O O
identify O O
putative O O
homologues O O
in O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
, O O
other O O
nematodes O O
and O O
other O O
organisms O O
( O O
e O O
- O O
value O O
of O O
<= O O
1e O O
- O O
05 O O
) O O
. O O

Peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inferred O O
from O O
ESTs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
classified O O
functionally O O
using O O
Interproscan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
http O B_ORGANIZATION/B_LOCATION
: O O
/ O O
/ O O
www O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
ebi O B_BIO/B_GENE
. O O
ac O B_LOCATION/B_DISEASE
. O O
uk O B_LOCATION/B_MEASURE
/ O O
InterProScan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
/ O O
) O O
employing O O
the O O
default O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
search O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

WormBase O O
( O O
www O O
. O O
wormbase O O
. O O
org O O
) O O
was O O
interrogated O O
extensively O O
for O O
relevant O O
information O O
on O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
homologues O O
/ O O
orthologues O O
, O O
including O O
RNAi O O
phenotypic O O
, O O
transcriptomic O O
, O O
proteomic O O
and O O
interactomic O O
data O O
. O O

ESTs O O
with O O
homologues O O
/ O O
orthologues O O
in O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
and O O
other O O
nematodes O O
were O O
also O O
subjected O O
to O O
analysis O O
employing O O
the O O
KEGG O O
Orthology O O
- O O
Based O O
Annotation O O
System O O
( O O
KOBAS O O
) O O
( O O
www O O
. O O
kobas O O
. O O
cbi O O
. O O
pku O O
. O O
edu O O
. O O
cn O O
) O O
, O O
which O O
predicts O O
the O O
biochemical O O
pathways O O
in O O
which O O
molecules O O
are O O
involved O O
. O O

The O O
open O O
reading O O
frames O O
( O O
ORFs O O
) O O
inferred O O
from O O
selected O O
ESTs O O
with O O
orthologues O O
in O O
C B B_SPECIES[BIO]/B_GENE
. I I_SPECIES[BIO]/I_GENE
elegans I I_SPECIES[BIO]/I_GENE
were O O
also O O
subjected O O
to O O
" O O
secretome O O
analysis O O
" O O
using O O
the O O
program O O
SignalP O O
v O O
. O O
2 O O
. O O
0 O O
www O O
. O O
cbs O O
. O O
dtu O O
. O O
dk O O
/ O O
services O O
/ O O
SignalP O O
/ O O
) O O
, O O
employing O O
both O O
the O O
neural O O
network O O
and O O
hidden O O
Markov O O
models O O
to O O
predict O O
signal O O
peptides O O
and O O
/ O O
or O O
anchors O O
[ O O
46 O O
] O O
- O O
[ O O
48 O O
] O O
. O O

Also O O
, O O
transmembrane O B_LOCATION
domains O I_LOCATION
were O O
predicted O O
using O O
the O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
TMHMM O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
www O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
cbs O B_ORGANIZATION/B_DISEASE
. O O
dtu O B_LOCATION/B_ORGANIZATION
. O O
dk O B_DISEASE/B_LOCATION
/ O O
services O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
TMHMM O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
; O O
[ O B_MEASURE
49 O I_MEASURE
] O I_MEASURE
- O O
[ O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
51 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
subcellular O B_TIME[MEASURE]/B_LOCATION
localization O I_TIME[MEASURE]/I_LOCATION
inferred O O
employing O O
the O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
WoLF O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PSORT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
http O B_ORGANIZATION/B_LOCATION
: O O
/ O O
/ O O
wolfpsort O B_LOCATION/B_ORGANIZATION
. O O
org O B_ORGANIZATION/B_LOCATION
/ O O
; O O
[ O B_MEASURE
52 O I_MEASURE
] O I_MEASURE
) O O
. O O

The O O
method O O
established O O
by O O
Zhong O O
and O O
Sternberg O O
[ O O
53 O O
] O O
was O O
used O O
to O O
predict O O
the O O
interactions O O
for O O
C B B_NUMBER[MEASURE]/B_SPECIES[BIO]
. I I_NUMBER[MEASURE]/I_SPECIES[BIO]
elegans I I_NUMBER[MEASURE]/I_SPECIES[BIO]
orthologues O O
of O O
the O O
L3 O O
- O O
enriched O O
molecules O O
from O O
Ascaris O O
. O O

In O O
brief O O
, O O
interaction O O
, O O
phenotypic O O
, O O
expression O O
and O O
gene O O
ontology O O
data O O
from O O
fruitfly B B_SPECIES[BIO]
, O O
yeast B B_SPECIES[BIO]
, O O
mouse B B_SPECIES[BIO]/B_DISEASE
and O O
human B B_SPECIES[BIO]
were O O
integrated O O
using O O
a O O
na O O
i O O
ve O O
Bayesian O O
model O O
to O O
predict O O
genetic O O
interactions O O
among O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
genes O O
( O O
[ O O
45 O O
] O O
, O O
[ O O
53 O O
] O O
; O O
Zhong O O
and O O
Sternberg O O
, O O
unpublished O O
) O O
. O O

The O O
predicted O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
networks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
resulting O O
from O O
the O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
saved O O
in O O
a O O
graphic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
display O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
file O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
gdf O B_LOCATION/B_ENT
) O O
format O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
examined O O
using O O
the O O
graph O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
exploration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
available O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
at O O
http O B_ORGANIZATION/B_LOCATION
: O O
/ O O
/ O O
graphexploration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
cond O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
org O B_ORGANIZATION/B_LOCATION
/ O O
. O O

Images O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
labeled O O
and O O
saved O O
in O O
the O O
joint O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
photographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
experts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
jpeg O B_DISEASE/B_GENE
) O O
format O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

To O O
identify O O
molecules O O
transcribed O O
abundantly O O
in O O
the O O
L3 O O
of O O
A B B_BIO
. I I_BIO
suum I I_BIO
, O O
an O O
enriched O O
cDNA O O
library O O
was O O
constructed O O
by O O
SSH O O
. O O

From O O
a O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
3075 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
this O O
library O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
2921 O B_NUMBER[MEASURE]
( O O
95 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
shown O O
to O O
contain O O
an O O
insert O B_GENE
( O O
which O O
could O O
be O O
amplified O O
by O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
. O O

From O O
2671 O B_NUMBER[MEASURE]/B_PERSON
( O O
92 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
these O O
clones O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
amplicons O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
representing O O
single O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bands O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
~ O B_MEASURE
400 O I_MEASURE
to O O
600 O B_TIME[MEASURE]
bp O I_TIME[MEASURE]
in O O
size O B_MEASURE
were O O
produced O O
. O O

These O O
latter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amplicons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
arrayed O O
( O O
in O O
duplicate O B_MEASURE/B_LOCATION
) O O
on O O
to O O
slides O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
then O O
hybridized O O
with O O
Cy3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
labeled O O
L3 O B_DISEASE/B_PROTEIN[GENE]
- O O
cDNA O B_GENE
or O O
with O O
Cy5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
labeled O O
cDNA O B_GENE
from O O
eggs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L3s O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
L4s O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
adult O B_PERSON/B_BIO
female O I_PERSON/I_BIO
or O O
adult O B_PERSON/B_BIO
male O I_PERSON/I_BIO
of O O
Ascaris O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Dye O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
flip O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
conducted O O
to O O
verify O O
the O O
hybridization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Of O O
the O O
2671 O O
( O O
duplicate O O
) O O
spots O O
, O O
1526 O O
had O O
a O O
significant O O
difference O O
in O O
hybridization O O
between O O
infective O O
L3 O O
cDNA O O
and O O
cDNAs O O
from O O
all O O
other O O
stages O O
or O O
sexes O O
of O O
A B B_SPECIES[BIO]/B_ORGANISM_FUNCTION
. I I_SPECIES[BIO]/I_ORGANISM_FUNCTION
suum I I_SPECIES[BIO]/I_ORGANISM_FUNCTION
, O O
of O O
which O O
515 O O
had O O
a O O
> O O
2 O O
. O O
0 O O
- O O
fold O O
increased O O
hybridization O O
for O O
the O O
L3 O O
. O O

In O O
order O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
independently O O
verify O O
the O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
microarray O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
a O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
based O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
selected O O
subset O B_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
17 O B_MEASURE
) O O
clones O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
conducted O O
using O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
primer O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pairs O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Having O O
verified O O
the O O
specificity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
identity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amplicons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
sequencing O O
, O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
reproducible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
based O O
on O O
multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
runs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
different O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
~ O O
94 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
16 O B_MEASURE/B_LOCATION
of O O
17 O B_NUMBER[MEASURE]/B_PERSON
) O O
concordant O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
those O O
of O O
the O O
microarray O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
not O O
shown O O
) O O
. O O

There O O
was O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concordance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
representative O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
a O O
differential O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
signal O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
>= O B_MEASURE
3 O I_MEASURE
. O O
0 O B_MEASURE
- O O
fold O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
microarray O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
clones O B_GENE/B_DISEASE
linked O O
to O O
the O O
515 O B_GENE/B_LOCATION
spots O I_GENE/I_LOCATION
representing O O
increased O O
transcription O B_GENE
( O O
> O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
. O O
0 O B_MEASURE
- O O
fold O B_MEASURE
) O O
in O O
infective O B_BIO/B_DISEASE
L3 O I_BIO/I_DISEASE
compared O O
with O O
the O O
other O B_TIME[MEASURE]/B_PERSON
developmental O I_TIME[MEASURE]/I_PERSON
stages O I_TIME[MEASURE]/I_PERSON
or O O
sexes O B_BIO/B_PERSON
included O O
were O O
subjected O O
to O O
sequencing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
498 O B_GENE/B_LOCATION
sequences O I_GENE/I_LOCATION
( O O
length O B_TIME[MEASURE]/B_LOCATION
: O O
550 O B_MEASURE
+/- O I_MEASURE
115 O B_MEASURE/B_BIO
bp O I_MEASURE
) O O
determined O O
were O O
then O O
subjected O O
to O O
detailed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bioinformatic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
were O O
91 O B_MEASURE
unique O I_MEASURE
clusters O I_MEASURE
( O O
accession O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
numbers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
ES290984 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
ES291074 O B_MEASURE
) O O
, O O
of O O
which O O
55 O B_MEASURE
were O O
singletons O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
sequences O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
determined O O
once O O
) O O
. O O

Of O O
56 O O
molecules O O
( O O
61 O O
. O O
5 O O
% O O
) O O
with O O
significant O O
similarity O O
to O O
sequences O O
other O O
than O O
A B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suum I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
databases O O
interrogated O O
, O O
50 O O
( O O
54 O O
. O O
9 O O
% O O
) O O
had O O
C B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
elegans I I_SPECIES[BIO]/I_PERSON
or O O
C B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
briggsae I I_SPECIES[BIO]/I_PERSON
homologues O O
, O O
and O O
six O O
had O O
similarity O O
to O O
ESTs O O
already O O
sequenced O O
from O O
ascaridoid O O
and O O
/ O O
or O O
other O O
parasitic O O
nematodes O O
, O O
and O O
/ O O
or O O
other O O
organisms O O
( O O
Table O O
1 O O
) O O
. O O

A O O
significant O B_SEQUENCE[MEASURE]/B_PERSON
proportion O I_SEQUENCE[MEASURE]/I_PERSON
( O O
38 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
did O O
not O O
have O O
any O O
similarity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
sequence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
any O O
organisms O B_BIO/B_GENE
for O O
which O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
presently O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Comparative O O
analysis O O
specifically O O
against O O
A B B_NUMBER[MEASURE]/B_PERSON
. I I_NUMBER[MEASURE]/I_PERSON
suum I I_NUMBER[MEASURE]/I_PERSON
EST O O
data O O
sets O O
( O O
n O O
~ O O
42 O O
, O O
000 O O
) O O
available O O
in O O
public O O
databases O O
confirmed O O
independently O O
that O O
the O O
majority O O
of O O
molecules O O
( O O
> O O
60 O O
% O O
) O O
were O O
present O O
exclusively O O
in O O
the O O
infective O O
L3 O O
stage O O
or O O
were O O
orphans O O
. O O

As O O
gene O O
ontology O O
( O O
GO O O
) O O
provides O O
a O O
hierarchy O O
that O O
unifies O O
the O O
descriptions O O
of O O
biological O O
, O O
cellular O O
and O O
molecular O O
functions O O
[ O O
54 O O
] O O
, O O
this O O
approach O O
was O O
employed O O
to O O
predict O O
the O O
classification O O
and O O
gene O O
function O O
of O O
molecules O O
enriched O O
in O O
infective O O
L3 O O
of O O
A B B_SPECIES[BIO]/B_DISEASE
. I I_SPECIES[BIO]/I_DISEASE
suum I I_SPECIES[BIO]/I_DISEASE
. O O

A O O
summary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
the O O
GO O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
categories O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
these O O
molecules O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
displayed O O
in O O
Fig O B_TIME[MEASURE]/B_LOCATION
. O O

1 O B_NUMBER[MEASURE]
. O O

Of O O
the O O
91 O B_NUMBER[MEASURE]/B_LOCATION
contigs O I_NUMBER[MEASURE]/I_LOCATION
, O O
32 O B_MEASURE
( O O
35 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
could O O
be O O
functionally O O
assigned O O
to O O
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
' O O
( O O
n O B_OTHER/B_MEASURE
= O O
38 O B_MEASURE
) O O
, O O
' O O
cellular O B_GENE/B_BIO
component O I_GENE/I_BIO
' O O
( O O
n O B_OTHER/B_MEASURE
= O O
17 O B_MEASURE
) O O
and O O
' O O
molecular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
function O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' O O
( O O
n O B_OTHER/B_MEASURE
= O O
64 O B_MEASURE
) O O
. O O

The O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
subcategories O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
gluconeogenesis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
13 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
metabolic O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
process O I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
13 O B_MEASURE
% O I_MEASURE
) O O
within O O
' O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
' O O
, O O
extracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
region O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
( O O
24 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
within O O
' O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ENZYME[GENE]
cellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ENZYME[GENE]
component O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ENZYME[GENE]
' O O
, O O
and O O
catalytic O B_ENZYME[GENE]
activity O I_ENZYME[GENE]
( O O
11 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
phosphoenolpyruvate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
carboxykinase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
( O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
within O O
' O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
' O O
( O O
Table O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
S1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

A O O
focused O O
KOBAS O O
analysis O O
inferred O O
the O O
50 O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
orthologues O O
/ O O
homologues O O
to O O
be O O
involved O O
in O O
apoptosis O O
and O O
insulin O O
signaling O O
( O O
2 O O
% O O
) O O
, O O
ATP O O
synthesis O O
( O O
2 O O
% O O
) O O
, O O
carbon O O
metabolism O O
( O O
6 O O
% O O
) O O
, O O
fatty O O
acid O O
biosynthesis O O
( O O
2 O O
% O O
) O O
, O O
gap O O
junction O O
( O O
2 O O
% O O
) O O
, O O
glucose O O
metabolism O O
( O O
6 O O
% O O
) O O
or O O
porphyrin O O
metabolism O O
( O O
2 O O
% O O
) O O
, O O
although O O
34 O O
( O O
68 O O
% O O
) O O
of O O
them O O
could O O
not O O
be O O
mapped O O
to O O
a O O
specific O O
metabolic O O
pathway O O
( O O
Table O O
2 O O
) O O
. O O

Of O O
these O O
50 O B_GENE/B_MEASURE
molecules O I_GENE/I_MEASURE
, O O
small O B_MEASURE
numbers O I_MEASURE
were O O
predicted O O
to O O
be O O
secreted O O
( O O
10 O B_MEASURE
% O I_MEASURE
) O O
, O O
anchored O O
( O O
2 O B_MEASURE
% O I_MEASURE
) O O
and O O
/ O O
or O O
transmembrane O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
( O O
12 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
proteins O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
Table O B_MEASURE/B_PERSON
2 O I_MEASURE/I_PERSON
) O O
. O O

Functionally O O
, O O
17 O O
( O O
34 O O
% O O
) O O
of O O
the O O
50 O O
molecules O O
were O O
associated O O
with O O
( O O
non O O
- O O
wild O O
- O O
type O O
) O O
RNAi O O
phenotypes O O
in O O
C B B_BIO/B_PERSON
. I I_BIO/I_PERSON
elegans I I_BIO/I_PERSON
, O O
the O O
majority O O
displaying O O
embryonic O O
lethality O O
( O O
Emb O O
) O O
( O O
13 O O
types O O
; O O
58 O O
. O O
8 O O
% O O
) O O
, O O
larval O O
arrest O O
( O O
Lva O O
) O O
( O O
23 O O
. O O
5 O O
% O O
) O O
and O O
larval O O
lethality O O
( O O
Lvl O O
) O O
( O O
47 O O
% O O
) O O
( O O
Table O O
2 O O
) O O
. O O

Extending O O
this O O
analysis O O
, O O
a O O
relatively O O
complex O O
genetic O O
interaction O O
network O O
was O O
predicted O O
for O O
the O O
17 O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
orthologues O O
( O O
i O O
. O O
e O O
. O O
, O O
with O O
non O O
- O O
wild O O
- O O
type O O
RNAi O O
phenotypes O O
) O O
( O O
see O O
Table O O
S2 O O
) O O
. O O

Statistically O O
highly O O
significant O O
interactions O O
were O O
predicted O O
for O O
nine O O
of O O
the O O
C B B_NUMBER[MEASURE]/B_PERSON
. I I_NUMBER[MEASURE]/I_PERSON
elegans I I_NUMBER[MEASURE]/I_PERSON
genes O O
; O O
the O O
top O O
five O O
interactors O O
are O O
displayed O O
in O O
Fig O O
. O O

2 O B_NUMBER[MEASURE]
. O O

The O O
gene O O
ontology O O
categories O O
for O O
eight O O
selected O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
genes O O
( O O
F33D11 O O
. O O
10 O O
, O O
F55A12 O O
. O O
8 O O
, O O
kin O O
- O O
2 O O
, O O
mec O O
- O O
12 O O
, O O
mup O O
- O O
2 O O
, O O
pab O O
- O O
1 O O
, O O
rpl O O
- O O
22 O O
and O O
T21B10 O O
. O O
2 O O
) O O
included O O
: O O
embryonic O O
development O O
, O O
egg O O
hatching O O
, O O
larval O O
development O O
and O O
/ O O
or O O
growth O O
. O O

The O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
categories O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
included O O
: O O
positive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regulation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
rate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
( O O
F55A12 O B_PROTEIN[GENE]/B_MEASURE
. O O
8 O B_MEASURE
, O O
kin O B_GENE
- O O
2 O B_NUMBER[MEASURE]
, O O
mup O B_GENE/B_BACTERIUM[BIO]
- O O
2 O B_NUMBER[MEASURE]
, O O
pab O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
, O O
rpl O B_PROTEIN[GENE]/B_LOCATION
- O O
22 O B_NUMBER[MEASURE]
and O O
T21B10 O B_MEASURE/B_GENE
. O O
2 O B_MEASURE
) O O
and O O
gamete O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
generation O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
and O O
locomotory O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
behaviour O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
kin O B_PROTEIN[GENE]
- O O
2 O B_NUMBER[MEASURE]
, O O
mup O B_GENE/B_BACTERIUM[BIO]
- O O
2 O B_NUMBER[MEASURE]
, O O
pab O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
and O O
F55A12 O B_MEASURE/B_PROTEIN[GENE]
. O O
8 O B_MEASURE
, O O
kin O B_GENE/B_LOCATION
- O O
2 O B_NUMBER[MEASURE]
, O O
mup O B_GENE/B_BACTERIUM[BIO]
- O O
2 O B_MEASURE
, O O
respectively O O
) O O
. O O

The O O
C B B_SPECIES[BIO]/B_GENE
. I I_SPECIES[BIO]/I_GENE
elegans I I_SPECIES[BIO]/I_GENE
homologue O O
egl O O
- O O
3 O O
was O O
predicted O O
to O O
be O O
involved O O
in O O
proteolysis O O
( O O
see O O
www O O
. O O
wormbase O O
. O O
org O O
) O O
. O O

All O O
nine O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
orthologues O O
were O O
predicted O O
to O O
interact O O
directly O O
with O O
a O O
total O O
of O O
296 O O
( O O
range O O
: O O
5 O O
- O O
75 O O
) O O
other O O
genes O O
and O O
, O O
in O O
particular O O
, O O
a O O
direct O O
genetic O O
interaction O O
was O O
predicted O O
between O O
pab O O
- O O
1 O O
and O O
T21B10 O O
. O O
2 O O
( O O
Fig O O
. O O
2 O O
) O O
. O O

The O O
296 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
interactors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
associated O O
with O O
embryonic O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
larval O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
development O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
n O B_OTHER/B_MEASURE
= O O
198 O B_MEASURE
; O O
66 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
information O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
storage O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O O
processing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O O
n O B_MEASURE/B_LOCATION
= O O
15 O B_MEASURE
; O O
5 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
, O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
processes O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
signalling O O
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
45 O B_MEASURE
; O O
15 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
) O O
and O O
metabolism O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
18 O B_MEASURE
; O O
6 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
; O O
the O O
precise O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
some O O
of O O
the O O
interactors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
20 O B_MEASURE
; O O
6 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
is O O
presently O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
( O O
Table O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
S2 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
present O O
study O O
investigated O O
transcripts O O
in O O
infective O O
L3s O O
of O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
using O O
a O O
genomic O O
- O O
bioinformatic O O
platform O O
. O O

The O O
focus O O
was O O
on O O
comparisons O O
with O O
C B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
elegans I I_SPECIES[BIO]/I_PERSON
homologues O O
/ O O
orthologues O O
, O O
because O O
the O O
entire O O
genome O O
sequence O O
of O O
this O O
nematode O O
is O O
known O O
[ O O
9 O O
] O O
and O O
because O O
there O O
is O O
a O O
wealth O O
of O O
information O O
on O O
the O O
localization O O
and O O
functionality O O
of O O
its O O
molecules O O
( O O
www O O
. O O
wormbase O O
. O O
org O O
; O O
http O O
: O O
/ O O
/ O O
elegans O O
. O O
bcgsc O O
. O O
bc O O
. O O
ca O O
/ O O
knockout O O
. O O
shtml O O
) O O
. O O

The O O
functions O O
of O O
most O O
genes O O
in O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
have O O
been O O
assessed O O
using O O
RNAi O O
( O O
e O O
. O O
g O O
. O O
, O O
[ O O
14 O O
] O O
, O O
[ O O
15 O O
] O O
, O O
[ O O
17 O O
] O O
, O O
[ O O
55 O O
] O O
, O O
[ O O
56 O O
] O O
) O O
in O O
the O O
hermaphroditic O O
stage O O
, O O
whereas O O
there O O
is O O
a O O
paucity O O
of O O
functional O O
information O O
available O O
for O O
Ascaris O O
and O O
other O O
parasitic O O
nematodes O O
of O O
animals O O
[ O O
57 O O
] O O
, O O
[ O O
58 O O
] O O
. O O

Following O O
the O O
microarray O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
analysis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
> O O
2500 O B_GENE
ESTs O I_GENE
from O O
the O O
SSH O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
498 O B_GENE/B_MEASURE
cDNAs O I_GENE/I_MEASURE
inferred O O
to O O
be O O
enriched O O
in O O
the O O
L3 O B_LOCATION/B_DISEASE
, O O
based O O
on O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
sequenced O O
and O O
subjected O O
to O O
comprehensive O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
silico O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Of O O
the O O
91 O O
clusters O O
of O O
molecules O O
categorized O O
, O O
50 O O
( O O
54 O O
. O O
9 O O
% O O
) O O
had O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
homologues O O
/ O O
orthologues O O
with O O
loss O O
- O O
of O O
- O O
function O O
phenotypes O O
could O O
be O O
mapped O O
to O O
key O O
pathways O O
. O O

The O O
statistically O O
significant O O
genetic O O
interactions O O
predicted O O
for O O
9 O O
of O O
the O O
50 O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
orthologues O O
[ O O
namely O O
egl O O
- O O
3 O O
, O O
F33D11 O O
. O O
10 O O
, O O
F55A12 O O
. O O
8 O O
, O O
kin O O
- O O
2 O O
, O O
mec O O
- O O
12 O O
, O O
mup O O
- O O
2 O O
, O O
pab O O
- O O
1 O O
, O O
rpl O O
- O O
22 O O
and O O
T21B10 O O
. O O
2 O O
( O O
= O O
enol O O
- O O
1 O O
) O O
] O O
and O O
the O O
interaction O O
network O O
included O O
genes O O
encoding O O
kinases O O
, O O
alpha O O
- O O
tubulins O O
, O O
enolases O O
, O O
troponin O O
and O O
other O O
named O O
and O O
unnamed O O
proteins O O
. O O

Eight O O
of O O
these O O
molecules O O
( O O
enol O O
- O O
1 O O
, O O
pab O O
- O O
1 O O
, O O
F33D11 O O
. O O
10 O O
, O O
rpl O O
- O O
22 O O
, O O
F55A12 O O
. O O
8 O O
mec O O
- O O
12 O O
, O O
mup O O
- O O
2 O O
and O O
kin O O
- O O
2 O O
) O O
have O O
known O O
or O O
predicted O O
roles O O
in O O
embryonic O O
and O O
larval O O
growth O O
and O O
development O O
, O O
gamete O O
generation O O
, O O
locomotory O O
behaviour O O
or O O
other O O
biological O O
processes O O
in O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
( O O
see O O
www O O
. O O
wormbase O O
. O O
org O O
) O O
. O O

The O O
enolase O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
encoded O O
by O O
enol O B_DISEASE/B_PROTEIN[GENE]
- O O
1 O B_NUMBER[MEASURE]
is O O
predicted O O
to O O
play O O
a O O
role O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
glycolysis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O O
gluconeogenesis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
phenylalanine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
tyrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
tryptophan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
biosynthesis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
cf O B_GENE
. O O
[ O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
59 O I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Since O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
the O O
main O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
source O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
ATP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
alteration O B_DISEASE_ADJECTIVE[DISEASE]
in O O
these O O
key O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycolytic O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzymes O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
lead O O
to O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]
dysfunction O I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
impaired O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ion O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
motive O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATPase O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
to O O
maintain O O
potential O B_MEASURE/B_BIO
gradients O I_MEASURE/I_BIO
, O O
operate O O
pumps O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
maintain O O
membrane O B_DISEASE_ADJECTIVE[DISEASE]
lipid O I_DISEASE_ADJECTIVE[DISEASE]
asymmetry O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
60 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Bioinformatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
transmembrane O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helices O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TMHMM O B_LOCATION/B_ORGANIZATION
) O O
and O O
peptide O B_GENE/B_LOCATION
signal O I_GENE/I_LOCATION
sequences O I_GENE/I_LOCATION
( O O
SignalP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
predicted O O
ENOL O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
to O O
be O O
a O O
non O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
secreted O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
protein O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
localized O O
to O O
the O O
cytoplasm O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
cf O B_LOCATION/B_GENE
. O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
) O O
. O O

Nonetheless O O
, O O
enolases O O
are O O
often O O
detected O O
in O O
the O O
excretory O O
/ O O
secretory O O
( O O
ES O O
) O O
products O O
of O O
parasitic O O
helminths O O
, O O
including O O
adult O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
[ O O
61 O O
] O O
, O O
and O O
appear O O
to O O
play O O
a O O
role O O
in O O
the O O
triggering O O
of O O
nitric O O
oxide O O
production O O
by O O
host O O
cells O O
. O O

The O O
enol O O
- O O
1 O O
orthologue O O
of O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
has O O
been O O
predicted O O
to O O
interact O O
specifically O O
with O O
the O O
polyadenylate O O
binding O O
protein O O
gene O O
, O O
pab O O
- O O
1 O O
, O O
inferred O O
to O O
be O O
involved O O
in O O
coordinated O O
gene O O
transcription O O
and O O
expression O O
during O O
normal O O
larval O O
development O O
[ O O
16 O O
] O O
. O O

Poly O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
A O O
) O O
- O O
binding O O
proteins O B_PROTEIN[GENE]/B_DISEASE
( O O
PABPs O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
are O O
recognized O O
to O O
be O O
central O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
regulation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
mRNA O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
translation O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
stability O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
[ O O
62 O B_SPECIES[BIO]/B_GENE
] O I_SPECIES[BIO]/I_GENE
. O O

Present O O
evidence O O
suggests O O
that O O
the O O
expression O O
of O O
PAB O O
- O O
1 O O
is O O
regulated O O
by O O
an O O
oligo O O
- O O
pyrimidine O O
tract O O
in O O
response O O
to O O
cell O O
growth O O
and O O
relates O O
to O O
coordinated O O
growth O O
regulation O O
in O O
C B B_BIO/B_DISEASE
. I I_BIO/I_DISEASE
elegans I I_BIO/I_DISEASE
[ O O
62 O O
] O O
. O O

Furthermore O O
, O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
silencing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
pab O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
and O O
its O O
selected O O
interactors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
( O O
see O O
Fig O B_MEASURE/B_PERSON
. O O
2 O B_NUMBER[MEASURE]
) O O
leads O O
to O O
embryonic O B_DISEASE/B_ORGANISM_FUNCTION
lethal O I_DISEASE/I_ORGANISM_FUNCTION
( O O
Emb O B_LOCATION/B_PERSON
) O O
, O O
slow O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Slo O B_PERSON/B_LOCATION
) O O
and O O
sterile O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
progeny O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
Stp O B_LOCATION/B_ORGANIZATION
) O O
phenotypes O B_DISEASE/B_GENE
( O O
see O O
www O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
wormbase O B_BIO/B_GENE
. O O
org O B_ORGANIZATION/B_LOCATION
) O O
. O O

Another O O
gene O O
( O O
F33D11 O O
. O O
10 O O
; O O
EST O O
code O O
4F10 O O
; O O
see O O
Table O O
2 O O
) O O
which O O
encodes O O
an O O
ATP O O
- O O
dependent O O
RNA O O
helicase O O
and O O
is O O
associated O O
with O O
embryonic O O
lethal O O
( O O
Emb O O
) O O
and O O
larval O O
lethal O O
( O O
Lvl O O
) O O
RNAi O O
phenotypes O O
, O O
was O O
shown O O
to O O
be O O
highly O O
transcribed O O
in O O
infective O O
L3s O O
of O O
A B B_BIO
. I I_BIO
suum I I_BIO
. O O

Helicases O O
are O O
involved O O
in O O
a O O
variety O O
of O O
RNA O O
metabolic O O
processes O O
, O O
including O O
translation O O
initiation O O
, O O
pre O O
- O O
mRNA O O
splicing O O
, O O
pre O O
- O O
rRNA O O
processing O O
, O O
rRNA O O
maturation O O
and O O
RNA O O
degradation O O
[ O O
63 O O
] O O
, O O
and O O
are O O
crucial O O
for O O
life O O
cycle O O
progression O O
, O O
sex O O
determination O O
and O O
early O O
embryogenesis O O
in O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
[ O O
60 O O
] O O
. O O

The O O
high O O
transcription O O
levels O O
of O O
a O O
homologue O O
/ O O
orthologue O O
in O O
the O O
L3 O O
of O O
A B B_BIO
. I I_BIO
suum I I_BIO
might O O
suggest O O
a O O
similar O O
role O O
in O O
this O O
ascaridoid O O
. O O

Similarly O O
, O O
the O O
coordination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
expression O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
large O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
required O O
for O O
normal O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
during O O
larval O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

The O O
high O O
transcription O O
level O O
for O O
the O O
ribosomal O O
protein O O
gene O O
homologue O O
rpl O O
- O O
22 O O
( O O
large O O
subunit O O
family O O
member O O
; O O
EST O O
code O O
26G12 O O
, O O
see O O
Table O O
2 O O
) O O
in O O
the O O
infective O O
L3 O O
of O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
compared O O
with O O
other O O
developmental O O
stages O O
is O O
likely O O
to O O
reflect O O
the O O
substantial O O
rate O O
of O O
cell O O
growth O O
in O O
this O O
stage O O
[ O O
64 O O
] O O
. O O

The O O
gene O O
( O O
F55A12 O O
. O O
8 O O
, O O
EST O O
code O O
4G11 O O
; O O
see O O
Table O O
2 O O
) O O
encoding O O
an O O
acetyl O O
- O O
transferase O O
with O O
a O O
putative O O
ATPase O O
domain O O
, O O
shown O O
to O O
be O O
enriched O O
in O O
the O O
L3 O O
of O O
A B B_BIO
. I I_BIO
suum I I_BIO
, O O
was O O
predicted O O
to O O
interact O O
with O O
75 O O
other O O
genes O O
all O O
involved O O
in O O
energy O O
production O O
and O O
/ O O
or O O
RNA O O
processing O O
( O O
see O O
Table O O
S2 O O
) O O
. O O

Several O O
molecules O O
involved O O
in O O
ATP O O
synthesis O O
and O O
mitochondrial O O
pathways O O
( O O
e O O
. O O
g O O
. O O
, O O
cytochrome O O
oxidase O O
c O O
subunits O O
1 O O
, O O
2 O O
and O O
3 O O
, O O
ADP O O
/ O O
ATP O O
translocases O O
, O O
NADH O O
dehydrogenases O O
, O O
ATPases O O
and O O
ATP O O
synthetases O O
) O O
have O O
been O O
reported O O
previously O O
to O O
be O O
highly O O
represented O O
in O O
the O O
L3 O O
stage O O
of O O
Anisakis B B_SPECIES[BIO]/B_DISEASE
simplex I I_SPECIES[BIO]/I_DISEASE
[ O O
65 O O
] O O
, O O
thus O O
supporting O O
the O O
proposal O O
that O O
substantial O O
energy O O
is O O
required O O
for O O
larval O O
development O O
as O O
well O O
as O O
the O O
transition O O
from O O
the O O
free O O
- O O
living O O
to O O
the O O
parasitic O O
stage O O
and O O
the O O
invasion O O
of O O
the O O
host O O
. O O

There O O
is O O
also O O
likely O O
to O O
be O O
a O O
substantial O O
energy O O
requirement O O
for O O
muscle O O
contraction O O
linked O O
to O O
larval O O
motility O O
in O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
, O O
as O O
the O O
L3s O O
penetrate O O
the O O
caecal O O
wall O O
in O O
the O O
porcine O O
host O O
, O O
before O O
undergoing O O
hepato O O
- O O
pulmonary O O
migration O O
[ O O
35 O O
] O O
. O O

Accordingly O O
, O O
genes O O
encoding O O
a O O
specialized O O
tubulin O O
expressed O O
in O O
mechanoreceptors O O
( O O
mec O O
- O O
12 O O
, O O
EST O O
code O O
13E09 O O
) O O
and O O
a O O
troponin O O
( O O
mup O O
- O O
2 O O
, O O
EST O O
code O O
01G03 O O
; O O
see O O
Table O O
2 O O
) O O
, O O
both O O
predicted O O
to O O
interact O O
with O O
a O O
total O O
number O O
of O O
32 O O
tubulin O O
- O O
and O O
myosin O O
- O O
encoding O O
genes O O
, O O
also O O
supported O O
a O O
link O O
to O O
extensive O O
muscle O O
contraction O O
and O O
motility O O
in O O
A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
suum I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
L3s O O
. O O

Also O O
, O O
neuroactive O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
peptides O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
are O O
required O O
to O O
regulate O O
the O O
responsiveness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
nematode O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
larvae O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
mechanical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimuli O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
66 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
homologue O O
encoded O O
by O O
egl O O
- O O
3 O O
was O O
shown O O
to O O
be O O
highly O O
transcribed O O
in O O
the O O
L3 O O
of O O
A B B_BIO
. I I_BIO
suum I I_BIO
; O O
EGL O O
- O O
3 O O
is O O
predicted O O
to O O
be O O
a O O
pro O O
- O O
hormone O O
convertase O O
involved O O
in O O
the O O
maturation O O
of O O
neuropeptides O O
and O O
could O O
be O O
associated O O
with O O
mechano O O
- O O
sensory O O
responses O O
and O O
touch O O
sensitivity O O
linked O O
to O O
the O O
host O O
invasion O O
. O O

A O O
regulatory O B_GENE/B_PERSON
subunit O I_GENE/I_PERSON
of O O
a O O
cAMP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_ENZYME[GENE]/B_LOCATION
protein O I_ENZYME[GENE]/I_LOCATION
kinase O I_ENZYME[GENE]/I_LOCATION
( O O
kin O B_GENE
- O O
2 O B_MEASURE/B_PROTEIN[GENE]
, O O
EST O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
22H01 O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
was O O
predicted O O
to O O
interact O O
with O O
72 O B_GENE/B_MEASURE
other O I_GENE/I_MEASURE
genes O I_GENE/I_MEASURE
all O O
involved O O
in O O
diverse O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
processes O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
trafficking O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
and O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]
replication O I_DISEASE_ADJECTIVE[DISEASE]
and O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O O
see O O
Table O B_MEASURE/B_LOCATION
S2 O I_MEASURE/I_LOCATION
) O O
. O O

Based O O
on O O
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ontology O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
terms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
kin O B_GENE
- O O
2 O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
implicated O O
in O O
gamete O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
generation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
growth O B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
larval O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
development O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
post O B_LOCATION/B_DISEASE
- O O
embryonic O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
body O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
morphogenesis O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
signal O B_GENE
transduction O I_GENE
and O O
/ O O
or O O
protein O B_DISEASE/B_GENE
amino O I_DISEASE/I_GENE
acid O I_DISEASE/I_GENE
phosphorylation O I_DISEASE/I_GENE
( O O
see O O
Table O B_LOCATION/B_PERSON
S2 O I_LOCATION/I_PERSON
) O O
. O O

Gene O O
silencing O O
of O O
kin O O
- O O
2 O O
in O O
C B B_BIO
. I I_BIO
elegans I I_BIO
leads O O
to O O
phenotypes O O
, O O
such O O
as O O
larval O O
lethal O O
( O O
Lvl O O
) O O
, O O
larval O O
arrest O O
( O O
Lva O O
) O O
, O O
body O O
morphology O O
defect O O
( O O
Bmd O O
) O O
, O O
dumpy O O
( O O
Dpy O O
) O O
, O O
uncoordinated O O
( O O
Unc O O
) O O
and O O
sterile O O
progeny O O
( O O
Stp O O
) O O
( O O
www O O
. O O
wormbase O O
. O O
org O O
) O O
, O O
suggesting O O
that O O
its O O
homologue O O
in O O
A B B_SPECIES[BIO]
. I I_SPECIES[BIO]
suum I I_SPECIES[BIO]
is O O
central O O
to O O
larval O O
maturation O O
. O O

The O O
KOBAS O O
analysis O O
predicted O O
the O O
protein O O
KIN O O
- O O
2 O O
to O O
be O O
involved O O
in O O
the O O
insulin O O
- O O
signaling O O
pathway O O
, O O
previously O O
implicated O O
in O O
controlling O O
the O O
exit O O
from O O
dauer O O
in O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
and O O
the O O
activation O O
of O O
L3s O O
of O O
the O O
canine B B_SPECIES[BIO]
hookworm I I_SPECIES[BIO]
, O O
Ancylostoma B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
caninum I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O O
following O O
exsheathment O O
[ O O
67 O O
] O O
. O O

In O O
a O O
recent O O
study O O
, O O
Brand O O
and O O
Hawdon O O
[ O O
68 O O
] O O
were O O
able O O
to O O
inhibit O O
( O O
with O O
a O O
phosphoinositide O O
- O O
3 O O
- O O
OH O O
- O O
kinase O O
inhibitor O O
) O O
the O O
activation O O
of O O
infective O O
L3s O O
of O O
both O O
of O O
the O O
hookworms O O
Ancylostoma B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
caninum I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
and O O
Ancylostoma B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
ceylanicum I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
via O O
the O O
insulin O O
signaling O O
pathway O O
, O O
thus O O
lending O O
some O O
credence O O
to O O
the O O
hypothesis O O
that O O
this O O
pathway O O
plays O O
an O O
critical O O
role O O
in O O
regulating O O
the O O
transition O O
from O O
the O O
free O O
- O O
living O O
to O O
the O O
parasitic O O
stage O O
[ O O
68 O O
] O O
. O O

Recently O O
, O O
it O O
has O O
been O O
proposed O O
that O O
transcriptional O O
and O O
feeding O O
responses O O
to O O
serum O O
- O O
stimulation O O
in O O
Ancylostoma B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
caninum I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
are O O
regulated O O
by O O
parallel O O
systems O O
, O O
with O O
the O O
insulin O O
signaling O O
pathway O O
playing O O
a O O
significant O O
role O O
in O O
the O O
' O O
resumption O O
of O O
feeding O O
' O O
in O O
activated O O
larvae O O
[ O O
69 O O
] O O
. O O

Protein O B_PERSON/B_GENE
kinases O I_PERSON/I_GENE
are O O
also O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
involved O O
in O O
pathways O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
linked O O
to O O
sexual O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
maturation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
developing O O
larvae O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

As O O
already O O
proposed O O
for O O
adult O O
stages O O
of O O
H B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
contortus I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
45 O O
] O O
, O O
the O O
protein O O
kinase O O
gene O O
cdk O O
- O O
1 O O
is O O
predicted O O
to O O
play O O
a O O
pivotal O O
role O O
in O O
the O O
germline O O
, O O
oogenesis O O
and O O
spermiogenesis O O
pathways O O
of O O
this O O
parasitic O O
nematode O O
. O O

Other O O
protein O O
kinases O O
, O O
such O O
as O O
PEPCK O O
, O O
and O O
phosphatases O O
, O O
were O O
shown O O
herein O O
to O O
be O O
transcribed O O
at O O
high O O
levels O O
in O O
the O O
L3 O O
stage O O
compared O O
with O O
other O O
developmental O O
stages O O
of O O
A B B_BIO
. I I_BIO
suum I I_BIO
( O O
see O O
Table O O
2 O O
) O O
, O O
which O O
is O O
in O O
accordance O O
to O O
findings O O
reported O O
recently O O
for O O
Anisakis B B_SPECIES[BIO]
simplex I I_SPECIES[BIO]
[ O O
65 O O
] O O
. O O

Due O O
to O O
their O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
regulatory O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
eukaryotic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
signaling O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
events O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O O
regulatory O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sensory O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
functions O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
protein O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
kinases O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
considered O O
interesting O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targets O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
parasitic O B_DISEASE/B_GENE
drugs O I_DISEASE/I_GENE
[ O O
70 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
conclusion O O
, O O
this O O
study O O
has O O
given O O
some O O
interesting O O
insights O O
into O O
early O O
molecular O O
processes O O
in O O
the O O
L3 O O
of O O
A B B_DISEASE
. I I_DISEASE
suum I I_DISEASE
. O O

Approximately O O
60 O O
% O O
of O O
the O O
transcripts O O
enriched O O
in O O
the O O
L3 O O
stage O O
of O O
A B B_ORGANISM_FUNCTION/B_BIO
. I I_ORGANISM_FUNCTION/I_BIO
suum I I_ORGANISM_FUNCTION/I_BIO
have O O
homologues O O
/ O O
orthologues O O
in O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
. O O

The O O
bioinformatic O O
analyses O O
of O O
selected O O
molecules O O
suggest O O
that O O
a O O
complex O O
genetic O O
network O O
regulates O O
or O O
controls O O
larval O O
growth O O
and O O
development O O
in O O
A B B_PERSON
. I I_PERSON
suum I I_PERSON
L3s O O
, O O
and O O
some O O
of O O
these O O
might O O
be O O
involved O O
in O O
or O O
regulate O O
the O O
switch O O
from O O
the O O
free O O
- O O
living O O
to O O
the O O
parasitic O O
stage O O
. O O

Some O O
caution O O
is O O
warranted O O
in O O
drawing O O
conclusions O O
regarding O O
molecular O O
mechanisms O O
regulating O O
the O O
transition O O
to O O
parasitism O O
in O O
parasitic O O
nematodes O O
from O O
information O O
on O O
C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]
, O O
as O O
latter O O
is O O
a O O
free O O
- O O
living O O
nematode O O
. O O

Also O O
, O O
while O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
reliable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prediction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
might O O
limit O O
the O O
capacity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
somewhat O O
to O O
infer O O
nematode O B_BIO/B_GENE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

As O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
datasets O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
gene O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
functions O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
become O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
various O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
parasitic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
nematodes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
more O O
informed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inferences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
made O O
regarding O O
the O O
functions O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nematode O B_BIO/B_PERSON
- O O
specific O B_GENE/B_BIO
genes O I_GENE/I_BIO
, O O
particularly O O
those O O
involved O O
in O O
the O O
transition O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
parasitism O B_DISEASE/B_ORGANISM_FUNCTION
. O O

The O O
imminent O O
genome O O
sequence O O
of O O
A B B_BIO
. I I_BIO
suum I I_BIO
( O O
http O O
: O O
/ O O
/ O O
www O O
. O O
sanger O O
. O O
ac O O
. O O
uk O O
/ O O
Projects O O
/ O O
Helminths O O
/ O O
) O O
should O O
all O O
assist O O
in O O
this O O
endeavour O O
. O O

Also O O
, O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
selected O O
molecules O B_BIO/B_GENE
representing O O
selected O O
ESTs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
identified O O
herein O B_TIME[MEASURE]/B_LOCATION
, O O
utilizing O O
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
silencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approaches O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
established O O
recently O O
[ O O
33 O B_MEASURE
] O I_MEASURE
, O O
[ O O
34 O B_MEASURE
] O I_MEASURE
, O O
could O O
provide O O
some O O
insights O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
developmental O B_DISEASE/B_GENE
processes O I_DISEASE/I_GENE
in O O
Ascaris O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
related O B_SPECIES[BIO]/B_PERSON
ascaridoid O I_SPECIES[BIO]/I_PERSON
nematodes O I_SPECIES[BIO]/I_PERSON
and O O
provide O O
avenues O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
novel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
their O O
control O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Supporting O O
Information O B_PERSON/B_ENT

Minocycline O B_DISEASE_ADJECTIVE[DISEASE]
attenuates O I_DISEASE_ADJECTIVE[DISEASE]
lipopolysaccharide O O
( O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
- O O
induced O O
neuroinflammation O B_DISEASE
, O O
sickness O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
anhedonia O B_DISEASE/B_GENE

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Activation O B_DISEASE/B_GENE
of O O
the O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
innate O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
immune O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
stimulates O O
the O O
secretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
CNS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
modulate O O
the O O
behavioral O B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
of O O
sickness O B_DISEASE/B_LOCATION
. O O

Excessive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
production O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cytokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
by O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
however O O
, O O
may O O
cause O O
long O O
- O O
lasting O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
behavioral O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
cognitive O B_DISEASE_ADJECTIVE[DISEASE]
complications O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
purpose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
if O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
agent O I_DISEASE_ADJECTIVE[DISEASE]
and O O
purported O O
microglial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
attenuates O O
lipopolysaccharide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
- O O
induced O O
neuroinflammation O B_DISEASE
, O O
sickness O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
anhedonia O B_DISEASE
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
microglia O B_DISEASE/B_GENE
activation O I_DISEASE/I_GENE
was O O
assessed O O
in O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
microglia O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cultures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
the O O
second O O
study O O
, O O
adult O O
( O O
3 O O
- O O
6 O O
m O O
) O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O O
an O O
intraperitoneal O O
( O O
i O O
. O O
p O O
. O O
) O O
injection O O
of O O
vehicle O O
or O O
minocycline O O
( O O
50 O O
mg O O
/ O O
kg O O
) O O
for O O
three O O
consecutive O O
days O O
. O O

On O O
the O O
third O O
day O O
, O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
also O O
injected O O
( O O
i O O
. O O
p O O
. O O
) O O
with O O
saline O O
or O O
Escherichia B B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coli I B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS O O
( O O
0 O O
. O O
33 O O
mg O O
/ O O
kg O O
) O O
and O O
behavior O O
( O O
i O O
. O O
e O O
. O O
, O O
sickness O O
and O O
anhedonia O O
) O O
and O O
markers O O
of O O
neuroinflammation O O
( O O
i O O
. O O
e O O
. O O
, O O
microglia O O
activation O O
and O O
inflammatory O O
cytokines O O
) O O
were O O
determined O O
. O O

In O O
the O O
final O O
study O O
, O O
adult O O
and O O
aged O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
treated O O
with O O
the O O
same O O
minocycline O O
and O O
LPS O O
injection O O
regimen O O
and O O
markers O O
of O O
neuroinflammation O O
were O O
determined O O
. O O

All O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
analyzed O O
using O O
Statistical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Analysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Systems O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
General O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Linear O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Model O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
procedures O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
were O O
subjected O O
to O O
one O B_NUMBER[MEASURE]/B_PERSON
- O O
, O O
two O B_NUMBER[MEASURE]/B_PERSON
- O O
, O O
or O O
three O B_NUMBER[MEASURE]
- O O
way O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ANOVA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
determine O O
significant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
main O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
interactions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O O
LPS O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_MEASURE
microglia O I_MEASURE
- O O
derived O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
reduced O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
Toll O B_GENE
- O O
like O B_BIO/B_PROTEIN[GENE]
- O O
receptor O B_GENE/B_BIO
- O O
2 O B_MEASURE
( O O
TLR2 O B_GENE
) O O
surface O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
brain O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
microglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Moreover O O
, O O
minocycline O O
facilitated O O
the O O
recovery O O
from O O
sickness O O
behavior O O
( O O
i O O
. O O
e O O
. O O
, O O
anorexia O O
, O O
weight O O
loss O O
, O O
and O O
social O O
withdrawal O O
) O O
and O O
prevented O O
anhedonia O O
in O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenged O O
with O O
LPS O O
. O O

Furthermore O O
, O O
the O O
minocycline O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
from O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
sickness O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
paralleled O O
by O O
reduced O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mRNA O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Interleukin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
1 O B_MEASURE/B_PROTEIN[GENE]
beta O I_MEASURE/I_PROTEIN[GENE]
, O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
, O O
and O O
indoleamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
3 O B_MEASURE/B_ENZYME[GENE]
dioxygenase O I_MEASURE/I_ENZYME[GENE]
( O O
IDO O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
the O O
cortex O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Finally O O
, O O
in O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
where O O
exaggerated O O
neuroinflammation O O
was O O
elicited O O
by O O
LPS O O
, O O
minocycline O O
pretreatment O O
was O O
still O O
effective O O
in O O
markedly O O
reducing O O
mRNA O O
levels O O
of O O
IL O O
- O O
1 O O
beta O O
, O O
TLR2 O O
and O O
IDO O O
in O O
the O O
hippocampus O O
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mitigates O O
neuroinflammation O B_DISEASE/B_GENE
in O O
the O O
adult O B_PERSON
and O O
aged O B_PERSON
brain O I_PERSON
and O O
modulates O O
the O O
cytokine O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
motivation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
behavior O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
bi O B_DISEASE/B_NUMBER[MEASURE]
- O O
directional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
communication O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O O
the O O
immune O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CNS O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
is O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
mounting O O
the O O
appropriate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
immunological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
physiological O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
behavioral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
immune O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
[ O O
1 O B_DISEASE
] O I_DISEASE
. O O

CNS O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
innate O O
immune O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
including O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
play O O
integral O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
roles O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
receiving O O
and O O
propagating O O
inflammatory O B_DISEASE
signals O I_DISEASE
that O O
are O O
initiated O O
at O O
the O O
periphery O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

Activation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
innate O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
immune O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
elicits O O
the O O
secretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
inflammatory O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
interleukin O B_GENE
( O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
1 O B_MEASURE
, O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
, O O
and O O
tumor O B_DISEASE/B_GENE
necrosis O B_DISEASE/I_GENE
factor O B_DISEASE/I_GENE
- O O
alpha O B_PROTEIN[GENE]
( O O
TNF O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
) O O
, O O
that O O
use O O
neural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
[ O O
2 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
] O O
, O O
humoral O O
[ O O
4 O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
blood O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
brain O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
barrier O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
5 O B_MEASURE
] O O
to O O
relay O O
this O O
signal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
CNS O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

This O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
signal O I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
turn O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
induces O O
CNS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
produce O O
the O O
same O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O O
6 O B_MEASURE
] O I_MEASURE
, O O
which O O
target O O
neuronal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
substrates O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
elicit O O
a O O
sickness O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
syndrome O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
normally O O
adaptive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
beneficial O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
host O B_PERSON/B_SPORT[ENT]
[ O I_PERSON/I_SPORT[ENT]
1 O I_PERSON/I_SPORT[ENT]
] O I_PERSON/I_SPORT[ENT]
. O O

An O O
amplified O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
excessive O B_DISEASE/B_MEASURE
inflammatory O I_DISEASE/I_MEASURE
cytokine O I_DISEASE/I_MEASURE
response O I_DISEASE/I_MEASURE
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
however O O
, O O
is O O
associated O O
with O O
a O O
myriad O B_MEASURE/B_LOCATION
of O O
complications O B_DISEASE_ADJECTIVE[DISEASE]
including O O
cognitive O B_DISEASE
dysfunction O I_DISEASE
[ O I_DISEASE
7 O I_DISEASE
- O O
10 O B_NUMBER[MEASURE]/B_LOCATION
] O I_NUMBER[MEASURE]/I_LOCATION
, O O
prolonged O B_DISEASE
sickness O I_DISEASE
behavior O I_DISEASE
[ O O
11 O B_SEQUENCE[MEASURE]
- O O
14 O B_MEASURE
] O I_MEASURE
, O O
and O O
depressive O B_DISEASE
- O O
like O B_DISEASE
behavior O I_DISEASE
[ O O
15 O B_MEASURE
] O I_MEASURE
. O O

Microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
are O O
primarily O O
involved O O
in O O
immune O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
16 O B_MEASURE
, O O
17 O B_MEASURE
] O I_MEASURE
, O O
but O O
when O O
activated O O
have O O
macrophage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
like O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
capabilities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
including O O
phagocytosis O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
cytokine O I_DISEASE_ADJECTIVE[DISEASE]
production O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
antigen O B_DISEASE_ADJECTIVE[DISEASE]
presentation O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
18 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

Normally O O
these O O
neuroinflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
transient O B_DISEASE_ADJECTIVE[DISEASE]
with O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
returning O O
to O O
a O O
resting O O
state O B_LOCATION/B_MEASURE
as O O
the O O
immune O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
resolved O O
. O O

Aging O O
or O O
neurological O B_DISEASE
disease O I_DISEASE
, O O
however O O
, O O
may O O
provide O O
a O O
brain O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
environment O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
where O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
are O O
more O B_DISEASE_ADJECTIVE[DISEASE]
" O O
reactive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
primed O O
" O O
to O O
a O O
peripheral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immune O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
challenge O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
19 O B_DISEASE
] O I_DISEASE
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
indicate O O
that O O
several O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
markers O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
glial O B_DISEASE
activation O I_DISEASE
such O I_DISEASE
as O O
major O B_GENE
histocompatibility O I_GENE
complex O I_GENE
( O O
MHC O B_LOCATION/B_ORGANIZATION
) O O
class O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
complement O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
scavenger O B_GENE
receptors O I_GENE
are O O
increased O O
in O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
during O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
aging O O
[ O O
13 O B_MEASURE
, O O
20 O B_MEASURE
- O O
26 O B_MEASURE
] O I_MEASURE
. O O

Furthermore O O
, O O
we O O
and O O
others O B_PERSON/B_BIO
have O O
reported O O
that O O
a O O
biological O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
consequence O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
this O O
reactive O B_DISEASE_ADJECTIVE[DISEASE]
glial O I_DISEASE_ADJECTIVE[DISEASE]
profile O I_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
exaggerated O B_DISEASE_ADJECTIVE[DISEASE]
neuroinflammatory O I_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
to O O
innate O O
immune O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
9 O B_MEASURE
, O O
10 O B_SEQUENCE[MEASURE]
, O O
12 O B_SEQUENCE[MEASURE]
- O O
14 O B_MEASURE
, O O
27 O B_MEASURE
, O O
28 O B_MEASURE
] O I_MEASURE
. O O

Active O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
microglia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
CNS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
contribute O O
to O O
the O O
production O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
oxidative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
neuroactive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediators O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
may O O
influence O O
behavior O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
instance O B_PERSON/B_DISEASE
, O O
inflammatory O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
CNS O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upregulate O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
enzyme O B_ENZYME[GENE]/B_LOCATION
IDO O I_ENZYME[GENE]/I_LOCATION
[ O O
29 O B_MEASURE
, O O
30 O B_MEASURE
] O I_MEASURE
, O O
which O O
metabolizes O O
tryptophan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TRP O B_PROTEIN[GENE]
) O O
into O O
L O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
kynurenine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
KYN O B_PROTEIN[GENE]/B_DISEASE
) O O
[ O O
31 O B_MEASURE
] O I_MEASURE
. O O

TRP O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degradation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
KYN O B_GENE/B_DISEASE
can O O
reduce O O
TRP O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
are O O
required O O
for O O
serotonin O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
32 O B_MEASURE
] O I_MEASURE
and O O
can O O
lead O O
to O O
the O O
production O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
neuroactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mediators O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O O
3 O B_NUMBER[MEASURE]
- O O
hydroxykynurenine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3HK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
and O O
quinolinic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
QUIN O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
[ O O
31 O B_MEASURE
] O I_MEASURE
. O O

High O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
3HK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
QUIN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induce O O
neuronal O B_DISEASE/B_GENE
damage O I_DISEASE/I_GENE
through O O
oxidative O B_DISEASE_ADJECTIVE[DISEASE]
stress O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
33 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
] O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
over O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
methyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
aspartate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NMDA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
[ O O
34 O B_MEASURE
, O O
35 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

A O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicates O O
that O O
while O O
several O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
types O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
CNS O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
express O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
IDO O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
only O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_NUMBER[MEASURE]
maintain O O
all O O
the O O
enzymes O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
to O O
produce O O
3HK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
QUIN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
36 O B_TIME[MEASURE]/B_LOCATION
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Because O O
IDO O B_DISEASE/B_GENE
mediated O O
TRP O B_DISEASE/B_GENE
degradation O I_DISEASE/I_GENE
impacts O O
both O O
serotonergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
glutamatergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathways O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
this O O
may O O
be O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
underlying O O
mood O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
behavior O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concomitant O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
inflammation O B_DISEASE/B_BACTERIUM[BIO]
[ O O
37 O B_MEASURE
- O O
39 O B_MEASURE
] O I_MEASURE
. O O

Because O O
activated O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
suspected O O
to O O
cause O O
or O O
exacerbate O O
several O B_DISEASE
neurodegenerative O I_DISEASE
diseases O I_DISEASE
, O O
pharmacological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strategies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
suppress O O
microglial O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activity O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
being O O
explored O O
as O O
therapies O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
tetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
derived O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
has O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
CNS O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
that O O
are O O
separate O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
its O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
action O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O O
40 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
readily O O
crosses O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
barrier O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
attenuates O B_DISEASE/B_LOCATION
inflammation O I_DISEASE/I_LOCATION
associated O O
with O O
microglial O B_DISEASE
activation O I_DISEASE
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocks O O
the O O
deleterious O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
neuroinflammation O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
neurogenesis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
potentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
, O O
and O O
neuronal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
survival O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
41 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
43 O B_MEASURE
] O I_MEASURE
. O O

The O O
mechanism O B_LOCATION
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abrogates O O
MAPkinase O B_GENE/B_DISEASE
and O O
NF O B_GENE
kappa O I_GENE
B O I_GENE
dependent O I_GENE
signaling O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O O
primary O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
microglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cultures O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
44 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Moreover O O
, O O
in O O
the O O
brain O O
of O O
rats B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
minocycline O O
abrogates O O
microglial O O
expression O O
of O O
CD11b O O
and O O
MHC O O
II O O
through O O
a O O
protein O O
kinase O O
- O O
c O O
dependent O O
mechanism O O
[ O O
45 O O
] O O
. O O

This O O
is O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
because O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attenuates O O
neuroinflammation O B_DISEASE/B_GENE
in O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
rodent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
disease O B_DISEASE
including O O
Amyotrophic O B_DISEASE/B_GENE
Lateral O I_DISEASE/I_GENE
Sclerosis O I_DISEASE/I_GENE
[ O I_DISEASE
46 O I_DISEASE
] O I_MEASURE/I_DISEASE
, O O
Experimental O B_DISEASE
Autoimmune O I_DISEASE
Encephalomyelitis O I_DISEASE
( O O
EAE O B_DISEASE
) O O
[ O O
45 O B_MEASURE
] O I_MEASURE
and O O
MPTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
Parkinson O B_DISEASE/B_GENE
' O O
s O B_DISEASE
disease O I_DISEASE
[ O O
47 O B_MEASURE
] O I_MEASURE
. O O

However O O
, O O
the O O
extent O B_DISEASE/B_MEASURE
to O O
which O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
facilitates O O
the O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
cytokine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mediated O O
sickness O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
investigated O O
the O O
degree O B_MEASURE/B_LOCATION
to O O
which O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
agent O I_DISEASE_ADJECTIVE[DISEASE]
and O O
purported O O
microglial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
reduced O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
neuroinflammation O B_DISEASE
and O O
sickness O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
show O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O O
LPS O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_MEASURE
microglia O I_MEASURE
- O O
derived O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
reduced O O
LPS O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
Toll O B_GENE
- O O
like O B_BIO/B_PROTEIN[GENE]
- O O
receptor O B_GENE/B_MEASURE
- O O
2 O B_MEASURE
( O O
TLR2 O B_GENE/B_LOCATION
) O O
surface O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
brain O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
microglia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Moreover O O
, O O
our O O
data O O
show O O
that O O
minocycline O O
pretreatment O O
attenuated O O
LPS O O
- O O
induced O O
weight O O
loss O O
, O O
social O O
withdrawal O O
, O O
and O O
anhedonia O O
in O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
attenuation O O
of O O
sickness O O
behavior O O
was O O
paralleled O O
with O O
minocycline O O
dependent O O
decrease O O
in O O
markers O O
of O O
neuroinflammation O O
( O O
IL O O
- O O
1 O O
beta O O
, O O
TLR2 O O
, O O
and O O
IDO O O
) O O
in O O
adult O O
and O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support O O
our O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
ability O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O O
mitigate O O
cytokine O B_DISEASE/B_GENE
expression O I_DISEASE/I_GENE
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
during O O
systemic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflammatory O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
preventing O O
cognitive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
behavioral O B_DISEASE
deficits O I_DISEASE
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Male O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
adults O O
( O O
3 O O
month O O
old O O
) O O
and O O
juvenile O O
( O O
3 O O
- O O
4 O O
week O O
old O O
) O O
were O O
purchased O O
from O O
Harlan O O
( O O
Indianapolis O O
, O O
IN O O
) O O
. O O

For O O
age O O
comparisons O O
, O O
male O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O O
- O O
4 O O
and O O
20 O O
- O O
22 O O
month O O
old O O
) O O
were O O
purchased O O
from O O
the O O
National O O
Institute O O
on O O
Aging O O
specific O O
pathogen O O
free O O
colony O O
. O O

Upon O O
arrival O O
, O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
individually O O
housed O O
in O O
polypropylene O O
cages O O
and O O
maintained O O
at O O
21 O O
degrees O O
C O O
under O O
a O O
12 O O
h O O
light O O
: O O
12 O O
h O O
dark O O
cycle O O
with O O
ad O O
libitum O O
access O O
to O O
water O O
and O O
rodent O O
chow O O
. O O

At O O
the O O
end O O
of O O
each O O
study O O
, O O
mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
examined O O
postmortem O O
for O O
gross O O
signs O O
of O O
disease O O
( O O
e O O
. O O
g O O
. O O
, O O
splenomeglia O O
or O O
tumors O O
) O O
. O O

Data O O
from O O
mice B B_BIO/B_PERSON
determined O O
to O O
be O O
unhealthy O O
were O O
excluded O O
from O O
analysis O O
( O O
< O O
5 O O
% O O
) O O
. O O

All O O
procedures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
in O O
accordance O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
National O B_ORGANIZATION/B_LOCATION
Institute O I_ORGANIZATION/I_LOCATION
of O O
Health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Guidelines O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
the O O
Care O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Laboratory O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Animals O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
were O O
approved O O
by O O
The O O
Ohio O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
State O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
University O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Institutional O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Laboratory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Animal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
Use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Committee O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microglia O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lines O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
cultured O O
in O O
growth O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
medium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O O
DMEM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
supplemented O O
with O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FBS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
sodium O B_MEASURE
bicarbonate O I_MEASURE
3 O I_MEASURE
. O O
7 O B_MEASURE
g O I_MEASURE
/ O O
l O B_OTHER/B_MEASURE
, O O
200 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
100 O B_MEASURE/B_LOCATION
U O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE/B_LOCATION
penicillin O I_MEASURE/I_LOCATION
G O I_MEASURE/I_LOCATION
, O O
100 O B_MEASURE
mu O I_MEASURE
g O I_MEASURE
/ O O
ml O B_MEASURE
streptomycin O I_MEASURE
, O O
0 O B_MEASURE/B_LOCATION
. O O
25 O B_MEASURE/B_LOCATION
mu O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE
fungizone O I_MEASURE
) O O
as O O
previously O O
described O O
[ O O
12 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Cultures O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
maintained O O
at O O
37 O B_LOCATION/B_MEASURE
degrees O I_LOCATION/I_MEASURE
C O I_LOCATION/I_MEASURE
with O O
95 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
humidity O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
CO2 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
medium O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
was O O
replenished O O
every O O
third O B_TIME[MEASURE]
day O I_TIME[MEASURE]
until O O
confluence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Cultures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
washed O O
twice O O
and O O
supplemented O O
with O O
warm O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
experimental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatments O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Cell O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
viability O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
was O O
measured O O
by O O
the O O
MTS O B_PERSON/B_ORGANIZATION
cell O I_PERSON/I_ORGANIZATION
proliferation O I_PERSON/I_ORGANIZATION
assay O I_PERSON/I_ORGANIZATION
according O O
to O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
instructions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
Promega O B_LOCATION/B_PERSON
, O O
Madison O B_PERSON/B_LOCATION
, O O
WI O B_MEASURE/B_LOCATION
) O O
. O O

CNS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
isolation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]

CNS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
collected O O
from O O
whole O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
homogenates O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
described O O
previously O O
[ O O
48 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
, O O
but O O
with O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
modifications O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mice B B_BIO/B_PERSON
were O O
euthanized O O
by O O
CO2 O O
asphyxiation O O
and O O
whole O O
brains O O
were O O
collected O O
. O O

Brains O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
homogenized O O
in O O
Hank O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_MEASURE
s O I_MEASURE
balanced O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
salt O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
HBSS O B_DISEASE/B_PROTEIN[GENE]
) O O
pH O B_MEASURE/B_LOCATION
7 O I_MEASURE/I_LOCATION
. O O
4 O B_MEASURE
. O O

Brain O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
homogenates O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
passed O O
through O O
a O O
70 O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mu O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
m O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nylon O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strainer O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
centrifuged O O
at O O
400 O B_MEASURE
x O O
g O B_OTHER/B_MEASURE
for O O
10 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
min O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Supernatants O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANIZATION
were O O
removed O O
and O O
cell O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pellets O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
re O O
- O O
suspended O O
in O O
70 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
isotonic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Percoll O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
GE O B_DISEASE/B_GENE
- O O
healthcare O B_NUMBER[MEASURE]/B_LOCATION
, O O
Uppsala O B_LOCATION
, O O
Sweden O B_LOCATION/B_MEASURE
) O O
at O O
room O B_MEASURE/B_LOCATION
temperature O B_MEASURE/I_LOCATION
. O O

A O O
discontinuous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Percoll O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
density O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gradient O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
set O O
up O O
as O O
follows O O
: O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
35 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
and O O
0 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
isotonic O I_MEASURE/I_LOCATION
Percoll O I_MEASURE/I_LOCATION
. O O

This O O
suspension O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
centrifuged O O
for O O
30 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
minutes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
400 O B_MEASURE
x O O
g O B_OTHER/B_MEASURE
. O O

A O O
mixed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
CNS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
collected O O
from O O
the O O
interphase O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
between O O
the O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
and O O
35 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
Percoll O I_MEASURE/I_LOCATION
layers O I_MEASURE/I_LOCATION
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
washed O O
and O O
then O O
re O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
suspended O O
in O O
sterile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
HBSS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
number O B_MEASURE/B_LOCATION
of O O
viable O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
was O O
determined O O
using O O
a O O
hemacytometer O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
0 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
trypan O I_MEASURE
blue O I_MEASURE
staining O I_MEASURE
. O O

Flow O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometry O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Flow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometric O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
microglial O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
surface O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
markers O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
performed O O
as O O
described O O
previously O O
, O O
but O O
with O O
a O O
few O B_MEASURE/B_PERSON
modifications O I_MEASURE/I_PERSON
[ O O
48 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

In O O
brief O B_MEASURE
, O O
Fc O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
blocked O O
with O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
CD16 O B_GENE
/ O O
CD32 O B_GENE/B_MEASURE
antibody O I_GENE/I_MEASURE
( O O
eBiosciences O B_LOCATION/B_ORGANIZATION
, O O
CA O B_LOCATION/B_MEASURE
) O O
. O O

Next O O
, O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
incubated O O
with O O
either O O
Panel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O B_NUMBER[MEASURE]
( O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
CD11b O B_GENE
APC O I_GENE
, O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
CD45 O B_GENE
FITC O I_GENE
, O O
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
MHC O B_GENE
II O I_GENE
PE O I_GENE
from O O
eBiosciences O B_LOCATION/B_ORGANIZATION
, O O
CA O B_LOCATION
) O O
or O O
Panel O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_MEASURE/B_PROTEIN[GENE]
antibodies O I_MEASURE/I_PROTEIN[GENE]
( O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
CD11b O B_GENE
APC O I_GENE
, O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
CD45 O B_GENE
FITC O I_GENE
, O O
and O O
anti O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
TLR2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PE O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
eBiosciences O B_LOCATION/B_ORGANIZATION
, O O
CA O B_LOCATION
) O O
. O O

Expression O B_GENE/B_MEASURE
of O O
these O O
surface O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
determined O O
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
a O O
Becton O B_PERSON/B_LOCATION
- O O
Dickinson O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FACSCaliber O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
four O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
color O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Cytometer O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Thirty O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
thousand O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
events O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O O
collected O O
and O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
differentiated O O
from O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
based O O
on O O
the O O
levels O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
CD11b O B_GENE
and O O
CD45 O B_GENE
surface O I_GENE
expression O I_GENE
. O O

Microglia O B_GENE
stain O I_GENE
CD11b O I_GENE
+ O I_GENE
/ O O
CD45low O B_GENE
and O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stain O O
CD11b O B_GENE
+ O I_GENE
/ O O
CD45high O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
[ O O
48 O B_MEASURE
, O O
49 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Flow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
analyzed O O
using O O
FlowJo O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Tree O B_MEASURE/B_ORGANIZATION
Star O I_MEASURE/I_ORGANIZATION
, O O
San O B_LOCATION/B_PERSON
Carlos O I_LOCATION/I_PERSON
, O O
CA O B_LOCATION/B_MEASURE
) O O
. O O

Behavior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Social O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exploratory O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

To O O
assess O O
the O O
motivation O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
engage O O
in O O
social O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exploratory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
novel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
juvenile O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conspecific O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
introduced O O
into O O
the O O
test O B_PERSON/B_BIO
subject O B_PERSON/I_BIO
' O O
s O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
home O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
cage O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
for O O
a O O
10 O B_NUMBER[MEASURE]
- O O
min O B_TIME[MEASURE]/B_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
. O O

Behavior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
video O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
taped O O
and O O
the O O
cumulative O B_MEASURE/B_LOCATION
amount O I_MEASURE/I_LOCATION
of O O
time O B_TIME[MEASURE]
the O O
subject O B_PERSON/B_ORGANIZATION
engaged O O
in O O
social O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
investigation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
was O O
determined O O
from O O
the O O
video O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
by O O
a O O
trained O O
observer O B_PERSON
who O O
was O O
blind O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Baseline O B_DISEASE
social O I_DISEASE
behavior O I_DISEASE
was O O
measured O O
at O O
time O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
0 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O O
all O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Social O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
determined O O
as O O
the O O
amount O B_MEASURE
of O O
time O B_TIME[MEASURE]
that O O
the O O
experimental O B_PERSON
subject O I_PERSON
spent O O
investigating O O
( O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
, O O
anogenital O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sniffing O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
trailing O O
) O O
the O O
juvenile O B_PERSON/B_BIO
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
expressed O O
as O O
percent O B_MEASURE
decrease O I_MEASURE
in O O
time O B_TIME[MEASURE]/B_PERSON
engaged O O
in O O
social O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
behavior O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
compared O O
to O O
respective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
baseline O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
measures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O

Sucrose O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

To O O
assess O O
sucrose O O
preference O O
, O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
provided O O
two O O
solutions O O
, O O
water O O
or O O
water O O
supplemented O O
with O O
2 O O
% O O
sucrose O O
, O O
in O O
50 O O
ml O O
conical O O
tubes O O
with O O
stoppers O O
fitted O O
with O O
ball O O
- O O
type O O
sipper O O
tubes O O
. O O

Prior O O
to O O
testing O O
conditions O O
, O O
all O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
acclimated O O
to O O
the O O
two O O
bottle O O
test O O
choice O O
. O O

All O O
mice B B_BIO/B_PERSON
drank O O
both O O
the O O
water O O
and O O
the O O
2 O O
% O O
sucrose O O
solution O O
, O O
but O O
preferred O O
drinking O O
the O O
sucrose O O
over O O
the O O
water O O
( O O
data O O
not O O
shown O O
) O O
. O O

On O O
the O O
day O O
of O O
testing O O
, O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
fluid O O
and O O
food O O
deprived O O
for O O
2 O O
h O O
prior O O
to O O
testing O O
[ O O
50 O O
] O O
. O O

At O O
the O O
start O B_LOCATION/B_TIME[MEASURE]
of O O
the O O
dark O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
phase O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
photoperiod O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
, O O
drinking O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
the O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sucrose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
solution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
placed O O
in O O
the O O
home O B_LOCATION
cage O I_LOCATION
overnight O O
( O O
15 O B_MEASURE
h O O
) O O
. O O

At O O
the O O
end O B_LOCATION/B_DISEASE
of O O
each O O
testing O B_TIME[MEASURE]/B_LOCATION
period O B_TIME[MEASURE]/I_LOCATION
the O O
fluid O B_MEASURE/B_LOCATION
content O I_MEASURE/I_LOCATION
of O O
the O O
conical O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
tubes O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
measured O O
and O O
sucrose O B_DISEASE/B_MEASURE
preference O I_DISEASE/I_MEASURE
was O O
determined O O
using O O
the O O
equation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Sucrose O B_MEASURE/B_LOCATION
intake O I_MEASURE/I_LOCATION
/ O O
Total O B_MEASURE/B_LOCATION
fluid O I_MEASURE/I_LOCATION
intake O I_MEASURE/I_LOCATION
( O O
water O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
sucrose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
x O B_MEASURE/B_LOCATION
100 O I_MEASURE/I_LOCATION
[ O O
51 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Plasma O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytokine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
were O O
measured O O
in O O
the O O
plasma O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
as O O
previously O O
described O O
[ O O
52 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

In O O
brief O O
, O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
euthanized O O
by O O
CO2 O O
asphyxiation O O
and O O
blood O O
was O O
collected O O
by O O
cardiac O O
puncture O O
into O O
EDTA O O
coated O O
syringes O O
. O O

Samples O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
centrifuged O O
( O O
6000 O B_MEASURE
x O O
g O B_OTHER/B_MEASURE
for O O
15 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
4 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
) O O
and O O
plasma O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O O
collected O O
and O O
stored O O
frozen O O
( O O
- O O
80 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
) O O
until O O
assaying O O
. O O

Plasma O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
assayed O O
for O O
IL O B_LOCATION/B_GENE
- O O
6 O B_NUMBER[MEASURE]
using O O
a O O
customized O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
we O O
have O O
described O O
in O O
detail O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
52 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
and O O
for O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
using O O
a O O
commercial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ELISA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kit O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Systems O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Minneapolis O B_LOCATION/B_PERSON
, O O
MN O B_LOCATION
) O O
. O O

Assays O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
8 O B_MEASURE
pg O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
of O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
and O O
1 O B_MEASURE
. O O
5 O B_MEASURE
pg O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
of O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
, O O
and O O
inter O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
assay O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
variation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
less O B_MEASURE
than O O
10 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Real O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
time O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
PCR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]

Total O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
isolated O O
from O O
brain O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
using O O
the O O
Tri O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Reagent O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
protocol O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Sigma O B_GENE
, O O
St O B_LOCATION/B_PERSON
. O O
Louis O B_PERSON
, O O
MO O B_LOCATION/B_MEASURE
) O O
. O O

RNA O B_PERSON/B_GENE
samples O I_PERSON/I_GENE
were O O
subjected O O
to O O
a O O
DNase O B_GENE/B_MEASURE
I O O
digestion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
then O O
reverse O O
transcribed O O
to O O
cDNA O B_GENE
using O O
a O O
RT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RETROscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Ambion O B_PERSON/B_TIME[MEASURE]
, O O
Austin O B_LOCATION/B_PERSON
, O O
TX O B_MEASURE/B_LOCATION
) O O
. O O

Quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
real O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
using O O
the O O
Applied O B_ORGANIZATION/B_TIME[MEASURE]
Biosystems O B_ORGANIZATION/I_TIME[MEASURE]
( O O
Foster O B_PERSON/B_LOCATION
, O O
CA O B_LOCATION/B_MEASURE
) O O
Assay O B_LOCATION/B_PERSON
- O O
on O O
Demand O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Gene O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
protocol O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
previously O O
described O O
[ O O
13 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

In O O
brief O B_MEASURE
, O O
cDNA O B_GENE
was O O
amplified O O
by O O
real O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
time O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
where O O
a O O
target O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE/B_PROTEIN[GENE]
beta O I_MEASURE/I_PROTEIN[GENE]
, O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
, O O
MHC O B_GENE
II O I_GENE
, O O
TLR2 O B_GENE
, O O
or O O
IDO O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
a O O
reference O B_GENE
cDNA O I_GENE
( O O
glyceraldehyde O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
3 O B_NUMBER[MEASURE]
- O O
phosphate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
dehydrogenase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
) O O
were O O
amplified O O
simultaneously O O
using O O
an O O
oligonucleotide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
probe O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
a O O
5 O B_NUMBER[MEASURE]
' O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reporter O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O B_MEASURE/B_LOCATION
- O O
FAM O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
a O O
3 O B_MEASURE
' O O
quencher O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NFQ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
. O O

Fluorescence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
determined O O
on O O
an O O
ABI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PRISM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
7300 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
sequence O B_MEASURE
detection O I_MEASURE
system O I_MEASURE
( O O
Applied O B_LOCATION/B_ORGANIZATION
Biosystems O I_LOCATION/I_ORGANIZATION
, O O
CA O B_LOCATION/B_MEASURE
) O O
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
analyzed O O
using O O
the O O
comparative O B_MEASURE
threshold O I_MEASURE
cycle O I_MEASURE
( O O
Ct O B_LOCATION
) O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
expressed O O
as O O
fold O B_MEASURE
difference O I_MEASURE
. O O

Experimental O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocols O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

For O O
the O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
prepared O O
in O O
dimethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfoxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
and O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
were O O
washed O O
and O O
replenished O O
with O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediumsupplemented O O
with O O
0 O B_MEASURE
, O O
25 O B_MEASURE
, O O
50 O B_MEASURE
, O O
100 O B_MEASURE
, O O
200 O B_MEASURE
, O O
or O O
400 O B_MEASURE
mu O I_MEASURE
g O I_MEASURE
/ O O
ml O B_MEASURE
minocycline O I_MEASURE
. O O

After O O
30 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
min O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O O
LPS O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
10 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
was O O
added O O
to O O
the O O
culture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
medium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

Supernatants O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPORT[ENT]
were O O
collected O O
4 O B_NUMBER[MEASURE]
h O O
later O O
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_NUMBER[MEASURE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
concentrations O I_MEASURE
were O O
determined O O
by O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Total O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
proteins O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
determined O O
from O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
culture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
homogenates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
by O O
the O O
Bio O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Rad O B_PERSON/B_LOCATION
Dc O I_PERSON/I_LOCATION
protein O I_PERSON/I_LOCATION
assay O I_PERSON/I_LOCATION
according O O
to O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
instructions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
Bio O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
Rad O B_ORGANIZATION/B_PERSON
Lboratories O B_ORGANIZATION/I_PERSON
, O O
Hercules O B_PERSON/B_LOCATION
, O O
CA O B_LOCATION/B_ORGANIZATION
) O O
. O O

Each O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
replicated O O
a O O
minimum O B_MEASURE/B_LOCATION
of O O
four O B_TIME[MEASURE]/B_ENT
times O I_TIME[MEASURE]/I_ENT
. O O

Cell O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
viability O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
the O O
MTS O B_ORGANIZATION/B_PERSON
cell O I_ORGANIZATION/I_PERSON
proliferation O I_ORGANIZATION/I_PERSON
assay O I_ORGANIZATION/I_PERSON
according O O
to O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
instructions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
Promega O B_LOCATION/B_PERSON
, O O
Madison O B_PERSON/B_LOCATION
, O O
WI O B_MEASURE/B_LOCATION
) O O
. O O

For O O
all O O
mouse B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies O O
, O O
minocycline O O
( O O
Sigma O O
, O O
St O O
. O O
Louis O O
, O O
MO O O
) O O
was O O
dissolved O O
in O O
sterile O O
water O O
and O O
sonicated O O
to O O
ensure O O
complete O O
solubilization O O
. O O

In O O
the O O
first O O
mouse B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
study O O
, O O
adult O O
male O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O O
an O O
intraperitoneal O O
( O O
i O O
. O O
p O O
. O O
) O O
injection O O
of O O
vehicle O O
or O O
minocycline O O
( O O
50 O O
mg O O
/ O O
kg O O
) O O
for O O
three O O
consecutive O O
days O O
. O O

On O O
the O O
3rd O O
day O O
, O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
also O O
injected O O
i O O
. O O
p O O
. O O
with O O
saline O O
or O O
Escherichia B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coli I B_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS O O
( O O
0 O O
. O O
33 O O
mg O O
/ O O
kg O O
; O O
serotype O O
0127 O O
: O O
B8 O O
, O O
Sigma O O
, O O
St O O
. O O
Louis O O
, O O
MO O O
) O O
and O O
were O O
euthanized O O
by O O
CO2 O O
asphyxiation O O
24 O O
h O O
later O O
( O O
n O O
= O O
6 O O
) O O
. O O

The O O
LPS O O
dosage O O
was O O
selected O O
because O O
it O O
elicits O O
a O O
proinflammatory O O
cytokine O O
response O O
in O O
the O O
brain O O
resulting O O
in O O
mild O O
transient O O
sickness O O
behavior O O
in O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
13 O O
, O O
53 O O
] O O
. O O

Macrophage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O O
microglial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
isolated O O
from O O
whole O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
homogenates O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
TLR2 O B_GENE
and O O
MHC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
surface O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
determined O O
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
minocycline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
injection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regimen O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
dosage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O O
selected O O
because O O
a O O
repeated O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
course O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
necessary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
attenuate O O
neuroinflammation O B_DISEASE
[ O O
41 O B_MEASURE
- O O
43 O B_MEASURE
, O O
45 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

In O O
the O O
second O O
study O O
, O O
adult O O
male O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O O
an O O
i O O
. O O
p O O
. O O
injection O O
with O O
vehicle O O
or O O
minocycline O O
for O O
three O O
consecutive O O
days O O
. O O

On O O
the O O
third O B_TIME[MEASURE]/B_LOCATION
day O B_TIME[MEASURE]/I_LOCATION
, O O
motivation O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
engage O O
in O O
social O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
determined O O
immediately O O
before O O
i O O
. O O
p O B_MEASURE/B_LOCATION
. O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE
. O O
33 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_TIME[MEASURE]
) O O
and O O
again O O
2 O B_NUMBER[MEASURE]/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
, O O
8 O B_NUMBER[MEASURE]
, O O
12 O B_MEASURE
, O O
and O O
24 O B_MEASURE
h O I_MEASURE
later O O
( O O
n O B_OTHER/B_MEASURE
= O O
8 O B_MEASURE
) O O
. O O

Body O B_TIME[MEASURE]/B_LOCATION
weight O I_TIME[MEASURE]/I_LOCATION
and O O
food O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
measured O O
at O O
each O O
time O B_TIME[MEASURE]/B_LOCATION
point O I_TIME[MEASURE]/I_LOCATION
over O O
the O O
24 O B_MEASURE
h O O
period O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
a O O
related O O
, O O
but O O
separate O O
study O O
, O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
treated O O
with O O
minocycline O O
and O O
LPS O O
as O O
described O O
and O O
anhedonia O O
was O O
assessed O O
24 O O
- O O
39 O O
h O O
following O O
i O O
. O O
p O O
. O O
injection O O
of O O
saline O O
or O O
LPS O O
( O O
0 O O
. O O
33 O O
mg O O
/ O O
kg O O
) O O
( O O
n O O
= O O
15 O O
) O O
. O O

Body O B_TIME[MEASURE]/B_LOCATION
weight O I_TIME[MEASURE]/I_LOCATION
, O O
food O B_DISEASE/B_ORGANISM_FUNCTION
intake O I_DISEASE/I_ORGANISM_FUNCTION
, O O
water O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
intake O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
and O O
sucrose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
intake O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
were O O
determined O O
over O O
the O O
testing O B_TIME[MEASURE]
period O I_TIME[MEASURE]
. O O

In O O
the O O
third O O
study O O
, O O
adult O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
treated O O
with O O
minocycline O O
and O O
then O O
LPS O O
as O O
described O O
. O O

Mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
euthanized O O
by O O
CO2 O O
asphyxiation O O
4 O O
later O O
. O O

Brains O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
removed O O
and O O
dissected O O
to O O
collect O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
brain O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
regions O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Brain O B_PERSON
regions O I_PERSON
were O O
stored O O
at O O
- O O
20 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
in O O
RNAlater O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Qiagen O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION/B_MEASURE
) O O
. O O

Total O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
isolated O O
from O O
brain O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
assayed O O
using O O
quantitative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
n O B_OTHER/B_MEASURE
= O O
8 O B_MEASURE
) O O
. O O

Plasma O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O O
also O O
collected O O
and O O
stored O O
( O O
- O O
80 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
) O O
until O O
assaying O O
. O O

In O O
a O O
final O O
study O O
, O O
adult O O
( O O
3 O O
- O O
4 O O
month O O
old O O
) O O
or O O
aged O O
( O O
20 O O
- O O
22 O O
month O O
old O O
) O O
male O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
treated O O
with O O
minocycline O O
and O O
LPS O O
as O O
described O O
and O O
euthanized O O
4 O O
h O O
later O O
. O O

Brains O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
dissected O O
to O O
collect O O
different O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
regions O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
were O O
stored O O
at O O
- O O
20 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
in O O
RNAlater O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Qiagen O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION/B_MEASURE
) O O
. O O

Total O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
isolated O O
from O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
assayed O O
using O O
quantitative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
n O B_OTHER/B_MEASURE
= O O
8 O B_MEASURE
) O O
. O O

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]

All O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
analyzed O O
using O O
Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Systems O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
SAS O B_LOCATION/B_DISEASE
) O O
General O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Linear O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
procedures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
subjected O O
to O O
one O B_NUMBER[MEASURE]/B_PERSON
, O O
two O B_NUMBER[MEASURE]/B_PERSON
- O O
( O O
Mino O B_PERSON/B_TIME[MEASURE]
x O O
LPS O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Age O B_TIME[MEASURE]/B_PERSON
x O O
LPS O B_TIME[MEASURE]/B_PERSON
, O O
Mino O B_PERSON/B_TIME[MEASURE]
x O O
Age O B_TIME[MEASURE]/B_LOCATION
) O O
or O O
three O B_NUMBER[MEASURE]
- O O
way O B_LOCATION/B_MEASURE
( O O
Mino O B_PERSON/B_TIME[MEASURE]
x O O
LPS O B_TIME[MEASURE]/B_LOCATION
x O O
Time O B_TIME[MEASURE]/B_PERSON
, O O
Mino O B_PERSON/B_TIME[MEASURE]
x O O
LPS O B_TIME[MEASURE]/B_LOCATION
x O O
Age O B_TIME[MEASURE]/B_LOCATION
) O O
ANOVA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
determine O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
main O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
interactions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O O
main O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

When O O
appropriate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
means O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
evaluated O O
by O O
an O O
F O B_OTHER/B_MEASURE
- O O
protected O O
t O B_OTHER/B_MEASURE
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
using O O
the O O
Least O O
- O O
Significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Difference O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
SAS O B_LOCATION/B_DISEASE
. O O

All O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
expressed O O
as O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
means O O
+/- O O
standard O B_MEASURE
error O I_MEASURE
of O O
the O O
mean O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SEM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
attenuates O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cytokine O B_DISEASE/B_GENE
production O I_DISEASE/I_GENE
in O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_LOCATION
microglia O I_LOCATION

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
tetracycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
type O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibiotic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
has O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
CNS O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
[ O O
41 O B_MEASURE
- O O
43 O B_MEASURE
, O O
45 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

To O O
determine O O
the O O
degree O B_MEASURE/B_LOCATION
to O O
which O O
minocycline O B_DISEASE_ADJECTIVE[DISEASE]
suppresses O I_DISEASE_ADJECTIVE[DISEASE]
microglia O O
activation O B_GENE/B_DISEASE
, O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_MEASURE
microglia O I_MEASURE
- O O
derived O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lines O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
used O O
. O O

In O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
were O O
treated O O
with O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
IL O B_LOCATION/B_GENE
- O O
6 O B_MEASURE/B_ORGANIZATION
production O I_MEASURE/I_ORGANIZATION
was O O
determined O O
4 O B_MEASURE
h O O
later O O
. O O

Fig O B_BIO/B_GENE
. O O

1A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
shows O O
that O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE/B_ORGANIZATION
production O I_MEASURE/I_ORGANIZATION
in O O
a O O
dose O B_MEASURE/B_LOCATION
dependent O I_MEASURE/I_LOCATION
manner O I_MEASURE/I_LOCATION
F O I_MEASURE/I_LOCATION
( O O
5 O B_MEASURE
, O O
23 O B_MEASURE
) O O
= O O
101 O B_MEASURE
, O O
P O B_OTHER/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

In O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
were O O
incubated O O
with O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
then O O
stimulated O O
with O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Minocycline O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE/B_ORGANIZATION
secretion O I_MEASURE/I_ORGANIZATION
in O O
a O O
dose O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Mino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
x O O
LPS O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
F O B_OTHER/B_LOCATION
( O O
4 O B_MEASURE
, O O
23 O B_MEASURE
) O O
= O O
16 O B_MEASURE
. O O
87 O B_MEASURE
, O O
P O B_OTHER/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
, O O
Fig O B_MEASURE/B_GENE
. O O
1B O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
had O O
a O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
stimulated O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
secretion O I_MEASURE
( O O
Fig O B_PROTEIN[GENE]/B_MEASURE
. O O
1C O B_MEASURE/B_PROTEIN[GENE]
) O O
. O O

In O O
a O O
third O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suppressed O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
MHC O B_GENE
II O I_GENE
, O O
TLR2 O B_GENE
, O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE/B_PROTEIN[GENE]
beta O I_MEASURE/I_PROTEIN[GENE]
, O O
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
mRNA O I_MEASURE
levels O I_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
, O O
for O O
each O O
, O O
Fig O B_MEASURE/B_GENE
. O O
1D O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

The O O
MTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
verified O O
that O O
neither O O
cell O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
survival O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
affected O O
by O O
the O O
experimental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatments O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

LPS O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
TLR2 O B_DISEASE_ADJECTIVE[DISEASE]
surface O I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
on O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
reduced O O
by O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

Because O O
minocycline O O
attenuated O O
LPS O O
- O O
induced O O
cytokine O O
secretion O O
and O O
TLR2 O O
mRNA O O
expression O O
in O O
BV O O
- O O
2 O O
cells O O
we O O
next O O
sought O O
to O O
determine O O
if O O
minocycline O O
suppresses O O
markers O O
of O O
microglial O O
activation O O
in O O
the O O
brain O O
of O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
injected O O
i O O
. O O
p O O
. O O
with O O
vehicle O O
or O O
minocycline O O
for O O
3 O O
consecutive O O
days O O
then O O
challenged O O
with O O
saline O O
or O O
LPS O O
i O O
. O O
p O O
. O O

Markers O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
activation O B_GENE/B_DISEASE
, O O
TLR2 O B_GENE
and O O
MHC O B_GENE
II O I_GENE
, O O
were O O
determined O O
on O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
collected O O
24 O B_MEASURE
h O O
later O O
. O O

The O O
representative O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
bivariate O O
density O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Fig O B_LOCATION/B_GENE
. O O

2A O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
shows O O
that O O
there O O
were O O
two O B_MEASURE/B_LOCATION
populations O I_MEASURE/I_LOCATION
of O O
CD11b O B_GENE
/ O O
CD45 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
positive O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
that O O
more O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
stained O O
CD11b O B_GENE
+ O I_GENE
/ O O
CD45low O B_GENE/B_DISEASE
( O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
than O O
CD11b O B_GENE/B_DISEASE
+ O I_GENE/I_DISEASE
/ O O
CD45high O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
CNS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

ANOVA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
revealed O O
that O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increased O O
TLR2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
20 O B_MEASURE
) O O
= O O
17 O B_MEASURE
. O O
6 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
004 O B_MEASURE
, O O
Fig O B_GENE
. O O
2B O B_PROTEIN[GENE]
& O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
but O O
this O O
induction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
abrogated O O
by O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Tendency O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Mino O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x O O
LPS O B_DISEASE/B_GENE
interaction O B_DISEASE/I_GENE
, O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
20 O B_MEASURE
) O O
= O O
2 O B_MEASURE
. O O
66 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
10 O B_MEASURE
, O O
Fig O B_MEASURE/B_GENE
. O O
2C O B_PROTEIN[GENE]/B_DISEASE
& O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

It O O
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
note O O
that O O
because O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
differ O O
in O O
their O O
TLR2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
these O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
grouped O O
together O O
as O O
the O O
Control O B_MEASURE/B_ORGANIZATION
group O I_MEASURE/I_ORGANIZATION
( O O
Fig O B_PROTEIN[GENE]/B_DISEASE
. O O
2B O B_MEASURE/B_PROTEIN[GENE]
& O O
C O B_PROTEIN[GENE]
) O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
neither O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nor O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
significant O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
main O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
MHC O B_DISEASE_ADJECTIVE[DISEASE]
class O I_DISEASE_ADJECTIVE[DISEASE]
II O I_DISEASE_ADJECTIVE[DISEASE]
surface O I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
on O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attenuated O O
LPS O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
TLR2 O B_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
on O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
facilitates O O
the O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
sickness O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

CNS O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
macrophages O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
produce O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_DISEASE_ADJECTIVE[DISEASE]
and O O
secondary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
messengers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
modulate O O
behavioral O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
we O O
next O O
investigated O O
if O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O O
the O O
sickness O B_DISEASE
response O I_DISEASE
associated O O
with O O
peripheral O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LPS O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
this O O
experiment O O
, O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
treated O O
with O O
minocycline O O
and O O
LPS O O
as O O
described O O
. O O

Social O B_DISEASE/B_PERSON
exploratory O I_DISEASE/I_PERSON
behavior O I_DISEASE/I_PERSON
was O O
measured O O
before O O
i O O
. O O
p O B_MEASURE/B_LOCATION
. O O

LPS O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
again O O
2 O B_SEQUENCE[MEASURE]
, O O
4 O B_SEQUENCE[MEASURE]
, O O
8 O B_MEASURE
, O O
and O O
24 O B_MEASURE
h O I_MEASURE
later O O
. O O

Fig O B_BIO/B_GENE
. O O

3A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
shows O O
that O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
caused O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
social O B_DISEASE
exploratory O I_DISEASE
behavior O I_DISEASE
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
57 O B_MEASURE
) O O
= O O
218 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
that O O
was O O
time O B_DISEASE_ADJECTIVE[DISEASE]
dependent O I_DISEASE_ADJECTIVE[DISEASE]
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
4 O B_NUMBER[MEASURE]
, O O
57 O B_MEASURE
) O O
= O O
66 O B_MEASURE
. O O
5 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Moreover O O
, O O
the O O
LPS O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]
in O O
social O B_DISEASE/B_GENE
exploration O I_DISEASE/I_GENE
was O O
attenuated O O
by O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Mino O B_PERSON/B_LOCATION
x O O
LPS O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
F O B_OTHER/B_PROTEIN[GENE]
( O O
1 O B_MEASURE
, O O
57 O B_MEASURE
) O O
= O O
7 O B_MEASURE
. O O
5 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
007 O B_MEASURE
) O O
. O O

For O O
example O O
, O O
at O O
8 O O
h O O
post O O
LPS O O
, O O
social O O
exploration O O
was O O
reduced O O
by O O
35 O O
% O O
in O O
minocycline O O
pretreated O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
LPS O O
compared O O
to O O
a O O
67 O O
% O O
reduction O O
in O O
vehicle O O
pretreated O O
mice B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
LPS O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

While O O
minocycline O O
administration O O
alone O O
reduced O O
food O O
intake O O
and O O
body O O
weight O O
in O O
control O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O O
< O O
0 O O
. O O
05 O O
, O O
for O O
each O O
) O O
, O O
it O O
also O O
protected O O
against O O
LPS O O
- O O
associated O O
anorexia O O
( O O
Mino O O
x O O
LPS O O
interaction O O
, O O
F O O
( O O
1 O O
, O O
60 O O
) O O
= O O
70 O O
. O O
0 O O
, O O
P O O
< O O
0 O O
. O O
001 O O
, O O
Fig O O
. O O
3B O O
) O O
and O O
weight O O
loss O O
( O O
Mino O O
x O O
LPS O O
interaction O O
, O O
F O O
( O O
1 O O
, O O
60 O O
) O O
= O O
29 O O
. O O
7 O O
, O O
P O O
< O O
0 O O
. O O
001 O O
, O O
Fig O O
. O O
3C O O
) O O
. O O

Because O O
sickness O B_DISEASE
can O O
also O O
be O O
associated O O
with O O
longer O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lasting O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
motivation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O O
38 O B_MEASURE
] O I_MEASURE
, O O
we O O
next O O
sought O O
to O O
determine O O
if O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
abrogated O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
anhedonia O B_DISEASE
[ O O
54 O B_MEASURE
, O O
55 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

In O O
this O O
experiment O O
, O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
subjected O O
to O O
the O O
same O O
minocycline O O
injection O O
regimen O O
and O O
LPS O O
challenge O O
as O O
above O O
and O O
sucrose O O
preference O O
was O O
assessed O O
24 O O
- O O
39 O O
h O O
post O O
LPS O O
injection O O
. O O

By O O
24 O O
h O O
post O O
LPS O O
injection O O
, O O
food O O
and O O
water O O
intake O O
returned O O
to O O
baseline O O
and O O
LPS O O
treated O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O O
exhibited O O
a O O
marked O O
reduction O O
in O O
sucrose O O
preference O O
from O O
24 O O
- O O
39 O O
h O O
( O O
F O O
( O O
1 O O
, O O
59 O O
) O O
= O O
14 O O
. O O
3 O O
, O O
P O O
< O O
0 O O
. O O
003 O O
) O O
. O O

Moreover O O
, O O
this O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
sucrose O B_DISEASE/B_GENE
preference O I_DISEASE/I_GENE
was O O
prevented O O
by O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Mino O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
F O B_OTHER/B_PROTEIN[GENE]
( O O
1 O B_MEASURE
, O O
59 O B_MEASURE
) O O
= O O
9 O B_MEASURE
. O O
9 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
004 O B_MEASURE
, O O
Fig O B_MEASURE/B_GENE
. O O
4 O B_NUMBER[MEASURE]
) O O
. O O

For O O
example O O
, O O
minocycline O O
pretreated O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injected O O
with O O
LPS O O
maintained O O
the O O
same O O
strong O O
preference O O
for O O
sucrose O O
as O O
saline O O
and O O
minocycline O O
controls O O
( O O
i O O
. O O
e O O
. O O
, O O
approximately O O
85 O O
% O O
preference O O
) O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
interpreted O O
to O O
indicate O O
that O O
minocycline O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocks O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anhedonia O O
associated O O
with O O
peripheral O B_DISEASE
LPS O I_DISEASE
challenge O I_DISEASE
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reduces O O
LPS O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
neuroinflammation O B_DISEASE

Pro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
CNS O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
are O O
partially O O
responsible O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
behavioral O B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
of O O
sickness O B_DISEASE/B_LOCATION
( O O
e O B_PROTEIN[GENE]/B_DISEASE
. O O
g O B_GENE/B_MEASURE
. O O
, O O
anorexia O B_DISEASE
, O O
social O B_DISEASE
withdrawal O I_DISEASE
, O O
and O O
anhedonia O B_DISEASE
) O O
[ O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Therefore O O
, O O
we O O
investigated O O
the O O
degree O B_MEASURE/B_LOCATION
to O O
which O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O O
neuroinflammation O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE/B_PROTEIN[GENE]
beta O I_MEASURE/I_PROTEIN[GENE]
, O O
IL O B_LOCATION/B_GENE
- O O
6 O B_MEASURE
, O O
and O O
IDO O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
after O O
peripheral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
this O O
experiment O O
, O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
subjected O O
to O O
the O O
minocycline O O
injection O O
regimen O O
and O O
LPS O O
challenge O O
as O O
above O O
and O O
cytokine O O
mRNA O O
levels O O
were O O
determined O O
in O O
the O O
cortex O O
and O O
hippocampus O O
4 O O
h O O
after O O
LPS O O
injection O O
. O O

In O O
mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreated O O
with O O
vehicle O O
, O O
LPS O O
markedly O O
increased O O
IL O O
- O O
1 O O
beta O O
mRNA O O
levels O O
in O O
the O O
hippocampus O O
( O O
F O O
( O O
1 O O
, O O
31 O O
) O O
= O O
62 O O
, O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
and O O
cortex O O
( O O
F O O
( O O
1 O O
, O O
31 O O
) O O
= O O
17 O O
. O O
25 O O
, O O
P O O
< O O
0 O O
. O O
0003 O O
) O O
. O O

The O O
LPS O O
- O O
induced O O
IL O O
- O O
1 O O
beta O O
mRNA O O
expression O O
was O O
reduced O O
in O O
both O O
brain O O
regions O O
in O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O O
minocycline O O
prior O O
to O O
LPS O O
injection O O
: O O
( O O
hippocampus O O
, O O
F O O
( O O
1 O O
, O O
31 O O
) O O
= O O
9 O O
. O O
63 O O
, O O
P O O
< O O
0 O O
. O O
01 O O
) O O
and O O
cortex O O
, O O
F O O
( O O
1 O O
, O O
31 O O
) O O
= O O
7 O O
. O O
23 O O
, O O
P O O
= O O
0 O O
. O O
08 O O
, O O
Fig O O
. O O

5A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
. O O

LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
caused O O
a O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
mRNA O I_MEASURE
levels O I_MEASURE
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
31 O B_MEASURE
) O O
= O O
37 O B_MEASURE
. O O
2 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
and O O
cortex O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
31 O B_MEASURE
) O O
= O O
22 O B_MEASURE
. O O
5 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
, O O
but O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
only O O
significantly O O
attenuated O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
mRNA O I_MEASURE
levels O I_MEASURE
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
31 O B_MEASURE
) O O
= O O
10 O B_MEASURE
. O O
27 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
004 O B_MEASURE
, O O
Fig O B_MEASURE
. O O
5B O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

IDO O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mRNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
determined O O
from O O
the O O
same O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
pool O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Fig O B_BIO/B_GENE
. O O

6D O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
shows O O
that O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increased O O
IDO O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
31 O B_MEASURE
) O O
= O O
11 O B_MEASURE
. O O
69 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
and O O
cortex O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
31 O B_MEASURE
) O O
= O O
5 O B_MEASURE
. O O
26 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
03 O B_MEASURE
) O O
. O O

This O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
IDO O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
attenuated O O
by O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
31 O B_MEASURE
) O O
= O O
11 O B_MEASURE
. O O
69 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
and O O
cortex O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
31 O B_MEASURE
) O O
= O O
5 O B_MEASURE
. O O
26 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
03 O B_MEASURE
) O O
. O O

It O O
is O O
important O O
to O O
note O O
that O O
IDO O O
mRNA O O
was O O
undetected O O
in O O
saline O O
treated O O
mice B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Therefore O O
, O O
the O O
fold O O
IDO O O
change O O
was O O
relative O O
to O O
the O O
IDO O O
mRNA O O
levels O O
in O O
mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O O
minocycline O O
prior O O
to O O
LPS O O
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
, O O
but O O
not O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
, O O
in O O
the O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE

Because O O
cytokine O B_DISEASE/B_GENE
signals O I_DISEASE/I_GENE
can O O
be O O
relayed O O
from O O
the O O
periphery O B_BODY_PART_OR_ORGAN_COMPONENT
to O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O O
humoral O B_DISEASE/B_GENE
pathways O B_DISEASE/I_GENE
[ O O
56 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
, O O
plasma O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokine O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
were O O
determined O O
4 O B_MEASURE/B_LOCATION
h O O
post O B_MEASURE
LPS O I_MEASURE
injection O I_MEASURE
. O O

As O O
expected O O
, O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
caused O O
a O O
marked O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
plasma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
1 O B_MEASURE
beta O I_MEASURE
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
36 O B_MEASURE
) O O
= O O
52 O B_MEASURE
. O O
5 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
levels O I_MEASURE
( O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
36 O B_MEASURE
) O O
34 O B_MEASURE
. O O
01 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
levels O I_MEASURE
in O O
the O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
( O O
F O B_OTHER/B_PROTEIN[GENE]
( O O
1 O B_MEASURE
, O O
36 O B_MEASURE/B_LOCATION
) O O
6 O B_MEASURE
. O O
68 O B_MEASURE
, O O
P O B_OTHER/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
but O O
had O O
no O O
significant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
main O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
levels O I_MEASURE
( O O
Fig O B_MEASURE
. O O
6 O B_NUMBER[MEASURE]
) O O
. O O

Minocycline O O
attenuates O O
LPS O O
- O O
induced O O
exaggerated O O
neuroinflammation O O
in O O
aged O O
mice B B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]

Aged O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
22 O O
- O O
24 O O
m O O
) O O
have O O
an O O
exaggerated O O
neuroinflammatory O O
response O O
to O O
LPS O O
injection O O
[ O O
10 O O
, O O
13 O O
, O O
14 O O
] O O
. O O

Therefore O O
, O O
we O O
next O O
sought O O
to O O
determine O O
if O O
the O O
heightened O O
inflammatory O O
response O O
in O O
the O O
brain O O
of O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
by O O
minocycline O O
. O O

In O O
this O O
experiment O O
, O O
adult O O
and O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
subjected O O
to O O
the O O
minocycline O O
injection O O
regimen O O
and O O
LPS O O
challenge O O
as O O
above O O
. O O

As O O
we O O
have O O
reported O O
previously O O
, O O
MHC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
increased O O
by O O
age O B_DISEASE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
03 O B_MEASURE
, O O
Fig O B_MEASURE
. O O
7A O B_MEASURE
) O O
[ O O
13 O B_MEASURE
, O O
14 O B_MEASURE
] O I_MEASURE
, O O
but O O
MHC O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
unaffected O B_DISEASE_ADJECTIVE[DISEASE]
by O O
either O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
not O O
shown O O
) O O
. O O

Consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
with O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
in O O
Fig O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

2 O B_MEASURE/B_PERSON
, O O
ANOVA O B_NUMBER[MEASURE]/B_LOCATION
revealed O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
main O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
TLR2 O B_GENE
mRNA O I_GENE
expression O I_GENE
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
F O B_OTHER/B_LOCATION
( O O
1 O B_MEASURE
, O O
63 O B_NUMBER[MEASURE]
) O O
= O O
85 O B_MEASURE
. O O
5 O B_MEASURE
, O O
P O B_OTHER/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Moreover O O
, O O
LPS O O
caused O O
a O O
greater O O
increase O O
in O O
TLR2 O O
mRNA O O
in O O
the O O
hippocampus O O
of O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
adults O O
( O O
LPS O O
x O O
Age O O
interaction O O
, O O
F O O
( O O
1 O O
, O O
63 O O
) O O
= O O
12 O O
. O O
70 O O
, O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Furthermore O O
, O O
minocycline O O
pretreatment O O
attenuated O O
LPS O O
- O O
induced O O
TLR2 O O
mRNA O O
levels O O
in O O
both O O
adult O O
and O O
aged O O
mice B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
Mino O O
x O O
LPS O O
interaction O O
, O O
F O O
( O O
1 O O
, O O
63 O O
) O O
= O O
9 O O
. O O
02 O O
, O O
P O O
< O O
0 O O
. O O
004 O O
) O O
. O O

Parallel O O
to O O
the O O
results O O
for O O
TLR2 O O
, O O
LPS O O
caused O O
a O O
greater O O
increase O O
in O O
IL O O
- O O
1 O O
beta O O
and O O
IDO O O
mRNA O O
levels O O
in O O
hippocampus O O
of O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
adults O O
( O O
Age O O
x O O
LPS O O
, O O
F O O
( O O
1 O O
, O O
60 O O
) O O
= O O
8 O O
. O O
64 O O
, O O
P O O
< O O
0 O O
. O O
01 O O
for O O
IL O O
- O O
1 O O
beta O O
and O O
F O O
( O O
1 O O
, O O
60 O O
) O O
= O O
4 O O
. O O
0 O O
, O O
P O O
< O O
0 O O
. O O
05 O O
for O O
IDO O O
) O O
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
attenuated O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
mRNA O B_DISEASE_ADJECTIVE[DISEASE]
levels O I_DISEASE_ADJECTIVE[DISEASE]
of O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
( O O
Mino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
x O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
60 O B_MEASURE
) O O
= O O
8 O B_MEASURE
. O O
76 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
, O O
Fig O B_MEASURE/B_GENE
. O O
7C O B_MEASURE/B_PROTEIN[GENE]
) O O
and O O
IDO O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Mino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
x O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
F O B_PROTEIN[GENE]/B_DISEASE
( O O
1 O B_NUMBER[MEASURE]
, O O
60 O B_MEASURE
) O O
= O O
9 O B_MEASURE
. O O
7 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
003 O B_MEASURE
, O O
Fig O B_MEASURE/B_GENE
. O O
7D O B_MEASURE/B_PERSON
) O O
. O O

While O O
LPS O O
induced O O
higher O O
IL O O
- O O
6 O O
mRNA O O
levels O O
in O O
the O O
hippocampus O O
of O O
both O O
adult O O
and O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
F O O
( O O
1 O O
, O O
59 O O
) O O
= O O
44 O O
. O O
5 O O
, O O
P O O
< O O
0 O O
. O O
001 O O
) O O
, O O
there O O
was O O
not O O
an O O
Age O O
x O O
LPS O O
interaction O O
. O O

Minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O O
the O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
hippocampal O B_GENE
IL O I_GENE
- O O
6 O B_MEASURE
mRNA O I_MEASURE
( O O
Mino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
x O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
F O B_OTHER/B_PROTEIN[GENE]
( O O
1 O B_MEASURE
, O O
59 O B_MEASURE
) O O
= O O
5 O B_MEASURE
. O O
4 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
02 O B_MEASURE
, O O
Fig O B_MEASURE
. O O
7E O B_MEASURE
) O O
. O O

Taken O O
together O O
these O O
data O O
indicate O O
that O O
minocycline O O
pretreatment O O
was O O
effective O O
in O O
attenuating O O
the O O
exaggerated O O
neuroinflammation O O
in O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
the O O
elderly O B_PERSON/B_DISEASE
, O O
systemic O B_DISEASE
infection O I_DISEASE
is O O
associated O O
with O O
an O O
increased O O
frequency O B_MEASURE/B_LOCATION
of O O
behavioral O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cognitive O B_DISEASE
complications O I_DISEASE
[ O I_DISEASE
57 O I_DISEASE
, O O
58 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

We O O
have O O
reported O O
that O O
stimulation O O
of O O
the O O
peripheral O O
immune O O
system O O
in O O
older O O
( O O
20 O O
- O O
24 O O
m O O
) O O
BALB O O
/ O O
c O O
mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O O
exaggerated O O
neuroinflammation O O
that O O
is O O
paralleled O O
by O O
prolonged O O
sickness O O
[ O O
13 O O
] O O
, O O
impaired O O
working O O
memory O O
[ O O
10 O O
] O O
, O O
and O O
depressive O O
- O O
like O O
behaviors O O
[ O O
15 O O
] O O
. O O

Therefore O O
, O O
it O O
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
understand O O
the O O
mechanisms O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
can O O
modulate O O
cytokine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mediated O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
we O O
show O O
that O O
minocycline O O
treatment O O
reduced O O
LPS O O
- O O
induced O O
TLR2 O O
expression O O
in O O
BV O O
- O O
2 O O
cells O O
and O O
on O O
microglia O O
isolated O O
from O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Moreover O O
, O O
we O O
demonstrate O O
that O O
minocycline O O
was O O
effective O O
in O O
facilitating O O
the O O
recovery O O
from O O
LPS O O
- O O
induced O O
sickness O O
and O O
preventing O O
anhedonia O O
in O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Furthermore O O
, O O
we O O
show O O
that O O
minocycline O O
attenuated O O
LPS O O
- O O
induced O O
neuroinflammation O O
in O O
adults O O
and O O
normalized O O
the O O
exaggerated O O
neuroinflammation O O
in O O
aged O O
mice B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
using O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
support O O
the O O
notion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
attenuates O O
microglial O B_DISEASE
activation O I_DISEASE
and O O
limits O O
production O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
inflammatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediators O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
instance O B_PERSON/B_DISEASE
, O O
minocycline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pretreatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cultures O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
stimulated O O
cytokine O B_DISEASE_ADJECTIVE[DISEASE]
production O I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
dose O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
dependent O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
manner O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fig O B_PROTEIN[GENE]/B_LOCATION
. O O
1A O B_NUMBER[MEASURE]
) O O
. O O

In O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_LOCATION
cells O I_LOCATION
, O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O O
attenuated O O
mRNA O B_GENE
expression O I_GENE
of O O
inflammatory O B_GENE
genes O I_GENE
including O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
, O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
, O O
MHC O B_GENE
II O I_GENE
, O O
and O O
TLR2 O B_GENE
( O O
Fig O B_MEASURE/B_PROTEIN[GENE]
. O O
1D O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
BV O B_PROTEIN[GENE]/B_LOCATION
- O O
2 O B_MEASURE/B_PERSON
cells O I_MEASURE/I_PERSON
[ O O
44 O B_MEASURE
, O O
59 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Based O O
on O O
these O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
next O O
investigated O O
if O O
microglial O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
could O O
be O O
attenuated O O
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Because O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increases O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
production O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
we O O
expected O O
that O O
MHC O B_DISEASE
II O I_DISEASE
expression O I_DISEASE
would O O
also O O
be O O
increased O O
. O O

Contrary O B_PERSON
to O O
our O O
predictions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
neither O O
MHC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fig O B_MEASURE/B_LOCATION
. O O
7 O B_NUMBER[MEASURE]
) O O
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nor O O
MHC O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
surface O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
expression O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
CD11b O B_GENE
+ O I_GENE
/ O O
CD45low O B_MEASURE/B_GENE
) O O
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
were O O
increased O O
by O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
an O O
EAE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
model O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduced O O
microglial O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
MHC O B_GENE
II O I_GENE
[ O O
45 O B_MEASURE
] O I_MEASURE
, O O
but O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
key O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
that O O
the O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
EAE O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathology O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requires O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presentation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
MHC O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
60 O B_MEASURE
] O I_MEASURE
. O O

It O O
is O O
postulated O O
that O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
states O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
depend O O
on O O
the O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inflammatory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stimulus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
61 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Thus O O
, O O
in O O
situations O B_LOCATION
of O O
transient O B_DISEASE
peripheral O I_DISEASE
innate O I_DISEASE
immune O I_DISEASE
stimulation O I_DISEASE
, O O
markers O B_GENE/B_DISEASE
in O O
the O O
CNS O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
such O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
as O O
Toll O B_GENE
- O O
Like O B_GENE/B_DISEASE
receptors O I_GENE/I_DISEASE
[ O O
6 O B_GENE
] O I_GENE
may O O
be O O
indicative O B_DISEASE/B_PERSON
of O O
microglia O B_DISEASE
activation O I_DISEASE
. O O

In O O
support O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
premise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O O
that O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increases O O
TLR2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
CD11b O B_GENE
+ O I_GENE
/ O O
CD45low O B_MEASURE/B_GENE
) O O
, O O
which O O
is O O
inhibited O O
by O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Fig O B_MEASURE/B_PROTEIN[GENE]
. O O
2 O B_NUMBER[MEASURE]
) O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showing O O
that O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
LPS O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
challenge O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
increases O O
TLR2 O B_GENE
mRNA O I_GENE
in O O
the O O
brain O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
[ O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
6 O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
14 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Taken O O
together O O
our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
interpreted O O
to O O
suggest O O
that O O
minocycline O B_DISEASE/B_GENE
attenuates O I_DISEASE/I_GENE
pathways O I_DISEASE/I_GENE
associated O O
with O O
microglia O B_DISEASE/B_GENE
activation O I_DISEASE/I_GENE
following O O
peripheral O B_DISEASE
LPS O I_DISEASE
challenge O I_DISEASE
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
that O O
reduction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
neuroinflammation O B_DISEASE/B_GENE
by O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
facilitated O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
sickness O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
akin O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
to O O
our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
oxidant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
alpha O B_PROTEIN[GENE]
- O O
tocopherol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
52 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
an O O
NFKB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decoy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
62 O B_NUMBER[MEASURE]/B_LOCATION
] O I_NUMBER[MEASURE]/I_LOCATION
. O O

Consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
52 O B_MEASURE
, O O
53 O B_MEASURE
, O O
62 O B_MEASURE
, O O
63 O B_MEASURE
] O I_MEASURE
, O O
reductions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
neuroinflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fig O B_MEASURE/B_GENE
. O O
5 O B_NUMBER[MEASURE]
) O O
did O O
not O O
prevent O O
the O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
sickness O B_DISEASE
response O I_DISEASE
( O O
2 O B_NUMBER[MEASURE]
- O O
4 O B_MEASURE
h O O
) O O
, O O
but O O
rather O O
facilitated O O
the O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
sickness O B_DISEASE
( O O
8 O B_MEASURE
- O O
24 O B_MEASURE
h O I_MEASURE
) O O
( O O
Fig O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
3A O B_MEASURE
) O O
. O O

Recovery O B_TIME[MEASURE]/B_DISEASE
may O O
be O O
a O O
critical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
issue O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
because O O
brain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cytokines O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
corresponding O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
physiological O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
beneficial O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
host O B_PERSON/B_SPORT[ENT]
[ O I_PERSON/I_SPORT[ENT]
1 O I_PERSON/I_SPORT[ENT]
] O I_PERSON/I_SPORT[ENT]
. O O

The O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
maladaptive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurs O O
when O O
the O O
normally O O
transient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neuroinflammatory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
response O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
amplified O O
or O O
protracted O O
[ O O
64 O B_DISEASE_ADJECTIVE[DISEASE]
] O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Therefore O O
pharmacological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
that O O
attenuate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuroinflammatory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
do O O
not O O
completely O O
inhibit O O
them O O
, O O
may O O
be O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
preventing O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
more O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
and O O
long O O
- O O
lasting O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
cognitive O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
behavioral O B_DISEASE
complications O I_DISEASE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
sucrose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support O O
the O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
limiting O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
to O O
neuroinflammation O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O O
the O O
duration O B_MEASURE
of O O
behavioral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
while O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O O
not O O
inhibit O O
cytokine O B_DISEASE/B_ORGANISM_FUNCTION
expression O I_DISEASE/I_ORGANISM_FUNCTION
( O O
Fig O B_GENE
. O O
5 O B_NUMBER[MEASURE]
) O O
or O O
the O O
induction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sickness O B_DISEASE/B_GENE
( O O
Fig O B_PROTEIN[GENE]/B_LOCATION
. O O
3A O B_MEASURE
) O O
, O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
completely O O
reversed O O
the O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]
in O O
sucrose O B_DISEASE
preference O I_DISEASE
( O O
i O O
. O O
e O O
. O O
, O O
anhedonia O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
associated O O
with O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
Fig O B_GENE
. O O
4 O B_MEASURE
) O O
. O O

It O O
is O O
also O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
to O O
mention O O
that O O
while O O
LPS O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
sickness O B_DISEASE
and O O
anhedonia O B_DISEASE_ADJECTIVE[DISEASE]
are O O
interrelated O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
these O O
behaviors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
be O O
differentiated O O
from O O
one O B_NUMBER[MEASURE]/B_LOCATION
another O O
. O O

For O O
instance O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reduced O O
social O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exploration O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
evident O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
- O O
24 O B_MEASURE
h O O
post O B_TIME[MEASURE]/B_LOCATION
injection O I_TIME[MEASURE]/I_LOCATION
( O O
Fig O B_GENE
. O O
3A O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
, O O
but O O
only O O
decreased O O
sucrose O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
exhibited O O
24 O B_MEASURE
to O O
39 O B_MEASURE
h O O
later O O
( O O
Fig O B_GENE
. O O
4 O B_NUMBER[MEASURE]
) O O
. O O

This O O
separation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
behaviors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
investigating O O
sickness O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
longer O O
- O O
lasting O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
motivation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O O
15 O B_MEASURE
, O O
65 O B_MEASURE
, O O
66 O B_MEASURE
] O I_MEASURE
. O O

IDO O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
TRP O B_DISEASE
metabolism O I_DISEASE
represents O O
a O O
potential O B_LOCATION/B_MEASURE
connection O I_LOCATION/I_MEASURE
between O O
activation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
CNS O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
innate O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
immune O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
longer O O
lasting O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavioral O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

IDO O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
TRP O B_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
may O O
affect O O
behavior O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
impacting O O
both O O
serotonin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
glutamate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathways O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
39 O B_MEASURE/B_PERSON
] O B_MEASURE/I_PERSON
. O O

We O O
have O O
reported O O
that O O
IDO O O
induction O O
and O O
activity O O
is O O
amplified O O
in O O
the O O
brain O O
of O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
is O O
associated O O
with O O
prolonged O O
depressive O O
- O O
like O O
behavior O O
[ O O
15 O O
] O O
. O O

Here O O
we O O
show O O
that O O
IDO O O
mRNA O O
induction O O
is O O
blocked O O
by O O
minocycline O O
in O O
the O O
brain O O
of O O
both O O
adult O O
and O O
aged O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figs O O
. O O
5 O O
& O O
7 O O
) O O
. O O

These O O
data O O
are O O
consistent O O
with O O
a O O
recent O O
report O O
showing O O
a O O
causal O O
relationship O O
between O O
IDO O O
activity O O
and O O
acute O O
depressive O O
effects O O
in O O
adult O O
CD O O
- O O
1 O O
mice B B_BIO/B_PERSON
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
O O B_OTHER/B_LOCATION
' O O
Connor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
et O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
al O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O
report O O
that O O
both O O
1 O B_MEASURE
- O O
methyl O B_LOCATION/B_PROTEIN[GENE]
tryptophan O B_LOCATION/I_PROTEIN[GENE]
( O O
a O O
competitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
IDO O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O O
IDO O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
prevented O O
depressive O B_DISEASE
- O O
like O B_DISEASE
immobility O I_DISEASE
in O O
the O O
tail O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suspension O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
forced O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
swimming O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
66 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Thus O O
, O O
in O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
minocycline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blockade O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
IDO O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induction O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
explain O O
the O O
abrogation O B_DISEASE_ADJECTIVE[DISEASE]
of O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
anhedonia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Another O O
interesting O O
finding O O
was O O
that O O
while O O
minocycline O O
pretreatment O O
in O O
adult O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O O
LPS O O
- O O
induced O O
brain O O
IL O O
- O O
1 O O
beta O O
at O O
4 O O
h O O
( O O
Fig O O
. O O
5 O O
) O O
, O O
it O O
had O O
no O O
effect O O
on O O
plasma O O
IL O O
- O O
1 O O
beta O O
levels O O
( O O
Fig O O
. O O
6 O O
) O O
. O O

Because O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
signals O I_MEASURE
can O O
be O O
relayed O O
from O O
the O O
periphery O B_BODY_PART_OR_ORGAN_COMPONENT
to O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O O
humoral O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
5 O B_DISEASE/B_SPECIES[BIO]
] O B_DISEASE/I_SPECIES[BIO]
, O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
related O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
readily O O
crosses O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
barrier O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O O
elicit O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE/B_GENE
effect O I_DISEASE/I_GENE
[ O O
41 O B_MEASURE
- O O
43 O B_MEASURE
] O I_MEASURE
. O O

With O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
, O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O O
both O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
4 O B_MEASURE
h O O
post O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LPS O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Because O O
circulating O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_MEASURE
levels O I_MEASURE
can O O
be O O
increased O O
by O O
CNS O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mediated O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
including O O
activation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
the O O
hypothalamus O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
pituitary O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
adrenal O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
HPA O B_LOCATION/B_ORGANIZATION
) O O
axis O B_LOCATION/B_DISEASE
[ O O
67 O B_MEASURE
] O I_MEASURE
and O O
the O O
sympathetic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
68 O B_MEASURE
] O I_MEASURE
, O O
the O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
6 O B_NUMBER[MEASURE]
by O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O O
reflect O O
the O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflammation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
4 O B_MEASURE
h O O
( O O
Fig O B_MEASURE
. O O
5 O B_NUMBER[MEASURE]
) O O
. O O

In O O
support O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
notion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
and O O
others O B_PERSON/B_BIO
have O O
reported O O
that O O
i O O
. O O
c O O
. O O
v O B_PROTEIN[GENE]/B_MEASURE
. O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_PROTEIN[GENE]/B_MEASURE
beta O I_PROTEIN[GENE]/I_MEASURE
increase O I_PROTEIN[GENE]/I_MEASURE
plasma O I_PROTEIN[GENE]/I_MEASURE
IL O I_PROTEIN[GENE]/I_MEASURE
- O O
6 O B_MEASURE
levels O I_MEASURE
, O O
but O O
not O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
levels O I_MEASURE
[ O O
14 O B_MEASURE
, O O
68 O B_MEASURE
, O O
69 O B_MEASURE
] O I_MEASURE
. O O

The O O
final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
critical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
effective O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
attenuating O O
neuroinflammation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independent O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
age O B_DISEASE/B_GENE
. O O

Consistent O O
with O O
other O O
aging O O
and O O
neuroinflammation O O
studies O O
, O O
our O O
data O O
show O O
that O O
LPS O O
caused O O
exaggerated O O
neuroinflammation O O
in O O
aged O O
mice B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
adults O O
[ O O
10 O O
, O O
13 O O
- O O
15 O O
] O O
. O O

It O O
is O O
important O O
to O O
mention O O
that O O
while O O
there O O
was O O
an O O
age O O
- O O
related O O
difference O O
in O O
MHC O O
II O O
expression O O
in O O
the O O
hippocampus O O
of O O
saline O O
treated O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fig O O
. O O
7A O O
) O O
there O O
was O O
not O O
an O O
age O O
- O O
related O O
difference O O
in O O
IL O O
- O O
1 O O
beta O O
and O O
IL O O
- O O
6 O O
mRNA O O
levels O O
. O O

These O O
data O O
differ O O
from O O
a O O
previous O O
report O O
using O O
BALB O O
/ O O
c O O
mice B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O O
an O O
increase O O
in O O
IL O O
- O O
6 O O
in O O
older O O
mice B B_BIO/B_PERSON
[ O O
70 O O
] O O
. O O

This O O
may O O
be O O
because O O
the O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
in O O
the O O
present O O
study O O
were O O
approximately O O
4 O O
months O O
younger O O
than O O
the O O
mice B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
previously O O
. O O

Nonetheless O O
, O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
can O O
be O O
primed O O
or O O
reactive O O
with O O
increased O O
MHC O B_DISEASE_ADJECTIVE[DISEASE]
II O I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
do O O
not O O
necessarily O O
produce O O
inflammatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
this O O
state O B_LOCATION
[ O O
19 O B_DISEASE
] O I_DISEASE
. O O

The O O
key O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
that O O
peripheral O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LPS O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
causes O O
a O O
greater O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
TLR2 O B_GENE
, O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
beta O I_MEASURE
, O O
and O O
IDO O B_GENE
mRNA O I_GENE
in O O
the O O
aged O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
brain O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
than O O
in O O
the O O
adult O B_PERSON/B_ENT
brain O I_PERSON/I_ENT
and O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
normalizes O O
this O O
age O B_TIME[MEASURE]/B_DISEASE
- O O
related O O
exaggerated O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuroinflammation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fig O B_MEASURE/B_PROTEIN[GENE]
. O O
7 O B_NUMBER[MEASURE]
) O O
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
also O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
an O O
amplified O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuroinflammatory O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
aged O B_BODY_PART_OR_ORGAN_COMPONENT
brain O I_BODY_PART_OR_ORGAN_COMPONENT
is O O
a O O
precursor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
complications O B_DISEASE
including O O
deficits O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
working O O
memory O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
memory O B_DISEASE_ADJECTIVE[DISEASE]
consolidation O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
depressive O B_DISEASE
- O O
like O B_DISEASE_ADJECTIVE[DISEASE]
behavior O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
9 O B_SEQUENCE[MEASURE]
, O O
10 O B_NUMBER[MEASURE]
, O O
15 O B_MEASURE
] O I_MEASURE
. O O

Based O O
on O O
the O O
biochemical O O
and O O
behavioral O O
data O O
obtained O O
from O O
this O O
study O O
, O O
we O O
predict O O
that O O
minocycline O O
will O O
abrogate O O
the O O
prolonged O O
LPS O O
- O O
induced O O
sickness O O
[ O O
13 O O
] O O
and O O
depressive O O
- O O
like O O
behavior O O
exhibited O O
by O O
aged O O
BALB O O
/ O O
c O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
15 O O
] O O
. O O

We O O
acknowledge O O
, O O
however O O
, O O
that O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
test O O
these O O
predictions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrates O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
microglial O B_DISEASE
activation O I_DISEASE
, O O
CNS O B_DISEASE
cytokine O I_DISEASE
production O I_DISEASE
, O O
and O O
behavioral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
sickness O B_DISEASE
( O O
e O B_GENE/B_DISEASE
. O O
g O B_GENE/B_MEASURE
. O O
, O O
social O B_DISEASE
withdrawal O I_DISEASE
and O O
anhedonia O B_DISEASE
) O O
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
potentially O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
they O O
indicate O O
that O O
minocycline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
used O O
to O O
mitigate O O
cytokine O B_DISEASE
expression O I_DISEASE
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
have O O
a O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
behavioral O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Taken O O
together O O
, O O
these O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O O
the O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
pharmacological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strategies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aimed O O
at O O
decreasing O O
neuroinflammation O B_DISEASE
associated O O
with O O
microglial O B_DISEASE/B_LOCATION
activation O I_DISEASE/I_LOCATION
are O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
improving O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
sickness O B_DISEASE
and O O
reducing O O
the O O
frequency O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
neurobehavioral O B_DISEASE
complications O I_DISEASE
. O O

List O B_LOCATION/B_MEASURE
of O O
abbreviations O B_PERSON/B_ENT

3 O O
- O O
Hydroxy O O
- O O
L O O
- O O
Kynuriene O O
( O O
3HK O O
) O O
, O O
Allophycocyanin O O
( O O
APC O O
) O O
, O O
Analysis O O
of O O
variance O O
( O O
ANOVA O O
) O O
, O O
Central O O
Nervous O O
System O O
( O O
CNS O O
) O O
, O O
Dulbecco O O
' O O
s O O
Modified O O
Eagle O O
' O O
s O O
Medium O O
( O O
DMEM O O
) O O
, O O
Dimethyl O O
Sulfoxide O O
( O O
DMSO O O
) O O
, O O
Experimental O O
Autoimmune O O
Encephalomyelitis O O
( O O
EAE O O
) O O
, O O
Enzyme O O
Linked O O
Immmunosorbent O O
Assay O O
( O O
ELISA O O
) O O
, O O
Fluorescein O O
Isothiocyanate O O
( O O
FITC O O
) O O
, O O
Fetal O O
Bovine B B_PERSON/B_BIO
Serum O O
( O O
FBS O O
) O O
, O O
Hank O O
' O O
s O O
Balanced O O
Salt O O
Solution O O
( O O
HBSS O O
) O O
, O O
Indoleamine O O
2 O O
, O O
3 O O
dioxygenase O O
( O O
IDO O O
) O O
, O O
Intraperitoneal O O
( O O
i O O
. O O
p O O
. O O
) O O
, O O
Intracerebroventricular O O
( O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
, O O
Interleukin O O
( O O
IL O O
) O O
, O O
Kynurenine O O
( O O
KYN O O
) O O
, O O
Lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
Major O O
Histocompatibility O O
Complex O O
class O O
II O O
( O O
MHC O O
II O O
) O O
, O O
Mitogen O O
Activated O O
Protein O O
Kinase O O
( O O
MAP O O
- O O
kinase O O
) O O
, O O
Nuclear O O
factor O O
kappa O O
B O O
( O O
NF O O
kappa O O
B O O
) O O
, O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartate O O
( O O
NMDA O O
) O O
, O O
R O O
- O O
Phycoerthrin O O
( O O
PE O O
) O O
, O O
Quinolinic O O
acid O O
( O O
QUIN O O
) O O
, O O
Statistical O O
Analysis O O
Systems O O
( O O
SAS O O
) O O
, O O
Standard O O
Error O O
of O O
the O O
Mean O O
( O O
SEM O O
) O O
, O O
Toll O O
- O O
like O O
Receptor O O
- O O
2 O O
( O O
TLR2 O O
) O O
, O O
and O O
Tryptophan O O
( O O
TRP O O
) O O
. O O

Competing O O
interests O B_DISEASE

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
declare O O
that O O
there O O
are O O
no O O
actual O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conflicts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
interest O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
authors O O
affirm O O
that O O
there O O
are O O
no O O
financial O O
, O O
personal O O
or O O
other O O
relationships O O
with O O
other O O
people B B_PERSON/B_ORGANIZATION
or O O
organizations O O
that O O
have O O
inappropriately O O
influenced O O
or O O
biased O O
their O O
research O O
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

CJH O B_PERSON
was O O
involved O O
in O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
experimentation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
completion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
and O O
writing O O
of O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

YH O B_PERSON/B_PROTEIN[GENE]
, O O
AW O B_LOCATION
, O O
MH O B_LOCATION/B_PERSON
and O O
JH O B_LOCATION/B_PERSON
assisted O O
with O O
experimentation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

MB O B_LOCATION/B_PERSON
and O O
JFS O B_LOCATION/B_PERSON
contributed O O
to O O
the O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
assisted O O
in O O
editing O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

JPG O B_PERSON/B_ORGANIZATION
directed O O
all O O
aspects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
including O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
experimentation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
completion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
and O O
writing O O
of O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

A O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
demand O B_DISEASE
ischemia O I_DISEASE
from O O
phendimetrazine O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Introduction O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Phendimetrazine O O
is O O
a O O
medication O O
currently O O
being O O
used O O
to O O
help O O
patients B B_PERSON
with O O
weight O O
loss O O
. O O

It O O
shares O O
a O O
chemical O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
amphetamines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
it O O
shares O O
some O O
of O O
the O O
same O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
can O O
include O O
cardiac O B_DISEASE
toxicity O I_DISEASE
. O O

This O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highlights O O
this O O
principle O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presentation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

a O O
54 O B_PERSON
year O I_PERSON
old O I_PERSON
Caucasian O I_PERSON
female O I_PERSON
presented O O
to O O
our O O
urgent O B_LOCATION/B_PERSON
care O I_LOCATION/I_PERSON
facility O I_LOCATION/I_PERSON
with O O
complaints O B_DISEASE_ADJECTIVE[DISEASE]
of O O
chest O B_DISEASE
pains O I_DISEASE
and O O
other O B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
suggestive O I_DISEASE_ADJECTIVE[DISEASE]
of O O
acute O B_DISEASE/B_LOCATION
coronary O I_DISEASE/I_LOCATION
syndrome O I_DISEASE/I_LOCATION
. O O

Ultimately O O
, O O
she O O
was O O
transferred O O
to O O
the O O
emergency O B_LOCATION/B_ORGANIZATION
room O I_LOCATION/I_ORGANIZATION
. O O

After O O
evaluation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
there O O
, O O
it O O
appeared O O
she O O
was O O
having O O
demand O B_DISEASE_ADJECTIVE[DISEASE]
ischemia O I_DISEASE_ADJECTIVE[DISEASE]
from O O
prescription O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pills O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

This O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrates O O
the O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dangers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
amphetamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
based O O
diet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pills O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
have O O
been O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
cardiomyopathies O B_DISEASE
related O O
to O O
phendimetrazine O B_DISEASE
, O O
but O O
it O O
is O O
something O B_DISEASE
that O O
is O O
rarely O O
recognized O O
in O O
an O O
outpatient O B_PERSON/B_LOCATION
setting O I_PERSON/I_LOCATION
. O O

A O O
case O O
such O O
as O O
this O O
demonstrates O O
the O O
importance O O
of O O
obtaining O O
a O O
careful O O
medication O O
history O O
in O O
all O O
patients B B_PERSON/B_LOCATION
and O O
in O O
recognizing O O
diet O O
pills O O
with O O
an O O
amphetamine O O
base O O
can O O
cause O O
cardiac O O
toxicity O O
. O O

Case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presentation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
54 O B_TIME[MEASURE]/B_PERSON
year O I_TIME[MEASURE]/I_PERSON
- O O
old O B_PERSON
Caucasian O I_PERSON
female O I_PERSON
presented O O
to O O
our O O
urgent O B_LOCATION/B_PERSON
care O I_LOCATION/I_PERSON
facility O I_LOCATION/I_PERSON
complaining O O
of O O
nausea O B_DISEASE
and O O
vomiting O B_DISEASE
, O O
sense O B_TIME[MEASURE]/B_DISEASE
of O O
impending O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
doom O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
vague O B_DISEASE/B_MEASURE
chest O I_DISEASE/I_MEASURE
pain O I_DISEASE/I_MEASURE
radiating O O
toward O O
her O O
left O B_BODY_PART_OR_ORGAN_COMPONENT
side O I_BODY_PART_OR_ORGAN_COMPONENT
for O O
about O O
five O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
. O O

She O O
never O O
had O O
similar O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
past O B_TIME[MEASURE]/B_LOCATION
. O O

She O O
also O O
denied O O
anything O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
that O O
could O O
have O O
precipitated O O
these O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Her O O
only O B_DISEASE_ADJECTIVE[DISEASE]
past O I_DISEASE_ADJECTIVE[DISEASE]
medical O I_DISEASE_ADJECTIVE[DISEASE]
history O I_DISEASE_ADJECTIVE[DISEASE]
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
spina O B_DISEASE/B_BACTERIUM[BIO]
bifida O I_DISEASE/I_BACTERIUM[BIO]
. O O

Her O O
medications O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
occasional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fiorinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
unknown O B_MEASURE
dose O I_MEASURE
) O O
, O O
Xanax O B_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
as O O
needed O O
, O O
and O O
Phendimetrazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
unclear O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Her O O
social O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
for O O
smoking O O
1 O B_NUMBER[MEASURE]
/ O O
2 O B_MEASURE/B_ENT
pack O I_MEASURE/I_ENT
per O O
day O B_TIME[MEASURE]/B_PERSON
cigarette O I_TIME[MEASURE]/I_PERSON
use O I_TIME[MEASURE]/I_PERSON
. O O

She O O
denied O O
alcohol O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
use O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Family O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
non O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
worked O O
from O O
home O B_LOCATION/B_PERSON
. O O

Her O O
physical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exam O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
a O O
tachycardia O B_DISEASE/B_MEASURE
of O O
around O O
100 O B_MEASURE
beats O I_MEASURE
per O O
minute O B_TIME[MEASURE]
, O O
respiratory O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
of O O
16 O B_MEASURE
, O O
temperature O B_MEASURE/B_DISEASE
of O O
98 O B_MEASURE
. O O
1 O B_MEASURE
, O O
and O O
O2 O B_MEASURE/B_ORGANISM_FUNCTION
saturation O I_MEASURE/I_ORGANISM_FUNCTION
of O O
100 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
room O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
air O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

She O O
was O O
approximately O O
5 O B_MEASURE
' O I_MEASURE
7 O I_MEASURE
" O O
and O O
145 O B_MEASURE/B_COLOR
pounds O I_MEASURE/I_COLOR
. O O

In O O
general O O
, O O
she O O
was O O
an O O
anxious O O
appearing O O
, O O
diaphoretic O O
woman B B_PERSON/B_LOCATION
in O O
moderate O O
distress O O
, O O
she O O
had O O
no O O
elevated O O
JVD O O
at O O
30 O O
degrees O O
, O O
her O O
heart O O
was O O
tachycardic O O
, O O
but O O
otherwise O O
without O O
murmur O O
, O O
gallops O O
, O O
or O O
rubs O O
, O O
her O O
lungs O O
were O O
clear O O
, O O
abdomen O O
soft O O
, O O
and O O
she O O
had O O
no O O
peripheral O O
edema O O
. O O

An O O
EKG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
checked O O
which O O
appears O O
below O O
( O O
figure O B_MEASURE
1 O I_MEASURE
) O O
. O O

After O O
examination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
there O O
was O O
concern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
acute O B_DISEASE
coronary O I_DISEASE
syndrome O I_DISEASE
( O O
ACS O B_DISEASE/B_LOCATION
) O O
. O O

She O O
was O O
given O O
nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
relief O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
her O O
chest O B_DISEASE
discomfort O I_DISEASE
. O O

She O O
was O O
also O O
given O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
chew O O
. O O

EMS O B_PERSON
was O O
called O O
and O O
she O O
was O O
transferred O O
to O O
a O O
local O B_LOCATION/B_PRODUCT[OBJECT]
emergency O B_LOCATION/I_PRODUCT[OBJECT]
room O B_LOCATION/I_PRODUCT[OBJECT]
. O O

She O O
was O O
hospitalized O O
there O O
for O O
three O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
and O O
after O O
her O O
discharge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
we O O
got O O
permission O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
her O O
to O O
request O B_PERSON/B_LOCATION
records O B_PERSON/I_LOCATION
. O O

While O O
hospitalized O O
, O O
she O O
was O O
ruled O O
out O O
for O O
ACS O B_DISEASE/B_LOCATION
with O O
negative O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
troponins O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
was O O
also O O
given O O
beta O O
blockade O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
resolved O O
her O O
tachycardia O B_DISEASE
and O O
her O O
T O B_DISEASE_ADJECTIVE[DISEASE]
wave O I_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
on O O
EKG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
next O B_TIME[MEASURE]/B_LOCATION
morning O I_TIME[MEASURE]/I_LOCATION
, O O
she O O
had O O
an O O
adenosine O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
revealed O O
normal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
uptake O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
no O O
areas O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ischemia O B_DISEASE
and O O
an O O
ejection O B_MEASURE
fraction O I_MEASURE
of O O
55 O B_MEASURE
% O I_MEASURE
. O O

She O O
was O O
monitored O O
for O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
day O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
then O O
discharged O O
with O O
instructions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
discontinue O O
her O O
diet O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pills O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Phendimetrazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
currently O O
being O O
used O O
for O O
weight O B_DISEASE
loss O I_DISEASE
, O O
with O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
illicit O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
has O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemical O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
composition O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
amphetamines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
thought O O
to O O
account O O
for O O
its O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
actions O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
1 O B_LOCATION/B_DISEASE
] O I_LOCATION/I_DISEASE
. O O

Amphetamines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
well O O
recognized O O
as O O
an O O
etiology O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiac O B_DISEASE
ischemia O I_DISEASE
, O O
however O O
phendimetrazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
more O O
rarely O O
described O O
in O O
the O O
literature O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
as O O
causing O O
cardiac O B_DISEASE
events O I_DISEASE
. O O

[ O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
, O O
3 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Acute O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
include O O
hyperpyrexia O B_DISEASE
, O O
mydriasis O B_DISEASE/B_BIO
, O O
chest O B_DISEASE
pain O I_DISEASE
, O O
arrhytmias O B_DISEASE
, O O
delirium O B_DISEASE
, O O
and O O
, O O
rhabdomylosis O B_DISEASE_ADJECTIVE[DISEASE]
, O O
among O O
others O B_PERSON/B_DISEASE
[ O O
2 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
] O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Long O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O O
been O O
associated O O
with O O
dilated O B_DISEASE
cardiomyopathies O I_DISEASE
, O O
some O O
of O O
which O O
have O O
resolved O O
with O O
discontinuation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

In O O
this O O
particular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
it O O
appears O O
she O O
may O O
have O O
developed O O
a O O
demand O B_DISEASE
ischemia O I_DISEASE
from O O
the O O
medication O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

It O O
is O O
not O O
known O O
how O O
much O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
she O O
was O O
taking O O
. O O

Initially O O
, O O
she O O
was O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
accepting O O
that O O
phendimetrazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
could O O
induce O O
side O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
there O O
was O O
suspicion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
she O O
could O O
have O O
been O O
taking O O
more O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
recommended O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
she O O
was O O
not O O
prescribed O O
the O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
would O O
not O O
admit O O
to O O
where O O
she O O
obtained O O
it O O
. O O

As O O
the O O
public O B_ORGANIZATION/B_PERSON
seems O O
to O O
have O O
more O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
focus O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
on O O
using O O
medications O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
induce O O
weight O B_DISEASE
loss O I_DISEASE
, O O
this O O
may O O
be O O
a O O
more O O
recognized O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complication O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
heart O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
conditions O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
should O O
likely O O
be O O
monitored O O
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
starting O O
amphetamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
based O O
weight O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pills O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

Due O O
to O O
potentially O O
detrimental O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
phendimetrazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
should O O
be O O
used O O
cautiously O O
in O O
many O B_PERSON/B_LOCATION
situations O I_PERSON/I_LOCATION
. O O

As O O
it O O
shares O O
its O O
chemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
amphetamines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
also O O
shares O O
many O B_NUMBER[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
abuse O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
/ O O
addiction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

There O O
have O O
been O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
literature O B_PERSON/B_LOCATION
describing O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
phendimetrazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medications O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
cautious O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
warranted O O
. O O

Abbreviations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

ACS O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Acute O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
Coronary O B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
Syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O O

Competing O O
interests O B_DISEASE

The O O
authors O B_PERSON
declare O O
that O O
they O O
have O O
no O O
competing O O
interests O B_PERSON/B_ORGANIZATION
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

DL O B_PROTEIN[GENE]/B_PERSON
, O O
JJ O B_LOCATION/B_PERSON
, O O
GG O B_PROTEIN[GENE]/B_LOCATION
have O O
all O O
been O O
involved O O
in O O
and O O
approve O O
of O O
the O O
writing O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
presentation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Consent O B_TIME[MEASURE]/B_PERSON

Written O O
informed O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consent O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
obtained O O
from O O
the O O
patient O B_PERSON/B_ORGANIZATION
for O O
publication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
purposes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

A O O
copy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
can O O
be O O
obtained O O
if O O
requested O O
by O O
the O O
Editor O B_PERSON
in O O
Chief O B_PERSON/B_LOCATION
of O O
this O O
journal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

Advanced O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concepts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
employing O O
microcomputers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O O
the O O

laboratory O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

IIII O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

II O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

, O O
Advanced O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
software O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
concepts O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O

employing O O
microcomputers O B_PERSON/B_ORGANIZATION
in O O
the O O
laboratory O B_LOCATION/B_PERSON
Scott O I_LOCATION/I_PERSON
B O I_LOCATION/I_PERSON
. O O
Tilden O B_PERSON/B_LOCATION
and O O
M O B_LOCATION
. O O
Bonner O B_PERSON
Denton O I_PERSON
, O O
Department O B_ORGANIZATION/B_PERSON
of O O
Chemistry O B_EDU[ORGANIZATION]/B_PERSON
, O O
University O B_LOCATION/B_ORGANIZATION
of O O
Arizona O B_LOCATION
, O O
Tucson O B_LOCATION/B_PERSON
, O O
Arizona O B_LOCATION
85721 O I_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
. O O

Introduction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
While O O
a O O
proliferation O B_MEASURE/B_LOCATION
of O O
commercial O B_ORGANIZATION/B_PERSON
chemical O I_ORGANIZATION/I_PERSON
instrumentation O I_ORGANIZATION/I_PERSON
is O O
appearing O O
today O B_DISEASE_ADJECTIVE[DISEASE]
employing O O
microprocessors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
for O O
a O O
variety O B_ENT/B_MEASURE
of O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
great O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
potential O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
microprocessors O B_ORGANIZATION/B_PERSON
has O O
not O O
been O O
exploited O O
extensively O O
for O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
custom O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
applications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

The O O
primary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reason O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
this O O
phenomenon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
altogether O O
too O O
clear O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
microprocessor O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
software O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
either O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
develop O O
or O O
inefficient O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
memory O B_MEASURE/B_LOCATION
requirements O I_MEASURE/I_LOCATION
and O O
speed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
. O O

This O O
problem O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
even O O
more O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
situations O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requiring O O
constant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
software O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE

modification O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Initially O O
, O O
most O B_ORGANIZATION/B_LOCATION
instrument O I_ORGANIZATION/I_LOCATION
manufacturers O I_ORGANIZATION/I_LOCATION
utilized O O
cross O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
assemblers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
supported O O
on O O
large O B_PERSON
" O I_PERSON
number O I_PERSON
cruncher O I_PERSON
" O O
computers O B_PRODUCT[OBJECT]/B_LOCATION
to O O
generate O O
the O O
required O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
machine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binary O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

More O O
recently O O
, O O
the O O
trend O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
toward O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
a O O
" O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
( O O
at O O
a O O
cost O B_MEASURE/B_PERSON
comparable O I_MEASURE/I_PERSON
to O O
a O O
moderate O B_PRODUCT[OBJECT]/B_PERSON
minicomputer O I_PRODUCT[OBJECT]/I_PERSON
- O O
the O O
authors O B_PERSON/B_LOCATION
use O O
the O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
mini O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
in O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
" O O
micro O B_MEASURE
" O O
reluctantly O O
because O O
of O O
the O O
ever O O
increasing O O
overlap O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
computing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
capability O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
to O O
write O O
and O O
debug O O
assembly O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
level O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
porgrams O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O O
are O O
subsequently O O
converted O O
to O O
binary O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
incorporated O O
into O O
an O O
instrument O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
" O O
read O O
only O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
memory O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
" O O
( O O
ROM O B_DISEASE
) O O
. O O

While O O
this O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

Interpretative O B_LOCATION/B_MEASURE
Machine O I_LOCATION/I_MEASURE
Code O I_LOCATION/I_MEASURE

Source O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
File O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

to O O
Execute O O
Command O B_PERSON
A O I_PERSON
Hachine O I_PERSON
Code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Various O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

to O O
Execute O O
Comma O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
nd O I_PERSON
B O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
ne O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

' O O
commands O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
making O O
up O O

, O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lachi O O

to O O
Execute O O
Command O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

users O B_PERSON/B_SEQUENCE[MEASURE]
source O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION

i O B_OTHER/B_PERSON

Machine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

to O O
Execute O O
Command O B_PERSON
D O I_PERSON

etc O B_LOCATION/B_DISEASE
. O O

Figure O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
. O O

The O O
interpretative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
cycle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
common O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
types O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
languages O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
such O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
BASIC O B_PERSON/B_LOCATION
. O O

After O O
examining O O
each O O
command O B_ORGANIZATION/B_PERSON
in O O
the O O
source O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
file O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
the O O
interpreter O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
searches O O
for O O
and O O
branches O B_LOCATION/B_PERSON
to O O
the O O
corresponding O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
machine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
code O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
; O O
thus O O
, O O
program O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
execution O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
always O O
remains O O
within O O
the O O
interpreter O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

128 O B_NUMBER[MEASURE]

The O O
Journal O B_ORGANIZATION
of O O
Automatic O B_EDU[ORGANIZATION]/B_PERSON
Chemistry O I_EDU[ORGANIZATION]/I_PERSON

Tilden O B_PERSON/B_LOCATION
& O O
Denton O B_PERSON/B_LOCATION
IIII O I_PERSON/I_LOCATION

Advanced O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

III O B_NUMBER[MEASURE]

Users O B_ORGANIZATION
Source O I_ORGANIZATION
File O I_ORGANIZATION

The O O
Compiler O B_PERSON/B_LOCATION

Command O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Comma O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
nd O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
B O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
Command O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
C O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
Command O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
D O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
etc O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
. O O

/ O O
z O B_OTHER/B_PERSON
/ O O
li O B_PERSON/B_MEASURE
i O O

II O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

. O O
Machine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Code O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

etc O B_LOCATION/B_DISEASE
. O O

. O O
lachi O B_LOCATION/B_PERSON
ne O B_DISEASE/B_PERSON
Code O I_DISEASE/B_LOCATION

to O O
Execute O O
Command O B_PERSON
A O I_PERSON

etc O B_NUMBER[MEASURE]/B_LOCATION
. O O
to O O
Execute O O

Machine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

to O O
Execute O O
Command O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Machine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

etc O B_LOCATION/B_DISEASE
. O O

Figure O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
. O O

Note O O
that O O
the O O
compiler O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transforms O O
each O O
source O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
command O B_ORGANIZATION/B_PERSON
" O O
into O O
executable O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
machine O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
code O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
will O O
, O O
subsequently O O
, O O
be O O
loaded O O
and O O
executed O O
independently O O
of O O
the O O
compiler O B_PERSON
. O O

has O O
proven O O
cost O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
high O B_TIME[MEASURE]/B_LOCATION
volume O I_TIME[MEASURE]/I_LOCATION
mass O I_TIME[MEASURE]/I_LOCATION
produced O O
applications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
it O O
possesses O O
serious O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
limitations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
updates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
custom O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Additionally O O
, O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
program O O
efficiently O O
at O O
the O O
assembly O B_LOCATION
level O I_LOCATION
is O O
a O O
talent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
requiring O O
a O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
expenditure O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
time O B_MEASURE/B_LOCATION
to O O
develop O O
. O O

During O O
the O O
past O B_TIME[MEASURE]/B_ENT
several O I_TIME[MEASURE]/I_ENT
years O I_TIME[MEASURE]/I_ENT
, O O
a O O
virtual O B_MEASURE/B_LOCATION
deluge O B_MEASURE/I_LOCATION
of O O
sophisticated O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
flexible O B_DISEASE_ADJECTIVE[DISEASE]
, O O
high O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
computer O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hardware O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
introduced O O
primarily O O
aimed O O
at O O
a O O
rapidly O O
growing O O
" O B_LOCATION/B_ORGANIZATION
hobbyist O B_LOCATION/I_ORGANIZATION
" O B_LOCATION/I_ORGANIZATION
market O B_LOCATION/I_ORGANIZATION
. O O

Manufacturers O B_PERSON/B_ORGANIZATION
quickly O O
realilsed O O
that O O
to O O
sell O O
the O O
public O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
hardware O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
some O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
reasonably O O
high O B_ORGANIZATION/B_TIME[MEASURE]
level O B_ORGANIZATION/I_TIME[MEASURE]
software O B_ORGANIZATION/I_TIME[MEASURE]
must O O
be O O
made O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
variety O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BASIC O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interpreters O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
ranging O O
from O O
rather O O
" O O
dumb O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
" O O
to O O
" O O
quite O O
intelligent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
" O O
have O O
since O O
evolved O O
. O O

The O O
more O O
intelligent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
BASIC O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
interpreters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
have O O
several O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
highly O O
attractive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attributes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
" O O
hobbyist O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
" O O
applications O B_PERSON/B_LANGUAGE
. O O

The O O
language O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
both O O
easy O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
master O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
conversational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Error O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
caution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
messages O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O O
provided O O
as O O
aids O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
programming O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SPORT[ENT]
. O O

Why O O
not O O
apply O O
the O O
" O O
hobbyist O B_PERSON/B_MEASURE
" O O
technology O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toward O O
the O O
implementation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
custom O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
laboratory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
? O O

Many O B_PERSON/B_NUMBER[MEASURE]
investigators O B_PERSON/I_NUMBER[MEASURE]
have O O
and O O
, O O
no O O
doubt O O
, O O
many O B_PERSON/B_ENT
more O I_PERSON/I_ENT
will O O
take O O
this O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
BASIC O B_PERSON
interpreters O I_PERSON
possess O O
serious O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
limitations O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
terms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
system O B_MEASURE
speed O I_MEASURE
, O O
flexibility O B_MEASURE
and O O
input O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
/ O O
output O B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
O O B_PROTEIN[GENE]/B_LOCATION
) O O
capabilities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
BASIC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
each O O
command O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O O
first O O
be O O
interpreted O O
and O O
then O O
executed O O
( O O
see O O
Figure O B_MEASURE
1 O I_MEASURE
) O O
. O O

In O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
the O O
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
takes O O
much O O
more O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
time O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
actual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
execution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O O

This O O
problem O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
compounded O O
by O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
commands O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpreted O O
in O O
the O O
past O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O O
be O O
re O O
- O O
interpreted O O
each O O
time O B_TIME[MEASURE]/B_LOCATION
they O O
are O O
used O O
causing O O
iterative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
programs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
be O O
very O O
slow O B_DISEASE_ADJECTIVE[DISEASE]
. O O

While O O
speed O B_MEASURE
is O O
often O O
not O O
a O O
serious O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
limitation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
playing O O
computer O B_SPORT[ENT]/B_ORGANIZATION
games O I_SPORT[ENT]/I_ORGANIZATION
, O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requiring O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
speed O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acquisition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manipulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
common O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Additionally O O
, O O
the O O
more O O
intelligent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
BASICs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
make O O
very O O
inefficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
memory O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
often O O
requiring O O
minimum O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
12 O B_NUMBER[MEASURE]
or O O
16 O B_MEASURE
K O I_MEASURE
bytes O I_MEASURE
( O O
twelve O B_NUMBER[MEASURE]
or O O
sixteen O B_NUMBER[MEASURE]/B_ENT
thousand O I_NUMBER[MEASURE]/I_ENT
eight O I_NUMBER[MEASURE]/I_ENT
bit O I_NUMBER[MEASURE]/I_ENT
words O I_NUMBER[MEASURE]/I_ENT
) O O
' O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Volume O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

cS O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

H O B_OTHER/B_PERSON

A O B_OTHER/B_PERSON

D O B_OTHER/B_PERSON

H O B_MEASURE/B_PERSON
Figure O I_MEASURE/I_PERSON
3 O I_MEASURE/I_PERSON
. O O

The O O
' O O
threaded O O
' O O
code O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
in O O
CONVERS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
' O O
threaded O O
' O O
code O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
programming O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
modules O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
sub O B_DISEASE
- O O
routines O B_LOCATION/B_PERSON
are O O
used O O
repetitively O O
in O O
a O O
variety O B_ENT/B_MEASURE
of O O
combinations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
allow O O
implementation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
an O O
infinite O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
functions O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Note O O
that O O
the O O
flow O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
logic O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
threads O O
its O O
way O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
very O O
non O B_DISEASE
. O O
linear O B_LOCATION/B_ORGANIZATION
fashion O I_LOCATION/I_ORGANIZATION
through O O
these O O
modules O B_LOCATION
. O O

No O O
. O O
3 O B_PERSON/B_MEASURE
April O I_PERSON/I_MEASURE
1979 O I_PERSON/I_MEASURE

129 O B_NUMBER[MEASURE]

Tilden O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

& O O
Denton O B_LOCATION/B_GENE

Advanced O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
software O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
concepts O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
| O O
I O O

Stack O B_LOCATION

Upper O B_DISEASE_ADJECTIVE[DISEASE]
Memory O I_DISEASE_ADJECTIVE[DISEASE]
Bound O O

User O B_PERSON/B_ORGANIZATION
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Application O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Dictionaries O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION

4 O O
. O O
5k O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Octal O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CONVERS O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Di O B_LOCATION/B_MEASURE
sk O I_LOCATION/I_MEASURE
Operating O I_LOCATION
System O I_LOCATION

3 O O
. O O
7k O B_MEASURE/B_LOCATION
Octal O I_MEASURE/I_LOCATION
Standard O I_MEASURE/I_LOCATION
High O I_MEASURE/I_LOCATION

Level O B_MEASURE
Dictionary O I_MEASURE
1 O I_MEASURE
. O O
2k O B_MEASURE/B_PERSON
Octal O I_MEASURE/I_PERSON
Initial O I_MEASURE/I_PERSON
Machine O I_MEASURE/I_PERSON

Code O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Dictionary O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

I O O
@ O O
@ O O
Octal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]

Figure O B_MEASURE/B_LOCATION
4 O I_MEASURE/I_LOCATION
. O O

Memory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
map O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
CON O B_LOCATION/B_PERSON
VERS O I_LOCATION/I_PERSON
dictionary O I_LOCATION/I_PERSON
. O O

The O O
stack O B_LOCATION
which O O
is O O
composed O O
of O O
data O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
etc O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
acts O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
constantly O O
expanding O O
or O O
contracting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
memory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
buffer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O O
allows O O
one O B_PERSON/B_LOCATION
subroutine O I_PERSON/I_LOCATION
to O O
communicate O O
with O O
another O O
without O O
either O O
needing O O
to O O
know O O
the O O
other O B_TIME[MEASURE]/B_PERSON
' O O
s O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
location O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
interpreters O B_MEASURE/B_ORGANIZATION
, O O
high O B_PERSON/B_ORGANIZATION
level O I_PERSON/I_ORGANIZATION
compilers O I_PERSON/I_ORGANIZATION
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
as O O
FORTRAN O B_PERSON/B_ORGANIZATION
, O O
offer O O
a O O
much O O
faster O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
" O O
run O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
time O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
" O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
execution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
speed O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

This O O
is O O
accomplished O O
through O O
generation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
the O O
required O O
machine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
during O O
a O O
series O B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
programming O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
operations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Compilers O B_ORGANIZATION/B_PERSON
using O O
FORTRAN O B_LOCATION/B_PERSON
, O O
which O O
are O O
designed O O
to O O
run O O
on O O
many O B_MEASURE/B_PRODUCT[OBJECT]
minicomputers O B_MEASURE/I_PRODUCT[OBJECT]
and O O
some O O
micros O B_PRODUCT[OBJECT]/B_PERSON
, O O
often O O
first O O
transform O O
user O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
symbolic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
source O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
into O O
assembly O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
code O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

An O O
assembler O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
subsequently O O
, O O
transforms O O
this O O
into O O
the O O
required O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
machine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

This O O
ready O B_MEASURE/B_PERSON
- O O
to O O
- O O
run O B_LOCATION/B_MEASURE
machine O I_LOCATION/I_MEASURE
code O I_LOCATION/I_MEASURE
is O O
often O O
loaded O O
along O O
with O O
a O O
run O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
time O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
package O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
which O O
executes O O
in O O
the O O
manner O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
shown O O
in O O
Figure O B_LOCATION/B_ENT
2 O B_LOCATION/I_ENT
. O O

While O O
this O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
greatly O O
improves O O
execution O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
speed O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
loading O O
several O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
soft O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ware O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
routines O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
increases O O
the O O
" O O
hassle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
" O O
associated O O
with O O
editing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
debugging O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
this O O
makes O O
some O O
form O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
mass O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
memory O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
disk O B_PRODUCT[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
magnetic O B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tape O I_PRODUCT[OBJECT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
almost O O
mandatory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Additionally O O
, O O
I O O
/ O O
O O B_LOCATION/B_PROTEIN[GENE]
algorithms O I_LOCATION/I_PROTEIN[GENE]
generally O O
must O O
be O O
implemented O O
in O O
assembly O B_MEASURE/B_PERSON
level O B_MEASURE/I_PERSON
code O B_MEASURE/I_PERSON
! O O

One O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
obvious O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
question O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
immediately O O
arises O O
- O O
why O O
not O O
incorporate O O
the O O
most O O
desirable O B_MEASURE/B_PERSON
characteristics O I_MEASURE/I_PERSON
of O O
both O O
interpreters O B_PERSON/B_LOCATION
and O O
compilers O B_PERSON
into O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
language O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
? O O

Additionally O O
, O O
due O O
to O O
the O O
unique O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
found O O
in O O
many O B_PERSON/B_ORGANIZATION
applications O I_PERSON/I_ORGANIZATION
, O O
why O O
not O O
allow O O
the O O
programmer O B_PERSON/B_LOCATION
additional O I_PERSON/I_LOCATION
flexibility O I_PERSON/I_LOCATION
by O O
providing O O
him O O
with O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
actually O O
develop O O
his O O
own O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
individual O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
modifications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
additions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O O
the O O
language O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O O
? O O

Other O B_MEASURE/B_PERSON
desirable O B_MEASURE/I_PERSON
features O B_MEASURE/I_PERSON
would O O
include O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
memory O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
efficiency O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
level O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
I O O
] O O
O O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
programming O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
ease O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
understanding O O
the O O
language O B_PERSON/B_PRODUCT[OBJECT]
' O O
s O B_PERSON/B_LOCATION
" O I_PERSON/I_LOCATION
inter O I_PERSON/I_LOCATION
- O O
working O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
" O O
and O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
be O O
transferred O O
from O O
one O B_NUMBER[MEASURE]/B_PERSON
CPU O I_NUMBER[MEASURE]/I_PERSON
to O O
another O O
with O O
minimum O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effort O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Type O B_TIME[MEASURE]/B_LOCATION
" O O
ACQUIRE O B_DISEASE_ADJECTIVE[DISEASE]
" O O

ACQUIRE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

# O O
of O O
characters O B_DISEASE/B_PERSON

A O O
G O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE

FORMAT O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
T O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
PLOT O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT

START O O
SCAN O O
GALC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
T O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

DISPLAY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RETURN O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

EXECUTIVE O B_PERSON/B_LOCATION

Figure O B_MEASURE/B_PERSON
5 O I_MEASURE/I_PERSON
. O O

If O O
a O O
previously O O
defined O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
name O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
A O B_LOCATION/B_PROTEIN[GENE]
CO O I_LOCATION/I_PROTEIN[GENE]
U O I_LOCATION/I_PROTEIN[GENE]
R O I_LOCATION/I_PROTEIN[GENE]
tQ O I_LOCATION/I_PROTEIN[GENE]
is O O
entered O O
when O O
in O O
EXECUTE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mode O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
a O O
dictionary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
search O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
takes O O
place O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locating O O
the O O
ACQUIRE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
entry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Once O O
found O O
, O O
this O O
entry O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O O
all O O
the O O
required O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
machine O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
code O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
/ O O
or O O
calls O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
addresses O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
other O B_NUMBER[MEASURE]/B_LOCATION
previously O O
compiled O O
machine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
code O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
modules O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
completely O O
execute O O
the O O
desired O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

130 O B_NUMBER[MEASURE]

The O O
Journal O B_ORGANIZATION
of O O
Automatic O B_EDU[ORGANIZATION]/B_PERSON
Chemistry O I_EDU[ORGANIZATION]/I_PERSON

Tilden O B_PERSON/B_LOCATION
& O O
Denton O B_LOCATION/B_PERSON

Advanced O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

2000 O B_NUMBER[MEASURE]

VARIABLE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
VARIABLE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

START O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
STOP O B_LOCATION/B_TIME[MEASURE]

5000 O B_TIME[MEASURE]
20 O I_TIME[MEASURE]

VARIABLE O B_MEASURE
VARIABLE O I_MEASURE
7 O I_MEASURE

INCREMENT O B_DISEASE/B_ORGANIZATION

0 O B_NUMBER[MEASURE]/B_PERSON

LOCATION O B_LOCATION

A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
D7 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

INDEVICE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
START O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

INITIALIZE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
STEP O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

@ O B_OTHER/B_PERSON

LOCATION O B_LOCATION

LOCATION O B_LOCATION

@ O B_OTHER/B_PERSON

INCREMENT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
INDEVICE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

@ O B_OTHER/B_PERSON

+ O B_MEASURE
10 O I_MEASURE

LOCATION O B_LOCATION

DELAY O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MOVE O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SCAN O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

BEGIN O O
- O O
HERE O O
LOCATION O B_LOCATION/B_PERSON

AND O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE

IF O O
DELAY O B_NUMBER[MEASURE]

A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
D7 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

ELSE O B_LOCATION/B_DISEASE

BEGIN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

THEN O B_LOCATION/B_PERSON

@ O B_OTHER/B_PERSON

5 O B_NUMBER[MEASURE]/B_PERSON

OUTDEVICE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

STEP O B_MOUSE_GENE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

INITIALIZE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

BEGIN O B_MEASURE/B_LOCATION
- O O
HERE O O

MOVE O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

LOCATION O B_LOCATION

@ O B_OTHER/B_PERSON

STOP O B_LOCATION/B_DISEASE

@ O B_OTHER/B_PERSON

> O B_OTHER/B_PERSON

IF O B_LOCATION/B_DISEASE

END O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

ELSE O B_LOCATION/B_DISEASE

BEGIN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

THEN O B_LOCATION/B_PERSON

3000 O B_TIME[MEASURE]
6500 O I_TIME[MEASURE]
10 O I_TIME[MEASURE]

START O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
START O B_LOCATION/B_TIME[MEASURE]

INCREMENT O B_DISEASE/B_ORGANIZATION

SCAN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE

Figure O B_MEASURE/B_PERSON
6 O I_MEASURE/I_PERSON
. O O

Ten O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lines O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
typical O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CONVERS O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O O
to O O
scan O O
wavelengths O B_LOCATION/B_MEASURE
between O O
two O B_NUMBER[MEASURE]/B_PERSON
easily O O
changed O O
limits O B_LOCATION
and O O
acquire O O
data O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

By O O
reference O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
notes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
the O O
text O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
it O O
can O O
be O O
easily O O
understood O O
. O O

NOTE O O
: O O
a O O
number O B_MEASURE
or O O
name O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pushes O O
the O O
number O B_MEASURE/B_LOCATION
of O O
address O B_LOCATION/B_BIO
occupied O O
by O O
the O O
name O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
stack O B_LOCATION
. O O

The O O
symbol O B_LOCATION/B_MEASURE
@ O O
, O O
pips O O
the O O
top O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
stack O B_LOCATION/B_MEASURE
uses O O
it O O
as O O
the O O
address O B_LOCATION/B_MEASURE
from O O
which O O
to O O
obtain O O
a O O
number O B_MEASURE
and O O
pushes O O
that O O
number O B_MEASURE/B_LOCATION
on O O
the O O
stack O B_LOCATION/B_ENT
. O O

Development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
CONVERS O B_ORGANIZATION/B_PERSON
During O O
the O O
past O B_TIME[MEASURE]
two O I_TIME[MEASURE]
years O I_TIME[MEASURE]
, O O
a O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
software O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
taking O O
place O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O O
the O O
University O B_LOCATION
of O O
Arizona O B_LOCATION
referred O O
to O O
as O O
an O O
" O O
Interpretive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Compiler O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
" O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
called O O
CONVERS O B_LOCATION/B_PERSON
. O O

This O O
package O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
conceptually O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
FORTH O B_PERSON/B_LOCATION
language O I_PERSON/I_LOCATION
currently O O
being O O
used O O
in O O
several O B_PERSON/B_LOCATION
minicomputerastronomical O I_PERSON/I_LOCATION
applications O I_PERSON/I_LOCATION
] O I_PERSON/I_LOCATION
, O O
is O O
able O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
provide O O
many O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
desirable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
features O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
found O O
in O O
both O O
interpreters O B_LOCATION/B_PERSON
and O O
compilers O B_PERSON/B_LOCATION
by O O
separating O O
the O O
compile O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
execute O O
states O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
as O O
a O O
compiler O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
) O O
while O O
maintaining O O
a O O
resident O B_PERSON/B_ORGANIZATION
user O I_PERSON/I_ORGANIZATION
interactive O I_PERSON/I_ORGANIZATION
and O O
conversational O B_PERSON/B_LOCATION
executive O I_PERSON/I_LOCATION
which O O
oversees O O
system O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
operation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

The O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
realise O O
such O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advanced O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
software O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
capabilities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
very O O
modest O B_MEASURE/B_PERSON
amount O I_MEASURE/I_PERSON
of O O
memory O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
less O B_MEASURE
than O O
4 O B_MEASURE
K O I_MEASURE
bytes O I_MEASURE
on O O
an O O
8080 O B_TIME[MEASURE]/B_ORGANIZATION
based O O
micro O B_MEASURE/B_PRODUCT[OBJECT]
) O O
is O O
the O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
exploiting O O
threaded O B_PERSON/B_LOCATION
code O I_PERSON/I_LOCATION
programming O I_PERSON/I_LOCATION
techniques O I_PERSON/I_LOCATION
( O O
see O O
Figure O B_MEASURE/B_LOCATION
3 O I_MEASURE/I_LOCATION
) O O
. O O

The O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
involves O O
highly O O
efficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
simple O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
macroinstructions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
build O O
more O O
complex O B_LOCATION/B_PERSON
subroutines O I_LOCATION/I_PERSON
which O O
are O O
recombined O O
with O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
macroinstructions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
form O O
super O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subroutines O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

This O O
process O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
combining O O
previously O O
defined O O
modules O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
form O O
ever O O
increasingly O O
sophisticated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
routines O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
for O O
performing O O
the O O
task O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
hand O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
the O O
essence O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
threaded O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programming O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
initially O O
loaded O O
and O O
running O O
, O O
CONVERS O B_MEASURE/B_PERSON
acts O O
much O O
like O O
an O O
interpreter O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
i O O
. O O
e O O
. O O
it O O
is O O
conversational O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ready O B_TIME[MEASURE]/B_PERSON
to O O
either O O
execute O O
a O O
previously O O
programmed O O
algorithm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
or O O
accept O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
one O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

However O O
, O O
in O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
BASIC O B_PERSON/B_PRODUCT[OBJECT]
, O O
when O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
being O O
entered O O
under O O
CONVERS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
it O O
is O O
immediately O O
transformed O O
into O O
binary O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
machine O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
to O O
the O O
binary O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
starting O O
addresses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
other O B_NUMBER[MEASURE]/B_LOCATION
previously O O
entered O O
and O O
compiled O O
machine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
programs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

During O O
this O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
operator O B_PERSON
is O O
kept O O
informed O O
of O O
the O O
status O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
by O O
a O O
series O B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
error O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
diagnostic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Volume O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

messages O B_ENT/B_PERSON
. O O

When O O
the O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O O
been O O
completed O O
, O O
it O O
is O O
entered O O
in O O
a O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
or O O
dictionary O B_PERSON/B_LOCATION
, O O
which O O
is O O
constantly O O
building O O
up O O
from O O
low O B_PERSON/B_LOCATION
memory O I_PERSON/I_LOCATION
( O O
see O O
Figure O B_MEASURE/B_LOCATION
4 O I_MEASURE/I_LOCATION
) O O
. O O

If O O
the O O
operator O B_PERSON
now O O
wants O O
to O O
execute O O
this O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
he O O
can O O
request O O
it O O
from O O
his O O
terminal O B_LOCATION/B_PERSON
. O O

A O O
dictionary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
search O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
will O O
begin O O
at O O
the O O
last O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
entry O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
progress O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
until O O
the O O
requested O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O O
located O O
. O O

Once O O
located O O
, O O
the O O
requested O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
will O O
run O O
in O O
its O O
entirety O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
without O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O O
any O O
additional O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
dictionary O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
searches O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
let O O
us O O
assume O O
an O O
algorithm O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
called O O
ACQUIRE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
has O O
been O O
programmed O O
to O O
take O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
some O O
hypothetical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
experimental O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O O

When O O
ACQUIRE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
requested O O
from O O
the O O
terminal O B_LOCATION/B_PERSON
, O O
a O O
dictionary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
search O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
initiated O O
. O O

The O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
names O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ACQUIRE O O
( O O
see O O
Figure O B_MEASURE/B_LOCATION
5 O I_MEASURE/I_LOCATION
) O O
, O O
once O O
located O O
, O O
contains O O
the O O
starting O O
addresses O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
series O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
previously O O
defined O O
modules O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
which O O
implement O O
the O O
various O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
steps O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
necessary O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
perform O O
the O O
desired O O
experiment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
module O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
SCAN O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O O
might O O
be O O
intended O O
to O O
scan O O
a O O
monochromator O B_PRODUCT[OBJECT]/B_PERSON
' O O
s O B_MEASURE/B_LOCATION
wavelength O I_MEASURE/I_LOCATION
in O O
some O O
desired O B_PERSON/B_LOCATION
manner O B_PERSON/I_LOCATION
has O O
been O O
previously O O
defined O O
and O O
tested O O
. O O

This O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
easily O O
test O O
each O O
module O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
separately O O
and O O
then O O
efficiently O O
combine O O
a O O
series O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
modules O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
perform O O
a O O
more O O
complex O B_DISEASE_ADJECTIVE[DISEASE]
function O I_DISEASE_ADJECTIVE[DISEASE]
, O O
test O O
this O O
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
and O O
then O O
employ O O
. O O
it O O
in O O
a O O
vastly O O
more O O
complex O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
etc O B_LOCATION/B_ORGANIZATION
. O O
, O O
i O O
. O O
e O O
. O O
testing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
each O O
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
as O O
the O O
threaded O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
made O O
increasingly O O
complex O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
a O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributing O O
to O O
the O O
speed O B_TIME[MEASURE]/B_SPORT[ENT]
with O O
which O O
software O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
developed O O
using O O
CONVERS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
software O B_PRODUCT[OBJECT]/B_LOCATION
stack O I_PRODUCT[OBJECT]/I_LOCATION
also O O
contributes O O
toward O O
improved O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
memory O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
efficiency O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
simplified O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
programming O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
stack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
an O O
area O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
memory O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
set O O
aside O O
to O O
handle O O
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
data O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
numbers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
etc O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

One O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
primary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advantages O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
stack O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
that O O
entries O B_PERSON/B_LOCATION
can O O
leave O O
temporary O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
stack O B_LOCATION/B_ORGANIZATION
without O O
having O O
to O O
assign O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
131 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

No O O
. O O
3 O B_PERSON/B_MEASURE
April O I_PERSON/I_MEASURE
1979 O I_PERSON/I_MEASURE

Tilden O B_PERSON/B_LOCATION
& O O
Denton O B_LOCATION/B_PERSON

Advanced O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

DUAL O B_TIME[MEASURE]/B_LOCATION
REGULATED O O
POWER O B_GENE
SUPPLY O I_GENE
I0 O I_GENE
KV O I_GENE
I00 O I_LOCATION

GRATING O B_LOCATION/B_ENT

PIEZOELECTRIC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
TRANSLATOR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

OP O B_ORGANIZATION
TOACOUS O I_ORGANIZATION
TIC O I_ORGANIZATION
CELL O I_ORGANIZATION

, O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
. O O

C02He O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N2 O B_MEASURE/B_LOCATION

MIRROR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
TRANSLATOR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON

CHOPPER O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

POWER O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
DE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
TECTOR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION

STEPPER O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
MOTOR O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

DRIVER O B_PERSON

ADC O B_DISEASE/B_MEASURE

LOCK O B_LOCATION/B_MEASURE
- O O
IN O B_LOCATION
AMP O I_LOCATION

CONTROLLER O B_PERSON/B_MEDICAL_DEVICE[OBJECT]

LOCK O B_LOCATION/B_DISEASE
- O O
IN O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

AMP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION

MICROFLOPPY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

DISK O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
24K O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
RAM O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

1 O B_NUMBER[MEASURE]/B_PERSON

Figure O B_MEASURE
7 O I_MEASURE
. O O

The O O
optoacoustic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
which O O
a O O
microcomputer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
is O O
used O O
to O O
control O O
laser O B_MEASURE
wavelength O I_MEASURE
and O O
to O O
monitor O O
laser O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
power O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
and O O
optoacoustic O B_MEASURE/B_ENT
signal O I_MEASURE/I_ENT
. O O

memory O B_MEASURE/B_PERSON
locations O B_MEASURE/I_PERSON
to O O
store O O
them O O
. O O

This O O
not O O
only O O
can O O
save O O
considerable O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
memory O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
also O O
allows O O
programs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
be O O
easily O O
relocatable O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
since O O
one O B_PERSON/B_ORGANIZATION
algorithm O I_PERSON/I_ORGANIZATION
need O O
only O O
know O O
that O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
routine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
left O O
so O O
many O B_MEASURE/B_ENT
words O I_MEASURE/I_ENT
of O O
data O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
etc O B_DISEASE/B_PROTEIN[GENE]
. O O
on O O
the O O
stack O B_LOCATION
. O O

It O O
need O O
not O O
know O O
where O O
the O O
previous O B_LOCATION
routine O I_LOCATION
is O O
nor O O
even O O
where O O
the O O
stack O B_LOCATION/B_SEQUENCE[MEASURE]
is O O
located O O
. O O

A O O
series O B_SPORT[ENT]/B_MEASURE
of O O
stack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
handling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
routines O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
which O O
should O O
appear O O
quite O O
familiar O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
many O B_PERSON
small O I_PERSON
calculator O I_PERSON
users O I_PERSON
, O O
provide O O
an O O
array O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
capabilities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
including O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
PUSH O O
a O O
number O B_MEASURE
on O O
the O O
stack O B_LOCATION
, O O
POP O B_DISEASE/B_GENE
, O O
it O O
off O O
, O O
duplicate O O
it O O
, O O
SWAP O O
the O O
top O B_MEASURE/B_ENT
two O I_MEASURE/I_ENT
numbers O I_MEASURE/I_ENT
, O O
locate O O
a O O
number O B_MEASURE
some O O
distance O B_MEASURE/B_LOCATION
into O O
the O O
stack O B_LOCATION
, O O
and O O
copy O O
it O O
on O O
top O B_PROTEIN[GENE]/B_LOCATION
of O O
the O O
stack O B_LOCATION/B_MEASURE
, O O
etc O B_LOCATION
. O O

Additionally O O
, O O
a O O
variety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
logic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
functions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
familiar O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
the O O
minicomputer O B_PERSON/B_LOCATION
user O I_PERSON/I_LOCATION
are O O
provided O O
including O O
OR O O
, O O
AND O O
, O O
shift O O
left O O
, O O
shift O O
right O O
, O O
greater O B_LOCATION/B_MEASURE
than O O
, O O
less O O
than O O
, O O
etc O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Input O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
output O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
O O B_PROTEIN[GENE]/B_LOCATION
) O O
is O O
normally O O
accomplished O O
using O O
the O O
stack O B_LOCATION/B_PERSON
in O O
conjunction O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
INDEVICE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
OUTDEVICE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
commands O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
to O O
take O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
a O O
device O B_PRODUCT[OBJECT]/B_LOCATION
located O O
at O O
I O O
/ O O
O O B_OTHER/B_LOCATION
, O O
port O B_LOCATION/B_MEASURE
7 O I_LOCATION/I_MEASURE
, O O
the O O
number O B_MEASURE/B_PERSON
seven O I_MEASURE/I_PERSON
is O O
" O O
pushed O O
" O O
onto O O
the O O
stack O B_LOCATION
( O O
7 O B_NUMBER[MEASURE]/B_LOCATION
) O O
, O O
goes O O
to O O
this O O
I O O
/ O O
O O B_LOCATION
port O I_LOCATION
, O O
takes O O
in O O
a O O
number O B_MEASURE
and O O
" O O
pushes O O
" O O
the O O
number O B_MEASURE
on O O
the O O
stack O B_LOCATION
. O O

OUTDEVICE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
functions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
a O O
similar O B_LOCATION/B_PERSON
manner O I_LOCATION/I_PERSON
, O O
requiring O O
the O O
number O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
sent O O
to O O
the O O
desired O B_PERSON
device O I_PERSON
to O O
be O O
" O O
pushed O O
" O O
onto O O
the O O
stack O B_LOCATION/B_PRODUCT[OBJECT]
followed O O
by O O
the O O
device O B_PRODUCT[OBJECT]/B_PERSON
' O O
s O B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
I O O
/ O O
O O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
port O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
address O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

Hence O O
, O O
to O O
send O O
the O O
number O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
131 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
to O O
device O B_NUMBER[MEASURE]/B_PERSON
11 O I_NUMBER[MEASURE]/I_PERSON
, O O
the O O
number O B_PERSON/B_PRODUCT[OBJECT]
131 O I_PERSON/I_PRODUCT[OBJECT]
is O O
pushed O O
on O O
the O O
stack O B_LOCATION/B_ENT
followed O O
by O O
11 O B_NUMBER[MEASURE]/B_PERSON
and O O
then O O
OUTDEVICE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

This O O
" O O
pops O O
" O O
the O O
top O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
( O O
11 O B_MEASURE
) O O
from O O
the O O
stack O B_LOCATION/B_ENT
, O O
uses O O
it O O
as O O
the O O
output O B_LOCATION/B_MEASURE
port O I_LOCATION/I_MEASURE
and O O
then O O
sends O O
the O O
number O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
131 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
that O O
location O B_LOCATION/B_MEASURE
. O O

SOUND O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

BELL O B_PERSON

BELL O B_PERSON

BELL O B_PERSON

The O O
colon O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
denotes O O
changing O O
from O O
EXECUTE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
COMPILE O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
mode O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

After O O
typing O O
the O O
name O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
new O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
routine O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
in O O
this O O
case O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
be O O
called O O
SOUND O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
typing O O
the O O
name O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
earlier O O
defined O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
routine O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
BELL O B_PERSON/B_TIME[MEASURE]
a O O
previously O O
defined O O
simple O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
rng O O
the O O
terminal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
initiates O O
a O O
dictionary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
search O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
locate O O
this O O
routine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O O
s O B_OTHER/B_DISEASE
starting O O
address O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
subsequentially O O
is O O
entered O O
three O B_TIME[MEASURE]/B_LOCATION
times O B_TIME[MEASURE]/I_LOCATION
. O O

The O O
resulting O O
SOUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
routine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
contains O O
machine O B_NUMBER[MEASURE]
code O I_NUMBER[MEASURE]
calls O O
to O O
the O O
BE O O
LL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
routine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O O
, O O
itself O O
, O O
is O O
composed O O
of O O
machine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Of O O
course O O
, O O
SOUND O B_ENT/B_PERSON
could O O
also O O
have O O
been O O
defined O O
using O O
a O O
DO O B_LOCATION/B_MEASURE
- O O
LOOP O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
i O O
. O O
e O B_DISEASE/B_LOCATION
. O O
SOUND O B_ENT/B_LOCATION
3 O I_ENT/I_LOCATION

DO O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

BELL O B_PERSON

LOOP O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

where O O
the O O
numbers O B_NUMBER[MEASURE]/B_ENT
three O I_NUMBER[MEASURE]/I_ENT
and O O
one O B_NUMBER[MEASURE]/B_LOCATION
set O O
the O O
upper O B_MEASURE
and O O
lower O B_MEASURE/B_LOCATION
indices O I_MEASURE/I_LOCATION
. O O

If O O
it O O
were O O
desirable O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
change O O
the O O
actual O B_MEASURE
number O I_MEASURE
of O O
bell O B_PERSON/B_ENT
rings O I_PERSON/I_ENT
from O O
some O O
other O B_MEASURE/B_LOCATION
program O I_MEASURE/I_LOCATION
, O O
this O O
value O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
defined O O
as O O
a O O
VARIABLE O B_PERSON/B_LOCATION
let O I_PERSON/I_LOCATION
' O O
s O B_OTHER/B_DISEASE
call O O
it O O
NOISE O B_ENT/B_MEASURE
. O O

3 O B_NUMBER[MEASURE]/B_PERSON

VARIABLE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOISE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
this O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
number O B_PERSON/B_MEASURE
three O I_PERSON/I_MEASURE
is O O
first O O
pushed O O
on O O
the O O
stack O B_LOCATION/B_BIO
, O O
VARIABLE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
transfers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
the O O
top O B_MEASURE
number O I_MEASURE
on O O
the O O
stack O B_LOCATION/B_MEASURE
( O O
the O O
three O B_MEASURE/B_LOCATION
) O O
to O O
a O O
dictionary O B_MEASURE
location O I_MEASURE
named O O
NOISE O B_ENT/B_MEASURE
. O O

If O O
SOUND O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
now O O
defined O O
as O O
: O O
SOUND O B_ENT/B_LOCATION

NOISE O B_ENT/B_DISEASE_ADJECTIVE[DISEASE]

@ O B_OTHER/B_PERSON

DO O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

BELL O B_PERSON

LOOP O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Applications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
CONVERS O B_EDU[ORGANIZATION]/B_PERSON
To O O
appreciate O O
the O O
ease O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
which O O
real O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
programs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
can O O
be O O
written O O
, O O
a O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
examples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
be O O
considered O O
. O O

A O O
trivial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
called O O
SOUND O B_MEASURE/B_ENT
, O O
which O O
rings O O
the O O
terminal O B_PERSON/B_LOCATION
bell O I_PERSON/I_LOCATION
three O I_PERSON/I_LOCATION
times O I_PERSON/I_LOCATION
, O O
might O O
be O O
written O O
: O O
132 O B_MEASURE/B_LOCATION

the O O
bell O B_PERSON/B_PRODUCT[OBJECT]
would O O
again O O
ring O O
three O B_TIME[MEASURE]/B_LOCATION
times O I_TIME[MEASURE]/I_LOCATION
. O O

In O O
this O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
when O O
the O O
word O B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOISE O I_SEQUENCE[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iS O O
encountered O O
, O O
its O O
address O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
pushed O O
on O O
the O O
stack O B_LOCATION/B_ENT
, O O
the O O
@ O O
is O O
a O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
which O O
goes O O
to O O
the O O
address O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O O
on O O
the O O
top O B_PROTEIN[GENE]/B_LOCATION
of O O
the O O
stack O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
that O O
of O O
NOISE O B_ENT/B_NUMBER[MEASURE]
) O O
and O O
replaces O O
it O O
with O O
the O O
actual O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
located O O
at O O
that O O
address O B_LOCATION/B_MEASURE
( O O
the O O
number O B_MEASURE/B_PERSON
three O I_MEASURE/I_PERSON
) O O
. O O

At O O
any O O
future O B_MEASURE/B_ENT
time O I_MEASURE/I_ENT
, O O
the O O
value O B_MEASURE/B_LOCATION
of O O
VARIABLE O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
changed O O
by O O
" O O
pushing O O
" O O
the O O
new O B_MEASURE
value O I_MEASURE
onto O O
the O O
stack O B_LOCATION/B_ENT
, O O
followed O O
by O O
the O O
address O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
variable O B_MEASURE
to O O
be O O
changed O O
, O O
generated O O
by O O
its O O
name O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
an O O
exclamation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mark O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

To O O
change O O
N O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IS O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
5 O B_TIME[MEASURE]/B_LOCATION
, O O
The O O
Journal O B_EDU[ORGANIZATION]
of O O
Automatic O B_EDU[ORGANIZATION]/B_PERSON
Chemistry O I_EDU[ORGANIZATION]/I_PERSON

Tilden O B_PERSON/B_LOCATION
& O O
Denton O B_LOCATION/B_PERSON

Advanced O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

5 O B_TIME[MEASURE]/B_LOCATION
NOISE O I_TIME[MEASURE]/I_LOCATION
a O O
number O B_MEASURE/B_PERSON
five O I_MEASURE/I_PERSON
is O O
pushed O O
onto O O
the O O
stack O B_LOCATION
, O O
NOISE O B_ENT/B_NUMBER[MEASURE]
pushes O O
its O O
address O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
on O O
the O O
stack O B_LOCATION/B_ENT
, O O
and O O
goes O O
to O O
the O O
address O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
by O O
the O O
" O O
top O B_GENE/B_MEASURE
" O O
number O B_MEASURE/B_LOCATION
on O O
the O O
stack O B_LOCATION/B_ENT
and O O
deposits O B_DISEASE/B_MEASURE
the O O
next O B_MEASURE
number O I_MEASURE
. O O

Now O O
sound O B_ENT/B_PERSON
would O O
ring O O
the O O
terminal O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
bell O B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
five O B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
times O B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

A O O
much O O
less O O
trivial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
which O O
could O O
be O O
written O O
to O O
scan O O
and O O
take O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
a O O
monochromator O B_PRODUCT[OBJECT]/B_PERSON
equipped O O
with O O
a O O

DENCO O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
SM2A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
stepper O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
motor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
controller O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
2 O B_PROTEIN[GENE]/B_MEASURE
] O I_PROTEIN[GENE]/I_MEASURE
( O O
the O O
SM2A O B_GENE/B_PERSON
takes O O
a O O
parallel O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
an O O
address O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sends O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
two O B_PERSON/B_NUMBER[MEASURE]
stepper O B_PERSON/I_NUMBER[MEASURE]
motors O B_PERSON/I_NUMBER[MEASURE]
to O O
this O O
location O B_LOCATION/B_ORGANIZATION
and O O
outputs O O
an O O
arrival O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flag O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
when O O
the O O
address O B_LOCATION/B_MEASURE
is O O
reached O O
) O O
is O O
given O O
in O O
Figure O B_MEASURE/B_PERSON
6 O I_MEASURE/I_PERSON
. O O

Assume O O
that O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
configured O O
so O O
the O O
SM2A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
at O O
I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
O O B_OTHER/B_PROTEIN[GENE]
, O O
port O B_MEASURE/B_LOCATION
5 O I_MEASURE/I_LOCATION
and O O
an O O
analog O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
digital O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
converter O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
to O O
acquire O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
at O O
I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
O O B_OTHER/B_LOCATION
, O O
port O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Let O O
us O O
assume O O
that O O
, O O
initially O O
, O O
a O O
scan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
designed O O
from O O
a O O
starting O O
stepper O B_MEASURE/B_LOCATION
motor O I_MEASURE/I_LOCATION
location O I_MEASURE/I_LOCATION
of O O
2000 O B_MEASURE
to O O
a O O
final O B_MEASURE/B_ENT
location O I_MEASURE/I_ENT
of O O
5000 O B_MEASURE
, O O
taking O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
every O O
20 O B_TIME[MEASURE]/B_ENT
steps O I_TIME[MEASURE]/I_ENT
. O O

The O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
illustrated O O
in O O
figure O B_MEASURE/B_LOCATION
6 O I_MEASURE/I_LOCATION
acts O I_MEASURE/I_LOCATION
in O O
the O O
following O B_LOCATION/B_ENT
manner O B_LOCATION/I_ENT
. O O

Line O B_LOCATION/B_ORGANIZATION
defines O O
a O O
variable O B_LOCATION/B_DISEASE
called O O
START O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
be O O
2000 O B_TIME[MEASURE]
, O O
which O O
is O O
the O O
starting O B_MEASURE
location O I_MEASURE
of O O
fhe O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scan O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
end O B_MEASURE/B_LOCATION
of O O
the O O
scan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
defined O O
as O O
5000 O B_NUMBER[MEASURE]/B_LOCATION
in O O
the O O
next O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
line O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
defines O O
the O O
increment O B_MEASURE/B_LOCATION
between O O
data O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
points O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
variable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
called O O
LOCATION O B_LOCATION/B_MEASURE
where O O
the O O
. O O
next O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
address O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
stored O O
is O O
defined O O
in O O
line O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
. O O

Colon O B_PERSON/B_NUMBER[MEASURE]
, O O
in O O
line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
5 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
puts O O
the O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
compile O B_LOCATION/B_PERSON
mode O I_LOCATION/I_PERSON
, O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
D7 O B_PROTEIN[GENE]/B_MEASURE
will O O
be O O
the O O
name O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
module O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
which O O
when O O
called O O
will O O
cause O O
a O O
7 O B_MEASURE/B_BIO
to O O
be O O
pushed O O
onto O O
the O O
stack O B_LOCATION/B_PRODUCT[OBJECT]
. O O

INDEVICE O B_PERSON
will O O
' O O
pop O O
' O O
it O O
back O O
off O O
and O O
use O O
it O O
as O O
a O O
device O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
address O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
go O O
and O O
take O O
a O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
point O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
push O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
onto O O
the O O
stack O B_LOCATION/B_PRODUCT[OBJECT]
. O O

Line O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defines O O
a O O
module O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
INITIALIZE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
START O B_LOCATION/B_PERSON
puts O O
its O O
address O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
the O O
stack O B_LOCATION/B_PERSON
, O O
@ O O
replaces O O
the O O
address O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
value O B_MEASURE
at O O
that O O
address O B_LOCATION/B_MEASURE
, O O
LOCATION O B_LOCATION
puts O O
its O O
address O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
stack O B_LOCATION/B_MEASURE
, O O
' O O
! O O
' O O
goes O O
to O O
the O O
address O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specified O O
by O O
the O O
number O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
stack O B_LOCATION/B_PERSON
and O O
deposits O B_LOCATION
the O O
second O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
net O B_MEASURE
result O I_MEASURE
value O I_MEASURE
at O O
START O B_LOCATION/B_MEASURE
is O O
put O O
into O O
LOCATION O B_LOCATION
. O O

Line O B_PERSON/B_LOCATION
7 O I_PERSON/I_LOCATION
defines O O
STEP O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
take O O
values O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
from O O

LOCATION O B_LOCATION/B_PERSON
and O O
INCREMENT O B_PERSON/B_ORGANIZATION
adds O O
them O O
together O O
and O O
puts O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
into O O
LOCATION O B_LOCATION/B_MEASURE
, O O
i O O
. O O
e O O
. O O
LOCATION O B_LOCATION/B_PERSON
puts O O
its O O
address O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
the O O
stack O B_LOCATION
, O O
@ O O
replaces O O
the O O
top O B_MEASURE
value O I_MEASURE
on O O
the O O
stack O B_LOCATION/B_MEASURE
with O O
the O O
number O B_MEASURE
stored O O
at O O
the O O
address O B_LOCATION/B_MEASURE
, O O
INCREMENT O B_LOCATION/B_ORGANIZATION
@ O O
gets O O
the O O
value O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
INCREMENT O B_LOCATION/B_MEASURE
and O O
puts O O
it O O
in O O
to O O
the O O
stack O B_LOCATION/B_MEASURE
, O O
and O O
adds O O
the O O
top O B_MEASURE/B_LOCATION
two O I_MEASURE/I_LOCATION
stack O I_MEASURE/I_LOCATION
numbers O I_MEASURE/I_LOCATION
and O O
pushes O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
the O O
stack O B_LOCATION
. O O

LOCATION O B_LOCATION/B_ORGANIZATION
puts O O
its O O
address O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
stack O B_LOCATION
and O O
goes O O
to O O
the O O
address O B_LOCATION/B_MEASURE
specified O O
by O O
the O O
top O B_PERSON/B_MEASURE
number O I_PERSON/I_MEASURE
on O O
the O O
stack O B_LOCATION
and O O
deposits O B_DISEASE/B_MEASURE
the O O
second O B_MEASURE
number O I_MEASURE
. O O

Themodule O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
defined O O
in O O
line O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
8 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
takes O O
a O O
number O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
stepper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
motor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
controller O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
assume O O
device O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbered O O
5 O B_NUMBER[MEASURE]
) O O
pushes O O
on O O
the O O
stack O B_LOCATION/B_PERSON
, O O
and O O
pushes O O
the O O
value O B_MEASURE/B_PRODUCT[OBJECT]
10 O B_MEASURE/I_PRODUCT[OBJECT]
on O O
the O O
stack O B_LOCATION/B_ORGANIZATION
and O O
does O O
a O O
logical O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O O
to O O
see O O
if O O
the O O
controllers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
flag O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
set O O
, O O
if O O
this O O
is O O
true O B_DISEASE_ADJECTIVE[DISEASE]
the O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
D7 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
module O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
called O O
to O O
input O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
if O O
the O O
flag O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
set O O
, O O
the O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
returned O O
to O O
BEGIN O O
- O O
HERE O O
. O O

Therefore O O
the O O
DELAY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
module O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
loop O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
waiting O O
for O O
the O O
stepper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
motor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
to O O
arrive O O
at O O
its O O
new O B_LOCATION/B_PERSON
location O I_LOCATION/I_PERSON
followed O O
by O O
a O O
call O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
D7 O B_LOCATION/B_PROTEIN[GENE]
data O I_LOCATION/I_PROTEIN[GENE]
acquisition O I_LOCATION/I_PROTEIN[GENE]
module O I_LOCATION/I_PROTEIN[GENE]
. O O

MOVE O B_LOCATION/B_PERSON
defined O O
in O O
line O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gets O O
the O O
value O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stored O O
at O O
LOCATION O B_LOCATION/B_PERSON
pushes O O
the O O
device O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
onto O O
the O O
stack O B_LOCATION/B_PRODUCT[OBJECT]
performs O O
an O O
outdevice O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
which O O
uses O O
the O O
top O B_LOCATION/B_MEASURE
stack O I_LOCATION/I_MEASURE
number O I_LOCATION/I_MEASURE
as O O
a O O
1 O B_MEASURE/B_LOCATION
/ O O
0 O B_MEASURE/B_LOCATION
port O I_MEASURE/I_LOCATION
address O I_MEASURE/I_LOCATION
to O O
send O O
the O O
next O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
call O O
the O O
STEP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
module O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
ie O O
the O O
value O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
LOCATION O B_LOCATION
) O O
, O O
this O O
increments O B_LOCATION/B_TIME[MEASURE]
LOCATION O B_LOCATION/I_TIME[MEASURE]
by O O
the O O
INCREM O B_MEASURE/B_LOCATION
E O I_MEASURE/I_LOCATION
N O I_MEASURE/I_LOCATION
T O I_MEASURE/I_LOCATION
value O I_MEASURE/I_LOCATION
and O O
finally O O
calls O O
D O B_LOCATION
E O I_LOCATION
L O I_LOCATION
A O I_LOCATION
Y O I_LOCATION
and O O
waits O O
for O O
a O O
flag O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
the O O
stepper O B_PERSON
motor O I_PERSON
controller O I_PERSON
to O O
signal O O
its O O
arrival O B_MEASURE
at O O
the O O
desired O B_LOCATION
address O I_LOCATION
and O O
then O O
takes O O
a O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
line O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shown O O
in O O
the O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Called O O
SCAN O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
itself O O
calls O O
the O O
INITIALIZE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
module O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
which O O
sets O O
LOCATION O B_LOCATION/B_MEASURE
to O O
the O O
START O B_LOCATION/B_PERSON
location O I_LOCATION/I_PERSON
for O O
the O O
Scan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
it O O
also O O
calls O O
MOVE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
which O O
sends O O
this O O
value O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
motor O B_PRODUCT[OBJECT]/B_PERSON
LOCATION O I_PRODUCT[OBJECT]/I_PERSON
controller O I_PRODUCT[OBJECT]/I_PERSON
, O O
increments O O
the O O
value O B_MEASURE
stored O O
in O O
LOCATION O B_LOCATION
by O O
INCREMENT O B_MEASURE/B_DISEASE
and O O
calls O B_TIME[MEASURE]/B_LOCATION
DELAY O I_TIME[MEASURE]/I_LOCATION
which O O
waits O O
for O O
the O O
motor O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
arrive O O
and O O
then O O
takes O O
a O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

Next O O
the O O
incremented O B_MEASURE/B_LOCATION
value O B_MEASURE/I_LOCATION
from O O
LOCATION O B_LOCATION/B_MEASURE
is O O
placed O O
on O O
the O O
stack O B_LOCATION/B_ENT
( O O
LOCATION O B_LOCATION
) O O
followed O O
by O O
the O O
STOP O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE

I0 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KW O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AMPLIFIER O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MATCHING O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

, O O
NETWORKIS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PREAMP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

MOTOR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
CON O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
TROL O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
ER O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION

MICRODISK O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
90K O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
byte O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

INTEL O B_LOCATION/B_ORGANIZATION
8080 O I_LOCATION/I_ORGANIZATION
based O O
MICROCOMPUTER O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
16K O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

RAM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

Figure O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
. O O

A O O
schematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
inductively O O
coupled O O
plasma O B_LOCATION
emission O I_LOCATION
spectrometer O I_LOCATION
in O O
which O O
the O O
microcomputer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
used O O
to O O
control O O
radio O B_MEASURE
frequency O I_MEASURE
power O I_MEASURE
and O O
' O O
flame O B_PERSON/B_LOCATION
' O O
positioning O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
as O O
well O O
as O O
to O O
monitor O O
light O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
intensity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Volume O B_MEASURE

No O O
. O O
3 O B_PERSON/B_MEASURE
April O I_PERSON/I_MEASURE
1979 O I_PERSON/I_MEASURE

133 O B_NUMBER[MEASURE]

Tilden O B_PERSON/B_LOCATION
& O O
Denton O B_LOCATION/B_PERSON

Advanced O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

value O B_MEASURE/B_LOCATION
( O O
STOP O B_LOCATION/B_MEASURE
@ O O
) O O
, O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
compared O O
to O O
to O O
see O O
if O O
the O O
incremented O B_MEASURE/B_LOCATION
value O I_MEASURE/I_LOCATION
at O O
LOCATION O B_LOCATION
is O O
larger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
then O O
the O O
STOP O B_MEASURE/B_LOCATION
value O I_MEASURE/I_LOCATION
, O O
if O O
it O O
is O O
the O O
program O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ends O O
, O O
if O O
not O O
, O O
it O O
repeats O O
the O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
starting O O
at O O
BEGIN O B_MEASURE/B_LOCATION
- O O
- O O
HERE O O
. O O

It O O
should O O
be O O
noted O O
that O O
whilst O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
variables O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
have O O
been O O
pushed O O
on O O
the O O
stack O B_LOCATION
, O O
only O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O O
remain O O
, O O
since O O
each O O
time O B_TIME[MEASURE]/B_LOCATION
a O O
value O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
used O O
it O O
is O O
' O O
popped O O
' O O
( O O
removed O O
) O O
from O O
the O O
stack O B_LOCATION
. O O

If O O
a O O
different O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectra O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
to O O
be O O
scanned O O
i O O
. O O
e O O
. O O
from O O
3000 O B_MEASURE
to O O
6500 O B_MEASURE
with O O
10 O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increments O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
variables O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
need O O
only O O
be O O

> O B_OTHER/B_PERSON

data O B_PERSON/B_ORGANIZATION
acquisition O I_PERSON/I_ORGANIZATION
programs O I_PERSON/I_ORGANIZATION
have O O
been O O
easily O O
implemented O O
. O O

Memory O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
operating O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
speed O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
found O O
to O O
be O O
far O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
conventional O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
approaches O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Additionally O O
, O O
new O B_PERSON/B_ORGANIZATION
system O I_PERSON/I_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
have O O
encountered O O
a O O
difficulty O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
utilising O O
previously O O
developed O O
custom O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O O
a O O
particular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
even O O
when O O
documentation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
vague O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
The O O
authors O B_PERSON/B_ORGANIZATION
hope O O
that O O
this O O
short O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
introduction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O O
only O O
a O O
few O B_MEASURE
of O O
the O O
concepts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
employed O O
in O O
CONVERS O B_ORGANIZATION/B_LOCATION
will O O
generate O O
interest O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O O
its O O
capabilities O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O O

A O O
much O O
more O O
complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discussion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
user O B_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
manual O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O O
3 O B_PERSON/B_MEASURE
] O I_PERSON/I_MEASURE
available O I_PERSON/I_MEASURE
from O O
the O O
authors O B_PERSON/B_ORGANIZATION
. O O

changed O O
thus O O
3000 O B_TIME[MEASURE]/B_LOCATION
START O I_TIME[MEASURE]
! O O

6500 O B_TIME[MEASURE]/B_LOCATION
STOP O O
10 O B_MEASURE
INCREMENT O I_MEASURE
and O O
type O B_MEASURE/B_LOCATION
SCAN O B_MEASURE/I_LOCATION
, O O
system O B_ORGANIZATION/B_PERSON
will O O
now O O
scan O O
from O O
3000 O B_NUMBER[MEASURE]
to O O
6500 O B_MEASURE/B_ORGANIZATION
taking O I_MEASURE/I_ORGANIZATION
data O I_MEASURE/I_ORGANIZATION
every O O
10 O B_TIME[MEASURE]/B_ENT
steps O I_TIME[MEASURE]/I_ENT
. O O

While O O
the O O
code O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
look O O
a O O
little O O
strange O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
first O O
, O O
it O O
quickly O O
becomes O O
very O O
easy O O
to O O
work O O
with O O
. O O

The O O
SCAN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
Figure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
combined O O
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
modules O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O O
shown O O
in O O
Figure O B_LOCATION/B_PERSON
5 O I_LOCATION/I_PERSON
to O O
perform O O
some O O
more O O
complex O B_DISEASE_ADJECTIVE[DISEASE]
experimental O I_DISEASE_ADJECTIVE[DISEASE]
function O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Each O O
module O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
the O O
program O B_ORGANIZATION/B_PRODUCT[OBJECT]
can O O
be O O
easily O O
tried O O
out O O
to O O
ensure O O
that O O
it O O
is O O
operational O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
proceeding O O
with O O
the O O
next O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
. O O

Presently O O
, O O
CONVERS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
being O O
used O O
in O O
the O O
authors O B_LOCATION/B_ORGANIZATION
' O I_LOCATION/I_ORGANIZATION
laboratories O I_LOCATION/I_ORGANIZATION
for O O
a O O
variety O B_ENT/B_MEASURE
of O O
spectrochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
investigations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
laser O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
excited O O
optoacoustic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectroscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_TIME[MEASURE]/B_ENT
7 O I_TIME[MEASURE]/I_ENT
) O O
and O O
inductively O O
coupled O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
optical O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emission O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectroscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
) O O
. O O

Rather O O
complex O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactive O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O

ACKNOWLEDGEMENTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
The O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
CONVERS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
was O O
partially O O
supported O O
by O O
the O O
Office O B_ORGANIZATION/B_LOCATION
of O O
Naval O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Research O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
Alfred O B_PERSON/B_LOCATION
P O I_PERSON/I_LOCATION
. O O
Cloan O B_PERSON/B_LOCATION
Foundation O I_PERSON/I_LOCATION
Research O I_PERSON/I_LOCATION
Fellowship O I_PERSON/I_LOCATION
to O O
M O B_OTHER/B_MEASURE
. O O

Bonnet O B_PERSON/B_LOCATION
Denton O I_PERSON/I_LOCATION
. O O

REFERENCES O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Moore O B_PERSON/B_TIME[MEASURE]
, O O
Astronomical O B_MEASURE/B_LOCATION
Astrophysics O I_MEASURE/I_LOCATION
Supplemental O I_MEASURE/I_LOCATION
, O O
15 O B_MEASURE
, O O
( O O
1974 O B_MEASURE
) O O
497 O B_MEASURE/B_LOCATION
. O O

[ O O
2 O B_TIME[MEASURE]
] O O
M O B_PROTEIN[GENE]/B_LOCATION
. O O
B O B_PROTEIN[GENE]/B_DISEASE
. O O

Denton O B_LOCATION/B_PERSON
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
D O B_OTHER/B_PERSON
. O O

Mack O B_PERSON/B_LOCATION
, O O
M O B_LOCATION
. O O
W O B_OTHER/B_PROTEIN[GENE]
. O O

Routh O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
B O B_OTHER/B_PERSON
. O O

SwartzClmerican O B_PERSON/B_BIO

[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Laboratory O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
8 O B_NUMBER[MEASURE]
, O O
69 O B_MEASURE
( O O
1976 O B_MEASURE
) O O
. O O

CONVERS O B_PERSON
An O O
Interpretive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Compiler O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
developed O O
by O O
Scott O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
Tilden O B_PERSON/B_COLOR
and O O
M O B_OTHER/B_PERSON
. O O

Bonner O B_PERSON/B_ORGANIZATION
Denton O I_PERSON/I_ORGANIZATION
, O O
Department O B_ORGANIZATION/B_PERSON
of O O
Chemistry O B_EDU[ORGANIZATION]/B_PERSON
, O O
University O B_LOCATION/B_ORGANIZATION
of O O
Arizona O B_LOCATION
, O O
Tucson O B_LOCATION/B_PERSON
, O O
Arizona O B_LOCATION
85721 O I_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
. O O

The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
a O O
microcomputer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
for O O
flexible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
automation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
a O O
liquid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT

chromatograph O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
D O B_OTHER/B_MEASURE
. O O

Mills O B_MEASURE/B_PERSON
, O O
i O O
. O O

Mackenzie O B_PERSON/B_COLOR
and O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
J O B_OTHER/B_PERSON
. O O

Dolphin O B_MEASURE/B_LOCATION
* O O
Philips O B_LOCATION
Research O I_LOCATION
Laboratories O I_LOCATION
, O O
Redhill O B_LOCATION/B_PERSON
, O O
Surrey O B_LOCATION
, O O
RH1 O B_LOCATION
5HA O I_LOCATION
, O O
U O B_LOCATION
. O O
K O B_OTHER/B_LOCATION
. O O

Introduction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Microprocessors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
being O O
used O O
to O O
add O O
inexpensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
automatic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
data O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
handling O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
facilities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
variety O B_ENT/B_MEASURE
of O O
chemical O B_ORGANIZATION/B_LOCATION
instruments O B_ORGANIZATION/I_LOCATION
. O O

With O O
a O O
microcomputer O B_PRODUCT[OBJECT]/B_PERSON
it O O
is O O
now O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
realise O O
the O O
flexibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
formerly O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
with O O
a O O
relatively O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
expensive O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
minicomputer O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O O
an O O
instrument O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
little O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
size O B_MEASURE/B_LOCATION
and O O
cost O B_MEASURE
from O O
one O B_TIME[MEASURE]/B_PERSON
controlled O O
by O O
inflexible O B_ORGANIZATION
hardware O I_ORGANIZATION
. O O

In O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ways O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chromatography O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
an O O
ideal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
such O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
automation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Most O B_PERSON
instruments O I_PERSON
are O O
given O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
workload O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
, O O
although O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
applications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
routine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
repetitive O B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
versatility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
requires O O
an O O
instrument O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
can O O
easily O O
be O O
used O O
in O O
a O O
variety O B_ENT/B_MEASURE
of O O
modes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
improving O O
the O O
convenience O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
user O B_PERSON
, O O
automation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PRODUCT[OBJECT]
of O O
a O O
liquid O B_ENT
chromatrograph O I_ENT
should O O
enhance O O
the O O
performance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
instrument O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Some O O
aspects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
high O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
liquid O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HPLC O B_LOCATION/B_ORGANIZATION
) O O
which O O
can O O
benefit O O
in O O
this O O
way O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
as O O
follows O O
: O O
( O O
1 O B_SEQUENCE[MEASURE]
) O O
Accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
solvent O B_MEASURE
flow O I_MEASURE
rate O I_MEASURE
will O O
compensate O O
for O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
pressure O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drop O O
and O O
lead O O
to O O
more O O
reliable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
retention O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
times O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

( O O
2 O O
) O O
The O O
composition O B_MEASURE/B_ENT
of O O
the O O
mobile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
can O O
be O O
accurately O O
controlled O O
in O O
either O O
isocratic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
gradient O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
elution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chromatography O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O O
, O O
for O O
example O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
a O O
proportioning O O
valve O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
the O O
low O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
pressure O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
side O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
pump O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

( O O
3 O O
) O O
Automatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sampling O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O O
be O O
operated O O
in O O
a O O
variety O B_ENT/B_MEASURE
of O O
modes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
process O O
a O O
number O B_MEASURE
of O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
supervision O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
also O O
more O O
precise O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
manual O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
injection O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

( O O
4 O O
) O O
A O O
built O O
- O O
in O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
handling O O
facility O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
present O O
the O O
analyst O B_PERSON
with O O
an O O
easily O O
read O O
post O B_LOCATION/B_MEASURE
- O O
run O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
the O O
analytical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
accurate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
peak O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
area O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
measurements O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
even O O
for O O
peaks O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
which O O
are O O
poorly O O
resolved O O
. O O

Although O O
liquid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatographs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incorporating O O
microprocessors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
handling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
purposes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
commercially O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
these O O
instruments O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
, O O
so O O
far O O
, O O
This O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
describes O O
, O O
in O O
detail O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
relatively O O
inflexible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O
automation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
of O O
a O O
liquid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
chromatograph O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O O
an O O
inexpensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
general O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
purpose O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microcomputer O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
has O O
previously O O
been O O
applied O O
in O O
atomic O B_LOCATION/B_ORGANIZATION
absorption O I_LOCATION/I_ORGANIZATION
spectrophotometry O I_LOCATION/I_ORGANIZATION
[ O O
1 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
for O O
column O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
switching O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
HPLC O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
2 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O O

Figure O B_PERSON/B_LOCATION
illustrates O O
the O O
interconnection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
chromatograph O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
and O O
the O O
microcomputer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
which O O
controls O O
the O O
mobile O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
operates O O
an O O
automatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sampler O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
analyses O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
the O O
detector O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
handling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
functions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
integrated O O
in O O
a O O
program O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
enables O O
the O O
user O B_PERSON
to O O
communicate O O
with O O
the O O
instrument O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
plain O B_MEASURE/B_LOCATION
English O I_MEASURE/I_LOCATION
, O O
via O O
a O O
visual O B_PRODUCT[OBJECT]/B_PERSON
display O I_PRODUCT[OBJECT]/I_PERSON
unit O I_PRODUCT[OBJECT]/I_PERSON
( O O
VDU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
or O O
teletypewriter O B_PRODUCT[OBJECT]/B_ENT
keyboard O I_PRODUCT[OBJECT]/I_ENT
. O O

A O O
variety O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
operational O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
modes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
offered O O
, O O
giving O O
the O O
analyst O B_PERSON
an O O
opportunity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
establish O O
the O O
best O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conditions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
a O O
particular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
separation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
before O O
leaving O O
the O O
instrument O B_SPORT[ENT]/B_LOCATION
to O O
perform O O
its O O
given O O
tasks O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
microcomputer O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hardware O I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
The O O
computer O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
purpose O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
instrument O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
constructed O O
using O O
a O O
set O B_GENE/B_LOCATION
of O O
ready O B_TIME[MEASURE]/B_LOCATION
made O O
circuit O B_PRODUCT[OBJECT]/B_PERSON
cards O I_PRODUCT[OBJECT]/I_PERSON
( O O
Philips O B_TIME[MEASURE]/B_EDU[ORGANIZATION]
, O O
Science O B_ORGANIZATION/B_LOCATION
and O O
The O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Journal O B_ORGANIZATION/B_LOCATION
of O O
Automatic O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chemistry O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

* O B_MEASURE/B_LOCATION
Present O I_MEASURE/I_LOCATION
address O I_MEASURE/I_LOCATION
: O O
lye O B_LOCATION/B_PERSON
Unicam O I_LOCATION/I_PERSON
Ltd O I_LOCATION/I_PERSON
. O O
, O O
York O B_LOCATION/B_ORGANIZATION
Street O I_LOCATION/I_ORGANIZATION
, O O
Cambridge O B_LOCATION
, O O
CB1 O B_LOCATION/B_PERSON
2PX O I_LOCATION/I_PERSON
, O O
U O B_LOCATION
. O O
K O B_OTHER/B_LOCATION
. O O

134 O B_NUMBER[MEASURE]

TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O O
Fast O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flexible O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
constraints O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
major O B_DISEASE_ADJECTIVE[DISEASE]
challenges O I_DISEASE_ADJECTIVE[DISEASE]
in O O
structural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
bioinformatics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O O

Despite O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
many O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
tools O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
algorithms O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
very O O
few O B_NUMBER[MEASURE]/B_PERSON
of O O
them O O
have O O
managed O O
to O O
capture O O
the O O
intuitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
understanding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O O
in O O
structural O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biology O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
especially O O
in O O
the O O
context O B_LOCATION
of O O
rapid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
database O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
searches O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
intuitions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
could O O
help O O
speed O O
up O O
similarity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
searches O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
make O O
it O O
easier O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
understand O O
the O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

We O O
developed O O
a O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
uses O O
an O O
intuitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
proteins O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
structures O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
captured O O
in O O
the O O
popular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
diagrams O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
limit O O
the O O
search O B_MEASURE
space O I_MEASURE
of O O
the O O
aligned O O
fragment O B_LOCATION/B_BIO
pairs O I_LOCATION/I_BIO
( O O
AFPs O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O O
by O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O O

The O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
faster O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
an O O
order O B_MEASURE/B_DISEASE
of O O
magnitude O B_NUMBER[MEASURE]
with O O
a O O
minimal O B_MEASURE
cost O I_MEASURE
in O O
classification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
accuracy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

For O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
its O O
accuracy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O O
because O O
the O O
TOPS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
+ O O
strings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
contains O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O O
parallel O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
hydrogen O B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
- O O
bond O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
patterns O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
beta O B_GENE/B_NUMBER[MEASURE]
- O O
strand O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
SSEs O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
Secondary O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Structural O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Elements O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

We O O
show O O
that O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
errors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rare O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
as O O
they O O
are O O
, O O
can O O
be O O
clearly O O
linked O O
to O O
oversimplifications O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
of O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagrams O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
can O O
be O O
corrected O O
by O O
the O O
development O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
more O O
precise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secondary O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
definitions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Software O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Availability O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

The O O
benchmark O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
the O O
compressed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
archive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Linux O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
platform O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O O
be O O
downloaded O O
from O O
the O O
following O O
web O B_LOCATION/B_ORGANIZATION
site O I_LOCATION/I_ORGANIZATION
: O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provides O O
FATCAT O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
accuracy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
insights O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
speed O B_MEASURE/B_LOCATION
comparable O I_MEASURE/I_LOCATION
to O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alignments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
opening O O
up O O
a O O
possibility O B_LOCATION/B_MEASURE
of O O
interactive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
protein O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
similarity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
searches O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Structural O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biology O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
most O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fields O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
modern O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biology O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Over O O
50 O B_MEASURE
, O O
000 O B_MEASURE
solved O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
illustrate O O
details O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
specific O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
biological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
also O O
provide O O
us O O
with O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O O
the O O
global O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
protein O B_LOCATION/B_BIO
structure O I_LOCATION/I_BIO
space O I_LOCATION/I_BIO
and O O
can O O
be O O
studied O O
to O O
discover O O
the O O
evolutionary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
physical O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
mathematical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
rules O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
governing O O
them O O
. O O

How O O
many O B_NUMBER[MEASURE]/B_PERSON
fundamentally O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
protein O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
shapes O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
folds O B_LOCATION/B_LANGUAGE
) O O
are O O
there O O
? O O

How O O
do O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
structures O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
evolve O O
? O O

How O O
do O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O O
, O O
and O O
if O O
they O O
are O O
coupled O O
with O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
how O O
does O O
this O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
occur O O
? O O

Such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
questions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O O
be O O
studied O O
by O O
classifying O O
, O O
comparing O O
and O O
analyzing O O
known O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
synergistic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
strategies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
are O O
typically O O
used O O
for O O
this O O
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
classification O O
systems O O
such O O
as O O
SCOP O O
[ O O
1 O O
] O O
or O O
CATH O O
[ O O
2 O O
] O O
, O O
human B B_PERSON/B_SPECIES[BIO]
intuition O O
is O O
used O O
to O O
simplify O O
the O O
description O O
of O O
protein O O
structures O O
to O O
a O O
manageable O O
size O O
, O O
and O O
a O O
human B B_PERSON/B_SPECIES[BIO]
eye O O
, O O
sometimes O O
supported O O
by O O
automated O O
analysis O O
, O O
can O O
recognize O O
patterns O O
and O O
types O O
of O O
structures O O
. O O

In O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
specialized O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
comparison O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
algorithms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
DALI O B_LOCATION/B_ORGANIZATION
[ O O
3 O B_MEASURE
] O I_MEASURE
, O O
CE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O O
4 O B_MEASURE
] O I_MEASURE
, O O
or O O
FATCAT O B_LOCATION
[ O O
5 O B_MEASURE
] O I_MEASURE
can O O
be O O
used O O
to O O
calculate O O
a O O
distance O B_MEASURE/B_LOCATION
- O O
like O B_MEASURE/B_LOCATION
metric O I_MEASURE/I_LOCATION
in O O
the O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
space O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

This O O
in O O
turn O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
used O O
to O O
cluster O O
proteins O B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
such O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
algorithms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
have O O
been O O
developed O O
over O O
the O O
past O B_TIME[MEASURE]
few O I_TIME[MEASURE]
decades O I_TIME[MEASURE]
and O O
have O O
been O O
mostly O O
used O O
for O O
the O O
classification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
structures O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
into O O
families O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

An O O
exact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
solution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
an O O
alignment O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
two O B_LOCATION/B_PERSON
structures O I_LOCATION/I_PERSON
is O O
formally O O
equivalent O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
threading O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
problem O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
is O O
therefore O O
NP O B_DISEASE/B_MEASURE
- O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O O
6 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

However O O
, O O
a O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
obtained O O
by O O
heuristics O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
reducing O O
the O O
problem O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
a O O
manageable O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
size O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
human B B_PERSON/B_BIO
classification O O
systems O O
, O O
the O O
protein O O
is O O
usually O O
reduced O O
to O O
a O O
set O O
of O O
several O O
structural O O
elements O O
, O O
which O O
obviously O O
involve O O
many O O
arbitrary O O
thresholds O O
. O O

Automated O O
algorithms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
the O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
also O O
suffer O O
from O O
inconsistencies O B_DISEASE_ADJECTIVE[DISEASE]
between O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
numerical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
protein O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
structure O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
similarity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
8 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

Interestingly O O
, O O
despite O O
these O O
problems O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
broadly O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

They O O
all O O
identify O O
approximately O O
a O O
few O B_MEASURE/B_LOCATION
hundred O I_MEASURE/I_LOCATION
general O I_MEASURE/I_LOCATION
classes O I_MEASURE/I_LOCATION
of O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
usually O O
called O O
folds O B_LOCATION/B_LANGUAGE
[ O O
1 O B_NUMBER[MEASURE]/B_LOCATION
] O I_NUMBER[MEASURE]/I_LOCATION
or O O
topologies O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
2 O B_NUMBER[MEASURE]/B_LOCATION
] O I_NUMBER[MEASURE]/I_LOCATION
, O O
distinguished O O
by O O
how O O
the O O
main O B_LOCATION/B_MEASURE
chain O I_LOCATION/I_MEASURE
of O O
the O O
protein O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
folds O O
around O O
itself O O
in O O
the O O
three O B_NUMBER[MEASURE]
- O O
dimensional O B_MEASURE/B_LOCATION
space O I_MEASURE/I_LOCATION
. O O

At O O
the O O
same O B_MEASURE/B_LOCATION
time O I_MEASURE/I_LOCATION
, O O
the O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
both O O
between O O
and O O
within O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
shows O O
that O O
fold O B_LOCATION/B_ORGANIZATION
/ O O
topologies O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
( O O
or O O
cluster O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
definitions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
somewhat O O
fuzzy O B_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
some O O
proteins O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O O
occasionally O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
classify O O
and O O
joining O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
groups O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
depending O O
on O O
various O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assumptions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

This O O
lead O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
some O O
to O O
question O O
the O O
concept O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
fold O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
[ O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
9 O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
] O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
leaves O O
little O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
doubt O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
protein O B_LOCATION/B_MEASURE
structure O I_LOCATION/I_MEASURE
space O I_LOCATION/I_MEASURE
has O O
some O O
natural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
granularity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
overlaps O O
well O O
with O O
the O O
traditional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fold O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
classification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
significantly O O
simplified O O
by O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
proteins O B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
naturally O O
modular O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
structures O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
being O O
mostly O O
composed O O
of O O
locally O O
regular O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
structures O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O O
alpha O B_PROTEIN[GENE]/B_LOCATION
helices O I_PROTEIN[GENE]/I_LOCATION
and O O
beta O B_LOCATION/B_BIO
strands O I_LOCATION/I_BIO
. O O

These O O
two O B_MEASURE/B_LOCATION
types O I_MEASURE/I_LOCATION
of O O
secondary O B_LOCATION/B_GENE
structures O B_LOCATION/I_GENE
constitute O O
a O O
little O B_PERSON/B_MEASURE
over O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
an O O
average O B_MEASURE/B_BIO
protein O B_MEASURE/I_BIO
' O O
s O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
. O O

With O O
the O O
average O B_MEASURE
length O I_MEASURE
of O O
a O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
being O O
around O O
10 O B_NUMBER[MEASURE]
amino O I_NUMBER[MEASURE]
acids O I_NUMBER[MEASURE]
, O O
this O O
makes O O
it O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
describe O O
protein O B_GENE/B_LOCATION
structure O I_GENE/I_LOCATION
as O O
an O O
arrangement O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
much O O
smaller O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
elements O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Protein O B_MEASURE/B_PERSON
structures O B_MEASURE/I_PERSON
are O O
often O O
visualized O O
in O O
a O O
simplified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
with O O
the O O
so O O
- O O
called O O
ribbon O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagram O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
secondary O B_LOCATION/B_PERSON
structures O I_LOCATION/I_PERSON
shown O O
as O O
helices O B_LOCATION/B_PERSON
and O O
arrows O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
being O O
the O O
most O O
popular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
see O O
Figure O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
) O O
. O O

This O O
picture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
be O O
simplified O O
further O O
by O O
showing O O
individual O B_PERSON/B_LOCATION
secondary O I_PERSON/I_LOCATION
structure O I_PERSON/I_LOCATION
elements O I_PERSON/I_LOCATION
as O O
simple O B_LOCATION/B_PERSON
symbols O I_LOCATION/I_PERSON
( O O
circles O B_LOCATION/B_BIO
or O O
boxes O B_LOCATION/B_BIO
/ O O
triangles O B_BIO/B_LOCATION
) O O
. O O

These O O
depictions O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
called O O
fold O B_LOCATION
diagrams O I_LOCATION
, O O
originally O O
proposed O O
in O O
the O O
70s O B_SEQUENCE[MEASURE]/B_LOCATION
[ O I_SEQUENCE[MEASURE]/I_LOCATION
10 O I_SEQUENCE[MEASURE]/I_LOCATION
- O O
12 O B_MEASURE
] O I_MEASURE
are O O
best O O
captured O O
by O O
a O O
TOPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
Topology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
Protein O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
Structures O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
) O O
algorithm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
, O O
which O O
attempts O O
to O O
automate O O
the O O
process O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
creation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
the O O
topology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cartoon O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
13 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

While O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
, O O
such O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
simplified O O
descriptions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
not O O
used O O
in O O
the O O
most O O
popular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
automated O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
algorithms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
DALI O B_LOCATION/B_ORGANIZATION
[ O I_LOCATION/I_ORGANIZATION
3 O I_LOCATION/I_ORGANIZATION
] O I_LOCATION/I_ORGANIZATION
or O O
CE O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
4 O B_MEASURE
] O I_MEASURE
. O O

Kleywegt O B_PERSON
and O O
Jones O B_PERSON
developed O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
finding O O
similar O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
motifs O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
comparing O O
distance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
matrices O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
are O O
constructed O O
by O O
representing O O
protein O B_BIO/B_GENE
as O O
a O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O O
SSEs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
their O O
directional O B_MEASURE/B_LOCATION
vectors O I_MEASURE/I_LOCATION
and O O
angle O B_MEASURE/B_LOCATION
between O O
those O O
vectors O B_PROTEIN[GENE]/B_LOCATION
[ O O
14 O B_MEASURE/B_PERSON
] O B_MEASURE/I_PERSON
. O O

Programs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
used O O
SSEs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
either O O
for O O
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O O
on O O
hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
superposition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
both O O
SSEs O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
atomic O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
representation O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
15 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
or O O
for O O
finding O O
common O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substructures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
based O O
on O O
subgraph O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
isomorphism O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
[ O B_TIME[MEASURE]
16 O I_TIME[MEASURE]
, O O
17 O B_MEASURE
] O I_MEASURE
and O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
applications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diagram O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
18 O B_MEASURE
, O O
19 O B_MEASURE
] O I_MEASURE
, O O
usually O O
struggle O O
with O O
translating O O
the O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O O
the O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
the O O
individual O B_MEASURE/B_PERSON
residue O B_MEASURE/I_PERSON
level O B_MEASURE/I_PERSON
. O O

Although O O
the O O
SSM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
uses O O
graph O B_MEASURE/B_LOCATION
- O O
matching O O
procedures O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O O
the O O
SSE O B_LOCATION/B_MEASURE
level O I_LOCATION/I_MEASURE
followed O O
by O O
an O O
interactive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3D O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
protein O B_DISEASE/B_PROTEIN[GENE]
C O B_DISEASE/I_PROTEIN[GENE]
- O O
alpha O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
atom O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
20 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
, O O
it O O
lacks O O
the O O
topological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relationships O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
the O O
SSEs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
which O O
are O O
essential O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
identifying O O
common O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scaffolds O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
distantly O O
related O O
proteins O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

A O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
to O O
guide O O
the O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
for O O
instance O B_TIME[MEASURE]/B_DISEASE
, O O
to O O
build O O
multiple O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structural O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignments O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
distantly O O
related O O
family O B_PERSON/B_LOCATION
of O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domains O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
21 O B_GENE/B_LOCATION
] O I_GENE/I_LOCATION
. O O

The O O
Multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Tool O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
MSAT O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
automates O O
this O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
merging O O
it O O
with O O
a O O
popular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ClustalW O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O O
22 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

DALI O B_MEASURE
[ O I_MEASURE
3 O I_MEASURE
] O O
, O O
CE O B_LOCATION
[ O O
4 O B_NUMBER[MEASURE]
] O O
or O O
FATCAT O B_LOCATION/B_ORGANIZATION
[ O O
5 O B_MEASURE
] O O
introduce O O
their O O
own O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
methods O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
decomposing O O
the O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O O
smaller O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
units O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
7 O B_MEASURE
x O O
7 O B_MEASURE/B_LOCATION
dense O I_MEASURE/I_LOCATION
distance O I_MEASURE/I_LOCATION
map O I_MEASURE/I_LOCATION
fragments O O
( O O
DALIs O B_LOCATION/B_ORGANIZATION
) O O
or O O
aligned O O
fragment O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pairs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
AFPs O B_DISEASE/B_GENE
) O O
( O O
CE O B_LOCATION
and O O
FATCAT O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
large O B_MEASURE/B_LOCATION
number O B_MEASURE/I_LOCATION
of O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fragments O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
the O O
combinations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
fragments O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
need O O
to O O
be O O
evaluated O O
by O O
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
programs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
the O O
main O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reason O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
computational O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
algorithms O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
more O O
importantly O O
, O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O B_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
used O O
here O O
to O O
enable O O
a O O
structural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
takes O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flexibility O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
not O O
only O O
classifies O O
the O O
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
but O O
also O O
can O O
recognize O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
rearrangements O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O O
which O O
is O O
a O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
the O O
SSEs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
language O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

In O O
this O O
contribution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
we O O
explore O O
the O O
question O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
whether O O
it O O
would O O
be O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
combine O O
insights O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provided O O
by O O
topology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diagrams O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
into O O
automated O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
algorithms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
focusing O O
on O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O O
previously O O
in O O
our O O
group O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
a O O
unique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
allows O O
for O O
flexibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
structures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
being O O
compared O O
. O O

It O O
builds O O
the O O
alignment O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
chaining O O
aligned O O
fragment O B_LOCATION/B_PERSON
pairs O I_LOCATION/I_PERSON
( O O
AFPs O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
[ O O
23 O B_TIME[MEASURE]/B_LOCATION
] O O
together O O
using O O
a O O
unified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
function O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
where O O
AFP O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
extensions O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
gaps O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
twists O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
each O O
have O O
their O O
specific O B_MEASURE/B_PERSON
scores O B_MEASURE/I_PERSON
( O O
Figure O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
) O O
. O O

Introducing O O
a O O
twist O B_MEASURE/B_PERSON
into O O
the O O
alignment O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
penalized O O
, O O
but O O
this O O
penalty O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
compensated O O
for O O
by O O
the O O
gain O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
score O B_MEASURE/B_LOCATION
of O O
the O O
resulting O O
alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
i O O
. O O
e O O
. O O
, O O
longer O O
alignment O B_DISEASE/B_MEASURE
and O O
/ O O
or O O
better O B_DISEASE/B_MEASURE
RMSD O I_DISEASE/I_MEASURE
) O O
. O O

Rigid O B_PERSON
alignment O I_PERSON
can O O
be O O
treated O O
as O O
a O O
special O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
in O O
which O O
no O O
twist O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
allowed O O
in O O
chaining O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

FATCAT O B_PERSON/B_ORGANIZATION
program O I_PERSON/I_ORGANIZATION
provides O O
alignment O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
, O O
" O O
rigid O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
" O O
mode O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
" O O
flexible O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
" O O
( O O
default O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
) O O
mode O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
as O O
well O O
as O O
most O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
protein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
structure O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
comparison O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
programs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
is O O
very O O
slow O B_DISEASE_ADJECTIVE[DISEASE]
when O O
compared O O
to O O
sequence O O
alignments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
computing O B_MEASURE
time O I_MEASURE
of O O
FATCAT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
determined O O
by O O
the O O
size O B_MEASURE/B_LOCATION
of O O
the O O
collection O B_LOCATION/B_MEASURE
of O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O O
between O O
the O O
two O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O O
compared O O
. O O

FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
a O O
server O B_PERSON/B_LOCATION
with O O
an O O
option O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O O
search O O
in O O
SCOP O B_ORGANIZATION/B_LOCATION
or O O
PDB O B_LOCATION/B_ORGANIZATION
databases O I_LOCATION/I_ORGANIZATION
for O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
search O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
typically O O
takes O O
between O O
8 O B_NUMBER[MEASURE]
to O O
16 O B_MEASURE/B_ENT
hours O I_MEASURE/I_ENT
of O O
CPU O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
time O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
this O O
is O O
the O O
main O B_MEASURE/B_LOCATION
obstacle O B_MEASURE/I_LOCATION
to O O
broader O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
this O O
option O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

FATCAT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O O
been O O
used O O
to O O
construct O O
a O O
Flexible O B_LOCATION
Structure O I_LOCATION
Neighborhood O I_LOCATION
( O O
FSN O B_LOCATION/B_ORGANIZATION
) O O
database O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
contains O O
pre O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
computed O O
results O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
structure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
similarity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
searches O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
it O O
takes O O
several O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
CPU O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
update O O
the O O
FSN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
protein O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
resources O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
DALI O B_LOCATION/B_ORGANIZATION
or O O
CE O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
very O O
similar O B_DISEASE_ADJECTIVE[DISEASE]
problems O I_DISEASE_ADJECTIVE[DISEASE]
. O O

TOPS O B_LOCATION/B_ENT
cartoons O I_LOCATION/I_ENT
and O O
TOPS O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
graph O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT

As O O
discussed O O
in O O
the O O
Background O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cartoons O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
capture O O
the O O
simplified O O
, O O
fold O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O O
level O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
protein O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
at O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O B_TIME[MEASURE]/I_LOCATION
can O O
be O O
automated O O
[ O O
24 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
uses O O
structural O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
hydrogen O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bonds O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
chirality O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
beta O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strands O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
provide O O
a O O
scoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
optimize O O
the O O
cartoon O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
see O O
Figure O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
b O B_OTHER/B_MEASURE
) O O
) O O
. O O

In O O
TOPS O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
the O O
secondary O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structural O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
elements O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SSEs O B_MEASURE/B_DISEASE
) O O
are O O
derived O O
from O O
the O O
DSSP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O O
25 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Based O O
on O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cartoons O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
a O O
formal O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
graph O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
graph O B_ORGANIZATION/B_MEASURE
- O O
based O O
definitions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
topology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
pattern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
discovery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O O
developed O O
[ O O
26 O B_MEASURE
, O O
27 O B_MEASURE/B_GENE
] O B_MEASURE/I_GENE
. O O

The O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pattern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discovery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
matching O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
accessible O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
. O O

Novel O B_PERSON/B_MEASURE
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_OTHER/B_LOCATION
and O O
TOPS O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ O I_LOCATION
strings O I_LOCATION
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

The O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
was O O
further O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
to O O
incorporate O O
features O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
such O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
protein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
ligand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
more O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secondary O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
segment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
enhanced O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
called O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
see O O
Figure O B_MEASURE/B_LOCATION
3a O I_MEASURE/I_LOCATION
) O O
. O O

This O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
described O O
formally O O
in O O
a O O
TOPS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
+ O I_LOCATION
strings O I_LOCATION
language O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
3b O B_MEASURE/I_PROTEIN[GENE]
) O O
at O O
a O O
reduced O O
linear O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
. O O

The O O
enhanced O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
can O O
be O O
used O O
in O O
fast O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
string O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
based O O
structure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
matching O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
comparison O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
at O O
the O O
same O B_MEASURE/B_LOCATION
time O I_MEASURE/I_LOCATION
avoiding O O
issues O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
NP O B_DISEASE/B_MEASURE
- O O
completeness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
associated O O
with O O
graph O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
alignments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

In O O
detail O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
each O O
node O B_LOCATION/B_MEASURE
( O O
SSE O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
segment O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
) O O
of O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
described O O
by O O
its O O
type O B_MEASURE/B_LOCATION
, O O
orientation O B_MEASURE/B_EDU[ORGANIZATION]
, O O
PDB O B_MEASURE/B_LOCATION
start O I_MEASURE/I_LOCATION
number O I_MEASURE/I_LOCATION
, O O
segment O B_MEASURE/B_LOCATION
length O B_MEASURE/I_LOCATION
, O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
incoming O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
InArc O B_LOCATION/B_ORGANIZATION
) O O
and O O
outgoing O B_TIME[MEASURE]/B_LOCATION
( O O
OutArc O B_LOCATION/B_ORGANIZATION
) O O
arcs O B_LOCATION/B_PERSON
( O O
edges O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
, O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
ArcTypes O B_LOCATION/B_ORGANIZATION
, O O
and O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
ligand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arcs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
LigArc O B_LOCATION/B_PERSON
) O O
. O O

The O O
type O B_MEASURE/B_LOCATION
of O O
the O O
segment O B_LOCATION/B_PROTEIN[GENE]
( O O
SSEType O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
could O O
be O O
one O B_MEASURE/B_PERSON
of O O
[ O O
E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
e O O
, O O
H O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
h O O
, O O
U O B_PROTEIN[GENE]/B_LOCATION
, O O
u O B_LOCATION/B_PROTEIN[GENE]
] O I_LOCATION/I_PROTEIN[GENE]
, O O
where O O
, O O
" O O
E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
and O O
" O O
e O O
" O O
represent O O
the O O
" O O
up O O
" O O
- O O
and O O
" O O
down O O
" O O
- O O
oriented O O
beta O B_LOCATION/B_PERSON
strands O I_LOCATION/I_PERSON
; O O
" O O
H O B_OTHER/B_PROTEIN[GENE]
" O O
and O O
" O O
h O O
" O O
indicate O O
the O O
" O O
up O O
" O O
- O O
and O O
" O O
down O O
" O O
- O O
oriented O O
alpha O B_LOCATION/B_BIO
helices O I_LOCATION/I_BIO
; O O
and O O
" O O
U O B_OTHER/B_PROTEIN[GENE]
" O O
and O O
" O O
u O B_OTHER/B_PROTEIN[GENE]
" O O
represent O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
bound O O
and O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]
loops O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
InArcType O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
be O O
classified O O
as O O
an O O
/ O O
a O O
[ O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
L O B_PROTEIN[GENE]/B_LOCATION
, O O
P O B_PROTEIN[GENE]/B_LOCATION
, O O
A O O
] O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
where O O
" O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
and O O
" O O
L O B_PROTEIN[GENE]/B_LOCATION
" O O
represent O O
right O B_SEQUENCE[MEASURE]/B_LOCATION
and O O
left O O
chiralities O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
; O O
and O O
" O O
P O B_PROTEIN[GENE]/B_LOCATION
" O O
and O O
" O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
" O O
represent O B_PERSON/B_LOCATION
parallel O B_PERSON/I_LOCATION
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
parallel O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrogen O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bonds O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

The O O
OutArcType O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
represented O O
in O O
a O O
similar O B_LOCATION/B_GENE
manner O I_LOCATION/I_GENE
by O O
[ O O
R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
, O O
L O B_OTHER/B_LOCATION
' O O
, O O
P O B_PROTEIN[GENE]/B_LOCATION
' O O
, O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O O
] O B_GENE/B_DISEASE
. O O

Ligand O B_PERSON/B_ORGANIZATION
arcs O I_PERSON/I_ORGANIZATION
are O O
indicated O O
by O O
LT O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
= O O
AA O B_LOCATION/B_ORGANIZATION
, O O
where O O
LT O B_PERSON/B_LOCATION
is O O
the O O
ligand O B_PROTEIN[GENE]/B_LOCATION
type O I_PROTEIN[GENE]/I_LOCATION
and O O
AA O B_LOCATION
is O O
the O O
PDB O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
Figure O B_NUMBER[MEASURE]/B_LOCATION
3 O I_NUMBER[MEASURE]/I_LOCATION
( O O
a O O
) O O
and O O
3 O B_NUMBER[MEASURE]
( O O
b O B_PROTEIN[GENE]/B_DISEASE
) O O
contain O O
visual O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
representations O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
TOPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
TOPS O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ O I_LOCATION
strings O I_LOCATION
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
respectively O O
, O O
for O O
the O O
protein O B_PROTEIN[GENE]/B_LOCATION
domain O I_PROTEIN[GENE]/I_LOCATION
d1fnb O I_PROTEIN[GENE]/I_LOCATION
_ O O
1 O B_MEASURE/B_LOCATION
. O O

Here O O
the O O
triangles O B_BIO/B_LOCATION
represent O O
the O O
beta O B_LOCATION
strands O I_LOCATION
; O O
the O O
red O B_LOCATION/B_COLOR
curve O I_LOCATION/I_COLOR
represents O O
the O O
alpha O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
helix O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
; O O
gray O B_COLOR/B_LOCATION
ellipsoids O I_COLOR/I_LOCATION
indicate O O
loops O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
and O O
green O B_LOCATION/B_ORGANIZATION
arcs O I_LOCATION/I_ORGANIZATION
indicate O O
hydrogen O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
bonds O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
between O O
two O B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strands O B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
called O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beta O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sheets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
length O B_MEASURE/B_LOCATION
of O O
a O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
strings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
defined O O
by O O
number O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
SSEs O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O O
thus O O
, O O
the O O
length O B_MEASURE/B_LOCATION
of O O
d1fnb O B_PROTEIN[GENE]/B_LOCATION
_ O O
1 O B_MEASURE/B_LOCATION
is O O
19 O B_MEASURE
. O O

For O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
details O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
see O O
[ O O
28 O B_GENE
] O I_GENE
. O O

TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

TOPS O B_MEASURE/B_PERSON
+ O B_MEASURE/I_PERSON
is O O
a O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
computes O O
a O O
distance O B_MEASURE/B_LOCATION
between O O
TOPS O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
two O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
a O O
dynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programming O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
identifies O O
the O O
longest O B_MEASURE/B_LOCATION
common O B_MEASURE/I_LOCATION
subsequence O B_MEASURE/I_LOCATION
( O O
LCS O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
consisting O O
of O O
the O O
list O B_ORGANIZATION/B_MEASURE
of O O
the O O
topologically O O
equivalent O B_MEASURE/B_LOCATION
SSEs O B_MEASURE/I_LOCATION
between O O
two O B_GENE/B_MEASURE
proteins O I_GENE/I_MEASURE
. O O

For O O
example O O
, O O
Figure O O
3 O O
( O O
c O O
) O O
shows O O
the O O
TOPS O O
+ O O
strings O O
alignment O O
between O O
Dihydropteridine O O
reductase O O
proteins O O
from O O
rat O O
( O O
1dhr O O
) O O
and O O
human B B_SPECIES[BIO]
( O O
1hdr O O
) O O
. O O

The O O
TOPS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
+ O O
strings O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
1dhr O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
1hdr O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
represented O O
by O O
a O O
linear O B_MEASURE/B_PROTEIN[GENE]
string O B_MEASURE/I_PROTEIN[GENE]
- O O
model O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
where O O
a O O
yellow O B_COLOR/B_LOCATION
triangle O I_COLOR/I_LOCATION
and O O
red O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
curves O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
indicate O O
the O O
beta O B_PROTEIN[GENE]
strands O I_PROTEIN[GENE]
and O O
alpha O B_LOCATION/B_GENE
helices O B_LOCATION/I_GENE
in O O
their O O
" O O
up O O
" O O
or O O
" O O
down O O
" O O
orientations O B_LOCATION/B_ORGANIZATION
, O O
respectively O O
. O O

The O O
grey O B_COLOR/B_LOCATION
line O I_COLOR/I_LOCATION
and O O
purple O B_BIO/B_COLOR
stubs O B_BIO/I_COLOR
represent O O
the O O
loop O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
NAD O B_LOCATION
ligand O I_LOCATION
interactions O I_LOCATION
, O O
respectively O O
. O O

Note O O
that O O
the O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O O
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
optional O B_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
this O O
work O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
have O O
not O O
used O O
it O O
. O O

The O O
incoming O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
outgoing O B_TIME[MEASURE]/B_PERSON
arcs O I_TIME[MEASURE]/I_PERSON
are O O
depicted O O
in O O
the O O
SSEs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
top O B_GENE/B_LOCATION
and O O
bottom O B_LOCATION/B_MEASURE
of O O
the O O
beta O B_LOCATION/B_MEASURE
strands O I_LOCATION/I_MEASURE
) O O
, O O
where O O
red O B_COLOR
and O O
green O B_COLOR/B_ORGANIZATION
arcs O I_COLOR/I_ORGANIZATION
represent O O
the O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
parallel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrogen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
bond O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
interactions O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
that O O
show O O
beta O O
- O O
sheet O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
while O O
yellow O B_COLOR
and O O
blue O B_COLOR/B_PERSON
arcs O I_COLOR/I_PERSON
indicate O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O O
left O O
chirality O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
relationships O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
SSEs O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

A O O
pink O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
arrow O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
the O O
TOPS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
+ O I_LOCATION
strings O I_LOCATION
elements O I_LOCATION
indicates O O
the O O
conserved O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
SSE O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
dotted O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arrows O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
indicate O O
the O O
conserved O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
helices O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
beta O B_LOCATION
strands O I_LOCATION
, O O
while O O
the O O
plain O B_LOCATION/B_BIO
arrows O I_LOCATION/I_BIO
indicate O O
the O O
conserved O B_LOCATION/B_MEASURE
loop O I_LOCATION/I_MEASURE
regions O I_LOCATION/I_MEASURE
. O O

TOPS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
+ O I_MEASURE
+ O I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

In O O
this O O
work O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
want O O
to O O
test O O
the O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
idea O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pruning O O
the O O
search O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
space O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O O
topological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
constraints O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Many O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O O
in O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
easily O O
eliminated O O
from O O
the O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O O
constraining O O
the O O
alignment O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
we O O
explore O O
constraints O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
obtained O O
from O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
identifies O O
topologically O O
equivalent O B_LOCATION
secondary O I_LOCATION
structure O I_LOCATION
elements O I_LOCATION
( O O
alpha O B_GENE
helices O I_GENE
, O O
beta O B_LOCATION/B_BIO
strands O I_LOCATION/I_BIO
, O O
and O O
loops O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
for O O
this O O
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Such O B_PERSON
equivalences O I_PERSON
define O O
blocks O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
that O O
restrict O O
the O O
alignment O B_LOCATION
region O I_LOCATION
; O O
AFPs O B_LOCATION/B_ORGANIZATION
that O O
fall O O
outside O O
these O O
regions O B_LOCATION
are O O
simply O O
not O O
considered O O
( O O
see O O
Figure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
4 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
b O B_OTHER/B_MEASURE
) O O
) O O
. O O

We O O
introduce O O
a O O
parameter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
r O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
control O O
the O O
strictness O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
constraints O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
by O O
TOPS O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O B_ENT/B_BIO
alignments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
; O O
r O B_PROTEIN[GENE]/B_OTHER
equals O O
0 O B_MEASURE/B_LOCATION
if O O
the O O
alignment O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
strictly O O
restrained O O
by O O
TOPS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
strings O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alignment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
r O B_OTHER/B_GENE
is O O
set O O
to O O
1 O B_MEASURE
by O O
default O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
our O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
allow O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flexibility O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
constrained O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
region O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Figure O B_PROTEIN[GENE]
4 O I_PROTEIN[GENE]
( O O
c O B_OTHER/B_MEASURE
) O O
) O O
. O O

We O O
then O O
can O O
speed O O
up O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
considering O O
only O O
the O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
within O O
the O O
constrained O B_LOCATION/B_MEASURE
alignment O I_LOCATION/I_MEASURE
area O I_LOCATION/I_MEASURE
( O O
Figure O B_LOCATION/B_MEASURE
4 O I_LOCATION/I_MEASURE
( O O
d O B_OTHER/B_PROTEIN[GENE]
) O O
) O O
. O O

The O O
rigid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structural O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O O
be O O
treated O O
as O O
a O O
special O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
in O O
which O O
no O O
twist O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
is O O
allowed O O
in O O
chaining O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

However O O
, O O
the O O
TOPS O B_LOCATION/B_SPORT[ENT]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_PERSON/B_LOCATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
provides O O
alignment O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
, O O
" O O
rigid O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
" O O
mode O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
" O O
flexible O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
" O O
mode O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
default O B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

Benchmarking O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

For O O
benchmarking O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
have O O
used O O
the O O
PDB40 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dataset O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
1 O B_MEASURE
, O O
901 O B_MEASURE
protein O I_MEASURE
domain O I_MEASURE
pairs O I_MEASURE
( O O
DP O B_PROTEIN[GENE]/B_DISEASE
) O O
corresponding O O
to O O
SCOP O B_MEASURE/B_LOCATION
version O I_MEASURE/I_LOCATION
1 O I_MEASURE/I_LOCATION
. O O
61 O B_MEASURE
from O O
the O O
ASTRAL O B_TIME[MEASURE]/B_ORGANIZATION
database O I_TIME[MEASURE]/I_ORGANIZATION
[ O O
29 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
provides O O
the O O
SCOP O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
superfamily O O
level O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
homolog O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
versus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
non O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
homolog O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
statistics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O O
the O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
main O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
SCOP O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
i O O
. O O
e O O
. O O
, O O
all O O
- O O
alpha O B_GENE
, O O
all O O
- O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
alpha O B_PROTEIN[GENE]/B_MEASURE
/ O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
alpha O B_GENE/B_MEASURE
+ O I_GENE/I_MEASURE
beta O I_GENE/I_MEASURE
, O O
and O O
all O O
proteins O B_BIO/B_PROTEIN[GENE]
regardless O O
of O O
their O O
structural O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
classes O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

We O O
performed O O
the O O
Receiver O B_LOCATION/B_ORGANIZATION
Operating O I_LOCATION/I_ORGANIZATION
Characteristics O I_LOCATION/I_ORGANIZATION
( O O
ROC O B_LOCATION/B_ORGANIZATION
) O O
curve O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
the O O
AUC O B_LOCATION/B_MEASURE
( O O
Area O B_LOCATION/B_ORGANIZATION
Under O O
the O O
ROC O B_MEASURE/B_LOCATION
Curve O I_MEASURE/I_LOCATION
) O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
compare O O
the O O
performance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
using O O
SCOP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
the O O
superfamily O B_MEASURE/B_LOCATION
level O B_MEASURE/I_LOCATION
as O O
a O O
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O O
30 O B_MEASURE/B_PERSON
] O B_MEASURE/I_PERSON
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

ROC O B_LOCATION/B_ORGANIZATION
and O O
AUC O B_ORGANIZATION/B_LOCATION
Analyses O B_ORGANIZATION/I_LOCATION

We O O
have O O
compared O O
the O O
performance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
against O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O O
the O O
SCOP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
the O O
superfamily O B_MEASURE/B_LOCATION
level O B_MEASURE/I_LOCATION
. O O

We O O
have O O
plotted O O
the O O
ROC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O O
on O O
P O B_MEASURE/B_PROTEIN[GENE]
- O O
values O B_MEASURE
obtained O O
from O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

We O O
have O O
plotted O O
the O O
ROC O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
separately O O
for O O
the O O
main O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
SCOP O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
i O O
. O O
e O B_OTHER/B_LOCATION
. O O
, O O
all O O
- O O
alpha O B_PROTEIN[GENE]
, O O
all O O
- O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
alpha O B_PROTEIN[GENE]/B_MEASURE
/ O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
alpha O B_PROTEIN[GENE]/B_MEASURE
+ O I_PROTEIN[GENE]/I_MEASURE
beta O I_PROTEIN[GENE]/I_MEASURE
, O O
and O O
all O O
proteins O B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regardless O O
of O O
the O O
class O B_PERSON/B_MEASURE
they O O
belong O O
to O O
( O O
see O O
Figure O B_NUMBER[MEASURE]/B_PERSON
5 O I_NUMBER[MEASURE]/I_PERSON
( O O
a O O
) O O
to O O
5 O B_NUMBER[MEASURE]
( O O
e O B_PROTEIN[GENE]/B_DISEASE
) O O
) O O
. O O

In O O
the O O
graph O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
x O O
- O O
and O O
y O B_PROTEIN[GENE]/B_MEASURE
- O O
axes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
represent O O
the O O
false O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
true O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
positive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rates O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
performance O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
respectively O O
. O O

In O O
the O O
legend O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rF O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
pvalue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
fF O B_PROTEIN[GENE]/B_LOCATION
- O O
pvalue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
rigid O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
; O O
similarly O O
, O O
rT2F O B_PROTEIN[GENE]/B_LOCATION
- O O
pvalue O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fT2F O B_PROTEIN[GENE]/B_LOCATION
- O O
pvalue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
represent O O
the O O
rigid O B_DISEASE_ADJECTIVE[DISEASE]
and O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

We O O
have O O
calculated O O
the O O
AUC O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
all O O
the O O
SCOP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O O
on O O
ROC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
obtained O O
from O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
the O O
flexible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
/ O O
rigid O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
options O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

For O O
all O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
rigid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performs O O
best O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
usually O O
followed O O
by O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
rigid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
and O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
performance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
all O O
four O B_NUMBER[MEASURE]
methods O I_NUMBER[MEASURE]
is O O
best O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
all O O
alpha O B_PROTEIN[GENE]
and O O
all O O
beta O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
all O O
four O B_NUMBER[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perform O O
markedly O O
worse O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
but O O
similar O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
each O O
other O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
alpha O B_PROTEIN[GENE]/B_DISEASE
/ O O
beta O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Only O O
alpha O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
beta O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
proteins O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O O
a O O
clear O B_MEASURE/B_PERSON
difference O I_MEASURE/I_PERSON
between O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
TOPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O B_MEASURE
+ O I_MEASURE
FATCAT O I_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

It O O
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
note O O
that O O
the O O
TOPS O B_PERSON/B_ORGANIZATION
+ O I_PERSON/I_ORGANIZATION
strings O I_PERSON/I_ORGANIZATION
models O I_PERSON/I_ORGANIZATION
consider O O
the O O
parallel O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
parallel O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
sheet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
the O O
form O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
incoming O B_TIME[MEASURE]/B_LOCATION
and O O
outgoing O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arcs O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
their O O
ArcTypes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Thus O O
, O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discriminates O O
the O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
domain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pairs O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
more O O
efficiently O O
compared O O
to O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

For O O
example O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
in O O
the O O
all O O
- O O
beta O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pairs O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
both O O
the O O
flexible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
the O O
rigid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
perform O O
well O O
. O O

The O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
covers O O
nearly O O
84 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
protein O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
domains O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
with O O
0 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
false O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
positives O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
but O O
the O O
flexible O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
rigid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cover O O
only O O
76 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
and O O
49 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
true O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
positives O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
respectively O O
, O O
with O O
0 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
false O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
positives O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
zoomed O O
- O O
in O O
version O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
ROC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curves O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
up O O
to O O
10 O B_MEASURE
% O I_MEASURE
false O I_MEASURE
positives O I_MEASURE
for O O
all O O
- O O
beta O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
rich O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
protein O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
families O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
is O O
shown O O
in O O
Figure O B_LOCATION/B_PERSON
5 O I_LOCATION/I_PERSON
( O O
f O O
) O O
; O O
where O O
both O O
the O O
rigid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
green O B_COLOR
) O O
and O O
flexible O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
( O O
red O B_COLOR
) O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
have O O
coverage O B_MEASURE
rates O I_MEASURE
of O O
82 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
84 O B_MEASURE
% O I_MEASURE
true O I_MEASURE
positives O I_MEASURE
respectively O O
with O O
0 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
false O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
positives O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
overall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
all O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O O
that O O
TOPS O B_DISEASE/B_GENE
+ O I_DISEASE
+ O B_MEASURE/B_LOCATION
FATCAT O I_DISEASE/I_MEASURE
performance O I_DISEASE/I_MEASURE
is O O
only O O
slightly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
3 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
- O O
7 O B_MEASURE
% O I_MEASURE
AUC O I_MEASURE
value O I_MEASURE
difference O I_MEASURE
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
) O O
as O O
compared O O
to O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
while O O
providing O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
more O B_MEASURE
than O O
10 O B_NUMBER[MEASURE]
- O O
fold O B_PERSON/B_MEASURE
speedup O B_PERSON/I_MEASURE
( O O
see O O
next O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
section O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

AFP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
Runtime O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Analyses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION

We O O
tested O O
both O O
the O O
FATCAT O B_MEASURE/B_LOCATION
and O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
the O O
Mac O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OS O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
version O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
4 O B_MEASURE
. O O
10 O B_MEASURE/B_LOCATION
computer O I_MEASURE/I_LOCATION
system O I_MEASURE/I_LOCATION
with O O
a O O
2 O B_MEASURE
x O O
2 O B_MEASURE
. O O
66 O B_MEASURE
- O O
GHz O B_MEASURE/B_LOCATION
Dual O I_MEASURE/I_LOCATION
- O O
Core O B_PERSON/B_LOCATION
Intel O B_PERSON/I_LOCATION
Xeon O B_PERSON/I_LOCATION
processor O B_PERSON/I_LOCATION
and O O
1 O B_MEASURE
- O O
GB O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
667 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
MHz O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
memory O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O

We O O
have O O
performed O O
runtime O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
1 O B_MEASURE
, O O
901 O B_MEASURE
protein O I_MEASURE
domain O I_MEASURE
pairs O I_MEASURE
and O O
counted O O
the O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
and O O
the O O
corresponding O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
runtime O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
both O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
an O O
exponential O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
AFPs O B_MEASURE/B_ORGANIZATION
( O O
Figure O B_MEASURE/B_PERSON
6 O I_MEASURE/I_PERSON
( O O
b O B_DISEASE/B_PROTEIN[GENE]
) O O
) O O
and O O
corresponding O B_MEASURE
runtime O I_MEASURE
( O O
Figure O B_MEASURE/B_PERSON
6 O I_MEASURE/I_PERSON
( O O
a O O
) O O
) O O
for O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
compared O O
to O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
average O B_MEASURE
number O I_MEASURE
of O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
for O O
the O O
TOPS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
530 O B_MEASURE
, O O
but O O
the O O
average O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
for O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
15 O B_MEASURE
, O O
019 O B_MEASURE
. O O

This O O
represents O O
the O O
number O B_MEASURE
of O O
average O B_MEASURE/B_LOCATION
AFPs O B_MEASURE/I_LOCATION
used O O
by O O
the O O
FATCAT O B_ORGANIZATION/B_LOCATION
method O I_ORGANIZATION/I_LOCATION
is O O
increased O O
by O O
a O O
factor O B_MEASURE
of O O
28 O B_NUMBER[MEASURE]
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

This O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
leads O O
to O O
the O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
TOPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O B_OTHER/B_MEASURE
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
22 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
times O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
faster O O
compared O O
to O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
because O O
this O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O O
take O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
more O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
number O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
in O O
the O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

Case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]

While O O
the O O
overall O O
accuracy O O
of O O
both O O
rigid O O
and O O
flexible O O
FATCAT O O
methods O O
is O O
better O O
than O O
their O O
TOPS O O
+ O O
+ O O
FATCAT O O
equivalents O O
, O O
an O O
interesting O O
example O O
where O O
the O O
opposite O O
is O O
true O O
lies O O
in O O
the O O
comparison O O
of O O
two O O
proteins O O
, O O
d2trxa O O
_ O O
( O O
108 O O
aa O O
) O O
from O O
Escherichia B B_SPECIES[BIO]
coli I I_SPECIES[BIO]
and O O
d1kte O O
_ O O
_ O O
( O O
105 O O
aa O O
) O O
from O O
Sus B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
scrofa I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
pig B B_PERSON/B_PROTEIN[GENE]
) O O
from O O
the O O
thioredoxin O O
- O O
like O O
superfamily O O
. O O

For O O
this O O
pair O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
_ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provides O O
an O O
alignment O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
88 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
equivalent O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
positions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
1 O B_MEASURE
. O O
67 O B_MEASURE
A O O
chain O B_MEASURE/B_LOCATION
RMSD O I_MEASURE/I_LOCATION
and O O
3 O B_MEASURE
. O O
06 O B_MEASURE
A O I_MEASURE
of O O
optimal O B_MEASURE/B_LOCATION
RMSD O B_MEASURE/I_LOCATION
without O O
any O O
twist O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
giving O O
the O O
alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
10 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
sequence O I_TIME[MEASURE]/I_LOCATION
identity O I_TIME[MEASURE]/I_LOCATION
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

On O O
the O O
other O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hand O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
flexible O B_LOCATION
_ O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
provides O O
an O O
alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
86 O B_NUMBER[MEASURE]/B_PERSON
aligned O O
positions O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
a O O
twist O B_MEASURE/B_LOCATION
in O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION
region O I_LOCATION
; O O
it O O
has O O
a O O
higher O B_MEASURE
chain O I_MEASURE
RMSD O I_MEASURE
of O O
5 O B_MEASURE
. O O
14 O B_MEASURE
A O I_MEASURE
, O O
and O O
its O O
optimal O B_MEASURE
RMSD O I_MEASURE
is O O
3 O B_MEASURE
. O O
48 O B_MEASURE
A O I_MEASURE
. O O

For O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O O
the O O
chain O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
optimal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RMSDs O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
refer O O
[ O O
5 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

The O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
_ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
uses O O
the O O
twist O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
align O O
a O O
helix O B_LOCATION/B_MEASURE
in O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION
region O I_LOCATION
, O O
which O O
is O O
positioned O O
incorrectly O O
with O O
a O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sheet O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
see O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
4 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
. O O

Figure O B_MEASURE/B_PERSON
7 O I_MEASURE/I_PERSON
( O O
a O O
) O O
shows O O
the O O
superposition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
d2trxa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
_ O O
( O O
gray O B_PERSON/B_COLOR
) O O
and O O
d1kte O B_PROTEIN[GENE]/B_BIO
_ O O
_ O O
( O O
orange O B_COLOR/B_SPORT[ENT]
) O O
domains O B_LOCATION/B_BIO
from O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
_ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
where O O
the O O
blue O B_SEQUENCE[MEASURE]/B_COLOR
color O I_SEQUENCE[MEASURE]/I_COLOR
indicates O O
the O O
d1kte O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
_ O O
_ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
the O O
flexible O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
_ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
TOPS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
FATCAT O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
method O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
. O O

The O O
incorrect O B_LOCATION
alignment O I_LOCATION
of O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION/B_GENE
domain O I_LOCATION/I_GENE
alpha O I_LOCATION/I_GENE
helix O I_LOCATION/I_GENE
of O O
the O O
d1kte O B_PROTEIN[GENE]
_ O I_PROTEIN[GENE]
_ O I_PROTEIN[GENE]
domain O I_PROTEIN[GENE]
( O O
orange O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
visible O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
core O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sheet O B_LOCATION
region O I_LOCATION
. O O

Figure O B_MEASURE
7 O I_MEASURE
( O O
b O O
) O O
and O O
7 O B_NUMBER[MEASURE]
( O O
c O B_PROTEIN[GENE]/B_DISEASE
) O O
shows O O
the O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
flexible O B_PROTEIN[GENE]/B_DISEASE
_ O O
FATCAT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
_ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
respectively O O
. O O

The O O
hinge O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
a O O
twist O B_MEASURE/B_LOCATION
in O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
_ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
indicated O O
by O O
an O O
arrow O B_LOCATION/B_MEASURE
and O O
the O O
AFPs O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
represented O O
by O O
a O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
color O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
see O O
Figure O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
b O B_OTHER/B_MEASURE
) O O
) O O
. O O

In O O
this O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constraints O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allow O O
the O O
TOPS O B_LOCATION/B_MEASURE
+ O I_LOCATION/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
avoid O O
a O O
spurious O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alignment O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
Erythrocruorin O O
protein O O
domain O O
d1eca O O
_ O O
_ O O
( O O
136 O O
aa O O
) O O
from O O
Chironomus B B_BIO
thummi I I_BIO
and O O
the O O
Phycocyanin O O
alpha O O
subunit O O
protein O O
domain O O
d1cpca O O
_ O O
( O O
162 O O
aa O O
) O O
from O O
Fremyella B B_BACTERIUM[BIO]
diplosiphon I I_BACTERIUM[BIO]
( O O
Cyanobacterium O O
) O O
belong O O
to O O
the O O
Globin O O
- O O
like O O
superfamily O O
. O O

For O O
these O O
protein O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
domain O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
pairs O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provides O O
a O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
120 O B_MEASURE
and O O
118 O B_MEASURE
aligned O O
positions O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
the O O
chain O B_MEASURE
RMSD O I_MEASURE
of O O
4 O B_MEASURE
. O O
02 O B_MEASURE
A O I_MEASURE
based O O
on O O
the O O
flexible O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O O
rigid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
options O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O O
respectively O O
. O O

The O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
_ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gives O O
an O O
alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
63 O B_NUMBER[MEASURE]/B_PERSON
aligned O O
positions O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
the O O
3 O B_NUMBER[MEASURE]
. O O
23 O B_MEASURE
A O I_MEASURE
optimal O I_MEASURE
RMSD O I_MEASURE
and O O
the O O
6 O B_NUMBER[MEASURE]
. O O
28 O B_MEASURE
A O I_MEASURE
chain O I_MEASURE
RMSD O I_MEASURE
. O O

In O O
this O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
_ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O B_TIME[MEASURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
misses O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION/B_GENE
region O I_LOCATION/I_GENE
helix O I_LOCATION/I_GENE
and O O
misaligns O O
some O O
helices O B_LOCATION/B_BIO
. O O

For O O
example O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
Figure O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
( O O
a O O
) O O
shows O O
the O O
superposition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
d1eca O B_PROTEIN[GENE]/B_LOCATION
_ O O
_ O O
( O O
gray O B_PERSON/B_COLOR
) O O
and O O
d1cpca O B_PROTEIN[GENE]/B_LOCATION
_ O O
( O O
orange O B_COLOR/B_SPORT[ENT]
) O O
domains O B_LOCATION
from O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
_ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
while O O
d1cpca O B_PROTEIN[GENE]/B_MEASURE
_ O O
( O O
blue O B_COLOR
) O O
domain O B_TIME[MEASURE]/B_LOCATION
is O O
from O O
the O O
flexible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
_ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
TOPS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
AFP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
chaining O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
the O O
actual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
FATCAT O B_MEASURE/B_LOCATION
are O O
shown O O
in O O
Figure O B_NUMBER[MEASURE]/B_LOCATION
8 O I_NUMBER[MEASURE]/I_LOCATION
( O O
b O B_OTHER/B_LOCATION
) O O
and O O
8 O B_MEASURE
( O O
e O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
respectively O O
. O O

Figure O B_NUMBER[MEASURE]/B_LOCATION
8 O I_NUMBER[MEASURE]/I_LOCATION
( O O
c O O
) O O
shows O O
the O O
AFP O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
TOPS O B_MEASURE
+ O I_MEASURE
+ O I_MEASURE
FATCAT O I_MEASURE
, O O
in O O
which O O
this O O
method O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
misses O O
the O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
terminal O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
and O O
incorrectly O O
aligns O O
some O O
of O O
the O O
C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_LOCATION/B_MEASURE
regions O I_LOCATION/I_MEASURE
( O O
see O O
Figure O B_MEASURE/B_PERSON
8 O I_MEASURE/I_PERSON
( O O
d O B_PROTEIN[GENE]/B_DISEASE
) O O
) O O
. O O

However O O
, O O
the O O
rigid O B_LOCATION/B_DISEASE
_ O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
produces O O
an O O
alignment O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
108 O B_NUMBER[MEASURE]/B_PERSON
aligned O O
positions O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
optimal O B_MEASURE/B_LOCATION
and O O
chain O B_MEASURE
RMSDs O I_MEASURE
of O O
3 O B_MEASURE
. O O
22 O B_MEASURE/B_PERSON
A O I_MEASURE/I_PERSON
and O O
6 O B_MEASURE
. O O
28 O B_MEASURE
A O I_MEASURE
respectively O O
. O O

In O O
general O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
TOPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
comparison O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
does O O
not O O
work O O
well O O
for O O
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
rich O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
proteins O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
due O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hydrogen O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bonds O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
SSEs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
26 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

The O O
same O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
true O B_DISEASE_ADJECTIVE[DISEASE]
for O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
strings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
some O O
extent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O O
however O O
, O O
this O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
takes O O
advantage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
compare O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
more O O
efficiently O O
; O O
for O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
the O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
motifs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
helix O B_LOCATION/B_GENE
- O O
turn O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
helix O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
helix O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
loop O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
helix O B_LOCATION/B_TIME[MEASURE]
can O O
be O O
easily O O
recognized O O
[ O O
28 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

However O O
, O O
we O O
have O O
not O O
explored O O
that O O
ligand O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
discovery O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
option O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
TOPS O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O B_MEASURE/B_LOCATION
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provides O O
only O O
a O O
basic O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
the O O
scoring O O
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
find O O
the O O
best O B_MEASURE/B_ENT
alignment O B_MEASURE/I_ENT
has O O
not O O
been O O
optimized O O
. O O

These O O
problems O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
be O O
addressed O O
in O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
considering O O
the O O
advanced O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TOPS O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TOPS O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O B_ORGANIZATION/B_LOCATION
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
based O O
on O O
helix O B_NUMBER[MEASURE]/B_LOCATION
- O O
helix O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
packing O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SSE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ligand O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interaction O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
properties O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
together O O
with O O
the O O
right O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
left O O
chiralities O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
can O O
be O O
optimized O O
in O O
both O O
the O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
in O O
the O O
alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
take O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
insertion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
/ O O
deletion O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
of O O
SSEs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
exist O O
in O O
nature O B_BIO/B_LOCATION
across O O
the O O
different O B_MEASURE/B_LOCATION
members O I_MEASURE/I_LOCATION
of O O
the O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
superfamilies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
[ O O
31 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION

The O O
overall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
all O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
classes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O O
that O O
TOPS O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_DISEASE
+ O B_MEASURE/B_LOCATION
FATCAT O I_DISEASE/I_MEASURE
performance O I_DISEASE/I_MEASURE
is O O
only O O
slightly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
3 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
- O O
7 O B_MEASURE
% O I_MEASURE
AUC O I_MEASURE
value O I_MEASURE
difference O I_MEASURE
) O O
as O O
compared O O
to O O
FATCAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
while O O
providing O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
more O B_MEASURE
than O O
10 O B_NUMBER[MEASURE]
- O O
fold O B_PERSON/B_MEASURE
speedup O B_PERSON/I_MEASURE
. O O

The O O
main O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reason O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
discrepancies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
that O O
TOPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O I_PERSON
strings O I_PERSON
alignments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
occasionally O O
misalign O O
the O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
elements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
subsequent O B_PERSON/B_LOCATION
FATCAT O I_PERSON/I_LOCATION
alignment O I_PERSON/I_LOCATION
, O O
constrained O O
by O O
the O O
TOPS O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cannot O B_PERSON/B_LOCATION
overcome O O
the O O
earlier O B_DISEASE_ADJECTIVE[DISEASE]
errors O I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
is O O
a O O
clear O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
trade O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
- O O
off O B_MEASURE/B_LOCATION
between O O
the O O
runtime O B_MEASURE
and O O
the O O
accuracy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O O
limiting O O
the O O
pool O B_LOCATION/B_MEASURE
of O O
fragments O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O O
compared O O
speeds O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
up O O
the O O
algorithm O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
but O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
( O O
slightly O O
) O O
lower O B_DISEASE_ADJECTIVE[DISEASE]
accuracy O I_DISEASE_ADJECTIVE[DISEASE]
. O O

At O O
the O O
same O B_MEASURE/B_LOCATION
time O I_MEASURE/I_LOCATION
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
offer O O
clear O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggestions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
future O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
development O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O O

Using O O
a O O
more O O
advanced O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
version O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
remove O O
some O O
of O O
the O O
false O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
positives O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
might O O
be O O
at O O
a O O
cost O B_MEASURE
of O O
significantly O O
slowing O O
the O O
total O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

MV O B_TIME[MEASURE]/B_PERSON
developed O O
the O O
TOPS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
algorithm O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
performed O O
the O O
calculations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prepared O O
the O O
figures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
YY O O
provided O O
advice O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oversight O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
project O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
verified O O
the O O
code O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
provided O O
FATCAT O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
AG O B_LOCATION/B_PERSON
contributed O O
to O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
idea O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
to O O
writing O O
of O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Are O O
there O O
sensitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
airborne O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
? O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
shown O O
that O O
particulate O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
hospitalization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
lung O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
; O O
however O O
, O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
what O O
subpopulations O B_PERSON/B_BIO
are O O
most O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
this O O
pollutant O B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
analyzed O O
Medicare O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hospital O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
admissions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
heart O B_DISEASE
disease O I_DISEASE
, O O
chronic O B_DISEASE
obstructive O I_DISEASE
pulmonary O I_DISEASE
disorders O I_DISEASE
( O O
COPD O B_DISEASE
) O O
and O O
pneumonia O B_DISEASE
in O O
Chicago O B_LOCATION/B_PERSON
, O O
Cook O B_LOCATION/B_PERSON
County O I_LOCATION/I_PERSON
, O O
Illinois O B_LOCATION
, O O
between O O
1985 O B_MEASURE
and O O
1994 O B_MEASURE
. O O

We O O
examined O O
whether O O
previous O O
admissions O O
or O O
secondary O O
diagnoses O O
for O O
selected O O
conditions O O
predisposed O O
persons B B_PERSON
to O O
having O O
a O O
greater O O
risk O O
from O O
air O O
pollution O O
. O O

We O O
also O O
considered O O
effect O B_PERSON
modification O I_PERSON
by O O
age O B_MEASURE/B_LOCATION
, O O
sex O B_PERSON/B_MEASURE
, O O
and O O
race O B_SPORT[ENT]/B_LOCATION
. O O

We O O
found O O
that O O
the O O
air O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O O
pollution O B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
hospital O B_DISEASE/B_GENE
admissions O I_DISEASE/I_GENE
for O O
cardiovascular O B_DISEASE
diseases O I_DISEASE
was O O
almost O O
doubled O O
in O O
subjects O B_PERSON/B_LOCATION
with O O
concurrent O B_DISEASE/B_GENE
respiratory O I_DISEASE/I_GENE
infections O I_DISEASE/I_GENE
. O O

The O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
was O O
also O O
increased O O
by O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admission O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
conduction O B_DISEASE
disorders O I_DISEASE
. O O

For O O
COPD O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
pneumonia O B_DISEASE
admissions O I_DISEASE
, O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
conduction O B_DISEASE
disorders O I_DISEASE
or O O
dysrhythmias O B_DISEASE
increased O O
the O O
risk O B_MEASURE/B_LOCATION
of O O
particulate O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
matter O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
< O O
10 O B_MEASURE
microm O I_MEASURE
in O O
aerodynamic O B_MEASURE/B_LOCATION
diameter O I_MEASURE/I_LOCATION
( O O
PM O B_LOCATION/B_PROTEIN[GENE]
( O O
10 O B_MEASURE/B_LOCATION
) O O
) O O
- O O
associated O O
admissions O B_DISEASE
. O O

Persons B B_PERSON
with O O
asthma O O
had O O
twice O O
the O O
risk O O
of O O
a O O
PM O O
( O O
10 O O
) O O
- O O
associated O O
pneumonia O O
admission O O
and O O
persons B B_PERSON
with O O
heart O O
failure O O
had O O
twice O O
the O O
risk O O
of O O
PM O O
( O O
10 O O
) O O
- O O
induced O O
COPD O O
admissions O O
. O O

The O O
PM O B_LOCATION/B_SEQUENCE[MEASURE]
( O O
10 O B_NUMBER[MEASURE]/B_LOCATION
) O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O O
not O O
vary O O
by O O
sex O B_PERSON/B_LOCATION
, O O
age O B_MEASURE/B_LOCATION
, O O
and O O
race O B_LOCATION/B_TIME[MEASURE]
. O O

These O O
results O O
suggest O O
that O O
patients B B_PERSON/B_BIO
with O O
acute O O
respiratory O O
infections O O
or O O
defects O O
in O O
the O O
electrical O O
control O O
of O O
the O O
heart O O
are O O
a O O
risk O O
group O O
for O O
particulate O O
matter O O
effects O O
. O O

Articles O B_PERSON

Are O O
There O O
Sensitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Subgroups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Airborne O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
? O O

Antonella O B_MEASURE/B_BIO
Zanobetti O I_MEASURE/I_BIO
, O O
1 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Joel O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Schwartz O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
1 O B_MEASURE
, O O
2 O B_MEASURE
and O O
Diane O B_MEASURE/B_PERSON
Gold1 O I_MEASURE/I_PERSON
, O O
2 O B_MEASURE/B_LOCATION
1Environmental O I_MEASURE/I_LOCATION

Epidemiology O O
Program O O
, O O
Department O O
of O O
Environmental O O
Health O O
, O O
Harvard O O
School O O
of O O
Public O O
Health O O
, O O
Boston O O
, O O
Massachusetts O O
, O O
USA O O
; O O
2Channing O O
Laboratory O O
, O O
Department O O
of O O
Medicine O O
, O O
Harvard O O
Medical O O
School O O
and O O
Brigham O O
and O O
Women B B_PERSON
' O O
s O O
Hospital O O
, O O
Boston O O
, O O
Massachusetts O O
, O O
USA O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
shown O O
that O O
particulate O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
hospitalization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
lung O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
; O O
however O O
, O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
what O O
subpopulations O B_PERSON/B_BIO
are O O
most O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
this O O
pollutant O B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
analyzed O O
Medicare O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hospital O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
admissions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
heart O B_DISEASE
disease O I_DISEASE
, O O
chronic O B_DISEASE
obstructive O I_DISEASE
pulmonary O I_DISEASE
disorders O I_DISEASE
( O O
COPD O B_DISEASE
) O O
and O O
pneumonia O B_DISEASE
in O O
Chicago O B_LOCATION/B_PERSON
, O O
Cook O B_LOCATION/B_PERSON
County O I_LOCATION/I_PERSON
, O O
Illinois O B_LOCATION
, O O
between O O
1985 O B_MEASURE
and O O
1994 O B_MEASURE
. O O

We O O
examined O O
whether O O
previous O O
admissions O O
or O O
secondary O O
diagnoses O O
for O O
selected O O
conditions O O
predisposed O O
persons B B_PERSON
to O O
having O O
a O O
greater O O
risk O O
from O O
air O O
pollution O O
. O O

We O O
also O O
considered O O
effect O B_PERSON
modification O I_PERSON
by O O
age O B_MEASURE/B_LOCATION
, O O
sex O B_PERSON/B_MEASURE
, O O
and O O
race O B_SPORT[ENT]/B_LOCATION
. O O

We O O
found O O
that O O
the O O
air O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O O
pollution O B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
hospital O B_DISEASE/B_GENE
admissions O I_DISEASE/I_GENE
for O O
cardiovascular O B_DISEASE
diseases O I_DISEASE
was O O
almost O O
doubled O O
in O O
subjects O B_PERSON/B_LOCATION
with O O
concurrent O B_DISEASE/B_GENE
respiratory O I_DISEASE/I_GENE
infections O I_DISEASE/I_GENE
. O O

The O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
was O O
also O O
increased O O
by O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admission O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
conduction O B_DISEASE
disorders O I_DISEASE
. O O

For O O
COPD O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
pneumonia O B_DISEASE
admissions O I_DISEASE
, O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
conduction O B_DISEASE
disorders O I_DISEASE
or O O
dysrhythmias O B_DISEASE
increased O O
the O O
risk O B_MEASURE/B_LOCATION
of O O
particulate O B_MEASURE
matter O I_MEASURE
< O O
10 O B_MEASURE/B_LOCATION
<FFFD> O I_MEASURE/I_LOCATION
m O I_MEASURE/I_LOCATION
in O O
aerodynamic O B_MEASURE
diameter O I_MEASURE
( O O
PM10 O B_DISEASE/B_SPECIES[BIO]
) O O
- O O
associated O O
admissions O B_DISEASE
. O O

Persons B B_PERSON
with O O
asthma O O
had O O
twice O O
the O O
risk O O
of O O
a O O
PM10 O O
- O O
associated O O
pneumonia O O
admission O O
and O O
persons B B_PERSON
with O O
heart O O
failure O O
had O O
twice O O
the O O
risk O O
of O O
PM10 O O
- O O
induced O O
COPD O O
admissions O O
. O O

The O O
PM10 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
did O O
not O O
vary O O
by O O
sex O B_PERSON/B_LOCATION
, O O
age O B_MEASURE/B_LOCATION
, O O
and O O
race O B_SPORT[ENT]/B_LOCATION
. O O

These O O
results O O
suggest O O
that O O
patients B B_PERSON/B_BIO
with O O
acute O O
respiratory O O
infections O O
or O O
defects O O
in O O
the O O
electrical O O
control O O
of O O
the O O
heart O O
are O O
a O O
risk O O
group O O
for O O
particulate O O
matter O O
effects O O
. O O

Key O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
words O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
modification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admissions O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
particulate O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
air O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pollution O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Environ O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspect O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
108 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
841 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
845 O I_MEASURE/I_PERSON
( O O
2000 O B_MEASURE
) O O
. O O

[ O B_ORGANIZATION/B_PERSON
Online O I_ORGANIZATION/I_PERSON
28 O I_ORGANIZATION/I_PERSON
July O I_ORGANIZATION/I_PERSON
2000 O I_ORGANIZATION/I_PERSON
] O I_ORGANIZATION/I_PERSON
http O I_ORGANIZATION/I_PERSON
: O O
/ O O
/ O O
ehpnet1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O
niehs O B_PERSON/B_BIO
. O O
nih O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
gov O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
docs O B_PERSON/B_MEASURE
/ O O
2000 O B_MEASURE/B_ENT
/ O O
108p841 O B_MEASURE
- O O
845zanobetti O B_MEASURE/B_PERSON
/ O O
abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
html O B_MEASURE/B_GENE

Particulate O B_DISEASE
air O I_DISEASE
pollution O I_DISEASE
has O O
been O O
associated O O
with O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
daily O B_DISEASE
deaths O I_DISEASE
and O O
hospital O B_DISEASE
admissions O I_DISEASE
in O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
all O O
over O O
the O O
world O B_LOCATION
( O O
1 O B_MEASURE/B_LOCATION
<FFFD> O I_MEASURE/I_LOCATION
15 O I_MEASURE/I_LOCATION
) O O
. O O

These O O
associations O O
are O O
now O O
well O O
documented O O
but O O
little O O
is O O
known O O
, O O
as O O
yet O O
, O O
of O O
the O O
characteristics O O
of O O
persons B B_PERSON/B_LOCATION
that O O
put O O
them O O
at O O
increased O O
risk O O
of O O
adverse O O
events O O
related O O
to O O
particulate O O
air O O
pollution O O
. O O

This O O
has O O
been O O
identified O O
as O O
a O O
key O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
gap O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
16 O B_MEASURE/B_LOCATION
) O O
. O O

Schwartz O O
and O O
Dockery O O
( O O
17 O O
) O O
reported O O
that O O
persons B B_PERSON
older O O
than O O
65 O O
years O O
of O O
age O O
had O O
a O O
somewhat O O
increased O O
risk O O
of O O
death O O
, O O
and O O
this O O
has O O
been O O
confirmed O O
in O O
other O O
studies O O
( O O
18 O O
) O O
. O O

A O O
more O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
particulate O B_DISEASE
matter O I_DISEASE
- O O
related O O
risk O B_DISEASE
by O O
deciles O B_TIME[MEASURE]/B_LOCATION
of O O
age O B_TIME[MEASURE]
( O O
19 O B_MEASURE
) O O
showed O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
beginning O O
to O O
increase O O
at O O
approximately O O
40 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
age O B_TIME[MEASURE]/B_PERSON
and O O
reaching O O
its O O
maximum O B_MEASURE/B_LOCATION
for O O
those O O
75 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
age O B_TIME[MEASURE]/B_PERSON
and O O
older O B_TIME[MEASURE]/B_LOCATION
. O O

In O O
addition O O
to O O
age O O
, O O
several O O
studies O O
suggest O O
that O O
persons B B_PERSON/B_BIO
with O O
respiratory O O
illness O O
are O O
at O O
increased O O
risk O O
for O O
cardiovascular O O
effects O O
associated O O
with O O
air O O
pollution O O
. O O

An O O
examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
death O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
certificates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
air O B_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DISEASE_ADJECTIVE[DISEASE]
days O I_DISEASE_ADJECTIVE[DISEASE]
reported O O
a O O
substantial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
proportion O B_MEASURE/B_PERSON
of O O
deaths O B_PERSON/B_DISEASE
from O O
cardiovascular O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
causes O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
that O O
had O O
respiratory O B_DISEASE
disease O I_DISEASE
as O O
a O O
contributing O O
cause O B_DISEASE/B_PERSON
of O O
death O B_DISEASE
( O O
19 O B_MEASURE
) O O
. O O

A O O
recent O O
follow O O
- O O
up O O
study O O
of O O
a O O
cohort O O
of O O
persons B B_PERSON
with O O
chronic O O
obstructive O O
pulmonary O O
disease O O
( O O
COPD O O
) O O
in O O
Barcelona O O
, O O
Spain O O
, O O
found O O
an O O
association O O
between O O
particulate O O
air O O
pollution O O
and O O
all O O
- O O
cause O O
mortality O O
in O O
the O O
cohort O O
( O O
20 O O
) O O
. O O

The O O
magnitude O B_MEASURE
of O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]
per O O
microgram O B_TIME[MEASURE]/B_PERSON
per O O
cubic O B_TIME[MEASURE]/B_PERSON
meter O I_TIME[MEASURE]/I_PERSON
of O O
exposure O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
substantially O O
greater O B_MEASURE
than O O
that O O
for O O
the O O
general O B_PERSON/B_MEASURE
population O I_PERSON/I_MEASURE
. O O

Environmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspectives O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Controlled O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
chronic O B_DISEASE/B_LOCATION
bronchitis O I_DISEASE/I_LOCATION
and O O
control O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
concentrated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
demonstrated O O
a O O
potentiating O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lung O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
airborne O B_LOCATION/B_PROTEIN[GENE]
particles O B_LOCATION/I_PROTEIN[GENE]
( O O
21 O B_MEASURE/B_LOCATION
) O O
. O O

This O O
has O O
led O O
to O O
the O O
hypothesis O O
that O O
the O O
cardiovascular O O
effects O O
of O O
air O O
pollution O O
are O O
predominantly O O
in O O
persons B B_PERSON/B_ORGANIZATION
with O O
chronic O O
lung O O
disease O O
. O O

There O O
has O O
been O O
even O O
less O O
done O O
to O O
examine O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifiers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
airborne O B_DISEASE
particles O I_DISEASE
on O O
hospital O B_DISEASE
admissions O I_DISEASE
. O O

The O O
existing O O
literature O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
comorbidity O B_DISEASE
shows O O
that O O
comorbidity O B_DISEASE
per O O
se O B_LOCATION/B_TIME[MEASURE]
seems O O
to O O
increase O O
the O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
22 O B_PROTEIN[GENE]/B_DISEASE
<FFFD> O I_PROTEIN[GENE]/I_DISEASE
30 O I_PROTEIN[GENE]/I_DISEASE
) O O
. O O

Little O B_PERSON/B_MEASURE
is O O
known O O
about O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
comorbidities O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifiers O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O O
air O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
study O O
uses O O
data O O
from O O
the O O
Medicare O O
system O O
to O O
examine O O
potential O O
short O O
- O O
term O O
and O O
long O O
- O O
term O O
medical O O
conditions O O
that O O
may O O
increase O O
a O O
person B B_PERSON/B_LOCATION
' O O
s O O
risk O O
of O O
hospital O O
admissions O O
associated O O
with O O
particulate O O
air O O
pollution O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
examine O O
potential O B_PERSON
effect O I_PERSON
modification O I_PERSON
by O O
age O B_MEASURE/B_LOCATION
, O O
race O B_SPORT[ENT]/B_PERSON
, O O
and O O
sex O B_PERSON/B_LOCATION
. O O

Materials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Health O O
Care O O
Financing O O
Administration O O
( O O
Baltimore O O
, O O
MD O O
) O O
maintains O O
records O O
of O O
every O O
hospital O O
admission O O
for O O
Medicare O O
participants B B_PERSON/B_ORGANIZATION
in O O
the O O
United O O
States O O
. O O

Persons B B_PERSON/B_ENT
in O O
this O O
database O O
have O O
a O O
unique O O
identifier O O
. O O

Using O O
this O O
identifier O O
, O O
we O O
traced O O
every O O
hospital O O
admission O O
for O O
heart O O
and O O
lung O O
disease O O
for O O
each O O
person B B_PERSON/B_LOCATION
in O O
Cook O O
County O O
, O O
Illinois O O
, O O
between O O
1985 O O
and O O
1994 O O
. O O

We O O
chose O O
Cook O B_LOCATION/B_PERSON
County O I_LOCATION/I_PERSON
because O O
it O O
is O O
the O O
most O O
populous O B_DISEASE_ADJECTIVE[DISEASE]

county O B_LOCATION/B_PERSON
in O O
the O O
United O B_LOCATION
States O I_LOCATION
with O O
daily O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
monitoring O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
particulate O B_PRODUCT[OBJECT]/B_LOCATION
matter O I_PRODUCT[OBJECT]/I_LOCATION
with O O
aerodynamic O B_MEASURE/B_LOCATION
diameter O I_MEASURE/I_LOCATION
< O O
10 O B_MEASURE/B_LOCATION
<FFFD> O I_MEASURE/I_LOCATION
m O I_MEASURE/I_LOCATION
( O O
PM10 O B_MEASURE/B_LOCATION
) O O
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
then O O
analyzed O O
to O O
look O O
at O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
concurrent O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
preexisting O O
conditions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
as O O
well O O
as O O
by O O
age O B_MEASURE/B_LOCATION
, O O
race O B_SPORT[ENT]/B_PERSON
, O O
and O O
sex O B_PERSON/B_LOCATION
. O O

To O O
establish O O
a O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
computed O O
daily O B_MEASURE
counts O I_MEASURE
of O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
cardiovascular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CVD O B_DISEASE/B_LOCATION
) O O
[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
International O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Disease O B_DISEASE
, O O
9th O B_MEASURE/B_ENT
edition O I_MEASURE/I_ENT
, O O
World O B_MEASURE/B_LOCATION
Health O I_MEASURE/I_LOCATION
Organization O I_MEASURE/I_LOCATION
, O O
Geneva O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ICD O B_DISEASE/B_MEASURE
- O O
9 O B_SEQUENCE[MEASURE]
) O O
code O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
390 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
<FFFD> O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
429 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
pneumonia O B_DISEASE
( O O
ICD O B_DISEASE/B_LOCATION
- O O
9 O B_MEASURE
code O I_MEASURE
480 O I_MEASURE
<FFFD> O I_MEASURE
487 O I_MEASURE
) O O
, O O
and O O
COPD O B_DISEASE
( O O
ICD O B_DISEASE/B_LOCATION
- O O
9 O B_MEASURE
code O I_MEASURE
490 O I_MEASURE
<FFFD> O I_MEASURE
496 O I_MEASURE
, O O
excluding O O
493 O B_TIME[MEASURE]/B_DISEASE
) O O
. O O

The O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
these O O
daily O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counts O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PM10 O B_DISEASE/B_SPECIES[BIO]
was O O
examined O O
for O O
the O O
years O B_TIME[MEASURE]
1988 O I_TIME[MEASURE]
<FFFD> O I_TIME[MEASURE]
1994 O I_TIME[MEASURE]
, O O
when O O
daily O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PM10 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Chicago O B_LOCATION
. O O

Once O O
our O O
baseline O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
risks O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
established O O
, O O
we O O
examined O O
three O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
classes O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
modifiers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

First O O
, O O
we O O
looked O O
at O O
whether O O
previous O O
admissions O O
for O O
selected O O
conditions O O
predisposed O O
persons B B_PERSON
to O O
having O O
a O O
greater O O
risk O O
from O O
air O O
pollution O O
. O O

For O O
each O O
of O O
the O O
three O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
admission O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
categories O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
CVD O B_DISEASE
, O O
pneumonia O B_DISEASE/B_LOCATION
, O O
and O O
COPD O B_DISEASE/B_PERSON
) O O
, O O
we O O
considered O O
10 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
causes O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
defined O O
by O O
a O O
previous O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
as O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifiers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
COPD O B_DISEASE
( O O
ICD O B_DISEASE/B_LOCATION
- O O
9 O B_MEASURE
code O I_MEASURE
490 O I_MEASURE
<FFFD> O I_MEASURE
496 O I_MEASURE
except O O
493 O B_TIME[MEASURE]/B_LOCATION
) O O
, O O
asthma O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
ICD O B_DISEASE/B_LOCATION
- O O
9 O B_MEASURE/B_LOCATION
code O I_MEASURE/I_LOCATION
493 O I_MEASURE/I_LOCATION
) O O
, O O
acute O B_DISEASE
bronchitis O I_DISEASE
( O O
ICD O B_DISEASE/B_LOCATION
- O O
9 O B_MEASURE/B_LOCATION
code O I_MEASURE/I_LOCATION
466 O I_MEASURE/I_LOCATION
) O O
, O O
acute O B_DISEASE
respiratory O I_DISEASE
illness O I_DISEASE
( O O
ICD O B_DISEASE/B_LOCATION
- O O
9 O B_MEASURE
code O I_MEASURE
460 O I_MEASURE
<FFFD> O I_MEASURE
466 O I_MEASURE
) O O
, O O
pneumonia O B_DISEASE
( O O
ICD O B_DISEASE/B_LOCATION
- O O
9 O B_MEASURE
code O I_MEASURE
480 O I_MEASURE
<FFFD> O I_MEASURE
487 O I_MEASURE
) O O
, O O
CVD O B_DISEASE
( O O
ICD O B_DISEASE/B_LOCATION
- O O
9 O B_MEASURE
code O I_MEASURE
390 O I_MEASURE
<FFFD> O I_MEASURE
429 O I_MEASURE
) O O
, O O
myocardial O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infarction O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
ICD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
9 O B_MEASURE
code O I_MEASURE
410 O I_MEASURE
) O O
, O O
congestive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ICD O B_MEASURE/B_DISEASE
- O O
9 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
428 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
conduction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disorders O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
ICD O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
9 O B_MEASURE/B_LOCATION
code O I_MEASURE/I_LOCATION
426 O I_MEASURE/I_LOCATION
) O O
, O O
and O O
dysrhythmias O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
ICD9 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
427 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

To O O
test O O
the O O
hypothesis O O
that O O
persons B B_PERSON
with O O
these O O
conditions O O
had O O
higher O O
risks O O
of O O
subsequent O O
PM10 O O
- O O
related O O
admissions O O
, O O
we O O
computed O O
separate O O
daily O O
counts O O
of O O
admissions O O
for O O
our O O
three O O
target O O
causes O O
, O O
stratified O O
by O O
whether O O
or O O
not O O
the O O
person B B_PERSON
admitted O O
had O O
been O O
previously O O
admitted O O
for O O
the O O
hypothesized O O
predisposing O O
condition O O
. O O

Separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
then O O
performed O O
within O O
each O O
strata O B_LOCATION/B_ORGANIZATION
to O O
see O O
if O O
the O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
PM10 O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
differed O O
by O O
strata O B_MEASURE/B_LOCATION
. O O

Address O O
correspondence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
A O B_OTHER/B_PERSON
. O O

Zanobetti O B_PERSON/B_LOCATION
, O O
Department O B_ORGANIZATION/B_PERSON
of O O
Environmental O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Environmental O B_LOCATION/B_PERSON
Epidemiology O I_LOCATION/I_PERSON
Program O I_LOCATION/I_PERSON
, O O
Harvard O B_LOCATION/B_ORGANIZATION
School O B_LOCATION/I_ORGANIZATION
of O O
Public O B_ORGANIZATION/B_LOCATION
Health O I_ORGANIZATION/I_LOCATION
, O O
665 O B_LOCATION/B_ORGANIZATION
Huntington O I_LOCATION/I_ORGANIZATION
Avenue O I_LOCATION/I_ORGANIZATION
, O O
Boston O B_LOCATION/B_PERSON
, O O
MA O B_LOCATION
02115 O I_LOCATION
USA O I_LOCATION
. O O

Telephone O B_PRODUCT[OBJECT]/B_MEASURE
: O O
( O O
617 O B_MEASURE/B_LOCATION
) O O
4324642 O B_MEASURE/B_LOCATION
. O O

Fax O B_MEASURE/B_PERSON
: O O
( O O
617 O O
) O O
277 O B_MEASURE
- O O
2382 O B_MEASURE
. O O

E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mail O B_TIME[MEASURE]/B_LOCATION
: O O
azanob O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
@ O O
sparc6a O B_LOCATION
. O O
harvard O B_LOCATION/B_DISEASE
. O O
edu O B_PERSON/B_LOCATION
Supported O O
by O O
NIEHS O B_ORGANIZATION/B_LOCATION
grant O I_ORGANIZATION/I_LOCATION
ES07937 O I_ORGANIZATION/I_LOCATION
. O O

Received O O
18 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
January O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
2000 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
; O O
accepted O O
18 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
April O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
2000 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

<FFFD> O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
VOLUME O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
108 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
NUMBER O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
9 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
September O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2000 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]

841 O B_NUMBER[MEASURE]

Articles O B_PERSON

<FFFD> O B_PERSON/B_MEASURE

Zanobetti O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O I_PERSON/I_LOCATION
. O O

The O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
predisposing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
included O O
secondary O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnoses O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
the O O
index O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
could O O
represent O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
chronic O B_DISEASE
condition O I_DISEASE
( O O
e O B_DISEASE/B_GENE
. O O
g O B_GENE/B_MEASURE
. O O
, O O
COPD O B_DISEASE
) O O
that O O
has O O
not O O
resulted O O
in O O
a O O
previous O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hospital O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

They O O
could O O
also O O
represent O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
may O O
have O O
increased O O
the O O
subjects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sensitivity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
air O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
example O O
, O O
if O O
respiratory O O
infections O O
modified O O
the O O
effect O O
of O O
particulate O O
matter O O
on O O
the O O
cardiovascular O O
health O O
of O O
persons B B_PERSON
with O O
underlying O O
heart O O
disease O O
, O O
then O O
the O O
risk O O
of O O
a O O
hospital O O
admission O O
for O O
heart O O
disease O O
might O O
be O O
different O O
in O O
persons B B_PERSON/B_LOCATION
with O O
infections O O
. O O

If O O
this O O
were O O
true O O
, O O
then O O
the O O
risk O O
ratio O O
of O O
a O O
10 O O
- O O
<FFFD> O O
g O O
/ O O
m3 O O
increase O O
of O O
PM10 O O
on O O
cardiovascular O O
admissions O O
of O O
persons B B_PERSON
with O O
a O O
concurrent O O
respiratory O O
infection O O
would O O
be O O
different O O
from O O
the O O
ratio O O
in O O
persons B B_PERSON/B_LOCATION
without O O
respiratory O O
infection O O
. O O

To O O
test O O
these O O
hypotheses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
we O O
computed O O
separate O B_MEASURE/B_ORGANIZATION
daily O I_MEASURE/I_ORGANIZATION
counts O I_MEASURE/I_ORGANIZATION
of O O
admissions O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
events O B_PERSON/B_LOCATION
with O O
and O O
without O O
the O O
concurrent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
conditions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
hypothesized O O
to O O
increase O O
sensitivity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
air O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pollution O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
were O O
taken O O
as O O
the O O
same O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
certain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
exclusions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
pairing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
would O O
be O O
illogical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

That O O
is O O
, O O
the O O
concurrent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
specific O B_DISEASE
cardiac O I_DISEASE
condition O I_DISEASE
was O O
not O O
treated O O
as O O
an O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifier O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
admissions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
any O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condition O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Likewise O O
, O O
pneumonia O B_DISEASE/B_LOCATION
and O O
COPD O B_DISEASE
were O O
not O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
concurrent O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
conditions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
each O O
other O B_PERSON/B_LOCATION
. O O

The O O
third O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
predisposing O O
conditions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
considered O O
was O O
being O O
older O B_TIME[MEASURE]
than O O
75 O B_TIME[MEASURE]/B_PERSON
years O I_TIME[MEASURE]/I_PERSON
of O O
age O B_TIME[MEASURE]/B_PERSON
, O O
nonwhite O B_PERSON/B_LOCATION
, O O
and O O
female O B_PERSON
. O O

These O O
were O O
examined O O
for O O
all O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
obtained O O
weather O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
O O B_OTHER/B_PERSON
' O O
Hare O B_PERSON/B_LOCATION
Airport O I_PERSON/I_LOCATION
from O O
the O O
EarthInfo O B_ENT/B_LOCATION
CD O I_ENT/I_LOCATION
- O O
ROM O B_DISEASE/B_NUMBER[MEASURE]
( O O
EarthInfo O B_MEASURE/B_DISEASE
CD O I_MEASURE/I_DISEASE
NCDC O I_MEASURE/I_DISEASE
Surface O I_MEASURE/I_DISEASE
Airways O I_MEASURE/I_DISEASE
, O O
EarthInfo O B_ORGANIZATION/B_LOCATION
Inc O I_ORGANIZATION/I_LOCATION
. O O
, O O
Boulder O B_LOCATION/B_LANGUAGE
, O O
CO O B_LOCATION
) O O
, O O
and O O
we O O
obtained O O
air O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pollution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O O
the O O
U O B_OTHER/B_LOCATION
. O O
S O B_OTHER/B_LOCATION
. O O

Environmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Protection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Agency O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Aerometric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Retrieval O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
System O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
network O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
31 O B_MEASURE/B_ORGANIZATION
) O O
. O O

running O O
- O O
line O B_MEASURE/B_LOCATION
smoother O I_MEASURE/I_LOCATION
, O O
loess O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
35 O B_MEASURE/B_LOCATION
) O O
, O O
was O O
chosen O O
to O O
estimate O O
the O O
smooth O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
control O O
for O O
weather O B_TIME[MEASURE]
variables O I_TIME[MEASURE]
and O O
day O B_TIME[MEASURE]
of O O
the O O
week O B_TIME[MEASURE]/B_LOCATION
, O O
we O O
chose O O
the O O
smoothing O B_MEASURE
parameter O I_MEASURE
that O O
minimized O O
the O O
Akaike O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
criterion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
36 O B_MEASURE/B_LOCATION
) O O
. O O

To O O
model O O
seasonality O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
we O O
chose O O
the O O
smoothing O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameter O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
minimized O O
the O O
sum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
autocorrelation O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
residuals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
while O O
removing O O
seasonal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O B_NUMBER[MEASURE]/B_LOCATION
autoregressive O I_NUMBER[MEASURE]/I_LOCATION
terms O I_NUMBER[MEASURE]/I_LOCATION
( O O
37 O B_MEASURE/B_LOCATION
) O O
were O O
added O O
in O O
the O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
eliminate O O
the O O
remaining O O
serial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
the O O
residuals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

We O O
used O O
the O O
mean O B_MEASURE
of O O
PM10 O B_DISEASE/B_MEASURE
on O O
the O O
day O B_TIME[MEASURE]
of O O
the O O
admission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
the O O
day O B_TIME[MEASURE]
before O O
the O O
admission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
as O O
our O O
exposure O B_TIME[MEASURE]/B_PERSON
variable O I_TIME[MEASURE]/I_PERSON
. O O

This O O
gives O O
results O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
are O O
similar O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
those O O
obtained O O
fitting O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
full O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
distributed O O
lag O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
38 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

PM10 O B_BIO/B_MEASURE
was O O
treated O O
linearly O O
. O O

Our O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
the O O
daily O B_MEASURE
counts O I_MEASURE
of O O
CVD O B_DISEASE
, O O
pneumonia O B_DISEASE
, O O
and O O
COPD O B_DISEASE
admissions O I_DISEASE
as O O
outcomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

We O O
then O O
subdivided O O
those O O
counts O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
the O O
presence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
absence O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
potential O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifier O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reestimated O O
our O O
regressions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
those O O
subgroups O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

We O O
considered O O
effect O O
modification O O
to O O
be O O
indicated O O
when O O
the O O
estimates O O
of O O
PM10 O O
in O O
the O O
group O O
with O O
the O O
condition O O
was O O
outside O O
of O O
the O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
of O O
the O O
effect O O
estimate O O
in O O
persons B B_PERSON/B_ORGANIZATION
without O O
the O O
condition O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Table O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O O
the O O
mean O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
COPD O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
cardiovascular O B_DISEASE
, O O
and O O
pneumonia O B_DISEASE
both O O
overall O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
the O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
modifiers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

For O O
some O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
modifiers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
conduction O B_DISEASE
disorders O I_DISEASE
or O O
myocardial O B_DISEASE
infarctions O I_DISEASE
, O O
the O O
counts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
conjunction O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
our O O
respiratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O

low O B_MEASURE/B_COLOR
, O O
which O O
limits O O
power O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

In O O
general O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
numbers O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
examining O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
previous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
for O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
concurrent O B_DISEASE/B_PERSON
diagnosis O I_DISEASE/I_PERSON
. O O

This O O
is O O
as O O
expected O O
because O O
many O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinically O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comorbidities O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
never O O
have O O
resulted O O
in O O
a O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O O
the O O
25th O B_SEQUENCE[MEASURE]
, O O
50th O B_SEQUENCE[MEASURE]
, O O
and O O
75th O B_SEQUENCE[MEASURE]
percentile O I_SEQUENCE[MEASURE]
values O I_SEQUENCE[MEASURE]
for O O
the O O
environmental O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
mean O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
PM10 O B_MEASURE/B_SPECIES[BIO]
is O O
33 O B_MEASURE
<FFFD> O I_MEASURE
g O I_MEASURE
/ O O
m3 O B_MEASURE
. O O

The O O
daily O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
PM10 O B_TIME[MEASURE]/B_PERSON
were O O
computed O O
as O O
the O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
of O O
10 O B_NUMBER[MEASURE]
monitors O I_NUMBER[MEASURE]
, O O
two O B_NUMBER[MEASURE]
of O O
which O O
measured O O
PM10 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
almost O O
every O O
day O B_TIME[MEASURE]
and O O
the O O
others O B_PERSON/B_SEQUENCE[MEASURE]
less O O
frequently O O
( O O
38 O B_TIME[MEASURE]
) O O
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O O
the O O
mean O B_MEASURE
daily O I_MEASURE
counts O I_MEASURE
of O O
CVD O B_DISEASE
, O O
COPD O B_DISEASE
, O O
and O O
pneumonia O B_DISEASE
by O O
sex O B_PERSON/B_LOCATION
, O O
age O B_MEASURE/B_PERSON
groups O B_MEASURE/I_PERSON
, O O
and O O
race O B_LOCATION
. O O

The O O
distribution O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O O
sex O B_PERSON
is O O
almost O O
even O O
, O O
although O O
the O O
counts O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
admissions O B_PERSON/B_DISEASE
for O O
males O B_PERSON/B_DISEASE
are O O
generally O O
lower O B_MEASURE
( O O
approximately O O
10 O B_MEASURE
% O I_MEASURE
) O O
than O O
for O O
females O B_PERSON
, O O
particularly O O
for O O
cardiovascular O B_PERSON
diseases O I_PERSON
. O O

The O O
counts O O
of O O
CVD O O
, O O
COPD O O
, O O
and O O
pneumonia O O
admissions O O
were O O
similar O O
for O O
people B B_PERSON/B_LOCATION
65 O O
<FFFD> O O
75 O O
or O O
75 O O
years O O
of O O
age O O
and O O
older O O
. O O

Tables O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
<FFFD> O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
6 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O O
the O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PM10 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
overall O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
stratifying O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
concurrent O B_TIME[MEASURE]/B_LOCATION
diagnosis O I_TIME[MEASURE]/I_LOCATION
and O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
are O O
expressed O O
as O O
the O O
percentage O B_MEASURE
increase O I_MEASURE
for O O
10 O B_MEASURE/B_LOCATION
<FFFD> O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
m3 O B_MEASURE
PM10 O I_MEASURE
. O O

Table O B_TIME[MEASURE]/B_LOCATION
4 O I_TIME[MEASURE]/I_LOCATION
shows O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
CVD O B_ORGANIZATION/B_MEASURE
. O O

A O O
10 O O
- O O
<FFFD> O O
g O O
/ O O
m3 O O
increase O O
in O O
PM10 O O
was O O
associated O O
with O O
a O O
1 O O
. O O
31 O O
% O O
( O O
5 O O
% O O
CI O O
, O O
0 O O
. O O
97 O O
% O O
; O O
95 O O
% O O
CI O O
, O O
1 O O
. O O
66 O O
% O O
) O O
increase O O
in O O
hospital O O
admissions O O
for O O
heart O O
disease O O
in O O
all O O
elderly O O
persons B B_PERSON/B_LOCATION
. O O

A O O
concurrent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
( O O
not O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
COPD O B_DISEASE
modified O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
PM10 O B_DISEASE/B_SPECIES[BIO]
- O O
associated O O
admissions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
heart O B_DISEASE
disease O I_DISEASE
. O O

However O O
, O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
associations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
still O O
seen O O
between O O
PM10 O B_PERSON/B_LOCATION

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Mean O O
daily O B_MEASURE/B_LOCATION
counts O I_MEASURE/I_LOCATION
of O O
admissions O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
Chicago O B_TIME[MEASURE]/B_LOCATION
1986 O I_TIME[MEASURE]/I_LOCATION
<FFFD> O I_TIME[MEASURE]/I_LOCATION
1994 O I_TIME[MEASURE]/I_LOCATION
, O O
for O O
COPD O B_DISEASE
, O O
CVD O B_DISEASE/B_GENE
, O O
and O O
pneumonia O B_DISEASE
overall O O
and O O
by O O
concurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
diagnosis O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
by O O
previous O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
concurrent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
COPD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
CVD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Pneumonia O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Overall O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Respiratory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
disease O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Acute O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
bronchitis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Acute O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
respiratory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
infections O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Pneumonia O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Asthma O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
COPD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Cardiovascular O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
disease O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
CVD O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Conduction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
disorders O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Cardiac O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
dysrhythmias O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Congestive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
heart O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
failure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Myocardial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
infarction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
NA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
not O O
applicable O B_MEASURE/B_DISEASE
. O O

By O O
previous O B_MEASURE
admissions O I_MEASURE
COPD O I_MEASURE
CVD O I_MEASURE
Pneumonia O I_MEASURE
7 O I_MEASURE
. O O
8 O B_MEASURE
0 O I_MEASURE
. O O
8 O B_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
1 O I_MEASURE
. O O
6 O B_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
2 O I_MEASURE
. O O
7 O B_MEASURE
2 O I_MEASURE
. O O
1 O B_MEASURE
0 O I_MEASURE
. O O
0 O B_MEASURE
0 O I_MEASURE
. O O
4 O B_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
0 O I_MEASURE
. O O
3 O B_MEASURE
102 O I_MEASURE
. O O
1 O B_MEASURE
1 O I_MEASURE
. O O
6 O B_MEASURE
1 O I_MEASURE
. O O
8 O B_MEASURE
7 O I_MEASURE
. O O
3 O B_MEASURE
1 O I_MEASURE
. O O
5 O B_MEASURE
2 O I_MEASURE
. O O
0 O B_MEASURE
54 O I_MEASURE
. O O
7 O B_MEASURE
1 O I_MEASURE
. O O
0 O B_MEASURE
9 O I_MEASURE
. O O
9 O B_TIME[MEASURE]
24 O I_TIME[MEASURE]
. O O
2 O B_MEASURE
11 O I_MEASURE
. O O
4 O B_TIME[MEASURE]
26 O I_TIME[MEASURE]
. O O
5 O B_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
1 O I_MEASURE
. O O
0 O B_MEASURE
6 O I_MEASURE
. O O
4 O B_MEASURE
0 O I_MEASURE
. O O
7 O B_MEASURE
1 O I_MEASURE
. O O
4 O B_MEASURE
7 O I_MEASURE
. O O
2 O B_MEASURE
0 O I_MEASURE
. O O
2 O B_MEASURE
1 O I_MEASURE
. O O
5 O B_MEASURE
3 O I_MEASURE
. O O
1 O B_MEASURE
1 O I_MEASURE
. O O
0 O B_MEASURE

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
We O O
analyzed O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
a O O
generalized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
additive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
robust O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Poisson O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
32 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

This O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
become O O
the O O
norm O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
14 O B_MEASURE
, O O
33 O B_MEASURE
, O O
34 O B_MEASURE
) O O
. O O

In O O
the O O
generalized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
additive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
the O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
assumed O O
to O O
depend O O
on O O
a O O
sum O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nonparametric O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
smooth O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
each O O
variable O B_TIME[MEASURE]/B_LOCATION
that O O
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O O
potential O B_MEASURE
nonlinear O I_MEASURE
dependence O I_MEASURE
of O O
daily O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
weather O B_LOCATION/B_TIME[MEASURE]
and O O
season O B_MEASURE/B_LOCATION
. O O

The O O
model O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
of O O
the O O
form O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
log O B_PROTEIN[GENE]
[ O I_PROTEIN[GENE]
E O I_PROTEIN[GENE]
( O O
Yt O B_MEASURE/B_PROTEIN[GENE]
) O O
] O B_OTHER/B_DISEASE
= O O
0 O B_MEASURE/B_PROTEIN[GENE]
+ O B_MEASURE/I_PROTEIN[GENE]
S1 O B_MEASURE/I_PROTEIN[GENE]
( O O
X1 O B_MEASURE/B_GENE
) O O
+ O B_OTHER/B_GENE
. O O
. O O
. O O

+ O O
Sp O B_LOCATION
( O O
Xp O B_LOCATION/B_MEASURE
) O O
where O O
E O B_OTHER/B_LOCATION
( O O
Yt O B_LOCATION/B_MEASURE
) O O
is O O
the O O
expected O B_MEASURE
value O I_MEASURE
of O O
the O O
daily O B_MEASURE/B_LOCATION
count O I_MEASURE/I_LOCATION
of O O
admissions O B_LOCATION/B_ORGANIZATION
Yt O I_LOCATION/I_ORGANIZATION
and O O
Si O B_LOCATION/B_PERSON
are O O
the O O
smooth O B_MEASURE/B_LOCATION
functions O I_MEASURE/I_LOCATION
of O O
the O O
covariates O B_MEASURE/B_LOCATION
Xi O I_MEASURE/I_LOCATION
. O O

We O O
examined O O
temperature O B_MEASURE/B_LOCATION
, O O
previous O B_TIME[MEASURE]/B_LOCATION
day O B_TIME[MEASURE]/I_LOCATION
' O O
s O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temperature O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
relative O B_MEASURE/B_LOCATION
humidity O B_MEASURE/I_LOCATION
, O O
barometric O B_MEASURE/B_LOCATION
pressure O B_MEASURE/I_LOCATION
, O O
and O O
day O B_TIME[MEASURE]/B_LOCATION
of O O
week O B_TIME[MEASURE]/B_LOCATION
covariates O I_TIME[MEASURE]/I_LOCATION
. O O

The O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
locally O O
weighted O O

7 O O
. O O
8 O B_MEASURE
0 O I_MEASURE
. O O
1 O B_MEASURE
0 O I_MEASURE
. O O
3 O B_MEASURE
0 O I_MEASURE
. O O
4 O B_MEASURE
0 O I_MEASURE
. O O
1 O B_MEASURE
NA O I_MEASURE
4 O I_MEASURE
. O O
7 O B_MEASURE
0 O I_MEASURE
. O O
2 O B_MEASURE
1 O I_MEASURE
. O O
4 O B_MEASURE
1 O I_MEASURE
. O O
8 O B_MEASURE
0 O I_MEASURE
. O O
1 O B_MEASURE

102 O O
. O O
1 O B_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
1 O I_MEASURE
. O O
3 O B_MEASURE
4 O I_MEASURE
. O O
0 O B_MEASURE
1 O I_MEASURE
. O O
8 O B_TIME[MEASURE]
13 O I_TIME[MEASURE]
. O O
4 O B_MEASURE/B_ENT
NA O I_MEASURE/I_ENT
NA O I_MEASURE/I_ENT
NA O I_MEASURE/I_ENT
NA O I_MEASURE/I_ENT
NA O I_MEASURE/I_ENT

26 O O
. O O
5 O B_MEASURE
0 O I_MEASURE
. O O
3 O B_MEASURE
0 O I_MEASURE
. O O
3 O B_MEASURE
NA O I_MEASURE
0 O I_MEASURE
. O O
9 O B_TIME[MEASURE]
6 O I_TIME[MEASURE]
. O O
9 O B_TIME[MEASURE]
14 O I_TIME[MEASURE]
. O O
7 O B_MEASURE
0 O I_MEASURE
. O O
6 O B_MEASURE
4 O I_MEASURE
. O O
6 O B_TIME[MEASURE]
7 O I_TIME[MEASURE]
. O O
3 O B_MEASURE
0 O I_MEASURE
. O O
4 O B_MEASURE

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

25th O O
, O O
50th O B_SEQUENCE[MEASURE]
, O O
and O O
75th O B_SEQUENCE[MEASURE]
percentile O I_SEQUENCE[MEASURE]
values O I_SEQUENCE[MEASURE]
for O O
the O O
environmental O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
variables O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
Chicago O B_LOCATION/B_TIME[MEASURE]
, O O
1988 O B_LOCATION
<FFFD> O I_LOCATION
1994 O I_LOCATION
. O O

Temperature O B_MEASURE
( O O
<FFFD> O B_MEASURE/B_LOCATION
F O I_MEASURE/I_LOCATION
) O O
35 O B_TIME[MEASURE]
51 O I_TIME[MEASURE]
67 O I_TIME[MEASURE]
Relative O I_TIME[MEASURE]
humidity O I_TIME[MEASURE]
62 O I_TIME[MEASURE]
70 O I_TIME[MEASURE]
79 O I_TIME[MEASURE]
Barometric O I_TIME[MEASURE]
pressure O I_TIME[MEASURE]
29 O I_TIME[MEASURE]
. O O
2 O B_MEASURE
29 O I_MEASURE
. O O
3 O B_TIME[MEASURE]
29 O I_TIME[MEASURE]
. O O
4 O B_TIME[MEASURE]
PM10 O I_TIME[MEASURE]
( O O
<FFFD> O B_MEASURE/B_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
m3 O B_MEASURE
) O O
23 O B_MEASURE/B_LOCATION
33 O I_MEASURE/I_LOCATION
46 O I_MEASURE/I_LOCATION

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Mean O O
daily O B_MEASURE/B_LOCATION
counts O I_MEASURE/I_LOCATION
of O O
admissions O B_PERSON/B_LOCATION
by O O
sex O B_PERSON/B_LOCATION
, O O
race O B_LOCATION
, O O
and O O
age O B_MEASURE/B_PERSON
groups O B_MEASURE/I_PERSON
, O O
Chicago O B_LOCATION/B_DISEASE
, O O
1986 O B_TIME[MEASURE]/B_LOCATION
<FFFD> O B_TIME[MEASURE]/I_LOCATION
1994 O B_TIME[MEASURE]/I_LOCATION
. O O

Group O B_TIME[MEASURE]/B_LOCATION
Overall O I_TIME[MEASURE]/I_LOCATION
Female O I_TIME[MEASURE]/I_LOCATION
Nonwhite O I_TIME[MEASURE]/I_LOCATION
Age O I_TIME[MEASURE]/I_LOCATION
> O O
75 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
COPD O I_MEASURE/I_ENT
7 O I_MEASURE/I_ENT
. O O
8 O B_MEASURE
4 O I_MEASURE
. O O
2 O B_MEASURE
1 O I_MEASURE
. O O
6 O B_MEASURE
3 O I_MEASURE
. O O
7 O B_MEASURE
CVD O I_MEASURE
102 O I_MEASURE
. O O
1 O B_MEASURE
59 O I_MEASURE
. O O
4 O B_TIME[MEASURE]
21 O I_TIME[MEASURE]
. O O
0 O B_MEASURE
55 O I_MEASURE
. O O
1 O B_TIME[MEASURE]
Pneumonia O I_TIME[MEASURE]
26 O I_TIME[MEASURE]
. O O
5 O B_TIME[MEASURE]
14 O I_TIME[MEASURE]
. O O
7 O B_MEASURE
5 O I_MEASURE
. O O
2 O B_MEASURE
17 O I_MEASURE
. O O
4 O B_MEASURE

842 O B_NUMBER[MEASURE]

VOLUME O B_MEASURE

108 O O
| O O
NUMBER O B_TIME[MEASURE]
9 O I_TIME[MEASURE]
| O O
September O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2000 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
<FFFD> O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Environmental O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Perspectives O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

Articles O B_PERSON

<FFFD> O B_PERSON/B_MEASURE

Effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
particles O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
sensitive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroups O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

and O O
heart O O
disease O O
admissions O O
in O O
persons B B_PERSON/B_LOCATION
without O O
COPD O O
listed O O
as O O
either O O
a O O
comorbidity O O
or O O
a O O
cause O O
of O O
previous O O
admission O O
( O O
Table O O
4 O O
) O O
. O O

A O O
significant O O
association O O
was O O
also O O
seen O O
in O O
persons B B_PERSON
without O O
any O O
respiratory O O
disease O O
as O O
a O O
concurrent O O
diagnosis O O
, O O
although O O
the O O
risk O O
is O O
much O O
lower O O
than O O
in O O
persons B B_PERSON
with O O
respiratory O O
disease O O
. O O

However O O
, O O
the O O
risk O O
associated O O
with O O
PM10 O O
was O O
roughly O O
doubled O O
in O O
subjects O O
with O O
concurrent O O
respiratory O O
infections O O
and O O
the O O
risk O O
estimates O O
in O O
those O O
subjects O O
were O O
outside O O
the O O
95 O O
% O O
CI O O
of O O
the O O
risk O O
in O O
patients B B_PERSON
without O O
concurrent O O
respiratory O O
infections O O
. O O

A O O
previous O O
admission O O
for O O
conduction O O
disorders O O
( O O
e O O
. O O
g O O
. O O
, O O
heart O O
block O O
) O O
increased O O
the O O
risk O O
of O O
a O O
PM10 O O
- O O
related O O
subsequent O O
admission O O
for O O
any O O
heart O O
condition O O
, O O
and O O
a O O
weaker O O
indication O O
of O O
effect O O
modification O O
was O O
seen O O
for O O
persons B B_PERSON
with O O
previous O O
admission O O
for O O
dysrhythmias O O
. O O

In O O
contrast O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
heart O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
failure O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
previous O B_DISEASE/B_PERSON
myocardial O I_DISEASE/I_PERSON
infarctions O I_DISEASE/I_PERSON
were O O
highly O O
insignificant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifiers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Table O B_MEASURE/B_LOCATION
5 O I_MEASURE/I_LOCATION
shows O O
the O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
COPD O B_MEASURE/B_PERSON
. O O

Overall O O
, O O
there O O
is O O
a O O
1 O B_MEASURE
. O O
89 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
CI O I_MEASURE/I_LOCATION
, O O
0 O B_MEASURE
. O O
8 O B_MEASURE
<FFFD> O I_MEASURE
3 O I_MEASURE
. O O
0 O B_MEASURE
) O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
COPD O B_DISEASE/B_GENE
admissions O I_DISEASE/I_GENE
for O O
a O O
10 O B_MEASURE/B_LOCATION
<FFFD> O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
m3 O B_MEASURE
increase O I_MEASURE
in O O
PM10 O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
stratified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
preexisting O O
heart O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifies O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
4 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Percentage O O
increase O O
in O O
hospital O O
admissions O O
for O O
CVD O O
in O O
all O O
persons B B_PERSON/B_LOCATION
and O O
by O O
concurrent O O
diagnosis O O
and O O
previous O O
admissions O O
. O O

PM10 O O
2 O O
. O O
5 O O
% O O
CI O O
97 O O
. O O
5 O O
% O O
CI O O
All O O
persons B B_PERSON/B_TIME[MEASURE]
1 O O
. O O
31 O O
By O O
concurrent O O
diagnosis O O
Respiratory O O
disease O O
All O O
respiratory O O
disease O O
With O O
1 O O
. O O
65 O O
Without O O
0 O O
. O O
98 O O
Acute O O
bronchitis O O
With O O
2 O O
. O O
50 O O
Without O O
1 O O
. O O
07 O O
Acute O O
respiratory O O
infections O O
With O O
2 O O
. O O
71 O O
Without O O
1 O O
. O O
06 O O
Pneumonia O O
With O O
1 O O
. O O
95 O O
Without O O
1 O O
. O O
03 O O
COPD O O
With O O
1 O O
. O O
59 O O
Without O O
1 O O
. O O
08 O O
By O O
previous O O
admissions O O
Respiratory O O
disease O O
All O O
respiratory O O
disease O O
With O O
1 O O
. O O
18 O O
Without O O
1 O O
. O O
08 O O
COPD O O
With O O
1 O O
. O O
48 O O
Without O O
1 O O
. O O
09 O O
Asthma O O
With O O
1 O O
. O O
71 O O
Without O O
1 O O
. O O
08 O O
Cardiovascular O O
disease O O
Conduction O O
disorders O O
With O O
2 O O
. O O
89 O O
Without O O
1 O O
. O O
07 O O
Cardiac O O
dyshrethmias O O
With O O
1 O O
. O O
61 O O
Without O O
1 O O
. O O
04 O O
0 O O
. O O
97 O O
1 O O
. O O
66 O O

the O O
risk O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
COPD O B_DISEASE
admissions O I_DISEASE
on O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
particle O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
days O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
any O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
increased O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
a O O
PM10associated O B_DISEASE
COPD O I_DISEASE
admission O I_DISEASE
approximately O O
2 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
- O O
fold O B_TIME[MEASURE]/B_LOCATION
. O O

A O O
previous O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O O
an O O
even O O
more O O
striking O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
PM10 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
dysrhythmias O B_DISEASE
and O O
conduction O B_DISEASE
defects O I_DISEASE
were O O
rare O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Table O B_MEASURE
1 O I_MEASURE
) O O
with O O
no O O
power O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
examine O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
modifications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Listings O B_DISEASE
as O O
concurrent O B_DISEASE/B_PERSON
diagnoses O I_DISEASE/I_PERSON
were O O
more O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
here O O
they O O
joined O O
heart O B_DISEASE_ADJECTIVE[DISEASE]
failure O I_DISEASE_ADJECTIVE[DISEASE]
in O O
increasing O O
the O O
risk O B_MEASURE
of O O
PM O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
COPD O B_DISEASE/B_LOCATION
admissions O I_DISEASE/I_LOCATION
. O O

For O O
COPD O B_DISEASE/B_PERSON
there O O
was O O
also O O
some O O
indication O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
concurrent O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pneumonia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
an O O
acute O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
respiratory O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
last O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
year O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
increased O O
risk O B_DISEASE
. O O

The O O
low O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
numbers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
made O O
these O O
estimates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
less O O
precise O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
. O O

The O O
percentage O B_MEASURE
increase O I_MEASURE
in O O
pneumonia O B_DISEASE/B_PROTEIN[GENE]
admission O B_DISEASE/I_PROTEIN[GENE]
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
6 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
for O O
10 O B_MEASURE/B_LOCATION
<FFFD> O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
m3 O B_MEASURE
PM10 O I_MEASURE
is O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
for O O
COPD O B_DISEASE/B_LOCATION
or O O
CVD O B_DISEASE/B_LOCATION
with O O
an O O
increase O B_PROTEIN[GENE]/B_DISEASE
of O O
2 O B_MEASURE
. O O
34 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
CI O I_MEASURE/I_LOCATION
, O O
1 O B_MEASURE
. O O
66 O B_MEASURE
<FFFD> O I_MEASURE
3 O I_MEASURE
. O O
0 O B_MEASURE
) O O
. O O

As O O
with O O
COPD O O
, O O
persons B B_PERSON
with O O
heart O O
disease O O
appeared O O
at O O
higher O O
risk O O
of O O
pneumonia O O
hospital O O
admissions O O
associated O O
with O O
particulate O O
air O O
pollution O O
. O O

Here O O
diagnoses O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggestive O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
impaired O B_DISEASE_ADJECTIVE[DISEASE]
autonomic O I_DISEASE_ADJECTIVE[DISEASE]
control O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
conduction O B_DISEASE
disorders O I_DISEASE
or O O
dysrhythmias O B_DISEASE
, O O
were O O
associated O O
with O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
PM O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
pneumonia O B_DISEASE
admissions O I_DISEASE
. O O

Unlike O O
COPD O B_DISEASE/B_PERSON
, O O
no O O
difference O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
seen O O
for O O
congestive O B_DISEASE
heart O I_DISEASE
failure O I_DISEASE
. O O

Persons B B_PERSON
with O O
asthma O O
Table O O
5 O O
. O O

Percentage O O
increase O O
in O O
hospital O O
admissions O O
for O O
COPD O O
in O O
all O O
persons B B_PERSON/B_DISEASE
and O O
by O O
concurrent O O
diagnosis O O
and O O
previous O O
admissions O O
. O O

PM10 O O
2 O O
. O O
5 O O
% O O
CI O O
97 O O
. O O
5 O O
% O O
CI O O
All O O
persons B B_TIME[MEASURE]/B_DISEASE
1 O O
. O O
89 O O
By O O
concurrent O O
diagnosis O O
Respiratory O O
disease O O
Pneumonia O O
With O O
4 O O
. O O
00 O O
Without O O
1 O O
. O O
51 O O
Cardiovascular O O
disease O O
Conduction O O
disorders O O
With O O
2 O O
. O O
34 O O
Without O O
1 O O
. O O
60 O O
Cardiac O O
dysrhythmias O O
With O O
3 O O
. O O
09 O O
Without O O
1 O O
. O O
43 O O
Congestive O O
heart O O
failure O O
With O O
2 O O
. O O
90 O O
Without O O
1 O O
. O O
39 O O
By O O
previous O O
admissions O O
Respiratory O O
disease O O
Acute O O
respiratory O O
infections O O
With O O
3 O O
. O O
20 O O
Without O O
1 O O
. O O
70 O O
Cardiovascular O O
disease O O
CVD O O
With O O
2 O O
. O O
90 O O
Without O O
1 O O
. O O
18 O O
Congestive O O
heart O O
failure O O
With O O
4 O O
. O O
37 O O
Without O O
1 O O
. O O
14 O O
Within O O
1 O O
year O O
6 O O
. O O
04 O O
0 O O
. O O
80 O O
2 O O
. O O
99 O O

had O O
twice O O
the O O
risk O O
of O O
a O O
PM10 O O
- O O
induced O O
pneumonia O O
admission O O
as O O
persons B B_PERSON/B_LOCATION
without O O
asthma O O
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
7 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O O
sex O B_PERSON/B_LOCATION
, O O
age O B_TIME[MEASURE]/B_LOCATION
, O O
and O O
race O B_SPORT[ENT]/B_LOCATION
. O O

None O B_PERSON/B_NUMBER[MEASURE]
of O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
size O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
estimates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
any O O
of O O
the O O
stratification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
outside O B_LOCATION/B_DISEASE
of O O
the O O
95 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CI O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
opposite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strata O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

There O O
was O O
a O O
tendency O B_MEASURE/B_DISEASE
for O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PM10 O B_DISEASE/B_SPECIES[BIO]
on O O
CVD O B_DISEASE
admissions O I_DISEASE
to O O
be O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
females O B_PERSON
, O O
whereas O O
the O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
pneumonia O B_DISEASE
admissions O I_DISEASE
was O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
males O B_PERSON
. O O

In O O
general O O
, O O
we O O
found O O
somewhat O O
larger O O
effects O O
on O O
whites O O
compared O O
to O O
nonwhites O O
, O O
and O O
for O O
persons B B_PERSON
older O O
than O O
75 O O
years O O
of O O
age O O
compared O O
to O O
younger O O
persons B B_PERSON
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
In O O
this O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
examined O O
whether O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PM10 O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
risk O B_MEASURE
of O O
hospital O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
lung O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O O
on O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
comorbidities O B_DISEASE
. O O

We O O
found O O
that O O
PM10 O B_DISEASE/B_SPECIES[BIO]
was O O
associated O O
with O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_DISEASE_ADJECTIVE[DISEASE]
for O O
all O O
three O B_DISEASE_ADJECTIVE[DISEASE]
causes O I_DISEASE_ADJECTIVE[DISEASE]
( O O
CVD O B_DISEASE
, O O
COPD O B_DISEASE
, O O
and O O
pneumonia O B_DISEASE
) O O
and O O
we O O
found O O
not O O
a O O
general O B_MEASURE/B_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
PM10 O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
related O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
risk O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
comorbidities O B_DISEASE
, O O
but O O
a O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
is O O
suggestive O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O O
potential O B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]
and O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epidemiologic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
toxicologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

One O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
major O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
finding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
that O O
preexisting O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
, O O
particularly O O
impaired O O
autonomic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
conduction O B_DISEASE
defects O I_DISEASE
and O O
dysrhythmias O B_DISEASE
) O O
and O O
heart O B_DISEASE
failure O I_DISEASE
, O O
substantially O O
increased O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
respiratory O B_DISEASE
admissions O I_DISEASE
associated O O
with O O
airborne O B_DISEASE
particles O I_DISEASE
. O O

In O O
fact O O
, O O
recent O O
human B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
studies O O
have O O
shown O O
that O O
exposure O O
to O O
particulate O O
air O O
pollution O O
is O O
a O O
risk O O
factor O O
for O O
reduced O O
heart O O
rate O O
variability O O
( O O
39 O O
<FFFD> O O
41 O O
) O O
. O O

Reduced O O
heart O B_DISEASE/B_PROTEIN[GENE]
rate O B_DISEASE/I_PROTEIN[GENE]
variability O B_DISEASE/I_PROTEIN[GENE]
is O O
an O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
arrhythmia O B_DISEASE
. O O

A O O
new O O
study O O
of O O
defibrillator O O
discharges O O
in O O
patients B B_PERSON/B_BIO
with O O
implanted O O
cardioverter O O
defibrillators O O
found O O
that O O
discharges O O
were O O
associated O O
with O O
air O O
pollution O O
( O O
42 O O
) O O
. O O

Exposure O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
combustion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Table O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
6 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Percentage O O
increase O O
in O O
hospital O O
admissions O O
for O O
pneumonia O O
in O O
all O O
persons B B_PERSON/B_DISEASE
and O O
by O O
concurrent O O
diagnosis O O
and O O
previous O O
admissions O O
. O O

PM10 O O
All O O
persons B B_PERSON/B_DISEASE
By O O
concurrent O O
diagnosis O O
Respiratory O O
disease O O
Asthma O O
With O O
Without O O
Cardiovascular O O
disease O O
Conduction O O
disorders O O
With O O
Without O O
Cardiac O O
dysrhythmias O O
With O O
Without O O
By O O
previous O O
admissions O O
Cardiovascular O O
disease O O
Cardiac O O
dysrhythmias O O
With O O
Without O O
2 O O
. O O
34 O O
2 O O
. O O
5 O O
% O O
CI O O
97 O O
. O O
5 O O
% O O
CI O O
1 O O
. O O
66 O O
3 O O
. O O
02 O O

1 O O
. O O
10 O B_MEASURE
0 O I_MEASURE
. O O
64 O B_MEASURE
<FFFD> O I_MEASURE
0 O I_MEASURE
. O O
47 O B_MEASURE
0 O I_MEASURE
. O O
76 O B_MEASURE
0 O I_MEASURE
. O O
18 O B_MEASURE
0 O I_MEASURE
. O O
76 O B_MEASURE
0 O I_MEASURE
. O O
55 O B_MEASURE
0 O I_MEASURE
. O O
72 O B_MEASURE
0 O I_MEASURE
. O O
85 O B_MEASURE
0 O I_MEASURE
. O O
75 O B_MEASURE

2 O O
. O O
20 O B_TIME[MEASURE]
1 O I_TIME[MEASURE]
. O O
33 O B_MEASURE
5 O I_MEASURE
. O O
55 O B_MEASURE
1 O I_MEASURE
. O O
37 O B_MEASURE
5 O I_MEASURE
. O O
30 O B_MEASURE
1 O I_MEASURE
. O O
37 O B_MEASURE
3 O I_MEASURE
. O O
36 O B_MEASURE
1 O I_MEASURE
. O O
35 O B_MEASURE
2 O I_MEASURE
. O O
34 O B_MEASURE
1 O I_MEASURE
. O O
41 O B_MEASURE

<FFFD> O B_MEASURE
0 O I_MEASURE
. O O
45 O B_MEASURE
0 O I_MEASURE
. O O
47 O B_MEASURE
<FFFD> O I_MEASURE
4 O I_MEASURE
. O O
42 O B_MEASURE
0 O I_MEASURE
. O O
58 O B_MEASURE
0 O I_MEASURE
. O O
64 O B_MEASURE
0 O I_MEASURE
. O O
33 O B_MEASURE
0 O I_MEASURE
. O O
77 O B_MEASURE
0 O I_MEASURE
. O O
24 O B_MEASURE

8 O O
. O O
65 O B_MEASURE
2 O I_MEASURE
. O O
57 O B_MEASURE
9 O I_MEASURE
. O O
59 O B_MEASURE
2 O I_MEASURE
. O O
64 O B_MEASURE
5 O I_MEASURE
. O O
60 O B_MEASURE
2 O I_MEASURE
. O O
55 O B_MEASURE
5 O I_MEASURE
. O O
08 O B_MEASURE
2 O I_MEASURE
. O O
55 O B_MEASURE

0 O O
. O O
45 O B_MEASURE
0 O I_MEASURE
. O O
76 O B_MEASURE
<FFFD> O I_MEASURE
0 O I_MEASURE
. O O
40 O B_MEASURE
0 O I_MEASURE
. O O
78 O B_MEASURE
<FFFD> O I_MEASURE
0 O I_MEASURE
. O O
43 O B_MEASURE
0 O I_MEASURE
. O O
77 O B_MEASURE
0 O I_MEASURE
. O O
22 O B_MEASURE
0 O I_MEASURE
. O O
76 O B_MEASURE
0 O I_MEASURE
. O O
75 O B_MEASURE
0 O I_MEASURE
. O O
72 O B_MEASURE

1 O O
. O O
91 O B_MEASURE
1 O I_MEASURE
. O O
41 O B_MEASURE
3 O I_MEASURE
. O O
40 O B_MEASURE
1 O I_MEASURE
. O O
40 O B_MEASURE
3 O I_MEASURE
. O O
89 O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
. O O
39 O B_MEASURE
5 O I_MEASURE
. O O
63 O B_MEASURE
1 O I_MEASURE
. O O
38 O B_MEASURE
2 O I_MEASURE
. O O
48 O B_MEASURE
1 O I_MEASURE
. O O
36 O B_MEASURE

4 O O
. O O
18 O B_MEASURE
2 O I_MEASURE
. O O
07 O B_MEASURE
7 O I_MEASURE
. O O
92 O B_MEASURE
1 O I_MEASURE
. O O
99 O B_MEASURE
<FFFD> O I_MEASURE
<FFFD> O I_MEASURE

1 O O
. O O
01 O B_MEASURE
1 O I_MEASURE
. O O
46 O B_MEASURE
4 O I_MEASURE
. O O
28 O B_MEASURE
1 O I_MEASURE
. O O
37 O B_MEASURE
<FFFD> O I_MEASURE
<FFFD> O I_MEASURE

7 O O
. O O
46 O B_MEASURE
2 O I_MEASURE
. O O
69 O B_MEASURE
11 O I_MEASURE
. O O
69 O B_MEASURE
2 O I_MEASURE
. O O
61 O B_MEASURE
<FFFD> O I_MEASURE
<FFFD> O I_MEASURE

<FFFD> O B_MEASURE
1 O I_MEASURE
. O O
38 O B_MEASURE
0 O I_MEASURE
. O O
66 O B_MEASURE
0 O I_MEASURE
. O O
99 O B_MEASURE
<FFFD> O I_MEASURE
0 O I_MEASURE
. O O
01 O B_MEASURE
1 O I_MEASURE
. O O
43 O B_MEASURE
0 O I_MEASURE
. O O
05 O B_MEASURE
2 O I_MEASURE
. O O
10 O B_MEASURE

8 O O
. O O
01 O B_MEASURE
2 O I_MEASURE
. O O
76 O B_MEASURE
4 O I_MEASURE
. O O
85 O B_MEASURE
2 O I_MEASURE
. O O
39 O B_MEASURE
7 O I_MEASURE
. O O
40 O B_MEASURE
2 O I_MEASURE
. O O
24 O B_TIME[MEASURE]
10 O I_TIME[MEASURE]
. O O
14 O B_MEASURE

3 O O
. O O
47 O B_MEASURE
2 O I_MEASURE
. O O
08 O B_MEASURE

1 O O
. O O
21 O B_MEASURE
1 O I_MEASURE
. O O
45 O B_MEASURE

5 O O
. O O
79 O B_MEASURE
2 O I_MEASURE
. O O
71 O B_MEASURE

Increases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
for O O
a O O
10 O B_MEASURE
- O O
<FFFD> O B_MEASURE/B_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
m3 O B_MEASURE/B_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
PM10 O B_SPECIES[BIO]/B_PROTEIN[GENE]
. O O

Increases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
for O O
a O O
10 O B_MEASURE
- O O
<FFFD> O B_MEASURE/B_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
m3 O B_MEASURE/B_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
PM10 O B_SPECIES[BIO]/B_PROTEIN[GENE]
. O O

Increases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
for O O
a O O
10 O B_MEASURE
- O O
<FFFD> O B_MEASURE/B_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
m3 O B_MEASURE/B_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
PM10 O B_SPECIES[BIO]/B_PROTEIN[GENE]
. O O

Environmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspectives O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

<FFFD> O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
VOLUME O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
108 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
NUMBER O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
9 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
September O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2000 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]

843 O B_NUMBER[MEASURE]

Articles O B_PERSON

<FFFD> O B_PERSON/B_MEASURE

Zanobetti O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O I_PERSON/I_LOCATION
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
7 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
sex O B_PERSON/B_LOCATION
, O O
race O B_SPORT[ENT]/B_PERSON
, O O
and O O
age O B_MEASURE/B_LOCATION
groups O B_MEASURE/I_LOCATION
for O O
10 O B_MEASURE/B_LOCATION
<FFFD> O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
m3 O B_MEASURE
PM10 O I_MEASURE
. O O

% O O
All O O
persons B B_PERSON/B_LOCATION
Male O O
Female O O
White O O
Non O O
- O O
white O O
Age O O
> O O
75 O O
Age O O
75 O O
1 O O
. O O
89 O O
1 O O
. O O
34 O O
2 O O
. O O
19 O O
1 O O
. O O
65 O O
1 O O
. O O
07 O O
2 O O
. O O
20 O O
1 O O
. O O
33 O O
COPD O O
( O O
95 O O
% O O
CI O O
) O O
( O O
0 O O
. O O
80 O O
, O O
2 O O
. O O
99 O O
) O O
( O O
<FFFD> O O
0 O O
. O O
14 O O
, O O
2 O O
. O O
84 O O
) O O
( O O
0 O O
. O O
81 O O
, O O
3 O O
. O O
59 O O
) O O
( O O
0 O O
. O O
51 O O
, O O
2 O O
. O O
81 O O
) O O
( O O
<FFFD> O O
1 O O
. O O
11 O O
, O O
3 O O
. O O
3 O O
) O O
( O O
0 O O
. O O
72 O O
, O O
3 O O
. O O
69 O O
) O O
( O O
0 O O
. O O
03 O O
, O O
2 O O
. O O
65 O O
) O O
% O O
1 O O
. O O
31 O O
1 O O
. O O
07 O O
1 O O
. O O
21 O O
1 O O
. O O
20 O O
0 O O
. O O
70 O O
1 O O
. O O
28 O O
0 O O
. O O
93 O O
CVD O O
( O O
95 O O
% O O
CI O O
) O O
( O O
0 O O
. O O
97 O O
, O O
1 O O
. O O
66 O O
) O O
( O O
0 O O
. O O
62 O O
, O O
1 O O
. O O
51 O O
) O O
( O O
0 O O
. O O
83 O O
, O O
1 O O
. O O
6 O O
) O O
( O O
0 O O
. O O
86 O O
, O O
1 O O
. O O
55 O O
) O O
( O O
0 O O
. O O
1 O O
, O O
1 O O
. O O
3 O O
) O O
( O O
0 O O
. O O
88 O O
, O O
1 O O
. O O
69 O O
) O O
( O O
0 O O
. O O
51 O O
, O O
1 O O
. O O
35 O O
) O O
% O O
2 O O
. O O
34 O O
2 O O
. O O
65 O O
1 O O
. O O
91 O O
2 O O
. O O
45 O O
1 O O
. O O
91 O O
2 O O
. O O
12 O O
2 O O
. O O
52 O O
Pneumonia O O
( O O
95 O O
% O O
CI O O
) O O
( O O
1 O O
. O O
66 O O
, O O
3 O O
. O O
02 O O
) O O
( O O
1 O O
. O O
81 O O
, O O
3 O O
. O O
5 O O
) O O
( O O
1 O O
. O O
11 O O
, O O
2 O O
. O O
72 O O
) O O
( O O
1 O O
. O O
77 O O
, O O
3 O O
. O O
14 O O
) O O
( O O
0 O O
. O O
69 O O
, O O
3 O O
. O O
14 O O
) O O
( O O
1 O O
. O O
38 O O
, O O
2 O O
. O O
86 O O
) O O
( O O
1 O O
. O O
57 O O
, O O
3 O O
. O O
48 O O
) O O

Figures O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O O
are O O
the O O
percentage O B_MEASURE/B_PERSON
increase O I_MEASURE/I_PERSON
in O O
admissions O B_DISEASE/B_MEASURE
( O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
CI O I_MEASURE/I_LOCATION
) O O
. O O

particles O B_DISEASE/B_LOCATION
has O O
also O O
been O O
associated O O
with O O
arrhythmia O B_DISEASE/B_LOCATION
in O O
an O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
43 O B_MEASURE
) O O
and O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
ST O B_DISEASE_ADJECTIVE[DISEASE]
segments O I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
noted O O
as O O
well O O
( O O
44 O B_MEASURE
) O O
. O O

This O O
is O O
the O O
first O O
study O O
to O O
suggest O O
persons B B_PERSON/B_BIO
with O O
defects O O
in O O
the O O
electrical O O
control O O
of O O
the O O
heart O O
are O O
also O O
at O O
higher O O
risk O O
of O O
respiratory O O
illness O O
after O O
exposure O O
to O O
airborne O O
particles O O
. O O

These O O
data O O
also O O
suggest O O
that O O
persons B B_PERSON/B_BIO
admitted O O
to O O
hospitals O O
for O O
pneumonia O O
during O O
an O O
air O O
pollution O O
episode O O
may O O
be O O
at O O
high O O
risk O O
for O O
clinically O O
significant O O
conduction O O
disorders O O
during O O
that O O
hospital O O
admission O O
. O O

Patients B B_PERSON/B_BIO
with O O
congestive O O
heart O O
failure O O
were O O
at O O
greater O O
risk O O
of O O
hospital O O
admissions O O
for O O
COPD O O
in O O
association O O
with O O
airborne O O
particles O O
. O O

Heart O B_DISEASE/B_LOCATION
failure O I_DISEASE/I_LOCATION
and O O
COPD O B_DISEASE
is O O
not O O
an O O
uncommon O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
finding O O
that O O
these O O
patients B B_PERSON/B_BIO
are O O
at O O
higher O O
risk O O
for O O
admissions O O
associated O O
with O O
particulate O O
air O O
pollution O O
is O O
new O O
but O O
is O O
also O O
consistent O O
with O O
several O O
other O O
recent O O
reports O O
. O O

The O O
spontaneous O O
hypertensive O O
rat B B_SPECIES[BIO]/B_GENE
develops O O
a O O
model O O
of O O
heart O O
failure O O
, O O
and O O
recent O O
studies O O
have O O
reported O O
greater O O
sensitivity O O
to O O
particulate O O
air O O
pollution O O
in O O
these O O
rats B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
include O O
both O O
electrocardiogram O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
abnormalities O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
44 O B_MEASURE
) O O
and O O
pulmonary O B_DISEASE
toxicity O I_DISEASE
( O O
45 O B_MEASURE
, O O
46 O B_MEASURE
) O O
. O O

Similarly O O
, O O
in O O
an O O
epidemiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
Hoek O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
47 O B_MEASURE
) O O
, O O
found O O
a O O
higher O B_MEASURE
relative O I_MEASURE
risk O I_MEASURE
of O O
death O B_DISEASE
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
PM10 O B_DISEASE/B_SPECIES[BIO]
for O O
congestive O B_DISEASE/B_PERSON
heart O I_DISEASE/I_PERSON
failure O I_DISEASE/I_PERSON
deaths O I_DISEASE/I_PERSON
than O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deaths O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
COPD O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
those O O
heart O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deaths O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
examined O O
. O O

Another O O
consistent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
of O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
respiratory O I_DISEASE_ADJECTIVE[DISEASE]
infections O I_DISEASE_ADJECTIVE[DISEASE]
increasing O O
susceptibility O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
airborne O B_DISEASE
particles O I_DISEASE
. O O

Acute O B_DISEASE_ADJECTIVE[DISEASE]
bronchitis O I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
more O O
generally O O
acute O B_DISEASE
upper O I_DISEASE
respiratory O I_DISEASE
illnesses O I_DISEASE
, O O
as O O
well O O
as O O
pneumonia O B_DISEASE/B_PERSON
, O O
increased O O
susceptibility O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
particle O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
associated O O
admissions O B_DISEASE
for O O
CVD O B_DISEASE
and O O
COPD O B_DISEASE
. O O

The O O
notion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
air O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exacerbates O O
acute O B_DISEASE
respiratory O I_DISEASE
infections O I_DISEASE
is O O
well O O
supported O O
by O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
which O O
report O O
associations O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
airborne O B_DISEASE
particles O I_DISEASE
and O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
respiratory O B_DISEASE/B_PERSON
infections O I_DISEASE/I_PERSON
( O O
48 O B_MEASURE/B_PERSON
, O O
49 O B_MEASURE
) O O
. O O

Zelikoff O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
50 O O
) O O
exposed O O
rats B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infected O O
with O O
streptococcus O O
to O O
concentrated O O
air O O
particles O O
and O O
reported O O
a O O
significant O O
increase O O
in O O
bacterial O O
burdens O O
and O O
in O O
the O O
extent O O
of O O
pneumonia O O
compared O O
to O O
animals O O
exposed O O
to O O
filtrated O O
air O O
. O O

This O O
suggests O O
an O O
impaired O B_DISEASE_ADJECTIVE[DISEASE]
immune O I_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Similarly O O
, O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
combustion O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

particles O O
enhances O O
influenza O O
infections O O
in O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
51 O O
) O O
. O O

An O O
impaired O O
defense O O
to O O
respiratory O O
infection O O
is O O
a O O
major O O
reason O O
that O O
persons B B_PERSON
with O O
COPD O O
require O O
hospital O O
admission O O
. O O

If O O
airborne O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
result O O
in O O
further O B_DISEASE_ADJECTIVE[DISEASE]
impairment O I_DISEASE_ADJECTIVE[DISEASE]
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
modification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
we O O
observe O O
makes O O
good O B_DISEASE_ADJECTIVE[DISEASE]
sense O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
heart O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
more O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
modification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
earlier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Schwartz O B_PERSON
( O O
19 O B_MEASURE
) O O
, O O
who O O
found O O
greater O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
respiratory O B_DISEASE/B_PERSON
complications O I_DISEASE/I_PERSON
on O O
death O B_PERSON
certificates O I_PERSON
with O O
an O O
underlying O O
cause O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
heart O B_DISEASE
disease O I_DISEASE
if O O
the O O
death O B_PERSON/B_DISEASE
occurred O O
on O O
a O O
day O B_TIME[MEASURE]/B_LOCATION
with O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
airborne O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
airborne O B_DISEASE
particle O I_DISEASE
exposure O I_DISEASE
has O O
been O O
associated O O
with O O
increased O O
exacerbation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
asthma O B_DISEASE
( O O
2 O B_MEASURE
, O O
12 O B_MEASURE
, O O
48 O B_MEASURE
, O O
52 O B_MEASURE
<FFFD> O I_MEASURE
59 O I_MEASURE
) O O
, O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
first O B_SEQUENCE[MEASURE]/B_LOCATION
to O O
suggest O O
that O O
asthmatics O B_PERSON/B_BIO
are O O
more O O
susceptible O B_DISEASE_ADJECTIVE[DISEASE]
to O O
PM10 O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
pneumonia O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
exacerbation O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
to O O
cardiovascular O B_DISEASE
effects O I_DISEASE
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
pneumonia O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
admissions O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
plausible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
given O O
the O O
impaired O B_DISEASE_ADJECTIVE[DISEASE]
ability O I_DISEASE_ADJECTIVE[DISEASE]
to O O
fight O O
off O O
infections O B_DISEASE/B_BIO
in O O
asthmatics O B_PERSON/B_LOCATION
with O O
mucus O B_DISEASE
plugs O I_DISEASE
and O O
the O O
evidence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O O
airborne O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
impair O O
the O O
lungs O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ability O B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
fight O O
off O O
bacterial O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
viral O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
infections O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O O
as O O
noted O O
earlier O O
. O O

The O O
increased O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
albeit O O
weaker O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
is O O
interesting O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

If O O
airborne O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
affect O O
the O O
cardiovascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
via O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
autonomic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
asthmatics O B_PERSON/B_BIO
would O O
be O O
more O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
effects O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
asthma O B_DISEASE/B_LOCATION
showed O O
that O O
combustion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhance O O
the O O
asthmatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
aeroallergen O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenges O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
59 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

This O O
suggests O O
an O O
enhancement O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
pulmonary O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
asthmatics O B_DISEASE/B_LOCATION
. O O

On O O
the O O
other O B_PERSON/B_MEASURE
hand O I_PERSON/I_MEASURE
, O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
asthma O B_DISEASE/B_LOCATION
is O O
problematic O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
elderly O B_PERSON/B_DISEASE
, O O
and O O
crossover O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
with O O
COPD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
this O O
explains O O
our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
reduced O O
by O O
our O O
failure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
find O O
previous O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hospital O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
COPD O B_DISEASE/B_GENE
was O O
an O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifier O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
particles O B_DISEASE
on O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
must O O
acknowledge O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
potential O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
limitations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

First O O
, O O
we O O
considered O O
only O O
previous O B_NUMBER[MEASURE]/B_PERSON
admissions O B_NUMBER[MEASURE]/I_PERSON
that O O
occurred O O
within O O
Cook O B_LOCATION/B_TIME[MEASURE]
County O I_LOCATION/I_TIME[MEASURE]
. O O

Hence O O
persons B B_PERSON
with O O
previous O O
admissions O O
elsewhere O O
would O O
be O O
misclassified O O
to O O
our O O
reference O O
group O O
. O O

The O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
would O O
be O O
to O O
reduce O O
the O O
difference O B_MEASURE
in O O
PM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
10 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

VOLUME O B_MEASURE

Nevertheless O O
, O O
we O O
identified O O
some O O
interesting O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
cannot O O
exclude O O
the O O
possibility O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
there O O
are O O
areas O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
missed O O
for O O
this O O
reason O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
also O O
examined O O
interactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
log O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
which O O
is O O
inherently O O
multiplicative O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Although O O
we O O
believe O O
this O O
is O O
justified O O
because O O
doubling O O
the O O
population O B_PERSON/B_LOCATION
exposed O O
would O O
be O O
expected O O
to O O
double O O
the O O
pollution O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
associated O O
admissions O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
it O O
results O O
in O O
a O O
more O O
conservative O B_MEASURE/B_PERSON
definition O I_MEASURE/I_PERSON
of O O
interaction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O O
would O O
an O O
additive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Finally O O
, O O
our O O
exposure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
clearly O O
measured O O
with O O
error O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Most O B_DISEASE/B_NUMBER[MEASURE]
of O O
this O O
error O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
Berkson O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
error O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
60 O B_MEASURE
) O O
and O O
hence O O
will O O
introduce O O
no O O
bias O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
Zeger O B_LOCATION/B_PERSON
et O I_LOCATION/I_PERSON
al O O
. O O

( O O
60 O O
) O O
showed O O
that O O
the O O
remaining O O
error O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
would O O
have O O
to O O
have O O
pathologic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
other O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variables O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
result O O
in O O
an O O
upward O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bias O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Another O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
result O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
of O O
course O O
, O O
is O O
an O O
estimate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
magnitude O B_MEASURE
of O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
airborne O B_DISEASE
particles O I_DISEASE
on O O
public O B_DISEASE
health O I_DISEASE
. O O

The O O
PM10 O B_DISEASE_ADJECTIVE[DISEASE]
concentrations O I_DISEASE_ADJECTIVE[DISEASE]
in O O
Chicago O B_LOCATION/B_PERSON
during O O
this O O
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
were O O
associated O O
with O O
approximately O O
1 O B_MEASURE
, O O
600 O B_MEASURE
additional O I_MEASURE
admissions O I_MEASURE
per O O
year O B_TIME[MEASURE]
for O O
heart O B_DISEASE
disease O I_DISEASE
, O O
740 O B_MEASURE
additional O I_MEASURE
admissions O I_MEASURE
per O O
year O B_TIME[MEASURE]/B_PERSON
for O O
pneumonia O B_DISEASE
, O O
and O O
170 O B_MEASURE
additional O I_MEASURE
admissions O I_MEASURE
per O O
year O B_TIME[MEASURE]
for O O
COPD O B_DISEASE
. O O

These O O
are O O
not O O
trivial O B_DISEASE_ADJECTIVE[DISEASE]
increases O I_DISEASE_ADJECTIVE[DISEASE]
in O O
serious O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
morbidity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
replicated O O
in O O
additional O B_TIME[MEASURE]/B_LOCATION
cities O I_TIME[MEASURE]/I_LOCATION
, O O
although O O
they O O
do O O
begin O O
to O O
fill O O
in O O
some O O
missing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
information O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
about O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
airborne O B_DISEASE
particles O I_DISEASE
on O O
health O B_PERSON/B_LOCATION
. O O

More O O
generally O O
airborne O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
been O O
associated O O
with O O
a O O
broad O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
of O O
systemic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O O
heart O B_DISEASE
rate O I_DISEASE
variability O I_DISEASE
( O O
39 O B_MEASURE
<FFFD> O I_MEASURE
41 O I_MEASURE
) O O
, O O
increased O O
peripheral O B_DISEASE/B_GENE
neutrophils O I_DISEASE/I_GENE
( O O
61 O B_MEASURE
<FFFD> O I_MEASURE
63 O I_MEASURE
) O O
, O O
increased O O
plasma O B_DISEASE
viscosity O I_DISEASE
( O O
64 O B_MEASURE
) O O
, O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
blood O B_DISEASE/B_GENE
pressure O B_DISEASE/I_GENE
( O O
65 O B_MEASURE
) O O
, O O
and O O
the O O
outcomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mentioned O O
previously O O
. O O

The O O
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
systemic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
potential O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sources O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
specific O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifications O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
have O O
seen O O
should O O
be O O
an O O
area O B_LOCATION/B_PERSON
of O O
fruitful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
future O B_TIME[MEASURE]/B_LOCATION
. O O

REFERENCES O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O O
NOTES O B_MEASURE/B_PERSON
1 O B_MEASURE/I_PERSON
. O O

Katsouyanni O B_PERSON/B_LOCATION
K O I_PERSON/I_LOCATION
, O O
Touloumi O B_PERSON/B_LOCATION
G O I_PERSON/I_LOCATION
, O O
Spix O B_PERSON/B_LOCATION
C O I_PERSON/I_LOCATION
, O O
Schwartz O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Balducci O B_PERSON
F O I_PERSON
, O O
Medina O B_PERSON
S O I_PERSON
, O O
Rossi O B_PERSON
G O I_PERSON
, O O
Wojtyniak O B_PERSON
D O I_PERSON
, O O
Sunyer O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Bacharova O B_PERSON
L O I_PERSON
, O O
et O B_PERSON/B_LOCATION
al O I_PERSON/I_LOCATION
. O O

Short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ambient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulphur O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dioxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
particulate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
matter O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
mortality O B_DISEASE
in O O
12 O B_LOCATION/B_BIO
European O I_LOCATION/I_BIO
cities O I_LOCATION/I_BIO
: O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
time O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
the O O
APHEA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
project O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Br O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
314 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
1658 O B_MEASURE
<FFFD> O I_MEASURE
1663 O I_MEASURE
( O O
1997 O B_MEASURE
) O O
. O O

Pope O B_PERSON/B_MEASURE
CA O B_PERSON/I_MEASURE
, O O
Dockery O B_MEASURE/B_LOCATION
DW O I_MEASURE/I_LOCATION
, O O
Schwartz O B_MEASURE
J O I_MEASURE
. O O
Review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
epidemiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
particulate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
air O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Inhal O B_MEASURE/B_PERSON
Toxicol O I_MEASURE/I_PERSON
7 O I_MEASURE/I_PERSON
: O O
1 O B_MEASURE
<FFFD> O I_MEASURE
18 O I_MEASURE
( O O
1995 O B_MEASURE
) O O
. O O

Schwartz O B_LOCATION/B_MEASURE
J O I_LOCATION/I_MEASURE
. O O

Air O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pollution O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
daily O B_DISEASE
mortality O I_DISEASE
: O O
a O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
meta O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Environ O B_MEASURE
Res O I_MEASURE
64 O I_MEASURE
: O O
36 O B_MEASURE
<FFFD> O I_MEASURE
52 O I_MEASURE
( O O
1994 O B_MEASURE
) O O
. O O

Dominici O B_PERSON/B_ORGANIZATION
F O I_PERSON/I_ORGANIZATION
, O O
Samet O B_PERSON
J O I_PERSON
, O O
Zeger O B_PERSON/B_LOCATION
SL O I_PERSON/I_LOCATION
. O O

Combining O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
air O B_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DISEASE_ADJECTIVE[DISEASE]
and O O
daily O B_DISEASE/B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality O B_DISEASE/I_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
largest O B_LOCATION
20 O I_LOCATION
US O I_LOCATION
cities O I_LOCATION
: O O
a O O
hierarchical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
modeling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
strategy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

R O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Stat O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Soc O I_MEASURE
Ser O I_MEASURE
A O I_MEASURE
, O O
in O O
press O B_PERSON/B_ENT
. O O

Burnett O B_MEASURE/B_LOCATION
RT O I_MEASURE/I_LOCATION
, O O
Dales O B_PERSON/B_LOCATION
RE O B_PERSON/I_LOCATION
, O O
Raizenne O O
ME O B_LOCATION
, O O
Krewski O B_LOCATION
D O I_LOCATION
, O O
Summers O B_PERSON/B_LOCATION
PW O B_PERSON/I_LOCATION
, O O
Roberts O B_PERSON/B_LOCATION
GR O B_PERSON/I_LOCATION
, O O
Raad O B_PERSON
- O O
Young O B_PERSON/B_LOCATION
M O B_PERSON/I_LOCATION
, O O
Dann O B_PERSON
T O I_PERSON
, O O
Brooke O B_MEASURE/B_LOCATION
T O I_MEASURE/I_LOCATION
. O O
Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
low O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ambient O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
ozone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sulfates O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
frequency O B_MEASURE/B_PERSON
of O O
respiratory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Ontario O B_LOCATION/B_ORGANIZATION
hospitals O I_LOCATION/I_ORGANIZATION
. O O

Environ O B_MEASURE
Res O I_MEASURE
65 O I_MEASURE
: O O
172 O B_MEASURE
<FFFD> O I_MEASURE
194 O I_MEASURE
( O O
1994 O B_MEASURE
) O O
. O O

Anderson O B_MEASURE/B_LOCATION
HR O I_MEASURE/I_LOCATION
, O O
Spix O B_LOCATION
C O I_LOCATION
, O O
Medina O B_LOCATION/B_PERSON
S O I_LOCATION/I_PERSON
, O O
Schouten O B_PERSON
JP O I_PERSON
, O O
Castellsague O B_PERSON/B_LOCATION
J O B_PERSON/I_LOCATION
, O O
Rossi O B_PERSON/B_LOCATION
G O B_PERSON/I_LOCATION
, O O
Zmirou O B_PERSON/B_LOCATION
D O I_PERSON/I_LOCATION
, O O
Touloumi O B_PERSON/B_LOCATION
G O I_PERSON/I_LOCATION
, O O
Wojtyniak O B_PERSON
B O I_PERSON
, O O
Ponka O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
, O O
et O B_PERSON/B_LOCATION
al O I_PERSON/I_LOCATION
. O O

Air O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
pollution O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
daily O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O

2 O B_NUMBER[MEASURE]
. O O

3 O B_NUMBER[MEASURE]
. O O

4 O B_NUMBER[MEASURE]
. O O

5 O B_NUMBER[MEASURE]
. O O

6 O B_NUMBER[MEASURE]
. O O

844 O B_NUMBER[MEASURE]

108 O O
| O O
NUMBER O B_TIME[MEASURE]
9 O I_TIME[MEASURE]
| O O
September O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2000 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
<FFFD> O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Environmental O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Perspectives O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

Articles O B_PERSON

<FFFD> O B_PERSON/B_MEASURE

Effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
particles O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
sensitive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroups O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

7 O B_NUMBER[MEASURE]
. O O

8 O B_NUMBER[MEASURE]
. O O

9 O B_NUMBER[MEASURE]
. O O

10 O B_NUMBER[MEASURE]
. O O

11 O B_NUMBER[MEASURE]
. O O

12 O B_NUMBER[MEASURE]
. O O

13 O B_NUMBER[MEASURE]
. O O

14 O B_NUMBER[MEASURE]
. O O

15 O B_NUMBER[MEASURE]
. O O

16 O B_NUMBER[MEASURE]
. O O

17 O B_NUMBER[MEASURE]
. O O

18 O B_NUMBER[MEASURE]
. O O

19 O B_NUMBER[MEASURE]
. O O

20 O B_NUMBER[MEASURE]
. O O

21 O B_NUMBER[MEASURE]
. O O

22 O B_NUMBER[MEASURE]
. O O

23 O B_NUMBER[MEASURE]
. O O

24 O B_NUMBER[MEASURE]
. O O

25 O B_NUMBER[MEASURE]
. O O

26 O B_NUMBER[MEASURE]
. O O

27 O B_NUMBER[MEASURE]
. O O

28 O B_NUMBER[MEASURE]
. O O

29 O B_NUMBER[MEASURE]
. O O

30 O B_NUMBER[MEASURE]
. O O

chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obstructive O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
6 O B_LOCATION/B_PERSON
European O I_LOCATION/I_PERSON
cities O I_LOCATION/I_PERSON
: O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
the O O
APHEA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Eur O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
1064 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
1071 O I_MEASURE/I_PERSON
( O O
1997 O B_MEASURE
) O O
. O O

Schwartz O B_MEASURE
J O I_MEASURE
. O O
Short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluctuations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
air O B_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DISEASE_ADJECTIVE[DISEASE]
and O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
elderly O B_PERSON/B_DISEASE
for O O
respiratory O B_DISEASE
disease O I_DISEASE
. O O

Thorax O B_MEASURE
50 O I_MEASURE
: O O
531 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
538 O I_MEASURE/I_PERSON
( O O
1995 O B_MEASURE
) O O
. O O

Schwartz O B_LOCATION/B_MEASURE
J O I_LOCATION/I_MEASURE
. O O

Air O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pollution O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
heart O B_DISEASE/B_PERSON
disease O I_DISEASE/I_PERSON
in O O
eight O B_LOCATION/B_PERSON
U O I_LOCATION/I_PERSON
. O O
S O B_OTHER/B_LOCATION
. O O
counties O B_LOCATION
. O O

Epidemiology O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
17 O B_MEASURE
<FFFD> O I_MEASURE
22 O I_MEASURE
( O O
1999 O B_MEASURE
) O O
. O O

Schwartz O B_LOCATION/B_MEASURE
J O I_LOCATION/I_MEASURE
. O O

Air O B_PERSON/B_LOCATION
pollution O I_PERSON/I_LOCATION
and O O
hospital O B_DISEASE
admissions O I_DISEASE
for O O
the O O
elderly O B_PERSON/B_DISEASE
in O O
Minneapolis O B_LOCATION
. O O

Arch O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Environ O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
49 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
366 O B_MEASURE
<FFFD> O I_MEASURE
374 O I_MEASURE
( O O
1994 O B_MEASURE
) O O
. O O

Schwartz O B_LOCATION/B_MEASURE
J O I_LOCATION/I_MEASURE
. O O

Air O B_PERSON/B_LOCATION
pollution O B_PERSON/I_LOCATION
and O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]
admissions O I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
elderly O B_PERSON/B_LOCATION
in O O
Birmingham O B_LOCATION/B_PERSON
, O O
Alabama O B_LOCATION
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
139 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
589 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
598 O I_MEASURE/I_PERSON
( O O
1994 O B_MEASURE
) O O
. O O

Schwartz O B_LOCATION/B_MEASURE
J O I_LOCATION/I_MEASURE
. O O

Air O B_PERSON/B_LOCATION
pollution O B_PERSON/I_LOCATION
and O O
hospital O B_DISEASE
admissions O I_DISEASE
for O O
the O O
elderly O B_PERSON/B_LOCATION
in O O
Detroit O B_LOCATION/B_PERSON
, O O
MI O B_LOCATION
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Crit O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Care O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
150 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
648 O B_MEASURE
<FFFD> O I_MEASURE
655 O I_MEASURE
( O O
1994 O B_MEASURE
) O O
. O O

Pope O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
CA O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
III O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Respiratory O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
associated O O
with O O
community O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
steel O B_LOCATION/B_MEASURE
mill O I_LOCATION/I_MEASURE
, O O
Utah O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
valley O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Am O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Public O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
79 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
623 O B_MEASURE
<FFFD> O I_MEASURE
628 O I_MEASURE
( O O
1989 O B_MEASURE
) O O
. O O

Saldiva O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
PH O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Pope O B_MEASURE/B_DISEASE
CA O I_MEASURE/I_DISEASE
, O O
Schwartz O B_LOCATION
J O I_LOCATION
, O O
Dockery O B_LOCATION/B_ORGANIZATION
DW O I_LOCATION/I_ORGANIZATION
, O O
Lichtenfels O B_LOCATION/B_PERSON
AJ O I_LOCATION/I_PERSON
, O O
Salge O B_PERSON/B_LOCATION
JM O B_PERSON/I_LOCATION
, O O
Barone O B_PERSON/B_LOCATION
I O B_PERSON/I_LOCATION
, O O
Bohm O B_PERSON/B_LOCATION
GM O B_PERSON/I_LOCATION
. O O

Air O O
pollution O O
and O O
mortality O O
in O O
elderly O O
people B B_PERSON/B_LOCATION
: O O
a O O
time O O
series O O
study O O
in O O
Sao O O
Paulo O O
, O O
Brazil O O
. O O

Arch O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Environ O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
159 O B_MEASURE
<FFFD> O I_MEASURE
163 O I_MEASURE
( O O
1995 O B_MEASURE
) O O
. O O

Schwartz O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

Air O B_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DISEASE_ADJECTIVE[DISEASE]
and O O
hospital O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
cardiovascular O B_DISEASE/B_GENE
disease O I_DISEASE/I_GENE
in O O
Tucson O B_LOCATION/B_PERSON
. O O

Epidemiology O B_MEASURE
8 O I_MEASURE
: O O
371 O B_MEASURE
<FFFD> O I_MEASURE
177 O I_MEASURE
( O O
1997 O B_MEASURE
) O O
. O O

Delfino O B_LOCATION/B_MEASURE
RJ O I_LOCATION/I_MEASURE
, O O
Murphy O B_LOCATION/B_PERSON
Moulton O I_LOCATION/I_PERSON
AM O I_LOCATION/I_PERSON
, O O
Becklake O B_LOCATION/B_PERSON
MR O I_LOCATION/I_PERSON
. O O

Emergency O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
room O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visits O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
respiratory O B_DISEASE
illnesses O I_DISEASE
among O O
the O O
elderly O B_PERSON/B_LOCATION
in O O
Montreal O B_LOCATION/B_PERSON
: O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
low O B_DISEASE/B_PERSON
level O I_DISEASE/I_PERSON
ozone O I_DISEASE/I_PERSON
exposure O I_DISEASE/I_PERSON
. O O

Environ O B_MEASURE
Res O I_MEASURE
76 O I_MEASURE
: O O
67 O B_MEASURE
<FFFD> O I_MEASURE
77 O I_MEASURE
( O O
1998 O B_MEASURE
) O O
. O O

National O B_PERSON/B_LOCATION
Research O I_PERSON/I_LOCATION
Council O I_PERSON/I_LOCATION
. O O

Research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Priorities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
Airborne O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Particulate O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Matter O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Washington O B_LOCATION/B_PERSON
, O O
DC O B_LOCATION
: O O
National O B_PERSON/B_MEASURE
Academy O I_PERSON/I_MEASURE
Press O I_PERSON/I_MEASURE
, O O
1998 O B_MEASURE
. O O

Schwartz O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Dockery O B_PERSON/B_PROTEIN[GENE]
DW O I_PERSON/I_PROTEIN[GENE]
. O O

Increased O O
mortality O B_DISEASE/B_ORGANISM_FUNCTION
in O O
Philadelphia O B_LOCATION/B_PERSON
associated O O
with O O
daily O B_DISEASE
air O I_DISEASE
pollution O I_DISEASE
concentrations O I_DISEASE
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rev O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dis O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
145 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
600 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
604 O I_MEASURE/I_PERSON
( O O
1992 O B_MEASURE
) O O
. O O

Samet O B_PERSON
JM O I_PERSON
, O O
Zeger O B_PERSON/B_LOCATION
SL O I_PERSON/I_LOCATION
, O O
Berhane O B_PERSON/B_MEASURE
K O I_PERSON/I_MEASURE
. O O

The O O
association O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mortality O B_DISEASE/B_LOCATION
and O O
particulate O B_DISEASE_ADJECTIVE[DISEASE]
air O I_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
: O O
Particulate O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
Air O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
Pollution O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
Daily O B_DISEASE
Mortality O I_DISEASE
. O O

The O O
Phase O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
Report O O
of O O
the O O
Particle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Epidemiology O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Boston O B_LOCATION/B_PERSON
, O O
MA O B_LOCATION
: O O
Health O B_PERSON/B_MEASURE
Effects O I_PERSON/I_MEASURE
Institute O I_PERSON/I_MEASURE
, O O
1995 O B_MEASURE/B_ORGANIZATION
. O O

Schwartz O O
J O O
. O O
What O O
are O O
people B B_PERSON/B_BIO
dying O O
of O O
on O O
high O O
air O O
pollution O O
days O O
? O O

Environ O B_MEASURE
Res O I_MEASURE
64 O I_MEASURE
: O O
26 O B_MEASURE
<FFFD> O I_MEASURE
35 O I_MEASURE
( O O
1994 O B_MEASURE
) O O
. O O

Sunyer O B_PERSON
J O I_PERSON
, O O
Schwartz O B_PERSON
J O I_PERSON
, O O
Tobias O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
, O O
MacFarlane O B_PERSON
D O I_PERSON
, O O
Garcia O B_PERSON
J O I_PERSON
, O O
Anto O B_PERSON/B_LOCATION
JM O I_PERSON/I_LOCATION
. O O

Patients B B_PERSON/B_LOCATION
with O O
chronic O O
obstructive O O
pulmonary O O
disease O O
are O O
a O O
susceptible O O
population O O
of O O
dying O O
due O O
to O O
urban O O
particles O O
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
151 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_MEASURE
) O O
: O O
50 O B_MEASURE
<FFFD> O I_MEASURE
56 O I_MEASURE
( O O
2000 O B_MEASURE
) O O
. O O

Godleski O B_PERSON/B_LOCATION
JJ O I_PERSON/I_LOCATION
, O O
Sioutas O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
, O O
Katler O B_LOCATION/B_PERSON
M O I_LOCATION/I_PERSON
, O O
Koutrakis O B_MEASURE/B_PERSON
P O I_MEASURE/I_PERSON
. O O
Death O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
inhalation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
concentrated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
air O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
pulmonary O B_DISEASE
disease O I_DISEASE
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Crit O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Care O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
153 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
A15 O B_MEASURE/B_LOCATION
( O O
1996 O B_MEASURE
) O O
. O O

Matsui O O
K O O
, O O
Goldman O O
L O O
. O O
Comorbidity O O
as O O
a O O
correlate O O
of O O
length O O
of O O
stay O O
for O O
hospitalized O O
patients B B_PERSON
with O O
acute O O
chest O O
pain O O
. O O

J O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Gen O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Intern O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
262 O B_MEASURE
<FFFD> O I_MEASURE
268 O I_MEASURE
( O O
1996 O B_MEASURE
) O O
. O O

Charlson O B_LOCATION/B_MEASURE
M O I_LOCATION/I_MEASURE
, O O
Szatrowshi O B_PERSON/B_LOCATION
TP O I_PERSON/I_LOCATION
, O O
Peterson O B_PERSON/B_LOCATION
J O B_PERSON/I_LOCATION
, O O
Gold O B_MEASURE/B_COLOR
J O I_MEASURE/I_COLOR
. O O
Validation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
a O O
combined O O
comorbidity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
index O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

J O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
47 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
1245 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
1251 O I_MEASURE/I_PERSON
( O O
1994 O B_MEASURE
) O O
. O O

Monane O B_LOCATION/B_PERSON
M O I_LOCATION/I_PERSON
, O O
Kanter O B_LOCATION/B_PERSON
DS O I_LOCATION/I_PERSON
, O O
Glynn O B_PERSON
RJ O I_PERSON
, O O
Avorn O B_MEASURE/B_PERSON
J O I_MEASURE/I_PERSON
. O O
Variability O B_MEASURE
in O O
length O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hospitalization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
stroke O B_DISEASE/B_GENE
. O O

The O O
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
managed O O
care O B_PERSON/B_LOCATION
in O O
an O O
elderly O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Arch O B_MEASURE
Neurol O I_MEASURE
53 O I_MEASURE
: O O
848 O B_MEASURE
( O O
1996 O B_MEASURE
) O O
. O O

Hallstrom O B_DISEASE/B_PERSON
AP O I_DISEASE/I_PERSON
, O O
Cobb O B_LOCATION/B_PERSON
LA O I_LOCATION/I_PERSON
, O O
Yu O B_PERSON/B_LOCATION
BH O B_PERSON/I_LOCATION
. O O

Influence O O
of O O
comorbidity O O
on O O
the O O
outcome O O
of O O
patients B B_PERSON
treated O O
for O O
out O O
- O O
of O O
- O O
hospital O O
ventricular O O
fibrillation O O
. O O

Circulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
93 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
2019 O B_TIME[MEASURE]
<FFFD> O I_TIME[MEASURE]
2022 O I_TIME[MEASURE]
( O O
1996 O B_MEASURE/B_LOCATION
) O O
. O O

Malenka O B_PERSON/B_COLOR
DJ O I_PERSON/I_COLOR
, O O
Mclerran O B_PERSON/B_LOCATION
D O I_PERSON/I_LOCATION
, O O
Roos O B_PERSON/B_LOCATION
N O I_PERSON/I_LOCATION
, O O
Fisher O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ES O I_LOCATION
, O O
Wennberg O B_LOCATION/B_PROTEIN[GENE]
JE O B_LOCATION/I_PROTEIN[GENE]
. O O

Using O O
administrative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
describe O O
case O B_PERSON/B_LOCATION
- O O
mix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
: O O
a O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
the O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
record O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

J O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
47 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
1027 O B_MEASURE
<FFFD> O I_MEASURE
1032 O I_MEASURE
( O O
1994 O B_MEASURE
) O O
. O O

Romano O B_PERSON/B_COLOR
PS O I_PERSON/I_COLOR
, O O
Roos O B_LOCATION/B_PERSON
LL O I_LOCATION/I_PERSON
, O O
Jollis O B_LOCATION/B_PERSON
JG O I_LOCATION/I_PERSON
. O O

Adapting O O
a O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comorbidity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
index O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
ICD O B_MEASURE/B_DISEASE
- O O
9 O B_TIME[MEASURE]
- O O
CM O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administrative O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
differing O O
perspectives O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

J O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
46 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
1075 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
1079 O I_MEASURE/I_PERSON
( O O
1993 O B_MEASURE
) O O
. O O

Deyo O B_MEASURE/B_DISEASE
RA O I_MEASURE/I_DISEASE
, O O
Cherkin O B_LOCATION/B_PERSON
DC O I_LOCATION/I_PERSON
, O O
Ciol O B_LOCATION/B_PERSON
MA O I_LOCATION/I_PERSON
. O O

Adapting O O
a O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comorbidity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
index O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
ICD O B_DISEASE/B_LOCATION
- O O
9CM O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administrative O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
databases O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

J O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
45 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
613 O B_MEASURE
<FFFD> O I_MEASURE
619 O I_MEASURE
( O O
1992 O B_MEASURE
) O O
. O O

Charlson O B_PERSON/B_PROTEIN[GENE]
ME O I_PERSON/I_PROTEIN[GENE]
, O O
Pompei O B_LOCATION/B_PERSON
P O I_LOCATION/I_PERSON
, O O
Ales O B_LOCATION/B_PERSON
KL O I_LOCATION/I_PERSON
, O O
MacKenzie O B_PERSON/B_LOCATION
CR O I_PERSON/I_LOCATION
. O O

A O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
classifying O O
prognostic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comorbidity O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
longitudinal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
: O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
validation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

J O B_MEASURE/B_LOCATION
Chronic O I_MEASURE/I_LOCATION
Dis O I_MEASURE/I_LOCATION
40 O I_MEASURE/I_LOCATION
: O O
373 O B_MEASURE
<FFFD> O I_MEASURE
383 O I_MEASURE
( O O
1987 O B_MEASURE
) O O
. O O

Librero O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Peir O B_PERSON/B_MEASURE
<FFFD> O I_PERSON/I_MEASURE
S O I_PERSON/I_MEASURE
, O O
Ordi O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
<FFFD> O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ana O I_LOCATION
R O I_LOCATION
. O O

Chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comorbidity O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
outcomes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
hospital O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
care O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O O
length O B_MEASURE
of O O
stay O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
mortality O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
readmission O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
30 O B_MEASURE
and O O
365 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
. O O

J O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
52 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
171 O B_MEASURE
<FFFD> O I_MEASURE
179 O I_MEASURE
( O O
1999 O B_MEASURE
) O O
. O O

31 O B_NUMBER[MEASURE]
. O O

Nehls O B_LOCATION/B_PERSON
GJ O I_LOCATION/I_PERSON
, O O
Akland O B_LOCATION/B_PERSON
GG O I_LOCATION/I_PERSON
. O O

Procedures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
handling O O
aerometric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O O

J O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Air O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Pollut O I_MEASURE
Control O I_MEASURE
Assoc O I_MEASURE
23 O I_MEASURE
: O O
180 O B_MEASURE
<FFFD> O I_MEASURE
184 O I_MEASURE
( O O
1973 O B_MEASURE
) O O
. O O

32 O B_NUMBER[MEASURE]
. O O

Hastie O B_PERSON
T O I_PERSON
, O O
Tibshirani O B_MEASURE/B_PERSON
R O I_MEASURE/I_PERSON
. O O
Generalized O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Additive O B_EDU[ORGANIZATION]/B_LOCATION
Models O I_PROTEIN[GENE]/I_EDU[ORGANIZATION]
. O O

London O B_LOCATION
: O O
Chapman O B_PERSON/B_LOCATION
and O O
Hall O B_LOCATION/B_PERSON
, O O
1990 O B_MEASURE/B_ORGANIZATION
. O O

33 O B_NUMBER[MEASURE]
. O O

Schwartz O B_MEASURE
J O I_MEASURE
. O O
Generalized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
additive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
epidemiology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
: O O
International O B_PERSON/B_TIME[MEASURE]
Biometric O B_PERSON/I_TIME[MEASURE]
Society O B_PERSON/I_TIME[MEASURE]
, O O
Invited O O
Papers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

17th O B_TIME[MEASURE]
International O I_TIME[MEASURE]
Biometric O I_TIME[MEASURE]
Conference O I_TIME[MEASURE]
, O O
8 O B_TIME[MEASURE]/B_LOCATION
<FFFD> O I_TIME[MEASURE]/I_LOCATION
12 O I_TIME[MEASURE]/I_LOCATION
August O I_TIME[MEASURE]/I_LOCATION
1994 O I_TIME[MEASURE]/I_LOCATION
, O O
Hamilton O B_PERSON/B_LOCATION
, O O
Ontario O B_LOCATION
, O O
Canada O B_LOCATION
. O O

Washington O B_LOCATION/B_PERSON
, O O
DC O B_LOCATION
: O O
International O B_PERSON/B_MEASURE
Biometric O I_PERSON/I_MEASURE
Society O I_PERSON/I_MEASURE
, O O
1994 O B_MEASURE
; O O
55 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
80 O I_MEASURE/I_PERSON
. O O

34 O B_NUMBER[MEASURE]
. O O

Rossi O B_MEASURE/B_LOCATION
G O I_MEASURE/I_LOCATION
, O O
Vigotti O B_PERSON/B_LOCATION
MA O I_PERSON/I_LOCATION
, O O
Zanobetti O B_LOCATION
A O I_LOCATION
, O O
Repetto O B_LOCATION/B_PERSON
F O I_LOCATION/I_PERSON
, O O
Giannelle O B_PERSON
V O I_PERSON
, O O
Schwartz O B_LOCATION/B_PERSON
J O I_LOCATION/I_PERSON
. O O

Air O B_DISEASE/B_MEASURE
pollution O I_DISEASE/I_MEASURE
and O O
cause O O
specific O B_DISEASE_ADJECTIVE[DISEASE]
mortality O I_DISEASE_ADJECTIVE[DISEASE]
in O O
Milan O B_LOCATION
, O O
Italy O B_LOCATION
, O O
1980 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
<FFFD> O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1989 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Arch O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Environ O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
54 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
158 O B_MEASURE
<FFFD> O I_MEASURE
164 O I_MEASURE
( O O
1999 O B_MEASURE
) O O
. O O

35 O B_NUMBER[MEASURE]
. O O

Cleveland O B_PERSON/B_LOCATION
WS O I_PERSON/I_LOCATION
, O O
Devlin O B_PERSON/B_LOCATION
SJ O B_PERSON/I_LOCATION
. O O

Robust O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locally O O
- O O
weighted O O
regression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
smoothing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scatterplots O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

J O B_MEASURE
Am O I_MEASURE
Stat O I_MEASURE
Assoc O I_MEASURE
74 O I_MEASURE
: O O
829 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
836 O I_MEASURE/I_PERSON
( O O
1988 O B_MEASURE
) O O
. O O

36 O B_NUMBER[MEASURE]
. O O

Akaike O B_MEASURE/B_PERSON
H O I_MEASURE/I_PERSON
. O O
Information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
an O O
extension O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
maximum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
likelihood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
principal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

In O O
: O O
2nd O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
International O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Symposium O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
on O O
Information O B_DISEASE/B_EDU[ORGANIZATION]
Theory O I_DISEASE/I_EDU[ORGANIZATION]
( O O
Petrov O B_PERSON
BN O I_PERSON
, O O
Csaki O B_LOCATION/B_MEASURE
F O I_LOCATION/I_MEASURE
, O O
eds O B_MEASURE/B_LOCATION
) O O
. O O

Budapest O B_LOCATION
: O O
Akademiai O B_PERSON/B_LOCATION
Kaiado O I_PERSON/I_LOCATION
, O O
1973 O B_MEASURE
; O O
267 O B_PERSON/B_MEASURE
<FFFD> O I_PERSON/I_MEASURE
281 O I_PERSON/I_MEASURE
. O O

37 O B_NUMBER[MEASURE]
. O O

Brumback O B_PERSON/B_COLOR
BA O I_PERSON/I_COLOR
, O O
Ryan O B_LOCATION/B_PERSON
LM O I_LOCATION/I_PERSON
, O O
Schwartz O B_PERSON
J O I_PERSON
, O O
Neas O B_LOCATION/B_PERSON
LM O I_LOCATION/I_PERSON
, O O
Stark O B_PERSON
PC O I_PERSON
, O O
Burge O B_LOCATION/B_PERSON
HA O B_LOCATION/I_PERSON
. O O

Transitional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
application O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
environmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
time O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

J O B_MEASURE
Acoust O I_MEASURE
Soc O I_MEASURE
Am O I_MEASURE
95 O I_MEASURE
( O O
449 O B_MEASURE
) O O
: O O
16 O B_MEASURE
<FFFD> O I_MEASURE
28 O I_MEASURE
( O O
2000 O B_MEASURE
) O O
. O O

38 O B_NUMBER[MEASURE]
. O O

Schwartz O B_LOCATION/B_MEASURE
J O I_LOCATION/I_MEASURE
. O O

The O O
distributed O O
lag O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O O
air O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
pollution O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
daily O B_DISEASE
deaths O I_DISEASE
. O O

Epidemiology O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
320 O B_MEASURE
<FFFD> O I_MEASURE
326 O I_MEASURE
( O O
2000 O B_MEASURE
) O O
. O O

39 O B_NUMBER[MEASURE]
. O O

Pope O B_PERSON/B_LOCATION
CA O I_PERSON/I_LOCATION
III O I_PERSON/I_LOCATION
, O O
Verrier O B_LOCATION/B_PERSON
RL O I_LOCATION/I_PERSON
, O O
Lovett O B_PERSON/B_LOCATION
EG O I_PERSON/I_LOCATION
, O O
Larson O B_PERSON/B_LOCATION
AC O I_PERSON/I_LOCATION
, O O
Raizenne O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ME O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Kanner O B_PERSON/B_LOCATION
RE O B_PERSON/I_LOCATION
, O O
Schwartz O B_LOCATION/B_ORGANIZATION
J O I_LOCATION/I_ORGANIZATION
, O O
Villegas O B_LOCATION/B_PERSON
GM O I_LOCATION/I_PERSON
, O O
Dockery O B_LOCATION/B_ORGANIZATION
DW O I_LOCATION/I_ORGANIZATION
. O O

Heart O B_DISEASE_ADJECTIVE[DISEASE]
rate O I_DISEASE_ADJECTIVE[DISEASE]
variability O I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
particulate O B_DISEASE
air O I_DISEASE
pollution O I_DISEASE
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Heart O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
138 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
890 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
899 O I_MEASURE/I_PERSON
( O O
1999 O B_MEASURE
) O O
. O O

40 O B_NUMBER[MEASURE]
. O O

Gold O B_MEASURE/B_LOCATION
DR O I_MEASURE/I_LOCATION
, O O
Litonjua O B_LOCATION/B_PERSON
A O I_LOCATION/I_PERSON
, O O
Schwartz O B_PERSON
J O I_PERSON
, O O
Lovett O B_PERSON
E O I_PERSON
, O O
Larson O B_PERSON
A O I_PERSON
, O O
Nearing O O
B O B_OTHER/B_LOCATION
, O O
Allen O B_PERSON
G O I_PERSON
, O O
Verrier O B_PERSON/B_COLOR
M O I_PERSON/I_COLOR
, O O
Cherry O B_PERSON/B_COLOR
R O I_PERSON/I_COLOR
, O O
Verrier O B_MEASURE/B_PERSON
R O I_MEASURE/I_PERSON
. O O
Ambient O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pollution O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
heart O B_MEASURE/B_LOCATION
rate O B_MEASURE/I_LOCATION
variability O B_MEASURE/I_LOCATION
. O O

Circulation O B_TIME[MEASURE]
101 O I_TIME[MEASURE]
( O O
11 O B_MEASURE
) O O
: O O
1267 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
1273 O I_MEASURE/I_PERSON
( O O
2000 O B_MEASURE
) O O
. O O

41 O B_NUMBER[MEASURE]
. O O

Liao O B_PERSON/B_COLOR
D O I_PERSON/I_COLOR
, O O
Creason O B_PERSON
J O I_PERSON
, O O
Shy O B_PERSON/B_LOCATION
C O I_PERSON/I_LOCATION
, O O
Williams O B_PERSON
R O I_PERSON
, O O
Watts O B_PERSON/B_LOCATION
R O I_PERSON/I_LOCATION
, O O
Zweidinger O B_MEASURE/B_PERSON
R O I_MEASURE/I_PERSON
. O O
Daily O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
variation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
particulate O B_DISEASE
air O I_DISEASE
pollution O I_DISEASE
and O O
poor O B_DISEASE_ADJECTIVE[DISEASE]
cardiac O I_DISEASE_ADJECTIVE[DISEASE]
autonomic O I_DISEASE_ADJECTIVE[DISEASE]
control O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
elderly O B_PERSON/B_DISEASE
. O O

Environ O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspect O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
107 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
521 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
525 O I_MEASURE/I_PERSON
( O O
1999 O B_MEASURE
) O O
. O O

42 O B_NUMBER[MEASURE]
. O O

Peters O B_PERSON
A O I_PERSON
, O O
Liu O B_PERSON/B_LOCATION
E O B_PERSON/I_LOCATION
, O O
Verrier O B_PERSON/B_LOCATION
RL O I_PERSON/I_LOCATION
, O O
Schwartz O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Gold O B_PERSON/B_LOCATION
DR O I_PERSON/I_LOCATION
, O O
Mittelman O B_LOCATION/B_PERSON
M O I_LOCATION/I_PERSON
, O O
Baliff O B_PERSON
J O I_PERSON
, O O
Allen O B_PERSON/B_LOCATION
G O I_PERSON/I_LOCATION
, O O
Monahan O B_PERSON/B_LOCATION
K O I_PERSON/I_LOCATION
, O O
Dockery O B_PERSON/B_ORGANIZATION
DW O I_PERSON/I_ORGANIZATION
. O O

Air O B_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DISEASE_ADJECTIVE[DISEASE]
and O O
incidences O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
cardiac O B_DISEASE
arrhythmia O I_DISEASE
. O O

Epidemiology O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_MEASURE
) O O
: O O
11 O B_MEASURE
<FFFD> O I_MEASURE
17 O I_MEASURE
( O O
2000 O B_MEASURE
) O O
. O O

43 O B_NUMBER[MEASURE]
. O O

Godleski O B_PERSON
JJ O I_PERSON
, O O
Verrier O B_LOCATION/B_PERSON
RL O I_LOCATION/I_PERSON
, O O
Koutrakis O B_PERSON/B_LOCATION
P O B_PERSON/I_LOCATION
, O O
Catalano O B_MEASURE/B_PERSON
P O I_MEASURE/I_PERSON
. O O
Mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Morbidity O B_DISEASE
and O O
Mortality O B_DISEASE
from O O
Exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
Ambient O B_DISEASE
Air O I_DISEASE
Particles O I_DISEASE
. O O

Health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Institute O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
91 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Cambridge O B_LOCATION/B_PERSON
, O O
MA O B_LOCATION
: O O
Health O B_PERSON/B_MEASURE
Effects O I_PERSON/I_MEASURE
Institute O I_PERSON/I_MEASURE
, O O
2000 O B_MEASURE/B_LOCATION
. O O

44 O B_NUMBER[MEASURE]
. O O

Watkinson O B_PERSON/B_LOCATION
WP O B_PERSON/I_LOCATION
, O O
Campen O B_PERSON/B_LOCATION
MJ O B_PERSON/I_LOCATION
, O O
Kodavanti O B_PERSON
UP O O
, O O
Ledbetter O B_DISEASE/B_LOCATION
AD O B_DISEASE/I_LOCATION
, O O
Costa O B_PERSON/B_LOCATION
DL O B_PERSON/I_LOCATION
. O O

Effects O O
of O O
inhaled O O
residual O O
oil O O
fly O O
ash O O
particles O O
on O O
electrocardiographic O O
and O O
thermoregulatory O O
parameters O O
in O O
normal O O
and O O
compromised O O
rats B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
Abstract O O
] O O
. O O

Am O B_MEASURE/B_LOCATION
J O I_MEASURE/I_LOCATION
Respir O I_MEASURE/I_LOCATION
Crit O I_MEASURE/I_LOCATION
Care O I_MEASURE/I_LOCATION
Med O I_MEASURE/I_LOCATION
157 O I_MEASURE/I_LOCATION
: O O
A150 O B_MEASURE/B_LOCATION
( O O
1998 O B_MEASURE
) O O
. O O

45 O B_NUMBER[MEASURE]
. O O

Watkinson O B_PERSON/B_LOCATION
WP O I_PERSON/I_LOCATION
, O O
Campen O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MJ O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Costa O B_PERSON/B_LOCATION
DL O I_PERSON/I_LOCATION
. O O

Cardiac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrhythmia O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
residual O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oil O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fly O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ash O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
rodent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
pulmonary O B_DISEASE
hypertension O I_DISEASE
. O O

Toxicol O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sci O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
41 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
209 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
216 O I_MEASURE/I_PERSON
( O O
1998 O B_MEASURE
) O O
. O O

46 O B_NUMBER[MEASURE]
. O O

Kodavanti O B_PERSON
UP O O
, O O
Jackson O B_LOCATION/B_PERSON
MC O I_LOCATION/I_PERSON
, O O
Richards O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Ledbetter O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
, O O
Costa O B_PERSON/B_PROTEIN[GENE]
DL O I_PERSON/I_PROTEIN[GENE]
. O O

Differential O O
pulmonary O O
responses O O
to O O
inhaled O O
emission O O
particulate O O
matter O O
( O O
PM O O
) O O
in O O
systemically O O
hypertensive O O
vs O O
. O O
normotensive O O
rats B B_BIO/B_PERSON
[ O O
Abstract O O
] O O
. O O

Am O B_MEASURE/B_LOCATION
J O I_MEASURE/I_LOCATION
Respir O I_MEASURE/I_LOCATION
Crit O I_MEASURE/I_LOCATION
Care O I_MEASURE/I_LOCATION
Med O I_MEASURE/I_LOCATION
157 O I_MEASURE/I_LOCATION
: O O
A260 O B_MEASURE
( O O
1998 O B_MEASURE
) O O
. O O

47 O B_NUMBER[MEASURE]
. O O

Hoek O B_PERSON/B_LOCATION
G O I_PERSON/I_LOCATION
, O O
Brunekreef O B_PERSON/B_LOCATION
B O I_PERSON/I_LOCATION
, O O
van O B_PERSON/B_LOCATION
Wijnen O I_PERSON/I_LOCATION
JH O I_PERSON/I_LOCATION
. O O

Cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]
mortality O I_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
to O O
air O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
strongest O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
failure O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
thrombotic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
causes O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
death O B_DISEASE
[ O O
Abstract O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Epidemiology O B_MEASURE
10 O I_MEASURE
: O O
S177 O B_MEASURE/B_PERSON
( O O
1999 O B_MEASURE
) O O
. O O

48 O B_NUMBER[MEASURE]
. O O

Bates O B_PERSON
DV O I_PERSON
, O O
Szito O B_MEASURE/B_LOCATION
R O I_MEASURE/I_LOCATION
. O O
Hospital O B_LOCATION/B_ORGANIZATION
admissions O I_LOCATION/I_ORGANIZATION
and O O
air O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pollutants O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
southern O B_LOCATION
Ontario O I_LOCATION
: O O
the O O
acid O B_LOCATION/B_TIME[MEASURE]
summer O I_LOCATION/I_TIME[MEASURE]
haze O I_LOCATION/I_TIME[MEASURE]
effect O I_LOCATION/I_TIME[MEASURE]
. O O

Environ O B_MEASURE
Res O I_MEASURE
43 O I_MEASURE
: O O
317 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
331 O I_MEASURE/I_PERSON
( O O
1987 O B_MEASURE
) O O
. O O

49 O B_NUMBER[MEASURE]
. O O

Pope O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
CA O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
III O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Respiratory O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
associated O O
with O O
community O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
steel O B_LOCATION/B_MEASURE
mill O I_LOCATION/I_MEASURE
, O O
Utah O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
valley O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Am O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Public O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
79 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
623 O B_MEASURE
<FFFD> O I_MEASURE
628 O I_MEASURE
( O O
1989 O B_MEASURE
) O O
. O O

50 O B_NUMBER[MEASURE]
. O O

Zelikoff O B_PERSON
JT O I_PERSON
, O O
Nadziejko O B_PERSON/B_LOCATION
C O I_PERSON/I_LOCATION
, O O
Fang O B_PERSON/B_LOCATION
T O B_PERSON/I_LOCATION
, O O
Gordon O B_PERSON/B_LOCATION
C O B_PERSON/I_LOCATION
, O O
Premdass O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
, O O
Cohen O B_PERSON/B_LOCATION
MD O I_PERSON/I_LOCATION
. O O

Short O B_MEASURE/B_LOCATION
term O I_MEASURE/I_LOCATION
, O O
low O B_MEASURE/B_COLOR
- O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
inhalation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
ambient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
particulate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
matter O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
exacerbates O O
ongoing O B_DISEASE
pneumococcal O I_DISEASE
infections O I_DISEASE
in O O
Streptococcus O B_DISEASE/B_BACTERIUM[BIO]
Pneumoniae O I_DISEASE/I_BACTERIUM[BIO]
- O O
infected O O
rates O B_MEASURE/B_PERSON
. O O

In O O
: O O
Proceedings O O
of O O
the O O
Third O O
Colloquium O O
on O O
Particulate O O
Air O O
Pollution O O
and O O
Human B B_PERSON/B_LOCATION
Health O O
( O O
Phalen O O
RF O O
, O O
Bell O O
YM O O
, O O
eds O O
) O O
. O O

Irvine O B_LOCATION/B_PERSON
, O O
CA O B_LOCATION
: O O
Air O B_LOCATION/B_PERSON
Pollution O I_LOCATION/I_PERSON
Health O I_LOCATION/I_PERSON
Effects O I_LOCATION/I_PERSON
Laboratory O I_LOCATION/I_PERSON
, O O
University O B_LOCATION/B_ORGANIZATION
of O O
California O B_LOCATION
, O O
1999 O B_NUMBER[MEASURE]/B_LOCATION
; O O
8 O B_MEASURE
- O O
94 O B_MEASURE
<FFFD> O I_MEASURE
8 O I_MEASURE
- O O
101 O B_MEASURE
. O O

51 O B_NUMBER[MEASURE]
. O O

Clarke O B_PERSON/B_LOCATION
RW O I_PERSON/I_LOCATION
, O O
Hemenway O B_LOCATION
DR O I_LOCATION
, O O
Frank O B_LOCATION/B_DISEASE
R O I_LOCATION/I_DISEASE
, O O
Kleeberger O B_LOCATION
SR O I_LOCATION
, O O
Longphre O B_LOCATION
MV O I_LOCATION
, O O
Jakab O B_PERSON/B_LOCATION
GJ O I_PERSON/I_LOCATION
. O O

Particle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
associated O O
sulfate O B_DISEASE
exposure O I_DISEASE
enhances O O
murine O B_DISEASE
influenza O I_DISEASE
mortality O I_DISEASE
[ O I_DISEASE
Abstract O I_DISEASE
] O I_DISEASE
. O O

Am O B_MEASURE
J O I_MEASURE
Respir O I_MEASURE
Crit O I_MEASURE
Care O I_MEASURE
Med O I_MEASURE
155 O I_MEASURE
: O O
A245 O B_MEASURE
( O O
1997 O B_MEASURE
) O O
. O O

52 O B_NUMBER[MEASURE]
. O O

Pope O B_PERSON/B_LOCATION
CA O I_PERSON/I_LOCATION
, O O
Dockery O B_LOCATION/B_ORGANIZATION
DW O I_LOCATION/I_ORGANIZATION
, O O
Spengler O B_LOCATION/B_PERSON
JD O I_LOCATION/I_PERSON
, O O
Raizenne O O
ME O O
. O O

Respiratory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
PM10 O B_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DISEASE_ADJECTIVE[DISEASE]
: O O
a O O
daily O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
time O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rev O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dis O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
144 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
668 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
674 O I_MEASURE/I_PERSON
( O O
1991 O B_MEASURE
) O O
. O O

53 O B_NUMBER[MEASURE]
. O O

Schwartz O B_PERSON/B_COLOR
J O I_PERSON/I_COLOR
, O O
Koenig O B_PERSON/B_LOCATION
J O I_PERSON/I_LOCATION
, O O
Slater O B_PERSON
D O I_PERSON
, O O
Larson O B_MEASURE/B_PERSON
T O I_MEASURE/I_PERSON
. O O
Particulate O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
air O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pollution O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
hospital O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
emergency O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
visits O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
asthma O B_PERSON
in O O
Seattle O B_LOCATION/B_PERSON
. O O

Am O B_MEASURE/B_PERSON
Rev O I_MEASURE/I_PERSON
Respir O I_MEASURE/I_PERSON
Dis O I_MEASURE/I_PERSON
147 O I_MEASURE/I_PERSON
: O O
826 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
831 O I_MEASURE/I_PERSON
( O O
1993 O B_MEASURE
) O O
. O O

54 O B_NUMBER[MEASURE]
. O O

Thurston O B_PERSON
GD O I_PERSON
, O O
Ito O B_LOCATION/B_PERSON
K O I_LOCATION/I_PERSON
, O O
Lippman O B_LOCATION/B_PERSON
M O I_LOCATION/I_PERSON
, O O
Hayes O B_PERSON/B_LOCATION
CG O B_PERSON/I_LOCATION
, O O
Bates O B_PERSON/B_LOCATION
DV O I_PERSON/I_LOCATION
. O O

Respiratory O B_TIME[MEASURE]/B_LOCATION
hospital O I_TIME[MEASURE]/I_LOCATION
admissions O I_TIME[MEASURE]/I_LOCATION
and O O
summertime O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
haze O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
air O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
pollution O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Toronto O B_LOCATION/B_PERSON
, O O
Ontario O B_LOCATION/B_MEASURE
: O O
consideration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
role O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
acid O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
aerosols O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O O

Environ O B_MEASURE
Res O I_MEASURE
65 O I_MEASURE
: O O
271 O B_MEASURE
<FFFD> O I_MEASURE
290 O I_MEASURE
( O O
1994 O B_MEASURE
) O O
. O O

55 O B_NUMBER[MEASURE]
. O O

Norris O B_PERSON/B_ORGANIZATION
G O B_PERSON/I_ORGANIZATION
, O O
YoungPong O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SN O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Koenig O B_PERSON/B_ORGANIZATION
JQ O B_PERSON/I_ORGANIZATION
, O O
Larson O B_PERSON/B_ORGANIZATION
TV O I_PERSON/I_ORGANIZATION
, O O
Sheppard O B_PERSON/B_ORGANIZATION
L O B_PERSON/I_ORGANIZATION
, O O
Stout O B_PERSON/B_LOCATION
JW O B_PERSON/I_LOCATION
. O O

An O O
association O O
between O O
fine O O
particles O O
and O O
asthma O O
emergency O O
department O O
visits O O
for O O
children B B_PERSON
in O O
Seattle O O
. O O

Environ O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspect O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
107 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
489 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
493 O I_MEASURE/I_PERSON
( O O
1999 O B_MEASURE
) O O
. O O

56 O B_NUMBER[MEASURE]
. O O

Hamada O B_PERSON/B_LOCATION
K O I_PERSON/I_LOCATION
, O O
Goldsmith O B_PERSON/B_LOCATION
CW O I_PERSON/I_LOCATION
, O O
Kobzik O B_LOCATION/B_PERSON
L O I_LOCATION/I_PERSON
. O O

Air O O
pollutant O O
aerosols O O
allow O O
airway O O
sensitization O O
to O O
allergen O O
in O O
juvenile O O
mice B B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Am O B_PERSON
J O I_PERSON
Resp O I_PERSON
Crit O I_PERSON
Care O I_PERSON
Med O I_PERSON
A28 O I_PERSON
( O O
1999 O B_MEASURE
) O O
. O O

57 O B_NUMBER[MEASURE]
. O O

Lambert O B_PERSON
AL O I_PERSON
, O O
Selgrade O B_PERSON/B_LOCATION
M O I_PERSON/I_LOCATION
, O O
Dong O B_PERSON
W O I_PERSON
, O O
Winsett O B_PERSON/B_LOCATION
D O I_PERSON/I_LOCATION
, O O
Gilmour O B_MEASURE/B_PERSON
M O I_MEASURE/I_PERSON
. O O
Enhanced O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
allergic O B_TIME[MEASURE]/B_PERSON
sensitization O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
by O O
residual O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oil O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fly O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ash O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
particles O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
mediated O O
by O O
soluble O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
metal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
constituents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O O
Abstract O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Am O B_MEASURE/B_PERSON
J O I_MEASURE/I_PERSON
Respir O I_MEASURE/I_PERSON
Crit O I_MEASURE/I_PERSON
Care O I_MEASURE/I_PERSON
Med O I_MEASURE/I_PERSON
159 O I_MEASURE/I_PERSON
: O O
A26 O B_MEASURE
( O O
1999 O B_MEASURE
) O O
. O O

58 O B_NUMBER[MEASURE]
. O O

Dailey O B_DISEASE/B_LOCATION
LA O B_DISEASE/I_LOCATION
, O O
Madden O B_LOCATION
MC O I_LOCATION
, O O
Devlin O B_PERSON/B_LOCATION
RB O I_PERSON/I_LOCATION
. O O

Do O O
airway O O
epithelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
normal O B_PERSON/B_DISEASE
and O O
asthmatic O B_DISEASE/B_MEASURE
donors O I_DISEASE/I_MEASURE
respond O O
differently O O
to O O
an O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
challenge O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
a O O
particulate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pollutant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
? O O

[ O O
Abstract O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Am O B_MEASURE
J O I_MEASURE
Respir O I_MEASURE
Crit O I_MEASURE
Care O I_MEASURE
Med O I_MEASURE
157 O I_MEASURE
: O O
A598 O B_MEASURE/B_LOCATION
( O O
1998 O B_MEASURE
) O O
. O O

59 O B_NUMBER[MEASURE]
. O O

Gilmour O B_PERSON/B_COLOR
MI O I_PERSON/I_COLOR
, O O
Winsett O B_LOCATION/B_PERSON
D O I_LOCATION/I_PERSON
, O O
Selgrade O B_LOCATION/B_PERSON
MJ O I_LOCATION/I_PERSON
, O O
Costa O B_PERSON/B_LOCATION
DL O I_PERSON/I_LOCATION
. O O

Residual O O
oil O O
fly O O
ash O O
exposure O O
enhances O O
allergic O O
sensitization O O
to O O
house O O
dust O O
mite O O
in O O
rats B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
augments O O
immune O O
- O O
mediated O O
inflammation O O
[ O O
Abstract O O
] O O
. O O

Am O B_MEASURE
J O I_MEASURE
Respir O I_MEASURE
Crit O I_MEASURE
Care O I_MEASURE
Med O I_MEASURE
155 O I_MEASURE
: O O
A244 O B_MEASURE/B_LOCATION
( O O
1997 O B_MEASURE
) O O
. O O

60 O B_NUMBER[MEASURE]
. O O

Zeger O B_PERSON
SL O I_PERSON
, O O
Thomas O B_LOCATION/B_PERSON
D O I_LOCATION/I_PERSON
, O O
Dominici O B_PERSON/B_SPECIES[BIO]
F O I_PERSON/I_SPECIES[BIO]
, O O
Samet O B_PERSON
JM O I_PERSON
, O O
Schwartz O B_PERSON/B_LOCATION
JM O I_PERSON/I_LOCATION
, O O
Dockery O B_PERSON/B_ORGANIZATION
D O I_PERSON/I_ORGANIZATION
, O O
Cohen O B_MEASURE/B_PERSON
A O I_MEASURE/I_PERSON
. O O
Exposure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurement O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
error O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
time O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
<FFFD> O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
air O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
concepts O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
consequences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Environ O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspect O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
108 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
419 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
426 O I_MEASURE/I_PERSON
( O O
2000 O B_MEASURE
) O O
. O O

61 O B_NUMBER[MEASURE]
. O O

Salvi O O
S O O
, O O
Blomberg O O
A O O
, O O
Rudell O O
B O O
, O O
Kelly O O
F O O
, O O
Sandstrom O O
T O O
, O O
Holgate O O
ST O O
, O O
Frew O O
A O O
. O O
Acute O O
inflammatory O O
responses O O
in O O
the O O
airways O O
and O O
peripheral O O
blood O O
after O O
short O O
- O O
term O O
exposure O O
to O O
diesel O O
exhaust O O
in O O
healthy O O
human B B_PERSON/B_SPECIES[BIO]
volunteers O O
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Crit O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Care O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
159 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
702 O B_MEASURE
<FFFD> O I_MEASURE
709 O I_MEASURE
( O O
1999 O B_MEASURE
) O O
. O O

62 O B_NUMBER[MEASURE]
. O O

Tan O B_PERSON
WC O I_PERSON
, O O
van O B_PERSON/B_LOCATION
Eeden O I_PERSON/I_LOCATION
S O I_PERSON/I_LOCATION
, O O
Qiu O B_PERSON/B_LOCATION
DW O I_PERSON/I_LOCATION
, O O
Liam O B_PERSON/B_LOCATION
BL O B_PERSON/I_LOCATION
, O O
Dyachokova O B_PERSON/B_LOCATION
Y O B_PERSON/I_LOCATION
, O O
Hogg O B_PERSON/B_LOCATION
JL O I_PERSON/I_LOCATION
. O O

Particulate O B_DISEASE_ADJECTIVE[DISEASE]
air O I_DISEASE_ADJECTIVE[DISEASE]
pollution O I_DISEASE_ADJECTIVE[DISEASE]
, O O
bone O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
marrow O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
pathogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
excess O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cardiovascular O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
deaths O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Am O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Crit O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Care O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
155 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
1441 O B_MEASURE/B_PERSON
<FFFD> O I_MEASURE/I_PERSON
1447 O I_MEASURE/I_PERSON
( O O
1997 O B_MEASURE
) O O
. O O

63 O B_NUMBER[MEASURE]
. O O

Gordon O B_PERSON
T O I_PERSON
, O O
Nadziejko O B_LOCATION/B_PERSON
C O I_LOCATION/I_PERSON
, O O
Schlesinger O B_PERSON
R O I_PERSON
, O O
Chen O B_PERSON/B_LOCATION
LC O I_PERSON/I_LOCATION
. O O

Pulmonary O O
and O O
cardiovascular O O
effects O O
of O O
acute O O
exposure O O
to O O
concentrated O O
ambient O O
particulate O O
matter O O
in O O
rats B B_BIO/B_PERSON
. O O

Toxicol O B_MEASURE
Lett O I_MEASURE
96 O I_MEASURE
<FFFD> O I_MEASURE
97 O I_MEASURE
: O O
285 O B_MEASURE
<FFFD> O I_MEASURE
288 O I_MEASURE
( O O
1998 O B_MEASURE
) O O
. O O

64 O B_NUMBER[MEASURE]
. O O

Peters O B_PERSON
A O I_PERSON
, O O
Doering O B_PERSON
A O I_PERSON
, O O
Wichmann O B_PERSON/B_MEASURE
HE O O
, O O
Koenig O B_MEASURE/B_PERSON
W O I_MEASURE/I_PERSON
. O O
Increased O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma O B_MEASURE/B_DISEASE
viscosity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
during O O
an O O
air O B_DISEASE
pollution O I_DISEASE
episode O I_DISEASE
: O O
a O O
link O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
mortality O B_DISEASE
? O O

Lancet O B_MEASURE
349 O I_MEASURE
( O O
9065 O B_MEASURE
) O O
: O O
1582 O B_MEASURE
<FFFD> O I_MEASURE
1587 O I_MEASURE
( O O
1997 O B_MEASURE
) O O
. O O

65 O B_NUMBER[MEASURE]
. O O

Peters O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
, O O
Stieberv O B_PERSON
J O I_PERSON
, O O
Doering O B_PERSON
A O I_PERSON
, O O
Wichmann O B_PERSON
HE O O
. O O

Is O O
systolic O B_DISEASE
blood O I_DISEASE
pressure O I_DISEASE
associated O O
with O O
air O B_DISEASE
pollution O I_DISEASE
? O O

[ O O
Abstract O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Epidemiology O B_MEASURE
10 O I_MEASURE
( O O
4 O B_MEASURE
) O O
: O O
S177 O B_MEASURE/B_PERSON
( O O
1999 O B_MEASURE
) O O
. O O

Environmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspectives O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

<FFFD> O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
VOLUME O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
108 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
NUMBER O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
9 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
September O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2000 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]

845 O B_NUMBER[MEASURE]

Syndrome O O
of O O
arachnomelia O O
in O O
Simmental O O
cattle B B_BIO/B_PERSON

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
syndrome O O
of O O
arachnomelia O O
is O O
an O O
inherited O O
malformation O O
mainly O O
of O O
limbs O O
, O O
back O O
and O O
head O O
in O O
cattle B B_BIO/B_PERSON
. O O

At O O
present O O
the O O
arachnomelia O O
syndrome O O
has O O
been O O
well O O
known O O
mainly O O
in O O
Brown O O
Swiss O O
cattle B B_BIO/B_DISEASE
. O O

Nevertheless O O
, O O
the O O
arachnomelia O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
had O O
been O O
observed O O
in O O
the O O
Hessian O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Simmental O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
decade O B_TIME[MEASURE]
1964 O I_TIME[MEASURE]
- O O
1974 O B_MEASURE
. O O

Recently O O
, O O
stillborn O O
Simmental O O
calves B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
having O O
a O O
morphology O O
similar O O
to O O
the O O
arachnomelia O O
syndrome O O
. O O

The O O
goal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O O
this O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
the O O
characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
morphology O B_DISEASE
and O O
genealogy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
syndrome O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
Simmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
establish O O
the O O
basis O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
an O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
disease O B_DISEASE/B_PERSON
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
first O B_SEQUENCE[MEASURE]
pathologically O O
confirmed O O
arachnomelia O B_DISEASE/B_LOCATION
syndrome O I_DISEASE/I_LOCATION
- O O
cases O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Simmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
population O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
appeared O O
in O O
the O O
year O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2005 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

By O O
2007 O O
, O O
an O O
additional O O
140 O O
calves B B_PERSON/B_BIO
with O O
the O O
arachnomelia O O
syndrome O O
were O O
identified O O
. O O

The O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pathological O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
findings O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
malformed O O
bones O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
affecting O O
the O O
head O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
long O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bones O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
vertebral O B_BODY_PART_OR_ORGAN_COMPONENT
column O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

It O O
could O O
be O O
shown O O
that O O
, O O
with O O
the O O
exception O O
of O O
two O O
cases O O
that O O
were O O
considered O O
as O O
phenocopies O O
, O O
all O O
of O O
the O O
paternal O O
and O O
about O O
two O O
- O O
third O O
of O O
the O O
maternal O O
pedigrees O O
of O O
the O O
affected O O
calves B B_PERSON
could O O
be O O
traced O O
back O O
to O O
one O O
common O O
founder O O
. O O

Together O O
with O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
experimental O B_MEASURE
matings O I_MEASURE
, O O
the O O
pedigree O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
support O O
an O O
autosomal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recessive O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O O
the O O
etiology O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
arachnomelia O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
. O O

The O O
frequency O B_MEASURE
of O O
the O O
mutation O B_DISEASE/B_GENE
in O O
the O O
current O B_PERSON/B_BIO
population O B_PERSON/I_BIO
was O O
estimated O O
to O O
be O O
3 O B_MEASURE
. O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

We O O
describe O O
the O O
repeated O O
occurrence O O
of O O
the O O
arachnomelia O O
syndrome O O
in O O
Simmental O O
calves B B_PERSON/B_SPECIES[BIO]
. O O

It O O
resembles O O
completely O O
the O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defect O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurring O O
in O O
the O O
Brown O B_BIO/B_MEASURE
Swiss O I_BIO/I_MEASURE
breed O I_BIO/I_MEASURE
. O O

The O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]
became O O
relatively O O
widespread O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
amongst O O
the O O
current O B_PERSON/B_LOCATION
population O I_PERSON/I_LOCATION
. O O

Therefore O O
, O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O O
to O O
be O O
established O O
and O O
it O O
is O O
highly O O
desirable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
map O O
the O O
disease O B_DISEASE/B_GENE
and O O
develop O O
a O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
the O O
year O O
2006 O O
a O O
syndrome O O
was O O
described O O
in O O
the O O
German O O
and O O
Austrian O O
Simmental O O
( O O
Fleckvieh O O
, O O
as O O
it O O
is O O
locally O O
called O O
, O O
is O O
the O O
main O O
dual O O
- O O
purpose O O
breed O O
in O O
Germany O O
, O O
in O O
short O O
called O O
Simmental O O
in O O
the O O
further O O
text O O
) O O
population O O
, O O
that O O
was O O
pathologically O O
similar O O
to O O
the O O
arachnomelia O O
syndrome O O
in O O
Brown O O
Swiss O O
cattle B B_SPECIES[BIO]
[ O O
1 O O
] O O
. O O

The O O
congenital O O
arachnomelia O O
syndrome O O
( O O
AS O O
, O O
OMIA O O
Phene O O
ID O O
139 O O
, O O
Group O O
000059 O O
) O O
is O O
mainly O O
a O O
malformation O O
of O O
the O O
skeletal O O
system O O
in O O
cattle B B_SPECIES[BIO]/B_PERSON
that O O
was O O
initially O O
described O O
by O O
Rieck O O
and O O
Schade O O
[ O O
2 O O
] O O
in O O
Holstein O O
Friesian O O
, O O
Red O O
Holstein O O
and O O
Simmental O O
. O O

The O O
main O B_DISEASE_ADJECTIVE[DISEASE]
pathological O I_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
are O O
skeletal O B_DISEASE
malformations O I_DISEASE
of O O
the O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
column O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
skull O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
are O O
thinner O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
appear O O
longer O O
than O O
normal O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
dolichostenomelia O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
arachnomelia O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
since O O
the O O
diameter O B_MEASURE/B_LOCATION
of O O
the O O
diaphyses O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
reduced O O
. O O

These O O
long O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bones O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
more O O
fragile O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
, O O
in O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O O
stiffened O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
joints O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
they O O
tend O O
to O O
fracture O O
during O O
calving O O
. O O

The O O
fetlock O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
joints O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
deformed O O
, O O
often O O
stiffened O O
and O O
show O B_DISEASE_ADJECTIVE[DISEASE]
hyperextension O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
malformation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
column O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
kyphosis O B_DISEASE
and O O
scoliosis O B_DISEASE
. O O

The O O
skull O B_DISEASE/B_PERSON
malformations O I_DISEASE/I_PERSON
are O O
characterized O O
by O O
a O O
shortened O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
jaw O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
brachygnathia O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
inferior O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
, O O
convex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rounding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
frontal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_BODY_PART_OR_ORGAN_COMPONENT/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O O
to O O
a O O
marked O O
stop O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
" O O
pointer O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
head O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
" O O
) O O
and O O
rotation O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
anterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cranium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
some O O
cases O B_PERSON/B_BIO
, O O
additional O B_DISEASE_ADJECTIVE[DISEASE]
malformations O I_DISEASE_ADJECTIVE[DISEASE]
like O O
hydrocephalus O B_DISEASE/B_PERSON
externus O I_DISEASE/I_PERSON
develop O O
[ O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
5 O B_MEASURE
] O I_MEASURE
. O O

Since O O
the O O
report O O
of O O
Rieck O O
and O O
Schade O O
[ O O
2 O O
] O O
no O O
further O O
cases O O
were O O
reported O O
in O O
Simmental O O
cattle B B_SPECIES[BIO]/B_LOCATION
, O O
but O O
in O O
the O O
1980s O O
the O O
syndrome O O
was O O
dispersed O O
in O O
another O O
breed O O
, O O
the O O
European O O
Brown O O
Swiss O O
cattle B B_SPECIES[BIO]/B_LOCATION
, O O
by O O
the O O
use O O
of O O
American O O
Brown O O
Swiss O O
sires O O
[ O O
4 O O
, O O
6 O O
] O O
. O O

In O O
Brown O B_MEASURE/B_PERSON
Swiss O I_MEASURE/I_PERSON
an O O
autosomal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recessive O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mode O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
inheritance O B_DISEASE
was O O
supposed O O
and O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
based O O
on O O
the O O
identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
carriers O B_PERSON/B_BIO
by O O
pedigree O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
established O O
[ O O
5 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

Recently O O
, O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
arachnomelia O B_DISEASE
syndrome O I_DISEASE
were O O
reported O O
in O O
Italy O B_LOCATION
[ O O
3 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
we O O
present O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
152 O B_NUMBER[MEASURE]
pathologically O O
confirmed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
arachnomelia O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
in O O
Simmental O B_LOCATION
that O O
were O O
collected O O
from O O
October O B_TIME[MEASURE]/B_LOCATION
2005 O I_TIME[MEASURE]/I_LOCATION
to O O
March O B_TIME[MEASURE]/B_LOCATION
2007 O I_TIME[MEASURE]/I_LOCATION
. O O

We O O
describe O O
the O O
pathological O O
findings O O
, O O
the O O
familial O O
occurrence O O
and O O
an O O
estimate O O
of O O
the O O
frequency O O
of O O
the O O
diseases O O
allele O O
in O O
Simmental O O
cattle B B_BIO/B_PERSON
. O O

Additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
the O O
mode O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
inheritance O B_DISEASE
and O O
the O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]
basis O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
arachnomelia O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
is O O
given O O
by O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
obligate O B_PERSON/B_BIO
carriers O I_PERSON/I_BIO
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

AS O O
has O O
not O O
been O O
reported O O
again O O
in O O
Simmental O B_LOCATION/B_BIO
since O O
its O O
first O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
description O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
1970s O B_TIME[MEASURE]/B_LOCATION
, O O
more O B_MEASURE/B_PERSON
than O O
thirteen O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
ago O O
. O O

In O O
autumn O O
2004 O O
a O O
number O O
of O O
stillborn O O
calves B B_PERSON/B_BIO
with O O
similar O O
malformations O O
of O O
the O O
legs O O
and O O
head O O
were O O
recorded O O
within O O
the O O
monitoring O O
system O O
of O O
anomalies O O
in O O
Simmental O O
. O O

Some O O
of O O
these O O
calves B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
sent O O
to O O
the O O
veterinary O O
service O O
laboratory O O
for O O
examination O O
, O O
and O O
in O O
December O O
2005 O O
the O O
first O O
15 O O
cases O O
of O O
AS O O
were O O
pathologically O O
confirmed O O
. O O

Subsequently O O
, O O
farmers O B_PERSON
and O O
veterinarians O B_PERSON
had O O
been O O
encouraged O O
to O O
report O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
an O O
information O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leaflet O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
various O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
articles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
local O B_ORGANIZATION/B_LOCATION
trade O I_ORGANIZATION/I_LOCATION
journals O I_ORGANIZATION/I_LOCATION
. O O

An O O
increasing O O
number O O
of O O
suspected O O
cases O O
was O O
reported O O
and O O
an O O
additional O O
136 O O
affected O O
calves B B_PERSON/B_BIO
were O O
identified O O
by O O
pathological O O
examination O O
by O O
June O O
2007 O O
. O O

Familial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
occurrence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
presentation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
syndrome O B_DISEASE
of O O
arachnomelia O B_DISEASE/B_SPECIES[BIO]

The O O
geographical O B_LOCATION/B_MEASURE
origins O I_LOCATION/I_MEASURE
of O O
the O O
cases O B_PERSON/B_SPECIES[BIO]
were O O
the O O
southern O B_LOCATION/B_PERSON
part O I_LOCATION/I_PERSON
of O O
Germany O B_LOCATION
and O O
Austria O B_LOCATION
, O O
reflecting O O
the O O
regional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Simmental O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
breed O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Both O O
sexes O O
were O O
equally O O
represented O O
in O O
the O O
152 O O
( O O
80 O O
male O O
, O O
72 O O
female O O
, O O
chi O O
2 O O
= O O
0 O O
. O O
21 O O
, O O
p O O
= O O
0 O O
. O O
64 O O
) O O
affected O O
calves B B_PERSON/B_LOCATION
. O O

The O O
largest O B_MEASURE
number O I_MEASURE
of O O
cases O B_PERSON/B_LOCATION
was O O
registered O O
in O O
2006 O B_MEASURE
( O O
Figure O B_LOCATION/B_TIME[MEASURE]
1 O B_LOCATION/I_TIME[MEASURE]
) O O
. O O

In O O
retrospect O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
could O O
be O O
shown O O
that O O
the O O
main O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reason O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
of O O
cases O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
years O B_TIME[MEASURE]/B_LOCATION
2005 O I_TIME[MEASURE]/I_LOCATION
and O O
2006 O B_TIME[MEASURE]
was O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
popularity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
certain O B_PERSON/B_ENT
sires O I_PERSON/I_ENT
carrying O O
the O O
AS O B_DISEASE/B_GENE
mutation O I_DISEASE/I_GENE
( O O
ROMEL O B_LOCATION/B_ORGANIZATION
, O O
ISO O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Nr O B_LOCATION/B_MEASURE
. O O
276000911043667 O B_NUMBER[MEASURE]
, O O
born O O
in O O
1995 O B_MEASURE
; O O
EGEL O B_LOCATION/B_ORGANIZATION
, O O
276000915512806 O B_NUMBER[MEASURE]/B_LOCATION
, O O
1985 O B_MEASURE
; O O
REXON O B_ORGANIZATION/B_LOCATION
, O O
276000913008210 O B_NUMBER[MEASURE]/B_LOCATION
, O O
1989 O B_MEASURE
) O O
. O O

The O O
latter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
two O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
sires O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
represent O O
the O O
key O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
nodes O B_LOCATION/B_PERSON
of O O
the O O
pedigree O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathways O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
from O O
the O O
founder O B_PERSON/B_TIME[MEASURE]
into O O
the O O
current O B_PERSON
population O I_PERSON
( O O
Figure O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
) O O
. O O

ROMEL O O
, O O
for O O
example O O
, O O
sired O O
more O O
than O O
40 O O
, O O
000 O O
cows B B_BIO/B_PERSON
4 O O
to O O
6 O O
years O O
ago O O
. O O

Furthermore O O
, O O
115 O B_PERSON/B_MEASURE
sons O I_PERSON/I_MEASURE
of O O
ROMEL O B_PERSON/B_ORGANIZATION
born O O
from O O
2001 O B_MEASURE
to O O
2005 O B_MEASURE
are O O
registered O O
and O O
listed O O
in O O
the O O
breeding O O
database O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O O
7 O B_MEASURE/B_LOCATION
] O B_MEASURE/I_LOCATION
. O O

These O O
progeny O O
were O O
now O O
mated O O
to O O
ROMEL O O
and O O
sons O O
or O O
grandsons O O
of O O
EGEL O O
and O O
REXON O O
resulting O O
in O O
a O O
high O O
probability O O
for O O
the O O
occurrence O O
of O O
affected O O
calves B B_PERSON/B_BIO
. O O

Increasing O O
awareness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
disease O B_DISEASE/B_PERSON
and O O
abandoning O O
of O O
selling O O
the O O
semen O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
carriers O B_PERSON/B_BIO
led O O
to O O
a O O
sharp O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drop O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cases O B_PERSON/B_DISEASE
in O O
2007 O B_NUMBER[MEASURE]/B_LOCATION
. O O

The O O
disease O B_DISEASE
was O O
successfully O O
managed O O
by O O
efficient O B_PERSON/B_ORGANIZATION
collaboration O I_PERSON/I_ORGANIZATION
of O O
the O O
Institute O B_ORGANIZATION/B_LOCATION
for O O
Animal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Breeding O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Bavarian O B_ORGANIZATION/B_LOCATION
State O I_ORGANIZATION/I_LOCATION
Research O I_ORGANIZATION/I_LOCATION
Centre O I_ORGANIZATION/I_LOCATION
for O O
Agriculture O B_EDU[ORGANIZATION]/B_LOCATION
( O O
LfL O B_LOCATION/B_ORGANIZATION
) O O
, O O
the O O
Landeskuratorium O B_LOCATION/B_ORGANIZATION
der O I_LOCATION/I_ORGANIZATION
Erzeugerringe O I_LOCATION/I_ORGANIZATION
f O O
u O B_EDU[ORGANIZATION]/B_GENE
r O I_EDU[ORGANIZATION]/I_GENE
tierische O I_EDU[ORGANIZATION]/I_GENE
Veredelung O I_EDU[ORGANIZATION]/I_GENE
in O O
Bayern O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
e O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
V O B_OTHER/B_TIME[MEASURE]
( O O
LKV O B_MEASURE/B_LOCATION
) O O
, O O
the O O
Bavarian O B_ORGANIZATION/B_LOCATION
Animal O I_ORGANIZATION/I_LOCATION
Health O I_ORGANIZATION/I_LOCATION
Service O I_ORGANIZATION/I_LOCATION
( O O
TGD O B_DISEASE/B_ORGANIZATION
) O O
and O O
breeding O B_PERSON/B_ORGANIZATION
organizations O I_PERSON/I_ORGANIZATION
. O O

Pathological O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
findings O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE

Calves B B_PERSON
under O O
suspicion O O
of O O
the O O
arachnomelia O O
syndrome O O
were O O
sent O O
to O O
the O O
pathology O O
department O O
of O O
the O O
TGD O O
for O O
macroscopic O O
examination O O
. O O

The O O
observed O B_DISEASE_ADJECTIVE[DISEASE]
major O I_DISEASE_ADJECTIVE[DISEASE]
pathological O I_DISEASE_ADJECTIVE[DISEASE]
findings O I_DISEASE_ADJECTIVE[DISEASE]
were O O
( O O
1 O B_SEQUENCE[MEASURE]/B_PERSON
) O O
facial O B_DISEASE
deformation O I_DISEASE
, O O
including O O
brachygnathia O B_DISEASE_ADJECTIVE[DISEASE]
inferior O I_DISEASE_ADJECTIVE[DISEASE]
and O O
concave O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rounding O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
maxilla O B_BODY_PART_OR_ORGAN_COMPONENT
forming O O
a O O
dent O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
' O O
pointer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
head O B_BODY_PART_OR_ORGAN_COMPONENT
' O O
) O O
; O O
( O O
2 O B_SEQUENCE[MEASURE]
) O O
abnormally O O
thin O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diaphyses O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
long O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bones O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
the O O
outer O B_MEASURE/B_LOCATION
diameter O I_MEASURE/I_LOCATION
of O O
the O O
diaphyses O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
diminished O O
, O O
whereas O O
the O O
width O B_MEASURE/B_LOCATION
of O O
the O O
substantia O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compacta O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
leading O O
to O O
frequent O B_DISEASE
fractures O I_DISEASE
of O O
the O O
metacarpus O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
and O O
metatarsus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
course O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
forced O O
birth O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
assistance O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
' O O
spider O B_BIO/B_DISEASE
- O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
' O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
dolichostenomelia O B_MEASURE/B_BIO
) O O
. O O

The O O
deformations O B_DISEASE_ADJECTIVE[DISEASE]
of O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
bones O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT
were O O
less O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
scapula O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
was O O
usually O O
unaffected O O
; O O
( O O
3 O O
) O O
angular O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deformations O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
distal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
parts O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT
characterized O O
by O O
bilateral O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stiff O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
hyperextended O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fetlocks O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
the O O
extremity O B_LOCATION/B_BIO
of O O
the O O
toe O B_BODY_PART_OR_ORGAN_COMPONENT
forward O O
and O O
parallel O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
trunk O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT
; O O
and O O
( O O
4 O B_NUMBER[MEASURE]
) O O
defects O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
vertebral O B_BODY_PART_OR_ORGAN_COMPONENT
column O I_BODY_PART_OR_ORGAN_COMPONENT
( O O
kyphosis O B_DISEASE
and O O
scoliosis O B_DISEASE
) O O
, O O
but O O
not O O
of O O
the O O
ribs O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
Figure O B_PROTEIN[GENE]/B_DISEASE
3A O I_PROTEIN[GENE]/I_DISEASE
- O O
C O B_MEASURE/B_GENE
) O O
. O O

Additionally O O
, O O
inconsistent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pathological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
included O O
cerebral O B_DISEASE
herniation O I_DISEASE
combined O O
with O O
a O O
malformed O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
foramen O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
magnum O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
microphthalmia O B_DISEASE
, O O
and O O
external O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
internal O B_DISEASE_ADJECTIVE[DISEASE]
hydrocephalus O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
latter O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seem O O
to O O
develop O O
secondarily O O
, O O
due O O
to O O
the O O
enlarged O O
foramen O B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnum O I_BODY_PART_OR_ORGAN_COMPONENT/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Histological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
selected O O
cases O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
the O O
presence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
hemorrhages O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
the O O
osteochondral O B_LOCATION/B_BIO
junction O I_LOCATION/I_BIO
of O O
the O O
epiphysis O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
an O O
abrupt O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transmission O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
chondral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
osteogenic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

Cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
never O O
showed O O
isolated O B_DISEASE_ADJECTIVE[DISEASE]
malformations O I_DISEASE_ADJECTIVE[DISEASE]
, O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
of O O
the O O
head O B_BODY_PART_OR_ORGAN_COMPONENT
or O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
usually O O
a O O
combination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
all O O
pathological O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
syndrome O B_DISEASE/B_PERSON
. O O

Nevertheless O O
, O O
the O O
degree O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
lesions O B_DISEASE_ADJECTIVE[DISEASE]
ranged O O
from O O
obvious O B_PERSON/B_BIO
spider O I_PERSON/I_BIO
- O O
leg O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cases O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
moderate O O
or O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
making O O
a O O
definite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
difficult O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

The O O
latter O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
( O O
3 O B_MEASURE
) O O
were O O
excluded O O
from O O
the O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pedigree O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Meanwhile O O
, O O
an O O
indirect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
gene O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
has O O
been O O
developed O O
at O O
the O O
Institute O B_ORGANIZATION/B_LOCATION
for O O
Animal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Breeding O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Bavarian O B_LOCATION/B_ORGANIZATION
State O B_LOCATION/I_ORGANIZATION
Research O B_LOCATION/I_ORGANIZATION
Centre O B_LOCATION/I_ORGANIZATION
for O O
Agriculture O B_LOCATION/B_DISEASE
( O O
ITZ O B_MEASURE/B_LOCATION
) O O
and O O
it O O
could O O
be O O
shown O O
that O O
these O O
cases O B_PERSON/B_BIO
are O O
most O O
probably O O
not O O
genetically O O
affected O B_DISEASE_ADJECTIVE[DISEASE]
( O O
Buitkamp O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O O
. O O
, O O
in O O
preparation O B_MEASURE
) O O
. O O

Carrier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Two O B_NUMBER[MEASURE]/B_PERSON
criteria O B_NUMBER[MEASURE]/I_PERSON
were O O
used O O
for O O
carrier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
first O O
was O O
the O O
presence O O
of O O
a O O
calf B B_DISEASE
that O O
was O O
diagnosed O O
by O O
pathological O O
investigation O O
. O O

In O O
many O O
cases O O
more O O
than O O
one O O
affected O O
calf B B_BIO/B_PERSON
per O O
sire O O
was O O
identified O O
[ O O
8 O O
] O O
. O O

Some O O
sires O O
had O O
only O O
one O O
affected O O
calf B B_PERSON/B_BIO
, O O
but O O
a O O
large O O
number O O
of O O
risk O O
- O O
matings O O
. O O

In O O
these O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criterion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
risk O B_MEASURE/B_DISEASE
- O O
matings O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
was O O
used O O
to O O
identify O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phenocopies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

For O O
this O O
purpose O O
, O O
the O O
probability O O
of O O
observing O O
only O O
a O O
single O O
affected O O
calf B B_BIO/B_PERSON
among O O
a O O
certain O O
number O O
of O O
risk O O
- O O
matings O O
of O O
the O O
sire O O
in O O
question O O
was O O
calculated O O
. O O

Risk O B_MEASURE/B_LOCATION
- O O
matings O B_PERSON/B_LOCATION
were O O
defined O O
as O O
matings O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
direct O B_PERSON/B_ORGANIZATION
progenies O I_PERSON/I_ORGANIZATION
of O O
identified O O
AS O O
carriers O B_PERSON/B_BIO
. O O

The O O
probability O O
of O O
observing O O
an O O
affected O O
calf B B_BIO/B_PERSON
depends O O
also O O
on O O
the O O
probability O O
that O O
such O O
a O O
calf B B_BIO/B_PERSON
is O O
reported O O
to O O
the O O
LKV O O
. O O

We O O
assumed O O
this O O
probability O B_MEASURE/B_PERSON
to O O
be O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Under O O
these O O
conditions O O
, O O
the O O
probability O O
of O O
observing O O
only O O
one O O
affected O O
calf B B_BIO/B_PERSON
is O O
lower O O
than O O
1 O O
. O O
0 O O
percent O O
, O O
if O O
at O O
least O O
104 O O
risk O O
- O O
matings O O
are O O
given O O
for O O
a O O
single O O
sire O O
. O O

In O O
this O O
case O O
it O O
is O O
very O O
likely O O
that O O
the O O
single O O
affected O O
calf B B_PERSON/B_BIO
is O O
a O O
phenocopy O O
. O O

In O O
2006 O B_MEASURE
and O O
2007 O B_MEASURE
this O O
was O O
the O O
case O B_PERSON/B_MEASURE
for O O
two O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sires O I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
for O O
artificial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
insemination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
that O O
had O O
no O O
pedigree O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
connection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
SEMPER O B_PERSON/B_ORGANISM_FUNCTION
( O O
see O O
below O O
) O O
. O O

Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
matings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
obligate O B_SPECIES[BIO]/B_PERSON
carriers O I_SPECIES[BIO]/I_PERSON

Four O O
out O O
of O O
seven O O
cows B B_BIO/B_PERSON
that O O
were O O
known O O
AS O O
carriers O O
brought O O
to O O
the O O
facilities O O
of O O
the O O
ITZ O O
were O O
used O O
for O O
embryo O O
transfer O O
( O O
Table O O
1 O O
) O O
. O O

33 O B_NUMBER[MEASURE]
of O O
the O O
60 O B_PERSON
recipients O I_PERSON
( O O
55 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
confirmed O O
pregnant O B_PERSON/B_LOCATION
on O O
day O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
35 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Four O B_NUMBER[MEASURE]
of O O
the O O
33 O B_PERSON
pregnant O I_PERSON
heifers O I_PERSON
( O O
12 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
aborted O O
between O O
days O B_TIME[MEASURE]
36 O I_TIME[MEASURE]
and O O
49 O B_MEASURE
of O O
pregnancy O B_TIME[MEASURE]/B_ORGANISM_FUNCTION
. O O

Of O O
the O O
remaining O O
29 O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recipients O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
6 O B_MEASURE
were O O
slaughtered O O
on O O
day O B_TIME[MEASURE]/B_PERSON
150 O I_TIME[MEASURE]/I_PERSON
, O O
6 O B_MEASURE
on O O
day O B_TIME[MEASURE]
200 O I_TIME[MEASURE]
, O O
and O O
17 O B_MEASURE/B_ENT
animals O I_MEASURE/I_ENT
on O O
day O B_TIME[MEASURE]
225 O I_TIME[MEASURE]
of O O
pregnancy O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Table O B_MEASURE
1 O I_MEASURE
) O O
. O O

Four O B_MEASURE/B_ENT
fetuses O I_MEASURE/I_ENT
( O O
three O B_PERSON/B_NUMBER[MEASURE]
male O B_PERSON/I_NUMBER[MEASURE]
and O O
one O B_PERSON
female O I_PERSON
) O O
out O O
of O O
29 O B_NUMBER[MEASURE]
( O O
14 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
showed O O
the O O
typical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pathological O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
arachnomelia O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
described O O
above O O
( O O
Figure O B_PERSON/B_PROTEIN[GENE]
4C O I_PERSON/I_PROTEIN[GENE]
, O O
D O B_OTHER/B_MEASURE
) O O
. O O

All O O
other O B_PERSON/B_NUMBER[MEASURE]
fetuses O I_PERSON/I_NUMBER[MEASURE]
showed O O
no O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
AS O B_DISEASE
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
4A O I_PROTEIN[GENE]/I_LOCATION
, O O
B O B_OTHER/B_MEASURE
) O O
. O O

Male O B_PERSON
fetuses O I_PERSON
represented O O
76 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
22 O B_MEASURE/B_LOCATION
of O O
29 O B_MEASURE/B_PERSON
) O O
of O O
pregnancies O B_PERSON/B_BIO
( O O
chi O B_MEASURE/B_PROTEIN[GENE]
2 O I_MEASURE/I_PROTEIN[GENE]
= O O
3 O B_MEASURE
. O O
123 O B_MEASURE
, O O
p O O
= O O
0 O B_MEASURE
. O O
077 O B_MEASURE
, O O
Yates O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
corrected O O
for O O
sample O B_MEASURE
size O I_MEASURE
< O O
30 O B_MEASURE
) O O
. O O

Female O B_MEASURE/B_LOCATION
weight O I_MEASURE/I_LOCATION
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
, O O
crown O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O O
rump O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
at O O
day O B_TIME[MEASURE]/B_PERSON
225 O I_TIME[MEASURE]/I_PERSON
and O O
chest O B_MEASURE/B_PERSON
circumference O I_MEASURE/I_PERSON
at O O
day O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
225 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
normal O B_PERSON/B_BIO
fetuses O I_PERSON/I_BIO
were O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
of O O
male O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
fetuses O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Fetuses O B_PERSON/B_LOCATION
that O O
were O O
affected O O
by O O
the O O
arachnomelia O B_DISEASE_ADJECTIVE[DISEASE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]
showed O O
lower O B_MEASURE
weight O I_MEASURE
than O O
normal O B_PERSON
fetuses O I_PERSON
. O O

The O O
affected O O
and O O
the O O
normal O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
fetuses O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
had O O
similar O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
crown O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
- O O
rump O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
, O O
but O O
the O O
chest O B_MEASURE
circumference O I_MEASURE
of O O
affected O O
fetuses O B_PERSON/B_LOCATION
was O O
higher O B_TIME[MEASURE]
than O O
that O O
of O O
normal O B_PERSON/B_BIO
fetuses O I_PERSON/I_BIO
( O O
Table O B_MEASURE/B_PERSON
2 O I_MEASURE/I_PERSON
) O O
. O O

Due O O
to O O
the O O
small O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
affected O B_PERSON/B_BIO
female O I_PERSON/I_BIO
fetuses O I_PERSON/I_BIO
, O O
a O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
unaffected O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
sex O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
compare O O
unaffected O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
affected O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
animals O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O O
total O B_MEASURE/B_LOCATION
, O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
analyzed O O
for O O
statistical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
the O O
non O B_PERSON
parametric O I_PERSON
Mann O I_PERSON
- O O
Whitney O B_PERSON/B_ORGANIZATION
- O O
Test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
only O B_MEASURE/B_PERSON
trait O I_MEASURE/I_PERSON
that O O
was O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
unaffected O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
affected O O
fetuses O B_PERSON/B_LOCATION
was O O
the O O
chest O B_MEASURE/B_BIO
circumference O B_MEASURE/I_BIO
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
004 O B_MEASURE
, O O
Table O B_MEASURE
2 O I_MEASURE
) O O
. O O

The O O
body O O
weight O O
of O O
AS O O
affected O O
calves B B_PERSON/B_SPECIES[BIO]
was O O
tendentially O O
lower O O
than O O
that O O
of O O
normal O O
calves B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Since O O
affected O O
calves B B_PERSON/B_BIO
did O O
not O O
have O O
different O O
crown O O
- O O
rump O O
- O O
length O O
and O O
their O O
chest O O
circumference O O
was O O
even O O
higher O O
, O O
this O O
can O O
best O O
be O O
explained O O
by O O
a O O
reduced O O
bone O O
mass O O
. O O

Pedigree O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
mode O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
inheritance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE

Eight O B_SEQUENCE[MEASURE]
- O O
generation O B_SEQUENCE[MEASURE]/B_ORGANIZATION
pedigrees O I_SEQUENCE[MEASURE]/I_ORGANIZATION
of O O
all O O
cases O B_PERSON
were O O
extracted O O
from O O
the O O
joint O B_LOCATION/B_ORGANIZATION
German O I_LOCATION/I_ORGANIZATION
and O O
Austria O B_PERSON/B_ORGANIZATION
pedigree O I_PERSON/I_ORGANIZATION
data O I_PERSON/I_ORGANIZATION
and O O
screened O O
for O O
common O B_DISEASE/B_GENE
ancestors O I_DISEASE/I_GENE
. O O

The O O
pedigree O O
of O O
the O O
majority O O
of O O
affected O O
calves B B_PERSON/B_SPECIES[BIO]
( O O
paternal O O
line O O
150 O O
, O O
maternal O O
line O O
106 O O
out O O
of O O
152 O O
, O O
Table O O
3 O O
) O O
could O O
be O O
traced O O
back O O
to O O
one O O
founder O O
, O O
SEMPER O O
( O O
ISO O O
- O O
Nr O O
. O O
27000979299305 O O
) O O
, O O
a O O
sire O O
born O O
in O O
1964 O O
, O O
6 O O
- O O
9 O O
generations O O
before O O
the O O
affected O O
calves B B_PERSON/B_BIO
were O O
born O O
( O O
Figure O O
2 O O
) O O
. O O

Most O O
of O O
the O O
affected O O
calves B B_PERSON/B_BIO
inherited O O
the O O
AS O O
mutation O O
via O O
REXON O O
or O O
EGEL O O
( O O
Table O O
3 O O
, O O
Figure O O
2 O O
) O O
. O O

In O O
44 O B_PERSON/B_TIME[MEASURE]
cases O I_PERSON/I_TIME[MEASURE]
the O O
maternal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
paths O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
not O O
linked O O
to O O
the O O
common O B_PERSON
pedigree O I_PERSON
( O O
Table O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

One O B_LOCATION/B_PERSON
explanation O B_LOCATION/I_PERSON
would O O
be O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
additional O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
hereto O B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
unknown O I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
origins O I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
mutation O B_DISEASE
. O O

This O O
could O O
happen O O
if O O
the O O
AS O B_GENE/B_DISEASE
mutation O I_GENE/I_DISEASE
is O O
much O O
more O O
ancient O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
additional O B_LOCATION/B_PERSON
pedigree O I_LOCATION/I_PERSON
paths O I_LOCATION/I_PERSON
exist O O
or O O
if O O
an O O
independent O B_DISEASE_ADJECTIVE[DISEASE]
mutation O I_DISEASE_ADJECTIVE[DISEASE]
event O I_DISEASE_ADJECTIVE[DISEASE]
happened O O
leading O O
to O O
the O O
same O B_DISEASE/B_GENE
phenotype O I_DISEASE/I_GENE
. O O

An O O
alternative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
more O O
plausible O B_DISEASE_ADJECTIVE[DISEASE]
explanation O I_DISEASE_ADJECTIVE[DISEASE]
could O O
be O O
the O O
occurrence O B_DISEASE/B_PROTEIN[GENE]
of O O
misparentages O B_DISEASE
. O O

It O O
is O O
well O O
known O O
that O O
in O O
the O O
pre O O
parentage O O
- O O
test O O
era O O
, O O
the O O
frequency O O
of O O
false O O
paternity O O
, O O
especially O O
of O O
the O O
cows B B_BIO/B_PERSON
, O O
was O O
reasonable O O
high O O
( O O
up O O
to O O
23 O O
% O O
[ O O
9 O O
] O O
) O O
. O O

Therefore O O
, O O
there O O
is O O
a O O
good O B_PERSON/B_ENT
chance O I_PERSON/I_ENT
of O O
a O O
false O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
registry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
within O O
6 O B_NUMBER[MEASURE]
- O O
9 O B_TIME[MEASURE]
generations O I_TIME[MEASURE]
. O O

There O O
is O O
strong O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
assumption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
that O O
the O O
AS O B_DISEASE/B_GENE
is O O
regulated O O
by O O
a O O
single O B_MEASURE/B_ORGANIZATION
autosomal O B_MEASURE/I_ORGANIZATION
locus O B_MEASURE/I_ORGANIZATION
acting O O
in O O
a O O
recessive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
manner O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

First O O
of O O
all O O
, O O
the O O
pedigree O O
structure O O
of O O
the O O
affected O O
calves B B_PERSON
in O O
Simmental O O
can O O
best O O
be O O
explained O O
by O O
a O O
recessive O O
mode O O
of O O
inheritance O O
. O O

The O O
paternal O O
branch O O
of O O
the O O
pedigree O O
could O O
be O O
traced O O
back O O
to O O
one O O
sire O O
, O O
SEMPER O O
, O O
for O O
all O O
affected O O
calves B B_PERSON/B_BIO
, O O
the O O
maternal O O
branch O O
in O O
the O O
majority O O
of O O
the O O
cases O O
. O O

Inbreeding O O
loops O O
over O O
a O O
few O O
generations O O
are O O
present O O
in O O
several O O
pedigrees O O
of O O
affected O O
calves B B_PERSON/B_BIO
, O O
e O O
. O O
g O O
. O O
cases O O
P3364 O O
and O O
P1787 O O
( O O
Figure O O
2 O O
) O O
. O O

Sex O B_PERSON/B_LOCATION
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inheritance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
obviously O O
be O O
excluded O O
and O O
a O O
dominant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mode O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
reduced O O
penetrance O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
seems O O
to O O
be O O
unlikely O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Secondly O O
, O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
4 O B_MEASURE
affected O O
and O O
25 O B_PERSON/B_TIME[MEASURE]
unaffected O I_PERSON/I_TIME[MEASURE]
fetuses O I_PERSON/I_TIME[MEASURE]
, O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O O
most O O
closely O O
resembles O O
the O O
expectation O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
recessive O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mode O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
inheritance O B_DISEASE/B_ORGANISM_FUNCTION
. O O

Thirdly O O
, O O
the O O
occurrence O B_DISEASE/B_MEASURE
of O O
cases O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corresponded O O
well O O
with O O
the O O
numbers O B_MEASURE
expected O O
under O O
the O O
assumption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
recessively O O
acting O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

We O O
tested O O
this O O
on O O
the O O
progeny O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ROMEL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
largest O B_MEASURE/B_PERSON
dataset O I_MEASURE/I_PERSON
available O I_MEASURE/I_PERSON
from O O
one O B_LOCATION/B_ORGANIZATION
carrier O I_LOCATION/I_ORGANIZATION
. O O

We O O
analyzed O O
the O O
period O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
beginning O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
recording O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
malformations O B_TIME[MEASURE]
to O O
May O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2007 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
that O O
period O O
44 O O
, O O
170 O O
calves B B_PERSON/B_SPECIES[BIO]
were O O
born O O
that O O
were O O
sired O O
by O O
ROMEL O O
. O O

From O O
these O O
, O O
662 O O
were O O
considered O O
as O O
risk O O
pairings O O
, O O
i O O
. O O
e O O
. O O
the O O
mother O O
had O O
a O O
risk O O
of O O
0 O O
. O O
5 O O
to O O
be O O
a O O
carrier O O
( O O
i O O
. O O
e O O
. O O
one O O
of O O
the O O
grandparents O O
was O O
an O O
obligate O O
carrier O O
) O O
and O O
35 O O
calves B B_PERSON/B_MEASURE
out O O
of O O
these O O
were O O
diagnosed O O
as O O
affected O O
. O O

Since O O
it O O
is O O
expected O O
that O O
about O O
1 O O
/ O O
2 O O
to O O
1 O O
/ O O
3 O O
of O O
the O O
affected O O
calves B B_PERSON/B_SPECIES[BIO]
were O O
recorded O O
, O O
this O O
result O O
is O O
very O O
close O O
to O O
the O O
expected O O
1 O O
: O O
7 O O
ratio O O
of O O
affected O O
to O O
unaffected O O
calves B B_PERSON/B_SPECIES[BIO]
. O O

Moreover O O
, O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
concordant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
historical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
arachnomelia O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndrome O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
Simmental O B_PERSON/B_LOCATION
[ O O
2 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
and O O
the O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cases O B_PERSON/B_DISEASE
in O O
Brown O B_LOCATION/B_PERSON
Swiss O I_LOCATION/I_PERSON
[ O O
5 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Finally O O
, O O
when O O
applying O O
linkage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
microsatellite O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
markers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
evaluations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
a O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assuming O O
recessive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autosomal O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inheritance O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gave O O
the O O
highest O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lod O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Buitkamp O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
in O O
preparation O B_MEASURE
) O O
. O O

Allelic O O
frequency O O
of O O
carriers O O
in O O
the O O
present O O
Simmental O O
cow B B_BIO/B_LOCATION
population O O

Since O O
the O O
arachnomelia O B_DISEASE_ADJECTIVE[DISEASE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]
- O O
allele O B_GENE/B_PERSON
was O O
passed O O
to O O
the O O
current O B_PERSON
population O I_PERSON
through O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
parental O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
lines O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
REXON O B_LOCATION/B_ORGANIZATION
and O O
EGEL O B_LOCATION/B_ORGANIZATION
) O O
and O O
the O O
main O B_GENE/B_ORGANIZATION
carriers O I_GENE/I_ORGANIZATION
are O O
known O O
, O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
estimate O O
the O O
frequency O B_MEASURE/B_LOCATION
of O O
the O O
disease O B_GENE/B_DISEASE
allele O I_GENE/I_DISEASE
by O O
an O O
allele O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
counting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
10 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

The O O
allelic O O
frequency O O
was O O
calculated O O
for O O
all O O
cows B B_BIO/B_PERSON
from O O
the O O
breeding O O
population O O
who O O
were O O
alive O O
in O O
June O O
2007 O O
. O O

In O O
10 O O
. O O
4 O O
percent O O
of O O
the O O
pedigrees O O
of O O
540 O O
, O O
725 O O
cows B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
an O O
identified O O
carrier O O
was O O
found O O
and O O
the O O
probability O O
that O O
individual O O
cows B B_BIO/B_PERSON
were O O
carrier O O
of O O
the O O
arachnomelia O O
syndrome O O
- O O
allele O O
was O O
calculated O O
. O O

E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
g O B_OTHER/B_PROTEIN[GENE]
. O O
in O O
14 O B_MEASURE
, O O
740 O B_MEASURE
and O O
41 O B_MEASURE
, O O
032 O B_MEASURE/B_LOCATION
cases O B_MEASURE/I_LOCATION
a O O
known O B_PERSON/B_BIO
carrier O I_PERSON/I_BIO
appeared O O
as O O
sire O B_PERSON
and O O
grandsire O B_PERSON/B_BIO
, O O
respectively O O
. O O

In O O
these O O
cases O B_PERSON
the O O
probability O B_MEASURE/B_PERSON
of O O
transmitting O O
the O O
allele O B_GENE/B_PERSON
is O O
50 O B_MEASURE
and O O
25 O B_MEASURE
percent O I_MEASURE
, O O
respectively O O
, O O
if O O
no O O
further O B_PERSON/B_MEASURE
carrier O I_PERSON/I_MEASURE
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
two O B_PERSON/B_LOCATION
generation O I_PERSON/I_LOCATION
pedigree O I_PERSON/I_LOCATION
. O O

The O O
averaged O O
rate O O
of O O
the O O
arachnomelia O O
syndrome O O
carriers O O
based O O
on O O
known O O
carriers O O
over O O
all O O
cows B B_BIO/B_PERSON
alive O O
in O O
Bavarian O O
Simmental O O
was O O
3 O O
. O O
32 O O
percent O O
. O O

Using O O
this O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
the O O
frequency O B_MEASURE/B_PERSON
of O O
carriers O B_PERSON/B_LOCATION
was O O
calculated O O
for O O
each O O
year O B_TIME[MEASURE]/B_LOCATION
( O O
always O O
based O O
on O O
the O O
actual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
datasets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
from O O
August O B_TIME[MEASURE]/B_LOCATION
2008 O I_TIME[MEASURE]/I_LOCATION
) O O
from O O
2003 O B_MEASURE
to O O
2008 O B_MEASURE
( O O
Figure O B_TIME[MEASURE]/B_LOCATION
1 O I_TIME[MEASURE]/I_LOCATION
) O O
. O O

The O O
calculations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
done O O
twice O O
, O O
considering O O
all O O
known O O
carriers O B_PERSON/B_MEASURE
together O O
, O O
and O O
also O O
by O O
using O O
only O B_PERSON/B_LOCATION
ROMEL O I_PERSON/I_LOCATION
as O O
a O O
carrier O B_PERSON
to O O
show O O
the O O
numeric O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contribution O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
his O O
progeny O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
Figure O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
) O O
. O O

For O O
these O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
sires O B_PERSON/B_BIO
that O O
are O O
designated O O
to O O
be O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
carriers O B_PERSON
by O O
the O O
number O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
risk O B_PERSON
pairings O I_PERSON
without O O
having O O
a O O
case O B_PERSON/B_MEASURE
or O O
the O O
indirect O B_PERSON/B_MEASURE
gene O I_PERSON/I_MEASURE
test O I_PERSON/I_MEASURE
are O O
set O O
as O O
non O B_DISEASE/B_MEASURE
- O O
carrier O B_PERSON/B_LOCATION
. O O

Therefore O O
, O O
these O O
frequencies O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
slightly O O
lower O B_MEASURE
than O O
the O O
initial O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
estimate O I_MEASURE/I_LOCATION
of O O
3 O B_MEASURE
. O O
32 O B_MEASURE/B_PERSON
percent O I_MEASURE/I_PERSON
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

The O O
cases O O
of O O
malformed O O
Simmental O O
calves B B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
here O O
showed O O
the O O
same O O
morphology O O
described O O
in O O
the O O
arachnomelia O O
syndrome O O
in O O
Brown O O
Swiss O O
[ O O
e O O
. O O
g O O
. O O
[ O O
3 O O
] O O
] O O
, O O
even O O
though O O
there O O
is O O
a O O
certain O O
morphological O O
variation O O
from O O
mild O O
to O O
severe O O
malformations O O
. O O

The O O
main O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
brachygnathia O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
inferior O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
convex O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
frontal O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
bone O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
face O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
deformation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
vertebrae O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
dysplasia O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
limbs O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
namely O O
the O O
diaphyses O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
metatarsus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
- O O
carpus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
fetlocks O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O O
can O O
best O O
be O O
explained O O
by O O
irregularly O O
developed O O
bone O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
structure O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
at O O
the O O
corresponding O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
locations O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O O

Without O O
pathological O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
examination O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
it O O
is O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
distinguish O O
the O O
arachnomelia O B_DISEASE/B_MEASURE
syndrome O I_DISEASE/I_MEASURE
from O O
other O B_DISEASE
malformations O I_DISEASE
of O O
the O O
limbs O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Therefore O O
, O O
low O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
numbers O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cases O B_PERSON/B_LOCATION
in O O
Simmental O B_LOCATION
probably O O
passed O O
unrecognized O B_DISEASE/B_MEASURE
before O O
2005 O B_TIME[MEASURE]/B_LOCATION
. O O

In O O
that O O
year O O
the O O
allelic O O
frequency O O
of O O
the O O
disease O O
in O O
the O O
cow B B_BIO/B_PERSON
population O O
increased O O
sharply O O
because O O
some O O
sires O O
that O O
had O O
been O O
carriers O O
of O O
the O O
mutation O O
had O O
become O O
very O O
popular O O
2 O O
- O O
4 O O
years O O
before O O
. O O

The O O
identification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
a O O
common O B_PERSON/B_BIO
ancestor O I_PERSON/I_BIO
, O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
matings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
the O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
numbers O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cases O B_PERSON/B_BIO
from O O
risk O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matings O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strongly O O
support O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
an O O
autosomal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
recessively O O
inherited O O
disease O B_DISEASE/B_GENE
. O O

Furthermore O O
, O O
this O O
assumption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
concordant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
historical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
syndrome O B_DISEASE
in O O
Simmental O B_PERSON/B_LOCATION
and O O
Brown O B_PERSON/B_LOCATION
Swiss O I_PERSON/I_LOCATION
. O O

The O O
allelic O B_MEASURE
frequency O I_MEASURE
of O O
the O O
arachnomelia O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
current O B_PERSON/B_LOCATION
population O I_PERSON/I_LOCATION
is O O
well O O
above O O
3 O B_MEASURE/B_LOCATION
percent O I_MEASURE/I_LOCATION
and O O
a O O
substantial O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
progeny O B_PERSON/B_BIO
from O O
known O O
carriers O B_PERSON/B_BIO
with O O
superior O B_DISEASE/B_GENE
genetic O I_DISEASE/I_GENE
merit O I_DISEASE/I_GENE
shall O O
be O O
used O O
as O O
sires O B_PERSON
during O O
the O O
next O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
years O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O O

Therefore O O
, O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
has O O
to O O
be O O
established O O
and O O
the O O
arachnomelia O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O O
gene O B_GENE/B_DISEASE
should O O
be O O
mapped O O
as O O
a O O
prerequisite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
an O O
indirect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
gene O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
carrier O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
availability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
pathologically O O
well O O
characterized O O
cases O B_PERSON/B_BIO
from O O
the O O
field O B_LOCATION/B_PERSON
and O O
from O O
the O O
ET O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
generated O O
full O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
sib O B_PERSON/B_MEASURE
families O B_PERSON/I_MEASURE
will O O
be O O
an O O
excellent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
material O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O O
a O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mapping O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Recording O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
for O O
congenital O B_ENT
malformations O I_ENT

A O O
system O O
for O O
monitoring O O
inherited O O
congenital O O
malformations O O
in O O
Bavarian O O
cattle B B_SPECIES[BIO]
populations O O
was O O
established O O
by O O
the O O
Institute O O
for O O
Animal O O
Breeding O O
of O O
the O O
Bavarian O O
State O O
Research O O
Centre O O
for O O
Agriculture O O
( O O
ITZ O O
) O O
in O O
cooperation O O
with O O
the O O
Bavarian O O
milk O O
recording O O
organization O O
( O O
LKV O O
) O O
[ O O
11 O O
] O O
. O O

In O O
short O O
, O O
a O O
questionnaire O O
was O O
developed O O
for O O
detailed O O
recording O O
of O O
malformed O O
calves B B_PERSON/B_BIO
. O O

The O O
malformation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
described O O
according O O
to O O
its O O
location O B_LOCATION/B_MEASURE
( O O
e O B_DISEASE/B_PROTEIN[GENE]
. O O
g O B_PROTEIN[GENE]/B_MEASURE
. O O
head O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
legs O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
its O O
characteristics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
e O B_PROTEIN[GENE]/B_DISEASE
. O O
g O B_PROTEIN[GENE]/B_MEASURE
. O O
hernia O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
) O O
. O O

The O O
standardized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
stored O O
in O O
a O O
database O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O O
the O O
LKV O B_LOCATION/B_PERSON
, O O
that O O
is O O
evaluated O O
monthly O O
for O O
a O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
background O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
malformations O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sires O O
that O O
fit O O
into O O
the O O
pedigree O O
( O O
progeny O O
of O O
REXON O O
or O O
EGEL O O
) O O
with O O
at O O
least O O
one O O
affected O O
calf B B_BIO/B_PERSON
with O O
confirmed O O
paternity O O
were O O
defined O O
as O O
obligate O O
carriers O O
and O O
marked O O
in O O
the O O
breeding O O
information O O
system O O
[ O O
7 O O
] O O
. O O

In O O
cases O O
without O O
connection O O
to O O
the O O
pedigree O O
and O O
only O O
one O O
recorded O O
calf B B_PERSON/B_BIO
the O O
number O O
of O O
" O O
risk O O
pairings O O
" O O
( O O
matings O O
to O O
cows B B_BIO/B_PERSON
where O O
at O O
least O O
one O O
parent O O
is O O
a O O
known O O
carrier O O
, O O
enabling O O
the O O
calculation O O
of O O
the O O
probability O O
for O O
the O O
occurrence O O
of O O
cases O O
) O O
was O O
calculated O O
. O O

When O O
the O O
probability O B_MEASURE/B_PERSON
that O O
a O O
case O B_PERSON/B_DISEASE
occurs O O
was O O
above O O
99 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
for O O
the O O
sire O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
question O B_LOCATION/B_BIO
the O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
considered O O
to O O
be O O
a O O
phenocopy O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

The O O
number O O
of O O
calves B B_PERSON/B_BIO
affected O O
by O O
the O O
arachnomelia O O
syndrome O O
and O O
their O O
parentage O O
is O O
routinely O O
published O O
[ O O
8 O O
] O O
. O O

Pathological O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
examinations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE

Pathological O B_PERSON
examinations O I_PERSON
followed O O
standard O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
procedures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
. O O

Calves B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
photographed O O
and O O
size O O
and O O
weight O O
measurements O O
were O O
recorded O O
. O O

Tissue O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
condyle O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
epiphysis O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
) O O
and O O
from O O
the O O
diaphysis O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
femur O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O O
collected O O
for O O
histological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Specimens O B_BIO/B_PERSON
were O O
fixed O O
in O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formalin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
kept O O
in O O
a O O
decalcifying O O
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ossafixonafor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
for O O
24 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thereafter O O
, O O
specimens O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
processed O O
in O O
an O O
automated O O
embedding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
sectioned O O
at O O
4 O B_MEASURE
- O O
6 O B_MEASURE
microns O I_MEASURE
and O O
finally O O
stained O O
with O O
haematoxyline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
eosin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
embryo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Known O O
carriers O O
of O O
the O O
arachnomelia O O
syndrome O O
( O O
seven O O
cows B B_BIO/B_PERSON
that O O
had O O
produced O O
at O O
least O O
one O O
affected O O
calf B B_BIO/B_PERSON
) O O
were O O
brought O O
to O O
the O O
facilities O O
of O O
the O O
ITZ O O
for O O
embryo O O
transfer O O
( O O
Table O O
1 O O
) O O
. O O

Late O O
morulae O O
and O O
blastocysts O O
collected O O
on O O
day O O
7 O O
( O O
day O O
0 O O
= O O
estrus O O
) O O
from O O
superovulated O O
donor O O
cows B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
nonsurgically O O
transferred O O
to O O
heifers O O
[ O O
12 O O
] O O
. O O

Mode O B_MEASURE/B_DISEASE
of O O
inheritance O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
allele O B_MEASURE/B_PERSON
frequency O B_MEASURE/I_PERSON

The O O
pedigree O B_PERSON/B_MEASURE
of O O
all O O
cases O B_PERSON/B_BIO
was O O
constructed O O
from O O
the O O
pedigree O B_PERSON/B_BIO
that O O
is O O
used O O
for O O
the O O
joint O B_PERSON/B_LOCATION
breeding O B_PERSON/I_LOCATION
evaluation O B_PERSON/I_LOCATION
of O O
Germany O B_LOCATION
and O O
Austria O B_LOCATION
. O O

The O O
graphical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
presentation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
the O O
pedigree O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
with O O
the O O
Pedigraph O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
TM O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O O
13 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
allelic O O
frequency O O
of O O
the O O
AS O O
mutation O O
in O O
the O O
current O O
cow B B_BIO/B_LOCATION
population O O
was O O
estimated O O
from O O
ancestors O O
with O O
known O O
genotypes O O
following O O
the O O
allele O O
- O O
counting O O
method O O
[ O O
10 O O
] O O
. O O

For O O
this O O
reason O O
two O O
generation O O
pedigrees O O
of O O
herd O O
book O O
cows B B_BIO/B_PERSON
in O O
Bavarian O O
Simmental O O
were O O
analyzed O O
for O O
obligate O O
carriers O O
. O O

We O O
considered O O
all O O
cows B B_BIO/B_PERSON
that O O
were O O
alive O O
in O O
June O O
2007 O O
and O O
included O O
in O O
the O O
herd O O
book O O
. O O

All O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
bred O O
by O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
artificial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
insemination O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
non O B_PERSON/B_LOCATION
parametric O I_PERSON/I_LOCATION
Mann O I_PERSON/I_LOCATION
- O O
Whitney O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
performed O O
using O O
SPSS O B_MEASURE
Version O I_MEASURE
14 O I_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
, O O
the O O
Chi O B_PERSON/B_NUMBER[MEASURE]
- O O
square O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
performed O O
using O O
R O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
4 O B_MEASURE
. O O
0 O B_MEASURE
[ O I_MEASURE
14 O I_MEASURE
] O I_MEASURE
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

JB O B_PERSON
drafted O O
the O O
manuscript O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
analyzed O O
the O O
pedigrees O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

BL O B_PERSON
conceived O O
the O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
inherited O O
diseases O B_DISEASE/B_GENE
. O O

RE O B_PERSON
extracted O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
the O O
database O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
estimated O O
the O O
allelic O B_MEASURE
frequencies O I_MEASURE
of O O
the O O
arachnomelia O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

HR O B_LOCATION/B_ORGANIZATION
and O O
MW O B_MEASURE/B_LOCATION
performed O O
the O O
embryo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
transfer O O
and O O
recorded O O
the O O
morpho O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
metrical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
experimental O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
matings O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

BS O O
examined O O
the O O
calves B B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathologically O O
. O O

NM O B_MEASURE/B_LOCATION
and O O
KG O B_MEASURE/B_LOCATION
participated O O
in O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
coordination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
critically O O
revised O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
authors O B_PERSON/B_NUMBER[MEASURE]
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

Suggestions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Concerning O O
the O O
Use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
Subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
which O O
Arises O O
from O O
the O O
Aorta O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
the O O
Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
Tetralogy O B_DISEASE_ADJECTIVE[DISEASE]
of O O
Fallot O B_LOCATION/B_PERSON
* O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Images O B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

SUGGESTIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CONCERNING O O
THE O O
USE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
OF O O
THE O O
SUBCLAVIAN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION

WHICH O O
ARISES O O
FROM O O
THE O O
AORTA O B_DISEASE/B_ORGANIZATION
IN O O
THE O O
TREATMENT O B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

OF O O
THE O O
TETRALOGY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
OF O O
FALLOT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
* O O

HARRIS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
B O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

SHUMACKER O B_PERSON/B_LOCATION
, O O
JR O B_LOCATION/B_PERSON
. O O
* O O
* O O

In O O
Blalock O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
early O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
experience O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
the O O
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
the O O
tetralogy O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
Fallot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
two O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
subclavian O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
the O O
innominate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
carotid O B_BODY_PART_OR_ORGAN_COMPONENT/B_NUMBER[MEASURE]
arteries O I_BODY_PART_OR_ORGAN_COMPONENT/I_NUMBER[MEASURE]
were O O
all O O
used O O
for O O
anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Soon O O
, O O
however O O
, O O
it O O
became O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
innominate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
carotid O B_LOCATION
was O O
followed O O
by O O
a O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
complications O B_DISEASE
resulting O O
from O O
cerebral O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Blalock O B_PERSON
suggested O O
, O O
therefore O O
, O O
that O O
the O O
subclavian O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
be O O
used O O
by O O
preference O B_PERSON/B_TIME[MEASURE]
. O O

The O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
branch O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
innominate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
become O O
kinked O O
or O O
badly O O
angulated O O
when O O
it O O
is O O
turned O O
down O O
for O O
the O O
anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
a O O
good O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functional O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
result O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
almost O O
invariably O O
follows O O
the O O
completion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
a O O
satisfactory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anastomosis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
which O O
arises O O
directly O O
from O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
on O O
the O O
other O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
hand O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
tends O O
to O O
form O O
a O O
bad O B_DISEASE/B_LOCATION
angle O B_DISEASE/I_LOCATION
when O O
it O O
is O O
brought O O
down O O
for O O
the O O
anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
, O O
and O O
, O O
indeed O O
, O O
near O O
its O O
point O B_LOCATION/B_MEASURE
of O O
origin O B_DISEASE/B_LOCATION
it O O
may O O
be O O
so O O
flattened O O
out O O
against O O
the O O
relatively O O
rigid O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aortic O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
to O O
obstruct O O
all O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
it O O
. O O

These O O
considerations O O
led O O
Blalock O O
to O O
recommend O O
the O O
use O O
of O O
the O O
former O O
except O O
in O O
infants B B_PERSON
under O O
two O O
years O O
of O O
age O O
in O O
whom O O
this O O
artery O O
may O O
be O O
too O O
small O O
and O O
in O O
adults O O
or O O
children B B_PERSON
over O O
twelve O O
years O O
old O O
or O O
five O O
feet O O
tall O O
with O O
a O O
left O O
aortic O O
arch O O
in O O
whom O O
it O O
is O O
often O O
too O O
short O O
to O O
permit O O
a O O
satisfactory O O
anastomosis O O
. O O
7 O O
' O O

In O O
contrast O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Paine O B_PERSON
and O O
Varco O B_PERSON
, O O
' O O
Lam O B_PERSON/B_NUMBER[MEASURE]
, O O
6 O B_MEASURE/B_PERSON
Holman O I_MEASURE/I_PERSON
, O O
' O O
Olim O B_MEASURE/B_PERSON
, O O
7 O B_TIME[MEASURE]/B_PERSON
and O O
others O B_SEQUENCE[MEASURE]
have O O
preferred O O
to O O
use O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
which O O
arises O O
from O O
the O O
aorta O B_DISEASE/B_BIO
and O O
have O O
obtained O O
generally O O
excellent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

They O O
point O O
out O O
that O O
the O O
tendency O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
kinking O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
artery O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
more O O
a O O
theoretical O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
a O O
practical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
disadvantage O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
that O O
the O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
dissection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
both O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
are O O
easier O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
the O O
side O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
aortic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
arch O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
that O O
both O O
vessels O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O O
generally O O
longer O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
on O O
the O O
opposite O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
side O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
and O O
that O O
, O O
as O O
a O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rule O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
be O O
accomplished O O
more O O
readily O O
. O O

The O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
third O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
systemic O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
vessel O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
namely O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
was O O
demonstrated O O
by O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
technique O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
to O O
- O O
side O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
aortic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
pulmonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
by O O
Potts O B_PERSON
and O O
his O O
associates O B_PERSON/B_ORGANIZATION
. O O
" O O
0 O B_NUMBER[MEASURE]
In O O
spite O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
preferences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
held O O
by O O
individual O B_PERSON
operators O I_PERSON
for O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
one O B_NUMBER[MEASURE]/B_PERSON
vessel O B_NUMBER[MEASURE]/I_PERSON
or O O
another O O
, O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
remains O O
, O O
as O O
Blalock O B_PERSON
has O O
emphasized O O
, O O
that O O
there O O
is O O
always O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
a O O
usable O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
systemic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
vessel O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
provided O O
a O O
suitable O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
pulmonary O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
artery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nevertheless O O
, O O
the O O
choice O O
of O O
the O O
systemic O O
artery O O
in O O
each O O
individual O O
patient B B_PERSON/B_LOCATION
is O O
important O O
since O O
in O O
certain O O
cases O O
one O O
or O O
another O O
is O O
unsuitable O O
. O O

* O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
From O O
the O O
Department O B_ORGANIZATION/B_LOCATION
of O O
Surgery O B_EDU[ORGANIZATION]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
the O O
Indiana O B_LOCATION/B_ORGANIZATION
University O I_LOCATION/I_ORGANIZATION
Medical O I_LOCATION/I_ORGANIZATION
Center O I_LOCATION/I_ORGANIZATION
, O O
Indianapolis O B_LOCATION/B_PERSON
, O O
Indiana O B_LOCATION
. O O

Aided O O
by O O
a O O
contract O B_ORGANIZATION/B_PERSON
between O O
the O O
Office O B_ORGANIZATION/B_LOCATION
of O O
Naval O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Research O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Department O B_ORGANIZATION/B_LOCATION
of O O
the O O
Navy O B_ORGANIZATION/B_LOCATION
, O O
and O O
Indiana O B_ORGANIZATION/B_LOCATION
University O I_ORGANIZATION/I_LOCATION
. O O

* O B_PERSON
* O I_PERSON
Resident O I_PERSON
Surgeon O I_PERSON
, O O
New O B_LOCATION
Haven O I_LOCATION
Hospital O I_LOCATION
, O O
1937 O B_MEASURE
- O O
1938 O B_MEASURE
. O O

Received O O
for O O
publication O B_TIME[MEASURE]/B_PERSON
April O I_TIME[MEASURE]/I_PERSON
26 O I_TIME[MEASURE]/I_PERSON
, O O
1951 O B_MEASURE
. O O

TREATMENT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
OF O O
TETRALOGY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
OF O O
FALLOT O B_PERSON/B_LOCATION

It O O
has O O
been O O
my O O
custom O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
follow O O
a O O
policy O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rather O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
outlined O O
by O O
Blalock O B_PERSON
. O O

The O O
subclavian O O
branch O O
of O O
the O O
innominate O O
has O O
generally O O
been O O
preferred O O
in O O
patients B B_PERSON/B_BIO
ranging O O
between O O
two O O
and O O
twelve O O
years O O
of O O
age O O
and O O
in O O
older O O
individuals O O
in O O
whom O O
there O O
is O O
a O O
right O O
aortic O O
arch O O
. O O

In O O
others O B_PERSON
the O O
thoracotomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
usually O O
made O O
on O O
the O O
side O B_LOCATION/B_MEASURE
of O O
the O O
aortic O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arch O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
either O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
itself O O
or O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
arising O O
from O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
used O O
for O O
the O O
anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

My O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
originating O B_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
is O O
small O B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
not O O
been O O
as O O
good O B_DISEASE_ADJECTIVE[DISEASE]
as O O
those O O
which O O
others O B_PERSON
have O O
reported O O
. O O

One O O
eighteen O O
- O O
month O O
- O O
old O O
child B B_PERSON
died O O
the O O
day O O
after O O
operation O O
and O O
was O O
found O O
at O O
post O O
- O O
mortem O O
examination O O
to O O
have O O
an O O
occluded O O
anastomosis O O
. O O

In O O
one O O
three O O
- O O
year O O
- O O
old O O
child B B_PERSON
and O O
one O O
twenty O O
- O O
year O O
- O O
old O O
woman B B_PERSON
a O O
poor O O
result O O
was O O
obtained O O
and O O
a O O
second O O
operation O O
upon O O
the O O
other O O
side O O
was O O
necessary O O
. O O

In O O
two O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
additional O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
only O O
fair O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Excluding O O
the O O
patients B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mentioned O O
in O O
the O O
present O O
report O O
, O O
only O O
in O O
two O O
was O O
an O O
unquestionably O O
good O O
result O O
obtained O O
. O O

Recently O O
, O O
in O O
several O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
failure O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seemed O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
modification O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
been O O
required O O
in O O
order O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
obtain O O
a O O
functioning O O
shunt O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Since O O
these O O
modifications O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
proved O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
since O O
these O O
threats O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
failure O B_PERSON
tax O I_PERSON
one O I_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ingenuiity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O O
the O O
time O B_MEASURE/B_LOCATION
of O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
I O O
have O O
thought O O
it O O
might O O
be O O
helpful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
describe O O
the O O
procedures O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
employed O O
and O O
to O O
illustrate O O
them O O
with O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

One O B_NUMBER[MEASURE]/B_PERSON
is O O
a O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
obviously O O
has O O
very O O
limited O B_DISEASE_ADJECTIVE[DISEASE]
applicability O I_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
the O O
otlher O B_PERSON/B_SEQUENCE[MEASURE]
would O O
seem O O
to O O
be O O
rather O O
generally O O
applicable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
first O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
consists O O
of O O
the O O
transplantation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
origin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
to O O
a O O
more O O
suitable O B_LOCATION/B_MEASURE
portion O I_LOCATION/I_MEASURE
of O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

The O O
patient B B_PERSON
was O O
a O O
19 O O
- O O
year O O
- O O
old O O
girl B B_PERSON
who O O
had O O
been O O
cyanotic O O
since O O
the O O
age O O
of O O
six O O
months O O
. O O

She O O
had O O
developed O O
normally O O
but O O
was O O
always O O
limited O O
in O O
exercise O B_MEASURE
capacity O I_MEASURE
. O O

In O O
her O O
early O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
school O B_LOCATION/B_PERSON
she O O
was O O
taken O O
to O O
school O B_LOCATION
by O O
her O O
parents O B_PERSON
and O O
carried O O
to O O
and O O
from O O
her O O
seat O B_LOCATION/B_PERSON
in O O
the O O
classroom O B_LOCATION
. O O

She O O
did O O
reasonably O O
well O O
in O O
high O B_LOCATION/B_ORGANIZATION
school O I_LOCATION/I_ORGANIZATION
, O O
being O O
driven O O
to O O
and O O
from O O
the O O
school O B_LOCATION
, O O
but O O
she O O
got O O
into O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
difficulty O I_DISEASE_ADJECTIVE[DISEASE]
when O O
she O O
attempted O O
to O O
attend O O
college O B_LOCATION/B_PERSON
. O O

The O O
longer O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distances O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
classes O B_PERSON/B_LOCATION
and O O
the O O
necessity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
climbing O O
stairs O B_LOCATION/B_TIME[MEASURE]
precipitated O O
a O O
downhill O B_DISEASE_ADJECTIVE[DISEASE]
course O I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
increasing O O
dyspnea O B_DISEASE/B_MEASURE
, O O
more O O
marked O B_DISEASE
cyanosis O I_DISEASE
and O O
fatigue O B_DISEASE
, O O
and O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
bouts O B_DISEASE
of O O
loss O B_DISEASE_ADJECTIVE[DISEASE]
of O O
consciousness O B_DISEASE
. O O

The O O
latter O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
occurred O O
several O B_MEASURE/B_LOCATION
times O I_MEASURE/I_LOCATION
daily O O
. O O

One O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
which O O
was O O
witnessed O O
by O O
her O O
physician O B_PERSON
lasted O O
45 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
; O O
he O O
feared O O
it O O
would O O
prove O O
fatal O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Ordinarily O O
, O O
she O O
could O O
not O O
walk O O
more O B_MEASURE
than O O
half O O
a O O
block O B_LOCATION/B_TIME[MEASURE]
. O O

There O O
was O O
marked O O
cyanosis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
nails O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
mucous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membranes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
a O O
lesser O B_DISEASE
extent O I_DISEASE
of O O
the O O
skin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Clubbing O B_DISEASE/B_PERSON
was O O
very O O
prominent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
physical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fitted O O
in O O
with O O
a O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tetralogy O B_DISEASE/B_LOCATION
of O O
Fallot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
hematocrit O B_MEASURE
ranged O O
between O O
83 O B_MEASURE
and O O
90 O B_MEASURE
. O O

Oxygen O B_MEASURE
saturation O I_MEASURE
of O O
arterial O B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_BODY_PART_OR_ORGAN_COMPONENT/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
65 O B_MEASURE
per O O
cent O B_MEASURE
at O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
rest O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O

The O O
aortic O B_LOCATION
arch O I_LOCATION
was O O
on O O
the O O
left O B_LOCATION
side O I_LOCATION
. O O

On O O
October O B_TIME[MEASURE]
26 O I_TIME[MEASURE]
, O O
1949 O B_MEASURE
a O O
left O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lateral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thoracotomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
performed O O
, O O
the O O
pleural O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cavity O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
being O O
entered O O
through O O
the O O
bed O B_LOCATION/B_MEASURE
of O O
the O O
fifth O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
rib O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

There O O
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
greatly O O
increased O O
collateral O B_DISEASE/B_MEASURE
circulation O B_DISEASE/I_MEASURE
in O O
the O O
mediastinum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
hilum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
appeared O O
to O O
have O O
markedly O O
reduced O O
blood O B_MEASURE/B_LOCATION
flow O I_MEASURE/I_LOCATION
, O O
was O O
very O O
short O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
and O O
thin O B_MEASURE
- O O
walled O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Its O O
diameter O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
less O B_MEASURE
than O O
5 O B_MEASURE/B_LOCATION
mm O I_MEASURE/I_LOCATION
. O O

The O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
seemed O O
to O O
be O O
bowed O O
out O O
laterally O O
in O O
an O O
unusual O B_PERSON/B_LOCATION
fashion O I_PERSON/I_LOCATION
and O O
the O O
short O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pulmonary O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O O
not O O
possibly O O
be O O
brought O O
out O O
over O O
it O O
. O O

The O O
subclavian O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
relatively O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
having O O

487 O B_NUMBER[MEASURE]

YALE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
JOURNAL O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
OF O O
BIOLOGY O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O O
MEDICINE O B_EDU[ORGANIZATION]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

a O O
diameter O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
only O O
about O O
4 O B_NUMBER[MEASURE]
mm O I_NUMBER[MEASURE]
. O O
but O O
it O O
seemed O O
rather O O
long O O
. O O

It O O
was O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
a O O
Pott O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
s O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
impossible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
that O O
an O O
end O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
to O O
- O O
side O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subclavian O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
anastomosis O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
would O O
be O O
doomed O O
to O O
failure O O
. O O

Hence O O
, O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O O
divided O O
at O O
the O O
level O B_TIME[MEASURE]/B_LOCATION
of O O
its O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
branch O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
divided O O
proximally O O
, O O
and O O
an O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
to O O
- O O
end O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
subclavian O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O O
pulmonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
anastomosis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
carried O O
out O O
. O O

This O O
was O O
done O O
with O O
ease O B_PERSON
. O O

When O O
the O O
clamps O B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
were O O
removed O O
, O O
however O O
, O O
no O O
blood O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
flowed O O
through O O
it O O
. O O

The O O
softwalled O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
subclavian O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
completely O O
flattened O O
out O O
against O O
the O O
relatively O O
rigid O B_LOCATION/B_MEASURE
aorta O I_LOCATION/I_MEASURE
( O O
Fig O B_MEASURE/B_LOCATION
. O O
1 O B_NUMBER[MEASURE]
) O O
. O O

When O O
the O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
structures O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
were O O
forcibly O O
elevated O O
in O O
a O O
cephalad O B_LOCATION/B_ORGANIZATION
direction O I_LOCATION/I_ORGANIZATION
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
immediately O O
filled O O
and O O
pulsated O O
normally O O
and O O
a O O
thrill O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O O
be O O
felt O O
. O O

Simple O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
expansion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
lungs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
however O O
, O O
failed O O
to O O
achieve O O
this O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
I O O
could O O
conceive O O
of O O
no O O
way O B_LOCATION/B_PERSON
in O O
which O O
the O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
could O O
be O O
held O O
in O O
a O O
more O O
cephalad O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
direction O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT
was O O
then O O
ligated O O
at O O
the O O
point O B_LOCATION/B_MEASURE
where O O
it O O
came O O
off O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
its O O
proximal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
end O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
was O O
anastomosed O O
end O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
to O O
- O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
to O O
the O O
descending O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

It O O
now O O
pulsated O O
vigorously O O
as O O
did O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O O

In O O
spite O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
good O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
pulsation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
no O O
thrill O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
palpable O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
patient B B_PERSON/B_LOCATION
had O O
an O O
uneventful O O
but O O
disappointing O O
convalescence O O
. O O

She O O
remained O O
markedly O O
cyanotic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O O
no O O
continuous O B_DISEASE
bruit O I_DISEASE
was O O
audible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
she O O
left O O
the O O
hospital O B_LOCATION/B_MEASURE
14 O I_LOCATION/I_MEASURE
days O I_LOCATION/I_MEASURE
after O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
there O O
was O O
no O O
improvement O B_DISEASE_ADJECTIVE[DISEASE]
in O O
her O O
appearance O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
hematocrit O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
or O O
arterial O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Surprisingly O O
enough O O
she O O
reported O O
progress O B_DISEASE
on O O
each O O
follow O O
- O O
up O O
examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

By O O
the O O
end O B_LOCATION/B_MEASURE
of O O
seven O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
she O O
was O O
obviously O O
less O O
cyanotic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O O
her O O
hematocrit O B_MEASURE/B_DISEASE
was O O
77 O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
she O O
was O O
able O B_TIME[MEASURE]/B_PERSON
to O O
walk O O
a O O
number O B_MEASURE/B_PERSON
of O O
blocks O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
to O O
climb O O
a O O
flight O B_LOCATION/B_PRODUCT[OBJECT]
of O O
stairs O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
without O O
difficulty O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
reported O O
that O O
she O O
had O O
danced O O
and O O
roller O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
skated O O
without O O
much O B_DISEASE
trouble O I_DISEASE
. O O

Shortly O O
thereafter O O
a O O
continuous O B_DISEASE/B_MEASURE
murmur O I_DISEASE/I_MEASURE
was O O
audible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
left O B_LOCATION
chest O I_LOCATION
. O O

She O O
continued O O
to O O
improve O O
and O O
in O O
January O B_TIME[MEASURE]
entered O O
a O O
southern O B_LOCATION
college O I_LOCATION
. O O

She O B_PERSON
did O O
well O O
. O O

At O O
least O O
once O O
a O O
day O B_TIME[MEASURE]
, O O
often O O
twice O O
, O O
she O O
walked O O
without O O
difficulty O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
the O O
campus O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
into O O
town O B_LOCATION
and O O
back O O
, O O
a O O
distance O B_MEASURE/B_LOCATION
of O O
ten O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
blocks O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
each O O
way O B_LOCATION/B_TIME[MEASURE]
. O O

She O O
played O O
a O O
little O B_ENT
tennis O I_ENT
, O O
learned O O
to O O
swim O O
, O O
and O O
began O O
to O O
dance O O
, O O
including O O
jitterbugging O B_ENT/B_PERSON
. O O

When O O
she O O
xvas O O
seen O O
in O O
June O B_TIME[MEASURE]/B_ENT
, O O
her O O
color O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
although O O
there O O
was O O
still O O
slight O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cyanosis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
lips O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
nail O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
beds O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
was O O
a O O
very O O
loud O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
continuous O B_DISEASE
murmur O I_DISEASE
in O O
the O O
left O B_LOCATION
chest O I_LOCATION
. O O

The O O
following O B_TIME[MEASURE]/B_ENT
fall O I_TIME[MEASURE]/I_ENT
she O O
transferred O O
to O O
a O O
midwestern O B_LOCATION/B_PERSON
university O I_LOCATION/I_PERSON
. O O

She O O
got O O
along O O
reasonably O O
well O O
but O O
not O O
as O O
well O O
as O O
she O O
had O O
in O O
a O O
warmer O B_LOCATION
climate O I_LOCATION
and O O
on O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
terrain O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

She O O
walked O O
four O B_NUMBER[MEASURE]
or O O
five O B_NUMBER[MEASURE]
blocks O I_NUMBER[MEASURE]
up O O
and O O
down O O
hills O B_LOCATION/B_TIME[MEASURE]
between O O
classes O B_PERSON/B_LOCATION
without O O
difficulty O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
weather O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
but O O
complained O O
of O O
some O O
dyspnea O B_DISEASE
and O O
fatigue O B_DISEASE
on O O
cold O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
windy O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
attended O O
dances O B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
often O O
danced O O
each O O
number O B_TIME[MEASURE]/B_ENT
throughout O O
the O O
evening O B_TIME[MEASURE]/B_LOCATION
without O O
trouble O B_DISEASE
. O O

When O O
seen O O
in O O
December O B_TIME[MEASURE]/B_COLOR
she O O
looked O O
well O O
. O O

Her O O
color O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
good O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
clubbing O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O O
definitely O O
less O O
marked O B_DISEASE_ADJECTIVE[DISEASE]
than O O
it O O
had O O
been O O
previously O O
. O O

She O O
had O O
a O O
severe O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cold O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
the O O
time O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Her O O
oxygen O B_MEASURE
saturation O I_MEASURE
of O O
arterial O B_BODY_PART_OR_ORGAN_COMPONENT
blood O I_BODY_PART_OR_ORGAN_COMPONENT
was O O
75 O B_NUMBER[MEASURE]
per O O
cent O B_MEASURE
at O O
rest O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
it O O
did O O
not O O
fall O O
when O O
she O O
stood O O
or O O
still O O
- O O
walked O O
. O O

The O O
hematocrit O B_BIO/B_PERSON
was O O
69 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
was O O
audible O B_PROTEIN[GENE]/B_MEASURE
the O O
same O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
loud O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
continuous O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
murmur O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
left O B_LOCATION
chest O I_LOCATION
. O O

Though O O
the O O
patient B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
been O O
markedly O O
improved O O
, O O
it O O
is O O
recognized O O
that O O
the O O
result O O
is O O
not O O
as O O
good O O
as O O
is O O
commonly O O
obtained O O
when O O
patients B B_PERSON/B_DISEASE
with O O
more O O
adequate O O
pulmonary O O
arteries O O
are O O
treated O O
by O O
the O O
conventional O O
anastomosis O O
of O O
a O O
systemic O O
artery O O
to O O
the O O
side O O
of O O
the O O
pulmonary O O
artery O O
. O O

Nevertheless O O
, O O
the O O
patient B B_PERSON/B_LOCATION
has O O
thus O O
far O O
been O O
given O O
such O O
good O O
health O O
and O O
relatively O O
normal O O
capacity O O
for O O
ordinary O O
activity O O
that O O
further O O
operation O O
has O O
seemed O O
unwarranted O O
, O O
though O O
the O O
possibility O O
of O O
some O O
future O O
attempt O O
at O O
creation O O
of O O
an O O
additional O O
shunt O O
is O O
being O O
kept O O
in O O
mind O O
. O O

The O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
embodies O O
the O O
cephalad O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O O
a O O
plastic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O O
the O O
incision O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
the O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
mediastinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pleural O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
structures O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

488 O B_NUMBER[MEASURE]

FIG O B_ORGANIZATION/B_GENE
. O O

1 O B_NUMBER[MEASURE]
. O O

Drawing O O
illustrating O O
the O O
condition O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
existed O O
in O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
completion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
the O O
anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
its O O
correction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
origin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
B O B_PROTEIN[GENE]/B_DISEASE
) O O
. O O

FIG O B_ORGANIZATION/B_GENE
. O O

2 O B_NUMBER[MEASURE]
. O O

Drawing O O
illustrating O O
correction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
obstruction O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
through O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
by O O
inverted O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
L O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
plastic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
closure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
of O O
the O O
defect O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
mediastinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
structures O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

TREATMENT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
OF O O
TETRALOGY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
OF O O
FALLOT O B_PERSON/B_LOCATION

Case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]

The O O
first O O
patient B B_PERSON
was O O
a O O
fully O O
grown O O
young O O
man B B_PERSON
of O O
17 O O
with O O
tetralogy O O
of O O
Fallot O O
which O O
caused O O
considerable O O
incapacity O O
. O O

He O O
was O O
admitted O O
to O O
the O O
hospital O B_LOCATION/B_ORGANIZATION
on O O
July O B_TIME[MEASURE]
18 O I_TIME[MEASURE]
, O O
1950 O B_MEASURE
and O O
was O O
operated O O
upon O O
two O B_TIME[MEASURE]/B_LOCATION
days O I_TIME[MEASURE]/I_LOCATION
later O O
. O O

He O O
was O O
known O O
to O O
have O O
a O O
left O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
aortic O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
arch O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
a O O
left O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lateral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thoracotomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
performed O O
. O O

The O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
freed O O
for O O
a O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
to O O
- O O
side O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
anastomosis O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
the O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

So O O
much O B_DISEASE_ADJECTIVE[DISEASE]
difficulty O I_DISEASE_ADJECTIVE[DISEASE]
was O O
encountered O O
, O O
however O O
, O O
in O O
placing O O
the O O
aortic O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
clamp O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
proper O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position O I_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
making O O
a O O
satisfactory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
incision O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
that O O
the O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
abandoned O O
and O O
an O O
end O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
to O O
- O O
side O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subclavian O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O O
pulmonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
anastomosis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
accomplished O O
instead O O
. O O

The O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
of O O
fair O B_MEASURE
size O I_MEASURE
, O O
having O O
an O O
estimated O O
diameter O B_MEASURE/B_LOCATION
of O O
1 O B_NUMBER[MEASURE]
cm O I_NUMBER[MEASURE]
. O O

The O O
subclavian O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
appeared O O
to O O
be O O
quite O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
it O O
was O O
of O O
very O O
satisfactory O B_MEASURE/B_COLOR
size O I_MEASURE/I_COLOR
, O O
having O O
a O O
diameter O B_MEASURE/B_LOCATION
of O O
about O O
6 O B_NUMBER[MEASURE]/B_LOCATION
mm O I_NUMBER[MEASURE]/I_LOCATION
. O O

To O O
my O O
dismay O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
first O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
portion O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
soft O B_NUMBER[MEASURE]/B_DISEASE
- O O
walled O B_BODY_PART_OR_ORGAN_COMPONENT
subclavian O I_BODY_PART_OR_ORGAN_COMPONENT
artery O I_BODY_PART_OR_ORGAN_COMPONENT
was O O
completely O O
flattened O O
out O O
against O O
the O O
rather O O
rigid O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
wall O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
no O O
blood O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
flow O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
through O O
it O O
could O O
be O O
demonstrated O O
, O O
there O O
being O O
no O O
subclavian O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulsation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
thrill O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

If O O
one O B_NUMBER[MEASURE]/B_PERSON
forcefully O O
elevated O O
the O O
hilum O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
a O O
cephalad O B_LOCATION/B_ORGANIZATION
direction O I_LOCATION/I_ORGANIZATION
, O O
the O O
obstruction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disappeared O O
, O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
began O O
to O O
pulsate O O
, O O
and O O
a O O
thrill O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
could O O
be O O
palpated O O
. O O

When O O
the O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
allowed O O
to O O
assume O O
its O O
usual O B_PERSON/B_MEASURE
position O B_PERSON/I_MEASURE
, O O
the O O
subclavian O B_DISEASE_ADJECTIVE[DISEASE]
obstruction O I_DISEASE_ADJECTIVE[DISEASE]
was O O
again O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
could O O
not O O
be O O
prevented O O
by O O
full O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
expansion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

It O O
was O O
found O O
that O O
the O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
could O O
be O O
maintained O O
in O O
a O O
satisfactory O B_LOCATION
cephalad O I_LOCATION
position O I_LOCATION
by O O
traction O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
upward O O
upon O O
the O O
cuff O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pleura O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
the O O
adjacent O B_BODY_PART_OR_ORGAN_COMPONENT
vascular O I_BODY_PART_OR_ORGAN_COMPONENT
sheath O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
that O O
these O O
structures O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
sufficiently O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
so O O
that O O
traction O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O O
be O O
maintained O O
upon O O
them O O
with O O
a O O
small O B_MEDICAL_DEVICE[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
hemostat O I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
defect O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
mediastinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
then O O
repaired O O
using O O
a O O
sort O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
inverted O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
T O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
plastic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
closure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

By O O
this O O
maneuver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
success O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
achieved O O
in O O
elevating O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
cephalad O B_LOCATION/B_ORGANIZATION
direction O I_LOCATION/I_ORGANIZATION
so O O
that O O
the O O
subclavian O B_DISEASE/B_MEASURE
obstruction O I_DISEASE/I_MEASURE
was O O
relieved O B_DISEASE_ADJECTIVE[DISEASE]
and O O
excellent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulsation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fig O B_PROTEIN[GENE]/B_MEASURE
. O O
2B O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

A O O
fairly O O
good O B_DISEASE/B_MEASURE
continuous O I_DISEASE/I_MEASURE
thrill O I_DISEASE/I_MEASURE
was O O
palpable O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
patient B B_PERSON
had O O
an O O
uneventful O O
convalescence O O
. O O

When O O
last O O
seen O O
on O O
January O B_TIME[MEASURE]
16 O I_TIME[MEASURE]
, O O
1951 O B_MEASURE
he O O
had O O
excellent O B_DISEASE
color O I_DISEASE
without O O
any O O
visible O B_DISEASE
cyanosis O I_DISEASE
. O O

The O O
clubbing O B_DISEASE/B_MEASURE
seemed O O
to O O
have O O
decreased O O
somewhat O O
. O O

A O O
continuous O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
murmur O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
audible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

He O O
stated O O
that O O
he O O
noted O O
no O O
limitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
exercise O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
outlining O O
his O O
activities O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
he O O
said O O
that O O
, O O
among O O
other O B_PERSON/B_ENT
things O I_PERSON/I_ENT
, O O
he O O
was O O
doing O O
a O O
great O B_TIME[MEASURE]/B_ORGANIZATION
deal O I_TIME[MEASURE]/I_ORGANIZATION
of O O
ice O B_LOCATION/B_PERSON
- O O
skating O B_SPORT[ENT]
and O O
was O O
playing O O
ice O B_SPORT[ENT]/B_PERSON
hockey O I_SPORT[ENT]/I_PERSON
regularly O O
. O O

He O O
was O O
planning O O
to O O
start O O
college O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
work O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
following O B_TIME[MEASURE]/B_LOCATION
month O I_TIME[MEASURE]/I_LOCATION
. O O

The O O
second O O
patient B B_PERSON
was O O
a O O
16 O O
- O O
year O O
- O O
old O O
boy B B_PERSON
who O O
had O O
been O O
cyanotic O O
since O O
birth O O
. O O

His O O
physical O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
was O O
somewhat O O
retarded O B_DISEASE_ADJECTIVE[DISEASE]
and O O
he O O
was O O
slow O B_DISEASE_ADJECTIVE[DISEASE]
in O O
learning O O
to O O
sit O O
and O O
walk O O
. O O

Until O O
he O O
had O O
grown O O
old O B_DISEASE_ADJECTIVE[DISEASE]
enough O O
to O O
be O O
self O B_PERSON/B_DISEASE
- O O
conscious O B_PERSON
about O O
it O O
he O O
had O O
always O O
squatted O O
when O O
he O O
was O O
tired O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

By O O
perseverance O B_TIME[MEASURE]/B_PERSON
he O O
had O O
managed O O
to O O
do O O
more O B_MEASURE
than O O
one O O
would O O
have O O
suspected O O
he O O
could O O
from O O
the O O
degree O B_DISEASE_ADJECTIVE[DISEASE]
of O O
his O O
cyanosis O B_DISEASE
. O O

He O O
could O O
walk O O
as O O
much O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
five O B_NUMBER[MEASURE]
or O O
six O B_NUMBER[MEASURE]
blocks O I_NUMBER[MEASURE]
at O O
a O O
slow O B_TIME[MEASURE]/B_LOCATION
pace O I_TIME[MEASURE]/I_LOCATION
. O O

He O O
was O O
fond O B_PERSON
of O O
drums O B_ENT/B_DISEASE
and O O
managed O O
to O O
play O O
occasionally O O
with O O
an O O
orchestra O B_ENT/B_PERSON
in O O
a O O
somewhat O O
restricted O B_LOCATION/B_PERSON
fashion O I_LOCATION/I_PERSON
. O O

For O O
the O O
past O B_TIME[MEASURE]
few O I_TIME[MEASURE]
months O I_TIME[MEASURE]
he O O
had O O
had O O
more O B_DISEASE
dyspnea O I_DISEASE
, O O
fatigability O B_DISEASE
, O O
and O O
seemed O O
to O O
be O O
going O O
downhill O O
generally O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
physical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
rather O O
typical O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
tetralogy O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
Fallot O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Clubbing O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O O
marked O O
, O O
the O O
nailbeds O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
and O O
mucous O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
membranes O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
a O O
rather O O
deep O B_COLOR/B_ENT
purplish O I_COLOR/I_ENT
- O O
blue O B_COLOR
color O I_COLOR
, O O
and O O
the O O
skin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
had O O
a O O
dusky O B_DISEASE/B_BIO
cyanotic O I_DISEASE/I_BIO
tint O I_DISEASE/I_BIO
. O O

The O O
aortic O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arch O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
determined O O
to O O
be O O
on O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

On O O
July O B_TIME[MEASURE]
21 O I_TIME[MEASURE]
, O O
1950 O B_MEASURE
a O O
left O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lateral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thoracotomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
performed O O
, O O
the O O
pleural O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cavity O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
being O O
entered O O
through O O
the O O
bed O B_LOCATION/B_MEASURE
of O O
the O O
fourth O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
rib O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

There O O
was O O
a O O
rather O O
marked O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
collateral O B_DISEASE/B_MEASURE
circulation O B_DISEASE/I_MEASURE
in O O
the O O
mediastinum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
the O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

The O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
easily O O
dissected O O
free O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
was O O
fairly O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
was O O
about O O
1 O B_MEASURE
cm O I_MEASURE
. O O
in O O
diameter O B_MEASURE/B_LOCATION
. O O

The O O
subclavian O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
seemed O O
quite O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
was O O
of O O
adequate O B_MEASURE/B_LOCATION
size O I_MEASURE/I_LOCATION
, O O
having O O
a O O
diameter O B_MEASURE/B_LOCATION
of O O
about O O
5 O B_NUMBER[MEASURE]
mm O I_NUMBER[MEASURE]
. O O

An O O
end O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
to O O
- O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sub9lavian O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
pulmonary O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anastomosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
performed O O
. O O

Again O O
in O O
this O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
acutely O O
angulated O O
and O O
completely O O
flattened O O
out O O
against O O
the O O
aortic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O B_LOCATION/B_PERSON
was O O
no O O

489 O B_NUMBER[MEASURE]

YALE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
JOURNAL O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
OF O O
BIOLOGY O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O O
MEDICINE O B_EDU[ORGANIZATION]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

pulsation O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
no O O
thrill O B_DISEASE/B_MEASURE
in O O
the O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
this O O
instance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
also O O
, O O
good O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blood O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
flow O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
through O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT
artery O I_BODY_PART_OR_ORGAN_COMPONENT
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whenever O O
the O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
structures O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
elevated O O
in O O
a O O
cephalad O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
direction O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
but O O
no O O
pulsation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
demonstrable O B_DISEASE_ADJECTIVE[DISEASE]
simply O O
by O O
expanding O O
fully O O
the O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Again O O
, O O
a O O
sort O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
inverted O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
T O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
plastic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
closure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O O
the O O
defect O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
hilum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
mediastinum O B_BODY_PART_OR_ORGAN_COMPONENT
brought O O
about O O
a O O
cephalad O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
elevation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
so O O
that O O
tension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
released O O
and O O
there O O
was O O
excellent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulsation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT
artery O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

A O O
thrill O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
now O O
palpable O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Convalescence O B_TIME[MEASURE]/B_PERSON
was O O
uneventful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Improvement O B_DISEASE_ADJECTIVE[DISEASE]
in O O
color O B_ENT/B_DISEASE
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
a O O
few O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
and O O
his O O
color O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
excellent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
he O O
was O O
discharged O O
from O O
the O O
hospital O B_LOCATION/B_ORGANIZATION
on O O
the O O
thirteenth O B_SEQUENCE[MEASURE]
postoperative O I_SEQUENCE[MEASURE]
day O I_SEQUENCE[MEASURE]
. O O

He O O
rapidly O O
found O O
that O O
he O O
was O O
now O O
able O B_TIME[MEASURE]/B_PERSON
to O O
lead O O
a O O
quite O O
normal O B_MEASURE/B_PERSON
sort O I_MEASURE/I_PERSON
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
he O O
was O O
seen O O
on O O
December O B_ENT/B_LOCATION
9 O I_ENT/I_LOCATION
he O O
stated O O
that O O
he O O
had O O
no O O
limitation O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
exercise O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
capacity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

He O O
could O O
walk O O
rapidly O O
without O O
fatigue O B_DISEASE
. O O

He O O
was O O
going O O
to O O
school O B_LOCATION
and O O
was O O
playing O O
the O O
drums O B_ENT
in O O
a O O
professional O B_TIME[MEASURE]/B_ENT
orchestra O I_TIME[MEASURE]/I_ENT
three O I_TIME[MEASURE]/I_ENT
or O O
four O B_NUMBER[MEASURE]/B_ENT
nights O I_NUMBER[MEASURE]/I_ENT
each O O
week O B_TIME[MEASURE]
. O O

There O O
was O O
some O O
diminution O B_DISEASE/B_MEASURE
in O O
the O O
clubbing O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
his O O
color O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
excellent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

There O O
was O O
a O O
loud O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continuous O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bruit O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
audible O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
chest O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

On O O
March O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
27 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
arterial O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
oxygen O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
saturation O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
88 O B_MEASURE
. O O
2 O B_MEASURE
per O O
cent O B_MEASURE
. O O

When O O
I O O
first O O
used O O
this O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
was O O
rather O O
surprised O B_PERSON
that O O
such O B_PERSON
tissues O I_PERSON
would O O
hold O O
sutures O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
serve O O
satisfactorily O O
to O O
elevate O O
the O O
hilum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
occasions O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
had O O
previously O O
toyed O O
with O O
the O O
idea O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
suturing O O
hilar O B_DISEASE/B_LOCATION
pleura O I_DISEASE/I_LOCATION
to O O
the O O
mediastinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pleura O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
but O O
had O O
abandoned O O
it O O
as O O
impractical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
because O O
the O O
sutures O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
seemed O O
to O O
pull O O
out O O
whenever O O
there O O
was O O
any O O
tension O B_DISEASE
whatsoever O O
. O O

If O O
the O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
to O O
be O O
successful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
is O O
essential O B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
sutures O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
encompass O O
any O O
adjacent O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
areolar O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
fibrous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
especially O O
the O O
so O O
- O O
called O O
vascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sheath O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O O
surrounds O O
both O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
is O O
dissected O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
during O O
the O O
course O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Fortunately O O
, O O
in O O
its O O
proximal O B_LOCATION
portion O I_LOCATION
the O O
sheath O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
about O O
the O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
gains O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
added O O
strength O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
from O O
the O O
extension O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
into O O
it O O
of O O
a O O
reflection O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
fibrous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pericardium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Sutures O B_MEASURE/B_PERSON
through O O
the O O
mediastinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pleura O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
in O O
the O O
region O B_LOCATION/B_MEASURE
of O O
the O O
aortic O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arch O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
purposely O O
include O O
the O O
perivascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
which O O
have O O
been O O
stripped O O
off O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
also O O
any O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
may O O
lend O O
strength O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
the O O
divided O O
ends O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
supreme O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
intercostal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
vein O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
vessels O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
which O O
lhave O O
been O O
transected O O
and O O
ligated O O
. O O

The O O
exact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
repair O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
vary O O
from O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

By O O
placing O O
the O O
sutures O B_MEDICAL_DEVICE[OBJECT]/B_MEASURE
properly O O
it O O
would O O
seem O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sometimes O O
to O O
displace O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
laterally O O
as O O
well O O
as O O
in O O
a O O
cephalad O B_LOCATION/B_ORGANIZATION
direction O I_LOCATION/I_ORGANIZATION
if O O
such O O
a O O
maneuver O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
thought O O
to O O
be O O
desirable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fig O B_MEASURE/B_GENE
. O O
2C O B_MEASURE
) O O
. O O

On O O
occasions O B_NUMBER[MEASURE]/B_PERSON
one O B_NUMBER[MEASURE]/I_PERSON
would O O
close O O
the O O
pleural O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
defect O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
fairly O O
snugly O O
, O O
on O O
others O B_PERSON/B_TIME[MEASURE]
leave O O
it O O
wide O B_SPORT[ENT]/B_DISEASE_ADJECTIVE[DISEASE]
open O I_SPORT[ENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
places O B_LOCATION/B_DISEASE
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Though O O
there O O
is O O
always O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
some O O
suitable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
systemic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
vessel O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
though O O
the O O
major O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
of O O
the O O
tetralogy O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
Fallot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
adequacy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
pulmonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
from O O
time O B_TIME[MEASURE]/B_LOCATION
to O O
time O B_TIME[MEASURE]/B_LOCATION
one O O
may O O
find O O
the O O
achievement O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
satisfactory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
result O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
thwarted O O
by O O
the O O
local O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anatomical O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regardless O O
of O O
one O B_NUMBER[MEASURE]/B_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
choice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Consequently O O
, O O
those O O
modifications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O O
may O O
add O O
to O O
the O O
likelihood O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
successful O B_DISEASE_ADJECTIVE[DISEASE]
outcome O I_DISEASE_ADJECTIVE[DISEASE]
are O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Blalock O B_PERSON
" O O
' O O
pointed O O
out O O
the O O
practicability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
performing O O
an O O
end O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
toend O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
subclavian O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O O
pulmonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
anastomosis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
whenever O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
judged O O
too O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
too O O
short O O
for O O
a O O
satisfactory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
end O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT

490 O B_NUMBER[MEASURE]

TREATMENT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
OF O O
TETRALOGY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
OF O O
FALLOT O B_PERSON/B_LOCATION
491 O I_PERSON/I_LOCATION

to O O
- O O
side O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
anastomosis O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Holman O B_PERSON
' O O
feels O O
that O O
a O O
poorly O O
functioning O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
shunt O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
after O O
end O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
to O O
- O O
side O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
anastomosis O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
can O O
usually O O
be O O
corrected O O
by O O
proximal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
division O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
thus O O
in O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
converting O O
the O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
into O O
an O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
to O O
- O O
end O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
anastomosis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

If O O
a O O
satisfactory O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
end O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
to O O
- O O
side O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
suture O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
to O O
- O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aortic O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
pulmonary O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
anastomosis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
seems O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
achieve O O
, O O
one O O
may O O
occasionally O O
find O O
it O O
useful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
divide O O
the O O
upper O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lobe O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
branch O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
carry O O
out O O
an O O
end O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
to O O
- O O
end O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suture O I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
proximal O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
end O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lobe O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
branch O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Potts O B_PERSON
and O O
Smith O B_PERSON/B_LOCATION
' O I_PERSON
performed O O
an O O
anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O O
the O O
proximal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
end O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
upper O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lobe O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
branch O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
side O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
a O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
which O O
complete O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temporary O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
main O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pulmonary O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O O
withstood O O
poorly O O
. O O

I O O
have O O
found O O
this O O
principle O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
division O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lobe O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
branch O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
its O O
proximal O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
value O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
obtaining O O
a O O
suitable O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
subclavian O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
pulmonary O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
anastomosis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
when O O
the O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seemed O O
to O O
have O O
inadequate O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
occasions O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
when O O
the O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vessel O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seems O O
too O O
short O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
one O O
may O O
elect O O
to O O
interpose O O
a O O
free O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
vascular O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
transplant O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
3 O B_MEASURE/B_LOCATION
" O O
' O O
a O O
modification O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
I O O
first O O
employed O O
in O O
1946 O B_MEASURE
though O O
unfortunately O O
not O O
with O O
success O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
instance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
operation O O
performed O O
in O O
my O O
first O O
patient B B_PERSON/B_TIME[MEASURE]
constitutes O O
in O O
reality O O
the O O
use O O
of O O
the O O
subclavian O O
artery O O
as O O
an O O
autogenous O O
graft O O
between O O
the O O
aorta O O
and O O
pulmonary O O
artery O O
. O O

It O O
will O O
obviously O O
not O O
often O O
be O O
the O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
choice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
but O O
sometimes O O
may O O
be O O
found O O
a O O
useful O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
converting O O
an O O
apparently O O
inadequate O B_DISEASE_ADJECTIVE[DISEASE]
functional O I_DISEASE_ADJECTIVE[DISEASE]
shunt O I_DISEASE_ADJECTIVE[DISEASE]
into O O
a O O
good O B_PRODUCT[OBJECT]/B_DISEASE
one O I_PRODUCT[OBJECT]/I_DISEASE
. O O

If O O
my O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
plastic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
defect O B_DISEASE/B_LOCATION
in O O
the O O
mediastinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
structures O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
what O O
may O O
be O O
expected O O
of O O
this O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
it O O
would O O
seem O O
to O O
have O O
wide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
applicability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whenever O O
a O O
poorly O O
functioning O O
subclavian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
shunt O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
seems O O
correctable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
cephalad O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
hilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
structures O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
consequent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
release O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
tension O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

I O O
was O O
unaware O B_PERSON
of O O
any O O
reference O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
in O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
its O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
until O O
belatedly O O
I O O
discovered O O
that O O
I O O
had O O
overlooked O O
a O O
statement O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
the O O
legend O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
excellent O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drawings O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Blalock O B_LOCATION/B_PERSON
' O I_LOCATION/I_PERSON
s O I_LOCATION/I_PERSON
paper O I_LOCATION/I_PERSON
on O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
procedures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
pulmonic O B_MEASURE
stenosis O I_MEASURE
. O O
' O O
Here O O
he O O
states O O
that O O
suture O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
pleura O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
superior O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
aspect O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
hilum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
mediastinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pleura O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
may O O
effectively O O
elevate O O
a O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
the O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Perhaps O O
our O O
more O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
consideration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
this O O
maneuver O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
add O O
to O O
its O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

REFERENCES O B_PERSON/B_DISEASE

1 O B_PERSON
Blalock O I_PERSON
, O O
A O B_OTHER/B_PERSON
. O O
: O O
The O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
creation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O O
an O O
artificial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
ductus O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
arteriosus O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
the O O

treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
pulmonic O B_DISEASE
stenosis O I_DISEASE
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thorac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
. O O

Surg O B_PERSON/B_GENE
. O O
, O O
1947 O B_NUMBER[MEASURE]
, O O
16 O B_MEASURE
, O O
244 O B_MEASURE/B_LOCATION
. O O

2 O B_PERSON
Blalock O I_PERSON
, O O
A O B_OTHER/B_PERSON
. O O
: O O
Surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
procedures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
employed O O
and O O
anatomical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variations O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encountered O O

in O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
congenital O B_DISEASE
pulmonic O I_DISEASE
stenosis O I_DISEASE
. O O

Surg O B_LOCATION/B_PERSON
. O O
, O O
Gyn O B_PERSON/B_LOCATION
. O O

Obst O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
1948 O B_MEASURE
, O O
87 O B_MEASURE
, O O
385 O B_MEASURE
. O O

3 O B_PERSON/B_COLOR
Gross O I_PERSON/I_COLOR
, O O
R O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

E O O
. O O
, O O
Bill O B_PERSON
, O O
A O B_OTHER/B_PERSON
. O O

H O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Jr O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
and O O
Pierce O B_PERSON/B_ORGANIZATION
, O O
E O B_OTHER/B_PERSON
. O O

C O B_OTHER/B_PROTEIN[GENE]
. O O
: O O
Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O O
preservation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O O

transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
aortic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
grafts O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Observation O O
on O O
arterial O O
grafts O O
in O O
dogs B B_BIO/B_PERSON
. O O

Report O O
of O O
transplantation O O
of O O
preserved O O
arterial O O
grafts O O
in O O
nine O O
human B B_PERSON/B_SPECIES[BIO]
cases O O
. O O

Surg O B_LOCATION/B_PERSON
. O O
, O O
Gyn O B_PERSON/B_LOCATION
. O O

Obst O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O
, O O
1949 O B_MEASURE
, O O
88 O B_MEASURE
, O O
689 O B_MEASURE/B_LOCATION
. O O

4 O B_PERSON/B_LOCATION
Holman O I_PERSON/I_LOCATION
, O O
E O B_OTHER/B_PERSON
. O O
: O O
The O O
surgery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stenosis O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Experiences O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O O
left O B_DISEASE/B_PERSON
subclavian O I_DISEASE/I_PERSON

to O O
left O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
anastomosis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thorac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
. O O

Surg O B_PERSON/B_GENE
. O O
, O O
1949 O B_MEASURE
, O O
18 O B_MEASURE
, O O
827 O B_MEASURE/B_LOCATION
. O O

5 O B_PERSON/B_COLOR
Johnson O I_PERSON/I_COLOR
, O O
J O B_OTHER/B_LOCATION
. O O
, O O
Kirby O B_PERSON/B_COLOR
, O O
C O B_OTHER/B_PERSON
. O O

K O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Greifenstein O B_PERSON
, O O
F O B_OTHER/B_PERSON
. O O

E O O
. O O
, O O
and O O
Costillo O B_LOCATION/B_PERSON
, O O
A O B_OTHER/B_PERSON
. O O
: O O
The O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

and O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vein O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grafts O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
replace O O
defects O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
large O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Surgery O B_MEASURE/B_ORGANIZATION
, O O
1949 O B_MEASURE
, O O
26 O B_MEASURE
, O O
945 O B_MEASURE/B_LOCATION
. O O

492 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
YALE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
JOURNAL O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
OF O O
BIOLOGY O B_EDU[ORGANIZATION]/B_DISEASE
AND O O
MEDICINE O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

6 O B_PERSON/B_COLOR
Lam O I_PERSON/I_COLOR
, O O
C O B_MEASURE/B_GENE
. O O

R O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
: O O
The O O
choice O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
approach O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
operations O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
for O O
pulmonary O B_DISEASE

stenosis O B_DISEASE
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thorac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
. O O

Surg O B_PERSON/B_GENE
. O O
, O O
1949 O B_MEASURE
, O O
18 O B_MEASURE
, O O
661 O B_MEASURE/B_LOCATION
. O O

7 O B_PERSON/B_LOCATION
Olim O I_PERSON/I_LOCATION
, O O
C O B_OTHER/B_LOCATION
. O O

B O B_OTHER/B_MEASURE
. O O
: O O
Experiences O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O O
congenital O B_DISEASE/B_LOCATION
pulmonary O I_DISEASE/I_LOCATION

stenosis O B_DISEASE
. O O

American O B_MEASURE/B_PERSON
Surgeon O I_MEASURE/I_PERSON
, O O
1951 O B_MEASURE
, O O
17 O B_MEASURE
, O O
245 O B_MEASURE
. O O

8 O B_PERSON/B_COLOR
Paine O I_PERSON/I_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

R O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Varco O B_PERSON/B_LOCATION
, O O
R O B_OTHER/B_PERSON
. O O

C O B_MEASURE/B_GENE
. O O
: O O
Experiences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
the O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
pul O B_DISEASE/B_LOCATION

monic O B_DISEASE_ADJECTIVE[DISEASE]
stenosis O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Surgery O B_MEASURE/B_ORGANIZATION
, O O
1948 O B_MEASURE
, O O
24 O B_NUMBER[MEASURE]
, O O
355 O B_MEASURE/B_LOCATION
. O O

9 O B_PERSON/B_LOCATION
Potts O I_PERSON/I_LOCATION
, O O
W O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Smith O B_PERSON
, O O
S O B_OTHER/B_DISEASE
. O O
: O O
New O B_DISEASE_ADJECTIVE[DISEASE]
surgical O I_DISEASE_ADJECTIVE[DISEASE]
procedures O I_DISEASE_ADJECTIVE[DISEASE]
in O O
certain O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cases O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
congenital O B_DISEASE

pulmonary O B_DISEASE_ADJECTIVE[DISEASE]
stenosis O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Arch O B_LOCATION/B_BIO
. O O

Surg O B_PERSON/B_GENE
. O O
, O O
1949 O B_MEASURE
, O O
59 O B_MEASURE
, O O
491 O B_MEASURE/B_LOCATION
. O O

10 O B_PERSON/B_LOCATION
Potts O I_PERSON/I_LOCATION
, O O
W O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Smith O B_LOCATION/B_PERSON
S O I_LOCATION/I_PERSON
. O O
, O O
and O O
Gibson O B_PERSON/B_COLOR
, O O
S O B_OTHER/B_LOCATION
. O O
: O O
Anastomosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
of O O
the O O
aorta O B_BODY_PART_OR_ORGAN_COMPONENT
to O O
a O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT

artery O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
; O O
certain O B_DISEASE_ADJECTIVE[DISEASE]
types O I_DISEASE_ADJECTIVE[DISEASE]
in O O
congenital O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
heart O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Am O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

M O B_OTHER/B_MEASURE
. O O

Ass O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
1946 O B_MEASURE
, O O
132 O B_MEASURE
, O O
627 O B_MEASURE/B_LOCATION
. O O

Tissue O O
remodeling O O
: O O
a O O
mating O O
- O O
induced O O
differentiation O O
program O O
for O O
the O O
Drosophila B B_SPECIES[BIO]/B_PERSON
oviduct O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
both O O
vertebrates O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
invertebrates O B_SPECIES[BIO]
, O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
epithelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
tube O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
surrounded O O
by O O
visceral O B_BODY_PART_OR_ORGAN_COMPONENT
muscles O I_BODY_PART_OR_ORGAN_COMPONENT
that O O
serves O O
as O O
a O O
conduit O B_LOCATION
for O O
gamete O B_ORGANIZATION/B_LOCATION
transport O B_ORGANIZATION/I_LOCATION
between O O
the O O
ovary O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O O
uterus O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

While O O
Drosophila O O
is O O
a O O
model O O
system O O
for O O
tubular O O
organ O O
development O O
, O O
few O O
studies O O
have O O
addressed O O
the O O
development O O
of O O
the O O
fly B B_SPECIES[BIO]/B_PERSON
' O O
s O O
oviduct O O
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
Drosophila O B_SPECIES[BIO]
have O O
identified O O
mating O O
- O O
responsive O B_GENE
genes O I_GENE
and O O
proteins O B_BIO/B_GENE
whose O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
are O O
altered O O
by O O
mating O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Since O O
many O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
molecules O B_BIO/B_GENE
( O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
Muscle O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LIM O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
84B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Coracle O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
Neuroglian O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
have O O
known O O
roles O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O O
the O O
differentiation O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
of O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
epithelia O B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
of O O
other O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
organs O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
mating O B_BIO/B_PERSON
may O O
trigger O O
similar O B_DISEASE/B_ORGANISM_FUNCTION
differentiation O I_DISEASE/I_ORGANISM_FUNCTION
events O I_DISEASE/I_ORGANISM_FUNCTION
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
led O O
us O O
to O O
hypothesize O O
that O O
mating O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediates O O
the O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
stages O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
oviduct O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
organ O B_ENT/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specializations O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
arise O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Using O O
electron O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
and O O
confocal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
microscopy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
identified O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
wide O B_MEASURE/B_LOCATION
post O B_MEASURE/I_LOCATION
- O O
mating O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
including O O
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
cellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
junctions O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
remodeling O O
of O O
extracellular O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
matrix O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
increased O O
myofibril O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
and O O
increased O O
innervation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
once O O
- O O
and O O
twice O O
- O O
mated O O
females O B_PERSON/B_BIO
reveals O O
that O O
some O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
responsive O B_PERSON/B_BIO
proteins O I_PERSON/I_BIO
respond O O
only O O
to O O
the O O
first O B_PERSON
mating O I_PERSON
, O O
while O O
others O B_PERSON
respond O O
to O O
both O O
matings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]

We O O
uncovered O O
ultrastructural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
mated O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
roles O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
responsive O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
play O O
in O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
and O O
epithelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
elsewhere O O
. O O

This O O
suggests O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
triggers O O
the O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
we O O
suggest O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
responsive O B_GENE
proteins O I_GENE
that O O
respond O O
only O O
to O O
the O O
first O B_PERSON/B_BIO
mating O I_PERSON/I_BIO
are O O
involved O O
in O O
the O O
final O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
maturation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
while O O
proteins O B_BIO/B_GENE
that O O
remain O O
responsive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
later O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
matings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
are O O
also O O
involved O O
in O O
maintenance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O O
ongoing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Taken O O
together O O
, O O
our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
establish O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
as O O
an O O
attractive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
address O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
regulate O O
the O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
differentiation O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
and O O
maintenance O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
tubular O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
organ O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Most O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
internal O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
organs O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
including O O
the O O
vascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
respiratory O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
systems O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
gastro O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
intestinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
genital O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tracts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
comprised O O
of O O
a O O
single O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelial O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tube O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O O
a O O
network O B_ORGANIZATION/B_LOCATION
of O O
tubes O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Tubular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
organs O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
serve O O
as O O
conduits O B_LOCATION
for O O
the O O
transport O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
gases O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
liquids O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
solutes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
serve O O
as O O
barriers O B_LOCATION
between O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compartments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
create O O
tubes O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
with O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
flow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
barrier O B_MEASURE/B_LOCATION
properties O I_MEASURE/I_LOCATION
, O O
the O O
morphology O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
tube O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
must O O
be O O
precisely O O
specified O O
during O O
development O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
modulated O O
by O O
physiology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

To O O
accommodate O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
physiological O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
roles O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programs O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
employed O O
at O O
the O O
last O B_LOCATION/B_MEASURE
stages O I_LOCATION/I_MEASURE
of O O
development O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

While O O
much O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
the O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cellular O B_LOCATION/B_GENE
basis O I_LOCATION/I_GENE
of O O
tube O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
formation O I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 O I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
6 O B_MEASURE
] O I_MEASURE
, O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
the O O
mechanisms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
regulate O O
the O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
which O O
organ O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specializations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
arise O O
. O O

The O O
conservation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
similarity O B_TIME[MEASURE]/B_LOCATION
in O O
tubular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
organ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
across O O
taxa O B_BIO
make O O
Drosophila O B_SPECIES[BIO]/B_PERSON
an O O
excellent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
understanding O O
organogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
in O O
higher O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
Drosophila O B_SPECIES[BIO]/B_PERSON
, O O
the O O
best O B_MEASURE
understood O O
tubular O B_LOCATION/B_BIO
organs O I_LOCATION/I_BIO
from O O
a O O
developmental O B_LOCATION/B_MEASURE
point O I_LOCATION/I_MEASURE
of O O
view O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
are O O
the O O
trachea O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
salivary O B_BODY_PART_OR_ORGAN_COMPONENT
gland O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
organs O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
reveal O O
a O O
general O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
tubular O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
organ O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
development O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
which O O
combinatorial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
global O B_GENE
patterning O I_GENE
genes O I_GENE
specifies O O
positions O B_LOCATION
within O O
the O O
embryo O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
for O O
the O O
subsequent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
transcription O B_GENE
factors O I_GENE
. O O

This O O
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results O O
in O O
the O O
activation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
downstream O B_GENE
genes O I_GENE
involved O O
in O O
terminal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O O
organ O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specializations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
the O O
cuticle O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
that O O
lines O O
the O O
tracheal O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
lumen O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
[ O O
1 O B_NUMBER[MEASURE]
, O O
2 O B_SEQUENCE[MEASURE]
, O O
4 O B_SEQUENCE[MEASURE]
, O O
7 O B_SEQUENCE[MEASURE]
- O O
9 O B_MEASURE
] O O
. O O

The O O
Drosophila B B_SPECIES[BIO]/B_PERSON
female O O
reproductive O O
tract O O
is O O
another O O
tubular O O
system O O
, O O
consisting O O
of O O
the O O
uterus O O
and O O
a O O
common O O
oviduct O O
( O O
the O O
main O O
tube O O
) O O
that O O
branches O O
into O O
two O O
lateral O O
oviducts O O
. O O

Regional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
are O O
observed O O
along O O
the O O
length O B_MEASURE/B_LOCATION
of O O
the O O
tract O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O O
with O O
egg O B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation O I_ORGANISM_FUNCTION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurring O O
largely O O
at O O
the O O
proximal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
end O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
in O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
fertilization O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
occurring O O
at O O
the O O
distal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
end O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
in O O
the O O
uterus O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
[ O O
10 O B_NUMBER[MEASURE]
, O O
11 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Unlike O O
other O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
tubular O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
organs O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
female O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
regional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suggest O O
the O O
presence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
region O B_LOCATION/B_PERSON
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_DISEASE_ADJECTIVE[DISEASE]
programs O I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
female O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
Drosophila O B_SPECIES[BIO]/B_PERSON
, O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
female O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
behavior O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
physiology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
via O O
molecules O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transmitted O O
in O O
the O O
seminal O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
fluid O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
. O O

These O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
lead O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
mated O O
female O B_PERSON/B_LOCATION
state O I_PERSON/I_LOCATION
which O O
is O O
profoundly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
from O O
the O O
unmated O B_PERSON
female O I_PERSON
state O I_PERSON
. O O

While O O
an O O
unmated O B_PERSON/B_BIO
female O I_PERSON/I_BIO
lays O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
eggs O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
readily O O
accepts O O
the O O
courtship O B_PERSON/B_BIO
efforts O I_PERSON/I_BIO
of O O
a O O
male O B_PERSON
, O O
a O O
mated O B_PERSON
female O I_PERSON
exhibits O I_PERSON
increased O O
egg O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
laying O O
and O O
actively O O
rejects O O
males O B_PERSON/B_BIO
[ O O
12 O B_MEASURE
- O O
19 O B_MEASURE
] O I_MEASURE
. O O

Microarray O O
studies O O
of O O
whole O O
flies B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveal O O
that O O
the O O
changes O O
in O O
egg O O
- O O
laying O O
rate O O
are O O
accompanied O O
by O O
a O O
change O O
in O O
gene O O
expression O O
. O O

Within O O
three O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
of O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
there O O
is O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
expression O B_GENE
of O O
a O O
small O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
genes O B_GENE
[ O I_GENE
20 O I_GENE
, O O
21 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
as O O
well O O
as O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
abundance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O O
have O O
also O O
been O O
observed O O
in O O
the O O
female O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
22 O B_MEASURE
, O O
23 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

In O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
lateral O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
hereafter O O
, O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
immune O B_DISEASE/B_ORGANISM_FUNCTION
related O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
down O O
regulates O O
transcription O B_GENE/B_BIO
factors O I_GENE/I_BIO
involved O O
in O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

At O O
the O O
protein O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
increased O O
abundance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
proteins O B_BIO/B_GENE
associated O O
with O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
assembly O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
cytoskeletal O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
associated O O
with O O
epithelial O B_DISEASE
morphogenesis O I_DISEASE
[ O O
23 O B_DISEASE
] O I_DISEASE
. O O

Since O O
many O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
responsive O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
act O O
in O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
epithelia O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
elsewhere O O
( O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
Bent O B_GENE/B_DISEASE
, O O
Muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
LIM O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
protein O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
84B O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
( O O
Mlp84B O B_GENE/B_BACTERIUM[BIO]
) O O
, O O
Neuroglian O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Nrg O B_PERSON/B_LOCATION
) O O
, O O
Coracle O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
( O O
Cora O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
) O O
) O O
, O O
we O O
hypothesize O O
that O O
mating O B_BIO/B_PERSON
triggers O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
test O O
our O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
we O O
characterized O O
the O O
ultrastructure O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
as O O
well O O
as O O
the O O
pattern O B_MEASURE/B_DISEASE
of O O
innervation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
before O O
and O O
after O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

We O O
then O O
examined O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimes O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
oviduct O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mating O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
responsive O B_MEASURE
cytoskeletal O I_MEASURE
proteins O I_MEASURE
and O O
on O O
female O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
reproductive O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
output O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
active O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
tissue O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
remodeling O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
takes O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
musculature O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Furthermore O O
, O O
we O O
found O O
a O O
striking O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
in O O
innervation O B_MEASURE
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
after O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
the O O
reproductive O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
is O O
an O O
attractive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
address O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
regulate O O
the O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
tissue O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
tubular O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
organ O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Unlike O O
other O B_PERSON/B_ORGANISM_FUNCTION
tubular O I_PERSON/I_ORGANISM_FUNCTION
organs O I_PERSON/I_ORGANISM_FUNCTION
, O O
the O O
last O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
stage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
triggered O O
by O O
an O O
extrinsic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
cue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
. O O

This O O
makes O O
it O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
experimentally O O
control O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
differentiation O B_ORGANISM_FUNCTION/B_GENE
, O O
with O O
an O O
opportunity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
independently O O
examine O O
the O O
effects O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mating O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
age O B_TIME[MEASURE]/B_PERSON
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
it O O
allows O O
us O O
to O O
examine O O
processes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
essential O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
reproduction O B_DISEASE/B_ORGANISM_FUNCTION
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O O
changes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lumen O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
promotes O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
actin O B_GENE/B_BACTERIUM[BIO]
- O O
based O O
cytoskeletal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
molecules O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
suggests O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
triggers O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
tissue O B_DISEASE_ADJECTIVE[DISEASE]
remodeling O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
female O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
mediate O O
its O O
progression O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
mature O B_MEASURE/B_LOCATION
functional O B_MEASURE/I_LOCATION
stage O B_MEASURE/I_LOCATION
[ O O
23 O B_ORGANISM_FUNCTION/B_BIO
] O I_ORGANISM_FUNCTION/I_BIO
. O O

To O O
gain O O
insight O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
underlie O O
this O O
progression O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
used O O
light O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
electron O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
determine O O
the O O
morphological O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
status O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O O
unmated O B_PERSON
and O O
mated O O
3 O B_NUMBER[MEASURE]
- O O
day O B_PERSON/B_TIME[MEASURE]
old O B_PERSON/I_TIME[MEASURE]
females O B_PERSON/I_TIME[MEASURE]
. O O

In O O
nearly O O
all O O
mated O O
reproductive O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processed O O
for O O
microscopy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
( O O
8 O B_MEASURE
/ O O
9 O B_MEASURE
) O O
, O O
an O O
egg O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
located O O
in O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
an O O
egg O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
never O O
observed O O
in O O
the O O
oviduct O B_LOCATION/B_MEASURE
of O O
unmated O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
reproductive O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tracts O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
5 O B_MEASURE
/ O O
5 O B_NUMBER[MEASURE]
) O O
( O O
Figure O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
) O O
. O O

This O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
report O O
increased O O
ovulation O B_ORGANISM_FUNCTION/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
egg O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
laying O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
6 O B_MEASURE
h O O
post O B_LOCATION
- O O
mating O O
[ O O
24 O B_GENE/B_LOCATION
] O I_GENE/I_LOCATION
. O O

In O O
all O O
unmated O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
reproductive O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tracts O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
examined O O
, O O
the O O
region O B_LOCATION/B_MEASURE
between O O
the O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
oviducts O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
middle O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
the O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
either O O
tapered O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
constricted O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
this O O
region O B_LOCATION/B_MEASURE
appeared O O
relaxed O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O O
the O O
mated O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reproductive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
tract O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
1A O I_PROTEIN[GENE]/I_LOCATION
and O O
1D O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

These O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
raise O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
lumen O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
is O O
narrow O B_MEASURE
in O O
the O O
unmated O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
oviduct O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
larger O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
mated O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
address O O
this O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
collected O O
serial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
mu O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
m O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
longitudinal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
sections O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
through O O
the O O
reproductive O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
unmated O B_PERSON/B_BIO
and O O
mated O B_PERSON
females O I_PERSON
and O O
stained O O
these O O
sections O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
with O O
toluidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
survey O O
the O O
appearance O B_PERSON/B_MEASURE
of O O
the O O
lumen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
along O O
the O O
entire O B_LOCATION/B_MEASURE
length O I_LOCATION/I_MEASURE
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
1B O I_PROTEIN[GENE]/I_LOCATION
and O O
1E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Our O O
examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
that O O
, O O
in O O
unmated O B_SPECIES[BIO]/B_PERSON
reproductive O I_SPECIES[BIO]/I_PERSON
tracts O I_SPECIES[BIO]/I_PERSON
, O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lumen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O O
an O O
irregular O B_DISEASE/B_LOCATION
shape O B_DISEASE/I_LOCATION
, O O
while O O
the O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lumen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appears O O
straight O O
. O O

Moreover O O
, O O
in O O
all O O
the O O
unmated O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
reproductive O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
tracts O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
sectioned O O
, O O
we O O
detected O O
patches O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
darkly O O
stained O O
material O B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
lumen O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
mated O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
reproductive O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
tract O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O O
the O O
lumen O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
defined O O
as O O
the O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
upper O B_LOCATION/B_MEASURE
part O I_LOCATION/I_MEASURE
of O O
the O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
has O O
an O O
irregular O B_DISEASE/B_LOCATION
shape O B_DISEASE/I_LOCATION
, O O
and O O
the O O
lumen O B_LOCATION/B_PERSON
of O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
defined O O
as O O
the O O
lower O B_LOCATION/B_MEASURE
part O I_LOCATION/I_MEASURE
of O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
appears O O
straight O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
lumen O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
of O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appears O O
wider O O
in O O
mated O O
than O O
unmated O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
reproductive O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tracts O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
Figure O B_PROTEIN[GENE]
1C O I_PROTEIN[GENE]
and O O
1F O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Interestingly O O
, O O
darkly O O
stained O B_COLOR/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
material O I_COLOR/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
detected O O
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lumen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
mated O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
females O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

This O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
appears O O
to O O
be O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
description O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
made O O
by O O
Mahowald O B_PERSON
et O I_PERSON
al O I_PERSON
. O O

[ O O
25 O B_PERSON/B_LOCATION
] O I_PERSON/I_LOCATION
, O O
who O O
reported O O
that O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lumen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
unmated O B_SPECIES[BIO]
females O I_SPECIES[BIO]
is O O
nearly O O
filled O O
with O O
an O O
intima O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
like O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
matrix O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
that O O
this O O
matrix O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
reduced O O
after O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

Because O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON/B_BIO
mated O I_PERSON/I_BIO
females O I_PERSON/I_BIO
lay O O
eggs O B_BIO/B_PERSON
, O O
it O O
is O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whether O O
the O O
lack O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
lumenal O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
material O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O O
increase O O
in O O
lumen O B_MEASURE
size O I_MEASURE
in O O
mated O B_PERSON/B_BIO
females O I_PERSON/I_BIO
occurred O O
before O O
or O O
after O O
the O O
passage O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
eggs O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
suggest O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
directly O O
or O O
indirectly O O
induces O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
that O O
facilitate O O
egg O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
passage O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
through O O
the O O
duct O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Taken O O
together O O
, O O
our O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lead O O
us O O
to O O
propose O O
that O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lumen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
closed O O
and O O
/ O O
or O O
obstructed O O
in O O
the O O
unmated O B_SPECIES[BIO]/B_PERSON
reproductive O I_SPECIES[BIO]/I_PERSON
tract O I_SPECIES[BIO]/I_PERSON
, O O
and O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
epithelia O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
/ O O
or O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
that O O
" O O
open O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lumen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
junctions O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
oviduct O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE

To O O
determine O O
whether O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
specific O B_DISEASE_ADJECTIVE[DISEASE]
morphological O I_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
oviduct O B_DISEASE/B_PERSON
epithelia O I_DISEASE/I_PERSON
post O I_DISEASE/I_PERSON
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
we O O
next O O
examined O O
the O O
ultrastructure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
unmated O B_PERSON/B_BIO
and O O
mated O O
reproductive O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Since O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
demonstrates O O
that O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
associated O O
with O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
junctions O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
such O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
as O O
alpha O B_PROTEIN[GENE]
- O O
and O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Spectrin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Spec O B_MEASURE
) O O
, O O
Cora O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
Nrg O B_GENE/B_BACTERIUM[BIO]
[ O O
23 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
increase O O
post O B_DISEASE/B_MEASURE
- O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
first O O
determined O O
the O O
status O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
junctions O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
unmated O B_SPECIES[BIO]
females O I_SPECIES[BIO]
, O O
and O O
whether O O
these O O
junctions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
change O O
post O B_DISEASE/B_MEASURE
- O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
Drosophila O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
most O O
ectodermally O O
derived O O
epithelia O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
epidermis O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
trachea O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
, O O
with O O
a O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
exceptions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
are O O
joined O O
apically O O
by O O
a O O
belt O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
like O B_LOCATION/B_MEASURE
adherens O I_LOCATION/I_MEASURE
junction O I_LOCATION/I_MEASURE
called O O
the O O
zonal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
adherens O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
junction O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ZA O B_LOCATION/B_PROTEIN[GENE]
) O O
followed O O
basally O O
by O O
a O O
septate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
junction O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SJ O B_LOCATION
) O O
[ O O
26 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
that O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
lined O O
, O O
along O O
its O O
entire O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
length O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
, O O
by O O
a O O
monolayered O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
comprised O O
of O O
squamous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
type O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
region O B_LOCATION/B_BIO
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
morphology O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
, O O
all O O
oviduct O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
examined O O
, O O
in O O
both O O
unmated O B_PERSON/B_ORGANISM_FUNCTION
and O O
mated O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
females O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
are O O
joined O O
along O O
their O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
membranes O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
by O O
an O O
extensive O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
SJ O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
lack O O
an O O
apical O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ZA O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
Figure O B_MEASURE
2 O I_MEASURE
) O O
. O O

SJs O B_LOCATION/B_PERSON
and O O
ZAs O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
form O O
complete O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belts O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
surround O O
the O O
epithelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thus O O
making O O
these O O
junctions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
easily O O
visible O B_DISEASE_ADJECTIVE[DISEASE]
in O O
transverse O B_MEASURE/B_LOCATION
sections O B_MEASURE/I_LOCATION
through O O
the O O
epithelium O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Because O O
ZAs O B_DISEASE/B_PERSON
were O O
not O O
detected O O
in O O
our O O
transverse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sections O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
through O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
this O O
implies O O
that O O
ZAs O B_PERSON
never O O
formed O O
, O O
or O O
developed O O
earlier O O
and O O
were O O
lost O O
( O O
Figure O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
2D O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Interestingly O O
, O O
we O O
did O O
not O O
detect O O
any O O
ultrastructural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
SJs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
at O O
6 O B_MEASURE
h O O
post O B_DISEASE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
but O O
we O O
did O O
uncover O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
SJ O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ultrastructure O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
regions O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Based O O
on O O
their O O
ultrastructure O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
two O B_LOCATION/B_MEASURE
types O I_LOCATION/I_MEASURE
of O O
SJs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
smooth O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
pleated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O O
can O O
be O O
distinguished O O
in O O
Drosophila O B_SPECIES[BIO]/B_MEASURE
[ O I_SPECIES[BIO]/I_MEASURE
26 O I_SPECIES[BIO]/I_MEASURE
] O I_SPECIES[BIO]/I_MEASURE
. O O

Smooth O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
SJs O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
distinguished O O
by O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
visible O B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
septae O B_DISEASE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
the O O
appearance O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
electron O B_LOCATION/B_BIO
dense O I_LOCATION/I_BIO
material O I_LOCATION/I_BIO
in O O
the O O
intercellular O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
space O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
while O O
pleated O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
SJs O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
distinguished O O
by O O
the O O
ladder O B_LOCATION/B_PRODUCT[OBJECT]
- O O
like O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
appearance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
septae O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
. O O

In O O
the O O
lateral O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
septa O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
not O O
detected O O
in O O
the O O
SJ O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
thus O O
these O O
SJs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
represent O O
smooth O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
SJs O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
an O O
immature O B_MEASURE/B_DISEASE
stage O I_MEASURE/I_DISEASE
of O O
pleated O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SJ O I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
2A O I_PROTEIN[GENE]/I_LOCATION
, O O
2A O B_PROTEIN[GENE]/B_DISEASE
' O O
, O O
2A O B_PROTEIN[GENE]/B_DISEASE
" O O
) O O
. O O

In O O
contrast O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
ladder O B_LOCATION/B_PRODUCT[OBJECT]
- O O
like O B_LOCATION
arrangement O I_LOCATION
of O O
septae O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
was O O
often O O
visible O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
SJs O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
lower O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
common O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
2C O I_MEASURE/I_PROTEIN[GENE]
' O O
) O O
, O O
thus O O
these O O
SJs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
classified O O
as O O
pleated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Unlike O O
the O O
smooth O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
like O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
SJs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
pleated O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
SJs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
followed O O
basally O O
by O O
spot O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
type O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
adherens O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
junction O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
spot O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AJs O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
Figure O B_TIME[MEASURE]/B_LOCATION
2B O I_TIME[MEASURE]/I_LOCATION
, O O
2B O B_MEASURE/B_LOCATION
' O O
; O O
additional O B_MEASURE/B_LOCATION
file O B_MEASURE/I_LOCATION
1 O B_MEASURE/I_LOCATION
) O O
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
determine O O
if O O
the O O
SJs O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
upper O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
represent O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
the O O
initial O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
SJs O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
as O O
well O O
as O O
spot O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
AJs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
the O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
oviduct O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
are O O
mating O O
- O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
raises O O
an O O
interesting O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
question O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Why O O
are O O
SJ O B_PERSON/B_LOCATION
proteins O I_PERSON/I_LOCATION
such O I_PERSON/I_LOCATION
as O O
Cora O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
Nrg O B_PERSON/B_LOCATION
up O O
- O O
regulated O O
post O B_DISEASE/B_MEASURE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
if O O
SJs O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
are O O
formed O O
prior O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
? O O

It O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
increased O O
expression O B_GENE/B_MEASURE
of O O
SJ O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
associated O O
with O O
functional O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
polarized O B_DISEASE/B_LOCATION
secretion O I_DISEASE/I_LOCATION
post O I_DISEASE/I_LOCATION
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
shown O O
that O O
SJs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
play O O
an O O
unexpected O B_DISEASE_ADJECTIVE[DISEASE]
role O I_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
the O O
apical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
specialized O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extracellular O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecules O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
trachea O B_BODY_PART_OR_ORGAN_COMPONENT
[ O O
27 O B_MEASURE
, O O
28 O B_MEASURE
] O I_MEASURE
, O O
and O O
that O O
these O O
molecules O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
important O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
regulators O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
lumen O B_MEASURE/B_ORGANISM_FUNCTION
size O B_MEASURE/I_ORGANISM_FUNCTION
. O O

Mating O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
modulates O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
apical O O
secretory O B_ORGANISM_FUNCTION
activity O I_ORGANISM_FUNCTION
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]

Given O O
the O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
extensive O B_DISEASE/B_GENE
SJs O B_DISEASE/I_GENE
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
SJs O B_PERSON/B_DISEASE
in O O
regulating O O
apical O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
secretion O I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
extracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
matrix O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
e O B_PROTEIN[GENE]/B_DISEASE
. O O
g O B_GENE/B_MEASURE
. O O
trachea O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
, O O
we O O
asked O O
if O O
mating O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
modulates O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
apical O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
ultrastructural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
that O O
different O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
regions O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
display O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
different O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
apical O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
morphology O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
i O O
. O O
e O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
microvilli O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O O
pleats O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
see O O
Figures O B_MEASURE/B_PERSON
2 O I_MEASURE/I_PERSON
and O O
additional O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
2A O B_TIME[MEASURE]/B_LOCATION
) O O
, O O
but O O
all O O
epithelia O B_LOCATION
are O O
covered O O
by O O
an O O
electron O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dense O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
apical O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
extracellular O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
matrix O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AECM O B_DISEASE/B_PROTEIN[GENE]
) O O
and O O
a O O
thin O B_MEASURE/B_LOCATION
layer O I_MEASURE/I_LOCATION
of O O
cuticle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
found O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
ultrastructural O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
AECM O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
cuticle O B_LOCATION
in O O
both O O
the O O
upper O B_LOCATION/B_MEASURE
and O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

In O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
unmated O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
female O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
AECM O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
varies O O
in O O
thickness O B_MEASURE/B_LOCATION
along O O
the O O
apical O B_BODY_PART_OR_ORGAN_COMPONENT
surface O I_BODY_PART_OR_ORGAN_COMPONENT
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
3A O I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

Some O O
areas O B_LOCATION
have O O
little O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
AECM O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
while O O
other O B_MEASURE/B_PERSON
areas O B_MEASURE/I_PERSON
are O O
covered O O
by O O
a O O
distinct O B_MEASURE/B_LOCATION
layer O B_MEASURE/I_LOCATION
of O O
AECM O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
~ O B_MEASURE
1 O I_MEASURE
- O O
2 O B_MEASURE
mu O I_MEASURE
m O I_MEASURE
in O O
thickness O B_MEASURE/B_LOCATION
; O O
Figure O B_MEASURE/B_LOCATION
3B O I_MEASURE/I_LOCATION
) O O
. O O

However O O
, O O
the O O
AECM O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
mated O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
females O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
is O O
more O O
evenly O O
distributed O O
along O O
the O O
apical O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
surface O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
( O O
~ O B_TIME[MEASURE]
2 O I_TIME[MEASURE]
mu O I_TIME[MEASURE]
m O I_TIME[MEASURE]
in O O
thickness O B_MEASURE/B_PERSON
; O O
Figure O B_MEASURE/B_PERSON
3E O I_MEASURE/I_PERSON
) O O
. O O

Strikingly O O
, O O
the O O
AECM O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cuticle O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
mated O B_BIO
females O I_BIO
have O O
a O O
ruffled O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
appearance O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
suggesting O O
that O O
the O O
AECM O B_DISEASE/B_LOCATION
and O O
cuticle O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
have O O
increased O O
in O O
surface O B_MEASURE/B_COLOR
area O I_MEASURE/I_COLOR
( O O
Figure O B_LOCATION
3F O I_LOCATION
) O O
. O O

Electron O B_LOCATION/B_NUMBER[MEASURE]
dense O B_LOCATION/I_NUMBER[MEASURE]
granules O I_BIO
up O O
to O O
~ O B_MEASURE
1 O I_MEASURE
. O O
5 O B_TIME[MEASURE]
mu O I_TIME[MEASURE]
m O I_TIME[MEASURE]
in O O
diameter O B_MEASURE
were O O
occasionally O O
observed O O
in O O
both O O
the O O
AECM O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
cell O B_LOCATION/B_ORGANIZATION
cytoplasm O I_LOCATION/I_ORGANIZATION
( O O
Figure O B_LOCATION/B_BIO
3F O I_LOCATION/I_BIO
) O O
. O O

Although O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
needed O O
to O O
determine O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
these O O
granules O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
these O O
granules O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
participate O O
in O O
the O O
secretion O B_ORGANISM_FUNCTION/B_MEASURE
and O O
deposition O B_DISEASE/B_ORGANISM_FUNCTION
of O O
the O O
AECM O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

Taken O O
together O O
, O O
our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
polarized O O
secretion O B_ORGANISM_FUNCTION/B_GENE
via O O
the O O
AECM O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
ongoing O O
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
unmated O B_PERSON/B_BIO
female O B_PERSON/I_BIO
is O O
enhanced O O
and O O
/ O O
or O O
modulated O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
post O I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

Post O B_LOCATION/B_DISEASE
- O O
mating O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
AECM O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ultrastructure O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
are O O
also O O
observed O O
in O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

However O O
, O O
unlike O O
the O O
AECM O B_DISEASE/B_LOCATION
of O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
, O O
the O O
AECM O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
well O O
developed O O
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
unmated O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
female O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
AECM O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
consists O O
of O O
an O O
amorphous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
electron O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
dense O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
material O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
is O O
unevenly O O
distributed O O
, O O
forming O O
a O O
thick O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
bulbous O B_LOCATION
layer O I_LOCATION
above O O
the O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
some O O
regions O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
additional O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Matrix O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
like O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
material O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
is O O
also O O
observed O O
in O O
the O O
lumen O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
but O O
this O O
material O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
is O O
more O O
electron O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dense O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
the O O
AECM O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
( O O
additional O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
2A O B_PROTEIN[GENE]/B_DISEASE
) O O
. O O

In O O
the O O
mated O O
female O B_PERSON/B_LOCATION
, O O
the O O
AECM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
flattened O O
against O O
the O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
is O O
uniformly O O
distributed O O
along O O
the O O
apical O B_BODY_PART_OR_ORGAN_COMPONENT
surface O I_BODY_PART_OR_ORGAN_COMPONENT
( O O
additional O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2B O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
2B O B_PROTEIN[GENE]
) O O
. O O

Matrix O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
like O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
material O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
not O O
observed O O
in O O
the O O
center O B_LOCATION
of O O
the O O
lumen O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
but O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pools O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
very O O
electron O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dense O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
material O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
detected O O
in O O
the O O
spaces O B_LOCATION/B_BIO
between O O
the O O
epithelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
folds O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
additional O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2C O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
2C O B_MEASURE/B_DISEASE
) O O
. O O

This O O
may O O
explain O O
why O O
lumenal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
matrix O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
not O O
detected O O
at O O
the O O
light O B_MEASURE/B_LOCATION
microscopic O B_MEASURE/I_LOCATION
level O B_MEASURE/I_LOCATION
in O O
the O O
mated O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
female O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
see O O
Figure O B_PROTEIN[GENE]
1E O I_PROTEIN[GENE]
and O O
1F O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Taken O O
together O O
, O O
our O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
site O B_LOCATION/B_PERSON
of O O
active O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
apical O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
both O O
mated O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
unmated O B_PERSON
females O I_PERSON
, O O
and O O
that O O
matrix O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
particularly O O
in O O
the O O
lumen O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
is O O
reduced O O
post O B_DISEASE/B_MEASURE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
raise O O
the O O
intriguing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibility O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
AECM O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
lumenal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
plug O B_PRODUCT[OBJECT]/B_LOCATION
in O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
the O O
breakdown O B_DISEASE/B_ORGANISM_FUNCTION
of O O
this O O
plug O B_PRODUCT[OBJECT]/B_LOCATION
. O O

Mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
hemi O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
adherens O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
junctions O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
upper O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
modulating O O
secretion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
the O O
apical O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
, O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
at O O
the O O
basolateral O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
. O O

In O O
many O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
steps O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
the O O
development O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
layer O B_LOCATION/B_MEASURE
of O O
extracellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ECM O B_PROTEIN[GENE]/B_LOCATION
) O O
called O O
the O O
basal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lamina O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
covers O O
the O O
apical O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
/ O O
or O O
basal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membranes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
concomitant O B_LOCATION/B_ORGANIZATION
development O I_LOCATION/I_ORGANIZATION
of O O
hemi O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
adherens O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
junctions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HAJs O B_LOCATION/B_ORGANIZATION
) O O
. O O

HAJs O B_PERSON/B_ORGANIZATION
connect O O
the O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeleton O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
ECM O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
are O O
formed O O
at O O
virtually O O
all O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
surfaces O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O O
contact O O
an O O
ECM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

HAJs O B_PERSON/B_ORGANIZATION
can O O
be O O
distinguished O O
at O O
the O O
ultrastructural O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
level O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
as O O
a O O
patch O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
like O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O O
electron O B_LOCATION/B_MEASURE
dense O I_LOCATION/I_MEASURE
undercoat O I_LOCATION/I_MEASURE
of O O
the O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
opposes O O
the O O
basal O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lamina O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
[ O B_MEASURE/B_LOCATION
26 O I_MEASURE/I_LOCATION
] O I_MEASURE/I_LOCATION
; O O
Figure O B_MEASURE/B_PERSON
3G O I_MEASURE/I_PERSON
, O O
3H O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

In O O
the O O
Drosophila B B_SPECIES[BIO]/B_PERSON
embryo O O
, O O
the O O
HAJs O O
and O O
basal O O
lamina O O
are O O
formed O O
at O O
the O O
same O O
time O O
[ O O
26 O O
] O O
. O O

Because O O
the O O
basal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
lamina O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
is O O
established O O
at O O
a O O
time O B_TIME[MEASURE]/B_LOCATION
when O O
the O O
majority O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
extracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
matrix O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
actively O O
secreted O O
[ O B_TIME[MEASURE]/B_LOCATION
26 O I_TIME[MEASURE]/I_LOCATION
, O O
29 O B_MEASURE
] O I_MEASURE
, O O
this O O
suggests O O
that O O
the O O
formation O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
HAJs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
tightly O O
coordinated O O
with O O
the O O
secretion O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_ORGANIZATION
of O O
the O O
ECM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
most O O
striking O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mating O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
the O O
appearance O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
numerous O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
HAJs O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
along O O
the O O
basolateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
3 O B_MEASURE/I_PROTEIN[GENE]
) O O
. O O

The O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HAJs O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
particularly O O
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
underscored O O
by O O
the O O
extensive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
infolding O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
basolateral O B_BODY_PART_OR_ORGAN_COMPONENT
membrane O I_BODY_PART_OR_ORGAN_COMPONENT
that O O
is O O
observed O O
in O O
both O O
unmated O B_PERSON
and O O
mated O O
females O B_PERSON/B_BIO
( O O
Figure O B_PROTEIN[GENE]
3A O I_PROTEIN[GENE]
and O O
3E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
infolded O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gives O O
rise O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
highly O O
branched O O
intercellular O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
space O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
that O O
is O O
filled O O
with O O
an O O
ECM O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
3C O I_PROTEIN[GENE]/I_LOCATION
and O O
3G O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

This O O
ECM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
is O O
contiguous O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
basal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lamina O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
surrounds O O
the O O
epithelia O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Few O B_NUMBER[MEASURE]/B_PERSON
HAJs O B_NUMBER[MEASURE]/I_PERSON
were O O
observed O O
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
unmated O B_PERSON/B_SPECIES[BIO]
female O B_PERSON/I_SPECIES[BIO]
, O O
and O O
these O O
were O O
largely O O
restricted O O
to O O
the O O
basal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
not O O
observed O O
along O O
the O O
basolateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infolding O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
3C O I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
numerous O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
HAJs O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
appear O O
along O O
the O O
basolateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
infolding O O
post O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
mating O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
region O B_LOCATION/B_MEASURE
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
3F O I_MEASURE/I_PROTEIN[GENE]
- O O
3H O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
intercellular O B_MEASURE/B_GENE
space O I_MEASURE/I_GENE
appears O O
wider O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
3C O I_PROTEIN[GENE]/I_LOCATION
- O O
3D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
3G O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
, O O
suggesting O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
increased O O
secretion O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_GENE
and O O
/ O O
or O O
deposition O B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
ECM O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
compartment O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
brings O O
the O O
ECM O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
a O O
threshold O B_MEASURE/B_LOCATION
concentration O B_MEASURE/I_LOCATION
that O O
can O O
support O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
HAJs O B_DISEASE/B_ORGANISM_FUNCTION
. O O

HAJs O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
were O O
also O O
detected O O
along O O
the O O
basal O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
they O O
were O O
not O O
detected O O
along O O
the O O
apical O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
even O O
though O O
this O O
membrane O B_LOCATION/B_GENE
was O O
covered O O
by O O
an O O
ECM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Interestingly O O
, O O
while O O
the O O
basolateral O B_BODY_PART_OR_ORGAN_COMPONENT
membrane O I_BODY_PART_OR_ORGAN_COMPONENT
forms O O
very O O
shallow O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
folds O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
see O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
file O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
) O O
, O O
HAJs O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
were O O
observed O O
along O O
this O O
membrane O B_LOCATION/B_MEASURE
in O O
unmated O B_MEASURE
reproductive O I_MEASURE
tracts O I_MEASURE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
, O O
thus O O
suggesting O O
that O O
the O O
epithelia O B_BODY_PART_OR_ORGAN_COMPONENT
is O O
more O O
differentiated O O
in O O
this O O
region O B_LOCATION/B_MEASURE
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
the O O
differentiation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
of O O
the O O
upper O B_LOCATION/B_MEASURE
and O O
lower O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
under O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O O

Muscle O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
enhanced O O
post O B_LOCATION/B_MEASURE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE

While O O
we O O
uncovered O O
post O B_LOCATION/B_DISEASE
- O O
mating O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
oviduct O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
epithelia O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
might O O
facilitate O O
its O O
transition O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
to O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
egg O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
- O O
laying O O
state O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
this O O
transition O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
also O O
be O O
mediated O O
by O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
muscle O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
/ O O
or O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
lined O O
by O O
circular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
fibers O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
with O O
supercontractile O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
30 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
mef2 O B_GENE
and O O
mlp84B O B_GENE/B_BIO
genes O I_GENE/I_BIO
that O O
regulate O O
muscle O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
are O O
expressed O O
and O O
increased O O
post O B_LOCATION/B_DISEASE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
in O O
the O O
sperm O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
storage O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
reproductive O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
[ O O
22 O B_MEASURE
, O O
23 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

This O O
suggests O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
muscle O B_DISEASE/B_ORGANISM_FUNCTION
differentiation O I_DISEASE/I_ORGANISM_FUNCTION
in O O
the O O
reproductive O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

Muscle O B_DISEASE/B_LOCATION
differentiation O I_DISEASE/I_LOCATION
is O O
characterized O O
by O O
the O O
assembly O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
myofilaments O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
into O O
bundles O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
called O O
myofibrils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
muscles O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiate O O
, O O
myofibrils O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
z O B_MEASURE/B_PROTEIN[GENE]
- O O
bodies O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
appear O O
simultaneously O O
, O O
and O O
increase O O
in O O
number O B_MEASURE
until O O
the O O
cytoplasm O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
is O O
filled O O
with O O
myofibrils O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
[ O O
31 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Like O O
epithelia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
, O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
steps O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O O
muscle O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
secretion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
a O O
basal O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lamina O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
surrounds O O
the O O
muscle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
fiber O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
determine O O
if O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O O
structural O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
muscles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
increased O O
myofibrils O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O O
we O O
examined O O
the O O
ultrastructure O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fibers O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O O
lower O B_LOCATION/B_MEASURE
parts O I_LOCATION/I_MEASURE
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
that O O
, O O
in O O
both O O
unmated O B_PERSON/B_ORGANISM_FUNCTION
and O O
mated O O
reproductive O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
muscles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
are O O
highly O O
differentiated O O
as O O
evidenced O O
by O O
the O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
density O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
myofibrils O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
well O O
developed O O
and O O
aligned O O
z O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
bodies O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
secretion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
a O O
thick O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
electron O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
dense O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
basal O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
lamina O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
Figure O B_PROTEIN[GENE]
4E O I_PROTEIN[GENE]
and O O
4F O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fibers O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
lateral O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appear O O
less O O
differentiated O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
muscles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
evidenced O O
by O O
the O O
lesser O B_MEASURE/B_DISEASE
density O I_MEASURE/I_DISEASE
of O O
myofibrils O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
z O B_MEASURE/B_PROTEIN[GENE]
- O O
bodies O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
no O O
basal O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lamina O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_PROTEIN[GENE]/B_MEASURE
4A O I_PROTEIN[GENE]/I_MEASURE
and O O
4B O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Moreover O O
, O O
the O O
muscles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appear O O
more O O
differentiated O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
mated O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
in O O
unmated O B_PERSON/B_BIO
reproductive O I_PERSON/I_BIO
tracts O I_PERSON/I_BIO
( O O
Figure O B_PROTEIN[GENE]
4A O I_PROTEIN[GENE]
- O O
4D O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

Interestingly O O
, O O
we O O
observed O O
neighboring O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscle O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibers O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
different O B_LOCATION/B_MEASURE
states O I_LOCATION/I_MEASURE
of O O
differentiation O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
unmated O B_PERSON/B_BIO
and O O
mated O O
reproductive O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
elsewhere O O
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
4B O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enhances O O
the O O
rate O B_MEASURE
of O O
muscle O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
upper O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
muscle O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
is O O
delayed O O
in O O
the O O
upper O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
as O O
compared O O
to O O
the O O
lower O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
increased O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
the O O
upper O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
dramatic O B_DISEASE_ADJECTIVE[DISEASE]
and O O
likely O O
reflects O O
the O O
short O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mating O B_TIME[MEASURE]
period O I_TIME[MEASURE]
examined O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

The O O
delayed O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
resembles O O
the O O
delay O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
onset O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O O
the O O
adult O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
thoracic O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
abdominal O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
during O O
metamorphosis O B_ORGANISM_FUNCTION/B_TIME[MEASURE]
[ O I_ORGANISM_FUNCTION/I_TIME[MEASURE]
32 O I_ORGANISM_FUNCTION/I_TIME[MEASURE]
] O I_ORGANISM_FUNCTION/I_TIME[MEASURE]
. O O

Since O O
the O O
ovaries O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
parts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
reproductive O B_BODY_PART_OR_ORGAN_COMPONENT
tract O I_BODY_PART_OR_ORGAN_COMPONENT
are O O
known O O
to O O
have O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
segmental O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
origins O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
33 O B_ORGANISM_FUNCTION/B_BIO
] O I_ORGANISM_FUNCTION/I_BIO
, O O
we O O
hypothesize O O
that O O
different O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
parts O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
develop O O
at O O
different O B_TIME[MEASURE]/B_LOCATION
rates O I_TIME[MEASURE]/I_LOCATION
or O O
begin O O
development O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
different O B_TIME[MEASURE]/B_ENT
times O I_TIME[MEASURE]/I_ENT
. O O

Increased O O
innervation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
the O O
oviduct O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION

Nerve O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O O
muscle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
interactions O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
play O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
adult O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
muscle O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
refining O O
the O O
final O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
innervation O B_DISEASE/B_ORGANISM_FUNCTION
[ O B_DISEASE/I_ORGANISM_FUNCTION
34 O B_DISEASE/I_ORGANISM_FUNCTION
, O O
35 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Given O O
that O O
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
muscle O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O O
enhanced O O
post O B_LOCATION/B_MEASURE
- O O
mating O B_ORGANISM_FUNCTION/B_BIO
, O O
we O O
predicted O O
that O O
mating O O
either O O
directly O O
or O O
indirectly O O
induces O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
innervation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O O

To O O
address O O
this O O
prediction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
quantified O O
the O O
number O B_MEASURE
of O O
nerve O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
terminals O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
boutons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
innervating O O
the O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
oviducts O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
unmated O B_PERSON/B_BIO
and O O
mated O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
reproductive O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
tracts O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O O

Studies O O
of O O
oviduct O O
innervation O O
in O O
Drosophila O O
reveal O O
that O O
the O O
fly B B_SPECIES[BIO]/B_PERSON
' O O
s O O
oviduct O O
receives O O
aminergic O O
, O O
peptidergic O O
and O O
glutamatergic O O
input O O
[ O O
30 O O
, O O
36 O O
- O O
39 O O
] O O
. O O

In O O
both O O
larval O B_PERSON/B_BIO
and O O
adult O B_PERSON/B_BIO
Drosophila O I_PERSON/I_BIO
, O O
different O B_LOCATION/B_MEASURE
types O I_LOCATION/I_MEASURE
of O O
boutons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
formed O O
by O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
express O O
different O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neurotransmitters O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
modulators O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O O
40 O B_MEASURE
- O O
42 O B_MEASURE
] O I_MEASURE
. O O

By O O
similarity O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
boutons O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
described O O
at O O
the O O
larval O B_PERSON
and O O
adult O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
neuromuscular O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
junction O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
Middleton O B_LOCATION/B_GENE
et O B_LOCATION/I_GENE
al O B_LOCATION/I_GENE
. O O

[ O O
30 O O
] O O
report O O
that O O
the O O
fly B B_SPECIES[BIO]
' O O
s O O
oviduct O O
is O O
innervated O O
by O O
glutamatergic O O
type O O
I O O
boutons O O
and O O
tyraminergic O O
/ O O
octopaminergic O O
type O O
II O O
boutons O O
. O O

Rodgriguez O B_PERSON
- O O
Valentin O B_PERSON/B_LOCATION
et O B_PERSON/I_LOCATION
al O B_PERSON/I_LOCATION
. O O

[ O O
43 O O
] O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
express O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
octopamine O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
glutamate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O O
give O O
rise O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
type O B_MEASURE/B_DISEASE
I O O
innervation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O O
not O O
been O O
identified O O
. O O

However O O
, O O
it O O
is O O
well O O
established O O
that O O
type O B_DISEASE
II O I_DISEASE
innervation O I_DISEASE
arises O O
from O O
octopaminergic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
located O O
in O O
the O O
abdominal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglion O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
30 O B_MEASURE
, O O
43 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
it O O
has O O
been O O
shown O O
that O O
some O O
or O O
all O O
of O O
these O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
express O O
a O O
GAL4 O B_GENE/B_MEASURE
insertion O I_GENE/I_MEASURE
line O I_GENE/I_MEASURE
for O O
the O O
bullwinkle O B_SPECIES[BIO]/B_GENE
( O O
bwk O B_PROTEIN[GENE]/B_DISEASE
) O O
gene O B_GENE
[ O O
43 O B_TIME[MEASURE]
] O O
. O O

Bwk O B_GENE/B_DISEASE
encodes O O
a O O
HMG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
box O B_LOCATION/B_MEASURE
containing O O
putative O B_ENZYME[GENE]/B_LOCATION
transcription O I_ENZYME[GENE]/I_LOCATION
factor O I_ENZYME[GENE]/I_LOCATION
[ O O
44 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

To O O
determine O O
if O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
any O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
number O B_MEASURE/B_LOCATION
of O O
type O B_DISEASE/B_MEASURE
I O O
and O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
innervating O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
used O O
the O O
pan O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
neural O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marker O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
anti O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
HRP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
label O O
all O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
unmated O B_PERSON
and O O
mated O B_PERSON
females O I_PERSON
. O O

To O O
distinguish O O
between O O
type O B_MEASURE/B_PERSON
I O O
and O O
II O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons O O
we O O
used O O
an O O
antibody O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
the O O
Disc O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Large O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DLG O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
protein O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
[ O O
45 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

Type O B_MEASURE/B_PERSON
I O O
boutons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
identified O O
by O O
their O O
DLG O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
postsynaptic O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
staining O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
large O B_MEASURE/B_LOCATION
size O I_MEASURE/I_LOCATION
( O O
> O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
8 O B_MEASURE
mu O I_MEASURE
m O I_MEASURE
in O O
diameter O B_MEASURE/B_BIO
) O O
( O O
Figure O B_PROTEIN[GENE]
4G O I_PROTEIN[GENE]
) O O
, O O
while O O
type O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
boutons O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
distinguished O O
by O O
their O O
absence O B_MEASURE/B_DISEASE
of O O
DLG O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
smaller O B_MEASURE
size O I_MEASURE
( O O
< O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
mu O I_MEASURE/I_LOCATION
m O I_MEASURE/I_LOCATION
) O O
( O O
Figure O B_MEASURE
4H O I_MEASURE
) O O
. O O

We O O
find O O
that O O
type O B_MEASURE/B_DISEASE
I O O
and O O
II O B_TIME[MEASURE]/B_PROTEIN[GENE]
boutons O I_TIME[MEASURE]/I_PROTEIN[GENE]
innervate O O
the O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
oviducts O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
the O O
type O B_MEASURE/B_LOCATION
I O O
innervation O O
is O O
restricted O O
to O O
a O O
few O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
run O O
parallel O O
to O O
the O O
length O B_MEASURE/B_LOCATION
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
the O O
type O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
II O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
innervation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
more O O
widespread O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

We O O
quantified O O
the O O
number O B_MEASURE/B_LOCATION
of O O
boutons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
oviducts O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
and O O
observed O O
a O O
74 O B_MEASURE
% O I_MEASURE
increase O I_MEASURE
in O O
bouton O B_MEASURE/B_ORGANISM_FUNCTION
number O I_MEASURE/I_ORGANISM_FUNCTION
in O O
the O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
a O O
66 O B_MEASURE
% O I_MEASURE
increase O I_MEASURE
in O O
the O O
common O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
4I O I_MEASURE/I_PROTEIN[GENE]
) O O
. O O

More O B_NUMBER[MEASURE]
over O O
, O O
we O O
observed O O
no O O
significant O B_MEASURE
change O I_MEASURE
in O O
the O O
number O B_MEASURE/B_LOCATION
of O O
type O B_MEASURE/B_DISEASE
I O O
boutons O O
in O O
the O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
we O O
detected O O
a O O
1 O B_MEASURE
. O O
5 O B_MEASURE
- O O
fold O B_MEASURE
increase O I_MEASURE
in O O
the O O
number O B_MEASURE
of O O
type O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
II O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
boutons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
1 O B_MEASURE
. O O
8 O B_MEASURE
- O O
fold O B_MEASURE/B_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
type O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
innervation O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Dramatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
increases O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
bouton O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
also O O
observed O O
during O O
development O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
a O O
ten O B_NUMBER[MEASURE]
- O O
fold O B_MEASURE/B_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
bouton O B_MEASURE
number O I_MEASURE
is O O
observed O O
at O O
the O O
neuromuscular O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
junction O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
during O O
the O O
larval O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
46 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

To O O
determine O O
if O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
innervation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
mating O B_PERSON/B_ORGANISM_FUNCTION
or O O
reflected O O
normal O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
3 O B_TIME[MEASURE]
day O I_TIME[MEASURE]
- O O
old O B_PERSON/B_TIME[MEASURE]
females O B_PERSON/I_TIME[MEASURE]
, O O
we O O
quantified O O
type O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
I O O
and O O
II O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
innervation O I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
5 O B_TIME[MEASURE]
day O I_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
females O I_PERSON
. O O

We O O
found O O
no O O
significant O B_MEASURE
difference O I_MEASURE
in O O
type O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
I O O
and O O
II O B_MEASURE/B_PROTEIN[GENE]
innervation O I_MEASURE/I_PROTEIN[GENE]
in O O
unmated O B_TIME[MEASURE]/B_ENT
3 O I_TIME[MEASURE]/I_ENT
day O I_TIME[MEASURE]/I_ENT
- O O
old O B_TIME[MEASURE]/B_PERSON
and O O
5 O B_MEASURE
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
, O O
indicating O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
, O O
either O O
directly O O
or O O
indirectly O O
, O O
induces O O
a O O
dramatic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
II O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
innervation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
Figure O B_LOCATION/B_PROTEIN[GENE]
4I O I_LOCATION/I_PROTEIN[GENE]
) O O
. O O

To O O
determine O O
if O O
the O O
post O B_LOCATION/B_DISEASE
- O O
mating O B_MEASURE
increase O I_MEASURE
in O O
innervation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
unique O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O O
we O O
asked O O
if O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
induces O O
a O O
global O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
change O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
innervation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
quantified O O
bouton O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
number O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
adult O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
ventral O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
midline O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
muscles O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O O
the O O
5th O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
abdominal O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
segment O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
muscles O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
innervated O O
by O O
boutons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
increase O O
in O O
number O B_MEASURE
during O O
metamorphosis O B_DISEASE/B_ORGANISM_FUNCTION
[ O I_DISEASE/I_ORGANISM_FUNCTION
47 O I_DISEASE/I_ORGANISM_FUNCTION
] O I_DISEASE/I_ORGANISM_FUNCTION
. O O

No O O
significant O B_MEASURE
difference O I_MEASURE
in O O
bouton O B_MEASURE
number O I_MEASURE
was O O
detected O O
at O O
these O O
muscles O B_TIME[MEASURE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
unmated O B_PERSON
and O O
mated O O
females O B_PERSON/B_BIO
( O O
additional O B_MEASURE
file O I_MEASURE
3 O I_MEASURE
) O O
. O O

Though O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
needed O O
, O O
this O O
suggests O O
that O O
the O O
post O B_LOCATION/B_DISEASE
- O O
mating O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
increase O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
innervation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
oviduct O B_BIO/B_PERSON
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Because O O
the O O
type O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
II O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
boutons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
octopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
increased O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
innervation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
result O O
in O O
increased O O
octopamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
OA O B_PROTEIN[GENE]/B_DISEASE
) O O
release O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
support O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
have O O
preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
OA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
released O O
in O O
the O O
oviduct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
post O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O O
Heifetz O B_PERSON
and O O
Wolfner O B_PERSON
, O O
in O O
preparation O B_MEASURE
) O O
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
locust O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Drosophila O B_SPECIES[BIO]
demonstrate O O
that O O
OA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibits O O
oviduct O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
contraction O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
while O O
glutamate O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct O O
contraction O B_DISEASE/B_ORGANISM_FUNCTION
[ O O
30 O B_MEASURE
, O O
43 O B_MEASURE
, O O
48 O B_MEASURE
] O I_MEASURE
. O O

In O O
Drosophila O B_SPECIES[BIO]
, O O
electrical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
abdominal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
nerve O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
gives O O
rise O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
a O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]
contractions O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
followed O O
by O O
a O O
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
muscle O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fatigue O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
relaxation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O O
43 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

This O O
pattern O B_MEASURE/B_DISEASE
of O O
muscle O B_DISEASE/B_ORGANISM_FUNCTION
contraction O I_DISEASE/I_ORGANISM_FUNCTION
and O O
relaxation O B_DISEASE/B_ORGANISM_FUNCTION
may O O
facilitate O O
the O O
proper O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
movement O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
the O O
egg O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
their O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
bwk O B_GENE/B_DISEASE
expressing O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O O
innervate O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Rodriguez O B_PERSON
- O O
Valentin O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O I_PERSON/I_LOCATION
. O O

[ O O
43 O O
] O O
show O O
that O O
OA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
glutamate O O
interact O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
produce O O
the O O
pattern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
oviduct O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contraction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
relaxation O B_DISEASE/B_ORGANISM_FUNCTION
described O O
above O O
. O O

It O O
is O O
therefore O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
post O B_DISEASE/B_MEASURE
- O O
mating O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
type O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
II O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
innervation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
increased O O
rate O B_MEASURE
of O O
ovulation O B_ORGANISM_FUNCTION/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
egg O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
laying O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
observed O O
post O B_LOCATION/B_DISEASE
- O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Female O B_DISEASE/B_TIME[MEASURE]
mating O I_DISEASE/I_TIME[MEASURE]
history O I_DISEASE/I_TIME[MEASURE]
affects O O
the O O
enrichment O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cytosekeletal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]

To O O
gain O O
insights O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cytoskeletal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
enrichment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
[ O O
23 O B_MEASURE
] O I_MEASURE
; O O
additional O B_MEASURE
file O I_MEASURE
4 O I_MEASURE
) O O
in O O
mediating O O
the O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
we O O
examined O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimes O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
cytoskeletal O B_MEASURE/B_PERSON
protein O B_MEASURE/I_PERSON
abundance O B_MEASURE/I_PERSON
. O O

We O O
focused O O
on O O
a O O
subset O B_MEASURE/B_LOCATION
of O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
responsive O B_GENE/B_MEASURE
cytoskeletal O I_GENE/I_MEASURE
proteins O I_GENE/I_MEASURE
with O O
well O O
established O O
roles O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O O
the O O
differentiation O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
of O O
muscle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
epithelia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
include O O
: O O
( O O
i O B_DISEASE/B_PROTEIN[GENE]
) O O
Mlp84B O B_GENE/B_BACTERIUM[BIO]
which O O
regulates O O
the O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
muscle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
49 O B_MEASURE
] O O
; O O
( O O
ii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
Cora O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
Nrg O B_GENE/B_PERSON
which O O
are O O
required O O
for O O
the O O
formation O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
septate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
junctions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
epithelia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
[ O O
50 O B_MEASURE
] O I_MEASURE
, O O
and O O
( O O
iii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
Hu O B_PERSON/B_LOCATION
- O O
li O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
tai O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
shao O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Hts O B_MEASURE/B_PROTEIN[GENE]
) O O
, O O
also O O
known O O
as O O
adducin O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
like O B_PROTEIN[GENE]/B_MEASURE
protein O B_PROTEIN[GENE]/I_MEASURE
, O O
which O O
functions O O
in O O
assembly O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
cytoskeletal O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
network O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Na O B_GENE
+ O I_GENE
pump O I_GENE
alpha O I_GENE
subunit O I_GENE
( O O
ATP O B_PROTEIN[GENE]/B_LOCATION
alpha O I_PROTEIN[GENE]/I_LOCATION
) O O
, O O
another O O
protein O B_ENZYME[GENE]/B_BACTERIUM[BIO]
associated O O
with O O
septate O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
junctions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
epithelia O B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
is O O
not O O
a O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
responsive O B_GENE/B_PERSON
protein O I_GENE/I_PERSON
and O O
was O O
used O O
as O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Using O O
western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blots O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
first O O
determined O O
the O O
abundance O B_MEASURE/B_LOCATION
of O O
the O O
cytoskeletal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_TIME[MEASURE]/B_PERSON
unmated O I_TIME[MEASURE]/I_PERSON
and O O
mated O O
females O B_PERSON/B_BIO
at O O
6 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

We O O
confirmed O O
the O O
proteomic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Kalpenikov O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O O
. O O

[ O O
23 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
found O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increases O O
the O O
abundance O B_MEASURE/B_LOCATION
of O O
all O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
except O O
ATP O B_GENE
alpha O I_GENE
in O O
mated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oviducts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
relative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
their O O
abundance O B_MEASURE/B_LOCATION
in O O
unmated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
oviducts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
Figure O B_MEASURE/B_PERSON
5A O I_MEASURE/I_PERSON
) O O
. O O

To O O
determine O O
whether O O
the O O
increased O O
abundance O B_MEASURE/B_LOCATION
of O O
mating O B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
responsive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
persists O O
for O O
longer O B_TIME[MEASURE]/B_LOCATION
times O I_TIME[MEASURE]/I_LOCATION
post O I_TIME[MEASURE]/I_LOCATION
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
we O O
examined O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
10 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
that O O
mated O O
once O O
at O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
age O B_ORGANISM_FUNCTION
, O O
and O O
calculated O O
the O O
abundance O B_MEASURE
of O O
the O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
- O O
responsive O B_GENE
proteins O I_GENE
relative O I_GENE
to O O
their O O
level O B_MEASURE/B_LOCATION
in O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
3 O B_MEASURE
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
females O I_PERSON
. O O

We O O
found O O
no O O
change O B_MEASURE
or O O
a O O
slight O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
relative O B_MEASURE/B_LOCATION
abundance O I_MEASURE/I_LOCATION
of O O
all O O
cytoskeletal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
except O O
Mlp84B O B_GENE/B_BACTERIUM[BIO]
at O O
7 O B_DISEASE/B_MEASURE
days O I_DISEASE/I_MEASURE
post O I_DISEASE/I_MEASURE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
Figure O B_TIME[MEASURE]/B_PROTEIN[GENE]
5A O I_TIME[MEASURE]/I_PROTEIN[GENE]
) O O
. O O

Strikingly O O
, O O
the O O
level O B_MEASURE/B_DISEASE
of O O
Mlp84B O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
declines O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
by O O
7 O B_TIME[MEASURE]/B_DISEASE
days O B_TIME[MEASURE]/I_DISEASE
post O B_TIME[MEASURE]/I_DISEASE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
to O O
the O O
level O B_MEASURE/B_LOCATION
observed O O
prior O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
Mlp84B O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
levels O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
rise O O
and O O
fall O O
after O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
while O O
the O O
epithelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
- O O
related O O
proteins O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
rapidly O O
rise O O
and O O
are O O
maintained O O
at O O
a O O
high O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
after O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
raises O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
a O O
second O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mating O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
might O O
trigger O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
Mlp84B O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
observed O O
in O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON/B_BIO
females O I_PERSON/I_BIO
at O O
6 O B_MEASURE
h O O
post O B_DISEASE/B_MEASURE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

To O O
test O O
this O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
females O B_PERSON/B_SPECIES[BIO]
were O O
mated O O
twice O O
( O O
once O O
at O O
day O B_TIME[MEASURE]/B_ORGANISM_FUNCTION
3 O I_TIME[MEASURE]/I_ORGANISM_FUNCTION
, O O
and O O
once O O
on O O
day O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
age O B_TIME[MEASURE]/B_ORGANISM_FUNCTION
) O O
, O O
and O O
their O O
oviducts O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
examined O O
at O O
6 O B_TIME[MEASURE]/B_LOCATION
hrs O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
second O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
mating O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

We O O
calculated O O
the O O
abundance O B_MEASURE/B_LOCATION
of O O
the O O
cytoskeletal O B_GENE/B_BIO
proteins O B_GENE/I_BIO
in O O
the O O
twice O B_BODY_PART_OR_ORGAN_COMPONENT
mated O I_BODY_PART_OR_ORGAN_COMPONENT
oviducts O I_BODY_PART_OR_ORGAN_COMPONENT
relative O I_BODY_PART_OR_ORGAN_COMPONENT
to O O
their O O
abundance O B_MEASURE/B_LOCATION
in O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_TIME[MEASURE]
unmated O I_TIME[MEASURE]
females O I_TIME[MEASURE]
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
a O O
second O B_GENE
mating O I_GENE
has O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
Mlp84B O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
abundance O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

Thus O O
, O O
Mlp84B O B_GENE/B_PERSON
may O O
represent O O
a O O
class O B_PERSON/B_LOCATION
of O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
responsive O B_GENE/B_MEASURE
proteins O I_GENE/I_MEASURE
that O O
is O O
only O O
needed O O
after O O
the O O
first O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mating O B_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Interestingly O O
, O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
second O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
epithelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
- O O
related O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
responsive O B_PROTEIN[GENE]/B_LOCATION
proteins O I_PROTEIN[GENE]/I_LOCATION
appears O O
to O O
be O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
each O O
protein O B_BIO/B_PERSON
. O O

While O O
Cora O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
drop O O
to O O
the O O
level O B_MEASURE/B_LOCATION
observed O O
in O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
unmated O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
females O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
Nrg O B_LOCATION/B_PROTEIN[GENE]
and O O
Hts O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
are O O
maintained O O
at O O
a O O
high O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
. O O

To O O
determine O O
if O O
the O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cytoskeletal O B_MEASURE/B_BIO
protein O B_MEASURE/I_BIO
abundance O B_MEASURE/I_BIO
are O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
we O O
measured O O
their O O
abundance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
the O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
unmated O B_NUMBER[MEASURE]
5 O I_NUMBER[MEASURE]
- O O
and O O
10 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
. O O

We O O
calculated O O
their O O
abundance O B_MEASURE
relative O I_MEASURE
to O O
their O O
level O B_MEASURE/B_LOCATION
in O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
of O O
unmated O B_NUMBER[MEASURE]
3 O I_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_TIME[MEASURE]/B_PERSON
females O I_TIME[MEASURE]/I_PERSON
( O O
Figure O B_TIME[MEASURE]/B_PERSON
5B O I_TIME[MEASURE]/I_PERSON
) O O
. O O

We O O
rationalized O O
that O O
if O O
the O O
change O B_MEASURE
in O O
cytoskeletal O B_MEASURE/B_PERSON
protein O B_MEASURE/I_PERSON
abundance O B_MEASURE/I_PERSON
is O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
we O O
will O O
not O O
see O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
unmated O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
females O B_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
observed O O
a O O
slow O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
relative O B_MEASURE/B_ENT
abundance O I_MEASURE/I_ENT
of O O
all O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
responsive O B_GENE/B_PERSON
proteins O I_GENE/I_PERSON
with O O
time O B_MEASURE/B_LOCATION
post O B_MEASURE/I_LOCATION
- O O
eclosion O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
5B O I_MEASURE/I_PROTEIN[GENE]
) O O
. O O

Because O O
unmated O B_PERSON/B_BIO
females O I_PERSON/I_BIO
lay O O
more O B_MEASURE/B_LOCATION
eggs O B_MEASURE/I_LOCATION
as O O
they O O
age O O
( O O
see O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
file O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
5C O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possible O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
increased O O
level O B_MEASURE/B_PERSON
of O O
cytoskeletal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
unmated O B_PERSON/B_BIO
females O I_PERSON/I_BIO
is O O
that O O
these O O
proteins O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
associated O O
with O O
an O O
intrinsic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
oviduct O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
maturation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
accelerates O O
this O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
maximize O O
egg O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
laying O O
efficacy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Alternatively O O
, O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
slow O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
in O O
protein O B_MEASURE/B_ORGANISM_FUNCTION
abundance O I_MEASURE/I_ORGANISM_FUNCTION
observed O O
in O O
unmated O B_PERSON/B_BIO
females O B_PERSON/I_BIO
is O O
due O O
to O O
the O O
passage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
eggs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Taken O O
together O O
, O O
our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
fine O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
tune O O
the O O
levels O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
responsive O B_GENE/B_MEASURE
proteins O I_GENE/I_MEASURE
examined O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Because O O
the O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cytoskeletal O B_MEASURE/B_BIO
protein O I_MEASURE/I_BIO
abundance O I_MEASURE/I_BIO
are O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
unmated O B_PERSON
and O O
mated O B_PERSON/B_DISEASE
females O I_PERSON/I_DISEASE
, O O
this O O
suggests O O
that O O
the O O
post O B_DISEASE/B_LOCATION
- O O
mating O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
mating O O
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
we O O
suggest O O
that O O
these O O
post O B_LOCATION/B_DISEASE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
changes O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
are O O
linked O O
to O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
oviduct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O O

Early O B_TIME[MEASURE]/B_PERSON
or O O
prior O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
mating O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
increases O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
fecundity O O

In O O
Drosophila O B_SPECIES[BIO]/B_PERSON
, O O
female O B_DISEASE/B_GENE
fecundity O I_DISEASE/I_GENE
decreases O O
with O O
age O B_MEASURE/B_PERSON
[ O O
51 O B_MEASURE
- O O
54 O B_MEASURE
] O I_MEASURE
. O O

It O O
has O O
been O O
proposed O O
that O O
this O O
decrease O B_DISEASE
is O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
to O O
the O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
germline O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O O
somatic O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
55 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Since O O
the O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
oviduct O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeletal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
examined O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
change O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
age O B_TIME[MEASURE]/B_ORGANISM_FUNCTION
and O O
mating O B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experience O I_ORGANISM_FUNCTION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
state O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
may O O
also O O
play O O
a O O
role O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
fecundity O B_ORGANISM_FUNCTION/B_DISEASE
. O O

To O O
separate O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O O
age O B_ORGANISM_FUNCTION
and O O
mating O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
, O O
we O O
measured O O
the O O
fecundity O B_MEASURE
of O O
females O B_PERSON/B_BIO
that O O
mated O O
twice O O
, O O
first O O
at O O
3 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
eclosion O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
and O O
again O O
at O O
10 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
and O O
compared O O
that O O
to O O
the O O
fecundity O B_MEASURE
of O O
females O B_PERSON
that O O
mated O O
once O O
at O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
and O O
females O B_PERSON
that O O
mated O O
once O O
at O O
10 O B_ENT/B_TIME[MEASURE]
days O B_ENT/I_TIME[MEASURE]
. O O

Fecundity O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
measured O O
as O O
the O O
number O B_MEASURE
of O O
eggs O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laid O O
per O O
day O B_TIME[MEASURE]/B_PERSON
per O O
female O B_PERSON
during O O
the O O
first O B_TIME[MEASURE]/B_ENT
three O I_TIME[MEASURE]/I_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

Once O O
- O O
mated O O
3 O B_MEASURE
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
laid O O
nearly O O
twice O O
as O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
eggs O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
as O O
once O O
- O O
mated O O
10 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
during O O
the O O
three O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
examined O O
( O O
24 O B_MEASURE
. O O
5 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
. O O
7 O B_MEASURE
versus O I_MEASURE
13 O I_MEASURE
. O O
3 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
, O O
p O O
< O B_MEASURE
0 O I_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

Twice O B_NUMBER[MEASURE]/B_PERSON
- O O
mated O O
10 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
also O O
laid O O
about O O
50 O B_MEASURE
% O I_MEASURE
more O I_MEASURE
eggs O I_MEASURE
than O O
once O O
- O O
mated O O
females O B_PERSON/B_BIO
of O O
the O O
same O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
age O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
19 O B_MEASURE
. O O
3 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
versus O I_MEASURE
13 O I_MEASURE
. O O
3 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
, O O
p O O
< O B_NUMBER[MEASURE]/B_LOCATION
0 O I_NUMBER[MEASURE]/I_LOCATION
. O O
0001 O B_MEASURE
) O O
, O O
but O O
about O O
20 O B_MEASURE
% O I_MEASURE
fewer O I_MEASURE
than O O
laid O O
by O O
once O O
- O O
mated O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
during O O
the O O
three O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
examined O O
( O O
19 O B_MEASURE
. O O
3 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
. O O
9 O B_MEASURE
versus O I_MEASURE
24 O I_MEASURE
. O O
5 O B_MEASURE
+/- O I_MEASURE
0 O I_MEASURE
. O O
7 O B_MEASURE
, O O
p O O
< O B_MEASURE
0 O I_MEASURE
. O O
0001 O B_MEASURE
) O O
( O O
Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
6A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
see O O
also O O
additional O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5A O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5B O B_MEASURE/B_LOCATION
) O O
. O O

Thus O O
, O O
the O O
difference O B_MEASURE
in O O
fecundity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
between O O
once O O
- O O
mated O O
10 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_TIME[MEASURE]/B_PERSON
and O O
once O O
- O O
mated O O
3 O B_MEASURE
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
is O O
not O O
a O O
result O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
age O B_TIME[MEASURE]/B_PERSON
alone O O
. O O

Rather O O
the O O
main O B_MEASURE
determinant O I_MEASURE
of O O
fecundity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
10 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
is O O
whether O O
there O O
had O O
been O O
a O O
prior O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mating O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

We O O
also O O
calculated O O
the O O
fertility O B_ORGANISM_FUNCTION/B_MEASURE
( O O
number O B_MEASURE/B_PERSON
of O O
adults O B_PERSON/B_LOCATION
eclosed O O
) O O
of O O
once O O
- O O
and O O
twice O B_NUMBER[MEASURE]/B_LOCATION
- O O
mated O O
females O B_PERSON/B_BIO
. O O

Once O O
- O O
mated O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
are O O
more O O
fertile O B_LOCATION/B_PERSON
than O O
once O O
- O O
mated O B_NUMBER[MEASURE]/B_PERSON
10 O I_NUMBER[MEASURE]/I_PERSON
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
( O O
69 O B_MEASURE
. O O
5 O B_MEASURE
+/- O I_MEASURE
1 O I_MEASURE
. O O
6 O B_MEASURE
% O I_MEASURE
versus O I_MEASURE
56 O I_MEASURE
. O O
1 O B_MEASURE
+/- O I_MEASURE
3 O I_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
and O O
slightly O O
more O O
fertile O B_LOCATION/B_PERSON
than O O
twice O O
- O O
mated O B_NUMBER[MEASURE]/B_PERSON
10 O I_NUMBER[MEASURE]/I_PERSON
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
( O O
69 O B_MEASURE
. O O
5 O B_MEASURE
+/- O I_MEASURE
1 O I_MEASURE
. O O
6 O B_MEASURE
% O I_MEASURE
versus O I_MEASURE
62 O I_MEASURE
. O O
7 O B_MEASURE
+/- O I_MEASURE
2 O I_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
p O O
< O O
0 O B_MEASURE
. O O
015 O B_MEASURE
) O O
( O O
Figure O B_MEASURE/B_LOCATION
6B O I_MEASURE/I_LOCATION
, O O
see O O
also O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
file O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
5D O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

Because O O
there O O
is O O
no O O
significant O B_MEASURE
difference O I_MEASURE
in O O
fertility O B_PERSON/B_ORGANISM_FUNCTION
between O O
once O O
- O O
mated O O
and O O
twice O O
- O O
mated O O
10 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
, O O
this O O
suggests O O
that O O
( O O
1 O B_TIME[MEASURE]
) O O
a O O
prior O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mating O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
has O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
fertility O B_ORGANISM_FUNCTION
of O O
10 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_TIME[MEASURE]/B_PERSON
mated O O
females O B_PERSON/B_BIO
and O O
( O O
2 O B_NUMBER[MEASURE]
) O O
fertility O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
age O B_MEASURE/B_PERSON
. O O

One O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intriguing O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
that O O
an O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fecundity O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
partially O O
compensates O O
for O O
the O O
age O B_TIME[MEASURE]/B_PERSON
- O O
related O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
fertility O B_PERSON/B_ORGANISM_FUNCTION
. O O

Thus O O
, O O
cytoskeletal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mating O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
responsive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protein O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O O
be O O
associated O O
with O O
structural O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
that O O
result O O
in O O
increased O O
fecundity O B_ORGANISM_FUNCTION/B_DISEASE
. O O

This O O
may O O
counteract O O
the O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
decreased O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fertility O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
reproductive O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
output O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Despite O O
the O O
use O O
of O O
Drosophila O O
as O O
a O O
model O O
system O O
for O O
organ O O
- O O
level O O
biology O O
and O O
the O O
emerging O O
parallels O O
between O O
mammalian O O
and O O
Drosophila B B_SPECIES[BIO]
reproductive O O
biology O O
[ O O
56 O O
] O O
, O O
this O O
is O O
the O O
first O O
integrative O O
tissue O O
- O O
wide O O
study O O
of O O
post O O
- O O
mating O O
changes O O
in O O
the O O
Drosophila B B_SPECIES[BIO]/B_PERSON
oviduct O O
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
several O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
lines O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
at O O
the O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
morphological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
physiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
wide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Moreover O O
, O O
we O O
identify O O
ultrastructural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
mated O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
roles O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
some O O
of O O
the O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
responsive O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
examined O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
Mlp84B O B_GENE/B_BACTERIUM[BIO]
, O O
Cora O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Nrg O B_GENE/B_BACTERIUM[BIO]
) O O
are O O
reported O O
to O O
play O O
in O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
and O O
epithelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
elsewhere O O
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
the O O
increased O O
abundance O B_MEASURE
of O O
Mlp84B O B_GENE/B_BACTERIUM[BIO]
, O O
a O O
major O B_PERSON/B_LOCATION
regulator O I_PERSON/I_LOCATION
of O O
the O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
muscle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
[ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
49 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
] O O
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
increased O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
upper O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Figure O B_LOCATION/B_PROTEIN[GENE]
4A O I_LOCATION/I_PROTEIN[GENE]
- O O
4F O B_MEASURE/B_PROTEIN[GENE]
) O O
. O O

Similarly O O
, O O
the O O
increased O O
abundance O B_MEASURE/B_LOCATION
of O O
Cora O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
Nrg O B_GENE/B_BACTERIUM[BIO]
, O O
molecules O B_BIO/B_GENE
that O O
are O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
SJ O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development O I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
function O B_ORGANISM_FUNCTION/B_DISEASE
[ O I_ORGANISM_FUNCTION/I_DISEASE
50 O I_ORGANISM_FUNCTION/I_DISEASE
] O I_ORGANISM_FUNCTION/I_DISEASE
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
SJs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
immature O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
/ O O
or O O
that O O
mating O B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
apical O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
extracellular O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
whose O O
secretion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
may O O
be O O
regulated O O
, O O
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
by O O
SJs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
occurs O O
in O O
the O O
trachea O B_BODY_PART_OR_ORGAN_COMPONENT
[ O O
27 O B_MEASURE
, O O
28 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
post O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
mating O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
indicate O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
wide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
include O O
increased O O
HAJs O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O O
the O O
basolateral O B_BODY_PART_OR_ORGAN_COMPONENT
membrane O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
increased O O
innervation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
protein O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
abundance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
following O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mating O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
regimes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
unmated O B_TIME[MEASURE]/B_LOCATION
, O O
once O O
- O O
mated O O
, O O
twice O B_NUMBER[MEASURE]/B_LOCATION
- O O
mated O O
) O O
gave O O
us O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insights O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
into O O
the O O
possible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
roles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
responsive O B_GENE/B_LOCATION
proteins O I_GENE/I_LOCATION
play O O
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
Mlp84B O B_GENE/B_BACTERIUM[BIO]
is O O
only O O
responsive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
first O B_PERSON/B_SEQUENCE[MEASURE]
mating O I_PERSON/I_SEQUENCE[MEASURE]
, O O
while O O
the O O
epithelial O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
proteins O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
examined O O
( O O
Cora O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Nrg O B_GENE/B_BACTERIUM[BIO]
and O O
Hts O B_GENE/B_BIO
) O O
are O O
responsive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
first O B_SEQUENCE[MEASURE]/B_PERSON
and O O
second O B_SEQUENCE[MEASURE]/B_LOCATION
mating O I_SEQUENCE[MEASURE]/I_LOCATION
. O O

Furthermore O O
, O O
the O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
second O B_SEQUENCE[MEASURE]/B_PERSON
mating O I_SEQUENCE[MEASURE]/I_PERSON
is O O
different O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
first O B_TIME[MEASURE]/B_PERSON
mating O I_TIME[MEASURE]/I_PERSON
. O O

Taken O O
together O O
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
Mlp84B O B_GENE/B_BACTERIUM[BIO]
is O O
required O O
for O O
the O O
final O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maturation O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
the O O
epithelial O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
proteins O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
examined O O
are O O
required O O
for O O
both O O
the O O
maturation O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
and O O
maintenance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
at O O
a O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
functional O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
state O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Moreover O O
, O O
the O O
post O B_LOCATION/B_DISEASE
- O O
mating O O
pattern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
Mlp84B O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
supports O O
the O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
the O O
first O B_PERSON/B_BIO
mating O B_PERSON/I_BIO
induces O O
the O O
final O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
maturation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
the O O
oviduct O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
rise O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
fall O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Mlp84B O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
abundance O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
after O O
the O O
first O B_PERSON/B_DISEASE
mating O B_PERSON/I_DISEASE
( O O
Figure O B_MEASURE/B_PERSON
5 O I_MEASURE/I_PERSON
) O O
parallels O O
the O O
expression O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Mlp84B O B_GENE/B_BACTERIUM[BIO]
during O O
development O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
where O O
peaks O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
Mlp84B O B_GENE
transcription O I_GENE
occur O O
during O O
periods O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
embryogenesis O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
metamorphosis O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
when O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
is O O
differentiating O O
[ O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
49 O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
] O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Using O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
tested O O
whether O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
early O B_SEQUENCE[MEASURE]/B_PERSON
mating O I_SEQUENCE[MEASURE]/I_PERSON
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
maintenance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reproductive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
output O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
second O B_PERSON/B_SPECIES[BIO]
mating O I_PERSON/I_SPECIES[BIO]
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
mating O O
at O O
an O O
early O B_MEASURE/B_LOCATION
age O B_MEASURE/I_LOCATION
is O O
essential O B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
achieve O O
maximum O B_MEASURE/B_PERSON
reproductive O B_MEASURE/I_PERSON
output O B_MEASURE/I_PERSON
( O O
i O O
. O O
e O O
. O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
fecundity O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
fertility O B_ORGANISM_FUNCTION
) O O
. O O

Since O O
the O O
first O B_BIO/B_PERSON
mating O I_BIO/I_PERSON
increases O O
reproductive O B_ORGANISM_FUNCTION/B_MEASURE
output O I_ORGANISM_FUNCTION/I_MEASURE
( O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
our O O
mating O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regime O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
, O O
it O O
is O O
likely O B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
ultrastructural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O O
in O O
mated O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
females O I_PERSON
lead O O
to O O
a O O
highly O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
oviduct O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

We O O
suggest O O
that O O
the O O
final O B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maturation O I_ORGANISM_FUNCTION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
oviduct O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
includes O O
a O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O B_MEASURE/B_LOCATION
stage O B_MEASURE/I_LOCATION
. O O

We O O
propose O O
that O O
during O O
the O O
first O B_DISEASE/B_MEASURE
few O I_DISEASE/I_MEASURE
days O I_DISEASE/I_MEASURE
post O I_DISEASE/I_MEASURE
- O O
eclosion O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
undergoes O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
after O O
which O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O O
developmentally O O
poised O O
for O O
a O O
rapid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
an O O
extrinsic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
. O O

Mating O B_BIO/B_PERSON
then O O
triggers O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
maturation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
tissue O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
remodeling O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
modulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
) O O
which O O
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O O
proper O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
function O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_LOCATION/B_MEASURE
7 O I_LOCATION/I_MEASURE
) O O
. O O

We O O
further O O
propose O O
that O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
maturation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
consists O O
of O O
processes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
are O O
mating O O
- O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
both O O
of O O
these O O
pathways O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
essential O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
produce O O
a O O
functional O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
initial O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
SJs O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
occurs O O
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
mating O B_BIO/B_PERSON
- O O
independent O B_DISEASE_ADJECTIVE[DISEASE]
) O O
while O O
the O O
increased O O
apical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
secretion O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
HAJs O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
mating O B_ORGANISM_FUNCTION/B_PERSON
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
oviduct O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
musculature O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
example O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
where O O
both O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
independent O B_DISEASE_ADJECTIVE[DISEASE]
and O O
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
processes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
play O O
a O O
role O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O O

Muscles O B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
highly O O
differentiated O O
in O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prior O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
while O O
muscle O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
is O O
ongoing O O
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
after O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
muscle O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
both O O
regions O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
mating O O
- O O
independent O B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
further O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
muscle O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
mating O B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Another O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
on O O
oviduct O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
maturation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
is O O
that O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
accelerates O O
and O O
synchronizes O O
processes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
maturation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
will O O
therefore O O
be O O
interesting O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
examine O O
the O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
older O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
females O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
determine O O
the O O
status O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
oviduct O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
maturation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

What O O
is O O
the O O
benefit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
differentiation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
? O O

Unmated O B_PERSON
females O I_PERSON
are O O
capable O B_PERSON
of O O
laying O O
eggs O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
albeit O O
at O O
a O O
reduced O O
rate O B_MEASURE
as O O
compared O O
to O O
mated O O
females O B_PERSON/B_BIO
of O O
the O O
same O B_PERSON/B_BIO
age O B_PERSON/I_BIO
. O O

One O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possible O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
that O O
reproduction O B_ORGANISM_FUNCTION
is O O
energetically O O
costly O B_DISEASE_ADJECTIVE[DISEASE]
, O O
thus O O
delaying O O
oviduct O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
maturation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
until O O
sperm O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
advantageous O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
female O B_PERSON/B_BIO
. O O

This O O
may O O
reflect O O
the O O
evolution O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
mechanism O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
optimize O O
reproductive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
capacity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
in O O
early O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
adulthood O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O O
short O O
- O O
lived O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
summary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
have O O
identified O O
events O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
the O O
cellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
physiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
levels O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
that O O
are O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
efficient O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
reproduction O B_ORGANISM_FUNCTION/B_GENE
. O O

Drosophila O B_SPECIES[BIO]/B_PERSON
affords O O
us O O
the O O
opportunity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
uncover O O
the O O
signaling O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
that O O
coordinate O O
these O O
events O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
produce O O
a O O
physiologically O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organ O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Flies O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Wild O O
- O O
type O O
Canton O O
- O O
S O O
flies B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
for O O
the O O
fecundity O O
/ O O
fertility O O
experiments O O
and O O
confocal O O
analysis O O
. O O

Wild O O
- O O
type O O
Canton O O
- O O
S5 O O
[ O O
57 O O
] O O
flies B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
for O O
electron O O
microscopy O O
. O O

All O O
flies B B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
kept O O
in O O
a O O
12 O O
hrs O O
light O O
/ O O
dark O O
cycle O O
at O O
23 O O
+/- O O
2 O O
degrees O O
C O O
. O O

Upon O O
eclosion O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
, O O
females O B_PERSON/B_BIO
and O O
males O B_PERSON/B_BIO
were O O
collected O O
on O O
ice O B_LOCATION/B_BIO
and O O
held O O
separately O O
until O O
3 O B_NUMBER[MEASURE]
( O O
females O B_PERSON/B_BIO
and O O
males O B_PERSON
) O O
or O O
10 O B_NUMBER[MEASURE]
( O O
females O B_PERSON/B_MEASURE
) O O
days O B_TIME[MEASURE]/B_LOCATION
of O O
age O B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
preparation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

For O O
all O O
assays O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
unless O O
described O O
differently O O
) O O
unmated O B_PERSON/B_BIO
females O I_PERSON/I_BIO
were O O
placed O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON/B_TIME[MEASURE]
unmated O I_PERSON/I_TIME[MEASURE]
males O I_PERSON/I_TIME[MEASURE]
and O O
observed O O
until O O
mating O B_ORGANISM_FUNCTION/B_TIME[MEASURE]
initiated O O
. O O

At O O
the O O
end O B_LOCATION/B_TIME[MEASURE]
of O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
females O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O O
aspirated O O
into O O
fresh O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vials O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
held O O
for O O
6 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
hrs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O O

At O O
6 O B_TIME[MEASURE]
hrs O I_TIME[MEASURE]
after O O
the O O
start O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
females O B_PERSON/B_BIO
were O O
placed O O
on O O
ice O B_LOCATION/B_BIO
for O O
dissection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
molecular O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
protein O B_GENE
abundance O I_GENE
at O O
3 O B_DISEASE/B_LOCATION
hrs O I_DISEASE/I_LOCATION
post O I_DISEASE/I_LOCATION
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

We O O
hypothesize O O
that O O
these O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
translate O O
into O O
morphological O B_DISEASE
changes O I_DISEASE
in O O
the O O
next O B_BODY_PART_OR_ORGAN_COMPONENT
few O I_BODY_PART_OR_ORGAN_COMPONENT
hours O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
chose O O
to O O
analyze O O
the O O
morphology O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
mated O O
females O B_PERSON/B_BIO
at O O
6 O B_MEASURE
h O O
post O B_LOCATION/B_DISEASE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
as O O
opposed O O
to O O
later O O
times O B_TIME[MEASURE]/B_DISEASE
post O B_TIME[MEASURE]/I_DISEASE
- O O
mating O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
the O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
at O O
later O B_TIME[MEASURE]/B_ENT
times O I_TIME[MEASURE]/I_ENT
may O O
be O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
to O O
the O O
high O B_MEASURE/B_LOCATION
rate O I_MEASURE/I_LOCATION
of O O
eggs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
passing O O
through O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
. O O

Electron O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Reproductive O O
tracts O O
were O O
dissected O O
in O O
Schneider O O
' O O
s O O
Drosophila B B_SPECIES[BIO]/B_MEASURE
medium O O
( O O
Sigma O O
) O O
on O O
ice O O
and O O
processed O O
for O O
electron O O
microscopy O O
as O O
described O O
in O O
[ O O
42 O O
] O O
. O O

Tracts O B_NUMBER[MEASURE]/B_PERSON
were O O
flat O O
- O O
embedded O O
between O O
two O B_LOCATION/B_ENT
sheets O I_LOCATION/I_ENT
of O O
Aclar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
Electron O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
Microscopy O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
Sciences O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
which O O
allowed O O
us O O
to O O
image O O
the O O
entire O B_BODY_PART_OR_ORGAN_COMPONENT
tract O I_BODY_PART_OR_ORGAN_COMPONENT
at O O
the O O
light O B_MEASURE/B_PERSON
microscopic O I_MEASURE/I_PERSON
level O I_MEASURE/I_PERSON
prior O I_MEASURE/I_PERSON
to O O
sectioning O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sections O B_LOCATION/B_NUMBER[MEASURE]
were O O
cut O O
on O O
a O O
Reichart O B_LOCATION
Ultracut O I_LOCATION
microtome O I_LOCATION
. O O

One O B_TIME[MEASURE]/B_LOCATION
- O O
mu O B_SEQUENCE[MEASURE]
m O I_SEQUENCE[MEASURE]
thick O I_SEQUENCE[MEASURE]
sections O I_SEQUENCE[MEASURE]
were O O
stained O O
with O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
toluidine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
blue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
viewed O O
with O O
a O O
Zeiss O B_PERSON/B_PRODUCT[OBJECT]
Axoplan O B_PERSON/I_PRODUCT[OBJECT]
microscope O B_PERSON/I_PRODUCT[OBJECT]
. O O

Ultrathin O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sections O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
~ O B_LOCATION/B_MEASURE
100 O I_LOCATION/I_MEASURE
nm O I_LOCATION/I_MEASURE
) O O
were O O
mounted O O
on O O
formvar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
grids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
stained O O
with O O
lead O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
citrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
viewed O O
with O O
a O O
Philips O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
FEI O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Morgagni O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
268 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
TEM O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O O
80 O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kV O I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
based O O
on O O
4 O B_MEASURE
unmated O I_MEASURE
samples O I_MEASURE
and O O
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mated O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
unmated O I_NUMBER[MEASURE]/I_PERSON
samples O I_NUMBER[MEASURE]/I_PERSON
were O O
cut O O
in O O
the O O
longitudinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
plane O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O O
two O B_NUMBER[MEASURE]/B_PERSON
additional O I_NUMBER[MEASURE]/I_PERSON
unmated O I_NUMBER[MEASURE]/I_PERSON
samples O I_NUMBER[MEASURE]/I_PERSON
were O O
cut O O
in O O
the O O
transverse O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
plane O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
while O O
one O B_NUMBER[MEASURE]/B_PERSON
mated O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
cut O O
in O O
the O O
longitudinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
plane O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
and O O
two O B_NUMBER[MEASURE]/B_PERSON
additional O I_NUMBER[MEASURE]/I_PERSON
mated O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
cut O O
in O O
the O O
transverse O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
plane O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

For O O
longitudinal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sections O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
entire O B_BODY_PART_OR_ORGAN_COMPONENT
tract O I_BODY_PART_OR_ORGAN_COMPONENT
was O O
re O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
embedded O O
and O O
cut O O
. O O

For O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cut O O
in O O
the O O
transverse O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
plane O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
the O O
flat O O
- O O
embedded O O
reproductive O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
was O O
divided O O
into O O
three O B_LOCATION
regions O I_LOCATION
: O O
( O O
1 O B_NUMBER[MEASURE]
) O O
lateral O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
( O O
2 O B_NUMBER[MEASURE]
) O O
middle O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
( O O
3 O O
) O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Each O O
region O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
re O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
embedded O O
and O O
sectioned O O
. O O

It O O
is O O
beyond O O
the O O
scope O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
to O O
describe O O
all O O
three O B_LOCATION
regions O I_LOCATION
, O O
and O O
our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
focuses O O
on O O
the O O
uppermost O B_SEQUENCE[MEASURE]/B_LOCATION
and O O
lowermost O B_SEQUENCE[MEASURE]/B_LOCATION
regions O I_SEQUENCE[MEASURE]/I_LOCATION
. O O

Immunocytochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Reproductive O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
tracts O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
were O O
dissected O O
in O O
Yamamoto O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
s O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Ringer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
10 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MOPS O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
80 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaCl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KCL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
0 O B_MEASURE
. O O
2 O B_MEASURE
mM O I_MEASURE
MgCl2 O I_MEASURE
; O O
0 O B_MEASURE
. O O
1 O B_MEASURE
mM O I_MEASURE
CaCl2 O I_MEASURE
) O O
with O O
5 O B_MEASURE/B_COLOR
% O B_MEASURE/I_COLOR
( O O
w O O
/ O O
v O O
) O O
sucrose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
ice O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
fixed O O
in O O
4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
paraphormaldehyde O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
PBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
phosphate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
buffered O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
0 O B_MEASURE
. O O
85 O B_MEASURE
% O I_MEASURE
NaCl O I_MEASURE
, O O
1 O B_MEASURE
. O O
4 O B_MEASURE
mM O I_MEASURE
KH2 O I_MEASURE
PO4 O I_MEASURE
, O O
8 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Na2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
HPO4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
pH O B_MEASURE/B_LOCATION
7 O I_MEASURE/I_LOCATION
. O O
4 O B_MEASURE
) O O
for O O
45 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
min O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
then O O
washed O O
in O O
PBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
reproductive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
then O O
incubated O O
in O O
blocking O O
solution O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
0 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
Triton O I_MEASURE
x O O
- O O
100 O B_MEASURE/B_BIO
, O O
3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NGS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
BSA O I_MEASURE
) O O
for O O
2 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
room O B_MEASURE/B_LOCATION
temperature O I_MEASURE/I_LOCATION
. O O

The O O
following O O
primary O O
antibodies O O
, O O
reagents O O
, O O
and O O
dilutions O O
were O O
used O O
: O O
Cy3 O O
- O O
conjugated O O
goat B B_SPECIES[BIO]
anti O O
- O O
HRP O O
, O O
1 O O
: O O
200 O O
( O O
Jackson O O
Immunochemicals O O
, O O
West O O
Grove O O
, O O
PA O O
) O O
; O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
Disc O O
Large O O
( O O
DLG O O
) O O
, O O
1 O O
: O O
1000 O O
( O O
Developmental O O
Hybridoma O O
Bank O O
) O O
, O O
Alexa O O
Fluor O O
488 O O
- O O
phalloidin O O
, O O
1 O O
: O O
200 O O
( O O
Invitrogen O O
, O O
Molecular O O
Probes O O
, O O
Scotland O O
) O O
. O O

Secondary O O
antibodies O O
were O O
Alexa O O
Flour O O
488 O O
- O O
conjugated O O
Goat B B_SPECIES[BIO]/B_GENE
anti O O
- O O
mouse B B_SPECIES[BIO]/B_DISEASE
, O O
1 O O
: O O
200 O O
and O O
Alexa O O
Flour O O
546 O O
- O O
conjugated O O
Goat B B_SPECIES[BIO]/B_GENE
anti O O
- O O
rabbit B B_SPECIES[BIO]
, O O
1 O O
: O O
200 O O
( O O
Invitrogen O O
, O O
Molecular O O
Probes O O
, O O
Scotland O O
) O O
. O O

Reproductive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
tracts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O O
incubated O O
with O O
the O O
different O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
primary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
diluted O O
in O O
PBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O O
0 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
Triton O I_MEASURE
x O O
- O O
100 O B_MEASURE/B_BIO
) O O
for O O
2 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hr O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
room O B_MEASURE/B_LOCATION
temperature O I_MEASURE/I_LOCATION
, O O
washed O O
with O O
PBST O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
incubated O O
with O O
secondary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O O
2 O B_MEASURE
hrs O I_MEASURE
at O O
room O B_MEASURE/B_LOCATION
temperature O B_MEASURE/I_LOCATION
and O O
washed O O
with O O
PBS O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Reproductive O B_NUMBER[MEASURE]
tracts O I_NUMBER[MEASURE]
of O O
the O O
different O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
mounted O O
with O O
Antifade O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
media O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
58 O B_TIME[MEASURE]/B_LOCATION
] O O
on O O
a O O
multi O B_NUMBER[MEASURE]/B_ENT
- O O
well O O
glass O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
slide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Hendley O B_PERSON/B_LOCATION
- O O
Essex O B_LOCATION/B_PERSON
, O O
UK O B_LOCATION/B_MEASURE
) O O
. O O

For O O
each O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
unmated O B_PERSON/B_MEASURE
, O O
mated O O
) O O
and O O
antibody O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O O
reagent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
HRP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
DLG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
phalloidin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
a O O
minimum O B_MEASURE
of O O
ten O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
reproductive O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
tracts O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
at O O
least O O
two O B_NUMBER[MEASURE]/B_PERSON
independent O I_NUMBER[MEASURE]/I_PERSON
biological O I_NUMBER[MEASURE]/I_PERSON
replicates O I_NUMBER[MEASURE]/I_PERSON
were O O
prepared O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Confocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]

Reproductive O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
viewed O O
with O O
a O O
Zeiss O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
510 O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
laser O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
scanning O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
confocal O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
microscope O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
using O O
20 O B_MEASURE/B_LOCATION
x O I_MEASURE/I_LOCATION
and O O
60 O B_MEASURE
x O I_MEASURE
objective O I_MEASURE
with O O
additional O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
zooming O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Optical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sections O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
focal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
plans O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
each O O
reproductive O B_PERSON/B_MEASURE
tract O I_PERSON/I_MEASURE
region O I_PERSON/I_MEASURE
( O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
uterus O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
were O O
collected O O
and O O
projected O O
as O O
a O O
reconstructed O B_NUMBER[MEASURE]
three O I_NUMBER[MEASURE]
- O O
dimensional O B_MEASURE/B_LOCATION
image O I_MEASURE/I_LOCATION
using O O
LSM O B_ORGANIZATION
image O I_ORGANIZATION
browser O I_ORGANIZATION
( O O
version O B_MEASURE
3 O I_MEASURE
, O O
5 O B_MEASURE
, O O
0 O B_MEASURE
, O O
376 O B_MEASURE
) O O
software O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Image O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
collections O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
identical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
each O O
of O O
the O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reproductive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tract O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analyzed O O
. O O

Quantitation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
bouton O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
number O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE

To O O
quantify O O
the O O
number O B_MEASURE/B_LOCATION
of O O
boutons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
lateral O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
common O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
oviducts O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
we O O
used O O
ImageJ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
software O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
1 O B_MEASURE/B_LOCATION
. O O
37b O B_MEASURE
, O O
National O B_ORGANIZATION/B_LOCATION
Institutes O I_ORGANIZATION/I_LOCATION
of O O
Health O B_PERSON/B_ORGANIZATION
) O O
to O O
analyze O O
confocal O B_MEASURE/B_ORGANIZATION
images O I_MEASURE/I_ORGANIZATION
of O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
HRP O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
DLG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labeled O O
boutons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
number O B_MEASURE/B_LOCATION
of O O
boutons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
per O O
unit O B_MEASURE
area O I_MEASURE
was O O
quantified O O
with O O
the O O
Particle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tool O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Briefly O O
, O O
to O O
differentiate O O
between O O
the O O
boutons O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
particle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tool O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
requires O O
the O O
image O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
be O O
a O O
" O O
binary O B_DISEASE/B_TIME[MEASURE]
" O O
image O B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
i O O
. O O
e O O
. O O
, O O
black O B_COLOR
or O O
white O B_COLOR
) O O
, O O
thus O O
we O O
first O O
converted O O
the O O
images O B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
gray O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
then O O
set O O
a O O
" O O
threshold O B_LOCATION/B_MEASURE
" O O
range O B_MEASURE
so O O
that O O
pixels O O
in O O
the O O
image O B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whose O O
value O B_MEASURE/B_LOCATION
lies O O
in O O
this O O
range O B_LOCATION/B_MEASURE
are O O
converted O O
to O O
black O B_COLOR
; O O
pixels O B_LOCATION/B_ENT
with O O
values O B_MEASURE
outside O O
this O O
range O B_LOCATION/B_MEASURE
are O O
converted O O
to O O
white O B_COLOR
. O O

We O O
next O O
defined O O
a O O
region O B_LOCATION/B_MEASURE
of O O
interest O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ROI O B_LOCATION/B_PROTEIN[GENE]
) O O
within O O
the O O
oviduct O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
to O O
count O O
particles O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
i O O
. O O
e O O
. O O
count O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

This O O
ROI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
saved O O
and O O
served O O
to O O
measure O O
the O O
number O B_MEASURE
of O O
boutons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
per O O
unit O B_TIME[MEASURE]/B_PERSON
area O I_TIME[MEASURE]/I_PERSON
in O O
each O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

For O O
each O O
oviduct O B_BIO/B_PERSON
we O O
counted O O
the O O
number O B_MEASURE/B_LOCATION
of O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
HRP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
DLG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labeled O O
boutons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
two O B_MEASURE/B_LOCATION
ROIs O B_MEASURE/I_LOCATION
within O O
the O O
lateral O B_LOCATION/B_PERSON
oviducts O I_LOCATION/I_PERSON
and O O
two O B_NUMBER[MEASURE]/B_PERSON
ROIs O I_NUMBER[MEASURE]/I_PERSON
in O O
the O O
common O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

One O B_NUMBER[MEASURE]
- O O
way O B_MEASURE/B_LOCATION
ANOVA O I_MEASURE/I_LOCATION
( O O
SPSS O B_MEASURE
15 O I_MEASURE
. O O
0 O B_MEASURE
) O O
was O O
used O O
to O O
measure O O
the O O
difference O B_MEASURE
in O O
bouton O B_MEASURE
number O I_MEASURE
per O O
unit O B_TIME[MEASURE]/B_PERSON
area O B_TIME[MEASURE]/I_PERSON
in O O
different O B_NUMBER[MEASURE]/B_LOCATION
regions O I_NUMBER[MEASURE]/I_LOCATION
of O O
the O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
both O O
unmated O B_PERSON/B_ORGANISM_FUNCTION
and O O
mated O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
females O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Quantitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cytoskeleton O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
preparation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

To O O
evaluate O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mating O B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
the O O
abundance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
cytoskeleton O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tested O O
, O O
females O B_PERSON/B_BIO
were O O
: O O
( O O
i O O
) O O
aged O O
for O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
mated O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
males O I_PERSON
and O O
their O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O O
dissected O O
after O O
6 O B_LOCATION/B_DISEASE
hrs O I_LOCATION/I_DISEASE
post O I_LOCATION/I_DISEASE
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O O
Once3 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
; O O
( O O
ii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
aged O O
for O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
mated O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
males O I_PERSON
and O O
their O O
oviducts O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O O
dissected O O
after O O
7 O B_TIME[MEASURE]/B_ORGANISM_FUNCTION
days O B_TIME[MEASURE]/I_ORGANISM_FUNCTION
( O O
Once3 O B_PROTEIN[GENE]
day10 O I_PROTEIN[GENE]
) O O
; O O
( O O
iii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
aged O O
for O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
mated O O
first O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
males O I_PERSON
and O O
held O O
singly O O
for O O
7 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
days O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

At O O
10 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
age O B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
female O B_PERSON/B_BIO
were O O
mated O O
again O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON/B_TIME[MEASURE]
unmated O B_PERSON/I_TIME[MEASURE]
males O B_PERSON/I_TIME[MEASURE]
. O O

Oviducts O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
were O O
dissected O O
at O O
6 O B_NUMBER[MEASURE]/B_LOCATION
hrs O I_NUMBER[MEASURE]/I_LOCATION
post O I_NUMBER[MEASURE]/I_LOCATION
- O O
second O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
mating O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
( O O
Twice3 O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
& O O
10 O B_MEASURE
) O O
. O O

We O O
also O O
examined O O
5 O B_MEASURE
- O O
day O B_TIME[MEASURE]
- O O
old O B_TIME[MEASURE]/B_PERSON
and O O
10 O B_MEASURE
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
females O I_PERSON
( O O
UM5 O B_PROTEIN[GENE]
, O O
UM10 O B_MEASURE/B_PROTEIN[GENE]
respectively O O
) O O
. O O

SDS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polyacrylamide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gel O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SDS O B_PROTEIN[GENE]/B_DISEASE
- O O
PAGE O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

For O O
each O O
mating O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
regime O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
sixty O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviducts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
pooled O O
and O O
30 O B_MEASURE/B_LOCATION
mu O I_MEASURE/I_LOCATION
l O I_MEASURE/I_LOCATION
of O O
SDS O B_MEASURE/B_PROTEIN[GENE]
- O O
PAGE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sample O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
buffer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
added O O
as O O
described O O
in O O
[ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
59 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
boiled O O
, O O
and O O
then O O
frozen O O
at O O
- O O
20 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
until O O
loading O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

SDS O B_PROTEIN[GENE]/B_DISEASE
- O O
PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
performed O O
on O O
12 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polyacrylamide O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gels O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
western O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blotted O O
as O O
in O O
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
60 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Proteins O B_BIO/B_PERSON
were O O
cross O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
linked O O
to O O
the O O
filter O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
following O O
primary O O
antibodies O O
and O O
dilutions O O
were O O
used O O
: O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
Neuroglian O O
( O O
kindly O O
provided O O
by O O
M O O
. O O
Hortsch O O
) O O
1 O O
: O O
250 O O
; O O
Guinea B B_SPECIES[BIO]
pig I I_SPECIES[BIO]
anti O O
- O O
Coracle O O
( O O
kindly O O
provided O O
by O O
R O O
. O O
G O O
. O O
Fehon O O
) O O
1 O O
: O O
2500 O O
; O O
rabbit B B_SPECIES[BIO]
anti O O
- O O
Mlp84B O O
( O O
kindly O O
provided O O
by O O
M O O
. O O
Beckerle O O
) O O
1 O O
: O O
1000 O O
; O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
hts O O
( O O
1B1 O O
, O O
Developmental O O
Studies O O
Hybridoma O O
Bank O O
, O O
DSHB O O
) O O
1 O O
: O O
75 O O
; O O
mouse B B_SPECIES[BIO]/B_DISEASE
anti O O
- O O
Na O O
, O O
K O O
- O O
ATPase O O
( O O
alpha O O
5 O O
, O O
DSHB O O
) O O
1 O O
: O O
100 O O
. O O

Secondary O O
antibodies O O
included O O
: O O
anti O O
- O O
Guinea B B_SPECIES[BIO]
pig I I_SPECIES[BIO]
IgG O O
( O O
peroxidase O O
conjugated O O
) O O
, O O
anti O O
- O O
Rabbit B B_SPECIES[BIO]
IgG O O
and O O
anti O O
- O O
Mouse B B_SPECIES[BIO]/B_DISEASE
IgG O O
( O O
developed O O
in O O
goat B B_BIO/B_LOCATION
, O O
Sigma O O
, O O
Israel O O
) O O
1 O O
: O O
10 O O
, O O
000 O O
. O O

Proteins O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
visualized O O
using O O
an O O
enhanced O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemiluminescence O B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ECL O B_DISEASE/B_PROTEIN[GENE]
) O O
detection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Amersham O B_LOCATION/B_PERSON
Piscataway O I_LOCATION/I_PERSON
, O O
NJ O B_LOCATION/B_MEASURE
) O O
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
developed O O
film O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
scanned O O
and O O
the O O
signal O B_MEASURE/B_LOCATION
intensity O I_MEASURE/I_LOCATION
( O O
protein O B_LOCATION
abundance O I_LOCATION
) O O
of O O
each O O
band O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
determined O O
using O O
ImageJ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
software O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
1 O B_TIME[MEASURE]/B_LOCATION
. O O
37d O B_TIME[MEASURE]
, O O
National O B_ORGANIZATION/B_LOCATION
Institutes O I_ORGANIZATION/I_LOCATION
of O O
Health O B_PERSON/B_EDU[ORGANIZATION]
) O O
. O O

We O O
evaluated O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
abundance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O O
measuring O O
the O O
mean O B_MEASURE/B_LOCATION
gray O I_MEASURE/I_LOCATION
value O I_MEASURE/I_LOCATION
of O O
a O O
specific O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
band O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
background O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
mean O B_MEASURE/B_LOCATION
gray O I_MEASURE/I_LOCATION
value O I_MEASURE/I_LOCATION
of O O
the O O
background O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
then O O
subtracted O O
from O O
that O O
of O O
the O O
measured O B_LOCATION/B_COLOR
band O I_LOCATION/I_COLOR
. O O

Relative O B_TIME[MEASURE]/B_PERSON
protein O I_TIME[MEASURE]/I_PERSON
abundance O I_TIME[MEASURE]/I_PERSON
in O O
mated O B_MEASURE
oviduct O I_MEASURE
vs O I_MEASURE
. O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_TIME[MEASURE]/B_PERSON
unmated O I_TIME[MEASURE]/I_PERSON
oviduct O I_TIME[MEASURE]/I_PERSON
was O O
then O O
calculated O O
. O O

Four O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independent O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replicates O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
prepared O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
each O O
mating O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
status O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
reported O O
abundance O B_MEASURE
( O O
see O O
Figure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
the O O
relative O B_MEASURE/B_LOCATION
ratio O I_MEASURE/I_LOCATION
( O O
mated O O
/ O O
unmated O B_PERSON
or O O
unmated O B_PERSON/B_MEASURE
/ O O
unmated O O
) O O
of O O
at O O
least O O
three O B_NUMBER[MEASURE]/B_PERSON
replicates O B_NUMBER[MEASURE]/I_PERSON
that O O
showed O O
the O O
same O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
trend O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Examination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
female O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reproductive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
output O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE

Mating O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
regimes O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO

To O O
evaluate O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mating O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O O
reproductive O B_PERSON/B_BIO
output O I_PERSON/I_BIO
females O I_PERSON/I_BIO
were O O
treated O O
as O O
follows O O
: O O
( O O
i O O
) O O
aged O O
for O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
and O O
mated O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
males O I_PERSON
( O O
Once3 O B_MEASURE/B_PROTEIN[GENE]
) O O
; O O
( O O
ii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
aged O O
for O O
10 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
and O O
mated O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
males O I_PERSON
( O O
Once10 O B_MEASURE
) O O
; O O
( O O
iii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
aged O O
for O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
mated O O
first O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
males O I_PERSON
, O O
held O O
for O O
7 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
and O O
mated O O
again O O
with O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
- O O
old O B_PERSON
unmated O I_PERSON
males O I_PERSON
( O O
Twice3 O B_NUMBER[MEASURE]/B_GENE
& O O
10 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

In O O
all O O
cases O B_PERSON/B_LOCATION
male O I_PERSON/I_LOCATION
and O O
female O B_PERSON
pairs O I_PERSON
were O O
observed O O
to O O
record O O
mating O B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
initiation O I_ORGANISM_FUNCTION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Following O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
females O B_PERSON/B_BIO
were O O
aspirated O O
into O O
fresh O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vials O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
held O O
singly O O
and O O
allowed O O
to O O
lay O O
eggs O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
6 O B_TIME[MEASURE]/B_PERSON
hrs O I_TIME[MEASURE]/I_PERSON
, O O
then O O
transferred O O
daily O O
( O O
each O O
24 O B_TIME[MEASURE]
hrs O I_TIME[MEASURE]
) O O
to O O
fresh O B_PERSON/B_BIO
vials O I_PERSON/I_BIO
. O O

The O O
number O B_MEASURE
of O O
eggs O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laid O O
and O O
the O O
number O B_MEASURE/B_LOCATION
of O O
eclosed O B_BIO/B_PERSON
adults O I_BIO/I_PERSON
were O O
counted O O
from O O
vials O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
created O O
at O O
6 O B_MEASURE
hrs O I_MEASURE
, O O
1 O B_TIME[MEASURE]/B_LOCATION
, O O
2 O B_SEQUENCE[MEASURE]
and O O
3 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

To O O
ascertain O O
the O O
baseline O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
female O B_DISEASE/B_BIO
egg O B_DISEASE/I_BIO
- O O
laying O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
also O O
included O O
in O O
our O O
experiment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
unmated O O
females O B_PERSON/B_BIO
that O O
were O O
kept O O
in O O
the O O
same O B_LOCATION/B_BIO
conditions O I_LOCATION/I_BIO
as O O
mated O B_PERSON/B_LOCATION
females O I_PERSON/I_LOCATION
. O O

The O O
number O B_MEASURE/B_PERSON
of O O
eggs O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
laid O O
by O O
unmated O B_PERSON/B_BIO
females O I_PERSON/I_BIO
was O O
counted O O
from O O
vials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
created O O
at O O
6 O B_MEASURE
hrs O I_MEASURE
, O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
, O O
2 O B_SEQUENCE[MEASURE]
and O O
3 O B_NUMBER[MEASURE]/B_ENT
days O I_NUMBER[MEASURE]/I_ENT
after O O
placing O O
the O O
females O B_PERSON/B_BIO
in O O
the O O
holding O O
vials O B_PERSON/B_LOCATION
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
we O O
also O O
recorded O O
the O O
pattern O B_MEASURE/B_DISEASE
of O O
unmated O B_PERSON/B_BIO
female O B_PERSON/I_BIO
egg O B_PERSON/I_BIO
- O O
laying O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
10 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

To O O
determine O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimes O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
female O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
reproductive O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
output O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
i O O
. O O
e O O
. O O
fecundity O B_ORGANISM_FUNCTION/B_MEASURE
and O O
fertility O B_ORGANISM_FUNCTION/B_MEASURE
) O O
, O O
we O O
used O O
One O B_NUMBER[MEASURE]
- O O
way O B_MEASURE/B_LOCATION
ANOVA O I_MEASURE/I_LOCATION
( O O
SPSS O B_MEASURE
15 O I_MEASURE
. O O
0 O B_MEASURE
) O O
. O O

Abbreviations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Nrg O O
: O O
Neuroglian O O
; O O
Cora O O
: O O
Coracle O O
; O O
Spec O O
: O O
alpha O O
- O O
and O O
beta O O
- O O
Spectrin O O
; O O
SJ O O
: O O
septate O O
junction O O
; O O
SSJ O O
: O O
smooth O O
septate O O
junction O O
; O O
PSJ O O
: O O
pleated O O
septate O O
junction O O
; O O
ZA O O
: O O
zonal O O
adherens O O
junction O O
; O O
AJ O O
: O O
adherens O O
junction O O
; O O
AECM O O
: O O
apical O O
extracellular O O
matrix O O
; O O
ECM O O
: O O
extracellular O O
matrix O O
; O O
HAJ O O
: O O
hemi O O
- O O
adherens O O
junction O O
; O O
SAJ O O
: O O
spot O O
adherens O O
junction O O
; O O
OA O O
: O O
Octopamine O O
; O O
Hts O O
: O O
Hu O O
- O O
li O O
tai O O
shao O O
; O O
ATP O O
alpha O O
: O O
Na O O
+ O O
pump O O
alpha O O
subunit O O
; O O
Mlp84B O O
: O O
Muscle O O
LIM O O
protein O O
at O O
84B O O
; O O
DLG O O
: O O
Disc O O
Large O O
; O O
HRP O O
: O O
horseradish B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peroxidas O O
; O O
UM O O
: O O
unmated O O
; O O
M O O
: O O
mated O O
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

AK O B_LOCATION/B_PERSON
and O O
PKR O B_LOCATION
contributed O O
equally O O
to O O
this O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

AK O B_LOCATION/B_TIME[MEASURE]
, O O
PKR O B_LOCATION/B_PERSON
and O O
YH O B_ORGANIZATION/B_PERSON
conceived O O
and O O
designed O O
the O O
project O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
analyzed O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

AK O B_LOCATION/B_PERSON
performed O O
the O O
confocal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Western O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blots O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fertility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

PKR O B_PERSON/B_LOCATION
and O O
AK O B_LOCATION/B_DISEASE
performed O O
the O O
light O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

PKR O B_PERSON/B_LOCATION
conducted O O
the O O
electron O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

AK O B_LOCATION/B_MEASURE
, O O
PKR O B_LOCATION
and O O
YH O B_PERSON/B_LOCATION
wrote O O
the O O
manuscript O B_TIME[MEASURE]/B_ENT
. O O

RRH O B_PERSON
contributed O O
to O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
revision O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
authors O B_PERSON
participated O O
in O O
the O O
discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
approval O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
the O O
final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
manuscript O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Supplementary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
Material O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE

Efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
hyaluronan O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
Synvisc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
(R) O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
osteoarthritis O B_DISEASE
affecting O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
metatarsophalangeal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
joint O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O O
hallux O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
limitus O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
) O O
: O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
randomised O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
controlled O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Osteoarthritis O B_DISEASE
of O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metatarsophalangeal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
joint O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
MPJ O B_DISEASE/B_PROTEIN[GENE]
) O O
of O O
the O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
termed O O
hallux O B_DISEASE/B_BIO
limitus O I_DISEASE/I_BIO
, O O
is O O
common O B_DISEASE_ADJECTIVE[DISEASE]
and O O
painful O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Numerous O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
non O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
surgical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interventions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
proposed O O
for O O
this O O
disorder O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
there O O
is O O
limited O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
their O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Intra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injections O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
shown O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
case O B_PERSON/B_MEASURE
- O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
and O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
osteoarthritis O B_DISEASE
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsophalangeal O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
joint O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
no O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O O
evaluated O O
the O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
using O O
a O O
randomised O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
placebo O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
controlled O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

This O O
article O O
describes O O
the O O
design O O
of O O
a O O
randomised O O
placebo O O
controlled O O
trial O O
to O O
evaluate O O
the O O
efficacy O O
of O O
intra O O
- O O
articular O O
hyaluronan O O
( O O
Synvisc O O
(R) O O
) O O
to O O
reduce O O
pain O O
and O O
improve O O
function O O
in O O
people B B_PERSON/B_BIO
with O O
hallux O O
limitus O O
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

One O O
hundred O O
and O O
fifty O O
community O O
- O O
dwelling O O
men B B_PERSON
and O O
women B B_PERSON
aged O O
18 O O
years O O
and O O
over O O
with O O
hallux O O
limitus O O
( O O
who O O
satisfy O O
inclusion O O
and O O
exclusion O O
criteria O O
) O O
will O O
be O O
recruited O O
. O O

Participants B B_PERSON
will O O
be O O
randomised O O
, O O
using O O
a O O
computer O O
- O O
generated O O
random O O
number O O
sequence O O
, O O
to O O
receive O O
a O O
single O O
intra O O
- O O
articular O O
injection O O
of O O
up O O
to O O
1 O O
ml O O
hyaluronan O O
( O O
Synvisc O O
(R) O O
) O O
or O O
sterile O O
saline O O
( O O
placebo O O
) O O
into O O
the O O
first O O
MPJ O O
. O O

The O O
injections O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
will O O
be O O
performed O O
by O O
an O O
interventional O B_PERSON
radiologist O I_PERSON
using O O
fluoroscopy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
ensure O O
accurate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
deposition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
joint O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Participants B B_PERSON
will O O
be O O
given O O
the O O
option O O
of O O
a O O
second O O
and O O
final O O
intra O O
- O O
articular O O
injection O O
( O O
of O O
Synvisc O O
(R) O O
or O O
sterile O O
saline O O
according O O
to O O
the O O
treatment O O
group O O
they O O
are O O
in O O
) O O
either O O
1 O O
or O O
3 O O
months O O
post O O
- O O
treatment O O
if O O
there O O
is O O
no O O
improvement O O
in O O
pain O O
and O O
the O O
participant B B_PERSON
has O O
not O O
experienced O O
severe O O
adverse O O
effects O O
after O O
the O O
first O O
injection O O
. O O

The O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
be O O
the O O
pain O B_DISEASE
and O O
function O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subscales O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Foot O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
Health O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
Status O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
Questionnaire O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
be O O
pain O B_DISEASE/B_MEASURE
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
during O O
walking O O
and O O
at O O
rest O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
stiffness O O
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
passive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
non O O
- O O
weightbearing O O
dorsiflexion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
plantar O B_DISEASE/B_MEASURE
flexion O I_DISEASE/I_MEASURE
strength O I_DISEASE/I_MEASURE
of O O
the O O
toe O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
flexors O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hallux O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
global O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
satisfaction O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
health O B_PERSON/B_DISEASE
- O O
related O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
assessed O O
using O O
the O O
Short O B_PERSON/B_LOCATION
- O O
Form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
36 O B_MEASURE
version O I_MEASURE
two O I_MEASURE
questionnaire O I_MEASURE
) O O
, O O
magnitude O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
symptom O B_DISEASE
change O I_DISEASE
, O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
pain O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
relieving O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
dynamic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plantar O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pressure O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
distribution O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
maximum O B_MEASURE
force O I_MEASURE
and O O
peak O B_MEASURE/B_DISEASE
pressure O I_MEASURE/I_DISEASE
) O O
during O O
walking O O
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
collected O O
at O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
then O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
, O O
3 O B_MEASURE
and O O
6 O B_LOCATION/B_MEASURE
months O I_LOCATION/I_MEASURE
post O I_LOCATION/I_MEASURE
- O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O O
be O O
analysed O O
using O O
the O O
intention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
treat O O
principle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
randomised O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
placebo O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
controlled O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
evaluate O O
the O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyaluronan O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Synvisc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
(R) O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
osteoarthritis O B_DISEASE
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
hallux O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
limitus O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
) O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O O
been O O
pragmatically O O
designed O O
to O O
ensure O O
that O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
implemented O O
into O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
practice O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
if O O
this O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
is O O
found O O
to O O
be O O
an O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
registration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Australian O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
New O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Zealand O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Registry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
ACTRN12607000654459 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Osteoarthritis O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
OA O B_LOCATION/B_PROTEIN[GENE]
) O O
is O O
a O O
degenerative O B_DISEASE
joint O I_DISEASE
disease O I_DISEASE
that O O
commonly O O
presents O O
within O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsophalangeal O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
joint O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MPJ O B_DISEASE/B_PROTEIN[GENE]
) O O
of O O
the O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

The O O
terms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hallux O O
limitus O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
hallux O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
rigidus O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
have O O
frequently O O
been O O
used O O
interchangeably O O
to O O
describe O O
differing O O
severities O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pain O B_DISEASE
and O O
limitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
motion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O O
with O O
OA O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
1 O B_LOCATION/B_DISEASE
] O I_LOCATION/I_DISEASE
. O O

Hallux O B_DISEASE/B_LOCATION
limitus O I_DISEASE/I_LOCATION
is O O
a O O
progressive O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
osteoarthritic O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
condition O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
may O O
advance O O
to O O
an O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_DISEASE/B_MEASURE
presentation O I_DISEASE/I_MEASURE
of O O
hallux O B_DISEASE/B_LOCATION
rigidus O I_DISEASE/I_LOCATION
where O O
the O O
joint O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
fuses O O
and O O
there O O
is O O
a O O
complete O B_DISEASE_ADJECTIVE[DISEASE]
restriction O I_DISEASE_ADJECTIVE[DISEASE]
of O O
motion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
] O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

First O B_DISEASE
MPJ O I_DISEASE
OA O I_DISEASE
is O O
the O O
second O B_SEQUENCE[MEASURE]
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disorder O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
affecting O O
the O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
after O O
hallux O B_DISEASE/B_LOCATION
valgus O I_DISEASE/I_LOCATION
[ O O
2 O B_LOCATION/B_PROTEIN[GENE]
] O I_LOCATION/I_PROTEIN[GENE]
. O O

The O O
prevalence O O
of O O
the O O
condition O O
increases O O
with O O
age O O
, O O
and O O
it O O
has O O
been O O
reported O O
that O O
radiographic O O
changes O O
in O O
the O O
first O O
MPJ O O
affect O O
are O O
evident O O
in O O
approximately O O
46 O O
% O O
of O O
women B B_PERSON/B_BIO
and O O
32 O O
% O O
of O O
men B B_PERSON
at O O
60 O O
years O O
of O O
age O O
[ O O
3 O O
] O O
. O O

Osteoarthritis O B_DISEASE
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
characterised O O
by O O
the O O
symptoms O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
pain O B_DISEASE
and O O
stiffness O B_DISEASE
at O O
the O O
joint O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
[ O O
1 O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
] O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O O

Secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
painful O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
symptoms O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
relate O O
to O O
compensations O B_DISEASE_ADJECTIVE[DISEASE]
during O O
gait O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
that O O
may O O
occur O O
due O O
to O O
the O O
reduced O O
motion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
1 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
pain O B_DISEASE
associated O O
with O O
first O B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_DISEASE_ADJECTIVE[DISEASE]
OA O I_DISEASE_ADJECTIVE[DISEASE]
impacts O I_DISEASE_ADJECTIVE[DISEASE]
on O O
normal O B_DISEASE_ADJECTIVE[DISEASE]
walking O I_DISEASE_ADJECTIVE[DISEASE]
and O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
4 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
hallux O B_DISEASE
limitus O I_DISEASE
involves O O
conservative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
measures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
physical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
foot O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
orthoses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
footwear O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
modification O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
joint O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
manipulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
corticosteroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
[ O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
5 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
] O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
or O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intervention O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
either O O
joint O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
salvage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
joint O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
destructive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
) O O
[ O O
6 O B_MEASURE
] O I_MEASURE
. O O

Pharmacological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O O
also O O
often O O
undertaken O O
as O O
an O O
adjunct O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
for O O
pain O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
relief O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
management O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
hallux O B_DISEASE/B_LOCATION
limitus O I_DISEASE/I_LOCATION
[ O O
6 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

However O O
, O O
although O O
non O B_DISEASE/B_MEASURE
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
and O O
cyclooxygenase O B_GENE
- O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
found O O
to O O
be O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
management O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
various O B_DISEASE_ADJECTIVE[DISEASE]
forms O I_DISEASE_ADJECTIVE[DISEASE]
of O O
OA O B_DISEASE/B_LOCATION
, O O
gastrointestinal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O O
a O O
concern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ O O
7 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

In O O
light O B_COLOR/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
these O O
limitations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
existing O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
an O O
alternative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
termed O O
' O B_LOCATION
viscosupplementation O I_LOCATION
' O O
- O O
the O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O O
arthritic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
joints O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
the O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
restoring O O
the O O
viscoelasticity O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
synovial O B_BODY_PART_OR_ORGAN_COMPONENT
fluid O I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
8 O B_MEASURE
] O I_MEASURE
- O O
has O O
been O O
proposed O O
and O O
has O O
attracted O O
considerable O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attention O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
medical O B_LOCATION/B_PERSON
literature O I_LOCATION/I_PERSON
as O O
a O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
OA O B_DISEASE
[ O O
9 O B_NUMBER[MEASURE]/B_LOCATION
] O I_NUMBER[MEASURE]/I_LOCATION
. O O

In O O
particular O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
both O O
the O O
American O B_LOCATION/B_ORGANIZATION
College O B_LOCATION/I_ORGANIZATION
of O O
Rheumatology O B_DISEASE/B_PERSON
( O O
ACR O B_ORGANIZATION/B_LOCATION
) O O
and O O
European O B_LOCATION/B_ORGANIZATION
League O B_LOCATION/I_ORGANIZATION
Against O I_LOCATION
Rheumatism O I_LOCATION
( O O
EULAR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
recommend O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
the O O
management O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
OA O B_DISEASE/B_LOCATION
of O O
the O O
knee O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
[ O O
10 O B_NUMBER[MEASURE]
, O O
11 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Although O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
systematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigating O O
the O O
effectiveness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
this O O
type O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
knee O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
OA O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O O
controversial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
most O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
update O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
the O O
Cochrane O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systematic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
evaluating O O
viscosupplementation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
knee O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
OA O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
concluded O O
that O O
viscosupplementation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
both O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
effective O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
OA O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
was O O
superior O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
equivalent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
any O O
form O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
systemic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
intervention O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
corticosteroids O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O O
9 O B_MEASURE
, O O
12 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Despite O O
there O O
being O O
a O O
large O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigating O O
the O O
effectiveness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
knee O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
OA O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
few O B_PERSON
studies O I_PERSON
have O O
investigated O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
OA O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
the O O
first O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
MPJ O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
13 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

In O O
a O O
case O O
- O O
series O O
retrospective O O
study O O
, O O
14 O O
patients B B_PERSON
with O O
radiographically O O
confirmed O O
OA O O
at O O
the O O
first O O
MPJ O O
that O O
received O O
up O O
to O O
3 O O
intra O O
- O O
articular O O
injections O O
of O O
1 O O
ml O O
hyaluronan O O
( O O
Ostenil O O
(R) O O
Mini O O
) O O
( O O
sodium O O
hyaluronate O O
) O O
reported O O
a O O
statistically O O
significant O O
reduction O O
in O O
pain O O
( O O
reported O O
using O O
a O O
visual O O
analogue O O
scale O O
) O O
after O O
6 O O
months O O
[ O O
14 O O
] O O
. O O

The O O
treatment O O
was O O
well O O
tolerated O O
, O O
with O O
3 O O
/ O O
14 O O
( O O
21 O O
% O O
) O O
participants B B_PERSON
reporting O O
mild O O
adverse O O
reactions O O
at O O
the O O
injection O O
site O O
. O O

In O O
another O O
study O O
, O O
Pons O O
et O O
al O O
[ O O
13 O O
] O O
compared O O
a O O
single O O
intra O O
- O O
articular O O
injection O O
of O O
1 O O
ml O O
Ostenil O O
(R) O O
Mini O O
( O O
sodium O O
hyaluronate O O
) O O
with O O
1 O O
ml O O
Trigon O O
depot O O
(R) O O
( O O
triamcinolone O O
acetonide O O
, O O
a O O
corticosteroid O O
) O O
for O O
the O O
treatment O O
of O O
painful O O
, O O
grade O O
1 O O
hallux O O
limitus O O
( O O
Karasick O O
and O O
Wapner O O
[ O O
15 O O
] O O
scale O O
) O O
in O O
37 O O
participants B B_PERSON/B_MEASURE
( O O
40 O O
feet O O
) O O
[ O O
13 O O
] O O
. O O

Both O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
groups O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
showed O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]
in O O
pain O B_DISEASE/B_MEASURE
at O O
rest O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
or O O
on O O
palpation O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
up O O
to O O
12 O B_NUMBER[MEASURE]/B_LOCATION
weeks O I_NUMBER[MEASURE]/I_LOCATION
post O I_NUMBER[MEASURE]/I_LOCATION
- O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

However O O
, O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
resulted O O
in O O
a O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
greater O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
pain O B_DISEASE/B_MEASURE
during O O
walking O B_SPORT[ENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
American O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
Orthopaedic O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
Foot O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
Ankle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
Society O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
AOFAS O B_DISEASE/B_ORGANIZATION
) O O
hallux O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
MPJ O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
score O O
compared O O
to O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O O
triamcinolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acetonide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
treatment O O
with O O
hyaluronan O O
was O O
well O O
tolerated O O
, O O
with O O
2 O O
/ O O
20 O O
( O O
10 O O
% O O
) O O
participants B B_PERSON
reporting O O
mild O O
adverse O O
reactions O O
at O O
the O O
injection O O
site O O
. O O

Although O O
both O O
of O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyaluronan O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hallux O B_DISEASE/B_LOCATION
limitus O I_DISEASE/I_LOCATION
, O O
neither O O
used O O
a O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
13 O B_MEASURE
, O O
14 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

This O O
limitation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
placebo O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
effect O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
can O O
account O O
for O O
79 O B_MEASURE
% O I_MEASURE
of O O
the O O
efficacy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hyaluronan O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O O
16 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Further O O
, O O
both O O
studies O O
are O O
limited O O
in O O
that O O
neither O O
of O O
the O O
studies O O
used O O
blinding O O
of O O
both O O
the O O
participants B B_PERSON
and O O
assessors O O
in O O
their O O
protocols O O
. O O

It O O
is O O
therefore O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
positive O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
have O O
been O O
overestimated O O
. O O

Accordingly O O
, O O
the O O
aims O O
of O O
this O O
project O O
are O O
to O O
conduct O O
a O O
double O O
blind O O
randomised O O
controlled O O
trial O O
to O O
determine O O
the O O
effectiveness O O
of O O
intra O O
- O O
articular O O
hyaluronan O O
( O O
Synvisc O O
(R) O O
) O O
on O O
( O O
i O O
) O O
foot O O
pain O O
and O O
function O O
; O O
( O O
ii O O
) O O
the O O
range O O
of O O
motion O O
of O O
the O O
first O O
MPJ O O
; O O
( O O
iii O O
) O O
the O O
strength O O
of O O
the O O
plantarflexor O O
muscles O O
of O O
the O O
first O O
MPJ O O
; O O
( O O
iv O O
) O O
the O O
health O O
related O O
quality O O
of O O
life O O
; O O
and O O
( O O
v O O
) O O
the O O
use O O
of O O
pain O O
- O O
relieving O O
medications O O
in O O
people B B_PERSON/B_ORGANIZATION
with O O
hallux O O
limitus O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
presented O O
in O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
, O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
with O O
the O O
recommendations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
Editorial O B_PERSON/B_ORGANIZATION
Board O I_PERSON/I_ORGANIZATION
of O O
BioMed O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Central O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
17 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Design O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

This O O
study O O
is O O
a O O
parallel O O
group O O
, O O
participant B B_PERSON
and O O
assessor O O
blinded O O
, O O
randomised O O
controlled O O
trial O O
with O O
a O O
6 O O
month O O
follow O O
- O O
up O O
( O O
Figure O O
1 O O
) O O
. O O

It O O
has O O
been O O
developed O O
using O O
the O O
principles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
described O O
by O O
Osteoarthritis O B_LOCATION/B_ORGANIZATION
Research O B_LOCATION/I_ORGANIZATION
Society O B_LOCATION/I_ORGANIZATION
International O B_LOCATION/I_ORGANIZATION
( O O
OARSI O B_DISEASE/B_ORGANIZATION
) O O
Clinical O B_MEASURE
Trials O I_MEASURE
Task O I_MEASURE
Force O I_MEASURE
guidelines O I_MEASURE
[ O O
18 O B_MEASURE
] O O
. O O

Participants B B_PERSON
will O O
be O O
randomised O O
to O O
receive O O
a O O
single O O
intra O O
- O O
articular O O
injection O O
of O O
up O O
to O O
1 O O
ml O O
hyaluronan O O
( O O
Synvisc O O
(R) O O
) O O
or O O
sterile O O
saline O O
( O O
placebo O O
) O O
into O O
the O O
first O O
MPJ O O
. O O

Allocation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
either O O
the O O
Synvisc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
will O O
be O O
achieved O O
using O O
a O O
computer O B_PRODUCT[OBJECT]/B_PERSON
- O O
generated O O
random O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
number O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
allocation O O
sequence O O
will O O
be O O
generated O O
and O O
held O O
by O O
an O O
external O O
person B B_PERSON/B_ORGANIZATION
not O O
directly O O
involved O O
in O O
the O O
trial O O
. O O

Concealment O O
of O O
the O O
allocation O O
sequence O O
will O O
be O O
ensured O O
as O O
each O O
participant B B_PERSON/B_ORGANIZATION
' O O
s O O
allocation O O
will O O
be O O
contained O O
in O O
a O O
sealed O O
opaque O O
envelope O O
. O O

Envelopes O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
made O O
opaque O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O O
using O O
a O O
sheet O B_PRODUCT[OBJECT]/B_LOCATION
of O O
aluminium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
foil O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inside O O
the O O
envelope O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
a O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
using O O
carbon O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
paper O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
will O O
be O O
employed O O
so O O
the O O
details O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
name O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
date O B_LOCATION/B_MEASURE
of O O
recruitment O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
are O O
transferred O O
from O O
the O O
outside O B_LOCATION
of O O
the O O
envelope O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
paper O B_PRODUCT[OBJECT]/B_LOCATION
inside O O
the O O
envelope O B_PRODUCT[OBJECT]/B_LOCATION
containing O O
the O O
allocation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
opening O O
the O O
seal O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Assessors O O
and O O
participants B B_PERSON
will O O
be O O
blinded O O
to O O
group O O
allocation O O
. O O

Participants B B_PERSON
will O O
be O O
given O O
the O O
option O O
of O O
a O O
second O O
and O O
final O O
intra O O
- O O
articular O O
injection O O
( O O
of O O
Synvisc O O
(R) O O
or O O
sterile O O
saline O O
according O O
to O O
the O O
treatment O O
group O O
they O O
are O O
in O O
) O O
on O O
days O O
30 O O
or O O
90 O O
if O O
there O O
is O O
no O O
improvement O O
in O O
pain O O
and O O
the O O
participant B B_PERSON
has O O
not O O
experienced O O
severe O O
adverse O O
effects O O
after O O
the O O
first O O
injection O O
) O O
. O O

Participants B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
Human O B_ORGANIZATION/B_PERSON
Studies O I_ORGANIZATION/I_PERSON
Ethics O I_ORGANIZATION/I_PERSON
Committee O I_ORGANIZATION/I_PERSON
at O O
La O B_LOCATION/B_ORGANIZATION
Trobe O I_LOCATION/I_ORGANIZATION
University O I_LOCATION/I_ORGANIZATION
( O O
Human O B_MEASURE
Ethics O I_MEASURE
Committee O I_MEASURE
Application O I_MEASURE
No O I_MEASURE
. O O
07 O B_MEASURE
- O O
45 O B_MEASURE
) O O
and O O
the O O
Radiation O B_PERSON/B_ORGANIZATION
Advisory O I_PERSON/I_ORGANIZATION
Committee O I_PERSON/I_ORGANIZATION
of O O
the O O
Victorian O B_ORGANIZATION/B_PERSON
Department O I_ORGANIZATION/I_PERSON
of O O
Human O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Services O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
given O O
approval O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Written O O
informed O O
consent O O
will O O
be O O
obtained O O
from O O
all O O
participants B B_PERSON/B_ORGANIZATION
prior O O
to O O
their O O
participation O O
. O O

People B B_PERSON
with O O
hallux O O
limitus O O
will O O
be O O
recruited O O
from O O
a O O
number O O
of O O
sources O O
: O O

( O O
i O O
) O O
advertisements O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
relevant O B_LOCATION
Melbourne O I_LOCATION
( O O
Australia O B_LOCATION
) O O
newspapers O B_LOCATION/B_PERSON
; O O

( O O
ii O B_TIME[MEASURE]
) O O
mail O B_MEASURE/B_PERSON
- O O
out O O
advertisements O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
health O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O O
care O B_PERSON/B_ORGANIZATION
practitioners O I_PERSON/I_ORGANIZATION
in O O
Melbourne O B_LOCATION
; O O

( O O
iii O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
advertisements O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
internet O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
web O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
- O O
sites O B_LOCATION/B_ENT
( O O
including O O
) O O
; O O

( O O
iv O B_MEASURE/B_PROTEIN[GENE]
) O O
posters O B_PERSON/B_LOCATION
displayed O O
in O O
local O B_LOCATION/B_ORGANIZATION
retirement O I_LOCATION/I_ORGANIZATION
villages O I_LOCATION/I_ORGANIZATION
, O O
community O B_LOCATION/B_ORGANIZATION
centres O I_LOCATION/I_ORGANIZATION
and O O
universities O B_LOCATION/B_ORGANIZATION
located O O
in O O
Melbourne O B_LOCATION
. O O

Respondents O B_PERSON/B_BIO
will O O
initially O O
be O O
screened O O
by O O
telephone O B_PERSON/B_ENT
interview O I_PERSON/I_ENT
to O O
ensure O O
they O O
are O O
suitable O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Suitable O B_PERSON
individuals O I_PERSON
will O O
then O O
be O O
invited O O
to O O
participate O O
in O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
attend O O
an O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

To O O
be O O
included O O
in O O
the O O
study O O
, O O
participants B B_PERSON
must O O
meet O O
the O O
following O O
inclusion O O
criteria O O
: O O

( O O
i O O
) O O
be O O
aged O O
at O O
least O O
18 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
; O O

( O O
ii O B_TIME[MEASURE]
) O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
having O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pain O B_DISEASE
, O O
during O O
walking O O
or O O
rest O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
in O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
for O O
at O O
least O O
3 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
; O O

( O O
iii O B_MEASURE/B_PROTEIN[GENE]
) O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
having O O
pain O B_DISEASE/B_MEASURE
rated O O
at O O
least O O
20 O B_MEASURE
mm O I_MEASURE
on O O
a O O
100 O B_TIME[MEASURE]/B_BIO
mm O B_TIME[MEASURE]/I_BIO
visual O B_TIME[MEASURE]/I_BIO
analogue O B_TIME[MEASURE]/I_BIO
pain O B_TIME[MEASURE]/I_BIO
scale O B_TIME[MEASURE]/I_BIO
( O O
VAPS O B_TIME[MEASURE]/B_DISEASE
) O O
; O O

( O O
iv O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
have O O
pain O B_DISEASE
upon O O
palpation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
dorsal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aspect O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
; O O

( O O
v O O
) O O
radiographic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
OA O B_DISEASE
( O O
score O B_NUMBER[MEASURE]/B_LOCATION
1 O I_NUMBER[MEASURE]/I_LOCATION
or O O
2 O B_MEASURE
for O O
either O O
osteophytes O B_DISEASE/B_BACTERIUM[BIO]
or O O
joint O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
space O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
narrowing O O
using O O
a O O
previously O O
published O O
radiographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
[ O O
19 O B_TIME[MEASURE]
] O O
at O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

( O O
vi O B_MEASURE/B_PERSON
) O O
able O B_TIME[MEASURE]/B_PERSON
to O O
walk O O
household O B_TIME[MEASURE]/B_LOCATION
distances O I_TIME[MEASURE]/I_LOCATION
( O O
> O B_MEASURE
50 O B_MEASURE
meters O I_MEASURE
) O O
without O O
the O O
aid O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
walker O B_PERSON/B_PRODUCT[OBJECT]
, O O
crutches O B_DISEASE_ADJECTIVE[DISEASE]/B_PRODUCT[OBJECT]
or O O
cane O B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O

( O O
vii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
be O O
willing O B_PERSON
to O O
attend O O
the O O
La O B_LOCATION/B_ORGANIZATION
Trobe O I_LOCATION/I_ORGANIZATION
University O I_LOCATION/I_ORGANIZATION
Medical O I_LOCATION/I_ORGANIZATION
Centre O I_LOCATION/I_ORGANIZATION
( O O
Melbourne O B_LOCATION
, O O
Australia O B_LOCATION/B_PERSON
) O O
for O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
either O O
Synvisc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
placebo O B_LOCATION
( O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
intra O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
attend O O
the O O
Health O B_LOCATION/B_ORGANIZATION
Sciences O I_LOCATION/I_ORGANIZATION
Clinic O I_LOCATION/I_ORGANIZATION
at O O
La O B_LOCATION/B_PERSON
Trobe O I_LOCATION/I_PERSON
University O I_LOCATION/I_PERSON
( O O
Melbourne O B_LOCATION
, O O
Australia O B_LOCATION/B_PERSON
) O O
for O O
the O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
the O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
at O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
1 O B_MEASURE/B_LOCATION
, O O
3 O B_NUMBER[MEASURE]
and O O
6 O B_LOCATION/B_TIME[MEASURE]
months O I_LOCATION/I_TIME[MEASURE]
post O I_LOCATION/I_TIME[MEASURE]
- O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
) O O
; O O

( O O
viii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
not O O
receive O O
other O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intra O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
injections O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
into O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
course O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
apart O O
from O O
those O O
dictated O O
by O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
; O O

( O O
ix O B_NUMBER[MEASURE]/B_LOCATION
) O O
be O O
willing O B_PERSON/B_TIME[MEASURE]
to O O
discontinue O O
taking O O
all O O
pain O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
relieving O O
medications O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
analgesics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
non O B_DISEASE/B_MEASURE
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medications O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
, O O
except O O
paracetamol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
up O O
to O O
4 O B_MEASURE
g O I_MEASURE
/ O O
day O B_MEASURE
, O O
taken O O
by O O
mouth O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
or O O
applied O O
topically O O
) O O
: O O

- O O
for O O
at O O
least O O
14 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
prior O I_TIME[MEASURE]/I_ENT
to O O
the O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O O

- O O
during O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O B_TIME[MEASURE]/B_LOCATION
months O B_TIME[MEASURE]/I_LOCATION
after O O
the O O
final O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O O
Synvisc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Participants B B_PERSON
who O O
do O O
take O O
paracetamol O O
need O O
to O O
discontinue O O
its O O
use O O
at O O
least O O
24 O O
hours O O
prior O O
to O O
the O O
baseline O O
assessment O O
and O O
follow O O
- O O
up O O
assessments O O
at O O
1 O O
, O O
3 O O
and O O
6 O O
months O O
after O O
the O O
treatment O O
; O O

( O O
x O O
) O O
be O O
willing O B_PERSON
to O O
not O O
receive O O
any O O
physical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
on O O
the O O
involved O O
MPJ O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
or O O
trial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
shoe O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modifications O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
foot O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
orthoses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Exclusion O O
criteria O O
for O O
participants B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
study O O
will O O
be O O
: O O

( O O
i O B_DISEASE/B_PROTEIN[GENE]
) O O
Severe O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
radiographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
OA O B_DISEASE
( O O
score O O
3 O B_MEASURE
for O O
either O O
osteophytes O B_DISEASE/B_BACTERIUM[BIO]
or O O
joint O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
space O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
narrowing O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
using O O
a O O
previously O O
published O O
radiographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
19 O B_TIME[MEASURE]/B_PROTEIN[GENE]
] O I_TIME[MEASURE]/I_PROTEIN[GENE]
; O O

( O O
ii O B_NUMBER[MEASURE]/B_DISEASE
) O O
previous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
; O O

( O O
iii O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
or O O
any O O
other O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intra O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
previous O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
6 O B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
months O B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
; O O

( O O
iv O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
systemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steroid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
excluding O O
inhalation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
topical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steroids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
immunosuppressives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
anticoagulants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
except O O
for O O
acetylsalicylic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
dosages O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
up O O
to O O
325 O B_MEASURE
mg O I_MEASURE
/ O O
day O B_TIME[MEASURE]
) O O
; O O

( O O
v O B_OTHER/B_PROTEIN[GENE]
) O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
joint O B_DISEASE/B_MEASURE
infection O I_DISEASE/I_MEASURE
( O O
s O B_OTHER/B_DISEASE
) O O
of O O
the O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
; O O

( O O
vi O B_TIME[MEASURE]
) O O
significant O B_DISEASE
deformity O I_DISEASE
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
including O O
hallux O B_DISEASE
abducto O I_DISEASE
valgus O I_DISEASE
( O O
grade O B_MEASURE/B_ENT
of O O
3 O B_SEQUENCE[MEASURE]
or O O
4 O B_MEASURE
scored O O
using O O
the O O
Manchester O B_MEASURE
Scale O I_MEASURE
[ O O
20 O B_TIME[MEASURE]/B_DISEASE
] O I_TIME[MEASURE]/I_DISEASE
; O O

( O O
vii O B_NUMBER[MEASURE]
) O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peripheral O B_DISEASE
vascular O I_DISEASE
disease O I_DISEASE
. O O

Peripheral O B_DISEASE
vascular O I_DISEASE
disease O I_DISEASE
will O O
be O O
considered O O
to O O
be O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O O
any O O
of O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21 O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O

* O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
past O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
history O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
, O O
vascular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
Raynaud O B_PERSON/B_LOCATION
' O O
s O B_DISEASE
phenomenon O I_DISEASE
, O O
vasculitis O B_DISEASE
associated O O
with O O
connective O B_DISEASE
tissue O I_DISEASE
diseases O I_DISEASE
, O O
Buerger O B_PERSON/B_DISEASE
' O O
s O B_DISEASE/B_LOCATION
disease O I_DISEASE/I_LOCATION
, O O
arterial O B_DISEASE
emboli O I_DISEASE
, O O
deep O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
vein O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
thrombosis O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
lower O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
limb O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ulcers O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O

* O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
intermittent O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
claudication O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
rest O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pain O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O

* O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
presence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
atrophy O B_DISEASE
, O O
ulcers O B_DISEASE
or O O
significant O B_DISEASE
oedema O I_DISEASE
; O O

* O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
inability O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
to O O
palpate O O
at O O
least O O
one O B_MEASURE/B_LOCATION
pedal O I_MEASURE/I_LOCATION
pulse O I_MEASURE/I_LOCATION
; O O

* O B_MEASURE/B_LOCATION
Ankle O I_MEASURE/I_LOCATION
Brachial O I_MEASURE/I_LOCATION
Pressure O I_MEASURE/I_LOCATION
Index O I_MEASURE/I_LOCATION
< O O
0 O B_MEASURE
. O O
9 O B_MEASURE
; O O

( O O
viii O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
one O B_NUMBER[MEASURE]
or O O
more O B_NUMBER[MEASURE]/B_LOCATION
conditions O I_NUMBER[MEASURE]/I_LOCATION
that O O
can O O
confound O O
pain O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
functional O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessments O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
metatarsalgia O B_DISEASE
, O O
plantar O B_DISEASE
fasciitis O I_DISEASE
, O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dislocation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
sprains O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
Achilles O B_DISEASE
tendinopathy O I_DISEASE
, O O
degenerative O B_DISEASE
joint O I_DISEASE
disease O I_DISEASE
of O O
the O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O O
other O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
or O O
painful O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corns O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
callus O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
; O O

( O O
ix O B_NUMBER[MEASURE]/B_LOCATION
) O O
planning O O
to O O
undergo O O
any O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
or O O
receive O O
any O O
injections O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
apart O O
from O O
those O O
dictated O O
by O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
at O O
the O O
involved O O
first O B_LOCATION/B_PERSON
MPJ O I_LOCATION/I_PERSON
during O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O

( O O
x O B_MEASURE/B_OTHER
) O O
presence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
systemic O B_DISEASE
inflammatory O I_DISEASE
condition O I_DISEASE
or O O
infection O B_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
inflammatory O B_DISEASE
arthritis O I_DISEASE
, O O
diagnosed O O
with O O
rheumatoid O B_DISEASE
arthritis O I_DISEASE
, O O
ankylosing O O
spondylitis O B_DISEASE
, O O
psoriatic O B_DISEASE
arthritis O I_DISEASE
, O O
reactive O B_DISEASE
arthritis O I_DISEASE
, O O
septic O B_DISEASE
arthritis O I_DISEASE
, O O
acute O B_DISEASE
pseudogout O I_DISEASE
, O O
or O O
any O O
other O B_DISEASE/B_PERSON
connective O I_DISEASE/I_PERSON
tissue O I_DISEASE/I_PERSON
disease O I_DISEASE/I_PERSON
; O O

( O O
xi O B_PERSON/B_NUMBER[MEASURE]
) O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
gout O B_DISEASE
or O O
other O B_DISEASE/B_MEASURE
musculoskeletal O I_DISEASE/I_MEASURE
disease O I_DISEASE/I_MEASURE
other O I_DISEASE/I_MEASURE
than O O
OA O B_DISEASE/B_LOCATION
within O O
the O O
feet O B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
. O O

Gout O B_PERSON/B_DISEASE
will O O
be O O
screened O O
for O O
using O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
physical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
painful O B_DISEASE/B_MEASURE
joint O I_DISEASE/I_MEASURE
, O O
abrupt O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
onset O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
swelling O O
) O O
, O O
radiographic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assessment O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
asymmetrical O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
joint O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
swelling O O
, O O
subcortical O B_DISEASE/B_LOCATION
cysts O I_DISEASE/I_LOCATION
without O O
erosion O B_DISEASE
and O O
tophi O B_DISEASE
) O O
as O O
well O O
as O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
uric O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
hyperuricaemia O B_DISEASE_ADJECTIVE[DISEASE]
= O O
serum O B_DISEASE/B_MEASURE
uric O I_DISEASE/I_MEASURE
acid O I_DISEASE/I_MEASURE
> O O
mean O O
+ O O
2 O B_MEASURE
SD O I_MEASURE
from O O
normal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
[ O O
22 O B_MEASURE
] O I_MEASURE
; O O

( O O
xii O B_BIO/B_DISEASE
) O O
active O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
skin O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
infection O B_DISEASE
in O O
the O O
area O B_LOCATION/B_BIO
of O O
the O O
injection O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O

( O O
xiii O O
) O O
any O O
medical O O
condition O O
that O O
, O O
in O O
the O O
opinion O O
of O O
the O O
investigators O O
, O O
makes O O
the O O
participant B B_PERSON/B_DISEASE
unsuitable O O
for O O
inclusion O O
( O O
e O O
. O O
g O O
. O O
, O O
severe O O
progressive O O
chronic O O
disease O O
, O O
malignancy O O
, O O
bleeding O O
disorder O O
, O O
clinically O O
important O O
pain O O
in O O
a O O
part O O
of O O
the O O
musculoskeletal O O
system O O
other O O
than O O
the O O
first O O
MPJ O O
, O O
or O O
fibromyalgia O O
) O O
; O O

( O O
xiv O O
) O O
pregnant O O
or O O
lactating O O
women B B_PERSON
, O O
or O O
women B B_PERSON
who O O
are O O
of O O
child B B_PERSON/B_BIO
bearing O O
age O O
or O O
have O O
not O O
undergone O O
menopause O O
( O O
Synvisc O O
(R) O O
has O O
not O O
been O O
tested O O
in O O
pregnant O O
women B B_PERSON
or O O
women B B_PERSON
who O O
are O O
nursing O O
) O O
; O O

( O O
xv O B_TIME[MEASURE]
) O O
cognitive O B_DISEASE_ADJECTIVE[DISEASE]
impairment O I_DISEASE_ADJECTIVE[DISEASE]
( O O
defined O O
as O O
a O O
score O B_MEASURE/B_ENT
of O O
< O O
7 O B_MEASURE
on O O
the O O
Short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Portable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Mental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Status O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Questionnaire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
[ O O
23 O B_TIME[MEASURE]
] O I_TIME[MEASURE]
; O O

( O O
xvi O B_NUMBER[MEASURE]/B_LOCATION
) O O
known O O
hypersensitivity O B_DISEASE
( O O
allergy O B_DISEASE/B_TIME[MEASURE]
) O O
to O O
hyaluronan O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
preparations O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
to O O
avian O O
proteins O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
feathers O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
egg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
; O O

( O O
xvii O B_NUMBER[MEASURE]/B_PERSON
) O O
involvement O B_PERSON/B_DISEASE
in O O
any O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
the O O
previous O B_TIME[MEASURE]/B_LOCATION
3 O B_TIME[MEASURE]/I_LOCATION
months O B_TIME[MEASURE]/I_LOCATION
that O O
could O O
be O O
considered O O
to O O
affect O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
injections O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
for O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

Participants B B_PERSON
will O O
be O O
randomised O O
to O O
receive O O
a O O
single O O
intra O O
- O O
articular O O
injection O O
of O O
up O O
to O O
1 O O
ml O O
of O O
hyaluronan O O
( O O
Synvisc O O
(R) O O
; O O
Genzyme O O
Biosurgery O O
, O O
Genzyme O O
Corporation O O
, O O
NJ O O
, O O
USA O O
) O O
or O O
sterile O O
saline O O
( O O
placebo O O
) O O
into O O
the O O
first O O
MPJ O O
. O O

Each O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ml O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ampoule O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Synvisc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O O
16 O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
hylan O B_LOCATION/B_PERSON
G O I_LOCATION/I_PERSON
- O O
F O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
cross O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
linked O O
hylan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
hylan O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
B O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
17 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_MEASURE
. O O
32 O B_MEASURE
mg O I_MEASURE
disodium O I_MEASURE
hydrogen O I_MEASURE
phosphate O I_MEASURE
, O O
0 O B_NUMBER[MEASURE]
. O O
08 O B_MEASURE
mg O I_MEASURE
sodium O I_MEASURE
dihydrogen O I_MEASURE
phosphate O I_MEASURE
monohydrate O I_MEASURE
. O O

The O O
hyaluronan O O
is O O
extracted O O
from O O
chicken B B_BIO
combs O O
and O O
the O O
purified O O
material O O
has O O
an O O
average O O
molecular O O
weight O O
of O O
6 O O
, O O
000 O O
kDa O O
. O O

The O O
injections O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
performed O O
by O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
experienced O O
interventional O B_PERSON/B_ORGANIZATION
radiologist O I_PERSON/I_ORGANIZATION
( O O
AEZ O B_LOCATION/B_PERSON
) O O
using O O
fluoroscopic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
ensure O O
accurate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
deposition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
the O O
joint O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

As O O
the O O
Synvisc O O
(R) O O
is O O
provided O O
in O O
ampoules O O
that O O
are O O
labelled O O
with O O
the O O
product O O
name O O
, O O
it O O
will O O
not O O
be O O
possible O O
to O O
blind O O
the O O
injector O O
, O O
however O O
this O O
person B B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
involved O O
in O O
generation O O
of O O
the O O
allocation O O
order O O
, O O
recruitment O O
, O O
assessment O O
or O O
data O O
analysis O O
. O O

The O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
will O O
be O O
performed O O
using O O
a O O
21 O B_MEASURE
gauge O I_MEASURE
( O O
0 O B_MEASURE/B_LOCATION
. O O
80 O B_MEASURE
x O O
19 O B_TIME[MEASURE]
mm O I_TIME[MEASURE]
) O O
Surflo O B_MEDICAL_DEVICE[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) O I_MEDICAL_DEVICE[OBJECT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Terumo O B_LOCATION/B_ORGANIZATION
(R) O I_LOCATION/I_ORGANIZATION
Corp O I_LOCATION/I_ORGANIZATION
. O O
, O O
Tokyo O B_LOCATION/B_ORGANIZATION
, O O
Japan O B_LOCATION/B_MEASURE
) O O
winged O O
infusion O B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
set O O
under O O
aseptic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Either O O
a O O
dorso O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT
or O O
dorso O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
medial O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
approach O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
will O O
be O O
used O O
at O O
the O O
discretion O B_LOCATION/B_PERSON
of O O
the O O
injector O B_PERSON
( O O
depending O O
on O O
which O O
approach O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
provides O O
minimum O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
interference O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
from O O
the O O
osteophytes O B_PERSON/B_BIO
at O O
the O O
first O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
MPJ O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
joint O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
margins O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

No O O
anaesthetic O B_PRODUCT[OBJECT]/B_LOCATION
will O O
be O O
used O O
. O O

If O O
the O O
participant B B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
has O O
bilateral O O
painful O O
first O O
MPJs O O
, O O
only O O
one O O
side O O
( O O
the O O
most O O
painful O O
side O O
) O O
will O O
be O O
treated O O
and O O
used O O
for O O
data O O
collection O O
. O O

The O O
injector O B_PRODUCT[OBJECT]/B_ENT
will O O
record O O
the O O
volume O B_MEASURE/B_LOCATION
of O O
the O O
agent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
injected O O
. O O

Participants B B_PERSON
will O O
be O O
given O O
the O O
option O O
of O O
a O O
second O O
and O O
final O O
intra O O
- O O
articular O O
injection O O
( O O
of O O
Synvisc O O
(R) O O
or O O
sterile O O
saline O O
according O O
to O O
the O O
treatment O O
group O O
they O O
are O O
in O O
) O O
on O O
days O O
30 O O
or O O
90 O O
if O O
there O O
is O O
no O O
improvement O O
in O O
pain O O
( O O
assessed O O
using O O
the O O
VAPS O O
for O O
pain O O
during O O
walking O O
or O O
at O O
rest O O
) O O
and O O
the O O
participant B B_PERSON
has O O
not O O
experienced O O
severe O O
adverse O O
effects O O
after O O
the O O
first O O
injection O O
) O O
. O O

Assessments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

An O O
initial O O
assessment O O
will O O
be O O
performed O O
to O O
determine O O
the O O
eligibility O O
of O O
participants B B_PERSON
for O O
this O O
study O O
. O O

Demographic O O
data O O
will O O
be O O
collected O O
including O O
the O O
age O O
, O O
gender O O
, O O
height O O
and O O
weight O O
of O O
participants B B_PERSON
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O O
also O O
be O O
obtained O O
concerning O O
the O O
presentation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
symptoms O B_DISEASE
( O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
affected O O
, O O
duration O B_MEASURE
of O O
symptoms O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
. O O

If O O
the O O
participant B B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
has O O
bilateral O O
painful O O
first O O
MPJs O O
, O O
the O O
most O O
painful O O
side O O
will O O
be O O
used O O
for O O
data O O
collection O O
and O O
subsequent O O
treatment O O
. O O

To O O
establish O O
eligibility O O
for O O
the O O
study O O
, O O
participants B B_PERSON
will O O
undergo O O
a O O
clinical O O
assessment O O
, O O
have O O
one O O
set O O
of O O
dorso O O
- O O
plantar O O
and O O
lateral O O
weight O O
- O O
bearing O O
x O O
- O O
rays O O
taken O O
of O O
their O O
feet O O
to O O
grade O O
the O O
severity O O
of O O
first O O
MPJ O O
OA O O
as O O
well O O
as O O
undergo O O
a O O
blood O O
test O O
to O O
assess O O
serum O O
uric O O
acid O O
levels O O
( O O
to O O
exclude O O
gout O O
) O O
. O O

Weightbearing O O
dorso O O
- O O
plantar O O
and O O
lateral O O
radiographic O O
views O O
will O O
be O O
obtained O O
from O O
both O O
feet O O
with O O
the O O
participant B B_PERSON/B_BIO
standing O O
in O O
a O O
relaxed O O
bipedal O O
stance O O
position O O
. O O

All O O
x O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rays O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
taken O O
by O O
the O O
same O B_PERSON/B_LOCATION
medical O I_PERSON/I_LOCATION
imaging O I_PERSON/I_LOCATION
department O I_PERSON/I_LOCATION
using O O
a O O
Shimadzu O B_MEASURE
UD150LRII O I_MEASURE
50 O I_MEASURE
kw O I_MEASURE
/ O O
30 O B_MEASURE
kHz O I_MEASURE
Generator O I_MEASURE
and O O
0 O B_TIME[MEASURE]/B_LOCATION
. O O
6 O B_MEASURE
/ O O
1 O B_MEASURE
. O O
2 O B_MEASURE
P18DE O I_MEASURE
- O O
80S O B_NUMBER[MEASURE]/B_SPORT[ENT]
high O I_NUMBER[MEASURE]/I_SPORT[ENT]
speed O I_NUMBER[MEASURE]/I_SPORT[ENT]
x O O
- O O
ray O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tube O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
a O O
ceiling O B_LOCATION/B_MEASURE
suspended O O
tube O B_LOCATION
mount O I_LOCATION
. O O

AGFA O B_NUMBER[MEASURE]
MD40 O I_NUMBER[MEASURE]
CR O I_NUMBER[MEASURE]
digital O I_NUMBER[MEASURE]
phosphor O I_NUMBER[MEASURE]
plates O O
in O O
a O O
24 O B_MEASURE
cm O I_MEASURE
x O O
30 O B_MEASURE
cm O I_MEASURE
cassette O I_MEASURE
will O O
be O O
used O O
. O O

For O O
dorso O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
plantar O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projections O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
x O B_MEASURE
- O O
ray O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
tube O B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
will O O
be O O
angled O O
15 O B_LOCATION/B_MEASURE
degrees O I_LOCATION/I_MEASURE
cephalad O I_LOCATION/I_MEASURE
and O O
centered O O
at O O
the O O
base O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
third O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsal O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
lateral O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projections O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
tube O B_BODY_PART_OR_ORGAN_COMPONENT
will O O
be O O
angled O O
90 O B_LOCATION/B_MEASURE
degrees O I_LOCATION/I_MEASURE
and O O
centered O O
at O O
the O O
base O B_LOCATION/B_MEASURE
of O O
the O O
third O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsal O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
film O B_MEASURE/B_ENT
focus O I_MEASURE/I_ENT
distance O I_MEASURE/I_ENT
will O O
be O O
set O O
at O O
100 O B_MEASURE/B_LOCATION
cm O I_MEASURE/I_LOCATION
[ O O
19 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Participants B B_PERSON
who O O
are O O
eligible O O
for O O
the O O
study O O
will O O
be O O
invited O O
to O O
attend O O
a O O
baseline O O
assessment O O
. O O

During O O
the O O
baseline O O
assessment O O
, O O
participants B B_PERSON
will O O
undergo O O
primary O O
and O O
secondary O O
outcome O O
measurements O O
prior O O
to O O
receiving O O
their O O
injection O O
. O O

The O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
been O O
developed O O
in O O
accordance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
recommendations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
the O O
OARSI O B_ORGANIZATION/B_PERSON
Clinical O I_ORGANIZATION/I_PERSON
Trials O I_ORGANIZATION/I_PERSON
Task O I_ORGANIZATION/I_PERSON
Force O I_ORGANIZATION/I_PERSON
guidelines O I_ORGANIZATION/I_PERSON
[ O O
18 O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
primary O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O O
secondary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
will O O
occur O O
at O O
four O B_NUMBER[MEASURE]/B_ENT
time O I_NUMBER[MEASURE]/I_ENT
- O O
points O B_LOCATION/B_TIME[MEASURE]
at O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
, O O
3 O B_NUMBER[MEASURE]
and O O
6 O B_TIME[MEASURE]/B_LOCATION
months O B_TIME[MEASURE]/I_LOCATION
post O B_TIME[MEASURE]/I_LOCATION
- O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
after O O
the O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
Synvisc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
placebo O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
assessor O O
performing O O
the O O
measurements O O
will O O
be O O
blinded O O
as O O
to O O
which O O
treatment O O
group O O
participants B B_PERSON/B_LOCATION
have O O
been O O
allocated O O
to O O
. O O

Participants B B_PERSON
who O O
receive O O
a O O
second O O
treatment O O
at O O
day O O
30 O O
or O O
90 O O
will O O
be O O
followed O O
for O O
a O O
further O O
30 O O
days O O
or O O
90 O O
days O O
respectively O O
and O O
undergo O O
outcome O O
measurements O O
at O O
7 O O
or O O
9 O O
months O O
respectively O O
. O O

The O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
be O O
the O O
Pain O B_DISEASE
and O O
Function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
subscales O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
Foot O B_DISEASE/B_GENE
Health O I_DISEASE/I_GENE
Status O I_DISEASE/I_GENE
Questionnaire O I_DISEASE/I_GENE
( O O
FHSQ O B_MEASURE/B_DISEASE
) O O
[ O O
24 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

The O O
FHSQ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
includes O O
13 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
questions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
assess O O
four O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
domains O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
foot O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
health O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, O O
Foot O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pain O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
Foot O B_DISEASE
function O I_DISEASE
, O O
Footwear O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
General O B_DISEASE_ADJECTIVE[DISEASE]
foot O I_DISEASE_ADJECTIVE[DISEASE]
health O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
FHSQ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O O
been O O
subjected O O
to O O
an O O
extensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
validation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
content O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
criterion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
construct O O
validity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

It O O
has O O
a O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
retest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reliability O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
intraclass O B_MEASURE/B_PROTEIN[GENE]
correlation O B_MEASURE/I_PROTEIN[GENE]
coefficients O B_MEASURE/I_PROTEIN[GENE]
ranging O O
from O O
0 O B_NUMBER[MEASURE]
. O O
74 O B_MEASURE
to O O
0 O B_NUMBER[MEASURE]
. O O
92 O B_MEASURE
) O O
and O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
degree O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
internal O B_MEASURE
consistency O I_MEASURE
( O O
Cronbach O B_PERSON/B_MEASURE
' O O
s O B_MEASURE/B_PERSON
alpha O I_MEASURE/I_PERSON
ranging O O
from O O
0 O B_NUMBER[MEASURE]
. O O
85 O B_MEASURE
to O O
0 O B_NUMBER[MEASURE]
. O O
88 O B_MEASURE
) O O
[ O O
24 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Rigorous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reviews O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
rated O O
it O O
as O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
highest O B_SEQUENCE[MEASURE]/B_PERSON
quality O I_SEQUENCE[MEASURE]/I_PERSON
foot O I_SEQUENCE[MEASURE]/I_PERSON
health O I_SEQUENCE[MEASURE]/I_PERSON
status O I_SEQUENCE[MEASURE]/I_PERSON
measures O I_SEQUENCE[MEASURE]/I_PERSON
currently O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
25 O B_MEASURE
- O O
27 O B_MEASURE
] O I_MEASURE
. O O

Secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

The O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
will O O
be O O
: O O

( O O
i O O
) O O
Severity O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pain O B_DISEASE

Severity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
pain O B_DISEASE
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O O
walking O O
, O O
and O O
during O O
rest O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
over O O
the O O
past O B_BODY_PART_OR_ORGAN_COMPONENT
week O I_BODY_PART_OR_ORGAN_COMPONENT
will O O
be O O
assessed O O
using O O
a O O
100 O B_MEASURE/B_PERSON
mm O B_MEASURE/I_PERSON
visual O B_MEASURE/I_PERSON
analogue O B_MEASURE/I_PERSON
pain O B_MEASURE/I_PERSON
scale O B_MEASURE/I_PERSON
. O O

The O O
left O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
side O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
scale O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE
mm O I_MEASURE
) O O
will O O
be O O
labelled O O
" O O
no O O
pain O B_DISEASE
" O O
and O O
the O O
right O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
side O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
scale O B_MEASURE
( O O
100 O B_MEASURE
mm O I_MEASURE
) O O
will O O
be O O
labelled O O
" O B_DISEASE_ADJECTIVE[DISEASE]
worst O I_DISEASE_ADJECTIVE[DISEASE]
pain O I_DISEASE_ADJECTIVE[DISEASE]
possible O I_DISEASE_ADJECTIVE[DISEASE]
" O O
for O O
each O O
question O B_TIME[MEASURE]/B_LOCATION
[ O O
25 O B_MEASURE
, O O
28 O B_MEASURE
] O I_MEASURE
. O O

( O O
ii O B_SEQUENCE[MEASURE]/B_DISEASE
) O O
Severity O B_MEASURE/B_LOCATION
and O O
duration O B_MEASURE/B_LOCATION
of O O
stiffness O B_DISEASE
at O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metatarsophalangeal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
joint O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT

The O O
severity O B_MEASURE
of O O
stiffness O B_DISEASE
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O O
walking O O
over O O
the O O
past O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
week O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
will O O
be O O
assessed O O
using O O
a O O
100 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visual O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogue O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
left O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
side O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
scale O B_MEASURE
( O O
0 O B_MEASURE
mm O I_MEASURE
) O O
will O O
be O O
labelled O O
" O O
not O O
stiff O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O O
all O O
" O O
and O O
the O O
right O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
side O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
scale O B_MEASURE/B_ENT
( O O
100 O B_MEASURE
mm O I_MEASURE
) O O
will O O
be O O
labelled O O
" O O
most O O
stiff O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
possible O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
" O O
. O O

The O O
average O B_MEASURE
duration O I_MEASURE
of O O
stiffness O B_DISEASE
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
over O O
the O O
past O B_TIME[MEASURE]/B_LOCATION
week O I_TIME[MEASURE]/I_LOCATION
will O O
be O O
assessed O O
using O O
a O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
category O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scale O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
response O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
responses O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
: O O
" O O
none O B_TIME[MEASURE]/B_PERSON
" O O
, O O
" O O
1 O B_NUMBER[MEASURE]
- O O
15 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
" O I_TIME[MEASURE]/I_ENT
, O O
" O O
16 O B_MEASURE
- O O
30 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
" O I_TIME[MEASURE]/I_ENT
and O O
" O O
greater O B_LOCATION/B_MEASURE
than O O
30 O B_NUMBER[MEASURE]/B_ENT
minutes O I_NUMBER[MEASURE]/I_ENT
" O I_NUMBER[MEASURE]/I_ENT
[ O O
29 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

( O O
iii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
Passive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
non O O
- O O
weightbearing O O
dorsiflexion O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
of O O
motion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsophalangeal O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
joint O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

First O B_LOCATION/B_PERSON
MPJ O I_LOCATION/I_PERSON
dorsiflexion O I_LOCATION/I_PERSON
range O I_LOCATION/I_PERSON
of O O
motion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
will O O
be O O
measured O O
using O O
a O O
goniometer O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
maximum O B_MEASURE/B_LOCATION
angle O I_MEASURE/I_LOCATION
at O O
which O O
the O O
hallux O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cannot O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
be O O
passively O O
moved O O
into O O
further O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extension O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
non O O
- O O
weightbearing O O
position O B_LOCATION
( O O
Figure O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
) O O
[ O O
30 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
performed O O
two O B_TIME[MEASURE]/B_LOCATION
times O I_TIME[MEASURE]/I_LOCATION
and O O
the O O
average O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
used O O
for O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

This O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
intra O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
reliability O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ICC O B_PROTEIN[GENE]/B_DISEASE
= O O
0 O B_MEASURE
. O O
95 O B_MEASURE
, O O
standard O B_MEASURE/B_LOCATION
error O I_MEASURE/I_LOCATION
of O O
mean O B_MEASURE/B_LOCATION
= O O
1 O B_MEASURE
. O O
3 O B_MEASURE
degrees O I_MEASURE
) O O
[ O O
30 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

( O O
iv O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
Plantar O B_DISEASE
flexion O I_DISEASE
strength O I_DISEASE
of O O
the O O
toe O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
flexors O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hallux O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]

Plantar O B_NUMBER[MEASURE]/B_PERSON
flexion O I_NUMBER[MEASURE]/I_PERSON
strength O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
toe O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
flexors O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hallux O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
will O O
be O O
measured O O
using O O
the O O
Mat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Scan O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
(R) O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
plantar O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pressure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
device O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
[ O O
31 O B_TIME[MEASURE]/B_PERSON
] O I_TIME[MEASURE]/I_PERSON
. O O

Participants B B_PERSON
will O O
be O O
seated O O
with O O
the O O
hip O O
, O O
knee O O
, O O
and O O
ankle O O
at O O
90 O O
degrees O O
and O O
their O O
foot O O
placed O O
over O O
the O O
Mat O O
Scan O O
(R) O O
plantar O O
pressure O O
measurement O O
device O O
( O O
Tekscan O O
, O O
Boston O O
, O O
MA O O
, O O
USA O O
) O O
( O O
Figure O O
3a O O
) O O
. O O

This O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
consists O O
of O O
a O O
5 O B_MEASURE
- O O
mm O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
thick O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
floor O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
mat O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
432 O B_MEASURE
x O O
368 O B_MEASURE
mm O I_MEASURE
) O O
incorporating O O
2288 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resistive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
sensors O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
1 O B_MEASURE
. O O
4 O B_MEASURE
sensors O I_MEASURE
/ O O
cm2 O B_MEASURE
) O O
sampling O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
at O O
a O O
rate O B_MEASURE
of O O
40 O B_NUMBER[MEASURE]/B_LOCATION
Hz O I_NUMBER[MEASURE]/I_LOCATION
. O O

The O O
mat O O
will O O
be O O
calibrated O O
for O O
each O O
participant B B_PERSON
using O O
his O O
or O O
her O O
own O O
bodyweight O O
before O O
each O O
testing O O
session O O
. O O

Participants B B_PERSON
will O O
be O O
instructed O O
to O O
use O O
their O O
toe O O
- O O
flexor O O
muscles O O
to O O
maximally O O
push O O
their O O
hallux O O
down O O
on O O
the O O
MatScan O O
(R) O O
device O O
and O O
forces O O
under O O
the O O
hallux O O
will O O
be O O
recorded O O
( O O
Figure O O
3b O O
) O O
. O O

The O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
performed O O
three O B_TIME[MEASURE]/B_LOCATION
times O I_TIME[MEASURE]/I_LOCATION
for O O
the O O
hallux O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
the O O
maximal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
force O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
used O O
for O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O O
retest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reliability O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
this O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
previously O O
been O O
shown O O
to O O
be O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
with O O
intraclass O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ICCs O B_DISEASE/B_LOCATION
) O O
= O O
0 O B_MEASURE
. O O
88 O B_MEASURE
( O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
0 O I_MEASURE
. O O
81 O B_MEASURE
- O O
0 O B_MEASURE
. O O
93 O B_MEASURE
) O O
[ O O
31 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

( O O
vi O B_MEASURE
) O O
Plantar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pressure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE

Plantar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
be O O
recorded O O
during O O
level O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
barefoot O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
walking O O
using O O
the O O
MatScan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
(R) O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
( O O
Tekscan O B_MEASURE/B_PERSON
(R) O I_MEASURE/I_PERSON
, O O
Boston O B_LOCATION/B_PERSON
, O O
MA O B_LOCATION
, O O
USA O B_LOCATION/B_MEASURE
) O O
. O O

The O O
two O B_NUMBER[MEASURE]
- O O
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
gait O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
initiation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
will O O
be O O
used O O
to O O
obtain O O
foot O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
as O O
it O O
requires O O
fewer O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
trials O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
mid O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
gait O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
has O O
similar O B_LOCATION/B_NUMBER[MEASURE]
re O B_LOCATION/I_NUMBER[MEASURE]
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reliability O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
32 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
be O O
recorded O O
, O O
which O O
has O O
been O O
found O O
to O O
be O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
ensure O O
adequate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reliability O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pressure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
32 O B_MEASURE
, O O
33 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

Following O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
Research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Foot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
version O B_MEASURE/B_LOCATION
5 O B_MEASURE/I_LOCATION
. O O
24 O B_MEASURE
) O O
will O O
be O O
used O O
to O O
construct O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
masks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
determine O O
maximum O B_MEASURE/B_DISEASE
force O I_MEASURE/I_DISEASE
( O O
kg O B_MEASURE/B_LOCATION
) O O
and O O
peak O B_MEASURE
pressure O I_MEASURE
( O O
kg O B_MEASURE
/ O O
cm2 O B_MEASURE
) O O
under O O
seven O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regions O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
: O O
hallux O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
lesser O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
toes O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
1st O B_BODY_PART_OR_ORGAN_COMPONENT
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
2nd O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
3rd O B_SEQUENCE[MEASURE]
to O O
5th O B_SEQUENCE[MEASURE]/B_PERSON
MPJs O I_SEQUENCE[MEASURE]/I_PERSON
, O O
midfoot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
heel O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
Figure O B_MEASURE/B_PERSON
4a O I_MEASURE/I_PERSON
) O O
. O O

For O O
each O O
region O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
median O B_MEASURE
of O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
be O O
used O O
for O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Typical O O
plantar O O
pressure O O
recordings O O
from O O
a O O
participant B B_PERSON/B_LOCATION
are O O
shown O O
in O O
Figure O O
4b O O
. O O

( O O
vi O B_NUMBER[MEASURE]
) O O
Global O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
satisfaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

Global O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
satisfaction O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
will O O
be O O
assessed O O
using O O
a O O
5 O B_NUMBER[MEASURE]
- O O
point O B_MEASURE/B_LOCATION
Likert O I_MEASURE/I_LOCATION
scale O I_MEASURE/I_LOCATION
, O O
as O O
well O O
as O O
a O O
dichotomous O B_BIO/B_MEASURE
( O O
yes O O
/ O O
no O O
) O O
scale O B_MEASURE
. O O

The O O
five O B_NUMBER[MEASURE]/B_DISEASE
point O I_NUMBER[MEASURE]/I_DISEASE
- O O
Likert O B_MEASURE/B_PERSON
scale O I_MEASURE/I_PERSON
will O O
ask O O
" O O
How O O
satisfied O O
are O O
you O O
with O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
you O O
received O O
for O O
your O O
big O B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
toe O B_DISEASE/B_PERSON
joint O B_DISEASE/I_PERSON
pain O B_DISEASE/I_PERSON
? O O
" O O
, O O
and O O
will O O
have O O
the O O
following O O
five O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
" O O
Dissatisfied O B_PERSON/B_TIME[MEASURE]
" O O
, O O
" O O
Only O O
moderately O O
satisfied O B_TIME[MEASURE]/B_PERSON
" O O
, O O
" O O
Fairly O O
satisfied O B_TIME[MEASURE]/B_PERSON
" O O
, O O
" O O
Clearly O O
satisfied O B_TIME[MEASURE]/B_PERSON
" O O
and O O
" O O
Very O O
satisfied O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
" O O
. O O

The O O
dichotomous O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
satisfaction O B_DISEASE
will O O
be O O
answered O O
as O O
" O O
Yes O O
" O O
' O O
or O O
" O O
No O O
" O O
in O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
question O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
" O O
Would O O
you O O
recommend O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
that O O
you O O
received O O
to O O
someone O B_PERSON
else O O
with O O
big O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
toe O B_DISEASE
joint O I_DISEASE
pain O I_DISEASE
" O O
. O O

( O O
vii O B_TIME[MEASURE]
) O O
Health O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
related O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
Short O B_PERSON/B_MEASURE
- O O
Form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- O O
36 O B_MEASURE/B_PERSON
( O O
version O B_LOCATION/B_MEASURE
two O I_LOCATION/I_MEASURE
) O O
( O O
SF O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
36 O B_MEASURE
) O O
questionnaire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O O
be O O
used O O
to O O
assess O O
health O B_PERSON/B_DISEASE
related O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
SF O B_LOCATION/B_DISEASE
- O O
36 O B_MEASURE
is O O
a O O
36 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
question O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
survey O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
measures O O
eight O B_PERSON/B_ORGANIZATION
health O I_PERSON/I_ORGANIZATION
concepts O I_PERSON/I_ORGANIZATION
most O O
affected O O
by O O
disease O B_DISEASE
and O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
eight O B_MEASURE
health O I_MEASURE
concepts O I_MEASURE
can O O
then O O
be O O
used O O
to O O
form O O
two O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
summary O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Physical O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
health O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
Mental O B_DISEASE_ADJECTIVE[DISEASE]
health O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
Short O B_LOCATION
Form O I_LOCATION
- O O
36 O B_MEASURE
( O O
SF O B_LOCATION
- O O
36 O B_MEASURE
) O O
has O O
been O O
extensively O O
validated O O
and O O
is O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
most O O
widely O O
used O O
instruments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
measure O O
health O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
SF O B_LOCATION/B_DISEASE
- O O
36 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O O
content O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
concurrent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
criterion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
construct O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
validity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
reliability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
eight O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concepts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
summary O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
been O O
assessed O O
using O O
both O O
internal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consistency O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
retest O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Reliability O B_PERSON/B_ORGANIZATION
statistics O I_PERSON/I_ORGANIZATION
have O O
exceeded O O
0 O B_MEASURE/B_LOCATION
. O O
80 O B_MEASURE
[ O I_MEASURE
34 O I_MEASURE
- O O
37 O B_MEASURE
] O I_MEASURE
. O O

( O O
viii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
Self O B_PERSON/B_LOCATION
- O O
reported O O
magnitude O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
symptom O B_DISEASE
change O I_DISEASE

Self O B_PERSON/B_LOCATION
- O O
reported O O
magnitude O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
symptom O B_DISEASE
change O I_DISEASE
will O O
be O O
measured O O
using O O
a O O
15 O B_NUMBER[MEASURE]
- O O
point O B_MEASURE/B_LOCATION
Likert O I_MEASURE/I_LOCATION
scale O I_MEASURE/I_LOCATION
. O O

The O O
scale O O
will O O
ask O O
participants B B_PERSON/B_LOCATION
" O O
how O O
much O O
have O O
your O O
symptoms O O
in O O
your O O
big O O
- O O
toe O O
joint O O
have O O
changed O O
from O O
the O O
beginning O O
of O O
the O O
study O O
to O O
now O O
? O O
" O O
. O O

The O O
fifteen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
range O O
from O O
" O O
A O O
very O O
great O B_DISEASE_ADJECTIVE[DISEASE]
deal O I_DISEASE_ADJECTIVE[DISEASE]
better O I_DISEASE_ADJECTIVE[DISEASE]
" O O
to O O
" O O
A O O
very O O
great O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deal O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
worse O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
" O O
. O O

( O O
ix O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
Use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
rescue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medications O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
relieve O O
pain O B_DISEASE
at O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metatarsophalangeal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
joint O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT

The O O
number O O
of O O
participants B B_PERSON
who O O
consumed O O
rescue O O
medication O O
( O O
e O O
. O O
g O O
. O O
, O O
paracetamol O O
) O O
and O O
mean O O
consumption O O
of O O
rescue O O
medication O O
to O O
relieve O O
pain O O
at O O
the O O
first O O
MPJ O O
( O O
mean O O
grams O O
of O O
paracetamol O O
/ O O
participant B B_PERSON/B_MEASURE
/ O O
month O O
] O O
will O O
be O O
assessed O O
using O O
a O O
medications O O
diary O O
that O O
participants B B_PERSON
will O O
self O O
- O O
complete O O
[ O O
38 O O
, O O
39 O O
] O O
. O O

The O O
diary O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
returned O O
to O O
the O O
assessor O B_PERSON/B_LOCATION
at O O
monthly O B_TIME[MEASURE]/B_LOCATION
intervals O B_TIME[MEASURE]/I_LOCATION
for O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
x O B_OTHER/B_NUMBER[MEASURE]
) O O
Frequency O B_MEASURE
and O O
severity O B_MEASURE/B_PERSON
of O O
adverse O B_DISEASE
events O I_DISEASE
as O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

The O O
frequency O O
( O O
number O O
of O O
participants B B_PERSON
affected O O
and O O
number O O
of O O
cases O O
) O O
and O O
types O O
of O O
adverse O O
events O O
( O O
including O O
adverse O O
drug O O
reactions O O
) O O
in O O
each O O
treatment O O
group O O
during O O
the O O
trial O O
will O O
be O O
recorded O O
using O O
a O O
questionnaire O O
that O O
participants B B_PERSON
will O O
complete O O
during O O
the O O
follow O O
- O O
up O O
appointments O O
at O O
1 O O
, O O
3 O O
and O O
6 O O
months O O
post O O
- O O
treatment O O
[ O O
40 O O
] O O
. O O

To O O
classify O O
the O O
' O O
type O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
' O O
of O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]
event O I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
blinded O B_PERSON/B_ORGANIZATION
assessor O I_PERSON/I_ORGANIZATION
will O O
classify O O
the O O
adverse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
event O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
being O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
or O O
non O O
- O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
[ O O
40 O B_MEASURE/B_PERSON
] O B_MEASURE/I_PERSON
. O O

Any O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
, O O
defined O O
as O O
adverse O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
leading O O
to O O
serious O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disability O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
hospital O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
or O O
prolongation O B_DISEASE/B_TIME[MEASURE]
of O O
hospitalisation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
life O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
threatening O O
events O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
or O O
death O B_DISEASE/B_PERSON
) O O
will O O
be O O
further O O
classified O O
using O O
the O O
International O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Diseases O B_DISEASE
( O O
ICD O B_DISEASE
) O O
codes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O O
41 O B_NUMBER[MEASURE]
] O O
. O O

Non O B_DISEASE
- O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
will O O
include O O
both O O
local O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
pain O B_DISEASE
, O O
effusion O B_DISEASE
and O O
heat O B_DISEASE/B_BIO
, O O
with O O
each O O
classified O O
as O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
adverse O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
events O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

An O O
open O O
- O O
response O O
type O O
format O O
will O O
also O O
be O O
available O O
for O O
participant B B_PERSON
responses O O
. O O

Sample O B_MEASURE
size O I_MEASURE

The O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
size O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O O
been O O
pre O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
specified O O
using O O
an O O
a O O
priori O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
power O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O O
the O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
pain O B_MEASURE
domain O I_MEASURE
of O O
the O O
FHSQ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O O
42 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

One O O
hundred O O
and O O
forty O O
two O O
participants B B_PERSON
( O O
i O O
. O O
e O O
. O O
71 O O
per O O
group O O
) O O
will O O
provide O O
power O O
of O O
90 O O
% O O
to O O
detect O O
a O O
minimally O O
important O O
difference O O
in O O
the O O
pain O O
domain O O
of O O
the O O
FHSQ O O
( O O
i O O
. O O
e O O
. O O
14 O O
points O O
on O O
the O O
FHSQ O O
questionnaire O O
) O O
with O O
the O O
significance O O
level O O
set O O
at O O
p O O
< O O
0 O O
. O O
05 O O
. O O

A O O
difference O B_MEASURE/B_LOCATION
of O O
14 O B_MEASURE
points O I_MEASURE
was O O
determined O O
to O O
be O O
a O O
clinically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
difference O I_DISEASE_ADJECTIVE[DISEASE]
worth O I_DISEASE_ADJECTIVE[DISEASE]
detecting O O
[ O O
43 O B_MEASURE
] O I_MEASURE
and O O
a O O
standard O B_MEASURE
deviation O I_MEASURE
of O O
25 O B_NUMBER[MEASURE]
was O O
derived O O
from O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
44 O B_MEASURE
] O I_MEASURE
. O O

This O O
calculation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
included O O
a O O
5 O B_DISEASE
% O I_DISEASE
drop O I_DISEASE
- O O
out O O
rate O B_MEASURE/B_LOCATION
[ O O
13 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

However O O
, O O
we O O
will O O
aim O O
to O O
recruit O O
150 O O
participants B B_PERSON
( O O
~ O O
75 O O
participants B B_PERSON
per O O
intervention O O
group O O
) O O
. O O

Further O O
, O O
we O O
have O O
conservatively O O
ignored O O
the O O
extra O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
precision O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provided O O
by O O
covariate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
when O O
estimating O O
the O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
size O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
undertaken O O
using O O
SPSS O B_MEASURE
version O I_MEASURE
14 O I_MEASURE
. O O
0 O B_MEASURE
( O O
SPSS O B_ORGANIZATION/B_LOCATION
Corp O I_ORGANIZATION/I_LOCATION
, O O
Chicago O B_LOCATION
, O O
Ill O B_LOCATION/B_DISEASE
, O O
USA O B_LOCATION/B_MEASURE
) O O
and O O
STATA O B_TIME[MEASURE]/B_PERSON
8 O I_TIME[MEASURE]/I_PERSON
( O O
Stata O B_ORGANIZATION/B_LOCATION
Corp O B_ORGANIZATION/I_LOCATION
, O O
College O B_LOCATION/B_PERSON
Station O I_LOCATION/I_PERSON
, O O
Tex O B_PERSON/B_LOCATION
. O O
, O O
USA O B_LOCATION/B_ORGANIZATION
) O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

All O O
analyses O O
will O O
be O O
conducted O O
on O O
an O O
intention O O
- O O
to O O
- O O
treat O O
principle O O
using O O
all O O
randomised O O
participants B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
45 O O
- O O
47 O O
] O O
. O O

Missing O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O O
be O O
replaced O O
with O O
the O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
score O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
carried O O
forward O O
[ O O
48 O B_MEASURE/B_PERSON
] O I_MEASURE/I_PERSON
. O O

Standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
distribution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
will O O
be O O
used O O
and O O
transformation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
carried O O
out O O
if O O
required O O
. O O

Demographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
gender O B_PERSON/B_MEASURE
, O O
age O B_MEASURE/B_PERSON
, O O
weight O B_MEASURE/B_LOCATION
, O O
height O B_LOCATION/B_MEASURE
, O O
body O B_MEASURE/B_PERSON
mass O I_MEASURE/I_PERSON
index O I_MEASURE/I_PERSON
) O O
will O O
be O O
determined O O
for O O
the O O
baseline O B_PERSON
visit O I_PERSON
for O O
each O O
treatment O B_PERSON/B_LOCATION
group O I_PERSON/I_LOCATION
. O O

Summary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
statistics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
will O O
be O O
calculated O O
for O O
duration O B_MEASURE
of O O
symptoms O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
affected O O
( O O
left O O
, O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O O
bilateral O B_LOCATION/B_MEASURE
) O O
, O O
grade O B_MEASURE/B_LOCATION
of O O
OA O B_DISEASE
at O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
19 O B_TIME[MEASURE]/B_LOCATION
] O O
as O O
well O O
as O O
all O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
each O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O O
be O O
conducted O O
on O O
1 O B_TIME[MEASURE]
, O O
3 O B_SEQUENCE[MEASURE]
and O O
6 O B_TIME[MEASURE]
month O I_TIME[MEASURE]
outcome O I_TIME[MEASURE]
measures O I_TIME[MEASURE]
. O O

The O O
continuously O O
- O O
scored O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
1 O B_SEQUENCE[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
and O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
will O O
be O O
compared O O
using O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
covariance O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
baseline O B_MEASURE/B_PERSON
scores O I_MEASURE/I_PERSON
and O O
intervention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
entered O O
as O O
independent O B_MEASURE/B_LOCATION
variables O I_MEASURE/I_LOCATION
[ O O
49 O B_MEASURE
, O O
50 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
exception O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
this O O
will O O
be O O
the O O
plantar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
which O O
will O O
be O O
analysed O O
at O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
, O O
3 O B_SEQUENCE[MEASURE]
and O O
6 O B_MEASURE/B_LOCATION
months O I_MEASURE/I_LOCATION
using O O
two O B_NUMBER[MEASURE]
- O O
way O B_LOCATION/B_TIME[MEASURE]
repeated O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
variance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
statistics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Post O B_DISEASE/B_LOCATION
- O O
hoc O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparisons O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
performed O O
using O O
Bonferroni O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adjusted O O
t O B_OTHER/B_DISEASE
- O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Nominal O B_TIME[MEASURE]/B_LOCATION
and O O
ordinal O B_MEASURE
scaled O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O O
be O O
compared O O
at O O
1 O B_SEQUENCE[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
and O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
using O O
Mann O B_PERSON/B_LOCATION
- O O
Whitney O B_PERSON/B_LOCATION
U O I_PERSON/I_LOCATION
- O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
chi O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
square O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
or O O
Fisher O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
s O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exact O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
where O O
appropriate O B_DISEASE_ADJECTIVE[DISEASE]
) O O
respectively O O
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sizes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O O
be O O
determined O O
using O O
Cohen O B_PERSON/B_MEASURE
' O O
s O B_PROTEIN[GENE]
d O I_PROTEIN[GENE]
( O O
continuous O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
scaled O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
or O O
odds O B_MEASURE/B_LOCATION
ratios O I_MEASURE/I_LOCATION
( O O
nominal O B_MEASURE
scaled O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
ordinal O B_MEASURE
scaled O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
as O O
appropriate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
outcome O O
measurements O O
obtained O O
at O O
7 O O
or O O
9 O O
months O O
for O O
participants B B_PERSON
that O O
receive O O
a O O
second O O
and O O
final O O
intra O O
- O O
articular O O
injection O O
( O O
of O O
Synvisc O O
(R) O O
or O O
sterile O O
saline O O
according O O
to O O
the O O
treatment O O
group O O
they O O
are O O
in O O
) O O
on O O
days O O
30 O O
or O O
90 O O
respectively O O
, O O
will O O
also O O
be O O
analysed O O
as O O
described O O
above O O
. O O

These O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
classified O O
as O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

This O O
study O O
is O O
a O O
randomised O O
placebo O O
controlled O O
trial O O
designed O O
to O O
investigate O O
the O O
efficacy O O
of O O
intra O O
- O O
articular O O
hyaluronan O O
( O O
Synvisc O O
(R) O O
) O O
to O O
reduce O O
pain O O
and O O
improve O O
function O O
in O O
people B B_PERSON/B_ORGANIZATION
with O O
OA O O
of O O
the O O
first O O
MPJ O O
( O O
hallux O O
limitus O O
) O O
. O O

Two O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
previously O O
investigated O O
the O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
first O B_DISEASE
MPJ O I_DISEASE
OA O I_DISEASE
[ O O
13 O B_MEASURE
, O O
14 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

However O O
, O O
neither O O
of O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
used O O
a O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

To O O
our O O
knowledge O B_PERSON/B_DISEASE
, O O
this O O
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
randomised O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
controlled O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
using O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O O
OA O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
a O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evaluating O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
therapies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
as O O
there O O
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
a O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
placebo O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O O
to O O
the O O
injection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
this O O
may O O
inflate O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
uncontrolled O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evaluations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
51 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Indeed O O
, O O
a O O
recent O B_DISEASE/B_MEASURE
meta O I_DISEASE/I_MEASURE
- O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hyaluronan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
knee O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
OA O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
concluded O O
that O O
a O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effect O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
accounted O O
for O O
79 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
efficacy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyaluronan O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
16 O B_GENE/B_LOCATION
] O I_GENE/I_LOCATION
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
developed O O
in O O
accordance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
recommendations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
the O O
OARSI O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clinical O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Trials O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Task O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Force O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
guidelines O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
18 O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
outcome O O
measures O O
are O O
pain O O
and O O
function O O
subscales O O
of O O
the O O
FHSQ O O
, O O
pain O O
and O O
stiffness O O
at O O
the O O
first O O
MPJ O O
, O O
range O O
of O O
motion O O
( O O
dorsiflexion O O
) O O
of O O
the O O
first O O
MPJ O O
, O O
plantar O O
flexion O O
strength O O
of O O
muscles O O
of O O
the O O
first O O
MPJ O O
, O O
generic O O
health O O
related O O
quality O O
of O O
life O O
( O O
SF O O
- O O
36 O O
) O O
, O O
patient B B_PERSON
satisfaction O O
with O O
treatment O O
, O O
consumption O O
of O O
rescue O O
medication O O
as O O
well O O
as O O
frequency O O
and O O
nature O O
of O O
adverse O O
effects O O
. O O

These O O
outcomes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O O
be O O
measured O O
at O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
then O O
at O O
1 O B_SEQUENCE[MEASURE]
, O O
3 O B_MEASURE
and O O
6 O B_SEQUENCE[MEASURE]/B_LOCATION
months O I_SEQUENCE[MEASURE]/I_LOCATION
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggests O O
that O O
the O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hyaluronan O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
persist O O
for O O
up O O
to O O
12 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
following O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
[ O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
9 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
38 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

Thus O O
, O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
follow O O
- O O
up O O
assessments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
6 O B_TIME[MEASURE]/B_LOCATION
month O B_TIME[MEASURE]/I_LOCATION
post O B_TIME[MEASURE]/I_LOCATION
- O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
will O O
allow O O
us O O
to O O
determine O O
if O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
if O O
any O O
, O O
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
articular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyaluronan O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persist O O
in O O
the O O
longer O B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
term O I_BODY_PART_OR_ORGAN_COMPONENT/I_TIME[MEASURE]
. O O

Participants B B_PERSON
will O O
be O O
given O O
the O O
option O O
of O O
a O O
second O O
and O O
final O O
intra O O
- O O
articular O O
injection O O
( O O
of O O
Synvisc O O
(R) O O
or O O
sterile O O
saline O O
according O O
to O O
the O O
treatment O O
group O O
they O O
are O O
in O O
) O O
on O O
days O O
30 O O
or O O
90 O O
if O O
there O O
is O O
no O O
improvement O O
in O O
their O O
symptoms O O
. O O

Although O O
this O O
has O O
the O O
potential O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
complicate O O
the O O
interpretation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
this O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
included O O
as O O
it O O
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
more O O
reflective O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
practice O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
14 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
this O O
is O O
in O O
keeping O O
with O O
the O O
pragmatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
summary O O
, O O
this O O
project O O
is O O
the O O
first O O
randomised O O
controlled O O
trial O O
to O O
be O O
conducted O O
to O O
evaluate O O
the O O
efficacy O O
of O O
intra O O
- O O
articular O O
hyaluronan O O
for O O
reducing O O
pain O O
and O O
improving O O
function O O
in O O
people B B_PERSON/B_BIO
with O O
hallux O O
limitus O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
interventions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
have O O
been O O
pragmatically O O
designed O O
to O O
ensure O O
that O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
generaliseable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
clinical O B_PERSON/B_ORGANIZATION
practice O I_PERSON/I_ORGANIZATION
. O O

Recruitment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O O
commence O O
in O O
June O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2008 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
we O O
expect O O
final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
be O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mid O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2010 O B_TIME[MEASURE]
. O O

Competing O O
interests O B_DISEASE

HBM O B_PERSON
and O O
KBL O B_PERSON/B_ORGANIZATION
are O O
Editor O B_PERSON
- O O
in O O
- O O
Chief O B_PERSON/B_ORGANIZATION
and O O
Deputy O B_PERSON
Editor O I_PERSON
- O O
in O O
- O O
Chief O B_PERSON/B_ORGANIZATION
, O O
respectively O O
, O O
of O O
Journal O B_ORGANIZATION/B_LOCATION
of O O
Foot O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
Ankle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

It O O
is O O
journal O B_DISEASE_ADJECTIVE[DISEASE]
policy O I_DISEASE_ADJECTIVE[DISEASE]
that O O
editors O B_PERSON
are O O
removed O O
from O O
the O O
peer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
editorial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
decision O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
making O O
processes O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
papers O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
they O O
have O O
co O B_LOCATION/B_PERSON
- O O
authored O O
. O O

Authors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

SEM O B_TIME[MEASURE]/B_LOCATION
, O O
HBM O B_ORGANIZATION/B_LOCATION
, O O
KBL O B_ORGANIZATION/B_LOCATION
and O O
CJH O B_ORGANIZATION/B_LOCATION
conceived O O
the O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
obtained O O
funding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

SEM O B_TIME[MEASURE]/B_ORGANIZATION
, O O
HBM O B_ORGANIZATION/B_LOCATION
, O O
KBL O B_ORGANIZATION/B_LOCATION
, O O
AEZ O B_ORGANIZATION/B_LOCATION
and O O
JDL O B_ORGANIZATION/B_PERSON
designed O O
the O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O O

SEM O B_TIME[MEASURE]/B_LOCATION
, O O
HBM O B_ORGANIZATION/B_LOCATION
, O O
KBL O B_ORGANIZATION/B_LOCATION
and O O
GVZ O B_ORGANIZATION/B_LOCATION
drafted O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

All O O
authors O B_PERSON
have O O
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

p8 O O
inhibits O O
the O O
growth O O
of O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O O
cancer O O
cells O O
and O O
its O O
expression O O
is O O
induced O O
through O O
pathways O O
involved O O
in O O
growth O O
inhibition O O
and O O
repressed O O
by O O
factors O O
promoting O O
cell O O
growth O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

p8 O B_GENE
is O O
a O O
stress O B_DISEASE
- O O
induced O O
protein O B_GENE/B_BACTERIUM[BIO]
with O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]
functions O I_DISEASE_ADJECTIVE[DISEASE]
and O O
biochemically O O
related O O
to O O
the O O
architectural O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HMG O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Y O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
analyzed O O
the O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
p8 O O
in O O
pancreatic O B_DISEASE
cancer O I_DISEASE
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Expression O O
of O O
p8 O O
was O O
silenced O O
in O O
the O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O O
cancer O O
cell O O
lines O O
Panc O O
- O O
1 O O
and O O
BxPc O O
- O O
3 O O
by O O
infection O O
with O O
a O O
retrovirus O O
expressing O O
p8 O O
RNA O O
in O O
the O O
antisense O O
orientation O O
. O O

Cell O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O O
measured O O
in O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
p8 O B_GENE
- O O
silenced O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

Influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
p8 O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
induction O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoting O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]
growth O I_DISEASE_ADJECTIVE[DISEASE]
or O O
growth O B_DISEASE_ADJECTIVE[DISEASE]
arrest O I_DISEASE_ADJECTIVE[DISEASE]
was O O
monitored O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

p8 O O
- O O
silenced O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
grew O O
more O O
rapidly O O
than O O
control O B_PERSON/B_BIO
cells O I_PERSON/I_BIO
transfected O O
with O O
the O O
empty O B_GENE/B_BIO
retrovirus O I_GENE/I_BIO
. O O

Activation O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Ras O B_GENE/B_DISEASE
--> O O
Raf O B_GENE/B_DISEASE
--> O O
MEK O B_GENE/B_LOCATION
--> O O
ERK O B_GENE
and O O
JNK O B_GENE
intracellular O I_GENE
pathways O O
down O O
- O O
regulated O O
p8 O B_GENE
expression O I_GENE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
MEK1 O B_GENE
/ O O
2 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U0126 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
JNK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SP600125 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
up O O
- O O
regulates O B_MEASURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O I_MEASURE/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
p8 O B_GENE
. O O

Conversely O O
, O O
p38 O O
or O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_GENE
induced O I_GENE
p8 O I_GENE
expression O I_GENE
whereas O O
the O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
p38 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
SB203580 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
down O O
- O O
regulated O O
p8 O B_GENE/B_LOCATION
expression O I_GENE/I_LOCATION
. O O

Finally O O
, O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O O
in O O
part O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O O
through O O
p38 O B_GENE
. O O

Conclusions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

p8 O O
inhibits O O
the O O
growth O O
of O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O O
cancer O O
cells O O
. O O

p8 O O
expression O B_GENE
is O O
induced O O
through O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
involved O O
in O O
growth O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
inhibition O B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
repressed O O
by O O
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
promote O O
cell O B_DISEASE
growth O I_DISEASE
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
p8 O O
belongs O O
to O O
a O O
pathway O B_LOCATION/B_GENE
regulating O O
the O O
growth O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pancreatic O B_DISEASE
cancer O I_DISEASE
cells O I_DISEASE
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

While O O
studying O O
the O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
injured O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pancreas O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O O
we O O
identified O O
a O O
new O B_GENE/B_MEASURE
gene O I_GENE/I_MEASURE
, O O
called O O
p8 O O
, O O
whose O O
expression O B_GENE
is O O
strongly O O
induced O O
during O O
the O O
acute O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pancreatitis O B_DISEASE/B_LOCATION
[ O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
shown O O
that O O
p8 O O
mRNA O B_GENE
is O O
activated O O
in O O
almost O O
all O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stresses O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
2 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
, O O
including O O
minimal O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stresses O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
such O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O O
after O O
routine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
change O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
culture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
medium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
absence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
any O O
added O O
substance O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O O
3 O B_MEASURE
] O I_MEASURE
, O O
indicating O O
that O O
p8 O B_GENE
is O O
a O O
ubiquitous O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
p8 O O
gene O O
was O O
cloned O O
in O O
human B B_SPECIES[BIO]
, O O
rat B B_SPECIES[BIO]/B_GENE
, O O
mouse B B_SPECIES[BIO]/B_DISEASE
, O O
and O O
Xenopus B B_SPECIES[BIO]
laevis I I_SPECIES[BIO]
[ O O
1 O O
, O O
4 O O
- O O
6 O O
] O O
, O O
conceptually O O
translated O O
from O O
the O O
Drosophila B B_SPECIES[BIO]/B_MEASURE
melanogaster I I_SPECIES[BIO]/I_MEASURE
genome O O
or O O
deduced O O
from O O
EST O O
libraries O O
( O O
Bos B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
taurus I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Xenopus B B_SPECIES[BIO]
tropicalis I I_SPECIES[BIO]
, O O
Zebrafish B B_SPECIES[BIO]
, O O
Orzzias B B_SPECIES[BIO]
latipes I I_SPECIES[BIO]
, O O
Bombyx B B_SPECIES[BIO]
mori I I_SPECIES[BIO]
and O O
Paralichthys B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
olivaceous I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
overall O O
degree O O
of O O
homology O O
with O O
human B B_SPECIES[BIO]/B_GENE
p8 O O
ranged O O
from O O
81 O O
to O O
40 O O
% O O
. O O

Secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
prediction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O O
that O O
within O O
the O O
homologous O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
of O O
the O O
eleven O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
there O O
is O O
a O O
basic O B_NUMBER[MEASURE]/B_LOCATION
Helix O I_NUMBER[MEASURE]/I_LOCATION
- O O
Loop O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Helix O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secondary O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
some O O
classes O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
transcription O B_GENE
factors O I_GENE
[ O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Even O O
though O O
a O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
protein O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
such O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
as O O
p8 O O
would O O
not O O
need O O
a O O
nuclear O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
localization O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
signal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
NLS O B_LOCATION/B_ORGANIZATION
) O O
to O O
be O O
transported O O
to O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
a O O
clear O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NLS O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
predicted O O
for O O
the O O
eleven O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
comprising O O
a O O
bipartite O B_LOCATION/B_MEASURE
domain O I_LOCATION/I_MEASURE
of O O
positively O O
charged O O
aminoacids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
, O O
a O O
nuclear O O
/ O O
cytoplasmic O O
location O O
has O O
been O O
demonstrated O O
for O O
human B B_SPECIES[BIO]/B_GENE
p8 O O
upon O O
overexpression O O
of O O
the O O
recombinant O O
protein O O
and O O
immunohistochemistry O O
[ O O
4 O O
] O O
, O O
and O O
for O O
recombinant O O
Xenopus B B_SPECIES[BIO]
laevis I I_SPECIES[BIO]
p8 O O
fused O O
to O O
green O O
fluorescent O O
protein O O
[ O O
6 O O
] O O
. O O

Homology O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
searching O O
in O O
databases O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
reveal O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
similarity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
p8 O O
with O O
other O B_GENE/B_NUMBER[MEASURE]
proteins O I_GENE/I_NUMBER[MEASURE]
of O O
known O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

However O O
, O O
biochemical O B_NUMBER[MEASURE]/B_PERSON
properties O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
mammalian O B_GENE/B_BIO
p8 O I_GENE/I_BIO
proteins O I_GENE/I_BIO
are O O
shared O O
by O O
some O O
high O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mobility O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
group O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HMG O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
[ O O
7 O B_TIME[MEASURE]/B_BIO
] O I_TIME[MEASURE]/I_BIO
, O O
particularly O O
by O O
the O O
HMG O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
I O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Y O B_PERSON/B_PROTEIN[GENE]
family O B_PERSON/I_PROTEIN[GENE]
. O O

The O O
overall O O
identity O O
of O O
human B B_SPECIES[BIO]/B_GENE
p8 O O
with O O
human B B_SPECIES[BIO]
HMG O O
- O O
I O O
/ O O
Y O O
is O O
only O O
about O O
35 O O
% O O
, O O
but O O
the O O
molecular O O
mass O O
, O O
isoelectric O O
point O O
, O O
hydrophilicity O O
plot O O
, O O
the O O
resistance O O
to O O
denaturation O O
after O O
heating O O
at O O
100 O O
degrees O O
C O O
and O O
the O O
charge O O
separation O O
are O O
very O O
similar O O
[ O O
8 O O
] O O
. O O

The O O
p8 O B_GENE
protein O I_GENE
seems O O
to O O
bind O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
weakly O O
, O O
as O O
shown O O
by O O
electrophoretic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shift O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O O
, O O
without O O
preference O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
DNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Finally O O
, O O
human B B_SPECIES[BIO]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p8 O O
has O O
also O O
been O O
shown O O
to O O
be O O
a O O
substrate O O
for O O
protein O O
kinase O O
A O O
in O O
vitro O O
and O O
phosphorylated O O
p8 O O
has O O
a O O
higher O O
content O O
of O O
secondary O O
structure O O
and O O
binding O O
to O O
DNA O O
is O O
highly O O
increased O O
[ O O
8 O O
] O O
. O O

An O O
architectural O B_DISEASE_ADJECTIVE[DISEASE]
role O I_DISEASE_ADJECTIVE[DISEASE]
in O O
transcription O B_GENE/B_DISEASE
has O O
been O O
proposed O O
for O O
this O O
protein O B_BIO/B_PROTEIN[GENE]
, O O
in O O
analogy O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
HMG O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
I O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
Y O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O O
to O O
confirm O O
this O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
[ O O
9 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

Functions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
p8 O B_GENE
appear O O
to O O
be O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
p8 O B_GENE/B_DISEASE
mRNA O I_GENE/I_DISEASE
expression O I_GENE/I_DISEASE
was O O
strongly O O
induced O O
in O O
3T3 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
upon O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
which O O
in O O
turn O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O O
the O O
Smad O B_GENE
- O O
transactivating O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responsible O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
[ O O
10 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
also O O
found O O
that O O
p8 O O
is O O
involved O O
in O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycle O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
regulation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
since O O
p8 O O
- O O
deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
embryonic O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
fibroblasts O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
grew O O
more O O
rapidly O O
and O O
incorporated O O
more O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
thymidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
BrdU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O O
p8 O B_GENE
- O O
expressing O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
11 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

Moreover O O
, O O
expression O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
p8 O O
in O O
breast O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
seems O O
to O O
mediate O O
the O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
cell O B_DISEASE
growth O I_DISEASE
induced O O
by O O
1 O B_MEASURE
, O O
25 O B_MEASURE
- O O
Dihydroxyvitamin O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
12 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

On O O
the O O
contrary O B_PERSON/B_LOCATION
, O O
we O O
also O O
reported O O
that O O
p8 O B_GENE
may O O
promote O O
cell O B_DISEASE/B_GENE
growth O I_DISEASE/I_GENE
when O O
overexpressed O O
in O O
Cos O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
7 O B_MEASURE
, O O
AR42J O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
HeLa O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
1 O B_NUMBER[MEASURE]
, O O
4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p8 O B_GENE
seems O O
to O O
be O O
involved O O
in O O
other O B_DISEASE_ADJECTIVE[DISEASE]
intracellular O I_DISEASE_ADJECTIVE[DISEASE]
functions O I_DISEASE_ADJECTIVE[DISEASE]
such O I_DISEASE_ADJECTIVE[DISEASE]
as O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
since O O
p8 O B_GENE/B_DISEASE
- O O
expressing O O
fibroblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
are O O
more O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
than O O
p8 O B_GENE
- O O
deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fibroblasts O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
the O O
apoptosis O B_DISEASE
induced O O
by O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Also O O
, O O
p8 O B_GENE
is O O
required O O
for O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
mesangial O B_DISEASE
cell O I_DISEASE
hypertrophy O I_DISEASE
in O O
diabetic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
kidney O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
in O O
a O O
mechanism O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O O
ERK O B_GENE
, O O
JNK O B_GENE
and O O
PI3 O B_GENE
kinase O I_GENE
[ O I_GENE
13 O I_GENE
] O I_GENE
. O O

p8 O O
seems O O
to O O
play O O
a O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
LH O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
embryonic O B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
14 O B_GENE/B_LOCATION
] O I_GENE/I_LOCATION
. O O

Moreover O O
, O O
the O O
Drosophila B B_SPECIES[BIO]
melanogaster I I_SPECIES[BIO]
p8 O O
homologue O O
is O O
involved O O
in O O
response O O
to O O
starvation O O
and O O
might O O
be O O
activated O O
to O O
stop O O
cell O O
growth O O
in O O
case O O
of O O
nutrient O O
deprivation O O
[ O O
15 O O
] O O
. O O

Finally O O
, O O
a O O
particularly O O
attractive O B_PERSON/B_MEASURE
role O B_PERSON/I_MEASURE
in O O
tumour O B_DISEASE/B_GENE
progression O I_DISEASE/I_GENE
was O O
recently O O
proposed O O
for O O
p8 O B_GENE
[ O O
16 O B_TIME[MEASURE]/B_GENE
] O I_TIME[MEASURE]/I_GENE
. O O

Fibroblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
obtained O O
from O O
p8 O B_GENE
- O O
expressing O O
or O O
p8 O B_GENE
- O O
deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
animals O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
were O O
transformed O O
with O O
a O O
retroviral O B_VIRUS[BIO]/B_GENE
vector O I_VIRUS[BIO]/I_GENE
expressing O O
both O O
the O O
rasV12 O B_GENE
mutated O O
protein O B_GENE/B_BACTERIUM[BIO]
and O O
the O O
E1A O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenoviral O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncogene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
soft O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
agar O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
assays O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
transformed O O
p8 O B_GENE
- O O
expressing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
formed O O
colonies O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
high O B_TIME[MEASURE]/B_LOCATION
frequency O I_TIME[MEASURE]/I_LOCATION
, O O
as O O
expected O O
, O O
but O O
p8 O B_GENE
- O O
deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transformed O O
fibroblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
unable O B_DISEASE_ADJECTIVE[DISEASE]
to O O
form O O
colonies O B_LOCATION/B_PERSON
. O O

Similarly O O
, O O
transformed O O
p8 O O
- O O
expressing O O
cells O O
produced O O
tumours O O
in O O
all O O
athymic O O
nude B B_BIO/B_LOCATION
mice I I_BIO/I_LOCATION
when O O
injected O O
subcutaneously O O
or O O
intraperitoneally O O
, O O
whereas O O
transformed O O
p8 O O
- O O
deficient O O
fibroblasts O O
did O O
not O O
. O O

On O O
the O O
other O O
hand O O
, O O
studies O O
by O O
another O O
laboratory O O
revealed O O
that O O
expression O O
of O O
the O O
Com1 O O
protein O O
[ O O
17 O O
] O O
, O O
which O O
is O O
identical O O
to O O
human B B_GENE/B_SPECIES[BIO]
p8 O O
, O O
mediates O O
the O O
growth O O
of O O
tumour O O
cells O O
after O O
metastatic O O
establishment O O
in O O
a O O
secondary O O
organ O O
, O O
indicating O O
that O O
activated O O
expression O O
of O O
Com1 O O
/ O O
p8 O O
in O O
metastatic O O
cells O O
is O O
required O O
for O O
tumour O O
progression O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strongly O O
suggest O O
that O O
p8 O B_GENE
is O O
involved O O
in O O
the O O
cellular O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
s O B_DISEASE/B_LOCATION
) O O
required O O
for O O
tumour O B_DISEASE/B_ORGANISM_FUNCTION
progression O I_DISEASE/I_ORGANISM_FUNCTION
and O O
metastasis O B_DISEASE/B_ORGANISM_FUNCTION
. O O

Our O O
aim O O
is O O
to O O
check O O
the O O
relevance O O
of O O
p8 O O
to O O
cancer O O
progression O O
in O O
human B B_PERSON/B_SPECIES[BIO]
. O O

As O O
a O O
first O O
step O O
, O O
we O O
investigated O O
in O O
the O O
present O O
study O O
the O O
function O O
of O O
p8 O O
in O O
two O O
cell O O
lines O O
derived O O
from O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O O
cancer O O
. O O

We O O
observed O O
that O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
p8 O B_GENE
expression O I_GENE
increased O O
the O O
cells O B_MEASURE
growth O I_MEASURE
rate O I_MEASURE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
activations O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
Ras O B_GENE/B_PERSON
--> O O
Raf O B_GENE/B_DISEASE
--> O O
MEK O B_GENE/B_LOCATION
--> O O
ERK O B_GENE
and O O
JNK O B_GENE/B_LOCATION
intracellular O I_GENE/I_LOCATION
pathways O I_GENE/I_LOCATION
, O O
which O O
promote O O
the O O
growth O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
down O O
- O O
regulated O O
p8 O B_GENE
expression O I_GENE
, O O
whereas O O
activation O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
p38 O B_GENE
or O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_TIME[MEASURE]/B_BIO
, O O
which O O
inhibit O O
cell O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
induced O O
its O O
expression O B_GENE
. O O

It O O
was O O
concluded O O
that O O
i O O
/ O O
p8 O O
inhibits O O
the O O
growth O O
of O O
human B B_SPECIES[BIO]/B_NUMBER[MEASURE]
pancreatic O O
cancer O O
cell O O
lines O O
, O O
ii O O
/ O O
p8 O O
expression O O
is O O
induced O O
through O O
pathways O O
involved O O
in O O
growth O O
inhibition O O
and O O
, O O
conversely O O
, O O
repressed O O
by O O
factors O O
that O O
promote O O
cell O O
growth O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

p8 O B_GENE
is O O
silenced O O
in O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cancer O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
a O O
retrovirus O B_VIRUS[BIO]/B_GENE
expressing O O
p8 O O
RNA O B_GENE/B_BIO
in O O
the O O
antisense O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
orientation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Panc O B_DISEASE/B_PROTEIN[GENE]
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
3 O B_MEASURE
pancreatic O I_MEASURE
cells O I_MEASURE
were O O
chosen O O
for O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
, O O
on O O
the O O
one O B_PERSON/B_MEASURE
hand O I_PERSON/I_MEASURE
, O O
both O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
express O O
higher O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
level O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
p8 O B_GENE
( O O
Figure O B_GENE
1 O I_GENE
) O O
and O O
, O O
on O O
the O O
other O B_PERSON/B_NUMBER[MEASURE]
hand O B_PERSON/I_NUMBER[MEASURE]
, O O
because O O
Panc O B_PROTEIN[GENE]/B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
is O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
Smad4 O B_GENE
/ O O
DPC4 O B_GENE/B_MEASURE
and O O
mutated O O
for O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ras O B_GENE/B_DISEASE
, O O
while O O
BxPc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
3 O B_NUMBER[MEASURE]
is O O
Smad4 O B_GENE
/ O O
DPC4 O B_GENE/B_MEASURE
mutated O O
and O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ras O B_GENE/B_DISEASE
wild O I_GENE/I_DISEASE
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
[ O O
18 O B_MEASURE
, O O
19 O B_MEASURE
] O I_MEASURE
, O O
therefore O O
representing O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
transformation O B_DISEASE/B_GENE
and O O
different O B_DISEASE/B_ORGANISM_FUNCTION
genetic O I_DISEASE/I_ORGANISM_FUNCTION
backgrounds O I_DISEASE/I_ORGANISM_FUNCTION
. O O

K O B_GENE/B_LOCATION
- O O
ras O B_GENE/B_DISEASE
and O O
Smad4 O B_GENE
/ O O
DPC4 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
the O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
involved O O
in O O
pancreatic O B_DISEASE/B_GENE
cancer O I_DISEASE/I_GENE
development O I_DISEASE/I_GENE
. O O

We O O
inhibited O O
p8 O O
expression O B_GENE
in O O
both O O
Panc O B_DISEASE/B_PROTEIN[GENE]
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
pancreatic O I_MEASURE
cells O I_MEASURE
by O O
infecting O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
a O O
retrovirus O B_VIRUS[BIO]/B_GENE
expressing O O
the O O
p8 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
asRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
antisense O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
carrying O O
the O O
puromycin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
selected O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O O
analyzed O O
by O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
evaluate O O
the O O
intracellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amounts O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
p8 O B_GENE
protein O I_GENE
. O O

As O O
shown O O
in O O
Figure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
p8 O B_GENE
protein O I_GENE
was O O
clearly O O
visible O B_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
Panc O B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
pancreatic O I_MEASURE
cells O I_MEASURE
infected O O
with O O
the O O
empty O B_VIRUS[BIO]/B_GENE
retrovirus O B_VIRUS[BIO]/I_GENE
but O O
almost O O
undetectable O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infected O O
with O O
the O O
retrovirus O B_VIRUS[BIO]/B_GENE
encoding O O
the O O
p8 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
asRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
, O O
indicating O O
that O O
our O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
sense O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
strategy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
is O O
efficient O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
silence O O
p8 O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
pancreatic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
had O O
been O O
conducted O O
to O O
select O O
the O O
best O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
inhibit O O
p8 O O
expression O B_GENE
. O O

We O O
compared O O
the O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
stable O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transfection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
siRNA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
using O O
a O O
retroviral O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vector O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
asRNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
strategy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
described O O
above O O
. O O

In O O
our O O
hands O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
antisense O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strategy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
worked O O
best O O
, O O
as O O
judged O O
from O O
Western O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
p8 O B_GENE
protein O I_GENE
expression O I_GENE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O O
shown O O
) O O
. O O

p8 O O
- O O
silenced O O
pancreatic O B_DISEASE
cells O I_DISEASE
grow O O
more O O
rapidly O O

We O O
compared O O
in O O
the O O
two O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines O O
the O O
influence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
growth O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
blocking O O
p8 O O
expression O B_GENE
with O O
the O O
p8 O O
asRNA O B_GENE/B_BIO
. O O

Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
3 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O O
that O O
both O O
Panc O B_DISEASE/B_PROTEIN[GENE]
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
cells O I_MEASURE
in O O
which O O
p8 O O
has O O
been O O
silenced O O
grew O O
more O O
rapidly O O
than O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infected O O
with O O
the O O
empty O B_GENE/B_LOCATION
vector O I_GENE/I_LOCATION
suggesting O O
that O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
p8 O B_GENE
of O O
pancreatic O B_DISEASE/B_VIRUS[BIO]
cancer O B_DISEASE/I_VIRUS[BIO]
cell O B_DISEASE/I_VIRUS[BIO]
growth O B_DISEASE/I_VIRUS[BIO]
is O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
from O O
the O O
mechanism O B_MEASURE/B_DISEASE
of O O
transformation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
background O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Serum O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
cellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
down O O
- O O
regulates O B_TIME[MEASURE]/B_LOCATION
p8 O I_TIME[MEASURE]/I_LOCATION
expression O I_TIME[MEASURE]/I_LOCATION

Fetal O O
calf B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O O
, O O
which O O
contains O O
a O O
complex O O
mix O O
of O O
growth O O
factors O O
, O O
can O O
be O O
used O O
as O O
inductor O O
of O O
cell O O
growth O O
. O O

As O O
shown O O
in O O
Figure O O
4 O O
expression O O
of O O
p8 O O
mRNA O O
was O O
down O O
- O O
regulated O O
in O O
both O O
Panc O O
- O O
1 O O
and O O
BxPc O O
- O O
3 O O
when O O
the O O
cells O O
were O O
shifted O O
from O O
culture O O
media O O
containing O O
0 O O
. O O
1 O O
% O O
fetal O O
calf B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O O
to O O
media O O
containing O O
10 O O
% O O
FCS O O
. O O

p8 O O
protein O B_LOCATION
showed O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
behavior O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O O
that O O
p8 O O
expression O B_GENE/B_MEASURE
is O O
down O O
- O O
regulated O O
in O O
growing O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
Ras O B_GENE/B_PERSON
--> O O
Raf O B_GENE/B_DISEASE
--> O O
MEK O B_GENE/B_LOCATION
--> O O
ERK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
down O O
- O O
regulates O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
p8 O O
expression O B_GENE
in O O
pancreatic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]

Most O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
pancreatic O O
cancers O O
harbor O O
mutations O O
in O O
the O O
K O O
- O O
ras O O
oncogene O O
, O O
which O O
happens O O
relatively O O
early O O
in O O
pancreatic O O
tumorigenesis O O
[ O O
20 O O
] O O
. O O

The O O
oncogenic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
mutation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ras O B_GENE/B_LOCATION
gene O I_GENE/I_LOCATION
stabilizes O O
the O O
Ras O B_GENE
protein O I_GENE
in O O
a O O
GTP O B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O O
bound O O
form O B_LOCATION
, O O
which O O
is O O
constitutively O O
active O B_DISEASE_ADJECTIVE[DISEASE]
and O O
make O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
grow O O
more O O
rapidly O O
. O O

Contrary O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
activated O O
Ras O B_GENE/B_LOCATION
protein O I_GENE/I_LOCATION
, O O
p8 O B_GENE
inhibits O O
cell O B_DISEASE/B_GENE
growth O B_DISEASE/I_GENE
( O O
Figure O B_MEASURE/B_GENE
3 O B_MEASURE/I_GENE
) O O
. O O

We O O
looked O O
whether O O
the O O
Ras O B_GENE/B_PERSON
--> O O
Raf O B_GENE/B_DISEASE
--> O O
MEK O B_GENE/B_LOCATION
--> O O
ERK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
also O O
involved O O
in O O
the O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
p8 O B_GENE
expression O I_GENE
, O O
and O O
which O O
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
s O O
) O O
were O O
critical O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Figure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O O
that O O
expression O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
mutated O B_MEASURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
form O I_MEASURE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O O
the O O
Ras O B_GENE/B_DISEASE
protein O I_GENE/I_DISEASE
( O O
rasV12 O B_GENE/B_DISEASE
) O O
in O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O O
which O O
are O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]
for O O
ras O B_GENE/B_DISEASE
, O O
resulted O O
in O O
decreased O O
p8 O B_GENE
mRNA O I_GENE
concentration O I_GENE
and O O
protein O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
that O O
the O O
activated O O
ras O B_GENE/B_DISEASE
inhibits O O
p8 O O
expression O B_GENE
. O O

Figure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O O
that O O
overexpression O B_GENE
of O O
Raf O B_GENE/B_DISEASE
, O O
but O O
not O O
of O O
Raf301 O B_GENE/B_LOCATION
( O O
a O O
negative O B_GENE/B_PERSON
mutant O I_GENE/I_PERSON
of O O
Raf O B_LOCATION/B_GENE
) O O
, O O
and O O
of O O
ERK O B_GENE/B_LOCATION
also O O
inhibited O O
the O O
expression O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
p8 O B_GENE
- O O
CAT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construct O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Panc O B_LOCATION/B_PERSON
- O O
1 O B_MEASURE
as O O
well O O
as O O
in O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_NUMBER[MEASURE]
. O O

Finally O O
, O O
the O O
MEK1 O B_GENE
/ O O
2 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U0126 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activated O O
p8 O O
mRNA O B_GENE
expression O I_GENE
in O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
whether O O
they O O
carry O O
mutated O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ras O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
Panc O B_GENE/B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
) O O
or O O
wild O B_BIO/B_GENE
- O O
type O B_GENE/B_DISEASE
( O O
BxPc O B_LOCATION/B_PERSON
- O O
3 O B_NUMBER[MEASURE]
) O O
. O O

Similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
when O O
expression O B_GENE
of O O
the O O
p8 O B_GENE
protein O I_GENE
was O O
monitored O O
by O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE/B_PROTEIN[GENE]
7 O B_MEASURE/I_PROTEIN[GENE]
) O O
. O O

Activation O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
JNK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
down O O
- O O
regulates O O
p8 O O
expression O B_GENE
in O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cancer O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]

c O O
- O O
Jun O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NH2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
terminal O B_ENZYME[GENE]
kinase O I_ENZYME[GENE]
( O O
JNK O B_GENE/B_LOCATION
) O O
is O O
another O O
major O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
MAPK O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
which O O
converts O O
extracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signals O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O O
expression O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
target O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O O
phosphorylation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
activation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
transcription O B_GENE
factors O I_GENE
. O O

JNK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
implicated O O
in O O
various O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
often O O
opposite O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cellular O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
cell O B_DISEASE
proliferation O I_DISEASE
, O O
transformation O B_DISEASE
and O O
apoptosis O B_DISEASE
. O O

As O O
shown O O
in O O
Figure O B_MEASURE/B_LOCATION
8 O I_MEASURE/I_LOCATION
, O O
overexpression O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
JNK O B_GENE
down O O
- O O
regulates O O
the O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
reporter O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
p8 O B_GENE
- O O
CAT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construct O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Panc O B_PROTEIN[GENE]/B_DISEASE
- O O
1 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
. O O

Similar O B_NUMBER[MEASURE]/B_PERSON
results O B_NUMBER[MEASURE]/I_PERSON
were O O
found O O
in O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
cells O I_MEASURE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
with O O
the O O
JNK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SP600125 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
22 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
up O O
- O O
regulates O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
p8 O B_GENE
mRNA O I_GENE
and O O
p8 O B_GENE
protein O B_BIO
( O O
Figure O B_NUMBER[MEASURE]/B_LOCATION
9 O I_NUMBER[MEASURE]/I_LOCATION
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
the O O
JNK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
involved O O
in O O
the O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
p8 O O
expression O B_GENE
. O O

The O O
p38 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
up O O
- O O
regulates O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
p8 O O
expression O B_GENE
in O O
pancreatic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]

The O O
p38 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transduction O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
plays O O
an O O
essential O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
role O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
including O O
growth O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
inflammation O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
differentiation O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
apoptosis O B_DISEASE/B_ORGANISM_FUNCTION
. O O

In O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
in O O
pancreatic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer O B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p38 O B_GENE
is O O
a O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
inhibitor O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O O
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
[ O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
23 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
] O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
contrary O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O O
the O O
Ras O B_GENE/B_DISEASE
--> O O
Raf O B_GENE/B_DISEASE
--> O O
MEK O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
--> O O
ERK O B_GENE/B_LOCATION
and O O
JNK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
therefore O O
analyzed O O
the O O
putative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
p38 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
p8 O O
expression O B_GENE/B_MEASURE
in O O
pancreatic O B_DISEASE
cancer O I_DISEASE
cells O I_DISEASE
. O O

Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
10 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O O
that O O
over O O
- O O
expression O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
plasmid O B_GENE
encoding O I_GENE
p38 O I_GENE
significantly O O
increases O O
p8 O B_GENE/B_LOCATION
- O O
CAT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Panc O B_DISEASE/B_PROTEIN[GENE]
- O O
1 O B_NUMBER[MEASURE]
as O O
well O O
as O O
in O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE/B_PROTEIN[GENE]
cells O I_MEASURE/I_PROTEIN[GENE]
. O O

Then O O
, O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
treated O O
with O O
SB203580 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
p38 O B_GENE
[ O O
24 O B_GENE
] O I_GENE
, O O
and O O
p8 O O
expression O B_GENE
was O O
measured O O
. O O

p8 O O
mRNA O B_GENE
as O O
well O O
as O O
the O O
encoded O B_GENE
protein O I_GENE
were O O
down O O
- O O
regulated O O
after O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
p38 O B_GENE
activity O I_GENE
( O O
Figure O B_MEASURE/B_GENE
11 O B_MEASURE/I_GENE
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
the O O
p38 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
positive O B_PERSON/B_GENE
regulator O I_PERSON/I_GENE
of O O
p8 O O
expression O B_GENE
in O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cancer O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_NUMBER[MEASURE]
up O O
- O O
regulates O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
p8 O O
expression O B_GENE
in O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cancer O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]

The O O
most O O
prominent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TGF O B_PROTEIN[GENE]/B_DISEASE
beta O I_PROTEIN[GENE]/I_DISEASE
- O O
1 O B_NUMBER[MEASURE]
is O O
its O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
a O O
wide O B_MEASURE
variety O I_MEASURE
of O O
cell O B_DISEASE
types O I_DISEASE
including O O
pancreatic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_LOCATION/B_GENE
signals O I_LOCATION/I_GENE
are O O
sent O O
through O O
two O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
types O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
transmembrane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
threonine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
receptors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O O

In O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
brings O O
together O O
the O O
type O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O O
and O O
type O B_GENE/B_TIME[MEASURE]
II O I_GENE/I_TIME[MEASURE]
receptors O I_GENE/I_TIME[MEASURE]
. O O

In O O
the O O
resulting O O
complex O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
constitutively O O
active O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TGF O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
1 O B_PROTEIN[GENE]/B_LOCATION
type O I_PROTEIN[GENE]/I_LOCATION
II O I_PROTEIN[GENE]/I_LOCATION
receptor O I_PROTEIN[GENE]/I_LOCATION
phosphorylates O O
the O O
type O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O O
receptor O B_GENE
, O O
which O O
then O O
plays O O
a O O
major O B_ENT/B_LOCATION
role O I_ENT/I_LOCATION
in O O
transducing O O
the O O
signal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
downstream O O
components O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
affect O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
phosphorylation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
SMAD O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Phosphorylated O B_LOCATION/B_MEASURE
receptor O I_LOCATION/I_MEASURE
- O O
regulated O O
SMADs O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
then O O
form O O
heteromeric O B_LOCATION/B_PERSON
complexes O I_LOCATION/I_PERSON
with O O
the O O
common O B_GENE
partner O I_GENE
SMAD4 O I_GENE
. O O

These O O
heteromeric O B_LOCATION/B_GENE
complexes O B_LOCATION/I_GENE
then O O
move O O
to O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
where O O
SMAD4 O B_GENE/B_PERSON
will O O
bind O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
contribute O O
to O O
transcriptional O B_DISEASE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
activation O B_DISEASE/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O O

In O O
general O B_PERSON/B_BIO
, O O
pancreatic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
defects O B_DISEASE_ADJECTIVE[DISEASE]
in O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_PROTEIN[GENE]
signaling O I_PROTEIN[GENE]
and O O
are O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_NUMBER[MEASURE]
- O O
mediated O O
growth O B_DISEASE_ADJECTIVE[DISEASE]
suppression O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Since O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_NUMBER[MEASURE]
and O O
p8 O B_GENE
are O O
inhibitors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
pancreatic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
we O O
analyzed O O
whether O O
p8 O O
could O O
mediate O O
, O O
at O O
least O O
in O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_NUMBER[MEASURE]/B_DISEASE
. O O

First O O
, O O
we O O
found O O
that O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Panc O B_PROTEIN[GENE]/B_DISEASE
- O O
1 O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
TGF O B_GENE/B_LOCATION
beta O I_GENE/I_LOCATION
- O O
1 O B_NUMBER[MEASURE]
increased O O
p8 O B_GENE
mRNA O I_GENE
levels O I_GENE
and O O
p8 O B_GENE
protein O I_GENE
as O O
judged O O
by O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_MEASURE
12 O I_MEASURE
) O O
. O O

Then O O
, O O
to O O
confirm O O
that O O
overexpression O B_GENE
is O O
regulated O O
at O O
the O O
transcriptional O B_GENE
level O I_GENE
, O O
we O O
analyzed O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
some O O
constructs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expressing O O
constitutively O O
activated O O
type O B_MEASURE/B_LOCATION
I O O
TGF O O
beta O B_GENE
receptor O I_GENE
, O O
dominant O B_GENE/B_DISEASE
negative O I_GENE/I_DISEASE
type O I_GENE/I_DISEASE
II O I_GENE/I_DISEASE
TGF O I_GENE/I_DISEASE
beta O I_GENE/I_DISEASE
receptor O I_GENE/I_DISEASE
, O O
a O O
dominant O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
negative O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
Smad4 O B_GENE
and O O
the O O
wild O B_BIO/B_PROTEIN[GENE]
- O O
type O B_PROTEIN[GENE]/B_MEASURE
Smad4 O I_PROTEIN[GENE]/I_MEASURE
on O O
the O O
p8 O B_GENE/B_LOCATION
- O O
CAT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
expected O O
, O O
the O O
constitutively O O
activated O O
type O B_MEASURE/B_ORGANIZATION
I O O
TGF O O
beta O B_GENE
receptor O I_GENE
but O O
not O O
the O O
dominant O B_DISEASE/B_GENE
negative O B_DISEASE/I_GENE
type O B_DISEASE/I_GENE
II O B_DISEASE/I_GENE
TGF O B_DISEASE/I_GENE
beta O B_DISEASE/I_GENE
receptor O B_DISEASE/I_GENE
increased O O
CAT O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Also O O
, O O
expression O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
Smad4 O B_GENE
, O O
contrary O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
the O O
negative O B_GENE/B_PERSON
mutant O I_GENE/I_PERSON
, O O
induced O O
p8 O B_GENE/B_DISEASE
transcription O I_GENE/I_DISEASE
( O O
Figure O B_GENE/B_DISEASE
13 O I_GENE/I_DISEASE
) O O
. O O

Together O O
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
p8 O B_GENE/B_DISEASE
is O O
positively O O
regulated O O
by O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_TIME[MEASURE]
. O O

Beside O O
the O O
Smad O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
proteins O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_NUMBER[MEASURE]
also O O
activates O O
the O O
p38 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MAPK O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
pancreas O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O O
which O O
may O O
play O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_NUMBER[MEASURE]
induced O O
genes O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
25 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Therefore O O
, O O
we O O
analyzed O O
the O O
p38 O O
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_TIME[MEASURE]
on O O
p8 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transcription O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

As O O
shown O O
in O O
Figure O B_MEASURE/B_BIO
13 O I_MEASURE/I_BIO
, O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
p38 O B_GENE
activity O I_GENE
with O O
the O O
SB203580 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
specific O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decreased O O
about O O
40 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
the O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_NUMBER[MEASURE]
on O O
the O O
p8 O B_GENE
promoter O I_GENE
indicating O O
that O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_NUMBER[MEASURE]
on O O
p8 O B_GENE
promoter O I_GENE
is O O
mediated O O
by O O
both O O
p38 O O
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
p38 O B_GENE
- O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pathways O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Pancreatic O B_DISEASE
adenocarcinoma O I_DISEASE
is O O
the O O
fourth O B_SEQUENCE[MEASURE]/B_LOCATION
leading O O
cause O B_DISEASE
of O O
death O B_DISEASE
from O O
malignant O B_DISEASE
diseases O I_DISEASE
[ O O
26 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
. O O

The O O
aggressive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
nature O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
neoplasia O B_DISEASE
, O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]
of O O
early O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
detection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
and O O
the O O
limited O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
such O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contribute O O
to O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]
mortality O I_DISEASE_ADJECTIVE[DISEASE]
rate O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
disease O B_DISEASE/B_PERSON
. O O

Therefore O O
, O O
a O O
better O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
understanding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
molecular O B_LOCATION/B_DISEASE
mechanism O I_LOCATION/I_DISEASE
leading O O
to O O
pancreatic O B_DISEASE/B_GENE
cancer O I_DISEASE/I_GENE
remains O O
a O O
major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
because O O
it O O
may O O
help O O
proposing O O
strategies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
earlier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
better O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
most O O
commonly O O
altered O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
pancreatic O B_DISEASE
adenocarcinoma O I_DISEASE
are O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ras O B_GENE/B_PERSON
( O O
75 O B_MEASURE
to O O
100 O B_MEASURE
% O I_MEASURE
) O O
, O O
p16INK4a O B_GENE
( O O
95 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
p53 O B_GENE
( O O
50 O B_MEASURE
to O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
and O O
DPC4 O B_GENE
( O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
[ O O
27 O B_MEASURE
- O O
31 O B_MEASURE
] O I_MEASURE
. O O

Whereas O O
K O B_GENE/B_LOCATION
- O O
ras O B_GENE/B_DISEASE
is O O
a O O
proto O B_DISEASE
- O O
oncogene O B_GENE/B_DISEASE
all O O
the O O
others O B_PERSON/B_DISEASE
are O O
tumour O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
suppressor O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Additional O B_NUMBER[MEASURE]/B_PERSON
genes O B_NUMBER[MEASURE]/I_PERSON
have O O
been O O
found O O
altered O O
at O O
lower O B_TIME[MEASURE]/B_LOCATION
frequency O I_TIME[MEASURE]/I_LOCATION
. O O

Panc O B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
3 O B_NUMBER[MEASURE]
pancreatic O I_NUMBER[MEASURE]
cells O I_NUMBER[MEASURE]
were O O
chosen O O
for O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
they O O
both O O
express O O
high O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
p8 O B_GENE
( O O
Figure O B_GENE
1 O I_GENE
) O O
and O O
because O O
they O O
present O O
with O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
transformation O B_DISEASE/B_GENE
and O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]
backgrounds O I_DISEASE_ADJECTIVE[DISEASE]
, O O
Panc O B_PROTEIN[GENE]/B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
being O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
Smad4 O B_GENE
/ O O
DPC4 O B_GENE/B_MEASURE
but O O
mutated O O
for O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ras O B_GENE/B_DISEASE
and O O
BxPc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
3 O B_NUMBER[MEASURE]
mutated O O
for O O
Smad4 O B_GENE
/ O O
DPC4 O B_GENE/B_MEASURE
and O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE/B_MEASURE
for O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ras O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
18 O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
19 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

This O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
presents O O
evidences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
p8 O O
inhibits O O
the O O
growth O B_DISEASE/B_ORGANISM_FUNCTION
rate O I_DISEASE/I_ORGANISM_FUNCTION
of O O
pancreatic O B_DISEASE
cancer O I_DISEASE
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
that O O
the O O
intracellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathways O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
promoting O O
cell O B_DISEASE
growth O I_DISEASE
down O O
- O O
regulate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
p8 O O
expression O B_GENE
whereas O O
those O O
promoting O O
growth O B_DISEASE_ADJECTIVE[DISEASE]
arrest O I_DISEASE_ADJECTIVE[DISEASE]
up O O
- O O
regulate O O
its O O
expression O B_GENE
. O O

Together O O
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
p8 O B_GENE
is O O
downstream O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
some O O
cell O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulators O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
therefore O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
p8 O O
expression O B_GENE
or O O
its O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
used O O
as O O
a O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
treating O O
pancreatic O B_DISEASE
cancer O I_DISEASE
. O O

Silencing O B_MEASURE/B_PERSON
p8 O B_GENE
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O O
able O B_DISEASE_ADJECTIVE[DISEASE]
to O O
strongly O O
promote O O
cell O B_DISEASE
growth O I_DISEASE
in O O
both O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
Panc O B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_NUMBER[MEASURE]
, O O
suggesting O O
that O O
p8 O B_GENE
may O O
act O O
downstream O O
of O O
the O O
ras O B_GENE/B_DISEASE
- O O
or O O
Smad4 O B_GENE/B_DISEASE
/ O O
DPC4 O B_MEASURE/B_PROTEIN[GENE]
- O O
dependent O B_PERSON/B_GENE
ways O B_PERSON/I_GENE
. O O

Also O O
, O O
we O O
found O O
that O O
stimulating O O
cell O O
growth O O
by O O
the O O
complex O O
combination O O
of O O
growth O O
factors O O
contained O O
in O O
fetal O O
calf B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O O
down O O
- O O
regulated O O
expression O O
of O O
p8 O O
whereas O O
, O O
on O O
the O O
contrary O O
, O O
treating O O
the O O
cells O O
with O O
TGF O O
beta O O
- O O
1 O O
, O O
which O O
promotes O O
cell O O
cycle O O
arrest O O
, O O
stimulates O O
p8 O O
expression O O
. O O

Therefore O O
, O O
p8 O O
gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O O
to O O
be O O
regulated O O
in O O
opposite O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directions O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
mechanisms O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoting O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
cell O B_DISEASE/B_ORGANISM_FUNCTION
cycle O I_DISEASE/I_ORGANISM_FUNCTION
arrest O I_DISEASE/I_ORGANISM_FUNCTION
. O O

It O O
is O O
interesting O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
note O O
that O O
while O O
p8 O O
expression O B_GENE
is O O
under O O
the O O
control O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
cell O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulatory O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
Ras O B_GENE/B_PERSON
--> O O
Raf O B_GENE/B_DISEASE
--> O O
MEK O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
--> O O
ERK O B_GENE
, O O
JNK O B_GENE
, O O
p38 O O
and O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_NUMBER[MEASURE]
, O O
p8 O B_GENE/B_PERSON
can O O
affect O O
cell O B_DISEASE_ADJECTIVE[DISEASE]
cycle O I_DISEASE_ADJECTIVE[DISEASE]
progression O I_DISEASE_ADJECTIVE[DISEASE]
, O O
suggesting O O
that O O
p8 O B_GENE
is O O
a O O
target O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulating O O
pancreatic O B_DISEASE
cell O I_DISEASE
growth O I_DISEASE
. O O

A O O
mechanism O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
which O O
p8 O O
could O O
regulate O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycle O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
progression O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
embryonic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibroblasts O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
previously O O
proposed O O
[ O O
11 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

In O O
fact O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
p8 O B_GENE
seems O O
to O O
take O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
upstream O O
from O O
cyclin O B_GENE
- O O
dependent O B_PROTEIN[GENE]/B_DISEASE
kinases O I_PROTEIN[GENE]/I_DISEASE
because O O
the O O
intracellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
activities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Cdk2 O B_GENE
and O O
Cdk4 O B_GENE
are O O
decreased O O
when O O
p8 O B_GENE
is O O
expressed O O
. O O

Concomitantly O O
, O O
the O O
cyclin O B_GENE
- O O
dependent O B_PROTEIN[GENE]
kinase O I_PROTEIN[GENE]
inhibitor O I_PROTEIN[GENE]
p27 O I_PROTEIN[GENE]
is O O
expressed O O
at O O
a O O
low O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
in O O
p8 O B_GENE
- O O
deficient O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
which O O
may O O
explain O O
the O O
increased O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Cdk2 O B_GENE
and O O
Cdk4 O B_GENE
. O O

The O O
mechanism O B_LOCATION
by O O
which O O
p8 O O
regulates O O
the O O
intracellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
those O O
proteins O B_GENE/B_DISEASE
remains O O
to O O
be O O
determined O O
. O O

However O O
, O O
because O O
p8 O O
is O O
a O O
transcriptional O B_GENE/B_PERSON
cofactor O I_GENE/I_PERSON
, O O
it O O
is O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
expression O B_GENE
of O O
these O O
molecules O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
takes O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
at O O
least O O
in O O
part O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
at O O
the O O
transcription O B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
level O B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Interestingly O O
, O O
expression O B_GENE
of O O
p8 O O
mRNA O B_GENE/B_LOCATION
seems O O
to O O
be O O
regulated O O
in O O
a O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
type O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
- O O
and O O
stimulus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O O
, O O
for O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
p38 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
induce O O
p8 O O
expression O B_GENE
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
stress O B_DISEASE/B_GENE
in O O
fibroblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O O
3 O B_MEASURE
] O I_MEASURE
but O O
not O O
in O O
renal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mesangial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
treated O O
with O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
13 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
pancreatic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
p38 O O
seems O O
to O O
play O O
a O O
major O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
role O B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
since O O
it O O
is O O
involved O O
in O O
p8 O O
activation O B_GENE
as O O
judged O O
by O O
transient O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
using O O
a O O
specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p38 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figures O B_NUMBER[MEASURE]
10 O I_NUMBER[MEASURE]
and O O
11 O B_MEASURE
) O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p38 O B_GENE
is O O
also O O
involved O O
in O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_NUMBER[MEASURE]
- O O
induced O O
p8 O O
expression O B_GENE
because O O
about O O
40 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
TGF O B_GENE
beta O I_GENE
- O O
1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
abolished O O
when O O
p38 O B_GENE
activity O I_GENE
was O O
specifically O O
blocked O O
( O O
Figure O B_GENE
13 O I_GENE
) O O
. O O

On O O
the O O
other O B_PERSON/B_MEASURE
hand O I_PERSON/I_MEASURE
, O O
ERK O B_GENE/B_LOCATION
and O O
JNK O B_GENE/B_LOCATION
are O O
inducers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
p8 O O
expression O B_GENE
in O O
mesangial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
treated O O
with O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
but O O
not O O
involved O O
in O O
the O O
activation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
p8 O O
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
stress O O
in O O
fibroblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
[ O O
3 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
even O O
repressors O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figures O B_GENE
5 O I_GENE
, O O
6 O B_SEQUENCE[MEASURE]
, O O
7 O B_SEQUENCE[MEASURE]
, O O
8 O B_NUMBER[MEASURE]
and O O
9 O B_NUMBER[MEASURE]
) O O
. O O

Finally O O
, O O
PI3 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
inducer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
p8 O O
expression O B_GENE
in O O
both O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mediated O O
p8 O O
activation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
mesangial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
13 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O O
pancreatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
not O O
shown O O
) O O
. O O

Based O O
on O O
these O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
overexpression O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
p8 O O
could O O
be O O
considered O O
a O O
possible O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
goal O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O O
treating O O
pancreatic O B_DISEASE
tumours O I_DISEASE
, O O
in O O
order O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
limit O O
their O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
we O O
previously O O
reported O O
that O O
p8 O O
repression O O
would O O
prevent O O
rasV12 O O
/ O O
E1A O O
transformed O O
fibroblasts O O
from O O
evolving O O
as O O
tumours O O
in O O
nude B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
16 O O
] O O
. O O

This O O
apparent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contradiction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
needs O O
to O O
be O O
resolved O O
before O O
considering O O
p8 O O
as O O
a O O
target O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
for O O
treating O O
cancer O B_DISEASE
progression O I_DISEASE
. O O

Conclusions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
see O O
Figure O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14 O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
we O O
report O O
in O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
p8 O O
expression O B_GENE
by O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
sense O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O O
the O O
growth O B_DISEASE_ADJECTIVE[DISEASE]
rate O I_DISEASE_ADJECTIVE[DISEASE]
of O O
both O O
Panc O B_DISEASE
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
pancreatic O I_MEASURE
cancer O I_MEASURE
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

Moreover O O
, O O
ERK O B_GENE
- O O
and O O
JNK O B_GENE
- O O
mediated O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
down O O
- O O
regulate O O
p8 O O
expression O B_GENE
, O O
whereas O O
p38 O B_GENE
and O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_MEASURE/B_LOCATION
pathways O I_MEASURE/I_LOCATION
induce O O
p8 O O
expression O B_GENE
. O O

Also O O
, O O
cell O O
growth O O
triggered O O
by O O
expression O O
of O O
a O O
RAS O O
mutated O O
protein O O
or O O
by O O
10 O O
% O O
fetal O O
calf B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O O
induces O O
down O O
- O O
regulation O O
of O O
p8 O O
expression O O
. O O

Together O O
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
p8 O B_GENE
is O O
an O O
intracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
it O O
is O O
oppositely O O
regulated O O
by O O
growth O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
promoting O O
or O O
growth O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
inhibiting O O
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
pancreatic O B_DISEASE
cancer O I_DISEASE
- O O
derived O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

Material O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lines O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cell O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
human B B_SPECIES[BIO]
pancreatic O O
cancer O O
cell O O
lines O O
Panc O O
- O O
1 O O
and O O
BxPc O O
- O O
3 O O
were O O
a O O
kind O O
gift O O
of O O
Dr O O
C O O
. O O

Susini O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
INSERM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
U O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O
531 O B_MEASURE/B_LOCATION
, O O
Toulouse O B_LOCATION/B_MEASURE
) O O
and O O
A O O
. O O

Hajri O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IRCAD O B_MEASURE/B_ORGANIZATION
, O O
Strasbourg O B_LOCATION/B_MEASURE
) O O
respectively O O
. O O

Panc O O
- O O
1 O O
cells O O
were O O
grown O O
in O O
Dulbecco O O
' O O
s O O
modified O O
Eagle O O
' O O
s O O
medium O O
( O O
DMEM O O
) O O
supplemented O O
with O O
10 O O
% O O
fetal O O
calf B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O O
, O O
2 O O
mM O O
L O O
- O O
glutamine O O
, O O
100 O O
IU O O
/ O O
ml O O
penicilin O O
G O O
and O O
100 O O
mu O O
g O O
/ O O
ml O O
streptomycin O O
. O O

BxPc O O
- O O
3 O O
were O O
cultivated O O
in O O
RPMI O O
1640 O O
medium O O
in O O
the O O
presence O O
of O O
2 O O
mM O O
L O O
- O O
glutamine O O
, O O
4 O O
. O O
5 O O
g O O
/ O O
L O O
glucose O O
, O O
10 O O
mM O O
Hepes O O
, O O
1 O O
. O O
0 O O
mM O O
sodium O O
pyruvate O O
, O O
10 O O
% O O
fetal O O
calf B B_SPECIES[BIO]
serum O O
and O O
100 O O
IU O O
/ O O
ml O O
penicilin O O
G O O
and O O
100 O O
mu O O
g O O
/ O O
ml O O
streptomycin O O
. O O

Human B B_PERSON/B_SPECIES[BIO]
recombinant O O
TGF O O
beta O O
- O O
1 O O
was O O
obtained O O
from O O
Sigma O O
, O O
and O O
specific O O
SB203580 O O
, O O
U0126 O O
and O O
SP600125 O O
inhibitors O O
were O O
from O O
Calbiochem O O
and O O
utilized O O
at O O
10 O O
mu O O
M O O
. O O

Expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plasmids O O

Expression O B_GENE/B_BIO
plamids O I_GENE
encoding O O
p38 O B_GENE
( O O
pCEFL O B_GENE
HA O I_GENE
p38 O I_GENE
) O O
, O O
Erk2 O B_GENE
( O O
pcDNAIII O B_GENE
HA O I_GENE
ERK2 O I_GENE
) O O
, O O
JNK O B_GENE
( O O
pcDNAIIIB O B_GENE/B_BACTERIUM[BIO]
HA O I_GENE/I_BACTERIUM[BIO]
JNK O I_GENE/I_BACTERIUM[BIO]
) O O
, O O
the O O
wild O B_BIO/B_PROTEIN[GENE]
- O O
type O B_GENE/B_MEASURE
Raf O B_GENE/I_MEASURE
( O O
pcDNA O B_GENE
RAF O I_GENE
BXB O I_GENE
) O O
and O O
the O O
Raf O B_GENE
dominant O I_GENE
negative O I_GENE
( O O
pcDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RAF O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
301 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
K375W O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
obtained O O
from O O
O O B_LOCATION/B_PERSON
Coso O I_LOCATION/I_PERSON
( O O
University O B_LOCATION
of O O
Buenos O B_LOCATION
Aires O I_LOCATION
) O O
. O O

Plamids O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
constitutively O O
activated O O
type O B_MEASURE/B_ORGANIZATION
I O O
TGF O O
beta O B_GENE
receptor O I_GENE
( O O
RI O B_LOCATION/B_ORGANIZATION
ACT O I_LOCATION/I_ORGANIZATION
) O O
, O O
the O O
dominant O B_GENE/B_DISEASE
negative O I_GENE/I_DISEASE
type O I_GENE/I_DISEASE
II O I_GENE/I_DISEASE
TGF O I_GENE/I_DISEASE
beta O I_GENE/I_DISEASE
receptor O I_GENE/I_DISEASE
( O O
RII O B_GENE/B_LOCATION
DN O I_GENE/I_LOCATION
) O O
and O O
the O O
Smad4 O B_GENE
dominant O I_GENE
negative O I_GENE
( O O
DPC4 O B_MEASURE/B_PROTEIN[GENE]
1 O I_MEASURE/I_PROTEIN[GENE]
- O O
514 O B_MEASURE
a O O
. O O
a O O
. O O
) O O
were O O
obtained O O
from O O
R O B_LOCATION/B_PERSON
Urrutia O I_LOCATION/I_PERSON
( O O
Mayo O B_LOCATION
Clinic O I_LOCATION
, O O
Rochester O B_LOCATION
) O O
and O O
the O O
wild O B_MEASURE/B_GENE
type O I_MEASURE/I_GENE
Smad4 O I_MEASURE/I_GENE
was O O
from O O
C O B_LOCATION/B_PERSON
Heldin O I_LOCATION/I_PERSON
( O O
Ludwig O B_LOCATION/B_ORGANIZATION
Institute O I_LOCATION/I_ORGANIZATION
, O O
Uppsala O B_LOCATION
) O O
. O O

Pancreatic O B_GENE
p8 O I_GENE
- O O
deficient O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]

To O O
silence O O
p8 O O
expression O O
in O O
pancreatic O O
cells O O
, O O
we O O
infected O O
these O O
cells O O
with O O
a O O
retrovirus O O
expressing O O
human B B_SPECIES[BIO]
p8 O O
in O O
the O O
antisense O O
orientation O O
. O O

The O O
retroviral O O
vector O O
was O O
constructed O O
as O O
follows O O
: O O
human B B_SPECIES[BIO]/B_GENE
p8 O O
cDNA O O
was O O
subcloned O O
in O O
HindIII O O
and O O
XhoI O O
restriction O O
sites O O
of O O
the O O
pLPC O O
plasmid O O
( O O
obtained O O
from O O
S O O
. O O
Lowe O O
) O O
in O O
the O O
antisense O O
orientation O O
. O O

Amphotrope O O
human B B_PROTEIN[GENE]/B_SPECIES[BIO]
p8 O O
expressing O O
retrovirus O O
was O O
then O O
generated O O
by O O
transient O O
transfection O O
using O O
Phoenix O O
amphotrope O O
packaging O O
cells O O
. O O

Viral O B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
supernatant O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
to O O
infect O O
Panc O B_DISEASE/B_PROTEIN[GENE]
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_MEASURE
pancreatic O I_MEASURE
cells O I_MEASURE
and O O
the O O
population O B_PERSON/B_MEASURE
of O O
p8 O B_GENE
- O O
silenced O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
was O O
isolated O O
by O O
selection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
puromycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
1 O B_MEASURE/B_LOCATION
mu O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE/B_PERSON
) O O
. O O

As O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
infected O O
with O O
the O O
pLPC O B_BIO/B_LOCATION
empty O I_BIO/I_LOCATION
vector O I_BIO/I_LOCATION
. O O

p8 O O
expression O B_GENE
in O O
arrested O O
and O O
growing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE

One O B_MEASURE/B_LOCATION
million O I_MEASURE/I_LOCATION
of O O
Panc O B_LOCATION/B_PERSON
- O O
1 O B_NUMBER[MEASURE]
or O O
BxPc O B_LOCATION
- O O
3 O B_MEASURE
cells O I_MEASURE
were O O
cultivated O O
on O O
10 O B_MEASURE
- O O
cm O B_TIME[MEASURE]/B_BIO
Petri O I_TIME[MEASURE]/I_BIO
plates O I_TIME[MEASURE]/I_BIO
in O O
standard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
with O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FCS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
. O O

After O O
48 O B_TIME[MEASURE]
h O O
, O O
culture O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
media O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
changed O O
for O O
fresh O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
media O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
FCS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
restricted O O
to O O
0 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
, O O
in O O
order O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
stop O O
growth O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
24 O O
hours O O
of O O
growth O O
arrest O O
, O O
culture O O
medium O O
was O O
replaced O O
either O O
by O O
medium O O
with O O
10 O O
% O O
fetal O O
calf B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O O
to O O
resume O O
cell O O
growth O O
or O O
, O O
as O O
control O O
, O O
by O O
medium O O
with O O
0 O O
. O O
1 O O
% O O
fetal O O
calf B B_SPECIES[BIO]
serum O O
. O O

Twenty O B_TIME[MEASURE]/B_ENT
four O I_TIME[MEASURE]/I_ENT
hours O I_TIME[MEASURE]/I_ENT
later O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
recovered O O
and O O
RNA O B_GENE/B_BIO
and O O
protein O B_GENE/B_BACTERIUM[BIO]
extracted O O
. O O

p8 O O
expression O B_GENE
in O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_NUMBER[MEASURE]
- O O
treated O O
Panc O B_DISEASE/B_PROTEIN[GENE]
- O O
1 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION

One O B_MEASURE/B_LOCATION
million O I_MEASURE/I_LOCATION
of O O
Panc O B_PROTEIN[GENE]/B_DISEASE
- O O
1 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
were O O
cultivated O O
in O O
10 O B_MEASURE
- O O
cm O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
culture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
dishes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
48 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O O
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
TGF O B_GENE/B_DISEASE
beta O I_GENE/I_DISEASE
- O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O O

Human B B_PERSON/B_SPECIES[BIO]
recombinant O O
TGF O O
beta O O
- O O
1 O O
( O O
5 O O
ng O O
/ O O
ml O O
) O O
was O O
added O O
to O O
cells O O
, O O
without O O
changing O O
the O O
culture O O
medium O O
, O O
and O O
cells O O
were O O
collected O O
12 O O
hours O O
later O O
for O O
RNA O O
and O O
protein O O
preparation O O
. O O

BxPc O B_PROTEIN[GENE]/B_MEASURE
- O O
3 O B_PROTEIN[GENE]/B_LOCATION
rasV12 O I_PROTEIN[GENE]/I_LOCATION
- O O
expressing O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]

pLPC O B_PROTEIN[GENE]/B_LOCATION
- O O
rasV12 O B_PROTEIN[GENE]
and O O
pLPC O B_MEASURE/B_PERSON
plasmids O I_MEASURE/I_PERSON
were O O
obtained O O
from O O
S O B_OTHER/B_BIO
. O O

Lowe O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Phoenix O B_NUMBER[MEASURE]/B_PERSON
amphotrope O I_NUMBER[MEASURE]/I_PERSON
packaging O I_NUMBER[MEASURE]/I_PERSON
cells O I_NUMBER[MEASURE]/I_PERSON
( O O
106 O B_TIME[MEASURE]/B_LOCATION
) O O
were O O
plated O O
in O O
a O O
6 O B_MEASURE/B_LOCATION
- O O
well O B_MEASURE/B_LOCATION
plate O I_MEASURE/I_LOCATION
, O O
incubated O O
for O O
24 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
, O O
then O O
transfected O O
with O O
PEI O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O O
5 O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mu O B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
g O B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
retroviral O B_GENE
plasmid O I_GENE
. O O

After O O
48 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
virus O B_VIRUS[BIO]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
was O O
filtered O O
( O O
0 O B_MEASURE/B_LOCATION
. O O
45 O B_MEASURE
mu O I_MEASURE
m O I_MEASURE
filter O I_MEASURE
, O O
Millipore O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
to O O
obtain O O
the O O
viral O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supernatant O B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Target O B_PROTEIN[GENE]/B_LOCATION
BxPc O I_PROTEIN[GENE]/I_LOCATION
- O O
3 O B_MEASURE/B_PRODUCT[OBJECT]
were O O
plated O O
at O O
2 O B_MEASURE
x O O
105 O B_MEASURE
cells O I_MEASURE
per O O
35 O B_MEASURE
- O O
mm O B_TIME[MEASURE]
dish O I_TIME[MEASURE]
and O O
incubated O O
overnight O O
. O O

For O O
infections O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
culture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
replaced O O
by O O
an O O
appropriate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
mix O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
viral O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
supernatant O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O O
culture O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPECIES[BIO]
medium O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_SPECIES[BIO]
( O O
V O B_PROTEIN[GENE]/B_LOCATION
/ O O
V O B_OTHER/B_PROTEIN[GENE]
) O O
, O O
supplemented O O
with O O
4 O B_MEASURE/B_LOCATION
mu O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE/B_LOCATION
polybrene O I_MEASURE/I_LOCATION
( O O
Sigma O B_PROTEIN[GENE]
) O O
, O O
and O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
incubated O O
at O O
37 O B_LOCATION/B_MEASURE
degrees O I_LOCATION/I_MEASURE
C O I_LOCATION/I_MEASURE
. O O

BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_GENE
rasV12 O I_GENE
- O O
expressing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
selected O O
with O O
puromycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
1 O B_MEASURE/B_LOCATION
mu O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
ml O B_MEASURE/B_PERSON
) O O
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infected O O
with O O
the O O
pLPC O B_SPECIES[BIO]/B_GENE
empty O I_SPECIES[BIO]/I_GENE
vector O I_SPECIES[BIO]/I_GENE
were O O
used O O
as O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Western O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
blot O B_LOCATION
analyses O I_LOCATION

One O B_MEASURE/B_LOCATION
hundred O B_MEASURE/I_LOCATION
mu O B_MEASURE/I_LOCATION
g O B_MEASURE/I_LOCATION
of O O
total O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
extracted O O
from O O
cells O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
was O O
separated O O
with O O
standard O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
procedures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
15 O B_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
SDS O I_MEASURE
- O O
PAGE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
using O O
the O O
Mini O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Protean O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
System O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Bio O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
Rad O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
transferred O O
to O O
a O O
nitrocellulose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
membrane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Sigma O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

The O O
intracellular O O
level O O
of O O
p8 O O
was O O
estimated O O
by O O
Western O O
blot O O
using O O
a O O
polyclonal O O
antibody O O
( O O
1 O O
: O O
1000 O O
) O O
raised O O
against O O
human B B_SPECIES[BIO]
p8 O O
[ O O
4 O O
] O O
. O O

Growth O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curves O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

One O B_NUMBER[MEASURE]/B_LOCATION
hundred O I_NUMBER[MEASURE]/I_LOCATION
thousand O I_NUMBER[MEASURE]/I_LOCATION
cells O I_NUMBER[MEASURE]/I_LOCATION
per O O
well O O
were O O
plated O O
in O O
a O O
series O B_SPORT[ENT]/B_LOCATION
of O O
35 O B_MEASURE
- O O
mm O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dishes O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
cell O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
number O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
estimated O O
daily O O
in O O
triplicate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
during O O
1 O B_NUMBER[MEASURE]/B_LOCATION
to O O
5 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
, O O
in O O
a O O
haemocytometer O B_MEASURE/B_LOCATION
. O O

Within O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
each O O
point O B_MEASURE
was O O
determined O O
at O O
least O O
two O B_TIME[MEASURE]/B_LOCATION
times O I_TIME[MEASURE]/I_LOCATION
. O O

Cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reporter O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O O

Panc O B_LOCATION/B_PERSON
- O O
1 O B_NUMBER[MEASURE]
and O O
BxPc O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
3 O B_NUMBER[MEASURE]
( O O
105 O B_NUMBER[MEASURE]/B_LOCATION
) O O
were O O
cultivated O O
in O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diameter O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dishes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
24 O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
then O O
transiently O O
transfected O O
with O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mu O I_MEASURE
g O I_MEASURE
of O O
p8 O B_GENE
- O O
CAT O B_GENE/B_MEASURE
reporter O I_GENE/I_MEASURE
plasmid O O
and O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mu O I_MEASURE
g O I_MEASURE
of O O
pCMV O B_GENE/B_BIO
/ O O
beta O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
to O O
control O O
transfection O B_MEASURE/B_DISEASE
efficiency O B_MEASURE/I_DISEASE
) O O
using O O
the O O
Fugene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reagent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
accordance O B_TIME[MEASURE]/B_ORGANIZATION
with O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
' O O
s O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
( O O
Roche O B_MEASURE/B_ORGANIZATION
Molecular O I_MEASURE/I_ORGANIZATION
Biochemicals O I_MEASURE/I_ORGANIZATION
) O O
. O O

The O O
p8 O B_GENE
- O O
CAT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasmid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
previously O O
reported O O
p O O
- O O
1471 O B_MEASURE/B_BIO
/ O O
+ O B_MEASURE
37p8 O I_MEASURE
- O O
CAT O B_MEASURE/B_GENE
promoter O I_MEASURE/I_GENE
construct O I_MEASURE/I_GENE
[ O O
5 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

Reporter O B_PERSON/B_ORGANIZATION
activities O I_PERSON/I_ORGANIZATION
were O O
measured O O
as O O
previously O O
described O O
[ O O
5 O B_MEASURE/B_GENE
] O I_MEASURE/I_GENE
. O O

Briefly O B_TIME[MEASURE]/B_LOCATION
, O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
prepared O O
with O O
the O O
reporter O B_GENE
lysis O I_GENE
buffer O I_GENE
( O O
Promega O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
24 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
after O O
transfection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
CAT O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
determined O O
by O O
the O O
phase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extraction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
32 O B_GENE
] O I_GENE
and O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
galactosidase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
performed O O
essentially O O
as O O
described O O
in O O
Sambrook O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
33 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CAT O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
normalized O O
to O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
galactosidase O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
carried O O
out O O
in O O
triplicate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
repeated O O
at O O
least O O
two O B_TIME[MEASURE]/B_LOCATION
times O I_TIME[MEASURE]/I_LOCATION
. O O

Expression O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
plasmids O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mu O I_MEASURE
g O I_MEASURE
) O O
were O O
co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
transfected O O
with O O
p8 O B_GENE
- O O
CAT O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
pCMV O B_GENE/B_BIO
/ O O
beta O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmids O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
indicated O O
. O O

RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O O
PCR O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
analysis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

RNA O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
extracted O O
using O O
the O O
Trizol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Life O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Technologies O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Total O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O B_PROTEIN[GENE]/B_LOCATION
mu O I_PROTEIN[GENE]/I_LOCATION
g O I_PROTEIN[GENE]/I_LOCATION
) O O
was O O
analyzed O O
by O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
the O O
SuperScript O B_NUMBER[MEASURE]/B_PERSON
(TM) O I_NUMBER[MEASURE]/I_PERSON
One O I_NUMBER[MEASURE]/I_PERSON
- O O
step O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
System O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
the O O
Platinum O B_LOCATION/B_ORGANIZATION
Taq O B_LOCATION/I_ORGANIZATION
kit O B_LOCATION/I_ORGANIZATION
( O O
Life O B_PROTEIN[GENE]/B_ORGANIZATION
Technologies O I_PROTEIN[GENE]/I_ORGANIZATION
) O O
. O O

RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
using O O
different O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
numbers O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cycles O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
verify O O
that O O
the O O
conditions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
chosen O O
were O O
within O O
the O O
linear O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
. O O

The O O
mRNA O B_GENE
coding O I_GENE
for O O
p8 O O
was O O
specifically O O
amplified O O
with O O
sense O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
5 O B_MEASURE
' O O
GAAGAGAGGCAGGGAAGACA O B_PROTEIN[GENE]/B_MEASURE
3 O I_PROTEIN[GENE]/I_MEASURE
' O O
) O O
and O O
antisense O B_GENE
( O O
5 O B_MEASURE
' O O
CTGCCGTGCGTGTCTATTTA O B_GENE/B_MEASURE
3 O B_GENE/I_MEASURE
' O O
) O O
primers O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
positions O B_MEASURE
72 O I_MEASURE
and O O
643 O B_MEASURE
of O O
the O O
cDNA O B_GENE
( O O
accession O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
# O O
NM O B_DISEASE/B_PROTEIN[GENE]
_ O I_MEASURE
012385 O I_MEASURE
) O O
, O O
respectively O O
. O O

As O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
transcript O B_GENE
coding O I_GENE
for O O
the O O
ribosomal O B_GENE
protein O I_GENE
RL3 O I_GENE
was O O
specifically O O
amplified O O
for O O
22 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cycles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
sense O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
5 O B_MEASURE
' O O
GAAAGAAGTCGTGGAGGCTG3 O B_PROTEIN[GENE]/B_LOCATION
' O O
) O O
and O O
antisense O B_GENE
( O O
5 O B_MEASURE
' O O
ATCTCATCCTGCCCAAACAC3 O B_PROTEIN[GENE]/B_LOCATION
' O O
) O O
primers O B_GENE/B_LOCATION
, O O
in O O
positions O B_MEASURE
216 O I_MEASURE
and O O
637 O B_MEASURE
of O O
the O O
cDNA O B_GENE
, O O
respectively O O
. O O

Author O B_PERSON
' O O
s O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributions O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

CM O B_DISEASE/B_PERSON
prepared O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
retrovirus O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
carried O O
out O O
RNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blots O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
NL O B_LOCATION/B_PERSON
carried O O
out O O
CAT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SV O B_LOCATION/B_ORGANIZATION
participated O O
in O O
the O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
JLI O B_DISEASE/B_LOCATION
participated O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
wrote O O
the O O
manuscript O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
authors O B_PERSON/B_NUMBER[MEASURE]
read O O
and O O
approved O O
the O O
final O B_TIME[MEASURE]/B_ENT
manuscript O B_TIME[MEASURE]/I_ENT
. O O

Enzymatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
multiplex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
problem O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reading O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
films O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
been O O
reformulated O O
using O O
an O O
easily O O
implemented O O
, O O
multiplex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
version O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
enzymatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

By O O
utilizing O O
a O O
uniquely O O
tagged O O
primer O B_GENE
for O O
each O O
base O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
the O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O O
be O O
pooled O O
and O O
electrophoresed O O
in O O
a O O
single O B_LOCATION/B_ORGANIZATION
lane O I_LOCATION/I_ORGANIZATION
. O O

This O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O O
been O O
previously O O
proposed O O
for O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
fluorescently O O
labelled O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O B_NUMBER[MEASURE]
) O O
, O O
and O O
is O O
analogous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
principle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
in O O
four O B_NUMBER[MEASURE]/B_COLOR
- O O
dye O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fluorescence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequencing O O
except O O
that O O
the O O
signals O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
resolved O O
following O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]
) O O
. O O

After O O
transfer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
a O O
nylon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
membrane O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
images O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
obtained O O
separately O O
for O O
each O O
of O O
the O O
four O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
oligonucleotide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
images O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O O
then O O
be O O
superimposed O O
to O O
reconstitute O O
a O O
complete O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pattern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
way O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
correction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
gel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
distortion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
accurate O B_DISEASE/B_MEASURE
band O I_DISEASE/I_MEASURE
registration O I_DISEASE/I_MEASURE
are O O
considerably O O
simplified O O
, O O
as O O
each O O
of O O
the O O
four O B_LOCATION/B_ORGANIZATION
base O I_LOCATION/I_ORGANIZATION
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ladders O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
require O O
very O O
similar O B_MEASURE
corrections O I_MEASURE
. O O

The O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therefore O O
provide O O
the O O
basis O B_PERSON/B_LOCATION
for O O
a O O
second O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
more O O
accurate O B_DISEASE_ADJECTIVE[DISEASE]
and O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
film O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reading O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programs O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
well O O
as O O
being O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
conventional O B_PERSON/B_ENT
multiplex O I_PERSON/I_ENT
sequencing O I_PERSON/I_ENT
. O O

Unlike O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
multiplex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
3 O B_TIME[MEASURE]/B_ORGANIZATION
) O O
, O O
the O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
described O O
is O O
suitable O B_DISEASE_ADJECTIVE[DISEASE]
for O O
small O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cloning O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
vectors O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
are O O
not O O
used O O
. O O

Although O O
more O B_MEASURE
than O O
one O B_NUMBER[MEASURE]/B_LOCATION
vector O I_NUMBER[MEASURE]/I_LOCATION
can O O
be O O
utilized O O
, O O
only O O
a O O
library O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fragments O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cloned O O
into O O
any O O
single O B_BACTERIUM[BIO]/B_GENE
phage O B_BACTERIUM[BIO]/I_GENE
, O O
phagemid O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
plasmid O B_GENE
vector O I_GENE
is O O
actually O O
required O O
, O O
together O O
with O O
a O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
tagged O O
oligonucleotide O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
primers O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
Images O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Nucleic O B_NUMBER[MEASURE]/B_LOCATION
Acids O I_NUMBER[MEASURE]/I_LOCATION
Research O I_NUMBER[MEASURE]/I_LOCATION
, O O
Vol O B_LOCATION/B_PERSON
. O O

19 O B_MEASURE
, O O
No O O
. O O
12 O B_NUMBER[MEASURE]/B_PERSON
3301 O I_NUMBER[MEASURE]/I_PERSON

Enzymatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
multiplex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]

Mark O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chee O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Medical O B_LOCATION/B_ORGANIZATION
Research O I_LOCATION/I_ORGANIZATION
Council O I_LOCATION/I_ORGANIZATION
Laboratory O I_LOCATION/I_ORGANIZATION
of O O
Molecular O B_EDU[ORGANIZATION]/B_LOCATION
Biology O I_EDU[ORGANIZATION]/I_LOCATION
, O O
Hills O B_LOCATION/B_ORGANIZATION
Road O I_LOCATION/I_ORGANIZATION
, O O
Cambridge O B_LOCATION
CB2 O I_LOCATION
20H O I_LOCATION
, O O
UK O B_LOCATION

Received O O
March O B_TIME[MEASURE]
15 O I_TIME[MEASURE]
, O O
1991 O B_MEASURE
; O O
Revised O O
and O O
Accepted O O
May O B_TIME[MEASURE]
2 O I_TIME[MEASURE]
, O O
1991 O B_MEASURE

ABSTRACT O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
problem O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reading O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
films O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
been O O
reformulated O O
using O O
an O O
easily O O
implemented O O
, O O
multiplex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
version O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
enzymatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

By O O
utilizing O O
a O O
uniquely O O
tagged O O
primer O B_GENE
for O O
each O O
base O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
the O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O O
be O O
pooled O O
and O O
electrophoresed O O
in O O
a O O
single O B_LOCATION/B_ORGANIZATION
lane O I_LOCATION/I_ORGANIZATION
. O O

This O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O O
been O O
previously O O
proposed O O
for O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
fluorescently O O
labelled O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O B_NUMBER[MEASURE]
) O O
, O O
and O O
is O O
analogous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
principle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
in O O
four O B_NUMBER[MEASURE]/B_COLOR
- O O
dye O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fluorescence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequencing O O
except O O
that O O
the O O
signals O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
resolved O O
following O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]
) O O
. O O

After O O
transfer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
a O O
nylon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
membrane O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
images O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
obtained O O
separately O O
for O O
each O O
of O O
the O O
four O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
oligonucleotide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
images O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O O
then O O
be O O
superimposed O O
to O O
reconstitute O O
a O O
complete O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pattern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
way O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
correction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
gel O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distortion O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
accurate O B_DISEASE/B_LOCATION
band O I_DISEASE/I_LOCATION
registration O I_DISEASE/I_LOCATION
are O O
considerably O O
simplified O O
, O O
as O O
each O O
of O O
the O O
four O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
basespecific O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ladders O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
require O O
very O O
similar O B_MEASURE
corrections O I_MEASURE
. O O

The O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therefore O O
provide O O
the O O
basis O B_PERSON/B_LOCATION
for O O
a O O
second O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
more O O
accurate O B_DISEASE_ADJECTIVE[DISEASE]
and O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
film O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reading O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programs O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
well O O
as O O
being O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
conventional O B_PERSON/B_ENT
multiplex O I_PERSON/I_ENT
sequencing O I_PERSON/I_ENT
. O O

Unlike O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
multiplex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
3 O B_TIME[MEASURE]/B_ORGANIZATION
) O O
, O O
the O O
approach O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
described O O
is O O
suitable O B_DISEASE_ADJECTIVE[DISEASE]
for O O
small O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cloning O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
vectors O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
are O O
not O O
used O O
. O O

Although O O
more O B_MEASURE
than O O
one O B_NUMBER[MEASURE]/B_LOCATION
vector O I_NUMBER[MEASURE]/I_LOCATION
can O O
be O O
utilized O O
, O O
only O O
a O O
library O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fragments O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cloned O O
into O O
any O O
single O B_MEASURE/B_BACTERIUM[BIO]
phage O I_MEASURE/I_BACTERIUM[BIO]
. O O
phagemid O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
plasmid O B_GENE/B_BIO
vector O I_GENE/I_BIO
is O O
actually O O
required O O
, O O
together O O
with O O
a O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
tagged O O
oligonucleotide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primers O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

INTRODUCTION O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
community O B_ORGANIZATION/B_LOCATION
of O O
biologists O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
undertaking O O
the O O
sequencing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
representative O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genomes O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
free O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
living O B_BIO/B_LOCATION
organisms O I_BIO/I_LOCATION
, O O
ranging O O
in O O
size O B_MEASURE/B_LOCATION
from O O
Mycoplasma O B_BIO
( O O
800kb O B_MEASURE
) O O
to O O
mammals O B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O B_MEASURE/B_SPECIES[BIO]
Gb O I_MEASURE/I_SPECIES[BIO]
) O O
( O O
4 O B_MEASURE
) O O
. O O

However O O
, O O
the O O
largest O B_NUMBER[MEASURE]/B_BIO
contiguous O I_NUMBER[MEASURE]/I_BIO
DNA O I_NUMBER[MEASURE]/I_BIO
sequences O I_NUMBER[MEASURE]/I_BIO
which O O
have O O
been O O
determined O O
so O O
far O O
are O O
the O O
genomes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
several O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
dsDNA O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
eukaryotic O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
viruses O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
5 O B_NUMBER[MEASURE]
, O O
6 O B_SEQUENCE[MEASURE]
, O O
7 O B_NUMBER[MEASURE]
, O O
8 O B_NUMBER[MEASURE]
, O O
9 O B_NUMBER[MEASURE]
) O O
and O O
plant O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloroplasts O I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O B_NUMBER[MEASURE]
, O O
11 O B_NUMBER[MEASURE]
, O O
12 O B_MEASURE
) O O
. O O

The O O
largest O O
of O O
these O O
is O O
the O O
229kb O O
genome O O
of O O
human B B_SPECIES[BIO]
cytomegalovirus I I_SPECIES[BIO]
( O O
8 O O
) O O
. O O

The O O
difficulty O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
sequencing O O
millions O B_LOCATION/B_MEASURE
of O O
base O B_MEASURE/B_DISEASE
pairs O I_MEASURE/I_DISEASE
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
that O O
several O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steps O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
methods O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
are O O
relatively O O
labour O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensive O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
although O O
the O O
sequencing O O
reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
themselves O O
are O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
easily O O
performed O O
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
limiting O O
steps O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
conventional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
the O O
size O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
fractionation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
sequencing O O
reaction O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
gel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
subsequent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
reading O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ladders O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
former O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
overcome O O
by O O
multiplexing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
which O O
theoretically O O
allows O O
an O O
enormous O B_DISEASE_ADJECTIVE[DISEASE]
amount O I_DISEASE_ADJECTIVE[DISEASE]
of O O

data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
obtained O O
from O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
gel O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O O
processing O O
clones O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
as O O
mixtures O B_LOCATION
rather O O
than O O
individually O O
( O O
3 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Each O O
sequence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
mixture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
labelled O O
by O O
a O O
unique O B_NUMBER[MEASURE]/B_PERSON
short O I_NUMBER[MEASURE]/I_PERSON
oligonucleotide O I_NUMBER[MEASURE]/I_PERSON
' O I_NUMBER[MEASURE]/I_PERSON
tag O I_NUMBER[MEASURE]/I_PERSON
' O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

This O O
allows O O
the O O
mixture O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
be O O
resolved O O
following O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
the O O
superimposed O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequence O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ladders O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
blotted O O
from O O
the O O
gel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
nylon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
membrane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
detected O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
time O B_TIME[MEASURE]/B_LOCATION
by O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
using O O
tag O B_GENE/B_LOCATION
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
oligonucleotide O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
probes O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

In O O
practice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
at O O
least O O
50 O B_NUMBER[MEASURE]
sets O I_NUMBER[MEASURE]
of O O
sequences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
obtained O O
from O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
gel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
3 O B_MEASURE/B_LOCATION
) O O
. O O

Unfortunately O O
, O O
a O O
bottleneck O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
multiplex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
the O O
reading O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
films O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
scale O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
projects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
this O O
task O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
performed O O
with O O
the O O
aid O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
sonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
digitizer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
13 O B_MEASURE
, O O
14 O B_MEASURE
) O O
. O O

Although O O
film O B_PERSON/B_ORGANIZATION
reading O I_PERSON/I_ORGANIZATION
programs O I_PERSON/I_ORGANIZATION
have O O
been O O
under O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
some O O
time O B_TIME[MEASURE]/B_PERSON
( O O
15 O B_MEASURE
) O O
, O O
and O O
some O O
programs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
commercially O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
their O O
error O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
rates O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
presently O O
more O O
variable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
unpredictable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
that O O
of O O
a O O
skilled O B_PERSON/B_ENT
person O B_PERSON/I_ENT
and O O
the O O
accurate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
interpretation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O O
film O B_ENT/B_LOCATION
- O O
imaged O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
ladders O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
by O O
computer O B_PERSON/B_ORGANIZATION
programs O I_PERSON/I_ORGANIZATION
is O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
achieve O O
in O O
routine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
practice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Programs O B_LOCATION/B_ENT
specifically O O
designed O O
to O O
read O O
multiplex O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
films O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
an O O
advantage O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
is O O
because O O
a O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
image O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
can O O
be O O
used O O
as O O
an O O
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
internal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
standard O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O O
to O O
help O O
interpret O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
images O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
the O O
same O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membrane O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
3 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

However O O
, O O
the O O
original O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
implementation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
multiplex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
chemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
16 O B_MEASURE
) O O
, O O
which O O
yields O O
a O O
more O O
complex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ladder O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
enzymatic O B_TIME[MEASURE]/B_GENE
dideoxynucleotide O I_TIME[MEASURE]/I_GENE
chain O I_TIME[MEASURE]/I_GENE
- O O
termination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
17 O B_MEASURE
) O O
. O O

Most O O
successful O O
large O O
scale O O
sequencing O O
projects O O
have O O
used O O
the O O
chaintermination O O
method O O
and O O
bacteriophage B B_BIO/B_DISEASE
M13 I I_BIO/I_DISEASE
vectors O O
, O O
which O O
allows O O
the O O
routine O O
production O O
of O O
clean O O
and O O
easily O O
interpretable O O
sequences O O
( O O
18 O O
) O O
. O O

It O O
was O O
therefore O O
decided O O
to O O
adapt O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
multiplex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O O
enzymatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
using O O
tagged O O
primers O B_GENE/B_LOCATION
. O O

MATERIALS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Eight O B_NUMBER[MEASURE]
oligonucleotide O I_NUMBER[MEASURE]
sequencing O I_NUMBER[MEASURE]
primers O I_NUMBER[MEASURE]
were O O
synthesized O O
, O O
each O O
37 O B_MEASURE
nucleotides O I_MEASURE
in O O
length O B_MEASURE/B_LOCATION
. O O

The O O
3 O B_NUMBER[MEASURE]
' O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
each O O
primer O B_GENE/B_LOCATION
consists O O
of O O
the O O
17 O B_NUMBER[MEASURE]
nucleotide O I_NUMBER[MEASURE]
M13 O I_NUMBER[MEASURE]
universal O I_NUMBER[MEASURE]
priming O I_NUMBER[MEASURE]
sequence O I_NUMBER[MEASURE]
[ O I_NUMBER[MEASURE]
GTAAAACGACGGCCAGT3 O I_NUMBER[MEASURE]
' O O
] O B_DISEASE/B_PROTEIN[GENE]
. O O

The O O
5 O B_NUMBER[MEASURE]/B_BIO
' O O
ends O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
primers O B_GENE
bear O O
different O B_DISEASE_ADJECTIVE[DISEASE]
20mer O I_DISEASE_ADJECTIVE[DISEASE]
tag O I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_DISEASE_ADJECTIVE[DISEASE]
( O O
Figure O B_PROTEIN[GENE]/B_LOCATION
1 O I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

In O O
four O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
primers O B_GENE/B_PERSON
, O O
UEO1C O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
UPOIC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
UE02C O B_DISEASE/B_PROTEIN[GENE]
and O O
UP02C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
these O O
tags O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
complementary O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
EO1 O B_PROTEIN[GENE]/B_LOCATION
, O O
PO1 O B_PROTEIN[GENE]
, O O
E02 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
P02 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
probe O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
respectively O O
( O O
copied O O
from O O
the O O
original O B_NUMBER[MEASURE]/B_PERSON
' O O
plex O B_DISEASE/B_NUMBER[MEASURE]
' O O
vectors O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O B_TIME[MEASURE]/B_LOCATION
) O O
) O O
. O O

A O O
second O B_MEASURE/B_LOCATION
set O B_MEASURE/I_LOCATION
of O O
four O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
primers O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
UJOL14C O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
UJOL15C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
UJOL16C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
UJOL17C O B_LOCATION/B_PROTEIN[GENE]
, O O
have O O
the O O
following O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
tag O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O O
5 O B_MEASURE
' O O
CAAGTTTGAAGGTACTCATT O B_GENE/B_MEASURE
, O O
TATCAATTAAATTGTllTGAC O B_GENE
, O O
GTGTTGCTACCCAAGAAGCA O B_GENE
, O O
and O O
TGTCACTAGAGCTGTCACTT O B_GENE
, O O
respectively O O
. O O

The O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

? O O
= O O
) O O
1991 O B_PERSON/B_MEASURE
Oxford O B_PERSON/I_MEASURE
University O B_PERSON/I_MEASURE
Press O B_PERSON/I_MEASURE

3302 O B_NUMBER[MEASURE]/B_ORGANIZATION
Nucleic O I_NUMBER[MEASURE]/I_ORGANIZATION
Acids O I_NUMBER[MEASURE]/I_ORGANIZATION
Research O I_NUMBER[MEASURE]/I_ORGANIZATION
, O O
Vol O B_LOCATION/B_MEASURE
. O O

19 O O
, O O
No O O
. O O
12 O B_NUMBER[MEASURE]

oligonucleotides O B_GENE/B_MEASURE
were O O
gel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
purified O O
( O O
19 O B_MEASURE
) O O
and O O
used O O
to O O
sequence O O
ssDNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
templates O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
prepared O O
by O O
phenol O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extraction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
20 O B_MEASURE
) O O
or O O
SDS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
denaturation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
21 O B_MEASURE
) O O
. O O

Conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reactions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
performed O O
as O O
previously O O
described O O
( O O
20 O B_MEASURE
) O O
. O O

For O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
experiments O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
radioactively O O
labelled O O
nucleotides O B_GENE/B_DISEASE
were O O
omitted O O
from O O
the O O
sequencing O O
reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Instead O O
, O O
the O O
21d O B_MEASURE
of O O
each O O
nucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mix O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
added O O
to O O
the O O
reaction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O O
of O O
the O O
following O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
' O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O O
mix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
6 O B_MEASURE
. O O
25MtM O B_MEASURE
dATP O I_MEASURE
, O O
62 O B_MEASURE
. O O
5lM O B_MEASURE/B_PERSON
ddATP O I_MEASURE/I_PERSON
; O O
' O O
C O B_PROTEIN[GENE]/B_LOCATION
' O O
mix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
6 O B_NUMBER[MEASURE]
. O O
25MM O B_MEASURE
dCTP O I_MEASURE
, O O
40MtM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ddCTP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O O
' O O
G O B_PROTEIN[GENE]/B_LOCATION
' O O
mix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
6 O B_NUMBER[MEASURE]
. O O
25MtM O B_MEASURE
dGTP O I_MEASURE
, O O
80MtM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ddGTP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O O
' O O
T O B_PROTEIN[GENE]/B_LOCATION
' O O
mix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
6 O B_NUMBER[MEASURE]
. O O
25MM O B_MEASURE
dTTP O I_MEASURE
, O O
250yM O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ddTTP O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
as O O
well O O
as O O
125MM O B_NUMBER[MEASURE]/B_PERSON
of O O
each O O
of O O
the O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
other O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dNTPs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
each O O
mix O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
. O O

Apart O O
from O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
these O O
modified O O
mixes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
no O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
made O O
to O O
the O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
procedure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
( O O
20 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

Sequencing O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
reactions O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
were O O
pooled O O
and O O
ethanol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
precipitated O O
as O O
appropriate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Precipitation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
microtitre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
trays O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
carried O O
out O O
as O O
follows O O
: O O
a O O
mixture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
3 O B_MEASURE
. O O
2M1 O B_MEASURE
3M O I_MEASURE
NaAc O I_MEASURE
pH O I_MEASURE
5 O I_MEASURE
. O O
0 O B_MEASURE
and O O
112Mi1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
EtOH O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
dispensed O O
to O O
individual O B_LOCATION/B_MEASURE
wells O I_LOCATION/I_MEASURE
of O O
a O O
microtitre O B_LOCATION
plate O I_LOCATION
( O O
Falcon O B_PERSON/B_LOCATION
3911 O I_PERSON/I_LOCATION
or O O
Corning O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
25855 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
using O O
an O O
8 O B_NUMBER[MEASURE]/B_LOCATION
- O O
channel O B_MEDICAL_DEVICE[OBJECT]/B_LOCATION
pipettor O I_MEDICAL_DEVICE[OBJECT]/I_LOCATION
. O O

Each O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
four O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
added O O
to O O
the O O
EtOH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
NaAc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mixture O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
and O O
the O O
tray O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sealed O O
using O O
a O O
Falcon O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
3073 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
plate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
sealer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
. O O

The O O
samples O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
mixed O O
by O O
inversion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
stored O O
at O O
- O O
20 O B_MEASURE
? O O
C O B_MEASURE/B_LOCATION
for O O
30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minutes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
DNA O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
was O O
collected O O
by O O
a O O
20 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
minute O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
centrifugation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
at O O
4 O B_MEASURE/B_LOCATION
000 O B_MEASURE/I_LOCATION
rpm O B_MEASURE/I_LOCATION
in O O
an O O
IEC O B_LOCATION
Centra O I_LOCATION
3C O I_LOCATION
centrifuge O I_LOCATION
. O O

The O O
sealer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
removed O O
, O O
and O O
the O O
plate O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inverted O O
to O O
discard O O
the O O
supernatant O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

After O O
blotting O O
the O O
tray O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
tissue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
paper O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
200MI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
95 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
EtOH O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
added O O
to O O
each O O
well O O
. O O

The O O
plate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
covered O O
with O O
a O O
plastic O B_PRODUCT[OBJECT]/B_LOCATION
lid O I_PRODUCT[OBJECT]/I_LOCATION
and O O
recentrifuged O O
for O O
2 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
minutes O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

The O O
EtOH O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
discarded O O
and O O
the O O
plate O B_BODY_PART_OR_ORGAN_COMPONENT
inverted O O
for O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minutes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
tissue O B_LOCATION/B_ORGANIZATION
paper O I_LOCATION/I_ORGANIZATION
, O O
then O O
left O O
for O O
20 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
to O O
air O O
dry O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Precipitated O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
samples O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
resuspended O O
in O O
6M1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deionized O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
vortexing O O
on O O
an O O
SMI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
multi O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
tube O B_MEDICAL_DEVICE[OBJECT]/B_LOCATION
vortexer O I_MEDICAL_DEVICE[OBJECT]/I_LOCATION
for O O
1 O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minute O B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
denatured O O
and O O
electrophoresed O O
on O O
6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polyacrylamide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
buffer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gradient O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
previously O O
described O O
( O O
20 O B_MEASURE
) O O
. O O

Following O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
gel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
transferred O O
to O O
a O O
dry O B_LOCATION/B_MEASURE
piece O I_LOCATION/I_MEASURE
of O O
Whatman O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3MM O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blotting O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
placed O O
on O O
a O O
second O B_LOCATION/B_PERSON
sheet O I_LOCATION/I_PERSON
of O O
blotting O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supported O O
on O O
a O O
glass O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
saturated O O
in O O
4 O B_MEASURE
x O O
SSC O B_MEASURE
( O O
SSC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
150mM O B_MEASURE
NaCl O I_MEASURE
, O O
l5mM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trisodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
citrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

This O O
sheet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
wicked O O
in O O
a O O
tray O B_LOCATION
containing O O
1 O B_PERSON/B_LOCATION
litre O B_PERSON/I_LOCATION
of O O
4 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x O O
SSC O B_MEASURE/B_LOCATION
. O O

The O O
DNA O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
transferred O O
to O O
a O O
nylon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
membrane O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
Amersham O B_MEASURE
Hybond O I_MEASURE
N O I_MEASURE
) O O
by O O
capillary O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
blotting O O
overnight O O
( O O
22 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

DNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
fixed O O
to O O
the O O
membranes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
U O B_OTHER/B_PROTEIN[GENE]
. O O
V O B_MEASURE/B_LOCATION
. O O
crosslinking O O
( O O
23 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

Plex O B_PERSON
oligonucleotide O I_PERSON
probes O I_PERSON
were O O
a O O
kind O B_PERSON
gift O I_PERSON
of O O
Dr O B_PERSON/B_LOCATION
. O O
George O B_PERSON
Church O I_PERSON
. O O

Probes O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
tailed O O
at O O
their O O
3 O B_LOCATION/B_GENE
' O I_LOCATION/I_GENE
ends O I_LOCATION/I_GENE
using O O
[ O B_OTHER/B_LOCATION
a O O
- O O
32p O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O O
dCTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
previously O O
described O O
( O O
3 O B_MEASURE
) O O
. O O

For O O
the O O
preparation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
digoxigenin O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DIG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
labelled O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
identical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tailing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reactions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
carried O O
out O O
substituting O O
I0pmols O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
DIG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
II O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dUTP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Boehringer O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
Mannheim O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
for O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
32P O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O O
dCTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Membranes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
prehybridized O O
for O O
at O O
least O O
10 O B_NUMBER[MEASURE]/B_ENT
minutes O I_NUMBER[MEASURE]/I_ENT
in O O
4 O B_MEASURE
x O O
SSC O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE
x O O
Denhardts O B_MEASURE/B_LOCATION
' O I_MEASURE/I_LOCATION
( O O
0 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
( O O
w O O
/ O O
v O O
) O O
each O O
of O O
BSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
heated O O
at O O
80 O B_MEASURE
? O O
C O B_OTHER/B_PROTEIN[GENE]
for O O
30 O B_TIME[MEASURE]
minutes O I_TIME[MEASURE]
to O O
inactivate O O
any O O
alkaline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphatase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Ficoll O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Pharmacia O B_MEASURE/B_ORGANIZATION
) O O
and O O
polyvinylpyrrolidone O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
0 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
( O O
w O B_PROTEIN[GENE]
/ O O
v O O
) O O
SDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
5mM O B_MEASURE/B_LOCATION
NaHPO4 O I_MEASURE/I_LOCATION
( O O
23 O B_MEASURE/B_LOCATION
) O O
. O O

Hybridization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
in O O
25 O B_MEASURE
- O O
50M1 O B_MEASURE/B_LOCATION
of O O
prehybridization O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
buffer O B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
per O O
cm2 O B_MEASURE/B_LOCATION
of O O
membrane O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
probe O B_MEASURE/B_LOCATION
concentration O I_MEASURE/I_LOCATION
was O O
approximately O O
lnM O O
. O O

After O O
lh O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
42 O B_MEASURE
? O O
C O B_OTHER/B_PROTEIN[GENE]
, O O
unbound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
removed O O
by O O
five O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minute O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
washes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
room O B_MEASURE
temperature O I_MEASURE
in O O
1 O B_MEASURE
x O O
SSC O B_MEASURE
, O O
0 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
SDS O I_MEASURE
( O O
200MI O B_MEASURE/B_LOCATION
/ O O
cm2 O B_MEASURE
membrane O I_MEASURE
) O O
. O O

Radioactive O B_PERSON/B_ENT
blots O I_PERSON/I_ENT
were O O
covered O O
in O O
Saran O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wrap O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
exposed O O
to O O
film O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O O
. O O

Detection O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DIG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labelled O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
an O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
DIG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodyalkaline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphatase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
conjugate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Boehringer O B_LOCATION/B_DISEASE
Mannheim O I_LOCATION/I_DISEASE
) O O
according O O
to O O
the O O
manufacturer O B_PERSON/B_ORGANIZATION
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
instructions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
except O O
that O O
all O O
volumes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
reduced O O
by O O
70 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
conjugate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
used O O
at O O
a O O
1 O B_MEASURE
: O O
10 O B_MEASURE
000 O I_MEASURE
dilution O I_MEASURE
. O O

Blots O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
developed O O
in O O
25M1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
100mM O B_MEASURE/B_LOCATION
Tris O I_MEASURE/I_LOCATION
. O O
Cl O B_MEASURE/B_LOCATION
pH9 O I_MEASURE/I_LOCATION
. O O
5 O B_MEASURE
, O O

mantane4 O B_MEASURE
- O O
methoxy4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
3 O B_MEASURE
" O I_MEASURE
- O O
phosphoryloxy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
phenyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE/B_LOCATION
, O O
2 O B_NUMBER[MEASURE]
- O O
dioxetane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
; O O
Tropix O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
/ O O
cm2 O B_MEASURE/B_SPORT[ENT]
for O O
30 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
minutes O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
37 O B_TIME[MEASURE]/B_LOCATION
? O O
C O B_OTHER/B_PROTEIN[GENE]
, O O
prior O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
film O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dioxetane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
stripped O O
from O O
the O O
membranes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
by O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minute O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
washes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
700C O B_MEASURE/B_PERSON
with O O
0 O B_MEASURE
. O O
2 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
SDS O I_MEASURE/I_PERSON
, O O
2mM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
EDTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
200 O B_MEASURE
, O O
ul O B_MEASURE
/ O O
cm2 O B_MEASURE/B_LOCATION
membrane O I_MEASURE/I_LOCATION
) O O
. O O

The O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
washing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
carried O O
out O O
in O O
plastic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bags O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

However O O
, O O
washing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steps O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
also O O
been O O
performed O O
with O O
gentle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agitation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
perspex O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
tub O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
( O O
43 O B_MEASURE
x O O
27 O B_MEASURE
x O O
15cm O B_MEASURE
) O O
mounted O O
on O O
a O O
reciprocal O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shaker O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
equivalent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
results O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
the O O
latter O B_TIME[MEASURE]/B_PERSON
case O I_TIME[MEASURE]/I_PERSON
a O O
minimum O B_MEASURE/B_LOCATION
wash O I_MEASURE/I_LOCATION
volume O I_MEASURE/I_LOCATION
of O O
500mls O B_MEASURE
was O O
used O O
. O O

The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
a O O
tub O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
is O O
more O O
convenient O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
batch O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
processing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
should O O
be O O
straightforward O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
automate O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Autoradiograms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
revealed O O
no O O
difference O B_MEASURE
in O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quality O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
when O O
tagged O O
primers O B_GENE
were O O
used O O
instead O O
of O O
the O O
17mer O B_MEASURE/B_GENE
universal O I_MEASURE/I_GENE
primer O I_MEASURE/I_GENE
in O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
[ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
a O O
- O O
35S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dATP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labelled O O
sequencing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
multiplex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hybridization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
using O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
- O O
32P O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dCTP O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tailed O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
not O O
shown O O
) O O
. O O

Experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
then O O
conducted O O
to O O
determine O O
the O O
feasibility O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
pooling O O
the O O
four O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
base O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
each O O
clone O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
fractionating O O
them O O
in O O
a O O
single O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lane O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
obtain O O
a O O
superimposed O O
but O O
interpretable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ladders O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
question O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
addressed O O
was O O
whether O O
or O O
not O O
difficulties O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
band O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
registration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
might O O
arise O O
as O O
a O O
result O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
mobility O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
different O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
primer O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
distortion O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
membrane O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
probings O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
that O O
an O O
automated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
film O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
reader O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
employing O O
an O O
internal O B_MEASURE
standard O I_MEASURE
requires O O
that O O
the O O
nylon O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
membrane O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
does O O
not O O
undergo O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distortions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
probings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
George O B_LOCATION/B_MEASURE
Church O I_LOCATION/I_MEASURE
, O O
personal O B_MEASURE
communication O I_MEASURE
) O O
. O O

Clones O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
sequenced O O
using O O
the O O
four O B_NUMBER[MEASURE]/B_BIO
tagged O O
primers O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
UEOlC O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
UPOIC O B_LOCATION/B_ORGANIZATION
, O O
UE02C O B_LOCATION/B_ORGANIZATION
, O O
and O O
UP02C O B_LOCATION/B_ORGANIZATION
, O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
each O O
base O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Figure O B_LOCATION/B_MEASURE
1 O I_LOCATION/I_MEASURE
) O O
. O O

The O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
C O B_OTHER/B_PROTEIN[GENE]
, O O
G O B_OTHER/B_PROTEIN[GENE]
and O O
T O B_LOCATION/B_PROTEIN[GENE]
reactions O I_LOCATION/I_PROTEIN[GENE]
for O O
each O O
clone O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
pooled O O
, O O
and O O
processed O O
as O O
described O O
above O O
. O O

A O O
complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
autoradiograms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
obtained O O
from O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consecutive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rounds O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
probing O O
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
32P O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dCTP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
labelled O O
oligonucleotides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Alignment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
films O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O O
that O O
sequence O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
distortion O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
membrane O B_LOCATION/B_GENE
between O O
probings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
sufficiently O O
minor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
allow O O
accurate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
registration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
bands O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
hence O O
accurate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reading O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

At O O
least O O
200 O B_NUMBER[MEASURE]/B_LOCATION
nucleotides O I_NUMBER[MEASURE]/I_LOCATION
of O O
sequence O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
read O O
accurately O O
from O O
a O O
single O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clone O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
simply O O
tracing O O
the O O
four O B_LOCATION/B_MEASURE
sets O I_LOCATION/I_MEASURE
of O O
bands O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
using O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
colours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
overlaying O O
the O O
tracings O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
reading O O
the O O
bands O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequentially O O
. O O

In O O
order O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
assess O O
the O O
practicality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
reading O O
the O O
sequences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
machine O B_PRODUCT[OBJECT]/B_PERSON
, O O
the O O
images O B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
scanned O O
to O O
provide O O
optical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
density O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
Figure O B_PROTEIN[GENE]/B_DISEASE
2 O I_PROTEIN[GENE]/I_DISEASE
) O O
. O O

These O O
profiles O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
overlaid O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
and O O
were O O
found O O
to O O
be O O
sufficiently O O
in O O
register O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
allow O O
accurate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interpretation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
at O O
least O O
300 O B_TIME[MEASURE]
nucleotides O I_TIME[MEASURE]
. O O

This O O
was O O
essentially O O
the O O
limit O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
resolution O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
gel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
accurate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manual O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reading O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
order O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
ensure O O
that O O
the O O
relatively O O
minor O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobility O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
between O O
the O O
four O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
primers O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
not O O
coincidental O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
the O O
oligonucleotides O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
used O O
, O O
a O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
four O B_NUMBER[MEASURE]
tagged O O
M13 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
universal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
primers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
synthesised O O
, O O
this O O
time O B_NUMBER[MEASURE]/B_LOCATION
incorporating O O
20mer O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
the O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
murine O B_LOCATION/B_ORGANIZATION
herpesvirus O I_LOCATION/I_ORGANIZATION
- O O
68 O B_NUMBER[MEASURE]
( O O
UJOL14C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
15C O B_MEASURE/B_PROTEIN[GENE]
, O O
16C O B_MEASURE/B_PERSON
, O O
17C O B_MEASURE/B_PERSON
) O O
. O O

Sequencing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
performed O O
using O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cx O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
35S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dATP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
label O O
the O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
directly O O
. O O

Various O B_LOCATION/B_PERSON
templates O I_LOCATION/I_PERSON
were O O
sequenced O O
, O O
and O O
in O O
all O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correctly O O
ordered O O
sequence O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ladders O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
obtained O O
following O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
the O O
four O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
run O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
by O O
- O O
side O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
not O O
shown O O
) O O
. O O

Initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hybridization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
conducted O O
using O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
f O O
- O O
32p O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

dCTP O B_NUMBER[MEASURE]/B_ORGANIZATION
tailed O O
oligonucleotide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
probes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

However O O
, O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O

lOOmM O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaCl O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5OmM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MgC12 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_MEASURE/B_LOCATION
. O O
15mM O B_MEASURE
AMPPD O I_MEASURE
( O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
( O O
2 O B_NUMBER[MEASURE]
' O O
- O O
ada O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

B O B_OTHER/B_PERSON

C O B_OTHER/B_PERSON

' O O
Ordinary O B_MEASURE/B_PROTEIN[GENE]
' O I_PROTEIN[GENE]
Plex O B_MEASURE/B_PERSON
' O I_MEASURE
4 O I_MEASURE
- O O
CJ3 O B_MEASURE/B_PROTEIN[GENE]
4 O I_MEASURE/I_PROTEIN[GENE]
- O O
rn O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION

Primeir O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
Primer O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT

" O O
All O O
" O O
C O B_PROTEIN[GENE]/B_LOCATION
" O O
" O O
G O B_OTHER/B_LOCATION
" O O
" O O
T O B_OTHER/B_PROTEIN[GENE]
" O O

' O O
Plex O B_PERSON
' O O
' O O
Ordinary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Pool O B_LOCATION/B_PERSON
and O O

Vector O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Vector O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
fractionate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

Resolve O O
by O O
sequential O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE

hybridizations O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE

Sequencing O O
reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE

SequencingreactIo O B_SPECIES[BIO]/B_ORGANIZATION
product O I_SPECIES[BIO]/I_ORGANIZATION

Sequencing O O
reaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

- O O
n O B_OTHER/B_PERSON
; O O

= O B_OTHER/B_PROTEIN[GENE]
= O O

- O B_OTHER/B_PROTEIN[GENE]
= O O

- O O
n O B_MEASURE/B_GENE
: O O
= O O

Figure O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
. O O
Approaches O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
enzymatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
multiplex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O
a O O
) O O
A O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
sequence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
tagged O O
vectors O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
used O O
. O O

The O O
tag O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
shown O O
in O O
red O B_COLOR
, O O
and O O
the O O
insert O B_GENE/B_LOCATION
to O O
be O O
sequenced O O
in O O
blue O B_COLOR
. O O

However O O
, O O
the O O
original O O
plex O O
vectors O O
( O O
3 O O
) O O
are O O
plasmids O O
, O O
and O O
therefore O O
amenable O O
only O O
to O O
dsDNA O O
sequencing O O
. O O
Sets O O
of O O
bacteriophage B B_NUMBER[MEASURE]/B_BACTERIUM[BIO]
M13 I I_NUMBER[MEASURE]/I_BACTERIUM[BIO]
vectors O O
have O O
been O O
constructed O O
bearing O O
either O O
one O O
( O O
32 O O
) O O
or O O
two O O
[ O O
Chee O O
, O O
unpublished O O
] O O
of O O
the O O
plex O O
tag O O
sites O O
flanking O O
the O O
polylinker O O
, O O
which O O
can O O
be O O
used O O
for O O
this O O
approach O O
. O O

b O O
) O O
The O O
strategy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
in O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O O
tag O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
carried O O
on O O
the O O
primer O B_GENE
. O O

c O O
) O O
If O O
tagged O O
primers O B_GENE
are O O
used O O
, O O
there O O
is O O
no O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
impediment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
performing O O
each O O
base O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O O
a O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primer O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
as O O
depicted O O
. O O

The O O
reactions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
then O O
be O O
pooled O O
in O O
any O O
combination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
desired O O
. O O

The O O
configuration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
shown O O
, O O
in O O
which O O
the O O
four O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reactions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
electrophoresed O O
in O O
a O O
single O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lane O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
designed O O
to O O
facilitate O O
accurate O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
band O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
registration O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
reading O O
by O O
an O O
automatic O B_PERSON/B_LOCATION
film O I_PERSON/I_LOCATION
reader O I_PERSON/I_LOCATION
. O O

In O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
read O O
the O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
manually O O
, O O
base O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
would O O
be O O
run O O
side O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
by O O
- O O
side O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
logistics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
processing O O
the O O
reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
essentially O O
the O O
same O B_MEASURE/B_LOCATION
with O O
either O O
configuration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O O
the O O
same O B_MEASURE
number O I_MEASURE
of O O
probings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
required O O
. O O

Figure O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
. O O

Four O B_NUMBER[MEASURE]/B_PERSON
overlaid O O
one O B_NUMBER[MEASURE]
- O O
dimensional O B_MEASURE/B_LOCATION
optical O I_MEASURE/I_LOCATION
density O I_MEASURE/I_LOCATION
profiles O I_MEASURE/I_LOCATION
for O O
a O O
single O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
clone O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
shown O O
in O O
two O B_NUMBER[MEASURE]
overlapping O O
sections O B_LOCATION/B_ENT
. O O

The O O
optical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
density O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
unprocessed O O
, O O
except O O
for O O
a O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transform O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
correct O O
for O O
the O O
relative O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displacement O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
translation O B_GENE/B_MEASURE
and O O
rotation O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
of O O
the O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
images O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O O
which O O
they O O
are O O
extracted O O
. O O

The O O
profiles O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
read O O
5 O B_MEASURE
' O O
to O O
3 O B_MEASURE
' O O
from O O
right O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
left O O
. O O

Nucleotides O B_MEASURE/B_LOCATION
positions O I_MEASURE/I_LOCATION
66 O I_MEASURE/I_LOCATION
to O O
214 O B_MEASURE
from O O
the O O
start O B_LOCATION
of O O
the O O
universal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
priming O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
shown O O
. O O

The O O
sequence O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
that O O
of O O
Bluescribe O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M13 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
template O B_GENE/B_TIME[MEASURE]
DNA O B_GENE/I_TIME[MEASURE]
obtained O O
by O O
rescue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
with O O
M13K07 O B_BACTERIUM[BIO]/B_PROTEIN[GENE]
helper O B_BACTERIUM[BIO]/I_PROTEIN[GENE]
phage O B_BACTERIUM[BIO]/I_PROTEIN[GENE]
( O O
30 O B_NUMBER[MEASURE]/B_LOCATION
) O O
) O O
, O O
and O O
was O O
determined O O
using O O
the O O
primers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
UEOIC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
UPOIC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
UE02C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
UP02C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
the O O
T O B_PROTEIN[GENE]/B_LOCATION
, O O
C O B_OTHER/B_PROTEIN[GENE]
, O O
G O B_PROTEIN[GENE]/B_OTHER
and O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]

specific O B_MEASURE/B_ENT
reactions O B_MEASURE/I_ENT
respectively O O
. O O

Detection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
by O O
autoradiography O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
a O O
- O O
32p O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dCTP O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tailed O O
plex O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

A O B_OTHER/B_PERSON

Nucleic O B_NUMBER[MEASURE]/B_LOCATION
Acids O I_NUMBER[MEASURE]/I_LOCATION
Research O I_NUMBER[MEASURE]/I_LOCATION
, O O
Vol O B_LOCATION/B_PERSON
. O O

19 O B_MEASURE
, O O
No O O
. O O
12 O B_TIME[MEASURE]
3303 O I_TIME[MEASURE]

I O B_OTHER/B_PERSON

3304 O B_NUMBER[MEASURE]/B_ORGANIZATION
Nucleic O I_NUMBER[MEASURE]/I_ORGANIZATION
Acids O I_NUMBER[MEASURE]/I_ORGANIZATION
Research O I_NUMBER[MEASURE]/I_ORGANIZATION
, O O
Vol O B_LOCATION/B_MEASURE
. O O

19 O O
, O O
No O O
. O O
12 O B_NUMBER[MEASURE]

a O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O

175 O B_MEASURE
- O O
. O O
. O O
. O O

- O O
w O B_OTHER/B_PERSON

. O O
m O B_MEASURE/B_OTHER
; O O

b O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O

182 O B_NUMBER[MEASURE]

a O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
. O O
. O O
. O O
. O O
. O O
. O O

F O B_MEASURE/B_OTHER
. O O
VW O B_LOCATION/B_PERSON

an O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

- O O
w O B_OTHER/B_PERSON

- O O
1 O B_MEASURE/B_LOCATION

S O B_OTHER/B_DISEASE
- O O
K O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
~ O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
~ O O
i O O

' O O
F O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
A O O
I1 O B_LOCATION
' O O
CG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]

Figure O B_MEASURE/B_LOCATION
3 O I_MEASURE/I_LOCATION
. O O

Four O B_LOCATION/B_GENE
separate O B_LOCATION/I_GENE
base O B_LOCATION/I_GENE
- O O
specific O B_LOCATION/B_PERSON
reactions O I_LOCATION/I_PERSON
imaged O O
from O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lane O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O O
chemiluminescent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
detection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
clones O B_DISEASE/B_GENE
sequenced O O
are O O
: O O
a O O
) O O
Bluescribe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
M13 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
obtained O O
by O O
rescue O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
M13K07 O B_BACTERIUM[BIO]/B_GENE
helper O B_BACTERIUM[BIO]/I_GENE
phage O B_BACTERIUM[BIO]/I_GENE
( O O
30 O B_MEASURE
) O O
) O O
and O O
b O O
) O O
an O O
M13 O B_GENE/B_TIME[MEASURE]
recombinant O I_GENE/I_TIME[MEASURE]
clone O I_GENE/I_TIME[MEASURE]
prepared O O
in O O
a O O
microtitre O B_TIME[MEASURE]/B_PRODUCT[OBJECT]
tray O B_TIME[MEASURE]/I_PRODUCT[OBJECT]
( O O
21 O B_MEASURE
) O O
( O O
a O O
kind O B_PERSON
gift O I_PERSON
of O O
Victoria O B_NUMBER[MEASURE]/B_PERSON
Smith O I_NUMBER[MEASURE]/I_PERSON
) O O
. O O

Nucleotide O B_LOCATION/B_ORGANIZATION
positions O I_LOCATION/I_ORGANIZATION
shown O O
on O O
the O O
figure O B_PERSON/B_LOCATION
are O O
numbered O O
from O O
the O O
start O B_LOCATION/B_MEASURE
of O O
the O O
universal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
priming O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
clones O B_GENE/B_DISEASE
were O O
sequenced O O
using O O
UEOlC O B_LOCATION/B_ORGANIZATION
, O O
UPOIC O B_LOCATION/B_ORGANIZATION
, O O
UE02C O B_LOCATION/B_ORGANIZATION
, O O
and O O
UP02C O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
T O B_PROTEIN[GENE]/B_LOCATION
, O O
C O B_PROTEIN[GENE]/B_OTHER
, O O
G O B_PROTEIN[GENE]/B_LOCATION
and O O
A O O
specific O B_LOCATION/B_PERSON
reactions O I_LOCATION/I_PERSON
respectively O O
. O O

The O O
blot O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
probed O O
with O O
corresponding O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DIG O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
11 O B_MEASURE/B_LOCATION
- O O
dUTP O B_MEASURE/B_GENE
labelled O I_MEASURE/I_GENE
oligonucleotides O I_MEASURE/I_GENE
. O O

radioactivity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
the O O
scale O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
envisioned O O
for O O
a O O
large O B_LOCATION/B_PRODUCT[OBJECT]
sequencing O B_LOCATION/I_PRODUCT[OBJECT]
project O B_LOCATION/I_PRODUCT[OBJECT]
is O O
undesirable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
reasons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
safety O B_DISEASE_ADJECTIVE[DISEASE]/B_SPORT[ENT]
. O O

The O O
relatively O O
long O B_TIME[MEASURE]
exposure O I_TIME[MEASURE]
times O I_TIME[MEASURE]
required O O
( O O
6 O B_MEASURE/B_LOCATION
to O O
24 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
) O O
and O O
the O O
short O B_MEASURE
half O I_MEASURE
lives O I_MEASURE
of O O
the O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
also O O
be O O
inconvenient O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
has O O
been O O
shown O O
that O O
a O O
biotin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O O
streptavidin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
/ O O
alkaline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
phosphatase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
based O O
detection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
used O O
in O O
conjunction O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
chemiluminescent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dioxetane O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
substrate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
overcomes O O
these O O
disadvantages O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
24 O B_MEASURE
, O O
25 O B_MEASURE
, O O
26 O B_MEASURE
) O O
. O O

We O O
utilized O O
a O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bridging O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
similar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Digoxigenin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
( O O
DIG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
labelled O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
oligonucleotide O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
probes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
detected O O
using O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
DIG O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
alkaline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
conjugates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
chemiluminescent O B_LOCATION/B_ENZYME[GENE]
dioxetane O B_LOCATION/I_ENZYME[GENE]
substrate O B_LOCATION/I_ENZYME[GENE]
. O O

Exposure O B_TIME[MEASURE]
times O I_TIME[MEASURE]
of O O
10 O B_NUMBER[MEASURE]
to O O
15 O B_MEASURE/B_ENT
minutes O I_MEASURE/I_ENT
were O O
typically O O
required O O
, O O
following O O
a O O
one O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hour O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
preincubation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
period O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Figure O B_TIME[MEASURE]/B_LOCATION
3 O I_TIME[MEASURE]/I_LOCATION
) O O
. O O

In O O
our O O
hands O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
DIG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bridging O O
system O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
sensitivity O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
streptavidin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
based O O
system O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
24 O B_TIME[MEASURE]/B_LOCATION
) O O
, O O
and O O
the O O
practical O B_MEASURE/B_LOCATION
lower O I_MEASURE/I_LOCATION
limit O I_MEASURE/I_LOCATION
of O O
template O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ssDNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
required O O
in O O
order O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
obtain O O
an O O
easily O O
interpretable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
ladder O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
estimated O O
to O O
be O O
in O O
the O O
range O B_LOCATION/B_MEASURE
of O O
20 O B_NUMBER[MEASURE]
to O O
50fmols O B_MEASURE/B_PERSON
per O O
reaction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

However O O
, O O
the O O
sensitivity O B_MEASURE
of O O
detection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
limited O O
only O O
by O O
enzymaticallytriggered O B_MEASURE/B_LOCATION
background O I_MEASURE/I_LOCATION
luminescence O I_MEASURE/I_LOCATION
, O O
and O O
not O O
by O O
the O O
level O B_MEASURE
of O O
signal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
. O O

The O O
nonradioactive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
described O O
have O O
been O O
used O O
successfully O O
in O O
an O O
8 O B_MEASURE/B_PROTEIN[GENE]
- O O
plex O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DISCUSSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Although O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
multiplex O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
based O O
on O O
a O O
set O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O O
tagged O O
vectors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
3 O B_MEASURE/B_BIO
) O O
, O O
tagged O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
primers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
also O O
been O O
used O O
or O O
proposed O O
for O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
multiplex O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
George O B_MEASURE/B_PERSON
Church O I_MEASURE/I_PERSON
, O O
personal O B_MEASURE
communication O I_MEASURE
; O O
2 O B_MEASURE
, O O
27 O B_MEASURE
) O O
. O O

For O O
example O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
a O O
proposal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
recently O O
put O O
forward O O
for O O
multiplex O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O O
using O O
sequence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
labelled O O
primers O B_GENE
and O O
fluorophor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
labelled O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE

( O O
1 O B_MEASURE
) O O
, O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
principle O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
here O O
. O O

However O O
, O O
we O O
use O O
tagged O O
primers O B_GENE
and O O
the O O
superposition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
four O B_NUMBER[MEASURE]/B_BIO
sequencing O O
reactions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
address O O
the O O
problem O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
reading O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
films O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O O
a O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
solution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
to O O
utilize O O
M13 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
dideoxynucleotide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
thereby O O
improving O O
the O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
be O O
analyzed O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
proposal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O O
fluorophor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
labelled O O
probes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
not O O
take O O
into O O
consideration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
any O O
of O O
the O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
addressed O O
here O O
, O O
and O O
, O O
in O O
the O O
version O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
described O O
, O O
remains O O
a O O
promising O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O O
unproven O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
scheme O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
for O O
large O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scale O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
are O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advantages O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
tagging O O
primers O B_GENE
instead O O
of O O
vectors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Firstly O O
, O O
there O O
is O O
no O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
to O O
prepare O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
libraries O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
clones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
special O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vectors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

This O O
means O O
that O O
workers O B_PERSON/B_ORGANIZATION
can O O
use O O
vector O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
host O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
combinations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
yield O O
good O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
their O O
hands O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
an O O
increased O O
depth O B_MEASURE
of O O
multiplexing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O O
easily O O
be O O
accomodated O O
by O O
synthesizing O O
more O B_ENT/B_LOCATION
primers O I_ENT/I_LOCATION
. O O

This O O
should O O
make O O
multiplexing O O
more O O
accessible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
workers O B_PERSON/B_ORGANIZATION
undertaking O O
smaller O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
theoretical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disadvantage O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tagged O O
primers O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
that O O
the O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
only O O
be O O
multiplexed O O
following O O
primer O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
annealing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
1 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
or O O
following O O
the O O
sequencing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
this O O
paper O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
in O O
practice O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pooling O O
immediately O O
after O O
the O O
annealing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
step O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
might O O
lead O O
to O O
increased O O
backgrounds O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
if O O
one O B_NUMBER[MEASURE]
or O O
more O B_NUMBER[MEASURE]/B_ENT
primers O I_NUMBER[MEASURE]/I_ENT
were O O
present O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
excess O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
over O O
their O O
template O B_TIME[MEASURE]/B_LOCATION
DNAs O I_TIME[MEASURE]/I_LOCATION
) O O
. O O

This O O
is O O
a O O
relatively O O
late O B_DISEASE_ADJECTIVE[DISEASE]
stage O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
original O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
3 O B_MEASURE
) O O
, O O
clones O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O O
pooled O O
prior O B_PERSON
to O O
amplification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
by O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
an O O
early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
we O O
do O O
not O O
believe O O
the O O
sacrifice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
be O O
of O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
importance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
when O O
using O O
phage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
vectors O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
our O O
experience O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
recombinant O B_BIO/B_PERSON
M13 O I_BIO/I_PERSON
phage O I_BIO/I_PERSON
have O O
variable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
competition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
severely O O
limit O O
the O O
number O B_MEASURE/B_LOCATION
of O O
clones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
can O O
usefully O O
be O O
pooled O O
for O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
contrast O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
by O O
growing O O
clones O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
individually O O
, O O
the O O
depth O B_MEASURE
of O O
multiplexing O O
is O O
only O O
really O O
limited O O
by O O
probe O B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
not O O
investigated O O
the O O
factors O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
influencing O O
variability O B_MEASURE
in O O
phage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
growth O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
rates O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

It O O
is O O
worth O B_LOCATION/B_DISEASE
noting O O
that O O
reliable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
protocols O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
have O O
been O O
developed O O
for O O
growing O O
large O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
numbers O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
individual O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
M13 O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
clones O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O O
preparing O O
high O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
quality O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
ssDNA O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
templates O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O O
microtitre O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
trays O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
28 O B_MEASURE
, O O
21 O B_MEASURE
) O O
. O O

It O O
is O O
relatively O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prepare O O
manually O O
two O B_MEASURE/B_LOCATION
microtitre O I_MEASURE/I_LOCATION
trays O I_MEASURE/I_LOCATION
of O O
ssDNA O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
templates O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
192 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
a O O
day O B_TIME[MEASURE]/B_LOCATION
. O O

Sufficient O B_PERSON
clones O I_PERSON
can O O
be O O
prepared O O
in O O
a O O
week O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
sequence O O
a O O
20kb O B_GENE/B_MEASURE
fragment O I_GENE/I_MEASURE
to O O
a O O
redundancy O B_MEASURE/B_LOCATION
of O O
10 O B_MEASURE
( O O
Victoria O B_PERSON/B_BIO
Smith O I_PERSON/I_BIO
, O O
personal O B_MEASURE
communication O I_MEASURE
) O O
. O O

In O O
this O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
ssDNA O B_BIO/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
now O O
prepared O O
with O O
the O O
aid O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
commercially O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
robotic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
workstation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O O
21 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

As O O
sequencing O O
reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
also O O
carried O O
out O O
in O O
microtitre O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
trays O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
manually O O
or O O
robotically O O
( O O
20 O B_MEASURE
, O O
29 O B_MEASURE
) O O
, O O
the O O
entire O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
M13 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
based O O
dideoxynucleotide O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
amenable O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
automation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
( O O
29 O B_MEASURE
) O O
. O O

For O O
these O O
reasons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
we O O
see O O
little O B_DISEASE_ADJECTIVE[DISEASE]
practical O I_DISEASE_ADJECTIVE[DISEASE]
advantage O I_DISEASE_ADJECTIVE[DISEASE]
in O O
pooling O O
clones O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early O O
. O O

Finally O O
, O O
by O O
not O O
pooling O O
clones O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early O O
, O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
easily O O
retrieve O O
individual O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clones O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
retained O O
, O O
which O O
may O O
facilitate O O
directed O O
sequencing O O
later O O
in O O
a O O
project O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
should O O
this O O
become O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Multiplex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
sequencing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
is O O
currently O O
limited O O
by O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
robust O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
computer O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O O
can O O
correct O O
for O O
the O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variety O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
gel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sequencing O O
artefacts O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
normally O O
encountered O O
. O O

The O O
foundation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
a O O
film O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reading O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
bring O O
into O O
register O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
precisely O O
vertical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arrays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
base O B_LOCATION/B_ENT
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bands O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

This O O
requires O O
the O O
ability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
track O O
lanes O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
correct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
distortions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
order O B_MEASURE
bands O I_MEASURE
based O O
on O O
their O O
relative O B_MEASURE/B_LOCATION
spacing O I_MEASURE/I_LOCATION
. O O

A O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sequencing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
has O O
successfully O O
overcome O O
the O O
problem O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reading O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
uses O O
real O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
time O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
fluorescently O O
labelled O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
migrating O O
through O O
the O O
gel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_MEASURE/B_LOCATION
) O O
. O O

This O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
also O O
utilizes O O
the O O
principle O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
running O O
the O O
four O B_PRODUCT[OBJECT]/B_LOCATION
base O I_PRODUCT[OBJECT]/I_LOCATION
reactions O I_PRODUCT[OBJECT]/I_LOCATION
down O O
the O O
same O B_LOCATION/B_PERSON
lane O I_LOCATION/I_PERSON
( O O
2 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

However O O
, O O
bands O B_PERSON/B_DISEASE
are O O
detected O O
at O O
a O O
fixed O B_MEASURE/B_LOCATION
location O I_MEASURE/I_LOCATION

in O O
space O B_LOCATION/B_MEASURE
, O O
and O O
their O O
detection O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
separated O O
in O O
time O B_MEASURE/B_LOCATION
. O O

Hence O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O

Nucleic O B_NUMBER[MEASURE]/B_LOCATION
Acids O I_NUMBER[MEASURE]/I_LOCATION
Research O I_NUMBER[MEASURE]/I_LOCATION
, O O
Vol O B_LOCATION/B_PERSON
. O O

19 O B_MEASURE
, O O
No O O
. O O
12 O B_NUMBER[MEASURE]/B_PERSON
3305 O I_NUMBER[MEASURE]/I_PERSON

problem O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
gel O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distortion O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
essentially O O
avoided O O
, O O
although O O
corrections O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
the O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobilities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
four O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dyes O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O O
be O O
carried O O
out O O
. O O

In O O
contrast O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
utilize O O
the O O
advantages O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
single O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lane O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
address O O
the O O
problem O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
superimposing O O
four O B_NUMBER[MEASURE]/B_LOCATION
relatively O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
complex O B_NUMBER[MEASURE]
two O I_NUMBER[MEASURE]
- O O
dimensional O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
images O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Furthermore O O
, O O
by O O
using O O
sequence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
tagged O O
oligonucleotides O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
are O O
detected O O
by O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
much O O
greater O B_MEASURE
depth O I_MEASURE
of O O
multiplexing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O O
realistically O O
be O O
achieved O O
than O O
by O O
real O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
time O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O O
two O B_NUMBER[MEASURE]
- O O
dimensional O B_MEASURE/B_LOCATION
colour O B_MEASURE/I_LOCATION
traces O B_MEASURE/I_LOCATION
to O O
depict O O
the O O
processed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
output O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
a O O
film O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reader O B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
displaying O O
fluorescence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
traces O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
, O O
and O O
should O O
facilitate O O
the O O
checking O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O O
editing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
sequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
databases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
which O O
both O O
kinds O B_LOCATION/B_DISEASE
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
have O O
been O O
entered O O
. O O

The O O
sequence O B_LOCATION/B_PRODUCT[OBJECT]
compilation O B_LOCATION/I_PRODUCT[OBJECT]
programs O B_LOCATION/I_PRODUCT[OBJECT]
used O O
in O O
this O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
which O O
are O O
already O O
capable O B_PERSON
of O O
handling O O
large O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
shotgun O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
databases O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
8 O B_MEASURE
, O O
31 O B_MEASURE
) O O
, O O
have O O
recently O O
undergone O O
extensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
improvements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O O
Rodger O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Staden O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O O
personal O B_MEASURE
communication O I_MEASURE
) O O
. O O

There O O
is O O
now O O
an O O
interactive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
editor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
which O O
allows O O
the O O
graphical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
display O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
fluorescence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
traces O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
it O O
is O O
envisaged O O
that O O
this O O
feature O B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
extended O O
to O O
allow O O
the O O
handling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
from O O
a O O
film O B_PERSON/B_LOCATION
reader O I_PERSON/I_LOCATION
when O O
a O O
suitable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
machine O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
is O O
developed O O
. O O

ACKNOWLEDGEMENTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

I O O
am O O
particularly O O
grateful O B_TIME[MEASURE]/B_PERSON
to O O
George O B_PERSON
Church O I_PERSON
for O O
thought O B_DISEASE
- O O
provoking O O
discussions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
and O O
gifts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
vectors O B_PROTEIN[GENE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oligonucleotide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
probes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
to O O
John O B_PERSON
Sulston O I_PERSON
for O O
advice O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

I O O
also O O
thank O O
Victoria O B_PERSON/B_ORGANIZATION
Smith O I_PERSON/I_ORGANIZATION
for O O
the O O
gift O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
Bart O B_PERSON/B_LOCATION
Barrell O I_PERSON/I_LOCATION
for O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
support O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
Tom O B_PERSON/B_ORGANIZATION
O O I_PERSON/I_ORGANIZATION
' O I_PERSON/I_ORGANIZATION
Keefe O I_PERSON/I_ORGANIZATION
of O O
Milligen O B_BACTERIUM[BIO]/B_LOCATION
/ O O
Biosearch O B_PERSON/B_ORGANIZATION
for O O
lessons O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
multiplexing O O
and O O
Amersham O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
International O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
optical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
density O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overlays O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O O
in O O
Figure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O O

M O B_OTHER/B_LOCATION
. O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O

is O O
supported O O
by O O
a O O
fellowship O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
Applied O B_LOCATION/B_ORGANIZATION
Biosystems O I_LOCATION/I_ORGANIZATION
. O O

12 O B_NUMBER[MEASURE]
. O O

Hiratsuka O B_PERSON
, O O
J O B_OTHER/B_LOCATION
. O O
, O O
Shimada O B_PERSON
, O O
H O B_OTHER/B_LOCATION
. O O
, O O
Whittier O B_PERSON
, O O
R O B_OTHER/B_LOCATION
. O O
, O O
Ishibashi O B_PERSON
, O O
T O B_OTHER/B_LOCATION
. O O
, O O
Sakamoto O B_PERSON
, O O
M O B_OTHER/B_LOCATION
. O O
, O O
Mori O B_PERSON/B_LOCATION
, O O

M O B_OTHER/B_LOCATION
. O O
, O O
Kondo O B_PERSON/B_LOCATION
, O O
C O B_OTHER/B_LOCATION
. O O
, O O
Honju O B_PERSON/B_LOCATION
, O O
Y O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Sun O B_LOCATION/B_PERSON
, O O
C O B_OTHER/B_PERSON
. O O

- O O
R O B_OTHER/B_PERSON
, O O
Meng O B_PERSON/B_LOCATION
, O O
B O B_OTHER/B_PERSON
. O O

- O O
Y O B_OTHER/B_PERSON
, O O
Li O B_PERSON/B_PROTEIN[GENE]
, O O
Y O B_OTHER/B_PERSON
. O O

- O O
Q O B_OTHER/B_PERSON
, O O
Kanno O B_PERSON
, O O
A O B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Nisizawa O B_PERSON/B_LOCATION
, O O
Y O O
. O O
, O O
Hirai O B_PERSON
, O O
A O B_OTHER/B_PERSON
. O O
, O O
Shinozaki O B_PERSON
, O O
K O B_OTHER/B_LOCATION
. O O
and O O
Sugiura O B_PERSON
, O O
M O B_OTHER/B_PERSON
. O O

( O O
1989 O O
) O O
Molecular O B_EDU[ORGANIZATION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
General O B_EDU[ORGANIZATION]/B_PERSON
Genetics O I_EDU[ORGANIZATION]/I_PERSON
, O O
217 O B_MEASURE
, O O
185 O B_MEASURE
- O O
194 O B_MEASURE
. O O

13 O B_NUMBER[MEASURE]
. O O

Komaromy O B_PERSON
, O O
M O B_OTHER/B_LOCATION
. O O
and O O
Govan O B_PERSON
, O O
H O B_OTHER/B_LOCATION
. O O

( O O
1984 O B_MEASURE
) O O
Nucleic O B_MEASURE/B_LOCATION
Acids O I_MEASURE/I_LOCATION
Research O I_MEASURE/I_LOCATION
, O O
12 O B_MEASURE
, O O
675 O B_MEASURE
- O O
678 O B_MEASURE
. O O

14 O B_NUMBER[MEASURE]
. O O

Staden O B_PERSON/B_LOCATION
, O O
R O B_OTHER/B_PERSON
. O O

( O O
1984 O B_MEASURE
) O O
Nucleic O B_MEASURE/B_LOCATION
Acids O I_MEASURE/I_LOCATION
Research O I_MEASURE/I_LOCATION
, O O
12 O B_MEASURE
, O O
499 O B_MEASURE
- O O
503 O B_MEASURE
. O O

15 O B_NUMBER[MEASURE]
. O O

Elder O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

K O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Green O B_COLOR/B_PERSON
, O O
D O B_OTHER/B_PERSON
. O O

K O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Southern O B_LOCATION/B_PERSON
, O O
E O B_OTHER/B_LOCATION
. O O

M O B_OTHER/B_MEASURE
. O O

( O O
1986 O B_NUMBER[MEASURE]
) O O
Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Research O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
14 O B_MEASURE
, O O
417 O B_MEASURE
- O O
424 O B_MEASURE
. O O

16 O B_NUMBER[MEASURE]
. O O

Maxam O B_PERSON/B_COLOR
, O O
A O O
. O O

M O B_OTHER/B_MEASURE
. O O
and O O
Gilbert O B_PERSON/B_LOCATION
, O O
W O B_OTHER/B_PERSON
. O O

( O O
1977 O O
) O O
Proceedings O B_TIME[MEASURE]/B_PERSON
of O O
the O O
National O B_ORGANIZATION/B_PERSON
Academy O I_ORGANIZATION/I_PERSON

of O O
Sciences O B_ORGANIZATION/B_LOCATION
, O O
U O B_OTHER/B_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
A O B_OTHER/B_PERSON
. O O
, O O
74 O B_MEASURE
, O O
560 O B_MEASURE
- O O
564 O B_MEASURE
. O O

17 O B_NUMBER[MEASURE]
. O O

Sanger O B_PERSON/B_COLOR
, O O
F O B_LOCATION/B_DISEASE
. O O
, O O
Nicklen O B_PERSON/B_COLOR
, O O
S O B_OTHER/B_LOCATION
. O O
and O O
Coulson O B_PERSON
, O O
A O B_OTHER/B_LOCATION
. O O

R O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1977 O O
) O O
Proceedings O B_TIME[MEASURE]/B_PERSON
of O O
the O O
National O B_LOCATION/B_ORGANIZATION

Academy O B_LOCATION/B_PERSON
of O O
Sciences O B_ORGANIZATION/B_LOCATION
, O O
U O B_OTHER/B_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
A O B_OTHER/B_LOCATION
. O O
, O O
74 O B_MEASURE
, O O
5463 O B_MEASURE
- O O
5467 O B_MEASURE
. O O

18 O B_NUMBER[MEASURE]
. O O

Sanger O B_PERSON/B_COLOR
, O O
F O B_OTHER/B_LOCATION
. O O
, O O
Coulson O B_PERSON/B_COLOR
, O O
A O B_OTHER/B_PERSON
. O O

R O B_OTHER/B_PERSON
. O O
, O O
Barrell O B_PERSON
, O O
B O B_OTHER/B_LOCATION
. O O

G O B_OTHER/B_PERSON
. O O
, O O
Smith O B_PERSON
, O O
A O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

H O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Roe O B_TIME[MEASURE]/B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

A O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1980 O B_MEASURE
) O O
Journal O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Molecular O B_EDU[ORGANIZATION]/B_PERSON
Biology O I_EDU[ORGANIZATION]/I_PERSON
, O O
143 O B_MEASURE
, O O
161 O B_MEASURE
- O O
178 O B_MEASURE
. O O

19 O B_NUMBER[MEASURE]
. O O

Applied O O
Biosystems O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
User O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Bulletin O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1987 O B_MEASURE
) O O
13 O B_MEASURE
, O O
11 O B_MEASURE
- O O
16 O B_MEASURE
. O O

20 O B_NUMBER[MEASURE]
. O O

Bankier O B_PERSON/B_COLOR
, O O
A O O
. O O

T O B_OTHER/B_PERSON
. O O
, O O
Weston O B_PERSON
, O O
K O B_OTHER/B_PERSON
. O O

M O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Barrell O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

G O B_OTHER/B_GENE
. O O

( O O
1987 O O
) O O
Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O

Enzymology O B_MEASURE
, O O
155 O B_MEASURE
, O O
51 O B_MEASURE
- O O
93 O B_MEASURE
. O O

21 O B_NUMBER[MEASURE]
. O O

Smith O B_PERSON/B_COLOR
, O O
V O B_OTHER/B_LOCATION
. O O
, O O
Brown O B_PERSON/B_COLOR
, O O
C O B_OTHER/B_LOCATION
. O O

M O B_OTHER/B_PERSON
. O O
, O O
Bankier O B_PERSON
, O O
A O B_OTHER/B_LOCATION
. O O

T O B_PROTEIN[GENE]/B_OTHER
. O O
and O O
Barrell O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

G O B_OTHER/B_GENE
. O O

( O O
1990 O B_NUMBER[MEASURE]
) O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]

Sequence O B_LOCATION/B_MEASURE
, O O
1 O B_MEASURE
, O O
73 O B_MEASURE
- O O
78 O B_MEASURE
. O O

22 O B_NUMBER[MEASURE]
. O O

Southern O B_LOCATION/B_PERSON
, O O
E O B_OTHER/B_LOCATION
. O O

M O B_OTHER/B_MEASURE
. O O

( O O
1975 O B_MEASURE
) O O
Journal O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Molecular O B_EDU[ORGANIZATION]/B_PERSON
Biology O I_EDU[ORGANIZATION]/I_PERSON
, O O
98 O B_MEASURE
, O O
503 O B_MEASURE
- O O
517 O B_MEASURE
. O O

23 O B_NUMBER[MEASURE]
. O O

Church O B_LOCATION/B_PERSON
, O O
G O B_OTHER/B_LOCATION
. O O

M O B_OTHER/B_MEASURE
. O O
and O O
Gilbert O B_PERSON/B_LOCATION
, O O
W O B_OTHER/B_PERSON
. O O

( O O
1984 O O
) O O
Proceedings O B_TIME[MEASURE]/B_PERSON
of O O
the O O
National O B_ORGANIZATION/B_PERSON
Academy O I_ORGANIZATION/I_PERSON

of O O
Sciences O B_ORGANIZATION/B_LOCATION
, O O
U O B_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
A O B_OTHER/B_LOCATION
. O O
, O O
81 O B_TIME[MEASURE]/B_LOCATION
, O O
1991 O B_MEASURE
- O O
1995 O B_MEASURE
. O O

24 O B_NUMBER[MEASURE]
. O O

Beck O B_PERSON/B_COLOR
, O O
S O B_PROTEIN[GENE]/B_DISEASE
. O O
, O O
O O B_OTHER/B_LOCATION
' O O
Keefe O B_PERSON
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Coull O B_PERSON
, O O
J O B_OTHER/B_LOCATION
. O O

M O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Koster O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_PERSON
. O O

( O O
1989 O B_NUMBER[MEASURE]
) O O
Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
17 O B_MEASURE
, O O
5115 O B_MEASURE
- O O
5123 O B_MEASURE
. O O

25 O B_NUMBER[MEASURE]
. O O

Tizard O B_PERSON/B_COLOR
, O O
R O B_OTHER/B_LOCATION
. O O
, O O
Cate O B_PERSON
, O O
R O B_OTHER/B_LOCATION
. O O

L O B_OTHER/B_PERSON
. O O
, O O
Ramachandran O B_PERSON
, O O
K O B_OTHER/B_PERSON
. O O

L O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Wysk O B_PERSON
, O O
M O B_LOCATION
. O O
, O O
Voyta O B_PERSON/B_LOCATION
, O O
J O B_OTHER/B_LOCATION
. O O

C O B_OTHER/B_MEASURE
. O O
, O O

Murphy O B_PERSON/B_MEASURE
, O O
0 O B_NUMBER[MEASURE]/B_PERSON
. O O

J O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Bronstein O B_PERSON
, O O
I O O
. O O

( O O
1990 O O
) O O
Proceedings O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
National O B_ORGANIZATION/B_PERSON
Academy O I_ORGANIZATION/I_PERSON
of O O
Sciences O B_EDU[ORGANIZATION]/B_PERSON
, O O
U O B_OTHER/B_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
A O B_OTHER/B_PERSON
. O O
, O O
87 O B_MEASURE
, O O
4514 O B_MEASURE
- O O
4518 O B_MEASURE
. O O

26 O B_NUMBER[MEASURE]
. O O

Beck O B_PERSON
, O O
S O B_LOCATION/B_DISEASE
. O O
and O O
Koster O B_PERSON
, O O
H O B_OTHER/B_LOCATION
. O O

( O O
1990 O B_MEASURE
) O O
Analytical O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chemistry O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
62 O B_MEASURE
, O O
2558 O B_MEASURE
- O O
2570 O B_MEASURE
. O O

27 O B_NUMBER[MEASURE]
. O O

Jacobson O B_PERSON
, O O
K O B_OTHER/B_PERSON
. O O

B O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Arlinghaus O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_PERSON
. O O

F O B_OTHER/B_LOCATION
. O O
, O O
Schmitt O B_PERSON/B_COLOR
, O O
H O B_OTHER/B_PERSON
. O O

W O B_OTHER/B_PERSON
. O O
, O O
Sachleben O B_PERSON/B_LOCATION
, O O
R O B_OTHER/B_PERSON
. O O

A O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O

Brown O B_PERSON/B_LOCATION
, O O
G O B_OTHER/B_PERSON
. O O

M O B_OTHER/B_LOCATION
. O O
, O O
Thonnard O B_PERSON/B_LOCATION
, O O
N O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Sloop O B_PERSON/B_LOCATION
, O O
F O B_OTHER/B_PROTEIN[GENE]
. O O

V O B_OTHER/B_MEASURE
. O O
, O O
Foote O B_PERSON
, O O
R O B_OTHER/B_PERSON
. O O

S O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Larimer O B_PERSON
, O O
F O B_OTHER/B_PERSON
. O O

W O B_OTHER/B_PERSON
. O O
, O O
Woychik O B_PERSON/B_COLOR
, O O
R O B_OTHER/B_PERSON
. O O

P O B_OTHER/B_PERSON
. O O
, O O
England O B_LOCATION/B_PERSON
, O O
M O B_OTHER/B_LOCATION
. O O

W O B_OTHER/B_MEASURE
. O O
, O O
Burchett O B_PERSON
, O O
K O B_OTHER/B_PERSON
. O O

L O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Jacobson O B_PERSON
, O O
D O B_OTHER/B_PERSON
. O O

A O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1991 O B_MEASURE
) O O
Genomics O B_MEASURE/B_ORGANIZATION
, O O
9 O B_MEASURE
, O O
51 O B_MEASURE
- O O
59 O B_MEASURE
. O O

28 O B_NUMBER[MEASURE]
. O O

Eperon O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
I O O
. O O

C O B_OTHER/B_GENE
. O O

( O O
1986 O B_MEASURE
) O O
Analytical O B_TIME[MEASURE]/B_PERSON
Biochemistry O I_TIME[MEASURE]/I_PERSON
, O O
56 O B_MEASURE
, O O
406 O B_MEASURE
- O O
412 O B_MEASURE
. O O

29 O B_NUMBER[MEASURE]
. O O

Bankier O B_PERSON/B_COLOR
, O O
A O O
. O O

T O B_PROTEIN[GENE]/B_OTHER
. O O
and O O
Barrell O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

G O B_OTHER/B_GENE
. O O

( O O
1989 O O
) O O
In O O
Howe O B_PERSON/B_ORGANIZATION
, O O
C O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Ward O B_PERSON/B_LOCATION
, O O
E O B_OTHER/B_PERSON
. O O

S O B_OTHER/B_DISEASE
. O O

( O O
ed O O
) O O
, O O
Nucleic O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O O
: O O
a O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

IRL O B_NUMBER[MEASURE]/B_PERSON
Press O I_NUMBER[MEASURE]/I_PERSON
, O O
Oxford O B_LOCATION/B_MEASURE
, O O
Vol O B_LOCATION/B_MEASURE
. O O

1 O B_NUMBER[MEASURE]
, O O
pp O O
. O O

37 O O
- O O
78 O B_MEASURE
. O O

30 O B_NUMBER[MEASURE]
. O O

Vieira O B_PERSON
, O O
J O B_OTHER/B_LOCATION
. O O
and O O
Messing O B_TIME[MEASURE]/B_PERSON
, O O
J O B_OTHER/B_PERSON
. O O

( O O
1987 O B_MEASURE
) O O
Methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
Enzymology O B_EDU[ORGANIZATION]/B_DISEASE
, O O
153 O B_MEASURE
, O O
3 O B_MEASURE
- O O
11 O B_MEASURE
. O O

31 O B_NUMBER[MEASURE]
. O O

Davison O B_PERSON/B_COLOR
, O O
A O B_OTHER/B_PERSON
. O O

DNA O B_MEASURE/B_LOCATION
Sequence O I_MEASURE/I_LOCATION
, O O
in O O
press O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

32 O B_NUMBER[MEASURE]
. O O

Heller O B_PERSON/B_COLOR
, O O
C O B_OTHER/B_LOCATION
. O O
, O O
Radley O B_PERSON
, O O
E O B_OTHER/B_LOCATION
. O O
, O O
Khurshid O B_PERSON/B_COLOR
, O O
F O B_OTHER/B_PERSON
. O O

A O O
. O O
and O O
Beck O B_PERSON
, O O
S O B_OTHER/B_PERSON
. O O

Gene O B_PERSON/B_MEASURE
, O O
in O O
press O B_PERSON/B_ENT
. O O

REFERENCES O B_PERSON/B_DISEASE

1 O B_NUMBER[MEASURE]
. O O

Yang O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

M O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Youvan O B_PERSON
, O O
D O B_OTHER/B_PERSON
. O O

C O B_OTHER/B_GENE
. O O

( O O
1989 O B_MEASURE
) O O
Biotechnology O B_MEASURE/B_ORGANIZATION
, O O
7 O B_MEASURE
, O O
576 O B_MEASURE
- O O
580 O B_MEASURE
. O O

2 O B_NUMBER[MEASURE]
. O O

Smith O B_PERSON/B_COLOR
, O O
L O B_OTHER/B_PERSON
. O O

M O B_OTHER/B_PERSON
. O O
, O O
Sanders O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

Z O B_OTHER/B_PERSON
. O O
, O O
Kaiser O B_PERSON/B_LANGUAGE
, O O
R O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_LOCATION
. O O
, O O
Hughes O B_PERSON/B_COLOR
, O O
P O B_LOCATION
. O O
, O O
Dodd O B_PERSON/B_LOCATION
, O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Connell O B_PERSON
, O O

C O B_OTHER/B_GENE
. O O

R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Heiner O B_PERSON/B_LOCATION
, O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Kent O B_LOCATION/B_PERSON
, O O
S O B_OTHER/B_LOCATION
. O O

B O B_OTHER/B_DISEASE
. O O

H O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Hood O B_PERSON/B_COLOR
, O O
L O B_OTHER/B_PERSON
. O O

E O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1986 O B_MEASURE
) O O
Nature O B_MEASURE
, O O
321 O B_MEASURE
, O O
674 O B_MEASURE
- O O
679 O B_MEASURE
. O O

3 O B_NUMBER[MEASURE]
. O O

Church O B_LOCATION/B_PERSON
, O O
G O B_OTHER/B_LOCATION
. O O

M O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Kieffer O B_PERSON
- O O
Higgins O B_PERSON
, O O
S O B_OTHER/B_PERSON
. O O

( O O
1988 O B_MEASURE
) O O
Science O B_EDU[ORGANIZATION]/B_MEASURE
, O O
240 O B_MEASURE
, O O
185 O B_MEASURE
- O O
188 O B_MEASURE
. O O

4 O B_NUMBER[MEASURE]
. O O

Watson O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

D O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1990 O B_MEASURE
) O O
Science O B_EDU[ORGANIZATION]/B_MEASURE
, O O
248 O B_MEASURE
, O O
44 O B_MEASURE
- O O
49 O B_MEASURE
. O O

5 O B_NUMBER[MEASURE]
. O O

Baer O B_PERSON
, O O
R O B_OTHER/B_LOCATION
. O O
, O O
Bankier O B_PERSON
, O O
A O B_OTHER/B_LOCATION
. O O

T O B_OTHER/B_GENE
. O O
, O O
Biggin O B_PERSON
, O O
M O B_OTHER/B_PERSON
. O O

D O B_OTHER/B_LOCATION
. O O
, O O
Deininger O B_PERSON/B_COLOR
, O O
P O B_OTHER/B_PERSON
. O O

L O B_OTHER/B_PERSON
. O O
, O O
Farrell O B_PERSON/B_ORGANIZATION
, O O
P O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_MEASURE
. O O
, O O

Gibson O B_PERSON
, O O
T O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Hatfull O B_PERSON
, O O
G O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Hudson O B_PERSON/B_COLOR
, O O
G O B_OTHER/B_PERSON
. O O

S O B_OTHER/B_MEASURE
. O O
, O O
Satchwell O B_PERSON
, O O
S O B_OTHER/B_PERSON
. O O

C O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Seguin O B_PERSON/B_COLOR
, O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Tuffnell O B_PERSON
, O O
P O B_OTHER/B_LOCATION
. O O

S O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Barrell O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

G O B_OTHER/B_GENE
. O O

( O O
1984 O B_MEASURE/B_PERSON
) O O
Nature O B_MEASURE
, O O
310 O B_MEASURE
, O O
207 O B_MEASURE
- O O
211 O B_MEASURE
. O O

6 O B_NUMBER[MEASURE]
. O O

Davison O B_PERSON/B_COLOR
, O O
A O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_LOCATION
. O O
and O O
Scott O B_PERSON/B_LOCATION
, O O
J O B_OTHER/B_PERSON
. O O

E O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1986 O B_MEASURE
) O O
Journal O B_EDU[ORGANIZATION]/B_TIME[MEASURE]
of O O
General O B_EDU[ORGANIZATION]/B_PERSON
Virology O I_EDU[ORGANIZATION]/I_PERSON
, O O
67 O B_TIME[MEASURE]/B_PERSON
, O O

1759 O O
- O O
1816 O B_TIME[MEASURE]
. O O

7 O B_NUMBER[MEASURE]
. O O

McGeoch O B_PERSON
, O O
D O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_PERSON
. O O
, O O
Dalrymple O B_PERSON/B_COLOR
, O O
M O B_OTHER/B_PERSON
. O O

A O O
. O O
, O O
Davison O B_PERSON
, O O
A O O
. O O

J O B_OTHER/B_PERSON
. O O
, O O
Dolan O B_PERSON
, O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Frame O B_PERSON
, O O

M O B_OTHER/B_MEASURE
. O O

C O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
McNab O B_PERSON/B_COLOR
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Perry O B_PERSON/B_COLOR
, O O
L O B_OTHER/B_LOCATION
. O O

J O B_OTHER/B_LOCATION
. O O
, O O
Scott O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

E O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Taylor O B_PERSON/B_COLOR
, O O
P O B_OTHER/B_PERSON
. O O

( O O
1988 O B_MEASURE
) O O
Journal O B_EDU[ORGANIZATION]/B_TIME[MEASURE]
of O O
General O B_EDU[ORGANIZATION]/B_PERSON
Virology O I_EDU[ORGANIZATION]/I_PERSON
, O O
69 O B_MEASURE
, O O
1531 O B_MEASURE
- O O
1574 O B_MEASURE
. O O

8 O B_NUMBER[MEASURE]
. O O

Chee O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_PERSON
. O O

S O B_OTHER/B_PERSON
. O O
, O O
Bankier O B_PERSON
, O O
A O B_OTHER/B_LOCATION
. O O

T O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Beck O B_PERSON
, O O
S O B_LOCATION/B_DISEASE
. O O
, O O
Bohni O B_PERSON/B_COLOR
, O O
R O B_OTHER/B_LOCATION
. O O
, O O
Brown O B_PERSON
, O O
C O B_OTHER/B_LOCATION
. O O

M O B_OTHER/B_PERSON
. O O
, O O
Cerny O B_MEASURE/B_LOCATION
, O O

R O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Horsnell O B_PERSON/B_COLOR
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Hutchison O B_PERSON/B_COLOR
III O I_PERSON/I_COLOR
, O O
C O B_OTHER/B_PERSON
. O O

A O O
. O O
, O O
Kouzarides O B_PERSON
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Martignetti O B_PERSON
, O O
J O B_OTHER/B_LOCATION
. O O

A O O
. O O
, O O
Satchwell O B_PERSON
, O O
S O B_OTHER/B_PERSON
. O O

C O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Tomlinson O B_PERSON/B_COLOR
, O O
P O B_LOCATION/B_PROTEIN[GENE]
. O O
, O O
Weston O B_PERSON
, O O
K O B_OTHER/B_LOCATION
. O O

M O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Barrell O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

G O B_OTHER/B_GENE
. O O

( O O
1990 O O
) O O
Current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Topics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O O
Microbiology O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Immunology O B_EDU[ORGANIZATION]/B_PERSON
, O O
154 O B_MEASURE
, O O
125 O B_MEASURE
- O O
169 O B_MEASURE
. O O

9 O B_NUMBER[MEASURE]
. O O

Goebel O B_PERSON
, O O
S O B_OTHER/B_PERSON
. O O

J O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Johnson O B_PERSON/B_COLOR
, O O
G O B_OTHER/B_PERSON
. O O

P O B_OTHER/B_PERSON
. O O
, O O
Perkus O B_PERSON
, O O
M O B_OTHER/B_PERSON
. O O

E O B_OTHER/B_PERSON
. O O
, O O
Davis O B_PERSON
, O O
S O B_OTHER/B_PERSON
. O O

W O B_OTHER/B_PERSON
. O O
, O O
Winslow O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

P O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Paoletti O B_PERSON/B_LOCATION
, O O
E O B_OTHER/B_PERSON
. O O

( O O
1990 O B_MEASURE
) O O
Virology O B_MEASURE
, O O
179 O B_MEASURE
, O O
247 O B_MEASURE
- O O
266 O B_MEASURE
. O O

10 O B_NUMBER[MEASURE]
. O O

Ohyama O B_PERSON
, O O
K O B_OTHER/B_LOCATION
. O O
, O O
Fukuzawa O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_LOCATION
. O O
, O O
Kohchi O B_PERSON
, O O
T O B_OTHER/B_LOCATION
. O O
, O O
Shirai O B_PERSON
, O O
H O B_OTHER/B_LOCATION
. O O
, O O
Sano O B_PERSON/B_LOCATION
, O O
T O B_OTHER/B_LOCATION
. O O
, O O
Sano O B_PERSON/B_LOCATION
, O O
S O B_OTHER/B_LOCATION
. O O
, O O

Umesono O B_PERSON/B_LOCATION
, O O
K O B_OTHER/B_LOCATION
. O O
, O O
Shiki O B_PERSON/B_LOCATION
, O O
Y O B_OTHER/B_LOCATION
. O O
, O O
Takeuchi O B_PERSON
, O O
M O B_OTHER/B_PERSON
. O O
, O O
Chang O B_PERSON
, O O
Z O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Aota O B_PERSON/B_LOCATION
, O O
S O B_OTHER/B_LOCATION
. O O

- O O
I O O
, O O
Inokuchi O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_LOCATION
. O O
and O O
Ozeki O B_PERSON
, O O
H O B_OTHER/B_PERSON
. O O

( O O
1986 O B_MEASURE
) O O
Nature O B_MEASURE
, O O
322 O B_MEASURE
, O O
572 O B_MEASURE
- O O
574 O B_MEASURE
. O O

11 O B_NUMBER[MEASURE]
. O O

Shinozaki O B_PERSON
, O O
K O B_OTHER/B_LOCATION
. O O
, O O
Ohme O B_PERSON
, O O
M O B_OTHER/B_LOCATION
. O O
, O O
Tanaka O B_PERSON/B_ORGANIZATION
, O O
M O B_OTHER/B_LOCATION
. O O
, O O
Wakasugi O B_PERSON
, O O
T O B_OTHER/B_LOCATION
. O O
, O O
Hayashida O B_PERSON
, O O
N O B_OTHER/B_LOCATION
. O O
, O O

Matsubayashi O B_PERSON
, O O
T O B_OTHER/B_LOCATION
. O O
, O O
Zaita O B_PERSON
, O O
N O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Chunwongse O B_PERSON/B_LOCATION
, O O
J O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Obokata O B_PERSON
, O O
J O B_OTHER/B_LOCATION
. O O
, O O
YamaguchiShinozaki O B_PERSON
, O O
K O B_OTHER/B_LOCATION
. O O
, O O
Ohto O B_PERSON
, O O
C O B_OTHER/B_PERSON
. O O
, O O
Torazawa O B_PERSON/B_LOCATION
, O O
K O B_OTHER/B_LOCATION
. O O
, O O
Meng O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

Y O B_OTHER/B_LOCATION
. O O
, O O
Sugita O B_PERSON
, O O
M O B_OTHER/B_LOCATION
. O O
, O O
Deno O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_LOCATION
. O O
, O O
Kamogashira O B_PERSON
, O O
T O B_OTHER/B_LOCATION
. O O
, O O
Yamada O B_PERSON
, O O
K O B_OTHER/B_LOCATION
. O O
, O O
Kusuda O B_PERSON
, O O
J O B_OTHER/B_LOCATION
. O O
, O O
Takaiwa O B_PERSON/B_LOCATION
, O O
F O B_OTHER/B_LOCATION
. O O
, O O
Kato O B_PERSON
, O O
A O B_OTHER/B_LOCATION
. O O
, O O
Tohdoh O B_PERSON/B_LOCATION
, O O
N O B_OTHER/B_LOCATION
. O O
, O O
Shimada O B_PERSON
, O O
H O B_OTHER/B_LOCATION
. O O
and O O
Sugiura O B_PERSON
, O O
M O B_OTHER/B_PERSON
. O O

( O O
1986 O B_MEASURE
) O O
EMBO O B_TIME[MEASURE]
Journal O I_TIME[MEASURE]
, O O
5 O B_MEASURE
, O O
2043 O B_MEASURE
- O O
2049 O B_MEASURE
. O O

Mapping O O
irradiation O O
hybrids O O
to O O
cosmid O O
and O O
yeast B B_SPECIES[BIO]/B_GENE
artificial O O
chromosome O O
libraries O O
by O O
direct O O
hybridization O O
of O O
Alu O O
- O O
PCR O O
products O O
. O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
direct O O
hybridization O O
protocol O O
is O O
described O O
for O O
screening O O
cosmid O O
and O O
yeast B B_SPECIES[BIO]
artificial O O
chromosome O O
libraries O O
with O O
pools O O
of O O
Alu O O
- O O
PCR O O
products O O
from O O
somatic O O
cell O O
or O O
irradiation O O
hybrids O O
. O O

This O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
eliminates O O
purification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cloning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
each O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
Alu O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
product O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
before O O
library O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

A O O
series O O
of O O
human B B_NUMBER[MEASURE]/B_SPECIES[BIO]
X O O
chromosome O O
irradiation O O
hybrids O O
were O O
mapped O O
by O O
this O O
method O O
, O O
using O O
a O O
cosmid O O
reference O O
library O O
for O O
comparisons O O
between O O
overlapping O O
hybrids O O
to O O
identify O O
interesting O O
clones O O
for O O
further O O
analysis O O
. O O
Images O O

Nucleic O B_NUMBER[MEASURE]/B_LOCATION
Acids O I_NUMBER[MEASURE]/I_LOCATION
Research O I_NUMBER[MEASURE]/I_LOCATION
, O O
Vol O B_LOCATION/B_PERSON
. O O

19 O B_MEASURE
, O O
No O O
. O O
12 O B_NUMBER[MEASURE]/B_PERSON
3315 O I_NUMBER[MEASURE]/I_PERSON

Mapping O O
irradiation O O
hybrids O O
to O O
cosmid O O
and O O
yeast B B_SPECIES[BIO]/B_GENE
artificial O O
chromosome O O
libraries O O
by O O
direct O O
hybridization O O
of O O
Alu O O
- O O
PCR O O
products O O

Anthony O B_PERSON/B_BIO
P O I_PERSON/I_BIO
. O O
Monaco O B_LOCATION/B_PERSON
* O O
, O O
Veronica O B_PERSON/B_LOCATION
M O I_PERSON/I_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
Lam2 O B_PERSON/B_LOCATION
, O O
Gunther O B_PERSON
Zehetner O I_PERSON
, O O
Gregory O B_PERSON
G O I_PERSON
. O O
Lennon O B_PERSON
, O O
Christal O B_PERSON
Douglas O I_PERSON
, O O
Dean O B_PERSON
Nizetic O I_PERSON
, O O
Peter O B_PERSON/B_LOCATION
N O I_PERSON/I_LOCATION
. O O
Goodfellow1 O B_PERSON
and O O
Hans O B_PERSON/B_LOCATION
Lehrach O I_PERSON/I_LOCATION

Genome O B_LOCATION/B_EDU[ORGANIZATION]
Analysis O B_LOCATION/I_EDU[ORGANIZATION]
Laboratory O B_LOCATION/I_EDU[ORGANIZATION]
and O O
' O O
Molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Human O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Genetics O O
Laboratory O B_LOCATION/B_ORGANIZATION
, O O
Imperial O B_LOCATION/B_ORGANIZATION
Cancer O I_LOCATION/I_ORGANIZATION
Research O I_LOCATION/I_ORGANIZATION
Fund O I_LOCATION/I_ORGANIZATION
, O O
44 O B_PERSON/B_LOCATION
Lincoln O I_PERSON/I_LOCATION
' O O
s O B_LOCATION
Inn O I_LOCATION
Fields O I_LOCATION
, O O
London O B_LOCATION
WC2A O I_LOCATION
3PX O I_LOCATION
, O O
UK O B_LOCATION/B_EDU[ORGANIZATION]
and O O
2Department O B_LOCATION/B_ORGANIZATION
of O O
Biochemistry O B_LOCATION/B_ORGANIZATION
, O O
Li O B_LOCATION/B_ORGANIZATION
Shu O I_LOCATION/I_ORGANIZATION
Fan O I_LOCATION/I_ORGANIZATION
Building O I_LOCATION/I_ORGANIZATION
, O O
Sassoon O B_LOCATION
Road O I_LOCATION
, O O
University O B_LOCATION/B_ORGANIZATION
of O O
Hong O B_LOCATION
Kong O I_LOCATION
, O O
Hong O B_LOCATION/B_PERSON
Kong O I_LOCATION/I_PERSON

Received O O
March O B_TIME[MEASURE]
12 O I_TIME[MEASURE]
, O O
1991 O B_MEASURE
; O O
Revised O O
and O O
Accepted O O
May O B_TIME[MEASURE]
16 O I_TIME[MEASURE]
, O O
1991 O B_MEASURE

ABSTRACT O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
direct O O
hybridization O O
protocol O O
is O O
described O O
for O O
screening O O
cosmid O O
and O O
yeast B B_SPECIES[BIO]
artificial O O
chromosome O O
libraries O O
with O O
pools O O
of O O
Alu O O
- O O
PCR O O
products O O
from O O
somatic O O
cell O O
or O O
irradiation O O
hybrids O O
. O O

This O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
eliminates O O
purification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cloning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
each O O
individual O B_GENE/B_MEASURE
AluPCR O I_GENE/I_MEASURE
product O I_GENE/I_MEASURE
before O O
library O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
screening O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

A O O
series O O
of O O
human B B_NUMBER[MEASURE]/B_SPECIES[BIO]
X O O
chromosome O O
irradiation O O
hybrids O O
were O O
mapped O O
by O O
this O O
method O O
, O O
using O O
a O O
cosmid O O
reference O O
library O O
for O O
comparisons O O
between O O
overlapping O O
hybrids O O
to O O
identify O O
interesting O O
clones O O
for O O
further O O
analysis O O
. O O

INTRODUCTION O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
generation O O
of O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O O
probes O O
specific O O
for O O
individual O O
chromosomes O O
and O O
subregions O O
of O O
chromosomes O O
has O O
been O O
advanced O O
with O O
Alu O O
- O O
sequence O O
primed O O
polymerase O O
chain O O
reaction O O
amplification O O
( O O
Alu O O
- O O
PCR O O
, O O
1 O O
- O O
3 O O
) O O
. O O

This O O
method O O
specifically O O
amplifies O O
sequences O O
between O O
Alu O O
repeats O O
from O O
human B B_SPECIES[BIO]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
DNA O O
in O O
somatic O O
cell O O
hybrids O O
and O O
yeast B B_SPECIES[BIO]
artificial O O
chromosomes O O
( O O
YACs O O
, O O
4 O O
) O O
. O O

Individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
Alu O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
purified O O
from O O
agarose O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gels O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
ligated O O
into O O
plasmid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
vectors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
screen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
for O O
single O B_DISEASE_ADJECTIVE[DISEASE]
copy O I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Unique O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Alu O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
then O O
localized O O
to O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
chromosome O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
regions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
using O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blots O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
somatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panels O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Once O O
localized O O
, O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
screened O O
against O O
genomic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
libraries O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
to O O
isolate O O
longer O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
region O B_LOCATION/B_BIO
of O O
interest O B_PERSON/B_DISEASE
. O O

As O O
an O O
alternative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
this O O
multistep O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
have O O
developed O O
a O O
hybridization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
screening O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
cosmid O B_DISEASE/B_GENE
and O O
YAC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
libraries O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
directly O O
with O O
pools O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
new O O
human B B_SPECIES[BIO]/B_GENE
specific O O
Alu O O
primers O O
were O O
used O O
to O O
generate O O
DNA O O
probes O O
from O O
a O O
series O O
of O O
irradiation O O
- O O
reduced O O
hybrids O O
containing O O
multiple O O
human B B_SPECIES[BIO]
X O O
chromosome O O
fragments O O
of O O
1 O O
- O O
2000 O O
kb O O
on O O
a O O
hamster O O
chromosome O O
background O O
( O O
5 O O
; O O
P O O
. O O
N O O
. O O
G O O
. O O
, O O
unpublished O O
) O O
. O O

The O O
Alu O B_LOCATION/B_PROTEIN[GENE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
hybridized O O
as O O
a O O
pool O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
probes O B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
X O B_GENE/B_DISEASE
- O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cosmid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
YAC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
libraries O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
after O O

competitive O O
reassociation O O
with O O
an O O
excess O O
of O O
human B B_PERSON/B_SPECIES[BIO]
DNA O O
to O O
both O O
the O O
library O O
filters O O
and O O
radioactively O O
labelled O O
Alu O O
- O O
PCR O O
products O O
. O O

Comparisons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
made O O
between O O
clones O B_GENE/B_DISEASE
identified O O
by O O
overlapping O O
irradiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hybrids O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
and O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
copy O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
DNA O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
probes O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
hybridized O O
to O O
the O O
cosmid O B_LOCATION/B_DISEASE
and O O
YAC O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
libraries O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Two O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
Alu O O
sequence O O
primers O O
were O O
generated O O
which O O
were O O
shown O O
to O O
be O O
human B B_SPECIES[BIO]/B_GENE
specific O O
; O O
3144 O O
from O O
the O O
3 O O
' O O
end O O
of O O
Alu O O
: O O
5 O O
' O O
- O O
GAGCGAGACTCCGTCTCAAA O O
- O O
3 O O
' O O
and O O
2729 O O
from O O
the O O
5 O O
' O O
end O O
of O O
Alu O O
: O O
5 O O
' O O
- O O
GTGGATCACCTGAGGTCAGGAGTTC O O
- O O
3 O O
' O O
. O O

All O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
carried O O
out O O
with O O
100 O B_MEASURE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ng O B_MEASURE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hybrid O B_GENE/B_BIO
DNA O I_GENE/I_BIO
and O O
0 O B_MEASURE
. O O
7 O B_MEASURE
, O O
^ O B_MEASURE/B_LOCATION
g O I_MEASURE/I_LOCATION
of O O
a O O
single O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Alu O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
primer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
100 O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
d41 O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
0 O B_MEASURE
. O O
01 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tris O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
HCl O B_MEASURE
pH O I_MEASURE
8 O I_MEASURE
. O O
3 O B_MEASURE
, O O
0 O B_MEASURE
. O O
0015 O B_MEASURE/B_PERSON
M O I_MEASURE/I_PERSON
MgCl2 O I_MEASURE/I_PERSON
, O O
0 O B_MEASURE
. O O
05 O B_MEASURE/B_PERSON
M O I_MEASURE/I_PERSON
KCI O I_MEASURE/I_PERSON
, O O
200 O B_NUMBER[MEASURE]/B_LOCATION
AtM O I_NUMBER[MEASURE]/I_LOCATION
each O O
of O O
dNTPs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dimethlysulfoxide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
2 O B_MEASURE
. O O
5 O B_MEASURE
units O I_MEASURE
of O O
Cetus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Taq O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polymerase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
30 O B_MEASURE/B_LOCATION
cycles O I_MEASURE/I_LOCATION
of O O
94 O B_MEASURE
? O O
C O B_OTHER/B_LOCATION
for O O
2 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
, O O
57 O B_MEASURE
? O O
C O B_OTHER/B_LOCATION
for O O
2 O B_MEASURE/B_PERSON
min O I_MEASURE/I_PERSON
, O O
and O O
74 O B_MEASURE
? O O
C O B_OTHER/B_LOCATION
for O O
4 O B_NUMBER[MEASURE]/B_PERSON
min O I_NUMBER[MEASURE]/I_PERSON
followed O O
by O O
a O O
final O B_MEASURE/B_LOCATION
extension O I_MEASURE/I_LOCATION
time O I_MEASURE/I_LOCATION
at O O
74 O B_MEASURE
? O O
C O B_OTHER/B_LOCATION
for O O
9 O B_NUMBER[MEASURE]/B_PERSON
min O I_NUMBER[MEASURE]/I_PERSON
. O O

Reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
products O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
analyzed O O
on O O
1 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agarose O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
shown O O
to O O
contain O O
between O O
five O B_NUMBER[MEASURE]
and O O
twenty O B_NUMBER[MEASURE]
fragments O I_NUMBER[MEASURE]
, O O
with O O
sizes O B_MEASURE
ranging O O
from O O
0 O B_MEASURE/B_LOCATION
. O O
1 O B_MEASURE
to O O
2 O B_MEASURE
. O O
0 O B_MEASURE
kb O I_MEASURE
. O O

Chinese B B_PERSON/B_NUMBER[MEASURE]
hamster I B_PERSON/I_NUMBER[MEASURE]
DNA O O
and O O
no O O
DNA O O
PCR O O
reactions O O
were O O
done O O
to O O
control O O
for O O
non O O
- O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
products O O
( O O
data O O
not O O
shown O O
) O O
. O O

Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
separated O O
from O O
Alu O B_LOCATION/B_GENE
oligomers O B_LOCATION/I_GENE
over O O
Qiagen O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
columns O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
and O O
approximately O O
50 O B_MEASURE
- O O
100 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
were O O
labelled O O
by O O
random O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hexamer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
priming O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
6 O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

The O O
radioactively O O
labelled O O
pool O O
of O O
fragments O O
was O O
prehybridized O O
with O O
37 O O
. O O
5 O O
, O O
^ O O
g O O
of O O
total O O
human B B_SPECIES[BIO]
DNA O O
and O O
12 O O
. O O
5 O O
tsg O O
of O O
hamster O O
DNA O O
immobilized O O
on O O
a O O
cellulose O O
support O O
matrix O O
, O O
prepared O O
as O O
previously O O
described O O
( O O
7 O O
) O O
. O O

Reactions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
at O O
65 O B_MEASURE/B_LOCATION
? O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
1 O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ml O I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
0 O B_MEASURE/B_LOCATION
. O O
75M O B_MEASURE
NaCl O I_MEASURE
, O O
0 O B_MEASURE
. O O
05M O B_MEASURE
sodium O I_MEASURE
phosphate O I_MEASURE
pH O O
7 O B_MEASURE
. O O
2 O B_MEASURE
, O O
0 O B_MEASURE
. O O
005M O B_MEASURE
EDTA O I_MEASURE
, O O
0 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
sodium O I_MEASURE
dodecyl O I_MEASURE
sulphate O I_MEASURE
( O O
SDS O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
heparin O I_MEASURE/I_PERSON
, O O
and O O
100 O B_MEASURE/B_PERSON
jig O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
denatured O O
salmon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sperm O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
cellulose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
pelleted O O
and O O
the O O
supernatant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
boiled O O
for O O
2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
min O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
every O O
12 O B_NUMBER[MEASURE]
- O O
16 O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
( O O
three O B_TIME[MEASURE]
times O I_TIME[MEASURE]
in O O
two O B_TIME[MEASURE]/B_LOCATION
days O I_TIME[MEASURE]/I_LOCATION
) O O
. O O

Cosmid O B_PERSON/B_LOCATION
and O O
YAC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
filters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Hybond O B_PERSON
N O I_PERSON
+ O I_PERSON
, O O
Amersham O B_LOCATION/B_MEASURE
) O O
were O O
prehybridized O O
at O O
42 O B_MEASURE/B_LOCATION
? O O
C O B_OTHER/B_MEASURE
for O O
16 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
100 O B_MEASURE/B_PERSON
jig O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON

* O B_OTHER/B_PERSON
To O O
whom O O
correspondence O B_NUMBER[MEASURE]/B_PERSON
should O O
be O O
addressed O O
at O O
Human O B_LOCATION/B_PERSON
Genetics O I_LOCATION/I_PERSON
Laboratory O I_LOCATION/I_PERSON
, O O
Imperial O B_LOCATION
Cancer O I_LOCATION
Research O I_LOCATION
Fund O I_LOCATION
, O O
Institute O B_ORGANIZATION/B_LOCATION
of O O
Molecular O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Medicine O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
John O B_LOCATION/B_ORGANIZATION
Radcliffe O I_LOCATION/I_ORGANIZATION
Hospital O I_LOCATION/I_ORGANIZATION
, O O
Headington O B_LOCATION/B_PERSON
, O O
Oxford O B_LOCATION
OX3 O I_LOCATION
9DU O I_LOCATION
, O O
UK O B_LOCATION

1991 O B_PERSON/B_LOCATION
Oxford O I_PERSON/I_LOCATION
University O I_PERSON/I_LOCATION
Press O I_PERSON/I_LOCATION

3316 O B_NUMBER[MEASURE]/B_ORGANIZATION
Nucleic O I_NUMBER[MEASURE]/I_ORGANIZATION
Acids O I_NUMBER[MEASURE]/I_ORGANIZATION
Research O I_NUMBER[MEASURE]/I_ORGANIZATION
, O O
Vol O B_LOCATION
. O O

19 O O
, O O
No O O
. O O
12 O B_NUMBER[MEASURE]

Chromosome O B_GENE/B_MEASURE
X O I_GENE/I_MEASURE

. O O
, O O
. O O
. O O
, O O
. O O
, O O
< O B_OTHER/B_LOCATION

_ O B_OTHER/B_LOCATION
. O O
, O O
. O O

< O B_MEASURE/B_OTHER
. O O
, O O

* O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
. O O
' O O
1 O B_MEASURE
- O O
7 O B_MEASURE
- O O
_ O B_MEASURE/B_OTHER

_ O O
- O O
_ O O
1 O B_MEASURE/B_LOCATION
. O O

J O B_OTHER/B_PERSON

, O O
. O O
1 O B_MEASURE/B_LOCATION
. O O
. O O

- O O
1 O B_NUMBER[MEASURE]
, O O
_ O B_MEASURE/B_DISEASE
i O O
- O O
_ O O
1 O B_NUMBER[MEASURE]
. O O

1 O B_NUMBER[MEASURE]/B_PERSON

1 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION

1 O B_LOCATION/B_PERSON
1 O I_LOCATION/I_PERSON
L O I_LOCATION/I_PERSON
L O I_LOCATION/I_PERSON
. O O

i O B_OTHER/B_PERSON

. O O
1 O B_MEASURE/B_LOCATION
. O O

_ O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

1 O B_LOCATION/B_MEASURE
1 O I_LOCATION/I_MEASURE
s O I_LOCATION/I_MEASURE
. O O

1 O B_MEASURE/B_LOCATION
i O O

1 O B_MEASURE/B_LOCATION
i O O
; O O
. O O

- O O
- O O
r O B_PROTEIN[GENE]
' O O
F O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O

1 O O
- O O
1 O B_MEASURE
- O O
l O B_OTHER/B_MEASURE

j O O
i O O
- O O
_ O O
1 O B_MEASURE/B_LOCATION
. O O

1 O B_NUMBER[MEASURE]/B_PERSON

- O O
_ O O
1 O B_MEASURE/B_LOCATION
. O O
. O O

s O B_OTHER/B_PERSON
- O O
S O B_OTHER/B_LOCATION
. O O

i O B_OTHER/B_MEASURE
n O O
- O O
. O O

. O B_OTHER/B_PERSON
. O O

: O O
, O O
1 O B_MEASURE/B_LOCATION
' O O
, O O
. O O

- O O
1 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
_ O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
i O O
? O O

, O B_OTHER/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

. O O
_ O O
_ O O
_ O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

G O B_OTHER/B_PROTEIN[GENE]
- O O

* O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
- O O
. O O
, O O
. O O
, O O
z O O

_ O B_OTHER/B_PERSON

_ O B_OTHER/B_DISEASE
, O O

z O O
; O O
- O O
[ O O
X1 O B_GENE/B_MEASURE

21 O B_NUMBER[MEASURE]/B_PERSON
, O O
In O O

27 O B_TIME[MEASURE]
38 O I_TIME[MEASURE]
45 O I_TIME[MEASURE]
48 O I_TIME[MEASURE]
54 O I_TIME[MEASURE]
74 O I_TIME[MEASURE]
86 O I_TIME[MEASURE]

I O O
1 O B_TIME[MEASURE]/B_LOCATION
I O O

I O B_OTHER/B_PERSON

I O B_OTHER/B_PERSON

107 O B_NUMBER[MEASURE]

MD O B_LOCATION/B_DISEASE

I O B_OTHER/B_PERSON

: O B_OTHER/B_MEASURE
I O O
I O O

I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O

I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O

Figur O O
2a O O
and O O
2b O O
: O O
Hybridization O O
of O O
Alu O O
- O O
PCR O O
products O O
generated O O
with O O
Alu O O
primer O O
3144 O O
from O O
irradiation O O
hybrid O O
48 O O
to O O
duplicate O O
copies O O
of O O
22 O O
x22cm O O
filters O O
containing O O
9216 O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
X O O
chromosome O O
cosmids O O
( O O
8 O O
) O O
. O O

2c O O
: O O
Hybridization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generated O O
with O O
Alu O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
primer O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3144 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
an O O
independent O B_PERSON/B_LOCATION
hybrid O B_PERSON/I_LOCATION
( O O
54 O B_NUMBER[MEASURE]/B_LOCATION
) O O
to O O
a O O
third O B_NUMBER[MEASURE]/B_PERSON
identical O B_NUMBER[MEASURE]/I_PERSON
cosmid O B_NUMBER[MEASURE]/I_PERSON
filter O B_NUMBER[MEASURE]/I_PERSON
. O O

Figure O O
1 O O
: O O
A O O
schematic O O
diagram O O
of O O
the O O
human B B_PERSON/B_SPECIES[BIO]
X O O
chromosome O O
alongside O O
the O O
approximate O O
cytogenetic O O
location O O
of O O
fragments O O
identified O O
in O O
nine O O
irradiation O O
hybrids O O
( O O
numbers O O
across O O
the O O
top O O
) O O
. O O

The O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
X O O
fragments O O
were O O
identified O O
by O O
hybridization O O
of O O
27 O O
known O O
DNA O O
markers O O
( O O
indicated O O
by O O
a O O
black O O
line O O
; O O
P O O
. O O
N O O
. O O
G O O
, O O
unpublished O O
) O O
or O O
by O O
cosmids O O
in O O
common O O
with O O
unique O O
X O O
chromosome O O
probes O O
in O O
the O O
reference O O
library O O
database O O
( O O
open O O
boxes O O
and O O
Table O O
1 O O
) O O
. O O

The O O
size O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
lines O B_LOCATION/B_PRODUCT[OBJECT]
and O O
boxes O B_LOCATION/B_PERSON
relate O O
to O O
the O O
best O B_MEASURE/B_ORGANIZATION
cytogenetic O I_MEASURE/I_ORGANIZATION
location O I_MEASURE/I_ORGANIZATION
of O O
the O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
used O O
according O O
to O O
Human O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Gene O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Mapping O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
10 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O
5 O B_MEASURE
( O O
14 O B_MEASURE
) O O
and O O
does O O
not O O
indicate O O
the O O
physical O B_MEASURE/B_LOCATION
extent O I_MEASURE/I_LOCATION
of O O
the O O
irradiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hybrid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
fragments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O O

denatured O O
and O O
sheared O O
total O O
human B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPECIES[BIO]
DNA O O
in O O
50 O O
% O O
formamide O O
, O O
4XSSC O O
, O O
0 O O
. O O
05 O O
M O O
sodium O O
phosphate O O
pH O O
7 O O
. O O
2 O O
, O O
0 O O
. O O
001 O O
M O O
EDTA O O
, O O
10 O O
% O O
dextran O O
sulphate O O
, O O
1 O O
. O O
0 O O
% O O
SDS O O
, O O
50 O O
isg O O
/ O O
ml O O
denatured O O
salmon O O
sperm O O
DNA O O
and O O
OxDenhardt O O
' O O
s O O
solution O O
. O O

The O O
radioactively O O
labelled O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
denatured O O
and O O
added O O
to O O
fresh O O

hybridization O O
solution O O
without O O
human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
DNA O O
competitor O O
at O O
1 O O
x O O
106 O O

cpm O B_MEASURE/B_LOCATION
/ O O
ml O B_TIME[MEASURE]/B_PERSON
and O O
hybridized O O
at O O
42 O B_TIME[MEASURE]
? O O
C O B_OTHER/B_MEASURE
for O O
16 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Filters O B_LOCATION/B_PERSON
were O O
washed O O
in O O
0 O B_MEASURE
. O O
1 O B_MEASURE
xSSC O I_MEASURE
and O O
1 O B_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
SDS O I_MEASURE
, O O
twice O O
at O O
room O B_MEASURE
temperature O I_MEASURE
and O O
twice O O
at O O
65 O B_MEASURE
? O O
C O B_OTHER/B_PROTEIN[GENE]
for O O
30 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
each O O
and O O
exposed O O
to O O
Kodak O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
X O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
OMAT O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
film O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
2 O B_NUMBER[MEASURE]/B_LOCATION
- O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
at O O
- O O
70 O B_MEASURE
? O O
C O B_OTHER/B_MEASURE
with O O
an O O
intensifying O O
screen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
each O O
hybridization O O
, O O
two O O
sets O O
of O O
duplicate O O
cosmid O O
filters O O
were O O
used O O
from O O
the O O
ICRF O O
reference O O
library O O
system O O
( O O
8 O O
) O O
, O O
each O O
containing O O
9216 O O
flow O O
- O O
sorted O O
human B B_SPECIES[BIO]/B_MEASURE
X O O
chromosome O O
cosmid O O
clones O O
or O O
approximately O O
2 O O
chromosome O O
equivalents O O
on O O
a O O
22 O O
x O O
22 O O
cm O O
filter O O
( O O
9 O O
) O O
. O O

The O O
coordinates O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
signals O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
positive O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
duplicate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cosmid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
filters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
entered O O
into O O
the O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
G O B_OTHER/B_LOCATION
. O O
Z O B_OTHER/B_MEASURE
, O O
unpublished O B_TIME[MEASURE]
) O O
using O O
a O O
digitizing O O
tablet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
the O O
X O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chromosome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
YAC O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
P O B_LOCATION
. O O
M O B_OTHER/B_LOCATION
. O O
and O O
H O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_OTHER/B_LOCATION
. O O
, O O
unpublished O B_TIME[MEASURE]/B_LOCATION
) O O
, O O
about O O
420 O B_MEASURE/B_GENE
YAC O I_MEASURE/I_GENE
colonies O I_MEASURE/I_GENE
were O O
spotted O O
manually O O
onto O O
filters O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
96 O B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O O
microtiter O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
dishes O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
using O O
a O O
96 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prong O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
device O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
selective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
media O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
3 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
YAC O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
filters O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O O
processed O O
for O O
hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
previously O O
described O O
( O O
10 O B_MEASURE
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

A O O
panel O O
of O O
195 O O
X O O
chromosome O O
irradiation O O
hybrids O O
was O O
constructed O O
( O O
50 O O
, O O
000 O O
rads O O
) O O
and O O
characterized O O
by O O
DNA O O
hybridization O O
using O O
27 O O
X O O
chromosome O O
markers O O
and O O
flourescence O O
in O O
situ O O
hybridization O O
using O O
total O O
human B B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DNA O O
as O O
probe O O
( O O
Benham O O
et O O
al O O
. O O
, O O
1989 O O
; O O
P O O
. O O
N O O
. O O
G O O
. O O
, O O
unpublished O O
) O O
. O O

This O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
the O O
hybrids O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contained O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
small O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
fragments O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
4 O B_NUMBER[MEASURE]
- O O
10 O B_MEASURE/B_LOCATION
fragments O B_MEASURE/I_LOCATION
of O O
1000 O B_MEASURE
- O O
5000 O B_MEASURE
kb O I_MEASURE
each O O
) O O
with O O
a O O
preferential O B_MEASURE/B_LOCATION
retaining O I_MEASURE/I_LOCATION
of O O
centromere O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
90 O B_MEASURE/B_PROTEIN[GENE]
% O B_MEASURE/I_PROTEIN[GENE]
) O O
. O O

From O O
this O O
panel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
nine O B_LOCATION/B_PERSON
irradiation O I_LOCATION/I_PERSON
hybrids O I_LOCATION/I_PERSON
were O O
chosen O O
that O O
contained O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
five O B_NUMBER[MEASURE]/B_ENT
different O I_NUMBER[MEASURE]/I_ENT
regions O I_NUMBER[MEASURE]/I_ENT
by O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
probe O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hybridizations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
mostly O O
from O O
the O O
short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arm O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
X O B_GENE
chromosome O I_GENE
( O O
Fig O B_TIME[MEASURE]/B_BIO
1 O I_TIME[MEASURE]/I_BIO
) O O
. O O

All O O
nine O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrids O I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
in O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reactions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
3 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Alu O B_LOCATION/B_PERSON
primer O I_LOCATION/I_PERSON
3144 O I_LOCATION/I_PERSON
and O O
two O B_NUMBER[MEASURE]
were O O
used O O
with O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
Alu O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]

Figure O O
3 O O
: O O
Hybridization O O
of O O
Alu O O
- O O
PCR O O
products O O
generated O O
with O O
Alu O O
primer O O
3144 O O
from O O
irradiation O O
hybrid O O
54 O O
to O O
a O O
filter O O
containing O O
420 O O
YAC O O
clones O O
from O O
the O O
human B B_PERSON/B_SPECIES[BIO]
X O O
chromosome O O
. O O

The O O
positive O B_GENE/B_DISEASE
YAC O I_GENE/I_DISEASE
was O O
also O O
identified O O
in O O
a O O
separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hybridization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
the O O
DMD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
P20 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
12 O B_NUMBER[MEASURE]
) O O
. O O

primer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2729 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Example O O
hybridizations O O
to O O
a O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
X O O
chromosome O O
cosmid O O
filter O O
in O O
Fig O O
2 O O
shows O O
the O O
intensity O O
and O O
reliability O O
of O O
positive O O
clones O O
identified O O
on O O
duplicate O O
filters O O
with O O
Alu O O
- O O
PCR O O
products O O
from O O
the O O
same O O
irradiation O O
hybrid O O
( O O
48 O O
) O O
and O O
the O O
independence O O
of O O
clones O O
identified O O
with O O
Alu O O
- O O
PCR O O
products O O
from O O
a O O
different O O
hybrid O O
( O O
54 O O
) O O
. O O

Fig O O
3 O O
shows O O
a O O
single O O
positive O O
YAC O O
clone O O
after O O
hybridization O O
of O O
Alu O O
- O O
PCR O O
products O O
from O O
irradiation O O
hybrid O O
54 O O
to O O
a O O
filter O O
containing O O
about O O
420 O O
YAC O O
clones O O
specific O O
for O O
the O O
human B B_PERSON/B_SPECIES[BIO]
X O O
chromosome O O
. O O

The O O
total O B_MEASURE/B_PERSON
number O B_MEASURE/I_PERSON
of O O
cosmids O B_BIO/B_GENE
identified O O
with O O
each O O
pool O B_LOCATION/B_MEASURE
of O O
AluPCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
each O O
hybrid O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
shown O O
in O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

From O O
the O O
average O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
cosmids O B_BIO/B_GENE
identified O O
( O O
24 O B_MEASURE
) O O
in O O
four O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
chromosome O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
equivalents O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
screened O O
and O O
the O O
estimated O O
average O B_MEASURE
DNA O I_MEASURE
content O I_MEASURE
in O O
each O O
hybrid O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3000 O B_MEASURE
- O O
15000 O B_MEASURE/B_LOCATION
kb O I_MEASURE/I_LOCATION
) O O
, O O
the O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
products O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
generated O O
by O O
a O O
single O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
primer O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
calculated O O
on O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
to O O
be O O
300 O B_MEASURE
- O O
1500 O B_MEASURE
kb O I_MEASURE
apart O O
, O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
published O O
estimates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
this O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O B_MEASURE
, O O
2 O B_MEASURE
) O O
. O O

Only O O
3 O B_MEASURE/B_PROTEIN[GENE]
- O O
4 O B_GENE/B_MEASURE
cosmids O I_GENE/I_MEASURE
were O O
identified O O
in O O
common O B_MEASURE
using O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
generated O O
with O O
either O O
3 O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
5 O B_MEASURE
' O O
Alu O B_LOCATION/B_GENE
primers O B_LOCATION/I_GENE
( O O
3144 O B_MEASURE
or O O
2729 O B_MEASURE
) O O
from O O
two O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrids O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
38 O B_MEASURE
and O O
45 O B_MEASURE
) O O
. O O

This O O
shows O O
that O O
separate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
products O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
amplified O O
with O O
the O O
two O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Alu O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
primers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
since O O
they O O
prime O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthesis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O O
opposite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ends O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
Alu O B_GENE
consensus O I_GENE
sequence O I_GENE
and O O
Alu O B_MEASURE/B_LOCATION
sequences O B_MEASURE/I_LOCATION
are O O
oriented O O
in O O
the O O
genome O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
either O O
head O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O O
head O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O

A O B_OTHER/B_PERSON

B O B_OTHER/B_PERSON

C O B_OTHER/B_PERSON

El O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

I0 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Nucleic O B_NUMBER[MEASURE]/B_LOCATION
Acids O I_NUMBER[MEASURE]/I_LOCATION
Research O I_NUMBER[MEASURE]/I_LOCATION
, O O
Vol O B_LOCATION/B_PERSON
. O O

19 O B_MEASURE
, O O
No O O
. O O
12 O B_NUMBER[MEASURE]/B_PERSON
3317 O I_NUMBER[MEASURE]/I_PERSON

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Cosmids O B_GENE/B_BACTERIUM[BIO]
identified O O
by O O
hybrids O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
unique O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
probes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

hybrids O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
21 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
27 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
38 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
38 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
45 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
45 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
48 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
54 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
74 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
86 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
107 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
unique O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]

primer O O
3144 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3144 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2729 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2729 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
33144 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
probes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

21 O B_MEASURE
3144 O I_MEASURE
59 O I_MEASURE
1 O I_MEASURE
27 O I_MEASURE
3144 O I_MEASURE
7 O I_MEASURE
14 O I_MEASURE
2 O I_MEASURE
38 O I_MEASURE
3144 O I_MEASURE
3 O I_MEASURE
1 O I_MEASURE
28 O I_MEASURE
2 O I_MEASURE
38 O I_MEASURE
2729 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
4 O I_MEASURE
25 O I_MEASURE
0 O I_MEASURE
45 O I_MEASURE
3144 O I_MEASURE
13 O I_MEASURE
2 O I_MEASURE
2 O I_MEASURE
0 O I_MEASURE
32 O I_MEASURE
3 O I_MEASURE
45 O I_MEASURE
2729 O I_MEASURE
1 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
3 O I_MEASURE
31 O I_MEASURE
0 O I_MEASURE
48 O I_MEASURE
3144 O I_MEASURE
10 O I_MEASURE
2 O I_MEASURE
4 O I_MEASURE
0 O I_MEASURE
2 O I_MEASURE
0 O I_MEASURE
28 O I_MEASURE
3 O I_MEASURE
54 O I_MEASURE
3144 O I_MEASURE
11 O I_MEASURE
3 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
5 O I_MEASURE
0 O I_MEASURE
5 O I_MEASURE
30 O I_MEASURE
2 O I_MEASURE
74 O I_MEASURE
3144 O I_MEASURE
5 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
4 O I_MEASURE
0 O I_MEASURE
5 O I_MEASURE
12 O I_MEASURE
20 O I_MEASURE
3 O I_MEASURE
86 O I_MEASURE
3144 O I_MEASURE
3 O I_MEASURE
1 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
4 O I_MEASURE
1 O I_MEASURE
3 O I_MEASURE
4 O I_MEASURE
3 O I_MEASURE
17 O I_MEASURE
0 O I_MEASURE
107 O I_MEASURE
3144 O I_MEASURE
1 O I_MEASURE
0 O I_MEASURE
1 O I_MEASURE
1 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
3 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
0 O I_MEASURE
13 O I_MEASURE
0 O I_MEASURE

tail O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O O
tail O O
or O O
head O O
to O O
tail O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
relative O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
to O O
each O O
other O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
by O O
using O O
the O O
3 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
5 O B_MEASURE
' O O
- O O
Alu O B_LOCATION/B_GENE
primers O B_LOCATION/I_GENE
in O O
separate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
reactions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
the O O
same O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hybrid O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
the O O
total O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
products O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
cosmid O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
identified O O
was O O
almost O O
doubled O O
. O O

Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O O
indicates O O
how O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cosmids O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O O
identified O O
by O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
other O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrids O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
16 O B_PERSON/B_LOCATION
cosmids O B_PERSON/I_LOCATION
previously O O
identified O O
with O O
unique O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
probes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

As O O
can O O
be O O
seen O O
in O O
Fig O B_TIME[MEASURE]/B_LOCATION
1 O I_TIME[MEASURE]/I_LOCATION
and O O
previous O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiation O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrid O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
is O O
a O O
preferential O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
retention O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
centromere O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
sequences O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
2 O B_NUMBER[MEASURE]
, O O
11 O B_MEASURE
) O O
. O O

However O O
, O O
there O O
were O O
no O O
cosmids O B_BIO/B_GENE
identified O O
in O O
common O B_DISEASE/B_GENE
from O O
all O O
the O O
hybrids O B_BIO/B_DISEASE
positive O I_BIO/I_DISEASE
with O O
centromere O B_VIRUS[BIO]/B_GENE
sequences O B_VIRUS[BIO]/I_GENE
. O O

This O O
is O O
probably O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
a O O
paucity O B_DISEASE_ADJECTIVE[DISEASE]
of O O
Alu O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repeats O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
correct O B_GENE
orientation O I_GENE
in O O
alphoid O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
centromere O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sequences O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
thus O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
no O O
Alu O B_LOCATION/B_PROTEIN[GENE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
would O O
be O O
amplified O O
from O O
the O O
centromere O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Cosmids O B_LOCATION/B_PERSON
identified O O
in O O
common O B_MEASURE/B_DISEASE
by O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
irradiation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hybrids O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
most O O
likely O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
regions O B_LOCATION
of O O
overlap O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
outside O O
the O O
centromere O B_LOCATION/B_GENE
area O I_LOCATION/I_GENE
as O O
shown O O
by O O
the O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
probe O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characterization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Fig O B_MEASURE
1 O I_MEASURE
) O O
. O O

The O O
overlap O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
hybrids O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O O
also O O
seen O O
by O O
16 O B_PERSON/B_GENE
cosmids O B_PERSON/I_GENE
( O O
Table O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Fig O B_MEASURE
1 O I_MEASURE
) O O
that O O
were O O
hybridization O B_MEASURE/B_PERSON
targets O B_MEASURE/I_PERSON
of O O
unique O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
mapped O O
in O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
the O O
overlap O B_LOCATION/B_BIO
region O I_LOCATION/I_BIO
. O O

At O O
least O O
for O O
several O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cosmids O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O O
showed O O
that O O
the O O
Alu O B_LOCATION/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
identified O O
target O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cosmids O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
were O O
definitely O O
from O O
the O O
expected O B_LOCATION/B_BIO
region O B_LOCATION/I_BIO
contained O O
in O O
the O O
hybrids O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

For O O
example O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
hybrids O B_MEASURE
21 O I_MEASURE
and O O
54 O B_MEASURE
were O O
both O O
shown O O
to O O
contain O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O O
the O O
Duchenne O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
muscular O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
dystrophy O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
DMD O B_DISEASE/B_PROTEIN[GENE]
) O O
locus O B_GENE/B_LOCATION
( O O
Fig O B_MEASURE
1 O I_MEASURE
; O O
P O B_OTHER/B_LOCATION
. O O
N O B_OTHER/B_PROTEIN[GENE]
. O O
G O B_OTHER/B_GENE
. O O
, O O
unpublished O B_TIME[MEASURE]
) O O
and O O
had O O
11 O B_NUMBER[MEASURE]/B_PERSON
cosmids O I_NUMBER[MEASURE]/I_PERSON
in O O
common O B_DISEASE/B_GENE
, O O
including O O
one O B_NUMBER[MEASURE]/B_PERSON
identified O O
by O O
the O O
probe O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P20 O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
deletion O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
hotspot O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
DMD O B_GENE/B_BIO
gene O I_GENE/I_BIO
( O O
12 O B_TIME[MEASURE]
) O O
. O O

In O O
Fig O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
hybridization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Alu O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
hybrid O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
54 O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
identified O O
a O O
YAC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clone O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
was O O
also O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
DMD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
P20 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
not O O
shown O O
) O O
. O O

This O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
identified O O
fragments O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
hybrids O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
were O O
not O O
seen O O
in O O
the O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characterization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
Fig O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Table O B_MEASURE
1 O I_MEASURE
) O O
. O O

Since O O
the O O
27 O B_GENE/B_LOCATION
DNA O I_GENE/I_LOCATION
probes O I_GENE/I_LOCATION
were O O
not O O
close O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enough O O
to O O
each O O
other O B_NUMBER[MEASURE]/B_PERSON
along O O
the O O
chromosome O B_GENE/B_LOCATION
to O O
detect O O
all O O
possible O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hybrid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragments O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1000 O B_MEASURE
- O O
5000 O B_MEASURE
kb O I_MEASURE
) O O
, O O
many O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O O
have O O
been O O
untested O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
example O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
AluPCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
hybrids O B_MEASURE
45 O I_MEASURE
and O O
48 O B_MEASURE
identified O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cosmids O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
also O O
seen O O
by O O
the O O
cDNA O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
granulomatous O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
CYBB O B_MEASURE
, O O
13 O B_NUMBER[MEASURE]/B_LOCATION
) O O
in O O
Xp2 O B_PROTEIN[GENE]/B_MEASURE
1 O I_PROTEIN[GENE]/I_MEASURE
. O O
1 O B_MEASURE
, O O
although O O
this O O
region O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
not O O
tested O O
in O O
the O O
original O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hybrid O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characterization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

DISCUSSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
direct O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hybridization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
somatic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
hybrids O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O O
genomic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
libraries O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
bypass O O
gel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
ligation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
fragments O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
into O O
plasmid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vectors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
individual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
single O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
copy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O

a O O
pool O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
ordered O O
array O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
libraries O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
flow O B_MEASURE/B_SPORT[ENT]
- O O
sorted O O
X O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
chromosome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cosmid O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
9 O B_TIME[MEASURE]/B_LOCATION
) O O
, O O
allows O O
the O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
overlapping O O
hybrids O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
pinpoint O O
cosmids O B_BIO/B_GENE
most O O
likely O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
be O O
from O O
the O O
region O B_LOCATION/B_BIO
of O O
interest O B_PERSON/B_TIME[MEASURE]
. O O

In O O
conjunction O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
library O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
G O B_OTHER/B_LOCATION
. O O
Z O B_OTHER/B_MEASURE
, O O
unpublished O O
) O O
with O O
183 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
X O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
chromosome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
probe O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hybridization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
entries O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
cosmids O B_BIO/B_GENE
identified O O
with O O
both O O
Alu O B_LOCATION/B_PROTEIN[GENE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
uniquely O O
mapped O O
X O B_LOCATION/B_ORGANIZATION
probes O I_LOCATION/I_ORGANIZATION
immediately O O
map O O
them O O
to O O
the O O
region O B_LOCATION/B_BIO
of O O
interest O B_PERSON/B_BIO
and O O
proove O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O O
worked O O
. O O

Similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybridization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
four O B_NUMBER[MEASURE]
overlapping O O
irradiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hybrids O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
identified O O
four O B_LOCATION/B_ENT
cosmids O I_LOCATION/I_ENT
in O O
common O B_LOCATION/B_DISEASE
that O O
mapped O O
to O O
the O O
region O B_LOCATION/B_MEASURE
of O O
overlap O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
F O B_OTHER/B_LOCATION
. O O
Muscatelli O B_PERSON
, O O
A O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
P O B_LOCATION
. O O
M O B_LOCATION
. O O
, O O
P O B_LOCATION
. O O
N O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
G O B_LOCATION/B_GENE
. O O
, O O
H O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_OTHER/B_LOCATION
. O O
and O O
M O B_LOCATION
. O O
Fontes O B_PERSON
, O O
in O O
preparation O B_MEASURE
) O O
. O O

Since O O
only O O
27 O O
probes O O
from O O
the O O
X O O
chromosome O O
were O O
used O O
to O O
initially O O
characterize O O
the O O
hybrids O O
and O O
the O O
length O O
of O O
individual O O
human B B_DISEASE/B_GENE
fragments O O
in O O
the O O
irradiation O O
hybrids O O
is O O
about O O
1000 O O
- O O
5000 O O
kb O O
, O O
many O O
regions O O
could O O
have O O
been O O
undetected O O
in O O
the O O
original O O
analysis O O
. O O

The O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hybridization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
the O O
cosmid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
library O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
detected O O
such O B_DISEASE/B_GENE
fragments O I_DISEASE/I_GENE
since O O
they O O
identified O O
cosmids O B_LOCATION/B_PERSON
in O O
common O B_LOCATION/B_DISEASE
with O O
uniquely O O
mapped O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
regions O B_LOCATION/B_DISEASE
not O O
tested O O
originally O O
( O O
Table O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
Fig O B_NUMBER[MEASURE]/B_LOCATION
1 O I_NUMBER[MEASURE]/I_LOCATION
) O O
. O O

This O O
should O O
prove O O
to O O
be O O
a O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
and O O
efficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
determine O O
content O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
overlap O O
of O O
irradiation O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hybrids O I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
conjunction O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hybridization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
since O O
the O O
exact O O
length O O
of O O
the O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O O
fragments O O
for O O
each O O
hybrid O O
and O O
the O O
spacing O O
of O O
Alu O O
- O O
PCR O O
products O O
along O O
the O O
chromosome O O
is O O
not O O
known O O
, O O
it O O
is O O
difficult O O
to O O
directly O O
correlate O O
the O O
number O O
of O O
target O O
cosmids O O
to O O
the O O
DNA O O
content O O
of O O
the O O
hybrids O O
. O O

The O O
direct O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hybridization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Alu O B_LOCATION/B_PROTEIN[GENE]
- O O
PCR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
irradiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
somatic O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
hybrids O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
to O O
total O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YAC O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
libraries O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
will O O
be O O
especially O O
useful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
construct O O
long O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
range O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YAC O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contigs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
specific O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subregions O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chromosomes O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
dissection O O
of O O
a O O
total O O
genomic O O
YAC O O
library O O
by O O
this O O
method O O
may O O
be O O
more O O
efficient O O
than O O
generating O O
chromosome O O
specific O O
YAC O O
libraries O O
from O O
somatic O O
cell O O
hybrids O O
( O O
usually O O
a O O
haploid O O
human B B_PERSON/B_SPECIES[BIO]
chromosome O O
on O O
a O O
diploid O O
or O O
greater O O
rodent O O
background O O
) O O
or O O
flow O O
- O O
sorted O O
chromosomes O O
, O O
because O O
of O O
the O O
low O O
transformation O O
efficiency O O
of O O
yeast B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

ACKNOWLEDGEMENTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

We O O
would O O
like O O
to O O
thank O O
Gert O B_PERSON
- O O
Jan O B_PERSON
Van O I_PERSON
Ommen O I_PERSON
for O O
the O O
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
P20 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
Stuart O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Orkin O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
CYBB O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
. O O
P O B_LOCATION
. O O
M O B_OTHER/B_PERSON
is O O
supported O O
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
a O O
research O B_PERSON/B_ORGANIZATION
fellowship O I_PERSON/I_ORGANIZATION
from O O
the O O
Muscular O B_ORGANIZATION/B_LOCATION
Dystrophy O I_ORGANIZATION/I_LOCATION
Association O I_ORGANIZATION/I_LOCATION
of O O
America O B_LOCATION
. O O

V O B_MEASURE
. O O
M O B_OTHER/B_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
L O B_OTHER/B_LOCATION
. O O

is O O
supported O O
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
the O O
Medical O B_PERSON/B_ORGANIZATION
Research O B_PERSON/I_ORGANIZATION
Grant O B_PERSON/I_ORGANIZATION
of O O
the O O
University O B_LOCATION/B_ORGANIZATION
of O O
Hong O B_LOCATION
Kong O I_LOCATION
. O O

Reference O B_GENE/B_BIO
library O I_GENE/I_BIO
filters O I_GENE/I_BIO
and O O
cosmids O B_LOCATION/B_BIO
identified O O
by O O
Alu O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
requested O O
from O O
the O O
Reference O B_ORGANIZATION/B_LOCATION
Library O I_ORGANIZATION/I_LOCATION
Database O I_ORGANIZATION/I_LOCATION
, O O
ICRF O B_LOCATION/B_ORGANIZATION
, O O
44 O B_PERSON/B_LOCATION
Lincoln O I_PERSON/I_LOCATION
' O O
s O B_LOCATION/B_MEASURE
Inn O I_LOCATION/I_MEASURE
Fields O I_LOCATION/I_MEASURE
, O O
London O B_LOCATION
WC2A O I_LOCATION
3PX O I_LOCATION
, O O
U O B_OTHER/B_LOCATION
. O O
K O B_OTHER/B_LOCATION
. O O

3318 O B_NUMBER[MEASURE]/B_ORGANIZATION
Nucleic O I_NUMBER[MEASURE]/I_ORGANIZATION
Acids O I_NUMBER[MEASURE]/I_ORGANIZATION
Research O I_NUMBER[MEASURE]/I_ORGANIZATION
, O O
Vol O B_LOCATION
. O O

19 O O
, O O
No O O
. O O
12 O B_NUMBER[MEASURE]

REFERENCES O B_PERSON/B_DISEASE

1 O B_NUMBER[MEASURE]
. O O

Nelson O B_PERSON
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Ledbetter O B_PERSON
, O O
S O B_LOCATION/B_DISEASE
. O O
A O B_OTHER/B_LOCATION
. O O
, O O
Corbo O B_PERSON
, O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Victoria O B_PERSON/B_LOCATION
, O O
M O B_LOCATION
. O O
F O B_OTHER/B_LOCATION
. O O
, O O
Ramirez O B_PERSON
- O O
Solis O B_PERSON
, O O

R O B_OTHER/B_PERSON
. O O
, O O
Webster O B_PERSON
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
D O B_OTHER/B_LOCATION
. O O
, O O
Ledbetter O B_PERSON
, O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
H O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Caskey O B_PERSON
, O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O
T O B_OTHER/B_PROTEIN[GENE]
. O O

( O O
1989 O B_MEASURE
) O O
Proc O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Natl O B_PERSON/B_BACTERIUM[BIO]
. O O

Acad O B_LOCATION
. O O

Sci O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

USA O B_LOCATION/B_EDU[ORGANIZATION]
, O O
86 O B_MEASURE
: O O
6686 O B_MEASURE
- O O
6690 O B_MEASURE
. O O

2 O B_NUMBER[MEASURE]
. O O

Ledbetter O B_PERSON
, O O
S O B_LOCATION/B_DISEASE
. O O
A O B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Nelson O B_PERSON
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Warren O B_PERSON
, O O
S O B_LOCATION/B_DISEASE
. O O
T O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Ledbetter O B_PERSON
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
H O B_OTHER/B_PROTEIN[GENE]
. O O

( O O
1990 O B_MEASURE
) O O

Genomics O B_MEASURE/B_ORGANIZATION
, O O
6 O B_MEASURE
: O O
475 O B_MEASURE
- O O
481 O B_MEASURE
. O O

3 O B_NUMBER[MEASURE]
. O O

Cotter O B_PERSON/B_COLOR
, O O
F O B_LOCATION/B_DISEASE
. O O
E O B_OTHER/B_LOCATION
. O O
, O O
Hampton O B_LOCATION/B_PERSON
, O O
G O B_LOCATION/B_GENE
. O O
M O B_OTHER/B_LOCATION
. O O
, O O
Nasipuri O B_PERSON/B_LOCATION
, O O
S O B_OTHER/B_LOCATION
. O O
, O O
Bodmer O B_PERSON
, O O
W O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O O
F O B_OTHER/B_LOCATION
. O O
, O O
and O O
Young O B_PERSON

B O B_MEASURE/B_DISEASE
. O O
D O B_OTHER/B_BACTERIUM[BIO]
. O O

( O O
1990 O B_MEASURE
) O O
Genomics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
7 O B_MEASURE
: O O
257 O B_MEASURE
- O O
263 O B_MEASURE
. O O

4 O B_NUMBER[MEASURE]
. O O

Burke O B_PERSON
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
T O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Carle O B_PERSON
, O O
G O B_PROTEIN[GENE]/B_LOCATION
. O O
F O B_OTHER/B_LOCATION
. O O
, O O
and O O
Olson O B_PERSON
, O O
M O B_LOCATION
. O O
V O B_OTHER/B_LOCATION
. O O

( O O
1987 O B_MEASURE
) O O
Science O B_EDU[ORGANIZATION]/B_TIME[MEASURE]
, O O
236 O B_MEASURE
: O O
806 O B_MEASURE
- O O
812 O B_MEASURE
. O O

5 O B_NUMBER[MEASURE]
. O O

Benham O B_PERSON
, O O
F O B_OTHER/B_LOCATION
. O O
, O O
Hart O B_PERSON
, O O
K O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Crolla O B_PERSON/B_LOCATION
, O O
J O B_OTHER/B_LOCATION
. O O
, O O
Bobrow O B_PERSON
, O O
M O B_LOCATION
. O O
, O O
Francavilla O B_PERSON/B_LOCATION
, O O
M O B_OTHER/B_LOCATION
. O O
, O O
and O O

Goodfellow O B_PERSON
, O O
P O B_LOCATION
. O O
N O B_OTHER/B_PERSON
. O O

( O O
1989 O B_MEASURE
) O O
Genomics O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4 O B_MEASURE
: O O
509 O B_MEASURE
- O O
517 O B_MEASURE
. O O

6 O B_NUMBER[MEASURE]
. O O

Feinberg O B_PERSON/B_COLOR
, O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
P O B_OTHER/B_LOCATION
. O O
, O O
and O O
Vogelstein O B_PERSON
, O O
B O B_OTHER/B_PERSON
. O O

( O B_OTHER/B_TIME[MEASURE]
1984 O B_MEASURE
) O O
Anal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Biochem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O
, O O
137 O B_MEASURE
: O O
266 O B_MEASURE
- O O
267 O B_MEASURE
. O O

7 O B_NUMBER[MEASURE]
. O O

Hochgeschwender O B_PERSON/B_LOCATION
, O O
U O B_OTHER/B_PERSON
. O O
, O O
Sutciffe O B_PERSON
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
G O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Brennan O B_PERSON
, O O
M O B_LOCATION
. O O
B O B_OTHER/B_LOCATION
. O O

( O O
1989 O B_MEASURE
) O O
Proc O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Natl O B_PERSON/B_BACTERIUM[BIO]
. O O

Acad O B_LOCATION
. O O

Sci O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

USA O B_LOCATION/B_EDU[ORGANIZATION]
, O O
86 O B_MEASURE
: O O
8482 O B_MEASURE
- O O
8486 O B_MEASURE
. O O

8 O B_NUMBER[MEASURE]
. O O

Lehrach O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Drmanac O B_PERSON
, O O
R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
, O O
Hoheisel O B_PERSON
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Larin O B_PERSON
, O O
Z O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Lennon O B_PERSON
, O O
G O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Monaco O B_LOCATION/B_PERSON
, O O

A O B_OTHER/B_PERSON
. O O
P O B_OTHER/B_LOCATION
. O O
, O O
Nizetic O B_PERSON
, O O
D O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Zehetner O B_PERSON
, O O
G O B_OTHER/B_LOCATION
. O O
, O O
and O O
Poustka O B_PERSON/B_LOCATION
, O O
A O B_OTHER/B_PERSON
. O O

( O O
1990 O O
) O O
In O O
Davies O B_PERSON
, O O
K O B_GENE/B_LOCATION
. O O
E O B_OTHER/B_PERSON
. O O

& O O
Tilghman O B_PERSON/B_COLOR
, O O
S O B_PROTEIN[GENE]/B_DISEASE
. O O
M O B_OTHER/B_PERSON
. O O

( O O
eds O B_PERSON/B_MEASURE
. O O
) O O
, O O
Genome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Volume O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Genetic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
and O O
Physical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Mapping O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cold O B_NUMBER[MEASURE]/B_PERSON
Spring O I_NUMBER[MEASURE]/I_PERSON
Harbor O I_NUMBER[MEASURE]/I_PERSON
Laboratory O I_NUMBER[MEASURE]/I_PERSON
Press O I_NUMBER[MEASURE]/I_PERSON
, O O
Cold O B_MEASURE/B_LOCATION
Spring O I_MEASURE/I_LOCATION
Harbor O I_MEASURE/I_LOCATION
, O O
pp O B_LOCATION
. O O

39 O O
- O O
81 O B_MEASURE
. O O

9 O B_NUMBER[MEASURE]
. O O

Nizetic O B_PERSON
, O O
D O B_OTHER/B_LOCATION
. O O
, O O
Zehetner O B_PERSON
, O O
G O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Monaco O B_LOCATION/B_PERSON
, O O
A O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
P O B_OTHER/B_LOCATION
. O O
, O O
Gellen O B_PERSON
, O O
L O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Young O B_PERSON
, O O
B O B_LOCATION/B_DISEASE
. O O
D O B_OTHER/B_LOCATION
. O O
, O O
and O O

Lehrach O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_PERSON
. O O

( O O
1991 O B_MEASURE
) O O
Proc O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Natl O B_PERSON/B_BACTERIUM[BIO]
. O O

Acad O B_LOCATION
. O O

Sci O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

USA O B_LOCATION/B_MEASURE
, O O
88 O B_MEASURE
: O O
3233 O B_MEASURE
- O O
3237 O B_MEASURE
. O O

10 O B_NUMBER[MEASURE]
. O O

Larin O B_PERSON
, O O
Z O B_OTHER/B_LOCATION
. O O
and O O
Lehrach O B_PERSON/B_LOCATION
, O O
H O B_OTHER/B_PERSON
. O O

( O O
1990 O B_MEASURE/B_LOCATION
) O O
Genet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Res O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
. O O

Camb O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O
, O O
56 O B_MEASURE
: O O
203 O B_MEASURE
- O O
208 O B_MEASURE
. O O

11 O B_NUMBER[MEASURE]
. O O

Cox O B_PERSON
, O O
D O B_OTHER/B_PERSON
, O O
R O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Pritchard O B_PERSON/B_COLOR
, O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Uglum O B_PERSON/B_LOCATION
, O O
E O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Casher O B_PERSON
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Koborl O B_PERSON/B_LOCATION
. O O

J O B_OTHER/B_MEASURE
. O O
and O O
Myers O B_PERSON/B_LOCATION
, O O

R O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O
M O B_OTHER/B_PERSON
. O O

( O O
1989 O B_MEASURE
) O O
Genomics O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4 O B_MEASURE
: O O
397 O B_MEASURE
- O O
407 O B_MEASURE
. O O

12 O B_NUMBER[MEASURE]
. O O

Wapenaar O B_PERSON/B_LOCATION
, O O
M O B_LOCATION
. O O
C O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Kievits O B_PERSON/B_LOCATION
, O O
T O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Hart O B_PERSON
, O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
A O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O
, O O
Abbs O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Blonden O B_PERSON/B_COLOR
, O O
L O B_PROTEIN[GENE]/B_LOCATION
. O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
J O B_OTHER/B_PROTEIN[GENE]
. O O
, O O

denDunnen O B_PERSON/B_LOCATION
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
T O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Grootscholten O B_PERSON
, O O
P O B_LOCATION
. O O
M O B_OTHER/B_LOCATION
. O O
, O O
Bakker O B_PERSON
, O O
E O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Verellen O B_PERSON
- O O
Dumoulin O B_PERSON/B_LOCATION
, O O
C O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Bobrow O B_PERSON
, O O
M O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
vanOmmen O B_PERSON
, O O
G O B_PROTEIN[GENE]/B_LOCATION
. O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
B O B_OTHER/B_LOCATION
. O O
, O O
and O O
Pearson O B_PERSON
, O O
P O B_LOCATION
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O

( O O
1988 O B_MEASURE
) O O
Genomics O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
2 O B_MEASURE
: O O
101 O B_MEASURE
- O O
108 O B_MEASURE
. O O

13 O B_NUMBER[MEASURE]
. O O

Royer O B_PERSON
- O O
Pokora O B_PERSON/B_LOCATION
, O O
B O B_OTHER/B_LOCATION
. O O
, O O
Kunkel O B_PERSON
, O O
L O B_PROTEIN[GENE]/B_LOCATION
. O O
M O B_OTHER/B_LOCATION
. O O
, O O
Monaco O B_LOCATION/B_PERSON
, O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
P O B_OTHER/B_LOCATION
. O O
, O O
Goff O B_PERSON
, O O
S O B_LOCATION/B_DISEASE
. O O
C O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Newburger O B_PERSON/B_LOCATION
, O O

P O B_LOCATION
. O O
E O B_OTHER/B_LOCATION
. O O
, O O
Baehner O B_PERSON/B_COLOR
, O O
R O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Cole O B_LOCATION
F O I_LOCATION
. O O
S O B_LOCATION/B_DISEASE
. O O
, O O
Curnette O B_LOCATION
J O I_LOCATION
. O O
T O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Orkin O B_PERSON/B_COLOR
, O O
S O B_LOCATION/B_DISEASE
. O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1986 O B_MEASURE
) O O
Nature O B_DISEASE/B_MEASURE
, O O
322 O B_MEASURE
: O O
32 O B_MEASURE
- O O
38 O B_MEASURE
. O O

14 O B_NUMBER[MEASURE]
. O O

Davies O B_PERSON
, O O
K O B_PROTEIN[GENE]/B_LOCATION
. O O
E O B_OTHER/B_LOCATION
. O O
, O O
Mandel O B_PERSON
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Monaco O B_LOCATION/B_PERSON
, O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
P O B_OTHER/B_LOCATION
. O O
, O O
Nussbaum O B_PERSON
, O O
R O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
and O O
Willard O B_PERSON
, O O

H O B_PROTEIN[GENE]/B_MEASURE
. O O
F O B_OTHER/B_DISEASE
. O O

( O O
1990 O B_MEASURE
) O O
Cytogenet O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Genet O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

55 O O
: O O
254 O O
- O O
313 O B_MEASURE
. O O

The O O
Caenorhabditis B B_VIRUS[BIO]/B_DISEASE
elegans I I_VIRUS[BIO]/I_DISEASE
genome O O
contains O O
monomorphic O O
minisatellites O O
and O O
simple O O
sequences O O
. O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Many O B_BIO/B_PERSON
species O I_BIO/I_PERSON
have O O
been O O
shown O O
to O O
contain O O
tandemly O O
repeated O O
short O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O O
as O O
minisatellites O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
motifs O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Due O O
to O O
allelic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
copy O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
the O O
repeat O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unit O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
these O O
loci O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
usually O O
highly O O
polymorphic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Here O O
we O O
demonstrate O O
the O O
presence O O
of O O
sequences O O
in O O
the O O
genome O O
of O O
the O O
nematode O O
Caenorhabditis B B_SPECIES[BIO]/B_GENE
elegans I I_SPECIES[BIO]/I_GENE
which O O
are O O
homologous O O
to O O
two O O
sets O O
of O O
short O O
sequence O O
DNA O O
. O O

However O O
, O O
when O O
two O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
independent O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
strains O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O O
compared O O
no O O
polymorphism O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
sequences O B_DISEASE/B_GENE
could O O
be O O
detected O O
. O O
Images O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

Volume O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
17 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Number O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1989 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Nucleic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
Caenorhabds B B_SPECIES[BIO]/B_MEASURE
elegans I I_SPECIES[BIO]/I_MEASURE
genome O O
contains O O
monomorphic O O
minisatellites O O
and O O
simple O O
sequences O O
Andrd O O
G O O
. O O
Uitterlinden O O
, O O
P O O
. O O
Eline O O
Slagboom O O
, O O
Thomas O O
E O O
. O O
Johnsonl O O
and O O
Jan O O
Vijg O O

Department O B_ORGANIZATION/B_LOCATION
of O O
Molecular O B_EDU[ORGANIZATION]/B_PERSON
Biology O I_EDU[ORGANIZATION]/I_PERSON
, O O
TNO O B_ORGANIZATION/B_LOCATION
Institute O I_ORGANIZATION/I_LOCATION
for O O
Experimental O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Gerontology O I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
PO O B_LOCATION
Box O I_LOCATION
5815 O I_LOCATION
, O O
2280 O B_LOCATION
HV O I_LOCATION
Rijswijk O I_LOCATION
, O O
The O O
Netherlands O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
lInstitute O B_LOCATION/B_PERSON
for O O
Behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Genetics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
University O B_LOCATION/B_ORGANIZATION
of O O
Colorado O B_LOCATION
, O O
Boulder O B_LOCATION/B_LANGUAGE
, O O
CO O B_LOCATION
80309 O I_LOCATION
, O O
USA O B_LOCATION/B_MEASURE

Received O O
October O B_TIME[MEASURE]
27 O I_TIME[MEASURE]
, O O
1989 O B_MEASURE
; O O
Accepted O O
November O B_TIME[MEASURE]
3 O I_TIME[MEASURE]
, O O
1989 O B_MEASURE

ABSTRACT O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Many O B_BIO/B_PERSON
species O I_BIO/I_PERSON
have O O
been O O
shown O O
to O O
contain O O
tandemly O O
repeated O O
short O B_GENE/B_LOCATION
sequence O I_GENE/I_LOCATION
DNA O I_GENE/I_LOCATION
kinown O I_GENE/I_LOCATION
as O O
minisatellites O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
motifs O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Due O O
to O O
allelic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
copy O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
the O O
repeat O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unit O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
these O O
loci O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
usually O O
highly O O
polymorphic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Here O O
we O O
demonstrate O O
the O O
presence O O
of O O
sequences O O
in O O
the O O
genome O O
of O O
the O O
nematode O O
Caenorhabditis B B_SPECIES[BIO]/B_GENE
elegans I I_SPECIES[BIO]/I_GENE
which O O
are O O
homologous O O
to O O
two O O
sets O O
of O O
short O O
sequence O O
DNA O O
. O O

However O O
, O O
when O O
two O B_PERSON/B_BIO
independent O I_PERSON/I_BIO
strains O I_PERSON/I_BIO
were O O
compared O O
no O O
polymorphism O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
sequences O B_DISEASE/B_GENE
could O O
be O O
detected O O
. O O

INTRODUCTION O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
many O B_BIO
species O I_BIO
, O O
including O O
lower O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
organisms O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
contain O O
minisatellite O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequences O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
so O O
- O O
called O O
simple O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
, O O
2 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
) O O
. O O

Due O O
to O O
extensive O B_DISEASE_ADJECTIVE[DISEASE]
variation O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
number O B_MEASURE/B_LOCATION
of O O
repeat O B_BIO/B_GENE
units O I_BIO/I_GENE
, O O
many O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
loci O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
shown O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
polymorphic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
markers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
e O B_GENE/B_DISEASE
. O O
g O B_GENE/B_MEASURE
. O O
for O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
linkage O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
identification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
purposes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Here O O
we O O
demonstrate O O
that O O
the O O
genome O O
of O O
the O O
nematode O O
Caenorhabditis B B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
elegans I I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
contains O O
sequences O O
that O O
are O O
homologous O O
to O O
the O O
minisatellite O O
core O O
sequence O O
33 O O
. O O
6 O O
( O O
1 O O
) O O
and O O
to O O
the O O
simple O O
sequence O O
motif O O
( O O
AGC O O
) O O
n O O
. O O

Surprisingly O O
, O O
these O O
sequences O O
did O O
not O O
display O O
polymorphism O O
when O O
two O O
independent O O
C B B_SPECIES[BIO]/B_LOCATION
. I I_SPECIES[BIO]/I_LOCATION
elegans I I_SPECIES[BIO]/I_LOCATION
strains O O
, O O
Bristol O O
and O O
Bergerac O O
, O O
were O O
compared O O
. O O

MATERIALS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
METHODS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Genomic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
DNA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
from O O
nematodes O B_BIO/B_DISEASE

Genomic O B_DISEASE/B_BACTERIUM[BIO]
DNA O B_DISEASE/I_BACTERIUM[BIO]
was O O
isolated O O
according O O
to O O
standard O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
procedures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
the O O
two O B_LOCATION
strains O I_LOCATION
Bergerac O I_LOCATION
( O O
BO O B_PROTEIN[GENE]/B_DISEASE
) O O
and O O
Bristol O B_LOCATION/B_BACTERIUM[BIO]
( O O
strain O B_LOCATION
N2 O I_LOCATION
) O O
. O O

These O O
strains O B_BIO
are O O
derived O O
from O O
two O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
different O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
individual O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
worms O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
isolated O O
in O O
France O B_LOCATION
and O O
England O B_LOCATION
, O O
respectively O O
. O O

Southern O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
blotting O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION

Genomic O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
digests O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Ag O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
were O O
separated O O
in O O
a O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
agarose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
gel O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
1 O B_MEASURE
x O O
TAE O B_MEASURE
( O O
40 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tris O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
HCl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pH O O
7 O B_MEASURE
. O O
4 O B_MEASURE
/ O O
20 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
I O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
NaEDTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
by O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
75 O B_MEASURE/B_LOCATION
V O I_MEASURE/I_LOCATION
for O O
16 O B_MEASURE
h O O
. O O

Separation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patterns O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
transferred O O
to O O
Zetaprobe O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
membrane O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
BIORAD O B_LOCATION/B_ORGANIZATION
) O O
in O O
0 O B_MEASURE
. O O
4 O B_MEASURE
N O I_MEASURE
NaOH O I_MEASURE
, O O
0 O B_MEASURE
. O O
6 O B_MEASURE
M O I_MEASURE
NaCl O I_MEASURE
in O O
a O O
vacu O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
- O O
blot O B_LOCATION
apparatus O I_LOCATION
( O O
LKB O B_LOCATION/B_PERSON
) O O
according O O
to O O
the O O
manufacturer O B_PERSON/B_LOCATION
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
instructions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

The O O
minisatellite O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
simple O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
probes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
used O O
were O O
prepared O O
essentially O O
as O O
described O O
( O O
5 O B_MEASURE
) O O
. O O

The O O
Tcl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
probe O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
a O O
plasmid O B_GENE
containing O O
an O O
insert O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
the O O
transposable O B_LOCATION/B_GENE
element O B_LOCATION/I_GENE
Tcl O B_LOCATION/I_GENE
( O O
4 O B_NUMBER[MEASURE]/B_BIO
) O O
. O O

All O O
probes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
labelled O O
by O O
random O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
priming O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Hybridization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
for O O
12 O B_MEASURE
h O O
in O O
7 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SDS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_MEASURE
. O O
5 O B_MEASURE
M O I_MEASURE
phosphate O I_MEASURE
buffer O I_MEASURE
, O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mM O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
Na2EDTA O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
at O O
650C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Blots O B_PERSON
were O O
washed O O
twice O O
in O O
2 O B_MEASURE
. O O
5 O B_MEASURE
x O O
SSC O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
650C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O O
exposed O O
to O O
Kodak O B_MEASURE/B_PROTEIN[GENE]
XAR O I_MEASURE/I_PROTEIN[GENE]
- O O
5 O B_MEASURE/B_ENT
film O I_MEASURE/I_ENT
with O O
intensifying O O
screens O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Exposure O B_TIME[MEASURE]/B_PERSON
times O B_TIME[MEASURE]/I_PERSON
are O O
indicated O O
in O O
Fig O B_MEASURE/B_LOCATION
. O O

1 O B_NUMBER[MEASURE]
. O O

( O O
IRL O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Press O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

Volume O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
17 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Number O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
23 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1989 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

9527 O B_NUMBER[MEASURE]

Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

C B B_PERSON/B_SPECIES[BIO]
. I I_PERSON/I_SPECIES[BIO]
elegans I I_PERSON/I_SPECIES[BIO]

N O B_LOCATION/B_MEASURE
0 O B_LOCATION/I_MEASURE
$ O O
8 O B_MEASURE

_ O B_MEASURE/B_GENE
_ O I_MEASURE/I_GENE

: O B_OTHER/B_PERSON
, O O
s O O
, O O
. O O
. O O
e O O
: O O
* O O
. O O

, O O
~ O B_OTHER/B_MEASURE
: O O
: O O
: O O
: O O
: O O

. O O
4i O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

. O O
t O O
_ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
- O O
: O O
: O O
? O O
J O B_OTHER/B_LOCATION
? O O
. O O
: O O

i O B_OTHER/B_DISEASE
- O O

. O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O

E O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
? O O
: O O
< O B_MEASURE/B_OTHER
. O O

: O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
y O O
: O O

* O B_GENE/B_MEASURE
01 O I_GENE/I_MEASURE

4 O B_MEASURE/B_LOCATION
? O O
j O O
* O O

. O B_DISEASE/B_GENE
- O O
I O O

kb O B_MEASURE/B_PERSON
- O O
27 O B_MEASURE/B_LOCATION

- O O
9A O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O

: O B_OTHER/B_MEASURE
. O O
: O O
: O O
. O O
. O O
. O O
. O O
. O O
. O O
. O O

Mi O B_LOCATION/B_PERSON
. O O
. O O
. O O
. O O

- O O
4v3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

IC O B_MEASURE/B_LOCATION
. O O
3 O B_TIME[MEASURE]/B_LOCATION

If O O
. O O
0r O B_LOCATION/B_PERSON

MW O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

! O O
5 O B_PERSON/B_MEASURE
c6 O I_PERSON/I_MEASURE

I O B_OTHER/B_PERSON

" O O
R O B_LOCATION/B_PERSON
1d O B_LOCATION/I_PERSON
~ O B_LOCATION/I_PERSON
! O O

; O B_OTHER/B_TIME[MEASURE]
, O O

Figure O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
. O O

Southern O O
hybridization O O
analysis O O
of O O
Hae O O
III O O
, O O
Rsa O O
I O O
and O O
Eco O O
RI O O
digested O O
genomic O O
DNA O O
isolated O O
from O O
the O O
two O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
strains O O
Bristol O O
( O O
N O O
) O O
and O O
Bergerac O O
( O O
B O O
) O O
. O O

The O O
probes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
used O O
and O O
the O O
exposure O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
times O B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
autoradiograph O B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
indicated O O
below O O
the O O
figure O B_PERSON/B_MEASURE
. O O

kb O B_MEASURE/B_LOCATION
= O O
kilo O B_MEASURE/B_PERSON
basepairs O I_MEASURE/I_PERSON
. O O

9528 O B_NUMBER[MEASURE]

* O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
. O O
. O O
? O O
. O O
; O O
. O O

. O B_OTHER/B_DISEASE
* O O
. O O

i O B_OTHER/B_LOCATION
. O O
. O O
. O O

: O B_OTHER/B_LOCATION
" O O
. O O

ANN O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O O

' O O
ROW O B_LOCATION/B_MEASURE
: O O
. O O
lwmwww O O
. O O

. O O
Ammkw O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O
l O B_OTHER/B_LOCATION

4w O B_SEQUENCE[MEASURE]/B_PERSON
, O O

9 O B_NUMBER[MEASURE]/B_PERSON

_ O B_OTHER/B_MEASURE
i O O
ob O O

Ill O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O

Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

In O O
Figure O O
1 O O
the O O
hybridization O O
patterns O O
are O O
shown O O
of O O
C B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
elegans I I_SPECIES[BIO]/I_PERSON
genomic O O
DNA O O
digested O O
with O O
Hae O O
II O O
, O O
Rsa O O
I O O
and O O
Eco O O
RI O O
, O O
and O O
subsequently O O
hybridized O O
to O O
minisatellite O O
core O O
probe O O
33 O O
. O O
6 O O
, O O
the O O
simple O O
sequence O O
probe O O
( O O
AGC O O
) O O
n O O
and O O
Tcl O O
. O O

The O O
latter O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
contains O O
a O O
member O B_PERSON/B_MEASURE
of O O
the O O
Tcl O B_PERSON/B_LOCATION
family O I_PERSON/I_LOCATION
of O O
transposable O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
copy O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
numbers O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
two O B_SPECIES[BIO]/B_GENE
different O B_SPECIES[BIO]/I_GENE
strains O B_SPECIES[BIO]/I_GENE
( O O
4 O B_TIME[MEASURE]/B_BIO
) O O
. O O

The O O
hybridization O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
patterns O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
probes O B_MEASURE/B_PROTEIN[GENE]
33 O I_MEASURE/I_PROTEIN[GENE]
. O O
6 O B_MEASURE
and O O
( O O
AGC O B_MEASURE
) O O
n O B_OTHER/B_MEASURE
obtained O O
after O O
Hae O B_DISEASE/B_ENZYME[GENE]
Im O B_DISEASE/I_ENZYME[GENE]
and O O
Rsa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
I O O
digestion O O
and O O
the O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
intensities O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hybridizing O O
bands O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
reminiscent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
fingerprint O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
patterns O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
obtained O O
with O O
these O O
probes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
species O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
( O O
1 O B_TIME[MEASURE]
, O O
2 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
) O O
. O O

However O O
, O O
identical O O
hybridization O O
patterns O O
for O O
the O O
two O O
strains O O
with O O
the O O
three O O
enzymes O O
tested O O
indicated O O
that O O
in O O
C B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
elegans I I_SPECIES[BIO]/I_PERSON
these O O
sequences O O
are O O
monomorphic O O
( O O
Fig O O
. O O
1 O O
) O O
. O O

Based O O
on O O
the O O
number O O
of O O
hybridizing O O
bands O O
we O O
estimate O O
the O O
C B B_SPECIES[BIO]/B_MEASURE
. I I_SPECIES[BIO]/I_MEASURE
elegans I I_SPECIES[BIO]/I_MEASURE
genome O O
to O O
contain O O
about O O
30 O O
33 O O
. O O
6 O O
homologous O O
loci O O
and O O
about O O
20 O O
( O O
AGC O O
) O O
n O O
homologous O O
loci O O
. O O

Rehybridization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
same O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
Tcl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
extensive O B_DISEASE_ADJECTIVE[DISEASE]
RFLPs O I_DISEASE_ADJECTIVE[DISEASE]
due O O
to O O
the O O
different O B_MEASURE
copy O I_MEASURE
number O I_MEASURE
of O O
the O O
transposon O B_GENE
in O O
the O O
two O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
strains O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
phenomenon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
which O O
has O O
been O O
described O O
previously O O
by O O
others O B_PERSON/B_MEASURE
( O O
4 O B_MEASURE
) O O
. O O

DISCUSSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
in O O
this O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
indicate O O
that O O
polymorphism O B_GENE/B_MEASURE
of O O
minisatellite O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequences O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sequence O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
is O O
not O O
a O O
general O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phenomenon O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
animal O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
species O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

So O O
far O O
, O O
only O O
some O O
species O B_BIO
of O O
whales O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
have O O
displayed O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
monomorphism O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
6 O B_MEASURE/B_LOCATION
) O O
. O O

In O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
species O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
thus O O
far O O
tested O O
both O O
minisatellites O B_DISEASE_ADJECTIVE[DISEASE]
and O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
display O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
to O O
very O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
polymorphism O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
should O O
be O O
noted O O
, O O
however O O
, O O
that O O
at O O
least O O
in O O
humans B B_PERSON/B_SPECIES[BIO]
, O O
a O O
substantial O O
part O O
of O O
the O O
minisatellites O O
detected O O
by O O
core O O
probes O O
also O O
displays O O
high O O
levels O O
of O O
monomorphism O O
as O O
analysed O O
by O O
cloning O O
( O O
1 O O
) O O
or O O
by O O
two O O
- O O
dimensional O O
DNA O O
fingerprinting O O
( O O
5 O O
) O O
. O O

The O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
nematodes O B_BIO/B_PERSON
are O O
hermaphrodites O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
and O O
thus O O
inbred O O
, O O
might O O
be O O
a O O
contributing O O
factor O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
observed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
polymorphism O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

However O O
, O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
polymorphism O B_GENE
detected O O
by O O
the O O
Tcl O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
do O O
not O O
indicate O O
a O O
general O B_MEASURE/B_LOCATION
absence O B_MEASURE/I_LOCATION
of O O
events O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
causing O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]
variation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Indeed O O
, O O
Eide O O
and O O
Anderson O O
( O O
7 O O
) O O
showed O O
that O O
tandemly O O
repeated O O
duplications O O
in O O
the O O
unc O O
- O O
54 O O
gene O O
of O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
revert O O
at O O
high O O
frequencies O O
. O O

Since O O
in O O
all O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
revertants O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O O
the O O
normal O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genomic O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
configuration O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O O
suggests O O
that O O
unequal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
crossing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O O
over O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
does O O
occur O O
in O O
the O O
nematode O B_BIO/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
. O O

A O O
more O O
likely O O
explanation O O
for O O
the O O
monomorphic O O
nature O O
of O O
the O O
sequences O O
detected O O
with O O
33 O O
. O O
6 O O
and O O
( O O
AGC O O
) O O
n O O
in O O
C B B_SPECIES[BIO]/B_PERSON
. I I_SPECIES[BIO]/I_PERSON
elegans I I_SPECIES[BIO]/I_PERSON
is O O
selection O O
against O O
sequence O O
variants O O
at O O
these O O
loci O O
. O O

This O O
might O O
be O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
particular O B_LOCATION/B_GENE
subset O I_LOCATION/I_GENE
of O O
minisatellites O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
/ O O
or O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
at O O
sites O B_LOCATION/B_MEASURE
in O O
the O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
organism O B_BIO/B_GENE
, O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
in O O
coding O B_BIO/B_GENE
sequences O I_BIO/I_GENE
, O O
in O O
which O O
variation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
copy O B_MEASURE
number O I_MEASURE
of O O
repeat O B_GENE/B_MEASURE
units O I_GENE/I_MEASURE
cannot O I_GENE/I_MEASURE
be O O
tolerated O O
. O O

An O O
example O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
such O O
a O O
coding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
the O O
High O B_GENE/B_BIO
Mobility O I_GENE/I_BIO
Group O I_GENE/I_BIO
proteins O I_GENE/I_BIO
which O O
usually O O
have O O
stretches O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
identical O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
acidic O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
amino O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
acids O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
2 O B_MEASURE
, O O
8 O B_MEASURE
) O O
. O O

An O O
interesting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
this O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
the O O
demonstration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
absence O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
any O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
electrophoretic O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparisons O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
24 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
enzymes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
the O O
Bristol O B_LOCATION/B_PERSON
and O O
Bergerac O B_LOCATION/B_PERSON
strains O I_LOCATION/I_PERSON
( O O
9 O B_MEASURE
) O O
. O O

An O O
important O O
step O O
in O O
understanding O O
this O O
phenomenon O O
will O O
therefore O O
be O O
the O O
isolation O O
and O O
analysis O O
of O O
individual O O
homologous O O
minisatellite O O
and O O
simple O O
sequence O O
loci O O
from O O
a O O
genomic O O
library O O
of O O
C B B_SPECIES[BIO]
. I I_SPECIES[BIO]
elegans I I_SPECIES[BIO]
. O O

REFERENCES O B_PERSON/B_DISEASE

1 O B_NUMBER[MEASURE]
. O O

Jeffreys O B_PERSON/B_COLOR
, O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
J O B_OTHER/B_LOCATION
. O O
, O O
Wilson O B_PERSON
, O O
V O B_LOCATION
. O O
, O O
and O O
Thein O B_PERSON/B_COLOR
, O O
S O B_LOCATION/B_DISEASE
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O

( O O
1985 O B_MEASURE
) O O
Nature O B_MEASURE/B_ORGANIZATION
314 O I_MEASURE/I_ORGANIZATION
, O O
67 O B_MEASURE
- O O
73 O B_MEASURE
. O O

2 O B_NUMBER[MEASURE]
. O O

Tautz O B_PERSON/B_COLOR
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
Trick O B_PERSON/B_MEASURE
M O I_PERSON/I_MEASURE
. O O
, O O
and O O
Dover O B_LOCATION/B_PERSON
, O O
G O B_PROTEIN[GENE]/B_LOCATION
. O O
A O B_OTHER/B_MEASURE
. O O

( O O
1986 O B_MEASURE
) O O
Nature O B_MEASURE/B_LOCATION
322 O I_MEASURE/I_LOCATION
, O O
652 O B_MEASURE
- O O
656 O B_MEASURE
. O O

3 O B_NUMBER[MEASURE]
. O O

Rogstad O B_PERSON/B_LOCATION
, O O
S O B_OTHER/B_PERSON
. O O
H O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Herwaldt O B_PERSON
, O O
B O B_LOCATION/B_DISEASE
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
Schlesinger O B_PERSON
, O O
P O B_PROTEIN[GENE]/B_LOCATION
. O O
H O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Krogstad O B_PERSON/B_LOCATION
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
J O B_OTHER/B_PROTEIN[GENE]
. O O

( O O
1989 O O
) O O
Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Res O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

17 O B_MEASURE
, O O
9 O B_MEASURE
, O O
3610 O B_NUMBER[MEASURE]
. O O

4 O B_NUMBER[MEASURE]
. O O

Emmons O B_PERSON
, O O
S O B_LOCATION/B_DISEASE
. O O
W O B_OTHER/B_LOCATION
. O O
, O O
Yesner O B_PERSON/B_COLOR
, O O
L O B_PROTEIN[GENE]/B_LOCATION
. O O
, O O
Ruan O B_PERSON
, O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
and O O
Katzenberg O B_PERSON
, O O
D O B_OTHER/B_PERSON
. O O

( O O
1983 O O
) O O
Cell O B_MEASURE
32 O I_MEASURE
, O O
55 O B_MEASURE
- O O
65 O B_MEASURE
. O O

9529 O B_NUMBER[MEASURE]

Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION

5 O B_NUMBER[MEASURE]
. O O

Uitterlinden O B_PERSON/B_LOCATION
, O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O
G O B_OTHER/B_LOCATION
. O O
, O O
Slagboom O B_PERSON
, O O
P O B_LOCATION
. O O
E O B_OTHER/B_LOCATION
. O O
, O O
Knook O B_PERSON
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
L O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Vijg O B_PERSON/B_COLOR
, O O
J O B_OTHER/B_PERSON
. O O

( O O
1989 O B_MEASURE
) O O
Proc O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Natl O B_PERSON/B_BACTERIUM[BIO]
. O O

Acad O B_LOCATION
. O O

USA O B_MEASURE/B_LOCATION
86 O I_MEASURE/I_LOCATION
, O O
2742 O B_MEASURE
- O O
2746 O B_MEASURE
. O O

6 O B_NUMBER[MEASURE]
. O O

Rus O B_PERSON
Hoelzel O I_PERSON
, O O
A O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
and O O
Amos O B_PERSON
, O O
W O B_OTHER/B_PERSON
. O O

( O O
1988 O B_MEASURE
) O O
Nature O B_MEASURE/B_LOCATION
333 O I_MEASURE/I_LOCATION
, O O
305 O B_MEASURE/B_LOCATION
. O O

7 O B_NUMBER[MEASURE]
. O O

Eide O B_PERSON/B_COLOR
, O O
D O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
, O O
and O O
Anderson O B_PERSON/B_COLOR
, O O
P O B_OTHER/B_PERSON
. O O

( O O
1985 O B_MEASURE
) O O
Genetics O B_MEASURE
109 O I_MEASURE
, O O
67 O B_MEASURE
- O O
79 O B_MEASURE
. O O

8 O B_NUMBER[MEASURE]
. O O

Pentecost O B_PERSON/B_LOCATION
, O O
B O B_PROTEIN[GENE]/B_LOCATION
. O O
T O B_OTHER/B_PERSON
. O O
, O O
Wright O B_PERSON/B_COLOR
, O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
M O B_OTHER/B_PROTEIN[GENE]
. O O
, O O
and O O
Dixon O B_PERSON/B_ORGANIZATION
, O O
G O B_PROTEIN[GENE]/B_LOCATION
. O O
H O B_OTHER/B_PROTEIN[GENE]
. O O

( O O
1985 O O
) O O
Nucleic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Acids O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Res O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

13 O B_MEASURE
, O O
4871 O B_MEASURE
- O O
4888 O B_MEASURE
. O O

9 O B_NUMBER[MEASURE]
. O O

Butler O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

( O O
1981 O B_MEASURE
) O O
J O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Molec O B_PERSON/B_DISEASE
. O O

Evolution O B_MEASURE
18 O I_MEASURE
, O O
18 O B_MEASURE
- O O
23 O B_MEASURE
. O O

9530 O B_NUMBER[MEASURE]

This O O
article O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
submitted O O
on O O
disc O B_ENT/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
has O O
been O O
automatically O O

converted O O
into O O
this O O
typeset O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
format O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
the O O
publisher O B_PERSON/B_ORGANIZATION
. O O

How O O
can O O
Health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
be O O
made O O
more O O
useful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
intervention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
? O O

Abstract O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
paper O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
expresses O O
the O O
author O B_PERSON/B_ORGANIZATION
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
views O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
about O O
the O O
practical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
utility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
Health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
intervention O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
views O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
skeptical O B_DISEASE_ADJECTIVE[DISEASE]
and O O
perhaps O O
even O O
a O O
bit O B_PERSON/B_DISEASE
exaggerated O I_PERSON/I_DISEASE
. O O

They O O
are O O
, O O
however O O
, O O
also O O
based O O
on O O
20 O B_NUMBER[MEASURE]
- O O
plus O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
in O O
- O O
the O O
- O O
trenches O B_LOCATION/B_ORGANIZATION
research O I_LOCATION/I_ORGANIZATION
focused O O
on O O
improving O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
practice O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
through O O
research O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
author O B_PERSON/B_ORGANIZATION
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
has O O
been O O
theoretically O O
driven O O
and O O
has O O
involved O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
varying O O
variables O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
considered O O
to O O
be O O
important O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theoretical O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediators O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
moderators O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
health O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Regretfully O O
, O O
much O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
work O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O O
found O O
these O O
variables O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wanting O O
in O O
basic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
scientific O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
merit O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
Behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
Theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
as O O
we O O
have O O
known O O
it O O
over O O
the O O
last O B_TIME[MEASURE]/B_ENT
25 O I_TIME[MEASURE]/I_ENT
years O I_TIME[MEASURE]/I_ENT
or O O
so O O
has O O
been O O
dominated O O
by O O
conceptualizations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
behavior O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
change O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
processes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
highlight O O
cognitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
decision O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
- O O
making O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
much O O
of O O
health O O
behavior O O
practice O O
targets O O
what O O
people B B_PERSON
do O O
rather O O
than O O
what O O
they O O
think O O
, O O
the O O
logic O O
of O O
focusing O O
on O O
thoughts O O
is O O
that O O
what O O
people B B_PERSON
think O O
about O O
is O O
the O O
key O O
to O O
what O O
they O O
will O O
do O O
in O O
the O O
future O O
, O O
and O O
that O O
interventions O O
that O O
can O O
measure O O
and O O
harness O O
those O O
processes O O
will O O
succeed O O
to O O
a O O
greater O O
extent O O
than O O
those O O
that O O
do O O
not O O
. O O

Unfortunately O O
, O O
in O O
the O O
author O B_PERSON/B_LOCATION
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
premise O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cognitive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theories O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
fallen O O
short O B_PERSON/B_MEASURE
empirically O O
in O O
a O O
number O B_MEASURE/B_PERSON
of O O
ways O B_LOCATION/B_LANGUAGE
. O O

The O O
cognitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
schemata O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
favored O O
by O O
most O B_PERSON
health O I_PERSON
behavior O I_PERSON
theories O I_PERSON
are O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
measure O O
, O O
they O O
do O O
not O O
predict O O
behavioral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcomes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
very O O
well O O
, O O
there O O
is O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
they O O
cause O O
behavior O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
they O O
are O O
hard O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
change O O
directly O O
. O O

Summary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

It O O
is O O
suggested O O
that O O
health O B_PERSON/B_ORGANIZATION
behavior O I_PERSON/I_ORGANIZATION
researchers O I_PERSON/I_ORGANIZATION
reconsider O O
their O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
these O O
theories O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
favor O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
models O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whose O O
variables O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
more O O
accessible O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manipulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
most O O
importantly O O
have O O
strong O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
empirical O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
support O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Background O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
author O B_PERSON/B_LOCATION
has O O
been O O
conducting O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O O
behavioral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
obesity O B_DISEASE
for O O
about O O
25 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
. O O

During O O
that O O
time O B_TIME[MEASURE]/B_LOCATION
, O O
the O O
dominant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
conceptual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
guiding O O
intervention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
development O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O O
been O O
cognitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
have O O
their O O
origin O B_TIME[MEASURE]/B_DISEASE
in O O
psychological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O O

Those O O
most O O
often O O
cited O O
include O O
the O O
Health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
Belief O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
Model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
[ O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
] O I_SEQUENCE[MEASURE]/I_LOCATION
, O O
Protection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
Motivation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
Theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
[ O O
2 O B_NUMBER[MEASURE]/B_LOCATION
] O I_NUMBER[MEASURE]/I_LOCATION
, O O
Subjective O B_DISEASE/B_LOCATION
Expected O O
Utility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O O
3 O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
] O I_SEQUENCE[MEASURE]/I_PROTEIN[GENE]
, O O
the O O
Theory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Reasoned O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Action O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
4 O B_SEQUENCE[MEASURE]
] O I_SEQUENCE[MEASURE]
, O O
Social O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
Cognitive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
Theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
[ O O
5 O B_NUMBER[MEASURE]
] O I_NUMBER[MEASURE]
, O O
and O O
the O O
Transtheoretical O B_ORGANIZATION/B_LOCATION
Model O I_ORGANIZATION/I_LOCATION
[ O O
6 O B_MEASURE
] O I_MEASURE
. O O

All O O
of O O
these O O
theories O O
are O O
concerned O O
with O O
how O O
people B B_PERSON/B_BIO
make O O
behavioral O O
choices O O
and O O
the O O
general O O
idea O O
is O O
that O O
people B B_PERSON
decide O O
what O O
to O O
do O O
based O O
on O O
the O O
extent O O
to O O
which O O
they O O
expect O O
that O O
their O O
choices O O
will O O
produce O O
results O O
that O O
they O O
value O O
. O O

Much O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
content O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
theories O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
concerned O O
with O O
factors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O O
may O O
affect O O
value O B_MEASURE/B_DISEASE
/ O O
expectancy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calculations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

As O O
summarized O O
by O O
Weinstein O B_PERSON
in O O
a O O
comparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
four O B_MEASURE
social O I_MEASURE
psychological O I_MEASURE
theories O I_MEASURE
[ O O
7 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
, O O
variables O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thought O O
to O O
influence O O
value O B_TIME[MEASURE]/B_PERSON
/ O O
expectancy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
judgments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
include O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
perceived O O
rewards O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
current O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
self O B_PERSON/B_LOCATION
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
normative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beliefs O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
motivation O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
perceived O O
consequences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
not O O
changing O O
behavior O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Weinstein O O
' O O
s O O
summary O O
is O O
illustrative O O
of O O
the O O
fact O O
that O O
Health O O
Behavior O O
Theory O O
has O O
tended O O
to O O
be O O
particularly O O
interested O O
in O O
understanding O O
people B B_PERSON
' O O
s O O
motivation O O
to O O
change O O
behavior O O
rather O O
than O O
ability O O
to O O
change O O
. O O

Moreover O O
, O O
motivation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
thought O O
to O O
be O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
a O O
relatively O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
logical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
interpretation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
large O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quantities O B_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
information O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O O
self O B_PERSON/B_LOCATION
and O O
environment O B_LOCATION/B_PERSON
. O O

The O O
theories O O
that O O
Weinstein O O
reviewed O O
deal O O
almost O O
exclusively O O
with O O
behavioral O O
decision O O
processes O O
in O O
people B B_PERSON
' O O
s O O
minds O O
. O O

They O O
have O O
few O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O O
any O O
terms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
relating O O
to O O
how O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
gets O O
into O O
peoples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
minds O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
how O O
subsets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
it O O
receive O O
more O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
less O B_MEASURE
attention O I_MEASURE
. O O

Broader O O
health O O
behavior O O
theories O O
such O O
as O O
Social O O
Cognitive O O
Theory O O
or O O
the O O
Transtheoretical O O
model O O
have O O
addressed O O
issues O O
and O O
variables O O
outside O O
the O O
person B B_PERSON
to O O
a O O
greater O O
extent O O
, O O
but O O
the O O
fundamental O O
interest O O
in O O
and O O
belief O O
in O O
psychological O O
variables O O
as O O
the O O
key O O
force O O
in O O
determining O O
health O O
behavior O O
remains O O
. O O

The O O
implications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
focus O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
psychological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
determinants O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
behavioral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
decision O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
- O O
making O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
my O O
own O B_LOCATION/B_PERSON
research O I_LOCATION/I_PERSON
area O I_LOCATION/I_PERSON
of O O
interest O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
obesity O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
are O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

One O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
is O O
the O O
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
psychological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
most O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
protocols O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
e O O
. O O
g O B_PROTEIN[GENE]/B_MEASURE
. O O
, O O
assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
behavioral O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intentions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
self O B_PERSON/B_LOCATION
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
perception O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
barriers O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
change O O
, O O
perception O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
social O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MENTAL_OR_BEHAVIORAL_DYSFUNCTION[DISEASE]
expectations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MENTAL_OR_BEHAVIORAL_DYSFUNCTION[DISEASE]
) O O
. O O

A O O
second O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
the O O
inclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
elements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
specifically O O
target O O
psychological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perceptions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
processes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
independent O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
diet O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
physical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
behaviors O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
actually O O
produce O O
weight O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
e O O
. O O
g O B_GENE/B_MEASURE
. O O
, O O
how O O
to O O
deal O O
with O O
emotional O B_DISEASE_ADJECTIVE[DISEASE]
eating O I_DISEASE_ADJECTIVE[DISEASE]
, O O
how O O
to O O
deal O O
with O O
the O O
frustration O B_DISEASE_ADJECTIVE[DISEASE]
of O O
lapses O B_DISEASE
and O O
relapses O B_DISEASE
, O O
and O O
how O O
to O O
talk O O
to O O
yourself O O
to O O
increase O O
self O B_PERSON/B_DISEASE
- O O
motivation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
) O O
. O O

A O O
third O B_SEQUENCE[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
belief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_RELIGION[SOCIAL_CIRCUMSTANCES]
that O O
psychological O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
treatment O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiences O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
themselves O O
are O O
very O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
deserve O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attention O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Common O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behavioral O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
prescriptions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
frequency O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
self O B_PERSON/B_LOCATION
- O O
weighing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
exemplary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
i O O
. O O
e O O
. O O
, O O
recommending O O
infrequent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
weighing O O
to O O
prevent O O
discouraging O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feedback O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
progress O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
encouraging O O
smaller O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
thus O O
" O O
more O O
attainable O B_DISEASE_ADJECTIVE[DISEASE]
" O I_DISEASE_ADJECTIVE[DISEASE]
behavior O I_DISEASE_ADJECTIVE[DISEASE]
and O O
weight O B_MEASURE/B_LOCATION
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
belief O B_RELIGION[SOCIAL_CIRCUMSTANCES]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
they O O
will O O
be O O
more O O
motivating O O
) O O
. O O

The O O
problem O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
emphasis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
on O O
cognitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
weight O B_MEASURE/B_PERSON
- O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
that O O
they O O
have O O
so O O
far O O
failed O O
to O O
meet O O
fundamental O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scientific O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
empirical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
verification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Thus O O
, O O
they O O
also O O
have O O
not O O
led O O
to O O
a O O
better O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
understanding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
have O O
not O O
improved O O
our O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
predict O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
have O O
not O O
led O O
to O O
improvement O B_DISEASE_ADJECTIVE[DISEASE]
in O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
methods O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O O

In O O
some O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
it O O
is O O
even O O
arguable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
they O O
have O O
made O O
treatment O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
worse O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

I O O
will O O
illustrate O O
these O O
problems O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
my O O
own O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Discussion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Like O O
most O B_PERSON
behavioral O I_PERSON
researchers O I_PERSON
in O O
the O O
obesity O B_LOCATION
area O I_LOCATION
, O O
I O O
have O O
attempted O O
to O O
measure O O
elements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
every O O
obesity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intervention O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
project O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
have O O
ever O O
conducted O O
. O O

I O O
have O O
assessed O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
behavioral O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
self O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
psychological O B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
well O O
- O O
being O O
, O O
perceived O O
barriers O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
diet O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
physical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
activity O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
change O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
stages O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
of O O
- O O
change O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
perceived O O
social O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

How O O
well O O
have O O
empirical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
examinations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
of O O
these O O
factors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
fared O O
as O O
predictors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
success O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
weight O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
control O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
? O O

Self O B_PERSON/B_LOCATION
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]

We O O
have O O
examined O O
the O O
predictive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
value O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
self O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
assessments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
several O B_NUMBER[MEASURE]
of O O
our O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
describe O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
three O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
here O O
in O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detail O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O O
8 O B_MEASURE
- O O
10 O B_MEASURE/B_LOCATION
] O I_MEASURE/I_LOCATION
. O O

In O O
the O O
first O O
study O O
, O O
self O O
- O O
efficacy O O
was O O
assessed O O
at O O
baseline O O
, O O
posttreatment O O
, O O
and O O
one O O
year O O
later O O
in O O
85 O O
men B B_PERSON
participating O O
in O O
a O O
15 O O
- O O
week O O
weight O O
- O O
loss O O
program O O
[ O O
8 O O
] O O
. O O

The O O
self O B_PERSON/B_MEASURE
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
instrument O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
had O O
subscales O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
emotional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
states O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
e O B_OTHER/B_PROTEIN[GENE]
. O O
g O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O
, O O
anxiety O B_DISEASE/B_PERSON
) O O
and O O
situations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
e O B_PROTEIN[GENE]/B_DISEASE
. O O
g O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O
, O O
eating O O
away O O
from O O
home O B_LOCATION/B_PERSON
) O O
. O O

Higher O B_MEASURE/B_LOCATION
baseline O B_MEASURE/I_LOCATION
self O B_MEASURE/I_LOCATION
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
on O O
both O O
subscales O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
associated O O
with O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
weight O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
loss O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
and O O
at O O
1 O B_NUMBER[MEASURE]
- O O
and O O
2 O B_NUMBER[MEASURE]
- O O
year O B_MEASURE/B_LOCATION
follow O I_MEASURE/I_LOCATION
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Emotional O B_LOCATION/B_DISEASE
self O I_LOCATION/I_DISEASE
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
at O O
posttreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
did O O
not O O
predict O O
weight O B_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
at O O
1 O B_SEQUENCE[MEASURE]
- O O
or O O
2 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
follow O I_TIME[MEASURE]/I_LOCATION
- O O
up O B_LOCATION/B_LANGUAGE
. O O

Situational O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
self O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
posttreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
predicted O O
weight O B_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
at O O
1 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
but O O
not O O
2 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
follow O I_TIME[MEASURE]/I_LOCATION
- O O
up O B_LOCATION/B_LANGUAGE
. O O

The O O
second O O
study O O
examined O O
mood O O
and O O
situational O O
self O O
- O O
efficacy O O
in O O
55 O O
men B B_PERSON
and O O
58 O O
women B B_PERSON/B_BIO
before O O
and O O
after O O
a O O
16 O O
- O O
week O O
weight O O
- O O
loss O O
treatment O O
with O O
a O O
1 O O
- O O
year O O
follow O O
- O O
up O O
[ O O
9 O O
] O O
. O O

Women B B_PERSON/B_BIO
had O O
lower O O
pretreatment O O
self O O
- O O
efficacy O O
than O O
men B B_PERSON
. O O

Self O O
- O O
efficacy O O
was O O
predictive O O
of O O
weight O O
loss O O
and O O
maintenance O O
in O O
men B B_PERSON/B_BIO
but O O
not O O
in O O
women B B_PERSON/B_BIO
. O O

Change O O
in O O
self O O
- O O
efficacy O O
over O O
time O O
was O O
positively O O
related O O
to O O
weight O O
change O O
in O O
women B B_PERSON/B_BIO
but O O
not O O
in O O
men B B_PERSON/B_BIO
. O O

The O O
third O O
study O O
examined O O
predictors O O
of O O
weight O O
change O O
over O O
a O O
2 O O
- O O
year O O
period O O
in O O
460 O O
men B B_PERSON
and O O
1172 O O
women B B_PERSON/B_BIO
who O O
received O O
a O O
low O O
- O O
intensity O O
weight O O
- O O
loss O O
intervention O O
delivered O O
through O O
their O O
HMO O O
[ O O
10 O O
] O O
. O O

The O O
self O B_PERSON/B_MEASURE
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
the O O
WEL O B_SEQUENCE[MEASURE]/B_LOCATION
questionnaire O I_SEQUENCE[MEASURE]/I_LOCATION
. O O

Men B B_PERSON
again O O
were O O
found O O
to O O
have O O
higher O O
baseline O O
self O O
- O O
efficacy O O
than O O
women B B_PERSON/B_BIO
. O O

Self O O
- O O
efficacy O O
did O O
not O O
predict O O
weight O O
change O O
in O O
men B B_PERSON/B_BIO
but O O
was O O
positively O O
, O O
though O O
weakly O O
, O O
related O O
to O O
weight O O
change O O
at O O
6 O O
months O O
only O O
in O O
women B B_PERSON
. O O

Our O O
overall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
conclusion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
the O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O O
above O O
, O O
as O O
well O O
as O O
others O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O O
pursued O O
in O O
as O O
great O B_MEASURE/B_LOCATION
detail O I_MEASURE/I_LOCATION
, O O
is O O
that O O
self O B_PERSON/B_MEASURE
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
a O O
weak O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
predictor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
weight O B_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
and O O
is O O
inconsistent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
populations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
gender O B_PERSON/B_LOCATION
. O O

It O O
tends O O
to O O
increase O O
with O O
weight O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
loss O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
efficacy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
not O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
longer O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_TIME[MEASURE]/B_LOCATION
weight O I_TIME[MEASURE]/I_LOCATION
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Barriers O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
Adherence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION

We O O
have O O
also O O
attempted O O
to O O
measure O O
barriers O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
adherence O O
to O O
weight O B_DISEASE
- O O
control O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behaviors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
many O B_NUMBER[MEASURE]
of O O
our O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O O
11 O B_MEASURE
- O O
14 O B_MEASURE
] O I_MEASURE
. O O

The O O
instruments O O
used O O
for O O
this O O
have O O
typically O O
been O O
formatted O O
similarly O O
to O O
efficacy O O
questionnaires O O
in O O
that O O
people B B_PERSON
are O O
asked O O
to O O
indicate O O
how O O
difficult O O
they O O
find O O
situational O O
, O O
knowledge O O
, O O
and O O
motivational O O
challenges O O
to O O
achieving O O
diet O O
and O O
exercise O O
changes O O
. O O

The O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
been O O
quite O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

Baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
perceived O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
barriers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
behavior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
change O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
are O O
not O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
weight O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
change O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Weight O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
associated O O
with O O
reported O O
decreases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
perceived O O
barriers O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
- O O
induced O O
change O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
perceived O O
barriers O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
weight O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
change O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
words O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
barrier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perceptions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
we O O
have O O
measured O O
them O O
do O O
not O O
appear O O
to O O
have O O
pragmatic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Weight O B_MEASURE
Goals O I_MEASURE

Goal O O
- O O
setting O O
has O O
long O O
been O O
of O O
interest O O
to O O
health O O
behavior O O
theory O O
and O O
in O O
recent O O
years O O
has O O
attracted O O
attention O O
in O O
weight O O
- O O
loss O O
research O O
when O O
it O O
was O O
realized O O
that O O
most O O
people B B_PERSON
who O O
enter O O
weight O O
- O O
loss O O
treatments O O
want O O
to O O
lose O O
a O O
lot O O
more O O
weight O O
than O O
is O O
realistic O O
given O O
the O O
potency O O
of O O
current O O
weight O O
- O O
loss O O
methodologies O O
[ O O
15 O O
] O O
. O O

When O O
asked O O
to O O
describe O O
weight O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
losses O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
they O O
deem O O
to O O
represent O O
" O O
dream O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
happy O B_DISEASE_ADJECTIVE[DISEASE]
, O O
acceptable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
disappointing O B_DISEASE_ADJECTIVE[DISEASE]
, O O
" O O
many O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
individuals O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
fail O O
to O O
reach O O
even O O
" O O
disappointing O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
" O O
weight O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
losses O I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O O
though O O
in O O
objective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
medical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
terms O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
the O O
results O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Based O O
on O O
the O O
argument O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
failure O B_DISEASE
to O O
reach O O
gratifying O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
goals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
leads O O
to O O
psychological O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
distress O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O O
lowers O O
weight O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
self O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
undermines O O
weight O B_MEASURE/B_LOCATION
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efforts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
has O O
become O O
popular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
recommend O O
counseling O O
in O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
specifically O O
targeting O O
the O O
lowering O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
theoretical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
argument O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
that O O
excessive O B_PERSON
outcome O I_PERSON
expectations O I_PERSON
undermine O O
behavioral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

We O O
have O O
now O O
completed O O
three O B_MEASURE/B_ENT
sets O I_MEASURE/I_ENT
of O O
formal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examining O O
whether O O
weight O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
weight O B_MEASURE/B_LOCATION
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
one O O
of O O
these O O
analyses O O
the O O
relationship O O
between O O
weight O O
- O O
loss O O
goals O O
, O O
weight O O
- O O
loss O O
goal O O
attainment O O
, O O
and O O
long O O
- O O
term O O
( O O
30 O O
months O O
) O O
weight O O
- O O
loss O O
attainment O O
and O O
psychological O O
well O O
- O O
being O O
were O O
assessed O O
in O O
69 O O
men B B_PERSON
and O O
61 O O
women B B_PERSON/B_BIO
participating O O
in O O
an O O
intensive O O
behavioral O O
treatment O O
program O O
[ O O
16 O O
] O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicated O O
that O O
weight O B_MEASURE/B_PERSON
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
goals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
unrealistically O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
on O O
average O B_MEASURE/B_PERSON
and O O
that O O
lower O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goals O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
more O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
reached O O
. O O

Nevertheless O O
, O O
weight O B_MEASURE/B_LOCATION
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
predict O O
either O O
short O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
or O O
long O B_MEASURE/B_LOCATION
- O O
term O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
weight O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
losses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
were O O
not O O
associated O O
with O O
elevated O B_DISEASE_ADJECTIVE[DISEASE]
psychological O I_DISEASE_ADJECTIVE[DISEASE]
distress O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O B_NUMBER[MEASURE]/B_LOCATION
more O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
have O O
conducted O O
looking O O
at O O
weight O B_MEASURE/B_PERSON
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
predictors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
success O B_DISEASE
have O O
produced O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
Linde O B_PERSON/B_LOCATION
JA O I_PERSON/I_LOCATION
, O O
Jeffery O B_PERSON/B_LOCATION
RW O I_PERSON/I_LOCATION
, O O
Levy O B_LOCATION/B_PERSON
RL O I_LOCATION/I_PERSON
, O O
Pronk O B_LOCATION
NP O I_LOCATION
and O O
Boyle O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RG O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
unpublished O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
17 O B_TIME[MEASURE]
] O O
] O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Weight O B_MEASURE/B_PERSON
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
goals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
either O O
did O O
not O O
predict O O
weight O B_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
at O O
all O O
or O O
were O O
slightly O O
positively O O
related O O
to O O
weight O B_MEASURE/B_BIO
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Perceived O O
Social O B_DISEASE_ADJECTIVE[DISEASE]
Support O I_DISEASE_ADJECTIVE[DISEASE]

Perceived O O
social O B_DISEASE_ADJECTIVE[DISEASE]
support O I_DISEASE_ADJECTIVE[DISEASE]
is O O
another O O
psychological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
thought O O
to O O
influence O O
health O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
decision O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
- O O
making O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
measured O O
social O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
support O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
a O O
variety O B_ENT/B_MEASURE
of O O
ways O B_LOCATION/B_LANGUAGE
in O O
our O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
ranging O O
from O O
single O B_NUMBER[MEASURE]
- O O
item O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
questions O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
multipaged O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
attempting O O
to O O
differentiate O O
among O O
informational O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
instrumental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
, O O
and O O
emotional O B_PERSON/B_EDU[ORGANIZATION]
support O I_PERSON/I_EDU[ORGANIZATION]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
unfortunately O O
, O O
have O O
closely O O
paralleled O O
those O O
we O O
have O O
seen O O
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
barriers O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
adherence O O
. O O

Assessments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
social O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
prior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
do O O
not O O
predict O O
weight O B_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Average O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
social O B_DISEASE
support O I_DISEASE
tend O O
to O O
parallel O O
weight O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O O
. O O

When O O
people B B_PERSON/B_BIO
lose O O
weight O O
they O O
report O O
more O O
social O O
support O O
. O O

When O O
they O O
regain O O
, O O
they O O
report O O
less O B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
words O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
perceptions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
social O B_DISEASE
support O I_DISEASE
are O O
not O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
success O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
weight O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Frequency O B_MEASURE/B_PERSON
Weight O B_MEASURE/I_PERSON
Self O B_MEASURE/I_PERSON
- O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Self O O
- O O
monitoring O O
of O O
health O O
behavior O O
is O O
incorporated O O
into O O
many O O
health O O
behavior O O
theories O O
, O O
usually O O
as O O
part O O
of O O
a O O
person B B_PERSON/B_ORGANIZATION
' O O
s O O
assessment O O
of O O
achieved O O
outcomes O O
. O O

Although O O
self O B_PERSON/B_LOCATION
- O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
usually O O
considered O O
a O O
positive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
element O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
adoption O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
health O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
behavior O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
in O O
obesity O B_PERSON/B_LOCATION
treatment O I_PERSON/I_LOCATION
frequent O I_PERSON/I_LOCATION
self O I_PERSON/I_LOCATION
- O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
weight O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
tended O O
to O O
be O O
down O O
- O O
played O O
or O O
even O O
discouraged O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
grounds O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
disappointing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
i O O
. O O
e O O
. O O
, O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
desired O B_MEASURE
weight O I_MEASURE
change O I_MEASURE
) O O
may O O
undermine O O
motivation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
is O O
another O O
example O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
which O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behavior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
theory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O O
have O O
indirectly O O
led O O
to O O
incorrect O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recommendations O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
active O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
discouragement O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
frequent O B_PERSON/B_LOCATION
self O I_PERSON/I_LOCATION
- O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
weight O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
become O O
popular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
the O O
premise O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
more O O
frequent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
weighting O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
will O O
cause O O
psychological O B_DISEASE/B_MEASURE
stress O I_DISEASE/I_MEASURE
and O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
self O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Recently O O
, O O
we O O
have O O
examined O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
frequency O B_MEASURE
of O O
self O B_PERSON/B_LOCATION
- O O
weighing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
body O B_MEASURE/B_DISEASE
weight O I_MEASURE/I_DISEASE
in O O
both O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
population O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
have O O
found O O
, O O
somewhat O O
to O O
our O O
surprise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
that O O
frequency O B_MEASURE
of O O
self O B_PERSON/B_LOCATION
- O O
weighing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
strongest O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
single O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
predictors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
body O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weight O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cross O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
sectionally O O
, O O
and O O
change O B_MEASURE
in O O
the O O
frequency O B_MEASURE
of O O
self O B_PERSON/B_LOCATION
- O O
weighing O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
strongest O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
predictors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
weight O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
Linde O B_PERSON
JA O I_PERSON
, O O
Jeffery O B_TIME[MEASURE]/B_PERSON
RW O I_TIME[MEASURE]/I_PERSON
and O O
French O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SA O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
unpublished O B_MEASURE/B_LOCATION
data O I_MEASURE/I_LOCATION
] O I_MEASURE/I_LOCATION
. O O

The O O
direction O B_MEASURE
of O O
predictions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
is O O
opposite O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
derived O O
from O O
theory O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

People B B_PERSON/B_BIO
who O O
weigh O O
themselves O O
more O O
weigh O O
less O O
and O O
are O O
more O O
successful O O
in O O
losing O O
weight O O
. O O

Stage O B_ENT/B_TIME[MEASURE]
- O O
of O O
- O O
Change O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

A O O
final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
failure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prove O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
weight O B_MEASURE/B_PERSON
- O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
a O O
stage O B_ENT/B_MEASURE
- O O
of O O
- O O
change O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
adopted O O
from O O
Prochaska O B_PERSON/B_BIO
and O O
short O B_MEASURE
- O O
and O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
18 O B_GENE/B_LOCATION
] O B_GENE/I_LOCATION
. O O

Categories O B_ORGANIZATION/B_TIME[MEASURE]
of O O
precontemplation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
contemplation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
preparation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
defined O O
based O O
on O O
questions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O O
weight O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intentions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
recent O B_MEASURE/B_LOCATION
weight O I_MEASURE/I_LOCATION
- O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attempts O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Despite O O
a O O
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sample O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
size O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
excellent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
follow O O
- O O
up O O
rates O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
well O O
- O O
measured O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
were O O
unable O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
demonstrate O O
that O O
staging O O
algorithms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recommended O O
by O O
proponents O B_PERSON
of O O
the O O
Transtheoretical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
could O O
predict O O
weight O B_MEASURE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Modification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Expectations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE

Our O O
most O O
recent O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effort O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
utilize O O
health O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
theory O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
obesity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
intervention O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
research O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
is O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
attempted O O
to O O
examine O O
the O O
effectiveness O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
experimentally O O
- O O
induced O O
outcome O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
expectancies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
weight O B_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
Finch O B_PERSON
EA O I_PERSON
, O O
Linde O B_PERSON/B_LOCATION
JA O B_PERSON/I_LOCATION
, O O
Jeffery O B_PERSON/B_COLOR
RW O I_PERSON/I_COLOR
, O O
Rothman O B_PERSON/B_COLOR
AJ O I_PERSON/I_COLOR
and O O
King O B_PERSON/B_LOCATION
CM O I_PERSON/I_LOCATION
, O O
unpublished O B_LOCATION/B_MEASURE
data O I_LOCATION/I_MEASURE
] O I_LOCATION/I_MEASURE
. O O

Obese O O
men B B_PERSON
and O O
women B B_PERSON
participated O O
in O O
an O O
8 O O
- O O
week O O
weight O O
- O O
loss O O
program O O
with O O
18 O O
- O O
month O O
follow O O
- O O
up O O
in O O
which O O
they O O
were O O
assigned O O
to O O
one O O
of O O
two O O
expectancy O O
groups O O
. O O

The O O
optimistic O B_ORGANIZATION/B_PERSON
group O B_ORGANIZATION/I_PERSON
was O O
told O O
that O O
focusing O O
exclusively O O
on O O
the O O
positive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
weight O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
be O O
valuable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
ensuring O O
that O O
they O O
remained O O
motivated O O
in O O
their O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efforts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
was O O
given O O
assignments O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
weekly O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
group O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
sessions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O O
homework O B_PERSON/B_TIME[MEASURE]
between O O
sessions O B_TIME[MEASURE]/B_PERSON
to O O
reinforce O O
this O O
optimistic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mindset O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

A O O
" O B_PERSON
balanced O I_PERSON
" O O
expectancy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
received O O
the O O
instructions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
focusing O O
on O O
both O O
the O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
negative O B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_DISEASE_ADJECTIVE[DISEASE]
of O O
weight O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
balanced O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
approach O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
would O O
be O O
most O O
conducive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
maintaining O O
weight O B_MEASURE/B_LOCATION
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
motivation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
group O B_ORGANIZATION/B_PERSON
also O O
received O O
assignments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
to O O
reinforce O O
their O O
message O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
the O O
expectation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
induction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
initially O O
but O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
maintain O O
in O O
the O O
face O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
real O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
experience O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

We O O
were O O
also O O
unable O B_PERSON/B_LOCATION
to O O
show O O
that O O
experimentally O O
- O O
induced O O
expectations O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influenced O O
weight O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
loss O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Summary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE

To O O
summarize O O
the O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O O
above O O
, O O
I O O
have O O
had O O
considerable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difficulty O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O O
the O O
last O B_TIME[MEASURE]/B_ENT
25 O I_TIME[MEASURE]/I_ENT
years O I_TIME[MEASURE]/I_ENT
in O O
confirming O O
that O O
the O O
psychosocial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variables O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
favored O O
by O O
health O B_PERSON
behavior O I_PERSON
theory O I_PERSON
are O O
of O O
much O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
value O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
obesity O B_PERSON/B_ORGANIZATION
intervention O I_PERSON/I_ORGANIZATION
research O I_PERSON/I_ORGANIZATION
. O O

They O O
do O O
not O O
predict O O
weight O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O O
, O O
either O O
as O O
mediators O B_PERSON/B_ORGANIZATION
or O O
moderators O B_PERSON/B_ORGANIZATION
. O O

There O O
is O O
little O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
support O O
the O O
idea O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O O
targeting O O
them O O
for O O
intervention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
improves O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
, O O
of O O
course O O
, O O
arguable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
the O O
weak O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relating O O
to O O
health O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theory O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variables O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
large O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
methodological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
weaknesses O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
either O O
in O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tools O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
their O O
frequency O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

I O O
would O O
argue O O
, O O
however O O
, O O
that O O
25 O B_PERSON/B_ENT
years O I_PERSON/I_ENT
is O O
long O O
enough O B_TIME[MEASURE]/B_LOCATION
to O O
wait O O
for O O
improved O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
that O O
it O O
is O O
time O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
look O O
elsewhere O O
for O O
variables O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
better O O
predict O O
weight O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
change O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
that O O
, O O
therefore O O
, O O
may O O
form O O
a O O
better O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
basis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
improving O O
future O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

Implication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Weight O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
Loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Given O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
success O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
finding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
cognitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mediators O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
behavior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
weight O B_DISEASE/B_PERSON
loss O I_DISEASE/I_PERSON
, O O
one O O
might O O
surmise O O
that O O
progress O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
improving O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interventions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O O
the O O
last O B_TIME[MEASURE]/B_ENT
20 O I_TIME[MEASURE]/I_ENT
years O I_TIME[MEASURE]/I_ENT
must O O
have O O
been O O
dreary O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indeed O O
. O O

Somewhat O O
surprisingly O O
, O O
however O O
, O O
that O O
is O O
not O O
the O O
case O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
short O B_PERSON/B_MEASURE
- O O
term O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O B_NUMBER[MEASURE]
to O O
12 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
success O B_MEASURE/B_DISEASE
of O O
weight O B_MEASURE/B_DISEASE
- O O
loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
approximately O O
doubled O O
over O O
that O O
time O B_TIME[MEASURE]/B_LOCATION
and O O
several O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
identified O O
that O O
reliably O O
enhance O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
has O O
been O O
clearly O O
shown O O
experimentally O O
that O O
increasing O O
treatment O B_MEASURE/B_DISEASE
length O B_MEASURE/I_DISEASE
[ O O
19 O B_MEASURE
] O I_MEASURE
, O O
prescribing O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
energy O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
intakes O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
20 O B_MEASURE
] O I_MEASURE
, O O
prescribing O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
energy O B_MEASURE/B_DISEASE
expenditure O I_MEASURE/I_DISEASE
[ O O
21 O B_MEASURE
] O I_MEASURE
, O O
using O O
a O O
deposit O B_PERSON/B_ORGANIZATION
contract O I_PERSON/I_ORGANIZATION
and O O
group O B_ORGANIZATION/B_PERSON
- O O
based O O
reward O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
systems O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
[ O O
22 O B_MEASURE
] O I_MEASURE
, O O
and O O
simplifying O O
adherence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
diet O O
through O O
meal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
substitutes O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
[ O O
23 O B_MEASURE
] O I_MEASURE
and O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
providing O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
equipment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
24 O B_MEASURE
] O I_MEASURE
all O O
improve O O
initial O B_DISEASE_ADJECTIVE[DISEASE]
weight O I_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
. O O

From O O
a O O
theoretical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perspective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
however O O
, O O
one O B_PERSON/B_LOCATION
thing O I_PERSON/I_LOCATION
is O O
noteworthy O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
about O O
these O O
successful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
innovations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
not O O
incompatible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
, O O
none O B_PERSON/B_NUMBER[MEASURE]
of O O
them O O
are O O
specifically O O
derived O O
from O O
cognitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
decision O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
making O O
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Indeed O O
, O O
health O B_ORGANIZATION/B_PERSON
behavior O I_ORGANIZATION/I_PERSON
theory O I_ORGANIZATION/I_PERSON
does O O
not O O
include O O
variables O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O O
these O O
in O O
its O O
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Where O B_LOCATION
Do O O
We O O
Go O O
From O O
Here O O
? O O

The O O
argument O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
above O O
about O O
the O O
practical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
limitations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
popular O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theories O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
health O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
behavior O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
is O O
not O O
meant O O
to O O
be O O
a O O
call O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
abandon O O
theory O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Behavior O O
scientists O O
have O O
amassed O O
much O O
useful O O
information O O
about O O
the O O
principles O O
underlying O O
human B B_PERSON/B_SPECIES[BIO]
behavior O O
that O O
should O O
be O O
valuable O O
for O O
health O O
behavior O O
interventions O O
. O O

Much O O
is O O
known O O
about O O
human B B_PERSON/B_SPECIES[BIO]
perception O O
, O O
learning O O
, O O
motivation O O
, O O
and O O
responsiveness O O
to O O
environmental O O
opportunities O O
and O O
contingencies O O
. O O

Health O O
behavior O O
intervention O O
lies O O
at O O
the O O
interface O O
between O O
people B B_PERSON
and O O
their O O
environment O O
. O O

Interventionists O O
change O O
aspects O O
of O O
the O O
environment O O
( O O
cues O O
, O O
information O O
, O O
behavioral O O
contingencies O O
) O O
with O O
the O O
intention O O
of O O
producing O O
changes O O
in O O
how O O
people B B_PERSON/B_BIO
behave O O
. O O

What O O
is O O
needed O O
to O O
advance O O
health O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
behavior O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
intervention O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
is O O
theory O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
addresses O O
relationships O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
modifiable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
environment O B_LOCATION/B_PERSON
and O O
behavior O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

There O O
is O O
no O O
doubt O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
cognitive O B_PERSON
processes O I_PERSON
are O O
involved O O
in O O
these O O
relationships O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

However O O
, O O
the O O
extent O B_MEASURE/B_LOCATION
to O O
which O O
current O B_PERSON/B_LOCATION
theories O I_PERSON/I_LOCATION
capture O O
this O O
is O O
questionable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Data O O
now O O
available O O
suggest O O
that O O
easily O O
obtainable O O
information O O
about O O
people B B_PERSON
' O O
s O O
cognitive O O
processes O O
adds O O
little O O
to O O
our O O
ability O O
to O O
predict O O
the O O
results O O
of O O
interventions O O
. O O

Thus O O
, O O
it O O
may O O
be O O
wise O B_DISEASE_ADJECTIVE[DISEASE]
to O O
pay O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
applied O O
theories O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
like O O
classical O B_EDU[ORGANIZATION]/B_PERSON
behavior O I_EDU[ORGANIZATION]/I_PERSON
theory O I_EDU[ORGANIZATION]/I_PERSON
[ O O
25 O B_MEASURE
] O I_MEASURE
, O O
communications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
theory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
[ O O
26 O B_MEASURE
] O I_MEASURE
, O O
and O O
learning O O
theory O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
27 O B_MEASURE
] O I_MEASURE
than O O
to O O
those O O
coming O O
out O O
of O O
the O O
social O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cognitive O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
traditions O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Competing O O
interests O B_DISEASE

None O B_PERSON
declared O O
. O O

